<SEC-DOCUMENT>0001558370-23-013756.txt : 20230808
<SEC-HEADER>0001558370-23-013756.hdr.sgml : 20230808
<ACCEPTANCE-DATETIME>20230808074130
ACCESSION NUMBER:		0001558370-23-013756
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		96
CONFORMED PERIOD OF REPORT:	20230630
FILED AS OF DATE:		20230808
DATE AS OF CHANGE:		20230808

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			XOMA Corp
		CENTRAL INDEX KEY:			0000791908
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				522154066
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39801
		FILM NUMBER:		231149374

	BUSINESS ADDRESS:	
		STREET 1:		2200 POWELL STREET
		STREET 2:		SUITE 310
		CITY:			EMERYVILLE
		STATE:			CA
		ZIP:			94608
		BUSINESS PHONE:		510-204-7239

	MAIL ADDRESS:	
		STREET 1:		2200 POWELL STREET
		STREET 2:		SUITE 310
		CITY:			EMERYVILLE
		STATE:			CA
		ZIP:			94608

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XOMA LTD /DE/
		DATE OF NAME CHANGE:	19990107

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XOMA CORP /DE/
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>xoma-20230630x10q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.3.0.9 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 8/8/2023 2:21:39 AM -->
      <!-- iXBRL Library version: 1.0.8528.25195 -->
      <!-- iXBRL Service Job ID: 980226bc-9fde-4ac1-908d-7caa1283ee28 -->

  <html xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:xoma="http://www.xoma.com/20230630" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2023" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" xs:nil="true" contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ" name="us-gaap:CommitmentsAndContingencies" id="Hidden_NPWKx_bg_0qAoDF6yFNvtg"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" xs:nil="true" contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg" name="us-gaap:CommitmentsAndContingencies" id="Hidden_NMX77_cSTku-OJ-pXw1IbA"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" xs:nil="true" contextRef="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_B7d29QvlcEe4N-_OPoM0aw" name="us-gaap:PreferredStockValue" id="Hidden_rG8qdelPsE2MZDrhfrBOUw"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" xs:nil="true" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_GAngHNpHWkmY3_zgBQQUhg" name="us-gaap:PreferredStockValue" id="Hidden_hwGUEJwvdUSJVpS6POw7GQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" xs:nil="true" contextRef="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_6973Ln0mrUSWVWSvhpZzAw" name="us-gaap:PreferredStockValue" id="Hidden_IsaLZDRs0E2--Y-WLDu3kw"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" xs:nil="true" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_brrjfnRro02jXTsYqcCsLA" name="us-gaap:PreferredStockValue" id="Hidden_yk9AWBRJokWIwrr3poqSwA"></ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" name="dei:EntityCentralIndexKey" id="Tc_0AW44bk-k0SF_-_g-ZyaIg_2_1">0000791908</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" name="dei:CurrentFiscalYearEndDate" id="Tc_SyvKAqS-I0ebvuIxboXhDg_3_1">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" name="dei:DocumentFiscalYearFocus" id="Tc_MI2QgBkQmk2Lc2tUtsQD9Q_4_1">2023</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" name="dei:DocumentFiscalPeriodFocus" id="Tc_nRomgyjoo06EUZeazLH85w_5_1">Q2</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" name="dei:AmendmentFlag" id="Tc_yTyHC_A3vkShen9-18t6Gw_6_1">false</ix:nonNumeric><ix:nonFraction unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg" contextRef="Duration_1_17_2023_To_1_17_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_lz1JUm8bHUSBbGCkkt6ACA" decimals="5" name="us-gaap:PreferredStockDividendsPerShareCashPaid" id="Hidden_6FlVNMctY0q9dw8fCOKxTg">0.53906</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg" contextRef="Duration_1_17_2023_To_1_17_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_I1U0dl2b_U6ewgR9AxdDcA" decimals="5" name="us-gaap:PreferredStockDividendsPerShareCashPaid" id="Hidden_9royLRcMl0Knqef269WU1Q">0.52344</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg" contextRef="Duration_4_17_2023_To_4_17_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_DiAyNLOtMkyP4bogjr0ljA" decimals="5" name="us-gaap:PreferredStockDividendsPerShareCashPaid" id="Hidden_qWHrIk0HxkKu1Feelg1QWg">0.53906</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg" contextRef="Duration_4_17_2023_To_4_17_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_Z6poHWjacUe3yoIoMnG5Gw" decimals="5" name="us-gaap:PreferredStockDividendsPerShareCashPaid" id="Hidden_zyL_9MT4C06Qx4obkYEVKw">0.52344</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg" contextRef="Duration_7_17_2023_To_7_17_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_tFHfgUHPO0eyTGuDDDFz_A" decimals="5" name="us-gaap:PreferredStockDividendsPerShareCashPaid" id="Hidden_hWIxlEMoI06Nfvonzanuzg">0.53906</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg" contextRef="Duration_7_17_2023_To_7_17_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_D4y9SqGnwUyCojdGJ8gVXQ" decimals="5" name="us-gaap:PreferredStockDividendsPerShareCashPaid" id="Hidden_Q-ZWoTYYE0qrtlCrmMWbHw">0.52344</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ" contextRef="Duration_10_1_2020_To_10_31_2020_dei_LegalEntityAxis_xoma_RezoluteIncMember_ajuHCP8Cvkqkr0Grn5eRPw" decimals="2" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" id="Hidden_U1OJbQlzmUOeCcJTMgU3Qw">0.02</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ" contextRef="Duration_5_1_2023_To_5_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_gHPGrk0L1EOQ1hUygp_Gpw" decimals="3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" id="Hidden_pz-y6RJKqkG2-1h8_aEPqw">0.333</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ" contextRef="Duration_5_1_2023_To_5_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_jGf-N4U7oEWRkZ347gsAlA" decimals="3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" id="Hidden_mBhYOSdezkKayi1Fqww_nQ">0.333</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ" contextRef="Duration_5_1_2023_To_5_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_aWe1HEcOJkO4GJNqP9UK8w" decimals="3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" id="Hidden_npSSwNAmG0yLnAtmVxINPw">0.333</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="xoma-20230630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardsMember_TzcgwgvPHk2deHWsM1h3OA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:ChiefInvestmentOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:StockOptionInducementAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-03</xbrli:startDate><xbrli:endDate>2023-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerInterimMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardsMember_whB55KBpZUikUKiuuCNJVw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:ChiefExecutiveOfficerInterimMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:StockOptionInducementAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-03</xbrli:startDate><xbrli:endDate>2023-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardsMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_oW0kv2blbEWaKJNbPntI9A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:ChiefInvestmentOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:StockOptionInducementAwardsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-03</xbrli:startDate><xbrli:endDate>2023-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_B01Z3JtpTkOkqmAnGrSDdg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:LadrxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_6_2017_To_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementRz358Member_qYjemo3WTUmBR58bLQH00g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementRz358Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-06</xbrli:startDate><xbrli:endDate>2017-12-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_6_2017_To_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementNonRz358ProductsMember_X1c9jKDf5EOZolxEicyXRw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementNonRz358ProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-06</xbrli:startDate><xbrli:endDate>2017-12-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2006_To_11_1_2006_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_srt_ProductOrServiceAxis_xoma_MezagitamabMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_nbtuFUC-fkqYmHeLy348AA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:MezagitamabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2006-11-01</xbrli:startDate><xbrli:endDate>2006-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_10_31_2023_srt_StatementScenarioAxis_srt_ScenarioForecastMember_srt_TitleOfIndividualAxis_xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_VlkReAnbnkaiZ8DMeCw8ZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:CurrentEmployeesExcludingChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_srt_TitleOfIndividualAxis_xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_tUWKdWxSsEqTeepdcpaR-g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:CurrentEmployeesExcludingChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2023_To_8_31_2023_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_srt_ProductOrServiceAxis_xoma_FaricimabSvoaVabysmoProductMember_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_REdIh2M4tEqC4XSc5ixlSg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffitechResearchAsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:FaricimabSvoaVabysmoProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-01</xbrli:startDate><xbrli:endDate>2023-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_MedexusMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_uvMhw-Lcqk-4prmxG0MKyQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:MedexusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_29_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_wWf39cBN3Ey7XT6o94A4AQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AptevoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-29</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember__RhK022Z4kyD4eKqg0JNCA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AptevoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_1_2023_To_2_28_2023_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_3qo6LMNvTEKUouebN2XnWA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffitechResearchAsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-01</xbrli:startDate><xbrli:endDate>2023-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_euIclIwai0uxoAqBVaGjlw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AptevoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2022_To_8_31_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_OH8fvv_h9keoJxZOMgPK5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffitechResearchAsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_MerckImmunoOncologyProductMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_NG5TrsNyD0Oet2286g9H0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AgenusIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:MerckImmunoOncologyProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_IncyteImmunoOncologyAssetsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember__94jAcnsd02lqy6kaK-0kQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AgenusIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:IncyteImmunoOncologyAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_9_20_2018_To_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_MerckImmunoOncologyProductMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_rdQZOj-p50uveOBE4byiYQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AgenusIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:MerckImmunoOncologyProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-20</xbrli:startDate><xbrli:endDate>2018-09-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_IL1TargetLicenseAgreementMember_1_yPty6sVUuiOqjDzbtIAg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:IL1TargetLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-24</xbrli:startDate><xbrli:endDate>2017-08-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_21_2016_To_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_SecondRoyaltyInterestAcquisitionAgreementMember_Ue-jD_6tzkiEEl7k3z6Zvg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:SecondRoyaltyInterestAcquisitionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-12-21</xbrli:startDate><xbrli:endDate>2016-12-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_21_2016_To_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_FirstRoyaltyInterestAcquisitionAgreementMember_1g3j3qkUPUilXtpAyP_pQg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:FirstRoyaltyInterestAcquisitionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-12-21</xbrli:startDate><xbrli:endDate>2016-12-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2022_To_11_1_2022_srt_TitleOfIndividualAxis_xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_r2cXPnKQNkCZpd4DuftB1Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:CurrentEmployeesExcludingChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_5_2021_To_8_5_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_AtMarketIssuanceSalesAgreement2021Member_aVcwCvFvaEm9M_QNOIF3YA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xoma:AtMarketIssuanceSalesAgreement2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-05</xbrli:startDate><xbrli:endDate>2021-08-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_18_2018_To_12_18_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_TwoThousandEighteenAtMarketAgreementMember_6lxjXvcF7UG8eC23SZUejg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xoma:TwoThousandEighteenAtMarketAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-18</xbrli:startDate><xbrli:endDate>2018-12-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_VZ3-yhq8FE25TUInBBrGZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandFifteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_qKDIT7AlPEumlQb_qY84ng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AptevoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_21_2023_To_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_e8EdDKpfoE63WcXU__Eu4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:LadrxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-21</xbrli:startDate><xbrli:endDate>2023-06-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_srt_StatementGeographicalAxis_srt_EuropeMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_91bx_J3VVUaNfNyS-gIThg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffitechResearchAsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_p8h6imE-V0uwNs1HrXGY2A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffitechResearchAsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_6_2021_To_10_6_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_7mFvjte_dEevmb4jPsGqCg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffitechResearchAsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-06</xbrli:startDate><xbrli:endDate>2021-10-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_22_2021_To_3_22_2021_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_Yzb76SH-JEWCZntLrcxS8w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:ViractaTherapeuticsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-22</xbrli:startDate><xbrli:endDate>2021-03-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_2_2020_To_11_2_2020_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementTwoMember_lIg02dx4pU2AOp3fc9Nh0Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:BioasisTechnologiesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-02</xbrli:startDate><xbrli:endDate>2020-11-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_26_2019_To_9_26_2019_srt_CounterpartyNameAxis_xoma_PalobiofarmaSLMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_aaICGPfxhkOTZpQUaO0Yqw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:PalobiofarmaSLMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-26</xbrli:startDate><xbrli:endDate>2019-09-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2019_To_9_30_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_gG7wFWBERkClqJ60IJyBXw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_o9TK8egh80G0mWjo56c-jg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:SiliconValleyBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-07</xbrli:startDate><xbrli:endDate>2019-04-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_20_2018_To_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_CDSnZwcrZEu2Ca2UBiaJ0g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AgenusIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-20</xbrli:startDate><xbrli:endDate>2018-09-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesEmeryvilleCaliforniaMember_j4Za8qhjGEunE9GIsiSNhg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xoma:LeasedFacilitiesEmeryvilleCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_1_2022_srt_TitleOfIndividualAxis_xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_rYMNfnEL9EOqQXV7Em0Nyg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:CurrentEmployeesExcludingChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_v_4086cVDUmoGR5d7CgO0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_e0nlQVVkQEC_RcJPbx3_LQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_qONAes1cy0G9lDzJGggO0Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_heK3HldCNE-r5gSRWagnnQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_20_2018_To_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_IncyteImmunoOncologyAssetsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_XSaCTgtO1EiCFqoqTgeZVw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AgenusIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:IncyteImmunoOncologyAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-20</xbrli:startDate><xbrli:endDate>2018-09-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_25_2019_To_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_YrCq7J8e4kyLGJ4RpNNinw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:BioasisTechnologiesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-25</xbrli:startDate><xbrli:endDate>2019-02-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2021_To_6_30_2021_xtjjCBFLBUi_Ojs50RRq5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2022_To_5_31_2022_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_ksZbC81p30-S2MPeTooszw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_7_31_2022_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_XIw7qGqY0EK6f05CwdTGoA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2020_To_11_30_2020_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_MerckImmunoOncologyProductMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_yWJTxLzPL0y7_WmwB5wNNw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AgenusIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:MerckImmunoOncologyProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2020_To_11_30_2020_dei_LegalEntityAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_MerckImmunoOncologyProductMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_gu6YuHtIt0y_GOYnfbfPoA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">xoma:AgenusIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:MerckImmunoOncologyProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_5_2021_To_8_5_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_AtMarketIssuanceSalesAgreement2021Member_cuvo8QXwwkSA9m8xw1ZRjg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xoma:AtMarketIssuanceSalesAgreement2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-05</xbrli:startDate><xbrli:endDate>2021-08-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_10_2021_To_3_10_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_TwoThousandEighteenAtMarketAgreementMember_lPXdwcXrLkWjZpFxVg8zQg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xoma:TwoThousandEighteenAtMarketAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-10</xbrli:startDate><xbrli:endDate>2021-03-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_18_2018_To_12_18_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_TwoThousandEighteenAtMarketAgreementMember_w7kNNs1WoE-BxhkhRzlqSg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xoma:TwoThousandEighteenAtMarketAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-18</xbrli:startDate><xbrli:endDate>2018-12-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_srt_ProductOrServiceAxis_xoma_AldoxorubicinMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_pNlSw8P-5EajUFyzP-8uPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:LadrxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:AldoxorubicinMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_srt_ProductOrServiceAxis_xoma_ArimoclomolMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementMember_K3A3TuR8B0uQ0wOH9CRISw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:LadrxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:ArimoclomolMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:AssignmentAndAssumptionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_P2FOnn42CUiAAEHfWUjQNw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffitechResearchAsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_NqbS9eqGFkerYvUUwG7Maw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:LadrxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_21_2022_srt_CounterpartyNameAxis_xoma_MerckKgaaMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_9bKtdq3Xq022OPaePZccLw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:MerckKgaaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_21_2022_us-gaap_AssetAcquisitionAxis_xoma_ObsevaIntellectualPropertyRightsMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_eP4cyYTR-k2h0sxHIlensA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">xoma:ObsevaIntellectualPropertyRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2019_To_8_31_2019_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_7abmyDQDN0asJM3WaMklhA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:JanssenBiotechInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2019-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_WO4UYUGV_02Sv2V6Sl4utw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffitechResearchAsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_21_2023_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_1-O-Wc5qm0GpfWvtLfA5QQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_6_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_utnG5LOjWkaEzqc0Xpgs4A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffitechResearchAsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_14_2021_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_Xh1jjLmK9029VV5PJj8xKg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_2_2020_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementTwoMember_EKVUME649EuA-3BW_SUmRA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:BioasisTechnologiesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_W3hVIOjItkyJRWGnXKpi0w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AgenusIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_12_6_2017_To_12_31_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_mT3lLicYEUilKoGSWcL_yw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementAndCommonStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-06</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_1_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesEmeryvilleCaliforniaMember_jFg3GanTsESUiaQdv4hx4g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xoma:LeasedFacilitiesEmeryvilleCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_20_2023_To_6_20_2023_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementAndSecondRoyaltyPurchaseAgreementMember_Eqxr4CXcuE-FFTbVv-ujhg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:BioasisTechnologiesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementAndSecondRoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-20</xbrli:startDate><xbrli:endDate>2023-06-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_ka9FAFONVkeMeIE9zPwx5Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:BioasisTechnologiesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_FirstRoyaltyInterestAcquisitionAgreementMember_gLlWNbiZNUK_fa6Qh_xfcA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:FirstRoyaltyInterestAcquisitionAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_14_2021_To_7_14_2021_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_s0z0PXoS5k-BNomvO5_j6g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-14</xbrli:startDate><xbrli:endDate>2021-07-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementRz358Member_k_y6teG2YUSWNLFytU9KEg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementRz358Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_LoKvCYQB9EOeQYU95Ohdpw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:XOMA052LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-08-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2015_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_AFuvSscA3kS3Ogj-V-41CQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_1_2006_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_srt_ProductOrServiceAxis_xoma_MezagitamabMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_eN1YCwnkIUCnKDhhfVJ8PA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:MezagitamabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2006-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_21_2022_srt_CounterpartyNameAxis_xoma_OrganonMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_VI6RYGqQZkeAVJnnIv4sTQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:OrganonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_2_1_2009_To_2_28_2009_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_srt_ProductOrServiceAxis_xoma_OtherAntibodiesMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_nb8ggrHRR0i-B34ppjt3fQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:OtherAntibodiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2009-02-01</xbrli:startDate><xbrli:endDate>2009-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_pn2tVWcS10-XUKZrEdxpPg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-07</xbrli:startDate><xbrli:endDate>2019-04-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_BayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_HRYppcTJikmUXTKgI4BWvQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:BayerProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-07</xbrli:startDate><xbrli:endDate>2019-04-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_BayerProductsMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_abyt3ov_LEidqaXYxUPESw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:BayerProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_QHXUcnameU2HPDbtouGcNQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:BioasisTechnologiesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_2Aj5seKcO0-XhIAauxBBGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:BioasisTechnologiesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_AronoraKurosAffitechObsevaAndMerckKgaaMember_Jg_8omFpTEO2btPaF3ItlQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraKurosAffitechObsevaAndMerckKgaaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_ContingentConsiderationByTypeAxis_xoma_ContingentConsiderationRegulatoryMilestonesMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_CJwILMODfU2DPiygsj2I2Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:LadrxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">xoma:ContingentConsiderationRegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_dUxKhnDLWESjshb_a_VOiQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:LadrxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_m3fGmRg0ukuCv0wBM5jhzQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:LadrxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_ILbmTBFAdkeabm8OMvrxMg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AptevoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_29_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_BVEo8QgBSkmfz1ozUkIwXw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AptevoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_6_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_ContingentConsiderationByTypeAxis_xoma_ContingentConsiderationRegulatoryMilestonesMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_vyMgtLcJvEi0juGqwh3ASQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffitechResearchAsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">xoma:ContingentConsiderationRegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_mAQNTbueYkGTdJGdXydMXQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:BioasisTechnologiesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_s8DXfaV1hU-kNpb0otcEew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_9t8qE3DtCUGDnjtaLsnr7g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerRetiredMember_-DtLW9eN0kelXo4Sr64YSg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:ChiefExecutiveOfficerRetiredMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_29_2023_To_3_29_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_7trh9U9BgEOiGwvVb10qXg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AptevoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-29</xbrli:startDate><xbrli:endDate>2023-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_6_2021_To_10_6_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_srt_ProductOrServiceAxis_xoma_FaricimabProductMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_wnbrqh2QZE2B_rph576ABA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffitechResearchAsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:FaricimabProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-06</xbrli:startDate><xbrli:endDate>2021-10-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_21_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_o0jHZU6txku5HZbpgBRroQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:LadrxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-21</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_A0raaKROwE6F7PlIHJx7HA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:LadrxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_6_2017_To_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_YD6dXAdo7E2njL-IcLEMGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-06</xbrli:startDate><xbrli:endDate>2017-12-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_30_2015_To_9_30_2015_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_27gU5riISEy0SIhW5x2uJg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-09-30</xbrli:startDate><xbrli:endDate>2015-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_22_2021_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_46O6ygYv-kiSXEivuByfuw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:ViractaTherapeuticsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_26_2019_srt_CounterpartyNameAxis_xoma_PalobiofarmaSLMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_zT4QsAb7u0eLPQ9twhpAFA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:PalobiofarmaSLMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_NonBayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_3_W-6bd8Rk-v259MRO0Muw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:NonBayerProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_HVql9Pa7t0Olldm6QQhOFg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_BayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_Pw_lMHeh_0G7t1NpeC5DRQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:BayerProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerRetiredMember_AOpX5sV2ukSJWYQ3A3lEaQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:ChiefExecutiveOfficerRetiredMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerRetiredMember_YyRGgFdv-E6X0DuiU_Edmg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:ChiefExecutiveOfficerRetiredMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_JyWKfa6Y2kCEdbWR9Enhww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Y8pSKqQVN0qvZ3Xp6DQmKg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_5_2021_To_3_31_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_AtMarketIssuanceSalesAgreement2021Member_LyhgNqHmQEOuPgMQ7sVrxA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xoma:AtMarketIssuanceSalesAgreement2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-05</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_18_2018_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_TwoThousandEighteenAtMarketAgreementMember_7W6KMaqUekmIWDswlSxORw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xoma:TwoThousandEighteenAtMarketAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-18</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_t9TRI6XjwEKzRs1Mh2hslQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:XOMA052LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-24</xbrli:startDate><xbrli:endDate>2017-08-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_q7cIlXaQfEaTUzSmFF8pow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_nZVAZEbax02Nn2_S_0USBA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2020_To_10_31_2020_dei_LegalEntityAxis_xoma_RezoluteIncMember_ajuHCP8Cvkqkr0Grn5eRPw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">xoma:RezoluteIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__SjruGbNMke6VHotvJqC3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_edqle5HbXEm7yuZsNCNZ5Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_6kc5MkORGEWUHpL16Dho2Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_x45gr-vUZEyje19LB7OGtA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_X5C7oga02EiygboostYHVw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ULAJkPFmo0GKfvexehN6Xw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_gXsLP4N9SkWM0pvx20VSug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_nRVamYzhRUqPa-9YjzTLLA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_YqOEWTXU0Ua6QvAhBoXz7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_YzMe_e-yGUGbNiPtf12IwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sHK3ZNTAH0aMwFqH9faHRw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_wXICAr6QekumvGjfUaFcqw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_oECYzd9liEiyvMRgwShVYg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_S54NSxp5yk2I3fcHshTcMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_mN21iu-7y0Ob71zpxfq1UQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_3elDeOQbAkSzA4XPNTMvKw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_czcB2xp3ZkO5ufWJGf_Lgg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_tKe_WjiZ-0ecu0LnoPu_Vw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_gUvLnlJ3mkOEbSXAHiiecQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_NVGVumu2RU2aSm58xyzVnQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__q8-WGlpF0afujkbjDrhAQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_PeotIRnSfEqGsKf-u1aQaA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_F7GJ2ijBaESNLxxCWOPV9Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_mjGDeVHtJEy-hmsEfPC5Jw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vprHlJrRr0yw8rVJERIeVg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_63gYMzNqtUeLw4EgBOljpw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_nAb-HKUTNkWZ5BAQ0-qIHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_vUW8gOL5lUS22XQyQHoMYg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_54FxiDHYMUSAo0wczwNo8w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_eGV1-nMv9EyGZf3q_EpMbw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_jps57Fyqu0WWl7CaOtheOg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_q6JWreHPR0i_czphX2lVDQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zdAm_dbVtUOANrU35KRi-w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_2zCuoTh9XU-z3zmcVTU37A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_6rQbM7sQNky8O85-NJM6Kw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_uuOaeeICIE63neZVbvxrYw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xTypNCJw2kecFDKsOR8hwA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vo9zKMnZO0aHN96tsj24CA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_31_2023_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar45Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_G0SYyex3eUy7MyZY9jFEqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">xoma:StockPriceHurdlesOfDollar45Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_31_2023_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar40Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_M7IRrCKea0iCZRqtsZ7RWg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">xoma:StockPriceHurdlesOfDollar40Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_31_2023_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar35Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_6tvbW7uZUEOHE7gMti2gpA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">xoma:StockPriceHurdlesOfDollar35Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_31_2023_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar30Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_k94cSi-Zwk2VBrdcAKVvmA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">xoma:StockPriceHurdlesOfDollar30Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_3_2023_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardsMember_O8EOxHD7p0K-aApJeodsyg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:StockOptionInducementAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_8Kg_25tsBUmCq2SIaH9sdg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:XOMA052LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-08-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_qMnU5lLEOEWtPeR71nBTRQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_-JwjlMwfKEGUbHpTjDxUDQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:StockOptionInducementAwardTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_jSfoRez_iE22iNJRZuTv-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:StockOptionInducementAwardOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_QvduteacZ0y6e-l0bH1cfQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandTenLongTermIncentiveAndStockAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_fvpJiV95o0G_Lx6Po8Z0Qg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:StockOptionInducementAwardTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_UkUp6s2yF0molMuQVionzw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:StockOptionInducementAwardOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_2sdFXHfUykChvD4tIF6z0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:ChiefInvestmentOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:StockOptionInducementAwardTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-03</xbrli:startDate><xbrli:endDate>2023-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_-tCFSx98TEGfywwRhcC7ZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:ChiefInvestmentOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:StockOptionInducementAwardOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-03</xbrli:startDate><xbrli:endDate>2023-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerInterimMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_ifxCZ1Dza0CPpbZTGry9HQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:ChiefExecutiveOfficerInterimMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:StockOptionInducementAwardTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-03</xbrli:startDate><xbrli:endDate>2023-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerInterimMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_iFhJ1Ec6iUaNhMqAZWDmbg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:ChiefExecutiveOfficerInterimMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:StockOptionInducementAwardOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-03</xbrli:startDate><xbrli:endDate>2023-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_HFe1p--7QUyXIpXph3Ep4A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:StockOptionInducementAwardTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_UCA8w-FN5E6MpfSkha4Snw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:StockOptionInducementAwardOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_nc6cD9y6eky4_H4Gmdgf2Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:StockOptionInducementAwardTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_OxGaeDYzykWU3vEhrxw_Mw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:StockOptionInducementAwardOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_xL-t6UGWVk6DJsv8uctHqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandTenLongTermIncentiveAndStockAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_-fCNRL3sJk2hkKbH29QN5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandTenLongTermIncentiveAndStockAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_kkqRS-Yr_kK7p5s-7yOqJg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:StockOptionInducementAwardTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_8s2qytOsIE6JM7loesF-Zg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:StockOptionInducementAwardOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_6P9--i9dukq4YkLcJp4PvQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandTenLongTermIncentiveAndStockAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_hI8wxtoK_020YtrtWXgEww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandTenLongTermIncentiveAndStockAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2023_To_5_31_2023_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar45Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_sJUAR2OjXECHMqedJgu-yQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">xoma:StockPriceHurdlesOfDollar45Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2023_To_5_31_2023_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar40Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_6r4sVlcI50y97OHzEy_aBg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">xoma:StockPriceHurdlesOfDollar40Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2023_To_5_31_2023_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar35Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_YZ1bWx-iUUeKV_tBnvEWAw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">xoma:StockPriceHurdlesOfDollar35Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2023_To_5_31_2023_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar30Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_nNrXvBglBEuLwgpeNxml8A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">xoma:StockPriceHurdlesOfDollar30Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2023_To_5_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_XYLfgmBs1kapqrjpQTeEpQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandTenLongTermIncentiveAndStockAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2023_To_5_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_gHPGrk0L1EOQ1hUygp_Gpw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardsMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_sfgRwFcTcUelc4rTBp-b3Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:ChiefInvestmentOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:StockOptionInducementAwardsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-03</xbrli:startDate><xbrli:endDate>2023-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2023_To_5_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_jGf-N4U7oEWRkZ347gsAlA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2023_To_5_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_aWe1HEcOJkO4GJNqP9UK8w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2023_To_5_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_Cf49xhpajkCvIANGtFeezA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_srt_TitleOfIndividualAxis_xoma_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_zTu1OSjDqkSzjQ_HoRydQw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:EmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandTenLongTermIncentiveAndStockAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_-kWVMpk2b0K-si5i-kPxAg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandTenLongTermIncentiveAndStockAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2023_To_5_31_2023_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar45Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_0Czk0OqbEkepDfJ3xsELBw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">xoma:StockPriceHurdlesOfDollar45Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2023_To_5_31_2023_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar40Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_QN3fukmQcEymV8gdhnI3ow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">xoma:StockPriceHurdlesOfDollar40Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2023_To_5_31_2023_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar35Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_lT2QTmiVC0-u-Gq59mHj8A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">xoma:StockPriceHurdlesOfDollar35Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2023_To_5_31_2023_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar30Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_eRdy_9rQG0eihqb4EruBVA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">xoma:StockPriceHurdlesOfDollar30Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2023_To_5_31_2023_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar45Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_132lsM87s0-SgeiFzFNGPw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">xoma:StockPriceHurdlesOfDollar45Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2023_To_5_31_2023_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar40Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_yYP93SxHqUaWiML_VD6qSQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">xoma:StockPriceHurdlesOfDollar40Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2023_To_5_31_2023_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar35Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_EP_RDzS2Y0G8ZWnpyMII1w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">xoma:StockPriceHurdlesOfDollar35Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2023_To_5_31_2023_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar30Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_NtPgJkGsykWMLfBzzhabEg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">xoma:StockPriceHurdlesOfDollar30Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_bltKeBtI3UmSSHjoiD4k4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandTenLongTermIncentiveAndStockAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_-e_kcpPy9Uijv53NXnwNjA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:StockOptionInducementAwardTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_YDoryzJQpUuWG8MDo2Kh5Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:StockOptionInducementAwardOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_m5ftMp6cYUSGHtQQJFDZ4g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyInterestAcquisitionAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_a3PpicXMp0e6hJa2jrYpvg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyInterestAcquisitionAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_n_zJPqyMuUyhRwCGh98ETg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyInterestAcquisitionAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_ydN4fj43pUqEu9cZio79ng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyInterestAcquisitionAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_srt_ProductOrServiceAxis_xoma_MilestonePursuantToAgreementMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_A9EfiA2PT0GB4VJ2dpb9fQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:JanssenBiotechInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:MilestonePursuantToAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_Ri7Rd8o8XUKc4YOMeBumXQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_V9oe_Umn1kmDzVa04Ga_yw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_ObsevaMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_K7Mk8P8VwES9_5DBUAZzMw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:ObsevaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_fDllYLxwC021lmWGRzTQow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_1mMiwj9oK0ik7StNSZF-NA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_JvsZS46lPEq8PkHBxYXxJw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:JanssenBiotechInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_AffimedMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_EbE0yio0rEiufpaULNthlw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffimedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_4_30_2023_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_srt_ProductOrServiceAxis_xoma_MilestoneDosingFirstPatientInClinicalTrialMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_d9RUr6mklkyYekHk6uD6mg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:JanssenBiotechInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:MilestoneDosingFirstPatientInClinicalTrialMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_VOxATG70-EaP_DZtrrA64w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_X4k_iI4JX0qMI82W0g9pVg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_ObsevaMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_XJPmp5bo-kmu5UyKiVXplA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:ObsevaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_m4wda9YuHE2PtS0eldU6mg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_mc8GGMwdb0i-WiWEDrANiQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_FSjLU5cFwkCknzTRDnkzlA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:JanssenBiotechInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_AffimedMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_79M6vRT4qEukxFoiKPpVGg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffimedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_QDr-ldinb0Wu3jl9Rx21UA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_vwInn_PHZEilesm4Dyrjqw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_jFCmb1gQLUCZ9hjyvX5kmw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_RLV8-2lAs0iAHxQrgpOq0w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_y5qiBk4TN0G3EitwLEYTCQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:JanssenBiotechInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_srt_CounterpartyNameAxis_xoma_AffimedMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_oY96KBMfAEOyCowvi6apdg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffimedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_vXBkO4OEpkinf_t3RM0D2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_vmQFJdPsf0mcV98nQ1FxGg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_rGGwTzCaJEKNgoHyMNh1gw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_9uhBqAbJnkGLmYVcrsplwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_jHYkB6cDy0SVSmvTMeT8oQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:JanssenBiotechInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_srt_CounterpartyNameAxis_xoma_AffimedMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_uepwPESgtkiCvIXYBSvbng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffimedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_84g9TjGclUmNwYUUvpo37g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2021_To_10_31_2021_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_xqc5RHdAf0e8Ok9zCOunNA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2020_To_11_30_2020_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_adu7bNhKOUupBKfuF3sIbA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2020_To_10_31_2020_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_HhVju1hJBE6OfB_ni4aRJg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_V2ptKzpjEUCLS85R4yB7vA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:JanssenBiotechInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_niKO_iOCski7xDCZeqBm0g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-24</xbrli:startDate><xbrli:endDate>2017-08-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2017_To_12_31_2017_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_Zf-09DuHLUy9gAfOBsfCZw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2015_To_12_31_2015_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_UKHVP4QfBUyD1MV8rF2yOQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2015-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_M2UiaYqolEG6eD-krPLPrQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:XOMA052LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-24</xbrli:startDate><xbrli:endDate>2017-08-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_B7d29QvlcEe4N-_OPoM0aw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_HnMB9b7CRUKpmLvME2vUuQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_6973Ln0mrUSWVWSvhpZzAw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_GAngHNpHWkmY3_zgBQQUhg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_ORljYJEjFUKKL0etVMNkrA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_brrjfnRro02jXTsYqcCsLA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_5_17_2023_To_5_17_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_IblNCk2dpE-dmOagVLa7JA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-17</xbrli:startDate><xbrli:endDate>2023-05-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_17_2023_To_5_17_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_zIuocAB-x0yti_KN6IbA-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-17</xbrli:startDate><xbrli:endDate>2023-05-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_22_2023_To_2_22_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_-2EK4u-0ckW1nFdNOq609w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-22</xbrli:startDate><xbrli:endDate>2023-02-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_22_2023_To_2_22_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_sYdPxIxRXkGzRg8T4Svv8w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-22</xbrli:startDate><xbrli:endDate>2023-02-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_26_2022_To_10_26_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_xycxsSZ67ECdvujJaYBpbg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-26</xbrli:startDate><xbrli:endDate>2022-10-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_26_2022_To_10_26_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_f-NSs0JDB0Om2BdwXRGLGw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-26</xbrli:startDate><xbrli:endDate>2022-10-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_17_2023_To_7_17_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_D4y9SqGnwUyCojdGJ8gVXQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-17</xbrli:startDate><xbrli:endDate>2023-07-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_17_2023_To_7_17_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_tFHfgUHPO0eyTGuDDDFz_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-17</xbrli:startDate><xbrli:endDate>2023-07-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_17_2023_To_4_17_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_Z6poHWjacUe3yoIoMnG5Gw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-17</xbrli:startDate><xbrli:endDate>2023-04-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_17_2023_To_4_17_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_DiAyNLOtMkyP4bogjr0ljA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-17</xbrli:startDate><xbrli:endDate>2023-04-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_17_2023_To_1_17_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_I1U0dl2b_U6ewgR9AxdDcA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-17</xbrli:startDate><xbrli:endDate>2023-01-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_17_2023_To_1_17_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_lz1JUm8bHUSBbGCkkt6ACA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-17</xbrli:startDate><xbrli:endDate>2023-01-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_-1YcQgV4D0GXoCudlGfzsQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_709bNt4Pc0ah6gEtj2ui5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_q_kRVdOaKUGqFvcO4YBRYg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_d2IDvzwTtEeRbBTwLkWiZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_WOYOn9euaESUo_Fdt2xQDQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_gy4yRQy_g0efVGsZ9JvfSg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_mZzBVYXOQEiwSAFnA-OODw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_vzagK5EjmEqHa32z1YO0qQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_xCuxHxFsWUK7HkZ9m3D7Zg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_A3D1KiJFt0CNaMkMfhVNww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_fyrP0G4Pj0-aaN04bSkICQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_7O1rzT-yJUuZnLhCfrcYOg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_KGG7iA9QeU-x58nvnAGyAA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_dei_LegalEntityAxis_xoma_BiotechnologyValueFundLPMember_srt_OwnershipAxis_xoma_XomaCorporationMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_OPWHgi5OoUOvpKGH_7ayMg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">xoma:BiotechnologyValueFundLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">xoma:XomaCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesTwoEmeryvilleCaliforniaMember_TMMvkmy6s0ygPCJWud7LzQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xoma:LeasedFacilitiesTwoEmeryvilleCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesEmeryvilleCaliforniaMember_qE4Q6lsyXk-n_6Q8orOVvg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xoma:LeasedFacilitiesEmeryvilleCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesTwoEmeryvilleCaliforniaMember_x-BSsUsmOEefcCTi34VfUw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xoma:LeasedFacilitiesTwoEmeryvilleCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_12_21_2016_To_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_u-wkh1XOjEKGxjaNdt0ZHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyInterestAcquisitionAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-12-21</xbrli:startDate><xbrli:endDate>2016-12-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AssetAcquisitionAxis_xoma_ObsevaIntellectualPropertyRightsMember_aKWzGNtzM0-dDhbT2Gyirg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">xoma:ObsevaIntellectualPropertyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_Gfw9LK-Od0iMS_KhAfKpsg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_ruM398xI60a2mOzUa9tLiw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_PwcTNnqVHEurE6RMUONPsw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_EPzxT9qkbUedyZWvfkZUhA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_NuaPtHy1BU6__HgLOoJDdw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_Abl8Ryg010astqw5xtuhDg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_LzgovgUcyUqFQMy5t8ndVg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_OFKp4An1GUS4-brDAQB8ew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_BSWfJSEpmEGBgXlGS4MC4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_79gnR1guSka7Q_vWe08uww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Nn8D-tR9RUaR3oXEwhegJw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_fUdJCDTZZkCC-dGe4IpNTw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_DFqUQBhRC0ifvbBc0bGVmg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_3UfIUbfYm0S1MerajhgXqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_rWEkuydSCkGeJt7pRAiu2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyInterestAcquisitionAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_AXaUv2IOz0qjMzgGNRTTfQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyInterestAcquisitionAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_12_31_2023_srt_StatementScenarioAxis_srt_ScenarioForecastMember_srt_TitleOfIndividualAxis_xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_MqTx9tpzQE-VCd4MN0ETHw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:CurrentEmployeesExcludingChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_srt_TitleOfIndividualAxis_xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_oCigQGadskqvS1qhL-UxEw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:CurrentEmployeesExcludingChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2020_To_10_31_2020_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_pUHf37jdqkO7GsZ6tJj4dA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:NovartisNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_ObsevaMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_zyUxaH6CvkmKfmQE_-3YjQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:ObsevaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_ObsevaMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_YH_2bboTUkyRnEvX6o0V4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:ObsevaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_t0Nk1HTAG0K7OHjnARYZew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:ViractaTherapeuticsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_PalobiofarmaSLMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_ipZkO7zZN06t3XJUxHlDgQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:PalobiofarmaSLMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_UCOXnlEMH0KhLJITjc3RcQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:LadrxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_l6eBrvgOik6JwWWl-dCq7g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementAndSecondRoyaltyPurchaseAgreementMember_FU0POSqmREazZyKHBvapXA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:BioasisTechnologiesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementAndSecondRoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_m716wsI3XE6pmBu2Tce2QA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_Ag4rXqT5_U2u9t7EHdT2Vw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AptevoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_AgenusIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_sSr_eim9wkmE2gHiwusgvQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AgenusIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_tbP6vsd5eUOJL3GPMRb5Sw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffitechResearchAsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_6tHZOwbzlkiu2oefkSmJmg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:ViractaTherapeuticsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_PalobiofarmaSLMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_YM8JsAYwe02uTcAIJfsjVw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:PalobiofarmaSLMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_1wOk0To-60ebzBx-MLxW0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementAndSecondRoyaltyPurchaseAgreementMember_p9m5gzIpdUSkItjQbZWuTA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:BioasisTechnologiesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementAndSecondRoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_o6zurAuWbE6ntKuKdPP1yg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_AgenusIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_bp0e2gt5REKDawtfAHfiFA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AgenusIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_t4tt47wP20iV85oZnDl0kQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffitechResearchAsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_srt_MajorCustomersAxis_xoma_Partner2Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_sqEiwRkHBkmAPGUe0Ez5pg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">xoma:Partner2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_srt_MajorCustomersAxis_xoma_Partner1Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_UPb9E7A4oUG9Ls-shtbyPg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">xoma:Partner1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_srt_MajorCustomersAxis_xoma_Partner2Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_R1d0cYWaYUKU7Z4Y59JDYQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">xoma:Partner2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_srt_MajorCustomersAxis_xoma_Partner1Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_TradeAccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_-LRlYQJJLk-TqPh3pxJ8_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">xoma:Partner1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_srt_MajorCustomersAxis_xoma_Partner1Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_3vOSN9-0P0-FLZiHWIajhw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">xoma:Partner1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_srt_MajorCustomersAxis_xoma_Partner2Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_uLAkeS_2ikqgahYM_BFpvQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">xoma:Partner2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_srt_MajorCustomersAxis_xoma_Partner1Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_3OysOB_GGkiYd3yyjB2f9A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">xoma:Partner1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_srt_MajorCustomersAxis_xoma_Partner4Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_SHilGTcI4ECxZyoz6P8uNQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">xoma:Partner4Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_srt_MajorCustomersAxis_xoma_Partner3Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_eW6Ihd4mvke6ewsUy3Hagg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">xoma:Partner3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_srt_MajorCustomersAxis_xoma_Partner2Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_VFb8t0MUH0G_Z4BDZPkyFw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">xoma:Partner2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_srt_MajorCustomersAxis_xoma_Partner1Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_OklwX0sEhUKh7TG7yMRNEw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">xoma:Partner1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_R8Pr3r4-T0atb20N_SOFQg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:TenYearWarrantsIssuedThirdRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_xvSWiZXzv0KYrc1BLRxaDA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:CommonStockWarrantExercisePrice14.71Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_TPmH3rSX0kqVVDT3mwjQVA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:TenYearWarrantsIssuedThirdRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_IW4xedCf1EONa-iq8razoA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:CommonStockWarrantExercisePrice14.71Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_lyjBTUwVbUyOd4KtP5Gu-g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021__kfZV7JTZUaYuVCcUwl-Cg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_9fLx36Xpp0Oo2wwcPihyCQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_8L7cEkq67EeCxAnI09lGvA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_0k9Iaqnwd06OsUIk7HwMEw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_wkmIyE0jUkOmFM4P8qQX2A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_7KGCjOdAWkKDUJtQiWx04A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_YKgnRcgp30yLgGtobgVXyQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_p69-pIRmOU6cPwJMvLqNSA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_m8qyydbCFEaJdTCv-WBD4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_akCqUsNekUK0f0Q6DuRi7A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_82zqclNhY0GJGFKyo32O1Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_-LsGHkQ-r0C10A2ulFZGhA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_Gr7k7W5HhEC0zf3RWdymsw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_LbLsp9ZkfkCPh5v5V7bOsw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:JanssenBiotechInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_AffimedMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_mOwWuP4wskCXg5lMAASlgQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffimedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_0J69dylAF0i8-z1WvitMYQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_f8hS_ZhC6kyh-a2nsLAegA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_GIL1i6m_ikWj4R2Nl1_z1Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_jNqsIu1EwE6fPsDB8xZzrg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember__kbO___xJkGjYQIiIFsysw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:JanssenBiotechInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_AffimedMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_U6vKLThuqke8EfnRv8dUJQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffimedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_2Ja-erVJsE2TwmalqlMXlA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_Ly-nCcCNVEyOwbUV0qBVsg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember_5ZLg9x5yckWz22fWebcY8g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_V2QHn9TZ1U2Os4nccw_I7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_lxT004blek2W7cHNT8xELA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember_4EdMPylUGUe0Dt4op523HQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_89XiQrxi6U-bxg6UnFGjBA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_s4acrI5TS06hk24i6x3lNw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember_oMboSz0lqEOTYykVt-gofg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_q9rTRUIKZEeJEnJsjreVeA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_NYjwGA24DUagvxCWxn84Ow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember_q5E1VWyBm0qYx76IUNrtVg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_us-gaap_AssetAcquisitionAxis_xoma_ObsevaIntellectualPropertyRightsMember_ZsDO0IohTEmlxBFNZXxV-w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">xoma:ObsevaIntellectualPropertyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_us-gaap_AssetAcquisitionAxis_xoma_ObsevaIntellectualPropertyRightsMember_sYlzh40hyE6ZDGRh_bcjVw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">xoma:ObsevaIntellectualPropertyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_aLWj_8kVOUatUIpAaoSESA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember__apnO9afP0Citfd-cUI30g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_pg3TjcmZJki500S9VQ6N9A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_SYto29SUgUamWkI0SK6jEA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_z5dcpbt0dECbfqWaQSAHWA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_ulujEwUlBE-e-GfNhQVDxA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_VNTGe6PXiUSOTsNqLTklWQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_c02-OgQ2jEOGpEYnSgm2XA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_jn81l2KzzkioG_n6D7Y7SA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_rx0lmQ0x-ka_ICeF8O4eFw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_MkbIQ9bQc0eX6Gc5LtLGHQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_C-Lb32e_Qk26nc_aMAPFCA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_FsR-R6AfnkSXmuWs510eUg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_21_2022_To_11_21_2022_us-gaap_AssetAcquisitionAxis_xoma_ObsevaIntellectualPropertyRightsMember_lo8MSWY_Dk2sar0rv1imYg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">xoma:ObsevaIntellectualPropertyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-21</xbrli:startDate><xbrli:endDate>2022-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_21_2022_To_11_21_2022_dk2CWh67HkeKPZD69Opgyw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-21</xbrli:startDate><xbrli:endDate>2022-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_5kIt1X7W_UGV93RZQkNN3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_CDvlhsZi9Uuy4KUBUsPHcA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_mma7TpqpuUuqcv9mj7e4bw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_3_2023_r6fXR4PsX0-CCWc7zpOJBg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-08-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000791908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_customer_DppB2cRPP0aciLos32fCZw"><xbrli:measure>xoma:customer</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_facility_xUSd_1xCIUaR1gnI0x8O9w"><xbrli:measure>xoma:facility</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_D_PCYEJUif70CZJGJolwi3Yw"><xbrli:measure>xoma:D</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_installment_8yYMWsdF_EOJHx1V1lAgKg"><xbrli:measure>xoma:installment</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_item_ZJDcTjbqbUC2tIGJY9M-pg"><xbrli:measure>xoma:item</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_product_mDp-u_9SnEGI1mu01OYOVA"><xbrli:measure>xoma:product</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_EUR_cFLXt4pWsUCag8uS-iVkYw"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_period_Oxx3Sge1w0O2HvNr__SG-A"><xbrli:measure>xoma:period</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_agreement_8WD-ZASWEUe8fofDOT9VGw"><xbrli:measure>xoma:agreement</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:7.2pt;min-height:20.15pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;text-indent:0pt;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_106c264e_e90a_4b18_899d_fefaa161b9e5"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:18pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Washington, D.C.&#160;20549</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:18pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" name="dei:DocumentType" id="Narr_Kc5wecrTWkyuEh5louYcIA"><b style="font-weight:bold;">10-Q</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:6pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"><a id="_b0e9037d_c346_461e_89f8_cfde342bd282"></a><a id="Tc_wdsVJ3MyjEa67d12BSWH5A_1_1"></a></div></div><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:95.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:12.25pt;"><td style="vertical-align:top;width:4%;margin:0pt;padding:0pt;"><div style="height:12.25pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 4pt 0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" name="dei:DocumentQuarterlyReport" id="Tc_FOyOapdRsUWdtbtVhk1LsA_1_0"><b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9746;</b></ix:nonNumeric></p></div></div></td><td style="vertical-align:top;width:95.99%;margin:0pt;padding:0pt;"><div style="height:12.25pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></div></div></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">For the quarterly period ended </b><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" name="dei:DocumentPeriodEndDate" id="Narr_Uz-8Qil1n0CP9dzozX_HKg"><b style="font-weight:bold;">June 30, 2023</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">OR</b></p><a id="_ecd3b331_91d2_4446_ab19_07ca508b12fd"></a><a id="Tc_Q0qponDAT0KGdUW4TPc7Hg_1_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:95.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:12.25pt;"><td style="vertical-align:top;width:4%;margin:0pt;padding:0pt;"><div style="height:12.25pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 4pt 0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" name="dei:DocumentTransitionReport" id="Tc_V9mb4Bv7k0KkITRo40qNZg_1_0"><b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9744;</b></ix:nonNumeric></p></div></div></td><td style="vertical-align:top;width:95.99%;margin:0pt;padding:0pt;"><div style="height:12.25pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></div></div></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">For the transition period from __________to__________</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Commission File No.&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" name="dei:EntityFileNumber" id="Narr_q6_xZRid50OQOn5HCtKM7g"><b style="font-weight:bold;">001-39801</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:24pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" name="dei:EntityRegistrantName" id="Narr_c_1KadjLv0uo04-DjCw5PA"><b style="font-weight:bold;">XOMA Corporation</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(Exact name of registrant as specified in its charter)</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:6pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"><a id="_15f1dce6_e2ae_4da9_a515_16aacd7b610f"></a><a id="Tc_9ql8QO61DUuOj9O5RpuXig_2_0"></a><a id="Tc_QB98IwEDeU2d7mDxTbzkiw_2_2"></a><a id="Tc_xdlYsvYEHEC9pGRnW-KjKA_3_0"></a><a id="Tc_Sk2DQcFgYkaXFcj6pOfXxw_3_2"></a><a id="Tc_XCctzrUSI0-YivkCI2VY3w_5_0"></a><a id="Tc_ttqL7cVqmEWL_7T7QKvrMw_6_0"></a><a id="Tc_YJwe1JjGQES1HFFHvHcEtA_7_0"></a><a id="Tc_8opGXqWIk02ycMUtUf7p8Q_7_2"></a></div></div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:48.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:6.85pt;"><td style="vertical-align:top;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" name="dei:EntityIncorporationStateCountryCode" id="Tc_eOMVIEvTIEabk_0Jr1NOhQ_1_0"><b style="font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" name="dei:EntityTaxIdentificationNumber" id="Tc_mnbhobmSbUuiqlqK3viJnQ_1_2"><b style="font-weight:bold;">52-2154066</b></ix:nonNumeric></p></td></tr><tr style="height:8.65pt;"><td style="vertical-align:top;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(State or other jurisdiction of</b></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(I.R.S. Employer</b></p></td></tr><tr style="height:3.3pt;"><td style="vertical-align:top;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">incorporation or organization)</b></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Identification No.)</b></p></td></tr><tr><td style="vertical-align:top;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;text-indent:0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;text-indent:0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:4pt;text-indent:0pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" name="dei:EntityAddressAddressLine1" id="Narr_IqhBfKiw1Ei5nLcApWnNvQ"><b style="font-weight:bold;">2200 Powell Street</b></ix:nonNumeric><b style="font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" name="dei:EntityAddressAddressLine2" id="Narr_M2f-8DpRBU2B-QMx7B2NXA"><b style="font-weight:bold;">Suite&#160;310</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"></td></tr><tr style="height:3.3pt;"><td style="vertical-align:top;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" name="dei:EntityAddressCityOrTown" id="Narr_9AO7inETmUK0mlIwjO5-FQ"><b style="font-weight:bold;">Emeryville</b></ix:nonNumeric><b style="font-weight:bold;">, </b><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" name="dei:EntityAddressStateOrProvince" id="Narr_344_jadOP0Ot2gocHbvMfQ"><b style="font-weight:bold;">California</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" name="dei:EntityAddressPostalZipCode" id="Tc_rdBzJX5Xa0elx-8_rZEBrA_6_2"><b style="font-weight:bold;">94608</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(Address of principal executive offices)</b></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(Zip Code)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Registrant&#8217;s telephone number, including area code: (</b><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" name="dei:CityAreaCode" id="Narr_lA4YAdsaZUKiaigVcrsMhw"><b style="font-weight:bold;">510</b></ix:nonNumeric><b style="font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" name="dei:LocalPhoneNumber" id="Narr_bGkQ3JSyfEK0AGUU5DkSWw"><b style="font-weight:bold;">204-7200</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</p><a id="_710ebf75_8d52_4e15_8ec6_fb992f85cba5"></a><a id="Tc_uSOL8iiQzU-gOuxhr9MrDw_1_0"></a><a id="Tc_Q0p5-NyuWEiJImxVf5veMw_1_1"></a><a id="Tc_gpoaEbfBAEenxgMQ2CwWjA_1_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:37.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:25.96%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:36.54%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:11.5pt;"><td style="vertical-align:top;width:37.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:11.5pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Title of each class:</b></p></div></div></td><td style="vertical-align:top;width:25.96%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:11.5pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Trading symbol(s):</b></p></div></div></td><td style="vertical-align:top;width:36.54%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:11.5pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Name of each exchange on which registered:</b></p></div></div></td></tr><tr style="height:11.5pt;"><td style="vertical-align:top;width:37.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:11.5pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 6pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_CDvlhsZi9Uuy4KUBUsPHcA" name="dei:Security12bTitle" id="Tc_7IZ-DSWeUUyeOGYIKzOB8w_2_0"><span style="font-size:9pt;">Common Stock, $0.0075 par value</span></ix:nonNumeric></p></div></div></td><td style="vertical-align:top;width:25.96%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:11.5pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 6pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_CDvlhsZi9Uuy4KUBUsPHcA" name="dei:TradingSymbol" id="Tc_PJAmnnlZ3EeDUk9X2UXUYA_2_1"><span style="font-size:9pt;">XOMA</span></ix:nonNumeric></p></div></div></td><td style="vertical-align:top;width:36.54%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:11.5pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 6pt 0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_CDvlhsZi9Uuy4KUBUsPHcA" name="dei:SecurityExchangeName" id="Tc_wTOsb6wqeUGaoq9fX41Gsg_2_2"><span style="font-size:9pt;">The Nasdaq Global Market </span></ix:nonNumeric></p></div></div></td></tr><tr style="height:23.05pt;"><td style="vertical-align:top;width:37.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:23.05pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 6pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_5kIt1X7W_UGV93RZQkNN3A" name="dei:Security12bTitle" id="Tc_oVvxkeqLzkK5hqYjnXgXvw_3_0"><span style="font-size:9pt;">8.625% Series A Cumulative Perpetual Preferred Stock, par value $0.05 </span></ix:nonNumeric></p></div></div></td><td style="vertical-align:middle;width:25.96%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:23.05pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 6pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_5kIt1X7W_UGV93RZQkNN3A" name="dei:TradingSymbol" id="Tc_olpGeYeqP0yvcDwiUwkR7g_3_1"><span style="font-size:9pt;">XOMAP</span></ix:nonNumeric></p></div></div></td><td style="vertical-align:middle;width:36.54%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:23.05pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 6pt 0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_5kIt1X7W_UGV93RZQkNN3A" name="dei:SecurityExchangeName" id="Tc_GVFnMUfgwUmGHWbayR2hMQ_3_2"><span style="font-size:9pt;">The Nasdaq Global Market</span></ix:nonNumeric></p></div></div></td></tr><tr style="height:32.05pt;"><td style="vertical-align:top;width:37.49%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:32.05pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 6pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_mma7TpqpuUuqcv9mj7e4bw" name="dei:Security12bTitle" id="Tc_gSCMX6NmeUKa4XOB-XzXoQ_4_0"><span style="font-size:9pt;">Depositary Shares (each representing 1/1000</span><sup style="font-size:6.75pt;line-height:100%;top:0pt;vertical-align:top;">th</sup><span style="font-size:9pt;"> interest in a share of 8.375% Series B Cumulative Perpetual Preferred Stock, par value $0.05)</span></ix:nonNumeric></p></div></div></td><td style="vertical-align:middle;width:25.96%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:32.05pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 6pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_mma7TpqpuUuqcv9mj7e4bw" name="dei:TradingSymbol" id="Tc_LPsUpwK7UkK1jZ-aasb34Q_4_1"><span style="font-size:9pt;">XOMAO</span></ix:nonNumeric></p></div></div></td><td style="vertical-align:middle;width:36.54%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:32.05pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 6pt 0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_mma7TpqpuUuqcv9mj7e4bw" name="dei:SecurityExchangeName" id="Tc_hqYKlUlmXk2UxEaAqOCqgA_4_2"><span style="font-size:9pt;">The Nasdaq Global Market</span></ix:nonNumeric></p></div></div></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:9pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. &#160; &#160;</span><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" name="dei:EntityCurrentReportingStatus" id="Narr_7p0kLGQDNEiAZiQ_E2-09A"><span style="font-size:9pt;">Yes</span></ix:nonNumeric><span style="font-size:9pt;">&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span><span style="font-size:9pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:9pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). &#160; </span><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" name="dei:EntityInteractiveDataCurrent" id="Narr_ejKl7Q2wIEi79yv1PKM-4g"><span style="font-size:9pt;">Yes</span></ix:nonNumeric><span style="font-size:9pt;">&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span><span style="font-size:9pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 6pt 0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</p><a id="_cb8630ca_c154_44da_8da1_f73b5a94b661"></a><a id="Tc_X5w-pS_eaEq4SwY-u2vagQ_1_0"></a><a id="Tc_XtQF7cNtREGIFECgkO8pLQ_1_1"></a><a id="Tc_LeH8Nghr7UyLe0H7D8gWxw_1_3"></a><a id="Tc_4x41QQVai0qyI1Sk5jo4Aw_1_4"></a><a id="Tc_dVrC4m5Ykk-HFEmxkYGH5g_2_1"></a><a id="Tc_3BFCfCVvnkOvTB7PaMK6-w_2_3"></a><a id="Tc_BYbI0nnF9EWLE9fnY-tAvg_3_3"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:20.69%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:50.09%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:20.88%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.69%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:0pt;margin:0pt 0pt 4pt 0pt;">Large accelerated filer</p></td><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt 0pt 4pt 0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:bottom;width:50.09%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:20.88%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:0pt;margin:0pt 0pt 4pt 0pt;">Accelerated filer</p></td><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt 0pt 4pt 0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.69%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 4pt 0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" name="dei:EntityFilerCategory" id="Tc_onaFXdfvLUq9loO7m474IQ_2_0"><span style="font-size:9pt;">Non-accelerated filer</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt 0pt 4pt 0pt;"><span style="font-family:'Segoe UI Symbol';">&#9746;</span></p></td><td style="vertical-align:bottom;width:50.09%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:20.88%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:0pt;margin:0pt 0pt 4pt 0pt;">Smaller reporting company</p></td><td style="vertical-align:bottom;width:4.16%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 4pt 0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" name="dei:EntitySmallBusiness" id="Tc_zw6amU5UFEGqcyNEZGjHSQ_2_4"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:20.69%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.16%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50.09%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.88%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:0pt;margin:0pt;">Emerging growth company</p></td><td style="vertical-align:middle;width:4.16%;margin:0pt;padding:0.75pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 4pt 0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" name="dei:EntityEmergingGrowthCompany" id="Tc_ln2jLcZE40GYBD9uJTIZlg_3_4"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 4pt 0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:9pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). &#160;&#160;Yes&#160;&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" name="dei:EntityShellCompany" id="Narr_1j_Rmwc3eUOncJ2G9dJimA"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric><span style="font-size:9pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-bottom:1pt;text-align:justify;text-indent:24.5pt;border-bottom:1px solid #000000;margin:0pt;">As of August 3, 2023, the registrant had <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_8_3_2023_r6fXR4PsX0-CCWc7zpOJBg" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_fibhZ2HWbk2Yw02UmupPnw">11,472,808</ix:nonFraction> shares of common stock, $0.0075 par value per share, outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:justify;text-indent:24.5pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_5da5fb15_f97e_4c99_979c_9d58d6fd2ed6"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">XOMA CORPORATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">FORM&#160;10-Q</p><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 6pt 0pt;">TABLE OF CONTENTS</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:80.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:9.75pt;"><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:80.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr style="height:9.75pt;"><td colspan="3" style="vertical-align:bottom;width:91.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#GLOSSARYOFTERMSANDABBREVIATIONS_784176"><span style="font-style:normal;font-weight:normal;">Glossary of Terms and Abbreviations</span></a></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">1</p></td></tr><tr style="height:9.75pt;"><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:80.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.4pt;"><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTIFINANCIALINFORMATION_600368"><b style="font-style:normal;font-weight:bold;">PART&#160;I</b></a></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:80.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTIFINANCIALINFORMATION_600368"><b style="font-style:normal;font-weight:bold;">FINANCIAL INFORMATION</b></a></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:7.2pt;"><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:80.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.4pt;"><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM1CONDENSEDCONSOLIDATEDFINANCIALSTATE"><span style="font-style:normal;font-weight:normal;">Item&#160;1.</span></a></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:80.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM1CONDENSEDCONSOLIDATEDFINANCIALSTATE"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Financial Statements</span></a></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">4</p></td></tr><tr style="height:6.6pt;"><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:80.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.4pt;"><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:80.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONDENSEDCONSOLIDATEDBALANCESHEETS_68199"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Balance Sheets as of June 30, 2023 (unaudited) and December&#160;31, 2022</span></a></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">4</p></td></tr><tr style="height:6pt;"><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:80.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:7.8pt;"><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:80.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12.25pt;text-indent:-12.25pt;margin:0pt;"><a href="#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATI"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Six Months Ended June 30, 2023 and 2022 (unaudited)</span></a></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">5</p></td></tr><tr style="height:6pt;"><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:80.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:6pt;"><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:80.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12.25pt;text-indent:-12.25pt;margin:0pt;"><a href="#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHO"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Statements of Stockholders&#8217; Equity for the Three and Six Months Ended June 30, 2023 and 2022 (unaudited)</span></a></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">6</p></td></tr><tr style="height:6pt;"><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:80.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:12pt;"><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:80.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:12.25pt;text-indent:-12.25pt;margin:0pt;"><a href="#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLO"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2023 and 2022 (unaudited)</span></a></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">7</p></td></tr><tr style="height:6.6pt;"><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:80.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:10.8pt;"><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:80.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#NOTESTOCONDENSEDCONSOLIDATEDFINANCIALSTA"><span style="font-style:normal;font-weight:normal;">Notes&#160;to Condensed Consolidated Financial Statements (unaudited)</span></a></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">8</p></td></tr><tr style="height:7.2pt;"><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:80.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:12pt;"><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM2MANAGEMENTSDISCUSSIONANDANALYSISOFF"><span style="font-style:normal;font-weight:normal;">Item&#160;2.</span></a></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:80.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM2MANAGEMENTSDISCUSSIONANDANALYSISOFF"><span style="font-style:normal;font-weight:normal;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">39</p></td></tr><tr style="height:7.8pt;"><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:80.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.4pt;"><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM3QUANTITATIVEANDQUALITATIVEDISCLOSUR"><span style="font-style:normal;font-weight:normal;">Item&#160;3.</span></a></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:80.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM3QUANTITATIVEANDQUALITATIVEDISCLOSUR"><span style="font-style:normal;font-weight:normal;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">46</p></td></tr><tr style="height:7.2pt;"><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:80.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:12pt;"><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM4CONTROLSANDPROCEDURES_732379"><span style="font-style:normal;font-weight:normal;">Item&#160;4.</span></a></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:80.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM4CONTROLSANDPROCEDURES_732379"><span style="font-style:normal;font-weight:normal;">Controls and Procedures</span></a></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">46</p></td></tr><tr style="height:6.6pt;"><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:80.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.4pt;"><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTIIOTHERINFORMATION_840286"><b style="font-style:normal;font-weight:bold;">PART&#160;II</b></a></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:80.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTIIOTHERINFORMATION_840286"><b style="font-style:normal;font-weight:bold;">OTHER INFORMATION</b></a></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">46</p></td></tr><tr style="height:6.6pt;"><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:80.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.4pt;"><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM1LEGALPROCEEDINGS_81705"><span style="font-style:normal;font-weight:normal;">Item&#160;1.</span></a></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:80.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM1LEGALPROCEEDINGS_81705"><span style="font-style:normal;font-weight:normal;">Legal Proceedings</span></a></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">46</p></td></tr><tr style="height:6.6pt;"><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:80.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:12pt;"><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM1ARISKFACTORS_925437"><span style="font-style:normal;font-weight:normal;">Item&#160;1A.</span></a></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:80.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM1ARISKFACTORS_925437"><span style="font-style:normal;font-weight:normal;">Risk Factors</span></a></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">46</p></td></tr><tr style="height:6.6pt;"><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:80.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:10.8pt;"><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM2UNREGISTEREDSALESOFEQUITYSECURITIES"><span style="font-style:normal;font-weight:normal;">Item&#160;2.</span></a></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:80.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM2UNREGISTEREDSALESOFEQUITYSECURITIES"><span style="font-style:normal;font-weight:normal;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">77</p></td></tr><tr style="height:4.8pt;"><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:80.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:10.8pt;"><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM3DEFAULTSUPONSENIORSECURITIES_154961"><span style="font-style:normal;font-weight:normal;">Item&#160;3.</span></a></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:80.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM3DEFAULTSUPONSENIORSECURITIES_154961"><span style="font-style:normal;font-weight:normal;">Defaults Upon Senior Securities</span></a></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">77</p></td></tr><tr style="height:7.2pt;"><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:80.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:12pt;"><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM4MINESAFETYDISCLOSURES_257142"><span style="font-style:normal;font-weight:normal;">Item&#160;4.</span></a></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:80.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM4MINESAFETYDISCLOSURES_257142"><span style="font-style:normal;font-weight:normal;">Mine Safety Disclosure</span></a></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">77</p></td></tr><tr style="height:6.6pt;"><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:80.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:10.2pt;"><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM5OTHERINFORMATION_588036"><span style="font-style:normal;font-weight:normal;">Item&#160;5.</span></a></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:80.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM5OTHERINFORMATION_588036"><span style="font-style:normal;font-weight:normal;">Other Information</span></a></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">77</p></td></tr><tr style="height:6pt;"><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:80.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:12pt;"><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM6EXHIBITS_976152"><span style="font-style:normal;font-weight:normal;">Item&#160;6.</span></a></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:80.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM6EXHIBITS_976152"><span style="font-style:normal;font-weight:normal;">Exhibits</span></a></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">78</p></td></tr><tr style="height:6pt;"><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:80.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:10.8pt;"><td colspan="3" style="vertical-align:bottom;width:91.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#SIGNATURES_103825"><span style="font-style:normal;font-weight:normal;">Signatures</span></a></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">80</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_bd81978e_917a_4fee_8634_ecbac5d134da"></a><a id="Glossary"></a><a id="GLOSSARYOFTERMSANDABBREVIATIONS_784176"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">GLOSSARY OF TERMS AND ABBREVIATIONS</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:71.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:25.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Abbreviations</b></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:71.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Definition</b></p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">2010 Plan</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">the Company&#39;s 2010 Long Term Incentive and Stock Award Plan, as amended</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">2018 Common Stock ATM Agreement</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">At The Market Issuance Sales Agreement with HCW dated December 18, 2018</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">2021 Series B Preferred Stock ATM Agreement</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">At The Market Issuance Sales Agreement with B. Riley dated August 5, 2021</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">&#8216;40 Act</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Investment Company Act of 1940</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">AAA</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Assignment and Assumption Agreement</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">ACA</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">The Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Affimed</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Affimed N.V.</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Affitech</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Affitech Research AS</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Affitech CPPA</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">the Company&#39;s Commercial Payment Purchase Agreement with Affitech dated October 6, 2021</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Agenus</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Agenus, Inc. and certain affiliates</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Agenus RPA</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">the Company&#39;s Royalty Purchase Agreement with Agenus dated September 20, 2018</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Anti-TGF&#946; Antibody License Agreement</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">the Company&#39;s License Agreement with Novartis dated September 30, 2015</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">April 2022 Letter Agreement</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">the Letter Agreement to Officer Employment Agreement dated August 7, 2017, between XOMA Corporation and Thomas Burns dated April 1, 2022</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Aptevo</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Aptevo Therapeutics Inc.</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Aptevo CPPA</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">the Company&#8217;s Payment Interest Purchase Agreement with Aptevo dated March 29, 2023, referred to herein as &#8220;Aptevo Commercial Payment Purchase Agreement&#8221; or &#8220;Aptevo CPPA&#8221;</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Aronora</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Aronora, Inc.</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Aronora RPA</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">the Company&#39;s Royalty Purchase Agreement with Aronora dated April 7, 2019</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">AstraZeneca</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">AstraZeneca plc</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">ASC</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Accounting Standards Codification</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">ASC 326</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ASC Topic 326, Financial Instruments &#8211; Credit Losses </p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">ASC 450</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">ASC Topic 450, Contingencies</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">ASC 606</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">ASC Topic 606, Revenue from Contracts with Customers</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">ASC 730</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">ASC Topic 730, Research and Development</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">ASC 805</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">ASC Topic 805, Business Combinations</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">ASC 815</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">ASC Topic 815, Derivatives and Hedging</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">ASC 842</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">ASC Topic 842, Leases</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">ASU</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Accounting Standards Update</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Bayer</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Bayer Pharma AG</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Bioasis</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Bioasis Technologies, Inc. and certain affiliates</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Bioasis RPA</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">the Company&#39;s Royalty Purchase Agreement with Bioasis dated February 25, 2019</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">BLA</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Biologic License Application</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Black-Scholes Model</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Black-Scholes Option Pricing Model</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">B. Riley</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">B. Riley Securities, Inc.</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">BVF</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Biotechnology Value Fund, L.P.</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CCPA</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">California Consumer Privacy Act of 2018, collectively the Act and its regulations</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CARES</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Coronavirus Aid, Relief, and Economic Security</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">cGMP</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">current Good Manufacturing Practice</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chiesi</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chiesi Farmaceutici S.p.A.</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Chiron</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Chiron Corporation</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Chiron Collaboration Agreement</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">the Company&#39;s Collaboration Agreement with Chiron dated February 27, 2004, as amended in May 2005, July 2008 and September 2015</p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Company</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">XOMA Corporation, including subsidiaries</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">CPPA</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Commercial Payment Purchase Agreement</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">CPRA</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">California Privacy Rights Act</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">EC</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">European Commission</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">EMA</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">European Medicines Agency</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">ESPP</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">2015 Employee Stock Purchase Plan, as amended</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">EU</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">European Union</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">FCPA</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">U.S. Foreign Corrupt Practices Act of 1977, as amended</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">FDA</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Food and Drug Administration</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">FDIC</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Federal Deposit Insurance Corporation</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">GAAP</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Generally accepted accounting principles</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">G&amp;A</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">GDPR</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General Data Protection Regulation</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Gevokizumab License Agreement</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">the Company&#39;s License Agreement with Novartis dated August 24, 2017</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">HCRP</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Healthcare Royalty Partners II, L.P.</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">HCW</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">H.C. Wainwright &amp; Co., LLC</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">HIPAA</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Federal Health Insurance Portability and Accountability Act of 1996</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ICE&#174;</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Innate cell engager</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ImmunityBio</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">ImmunityBio, Inc. (formerly NantCell, Inc.)</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ImmunityBio License Agreement</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Out-license agreement to ImmunityBio from LadRx dated July 27, 2017, related to the development and commercialization of Aldoxorubicin, as amended on September 27, 2018 </p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">IP</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Intellectual Property</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Janssen</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Janssen Biotech, Inc.</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Kuros</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Kuros Biosciences AG, Kuros US LLC and Kuros Royalty Fund (US) LLC, collectively</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Kuros RPA</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">the Company&#39;s Royalty Purchase Agreement with Kuros dated July 14, 2021</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">LadRx</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">LadRx Corporation (formerly CytRx Corporation)</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">LadRx Agreements </p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">LadRx AAA and LadRx RPA</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">LadRx AAA</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">the Company&#8217;s Assignment and Assumption Agreement with LadRx dated June 21, 2023</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">LadRx RPA</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">the Company&#8217;s Royalty Purchase Agreement with LadRx dated June 21, 2023</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Medexus</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Medexus Pharmaceuticals, Inc.</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Merck</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Merck Sharp &amp; Dohme Corp</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Merck KGaA</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Ares Trading SA </p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Merck KGaA License Agreement</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">In-license agreement from Merck KGaA to ObsEva related to ebopiprant dated June 10, 2015 and subsequently amended on July 8, 2016 (assumed by the Company as part of the ObsEva IP Acquisition Agreement)</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">NDA</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">New Drug Application</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">NIH</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">National Institutes of Health</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">NOL</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">net operating loss</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Novartis</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Novartis Pharma AG, Novartis International Pharmaceutical Ltd., Novartis Institutes for Biomedical Research, Inc. and/or Novartis Vaccines and Diagnostics, Inc.</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">November 2022 Letter Agreement</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">November 1, 2022 amendment to the April 2022 Letter Agreement</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">ObsEva</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">ObsEva SA</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">ObsEva IP Acquisition Agreement</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Company&#39;s IP Acquisition Agreement with ObsEva dated November 21, 2022</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Ology Bioservices </p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Ology Bioservices Inc. (formerly Nanotherapeutics Inc., now a wholly owned subsidiary of National Resilience, Inc.)</p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Organon</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Organon International GmbH</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Organon License Agreement</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Out-license agreement to Organon from ObsEva dated July 26, 2021, related to the development and commercialization of ebopiprant (assumed by the Company as part of the ObsEva IP Acquisition Agreement)</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Palo</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Palobiofarma, S.L.</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Palo RPA</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">the Company&#39;s Royalty Purchase Agreement with Palo dated September 26, 2019</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Pfizer</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Pfizer, Inc.</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">PSU</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Performance stock unit</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">R&amp;D</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Research and development</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Regeneron</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Regeneron Pharmaceuticals, Inc.</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Amended Retention Plan</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">October 25, 2022 amendment to the Retention Plan</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Retention Plan</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Retention and Severance Plan dated March 31, 2022</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Rezolute</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Rezolute, Inc., formerly Antria Bio, Inc.</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Rezolute License Agreement</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">the Company&#39;s License Agreement with Rezolute dated December 6, 2017, as amended in March 2018, January 2019 and March 2020</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">RPA</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Royalty Purchase Agreement</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Roche</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">F. Hoffmann-La Roche AG</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">SEC</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">U.S. Securities and Exchange Commission</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Second Bioasis RPA</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">the Company&#39;s Royalty Purchase Agreement with Bioasis dated November 2, 2020</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Series A Preferred Stock</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">the 8.625% Series A cumulative, perpetual preferred stock issued in December 2020</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Series B Preferred Stock</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">the 8.375% Series B cumulative, perpetual preferred stock issued in April 2021</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Series A and Series B Preferred Stock</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Series A Preferred Stock and Series B Preferred Stock, collectively<span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Series B Depositary Shares</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">the depositary shares, each representing 1/1000th interest in a share of Series B Preferred Stock</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Sonnet</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Sonnet BioTherapeutics, Inc., formerly Oncobiologics, Inc.</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Sonnet Collaboration Agreement</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">the Company&#39;s Collaboration Agreement with Sonnet dated July 23, 2012, as amended in May 2019</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">SOX</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Sarbanes-Oxley Act of 2002</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">SVB</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Silicon Valley Bank</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Takeda</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Takeda Pharmaceutical Company Limited</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Takeda Collaboration Agreement</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">the Company&#39;s Collaboration Agreement with Takeda dated November 1, 2006, as amended in February 2007 and February 2009</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">TGF&#946;</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">transforming growth factor beta</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">VABYSMO&#174;</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">faricimab-svoa</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Viracta</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Viracta Therapeutics, Inc.</p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Viracta RPA</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">the Company&#39;s Royalty Purchase Agreement with Viracta dated March 22, 2021</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">XOMA</p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">XOMA Corporation, a Delaware corporation, including subsidiaries </p></td></tr><tr><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Zevra</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Zevra Therapeutics, Inc. (formerly KemPharm Denmark A/S)</p></td></tr><tr><td style="vertical-align:top;width:25.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;">Zevra APA </p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:71.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Asset Purchase Agreement dated May 13, 2011 between LadRx and Orphazyme ApS, and assigned to Zevra as of June 1, 2022, related to the sale of arimoclomol from LadRx to Zevra (assumed by the Company as part of LadRx AAA)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_fcd9853b_cdb4_4140_a5c4_41d3b3ae0b4d"></a><a id="PARTIFINANCIALINFORMATION_600368"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;">PART&#160;I&#160;-&#160;FINANCIAL INFORMATION</p><a id="ITEM1CONDENSEDCONSOLIDATEDFINANCIALSTATE"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;">ITEM&#160;1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">XOMA CORPORATION</p><a id="CONDENSEDCONSOLIDATEDBALANCESHEETS_68199"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 4pt 0pt;">CONDENSED CONSOLIDATED BALANCE SHEETS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">(in thousands, except share and per share amounts)</b></p><a id="_fbd15a45_a8be_4563_8de3_e920eb5d6c94"></a><a id="Tc_YbNsZsdLekO5qfIyQ0g4zw_1_2"></a><a id="Tc_Y73R8AWarEeDyTLve-NsmQ_1_5"></a><a id="Tc_TRdGcVlyckOZFJPcdrFehw_2_2"></a><a id="Tc_rBrpB3BEKE6Wwq02dLaedg_2_5"></a><a id="Tc_vG0XF4XqskKTE7EYFOPdlg_3_2"></a><a id="Tc_2PUbQPIoiEql4GgBQQtzYw_3_5"></a><a id="Tc_hANWHK2Wr0GfHVUqnmadDA_4_0"></a><a id="Tc_SPMiZPcl2ESE1OdIFLwazA_5_0"></a><a id="Tc_XHEfitv5tEavV8TUYFm8SQ_6_0"></a><a id="Tc_QiUDmPTjlEigpLVrhrNRdw_6_2"></a><a id="Tc_h6GpJ9jahkK_0M723dZX8w_6_5"></a><a id="Tc_AnHnC4jgcUu9tHMuBqSJMA_7_0"></a><a id="Tc_Mbw-qkR8kk6Ob6WuI-Ps_g_8_0"></a><a id="Tc_z4uBskuCSEiTzNPYNc2s1A_9_0"></a><a id="Tc_BdGszGgtGEercqgMQJOeRQ_10_0"></a><a id="Tc_w8IG3KiD2kavXfqSC0ERgg_11_0"></a><a id="Tc_uMpPMDscRESEqys9W4SAYw_12_0"></a><a id="Tc_OKt8qunaSES5Qe01RPXPPQ_13_0"></a><a id="Tc_5BWAVvQsGUm6qd_1LxRIUQ_14_0"></a><a id="Tc_vkHY86yMSk69a6RvwZnHww_15_0"></a><a id="Tc_P8-Mg3-5F0C5QyuwgTJijA_16_0"></a><a id="Tc_wNm2fBfo5kiOaTtFWF4Kzg_17_0"></a><a id="Tc_tKUdU28ZrkmJILEu_4B8nA_17_2"></a><a id="Tc_OJFu9sZNmEOY2V8sFZJ9Tg_17_5"></a><a id="Tc_DI-IYN6Yj0iHXRzFOVCtoQ_19_0"></a><a id="Tc_UldcIuYookOajqM_sCLj5Q_20_0"></a><a id="Tc_Jvzq7uQ5dEemOcv29KydQg_21_0"></a><a id="Tc_R0rOoXS2cUOZQ45YZiPcMQ_21_2"></a><a id="Tc_PXKbMpu5EUWit9_ifQ6yBQ_21_5"></a><a id="Tc_uXoEiLwBRkqKPfHwWNK5BQ_22_0"></a><a id="Tc_kpqCxMlxEkSVDtwnkglg2Q_23_0"></a><a id="Tc_xvxQpFO26EK0G7x0NcQ9gA_24_0"></a><a id="Tc_KAYFstp9CEqAWFHIlJPzng_25_0"></a><a id="Tc_zEWwJPQXeEahkW9Nt79Ztg_26_0"></a><a id="Tc_s3Yo7B1U_EmRQKZDwDu75g_27_0"></a><a id="Tc_-2vSJOWW9keee6zf3LqzuQ_28_0"></a><a id="Tc_DK1QM4JesUqsqp8s7NQeFA_29_0"></a><a id="Tc_YTz3ngDVA0-KOvQWQG5uAw_31_0"></a><a id="Tc_7CoCPjsB1USuQLQfwzGMWg_33_0"></a><a id="Tc_gy1zvxPEpkKNAaM6NG2e3g_34_0"></a><a id="Tc_9GmQg4d3RUGNQbVrFlNTig_35_0"></a><a id="Tc_dQJY1NJY0kCNmsjHoGkN9Q_36_0"></a><a id="Tc_eyyy8fOEikyuBSpzqC_gkw_37_0"></a><a id="Tc_OP2N49xm2EumqLh-qw0fzA_38_0"></a><a id="Tc_teUhU8npTUC6CxDju-T04g_39_0"></a><a id="Tc_ASqIn1ifxU-cuAaLO_nKvQ_40_0"></a><a id="Tc_UN99MFUFPkWpC1582Js75Q_41_0"></a><a id="Tc_3YxmZIaUKUyGQuMXsl1cnQ_42_0"></a><a id="Tc_793U1JhoBkmiNIqRKKkH7w_42_2"></a><a id="Tc_jTc5Qgv5WEOfMz0KcaeHJQ_42_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(unaudited)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Note 1)</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">ASSETS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">Current assets:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7.5pt;">Cash and cash equivalents </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_mnBMrhlOH0CxBSRn0Q0lsw_6_3">31,445</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_7bisubx6-EKEF45xSo-ggA_6_6">57,826</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7.5pt;">Short-term equity securities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="3" id="Tc_wrMFB36xlUicnW_latYCaQ_7_3">320</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNi" scale="3" id="Tc_BBl1Fkqh9UK3ClWOGAOgOg_7_6">335</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7.5pt;">Trade and other receivables, net</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" scale="3" id="Tc_YhClj17fDk2d2jlH3OI5aQ_8_3">901</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" scale="3" id="Tc_tPAnJc0xQka95V09NA4u-A_8_6">1</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7.5pt;">Short-term royalty and commercial payment receivables</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ" decimals="-3" format="ixt:numdotdecimal" name="xoma:RightsReceivableCurrent" scale="3" id="Tc_6UvBAC3Cl0Sl2hqm_5UVlA_9_3">4,958</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg" decimals="-3" format="ixt:numdotdecimal" name="xoma:RightsReceivableCurrent" scale="3" id="Tc_amoMYgtYbkiIRk21mIDGNg_9_6">2,366</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7.5pt;">Prepaid expenses and other current assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_QH8YaiPbwE6Hg1oSyAas8A_10_3">799</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_k6w1iyE7wE6QLC4MMwpNJQ_10_6">725</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 12pt;"><span style="font-size:7.5pt;">Total current assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_qEE_a4lEUUShgnIfr4oVgw_11_3">38,423</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_p7-mZTCYrEWSPxv-GK4XnA_11_6">61,253</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7.5pt;">Property and equipment, net</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_99KZ4LWb50-6joCVyWHknA_12_3">5</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_G5AKC6vlSk6IYEcen--e7Q_12_6">7</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7.5pt;">Operating lease right-of-use assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_xVFmYnmDW0Sb75gAkXRQ_w_13_3">17</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_zbOfDpifSkiQ2iYn9VMNgQ_13_6">29</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7.5pt;">Long-term royalty and commercial payment receivables</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ" decimals="-3" format="ixt:numdotdecimal" name="xoma:LongTermRightsReceivableNonCurrent" scale="3" id="Tc_hn3LeFMK80a_9Wk5bKCtiA_14_3">72,232</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg" decimals="-3" format="ixt:numdotdecimal" name="xoma:LongTermRightsReceivableNonCurrent" scale="3" id="Tc_ccietED86E-c_APFZxNKLw_14_6">63,683</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7.5pt;">Intangible assets, net </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="Tc_H14ohIkH-kiMw5UgmeTlEw_15_3">14,701</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="Tc_Xx3kPRQ3-Eyym4Xez6Wt-A_15_6">15,150</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7.5pt;">Other assets - long term</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_J_1s3xvCQ0Ka_7fGqi7Yww_16_3">283</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_0OF1W-R4j0u3IoSmnszoBQ_16_6">260</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 12pt;"><span style="font-size:7.5pt;">Total assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_KHTpH93TZ0eYrsAbzz2zqQ_17_3">125,661</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_TnuZeym5Dk-H0FqLbupvcQ_17_6">140,382</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">Current liabilities:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7.5pt;">Accounts payable</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_fBySUXT1lkq6uKYNGY_xNg_21_3">740</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_e79ff7E1cEa7lKb384oHfA_21_6">524</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7.5pt;">Accrued and other liabilities </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ" decimals="-3" format="ixt:numdotdecimal" name="xoma:AccruedAndOtherLiabilitiesCurrent" scale="3" id="Tc_RKrp0pcFSkuZpziI63yY0Q_22_3">1,933</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg" decimals="-3" format="ixt:numdotdecimal" name="xoma:AccruedAndOtherLiabilitiesCurrent" scale="3" id="Tc__NbyUrSX0E6ccRp8ECqJLw_22_6">2,918</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7.5pt;">Contingent consideration under RPAs, AAAs and CPPAs </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ" decimals="-3" format="ixt:numdotdecimal" name="xoma:ContingentConsiderationUnderPurchaseAgreements" scale="3" id="Tc_0KikkdIKOUSOCFOPHbXZdw_23_3">1,000</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg" decimals="-3" format="ixt:numdotdecimal" name="xoma:ContingentConsiderationUnderPurchaseAgreements" scale="3" id="Tc_FzVmzvXwhku5MZSVJNxE5Q_23_6">75</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7.5pt;">Operating lease liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc__a29X3I0lUaZqBqJACrclQ_24_3">17</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_9ut3iumdlE2my3W8uk1Byw_24_6">34</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7.5pt;">Unearned revenue recognized under units-of-revenue method</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeCurrent" scale="3" id="Tc_cxAgVluMpUiDDLp5bJZ0Uw_25_3">2,029</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeCurrent" scale="3" id="Tc_Rahx76xc2EmUU-uA0NPb-g_25_6">1,899</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7.5pt;">Preferred stock dividend accrual </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ" decimals="-3" format="ixt:numdotdecimal" name="xoma:AccruedPreferredStockDividendCurrent" scale="3" id="Tc_EZCcAmv380ujzqitvLlosQ_26_3">1,368</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg" decimals="-3" format="ixt:numdotdecimal" name="xoma:AccruedPreferredStockDividendCurrent" scale="3" id="Tc_MICFAAf1n0e52qWInxfeVQ_26_6">1,368</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 12pt;"><span style="font-size:7.5pt;">Total current liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_oV4gp5YauUGZzV8dFyhapw_27_3">7,087</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_dutY5mp_bE-05iLXKgjI-A_27_6">6,818</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7.5pt;">Unearned revenue recognized under units-of-revenue method &#8211; long-term</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeNoncurrent" scale="3" id="Tc_Zj9mL5rWUUyZclGWwewfvA_28_3">8,450</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeNoncurrent" scale="3" id="Tc_1Vke-2w2akuuxEna425xkA_28_6">9,550</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 12pt;"><span style="font-size:7.5pt;">Total liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_fy66ePV-W0aztdngv2ZnwA_29_3">15,537</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_EyL5dcYx-0-svkx32KgD0g_29_6">16,368</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">Commitments and Contingencies (Note 9)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">Stockholders&#8217; equity:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7.5pt;">Preferred Stock, </span><span style="font-size:7.5pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg" contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_BtWhmKAXyECzt6havANjaA"><ix:nonFraction unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg" contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_vlm8cwM6FUmWGJtNHCufXg">0.05</ix:nonFraction></ix:nonFraction></span><span style="font-size:7.5pt;"> par value, </span><span style="font-size:7.5pt;"><ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_IOayXYMqZEqEXOXashOQLQ"><ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_G-Y6L21A2E-gaSWXPsBBMg">1,000,000</ix:nonFraction></ix:nonFraction></span><span style="font-size:7.5pt;"> shares authorized:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 12pt;"><span style="font-size:7.5pt;"><ix:nonFraction unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_5kIt1X7W_UGV93RZQkNN3A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendRatePercentage" scale="-2" id="Narr_k31wrLmgGkuiHRQToQ7wfQ"><ix:nonFraction unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_xCuxHxFsWUK7HkZ9m3D7Zg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendRatePercentage" scale="-2" id="Narr_j1QXeZ27Bki1E1X3h3ax0g">8.625</ix:nonFraction></ix:nonFraction>%</span><span style="font-size:7.5pt;"> Series A cumulative, perpetual preferred stock, </span><span style="font-size:7.5pt;"><ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_HnMB9b7CRUKpmLvME2vUuQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_cbOJ1ZtZAkS0dSBMISdTZA"><ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_ORljYJEjFUKKL0etVMNkrA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_B6MQVLttZ0uopFYadd3l7Q"><ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_HnMB9b7CRUKpmLvME2vUuQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_VE-44KbL1EWB4mSn9ARY_Q"><ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_ORljYJEjFUKKL0etVMNkrA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_PqWkPw7k7ke7e1cGphnK0g">984,000</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="font-size:7.5pt;"> shares issued and outstanding at June&#160;30,&#160;2023 and December 31, 2022</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_HnMB9b7CRUKpmLvME2vUuQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockValue" scale="3" id="Tc_FK8HfYnYrku8JQbt13UwKQ_35_3">49</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_ORljYJEjFUKKL0etVMNkrA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockValue" scale="3" id="Tc_4YSYYYZk80aXLbJ9w20l3w_35_6">49</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 12pt;"><span style="font-size:7.5pt;"><ix:nonFraction unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_mZzBVYXOQEiwSAFnA-OODw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendRatePercentage" scale="-2" id="Narr_pDPq4QE3y0eZ81WUQOnjwg"><ix:nonFraction unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_vzagK5EjmEqHa32z1YO0qQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendRatePercentage" scale="-2" id="Narr_juyuxGEQ_k-Ia3ZEjgUUng">8.375</ix:nonFraction></ix:nonFraction>%</span><span style="font-size:7.5pt;"> Series B cumulative, perpetual preferred stock, </span><span style="font-size:7.5pt;"><ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_B7d29QvlcEe4N-_OPoM0aw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_BGJwp-lyGUSrbokhHzJ0HA"><ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_GAngHNpHWkmY3_zgBQQUhg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_uEbvI7H1806S0PDvLKPxvQ"><ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_B7d29QvlcEe4N-_OPoM0aw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_4X0tbkbsDUONUBGPPNHAGA"><ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_GAngHNpHWkmY3_zgBQQUhg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_dvPT1vjIdkCnS6zrdXd_sw">1,600</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="font-size:7.5pt;"> shares issued and outstanding at June&#160;30,&#160;2023 and December 31, 2022</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_rG8qdelPsE2MZDrhfrBOUw;"><span style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_hwGUEJwvdUSJVpS6POw7GQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 12pt;"><span style="font-size:7.5pt;">Convertible preferred stock, </span><span style="font-size:7.5pt;"><ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_6973Ln0mrUSWVWSvhpZzAw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_woxZfLpr2kqrJoQHtHK7yQ"><ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_brrjfnRro02jXTsYqcCsLA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_QmROh7mnJUedeyseEj0wjg"><ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_6973Ln0mrUSWVWSvhpZzAw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_2gjH48B6iUq451f24MXHUw"><ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_brrjfnRro02jXTsYqcCsLA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_NTk0SkEcwk6XDI5eAz0fIQ">5,003</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="font-size:7.5pt;"> shares issued and outstanding at June&#160;30,&#160;2023 and December 31, 2022</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_IsaLZDRs0E2--Y-WLDu3kw;"><span style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_yk9AWBRJokWIwrr3poqSwA;"><span style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7.5pt;">Common stock, </span><span style="font-size:7.5pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg" contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_3PVWXd1C4UGyzAy-6dB61A"><ix:nonFraction unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg" contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_bCafT5MtyEi9lSV1HK97vA">0.0075</ix:nonFraction></ix:nonFraction></span><span style="font-size:7.5pt;"> par value, </span><span style="font-size:7.5pt;"><ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_HIgzcMH3Mkal3ueGN8htQQ"><ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_37l-LAElp0O6JxFfMWpIpA">277,333,332</ix:nonFraction></ix:nonFraction></span><span style="font-size:7.5pt;"> shares authorized, </span><span style="font-size:7.5pt;"><ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_SBlSaaI1tEu8bxT6fctDvA"><ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_rOKbC7NkcEOG4Y0dWp-j4w">11,472,808</ix:nonFraction></ix:nonFraction></span><span style="font-size:7.5pt;"> and </span><span style="font-size:7.5pt;"><ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_pQRohTiIjUuc6EWpCnRlxg"><ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_KqapPWwJzEGk-M1zYZVB2A">11,454,025</ix:nonFraction></ix:nonFraction></span><span style="font-size:7.5pt;"> shares issued and outstanding at June&#160;30,&#160;2023 and December 31, 2022, respectively</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_HXrpsloYTkqPgfj-KKKWoQ_38_3">86</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_98E4XZ9DAEi7b7JG_vm0pg_38_6">86</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7.5pt;">Additional paid-in capital</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_GWc_9_2OEU2vu8fxKdx5bA_39_3">1,307,594</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_I395dD7isUaL9fOEEQlvmw_39_6">1,306,271</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7.5pt;">Accumulated deficit</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_8JbMg0JBO0OmSiwZP2j_Mw_40_3">1,197,605</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_JrEy0dGCvUaNUlSRaetCmA_40_6">1,182,392</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 12pt;"><span style="font-size:7.5pt;">Total stockholders&#8217; equity</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_f0EfPPjgDEWVUxes6lTrfA_41_3">110,124</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_dm90CQ3U30iT-OIsRUpymw_41_6">124,014</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:middle;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 18pt;"><span style="font-size:7.5pt;">Total liabilities and stockholders&#8217; equity</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_v5s9VNgOoEOZHdfXY6kcnA_42_3">125,661</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">$</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_Qhekhl8UZEG2sf4x3U-NaA_42_6">140,382</ix:nonFraction></span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-style:italic;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The accompanying notes are an integral part of these condensed consolidated financial statements.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 3pt 0pt;"><i style="font-style:italic;">(Note&#160;1) The condensed consolidated balance sheet as of December&#160;31, 2022, has been derived from the audited consolidated financial statements as of that date included in the Company&#8217;s Annual Report on Form&#160;10-K for the&#160;year ended December&#160;31, 2022.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 3pt 0pt;"><span style="font-style:italic;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_6d3dd36a_9370_4cae_9c78_7f1ece9430c6"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">XOMA CORPORATION</p><a id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATI"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 4pt 0pt;">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 4pt 0pt;">(unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(in thousands, except per share amounts)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_67b9f766_07b6_49c2_b402_3556609fb72b"></a><a id="_8a79dbb6_9c17_4dbd_ab6d_1703915d0735"></a><a id="Tc_W-FL7lwPgUGkSAJEk3TiIA_1_2"></a><a id="Tc_6b208xyELEyYvd9AsmnBQA_1_8"></a><a id="Tc_KeCMkP2FS0eHgDvn26Ebyw_2_2"></a><a id="Tc_4p_dvjUr90OjtjZ4YvV_zg_2_8"></a><a id="Tc_HcGdDKffMEurd342Rk1Aeg_3_2"></a><a id="Tc_Box4S4pYTUKOBXwaFP3Xxg_3_5"></a><a id="Tc_DMrpgosrqkm8Kb_PzxTAWw_3_8"></a><a id="Tc_7qgb7Ar_s0mVkO3jNWkYuw_3_11"></a><a id="Tc_rVR4ZlOHQUKbKGWj5cXFnA_4_0"></a><a id="Tc_vfiQ7aQE7k6rV0QI4gHOGQ_5_0"></a><a id="Tc_8iKu9B8mYUux5t64-2o1ZA_5_2"></a><a id="Tc_sksOscdnnUuBpYkKFvxZJg_5_5"></a><a id="Tc_inhr0A3TtUW5q14Vgt9r1Q_5_8"></a><a id="Tc_jtBelk6OCUWbcX-LsXOOLg_5_11"></a><a id="Tc_l55nr4KZYkSDPjH5qBzkCQ_6_0"></a><a id="Tc_7fPEx_Sd0EaN5JAc9Yeanw_7_0"></a><a id="Tc_g2P-S4gbRUmArrGbjxfK7Q_9_0"></a><a id="Tc_Dz3iavpYU0CP2pQVzSeEmw_10_0"></a><a id="Tc_iWVdrLU9y0yDy-vViAlpSg_11_0"></a><a id="Tc_QjVCg70Z5kKycosylYLYbw_12_0"></a><a id="Tc_dY6jeK5X0U26Ju0qNtKzzQ_12_6"></a><a id="Tc_wibLOTn_I0SBTFZp1vRjSQ_12_12"></a><a id="Tc_RevVzNAQEUWuhZD0ic9EsA_13_0"></a><a id="Tc_xUjNsq3ilE6syQL6a_8fgw_13_3"></a><a id="Tc_8YLqd-BMC0aJpbxIRr69Pw_13_6"></a><a id="Tc_f_tbE8FkREuy1uM9XGAZqw_13_12"></a><a id="Tc_05sldWh_KEaHuds97SecVQ_14_0"></a><a id="Tc_jGSryYJkqEqhJE7ViBjvfQ_14_6"></a><a id="Tc_807_7gbsyUu_ngcp2ReRgg_14_12"></a><a id="Tc_DFdJbMujpU2nL2RNdYB1uA_15_0"></a><a id="Tc_BDfE_XpPKkyWZ4EuXbasqw_17_0"></a><a id="Tc_kVUgH1KjjE6wOlZHQPUCZg_18_0"></a><a id="Tc_q9hWCTva1kKOIRO78Qu2og_19_0"></a><a id="Tc_W3npHY6PX0CwB0OFEAVaww_19_2"></a><a id="Tc_QFTeINjx1UC5eqmvxWH6ag_19_5"></a><a id="Tc_hV62rXmM3keSe4ZpeZ5VEA_19_8"></a><a id="Tc_1-Z8aSIqRkeNpDhc9uENAA_19_11"></a><a id="Tc_mpMfjs7sSU2WB5dWmWZQaw_20_0"></a><a id="Tc_WVvsk73CBEenQ7j631xYTw_21_0"></a><a id="Tc_BkIAm_DE1Ea7TT4CkCcfVg_21_2"></a><a id="Tc_7g_BeeWNfEyFzYyYIpPzPw_21_5"></a><a id="Tc_NBz-iYgfJEC4xwyVsoH8kw_21_8"></a><a id="Tc_9MBPDmrwgUmfq9ei3ND7FA_21_11"></a><a id="Tc_EaHDNEt7MEOnufL_zPLWIQ_22_0"></a><a id="Tc_yaxnKmZwsUK5G8DsKggHpg_22_2"></a><a id="Tc_PGyFsw3QZ02RT-hjyeqjHg_22_5"></a><a id="Tc_xQR1oRrOIk2ODbUlhE_8bA_22_8"></a><a id="Tc_DZtjo4lEMUmT8jz1bFb1QQ_22_11"></a><a id="Tc_QefZWkF4FUiWQI9KaOxS2A_23_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:52.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Revenues:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Revenue from contracts with customers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_KYwslB6Rz0CPxYO1raADgQ_5_3">1,125</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2022_To_6_30_2022_MkbIQ9bQc0eX6Gc5LtLGHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_WViOMeN6ukyHVntbDbzluQ_5_6">525</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_gNUaOnrYNkaSOXMgiZENrw_5_9">1,125</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_Ent9xjGwvEKxbyHX1_LT8Q_5_12">3,275</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Revenue recognized under units-of-revenue method</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueNotFromContractWithCustomer" scale="3" id="Tc_AOGinyvjEkeS63-SCzb_9w_6_3">533</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2022_To_6_30_2022_MkbIQ9bQc0eX6Gc5LtLGHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueNotFromContractWithCustomer" scale="3" id="Tc_WLfV2-vOUk-Z8ayrJHO2Vw_6_6">458</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueNotFromContractWithCustomer" scale="3" id="Tc_pqkkutIFP0WpXmXx8KpKlQ_6_9">970</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueNotFromContractWithCustomer" scale="3" id="Tc_plVt_4shmkqhd0cHtBm9tQ_6_12">815</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Total revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_q6UhMiTKPU2OPahOvACDNg_7_3">1,658</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#ff0000;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2022_To_6_30_2022_MkbIQ9bQc0eX6Gc5LtLGHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_otJ1AirNOEivJKxTm-8P7A_7_6">983</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_jFRVr32d50a5d2o9z9sUbQ_7_9">2,095</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_i5p0sYZrcUWsCIEugwrAxw_7_12">4,090</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_2b1yCf2RekCsMeLYk4JgEw_10_3">39</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2022_To_6_30_2022_MkbIQ9bQc0eX6Gc5LtLGHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_-BPXF-VM50iE2Q8FWmF11w_10_6">40</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_0JBOOCL0nUWp9-wC1yGDsQ_10_9">93</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_eV6qnpiEnkiHubyKEysMCw_10_12">96</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_5Wnk5c-ukUuA2lyxs0k0Gg_11_3">5,777</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2022_To_6_30_2022_MkbIQ9bQc0eX6Gc5LtLGHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_2VExbtoBHkeDAOc-FGlDpA_11_6">5,710</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_bCjiUXVxw0CoOx7HrPoeNQ_11_9">11,973</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_Cw7oh8EEKEKRd41V8zQAnA_11_12">10,826</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Royalty purchase agreement asset impairment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg" decimals="-3" format="ixt:numdotdecimal" name="xoma:ImpairmentOfLongTermRightsReceivableNonCurrent" scale="3" id="Tc_sXCv4DS9ZEuZNW2GbC227w_12_3">1,575</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" decimals="-3" format="ixt:numdotdecimal" name="xoma:ImpairmentOfLongTermRightsReceivableNonCurrent" scale="3" id="Tc_HFL7-YNSH0ON8Rb2pvyzgw_12_9">1,575</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:52.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Arbitration settlement costs (Note 3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LitigationSettlementExpense" scale="3" id="Tc_7qpLO1eFS0akOpG6oicWbw_13_9">4,132</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:52.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Amortization of intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="Tc_sRP3kM3rZUaUp8YW_LQazw_14_3">224</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="Tc_DDco_JnhCEaf9Z-dHTX8SA_14_9">449</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:52.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_uU2ntOUt8EiSziZxBqxe7w_15_3">7,615</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2022_To_6_30_2022_MkbIQ9bQc0eX6Gc5LtLGHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_7EBD3cN3bk2DLSX_n09x8g_15_6">5,750</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_28QJw4UffE-PTrPk4st7qA_15_9">18,222</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_yDJmzwpf_E2_OamJrpBHbg_15_12">10,922</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:52.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_J6aNDZnpi0K-xqKqGZEq4Q_17_3">5,957</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2022_To_6_30_2022_MkbIQ9bQc0eX6Gc5LtLGHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_l1Rz2lRoGkChaMqfrKU8GQ_17_6">4,767</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_GcqcgNtAoEulHPyW6BdhEA_17_9">16,127</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_hCQnslicx0K-cNxMdwXhcQ_17_12">6,832</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:52.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Other income (expense), net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="Tc_7h3Rf6DhF0-fW2Es2gA4Ew_18_3">557</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2022_To_6_30_2022_MkbIQ9bQc0eX6Gc5LtLGHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="Tc_6DCbLMZTREuc5kkeHPBQMQ_18_6">97</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="Tc_JzHNhY8HkkyuA9ugaj8Y1g_18_9">914</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" sign="-" scale="3" id="Tc_8gSOx1aXY0uxyPQwhVtf3Q_18_12">118</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:52.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="white-space:pre-wrap;">Net loss and comprehensive loss   </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_qA_eJWfGs0eodEnej0JWrw_19_3"><ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_qA_eJWfGs0eodEnej0JWrw_19_3_2">5,400</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2022_To_6_30_2022_MkbIQ9bQc0eX6Gc5LtLGHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_L5sHkm8e3EOmSIHK7A_7sQ_19_6"><ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2022_To_6_30_2022_MkbIQ9bQc0eX6Gc5LtLGHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_L5sHkm8e3EOmSIHK7A_7sQ_19_6_2">4,670</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_RNHJpBL-KkSi4NhyPGiVZA_19_9"><ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_RNHJpBL-KkSi4NhyPGiVZA_19_9_2">15,213</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_7CBde6iyKkK_f8J58nUJCA_19_12"><ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_7CBde6iyKkK_f8J58nUJCA_19_12_2">6,950</ix:nonFraction></ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:52.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Less: accumulated dividends on Series A and Series B preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" scale="3" id="Tc_pb_U-xxAk0-Ze_jPfje92w_20_3">1,368</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2022_To_6_30_2022_MkbIQ9bQc0eX6Gc5LtLGHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" scale="3" id="Tc_sye2smMFckGXO9Q4_OFV3Q_20_6">1,368</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" scale="3" id="Tc_F0FQEtHXK0mWwGqOdD7Peg_20_9">2,736</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" scale="3" id="Tc_cjHu1cnPpUaa2Lvs0wpfvw_20_12">2,736</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:52.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Net loss and comprehensive loss attributable to common stockholders, basic and diluted </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_EtadPIiCMkaG5XVDghriHg_21_3"><ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" sign="-" scale="3" id="Tc_EtadPIiCMkaG5XVDghriHg_21_3_2">6,768</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2022_To_6_30_2022_MkbIQ9bQc0eX6Gc5LtLGHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc__g-RY8KLYEifyP2GwjfmeA_21_6"><ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2022_To_6_30_2022_MkbIQ9bQc0eX6Gc5LtLGHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" sign="-" scale="3" id="Tc__g-RY8KLYEifyP2GwjfmeA_21_6_2">6,038</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_NHqf0rRbZUWFvVqrTdcGiA_21_9"><ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" sign="-" scale="3" id="Tc_NHqf0rRbZUWFvVqrTdcGiA_21_9_2">17,949</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_L5-ZkzkFyEKHEPxnz9g3cA_21_12"><ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" sign="-" scale="3" id="Tc_L5-ZkzkFyEKHEPxnz9g3cA_21_12_2">9,686</ix:nonFraction></ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:52.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Basic and diluted net loss per share attributable to common stockholders </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg" contextRef="Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc__r4QnhvHJU-MZZsx5Uwu2A_22_3"><ix:nonFraction unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg" contextRef="Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc__r4QnhvHJU-MZZsx5Uwu2A_22_3_2">0.59</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg" contextRef="Duration_4_1_2022_To_6_30_2022_MkbIQ9bQc0eX6Gc5LtLGHQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_mUSmPJ84z0-AqDe3bsTwgQ_22_6"><ix:nonFraction unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg" contextRef="Duration_4_1_2022_To_6_30_2022_MkbIQ9bQc0eX6Gc5LtLGHQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_mUSmPJ84z0-AqDe3bsTwgQ_22_6_2">0.53</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg" contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_ER53x1tEQ06YE0aO-qyX2Q_22_9"><ix:nonFraction unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg" contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_ER53x1tEQ06YE0aO-qyX2Q_22_9_2">1.57</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg" contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_q4ATuF7RSEGtl9hZQK7yhg_22_12"><ix:nonFraction unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg" contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_q4ATuF7RSEGtl9hZQK7yhg_22_12_2">0.85</ix:nonFraction></ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:52.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Weighted average shares used in computing basic and diluted net loss per share attributable to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_3KpI8E4mTEuHRUVHMidqWg_23_3"><ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_3KpI8E4mTEuHRUVHMidqWg_23_3_2">11,466</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="Duration_4_1_2022_To_6_30_2022_MkbIQ9bQc0eX6Gc5LtLGHQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_l99oJ_fWl0Kxq6EeWOQsLg_23_6"><ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="Duration_4_1_2022_To_6_30_2022_MkbIQ9bQc0eX6Gc5LtLGHQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_l99oJ_fWl0Kxq6EeWOQsLg_23_6_2">11,421</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_kzQNd2w640q0wyr4NL2-Ww_23_9"><ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_kzQNd2w640q0wyr4NL2-Ww_23_9_2">11,463</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_MyaFDnapwEG2SzS41fVLZw_23_12"><ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_MyaFDnapwEG2SzS41fVLZw_23_12_2">11,376</ix:nonFraction></ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;"><i style="font-style:italic;">T</i><i style="font-style:italic;">he accompanying notes are an integral part of these condensed consolidated financial statements</i><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:8%;padding-right:8%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_27952fef_4c7e_43b1_8f77_c90cb9756042"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">XOMA CORPORATION</p><a id="CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHO"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 2pt 0pt;">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 2pt 0pt;">(unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">(in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_f7eeb721_2197_4d64_9ec1_2863d9854351"></a><a id="Tc_fZr8E5Y6bEKrNkiYh6O0Zw_1_1"></a><a id="Tc_HV0wf-R_Wka0XOVDPf9_ZA_1_6"></a><a id="Tc_mjPilXf-VEyyO47XJlpV1Q_1_11"></a><a id="Tc_OxOMf4mi2UyExVlz2VgPRA_1_21"></a><a id="Tc_-mFIZuCl_0q2FnbMkOT0PA_1_27"></a><a id="Tc_e2BQXzttr0WgFzlT9aW1EA_2_1"></a><a id="Tc_VmQ4eABSxkOY02TsfNPA5g_2_6"></a><a id="Tc_l4JlRqH1yU6YC_XFf32-FQ_2_11"></a><a id="Tc_rDBd5sAo9EuQhE34Ri3r2Q_2_16"></a><a id="Tc_Ms1JJADDkE-rM99aH-KXHA_2_21"></a><a id="Tc_OLvL-xhgCEiGBhfRLzfP1A_2_24"></a><a id="Tc_pBioWRLpNkSditMbilGBCA_2_27"></a><a id="Tc_q0lRELY520CSkhgBGbLELw_3_1"></a><a id="Tc_yMOfkE6K_EuWPVem5jTIpg_3_3"></a><a id="Tc_RNyEQG7p_0OYebckyvJKyA_3_6"></a><a id="Tc_QQ0a3Z1tAk-21qxE4nU-kg_3_8"></a><a id="Tc_4x1fXH-wEkmaE2NPPwl2Cw_3_11"></a><a id="Tc_AZ_zj1hsz0WTogEBh63u-Q_3_13"></a><a id="Tc_N4aVA_cRb06PGV_DaA5mMg_3_16"></a><a id="Tc_aVif1MTl_UeBNDlSRa9_gg_3_18"></a><a id="Tc_3HrQTbtXbEuQLKtrHqLYGQ_3_21"></a><a id="Tc_mW3yuhWiBE-lv1_m49wBuw_3_24"></a><a id="Tc_U9-VNRJv-kKc2V3bCGlXBg_3_27"></a><a id="Tc_8_jL-S2uDU6mEshZ1YPhfA_4_0"></a><a id="Tc_Kcbi_65Wi0-R2jnX_11DBQ_4_3"></a><a id="Tc_ZI26QdaDDkm-G2bLAmYsQA_4_8"></a><a id="Tc_jSaG5S4l6U68UpqMZkHdGw_4_9"></a><a id="Tc_Vluz0prqs0icLTEG8AJn9w_4_13"></a><a id="Tc_RxmveDEUGkGzKxqGF1NG2w_4_14"></a><a id="Tc_5cu3OnIKBUmjyN6sORqMxg_4_18"></a><a id="Tc_thTKaffrpUqF1ZO06zHyog_4_21"></a><a id="Tc_XcOUU3xbrEKuooSjb1q4rg_4_27"></a><a id="Tc_BpXnA4AbykqnZkc4THUrKA_5_0"></a><a id="Tc_SL1p94KpKE2Mv2qCA2Ea8w_5_1"></a><a id="Tc_cp8f3gCiQEiP0rprUebP0A_5_4"></a><a id="Tc_zADu11TYYk27VpsvfQD8sw_5_6"></a><a id="Tc_Gu2SkGPyOkOvZJ0x0JoWXA_5_9"></a><a id="Tc__ZbrDcPi5Em0ekFM116WEQ_5_11"></a><a id="Tc_YUwrRuc990G4JIM9ua4Yyw_5_14"></a><a id="Tc_Dj0BcWYAjUm4uhkTwvw07w_5_19"></a><a id="Tc_kcTD5tdmR0epWnYNzitK_g_5_25"></a><a id="Tc_TsANq_Nx4UmSuCzlNbC1aA_6_0"></a><a id="Tc_7MkZz1kYE0abnaA-1i9yoA_6_1"></a><a id="Tc_Whdo1jiIFEy4LCd8sYn53A_6_4"></a><a id="Tc_93Kgjj6l4UyGDZ-F_txh1g_6_6"></a><a id="Tc_zTczhuMF3EyMVfrtd0cPUQ_6_9"></a><a id="Tc_v4QmwhU0IEudqd9ZXJotvw_6_11"></a><a id="Tc_woT8I7qCckG9MhoaR8uwIg_6_14"></a><a id="Tc_KkbHwSCXZUOjNnCXijrzpQ_6_16"></a><a id="Tc_Kv5WJiOu00uF-XTt4vTI3g_6_19"></a><a id="Tc_lLlHCxV8v061qrMQEfitbw_6_25"></a><a id="Tc__7WrDi5zHkKvl3NVggpQsg_7_0"></a><a id="Tc_JDDMZe9OEEuoP2i9ghSRgQ_7_1"></a><a id="Tc_3dsXS3U6WEe0op2v14AVuQ_7_4"></a><a id="Tc_p-fAGHHJBUSOe_OuCV08zw_7_6"></a><a id="Tc_tOQC3K6RYkG-YVn0s3ygiQ_7_9"></a><a id="Tc_ocr4KXfxHkCRDzUSiCZGUw_7_11"></a><a id="Tc_UadxOrRgCUawolcipAT7vg_7_14"></a><a id="Tc_G_H2_C75pkWqLLE0xL5Ouw_7_16"></a><a id="Tc_0Ub1HwtZKEqux8VFTmhyvQ_7_19"></a><a id="Tc_zo0mJUQdXkuAfxjRJ_3PKg_7_25"></a><a id="Tc_a1tT3TEzFUqPwR16Le9mxg_8_0"></a><a id="Tc_GhG_Q5MXpkuQVKz-T7T2dw_8_1"></a><a id="Tc_MDGEM-Askka-ljbngCTIJw_8_4"></a><a id="Tc_NvQAZnLt-UeJxoOA5497RA_8_6"></a><a id="Tc_YGhI917KFUWev7o5YM7zWQ_8_9"></a><a id="Tc_7qJfRRn5-UqBK4NnCcD2OQ_8_11"></a><a id="Tc_jtALK2c4r0mxYVX4Cjc92g_8_14"></a><a id="Tc_L7NhHAaV3kK7fywkrco2tw_8_16"></a><a id="Tc_iEuJnq5ps0e7rzSfBFFDhw_8_19"></a><a id="Tc_GXwliY94YU2eynfQ9Ws4ag_8_22"></a><a id="Tc_WSjqo0fk80uTJ75DZqK91Q_9_0"></a><a id="Tc_0PpCi1PuOE-vHwNKx5n5dQ_9_3"></a><a id="Tc_UCB_U_Mso064-Z6NuakaUQ_9_8"></a><a id="Tc_eycvM2dbxESxNZ6kUzsFkA_9_9"></a><a id="Tc_EW6qrpORVUSQv8mMpSB_dg_9_13"></a><a id="Tc_lQpLJ7YcXkGs364L5FNLSg_9_14"></a><a id="Tc_lbUvX4kaC06GE3xPs_C78w_9_18"></a><a id="Tc_KRoDDqPGF0W0UxdCtud4Vg_9_21"></a><a id="Tc_CBxVsJebdEa6nKLBKEsxuA_9_24"></a><a id="Tc_qC9sNKaYVE-9nmd-a30-KA_9_27"></a><a id="Tc_H1ZUCaEJ4kG3n2-FygEdbw_10_0"></a><a id="Tc_WCsI7dF1sU-I4VrLW6YiFw_10_1"></a><a id="Tc__8L_V0cGLE6t5e6PRurHpw_10_4"></a><a id="Tc_7Bn5F3Z0jUaOvzuqxrSGbQ_10_6"></a><a id="Tc_mgzyysLDUU6t0W97zQlirQ_10_9"></a><a id="Tc_jPwebV2CDEG0BJqm5a0PQA_10_11"></a><a id="Tc_e-V4V9dov0qpi5DbTHKi4w_10_14"></a><a id="Tc_Eg2Gx5UDFke9PY6wR7TDXw_10_19"></a><a id="Tc_zjuiSrwmf0qcXFTDcjhyXQ_10_25"></a><a id="Tc_RZ22ek55KkGXq9iMkT_lUA_11_0"></a><a id="Tc_T8hZsETdP0qytcfynOM-tQ_11_1"></a><a id="Tc_x-R3fZkIXUy3ZWM7H8ksMQ_11_4"></a><a id="Tc_nCwNcEaV10OlVPLyNtcSag_11_6"></a><a id="Tc_a4xuYAfRzEaKwrNEKPB4UQ_11_9"></a><a id="Tc_fyGYEwRXvkOoXhu2zYTwzw_11_11"></a><a id="Tc_C1Bl9_IPGkSdoc0qwIsplQ_11_14"></a><a id="Tc_Z6-HgKst30aBX7eTXJlgsA_11_19"></a><a id="Tc_vw4sYN45Z0ehzHMrZhzgOQ_11_25"></a><a id="Tc_UIUqINa1AkCNCcZD3Oz0eg_12_0"></a><a id="Tc_CL7SxOVijEaUGLHV9a_v5Q_12_1"></a><a id="Tc_hceKvG88w0mHnVgHWjy-bQ_12_4"></a><a id="Tc_502gmAUx_kmnS_j4O2jKiQ_12_6"></a><a id="Tc_9hupdH9cD0O97H2nCfRf5w_12_9"></a><a id="Tc_ElZkNDh8vUa9qhPx2rha1g_12_11"></a><a id="Tc_NRLAShtM2UWjmmbEGrhmDw_12_14"></a><a id="Tc_HIL3ZMJDhUejeSzkICGM5g_12_16"></a><a id="Tc_ppEU_vdT1EehfxdhATyWyQ_12_19"></a><a id="Tc_66EhduVnj0eUN6F3BrWESg_12_25"></a><a id="Tc_i_oPflRcdkmky_C3zZXEIw_13_0"></a><a id="Tc_iu21Q9w1mUSdvRVtwALuuA_13_1"></a><a id="Tc_Qn_C8b9wU0C_C5D_sjjE8Q_13_4"></a><a id="Tc_Zf31tRykrEuIbdPqxCYvcg_13_6"></a><a id="Tc_MGGYQ_d6bEyelGRUq4nU6A_13_9"></a><a id="Tc__v8xqgLZ_0aoESAnlh2yPQ_13_11"></a><a id="Tc_omI8TcJe9k6WkA3zgDawfA_13_14"></a><a id="Tc_1swtrainbU2_75VHauTzGw_13_16"></a><a id="Tc_jtyVnnRbi0uf5swvw7VE4g_13_19"></a><a id="Tc_fGVO1HFlJEmfPsF-XrXBaA_13_25"></a><a id="Tc_MzCghxq2iUGfnI5_eVNFaA_14_0"></a><a id="Tc_XGGqTOB5b0WHq8El2n1Vog_14_1"></a><a id="Tc_stGk24WWUkefn_Y_Vb-r4Q_14_4"></a><a id="Tc_3iHALqqPu0-9pFPUgfD1GA_14_6"></a><a id="Tc_7bmgeLoQ-UiLerbHPQZTew_14_9"></a><a id="Tc_9wc5CFYfAUCh_zV8aB9Peg_14_11"></a><a id="Tc_7n64guzAwkCD0LMmZpnxEQ_14_14"></a><a id="Tc_Egn65BNZm0-L9dZKTzeCEw_14_16"></a><a id="Tc_oDJ-pBHGPEmpYEqlGcQgtw_14_19"></a><a id="Tc_xAZgorXYzEiiiM6irmdOzQ_14_22"></a><a id="Tc_OSMm_JKUK0O2Is9j_050Mg_15_0"></a><a id="Tc_TKss0TkE8k-3Cv0mYCLI6A_15_3"></a><a id="Tc_SC0CTZmjg0uR17UNO5jFwA_15_8"></a><a id="Tc_aXyMR2-yQkidoupCQMMuXg_15_9"></a><a id="Tc_WuDDJ8rj-katLyDrdMBhww_15_13"></a><a id="Tc_hTWLi7ZsdUK3iSahvC6x3Q_15_14"></a><a id="Tc_AZiZqLQXN02--b6eq500Uw_15_18"></a><a id="Tc_qkQymGSa6kaqA1qMm-h_3g_15_21"></a><a id="Tc_UQZJ2PLetkqBmMIziTUaXQ_15_24"></a><a id="Tc_YG1KxkUkT0S9WrVQLZiitQ_15_27"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:18.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:18.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:13.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Series A&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Series B</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Convertible</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:18.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:13.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Preferred Stock </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:13.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Preferred Stock </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:13.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Preferred Stock </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:13.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Paid-In</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stockholders&#8217;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:18.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;</b><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Equity</b></p></td></tr><tr><td style="vertical-align:bottom;width:18.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Balance, December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_F7GJ2ijBaESNLxxCWOPV9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_2Fpl34MVQEq8nvwvE1V4Zw_4_1">984</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_F7GJ2ijBaESNLxxCWOPV9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_1LwoGBpkhkCXXarf4sKYCQ_4_4">49</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_PeotIRnSfEqGsKf-u1aQaA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_mJ9ru5yRDk6bVh_lKuC0gg_4_6">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_mjGDeVHtJEy-hmsEfPC5Jw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_iFMkhEB-2kmDkD6hC4sVMA_4_11">5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vprHlJrRr0yw8rVJERIeVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_f10v1UPuykaB85QQgkKNew_4_16">11,454</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vprHlJrRr0yw8rVJERIeVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_BqGRGfaqA0KAQW33nRiDdA_4_19">86</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_gXsLP4N9SkWM0pvx20VSug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_z6EqXBCjh02Oy-j9-pRVHA_4_22">1,306,271</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ULAJkPFmo0GKfvexehN6Xw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_BME_NV1qWkKqceDA8l8MQQ_4_25">1,182,392</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_6L2pXaDWS0mLHygCNpdcbA_4_28">124,014</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:18.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Issuance of common stock related to 401(k) contribution </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_JyWKfa6Y2kCEdbWR9Enhww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="Tc_2BSDnpnKeUGmDeegUSPDpw_5_16">7</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_c02-OgQ2jEOGpEYnSgm2XA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="Tc_vNruytLBv0qDvNxq4hJEPg_5_22">123</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_3_31_2023_jn81l2KzzkioG_n6D7Y7SA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="Tc_A9GPlyx2Skm_PLn87hqlKw_5_28">123</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:18.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_c02-OgQ2jEOGpEYnSgm2XA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_UroshkgjaU6d9NvLAR1BWg_6_22">1,570</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_3_31_2023_jn81l2KzzkioG_n6D7Y7SA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_mRDJTayyY06quX7SzAcryQ_6_28">1,570</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:18.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Preferred stock dividends </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_c02-OgQ2jEOGpEYnSgm2XA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DividendsPreferredStockStock" scale="3" id="Tc_Ax-XVhfIrk2XlyHRBopXQg_7_22">1,368</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_3_31_2023_jn81l2KzzkioG_n6D7Y7SA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DividendsPreferredStockStock" scale="3" id="Tc_Q3UaekEgwkG5YhpIcoyp5w_7_28">1,368</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:18.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Net loss and comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_fyrP0G4Pj0-aaN04bSkICQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_rEGImT3yp0KxutSDTcG2tQ_8_25">9,813</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_3_31_2023_jn81l2KzzkioG_n6D7Y7SA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_zEncx1zLDEymZJHzH8pgGg_8_28">9,813</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:18.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Balance, March&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_gUvLnlJ3mkOEbSXAHiiecQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_nH_n9uz4WUSgAa7XCVTscg_9_1">984</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_gUvLnlJ3mkOEbSXAHiiecQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_jsmJvMUNU0SOjb1-IyJZ2w_9_4">49</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_tKe_WjiZ-0ecu0LnoPu_Vw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_MSjoan6JiU6jxOY6USUnnw_9_6">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_NVGVumu2RU2aSm58xyzVnQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_e0_WAJLK2kiRKHeIbh95Pw_9_11">5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__q8-WGlpF0afujkbjDrhAQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_QA9VRdqvk06juL8hWUognw_9_16">11,461</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__q8-WGlpF0afujkbjDrhAQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_Jm_wMjvUOU2HrSd4q6LyDA_9_19">86</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_x45gr-vUZEyje19LB7OGtA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_ruNsLux_wky_Htwd6bgIaQ_9_22">1,306,596</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_6kc5MkORGEWUHpL16Dho2Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_mWEMxJgfQUaCMAqNR7yNzg_9_25">1,192,205</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_3_31_2023_X5C7oga02EiygboostYHVw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_eZIecwjOS0yMdSwz_53Gow_9_28">114,526</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:18.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_q7cIlXaQfEaTUzSmFF8pow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="Tc_4b1_TVYAvka0UyQ5PLHLqg_10_16">8</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_VNTGe6PXiUSOTsNqLTklWQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_P6piJuK_lkCL8BVMUZVbbA_10_22">153</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_XtNYBKoglE2k1uyXKIHUhQ_10_28">153</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:18.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Issuance of common stock related to ESPP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_q7cIlXaQfEaTUzSmFF8pow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="Tc_ohe7QCCm8U20bgvYcTFuOA_11_16">3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_VNTGe6PXiUSOTsNqLTklWQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_hJRooew0SE2DLOD1GrVVLA_11_22">50</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#c00000;font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#c00000;font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#c00000;font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#c00000;font-size:8pt;font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_DaipW3h29UCWcQxDo9z4gw_11_28">50</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:18.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_VNTGe6PXiUSOTsNqLTklWQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_3SPe1PVTu0-KQrB47-mPpg_12_22">2,163</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_CoDjaKAbqEaVOCr0q60WBw_12_28">2,163</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:18.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Preferred stock dividends </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_VNTGe6PXiUSOTsNqLTklWQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DividendsPreferredStockStock" scale="3" id="Tc_HchDjdYtGEaHPnDwCWmhxA_13_22">1,368</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DividendsPreferredStockStock" scale="3" id="Tc_v08ImJc3b0e2AIM3pdj-PQ_13_28">1,368</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:18.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Net loss and comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_A3D1KiJFt0CNaMkMfhVNww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_MSNowiaRjEyTSQFJNXObog_14_25">5,400</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_mFAVq4PG50Onrq9HqVgeRw_14_28">5,400</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:18.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Balance, June&#160;30,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_3elDeOQbAkSzA4XPNTMvKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_ppLKPK-n0kyTHGJvJrjWjw_15_1">984</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_3elDeOQbAkSzA4XPNTMvKw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_0BPYG__Vik6FDtbKEtS6Cg_15_4">49</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_mN21iu-7y0Ob71zpxfq1UQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_jmER6xUpOU2RPwUm1broVw_15_6">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_czcB2xp3ZkO5ufWJGf_Lgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_Pl8NUHi8uUmBH7ZoYYM8rQ_15_11">5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vo9zKMnZO0aHN96tsj24CA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_p0IgP_fBuE2W6Pnnl_jt0A_15_16">11,472</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vo9zKMnZO0aHN96tsj24CA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_KJrDjyxDgUq8DbgZwiB0DQ_15_19">86</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_edqle5HbXEm7yuZsNCNZ5Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_uulqSvNU-U6k_DSCUQaLLQ_15_22">1,307,594</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__SjruGbNMke6VHotvJqC3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_Ioaowpj840mijIXc66Ffmw_15_25">1,197,605</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_pMCFgKtYOE6nVnB9MDgoNw_15_28">110,124</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_d1a950cb_baa2_497b_945c_97724bc4e8d8"></a><a id="Tc_2Ql3tMZITUuzZurGmAQ5LQ_1_1"></a><a id="Tc_MaR7PAcHdUuRtSzzyDgZwQ_1_6"></a><a id="Tc_6qyUzL47aE6qArEqL8zGBg_1_11"></a><a id="Tc_O-Kelg0B80W2zhotdJ6bPw_1_21"></a><a id="Tc_z3-EyD4fLUOvrv9vd8DxxQ_1_27"></a><a id="Tc_JY1W3kFUbEGci67-3fTIqQ_2_1"></a><a id="Tc_7AdxoxcKnUSeQyblG74p9A_2_6"></a><a id="Tc_4ATDfVOhyUSbZ8AmUweARA_2_11"></a><a id="Tc_mf5hpJ14mkC2ocAmfQw3gw_2_16"></a><a id="Tc_jH4ZPmfKIEqSsHfH8eVbRw_2_21"></a><a id="Tc_FmfHPj1_rUeAVxrxWJVqjA_2_24"></a><a id="Tc_8Q8f3t1gP0-I1DbZUEoKKQ_2_27"></a><a id="Tc_uF5y6Dy8yEaYgeibRwh19A_3_1"></a><a id="Tc_Dr283s9ePUu5EHfhp49EcA_3_3"></a><a id="Tc_ZWT6va7tLUCubrBL2tADVg_3_6"></a><a id="Tc_kYr215guPkKxR_uqBi_6mA_3_8"></a><a id="Tc_nKb96BHZ0k2oY3JyjE9ulw_3_11"></a><a id="Tc_LjngRkHn3UmEWOzWkg6rrQ_3_13"></a><a id="Tc_GqzCsi14y0a8rihVUy5-pw_3_16"></a><a id="Tc_U2uTH2lg-EKIaJ7Mb-xGyg_3_18"></a><a id="Tc_fLXfRf3EIka3QTPND5lg1Q_3_21"></a><a id="Tc_njlbdJMYU0m84lsaS1kV5Q_3_24"></a><a id="Tc_BPAt4MoM8EGQIQMlwMlxUA_3_27"></a><a id="Tc_u1BZX-Q5SkW7SyTHI0kq_g_4_0"></a><a id="Tc_tgotxkOXzkCaCmyceBqDaA_4_3"></a><a id="Tc_lWMlaykIIE2A9EldEcKR9A_4_8"></a><a id="Tc_5E91tUBdQEa8Z02LVfretw_4_9"></a><a id="Tc_H-Xvz_91VUCSZjUV0O3SCw_4_13"></a><a id="Tc_yM1tXQYzoUyUUg91qVzM8g_4_14"></a><a id="Tc_K0JJHC5GEkWfSr6uavr_cg_4_18"></a><a id="Tc_m26m5ROgwU-Q37fsaSferg_4_21"></a><a id="Tc_D9rPbrZyMUK6-Tp7AjxgOA_4_24"></a><a id="Tc_AmjEbB3H20eJqgL7HhPuUg_4_27"></a><a id="Tc_ADHmvf9OdUGnNkayY9y40g_5_0"></a><a id="Tc_zdRHe9rtcUaRtaYv8UPzAw_5_1"></a><a id="Tc_SsBr6PrVH0KakNjQtar4Dw_5_4"></a><a id="Tc_RsxWfohGVUauPk1FY4Npqw_5_6"></a><a id="Tc_ildWB0GH1k6o3cOMfDyuTg_5_9"></a><a id="Tc_6jIkEVkBC0mYznT-K7s_qA_5_11"></a><a id="Tc_ToSq058ZOkKGAJ7Xc3fr-A_5_14"></a><a id="Tc_WYJ2c8Mb3kWSrXUn0BY9wQ_5_25"></a><a id="Tc_iJ-iajaPxk-VfNBNZuxUbg_6_0"></a><a id="Tc_-B_cbeSh00WmWsn6AhickQ_6_1"></a><a id="Tc_QYFo8Mm9XEOpNET9wBG-Pg_6_4"></a><a id="Tc_LVuUlwFNPEaqo2FmVW7kWA_6_6"></a><a id="Tc_c9rigcppvUKkr6AlNvla4g_6_9"></a><a id="Tc_9hSbu6SAxEyd_kUv7hbHOQ_6_11"></a><a id="Tc_iJieJ6L8i0W3160mVu-OGA_6_14"></a><a id="Tc_bBQagkfYW0iJKdDHqV3yKQ_6_19"></a><a id="Tc_9F-KCzRNMk6zWyEImVE_WQ_6_25"></a><a id="Tc_fKlkPw5CXk-ej5KEC6HMHQ_7_0"></a><a id="Tc_k7cjX6N0WU2ZTKCQ8QOj8A_7_1"></a><a id="Tc_LH1ddwRiFEOa5AfxyxEJyw_7_4"></a><a id="Tc_QaCa_NQG_EmRAcfk_cSguA_7_6"></a><a id="Tc_eoH0h-ZVmkytJzsUDoJ_Gg_7_9"></a><a id="Tc_KxYOx7jgQ0el_rAvp09S2A_7_11"></a><a id="Tc_rH0GSBtiR0qyJrd1T308Uw_7_14"></a><a id="Tc_1fCfHuj6I0e7Ne4fROxTrA_7_16"></a><a id="Tc_XWgJ1q6NSU6Nx4TogUmGLA_7_19"></a><a id="Tc_JdrYbpEB7UC3fXq-NReCeg_7_25"></a><a id="Tc_0kJIsoyGFkehHPQz15USFg_8_0"></a><a id="Tc_2ltXCZ0ZvEid_DEBOvDsAw_8_1"></a><a id="Tc_sTQvtEIgtUy5SMe7B_pppQ_8_4"></a><a id="Tc_Y1v11WEYFEaoXJ4kDk8GLQ_8_6"></a><a id="Tc_DqyLYBSLUE2zAm_4qPJgQA_8_9"></a><a id="Tc_U5kCJi8mZU2-Zr9ljRbopA_8_11"></a><a id="Tc_UqLD1Aj2SEugiomtN5854A_8_14"></a><a id="Tc_AT1SykrD8EKDgpDiChL-hA_8_16"></a><a id="Tc_sy4hZLRGcUywxd4XIZ-xQA_8_19"></a><a id="Tc_3tv0BdAHN0GUTHK6v5OOzA_8_25"></a><a id="Tc_tMtnkAQZAkOjETTraMcaLQ_9_0"></a><a id="Tc_2ZzAp4zGn0ekgPzBDJq4QA_9_1"></a><a id="Tc_1lj9IfZ21EaeXxbNy69kfQ_9_4"></a><a id="Tc_9eF8Zl6f50G43go9lUAU-w_9_6"></a><a id="Tc_tbEBQutzl0q7ng0cT6LE1g_9_9"></a><a id="Tc_yETv-kmvlUuZQqCOgDbSIw_9_11"></a><a id="Tc_MbahX-utP0y5blKnYA88tA_9_14"></a><a id="Tc_iEA9sk6ZwU-s1FuH4HEUyw_9_16"></a><a id="Tc_j4udRiy0D0uuWWuTBsgf3Q_9_19"></a><a id="Tc_skw-f24kYE6KgBwNENkqpQ_9_22"></a><a id="Tc_9TCROXqQ_Uaj3b6G1wSaVA_10_0"></a><a id="Tc_8CwwBtATrk61h9Fa4LAL0Q_10_3"></a><a id="Tc__WeKgBC4a02TGjtVijm2bg_10_8"></a><a id="Tc_8p3FNvuESkSnbbVq3Kq66A_10_9"></a><a id="Tc_j891E6NXdUO5KyacC_mhNQ_10_13"></a><a id="Tc_WTQZRfoz2UCULMSWpEDW9g_10_14"></a><a id="Tc_pZnQY65jhESSNHVcVDrAyg_10_18"></a><a id="Tc_cD7I3K1KmkqgJFoeeQs6HA_10_21"></a><a id="Tc_A8ASY8xMDE6-oqgNNADPbw_10_24"></a><a id="Tc_VqwFKc4eqk-t6DCTQdjnEA_10_27"></a><a id="Tc_Y-C-dmS9jEWJgsQZUb-ooQ_11_0"></a><a id="Tc_GPdxwc_PtEmp5ChQNMvi0A_11_1"></a><a id="Tc_j_OzVTh5a0mCE09-tV4jyg_11_4"></a><a id="Tc_eRGf3WCK10aMtKaD7Ld-2w_11_6"></a><a id="Tc_2fJ2Dld-aUOzVgBEXh6hng_11_9"></a><a id="Tc_UIWaIK19BE604YR87qeKNQ_11_11"></a><a id="Tc_eLP4cnFSSUCAAEF8TnXNzQ_11_14"></a><a id="Tc_df1THIvg90CF_yVHRY1OWA_11_19"></a><a id="Tc_XCa_OUnMMEq1bI-vgItOQw_11_25"></a><a id="Tc_DkcaomgWKk6jZsX_ofy5jg_12_0"></a><a id="Tc_XhlcAnRjYkWwbldAF2GH2g_12_1"></a><a id="Tc_SSbmhpZ6FEa-bfWyZKlEgQ_12_4"></a><a id="Tc_9uIMrdFAF0Sfo5e_cB3vKA_12_6"></a><a id="Tc_-HsgbEIBX02FmLClyYX3sw_12_9"></a><a id="Tc_L32EGA2d20uuPqrSW62ECA_12_11"></a><a id="Tc_1g5e8x0Hekm_bihAfMh-ug_12_14"></a><a id="Tc_2ghKawaIEEOUaG9faiRK0w_12_19"></a><a id="Tc_f1EUS2LcjEm0QpmA8SIfWA_12_25"></a><a id="Tc_2mNQHTbJAk6W5CJJXBr6-g_13_0"></a><a id="Tc_3BWXLg3V9EaKuOlTiKD6yw_13_1"></a><a id="Tc_-4-GrlPde0aSyEIM6h9ryQ_13_4"></a><a id="Tc_T948qefZkUGRoRiLjDljSw_13_6"></a><a id="Tc_UiLbV2o7WE-RtCWzqnYNmA_13_9"></a><a id="Tc_VwC8NSBP9keUPL4a272YEw_13_11"></a><a id="Tc_CxbMvTISCEGb2-AqclSYeg_13_14"></a><a id="Tc_HkwTMAjKCkW57LlOVNxEpA_13_16"></a><a id="Tc_u5iHAoRVUUqb3uwe4nC9Zw_13_19"></a><a id="Tc_FdlTn_ut10ileNMBm2Ba3A_13_25"></a><a id="Tc_qcNi6wfIOEibICMgJfGN1Q_14_0"></a><a id="Tc_JCSy9Z_LKkKOBiO4Desjiw_14_1"></a><a id="Tc_aYGdW4hViUCKu9PiFPgbtA_14_4"></a><a id="Tc_HFli-F1Dt0CvNMDNk3nukA_14_6"></a><a id="Tc_RSRs4ZWpKEOVhUyaxr4mcQ_14_9"></a><a id="Tc_s8OleaPcaEqqg7CLtuZPDw_14_11"></a><a id="Tc_HofuVz1twkGNciD9zGL4gg_14_14"></a><a id="Tc_L7vmbWW7s0m2DVVueJE0wQ_14_16"></a><a id="Tc_K1krBXAeZUatbnsUIw6YUg_14_19"></a><a id="Tc_0WslnLz6Tk6k13jT2xO7EQ_14_25"></a><a id="Tc_EdZ9GunUsECbCfD1cG9iKg_15_0"></a><a id="Tc_13Tv_1v0pky047l0h_FsQA_15_1"></a><a id="Tc_o1CZwFFgME6bj5IiC42uHg_15_4"></a><a id="Tc_pj5ku2jUbE-KPqUVdeyXkw_15_6"></a><a id="Tc_Td1IRb-7FEiw7AM2mpeHbA_15_9"></a><a id="Tc_fA06zd6d9EKUfWKWiaK9lQ_15_11"></a><a id="Tc_fUPLhbrY0kS9gkhPqH-9Xw_15_14"></a><a id="Tc_hJDq7z6x0ka08q5B4f8pnQ_15_16"></a><a id="Tc_JnYYbR4SEEa52AYSwgXw4A_15_19"></a><a id="Tc_4Mcsx7MysEWPkbarooGtjA_15_22"></a><a id="Tc_WZ3ubvCrsECL3j7oyO8KSw_16_0"></a><a id="Tc_bpPR7NwNgk2Vk0DNJU5-Fw_16_3"></a><a id="Tc_FAwjCRVgT0mAnN6kSVQ3GQ_16_8"></a><a id="Tc_zpE7RfQu4k-h8M74FSfWaA_16_9"></a><a id="Tc_FUL-yBnqgUWqTTnGgIgazQ_16_13"></a><a id="Tc_8lUjp-9EfEuh1dzmM9x6ZQ_16_14"></a><a id="Tc_2bc8ffqRTk6KYalPV-090A_16_18"></a><a id="Tc_lvdwkBdWxU64hf18dIRglw_16_21"></a><a id="Tc_NDQkJDorXE-GoYK1xxNcew_16_24"></a><a id="Tc_KpLBxsPd-E-BQPeR48VFKQ_16_27"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.071395874%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:18.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:18.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:13.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series A&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:13.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series B</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:13.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Convertible</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:13.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:18.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:13.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Preferred Stock </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:13.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Preferred Stock </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:13.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Preferred Stock </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:13.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Paid-In</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stockholders&#8217;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:18.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;</b><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Equity</b></p></td></tr><tr><td style="vertical-align:bottom;width:18.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance, December&#160;31,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_6rQbM7sQNky8O85-NJM6Kw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_mlsLCXNwHUmcs-Rs1h1CuQ_4_1">984</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_6rQbM7sQNky8O85-NJM6Kw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_8A-yi7Om_UOP0jF4flp3eQ_4_4">49</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_2zCuoTh9XU-z3zmcVTU37A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_M7vFosx7OUmPlPp74emiew_4_6">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_uuOaeeICIE63neZVbvxrYw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_vsrBKXIQv06WOiEQWFuAqw_4_11">5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xTypNCJw2kecFDKsOR8hwA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_Ig5s-6V_c0OrSza3vmQ2Kg_4_16">11,315</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xTypNCJw2kecFDKsOR8hwA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_TvuqeA1DpkidDQQ4kVDHPA_4_19">85</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_S54NSxp5yk2I3fcHshTcMA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_MUNz_BK5eUyHHVXvw9z3AQ_4_22">1,307,030</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_oECYzd9liEiyvMRgwShVYg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_xXDEa-eTA0G1i06f7PxuZQ_4_25">1,165,288</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2021__kfZV7JTZUaYuVCcUwl-Cg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_x1ORCdXf3EG6ZgMqNoJpPw_4_28">141,876</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:18.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Y8pSKqQVN0qvZ3Xp6DQmKg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="Tc_lBv9xDd9TECLmNVDzHI7Ng_5_16">91</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Y8pSKqQVN0qvZ3Xp6DQmKg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_lMIWccllOEO-PMlc3KwzXA_5_19">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_C-Lb32e_Qk26nc_aMAPFCA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_qyzAamIac0OlLHHnukGaLA_5_22">632</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2022_To_3_31_2022_FsR-R6AfnkSXmuWs510eUg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_sPMCeEOnM0CwP40IIvwrtw_5_28">633</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:18.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock related to 401(k) contribution </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Y8pSKqQVN0qvZ3Xp6DQmKg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="Tc_-16ItjWPQk-PCN1j8yVrtg_6_16">4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_C-Lb32e_Qk26nc_aMAPFCA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="Tc__rfUGAHKgECKPxZ3PrGy9A_6_22">85</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2022_To_3_31_2022_FsR-R6AfnkSXmuWs510eUg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="Tc_RWnxy95MZkm8Vxum1E3atA_6_28">85</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:18.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_C-Lb32e_Qk26nc_aMAPFCA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_La_4MFX5YU21--WRgB3zSw_7_22">978</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2022_To_3_31_2022_FsR-R6AfnkSXmuWs510eUg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_Li7ulYn3ZkW_39VwZOjYeg_7_28">978</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:18.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Preferred stock dividends </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_C-Lb32e_Qk26nc_aMAPFCA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DividendsPreferredStockStock" scale="3" id="Tc_YJQmhSo5LE21Ykan7Dkqng_8_22">1,368</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2022_To_3_31_2022_FsR-R6AfnkSXmuWs510eUg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DividendsPreferredStockStock" scale="3" id="Tc_N218XHbT_0Kb8EtgDg6rYg_8_28">1,368</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:18.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net loss and comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_KGG7iA9QeU-x58nvnAGyAA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_ooWAvVSgfE61bEeIJg8yAw_9_25">2,280</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2022_To_3_31_2022_FsR-R6AfnkSXmuWs510eUg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_BLTh-SJBkE-BkwJbwbE_zw_9_28">2,280</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:18.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance, March&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="As_Of_3_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_jps57Fyqu0WWl7CaOtheOg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_3DKB05-YBkGSHefDaEJ-QA_10_1">984</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_3_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_jps57Fyqu0WWl7CaOtheOg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_eLwiW4AvWEiukcd-kKeLrA_10_4">49</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="As_Of_3_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_eGV1-nMv9EyGZf3q_EpMbw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_3oY_ojRcuUi1bEs5FXss4g_10_6">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="As_Of_3_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_q6JWreHPR0i_czphX2lVDQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_IKfmHK-_jkKtGs5FPdKCOw_10_11">5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zdAm_dbVtUOANrU35KRi-w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_fry31WtadkKMvL6A7F0faQ_10_16">11,410</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zdAm_dbVtUOANrU35KRi-w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_pviTtbP-2UG13QNwotDptw_10_19">86</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sHK3ZNTAH0aMwFqH9faHRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_AfFQR3GquUKsa5075Yb9uw_10_22">1,307,357</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_YzMe_e-yGUGbNiPtf12IwQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_mS1smY2URUGYVL088dRLuA_10_25">1,167,568</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_3_31_2022_wXICAr6QekumvGjfUaFcqw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_7eOahH-e1Emxg3DFOAgmgg_10_28">139,924</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:18.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_nZVAZEbax02Nn2_S_0USBA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="Tc_AoapxW74bEuNasjH8IzFKg_11_16">11</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_rx0lmQ0x-ka_ICeF8O4eFw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_vvt9xfsru06spCGUJYZQbQ_11_22">189</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2022_To_6_30_2022_MkbIQ9bQc0eX6Gc5LtLGHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_Sl0PCDMrd0ypimojZO1-Hw_11_28">189</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:18.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock related to ESPP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_nZVAZEbax02Nn2_S_0USBA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="Tc_D-9-crNysU-iRzvcc2Jhbg_12_16">3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_rx0lmQ0x-ka_ICeF8O4eFw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_4Szj5lKUHE6ZIaOFRRkoiQ_12_22">45</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2022_To_6_30_2022_MkbIQ9bQc0eX6Gc5LtLGHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_B_OUTnuDN0edk1TPizK7gw_12_28">45</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:18.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_rx0lmQ0x-ka_ICeF8O4eFw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_rPywTddWBkWOhOf3E_7OPw_13_22">836</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2022_To_6_30_2022_MkbIQ9bQc0eX6Gc5LtLGHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_vJfH12Yoz0KKWoOeTgzJqw_13_28">836</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:18.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Preferred stock dividends </p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_rx0lmQ0x-ka_ICeF8O4eFw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DividendsPreferredStockStock" scale="3" id="Tc_kIHm_4yRikSVWOjN_dRLXA_14_22">1,368</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2022_To_6_30_2022_MkbIQ9bQc0eX6Gc5LtLGHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DividendsPreferredStockStock" scale="3" id="Tc_vAa1l6skF0eOGm0SLXRRBg_14_28">1,368</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:18.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net loss and comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_7O1rzT-yJUuZnLhCfrcYOg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_f_vGeZEj8k-0WUFo74YXhQ_15_25">4,670</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2022_To_6_30_2022_MkbIQ9bQc0eX6Gc5LtLGHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_voj8Ni7cf0WlrSSQChG6Bg_15_28">4,670</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:18.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance, June&#160;30,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="As_Of_6_30_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_nAb-HKUTNkWZ5BAQ0-qIHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_pFd0TerwGk2av9sp8Xi4Ig_16_1">984</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_nAb-HKUTNkWZ5BAQ0-qIHA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_6QdERVv4906hkddIY91V4g_16_4">49</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="As_Of_6_30_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_63gYMzNqtUeLw4EgBOljpw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_Ic2DRbm_E0SGa3j0btCa8A_16_6">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="As_Of_6_30_2022_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_vUW8gOL5lUS22XQyQHoMYg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_WK-QP3quJEOuDuahf_vrjw_16_11">5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_54FxiDHYMUSAo0wczwNo8w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_1aBz_-z3Wkm74AefweJznA_16_16">11,424</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_54FxiDHYMUSAo0wczwNo8w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_XgKr2RQHtESI2zIQwHeQ6w_16_19">86</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_YqOEWTXU0Ua6QvAhBoXz7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_9LqSB5tov0O07MeeniFCWg_16_22">1,307,059</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_nRVamYzhRUqPa-9YjzTLLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_RLptXSHZh026MwQL3Rl7cQ_16_25">1,172,238</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2022_lyjBTUwVbUyOd4KtP5Gu-g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_eeF21vbgYUqD2rvUMg68Lw_16_28">134,956</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:3pt 0pt 0pt 0pt;"><span style="font-style:italic;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:3pt 0pt 0pt 0pt;"><i style="font-style:italic;">The accompanying notes are an integral part of these condensed consolidated financial statements.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:84%;border:0;margin:30pt 8% 30pt 8%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_1815c482_9d5d_45e8_9744_0af9a1d574e0"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">XOMA CORPORATION</p><a id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLO"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 4pt 0pt;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">(unaudited)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_738e2f0e_6d7b_4f81_a7ca_18ba09573448"></a><a id="Tc_FM-XOYenV0uKuErEgj-sSQ_1_2"></a><a id="Tc_lv7BgKKTd0ezeTJs-Jok7g_2_2"></a><a id="Tc_haVJh-I9bUOmV5FArd78gQ_2_5"></a><a id="Tc_-1kMZuSWQEm2vxi6mmBRFw_3_0"></a><a id="Tc_7IkazzdFrki9RPn7mrZ9nw_4_0"></a><a id="Tc_Fooj2sSA3ke-hv5Zq8ZLjQ_4_2"></a><a id="Tc_BXJXLJMtDEq1P3LKV3z0wQ_4_5"></a><a id="Tc_a287dUQ1gkeD3wa5RIos0A_5_0"></a><a id="Tc_GAp7pPSzdEiJFMero1b8Og_6_0"></a><a id="Tc_2D211g45ykm2xzEhA527Ww_7_0"></a><a id="Tc_DQTAV7YX50uX_HBYmkKFtQ_7_6"></a><a id="Tc_P-_mzShSaUe0mQD0uTPUkw_8_0"></a><a id="Tc_nigNVLnvoEOQwijubdwNYA_8_6"></a><a id="Tc_lSFLACjWJEWI8v-QqShH7g_9_0"></a><a id="Tc_xjrlVoiO4US7SkvyxYGqxA_10_0"></a><a id="Tc_qGpQsyfPS06ADPCFUTav9A_10_6"></a><a id="Tc_-alUA8cQOUaKHOlRGT-7lQ_11_0"></a><a id="Tc_NdUEFuMx-0Wp4-ApRhDfPg_12_0"></a><a id="Tc_q8wsIxNQnUeyIHiMIJsfzQ_13_0"></a><a id="Tc_NcDwdREBQk2cwo_Px0mPUA_14_0"></a><a id="Tc_74BI6jOChEuRPdlTH6OiPw_15_0"></a><a id="Tc_Q7k2Jfttz0e_qHhC1zl9Sw_16_0"></a><a id="Tc_2VZ8ZOLIu0-nCUXJ8ir1Lg_17_0"></a><a id="Tc_iUdc29DVm02ARcDB3h3crw_18_0"></a><a id="Tc_FY5PRdgmKkKTQ9tNTHretQ_18_3"></a><a id="Tc_A7JJ4icQM0mPGUPJw7ymLw_19_0"></a><a id="Tc_I8qVAsjkw0mC_YCdwpxdOg_20_0"></a><a id="Tc_i3R-EmK8GkiZXXA51tjj_Q_21_0"></a><a id="Tc_Gu3NeFvIk0Wrkn6fDIW7xA_23_0"></a><a id="Tc_rpxrvu11LEeCAdaXWFSd_w_24_0"></a><a id="Tc_qVZQan18vEWu7MEzj4C8Pg_25_0"></a><a id="Tc_Iyb63JjSvUOXEIaKdiZXRQ_25_6"></a><a id="Tc_O2dj-ndEi0Wp1gpkIBq6VA_26_0"></a><a id="Tc_-MYL_PS5Yk-yEI-IFlrqVw_28_0"></a><a id="Tc_trRfWAJmg0GziDL5Lht5uw_29_0"></a><a id="Tc_3jNxSNI8PU2FLypSXYJWHg_30_0"></a><a id="Tc_-UTL6W9UwUeMPVaVavaPbw_31_0"></a><a id="Tc_2pYxDj0COkiyNpTwh0Br_Q_32_0"></a><a id="Tc_uO7Ru1HOpUeM4G2Td3X6Dw_34_0"></a><a id="Tc_4QJ7-q6e3E-GEK3yuX8ovA_35_0"></a><a id="Tc_21cPvxkH7E2JW2PwopEBPw_36_0"></a><a id="Tc_ClFoY-rBikeD4ozan4eK2Q_36_2"></a><a id="Tc_TKH2TIUlN0O4ZrLWM88OeA_36_5"></a><a id="Tc_wTa14POPnEy02TIrTjiBag_38_0"></a><a id="Tc__F-J9MFMhUOEPMDtbttfwA_39_0"></a><a id="Tc__Dkp2WJBCEmFZe0MvQe1Mg_39_2"></a><a id="Tc_2f7DoDtRw0eqJB14YzJnFA_39_3"></a><a id="Tc_tuXe4BLGEEGkXpDXaxBt-A_39_5"></a><a id="Tc_jCX3KYG6c0yx_28Lj5O8sw_40_0"></a><a id="Tc_SnUWHqS0gk-ap_AWGGqd2Q_40_2"></a><a id="Tc_LHLeyGq9KU-FuO3GS_1JCQ_40_5"></a><a id="Tc_gVrRqIJUEEaUatOq07mlHA_40_6"></a><a id="Tc_vpKu7xBh4kCyn6a95sYn4A_41_0"></a><a id="Tc_zuHk4NhJhECjyQf2Tlr4KQ_42_0"></a><a id="Tc_wBkiuOd-RU2AjNTnB8R4Mw_42_2"></a><a id="Tc_DFX-CJ03oECjSr6TwPdw3A_42_5"></a><a id="Tc_2hL8n8Bng0qG-losXEfMaA_43_0"></a><a id="Tc_I5gOMsMhUUCANW5IGhypbA_43_2"></a><a id="Tc_HVOXs3XEz0SWSU-6uRbvew_43_5"></a><a id="Tc_CikKEVg9rEyckgEeMtvzYA_43_6"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six Months Ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Cash flows from operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_tBRcfxJMrUuXdOv_eNB_HQ_4_3">15,213</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_vaglJGBRI0OR6Y8ktxVruw_4_6">6,950</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_bWPxS25PS0GJvSoMoxu7Mg_6_3">3,733</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_aCSmmeK9nUuaarE2GcbczA_6_6">1,815</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Royalty purchase agreement asset impairment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" decimals="-3" format="ixt:numdotdecimal" name="xoma:ImpairmentOfLongTermRightsReceivableNonCurrent" scale="3" id="Tc_5DxC-6VLCEqQnfcQ_Xjbew_7_3">1,575</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:70.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Change in fair value of contingent consideration under RPAs, AAAs, and CPPAs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" decimals="-3" format="ixt:numdotdecimal" name="xoma:ChangesInEstimatedFairValueOfContingentConsideration" scale="3" id="Tc_e9lw8g7MTEqqr-yRjXawbQ_8_3">75</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:70.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Common stock contribution to 401(k)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" decimals="-3" format="ixt:numdotdecimal" name="xoma:DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims" scale="3" id="Tc_98O3wJqWY0qqUV4QVhRFxw_9_3">123</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw" decimals="-3" format="ixt:numdotdecimal" name="xoma:DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims" scale="3" id="Tc_Fqnoaq5cfUWAi7NuEe2pNQ_9_6">85</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Amortization of intangible assets </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="Tc_xnQlRfcUvUevkipDPpcMBA_10_3">449</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:70.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationNonproduction" scale="3" id="Tc_FXsUK8XEaE295kfxuCfakw_11_3">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationNonproduction" scale="3" id="Tc_8C7F1PswJk-zHK5Sh-djYw_11_6">3</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Non-cash lease expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" decimals="-3" format="ixt:numdotdecimal" name="xoma:OperatingLeasePaymentsNonCash" sign="-" scale="3" id="Tc_XIZCfcbWyEKlGRQDXa2iew_12_3">97</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw" decimals="-3" format="ixt:numdotdecimal" name="xoma:OperatingLeasePaymentsNonCash" sign="-" scale="3" id="Tc_mlMFHc-r3EqtSMaYZ0wMfQ_12_6">84</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Change in fair value of equity securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" sign="-" scale="3" id="Tc_6tRmxyvfkU2nkW3PX7JiEw_13_3">15</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" sign="-" scale="3" id="Tc_BvPQTVk54EOywKt4Adpgsg_13_6">251</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Changes in assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:4pt;"><td style="vertical-align:bottom;width:70.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 18pt;">Trade and other receivables, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" scale="3" id="Tc_x31zilHb4EW02Kl4KhZQIA_15_3">900</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables" sign="-" scale="3" id="Tc_rg29uwwzFEqrF1_DFKvNtQ_15_6">204</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 18pt;">Prepaid expenses and other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="Tc_z9oyFdpICEuXwue9xEHbmA_16_3">97</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="Tc_cHibKVJ6tUqI7KNRlqXAvw_16_6">398</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 18pt;">Accounts payable and accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" sign="-" scale="3" id="Tc_cJRXqWnbxU25YdtztYeMbw_17_3">769</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="Tc_m-aRFhJu60eofp384Ndzig_17_6">582</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 18pt;">Income taxes payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" sign="-" scale="3" id="Tc_JF9GKTQ8O0SkmsOsn5TgeA_18_6">91</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 18pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" sign="-" scale="3" id="Tc_RvGeofFMm0Kk2C2QAenzbA_19_3">102</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" sign="-" scale="3" id="Tc_BI50nIfRAkmQ3emoaiG6Ig_19_6">96</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 18pt;">Unearned revenue recognized under units-of-revenue method</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDeferredRevenue" sign="-" scale="3" id="Tc_wTrYwyzxKUGz_ia70_xoxw_20_3">970</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDeferredRevenue" sign="-" scale="3" id="Tc_-9fsj8GPe02d7BcTUz-Uxw_20_6">815</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 24pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_CVGUwkEtkEqoqZS6wmC9FQ_21_3">12,132</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_4E28U2Mly02v28rhSnOQMA_21_6">5,326</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Cash flows from investing activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Payments of consideration under RPAs, AAAs and CPPAs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" decimals="-3" format="ixt:numdotdecimal" name="xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities" scale="3" id="Tc_7lJ8-AG0006QGx3yrv63gg_24_3">14,650</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw" decimals="-3" format="ixt:numdotdecimal" name="xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities" scale="3" id="Tc_NxTsAVq__kWeNdVEeRWrVg_24_6">5,000</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Receipts under RPAs, AAAs and CPPAs </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" decimals="-3" format="ixt:numdotdecimal" name="xoma:ReceiptsUnderAgreementsInvestingActivities" scale="3" id="Tc_RfoCZC_r1UOAW-VQOyo3eQ_25_3">2,934</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:70.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 24pt;">Net cash used in investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_7ciEq_846EiavLKVke3bpQ_26_3">11,716</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_8Xt3Otlw0kScUb7Aijnf0g_26_6">5,000</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Cash flows from financing activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Payment of preferred stock dividends </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfDividends" scale="3" id="Tc_YmCQH82BYkOBrCXDP1hphQ_29_3">2,736</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfDividends" scale="3" id="Tc_wHKmQVMAP0mBjJRmEpNmyw_29_6">2,736</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Proceeds from exercise of options and other share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="Tc_eCnrxxRLPUaLMsg4wZY46Q_30_3">208</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="Tc_3EKXefh2hkG23f5vDp_hsQ_30_6">1,905</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Taxes paid related to net share settlement of equity awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="Tc_NIVcuu4rsEGmgvIegmSWLg_31_3">5</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="Tc_bdY3h9wLHk25hRdXbLKqwQ_31_6">1,038</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 24pt;">Net cash used in financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" sign="-" scale="3" id="Tc_OmboFEiBXkan6OVmAm__Ig_32_3">2,533</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" sign="-" scale="3" id="Tc_dWpH5eOGwE-Su0_qKMw-hg_32_6">1,869</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Net decrease in cash, cash equivalents and restricted cash </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_5Scs57uWsEq-55XEHHAg6w_34_3">26,381</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_7uXoDkLr1EeiHeCxSshqnw_34_6">12,195</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Cash, cash equivalents and restricted cash at the beginning of the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_48rxOQMGPUyoD2UtnHP7LA_35_3">57,826</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2021__kfZV7JTZUaYuVCcUwl-Cg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_HplmKhZ9RkWCIReWB8hevg_35_6">95,377</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Cash, cash equivalents and restricted cash at the end of the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_Wg5HPjf2EU2yKrPA3p8Fjw_36_3">31,445</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2022_lyjBTUwVbUyOd4KtP5Gu-g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_NfERUeMGZUywne2kATQdiQ_36_6">83,182</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Supplemental Cash Flow Information:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Cash paid for taxes </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="Tc_7_t5Ka0WZ0Kg7h5BsIwJ7g_39_6">95</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Right-of-use assets obtained in exchange for operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_5NIblfaBEEuTxTzYioHLyw_40_3">85</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:70.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Non-cash investing and financing activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Preferred stock dividend accrual</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DividendsPayableCurrentAndNoncurrent" scale="3" id="Tc_EXpNIWrK3Em5QPm0CYhxuw_42_3">1,368</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2022_lyjBTUwVbUyOd4KtP5Gu-g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DividendsPayableCurrentAndNoncurrent" scale="3" id="Tc_-yJ13vhftEydVpGPlCPAiw_42_6">1,368</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Estimated fair value of contingent consideration under the LadRx Agreements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" decimals="-3" format="ixt:numdotdecimal" name="xoma:EstimatedFairValueOfContingentConsiderationUnderAssetAcquisition" scale="3" id="Tc_RAqJPQKs40uSXycOimegJQ_43_3">1,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:70.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">The accompanying notes are an integral part of these condensed consolidated financial statements.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_6d1c6640_7534_4645_a265_75d60183679f"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 4pt 0pt;">XOMA CORPORATION</p><a id="NOTESTOCONDENSEDCONSOLIDATEDFINANCIALSTA"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 4pt 0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(unaudited)</b></p><a id="_Hlk98769140"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" name="us-gaap:NatureOfOperations" id="Tb_aOpjyGPa6UOmkUumc2Crxw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1. Description of Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">XOMA, a Delaware corporation, is a biotech royalty aggregator with a sizable portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company&#8217;s portfolio was built through the acquisition of rights to future milestones and royalties that the Company has made since the royalty aggregator business model was implemented in 2017 combined with out-licensing its proprietary products and platforms from its legacy discovery and development business. The Company&#8217;s drug royalty aggregator business is primarily focused on early to mid-stage clinical assets in Phase 1 and 2 with significant commercial sales potential that are licensed to large-cap partners. The Company expects that most of its future revenue will be based on payments the Company may receive for milestones and royalties related to these programs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Liquidity and Financial Condition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has incurred significant operating losses and negative cash flows from operations since its inception. As of June 30, 2023, the Company had cash and cash equivalents of $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="Narr_kJ2ReBWpXkmQOjL_jPHSQg">31.4</ix:nonFraction> million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Based on the Company&#8217;s current cash balance and its ability to control discretionary spending, such as milestone and royalty acquisitions, the Company has evaluated and concluded its financial condition is sufficient to fund its planned operations and commitments and contractual obligations for a period of at least one year following the date that these condensed consolidated financial statements are issued.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="Tb_WNFn53gzeUOY2PA0RZN8AA" continuedAt="Tb_WNFn53gzeUOY2PA0RZN8AA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2. Basis of Presentation and Significant Accounting Policies</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Tb_clHDyGq0n0aPaXNHJj74qg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions among consolidated entities were eliminated upon consolidation. The unaudited condensed consolidated financial statements were prepared in accordance with GAAP in the United States for interim financial information and with the instructions to Form&#160;10-Q and Article&#160;10 of Regulation S-X. As permitted under those rules&#160;certain footnotes or other financial information can be condensed or omitted. These condensed consolidated financial statements and related disclosures have been prepared with the assumption that users of the interim financial information have read or have access to the audited consolidated financial statements for the preceding fiscal&#160;year. Accordingly, these statements should be read in conjunction with the audited consolidated financial statements and related notes included in the Company&#8217;s Annual Report on Form&#160;10-K for the&#160;year ended December&#160;31, 2022, filed with the SEC on March&#160;9, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">These condensed consolidated financial statements have been prepared on the same basis as the Company&#8217;s annual consolidated financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal and recurring adjustments that are necessary for a fair statement of the Company&#8217;s consolidated financial information. The interim results of operations are not necessarily indicative of the results that may be expected for the full&#160;year.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" name="us-gaap:UseOfEstimates" id="Tb_VW3ZNDVNT026Ij1KHUOOaQ" continuedAt="Tb_VW3ZNDVNT026Ij1KHUOOaQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The preparation of financial statements in conformity with GAAP in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates including, but not limited to, those related to revenue recognition, revenue recognized under the units-of-revenue method, royalty and commercial payment receivables, </p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_WNFn53gzeUOY2PA0RZN8AA_cont1" continuedAt="Tb_WNFn53gzeUOY2PA0RZN8AA_cont2"><ix:continuation id="Tb_VW3ZNDVNT026Ij1KHUOOaQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">intangible assets, legal contingencies, contingent consideration and stock-based compensation. The Company bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Actual results may differ significantly from these estimates, such as the Company&#8217;s amortization of the payments received from HCRP. Under the contracts with HCRP, the amortization for the reporting period is calculated based on the payments expected to be made by the licensees to HCRP over the term of the arrangement. Any changes to the estimated payments by the licensees to HCRP can result in a material adjustment to revenue previously reported.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Tb_RPTILXPi90mCmWjXS_n4xw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash and Cash Equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash consists of bank deposits held in business checking and interest-bearing deposit accounts. As of June 30, 2023, the Company had a cash balance of $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Cash" scale="6" id="Narr_Xb9J82FfXE6CsNW-y_3Cpw">1.3</ix:nonFraction> million and cash equivalent balances of $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="Narr_PP5aeO_ciEuO7yaA_Tmxtg">30.1</ix:nonFraction> million, defined as highly liquid financial instruments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. As of December 31, 2022, the Company had a cash balance of $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Cash" scale="6" id="Narr_fHsCdSHrdU-oT1NGjYZqLQ">27.5</ix:nonFraction> million and cash equivalent balances of $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="Narr_C54cLEmIm0CnxExTb-IURQ">30.3</ix:nonFraction> million.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="Tb_-ZSovfvV8kqzRqktKc_v0w" continuedAt="Tb_-ZSovfvV8kqzRqktKc_v0w_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Revenue Recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes revenue from all contracts with customers according to ASC 606, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i)&#160;identify the contract(s)&#160;with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation based on relative fair values, when (or as) the performance obligation is satisfied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes revenue from its license and collaboration arrangements and royalties. The terms of the arrangements generally include payment to the Company of one or more of the following: non-refundable, upfront license fees, development, regulatory and commercial milestone payments, and royalties on net sales of licensed products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 18pt;">License of intellectual property</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, such as transfer of related materials, process and know-how, the Company utilizes judgement to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. Under the Company&#8217;s license agreements, the nature of the combined performance obligation is the granting of licenses to the customers as the other promises are not separately identifiable in the context of the arrangement. Since the Company grants the license to a customer as it exists at the point of transfer and is not involved in any future development or commercialization of the products related to the license, the nature of the license is a right to use the Company&#8217;s intellectual property as transferred. As such, the Company recognizes revenue related to the combined performance obligation upon completion of the delivery of the related materials, process and know-how (i.e., at a point in time).</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_WNFn53gzeUOY2PA0RZN8AA_cont2" continuedAt="Tb_WNFn53gzeUOY2PA0RZN8AA_cont3"><ix:continuation id="Tb_-ZSovfvV8kqzRqktKc_v0w_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 18pt;">Milestone payments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of each arrangement that includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price. ASC 606 suggests two alternatives to use when estimating the amount of variable consideration: the expected value method and the most likely amount method. Under the expected value method, an entity considers the sum of probability-weighted amounts in a range of possible consideration amounts. Under the most likely amount method, an entity considers the single most likely amount in a range of possible consideration amounts. The Company uses the most likely amount method for development and regulatory milestone payments. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If it is probable that a significant cumulative revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis. The Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability or achievement of each such milestone and any related constraint, and if necessary, adjusts its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and earnings in the period of adjustment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 18pt;">Royalties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upfront payments and fees are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts payable to the Company are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one&#160;year or less.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" name="xoma:RevenueRecognitionDeferredRevenuePolicyTextBlock" id="Tb_Eyglr_xazU643xHbj17Yfw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Sale of Future Revenue Streams</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has sold its rights to receive certain milestones and royalties on product sales. In the circumstance where the Company has sold its rights to future milestones and royalties under a license agreement and also maintains limited continuing involvement in the arrangement (but not significant continuing involvement in the generation of the cash flows that are due to the purchaser), the Company defers recognition of the proceeds it receives for the sale of milestone or royalty streams and recognizes such unearned revenue as revenue under the units-of-revenue method over the life of the underlying license agreement. Under the units-of-revenue method, amortization for a reporting period is calculated by computing a ratio of the proceeds received from the purchaser to the total payments expected to be made to the purchaser over the term of the agreement, and then applying that ratio to the period&#8217;s cash payment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Estimating the total payments expected to be received by the purchaser over the term of such arrangements requires management to use subjective estimates and assumptions. Changes to the Company&#8217;s estimate of the payments expected to be made to the purchaser over the term of such arrangements could have a material effect on the amount of revenues recognized in any particular period.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" id="Tb_nAR2T42qQUGZLf7frb5BJg" continuedAt="Tb_nAR2T42qQUGZLf7frb5BJg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company recognizes compensation expense for all stock-based payment awards made to the Company&#8217;s employees, consultants and directors that are expected to vest based on estimated fair values. The valuation of stock option awards is determined at the date of grant using the Black-Scholes Model. The Black-Scholes Model requires inputs such </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk93564945"></a><ix:continuation id="Tb_WNFn53gzeUOY2PA0RZN8AA_cont3" continuedAt="Tb_WNFn53gzeUOY2PA0RZN8AA_cont4"><ix:continuation id="Tb_nAR2T42qQUGZLf7frb5BJg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">as the expected term of the option, expected volatility and risk-free interest rate. To establish an estimate of expected term, the Company considers the vesting period and contractual period of the award and its historical experience of stock option exercises, post-vesting cancellations and volatility. The estimate of expected volatility is based on the Company&#8217;s historical volatility. The risk-free rate is based on the yield available on United States Treasury zero-coupon issues corresponding to the expected term of the award. The Company records forfeitures when they occur. The Company records compensation expense for service-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the award, or to the date on which retirement eligibility is achieved, if shorter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The grant date fair value of PSUs with market conditions are determined using the Monte Carlo valuation model. The Company records compensation expenses for PSUs based on graded expense attribution over the requisite service periods.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" name="xoma:EquitySecuritiesPolicy" id="Tb_efvJ4gkSaEKIYJY-28c8_w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Equity Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company entered into a license agreement with Rezolute in December 2017, in which it received shares of common stock from Rezolute (Note 4). Equity investments in Rezolute are classified in the condensed consolidated balance sheets as equity securities. The equity securities are measured at fair value, with changes in fair value recorded in the other income (expense), net line item of the condensed consolidated statement of operations and comprehensive loss at each reporting period. The Company remeasures its equity investments at each reporting period until such time that the investment is sold or disposed of. If the Company sells an investment, any realized gains and losses on the sale of the securities will be recognized in the condensed consolidated statement of operations and comprehensive loss in the period of sale.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" name="xoma:FutureMilestonesRoyaltiesPurchaseRightsAndCommercialPaymentsPolicyPolicyTextBlock" id="Tb_Bwjfd7tTokKoj0UyO-6oaw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Purchase of Rights to Future Milestones, Royalties and Commercial Payments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has purchased rights to receive a portion of certain future developmental, regulatory and commercial sales milestones, royalties and option fees on sales of products currently in clinical development or recently commercialized. The Company acquired such rights from various entities and recorded the amount paid for these rights as long-term royalty receivables (Note 5). In addition, the Company may be obligated to make contingent payments related to certain product development milestones, fees upon exercise of options related to future license products and sales-based milestones. The contingent payments are evaluated to determine if they are freestanding instruments or embedded derivatives. If the contingent payments fall within the scope of ASC 815, the contingent payments are measured at fair value at the inception of the arrangement, and subject to remeasurement to fair value each reporting period. Any changes in the estimated fair value are recorded in the condensed consolidated statement of operations and comprehensive loss. Contingent consideration payments that do not fall within the scope of ASC 815 are recognized when the amount is probable and estimable according to ASC 450.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for milestone and royalty rights related to developmental pipeline or recently commercialized products on a non-accrual basis using the cost recovery method. These developmental pipeline products are non-commercialized, non-approved products that require FDA or other regulatory approval, and thus have uncertain cash flows. The recently commercialized products do not have an established reliable sales pattern, and thus have uncertain cash flows. The Company is not yet able to reliably forecast future cash flows given their stages of development and commercialization. The related receivable balance is classified as noncurrent or current based on whether payments are probable and reasonably estimable to be received in the near term. Under the cost recovery method, any milestone or royalty payment received is recorded as a direct reduction of the recorded receivable balance. When the recorded receivable balance has been fully collected, any additional amounts collected are recognized as revenue.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" name="xoma:CreditLossContractWithCustomerAssetPolicyTextBlock" id="Tb_uW46dy75FUOFLbZ_pfNWbw" continuedAt="Tb_uW46dy75FUOFLbZ_pfNWbw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Allowance for Current Expected Credit Losses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company evaluates the long-term royalty and commercial payment receivables on a collective, i.e., pool, basis if they share similar risk characteristics. The Company would evaluate a royalty and commercial payment receivable individually if its risk characteristics are not similar to other royalty and commercial payment receivables. The Company reviews public information on clinical trials, press releases and updates from its partners regularly to identify any impairment indicators or changes in expected recoverability of the long-term royalty and commercial payment receivable </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_WNFn53gzeUOY2PA0RZN8AA_cont4" continuedAt="Tb_WNFn53gzeUOY2PA0RZN8AA_cont5"><ix:continuation id="Tb_uW46dy75FUOFLbZ_pfNWbw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">asset. At each reporting date, if the Company determines expected future cash flows discounted to the current period are less than the carrying value of the asset, the Company will record impairment. The impairment will be recognized as an allowance expense that increases the long-term royalty and commercial payment receivable asset&#8217;s cumulative allowance, which reduces the net carrying value of the long-term royalty and commercial payment receivable asset. In a subsequent period, if there is an increase in expected future cash flows, or if the actual cash flows are greater than previously expected, the Company will reduce the previously established cumulative allowance. Amounts not expected to be collected are written off against the allowance at the time that such a determination is made. &#160;</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" name="xoma:AssetAcquisitionsPolicyPolicyTextBlock" id="Tb_31L6rpdGjkKE5c3rb1LACA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Asset Acquisitions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As a first step, for each acquisition, the Company determines if it is an acquisition of a business or an asset acquisition under ASC 805. Acquisitions of assets or a group of assets that do not meet the definition of a business are accounted for as asset acquisitions under ASC 805-50, using the cost accumulation method, whereby the cost of the acquisition, including certain transaction costs, is allocated to the assets acquired on the basis of relative fair values (Note 4). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Contingent payments are evaluated whether they are freestanding instruments or embedded derivatives. If the contingent payments fall within the scope of ASC 815, the contingent payments are measured at fair value at the acquisition date, and subject to remeasurement to fair value each reporting period. The estimated fair value at the acquisition date is included in the cost of the acquired assets. Any subsequent changes in the estimated fair value are recorded in the condensed consolidated statement of operations and comprehensive loss. Contingent consideration payments that do not fall within the scope of ASC 815 are recognized when the amount is probable and estimable according to ASC 450. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash payments related to acquired assets are reflected as an investing cash flow in the Company&#8217;s condensed consolidated statement of cash flows. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" id="Tb_jkXjKzk1mEC5p2nVXiNl0w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Intangible Assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The identifiable intangible asset consists of IP acquired in the ObsEva IP Acquisition Agreement in 2022. This intangible asset is amortized on a straight-line basis over its estimated useful life of <ix:nonNumeric contextRef="Duration_11_21_2022_To_11_21_2022_dk2CWh67HkeKPZD69Opgyw" format="ixt-sec:durwordsen" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="Narr_5fY3Qs1Ky0WIL_gumb8IiA">17 years</ix:nonNumeric>. The straight-line method of amortization represents the Company&#8217;s best estimate of the distribution of the economic value of the identifiable intangible asset. The intangible asset is carried at cost less accumulated amortization. Amortization will be included in amortization of intangible assets in the condensed consolidated statement of operations and comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amount of an asset group to the future net undiscounted cash flows that the assets are expected to generate. If the carrying amount of an asset group exceeds its estimated future cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset group exceeds the fair value of the asset group. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" name="us-gaap:LesseeLeasesPolicyTextBlock" id="Tb_WY44v84YiUeJhRpQzID0jQ" continuedAt="Tb_WY44v84YiUeJhRpQzID0jQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company leases its headquarters office space in Emeryville, California.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company determines the initial classification and measurement of its right-of-use assets and lease liabilities at the lease commencement date and thereafter if modified. The lease term includes any renewal options and termination options that the Company is reasonably certain to exercise. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its incremental borrowing rate. The incremental borrowing rate is determined by using the rate of interest that the Company would pay to borrow on a collateralized basis an amount equal to the lease payments for a similar term and in a similar economic environment. The Company built its incremental borrowing rate starting with the interest rate on its fully collateralized debt and then adjusted it for lease term length.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk92310155"></a><ix:continuation id="Tb_WNFn53gzeUOY2PA0RZN8AA_cont5" continuedAt="Tb_WNFn53gzeUOY2PA0RZN8AA_cont6"><ix:continuation id="Tb_WY44v84YiUeJhRpQzID0jQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Rent expense for the operating lease is recognized on a straight-line basis, over the reasonably assured lease term based on the total lease payments and is included in operating expenses in the condensed consolidated statements of operations and comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has elected the practical expedient to not separate lease and non-lease components. The Company&#8217;s non-lease components are primarily related to property maintenance, which varies based on future outcomes, and thus is recognized in rent expense when incurred.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" name="us-gaap:IncomeTaxPolicyTextBlock" id="Tb_Tbq6k5CSZEuT00RZDM-oRg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for income taxes using the liability method under which deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount which is more likely than not to be realizable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The recognition, derecognition and measurement of a tax position is based on management&#8217;s best judgment given the facts, circumstances and information available at each reporting date. The Company&#8217;s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense. To date, there have been <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="6" id="Narr_qwJC_Ly8o0G7a83M0GKEuQ">no</ix:nonFraction> interest or penalties charged in relation to the unrecognized tax benefits.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_B60HWjHbTkKxxMBdVBXv8w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Net Loss per Share Attributable to Common Stockholders</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company calculates basic and diluted loss per share attributable to common stockholders using the two-class method. The Company&#8217;s convertible Series X preferred stocks participate in any dividends declared by the Company on its common stock and are therefore considered to be participating securities. The Company&#8217;s Series A and Series B Preferred Stock do not participate in any dividends or distribution by the Company on its common stock and are therefore not considered to be participating securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the two-class method, net income, as adjusted for any accumulated dividends on Series A and Series B Preferred Stock for the period, is allocated to each class of common stock and participating security as if all of the net income for the period had been distributed. Undistributed earnings allocated to participating securities are subtracted from net income in determining net income attributable to common stockholders. During periods of loss, the Company allocates no loss to participating securities because they have no contractual obligation to share in the losses of the Company. Basic net loss per share attributable to common stockholders is then calculated by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. All participating securities are excluded from the basic weighted average common shares outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Diluted net loss per share attributable to common stockholders is based on the weighted average number of shares outstanding during the period, adjusted to include the assumed exercise of certain stock options and warrants for common stock using the treasury method, if dilutive. The calculation assumes that any proceeds that could be obtained upon exercise of options and warrants would be used to purchase common stock at the average market price during the period. Adjustments to the denominator are required to reflect the related dilutive shares. The Company&#8217;s Series A and Series B Preferred Stock become convertible upon the occurrence of specific events other than a change in the Company&#8217;s share price and, therefore, are not included in the diluted shares until the contingency is resolved.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" name="us-gaap:ConcentrationRiskCreditRisk" id="Tb_LqVgkf9dZUGZA7aZ9GsbUw" continuedAt="Tb_LqVgkf9dZUGZA7aZ9GsbUw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Concentration of Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash, cash equivalents and receivables are financial instruments which potentially subject the Company to concentrations of credit risk, as well as liquidity risk. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company maintains cash balances at commercial banks. Balances commonly exceed the amount insured by the FDIC. The Company has not experienced any losses in such accounts.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_WNFn53gzeUOY2PA0RZN8AA_cont6"><ix:continuation id="Tb_LqVgkf9dZUGZA7aZ9GsbUw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company monitors the creditworthiness of its customers to which it grants credit terms in the normal course of business but does not generally require collateral on receivables. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the three months ended June 30, 2023, <ix:nonFraction unitRef="Unit_Standard_customer_DppB2cRPP0aciLos32fCZw" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_v_4086cVDUmoGR5d7CgO0A" decimals="INF" format="ixt-sec:numwordsen" name="xoma:NumberOfMajorPartners" scale="0" id="Narr_iQxDvbz2DUy8ZKeb77WHIw">two</ix:nonFraction> partners represented <ix:nonFraction unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ" contextRef="Duration_4_1_2023_To_6_30_2023_srt_MajorCustomersAxis_xoma_Partner1Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_UPb9E7A4oUG9Ls-shtbyPg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Narr_2INIojdWxkeumIHwLgnawQ">66</ix:nonFraction>% and <ix:nonFraction unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ" contextRef="Duration_4_1_2023_To_6_30_2023_srt_MajorCustomersAxis_xoma_Partner2Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_sqEiwRkHBkmAPGUe0Ez5pg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Narr_3w5u4Ym3RUauYIpNE_gZCA">32</ix:nonFraction>% of total revenues. For the six months ended June 30, 2023, <ix:nonFraction unitRef="Unit_Standard_customer_DppB2cRPP0aciLos32fCZw" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_e0nlQVVkQEC_RcJPbx3_LQ" decimals="INF" format="ixt-sec:numwordsen" name="xoma:NumberOfMajorPartners" scale="0" id="Narr_D5pWRXD4OE-yiAYTncXuig">two</ix:nonFraction> partners represented <ix:nonFraction unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ" contextRef="Duration_1_1_2023_To_6_30_2023_srt_MajorCustomersAxis_xoma_Partner1Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_3vOSN9-0P0-FLZiHWIajhw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Narr_dO1tfYcx5kSRuPqjFtA6DA">53</ix:nonFraction>% and <ix:nonFraction unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ" contextRef="Duration_1_1_2023_To_6_30_2023_srt_MajorCustomersAxis_xoma_Partner2Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_R1d0cYWaYUKU7Z4Y59JDYQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Narr_PbCbpUEEfEqL9XXON_pf_A">46</ix:nonFraction>% of total revenues. For the three months ended June 30, 2022, <ix:nonFraction unitRef="Unit_Standard_customer_DppB2cRPP0aciLos32fCZw" contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_qONAes1cy0G9lDzJGggO0Q" decimals="INF" format="ixt-sec:numwordsen" name="xoma:NumberOfMajorPartners" scale="0" id="Narr_zBXG57hUXkGVi5KBrlOxSA">two</ix:nonFraction> partners represented <ix:nonFraction unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ" contextRef="Duration_4_1_2022_To_6_30_2022_srt_MajorCustomersAxis_xoma_Partner1Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_3OysOB_GGkiYd3yyjB2f9A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Narr_zZAyhjpH1EqJsKCGLn2qKA">51</ix:nonFraction>% and <ix:nonFraction unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ" contextRef="Duration_4_1_2022_To_6_30_2022_srt_MajorCustomersAxis_xoma_Partner2Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_uLAkeS_2ikqgahYM_BFpvQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Narr_xpNVZRUe7ES6z2lnTPCRqA">47</ix:nonFraction>% of total revenues. For the six months ended June 30, 2022, <ix:nonFraction unitRef="Unit_Standard_customer_DppB2cRPP0aciLos32fCZw" contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_heK3HldCNE-r5gSRWagnnQ" decimals="INF" format="ixt-sec:numwordsen" name="xoma:NumberOfMajorPartners" scale="0" id="Narr_7WsgZsPEQEOvBqzFkkrzuw">four</ix:nonFraction> partners represented <ix:nonFraction unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ" contextRef="Duration_1_1_2022_To_6_30_2022_srt_MajorCustomersAxis_xoma_Partner1Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_OklwX0sEhUKh7TG7yMRNEw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Narr_n6S6yZ27lk6P9k8YDSiaGg">49</ix:nonFraction>%, <ix:nonFraction unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ" contextRef="Duration_1_1_2022_To_6_30_2022_srt_MajorCustomersAxis_xoma_Partner2Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_VFb8t0MUH0G_Z4BDZPkyFw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Narr_aWGY4bdwN0OiLgo_7tsaow">20</ix:nonFraction>%, <ix:nonFraction unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ" contextRef="Duration_1_1_2022_To_6_30_2022_srt_MajorCustomersAxis_xoma_Partner3Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_eW6Ihd4mvke6ewsUy3Hagg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Narr_2EnX5d5vqE-1sLm_2fTWtw">18</ix:nonFraction>% and <ix:nonFraction unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ" contextRef="Duration_1_1_2022_To_6_30_2022_srt_MajorCustomersAxis_xoma_Partner4Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_SHilGTcI4ECxZyoz6P8uNQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Narr_164wSxfCJUi_BjFTXIDpsA">12</ix:nonFraction>% of total revenues. <ix:nonFraction unitRef="Unit_Standard_customer_DppB2cRPP0aciLos32fCZw" contextRef="Duration_1_1_2023_To_6_30_2023_srt_MajorCustomersAxis_xoma_Partner1Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_TradeAccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_-LRlYQJJLk-TqPh3pxJ8_A" decimals="INF" format="ixt-sec:numwordsen" name="xoma:NumberOfMajorPartners" scale="0" id="Narr_yztWsDQ1x0CJIvQYgdkjHA">One</ix:nonFraction> partner represented <ix:nonFraction unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ" contextRef="Duration_1_1_2023_To_6_30_2023_srt_MajorCustomersAxis_xoma_Partner1Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_TradeAccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_-LRlYQJJLk-TqPh3pxJ8_A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Narr_mOMIoAwUcUSlDqOMKqG9ng">100</ix:nonFraction>% of the trade receivables, net balance as of June 30, 2023. There were <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ReceivablesLongTermContractsOrPrograms" scale="6" id="Narr_0DPdYAu5hk6XaKvqKiKhdA">no</ix:nonFraction> trade receivables, net balance as of December 31, 2022.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="Tb_Ilxq1TW2wkKQ6AWTHys1_w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Comprehensive Loss</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Comprehensive loss is comprised of two components: net loss and other comprehensive loss. Other comprehensive loss refers to gains and losses that under U.S. GAAP are recorded as an element of stockholders&#8217; equity but are excluded from net loss. The Company did not record any transactions within other comprehensive loss in the periods presented and, therefore, the net loss and comprehensive loss were the same for all periods presented.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_kGEkR1Ya-0mslUOmjoukYw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Accounting Pronouncements Recently Adopted</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (ASC 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 replaced the incurred loss impairment methodology under current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. ASU 2016-13 requires use of a forward-looking expected credit loss model for accounts receivables, loans, and other financial instruments. Adoption of the standard requires using a modified retrospective approach through a cumulative-effect adjustment to retained earnings as of the effective date to align existing credit loss methodology with the new standard. The Company adopted ASU 2016-13 and related updates on January 1, 2023. The adoption of ASU 2016-13 had no impact on the condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In October 2021, the FASB issued ASU 2021-08, Business Combinations &#8211; Accounting for Contract Assets and Contact Liabilities from Contracts with Customers. The guidance is intended to improve the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice. The guidance requires an acquirer to recognize and measure contract assets and liabilities acquired in a business combination in accordance with ASC 606 as if they had originated the contracts, as opposed to at fair value on the acquisition date. The Company adopted ASU 2021-08 and related updates on January 1, 2023. The adoption of ASU 2021-08 had no impact on the condensed consolidated financial statements.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" name="us-gaap:AdditionalFinancialInformationDisclosureTextBlock" id="Tb_Ol4NC3iHKUS9oWZCarVwpw" continuedAt="Tb_Ol4NC3iHKUS9oWZCarVwpw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">3.&#160;Condensed Consolidated Financial Statements Details</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Equity Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Equity securities consisted of an investment in Rezolute&#8217;s common stock of $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_LzgovgUcyUqFQMy5t8ndVg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFVNINoncurrent" scale="6" id="Narr_48MZe2-lVUmJGDPIKfNE7A"><ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_OFKp4An1GUS4-brDAQB8ew" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFVNINoncurrent" scale="6" id="Narr_HE2iAdTfck-Sokyb3ePnSg">0.3</ix:nonFraction></ix:nonFraction> million for both June 30, 2023 and December 31, 2022 (Note 4). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the three and six months ended June 30, 2023, the Company recognized a gain of $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2023_To_6_30_2023_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_PwcTNnqVHEurE6RMUONPsw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="0" id="Narr_tFx6rZbtyEuWNuX6WntqVA">10,000</ix:nonFraction> and a loss of $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_6_30_2023_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_EPzxT9qkbUedyZWvfkZUhA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" sign="-" scale="0" id="Narr_GiS66EJ1o0ynwkXZ_9Ayvg">15,000</ix:nonFraction>, respectively, due to the change in fair value of its investment in Rezolute&#8217;s common stock in the other income (expense), net line item of the condensed consolidated statements of operations and comprehensive loss. For the three and six months ended June 30, 2022, the Company recognized a loss of $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2022_To_6_30_2022_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_NuaPtHy1BU6__HgLOoJDdw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" sign="-" scale="0" id="Narr_7Jniw-K550q1w48xLyAzpw">25,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2022_To_6_30_2022_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_Abl8Ryg010astqw5xtuhDg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" sign="-" scale="6" id="Narr_pFB9b71otkO6jZOmp2tMWg">0.3</ix:nonFraction> million, respectively, due to the change in fair value of its investment.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_138e2443_dde3_4db2_813e_1d5856dddbf2"></a><a id="Tc_HPoAubNfNkGbLWsmPcoFwA_1_5"></a><a id="Tc_uUMp-cq6bEmhODfRF_cRpQ_1_8"></a><a id="Tc_1BEAtZkXIUWPmdFw-f5sZQ_2_2"></a><a id="Tc_tdFZJsLN9U6XjCqMrk6jzA_2_5"></a><a id="Tc_BGWqscJAmEOom37r8mIOWw_2_8"></a><a id="Tc_Cm3CQUGtU0qVD4lvh--zAw_3_0"></a><a id="Tc_apdYGHW0Fkm90wgICr6kIw_4_0"></a><a id="Tc_ApfW6ZiITkyk_jSdzONvXQ_4_2"></a><a id="Tc_YzEW_jrEFUysTAuaIFrsFw_4_5"></a><a id="Tc_s3FgL8nNJ0ujjkBtyJGWag_4_8"></a><a id="Tc_JIvmlp8RVEKLDDcD-SbFTA_5_0"></a><a id="Tc_ss64XELZU0-ymJrwitfQrA_5_2"></a><a id="Tc_5u8b5__ko0ubSI4kd6IutQ_5_5"></a><a id="Tc_ckbxoyXlYUSOuIw7nh9IRg_5_8"></a><a id="_654df3e2_a824_4fd7_929a_8d743fc528dd"></a><a id="Tc_k0ytpigxDkyKRiDAoy8JXw_1_5"></a><a id="Tc_k1TAuwvuj0-b-vDoWlib6A_1_8"></a><a id="Tc_gkKxOQjGdUCkuYUHuwlXTw_2_2"></a><a id="Tc_1fd1kTspnEewkp1e8JqBjA_2_5"></a><a id="Tc_mVDxTDMc6kW7Iu4GiKUMRA_2_8"></a><a id="Tc_BdyCGtC1dECWblny8T7xjw_3_0"></a><a id="Tc_eyF6L3C1l02HAxs33cgwKg_4_0"></a><a id="Tc_4XiZTMlAH0CgiQppO8VSxg_4_2"></a><a id="Tc_MGEf7IQ2ZkSp7mHEkLV8Pg_4_5"></a><a id="Tc_TMK7aiH-H0qd1xT6t-k-KQ_4_8"></a><a id="Tc_pdOLen8s8kmPh2uYc8g9MQ_5_0"></a><a id="Tc_Ozx345O2EkOCkGAfpj1xRg_5_2"></a><a id="Tc_-2USblT9q06O7RFRX7-chQ_5_5"></a><a id="Tc_Y1698G4W90WWLM-4PvgVrw_5_8"></a><a id="_33f442c3_b474_4f3a_b34b_6ee0613bcaf0"></a><a id="Tc_G83VG9eL-UqOKbRWdZ550Q_1_2"></a><a id="Tc_A88x_4qYiUql9xXuTwppwQ_2_2"></a><a id="Tc_0urnnwVXb0CSkkvn1-9ZtA_4_0"></a><a id="Tc_z_SV39-cAUuVLTqSn15jtQ_4_2"></a><a id="Tc_UTGJlyIS3U-ouzLm2w4uvQ_5_0"></a><a id="Tc_QqaoFcIXZUy97xbO5kSW5w_6_0"></a><a id="Tc_zNX7OT0jpUyqNXHSPVoGPA_7_0"></a><a id="Tc_McH4xgbL70mE0fzgcG_-mQ_8_0"></a><a id="Tc_Ogx0jXhkskKlsL4BAmxkRg_9_0"></a><a id="Tc_pqJpo4LTCUiUoMckeETGmg_9_2"></a><a id="_70efb590_d0c1_40c0_b7c5_c6a5ca3c471b"></a><a id="Tc_wzUjDxs_e0-HHyz7wKw3Ow_1_2"></a><a id="Tc_IcROhidEKEWydEAWFai2fQ_1_5"></a><a id="Tc_vkO5pCxjE0aXz33jo3anYQ_2_2"></a><a id="Tc_zV8cFhepB0CwgjEukqVuaw_2_5"></a><a id="Tc_PeLiEv-UZ0GdrskOWSyttw_3_0"></a><a id="Tc_Z2L2F3yJXEOucfM5QOsVag_4_0"></a><a id="Tc__Ag7zH5FXkmnYcB0vJPGbw_5_0"></a><a id="Tc_xp1QsTkCKUGt3rX8uYJsRQ_6_0"></a><a id="Tc_Cu9MLOQKKU21gtVo2yJajw_7_0"></a><a id="Tc_2yTf34_J50iqRzfife2CWQ_7_2"></a><a id="Tc_7tttamQdBEqWDnrD2dl6jQ_7_5"></a><ix:continuation id="Tb_Ol4NC3iHKUS9oWZCarVwpw_cont1" continuedAt="Tb_Ol4NC3iHKUS9oWZCarVwpw_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Intangible assets, net</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="Tb_U5QvpoG60U-qdRuHO5Tjnw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes cost, accumulated amortization, and net carrying value of the intangible assets as of June 30, 2023 (in thousands): </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net Carrying</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortization</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As of June 30, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Ebopiprant IP (Note 4) </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_Gfw9LK-Od0iMS_KhAfKpsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="Tc_8InTHeBuAU66vydABDpnDw_4_3">15,247</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_Gfw9LK-Od0iMS_KhAfKpsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="Tc_UeFrxKIKDECS5hKD4lvJ2A_4_6">546</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_Gfw9LK-Od0iMS_KhAfKpsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="Tc_Hd82jmIpL0qSbwbAwi3yHg_4_9">14,701</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total intangible assets </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="Tc_31xHGqxA00CYrlt8bGtOxg_5_3">15,247</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="Tc_7dng_N4fFU2Vy87ymgK7Qg_5_6">546</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="Tc__fW-QMH4vUS4Vd0ekkMZxA_5_9">14,701</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table summarizes cost, accumulated amortization, and net carrying value of the intangible assets as of December 31, 2022 (in thousands): </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net Carrying</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortization</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As of December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Ebopiprant IP (Note 4) </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_ruM398xI60a2mOzUa9tLiw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="Tc_sWQ88ybKkE2SCBBogkzO6w_4_3">15,247</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_ruM398xI60a2mOzUa9tLiw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="Tc__pviEn79mUSMg_dJkdE8aA_4_6">97</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_ruM398xI60a2mOzUa9tLiw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="Tc_PWEK9bkv-k2ALBKqC2wIcw_4_9">15,150</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total intangible assets </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="Tc_of_qWHAWCkmS_M-GxZRfng_5_3">15,247</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="Tc_ncJX3HtUxk2mbY2QPamYmA_5_6">97</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="Tc_ln7b-n-reka6JJVIMvuciA_5_9">15,150</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="Tb_ToyRHX3lA0ap040XPAJsJA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The remaining life of the intangible assets is <ix:nonNumeric contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" id="Narr_gtpIQfYVrkG5TvjAB8Nocg">16.4</ix:nonNumeric> years. The following table presents the projected amortization expense for the next five years (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;"> </span><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intangible Asset</b></p></td></tr><tr><td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortization</b></p></td></tr><tr><td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:83.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2023 (excluding six months ended June 30, 2023)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" scale="3" id="Tc_53zABuA2ekq0cjjnIAgmhA_4_3">448</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="3" id="Tc_xzphs7sMO0GcahPo3-9dKw_5_3">897</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:83.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="3" id="Tc_Xvj2v0fackGSjtnKw6MOlQ_6_3">897</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="3" id="Tc_AO7VXa2yBEW7tP2CUlWNBg_7_3">897</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:83.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="3" id="Tc_EWAITbryMUOZt_0YIQIaIw_8_3">897</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ" decimals="-3" format="ixt:numdotdecimal" name="xoma:FiniteLivedIntangibleAssetExpectedAmortizationThroughYearFive" scale="3" id="Tc_2q9y7P1NU0OpkypkY7Hmsw_9_3">4,036</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Accrued and Other Liabilities</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="Tb_krzR2S5j90yZnItSF81MMA" continuedAt="Tb_krzR2S5j90yZnItSF81MMA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Accrued and other liabilities consisted of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued payroll, severance and retention costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ" decimals="-3" format="ixt:numdotdecimal" name="xoma:AccruedSalariesAndEmployeeBenefitsCurrent" scale="3" id="Tc_-QSiiTg_hECwKVgSXpGqCg_3_3">978</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg" decimals="-3" format="ixt:numdotdecimal" name="xoma:AccruedSalariesAndEmployeeBenefitsCurrent" scale="3" id="Tc_NJAx2MZrcEikCW7hHIHHzg_3_6">1,449</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued incentive compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedBonusesCurrent" scale="3" id="Tc_m_6pbYKYDUSSnBPlniUnEA_4_3">604</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedBonusesCurrent" scale="3" id="Tc_3t-aABtqNkOUCjl6prkEeQ_4_6">562</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued legal and accounting fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="Tc_7B8YpVORm02U5F2iF9yf9A_5_3">331</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="Tc_Gz6A8jw0RE-K50EFkEUwcA_5_6">867</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_yhzqZ9HkpEOKE841TdhHaw_6_3">20</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_Y6xkk0PjIkOhVHG_CCJ_LQ_6_6">40</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ" decimals="-3" format="ixt:numdotdecimal" name="xoma:AccruedAndOtherLiabilitiesCurrent" scale="3" id="Tc_g5O81YcVBEihbmoGR2-BBQ_7_3">1,933</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg" decimals="-3" format="ixt:numdotdecimal" name="xoma:AccruedAndOtherLiabilitiesCurrent" scale="3" id="Tc_riTwS2f62kCDe1qPnjn5SQ_7_6">2,918</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_c66df204_b0d8_4b2c_b8ce_05dff38819fb"></a><a id="_bfe996eb_faf6_43e0_9b6d_4212ac7f8fc1"></a><a id="Tc_qStxzKnJSkqz4_c_Zy1u6A_1_2"></a><a id="Tc_gn_sOvC6wUyr8nq6UjkdMQ_1_8"></a><a id="Tc_TxXSjQIE7Uu45Iz7plk7mw_2_2"></a><a id="Tc_C1uKMBeeLUCVgGH6BWkNHg_2_5"></a><a id="Tc_23LX0Ho8BEa3-MIKYQiroA_2_8"></a><a id="Tc_KMFAUMSL9kizchRat8YpuA_2_11"></a><a id="Tc_TLQ0_jq8VkaAwKeQht2lqg_3_0"></a><a id="Tc_TTRuzCDVHUCiWzN5y3iXsQ_4_0"></a><a id="Tc_x6wUrz2PFUyndEB-rkP2Lg_4_2"></a><a id="Tc_7iCKcpLviEq06SiZOMY8dw_4_5"></a><a id="Tc_1FuxGVX8bkG8LVochPzVrQ_4_8"></a><a id="Tc_CHE2iZXQm0uqBDUHjkWfQg_4_11"></a><a id="Tc_IkhDMHhkZkW6HXfXwVOLIA_5_0"></a><a id="Tc_emuxar8OOkSWJGZ6ATIpJQ_6_0"></a><a id="Tc_uNRr46-d6UihpD7yt260zQ_7_0"></a><a id="Tc_Umkzc4w6WkqjzBzV-k0L1A_7_8"></a><a id="Tc_JSM8BlU380Klw6sod6426A_9_0"></a><a id="Tc__i6GWiEW50S2W19OL8tQog_10_0"></a><a id="Tc_SygYvyCDrUiy-hzsjU7Ftw_11_0"></a><a id="Tc_HUk_-jOeFUq2Ajcal96OSg_11_2"></a><a id="Tc_rUhH84FdV0CRUWK9n_KNeQ_11_8"></a><a id="Tc_b9kafMogUUaVLZqHIoZJxg_11_11"></a><a id="_27796615_b073_4bda_be69_0ae22386d9ec"></a><a id="Tc_7Xn3VTdeYkqzJbVHGNtnvQ_1_2"></a><a id="Tc_gRGAZCEAO0qEg0MHHBuNHw_1_6"></a><a id="Tc_CgTZi_Jv-kiSzA9frQgOsw_2_2"></a><a id="Tc_jXWcDSE5u0e5gwEXHSdGdg_2_4"></a><a id="Tc_QzRLo8JfHEO9DcYBirn4TA_2_6"></a><a id="Tc_HySoVAOYWE6yha-liPC9AA_2_8"></a><a id="Tc_ISvk_7i9mEi1d50WUbrXiw_3_0"></a><a id="Tc_EYCWGmUgg0iXpuvZ6oL1_g_4_0"></a><a id="Tc_UrxuOV9aiUWZjl-kDS9leQ_5_0"></a><a id="Tc_9GBF9ML0y0eaAx6Fec-GFA_6_0"></a><ix:continuation id="Tb_Ol4NC3iHKUS9oWZCarVwpw_cont2"><ix:continuation id="Tb_krzR2S5j90yZnItSF81MMA_cont1"></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Net Loss Per Share Attributable to Common Stockholders </p><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="Tb_A7wNBwO2vE6I2yjS8quQRw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following is a reconciliation of the numerator (net loss) and the denominator (number of shares) used in the calculation of basic and diluted net loss per share attributable to common stockholders (in thousands, except per share amounts):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six Months Ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Numerator</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:55.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_jtUGeNFJfUOGv7SI-OJ9Jg_4_3">5,400</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2022_To_6_30_2022_MkbIQ9bQc0eX6Gc5LtLGHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_fMiCQBZ_tESdilML6kCvHQ_4_6">4,670</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_5aXXg5Y_FkWMcyvtLYrtNA_4_9">15,213</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_vsOYh6FPgUGYGRBODV1Ldw_4_12">6,950</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:55.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: Series A accumulated dividends </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_709bNt4Pc0ah6gEtj2ui5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" scale="3" id="Tc_05X3Xj7r4UmJQBiZG14F0A_5_3">530</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_d2IDvzwTtEeRbBTwLkWiZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" scale="3" id="Tc_YpjQkHNFYkWcAHdprSUNjg_5_6">530</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_5kIt1X7W_UGV93RZQkNN3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" scale="3" id="Tc_M2Lpf2KV806Flc63A_t2WA_5_9">1,061</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_gy4yRQy_g0efVGsZ9JvfSg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" scale="3" id="Tc_6ih8LX22S0SELzj8ux7cOw_5_12">1,061</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:55.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: Series B accumulated dividends </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_-1YcQgV4D0GXoCudlGfzsQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" scale="3" id="Tc_5LQimo34KkiPbjygQV-fDQ_6_3">838</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_q_kRVdOaKUGqFvcO4YBRYg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" scale="3" id="Tc_dv9-BoOIkEeoe0WYTLhzDQ_6_6">838</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_mZzBVYXOQEiwSAFnA-OODw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" scale="3" id="Tc_QINOd5fm4U2PcNi7S2dACw_6_9">1,675</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_WOYOn9euaESUo_Fdt2xQDQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" scale="3" id="Tc_pmDah6DBKkqSkE137dr7wQ_6_12">1,675</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:55.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss attributable to common stockholders, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_ZCzEuDg56E2NgVqb6ztjGw_7_3"><ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" sign="-" scale="3" id="Tc_ZCzEuDg56E2NgVqb6ztjGw_7_3_2">6,768</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2022_To_6_30_2022_MkbIQ9bQc0eX6Gc5LtLGHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_sf1z9LdISUCYDFQL2VLywg_7_6"><ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2022_To_6_30_2022_MkbIQ9bQc0eX6Gc5LtLGHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" sign="-" scale="3" id="Tc_sf1z9LdISUCYDFQL2VLywg_7_6_2">6,038</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_k8bf7dpgs0KDmSVJfYuiGQ_7_9"><ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" sign="-" scale="3" id="Tc_k8bf7dpgs0KDmSVJfYuiGQ_7_9_2">17,949</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_bxiFoyh950O4bsxlPseiXg_7_12"><ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" sign="-" scale="3" id="Tc_bxiFoyh950O4bsxlPseiXg_7_12_2">9,686</ix:nonFraction></ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:55.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Denominator</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average shares used in computing basic and diluted net loss per share attributable to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_R-63WqtCcEuldX2oNjJpOw_10_3"><ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_R-63WqtCcEuldX2oNjJpOw_10_3_2">11,466</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="Duration_4_1_2022_To_6_30_2022_MkbIQ9bQc0eX6Gc5LtLGHQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_Z5MQAuG7pU60Xlt2N_4MPA_10_6"><ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="Duration_4_1_2022_To_6_30_2022_MkbIQ9bQc0eX6Gc5LtLGHQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_Z5MQAuG7pU60Xlt2N_4MPA_10_6_2">11,421</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_g2M52UF9TkisAZx6a52d1Q_10_9"><ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_g2M52UF9TkisAZx6a52d1Q_10_9_2">11,463</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_4B_uW7B47k-7ZuPRRKwcaA_10_12"><ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_4B_uW7B47k-7ZuPRRKwcaA_10_12_2">11,376</ix:nonFraction></ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:55.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Basic and diluted net loss per share attributable to common stockholders </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg" contextRef="Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_WZYCsQ7jekSnRJTe9nJj-A_11_3"><ix:nonFraction unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg" contextRef="Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_WZYCsQ7jekSnRJTe9nJj-A_11_3_2">0.59</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg" contextRef="Duration_4_1_2022_To_6_30_2022_MkbIQ9bQc0eX6Gc5LtLGHQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_WkeKTNVc5UaznFlr8iDovg_11_6"><ix:nonFraction unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg" contextRef="Duration_4_1_2022_To_6_30_2022_MkbIQ9bQc0eX6Gc5LtLGHQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_WkeKTNVc5UaznFlr8iDovg_11_6_2">0.53</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg" contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_xlrPlxAmgUmko1T2XGq98w_11_9"><ix:nonFraction unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg" contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_xlrPlxAmgUmko1T2XGq98w_11_9_2">1.57</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg" contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_niX5K8YRp06qiqwr9aKcmw_11_12"><ix:nonFraction unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg" contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_niX5K8YRp06qiqwr9aKcmw_11_12_2">0.85</ix:nonFraction></ix:nonFraction>)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Potentially dilutive securities are excluded from the calculation of diluted net loss per share attributable to common stockholders if their inclusion is anti-dilutive. </p><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Tb_bK69XbZe9U2WaRqQJ7c13A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table shows the weighted-average shares from outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net loss per share attributable to common stockholders (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six Months Ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Convertible preferred stock </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember_5ZLg9x5yckWz22fWebcY8g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_Q_TJlI5DSU-MHpCVlXR8oQ_3_2">5,003</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember_oMboSz0lqEOTYykVt-gofg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_qju7z5rJQUuCi9elCZAtWQ_3_4">5,003</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember_4EdMPylUGUe0Dt4op523HQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_IkP3EsyHoEu7-TOKBto67g_3_6">5,003</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember_q5E1VWyBm0qYx76IUNrtVg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_5Aahoe9F_UqlolcchEMypQ_3_8">5,003</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:55.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Common stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_Ly-nCcCNVEyOwbUV0qBVsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_58unOf4hrki0A2-03Ye32w_4_2">1,719</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_s4acrI5TS06hk24i6x3lNw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_jLiY5y3Kb06oIgSRwiZ3zA_4_4">889</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_lxT004blek2W7cHNT8xELA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_TVz6Y03ZRUaydWmPaIvBWw_4_6">1,634</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_NYjwGA24DUagvxCWxn84Ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_oL4OZySjNEqA6QpSazwvqA_4_8">813</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:55.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants for common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_2Ja-erVJsE2TwmalqlMXlA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_ukLDH-0XeE26j86Mo9tfUA_5_2">6</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_89XiQrxi6U-bxg6UnFGjBA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_EALJbi6Uh0-85lX3RzhdLg_5_4">6</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_V2QHn9TZ1U2Os4nccw_I7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_Z8VN6apZoU2I64Out4zAWA_5_6">6</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_q9rTRUIKZEeJEnJsjreVeA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_9QCcxcT9T0qqxY55HZ40Cw_5_8">6</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:55.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_1lTrp2yQIUqD2SQekSVx2g_6_2">6,728</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="Duration_4_1_2022_To_6_30_2022_MkbIQ9bQc0eX6Gc5LtLGHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_jdrReyVDv0a3n2WOatC9Hg_6_4">5,898</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_SsSRkYzZykWV5N963BIlzA_6_6">6,643</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_JfsbN7gBVkijqFbMdWACVg_6_8">5,822</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;background:#00ff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">For PSUs with market conditions, if the market conditions have not been satisfied by the end of the reporting period, the number of shares that would be issuable based on the market price at the end of the reporting period, as if the end of the reporting period were the end of the contingency period, will be included in the calculation of diluted earnings per share if the effect is dilutive. No shares would be issuable based on the market price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg" contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vo9zKMnZO0aHN96tsj24CA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_GKVNEPoD9k-PJD2Sdfun7A">18.89</ix:nonFraction> per share as of June 30, 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Arbitration Proceeding </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In June 2021, the Company initiated a binding arbitration proceeding with <ix:nonFraction unitRef="Unit_Standard_item_ZJDcTjbqbUC2tIGJY9M-pg" contextRef="Duration_6_1_2021_To_6_30_2021_xtjjCBFLBUi_Ojs50RRq5w" decimals="INF" format="ixt-sec:numwordsen" name="xoma:NumberOfArbitrationProceedingsInitiated" scale="0" id="Narr_6gA5ZE0xeUy8_UnqffYE1w">one</ix:nonFraction> of its licensees (the &#8220;Licensee&#8221;) at the American Arbitration Association/International Centre for Dispute Resolution, seeking milestone and royalty payments under its license agreement. A hearing before a panel of arbitrators was held in November 2022, and the parties submitted post-hearing briefs. On March 21, 2023, the Company received an adverse decision in this arbitration proceeding. The panel of arbitrators declined to award the Company damages and ruled that the license agreement has expired. The panel ruled that the Company is responsible for the Licensee&#8217;s costs as well as arbitrators&#8217; and administrative fees previously incurred by the Licensee of $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LitigationSettlementExpense" scale="6" id="Narr_BmcVSN9_vE-QGTGIUK9Ejw">4.1</ix:nonFraction> million, which the Company paid in April 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" name="xoma:LicensingAndOtherArrangementsTextBlock" id="Tb_rU4qsB3c40mxkEtUpzEhxQ" continuedAt="Tb_rU4qsB3c40mxkEtUpzEhxQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">4. Licensing and Other Arrangements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">ObsEva </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On November 21, 2022, the Company entered into the ObsEva IP Acquisition Agreement pursuant to which the Company acquired all of ObsEva&#8217;s intellectual property (patents and know-how) and license agreement rights related to ebopiprant, an investigational compound previously licensed by ObsEva from Merck KGaA. The Company also assumed ObsEva&#8217;s ongoing rights and obligations under the Organon License Agreement and the Merck KGaA License Agreement. Pursuant to the Organon License Agreement, XOMA is eligible to receive up to $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_11_21_2022_srt_CounterpartyNameAxis_xoma_OrganonMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_VI6RYGqQZkeAVJnnIv4sTQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentCommercializationAndSalesMilestones" scale="6" id="Narr_pSx_uLvC4E6q1-aIQoLdtA">475.0</ix:nonFraction> million in payments for ebopiprant development, commercialization and sales-based milestones. If ebopiprant is successfully commercialized, the Company will be entitled to receive royalties on net sales that range from low to mid-teens from Organon and will be required to make mid-single-digit royalty payments on net sales to Merck KGaA. The Company paid ObsEva a $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_11_21_2022_To_11_21_2022_us-gaap_AssetAcquisitionAxis_xoma_ObsevaIntellectualPropertyRightsMember_lo8MSWY_Dk2sar0rv1imYg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="Narr_oxW3YS_xP0maziaJwBqNnQ">15.0</ix:nonFraction> million upfront payment at closing and will pay potential earn-out payments of up to $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_11_21_2022_us-gaap_AssetAcquisitionAxis_xoma_ObsevaIntellectualPropertyRightsMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_eP4cyYTR-k2h0sxHIlensA" decimals="-5" format="ixt:numdotdecimal" name="xoma:MaximumEarnOutPayments" scale="6" id="Narr_o3FQrmp64EKYLmEyDJPPDg">97.5</ix:nonFraction> million for development, regulatory and sales-based milestones, representing a portion of what the Company would receive pursuant to the Organon License Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The transaction was treated as an acquisition of a finite-lived intangible asset (Note 2). As such, the Company&#8217;s cost to acquire said intangible asset of $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_11_21_2022_To_11_21_2022_us-gaap_AssetAcquisitionAxis_xoma_ObsevaIntellectualPropertyRightsMember_lo8MSWY_Dk2sar0rv1imYg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AssetAcquisitionConsiderationTransferred" scale="6" id="Narr_DL0K8u5nD0GeqFqtB972zA">15.2</ix:nonFraction> million, consisting of $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_11_21_2022_To_11_21_2022_us-gaap_AssetAcquisitionAxis_xoma_ObsevaIntellectualPropertyRightsMember_lo8MSWY_Dk2sar0rv1imYg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="Narr_G09_VXLldEG0exllFzVW5g">15.0</ix:nonFraction> million cash paid upon closing of the ObsEva IP Acquisition Agreement and direct incremental transaction costs of $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_11_21_2022_To_11_21_2022_us-gaap_AssetAcquisitionAxis_xoma_ObsevaIntellectualPropertyRightsMember_lo8MSWY_Dk2sar0rv1imYg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost" scale="6" id="Narr_fZQFi_6LOkKV5BjIUrYaaA">0.2</ix:nonFraction> million, was recognized as a long-term asset in the consolidated balance sheet for the year ended December 31, 2022. The estimated useful life of the intangible asset at acquisition represented <ix:nonNumeric contextRef="Duration_11_21_2022_To_11_21_2022_us-gaap_AssetAcquisitionAxis_xoma_ObsevaIntellectualPropertyRightsMember_lo8MSWY_Dk2sar0rv1imYg" format="ixt-sec:durwordsen" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="Narr_3RviYvaVgU-g_tcKTjBMow">17 years</ix:nonNumeric>. No impairment indicators were identified, and <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AssetAcquisitionAxis_xoma_ObsevaIntellectualPropertyRightsMember_sYlzh40hyE6ZDGRh_bcjVw" decimals="-6" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="6" id="Narr_28LMoJ6RDkiJrhOmPDCJZg"><ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AssetAcquisitionAxis_xoma_ObsevaIntellectualPropertyRightsMember_aKWzGNtzM0-dDhbT2Gyirg" decimals="-6" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="6" id="Narr__F-nqJrMlEifyZ1zSOSbZA">no</ix:nonFraction></ix:nonFraction> impairment was recorded as of June 30, 2023 and December 31, 2022. The Company recognized $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_AssetAcquisitionAxis_xoma_ObsevaIntellectualPropertyRightsMember_ZsDO0IohTEmlxBFNZXxV-w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="Narr__5kv_aNe_k6vXnISbhjwIA">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AssetAcquisitionAxis_xoma_ObsevaIntellectualPropertyRightsMember_sYlzh40hyE6ZDGRh_bcjVw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="Narr_AqvvT4CV9Uq7orXTs8GzQw">0.4</ix:nonFraction> million of amortization expense in the condensed consolidated statement of operations and comprehensive loss for the three and six months ended June 30, 2023, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company concluded that the development and regulatory milestone payments of $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_11_21_2022_srt_CounterpartyNameAxis_xoma_MerckKgaaMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_9bKtdq3Xq022OPaePZccLw" decimals="-5" format="ixt:numdotdecimal" name="xoma:MaximumEarnOutPaymentsDevelopmentAndRegulatoryMilestonePayments" scale="6" id="Narr_2caj2OhmYU2RmaoxmprgpA">46.5</ix:nonFraction> million, sales-based milestones payments of $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_11_21_2022_srt_CounterpartyNameAxis_xoma_MerckKgaaMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_9bKtdq3Xq022OPaePZccLw" decimals="-5" format="ixt:numdotdecimal" name="xoma:MaximumEarnOutPaymentsSalesBasedMilestonePayments" scale="6" id="Narr_SYJ7wYL76k-dcVxtkuK_SA">51.0</ix:nonFraction> million and royalty payments to Merck KGaA do not meet the definition of a derivative under ASC 815 and a liability will be recognized at the time that the underlying revenue is recognized under the Organon License Agreement for the corresponding development and regulatory milestone payments, sales-based milestone payments, and royalty payments. ASC 450 may require recognition of the contingent consideration if it is probable that a liability has been incurred and the amount of that liability can be reasonably estimated. Due to the nature of the non-sales and sales-based milestones the Company expects the contingent payments to be probable of payment at the same time that revenue from the Organon License Agreement would be recorded.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of June 30, 2023 and December 31, 2022, there were <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_ObsevaMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_zyUxaH6CvkmKfmQE_-3YjQ" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerLiability" scale="0" id="Narr_oiwBPlLwhUGFkUAh6adr-g"><ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_ObsevaMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_YH_2bboTUkyRnEvX6o0V4w" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerLiability" scale="0" id="Narr_VLhOefcFR0-z5Zxz8bO6dw"><ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_ObsevaMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_zyUxaH6CvkmKfmQE_-3YjQ" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetNet" scale="0" id="Narr_ziN4E2A7y0q883838_JKoQ"><ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_ObsevaMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_YH_2bboTUkyRnEvX6o0V4w" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetNet" scale="0" id="Narr_QkY8MFtoCkGXE80bGCUBLA">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> contract assets or contract liabilities related to this arrangement. The Company did <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_ObsevaMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_K7Mk8P8VwES9_5DBUAZzMw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="Narr_qRoKeGO-L0uG5ZD0onCyYA"><ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_ObsevaMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_XJPmp5bo-kmu5UyKiVXplA" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="Narr_gNJOP1s3yESxAC93ezkHaw">no</ix:nonFraction></ix:nonFraction>t recognize any revenue related to this arrangement during the three and six months ended June 30, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Novartis&#160;&#8211; Anti-TGF&#946; Antibody (NIS793)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On September&#160;30, 2015, the Company and Novartis entered into the Anti-TGF&#946; Antibody License Agreement under which the Company granted Novartis an exclusive, world-wide, royalty-bearing license to the Company&#8217;s anti-transforming growth factor beta (&#8220;TGF&#946;&#8221;) antibody program (now &#8220;NIS793&#8221;). Under the terms of the Anti-TGF&#946; Antibody License Agreement, Novartis has worldwide rights to NIS793 and is responsible for the development and commercialization of antibodies and products containing antibodies arising from NIS793. Unless terminated earlier, the Anti-TGF&#946; Antibody License Agreement will remain in effect, on a country-by-country and product-by-product basis, until Novartis&#8217; royalty obligations end. The Anti-TGF&#946; Antibody License Agreement contains customary termination rights relating to material breach by either party. Novartis also has a unilateral right to terminate the Anti-TGF&#946; Antibody License Agreement on an antibody-by-antibody and country-by-country basis or in its entirety on <ix:nonNumeric contextRef="Duration_9_30_2015_To_9_30_2015_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_27gU5riISEy0SIhW5x2uJg" format="ixt-sec:durwordsen" name="xoma:AgreementTerminationPriorWrittenNoticePeriod" id="Narr_7KbCso8g6Ea-IWs-pzkPEA">one hundred eighty days</ix:nonNumeric>&#8217; notice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company concluded that there were multiple promised goods and services under the Anti-TGF&#946; Antibody License Agreement, including the transfer of license, regulatory services and transfer of materials, process and know-how, which were determined to represent <ix:nonFraction unitRef="Unit_Standard_item_ZJDcTjbqbUC2tIGJY9M-pg" contextRef="Duration_9_30_2015_To_9_30_2015_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_27gU5riISEy0SIhW5x2uJg" decimals="INF" format="ixt-sec:numwordsen" name="xoma:NumberOfPerformanceObligations" scale="0" id="Narr_lPGXHLm7qUqfb2elgdrRcw">one</ix:nonFraction> combined performance obligation. The Company recognized the entire upfront </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk95303077"></a><a id="_Hlk94259450"></a><ix:continuation id="Tb_rU4qsB3c40mxkEtUpzEhxQ_cont1" continuedAt="Tb_rU4qsB3c40mxkEtUpzEhxQ_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">payment of $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2015_To_12_31_2015_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_UKHVP4QfBUyD1MV8rF2yOQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_klqmJ9DEiE26qElTePF_yg"><ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2015_To_12_31_2015_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_UKHVP4QfBUyD1MV8rF2yOQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:ProceedsFromUpfrontPayment" scale="6" id="Narr_xmQDA0f7wUueFlkJGok87Q">37.0</ix:nonFraction></ix:nonFraction> million as revenue in the consolidated statement of comprehensive loss in 2015 as it had completed its performance obligations as of December&#160;31, 2015.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company was eligible to receive up to a total of $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_9_30_2015_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_AFuvSscA3kS3Ogj-V-41CQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones" scale="6" id="Narr_6bNz3tIymk6JKe6k3X92OQ">480.0</ix:nonFraction> million in development, regulatory and commercial milestones under the Anti-TGF&#946; Antibody License Agreement. During the year ended December 31, 2017, Novartis achieved a clinical development milestone pursuant to the Anti-TGF&#946; Antibody License Agreement, and as a result, the Company earned a $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2017_To_12_31_2017_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_Zf-09DuHLUy9gAfOBsfCZw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_-MSdDBENnUOTvfg8elYv7w">10.0</ix:nonFraction> million milestone payment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company concluded that the development and regulatory milestone payments are solely dependent on Novartis&#8217; performance and achievement of the specified events. The Company determined that it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the remaining development and regulatory milestones are fully constrained and excluded from the transaction price. Any consideration related to commercial milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the licenses granted to Novartis and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is also eligible to receive royalties on sales of licensed products, which are tiered based on sales levels and range from a mid-single-digit percentage rate to up to a low double-digit percentage rate. Novartis&#8217; obligation to pay royalties with respect to a particular product and country will continue for the longer of the date of expiration of the last valid patent claim covering the product in that country, or <ix:nonNumeric contextRef="Duration_9_30_2015_To_9_30_2015_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_27gU5riISEy0SIhW5x2uJg" format="ixt-sec:durwordsen" name="xoma:RoyaltiesPeriodMinimum" id="Narr_AZ8TD9Fk7kCOqYsUqE-_6w">ten years</ix:nonNumeric> from the date of the first commercial sale of the product in that country.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In October 2020, the Company earned a $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_10_1_2020_To_10_31_2020_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_HhVju1hJBE6OfB_ni4aRJg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_RkDy6sOrZ06m7k-54YJuFQ">25.0</ix:nonFraction> million milestone upon the dosing of the first patient in Novartis&#8217; first NIS793 Phase 2 clinical trial. As specified under the terms of the Anti-TGF&#946; Antibody License Agreement, the Company received $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_10_1_2020_To_10_31_2020_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_HhVju1hJBE6OfB_ni4aRJg" decimals="-5" format="ixt:numdotdecimal" name="xoma:ProceedsFromUpfrontPayment" scale="6" id="Narr_rFOshff3REqF5fQ0JgbAhA">17.7</ix:nonFraction> million in cash, and the remaining balance of $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_10_1_2020_To_10_31_2020_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_pUHf37jdqkO7GsZ6tJj4dA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentIncreaseDecreaseForPeriodNet" sign="-" scale="6" id="Narr_3zm0Ef2hQ06vtzpziTUFyw">7.3</ix:nonFraction> million was recognized as a reduction to the Company&#39;s debt obligation to Novartis. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In October 2021, the Company earned a $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_10_1_2021_To_10_31_2021_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_xqc5RHdAf0e8Ok9zCOunNA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_DJQVJ6rQlk20vwKaDP6sOA">35.0</ix:nonFraction> million milestone payment upon dosing of the first patient in Novartis&#8217; first NIS793 Phase 3 clinical trial. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is eligible to receive remaining milestones up to a total of $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_Gr7k7W5HhEC0zf3RWdymsw" decimals="-5" format="ixt:numdotdecimal" name="xoma:EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones" scale="6" id="Narr_LMZaoi0x3UOQ7iiYLlFCYQ">410.0</ix:nonFraction> million under the Anti-TGF&#946; Antibody License Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of June 30, 2023 and December 31, 2022, there were <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_Gr7k7W5HhEC0zf3RWdymsw" decimals="-6" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerLiability" scale="6" id="Narr_0i61JTNs-ku5GSbmqhOCWQ"><ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_jNqsIu1EwE6fPsDB8xZzrg" decimals="-6" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerLiability" scale="6" id="Narr_Bt2ZK49geESc1H2UekibUg"><ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_Gr7k7W5HhEC0zf3RWdymsw" decimals="-6" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="Narr_wFKF9bBWeUyvAnldQ9u25g"><ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_jNqsIu1EwE6fPsDB8xZzrg" decimals="-6" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="Narr_OZ-BtTiS5E-xx2_Q8MkwCw">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> contract assets or contract liabilities related to this arrangement. <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_Gr7k7W5HhEC0zf3RWdymsw" decimals="-6" format="ixt-sec:numwordsen" name="us-gaap:CapitalizedContractCostNet" scale="6" id="Narr_W0NxlJ1NJkG-UVAprIP8cA"><ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_jNqsIu1EwE6fPsDB8xZzrg" decimals="-6" format="ixt-sec:numwordsen" name="us-gaap:CapitalizedContractCostNet" scale="6" id="Narr_s9p3Y141U0ut6qp6SNIpww">None</ix:nonFraction></ix:nonFraction> of the costs to obtain or fulfill the contract were capitalized. The Company did <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2022_To_6_30_2022_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_9uhBqAbJnkGLmYVcrsplwQ" decimals="-6" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_PFXSNhDpGEy0iKNovN3QKw"><ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2022_To_6_30_2022_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_RLV8-2lAs0iAHxQrgpOq0w" decimals="-6" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_J6HDCXIozUuHUNO3-3rYTA"><ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_mc8GGMwdb0i-WiWEDrANiQ" decimals="-6" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_LPbZMqRTukecpb3xXDETSQ"><ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_1mMiwj9oK0ik7StNSZF-NA" decimals="-6" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_RFQJZKiUP0Wx2EpFOnP52g">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>t recognize any revenue related to this arrangement during the three and six months ended June 30, 2023 and 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Novartis&#160;&#8211; Anti-IL-1&#946; Antibody (VPM087) </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On August&#160;24, 2017, the Company and Novartis entered into the Gevokizumab License Agreement under which the Company granted to Novartis an exclusive, worldwide, royalty-bearing license to gevokizumab (&#8220;VPM087&#8221;), a novel anti-Interleukin-1 (&#8220;IL-1&#8221;) beta allosteric monoclonal antibody and related know-how and patents. Under the terms of the Gevokizumab License Agreement, Novartis is solely responsible for the development and commercialization of VPM087 and products containing VPM087. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On August&#160;24, 2017, pursuant to a separate agreement (the &#8220;IL-1 Target License Agreement&#8221;), the Company granted to Novartis non-exclusive licenses to its intellectual property covering the use of IL-1 beta targeting antibodies in the treatment and prevention of cardiovascular disease and other diseases and conditions, and an option to obtain an exclusive license (the &#8220;Exclusivity Option&#8221;) to such intellectual property for the treatment and prevention of cardiovascular disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Under the Gevokizumab License Agreement, the Company received total consideration of $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_M2UiaYqolEG6eD-krPLPrQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:LicenseAgreementConsiderationReceived" scale="6" id="Narr_gTrP7b8-E0msepzZABe1og">30.0</ix:nonFraction> million for the license and rights granted to Novartis. Of the total consideration, $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_M2UiaYqolEG6eD-krPLPrQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:ProceedsFromUpfrontPayment" scale="6" id="Narr_jJRj_GVMB0CHfJNnq73T7g">15.7</ix:nonFraction> million was paid in cash and $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_M2UiaYqolEG6eD-krPLPrQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:LicenseAgreementConsiderationReceivedDebtRepayment" scale="6" id="Narr_I7m1yGMSkU6y1-5bAYZ7Zg">14.3</ix:nonFraction> million (equal </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_rU4qsB3c40mxkEtUpzEhxQ_cont2" continuedAt="Tb_rU4qsB3c40mxkEtUpzEhxQ_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">to &#8364;<ix:nonFraction unitRef="Unit_Standard_EUR_cFLXt4pWsUCag8uS-iVkYw" contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_M2UiaYqolEG6eD-krPLPrQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:LicenseAgreementConsiderationReceivedDebtRepayment" scale="6" id="Narr_Itw1MdDM0UicdRAOF6JbjA">12.0</ix:nonFraction> million) was paid by Novartis, on behalf of the Company, to settle the Company&#8217;s outstanding debt with Les Laboratories Servier (&#8220;Servier&#8221;) (the &#8220;Servier Loan&#8221;). In addition, Novartis extended the maturity date on the Company&#8217;s debt to Novartis. The Company also received $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_M2UiaYqolEG6eD-krPLPrQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_rsXm2Mdee0CTKkh3mWvboA">5.0</ix:nonFraction> million cash related to the sale of <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_t9TRI6XjwEKzRs1Mh2hslQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_f9xaPHpgAUuHkNeNmbxChQ">539,131</ix:nonFraction> shares of the Company&#8217;s common stock, at a purchase price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg" contextRef="As_Of_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_8Kg_25tsBUmCq2SIaH9sdg" decimals="5" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_fM2Uavj9UUWc9XTJFk7n5Q">9.2742</ix:nonFraction> per share. The fair market value of the common stock issued to Novartis was $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_t9TRI6XjwEKzRs1Mh2hslQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:StockIssuedDuringPeriodValueNewIssuesCommonStock" scale="6" id="Narr_-oJkXRBEmEWZUD66_pOSqQ">4.8</ix:nonFraction> million, based on the closing stock price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg" contextRef="As_Of_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_8Kg_25tsBUmCq2SIaH9sdg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_VOv6lxm470qAsElJXjSeCg">8.93</ix:nonFraction> per share on August&#160;24, 2017, resulting in a $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_M2UiaYqolEG6eD-krPLPrQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:CommonStockPremium" scale="6" id="Narr_HWWjzHbtRUqxykiSSbLaJg">0.2</ix:nonFraction> million premium paid to the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Based on the achievement of pre-specified criteria, the Company is eligible to receive up to $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_LoKvCYQB9EOeQYU95Ohdpw" decimals="-5" format="ixt:numdotdecimal" name="xoma:EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones" scale="6" id="Narr_mZGsIFA2xEiLReSqazKi_A">438.0</ix:nonFraction> million in development, regulatory and commercial milestones under the Gevokizumab License Agreement. The Company is also eligible to receive royalties on sales of licensed products, which are tiered based on sales levels and range from the high single-digits to mid teens. Under the IL-1 Target License Agreement, the Company received an upfront cash payment of $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_IL1TargetLicenseAgreementMember_1_yPty6sVUuiOqjDzbtIAg" decimals="-5" format="ixt:numdotdecimal" name="xoma:ProceedsFromUpfrontPayment" scale="6" id="Narr_JqcSwQbUt0uiUK7zrht8uQ">10.0</ix:nonFraction> million and is eligible to receive low single-digit royalties on canakinumab sales in cardiovascular indications covered by the Company&#8217;s patents. Should Novartis exercise the Exclusivity Option, the royalties on canakinumab sales will increase to the mid single-digits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Unless terminated earlier, the Gevokizumab License Agreement and IL-1 Target License Agreement will remain in effect, on a country-by-country and product-by-product basis, until Novartis&#8217; royalty obligations end. The <ix:nonFraction unitRef="Unit_Standard_agreement_8WD-ZASWEUe8fofDOT9VGw" contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_niKO_iOCski7xDCZeqBm0g" decimals="INF" format="ixt-sec:numwordsen" name="xoma:NumberOfLicenseAgreements" scale="0" id="Narr_5DnV0I2p2UyY3a6hpSAohQ">two</ix:nonFraction> agreements contain customary termination rights relating to material breach by either party. Novartis also has a unilateral right to terminate the Gevokizumab License Agreement on a product-by-product and country-by-country basis or in its entirety on <ix:nonNumeric contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_M2UiaYqolEG6eD-krPLPrQ" format="ixt-sec:durwordsen" name="xoma:AgreementTerminationPriorWrittenNoticePeriod" id="Narr_JPzEhj2Op0mMm3PKDXBr1A">six months</ix:nonNumeric>&#8217; prior written notice to the Company. Under the IL-1 Target License Agreement, Novartis has a unilateral right to terminate the agreement on a product-by-product and country-by-country basis or in its entirety upon a prior written notice. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Gevokizumab License Agreement and IL-1 Target License Agreement were accounted for as <ix:nonFraction unitRef="Unit_Standard_item_ZJDcTjbqbUC2tIGJY9M-pg" contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_niKO_iOCski7xDCZeqBm0g" decimals="INF" format="ixt-sec:numwordsen" name="xoma:ArrangementsNumber" scale="0" id="Narr_E-ium1JIiE6BtaCRYwtufA">one</ix:nonFraction> arrangement because they were entered into at the same time in contemplation of each other. The Company concluded that there are multiple promised goods and services under the combined arrangement, including the transfer of license to IL-1 beta targeting antibodies, and the transfer of license, know-how, process, materials and inventory related to the VPM087 antibody, which were determined to represent <ix:nonFraction unitRef="Unit_Standard_item_ZJDcTjbqbUC2tIGJY9M-pg" contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_niKO_iOCski7xDCZeqBm0g" decimals="INF" format="ixt-sec:numwordsen" name="xoma:NumberOfPerformanceObligations" scale="0" id="Narr_RYhRvtGXeUW6t_vmP4CCYw">two</ix:nonFraction> distinct performance obligations. The Company determined that the Exclusivity Option is not an option with material right because the upfront payments to the Company were not negotiated to provide an incremental discount for the future additional royalties upon exercise of the Exclusivity Option. Therefore, the Company concluded that the Exclusivity Option is not a performance obligation. The additional royalties will be recognized as revenue when, and if, Novartis exercises its option because the Company has <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_-LsGHkQ-r0C10A2ulFZGhA" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="Narr_fVKgQEucPEeP0tG4np281A">no</ix:nonFraction> further performance obligations at that point.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of the arrangement, the Company determined that the transaction price under the arrangement was $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_niKO_iOCski7xDCZeqBm0g" decimals="-5" format="ixt:numdotdecimal" name="xoma:LicenseAgreementTransactionPrice" scale="6" id="Narr_HQVAJuSqFkqH1VbiNoADsw">40.2</ix:nonFraction> million, which consisted of the $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_niKO_iOCski7xDCZeqBm0g" decimals="-5" format="ixt:numdotdecimal" name="xoma:ProceedsFromUpfrontPayment" scale="6" id="Narr_wl692D4dQEyny5vDjcaOgQ">25.7</ix:nonFraction> million upfront cash payments, the $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_niKO_iOCski7xDCZeqBm0g" decimals="-5" format="ixt:numdotdecimal" name="xoma:LicenseAgreementConsiderationReceivedDebtRepayment" scale="6" id="Narr_iybQSzIFV0OQDJfFl9Mu2g">14.3</ix:nonFraction> million Servier Loan payoff and the $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_niKO_iOCski7xDCZeqBm0g" decimals="-5" format="ixt:numdotdecimal" name="xoma:CommonStockPremium" scale="6" id="Narr_IenB3DPLPkOzPR0EifkJ4Q">0.2</ix:nonFraction> million premium on the sale of the common stock. The transaction price was allocated to the <ix:nonFraction unitRef="Unit_Standard_item_ZJDcTjbqbUC2tIGJY9M-pg" contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_niKO_iOCski7xDCZeqBm0g" decimals="INF" format="ixt-sec:numwordsen" name="xoma:NumberOfPerformanceObligations" scale="0" id="Narr_07tbyFioK0WZZevndjm1Aw">two</ix:nonFraction> performance obligations based on their standalone selling prices. The Company determined that the nature of the <ix:nonFraction unitRef="Unit_Standard_item_ZJDcTjbqbUC2tIGJY9M-pg" contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_niKO_iOCski7xDCZeqBm0g" decimals="INF" format="ixt-sec:numwordsen" name="xoma:NumberOfPerformanceObligations" scale="0" id="Narr_SM0hI-fjyUS8i1H1QXIhkQ">two</ix:nonFraction> performance obligations is the right to use the licenses as they exist at the point of transfer, which occurred when the transfer of materials, process and know-how, and filings to regulatory authority were completed. During the&#160;year ended December&#160;31, 2017, the Company recognized the entire transaction price of $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_niKO_iOCski7xDCZeqBm0g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_3BQdoqa3U0CwPVwRqXQpuQ">40.2</ix:nonFraction> million as revenue upon completion of the delivery of the licenses and related materials, process and know-how, and filings to regulatory authority.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company concluded that the development and regulatory milestone payments are solely dependent on Novartis&#8217; performance and achievement of specified events. The Company determined that it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the development and regulatory milestones are fully constrained and excluded from the transaction price until the respective milestone is achieved. Any consideration related to commercial milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the licenses granted to Novartis and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly. </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk98793843"></a><ix:continuation id="Tb_rU4qsB3c40mxkEtUpzEhxQ_cont3" continuedAt="Tb_rU4qsB3c40mxkEtUpzEhxQ_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of June 30, 2023 and December 31, 2022, there were <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_-LsGHkQ-r0C10A2ulFZGhA" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerLiability" scale="6" id="Narr_66MILv0U2UexMuzaa5Gp0w"><ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_GIL1i6m_ikWj4R2Nl1_z1Q" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerLiability" scale="6" id="Narr_5HTjJw_JJEq898nbntwhtQ"><ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_-LsGHkQ-r0C10A2ulFZGhA" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="Narr_OL9AWqgQgE-JkuAWvDGkcw"><ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_GIL1i6m_ikWj4R2Nl1_z1Q" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="Narr_dcGdeM-pMU-LADvnEgMq3w">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> contract assets or contract liabilities related to this arrangement, and <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_-LsGHkQ-r0C10A2ulFZGhA" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:CapitalizedContractCostNet" scale="6" id="Narr_QuBApTvTn0y4LXUb6EsP3w"><ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_GIL1i6m_ikWj4R2Nl1_z1Q" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:CapitalizedContractCostNet" scale="6" id="Narr_dxNs_rUM2kqbC79xt1PZfg">none</ix:nonFraction></ix:nonFraction> of the costs to obtain or fulfill the contract were capitalized. The Company did <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2022_To_6_30_2022_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_rGGwTzCaJEKNgoHyMNh1gw" decimals="-6" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_bH3IieF8jUq9bZtJroDQ7w"><ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2022_To_6_30_2022_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_jFCmb1gQLUCZ9hjyvX5kmw" decimals="-6" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_PAJhuEGNBEWRX2KVYAgoVQ"><ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_m4wda9YuHE2PtS0eldU6mg" decimals="-6" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_TJpVu6xYUky7ANLBVn6Npw"><ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_fDllYLxwC021lmWGRzTQow" decimals="-6" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_-LFcQzlef0e4noY-Tv4zBA">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>t recognize any revenue related to this arrangement during the three and six months ended June 30, 2023 and 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Takeda</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On November 1,&#160;2006, the Company entered into the Takeda Collaboration Agreement with Takeda under which the Company agreed to discover and optimize therapeutic antibodies against multiple targets selected by Takeda.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Takeda Collaboration Agreement, the Company may receive additional milestone payments aggregating up to $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_11_1_2006_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_srt_ProductOrServiceAxis_xoma_MezagitamabMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_eN1YCwnkIUCnKDhhfVJ8PA" decimals="-5" format="ixt:numdotdecimal" name="xoma:EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones" scale="6" id="Narr_zbLfHFr8Q0SOweCERE24NQ">19.0</ix:nonFraction> million relating to TAK-079 (mezagitamab) and TAK-169 (MT-0169), and low single-digit royalties on future sales of all products subject to this license. The Company&#8217;s right to milestone payments expires on the later of the receipt of payment from Takeda of the last amount to be paid under the agreement or the cessation by Takeda of all research and development activities with respect to all program antibodies, collaboration targets or collaboration products. The Company&#8217;s right to royalties expires on the later of <ix:nonNumeric contextRef="Duration_11_1_2006_To_11_1_2006_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_srt_ProductOrServiceAxis_xoma_MezagitamabMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_nbtuFUC-fkqYmHeLy348AA" format="ixt-sec:duryear" name="xoma:RoyaltiesPeriodMinimum" id="Narr_dDAorQXae0GLbBCVh96oLw">13.5</ix:nonNumeric>&#160;years from the first commercial sale of each royalty-bearing discovery product or the expiration of the last-to-expire licensed patent (or <ix:nonNumeric contextRef="Duration_11_1_2006_To_11_1_2006_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_srt_ProductOrServiceAxis_xoma_MezagitamabMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_nbtuFUC-fkqYmHeLy348AA" format="ixt-sec:durwordsen" name="xoma:RoyaltiesPeriodMinimumScenarioOne" id="Narr_iBOzlH4ZpEGQXa8w9HK5wA">12 years</ix:nonNumeric> from first commercial sale if there is significant generic competition post patent-expiration).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In February&#160;2009, the Company expanded the existing collaboration to provide Takeda with access to multiple antibody technologies, including a suite of research and development technologies and integrated information and data management systems. The Company may receive milestones of up to $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_2_1_2009_To_2_28_2009_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_srt_ProductOrServiceAxis_xoma_OtherAntibodiesMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_nb8ggrHRR0i-B34ppjt3fQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate" scale="6" id="Narr_m84CTE0NyESjUs9jlW5hsg">3.3</ix:nonFraction> million per discovery product candidate and low single-digit royalties on future sales of all antibody products subject to this license. The Company&#8217;s right to milestone payments expires on the later of the receipt of payment from Takeda of the last amount to be paid under the agreement or the cessation by Takeda of all research and development activities with respect to all program antibodies, collaboration targets or collaboration products. The Company&#8217;s right to royalties expires on the later of <ix:nonNumeric contextRef="Duration_2_1_2009_To_2_28_2009_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_srt_ProductOrServiceAxis_xoma_OtherAntibodiesMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_nb8ggrHRR0i-B34ppjt3fQ" format="ixt-sec:durwordsen" name="xoma:RoyaltiesPeriodMinimum" id="Narr_pRxWFvXQ4EKrVoJeZohAHw">10 years</ix:nonNumeric> from the first commercial sale of such royalty-bearing discovery product or the expiration of the last-to-expire licensed patent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2020, the first patient was dosed in Takeda&#8217;s Phase 2 study of mezagitamab and the Company earned a $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_11_1_2020_To_11_30_2020_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_adu7bNhKOUupBKfuF3sIbA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_tKuCE5YkcE2q1re7HR6iVA">2.0</ix:nonFraction> million milestone payment from Takeda. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In August 2021, Molecular Templates, Inc., assumed full rights to TAK-169 from Takeda, including full control of TAK-169 clinical development, per the terms of its terminated collaboration agreement with Takeda.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In January 2022, the Company earned a development milestone pursuant to the Takeda Collaboration and recognized $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2022_To_6_30_2022_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_vXBkO4OEpkinf_t3RM0D2g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_4QpmVco2F0qKg25fiGfBCg">0.8</ix:nonFraction> million as revenue from contracts with customers in the condensed consolidated statement of operations and comprehensive loss for the six months ended June 30, 2022. <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2022_To_6_30_2022_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_QDr-ldinb0Wu3jl9Rx21UA" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_IAXpak9Qw0Wayy8qFunKAA"><ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_VOxATG70-EaP_DZtrrA64w" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_YfO0nGVX2U6A8kRHGXlDhA"><ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_Ri7Rd8o8XUKc4YOMeBumXQ" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_DW5_FnhjWU-JOrKBev86dw">No</ix:nonFraction></ix:nonFraction></ix:nonFraction> revenue was recognized for the three and six months ended June 30, 2023, or for the three months ended June 30, 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of June 30, 2023 and December 31, 2022 there were <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_akCqUsNekUK0f0Q6DuRi7A" decimals="-6" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerLiability" scale="6" id="Narr_MSHQfYerCUihVEeazUHssw"><ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_0J69dylAF0i8-z1WvitMYQ" decimals="-6" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerLiability" scale="6" id="Narr_zlCQ2UoeBkWcdSkY_INNQw"><ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_akCqUsNekUK0f0Q6DuRi7A" decimals="-6" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="Narr_wjIq-u26_EWkomOHaPrV6Q"><ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_0J69dylAF0i8-z1WvitMYQ" decimals="-6" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="Narr_p30vxrsZbkGTWdk4HQ1AbA">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> contract assets or contract liabilities related to this arrangement and <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_akCqUsNekUK0f0Q6DuRi7A" decimals="-6" format="ixt-sec:numwordsen" name="us-gaap:CapitalizedContractCostNet" scale="6" id="Narr_Dr4WmgcVPkac6fU4jXHrCQ"><ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_0J69dylAF0i8-z1WvitMYQ" decimals="-6" format="ixt-sec:numwordsen" name="us-gaap:CapitalizedContractCostNet" scale="6" id="Narr_RT_DY3HXEEGQCsjtn-plVA">none</ix:nonFraction></ix:nonFraction> of the costs to obtain or fulfill the contract were capitalized. The Company is eligible to receive remaining milestones up to a total of $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_akCqUsNekUK0f0Q6DuRi7A" decimals="-5" format="ixt:numdotdecimal" name="xoma:EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones" scale="6" id="Narr_cLjGzC48M0qzwvGkhe0d0Q">16.0</ix:nonFraction> million under the Takeda Collaboration Agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Rezolute</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December&#160;6, 2017, the Company entered into a license agreement with Rezolute pursuant to which the Company granted an exclusive global license to Rezolute to develop and commercialize X358 (now &#8220;RZ358&#8221;) products for all indications. The Company and Rezolute also entered into a common stock purchase agreement pursuant to which Rezolute agreed to issue to the Company, as consideration for receiving the license for RZ358, a certain number of its common stock related to its future financing activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Under the terms of the license agreement, Rezolute is responsible for all development, regulatory, manufacturing and commercialization activities associated with RZ358 and is required to make certain development, regulatory and commercial milestone payments to the Company of up to $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementRz358Member_k_y6teG2YUSWNLFytU9KEg" decimals="-5" format="ixt:numdotdecimal" name="xoma:EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones" scale="6" id="Narr_jfFhSfD9IUG1d9Vjk6CNHA">232.0</ix:nonFraction> million in the aggregate based on the achievement of </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk7587136"></a><ix:continuation id="Tb_rU4qsB3c40mxkEtUpzEhxQ_cont4" continuedAt="Tb_rU4qsB3c40mxkEtUpzEhxQ_cont5"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">pre-specified criteria. Under the license agreement, the Company is also eligible to receive royalties ranging from the high single-digits to the mid-teens based upon annual net sales of any commercial product incorporating RZ358. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company concluded that the development and regulatory milestone payments are solely dependent on Rezolute&#8217;s performance and achievement of the specified events. The Company determined that it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the remaining development and regulatory milestones are fully constrained and excluded from the transaction price until the respective milestone is achieved. Any consideration related to commercial milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the licenses granted to Rezolute and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Rezolute&#8217;s obligation to pay royalties with respect to a particular RZ358 product and country will continue for the longer of the date of expiration of the last valid patent claim covering the product in that country, or <ix:nonNumeric contextRef="Duration_12_6_2017_To_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementRz358Member_qYjemo3WTUmBR58bLQH00g" format="ixt-sec:durwordsen" name="xoma:RoyaltiesPeriodMinimum" id="Narr_xAy9SCiukEm-9g-3anvd_g">twelve years</ix:nonNumeric> from the date of the first commercial sale of the product in that country. Rezolute&#8217;s future royalty obligations in the United States will be reduced by <ix:nonFraction unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ" contextRef="Duration_12_6_2017_To_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_YD6dXAdo7E2njL-IcLEMGA" decimals="2" format="ixt:numdotdecimal" name="xoma:PercentageOfDecreaseInFutureRoyaltyObligations" scale="-2" id="Narr_CDk1haDlXk-bdJnWPK0ozg">20</ix:nonFraction>% if the manufacture, use or sale of a licensed product is not covered by a valid XOMA patent claim, until such a claim is issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the license agreement, XOMA is eligible to receive a low single-digit royalty on sales of Rezolute&#8217;s other non-RZ358 products from its current programs, including RZ402 which is in Phase 2 clinical testing. Rezolute&#8217;s obligation to pay royalties with respect to a particular Rezolute product and country will continue for the longer of <ix:nonNumeric contextRef="Duration_12_6_2017_To_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementNonRz358ProductsMember_X1c9jKDf5EOZolxEicyXRw" format="ixt-sec:durwordsen" name="xoma:RoyaltiesPeriodMinimum" id="Narr_seFaZleZ3Eittiv0VL8FUQ">twelve years</ix:nonNumeric> from the date of the first commercial sale of the product in that country or for so long as Rezolute or its licensee is selling such product in such country, provided that any such licensee royalty will terminate upon the termination of the licensee&#8217;s obligation to make payments to Rezolute based on sales of such product in such country</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The license agreement contains customary termination rights relating to material breach by either party. Rezolute also has a unilateral right to terminate the license agreement in its entirety on <ix:nonNumeric contextRef="Duration_12_6_2017_To_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_YD6dXAdo7E2njL-IcLEMGA" format="ixt-sec:durwordsen" name="xoma:AgreementTerminationPriorWrittenNoticePeriod" id="Narr_Gvwh6orZEEm4Rp9l-LrGvQ">ninety days</ix:nonNumeric>&#8217; notice at any time. To the extent permitted by applicable laws, the Company has the right to terminate the license agreement if Rezolute challenges the licensed patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_12_6_2017_To_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_YD6dXAdo7E2njL-IcLEMGA" decimals="-5" format="ixt-sec:numwordsen" name="xoma:LicenseAgreementConsiderationReceived" scale="6" id="Narr_y7q48-v26UGtK9LFMDmveQ">No</ix:nonFraction> consideration was exchanged upon execution of the arrangement. In consideration for receiving the license for RZ358, Rezolute agreed to issue shares of its common stock and pay cash to the Company upon the occurrence of Rezolute&#8217;s financing activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The license agreement was subsequently amended in 2018, 2019 and 2020. Pursuant to the terms of the license agreement as amended, the Company received a total of $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_12_6_2017_To_12_31_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_mT3lLicYEUilKoGSWcL_yw" decimals="-5" format="ixt:numdotdecimal" name="xoma:LicenseAgreementConsiderationReceivedAchievementOfFinancingActivities" scale="6" id="Narr_NaJqJOYDKkW1IklPwp0WWQ">6.0</ix:nonFraction> million upon Rezolute&#8217;s financing and $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_12_6_2017_To_12_31_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_mT3lLicYEUilKoGSWcL_yw" decimals="-5" format="ixt:numdotdecimal" name="xoma:LicenseAgreementInstallmentPaymentsReceived" scale="6" id="Narr_bSlthcwP30amTNVFjAY6Xg">8.5</ix:nonFraction> million in installment payments through October 2020. The Company also received <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="Duration_12_6_2017_To_12_31_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_mT3lLicYEUilKoGSWcL_yw" decimals="INF" format="ixt:numdotdecimal" name="xoma:LicenseAgreementSharesReceived" scale="0" id="Narr_cKa9JnpK30iCN0_sApLCKg">161,861</ix:nonFraction> shares of Rezolute&#8217;s common stock (as adjusted for the <span style="-sec-ix-hidden:Hidden_U1OJbQlzmUOeCcJTMgU3Qw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1</span></span>:50 reverse stock split in October 2020). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In January 2022, Rezolute dosed the last patient in its Phase 2b clinical trial for RZ358, which triggered a $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_84g9TjGclUmNwYUUvpo37g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_vrtQE9SWc06PXUOM_g5P3g">2.0</ix:nonFraction> million milestone payment due to the Company pursuant to the Rezolute License Agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_X4k_iI4JX0qMI82W0g9pVg" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_VZtCscNdnkCW7suXyEvnRw"><ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_V9oe_Umn1kmDzVa04Ga_yw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_tWC0eghNwUOHIa4jbJSChg">No</ix:nonFraction></ix:nonFraction> revenue was recognized for the three and six months ended June 30, 2023. The Company recognized <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2022_To_6_30_2022_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_vwInn_PHZEilesm4Dyrjqw" decimals="-6" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_LrR4cCe4OkW_vWM-yXmzng">no</ix:nonFraction> revenue and $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2022_To_6_30_2022_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_vmQFJdPsf0mcV98nQ1FxGg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_t9pkduow2U2eDVEuTHNzjw">2.0</ix:nonFraction> million as revenue from contracts with customers in the condensed consolidated statement of operations and comprehensive loss for the three and six months ended June 30, 2022, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of June 30, 2023 and December 31, 2022 there were <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_82zqclNhY0GJGFKyo32O1Q" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerLiability" scale="0" id="Narr_9pUaxtJX4U2HJtQPfMWKtA"><ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_f8hS_ZhC6kyh-a2nsLAegA" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerLiability" scale="0" id="Narr_T1sTAU3DxE-hvPkpRRVptQ"><ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_82zqclNhY0GJGFKyo32O1Q" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetNet" scale="0" id="Narr_GT-MxAfkeEuGgc_fcuhupQ"><ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_f8hS_ZhC6kyh-a2nsLAegA" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetNet" scale="0" id="Narr_HJE8GBLEhkebIhwkaW7-5w">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> contract assets or contract liabilities related to this arrangement. <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_82zqclNhY0GJGFKyo32O1Q" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:CapitalizedContractCostNet" scale="0" id="Narr_IKnDyu1TSUSS3qvwcuXtzA"><ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_f8hS_ZhC6kyh-a2nsLAegA" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:CapitalizedContractCostNet" scale="0" id="Narr_Qjf1fuZ3I0SeH8tsZvoEJg">None</ix:nonFraction></ix:nonFraction> of the costs to obtain or fulfill the contract were capitalized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Janssen Biotech</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">The Company and Janssen were parties to a license agreement which was terminated in 2017.</span> In August 2019, the Company and Janssen entered into a new agreement pursuant to which the Company granted a non-exclusive license </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_rU4qsB3c40mxkEtUpzEhxQ_cont5" continuedAt="Tb_rU4qsB3c40mxkEtUpzEhxQ_cont6"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">to Janssen to develop and commercialize certain drug candidates under the XOMA patents and know-how. Under the new agreement, Janssen made a one-time payment of $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_8_1_2019_To_8_31_2019_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_7abmyDQDN0asJM3WaMklhA" decimals="-5" format="ixt:numdotdecimal" name="xoma:ProceedsFromUpfrontPayment" scale="6" id="Narr_CRKfbqAC9UiwjZ633o3UaA">2.5</ix:nonFraction> million to XOMA. Additionally, for each drug candidate, the Company is entitled to receive milestone payments of up to $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_8_1_2019_To_8_31_2019_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_7abmyDQDN0asJM3WaMklhA" decimals="-5" format="ixt:numdotdecimal" name="xoma:MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents" scale="6" id="Narr_jsfbIMJC-UmbSvwnSoKbaA">3.0</ix:nonFraction> million upon Janssen&#8217;s achievement of certain clinical development and regulatory approval events. Additional milestones may be due for drug candidates which are the subject of multiple clinical trials. Upon commercialization, the Company is eligible to receive <ix:nonFraction unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ" contextRef="Duration_8_1_2019_To_8_31_2019_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_7abmyDQDN0asJM3WaMklhA" decimals="4" format="ixt:numdotdecimal" name="xoma:PercentageOfRoyaltyOnNetSalesUponCommercialization" scale="-2" id="Narr_HAL2pqODpku-jL3d6ZuY4A">0.75</ix:nonFraction>% royalty on net sales of each product. Janssen&#8217;s obligation to pay royalties with respect to a particular product and country will continue until the eighth-year-and-sixth-month anniversary of the first commercial sale of the product in such country. The new agreement will remain in effect unless terminated by mutual written agreement of the parties. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company concluded that the new agreement should be accounted for separately from any prior arrangements with Janssen and that the license grant is the only performance obligation under the new agreement. The Company recognized the entire one-time payment of $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_V2ptKzpjEUCLS85R4yB7vA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_M97M57_7UkSofeJS9SIZdA">2.5</ix:nonFraction> million as revenue for the year ended December 31, 2019 as it had completed its performance obligation. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company concluded that the development and regulatory milestone payments are solely dependent on Janssen&#8217;s performance and achievement of specified events and thus it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the development and regulatory milestones are fully constrained and excluded from the transaction price until the respective milestone is achieved. Any consideration related to royalties will be recognized when the related sales occur as they were determined to relate predominantly to the license granted to Janssen and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of June 30, 2023 and December 31, 2022, there were <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_LbLsp9ZkfkCPh5v5V7bOsw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerLiability" scale="0" id="Narr_mSYUxHYDh0aJ5zkXoRqw9A"><ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember__kbO___xJkGjYQIiIFsysw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerLiability" scale="0" id="Narr_Xdtb-xy5-0y-kDDHy4Odkw"><ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_LbLsp9ZkfkCPh5v5V7bOsw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetNet" scale="0" id="Narr_VB0pcaq5hkuNpXXk_QqXwg"><ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember__kbO___xJkGjYQIiIFsysw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetNet" scale="0" id="Narr_qz4Ra9Qwa0mFBewU3GE7WA">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> contract assets or contract liabilities related to this arrangement. <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_LbLsp9ZkfkCPh5v5V7bOsw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:CapitalizedContractCostNet" scale="0" id="Narr_D8V6s_EtsUyBhZ84fLVz-Q"><ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember__kbO___xJkGjYQIiIFsysw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:CapitalizedContractCostNet" scale="0" id="Narr_PuSO72AGX0qGiaBa8T_VWw">None</ix:nonFraction></ix:nonFraction> of the costs to obtain or fulfill the contract were capitalized. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In April 2023, the Company earned a $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2023_To_4_30_2023_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_srt_ProductOrServiceAxis_xoma_MilestoneDosingFirstPatientInClinicalTrialMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_d9RUr6mklkyYekHk6uD6mg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_zsxZgnRKoUyka7ZJIJhf7w">0.5</ix:nonFraction> million milestone from Janssen, upon dosing of the first patient in a Phase 3 clinical trial evaluating one of Janssen&#8217;s biologic assets. In addition, during the second quarter of 2023, the Company also earned $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_srt_ProductOrServiceAxis_xoma_MilestonePursuantToAgreementMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_A9EfiA2PT0GB4VJ2dpb9fQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_Fg_KIa8630mztEJz8WhccQ">0.6</ix:nonFraction> million total for <ix:nonFraction unitRef="Unit_Standard_item_ZJDcTjbqbUC2tIGJY9M-pg" contextRef="Duration_4_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_JvsZS46lPEq8PkHBxYXxJw" decimals="INF" format="ixt-sec:numwordsen" name="xoma:NumberOfMilestonesEarned" scale="0" id="Narr_20XkmIVpZ0mSi0ic6Jzj8w">three</ix:nonFraction> additional milestones pursuant to its agreement with Janssen. The Company recognized milestone revenue of $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_FSjLU5cFwkCknzTRDnkzlA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_IWN1FlWwnUajLawRqtDhvA"><ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_JvsZS46lPEq8PkHBxYXxJw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_5xbyDdrxV0aQoRVpfCT8kQ">1.1</ix:nonFraction></ix:nonFraction> million for the three and six months ended June 30, 2023. The Company did <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2022_To_6_30_2022_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_y5qiBk4TN0G3EitwLEYTCQ" decimals="-6" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_4cQP9SlY7UyqptIbfZurcQ"><ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2022_To_6_30_2022_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_jHYkB6cDy0SVSmvTMeT8oQ" decimals="-6" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_pirkSKcAqUCskjuT2jZkTQ">no</ix:nonFraction></ix:nonFraction>t recognize any revenue related to this arrangement during the three and six months ended June 30, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Affimed</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In April 2021, the Company and Affimed entered into a contractual agreement, under which the Company is eligible to receive payments from Affimed on potential future commercial sales related to three ICE<span style="font-size:12pt;"> </span>molecules and preloaded natural killer cells containing the ICE molecules. Additionally, the Company is eligible to receive a milestone upon the first product candidate in each program achieving marketing approval. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company concluded that the commercial milestone payments are solely dependent on Affimed&#8217;s performance and achievement of specified events. The Company determined that it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the commercial milestones are fully constrained and excluded from the transaction price until the respective milestone is achieved. Any consideration related to commercial milestones (including royalties) will be recognized when the related approvals occur and therefore have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of June 30, 2023 and December 31, 2022, there were <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_AffimedMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_mOwWuP4wskCXg5lMAASlgQ" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetNet" scale="0" id="Narr_CJEXW7pA7U2eQYQTJ7Ukpw"><ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_AffimedMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_U6vKLThuqke8EfnRv8dUJQ" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetNet" scale="0" id="Narr_UOox7Rpv_kWinOHyNVunkg"><ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_AffimedMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_mOwWuP4wskCXg5lMAASlgQ" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerLiability" scale="0" id="Narr_p238B6QOqki7iWm9wBY4mQ"><ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_AffimedMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_U6vKLThuqke8EfnRv8dUJQ" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerLiability" scale="0" id="Narr_IbApm97Qcke8rYaLZALyTw">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> contract assets or contract liabilities related to this arrangement. <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_AffimedMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_mOwWuP4wskCXg5lMAASlgQ" decimals="-6" format="ixt-sec:numwordsen" name="us-gaap:CapitalizedContractCostNet" scale="6" id="Narr_RKjMblnyp0u8nFWgmqtd1w"><ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_AffimedMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_U6vKLThuqke8EfnRv8dUJQ" decimals="-6" format="ixt-sec:numwordsen" name="us-gaap:CapitalizedContractCostNet" scale="6" id="Narr_rVDD0u0ZXE-lX46sw88yqw">None</ix:nonFraction></ix:nonFraction> of the costs to obtain or fulfill the contract were capitalized. The Company did <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2022_To_6_30_2022_srt_CounterpartyNameAxis_xoma_AffimedMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_uepwPESgtkiCvIXYBSvbng" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="Narr__nrDWvB7R0a3qyfvCtNXBA"><ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2022_To_6_30_2022_srt_CounterpartyNameAxis_xoma_AffimedMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_oY96KBMfAEOyCowvi6apdg" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="Narr_kZKqxu0u406HcyxQ1vRKXQ"><ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_AffimedMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_79M6vRT4qEukxFoiKPpVGg" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="Narr_5dRfBmuQT0Sz0SUz-ibK4A"><ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_AffimedMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_EbE0yio0rEiufpaULNthlw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="Narr_as7bwwaGtUm_-5GMcThtAg">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>t recognize any revenue related to this arrangement during the three and six months ended June 30, 2023 and 2022.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_rU4qsB3c40mxkEtUpzEhxQ_cont6"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Sale of Future Revenue Streams</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December&#160;21, 2016, the Company entered into <ix:nonFraction unitRef="Unit_Standard_agreement_8WD-ZASWEUe8fofDOT9VGw" contextRef="Duration_12_21_2016_To_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_u-wkh1XOjEKGxjaNdt0ZHA" decimals="INF" format="ixt-sec:numwordsen" name="xoma:NumberOfRoyaltyInterestAcquisitionAgreements" scale="0" id="Narr_O5wAVY6mBEaoOpY0D7TSzA">two</ix:nonFraction> royalty interest sale agreements (together, the &#8220;Royalty Sale Agreements&#8221;) with HCRP. Under the first Royalty Sale Agreement, the Company sold its right to receive milestone payments and royalties on future sales of products subject to a License Agreement, dated August&#160;18, 2005, between XOMA and Wyeth Pharmaceuticals (subsequently acquired by Pfizer) for an upfront cash payment of $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_12_21_2016_To_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_FirstRoyaltyInterestAcquisitionAgreementMember_1g3j3qkUPUilXtpAyP_pQg" decimals="-5" format="ixt:numdotdecimal" name="xoma:ProceedsFromUpfrontPayment" scale="6" id="Narr_nL6vd_HvH0GADkGq-_1dgQ">6.5</ix:nonFraction> million, plus potential additional payments totaling $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_FirstRoyaltyInterestAcquisitionAgreementMember_gLlWNbiZNUK_fa6Qh_xfcA" decimals="-5" format="ixt:numdotdecimal" name="xoma:EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones" scale="6" id="Narr_whjAFu03jUKkgSdj5OQcaA">4.0</ix:nonFraction> million in the event <ix:nonFraction unitRef="Unit_Standard_period_Oxx3Sge1w0O2HvNr__SG-A" contextRef="As_Of_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_FirstRoyaltyInterestAcquisitionAgreementMember_gLlWNbiZNUK_fa6Qh_xfcA" decimals="INF" format="ixt-sec:numwordsen" name="xoma:MilestonePeriodsNumber" scale="0" id="Narr_Wo6jpf5JVU-w-BdXDctpnA">three</ix:nonFraction> specified net sales milestones were met in 2017, 2018 and 2019. Based on actual sales, 2017, 2018, and 2019 sales milestones were not achieved. Under the second Royalty Sale Agreement entered into in December&#160;2016, the Company sold its right to receive certain royalties under an Amended and Restated License Agreement dated October&#160;27, 2006 between XOMA and Dyax Corp. for a cash payment of $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_12_21_2016_To_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_SecondRoyaltyInterestAcquisitionAgreementMember_Ue-jD_6tzkiEEl7k3z6Zvg" decimals="-5" format="ixt:numdotdecimal" name="xoma:ProceedsFromUpfrontPayment" scale="6" id="Narr_bSjigKbdX0yh3TKw_g6hbg">11.5</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company classified the proceeds received from HCRP as unearned revenue, to be recognized as revenue under the units-of-revenue method over the life of the license agreements because of the Company&#8217;s limited continuing involvement in the Acquisition Agreements. Such limited continuing involvement is related to the Company&#8217;s undertaking to cooperate with HCRP in the event of litigation or a dispute related to the license agreements. Because the transaction was structured as a non-cancellable sale, the Company does not have significant continuing involvement in the generation of the cash flows due to HCRP and there are no guaranteed rates of return to HCRP, the Company recorded the total proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_12_21_2016_To_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_u-wkh1XOjEKGxjaNdt0ZHA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDeferredRevenue" scale="6" id="Narr_8-KCLDDIxEiz4aflRJyHHQ">18.0</ix:nonFraction> million as unearned revenue recognized under the units-of-revenue method. The Company allocated the total proceeds between the <ix:nonFraction unitRef="Unit_Standard_agreement_8WD-ZASWEUe8fofDOT9VGw" contextRef="Duration_12_21_2016_To_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_u-wkh1XOjEKGxjaNdt0ZHA" decimals="INF" format="ixt-sec:numwordsen" name="xoma:NumberOfRoyaltyInterestAcquisitionAgreements" scale="0" id="Narr_4Ygpxs5DfkWbkStehHL5AA">two</ix:nonFraction> Royalty Sale Agreements based on the relative fair value of expected payments to be made to HCRP under the license agreements. The unearned revenue is being recognized as revenue over the life of the underlying license agreements under the &quot;units-of-revenue&quot; method. Under this method, amortization for a reporting period is calculated by computing a ratio of the allocated proceeds received from HCRP to the payments expected to be made by the licensees to HCRP over the term of the Acquisition Agreements and then applying that ratio to the period&#8217;s cash payment. During the third quarter of 2018, the Shire product underlying the Dyax Corp. license agreement was approved, and the Company began recognizing revenue under the units-of-revenue method due to sales of the approved product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognized $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_m5ftMp6cYUSGHtQQJFDZ4g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueNotFromContractWithCustomer" scale="6" id="Narr_KfHsyMnYI0yNcr864N4arA">0.5</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_a3PpicXMp0e6hJa2jrYpvg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueNotFromContractWithCustomer" scale="6" id="Narr_kgoldRybHk2oi6YmuA7eHQ">1.0</ix:nonFraction> million as revenue under the units-of-revenue method under these arrangements during the three and six months ended June 30, 2023, respectively. The Company recognized $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2022_To_6_30_2022_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_n_zJPqyMuUyhRwCGh98ETg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueNotFromContractWithCustomer" scale="6" id="Narr_x4YdGj8-2kyeEnLuFAqY6g">0.5</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2022_To_6_30_2022_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_ydN4fj43pUqEu9cZio79ng" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueNotFromContractWithCustomer" scale="6" id="Narr_JgvQi-DB4UGskjLUG2L_5Q">0.8</ix:nonFraction> million as revenue under the units-of-revenue method under these arrangements during the three and six months ended June 30, 2022, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2022, the current and non-current portion of the remaining unearned revenue recognized under the units-of-revenue method was $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_AXaUv2IOz0qjMzgGNRTTfQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeCurrent" scale="6" id="Narr_N3XnK1CpJ0mgOsR_c_9ysw">1.9</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_AXaUv2IOz0qjMzgGNRTTfQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeNoncurrent" scale="6" id="Narr_GdeqEri7pEKiiIvLYq-Iiw">9.6</ix:nonFraction> million, respectively. As of June 30, 2023, the Company classified $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_rWEkuydSCkGeJt7pRAiu2g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeCurrent" scale="6" id="Narr_nUMFsloJSkmTBZtRjqYfog">2.0</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_rWEkuydSCkGeJt7pRAiu2g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeNoncurrent" scale="6" id="Narr_XVReJ6_Gwkm8rNi7B7PbPg">8.5</ix:nonFraction> million as current and non-current unearned revenue recognized under the units-of-revenue method, respectively.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_Hlk98833151"></a><a id="_Hlk140183954"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" name="xoma:RoyaltyPurchaseAgreementTextBlock" id="Tb_kLeOsNdGHU--0YTLdm9I3w" continuedAt="Tb_kLeOsNdGHU--0YTLdm9I3w_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">5. Royalty and Commercial Payment Purchase Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Short-term royalty and commercial payment receivables were $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:RightsReceivableCurrent" scale="6" id="Narr_Ed8Sey4_SEKutrECkjCKfQ">5.0</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg" decimals="-5" format="ixt:numdotdecimal" name="xoma:RightsReceivableCurrent" scale="6" id="Narr_r78ATcCb5UGbR--arWAyhA">2.4</ix:nonFraction> million as of June 30, 2023 and December 31, 2022, respectively. Long-term royalty and commercial payment receivables were $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:LongTermRightsReceivableNonCurrent" scale="6" id="Narr_qv6JxqvHrUijsw0tE4B7DQ">72.2</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg" decimals="-5" format="ixt:numdotdecimal" name="xoma:LongTermRightsReceivableNonCurrent" scale="6" id="Narr_wM9Vn4mTsUGoM8-Z4pZWGg">63.7</ix:nonFraction> million as of June 30, 2023 and December 31, 2022, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">LadRx Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On June 21, 2023, the Company entered into the LadRx AAA pursuant to which the Company acquired from LadRx all of its rights, title and interest related to arimoclomol under an asset purchase agreement dated May 13, 2011 between Zevra and LadRx. The Company also entered into the LadRx RPA, pursuant to which the Company acquired the right to receive all of the future royalties, regulatory and commercial milestones as well as other related payments due to LadRx from ImmunityBio related to aldoxorubicin under a license agreement dated July 27, 2017, as amended on September 27, 2018, between ImmunityBio and LadRx. </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_kLeOsNdGHU--0YTLdm9I3w_cont1" continuedAt="Tb_kLeOsNdGHU--0YTLdm9I3w_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The purchased rights related to arimoclomol include potential regulatory and commercial milestones of up to $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_srt_ProductOrServiceAxis_xoma_ArimoclomolMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementMember_K3A3TuR8B0uQ0wOH9CRISw" decimals="-5" format="ixt:numdotdecimal" name="xoma:MaximumPaymentsBasedOnAchievementOfRegulatoryAndCommercialMilestonesNet" scale="6" id="Narr_4kO4Lwpg5EyQyDltmpLa2A">52.5</ix:nonFraction> million (net of certain payment obligations of up to $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_srt_ProductOrServiceAxis_xoma_ArimoclomolMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementMember_K3A3TuR8B0uQ0wOH9CRISw" decimals="-5" format="ixt:numdotdecimal" name="xoma:MaximumPaymentObligationsBasedOnPortionOfRegulatoryAndCommercialPayments" scale="6" id="Narr_YsTEqkm15E-WtjVfd_UG5w">9.5</ix:nonFraction> million based on a portion of the regulatory and commercial milestone payments) and potential royalty payments in low single-digit percentages of aggregate net sales associated with arimoclomol. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The purchased payments related to aldoxorubicin include potential regulatory and commercial milestones of up to $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_srt_ProductOrServiceAxis_xoma_AldoxorubicinMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_pNlSw8P-5EajUFyzP-8uPA" decimals="-5" format="ixt:numdotdecimal" name="xoma:MaximumRegulatoryAndCommercialMilestones" scale="6" id="Narr_u1siqNUObUKMRq0LnvfV1Q">342.7</ix:nonFraction> million and royalty payments on aggregate net sales of aldoxorubicin in the low to mid-teens for sales of orphan indications and mid to high single-digit percentages on other licensed products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upon closing of the LadRx Agreements, the Company paid LadRx an upfront payment of $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_6_21_2023_To_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_e8EdDKpfoE63WcXU__Eu4Q" decimals="-5" format="ixt:numdotdecimal" name="xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities" scale="6" id="Narr_bCDwTG95yUOjOmPYNyn1CQ">5.0</ix:nonFraction> million and may pay up to an additional $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_NqbS9eqGFkerYvUUwG7Maw" decimals="-5" format="ixt:numdotdecimal" name="xoma:MaximumPaymentsBasedOnAchievementOfRegulatoryAndSalesMilestones" scale="6" id="Narr_9CJFIhVelEGi0AqBaxTPyw">6.0</ix:nonFraction> million in regulatory and commercial sales milestones which included $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_NqbS9eqGFkerYvUUwG7Maw" decimals="-5" format="ixt:numdotdecimal" name="xoma:MaximumPayableOnRegulatoryMilestone" scale="6" id="Narr_LoiMIb4DV0-EJZ67iB0I6w">5.0</ix:nonFraction> million related to regulatory milestones and $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_NqbS9eqGFkerYvUUwG7Maw" decimals="-5" format="ixt:numdotdecimal" name="xoma:MaximumPayableOnSalesMilestone" scale="6" id="Narr_0W6pxh8970CQfJEBbn7hXA">1.0</ix:nonFraction> million related to commercial sales milestones. The Company concluded that the regulatory milestone payments of $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_NqbS9eqGFkerYvUUwG7Maw" decimals="-5" format="ixt:numdotdecimal" name="xoma:MaximumPayableOnRegulatoryMilestone" scale="6" id="Narr_ZTF80S5R1EKF6AXGHHhBpg">5.0</ix:nonFraction> million met the definition of a derivative under ASC 815 and should be accounted for at fair value and recorded as a current liability at the inception of the transaction. The fair value of the regulatory milestone payments was estimated to be $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_ContingentConsiderationByTypeAxis_xoma_ContingentConsiderationRegulatoryMilestonesMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_CJwILMODfU2DPiygsj2I2Q" decimals="-5" format="ixt:numdotdecimal" name="xoma:ContingentConsiderationUnderPurchaseAgreements" scale="6" id="Narr_I_HK9XzKrE-iSMbQPQqmhg">1.0</ix:nonFraction> million. The Company concluded the commercial milestone payment of $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_NqbS9eqGFkerYvUUwG7Maw" decimals="-5" format="ixt:numdotdecimal" name="xoma:MaximumPayableOnSalesMilestone" scale="6" id="Narr_xeA4edmxj0aQgmI7IFdgbA">1.0</ix:nonFraction> million did not meet the definition of a derivative under ASC 815 and a liability will be recognized when probable and estimable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of the LadRx Agreements, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_21_2023_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_1-O-Wc5qm0GpfWvtLfA5QQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:LongTermRightsReceivableNonCurrent" scale="6" id="Narr_TW20mND00U69yMuCE4NTPg">6.0</ix:nonFraction> million as long-term royalty receivables related to the aggregate of the arimoclomol and aldoxorubicin<i style="font-style:italic;"> </i>payment rights acquired, which included the $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_6_21_2023_To_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_e8EdDKpfoE63WcXU__Eu4Q" decimals="-5" format="ixt:numdotdecimal" name="xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities" scale="6" id="Narr_VDMUjJ85YEe5y3AW3gqcoA">5.0</ix:nonFraction> million upfront payment and $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_NqbS9eqGFkerYvUUwG7Maw" decimals="-5" format="ixt:numdotdecimal" name="xoma:MaximumPayableOnSalesMilestone" scale="6" id="Narr_MVxgqXl3zEG75bWsvl-xNA">1.0</ix:nonFraction> million for the estimated fair value of the regulatory milestone payments.<span style="display:inline-block;width:33.22pt;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the cost recovery method, the Company does not expect to recognize any income related to royalties, milestones and other payments until the purchase price has been fully collected. The Company performed its impairment assessment and <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_UCOXnlEMH0KhLJITjc3RcQ" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" scale="6" id="Narr_FAA0OVJ5rUydFKa09P78Dw">no</ix:nonFraction> allowance for credit losses was recorded as of June 30, 2023. <span style="display:inline-block;width:0.76pt;"></span> <span style="display:inline-block;width:33.5pt;"></span><span style="display:inline-block;width:36pt;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Aptevo Commercial Payment Purchase Agreement </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On March 29, 2023, the Company entered into the Aptevo CPPA, pursuant to which the Company acquired from Aptevo a portion of its milestone and commercial payment rights under a sale agreement dated February 28, 2020 between Aptevo and Medexus, related to IXINITY, which is marketed by Medexus for the control and prevention of bleeding episodes and postoperative management in people with Hemophilia B. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is entitled to receive a mid-single digit percentage of all IXINITY quarterly net sales from January 1, 2023 into the first quarter of 2035, and will be entitled to milestone payments of up to $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_3_29_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_BVEo8QgBSkmfz1ozUkIwXw" decimals="-5" format="ixt:numdotdecimal" name="xoma:MilestonesReceivableMaximum" scale="6" id="Narr_Wp2dyBaa90K1D498kxtptA">5.3</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of the Aptevo CPPA, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_3_29_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_BVEo8QgBSkmfz1ozUkIwXw" decimals="-5" format="ixt:numdotdecimal" name="xoma:LongTermRightsReceivableNonCurrent" scale="6" id="Narr_FZd5t8Bn0E-yzAKv7G4yew">9.7</ix:nonFraction> million as long-term royalty receivables which included a $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_3_29_2023_To_3_29_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_7trh9U9BgEOiGwvVb10qXg" decimals="-5" format="ixt:numdotdecimal" name="xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities" scale="6" id="Narr_7mWPfTE8MEGzAIMWt_ORLA">9.6</ix:nonFraction> million upfront payment and a $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_3_29_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_BVEo8QgBSkmfz1ozUkIwXw" decimals="-3" format="ixt:numdotdecimal" name="xoma:ContingentConsiderationUnderPurchaseAgreements" scale="0" id="Narr_iq899mQxi0WCAhEA9NhVpg">50,000</ix:nonFraction> one-time payment in its condensed consolidated balance sheet, which would be due if XOMA received more than $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_3_29_2023_To_3_29_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_7trh9U9BgEOiGwvVb10qXg" decimals="-5" format="ixt:numdotdecimal" name="xoma:CommercialPaymentThresholdOneTimePayment" scale="6" id="Narr_K1oPM-JS-k63lhltOM3r6g">0.5</ix:nonFraction> million in receipts for first quarter 2023 sales of IXINITY. At inception of the agreement, the Company concluded the one-time payment of $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_3_29_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_BVEo8QgBSkmfz1ozUkIwXw" decimals="-3" format="ixt:numdotdecimal" name="xoma:ContingentConsiderationUnderPurchaseAgreements" scale="0" id="Narr_m-7Gu2L2zk-Na7-zqxLyLA">50,000</ix:nonFraction> was probable and reasonably estimable. Therefore, the payment was recorded as contingent liabilities under ASC 450 in its condensed consolidated balance sheet (the &#8220;Aptevo Contingent Consideration&#8221;) at inception and was paid in June 2023 when related receipts exceeded $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_3_29_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_wWf39cBN3Ey7XT6o94A4AQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:ReceiptsUnderAgreementsInvestingActivities" scale="6" id="Narr_o9M5m4rrnESd6ch1ZHaICg">0.5</ix:nonFraction> million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 2023, the Company received $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_6_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_MedexusMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_uvMhw-Lcqk-4prmxG0MKyQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:ReceiptsUnderAgreementsInvestingActivities" scale="6" id="Narr_Z0-uEDHabkq83PFApKFbog">0.6</ix:nonFraction> million from Medexus representing the first commercial payment attributable to net sales of IXINITY that occurred during the first quarter of 2023. In accordance with the cost recovery method, the $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_6_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember__RhK022Z4kyD4eKqg0JNCA" decimals="-5" format="ixt:numdotdecimal" name="xoma:ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" scale="6" id="Narr_Ctn-QPnBLEaoo1dS_W6IWg">0.6</ix:nonFraction> million received was recorded as a direct reduction of the long-term royalty receivable balance. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Based upon limited available information, the Company is unable to reasonably estimate its commercial payment stream from sales of future net sales and the commercial payments to be received during the twelve-month period following the balance sheet date of June 30, 2023 and, as such, <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_Ag4rXqT5_U2u9t7EHdT2Vw" decimals="-5" format="ixt-sec:numwordsen" name="xoma:RightsReceivableCurrent" scale="6" id="Narr_-KYIT1dAM0ea3eXkb493eg">no</ix:nonFraction> amounts are reflected as short-term royalty and commercial payment receivables.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk93562407"></a><ix:continuation id="Tb_kLeOsNdGHU--0YTLdm9I3w_cont2" continuedAt="Tb_kLeOsNdGHU--0YTLdm9I3w_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the cost recovery method, the Company does not expect to recognize any income related to milestones and commercial payment received until the purchase price has been fully collected.&#160;The Company performed its impairment assessment and <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_Ag4rXqT5_U2u9t7EHdT2Vw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" scale="6" id="Narr_cnptVPDlA0q_AILxiUZBvg">no</ix:nonFraction> allowance for credit losses was recorded as of June 30, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Agenus Royalty Purchase Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On September 20, 2018, the Company entered into the Agenus RPA, pursuant to which the Company acquired the right to receive <ix:nonFraction unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ" contextRef="Duration_9_20_2018_To_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_IncyteImmunoOncologyAssetsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_XSaCTgtO1EiCFqoqTgeZVw" decimals="2" format="ixt:numdotdecimal" name="xoma:RoyaltyReceivablePercentageOnNetSales" scale="-2" id="Narr_Fmx0r_BF9Ea0WWuOzmY_cA">33</ix:nonFraction>% of the future royalties on <ix:nonFraction unitRef="Unit_Standard_item_ZJDcTjbqbUC2tIGJY9M-pg" contextRef="Duration_9_20_2018_To_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_IncyteImmunoOncologyAssetsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_XSaCTgtO1EiCFqoqTgeZVw" decimals="INF" format="ixt-sec:numwordsen" name="xoma:NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased" scale="0" id="Narr_OHG4cWiaP0C4NqoCHyy2JQ">six</ix:nonFraction> Incyte Europe S.a.r.l. (&#8220;Incyte&#8221;) immuno-oncology assets, currently in development, due to Agenus from Incyte (net of certain royalties payable by Agenus to a third party) and <ix:nonFraction unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ" contextRef="As_Of_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_IncyteImmunoOncologyAssetsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember__94jAcnsd02lqy6kaK-0kQ" decimals="2" format="ixt:numdotdecimal" name="xoma:PurchasedPercentageOfMilestones" scale="-2" id="Narr_Aa4FbSsSNE2Jz9D97PYxvg">10</ix:nonFraction>% of all future developmental, regulatory and commercial milestones related to these assets. However, the Company did not have a right to the expected near-term milestone associated with the entry of INCAGN2390 (anti-TIM-3) into its Phase 1 clinical trial. The future royalties due to Agenus from Incyte are based on low single to mid teen-digit percentage of applicable net sales. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, the Company acquired the right to receive <ix:nonFraction unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ" contextRef="Duration_9_20_2018_To_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_MerckImmunoOncologyProductMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_rdQZOj-p50uveOBE4byiYQ" decimals="2" format="ixt:numdotdecimal" name="xoma:RoyaltyReceivablePercentageOnNetSales" scale="-2" id="Narr_zqgTGdanjUuHmFet80P_IQ">33</ix:nonFraction>% of the future royalties on MK-4830, an immuno-oncology product currently in clinical development, due to Agenus from Merck and <ix:nonFraction unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ" contextRef="As_Of_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_MerckImmunoOncologyProductMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_NG5TrsNyD0Oet2286g9H0A" decimals="2" format="ixt:numdotdecimal" name="xoma:PurchasedPercentageOfMilestones" scale="-2" id="Narr_eV8YTw-ml02yXPaJw-NE7g">10</ix:nonFraction>% of all future developmental, regulatory and commercial milestones related to this asset. The future royalties due to Agenus from Merck are based on low single-digit percentage of applicable net sales. Pursuant to the Agenus RPA, the Company&#8217;s share in future potential development, regulatory and commercial milestones is up to $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_9_20_2018_To_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_MerckImmunoOncologyProductMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_rdQZOj-p50uveOBE4byiYQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones" scale="6" id="Narr_pATui3KYKUOPy9JF0tbKJA">59.5</ix:nonFraction> million. There is no limit on the amount of future royalties on sales that the Company may receive under the agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Agenus RPA, the Company paid Agenus $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_9_20_2018_To_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_CDSnZwcrZEu2Ca2UBiaJ0g" decimals="-5" format="ixt:numdotdecimal" name="xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities" scale="6" id="Narr_t3hTNqPiQEiOEPrr4Js5cQ">15.0</ix:nonFraction> million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of the agreement, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_W3hVIOjItkyJRWGnXKpi0w" decimals="-5" format="ixt:numdotdecimal" name="xoma:LongTermRightsReceivableNonCurrent" scale="6" id="Narr_MTXjR70HwEaTHIEuhu4TXw">15.0</ix:nonFraction> million as long-term royalty receivables in the consolidated balance sheets. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2020, MK-4830 advanced into Phase 2 development, and Agenus earned a $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_11_1_2020_To_11_30_2020_dei_LegalEntityAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_MerckImmunoOncologyProductMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_gu6YuHtIt0y_GOYnfbfPoA" decimals="-5" format="ixt:numdotdecimal" name="xoma:MilestoneAchieved" scale="6" id="Narr_JzZ4RiylIU2nve32eP7EnA">10.0</ix:nonFraction> million clinical development milestone under its license agreement with Merck, of which the Company earned $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_11_1_2020_To_11_30_2020_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_MerckImmunoOncologyProductMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_yWJTxLzPL0y7_WmwB5wNNw" decimals="-5" format="ixt:numdotdecimal" name="xoma:MilestoneAchieved" scale="6" id="Narr_a_rC6Trf4UexdVVKT4rPrA">1.0</ix:nonFraction> million. In accordance with the cost recovery method, the $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_11_1_2020_To_11_30_2020_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_MerckImmunoOncologyProductMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_yWJTxLzPL0y7_WmwB5wNNw" decimals="-5" format="ixt:numdotdecimal" name="xoma:ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" scale="6" id="Narr_XRUKdffw3EqKWkUG5Uawjg">1.0</ix:nonFraction> million milestone received was recorded as a direct reduction of the recorded long-term royalty receivable balance. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company continues to assess that no further payments are probable to be received under this agreement in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to milestones and royalties received until the purchase price has been fully collected.&#160;The Company performed its impairment assessment and <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_AgenusIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_sSr_eim9wkmE2gHiwusgvQ" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" scale="6" id="Narr_uWxXKmGA8kCPwiCCrVDBUA"><ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_AgenusIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_bp0e2gt5REKDawtfAHfiFA" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" scale="6" id="Narr_vrpsoVByjkudrIN5AqVsBw">no</ix:nonFraction></ix:nonFraction> allowance for credit losses was recorded as of June 30, 2023 or December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Bioasis Royalty Purchase Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On February 25, 2019, the Company entered into the Bioasis RPA, pursuant to which the Company acquired potential future milestone and royalty rights from Bioasis for product candidates that are being developed pursuant to a license agreement between Bioasis and Prothena Biosciences Limited. In addition, the Company was granted options to purchase a <ix:nonFraction unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ" contextRef="As_Of_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_mAQNTbueYkGTdJGdXydMXQ" decimals="2" format="ixt:numdotdecimal" name="xoma:PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements" scale="-2" id="Narr_l7dXxC4wUUK-F1RD5QDfqw">1</ix:nonFraction>% royalty right on the next <ix:nonFraction unitRef="Unit_Standard_agreement_8WD-ZASWEUe8fofDOT9VGw" contextRef="Duration_2_25_2019_To_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_YrCq7J8e4kyLGJ4RpNNinw" decimals="INF" format="ixt-sec:numwordsen" name="xoma:NumberOfLicenseAgreementsFutureLicenseAgreements" scale="0" id="Narr_xe1c7bjBC0iYagUFKCmXVQ">two</ix:nonFraction> license agreements entered into between Bioasis and third-party licensees subject to certain payments and conditions as well as a right of first negotiation on the purchase of royalty rights on subsequent Bioasis license agreements with third parties. Upon exercise of the option related to the second license agreement executed by Bioasis, the Company would have been obligated to pay up to $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_mAQNTbueYkGTdJGdXydMXQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:PaymentsToBeMadeUponExerciseOfOptionSecondLicenseAgreement" scale="6" id="Narr_P9OULkGJwEGwNAUmieFRFw">0.3</ix:nonFraction> million per licensed product. Upon exercise of the option related to the third license agreement executed by Bioasis, the Company may be obligated to pay up to $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_2_25_2019_To_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_YrCq7J8e4kyLGJ4RpNNinw" decimals="-5" format="ixt:numdotdecimal" name="xoma:PaymentsToBeMadeUponExerciseOfOptionThirdLicenseAgreement" scale="6" id="Narr_6Atnx-M1GkWad_p_0Cj5IA">0.4</ix:nonFraction> million per licensed product. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Bioasis RPA, the Company paid $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_2_25_2019_To_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_YrCq7J8e4kyLGJ4RpNNinw" decimals="-5" format="ixt:numdotdecimal" name="xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities" scale="6" id="Narr_ciTZEX7gNUyy6x65ZCq90Q">0.3</ix:nonFraction> million and would have made contingent future cash payments of up to $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_QHXUcnameU2HPDbtouGcNQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:ContingentFutureCashPayments" scale="6" id="Narr_VErzBZ2uKE6xasqGgvKQPA">0.2</ix:nonFraction> million to Bioasis as the licensed product candidates reach certain development milestones (the &#8220;Bioasis Contingent Consideration&#8221;). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of the agreement, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_mAQNTbueYkGTdJGdXydMXQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:LongTermRightsReceivableNonCurrent" scale="6" id="Narr__Nt6wNOfY0O5DyoJFi2dqw">0.4</ix:nonFraction> million as long-term royalty receivables in its consolidated balance sheet, including the estimated fair value of the Bioasis Contingent Consideration of $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_mAQNTbueYkGTdJGdXydMXQ" decimals="-3" format="ixt:numdotdecimal" name="xoma:ContingentConsiderationUnderPurchaseAgreements" scale="0" id="Narr_AYKX9IAqy0iHn9Zg74aRNQ">75,000</ix:nonFraction>. </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk20239215"></a><a id="_Hlk93562521"></a><a id="_Hlk20239517"></a><ix:continuation id="Tb_kLeOsNdGHU--0YTLdm9I3w_cont3" continuedAt="Tb_kLeOsNdGHU--0YTLdm9I3w_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On November 2, 2020, the Company entered into the Second Bioasis RPA, pursuant to which the Company acquired potential future milestone and other payments, and royalty rights from Bioasis for product candidates that were being developed pursuant to a research collaboration and license agreement between Bioasis and Chiesi. The Company paid Bioasis $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_11_2_2020_To_11_2_2020_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementTwoMember_lIg02dx4pU2AOp3fc9Nh0Q" decimals="-5" format="ixt:numdotdecimal" name="xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities" scale="6" id="Narr_dFJVluVYUk6iKX1BqzlMRA">1.2</ix:nonFraction> million upon closing of the Second Bioasis RPA for the purchased rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of the Second Bioasis RPA, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_11_2_2020_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementTwoMember_EKVUME649EuA-3BW_SUmRA" decimals="-5" format="ixt:numdotdecimal" name="xoma:LongTermRightsReceivableNonCurrent" scale="6" id="Narr_RM82M5xYqki9Fwn-zSE7Bw">1.2</ix:nonFraction> million as long-term royalty receivables in its consolidated balance sheet. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On June 20, 2023, Bioasis announced the suspension of all its operations and the termination of the research collaboration and license agreement between Bioasis and Chiesi. As a result, the Company recorded an impairment of $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_6_20_2023_To_6_20_2023_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementAndSecondRoyaltyPurchaseAgreementMember_Eqxr4CXcuE-FFTbVv-ujhg" decimals="-5" format="ixt:numdotdecimal" name="xoma:ImpairmentOfLongTermRightsReceivableNonCurrent" scale="6" id="Narr_CCOoUTyXDk64UF6HZ4WntA">1.6</ix:nonFraction> million under royalty purchase agreement asset impairment in its condensed consolidated statement of operations and a reduction of $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_6_20_2023_To_6_20_2023_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementAndSecondRoyaltyPurchaseAgreementMember_Eqxr4CXcuE-FFTbVv-ujhg" decimals="-5" format="ixt:numdotdecimal" name="xoma:LongTermRightsReceivableNonCurrentIncreaseDecrease" scale="6" id="Narr_Gvoz3gCgrUaoeWTss5sq4w">1.6</ix:nonFraction> million under long-term royalty receivables related to the Bioasis RPA and Second Bioasis RPA. As the impaired amount was not expected to be collected, <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementAndSecondRoyaltyPurchaseAgreementMember_FU0POSqmREazZyKHBvapXA" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" scale="6" id="Narr_VTDHDAsR70ei7-AhSRAXdA">no</ix:nonFraction> allowance for credit losses was recorded as of June 30, 2023. There was <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementAndSecondRoyaltyPurchaseAgreementMember_p9m5gzIpdUSkItjQbZWuTA" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" scale="6" id="Narr_u696YGKo10ye6XsQn6L8RA">no</ix:nonFraction> allowance for credit losses recorded as of December 31, 2022. The fair value of the Bioasis Contingent Consideration was reduced to $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementAndSecondRoyaltyPurchaseAgreementMember_FU0POSqmREazZyKHBvapXA" decimals="-5" format="ixt:numdotdecimal" name="xoma:LongTermRightsReceivableNonCurrent" scale="0" id="Narr_i5Ph2EbUF0yInlxnVL32fQ">0</ix:nonFraction> with the change in the estimated fair value recognized in other income (expense), net in the condensed consolidated statement of operations and comprehensive loss. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Aronora<span style="font-style:normal;font-weight:normal;"> </span>Royalty Purchase Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On April 7, 2019, the Company entered into the Aronora RPA which closed on June 26, 2019. Under the Aronora RPA, the Company acquired the right to receive future royalties and a portion of upfront, milestone, and option payments (the &#8220;Non-Royalties&#8221;) related to <ix:nonFraction unitRef="Unit_Standard_item_ZJDcTjbqbUC2tIGJY9M-pg" contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_HVql9Pa7t0Olldm6QQhOFg" decimals="INF" format="ixt-sec:numwordsen" name="xoma:AgreementDrugCandidatesNumber" scale="0" id="Narr_7gLWqCNOqE-eoS-k8HeTSA">five</ix:nonFraction> anti-thrombotic hematology drug candidates. <ix:nonFraction unitRef="Unit_Standard_item_ZJDcTjbqbUC2tIGJY9M-pg" contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_BayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_Pw_lMHeh_0G7t1NpeC5DRQ" decimals="INF" format="ixt-sec:numwordsen" name="xoma:AgreementDrugCandidatesNumber" scale="0" id="Narr_8gjHnVICiEm9WVuFr1ZKiw">Three</ix:nonFraction> candidates were subject to Aronora&#8217;s collaboration with Bayer (the &#8220;Bayer Products&#8221;), including <ix:nonFraction unitRef="Unit_Standard_item_ZJDcTjbqbUC2tIGJY9M-pg" contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_BayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_Pw_lMHeh_0G7t1NpeC5DRQ" decimals="INF" format="ixt-sec:numwordsen" name="xoma:AgreementDrugCandidatesExclusiveLicenseOptionNumber" scale="0" id="Narr_UUKQPeLp_0ydVdPFEHyFxQ">one</ix:nonFraction> which was subject to an exclusive license option by Bayer. The Company will receive <ix:nonFraction unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ" contextRef="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_BayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_HRYppcTJikmUXTKgI4BWvQ" decimals="2" format="ixt:numdotdecimal" name="xoma:RoyaltyReceivablePercentageOnNetSales" scale="-2" id="Narr_kwWIhIe8REypic1P4ETGRw">100</ix:nonFraction>% of future royalties and <ix:nonFraction unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ" contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_BayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_Pw_lMHeh_0G7t1NpeC5DRQ" decimals="2" format="ixt:numdotdecimal" name="xoma:PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts" scale="-2" id="Narr_tzNOMBXjjUmqVJgTOweuIg">10</ix:nonFraction>% of future Non-Royalties economics from these Bayer Products. The other <ix:nonFraction unitRef="Unit_Standard_item_ZJDcTjbqbUC2tIGJY9M-pg" contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_NonBayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_3_W-6bd8Rk-v259MRO0Muw" decimals="INF" format="ixt-sec:numwordsen" name="xoma:AgreementDrugCandidatesNumber" scale="0" id="Narr_ftOCCgojdEq4yuacPUqAbw">two</ix:nonFraction> candidates are unpartnered (the &#8220;non-Bayer Products&#8221;) for which the Company will receive low single-digit percentage of net sales and <ix:nonFraction unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ" contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_NonBayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_3_W-6bd8Rk-v259MRO0Muw" decimals="2" format="ixt:numdotdecimal" name="xoma:PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts" scale="-2" id="Narr_HQBdBwwh1EqrbHRf9HXizQ">10</ix:nonFraction>% of Non-Royalties. The future payment percentage for Non-Royalties will be reduced from <ix:nonFraction unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ" contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_HVql9Pa7t0Olldm6QQhOFg" decimals="2" format="ixt:numdotdecimal" name="xoma:PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts" scale="-2" id="Narr_rV7l2xw5C0u-6otJUS8m9w">10</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ" contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_HVql9Pa7t0Olldm6QQhOFg" decimals="2" format="ixt:numdotdecimal" name="xoma:PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage" scale="-2" id="Narr_BZnvNrDhz0iyjBEcTXJ6-Q">5</ix:nonFraction>% upon the Company&#8217;s receipt of <ix:nonFraction unitRef="Unit_Standard_item_ZJDcTjbqbUC2tIGJY9M-pg" contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_HVql9Pa7t0Olldm6QQhOFg" decimals="INF" format="ixt-sec:numwordsen" name="xoma:AgreementPaymentPercentageFactor" scale="0" id="Narr_4tBOSZNyAEiTsAqIuqbUvQ">two</ix:nonFraction> times the total cumulative amount of consideration paid by the Company to Aronora. In July 2020, Bayer elected to not exercise its option on the third Bayer Product and that product is now subject to the same economics as the non-Bayer Products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Aronora RPA, the Company paid Aronora a $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_pn2tVWcS10-XUKZrEdxpPg" decimals="-5" format="ixt:numdotdecimal" name="xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities" scale="6" id="Narr_ozekyPLjy0uEjRm4YyFI0A">6.0</ix:nonFraction> million upfront payment at the close of the transaction. The Company financed $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_o9TK8egh80G0mWjo56c-jg" decimals="-5" format="ixt:numdotdecimal" name="xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities" scale="6" id="Narr_apgDSmp4GE2oeNAR7nSqnw">3.0</ix:nonFraction> million of the upfront payment with a term loan under its Loan and Security Agreement with SVB. The Company was required to make a contingent future cash payment of $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_BayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_HRYppcTJikmUXTKgI4BWvQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:ContingentFutureCashPaymentsPerProduct" scale="6" id="Narr_WVHiMVNENUqyoCCxTf86hw">1.0</ix:nonFraction> million for each of the <ix:nonFraction unitRef="Unit_Standard_item_ZJDcTjbqbUC2tIGJY9M-pg" contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_BayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_Pw_lMHeh_0G7t1NpeC5DRQ" decimals="INF" format="ixt-sec:numwordsen" name="xoma:AgreementDrugCandidatesNumber" scale="0" id="Narr_p0nWwmMduUimiBXR8JsMBA">three</ix:nonFraction> Bayer Products that were active on September 1, 2019 (up to a total of $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_BayerProductsMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_abyt3ov_LEidqaXYxUPESw" decimals="-5" format="ixt:numdotdecimal" name="xoma:ContingentFutureCashPayments" scale="6" id="Narr_fMpyN3NNJEOklX6gnzToPQ">3.0</ix:nonFraction> million, the &#8220;Aronora Contingent Consideration&#8221;). Pursuant to the Aronora RPA, if the Company receives $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_pn2tVWcS10-XUKZrEdxpPg" decimals="-5" format="ixt:numdotdecimal" name="xoma:CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount" scale="6" id="Narr_r3BeHA6W1U6X4zYH4CY3og">250.0</ix:nonFraction> million in cumulative royalties on net sales per product, the Company will be required to pay associated tiered milestone payments to Aronora in an aggregate amount of up to $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_pn2tVWcS10-XUKZrEdxpPg" decimals="-5" format="ixt:numdotdecimal" name="xoma:MilestonesPaymentsToAggregateAmountOfPerProduct" scale="6" id="Narr_gBDIEtNFZUCl4ULfb6Km7A">85.0</ix:nonFraction> million per product (the &#8220;Royalty Milestones&#8221;).&#160;The Royalty Milestones are paid based upon various royalty tiers prior to reaching $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_pn2tVWcS10-XUKZrEdxpPg" decimals="-5" format="ixt:numdotdecimal" name="xoma:CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount" scale="6" id="Narr_5HyGTzmoF0aS7FuP04RYMg">250.0</ix:nonFraction> million in cumulative royalties on net sales per product.&#160;Royalties per product in excess of $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_pn2tVWcS10-XUKZrEdxpPg" decimals="-5" format="ixt:numdotdecimal" name="xoma:CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount" scale="6" id="Narr_4MWJQ1O-EkKb2VIHm0C8SQ">250.0</ix:nonFraction> million are retained by the Company. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of the agreement, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_HVql9Pa7t0Olldm6QQhOFg" decimals="-5" format="ixt:numdotdecimal" name="xoma:LongTermRightsReceivableNonCurrent" scale="6" id="Narr_0NsquHiMdE6pKihozYvqxw">9.0</ix:nonFraction> million as long-term royalty receivables in its consolidated balance sheet, including the estimated fair value of the Aronora Contingent Consideration of $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_HVql9Pa7t0Olldm6QQhOFg" decimals="-5" format="ixt:numdotdecimal" name="xoma:ContingentConsiderationUnderPurchaseAgreements" scale="6" id="Narr_ulahkp1mikWWrT0vQ12gIg">3.0</ix:nonFraction> million. In September 2019, the Company paid the $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_9_1_2019_To_9_30_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_gG7wFWBERkClqJ60IJyBXw" decimals="-5" format="ixt:numdotdecimal" name="xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities" scale="6" id="Narr_UH_aSouApkuUyeuCSWqNtg">3.0</ix:nonFraction> million contingent consideration to Aronora. As the Company receives royalties from Aronora for a product, the Company will recognize the liability for future Royalty Milestones for such product when probable and estimable. The Company continues to assess that no payments are probable to be received under this agreement in the near term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the cost recovery method, the Company does not expect to recognize any income related to milestones and royalties received until the purchase price has been fully collected. The Company performed its impairment assessment and <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_m716wsI3XE6pmBu2Tce2QA" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" scale="6" id="Narr_8Th73X_1kUSkYdgM6jrCmg"><ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_o6zurAuWbE6ntKuKdPP1yg" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" scale="6" id="Narr_1Lxy2b-XoEqzj43_rNtgbw">no</ix:nonFraction></ix:nonFraction> allowance for credit losses was recorded as of June 30, 2023 or December 31, 2022.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk98833573"></a><a id="_Hlk138947369"></a><a id="_Hlk92457586"></a><ix:continuation id="Tb_kLeOsNdGHU--0YTLdm9I3w_cont4" continuedAt="Tb_kLeOsNdGHU--0YTLdm9I3w_cont5"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Palobiofarma Royalty Purchase Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On September 26, 2019, the Company entered into the Palo RPA, pursuant to which the Company acquired the rights to potential royalty payments in low single-digit percentages of aggregate net sales associated with <ix:nonFraction unitRef="Unit_Standard_item_ZJDcTjbqbUC2tIGJY9M-pg" contextRef="As_Of_9_26_2019_srt_CounterpartyNameAxis_xoma_PalobiofarmaSLMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_zT4QsAb7u0eLPQ9twhpAFA" decimals="INF" format="ixt-sec:numwordsen" name="xoma:AgreementDrugCandidatesNumber" scale="0" id="Narr_Pxq3lUdcnkGqrLt-F7A_jQ">six</ix:nonFraction> drug candidates in various clinical development stages, targeting the adenosine pathway with potential applications in solid tumors, non-Hodgkin&#8217;s lymphoma, asthma/chronic obstructive pulmonary disease, ulcerative colitis, idiopathic pulmonary fibrosis, lung cancer, psoriasis and nonalcoholic steatohepatitis and other indications (the &#8220;Palo Licensed Products&#8221;) that are being developed by Palo. Novartis is a development partner on NIR178, one of the Palo Licensed Products, and NIR178 is being developed pursuant to a license agreement between Palo and Novartis. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Palo RPA, the Company paid Palo a $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_9_26_2019_To_9_26_2019_srt_CounterpartyNameAxis_xoma_PalobiofarmaSLMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_aaICGPfxhkOTZpQUaO0Yqw" decimals="-5" format="ixt:numdotdecimal" name="xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities" scale="6" id="Narr_3hoQYUwZyEyBUc3uw7bSpw">10.0</ix:nonFraction> million payment at the close of the transaction, which occurred simultaneously upon parties&#8217; entry into the Palo RPA on September 26, 2019. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of the agreement, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_9_26_2019_srt_CounterpartyNameAxis_xoma_PalobiofarmaSLMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_zT4QsAb7u0eLPQ9twhpAFA" decimals="-5" format="ixt:numdotdecimal" name="xoma:LongTermRightsReceivableNonCurrent" scale="6" id="Narr_saezXYJO3kSMR7f_Jzi43A">10.0</ix:nonFraction> million as long-term royalty receivables in its consolidated balance sheet. The Company continues to assess that no payments are probable to be received under this agreement in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to royalties received until the purchase price has been fully collected. The Company performed its impairment assessment and <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_PalobiofarmaSLMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_ipZkO7zZN06t3XJUxHlDgQ" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" scale="6" id="Narr__VCKG8ROwkGJpbXhxK-o5Q"><ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_PalobiofarmaSLMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_YM8JsAYwe02uTcAIJfsjVw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" scale="6" id="Narr_DZ7MLyBtb0u8bocCxz2oLg">no</ix:nonFraction></ix:nonFraction> allowance for credit losses was recorded as of June 30, 2023 or December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Viracta Royalty Purchase Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On March 22, 2021, the Company entered into the Viracta RPA, pursuant to which the Company acquired the right to receive future royalties, milestones, and other payments related to <ix:nonFraction unitRef="Unit_Standard_item_ZJDcTjbqbUC2tIGJY9M-pg" contextRef="As_Of_3_22_2021_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_46O6ygYv-kiSXEivuByfuw" decimals="INF" format="ixt-sec:numwordsen" name="xoma:AgreementDrugCandidatesNumber" scale="0" id="Narr_9sO_q1OUZkSD7B9pQ51PuA">two</ix:nonFraction> clinical-stage drug candidates for $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_3_22_2021_To_3_22_2021_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_Yzb76SH-JEWCZntLrcxS8w" decimals="-5" format="ixt:numdotdecimal" name="xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities" scale="6" id="Narr_RaMo6KhtMEiBGj8jJIbC-w">13.5</ix:nonFraction> million. The first candidate, DAY101 (pan-RAF kinase inhibitor), is being developed by Day One Biopharmaceuticals, and the second candidate, vosaroxin (topoisomerase II inhibitor), is being developed by Denovo Biopharma. The Company acquired the right to receive (i) up to $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_3_22_2021_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_46O6ygYv-kiSXEivuByfuw" decimals="-5" format="ixt:numdotdecimal" name="xoma:MilestonesReceivableExcludingConsiderationRetainedMaximum" scale="6" id="Narr_ykOAeJ_ls0-fF2xWQrj9Xw">54.0</ix:nonFraction> million in potential milestones, potential royalties on sales, if approved, and other payments related to DAY101, excluding up to $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_3_22_2021_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_46O6ygYv-kiSXEivuByfuw" decimals="-5" format="ixt:numdotdecimal" name="xoma:MaximumConsiderationRetained" scale="6" id="Narr_eD7xyEo2akiz-O0t0x1Zsg">20.0</ix:nonFraction> million consideration retained by Viracta, and (ii) up to $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_3_22_2021_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_46O6ygYv-kiSXEivuByfuw" decimals="-5" format="ixt:numdotdecimal" name="xoma:RegulatoryAndCommercialMilestonesReceivableMaximum" scale="6" id="Narr_r9LWkBzCDEybhZGarrGPmw">57.0</ix:nonFraction> million in potential regulatory and commercial milestones and high single-digit royalties on sales related to vosaroxin, if approved. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of the Viracta RPA, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_3_22_2021_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_46O6ygYv-kiSXEivuByfuw" decimals="-5" format="ixt:numdotdecimal" name="xoma:LongTermRightsReceivableNonCurrent" scale="6" id="Narr_cS6SB7t4OEOQkX3HTXJD3Q">13.5</ix:nonFraction> million as long-term royalty receivables in its consolidated balance sheet. No payments are probable to be received under the Viracta RPA in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to royalties, milestones and other payments until the purchase price has been fully collected. The Company performed its impairment assessment and <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_t0Nk1HTAG0K7OHjnARYZew" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" scale="6" id="Narr_JtEAzCAw90uZAns0QT9DlA"><ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_6tHZOwbzlkiu2oefkSmJmg" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" scale="6" id="Narr_hYlESv86jkKfzWU701Ffaw">no</ix:nonFraction></ix:nonFraction> allowance for credit losses was recorded as of June 30, 2023 or December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Kuros Royalty Purchase Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On July 14, 2021, the Company entered into the Kuros RPA, pursuant to which the Company acquired the rights to <ix:nonFraction unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ" contextRef="Duration_7_14_2021_To_7_14_2021_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_s0z0PXoS5k-BNomvO5_j6g" decimals="INF" format="ixt:numdotdecimal" name="xoma:RoyaltyReceivablePercentageOnNetSales" scale="-2" id="Narr_PkZrRBscrEGzUIOOYNEpbw">100</ix:nonFraction>% of the potential future royalties from commercial sales, which are tiered from high single-digit to low double-digits, and up to $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_7_14_2021_To_7_14_2021_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_s0z0PXoS5k-BNomvO5_j6g" decimals="-5" format="ixt:numdotdecimal" name="xoma:EligibleMilestonePaymentsReceivableUponAchievementOfPreCommercialMilestones" scale="6" id="Narr_0Tqttc8oq06AD533soT8BQ">25.5</ix:nonFraction> million in pre-commercial milestone payments associated with an existing license agreement related to Checkmate Pharmaceuticals&#8217; vidutolimod (CMP-001), a Toll-like receptor 9 agonist, packaged in a virus-like particle, for an upfront payment of $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_7_14_2021_To_7_14_2021_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_s0z0PXoS5k-BNomvO5_j6g" decimals="-5" format="ixt:numdotdecimal" name="xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities" scale="6" id="Narr_fqSaY005eUyo732I31T-LQ">7.0</ix:nonFraction> million. The Company may pay up to an additional $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_7_14_2021_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_Xh1jjLmK9029VV5PJj8xKg" decimals="-5" format="ixt:numdotdecimal" name="xoma:MaximumPayableOnSalesMilestone" scale="6" id="Narr_dRj2R6hZqkGyK5KLUiDd6g">142.5</ix:nonFraction> million to Kuros in sales-based milestones. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of the Kuros RPA, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_7_14_2021_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_Xh1jjLmK9029VV5PJj8xKg" decimals="-5" format="ixt:numdotdecimal" name="xoma:LongTermRightsReceivableNonCurrent" scale="6" id="Narr_p1WEOVMsuUSVxY568rxMTQ">7.0</ix:nonFraction> million as long-term royalty receivables in its consolidated balance sheet. Under the cost recovery method, the Company does not expect to recognize any income related to royalties, milestones and other payments until the purchase price has been fully collected. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In May 2022, Regeneron completed its acquisition of Checkmate Pharmaceuticals resulting in a $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_5_1_2022_To_5_31_2022_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_ksZbC81p30-S2MPeTooszw" decimals="-5" format="ixt:numdotdecimal" name="xoma:MilestonePaymentReceivedCounterparty" scale="6" id="Narr_WfXkSPvTfECn5Wjc4S3RaQ">5.0</ix:nonFraction> million milestone payment to Kuros. Pursuant to the Kuros RPA, the Company is entitled to <ix:nonFraction unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ" contextRef="Duration_7_1_2022_To_7_31_2022_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_XIw7qGqY0EK6f05CwdTGoA" decimals="2" format="ixt:numdotdecimal" name="xoma:MilestonePaymentReceivablePercentage" scale="-2" id="Narr__eeAg0iL10KTzKi1DntV-g">50</ix:nonFraction>% of the milestone payment, which was received by XOMA in July 2022. In accordance with the cost recovery method, the $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_7_1_2022_To_7_31_2022_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_XIw7qGqY0EK6f05CwdTGoA" decimals="-5" format="ixt:numdotdecimal" name="xoma:ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" scale="6" id="Narr_MJdwyTAN9k6BsRNeSu3Q7w">2.5</ix:nonFraction> million milestone received was recorded as a direct reduction of the recorded long-term royalty receivable balance.<b style="font-weight:bold;"> </b>As of June 30, 2023, no payments are probable to be received under the Kuros RPA in the near term.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk98867428"></a><a id="_Hlk93563417"></a><ix:continuation id="Tb_kLeOsNdGHU--0YTLdm9I3w_cont5" continuedAt="Tb_kLeOsNdGHU--0YTLdm9I3w_cont6"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company performed its impairment assessment and <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_l6eBrvgOik6JwWWl-dCq7g" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" scale="6" id="Narr_wSzc399dW0C1gUSCMRGxAA"><ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_1wOk0To-60ebzBx-MLxW0A" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" scale="6" id="Narr_d7EFOrErsUWfnMVKp_1whg">no</ix:nonFraction></ix:nonFraction> allowance for credit losses was recorded as of June 30, 2023 or December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Commercial Payment Purchase Agreement with Affitech </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On October 6, 2021, the Company entered into the Affitech CPPA, pursuant to which, the Company purchased a future stream of commercial payment rights to Roche&#8217;s faricimab from Affitech for an upfront payment of $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_10_6_2021_To_10_6_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_7mFvjte_dEevmb4jPsGqCg" decimals="-5" format="ixt:numdotdecimal" name="xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities" scale="6" id="Narr_maSAWSbAD0GvwRDdeJXi6Q">6.0</ix:nonFraction> million. The Company is eligible to receive <ix:nonFraction unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ" contextRef="Duration_10_6_2021_To_10_6_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_srt_ProductOrServiceAxis_xoma_FaricimabProductMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_wnbrqh2QZE2B_rph576ABA" decimals="4" format="ixt:numdotdecimal" name="xoma:CommercialSalesReceivablePercentageOnNetSales" scale="-2" id="Narr_MTZsJxh2AEmfByemOxZ8UA">0.5</ix:nonFraction>% of future net sales of faricimab for a <ix:nonNumeric contextRef="Duration_10_6_2021_To_10_6_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_srt_ProductOrServiceAxis_xoma_FaricimabProductMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_wnbrqh2QZE2B_rph576ABA" format="ixt-sec:durwordsen" name="xoma:CommercialPaymentReceivableTerm" id="Narr_Xu6fy-a7ckiPY3reUR5bqA">ten-year</ix:nonNumeric> period following the first commercial sales in each applicable jurisdiction. Under the terms of the Affitech CPPA, the Company may pay up to an additional $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_10_6_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_utnG5LOjWkaEzqc0Xpgs4A" decimals="-5" format="ixt:numdotdecimal" name="xoma:MaximumPaymentsBasedOnAchievementOfRegulatoryAndSalesMilestones" scale="6" id="Narr_Seh5sZ-13EyMDKS8JtQ8VA">20.0</ix:nonFraction> million based on the achievement of certain regulatory and sales milestones. At the inception of the Affitech CPPA, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_10_6_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_utnG5LOjWkaEzqc0Xpgs4A" decimals="-5" format="ixt:numdotdecimal" name="xoma:LongTermRightsReceivableNonCurrent" scale="6" id="Narr_RlmQgqZDNU6Tqan5CkDqVw">14.0</ix:nonFraction> million as long-term royalty receivables which included the $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_10_6_2021_To_10_6_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_7mFvjte_dEevmb4jPsGqCg" decimals="-5" format="ixt:numdotdecimal" name="xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities" scale="6" id="Narr_bleVLtOPw0WFjPwOCsZyxg">6.0</ix:nonFraction> million upfront payment and $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_10_6_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_utnG5LOjWkaEzqc0Xpgs4A" decimals="-5" format="ixt:numdotdecimal" name="xoma:MaximumPayableOnRegulatoryMilestone" scale="6" id="Narr_ysG7oOKAzUi_BGYEMzf8dg">8.0</ix:nonFraction> million in regulatory milestones in its consolidated balance sheet. The Company concluded the regulatory milestone payments of $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_10_6_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_ContingentConsiderationByTypeAxis_xoma_ContingentConsiderationRegulatoryMilestonesMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_vyMgtLcJvEi0juGqwh3ASQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:ContingentConsiderationUnderPurchaseAgreements" scale="6" id="Narr_fHzZ3tWhL0O8g9WdLrTi7w">8.0</ix:nonFraction> million met the definition of a derivative under ASC 815 and should be accounted at fair value and recorded as a current liability at the inception of the transaction. Therefore, the regulatory milestone payments were recorded as contingent liabilities in its consolidated balance sheet. The Company concluded the sales-based milestone payments of $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_10_6_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_utnG5LOjWkaEzqc0Xpgs4A" decimals="-5" format="ixt:numdotdecimal" name="xoma:MaximumPayableOnSalesMilestone" scale="6" id="Narr_-wtiTpsovU-ug964YLNdgg">12.0</ix:nonFraction> million do not meet the definition of a derivative under ASC 815 and a liability will be recognized when probable and estimable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In January 2022, Roche received approval from the FDA to commercialize VABYSMO (faricimab-svoa) for the treatment of wet, or neovascular, age-related macular degeneration and diabetic macular edema. In September 2022, Roche received approval from the European Commission to commercialize VABYSMO for the treatment of wet, or neovascular, age-related macular degeneration and visual impairment due to diabetic macular edema. Pursuant to the Affitech CPPA, the Company paid Affitech a $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_p8h6imE-V0uwNs1HrXGY2A" decimals="-5" format="ixt:numdotdecimal" name="xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities" scale="6" id="Narr_itLrxG9c90-dasQFfiO4Eg">5.0</ix:nonFraction> million milestone tied to the U.S. marketing approvals and a $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_srt_StatementGeographicalAxis_srt_EuropeMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_91bx_J3VVUaNfNyS-gIThg" decimals="-5" format="ixt:numdotdecimal" name="xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities" scale="6" id="Narr_EbMXcIK8TEy4-Mcnerer-Q">3.0</ix:nonFraction> million milestone tied to the EC approvals. The Company may pay an additional $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_1_31_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_P2FOnn42CUiAAEHfWUjQNw" decimals="-5" format="ixt:numdotdecimal" name="xoma:MaximumPayableOnSalesMilestone" scale="6" id="Narr_gti87HHGxE2JNT8obmFneA">12.0</ix:nonFraction> million based on the achievement of certain sales milestones.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In August 2022, the Company received $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_8_1_2022_To_8_31_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_OH8fvv_h9keoJxZOMgPK5A" decimals="-5" format="ixt:numdotdecimal" name="xoma:ReceiptsUnderAgreementsInvestingActivities" scale="6" id="Narr_LVSwTIAUEEOgOQibJEwpaw">0.5</ix:nonFraction> million from Roche representing the first commercial payment for sales of VABYSMO during the first six months of 2022. In accordance with the cost recovery method, the $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_8_1_2022_To_8_31_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_OH8fvv_h9keoJxZOMgPK5A" decimals="-5" format="ixt:numdotdecimal" name="xoma:ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" scale="6" id="Narr_8E3nH8HrQEuIDjtLsC1Lwg">0.5</ix:nonFraction> million received was recorded as a direct reduction of the long-term royalty receivable balance. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In February 2023, the Company received $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_2_1_2023_To_2_28_2023_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_3qo6LMNvTEKUouebN2XnWA" decimals="-5" format="ixt:numdotdecimal" name="xoma:ReceiptsUnderAgreementsInvestingActivities" scale="6" id="Narr_LodfAq6FzE2CpTVe5SZ2kw">2.4</ix:nonFraction> million, representing its commercial payment stream from sales of VABYSMO during the last six months of 2022. The payment amount was classified as a short-term royalty and commercial payment receivable as of December 31, 2022. In accordance with the cost recovery method, the $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_2_1_2023_To_2_28_2023_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_3qo6LMNvTEKUouebN2XnWA" decimals="-5" format="ixt:numdotdecimal" name="xoma:ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" scale="6" id="Narr_dSj_UkQpeEm8sbMJVbOMSQ">2.4</ix:nonFraction> million received in February 2023 was recorded as a direct reduction of the short-term royalty receivable balance as of June 30, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company estimated $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_8_1_2023_To_8_31_2023_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_srt_ProductOrServiceAxis_xoma_FaricimabSvoaVabysmoProductMember_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_REdIh2M4tEqC4XSc5ixlSg" decimals="-5" format="ixt:numdotdecimal" name="xoma:ReceiptsUnderAgreementsInvestingActivities" scale="6" id="Narr_Lptux4XmgkGSJWVBo0XFJw">5.0</ix:nonFraction> million of commercial payments from sales of VABYSMO during the first six months of 2023 would be received in August 2023, within &#160;twelve-months of the balance sheet date of June 30, 2023 and, as such, reclassified this amount as short-term royalty and commercial payment receivable as of June 30, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the cost recovery method, the Company does not expect to recognize any income related to future commercial payment receipts until the purchase price has been fully collected. The Company performed its impairment assessment and <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_tbP6vsd5eUOJL3GPMRb5Sw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" scale="6" id="Narr_joxr9MTeHEas9Gpy1AvKYQ"><ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_t4tt47wP20iV85oZnDl0kQ" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" scale="6" id="Narr_mYo6sCIAeUG3313jJQTpcw">no</ix:nonFraction></ix:nonFraction> allowance for credit losses was recorded as of June 30, 2023 or December 31, 2022.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_b1ccc9c6_9216_4a19_b0ea_7d04bf41b80c"></a><a id="Tc_1aQtLp5N10CWUAQfzNDsZw_1_2"></a><a id="Tc_guvYZGNO_km2FWTKWyaOWQ_1_4"></a><a id="Tc_d63nVv0bl0OSkjMaIL_dMQ_2_0"></a><a id="Tc_d7BCbOVHNUGzwSq2FojhEA_2_2"></a><a id="Tc_D0ir-zxLyE2g6SB81wezng_2_4"></a><a id="Tc_d_WIc8xB3UKuX1muIQyM6Q_3_0"></a><a id="Tc_z0HdKlO0i0aLC34XPPNe0A_4_0"></a><a id="Tc_o0IS7CoU1kCxBUHMe_mMWw_4_3"></a><a id="Tc_b4jM-BfgEkS4nGAQJYMf5w_5_0"></a><a id="Tc_BKihAJIjSU6Hb9Xx3T5RZw_5_3"></a><a id="Tc_lFnvyA87lE-UQ4NBrGXw3w_6_0"></a><a id="Tc_M7CC9lAtbECoNVkikI2JxQ_7_0"></a><a id="Tc_3pCiISsTtk6B2dhDxf9m6A_8_0"></a><a id="Tc_e98_qFzzQEOQxcrwGZs6gA_9_0"></a><a id="Tc_MO0CAKyh6ku6SGIm-coz-Q_10_0"></a><a id="Tc_K3kSfqPPNEWpyOt988EsnQ_11_0"></a><a id="Tc_usyklClfPk2Y-pTHTZ08Qw_12_0"></a><a id="Tc_s7XjnKMSz0u37RIvSE6OCw_13_0"></a><a id="Tc_tPQBPGgr2EGakkfHtPSW_g_13_2"></a><a id="Tc_gHMt98FtrkaFNqbfMXgZSA_13_4"></a><ix:continuation id="Tb_kLeOsNdGHU--0YTLdm9I3w_cont6"><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" name="xoma:ScheduleOfRoyaltyAndCommercialPaymentReceivablesActivityTableTextBlock" id="Tb_8BNmxGrUok22vVjK3UgVog" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the royalty and commercial payment receivable activities during the six months ended June 30, 2023 (in thousands): </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Short-Term</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Long-Term</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at January 1, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg" decimals="-3" format="ixt:numdotdecimal" name="xoma:RightsReceivableCurrent" scale="3" id="Tc_WD5uktLIj0qIlEzN1THHhQ_2_3">2,366</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg" decimals="-3" format="ixt:numdotdecimal" name="xoma:LongTermRightsReceivableNonCurrent" scale="3" id="Tc_lH3L1L-QOkCfj8pUi7Y13Q_2_5">63,683</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Acquisition of royalty and commercial payment receivables:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Aptevo</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_euIclIwai0uxoAqBVaGjlw" decimals="-3" format="ixt:numdotdecimal" name="xoma:RoyaltyAndCommercialRightsAcquiredNonCurrent" scale="3" id="Tc_Wiv3oy-qOEutZ87lDwBmzw_4_5">9,650</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">LadRx</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_B01Z3JtpTkOkqmAnGrSDdg" decimals="-3" format="ixt:numdotdecimal" name="xoma:RoyaltyAndCommercialRightsAcquiredNonCurrent" scale="3" id="Tc_djnSNhjjMESSQGGdhs9P5Q_5_5">6,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Receipt of royalty and commercial payments:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Affitech</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_WO4UYUGV_02Sv2V6Sl4utw" decimals="-3" format="ixt:numdotdecimal" name="xoma:ReceiptOfRoyaltyAndCommercialPaymentReceivableCurrent" scale="3" id="Tc_3hoxFQqWFki8O1BRey32Wg_7_3">2,366</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Aptevo</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_euIclIwai0uxoAqBVaGjlw" decimals="-3" format="ixt:numdotdecimal" name="xoma:ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" scale="3" id="Tc_fOGDhEni0USGZKw1PGYt-A_8_5">568</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:75.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Impairment of royalty and commercial payment receivables:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Bioasis</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_ka9FAFONVkeMeIE9zPwx5Q" decimals="-3" format="ixt:numdotdecimal" name="xoma:ImpairmentOfLongTermRightsReceivableNonCurrent" scale="3" id="Tc_bVN0yasKsUGkQP4w1ctwiA_10_5">1,575</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:75.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Reclassification to short-term royalty and commercial payment receivables:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Affitech</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_WO4UYUGV_02Sv2V6Sl4utw" decimals="-3" format="ixt:numdotdecimal" name="xoma:ShortTermRightsReceivableReclassification" scale="3" id="Tc_NB3v8sMc6kWTdJenpy706Q_12_3">4,958</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_WO4UYUGV_02Sv2V6Sl4utw" decimals="-3" format="ixt:numdotdecimal" name="xoma:LongTermRightsReceivableReclassification" sign="-" scale="3" id="Tc_hRcEgH5hx0SFj0z2nP_L1g_12_5">4,958</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:75.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at June&#160;30,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ" decimals="-3" format="ixt:numdotdecimal" name="xoma:RightsReceivableCurrent" scale="3" id="Tc_YQSDJw0O_U2E1GxIRI-OmQ_13_3">4,958</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ" decimals="-3" format="ixt:numdotdecimal" name="xoma:LongTermRightsReceivableNonCurrent" scale="3" id="Tc_Dac8x5nycUWc9Z0oTy9yVA_13_5">72,232</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_Q84-uX5X0EK8CHj7JgLnXQ" continuedAt="Tb_Q84-uX5X0EK8CHj7JgLnXQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">6. Fair Value Measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company records its financial assets and liabilities at fair value. The carrying amounts of certain of the Company&#8217;s financial instruments, including cash, trade receivables, net and accounts payable, approximate their fair value due to their short maturities. Fair value is defined as the exchange price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The accounting guidance for fair value establishes a framework for measuring fair value and a fair value hierarchy that prioritizes the inputs used in valuation techniques. The accounting standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">Level 1&#160;&#8211; Observable inputs, such as unadjusted quoted prices in active markets for identical assets or liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">Level 2&#160;&#8211; Observable inputs, either directly or indirectly, other than quoted prices in active markets for identical assets or liabilities, such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">Level 3&#160;&#8211; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities; therefore, requiring an entity to develop its own valuation techniques and assumptions.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_0b25052d_36fe_448d_8787_82a4d4872653"></a><a id="Tc_W3nEU92Qu0-0Bkb2F3lZUg_1_2"></a><a id="Tc_Tj51UBg-VEmKHDYOySUy3A_2_2"></a><a id="Tc_YZveuFYuak-FE0jZqMgfmg_2_5"></a><a id="Tc_ix2d613W9UyHjvA27hxDcg_2_8"></a><a id="Tc_aq_GgKHaLEiN2L8974p1EA_3_2"></a><a id="Tc_S0KVS1G-K02JgOF3gweR_Q_3_5"></a><a id="Tc_Wm-HbyyuqU-nRj8A3uPcGA_3_8"></a><a id="Tc_6Kn-ctFOg0yGK1gsdoYhLQ_4_2"></a><a id="Tc_bByUBCiG9UGRmaKonBpEyA_4_5"></a><a id="Tc_h9Q3r1cpSkaITgSz976c-Q_4_8"></a><a id="Tc_3TTjynTDlke9nbF2OCmwYA_5_2"></a><a id="Tc_uN3e3Jpu00m6bswNVQajkA_5_5"></a><a id="Tc_rrAPgJzX60qn1FjYJiKXZg_5_8"></a><a id="Tc_56yn5ruunESw8n_KMzNgTQ_5_11"></a><a id="Tc_k2Jd3lir6kioZCvtEphqPw_6_0"></a><a id="Tc_1oHhSQ8K7UGOfVIK_BWiFg_7_0"></a><a id="Tc_dcpIAyIunEiIOVtFqxQ-Gg_8_0"></a><a id="Tc_feSOB-SAtUqVKl-vADbZZg_8_2"></a><a id="Tc_XuRw56h6HkisVqgZIXdZeA_8_5"></a><a id="Tc_beQe85pU8UCO5E7upTTdEA_8_6"></a><a id="Tc_8aWMFuZdEkuqTfTk0pACIQ_8_8"></a><a id="Tc_7FTXEvZjmEKvA4XyZvxdEQ_8_9"></a><a id="Tc_UeC-trsp7EekatilM4saDQ_8_11"></a><a id="Tc_lxS59y7nt0ilzZ6suLerUQ_9_0"></a><a id="Tc_mdnCd5wM6ky3ITJvZYRPgw_9_6"></a><a id="Tc_rw-B4Ar9VUqZYevCr5f01A_9_9"></a><a id="Tc_76r5RgKZlkWaova3aX_IPA_10_0"></a><a id="Tc_4gPVXyBCM0yseGdFksgI8Q_10_6"></a><a id="Tc_NoPW707eFEOVJU9Vl-T8zw_10_9"></a><a id="Tc_fJwO9c6cYUq-y1sVXdQSBQ_11_0"></a><a id="Tc_ZAAF0I2DU02JCQPwnU9ZDA_11_2"></a><a id="Tc_N6uZ1FHWl0qUspiat2kRHg_11_5"></a><a id="Tc_x3TBWeL9HU-E9S82ytqgTQ_11_6"></a><a id="Tc_4lz3p1-M1E6BaL9w59heUg_11_8"></a><a id="Tc_2SWq308EgUeRaGEyQhG03A_11_9"></a><a id="Tc_akPV62mjaEeJEjpQC82FFw_11_11"></a><a id="Tc__BdCf-x5t0W8WAdLg4joVA_12_0"></a><a id="Tc_c_pzl5w7hkKuOw3ITr7gZA_13_0"></a><a id="Tc_VrhP607OAkKLrask85FnxQ_13_2"></a><a id="Tc_LZOyEhRS6kORFiOJ5TAV_w_13_3"></a><a id="Tc_Zlz4z72hLk2EQFxvXz6LAw_13_5"></a><a id="Tc_5nseUhhkikOShig1TJv-JA_13_6"></a><a id="Tc_FFa4c-xJpEWbXwczZ0yH4w_13_8"></a><a id="Tc_v0pZtrH1fUOWNuV1F6dz-Q_13_11"></a><a id="_3631cff9_6004_47eb_90e2_631f288033b0"></a><a id="Tc_JNGqThYzUkaHTyfLoLYhdA_1_2"></a><a id="Tc_C7O4HuHhPE6UUS_kW9ut8Q_2_2"></a><a id="Tc_7JWj0NZti0u5D1EBtn--nw_2_5"></a><a id="Tc_j5DvYHtD_0mN33TtE85HoA_2_8"></a><a id="Tc_3GBLC0jWa0-qMUNngwy_Dw_3_2"></a><a id="Tc_2wza7jrohk694zsIVT2f1Q_3_5"></a><a id="Tc_5cbgt3aZN0m9I_lnlYenwQ_3_8"></a><a id="Tc_B1ZqXCLZwUmARqe3e_18xw_4_2"></a><a id="Tc_HK-yG_EnqkqBVVG7iNxC8A_4_5"></a><a id="Tc_QdSe8KnzNUqZ-tux7iqNPQ_4_8"></a><a id="Tc_jUxWrRIEMEWj5_QxI8Q4Ew_5_2"></a><a id="Tc_mvdq8Gvbqkulr9oa6KEnOQ_5_5"></a><a id="Tc_OXHLkzlS3ESe3dryZH3RVA_5_8"></a><a id="Tc_bKpT3V9_qUGmNuVOEfiChw_5_11"></a><a id="Tc_LZ3Z_ehacUS7y_6phfVFbQ_6_0"></a><a id="Tc_4L4CBaTMT0i_FDswiBQDTA_7_0"></a><a id="Tc_iqj13tfd10KYM43EdaeMhA_8_0"></a><a id="Tc__wXH2WEEsEyDev2GPEQZKw_8_2"></a><a id="Tc__y-GgzJiyUuk4kQunPKE9w_8_5"></a><a id="Tc_XlpCA5puN0WjkdFbjvAQiA_8_6"></a><a id="Tc_WYmVSm8B7Ei4Ig8hk9WNeg_8_8"></a><a id="Tc_Pfq7K1-jd0-Y4BGdT-tqlQ_8_9"></a><a id="Tc_Gr-RA4iViE-fyUC73y_i5A_8_11"></a><a id="Tc_KzWeeqG9P0GVO60N_mmNbw_9_0"></a><a id="Tc_QU6ZaCuQGkSg31Klp1c1sA_9_6"></a><a id="Tc_hHeIU4tJx0GfCxN8EzENpg_9_9"></a><a id="Tc_F3ejSQdt6EeAsshDrgOavA_10_0"></a><a id="Tc__nMyLhx6-kONnIJj9qKiRA_10_6"></a><a id="Tc_jN29kF6kHEWbZw-XLS80sw_10_9"></a><a id="Tc_0ZOwN07HXE-IS4UIfgK7XQ_11_0"></a><a id="Tc_bapkBW6SS0GRjBASjXMwyw_11_2"></a><a id="Tc_rFIzFYWnjUWcx_VWplk0Pg_11_5"></a><a id="Tc_BApjKDpsN0eIX0XBDA6g-w_11_6"></a><a id="Tc_6d7175cCn0avB7sic_F8Tg_11_8"></a><a id="Tc_6IyrB1TGYE6vRQddFKI0sg_11_9"></a><a id="Tc_l9LrhuSU40-TrBp6XMeidg_11_11"></a><a id="Tc_q59amIldc0WJ5kMnsC8Nxg_12_0"></a><a id="Tc_5vi3pr9mXEq5YwXr-qE64w_13_0"></a><a id="Tc_4mgNQk21CUy2ByYh4DEvNQ_13_2"></a><a id="Tc_vtxUXNqjpUu9oHP0_ana2A_13_3"></a><a id="Tc_4ehG89F7DkS7c7A8E6l8Eg_13_5"></a><a id="Tc_T0T5d2yjwUepMJCY5CGRTg_13_6"></a><a id="Tc_uSjvp9B-wkq61GX0zLs1eg_13_8"></a><a id="Tc_QCKmo0c-gkCn0i-yDy13Lw_13_11"></a><ix:continuation id="Tb_Q84-uX5X0EK8CHj7JgLnXQ_cont1" continuedAt="Tb_Q84-uX5X0EK8CHj7JgLnXQ_cont2"><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="Tb_gLExRHFIb0GPC_vStQwDxQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following tables set forth the Company&#8217;s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as follows (in thousands): </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements&#160;at&#160;June&#160;30,&#160;2023 Using: </b></p></td></tr><tr><td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Quoted&#160;Prices&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Active&#160;Markets&#160;for</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Identical&#160;Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_9fLx36Xpp0Oo2wwcPihyCQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_orTeOSg0NE-GFP2oHBjy3g_8_3">30,102</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_8L7cEkq67EeCxAnI09lGvA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_lyENrkBg1EuxPibZS9G4Nw_8_12">30,102</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total cash equivalents </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_0k9Iaqnwd06OsUIk7HwMEw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_dFb7dFodAUewi_Jk7UvZfQ_9_3">30,102</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_wkmIyE0jUkOmFM4P8qQX2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_2bCZifxzBkmQCb6eMhujbQ_9_12">30,102</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:50.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Equity securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_0k9Iaqnwd06OsUIk7HwMEw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_nvavo_FwNECcySBpfM4p-Q_10_3">320</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_wkmIyE0jUkOmFM4P8qQX2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_zBQsMuwjakuE0dSV09hKNg_10_12">320</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total financial assets </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_0k9Iaqnwd06OsUIk7HwMEw" decimals="-3" format="ixt:numdotdecimal" name="xoma:FinancialAssetsFairValueDisclosure" scale="3" id="Tc_AFlVwYhn90aOtCF1EYPFXg_11_3">30,422</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_wkmIyE0jUkOmFM4P8qQX2A" decimals="-3" format="ixt:numdotdecimal" name="xoma:FinancialAssetsFairValueDisclosure" scale="3" id="Tc_Je9mp2EmaE-PcP-itbMnqg_11_12">30,422</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:50.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Contingent consideration under RPAs, AAAs and CPPAs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_s8DXfaV1hU-kNpb0otcEew" decimals="-3" format="ixt:numdotdecimal" name="xoma:ContingentConsiderationFairValueDisclosure" scale="3" id="Tc_e8xkc7-hdUCJlYL5agD-ig_13_9">1,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_wkmIyE0jUkOmFM4P8qQX2A" decimals="-3" format="ixt:numdotdecimal" name="xoma:ContingentConsiderationFairValueDisclosure" scale="3" id="Tc__VeAL9jlx0CJmP8NVVhVmw_13_12">1,000</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements&#160;at&#160;December&#160;31,&#160;2022 Using:</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Quoted&#160;Prices&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Active&#160;Markets&#160;for</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Identical&#160;Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_7KGCjOdAWkKDUJtQiWx04A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_DqmXDDqMPkS0wQHSjSzXPg_8_3">30,334</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_YKgnRcgp30yLgGtobgVXyQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_TP0s5X0fkkSVGabIwbHlMg_8_12">30,334</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:49.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total cash equivalents </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_p69-pIRmOU6cPwJMvLqNSA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_KO7ck2eHJE2hRXNpt9Pbqw_9_3">30,334</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_m8qyydbCFEaJdTCv-WBD4Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_znOMbpim-0SBKT08_7OC8A_9_12">30,334</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:49.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Equity securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_p69-pIRmOU6cPwJMvLqNSA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_NYAufeGLL0uqUvQ0Gy2C6g_10_3">335</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_m8qyydbCFEaJdTCv-WBD4Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentsFairValueDisclosure" scale="3" id="Tc_FvSb2srt40mdEyinPCvz9A_10_12">335</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:49.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total financial assets </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_p69-pIRmOU6cPwJMvLqNSA" decimals="-3" format="ixt:numdotdecimal" name="xoma:FinancialAssetsFairValueDisclosure" scale="3" id="Tc_nv3zEPIvAUmxK8Vz9xUJfg_11_3">30,669</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_m8qyydbCFEaJdTCv-WBD4Q" decimals="-3" format="ixt:numdotdecimal" name="xoma:FinancialAssetsFairValueDisclosure" scale="3" id="Tc_zhkFsuXka02OmbIjiTFQ8w_11_12">30,669</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:49.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Contingent consideration under RPAs, AAAs and CPPAs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_9t8qE3DtCUGDnjtaLsnr7g" decimals="-3" format="ixt:numdotdecimal" name="xoma:ContingentConsiderationFairValueDisclosure" scale="3" id="Tc_kzziWCecbUWJH3ljZGY8BQ_13_9">75</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_m8qyydbCFEaJdTCv-WBD4Q" decimals="-3" format="ixt:numdotdecimal" name="xoma:ContingentConsiderationFairValueDisclosure" scale="3" id="Tc_A7SU8D-nEka3kkzkyRA_Ww_13_12">75</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:12pt 0pt 12pt 0pt;">Equity Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The equity securities consisted of an investment in Rezolute&#8217;s common stock and are classified on the condensed consolidated balance sheets as current assets as of June 30, 2023 and December&#160;31, 2022. The equity securities are revalued each reporting period with changes in fair value recorded in the other income (expense), net line item of the condensed consolidated statements of operations and comprehensive loss. As of June 30, 2023 and December&#160;31, 2022, the Company valued the equity securities using the closing price for Rezolute&#8217;s common stock traded on the Nasdaq Stock Market of $<ix:nonFraction unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ" contextRef="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_BSWfJSEpmEGBgXlGS4MC4w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiMeasurementInput" scale="0" id="Narr_fnmYrsypGU6fNErtDOXH9A">1.98</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ" contextRef="As_Of_12_31_2022_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_79gnR1guSka7Q_vWe08uww" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiMeasurementInput" scale="0" id="Narr_WgGYHxme6UyFAJTIIyIA2w">2.07</ix:nonFraction>, respectively. The inputs that were used to calculate the fair value of the equity securities were observable prices in active markets and therefore were classified as a Level 1 fair value measurement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Contingent Consideration</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The estimated fair value of the Bioasis Contingent Consideration liability at the inception of the Bioasis RPA represents the future consideration that is contingent upon the achievement of specified development milestones for a product candidate. The fair value measurement is based on significant Level 3 inputs such as anticipated timelines and probability of achieving development milestones of each licensed product candidate. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The estimated fair value of the LadRx contingent consideration liability at the inception of the LadRx Agreements represents the future consideration that is contingent upon the achievement of specified regulatory milestones for the product candidates related to arimoclomol and aldoxorubicin. The fair value measurement is based on significant Level 3 inputs such as anticipated timelines and probability of achieving development milestones of each product candidate. </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_Q84-uX5X0EK8CHj7JgLnXQ_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Changes in the fair value of the liability for contingent consideration will be recorded in the other income (expense), net line item of the condensed consolidated statements of operations and comprehensive loss until settlement. During the six months ended June 30, 2023, the estimated fair value of the contingent consideration recorded pursuant to the Bioasis RPA was reduced to $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_2Aj5seKcO0-XhIAauxBBGA" decimals="-5" format="ixt:numdotdecimal" name="xoma:ContingentConsiderationUnderPurchaseAgreements" scale="6" id="Narr_gpNP4LvyFUO0npMRX-YTIg">0</ix:nonFraction> from the initial value of $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_mAQNTbueYkGTdJGdXydMXQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:ContingentConsiderationUnderPurchaseAgreements" scale="6" id="Narr_d9Bg8eOmYUqwd4esnK3dXw">0.1</ix:nonFraction> million. There were <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_6_21_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_o0jHZU6txku5HZbpgBRroQ" decimals="-5" format="ixt-sec:numwordsen" name="xoma:ChangesInEstimatedFairValueOfContingentConsideration" scale="6" id="Narr_6SoLZ-O6Kku4gJrLDyZ8Dg">no</ix:nonFraction> changes in the estimated fair value of the contingent consideration recorded pursuant to the LadRx Agreements from the initial value of $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_m3fGmRg0ukuCv0wBM5jhzQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:ContingentConsiderationUnderPurchaseAgreements" scale="6" id="Narr_T6QHmZvxW0GViazDtPXr-w">1.0</ix:nonFraction> million.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_5df92fe9_6863_49cd_8738_20d83a95915a"></a><a id="Tc_TVXN1BFrXE6kNdvoh7_tkQ_1_2"></a><a id="Tc_GlfP2dZ5G0KfWDpQvT9d4g_1_8"></a><a id="Tc_7i7oSvTduUKNySchWN3bjg_2_2"></a><a id="Tc_y44crDUZH0yZFll5sOtO9w_2_5"></a><a id="Tc_dOXwQu2dgkykS0casgJ5fw_2_8"></a><a id="Tc_ccNhtFMJHkqdP4mJqJmi2g_2_11"></a><a id="Tc_YDGQXLv-UEyvyVos_F81vQ_3_0"></a><a id="Tc_BHg7QK6zwUWVqA2e8e9_vQ_4_0"></a><a id="Tc_uVzjfAo8lkmbffRulRVcAQ_4_2"></a><a id="Tc_WhhpOAMU50G3-4W56qmg6A_4_5"></a><a id="Tc_V_am73EIiEWv6cq5yUfoRA_4_8"></a><a id="Tc_XA1CxAaLvESK-54zu9m41g_4_11"></a><a id="Tc_pnZ8fq9oSE2bvWSlblvmcQ_5_0"></a><a id="Tc_9Xaahe3bOkq_KJVOPgIGTw_6_0"></a><a id="Tc_A74iduoU2U-7qmgDMbVNQw_6_2"></a><a id="Tc_u5W9bQGstkWPEgnuGXh9dQ_6_5"></a><a id="Tc_3gQOUMd9QEC4i1GGyeYpPA_6_8"></a><a id="Tc_9kE1lXSxfEa-GIU2KGEWig_6_11"></a><a id="_750dccd0_a946_4ae5_8ba6_dd75831c90ff"></a><a id="Tc_G7JYKBlorU-YggfeL2A2-w_1_2"></a><a id="Tc_k6Z4yI36HkmFVJzeO4xjig_2_2"></a><a id="Tc_kSdKVaCnrEyrtgfr2kP8aA_2_5"></a><a id="Tc_w3aqB5XjlkKP4Mu4kuGFUw_3_0"></a><a id="Tc_RqPbevdYukqMrzNx4Y2XOg_4_0"></a><a id="Tc_p3Dj5jXapE2_PRKynD6KHQ_4_2"></a><a id="Tc_GCTleLUFJk6crPXyYa6kmw_4_5"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" name="xoma:LeaseDisclosureTextBlock" id="Tb_ToHcy5IeCUK8hkQaetgmtg" continuedAt="Tb_ToHcy5IeCUK8hkQaetgmtg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">7. Lease Agreements </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">The Company leases <ix:nonFraction unitRef="Unit_Standard_facility_xUSd_1xCIUaR1gnI0x8O9w" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesEmeryvilleCaliforniaMember_j4Za8qhjGEunE9GIsiSNhg" decimals="INF" format="ixt-sec:numwordsen" name="xoma:OperatingLeasesNumberOfLeasedFacilities" scale="0" id="Narr_qlvgig6-uUyVC1Te6coKfQ">one</ix:nonFraction> facility in Emeryville, California under an operating lease. In January 2023, the Company amended the original lease to extend the lease term <ix:nonNumeric contextRef="As_Of_1_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesEmeryvilleCaliforniaMember_qE4Q6lsyXk-n_6Q8orOVvg" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="Narr_qgxd5RP7MECEV9xg4u1KSA">five months</ix:nonNumeric> from its original expiration of February 28, 2023 to July 31, 2023. The Company retains no option to further extend, renew or terminate the lease under the amended terms and all other material terms and conditions, including the monthly base rent, will remain consistent with the original lease. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">In accordance with ASC 842, the Company accounted for the amendment to extend the lease term as a modification of the original lease and, as such, remeasured the lease liability and recognized a corresponding adjustment to the&#160;right-of-use asset of $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_1_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesEmeryvilleCaliforniaMember_jFg3GanTsESUiaQdv4hx4g" decimals="-5" format="ixt:numdotdecimal" name="xoma:LesseeOperatingLeaseModificationAdjustmentToRightOfUseAsset" scale="6" id="Narr_uLnYCeteskGPWCi9tw_23g">0.1</ix:nonFraction> million to reflect the changes in the lease payments due to the extended lease term. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">On June 27, 2023, the Company executed an amended lease agreement for its corporate headquarters lease in Emeryville, California with the same counterparty, in a different location in the same building to replace its existing lease expiring in July 2023. The amended lease agreement has a term of <ix:nonNumeric contextRef="As_Of_12_31_2023_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesTwoEmeryvilleCaliforniaMember_TMMvkmy6s0ygPCJWud7LzQ" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="Narr_3V5K0dJiskKXiiwpUOFe_Q">65 months</ix:nonNumeric> and has an expected commencement date in the fourth quarter of 2023. Undiscounted future rent payments associated with the new lease through the <ix:nonNumeric contextRef="As_Of_9_30_2023_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesTwoEmeryvilleCaliforniaMember_x-BSsUsmOEefcCTi34VfUw" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="Narr_VRCLDOHaZkmRQ0UDqmzMdQ">65</ix:nonNumeric>-month term is expected to be $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_9_30_2023_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesTwoEmeryvilleCaliforniaMember_x-BSsUsmOEefcCTi34VfUw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="6" id="Narr_VoJoW9Bp8UOGdu04MKM9lw">0.5</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">As of June 30, 2023 and December 31, 2022 the total net lease liability was $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="Narr_hges0AYUV0CchpQHWWwxiw">17,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="Narr_BwNAlIOTkEGPpOBiKjgbFQ">34,000</ix:nonFraction>, respectively. &#160; </p><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" name="us-gaap:LeaseCostTableTextBlock" id="Tb_y0XAZ-vfF0qPKS8pMGzU_A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table summarizes the cost components of the Company&#8217;s operating lease for the three and six months ended June 30, 2023 and 2022 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:54.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six Months Ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:10.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease costs:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_QRV4sYLUkE2evGZTwRhI6w_4_3">51</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2022_To_6_30_2022_MkbIQ9bQc0eX6Gc5LtLGHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_0KYbUtjRTUKLFYQDOoVRrg_4_6">44</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_SmoyZBB_M02GzLTX0DzGuQ_4_9">99</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_wXkAUuHCoUy0BvdWU1ip-Q_4_12">88</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Variable lease cost <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:VariableLeaseCost" scale="3" id="Tc_5-yZeg9JSkCt83tajN9GuA_5_3">7</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2022_To_6_30_2022_MkbIQ9bQc0eX6Gc5LtLGHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:VariableLeaseCost" scale="3" id="Tc_BV4l9kVBHU6ZWh1atf1mLg_5_6">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:VariableLeaseCost" scale="3" id="Tc_j6VtmMkxFk2VAGsl30sCrQ_5_9">12</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:VariableLeaseCost" scale="3" id="Tc_UQkZaKi2rU2BiABMdVn9-g_5_12">5</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total lease costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="Tc_iTWP4_2zs0mQSXOUHOS3Ew_6_3">58</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2022_To_6_30_2022_MkbIQ9bQc0eX6Gc5LtLGHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="Tc_tvBz2KrgTE-Eo7-i61mMXQ_6_6">46</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="Tc_d_d8k7nxAECW3JwuzrYyeg_6_9">111</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="Tc_mM0Ot7bgqEet1JzI5KzNxw_6_12">93</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;padding-left:18pt;text-align:justify;text-indent:-18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">(1)</span>Under the terms of the lease agreement, the Company is also responsible for certain variable lease payments that are not included in the measurement of the lease liability. Variable lease payments include non-lease components such as common area maintenance fees.</div></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" name="xoma:LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock" id="Tb_G0sLITfT6U2Ig3KqmVANVg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following information represents supplemental disclosure for the statement of cash flows related to operating leases (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:12pt;"> </span><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> &#160;&#160;&#160;&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six Months Ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash paid for amounts included in the measurement of lease liabilities</p></td><td style="vertical-align:bottom;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating cash flows under operating leases</p></td><td style="vertical-align:bottom;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="Tc_5LSeLaEccUytGJJ72sycsw_4_3">104</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="Tc_OcqRCZbgvU-dXeX2sOzGeg_4_6">101</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk95210281"></a><a id="_92716e68_7c1a_4b94_b392_3deb5c805c97"></a><a id="Tc_MZxT4wxWHE2XZ21cAptclg_1_2"></a><a id="Tc_p2Mvfh7CoU2XmD826kCW8g_1_5"></a><a id="Tc_NHjlkvDSxkSI7LiXIXqw9g_2_2"></a><a id="Tc_CqI08XTTZkGkeXO3oPhTeQ_2_5"></a><a id="Tc_t8R7SHhtw0u0qRF5kL6V9w_3_0"></a><a id="Tc_5a-dVu_9zkGT7yOkVQDhwA_3_2"></a><a id="Tc_Ci642TW-i0mHO6XitiLg_w_3_5"></a><a id="Tc_IG2SvSEuUU-RUBfDX_1x9w_3_6"></a><a id="Tc_HBCcx_S5-kuPlBGNQTvvdA_4_0"></a><a id="Tc__rVfRTkb-EqgtcixtlbU9A_4_3"></a><a id="Tc_U0zZ5891806mFJx05CMQPQ_4_6"></a><ix:continuation id="Tb_ToHcy5IeCUK8hkQaetgmtg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The present value assumptions used in calculating the present value of the lease payments for the Company&#8217;s operating lease as of June 30, 2023 and December 31, 2022 were as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" name="xoma:LesseeOperatingLeaseSupplementalInformationTableTextBlock" id="Tb_kjNufZyMx06iy7sE59CB7w" escape="true"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;"> </span><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> &#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average remaining lease term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Narr_J3T4nT5xZE2m903ewPI6Pg">0.08</ix:nonNumeric> years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Narr_Ls9T--8MpkOtGxnCSeFzWw">0.17</ix:nonNumeric> years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average discount rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ" contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_9S0_QOwDpEqfNDkUS3GB0w_4_2">5.51</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ" contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_HSefDbfmykOIWSL0fbo6PA_4_5">5.51</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><span style="display:inline-block;min-width:18pt;white-space:nowrap;">(1)</span>Prior to the extension of the end of the lease term from February 28, 2023 to July 31, 2023 &#160;</div></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="Tc_dQdoWlP6qE2Y2Fk4NSpt2A_1_6"></a><a id="Tc_m_30gFiD1U-iQtxnP2K_KA_1_9"></a><a id="Tc_I22OdWPLGkO2aWzVhJ0OIA_1_11"></a><a id="Tc_vMuJH_M0nECng6RgaR13sQ_2_0"></a><a id="Tc_R8PlnOKb-k-WAKVMO0WvAQ_2_2"></a><a id="Tc_3Qvmkxkor0WaLYcSBevIAA_2_4"></a><a id="Tc_-az5lyi7VkOu9rbCPTqS_Q_2_6"></a><a id="Tc__MioVCgXQUugLyIkcyoH6g_2_9"></a><a id="Tc_VG0UJyx7eEmfZBE2mT7DEQ_2_11"></a><a id="Tc_VLumkwgWXkudrQWZ-tRGlA_3_0"></a><a id="Tc_TF4KvBUcykeCPDMOc1kIMw_3_2"></a><a id="Tc_yrg1KEukIEqzHj7nn4pg-A_3_4"></a><a id="Tc_k40yVQ1ARkCOiLYdcC1JCA_3_6"></a><a id="Tc_6c2Q06WBekqjMZFkkDC1Hw_4_0"></a><a id="Tc_QIoYdcY76EaLwVmRb505Hg_4_2"></a><a id="Tc_kiDdG7xVU0SaLNotumt_Uw_4_4"></a><a id="Tc_cZRL3QLWAEyA6W0zQqDCcg_4_6"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" name="xoma:CommonStockWarrantDisclosureTextBlock" id="Tb_jf3S5B2nH0GMpcMEVxTnZA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">8. Common Stock Warrants</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of June 30, 2023 and December&#160;31, 2022, the following common stock warrants were outstanding:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="Tb_QvfGS95J1E28RhJIkUzt8Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:18.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:18.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:18.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issuance Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Expiration&#160;Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance&#160;Sheet&#160;Classification</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">per&#160;Share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:18.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">May&#160;2018</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">May&#160;2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg" contextRef="As_Of_6_30_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_R8Pr3r4-T0atb20N_SOFQg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_ttqqiCPnIUaiathpVQLcZQ_3_7"><ix:nonFraction unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_TPmH3rSX0kqVVDT3mwjQVA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_ttqqiCPnIUaiathpVQLcZQ_3_7_2">23.69</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="As_Of_6_30_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_R8Pr3r4-T0atb20N_SOFQg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_BIvj1Ap1H0uu5Bs-PdyBXA_3_9">6,332</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_TPmH3rSX0kqVVDT3mwjQVA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_x-9Bl160PkCmtTZhKxirDA_3_11">6,332</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:18.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">March&#160;2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">March&#160;2029</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg" contextRef="As_Of_6_30_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_xvSWiZXzv0KYrc1BLRxaDA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_xWoElPG_5k-ne0BkeUm8WQ_4_7"><ix:nonFraction unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_IW4xedCf1EONa-iq8razoA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_xWoElPG_5k-ne0BkeUm8WQ_4_7_2">14.71</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="As_Of_6_30_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_xvSWiZXzv0KYrc1BLRxaDA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_6H5a8lAoZUSZrdzm4wK3Ew_4_9">4,845</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_IW4xedCf1EONa-iq8razoA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_eHNOxETwi0CjFUlOLCp5ow_4_11">4,845</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:18.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_cnm_yWb1XUeICDLR-kI4CA_5_9">11,177</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_WCcNqFVfcEOY0Coc1OBNig_5_11">11,177</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:3pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_fJfW970qt0a8aScYovWQwg" continuedAt="Tb_fJfW970qt0a8aScYovWQwg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">9. Commitments and Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Collaborative Agreements, Royalties and Milestone Payments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has committed to make potential future milestone payments and legal fees to third parties as part of licensing and development programs. Payments under these agreements become due and payable only upon the achievement of certain developmental, regulatory and commercial milestones by the Company&#8217;s licensees. Because it is uncertain if and when these milestones will be achieved, such contingencies, aggregating up to $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:ContractualObligationEstimatedMilestonePayments" scale="6" id="Narr_NCD_S3C0EEGGV1FLkx_p2Q">6.3</ix:nonFraction> million (assuming <ix:nonFraction unitRef="Unit_Standard_product_mDp-u_9SnEGI1mu01OYOVA" contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ" decimals="INF" format="ixt-sec:numwordsen" name="xoma:ContractualObligationEstimatedMilestonePaymentsNumberOfProducts" scale="0" id="Narr_31Jb9FYz9E-Aa8-IqUR3eA">one</ix:nonFraction> product per contract meets all milestone events) have not been recorded on the accompanying condensed consolidated balance sheets. The Company is unable to determine precisely when and if payment obligations under the agreements will become due as these obligations are based on milestone events, the achievement of which is subject to a significant number of risks and uncertainties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Contingent Consideration</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Company&#8217;s agreements with Bioasis, Aronora, Kuros, Affitech, ObsEva and Aptevo the Company has committed to pay the Bioasis Contingent Consideration, the Aronora Royalty Milestones, the Kuros Sales Milestones, the Affitech Sales Milestones, the ObsEva Sales Milestones, the ObsEva Non-Sales Milestones, the Merck KGaA royalties and the Aptevo Contingent Consideration.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_mAQNTbueYkGTdJGdXydMXQ" decimals="-3" format="ixt:numdotdecimal" name="xoma:ContingentConsiderationUnderPurchaseAgreements" scale="0" id="Narr_vN4S-EKHFkmj1-YCBhkaCQ">75,000</ix:nonFraction> for the Bioasis Contingent Consideration that represented the estimated fair value of the potential future payments at the inception of the Bioasis RPA. The Bioasis Contingent Consideration is remeasured at fair value at each reporting period, with changes in fair value recorded in other income (expense), net. As of June 30, 2023, the estimated fair value of the Bioasis Contingent Consideration was reduced to $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_2Aj5seKcO0-XhIAauxBBGA" decimals="-5" format="ixt:numdotdecimal" name="xoma:ContingentConsiderationUnderPurchaseAgreements" scale="6" id="Narr_wRf0StZVEUOLApD6fz3Z4g">0</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_dUxKhnDLWESjshb_a_VOiQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:ContingentConsiderationUnderPurchaseAgreements" scale="6" id="Narr_f6Oj_kHzlEKXw-ZmovJv-A">1.0</ix:nonFraction> million for the LadRx contingent consideration that represents the estimated fair value of the potential future payments upon the achievement of regulatory milestones related to arimoclomol and aldoxorubicin<i style="font-style:italic;"> </i>at the inception of the LadRx Agreements. Such contingent consideration related to regulatory milestones is remeasured at fair value at each reporting period, with changes in fair value recorded in other income (expense), net. As of June 30, 2023, there has been <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_A0raaKROwE6F7PlIHJx7HA" decimals="-5" format="ixt-sec:numwordsen" name="xoma:ChangesInEstimatedFairValueOfContingentConsideration" scale="6" id="Narr_UiaVC9lnYkaFBXWJe_5iGw">no</ix:nonFraction> change in the estimated fair value from the initial value. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In the first quarter of 2023, the Company recorded a contingent liability of $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_3_31_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_ILbmTBFAdkeabm8OMvrxMg" decimals="-3" format="ixt:numdotdecimal" name="xoma:ContingentConsiderationUnderPurchaseAgreements" scale="0" id="Narr_BXunQKKXCk6eruDXYVPXSw">50,000</ix:nonFraction> under ASC 450 for the Aptevo Contingent Consideration at the inception of the Aptevo CPPA. During the six months ended June 30, 2023, the contingent </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_fJfW970qt0a8aScYovWQwg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">liability recorded pursuant to the Aptevo CPPA decreased to <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_Ag4rXqT5_U2u9t7EHdT2Vw" decimals="-3" format="ixt-sec:numwordsen" name="xoma:ContingentConsiderationUnderPurchaseAgreements" scale="0" id="Narr_8JjlxPo1DUWCLVeAvEQHkA">zero</ix:nonFraction> after the Company paid Aptevo $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_qKDIT7AlPEumlQb_qY84ng" decimals="-3" format="ixt:numdotdecimal" name="xoma:PaymentOfContingentConsiderationUnderPurchaseAgreements" scale="0" id="Narr_91yPVW5eEkSpm3ErhQY7kA">50,000</ix:nonFraction> upon achievement of the related commercial sales milestone.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The liability for future Aronora Royalty Milestones, Kuros Sales Milestones, Affitech Sales Milestones and LadRx sales milestones will be recorded when the amounts, by product, are estimable and probable. The liability for future ObsEva Non-Sales Milestones, ObsEva Sales Milestones and Merck KGaA royalties will be recorded at the time that the corresponding underlying revenue under the Organon License Agreement is estimatable and probable. As of June 30, 2023, none of these Aronora Royalty Milestones, Kuros Sales Milestones, Affitech Sales Milestones, ObsEva Non-Sales Milestones, ObsEva Sales Milestones, or Merck KGaA royalties were assessed to be probable and as such, <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_AronoraKurosAffitechObsevaAndMerckKgaaMember_Jg_8omFpTEO2btPaF3ItlQ" decimals="-5" format="ixt-sec:numwordsen" name="xoma:ContingentConsiderationUnderPurchaseAgreements" scale="6" id="Narr_6noyMDDwnEGoI_Pi-kFXBw">no</ix:nonFraction> liability was recorded on the condensed consolidated balance sheet. </p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="Narr_t2UleUC9NUi12pf3X01RtQ"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Tb_ogFd1K6J9UW-1_F2CkoMFw" continuedAt="Tb_ogFd1K6J9UW-1_F2CkoMFw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">10. Stock Based Compensation </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company may grant qualified and non-qualified stock options, common stock, PSUs and other stock-based awards under various plans to directors, officers, employees and other individuals. Stock options are granted at exercise prices of not less than the fair market value of the Company&#8217;s common stock on the date of grant. Additionally, the Company has an ESPP that allows employees to purchase Company shares at a purchase price equal to <ix:nonFraction unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_VZ3-yhq8FE25TUInBBrGZQ" decimals="INF" format="ixt:numdotdecimal" name="xoma:PercentageOfCompensationOfEligibleEmployeesToPurchaseSharesOfEntityCommonStockAtDiscountThroughPayrollDeductions" scale="-2" id="Narr_owhlnngVSkqq0T6r7vSfdQ">85</ix:nonFraction>% of the lower of the fair market value of the Company&#8217;s common stock on the first trading day of the offering period or on the last day of the offering period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock Options and Other Benefit Plans</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">2010 Plan Stock Options </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Stock options issued under the 2010 Plan generally vest monthly over <ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_srt_TitleOfIndividualAxis_xoma_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_zTu1OSjDqkSzjQ_HoRydQw" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_EuYsuL38t06_XO4fR2Hogw">three years</ix:nonNumeric> for employees and <ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_-kWVMpk2b0K-si5i-kPxAg" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_CL3KzxcGS0-MGIbSU03GVA">one year</ix:nonNumeric> for directors. Stock options held by employees who qualify for retirement age (defined as employees that are a minimum of <ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_-fCNRL3sJk2hkKbH29QN5A" format="ixt-sec:durwordsen" name="xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward" id="Narr_mHM6GL1fEUW6UrlmJe74sw">55 years</ix:nonNumeric> of age and the sum of their age plus years of full-time employment with the Company exceeds <ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_-fCNRL3sJk2hkKbH29QN5A" format="ixt-sec:durwordsen" name="xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge" id="Narr_pGVyApSOxUuJqqIKcqQmjg">70 years</ix:nonNumeric>) vest on the earlier of scheduled vest date or the date of retirement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Stock Option Inducement Awards </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December&#160;30, 2022, the Board appointed Owen Hughes as Executive Chairman of the Board and Interim CEO (principal executive officer) and Bradley Sitko as the Company&#8217;s Chief Investment Officer, effective as of January&#160;1, 2023. Pursuant to the terms of their respective employment agreements, Mr. Hughes and Mr. Sitko were each granted <ix:nonFraction unitRef="Unit_Standard_item_ZJDcTjbqbUC2tIGJY9M-pg" contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardsMember_TzcgwgvPHk2deHWsM1h3OA" decimals="INF" format="ixt-sec:numwordsen" name="xoma:ShareBasedPaymentArrangementNumberOfAwardsGrants" scale="0" id="Narr__ahtGh-5WUayOrxQSkI4EA">two</ix:nonFraction> separate awards of non-qualified stock options on January 3, 2023 (collectively, the &#8220;Stock Option Inducement Awards&#8221;) when the Company&#8217;s stock price was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg" contextRef="As_Of_1_3_2023_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardsMember_O8EOxHD7p0K-aApJeodsyg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_ywai6pZOyUG4yZNEdVUh-Q">18.66</ix:nonFraction> per share. The Stock Option Inducement Awards were granted to Mr. Hughes and Mr. Sitko outside the 2010 Plan as an inducement material to entering into their respective employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) but are subject to the terms and conditions of the 2010 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On January 3, 2023, the Company granted Mr. Hughes <ix:nonFraction unitRef="Unit_Standard_item_ZJDcTjbqbUC2tIGJY9M-pg" contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerInterimMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardsMember_whB55KBpZUikUKiuuCNJVw" decimals="INF" format="ixt-sec:numwordsen" name="xoma:ShareBasedPaymentArrangementNumberOfAwardsGrants" scale="0" id="Narr_86jJpQAMoESj5ujXK8LzXQ">two</ix:nonFraction> separate non-qualified stock options to purchase: (i) <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerInterimMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_iFhJ1Ec6iUaNhMqAZWDmbg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_vDRWiSlNlUWfdIjZl34yfQ">100,000</ix:nonFraction> shares of the Company&#8217;s common stock at a fair market value exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg" contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerInterimMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_iFhJ1Ec6iUaNhMqAZWDmbg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_KlWdUwwIDkis_aFnt28FpA">18.66</ix:nonFraction> per share that will vest in a series of <ix:nonFraction unitRef="Unit_Standard_installment_8yYMWsdF_EOJHx1V1lAgKg" contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerInterimMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_iFhJ1Ec6iUaNhMqAZWDmbg" decimals="INF" format="ixt-sec:numwordsen" name="xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments" scale="0" id="Narr_EmmuhTnzP06EMFnOZtLuGQ">four</ix:nonFraction> equal installments on March 31, 2023, June 30, 2023, September 30, 2023 and December 31, 2023 and (ii) <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerInterimMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_ifxCZ1Dza0CPpbZTGry9HQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_4jECiuzJO0Gwo2etWgm4dA">75,000</ix:nonFraction> shares of the Company&#8217;s common stock at an above fair market value exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg" contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerInterimMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_ifxCZ1Dza0CPpbZTGry9HQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_uzvJxaom9Uu6G_qtBtLhoA">30.00</ix:nonFraction> per share that will vest in a series of <ix:nonFraction unitRef="Unit_Standard_installment_8yYMWsdF_EOJHx1V1lAgKg" contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerInterimMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_ifxCZ1Dza0CPpbZTGry9HQ" decimals="INF" format="ixt:numdotdecimal" name="xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments" scale="0" id="Narr_2pVTvVkKi06F6NQtcE2uOQ">36</ix:nonFraction> successive equal monthly installments measured from January 1, 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On January 3, 2023, the Company granted Mr. Sitko <ix:nonFraction unitRef="Unit_Standard_item_ZJDcTjbqbUC2tIGJY9M-pg" contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardsMember_TzcgwgvPHk2deHWsM1h3OA" decimals="INF" format="ixt-sec:numwordsen" name="xoma:ShareBasedPaymentArrangementNumberOfAwardsGrants" scale="0" id="Narr_FyWGAldPGE-z_6IZPeEFag">two</ix:nonFraction> separate non-qualified stock options to purchase: (i) <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_-tCFSx98TEGfywwRhcC7ZA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_DqKSiIQTFEOPgcPKns4V9g">300,000</ix:nonFraction> shares of the Company&#8217;s common stock at a fair market value exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg" contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_-tCFSx98TEGfywwRhcC7ZA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_PZlB_2hwc0WEYWhAe8kImw">18.66</ix:nonFraction> per share and (ii) <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_2sdFXHfUykChvD4tIF6z0A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_qgd_anUshUuGPYF0I1Gy6w">250,000</ix:nonFraction> shares of the Company&#8217;s common stock at an above fair market value exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg" contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_2sdFXHfUykChvD4tIF6z0A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_FF5kiWYOdEiEHfRfs_NhqA">30.00</ix:nonFraction> per share. <ix:nonFraction unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ" contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardsMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_sfgRwFcTcUelc4rTBp-b3Q" decimals="2" format="ixt-sec:numwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_iG_MN9SpqUS3cn1lmZmnJw">Twenty-five</ix:nonFraction> percent of the shares subject to Mr. Sitko&#8217;s option grants will vest and become exercisable on January 3, 2024, and the balance of the shares will vest and become exercisable in a series of <ix:nonFraction unitRef="Unit_Standard_installment_8yYMWsdF_EOJHx1V1lAgKg" contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardsMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_oW0kv2blbEWaKJNbPntI9A" decimals="INF" format="ixt:numdotdecimal" name="xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments" scale="0" id="Narr_ztuPrrVVYE2K1FvDDjCayA">36</ix:nonFraction> successive equal monthly installments thereafter.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_pB4Qog9CsEK4oEZlfEICEA_1_2"></a><a id="Tc_mWriTsehpkmS2V3J8j4XVA_1_7"></a><a id="Tc_fyQZlbt0TEWOZVtbVQC6Cw_2_2"></a><a id="Tc_Sog5Ls3dqk-gAgCsb_mDww_2_4"></a><a id="Tc_vt-8zjRMw0qabUloP-qCYw_2_7"></a><a id="Tc_cTaARfU0mEaEC0C8wv4tVQ_2_9"></a><a id="Tc_l101fwoTZ0uDfJu_YZEDcw_3_0"></a><a id="Tc_SeqiXOnXZUGTtLch_hKX-Q_3_3"></a><a id="Tc_dnKFEhwL2EWPCNx8MGAdwA_3_5"></a><a id="Tc_nYDFiQQVhUOu028Ipao5iA_3_8"></a><a id="Tc_KAu9SzTqNk-26_JvwD5czg_3_10"></a><a id="Tc_6_B_ieAyy0CJ31NGOM3QAw_4_0"></a><a id="Tc_fRnEDXW1pUmNPXl4ZKwQeA_4_3"></a><a id="Tc_1ow_tLAomEaq6Y_KnUg4RQ_4_5"></a><a id="Tc_r1ZLThO3JU6ItlEoN51UQw_4_8"></a><a id="Tc_JmiSPF00dUGrGl0_q_grPQ_4_10"></a><a id="Tc_mC-_1QVkOU6-jLXfLI3x9A_5_0"></a><a id="Tc_ZP-0AXismUOC5m2KsKAXrA_5_3"></a><a id="Tc_meXEh9SbVU-Ab2MfloFgMA_5_5"></a><a id="Tc_BklnOMnR10iD7gRX_BojwA_5_8"></a><a id="Tc_7zpCM2wRMk2n1U3Aw2WlvA_5_10"></a><a id="Tc_jXxM7qg0DkWQ4fd5wvvMEQ_6_0"></a><a id="Tc_ayLgE9t_WUqHmh4f4i8ivw_6_2"></a><a id="Tc_5xlg610UEEm_krTJvwfNVQ_6_4"></a><a id="Tc_jhrPnD1wukSl-K4JNBtAGw_6_7"></a><a id="Tc_HaauSmT_KESkCjYgl-ajeg_6_9"></a><a id="_decf89ff_3867_4111_8755_7bc208c687a1"></a><a id="Tc_oc646Giziky7VpnETX7m1Q_1_2"></a><a id="Tc_FXBgwodL8EG6LB9-4jreVA_1_7"></a><a id="Tc_uTnR3PzFNEmXuBwpX5HYxg_2_2"></a><a id="Tc_WA14kuVEmUWfagyKGqrsHA_2_4"></a><a id="Tc_hk2J-t-19k6umjZD_oEIQQ_2_7"></a><a id="Tc_cFQy2G9WikC1yI7-dCT33A_2_9"></a><a id="Tc_xSfWtys3DU-Vhq7opw3gwQ_3_0"></a><a id="Tc_K04llfSeq0ahPrDvEkrsUQ_3_2"></a><a id="Tc_ZaaCkmM5IEmUfZaqqUOZwg_3_4"></a><a id="Tc_fshvO__5HUSvKwLt1_PDQw_3_8"></a><a id="Tc_7E8G1KINr0ueVKbvj3aOAA_3_9"></a><a id="Tc_9bevIjLtKkGsGZkYENmr2A_4_0"></a><a id="Tc_pFMNQaPlD0qr9yqVyeYQEA_4_2"></a><a id="Tc_hOyZD7-v8UiFSgAU4NnMkw_4_4"></a><a id="Tc_WdpHwDWKUkCawMpA2Nz4yg_4_8"></a><a id="Tc_7BYNnteoUUyqfS84pq6pNw_4_9"></a><a id="Tc_sWAX88mgPkqk9W8Cb_ysnQ_5_0"></a><a id="Tc_TTlfQe8RIU-FFr2cKkN-hQ_5_2"></a><a id="Tc_pIwzLY0pqkCDFg1rlqP27A_5_4"></a><a id="Tc_lTJykfQTxkGfe50bj_-cNA_5_8"></a><a id="Tc_b9qUBhPWKEKq0CHRNIc4HA_5_9"></a><a id="Tc_FtxBBvWXpUKTtLpFDStPDg_6_0"></a><a id="Tc_PlcSCiq_6Ei-6jyhITpxQw_6_2"></a><a id="Tc_Q_ymb2yUgkW2gyTLNxLCTA_6_4"></a><a id="Tc_VTSFy3LAgESgSqY45GNNFA_6_7"></a><a id="Tc_fAHR_De6X0Kt3HELJAA4-Q_6_9"></a><a id="_38c4f61f_6240_4755_bf5d_c3e9f7b74b25"></a><a id="Tc_42gS_OonUEWNZIj_0jjULg_1_2"></a><a id="Tc_Pgu96gFWC06mQj4aoCvWDw_1_7"></a><a id="Tc_mwExEs4soUeDRRWmXR7q3Q_2_2"></a><a id="Tc_FpbQ2UPDVEKWmfMCC3g1Vw_2_4"></a><a id="Tc_sSy5AKDzeEKRaDzd_Z1eDQ_2_7"></a><a id="Tc_PZM_FmYOk0OCJOnEg9NyxQ_2_9"></a><a id="Tc_8oqwsjnoCUOW6KKq7rmHhQ_3_0"></a><a id="Tc_qsrnRlUr9kS1yHZgE72Ewg_3_2"></a><a id="Tc_Dc6VNA7Fv0OtzNSTtDP8KQ_3_4"></a><a id="Tc_PvanopRPZ0mUYC-Gqzp2fQ_3_8"></a><a id="Tc_vuhSX0vJPU2lIfY7kWmuIA_3_9"></a><a id="Tc_kcr5700jsE27iH7xnpYN2Q_4_0"></a><a id="Tc_WIrg0wnoykq3ETdNNBWZrg_4_2"></a><a id="Tc_hemj8mEbxEqbGKzYGtwDEg_4_4"></a><a id="Tc_zEs9C8yel0yXNxgcPF7yhw_4_8"></a><a id="Tc_TPs2hvOClkWCaWJw7WeV_A_4_9"></a><a id="Tc_qVVCwMppF0Ku2JQIKnAAyg_5_0"></a><a id="Tc_0KYJZxaSoUOg0GdEH09a2w_5_2"></a><a id="Tc_kRRi67h18kqKVDu3IwXtDA_5_4"></a><a id="Tc_dSpVJAvtxU-qQ1PyVGKfRA_5_8"></a><a id="Tc_Fknz55RxdE2sIQe77DFfWg_5_9"></a><a id="Tc_FnCnRQsNF0uK27JHNVFCaA_6_0"></a><a id="Tc_C2edSaVa1U2fmmzy4f0W3A_6_2"></a><a id="Tc_JeVp9h9bX0eZ2iKcPEj7pw_6_4"></a><a id="Tc_wnDVS8TXtUCGS93aDG-cCA_6_7"></a><a id="Tc_3y2hthgmC02H8jcBTkOWzw_6_9"></a><ix:continuation id="Tb_ogFd1K6J9UW-1_F2CkoMFw_cont1" continuedAt="Tb_ogFd1K6J9UW-1_F2CkoMFw_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Fair Value Assumptions</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The fair value of the stock options granted under the 2010 Plan during the three and six months ended June 30, 2023 and 2022, was estimated based on the following weighted average assumptions:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_bltKeBtI3UmSSHjoiD4k4Q" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_c3BeKRIX7Ue68R7vT3OMrA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six Months Ended June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_xL-t6UGWVk6DJsv8uctHqg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_MFZRoU0eRUC9fiKzV_Dr0w_3_2">0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ" contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_6P9--i9dukq4YkLcJp4PvQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_P0PSc0l3d0anvd9ZNDCANQ_3_4">0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_-fCNRL3sJk2hkKbH29QN5A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_Y4IqXdGjikaYSVKgKZlPUQ_3_7">0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ" contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_hI8wxtoK_020YtrtWXgEww" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_EE3lf9gbjU-cwwWluu1Kyg_3_9">0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:50.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_xL-t6UGWVk6DJsv8uctHqg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_nu_WP9ycek6ifMefmvRB5g_4_2">70</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ" contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_6P9--i9dukq4YkLcJp4PvQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_ADw_hySzPEOIHhCIJq39Pg_4_4">69</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_-fCNRL3sJk2hkKbH29QN5A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_Qzm9UKxpcku9_jCuqFTSQQ_4_7">70</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ" contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_hI8wxtoK_020YtrtWXgEww" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_3cJbGnWFSE2NGY2m8Mi6Tw_4_9">70</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:50.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_xL-t6UGWVk6DJsv8uctHqg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_GUHuMK8RwEqSexh4Sq4zog_5_2">3.60</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ" contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_6P9--i9dukq4YkLcJp4PvQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_Idkk6TM0p0aXxQ5akeqDUQ_5_4">2.90</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_-fCNRL3sJk2hkKbH29QN5A" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_rRrVD7hW50GW4IrZksBBdw_5_7">3.60</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ" contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_hI8wxtoK_020YtrtWXgEww" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_gZOnzDfpJEysJY3R7v1_Vw_5_9">2.17</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:50.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_xL-t6UGWVk6DJsv8uctHqg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_DkPMvwNB0kOHDaoZkqSz1Q">5.79</ix:nonNumeric> years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_6P9--i9dukq4YkLcJp4PvQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_hh3VsK4FiEO5TylSKkbzXg">5.61</ix:nonNumeric> years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_-fCNRL3sJk2hkKbH29QN5A" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_pMu8deuOJ0CjYSiDCDJ-Ig">5.79</ix:nonNumeric> years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_hI8wxtoK_020YtrtWXgEww" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_6Y0_GH_Yb02291_C84bc_Q">5.65</ix:nonNumeric> years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The weighted-average grant-date fair value per share of the options granted under the 2010 Plan during the six months ended June 30, 2023 and 2022 was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_bltKeBtI3UmSSHjoiD4k4Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_oifoPefHH0euAMl4hm2VQw">13.46</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg" contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_QvduteacZ0y6e-l0bH1cfQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_gG1PTjCbQkGF4OpH8czTKQ">12.21</ix:nonFraction>, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The fair value of the stock options granted to Mr. Hughes and Mr. Sitko at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_YDoryzJQpUuWG8MDo2Kh5Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_O1K6Mq7ft0Ct5QGDyK7fcQ">18.66</ix:nonFraction> per share during the six months ended June 30, 2023, was estimated based on the following weighted average assumptions: </p><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_YDoryzJQpUuWG8MDo2Kh5Q" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_0MxrhftarEOWB44Fy2P39g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six Months Ended June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023 </b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022 </b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_8s2qytOsIE6JM7loesF-Zg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_JhX_z-qQHUWQgZpCc2H9WQ_3_7">0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_8s2qytOsIE6JM7loesF-Zg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_5L-0ZMOJmEuJY9OGZOjBmg_4_7">69</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_8s2qytOsIE6JM7loesF-Zg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_6Hy7d8sH0k6tsvcHVMBHig_5_7">3.92</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_8s2qytOsIE6JM7loesF-Zg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_MZceAQPqXEOxpB68KfsG0w">5.79</ix:nonNumeric> years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:22.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_OxGaeDYzykWU3vEhrxw_Mw" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_PkZLYw5-a0endN0Yrjtk6w"><ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_UCA8w-FN5E6MpfSkha4Snw" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_3RJvCxtNLECpAX1nYUH8oA"><ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_UkUp6s2yF0molMuQVionzw" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_fVS8-zRYXUmyYHqSUP39Xw">No</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Stock Option Inducement Awards were granted during the three months ended June 30, 2023 or the three and six months ended June 30, 2022. </span></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The weighted-average grant-date fair value per share of options granted to Mr. Hughes and Mr. Sitko at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_jSfoRez_iE22iNJRZuTv-A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_Iapt7aTBLEyeHgFwFD1IEQ">18.66</ix:nonFraction> per share during the first quarter of 2023 was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_jSfoRez_iE22iNJRZuTv-A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_HX7Bs8NrKUitn3l9X2gkbw">11.91</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The fair value of the stock options granted to Mr. Hughes and Mr. Sitko at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_-JwjlMwfKEGUbHpTjDxUDQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_wqKfaS3Lv0StAsmw61YREA">30.00</ix:nonFraction> per share during the first quarter of 2023 was estimated based on the following weighted average assumptions: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_-e_kcpPy9Uijv53NXnwNjA" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_C6gCNVtgJEibS1UBtokjTw" escape="true"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six Months Ended June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023 </b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022 </b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_kkqRS-Yr_kK7p5s-7yOqJg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_wRJ5BH_zgkKCEst3qa9v4A_3_7">0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_kkqRS-Yr_kK7p5s-7yOqJg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_PSD6hMC3xk2aoS0RnsvThQ_4_7">91</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_kkqRS-Yr_kK7p5s-7yOqJg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_0GIVLUsBGkK5rOV4MKpSQA_5_7">3.86</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_kkqRS-Yr_kK7p5s-7yOqJg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_BZA1pr66f02VMWsZiHMc8g">8.01</ix:nonNumeric> years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:40.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_nc6cD9y6eky4_H4Gmdgf2Q" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_2uOTIUQJEk-Lgg4T6wLGqg"><ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_HFe1p--7QUyXIpXph3Ep4A" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_rjOnoRNnNU-oPXfltthcrw"><ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_fvpJiV95o0G_Lx6Po8Z0Qg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_PGxOQNZobUmBeKiHeyiLkA">No</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Stock Option Inducement Awards were granted during the three months ended June 30, 2023 or the three and six months ended June 30, 2022.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The weighted-average grant-date fair value per share of options granted to Mr. Hughes and Mr. Sitko at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_-JwjlMwfKEGUbHpTjDxUDQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_zIzTartVM0OAoKmulVYArQ">30.00</ix:nonFraction> per share during the first quarter of 2023 was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_-JwjlMwfKEGUbHpTjDxUDQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_o0tXaQPS3ku_v38oegRjuQ">14.68</ix:nonFraction>.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:24pt;"><a id="Tc_Noi4v9evW0az8c-6HSgNoA_1_5"></a><a id="Tc_-RvFt8rmfU-bSfw3qG7YzQ_1_8"></a><a id="Tc_Y84Hv7iCPEGOI4uGIWh3ag_2_5"></a><a id="Tc_N8HLLScwM0yOpw-a0LLYGw_2_8"></a><a id="Tc_hUJ6rc4QbkimEmev1Yq8cQ_2_11"></a><a id="Tc_8Cf8sccfdEOfdD7bgArDJQ_3_5"></a><a id="Tc_jy0mZRDCqEmHKU92Ar-enw_3_8"></a><a id="Tc_ioBSu71Cz0K3eDeEwwlVAA_3_11"></a><a id="Tc_5VndIKYAB0mEdJwIdn6m5Q_4_2"></a><a id="Tc_3f8vPZEd90K27rqra4mcHA_4_5"></a><a id="Tc_9_AyaudKRU-jylvt3EmHbQ_4_8"></a><a id="Tc_JoBNvSTfdke35ZKJFF4znw_4_11"></a><a id="Tc_te-JzP4C40WgWzslAbo3iw_5_2"></a><a id="Tc_7DzF5sTivUqZSJ6O6Vh7Fg_5_5"></a><a id="Tc_h_GdjNQ_Akqyb-ECdf2eUQ_5_8"></a><a id="Tc_HzEJWetUAkOJGCYUaen5WQ_5_11"></a><a id="Tc_I8i18GZ2K0uOdyRKq9XZMw_6_0"></a><a id="Tc_PprapDGh50OIBgmFCa2zoA_6_5"></a><a id="Tc_kJ23lcEOckK6V9YgVqMSBg_6_11"></a><a id="Tc_XR3jtZ8m40uKC-SvER0wfw_7_0"></a><a id="Tc_9jYAWZErzUWy5cnlZrd-dQ_8_0"></a><a id="Tc_0nEV3OhVeUCIc-MNZSFOmA_9_0"></a><a id="Tc_UWEtN_habE25kWUIZOlfkQ_10_0"></a><a id="Tc_weLtL55ZOEqRSrhkEqR-wg_10_5"></a><a id="Tc_KqGwnzqupUGWm6vWqLS48g_10_11"></a><a id="Tc_cbEIRRuD_EKWsO4WMvKk9Q_11_0"></a><a id="Tc_AIUcyEklZ0ah_YP2iKGWzg_11_5"></a><a id="Tc_G3mFJNjJfk-US_5qDBG0xQ_11_11"></a><a id="_643f3b96_afe3_453e_82b9_96becf6a46ed"></a><a id="Tc_XIidICxkeE2-t5VIPZgwPg_1_9"></a><a id="Tc_IGFZd4FZrEGwVOhu8ecwag_2_0"></a><a id="Tc_x_0CclRwHEmL0HYTSOx8mA_2_3"></a><a id="Tc_1QM-i7oJ2UaQCBZof_RPQQ_2_6"></a><a id="Tc_Hc6-AVv9AUabZW0VxKkkdg_2_9"></a><a id="Tc_Y_nqFGWkTEinBJseK2fsLw_3_0"></a><a id="Tc_HLbWhAAtEkODvLWBIS_2nQ_3_3"></a><a id="Tc_wVSrVcBrhUWrWjzhVUz3Zw_3_6"></a><a id="Tc_J-5niWKuoky-5v2OmT1HsQ_3_9"></a><a id="Tc_Bo_ZwhqbaUyE2mU1d42xuA_4_0"></a><a id="Tc_xiXAYpYkjkmJXXtH5CQ2kA_4_6"></a><a id="Tc_U4KMnsMiW0-uN0FvUNhHGA_4_7"></a><a id="Tc_7-KhLAcnHkS7xjf8wa7-iQ_4_10"></a><a id="Tc_aVT94JSL3k6j3cjjUnzS3Q_5_0"></a><a id="Tc_CGgHSEmrbUKxt-qS-xykiA_5_6"></a><a id="Tc_MmOvXnHUvUaZcK32qYgvOg_5_7"></a><a id="Tc_n1YRbgiD7UWtlVU3_6JJKg_5_10"></a><a id="Tc_KZkMQ83eC0u1m8poFVTWKQ_6_0"></a><a id="Tc_r0B6YBYk9EKgn7U-ojDeNA_6_6"></a><a id="Tc_lV551SMQa0ChAj85XlVeqg_6_7"></a><a id="Tc_r0gk6D9BM0W7PQZvxU-riQ_6_10"></a><a id="Tc_lGVo04_TXk2indz1Gx2kug_7_0"></a><a id="Tc_WW6waOKjwkewHWjSviojwg_7_6"></a><a id="Tc_QcvVYjg_nEOwl6V5sSxvnw_7_7"></a><a id="Tc_tPQVexqoZUyiUQmGcx77ZA_7_10"></a><ix:continuation id="Tb_ogFd1K6J9UW-1_F2CkoMFw_cont2" continuedAt="Tb_ogFd1K6J9UW-1_F2CkoMFw_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The activity for all stock options for the six months ended June 30, 2023, was as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb_9C3aa6GeQ0awHwiTCFtZ6g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.51%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual&#160;</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining Term</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">shares</b></p></td><td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Per&#160;Share</b></p></td><td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;years)</b></p></td><td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:15.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="vertical-align:middle;width:38.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at January 1, 2023</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_jxgto--yX0Gl9paiYCUd6A_6_3">2,025,542</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg" contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_G5YDqk-XFke9cehH2RNQNw_6_6">20.24</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_qMnU5lLEOEWtPeR71nBTRQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_l926NtawVUSKghou9NyrSA_6_9"> 6.10</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="Tc_gEIBzgTYMEOXKbs0w6XkMw_6_12">10,804</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_EwY7BG9ZlEOqQ1SLSKecxA_7_3">796,802</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg" contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_XIM6rb1RY0qP5vXUcKBYUw_7_6">23.50</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:middle;width:38.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_Vh_mXuRjEESFqOoPFmorKA_8_3">8,473</ix:nonFraction>)</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg" contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc__yQO5S3Qv0-zHyi8s97o_A_8_6">18.29</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:middle;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited, expired or cancelled</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" id="Tc_-SFgLj2uHUe5QA-4o6RzcA_9_3">71,123</ix:nonFraction>)</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg" contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_0vlfVIhaKkuCSWO787WMKA_9_6">36.36</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:middle;width:38.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at June 30, 2023</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_ga8K_TwD0Umg8xmoNyzrlw_10_3">2,742,748</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg" contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_-TYEaY1IzkuUeFK9jb0O3Q_10_6">20.78</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_C3T3Bbh7EEyc_ndmcGu7Vw_10_9"> 6.76</ix:nonNumeric></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="Tc_AlIzosbJH0CPBfDeKIhLVw_10_12">11,430</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable at June 30, 2023</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_ufDqbZk1v0aMUggBaXKGOA_11_3">1,815,920</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg" contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_l4szYi6cUUS9nTZnIubR2A_11_6">19.30</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Tc_m_ZCDcekq0eMk1639yHNZQ_11_9"> 5.44</ix:nonNumeric></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="Tc_9QxyCxLsBUWUztpNG0eleA_11_12">11,296</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The aggregate intrinsic value of stock options exercised during the six months ended June 30, 2023 and 2022 was $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="0" id="Narr_79NV5jiYpEGsc6ndVUfyUg">18,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="Narr_29NHgfHRSUWvMtxlrCm0HQ">2.1</ix:nonFraction> million, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of June 30, 2023, $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Nn8D-tR9RUaR3oXEwhegJw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="Narr_iW1c7IE2pES-IJAXlZSBmQ">11.0</ix:nonFraction> million of total unrecognized compensation expense related to stock options is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_3UfIUbfYm0S1MerajhgXqg" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_uuZlGHRnBka2K_g6YcaqVw">2.72</ix:nonNumeric> years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Performance Stock Unit Awards</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In May 2023, the Company granted employees <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="Duration_5_1_2023_To_5_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_XYLfgmBs1kapqrjpQTeEpQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_HNT7spNArUus9pY5bzme5w">430,400</ix:nonFraction> PSUs in the aggregate under the 2010 Plan. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The PSUs are subject to market-based vesting conditions and the number of PSUs vested will be based on the stock price of the Company&#8217;s common stock as compared to <ix:nonFraction unitRef="Unit_Standard_item_ZJDcTjbqbUC2tIGJY9M-pg" contextRef="As_Of_5_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_DFqUQBhRC0ifvbBc0bGVmg" decimals="INF" format="ixt-sec:numwordsen" name="xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfHurdles." scale="0" id="Narr_vGibJBIKMU2xqv97ze9ZxA">four</ix:nonFraction> stock price hurdles over a <ix:nonNumeric contextRef="Duration_5_1_2023_To_5_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_Cf49xhpajkCvIANGtFeezA" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_frIE3rq9UEae0WovI42liw">three-year</ix:nonNumeric> period from the May 2023 grant date (the &#8220;performance period&#8221;). A stock price hurdle is considered attained when, at any time during the performance period, the Company&#8217;s volume-weighted average stock price equals or exceeds the hurdle stock price value for <ix:nonFraction unitRef="Unit_Standard_D_PCYEJUif70CZJGJolwi3Yw" contextRef="As_Of_5_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_DFqUQBhRC0ifvbBc0bGVmg" decimals="INF" format="ixt:numdotdecimal" name="xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfCalendarDays" scale="0" id="Narr_uWp87CbDyEqr_Iw83W9phg">30</ix:nonFraction> consecutive calendar days. Upon attainment of a stock price hurdle, <span style="-sec-ix-hidden:Hidden_pz-y6RJKqkG2-1h8_aEPqw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1/3</span></span> of the earned PSUs will vest immediately upon achievement, <span style="-sec-ix-hidden:Hidden_mBhYOSdezkKayi1Fqww_nQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1/3</span></span> will vest upon the <ix:nonNumeric contextRef="Duration_5_1_2023_To_5_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_jGf-N4U7oEWRkZ347gsAlA" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_OaV_R4FXd0OwlmYMMGAx8A">two-year</ix:nonNumeric> anniversary of the grant date and <span style="-sec-ix-hidden:Hidden_npSSwNAmG0yLnAtmVxINPw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1/3</span></span> will vest on the <ix:nonNumeric contextRef="Duration_5_1_2023_To_5_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_aWe1HEcOJkO4GJNqP9UK8w" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_UbwY9gV1G0uXsK-GPRsSpw">three-year</ix:nonNumeric> anniversary of the grant date. If no stock price hurdle is attained during the performance period, then no PSUs will vest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The fair value of the PSUs granted was estimated based on Monte Carlo valuation model which incorporates into the valuation the possibility that the stock price hurdles may not be satisfied. </p><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" name="us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" id="Tb_BXxY40GS4EuBEo26CItDNg" escape="true"><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The range of grant date fair values of the PSUs issued in May 2023 were estimated as follows:<div style="display:inline-block;height:24pt;width:24pt;"><div style="height:24pt;left:0pt;padding-bottom:0pt;position:relative;width:24pt;"></div></div><div style="display:inline-block;height:24pt;width:24pt;"><div style="height:24pt;left:0pt;padding-bottom:0pt;position:relative;width:24pt;"></div></div></div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.8%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.8%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.8%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:25.89%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Derived</b></p></td></tr><tr><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Hurdle Price</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:25.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Service Period</b></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:21.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Per Share</b></p></td><td style="vertical-align:top;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:21.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">PSUs</b></p></td><td style="vertical-align:top;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:21.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Per&#160;Share</b></p></td><td style="vertical-align:top;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:25.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;years)</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg" contextRef="As_Of_5_31_2023_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar30Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_k94cSi-Zwk2VBrdcAKVvmA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Tc_dt9xeSzbS0iZAsfYWODb8g_4_1">30.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="Duration_5_1_2023_To_5_31_2023_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar30Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_nNrXvBglBEuLwgpeNxml8A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Tc_zWcHrhlptUGijdevUnIpFA_4_4">232,956</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg" contextRef="Duration_5_1_2023_To_5_31_2023_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar30Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_eRdy_9rQG0eihqb4EruBVA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_XZE7h3WbJEiGnD_LZvCnaA">16.36</ix:nonFraction>-<ix:nonFraction unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg" contextRef="Duration_5_1_2023_To_5_31_2023_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar30Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_NtPgJkGsykWMLfBzzhabEg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_gxazmwtPW0y2s3y405HEZA">17.45</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_5_1_2023_To_5_31_2023_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar30Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_eRdy_9rQG0eihqb4EruBVA" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="Narr_je7_AI3dREqQnrFlTL8knA">0.69</ix:nonNumeric>-<ix:nonNumeric contextRef="Duration_5_1_2023_To_5_31_2023_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar30Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_NtPgJkGsykWMLfBzzhabEg" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="Narr_0yCrRXl9Xk-GEGsygiN5lA">0.76</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:18.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg" contextRef="As_Of_5_31_2023_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar35Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_6tvbW7uZUEOHE7gMti2gpA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Tc_Mh-aagbSnkiLwUZpkwAHNQ_5_1">35.00</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="Duration_5_1_2023_To_5_31_2023_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar35Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_YZ1bWx-iUUeKV_tBnvEWAw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Tc_kpIBTXNyjk6R71hSFAzQZg_5_4">87,708</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:18.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg" contextRef="Duration_5_1_2023_To_5_31_2023_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar35Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_lT2QTmiVC0-u-Gq59mHj8A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_EDPfGcG8t0ud3TC69_6cqA">15.03</ix:nonFraction>-<ix:nonFraction unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg" contextRef="Duration_5_1_2023_To_5_31_2023_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar35Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_EP_RDzS2Y0G8ZWnpyMII1w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_UYDIbI6ZtUGuZCQkFJuKNQ">16.07</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_5_1_2023_To_5_31_2023_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar35Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_lT2QTmiVC0-u-Gq59mHj8A" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="Narr_EVVO7o4VVkiEW5z5EUjSCA">0.93</ix:nonNumeric>-<ix:nonNumeric contextRef="Duration_5_1_2023_To_5_31_2023_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar35Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_EP_RDzS2Y0G8ZWnpyMII1w" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="Narr_aG21w7c8dECOIxEl7_OIsQ">0.99</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:18.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg" contextRef="As_Of_5_31_2023_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar40Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_M7IRrCKea0iCZRqtsZ7RWg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Tc_C8LiGFT34ka0SbMpcueCDQ_6_1">40.00</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="Duration_5_1_2023_To_5_31_2023_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar40Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_6r4sVlcI50y97OHzEy_aBg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Tc_X483B_dyl0-FoTMt3dVK1Q_6_4">57,851</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:18.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg" contextRef="Duration_5_1_2023_To_5_31_2023_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar40Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_QN3fukmQcEymV8gdhnI3ow" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_WSFFGUO6GkeZO9jTptPg0w">13.82</ix:nonFraction>-<ix:nonFraction unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg" contextRef="Duration_5_1_2023_To_5_31_2023_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar40Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_yYP93SxHqUaWiML_VD6qSQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_JmOvyOGP_0WKmVyNRv7FLA">14.84</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_5_1_2023_To_5_31_2023_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar40Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_QN3fukmQcEymV8gdhnI3ow" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="Narr_63AP3VEJ70yK5_6q09UQ8Q">1.12</ix:nonNumeric>-<ix:nonNumeric contextRef="Duration_5_1_2023_To_5_31_2023_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar40Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_yYP93SxHqUaWiML_VD6qSQ" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="Narr_4_xZ-aksSkSmzwAK_fSwIg">1.18</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:18.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg" contextRef="As_Of_5_31_2023_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar45Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_G0SYyex3eUy7MyZY9jFEqg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Tc_SaFcbEupcEucWCTFAelCMA_7_1">45.00</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="Duration_5_1_2023_To_5_31_2023_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar45Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_sJUAR2OjXECHMqedJgu-yQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Tc_I5n0i-FaSEyl2664EM1gwg_7_4">51,885</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:18.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg" contextRef="Duration_5_1_2023_To_5_31_2023_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar45Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_0Czk0OqbEkepDfJ3xsELBw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_YSe73GHO4UuvQvXlPRkjVw">12.75</ix:nonFraction>-<ix:nonFraction unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg" contextRef="Duration_5_1_2023_To_5_31_2023_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar45Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_132lsM87s0-SgeiFzFNGPw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_jgRIOeLzu0uj2V_gjRojYQ">13.72</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_5_1_2023_To_5_31_2023_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar45Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_0Czk0OqbEkepDfJ3xsELBw" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="Narr_QC4-7FTeR0yEyNAX6oSQCg">1.27</ix:nonNumeric>-<ix:nonNumeric contextRef="Duration_5_1_2023_To_5_31_2023_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar45Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_132lsM87s0-SgeiFzFNGPw" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="Narr_Xl-UeI-r0US1sIW_WjGLkQ">1.33</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="Duration_5_1_2023_To_5_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_Cf49xhpajkCvIANGtFeezA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Tc_YuxUHdYVlUG9K7eemAF6bw_8_4">430,400</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company estimates that it will recognize total stock-based compensation expense of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_5_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_DFqUQBhRC0ifvbBc0bGVmg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="Narr_yMBu_VrhLku1sdI5yw3qvg">6.7</ix:nonFraction> million in aggregate using the graded expense attribution method over the requisite service period of each tranche. If the stock price hurdles are met sooner than the requisite service period, the stock-based compensation expense for the respective stock price hurdle will be accelerated. Stock-based compensation expense will be recognized over the requisite service period if the grantees continue to provide service to the Company, regardless of whether the PSU stock price hurdles are achieved.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_KCnaa4vnr0yoNbXUtrslsg_1_5"></a><a id="Tc_lekib35rzUSTHTtPrM4qAQ_2_5"></a><a id="Tc_fH0mzb-Wvk2uDvLbC5L8gw_3_5"></a><a id="Tc_NgZTWHmrAkKhnA14rW4IPQ_4_2"></a><a id="Tc_yZJwWXGqZU6CJmSJf_dLkQ_4_5"></a><a id="Tc_B-IVT1OOXES1enbUF-nUyQ_5_2"></a><a id="Tc_MwBWMexPC0SpOTKrtdyUww_5_5"></a><a id="Tc_GgefxwKOD0a7EGY9MUNVDw_6_0"></a><a id="Tc_UUFMlqmh1kyBnzmHTtDQJg_6_3"></a><a id="Tc_pJbod-nubEyG4IGSeatBTA_6_5"></a><a id="Tc_lZ8ctg2MvUGvpeeTSETMrw_6_6"></a><a id="Tc_HXW4wEWzqkCih7CkXn_paw_7_0"></a><a id="Tc_DyTnozYE0EKOmFK3XMONvw_8_0"></a><a id="Tc_4MG3ts4udEKjpAxLbaKwYg_8_3"></a><a id="Tc_tCNn_z-Ud0-k4WVnYdPc-Q_8_6"></a><a id="Tc_qnj7wOAOYkmd-_dNkWON_A_9_0"></a><a id="Tc_aFlJRmwBQk-fLSnG_wHNHQ_9_3"></a><a id="Tc_12TsvQvcj0OwKpQoInJvfg_9_6"></a><a id="Tc_r9tI0HFuNEW0LkqX6WuPQQ_10_0"></a><a id="Tc_ODtPm-WAvUuQ8r2pUw6WaQ_10_5"></a><a id="_Hlk98925593"></a><a id="_233dbe07_3134_4da9_9d4e_027f718ec0b2"></a><a id="Tc_8juahTZA9EqeFd31tDSo3w_1_2"></a><a id="Tc_SnNp4FQUYEm4XT6Mjn31rg_1_8"></a><a id="Tc_RRDWoI05qUSxWj7jjCz_UQ_2_2"></a><a id="Tc_0g2lrMRCO0a1JHtyma30SA_2_5"></a><a id="Tc_lLviUndx4UOROjkblmREzg_2_8"></a><a id="Tc_KLFrsoCJpEi1yA9B2Hpagw_2_11"></a><a id="Tc_Y4d01ZWZfEiam5QlID_RAg_3_0"></a><a id="Tc_c9Iqv8RRrE6_XMf3VY3EAA_3_2"></a><a id="Tc_sT-tbQCAqEmeOivBEOo48A_3_5"></a><a id="Tc_vakDTEfs8UC7A_6H53j1xw_3_8"></a><a id="Tc_XaLZFcUMHUSEH37Tu3KztQ_3_11"></a><ix:continuation id="Tb_ogFd1K6J9UW-1_F2CkoMFw_cont3" continuedAt="Tb_ogFd1K6J9UW-1_F2CkoMFw_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The activity for all PSUs for the six months ended June 30, 2023, was as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" name="us-gaap:ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" id="Tb_VWs96NrSWkSCcjaWg-6sNA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:56.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.24%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.56%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.22%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Grant Date</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:19.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unvested PSUs</b></p></td><td style="vertical-align:top;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:19.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Per&#160;Share</b></p></td></tr><tr><td style="vertical-align:middle;width:56.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested balance at January 1, 2023</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:56.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_pg3TjcmZJki500S9VQ6N9A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Tc_bH0hn_zNTUW2r9PWAc6quQ_7_3">430,400</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_pg3TjcmZJki500S9VQ6N9A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_zN_kAUpUJUSLG4DMyTERnA_7_6">15.61</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:56.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:16.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:56.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:56.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested balance at June 30, 2023</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="As_Of_6_30_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_fUdJCDTZZkCC-dGe4IpNTw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_nZnnPiX6sEqZJgUxb_Pi9w_10_3">430,400</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:16.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg" contextRef="As_Of_6_30_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_fUdJCDTZZkCC-dGe4IpNTw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_oLgmv0TWIEGZ6jyn5NRWxQ_10_6">15.61</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_pg3TjcmZJki500S9VQ6N9A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_8VsO8zjv7kaJhGZYVotOgQ"><ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_aLWj_8kVOUatUIpAaoSESA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_q8RGTThxJ0eJl_O2VuysUw">0.5</ix:nonFraction></ix:nonFraction> million of stock-based compensation expense related to the PSUs during the three and six months ended June 30, 2023. As of June 30, 2023, there was $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_fUdJCDTZZkCC-dGe4IpNTw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="Narr_h3y3gpzB2UmHFbGAeRmL3g">6.2</ix:nonFraction> million unrecognized stock-based compensation expense related to outstanding PSUs granted to employees, with a weighted-average remaining recognition period of <ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_pg3TjcmZJki500S9VQ6N9A" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_Ouca1nzxvEG8ace3GdfT2A">1.85</ix:nonNumeric> years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Stock-based Compensation Expense</i></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="Tb_jF9_KFQQBECZDWjQyZ5hyA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">All stock-based compensation expense is recorded in G&amp;A expense. The following table shows total stock-based compensation expense for stock options and PSUs issued under the 2010 Plan, the Stock Option Inducement Awards and ESPP in the condensed consolidated statements of operations and comprehensive loss (in thousands): </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six Months Ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total stock-based compensation expense included in G&amp;A </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember__apnO9afP0Citfd-cUI30g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_lvXVqiAwfEOcPZelg5Z7bw_3_3">2,163</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_z5dcpbt0dECbfqWaQSAHWA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_1QaoJpRhFUWJc-3LoUAs0A_3_6">837</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_SYto29SUgUamWkI0SK6jEA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc__O0S5MoV8kuuNwDIuSyfNQ_3_9">3,733</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_ulujEwUlBE-e-GfNhQVDxA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_fQ-hF3nYbUyJlvuwCQLcRw_3_12">1,815</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:6pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Employee Retention Bonus </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In October 2022, the Company approved the Amended Retention Plan which provides that each of its then current employees, excluding the CEO, will be eligible to receive a cash retention bonus if employed through each of <ix:nonFraction unitRef="Unit_Standard_period_Oxx3Sge1w0O2HvNr__SG-A" contextRef="As_Of_11_1_2022_srt_TitleOfIndividualAxis_xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_rYMNfnEL9EOqQXV7Em0Nyg" decimals="INF" format="ixt-sec:numwordsen" name="xoma:NumberOfPeriodsCashRetentionBonus" scale="0" id="Narr_Rko2rIAGSkejFPg1f-UNXg">two</ix:nonFraction> periods: (1) the <ix:nonNumeric contextRef="Duration_11_1_2022_To_11_1_2022_srt_TitleOfIndividualAxis_xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_r2cXPnKQNkCZpd4DuftB1Q" format="ixt-sec:durwordsen" name="xoma:PeriodOneRetentionBonusEligibility" id="Narr_Qja5dkFsp0uh1yDy-y9Qfw">three-month</ix:nonNumeric> anniversary of November 1, 2022 (the &#8220;Initial Period&#8221;) and (2) the <ix:nonNumeric contextRef="Duration_11_1_2022_To_11_1_2022_srt_TitleOfIndividualAxis_xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_r2cXPnKQNkCZpd4DuftB1Q" format="ixt-sec:durwordsen" name="xoma:PeriodTwoRetentionBonusEligibility" id="Narr_BP7NgCqc3E-T9MOZvr_1lw">nine-month</ix:nonNumeric> period immediately following the Initial Period. All other terms of the Amended Retention Plan remain consistent with the Retention Plan. The Company is accruing and recognizing the cost of the cash retention bonus as expense on a straight-line basis from November 1, 2022 through October 31, 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company paid $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_6_30_2023_srt_TitleOfIndividualAxis_xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_oCigQGadskqvS1qhL-UxEw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredCompensationArrangementWithIndividualDistributionPaid" scale="6" id="Narr_EM2DBvdCTUiO2YbT9tjrUw">0.2</ix:nonFraction> million of cash retention bonuses accrued over the Initial Period in January 2023. Pursuant to the Amended Retention Plan, as of June 30, 2023, the Company expects to pay an additional $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_7_1_2023_To_12_31_2023_srt_StatementScenarioAxis_srt_ScenarioForecastMember_srt_TitleOfIndividualAxis_xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_MqTx9tpzQE-VCd4MN0ETHw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredCompensationArrangementWithIndividualDistributionPaid" scale="6" id="Narr_8hpVP9z0HUyhdyCBBmsb5w">0.5</ix:nonFraction> million in cash in 2023 related to the cash retention bonuses. The Company recognized $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2023_To_6_30_2023_srt_TitleOfIndividualAxis_xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_tUWKdWxSsEqTeepdcpaR-g" decimals="-5" format="ixt:numdotdecimal" name="xoma:RetentionBonusExpenseAccrued" scale="6" id="Narr_8_OQebAp6UaKRgjxxD-3-w">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_6_30_2023_srt_TitleOfIndividualAxis_xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_oCigQGadskqvS1qhL-UxEw" decimals="-5" format="ixt:numdotdecimal" name="xoma:RetentionBonusExpenseAccrued" scale="6" id="Narr_E_pqm8-rXUiZ4CvDxlw5xw">0.4</ix:nonFraction> million for cash retention bonuses in operating expenses in the condensed consolidated statement of operations and comprehensive loss during the three and six months ended June 30, 2023, respectively, and will recognize the remaining amount of $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_7_1_2023_To_10_31_2023_srt_StatementScenarioAxis_srt_ScenarioForecastMember_srt_TitleOfIndividualAxis_xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_VlkReAnbnkaiZ8DMeCw8ZA" decimals="-5" format="ixt:numdotdecimal" name="xoma:RetentionBonusExpenseAccrued" scale="6" id="Narr__paNA88TGEe6Y6-W-XX7mg">0.2</ix:nonFraction> million for cash retention bonuses in operating expenses through October 31, 2023. The Company accrued cash retention bonuses in accrued and other liabilities in the condensed consolidated balance sheets of $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:AccruedRetentionBonus" scale="6" id="Narr_A2AMsN018k-xpd8PoFExYg">0.3</ix:nonFraction> million as of June 30, 2023 and $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg" decimals="-5" format="ixt:numdotdecimal" name="xoma:AccruedRetentionBonus" scale="6" id="Narr_DlOXRIFkZUmNlWlEo-7-1Q">0.1</ix:nonFraction> million as of December 31, 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_ogFd1K6J9UW-1_F2CkoMFw_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">James R. Neal Departure and Continuity Incentive</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:6pt 0pt 0pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">James R. Neal retired as the Company&#8217;s CEO effective as of December 31, 2022 (the &#8220;Departure Date&#8221;) and resigned as a member of the Board and Chairman of the Board, effective as of January 1, 2023. Pursuant to Mr. Neal&#8217;s Amended and Restated Employment Agreement, dated December 15, 2021, by and between the Company and Mr. Neal, following the Departure Date, Mr. Neal is entitled to a cash payment of </span><span style="font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_12_31_2022_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerRetiredMember_YyRGgFdv-E6X0DuiU_Edmg" decimals="-5" format="ixt:numdotdecimal" name="xoma:AccruedCompensationContinuityIncentive" scale="6" id="Narr_6d-K1tEaKkaPvnfTrrL9RQ">1.2</ix:nonFraction></span><span style="font-weight:normal;"> million (the &#8220;Continuity Incentive&#8221;) which will be made in equal monthly installments starting in January 2023 through December 2023, less deductions and withholdings. The Company accrued the full </span><span style="font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerRetiredMember_-DtLW9eN0kelXo4Sr64YSg" decimals="-5" format="ixt:numdotdecimal" name="xoma:CompensationExpenseEmploymentAgreement" scale="6" id="Narr_ydjr204XGUCx8QOO5pJ2jA">1.2</ix:nonFraction></span><span style="font-weight:normal;"> million Continuity Incentive in operating expenses in the consolidated statement of operations and comprehensive loss during the year ended December 31, 2022. The unpaid accrued Continuity Incentive</span><span style="font-weight:normal;"> recorded in accrued and other liabilities in the condensed consolidated balance sheets as of June 30, 2023 and December 31, 2022 was </span><span style="font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerRetiredMember_AOpX5sV2ukSJWYQ3A3lEaQ" decimals="-5" format="ixt:numdotdecimal" name="xoma:AccruedCompensationContinuityIncentive" scale="6" id="Narr_9OggBNpqJ0CVz3vToeciNg">0.6</ix:nonFraction></span><span style="font-weight:normal;"> million and </span><span style="font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerRetiredMember_-DtLW9eN0kelXo4Sr64YSg" decimals="-5" format="ixt:numdotdecimal" name="xoma:CompensationExpenseEmploymentAgreement" scale="6" id="Narr_CMPT0RGCpUaZo9Du_PTqpw">1.2</ix:nonFraction></span><span style="font-weight:normal;"> million, respectively</span>.</p></ix:continuation><a id="_Hlk95224052"></a><a id="Tc_51qPhlHIPkqqlXAX1JTuXw_1_2"></a><a id="Tc_Sl2_Ys07bk2LRyWvqWU5GQ_1_5"></a><a id="Tc_IDNCBA-xykmnq-V3PMShGQ_2_2"></a><a id="Tc_ZF8cLHHY_0-JBztg0oy0Uw_2_5"></a><a id="Tc_AhmNz6OWQ0mO6XMvAoR2LA_3_0"></a><a id="Tc_79JHCTC-IUewY5ZLA6xLQg_3_2"></a><a id="Tc_R2R0b_GIM02CG41Wb5vYJQ_3_5"></a><a id="Tc_a6yQGp8_ekqnFmi5Jorz_A_3_8"></a><a id="Tc__9iQnIiG4ky9T7y0RwCA5w_4_0"></a><a id="Tc_qNFmXVIsw0-DktQOzJCqgQ_4_8"></a><a id="Tc_wwR8IcnZ5Ua5kZ84EEm7Ag_5_0"></a><a id="Tc_aChnkbxRWESDZcBXRPYAWw_5_8"></a><a id="Tc_dO-sm1fEmkmL2tzjdy8imQ_6_0"></a><a id="Tc_zH3FXaReTkKLWK1apFAdoQ_6_8"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_pDD_YB06eEqHBqw3eCoeuA" continuedAt="Tb_pDD_YB06eEqHBqw3eCoeuA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">11. Capital Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Dividends</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the six months ended June 30, 2023, the Company&#8217;s Board of Directors declared and paid cash dividends on the Company&#8217;s Series A Preferred Stock and Series B Depositary shares as follows: </p><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" name="us-gaap:DividendsDeclaredTableTextBlock" id="Tb_RQxQd35ZKEO0YTSA0UMrmA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:42.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:16.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:42.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:17.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Series A&#160;Preferred Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:18.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Series B&#160;Depositary Share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:42.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:17.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cash Dividend Declared</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:18.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cash Dividend Declared</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:42.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dividend Declaration Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">($ per share)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">($ per share)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dividend Payment Date</b></p></td></tr><tr><td style="vertical-align:top;width:42.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">October 26, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_6FlVNMctY0q9dw8fCOKxTg;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg" contextRef="Duration_10_26_2022_To_10_26_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_f-NSs0JDB0Om2BdwXRGLGw" decimals="5" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendsPerShareDeclared" scale="0" id="Tc_E7M9LkUpsEioxIHcP48MtA_4_3">0.53906</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_9royLRcMl0Knqef269WU1Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg" contextRef="Duration_10_26_2022_To_10_26_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_xycxsSZ67ECdvujJaYBpbg" decimals="5" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendsPerShareDeclared" scale="0" id="Tc_v6m6IeuQIEmW1hwIbpkOMQ_4_6">0.52344</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">January 17, 2023</p></td></tr><tr><td style="vertical-align:top;width:42.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">February 22, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_qWHrIk0HxkKu1Feelg1QWg;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg" contextRef="Duration_2_22_2023_To_2_22_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_sYdPxIxRXkGzRg8T4Svv8w" decimals="5" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendsPerShareDeclared" scale="0" id="Tc_m2OzFqLxSEGuDz296XwaGg_5_3">0.53906</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_zyL_9MT4C06Qx4obkYEVKw;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg" contextRef="Duration_2_22_2023_To_2_22_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_-2EK4u-0ckW1nFdNOq609w" decimals="5" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendsPerShareDeclared" scale="0" id="Tc_TIEkHh8w1k27wSCpiytYTQ_5_6">0.52344</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">April 17, 2023</p></td></tr><tr><td style="vertical-align:top;width:42.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">May 17, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_hWIxlEMoI06Nfvonzanuzg;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg" contextRef="Duration_5_17_2023_To_5_17_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_zIuocAB-x0yti_KN6IbA-Q" decimals="5" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendsPerShareDeclared" scale="0" id="Tc_vK6Pjh_yKkCwjftolUB6sw_6_3">0.53906</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_Q-ZWoTYYE0qrtlCrmMWbHw;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg" contextRef="Duration_5_17_2023_To_5_17_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_IblNCk2dpE-dmOagVLa7JA" decimals="5" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendsPerShareDeclared" scale="0" id="Tc_LkGNc7orYUCehaBO8AT-eA_6_6">0.52344</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">July 17, 2023</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">BVF Ownership</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of June 30, 2023, BVF owned approximately <ix:nonFraction unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ" contextRef="As_Of_6_30_2023_dei_LegalEntityAxis_xoma_BiotechnologyValueFundLPMember_srt_OwnershipAxis_xoma_XomaCorporationMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_OPWHgi5OoUOvpKGH_7ayMg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="Narr_ZVqltUTqGk-OBMDaT8lUFQ">31.7</ix:nonFraction>% of the Company&#8217;s total outstanding shares of common stock, and if all the Series X convertible preferred shares were converted, BVF would own <ix:nonFraction unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ" contextRef="As_Of_6_30_2023_dei_LegalEntityAxis_xoma_BiotechnologyValueFundLPMember_srt_OwnershipAxis_xoma_XomaCorporationMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_OPWHgi5OoUOvpKGH_7ayMg" decimals="3" format="ixt:numdotdecimal" name="xoma:NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted" scale="-2" id="Narr_0FvbmJ4uikq42EUIdORH6Q">52.4</ix:nonFraction>% of the Company&#8217;s total outstanding shares of common stock. The Company&#8217;s Series A Preferred Stock becomes convertible upon the occurrence of specific events and as of June 30, 2023, the contingency was not met, therefore the Series A Preferred Stock owned by BVF is not included in the as-converted ownership calculation. Due to its significant equity ownership, BVF is considered a related party of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2018 Common Stock ATM Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December 18, 2018, the Company entered into the 2018 Common Stock ATM Agreement with HCW, under which the Company may offer and sell from time to time at its sole discretion shares of its common stock through HCW as its sales agent, in an aggregate amount not to exceed $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_12_18_2018_To_12_18_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_TwoThousandEighteenAtMarketAgreementMember_w7kNNs1WoE-BxhkhRzlqSg" decimals="-5" format="ixt:numdotdecimal" name="xoma:MaximumValueOfStockToBeIssued" scale="6" id="Narr_Rdf3SaYnDkWuNBC3di0ejw">30.0</ix:nonFraction> million. HCW may sell the shares by any method permitted by law deemed to be an &#8220;at the market&#8221; offering as defined in Rule 415 of the Securities Act and will use its commercially reasonable efforts consistent with its normal trading and sales practices to sell the shares up to the amount specified. The Company will pay HCW a commission of up to <ix:nonFraction unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ" contextRef="Duration_12_18_2018_To_12_18_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_TwoThousandEighteenAtMarketAgreementMember_6lxjXvcF7UG8eC23SZUejg" decimals="2" format="ixt:numdotdecimal" name="xoma:PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares" scale="-2" id="Narr_zcuDyPTLNUKxpYxcd1GD5g">3</ix:nonFraction>% of the gross proceeds of any shares of common stock sold under the 2018 Common Stock ATM Agreement. On March 10, 2021, the Company amended the 2018 Common Stock ATM Agreement with HCW to increase the aggregate amount of shares of its common stock that it could sell through HCW as its sales agent to $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_3_10_2021_To_3_10_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_TwoThousandEighteenAtMarketAgreementMember_lPXdwcXrLkWjZpFxVg8zQg" decimals="-5" format="ixt:numdotdecimal" name="xoma:MaximumValueOfStockToBeIssued" scale="6" id="Narr_hKBa7k0-0kChx0z-3ULyOg">50.0</ix:nonFraction> million. <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="Duration_12_18_2018_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_TwoThousandEighteenAtMarketAgreementMember_7W6KMaqUekmIWDswlSxORw" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_zTYvAFh5qEmyHFG0axLPKg">No</ix:nonFraction> shares have been sold under the 2018 Common Stock ATM Agreement since the agreement was executed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2021 Series B Preferred Stock ATM Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On August 5, 2021, the Company entered into the 2021 Series B Preferred Stock ATM Agreement with B. Riley, under which the Company may offer and sell from time to time, at its sole discretion, through or to B. Riley, as agent or principal an aggregate amount not to exceed $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_8_5_2021_To_8_5_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_AtMarketIssuanceSalesAgreement2021Member_cuvo8QXwwkSA9m8xw1ZRjg" decimals="-5" format="ixt:numdotdecimal" name="xoma:MaximumValueOfStockToBeIssued" scale="6" id="Narr_Ky2cWYV8GUisY9nIG8loXw">50.0</ix:nonFraction> million of its Series B Depositary Shares. B. Riley may sell the shares by any method permitted by law deemed to be an &#8220;at the market&#8221; offering as defined in Rule 415 of the Securities Act and </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_pDD_YB06eEqHBqw3eCoeuA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">will use its commercially reasonable efforts consistent with its normal trading and sales practices to sell the shares up to the amount specified. The Company will pay B. Riley a commission of up to <ix:nonFraction unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ" contextRef="Duration_8_5_2021_To_8_5_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_AtMarketIssuanceSalesAgreement2021Member_aVcwCvFvaEm9M_QNOIF3YA" decimals="2" format="ixt:numdotdecimal" name="xoma:PercentageOfGrossProceedsPaidToAgentForSaleOfShares" scale="-2" id="Narr_8sAb_jRI_E6NvYNYuQUi-w">3</ix:nonFraction>% of the gross proceeds of any Series B Depositary Shares sold under the 2021 Series B Preferred Stock ATM Agreement. <ix:nonFraction unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q" contextRef="Duration_8_5_2021_To_3_31_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_AtMarketIssuanceSalesAgreement2021Member_LyhgNqHmQEOuPgMQ7sVrxA" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_G1iAtbxG30We-vNj0V0GBQ">No</ix:nonFraction> shares have been sold under the 2021 Series B Preferred Stock ATM Agreement since the agreement was executed. </p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_Hlk37628211"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_xMX_1-joikuYRxLXIJBacQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">12. Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations" scale="6" id="Narr_ktn47z1WrEGxx_hrOZqNRw"><ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2022_To_6_30_2022_MkbIQ9bQc0eX6Gc5LtLGHQ" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations" scale="6" id="Narr_QlTp-kN6702qbiotpUxmsw"><ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations" scale="6" id="Narr_uIpTM_-OoE2Spu-eyqGJQw"><ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations" scale="6" id="Narr_CcZvvEzTskyMy2-2DTnt_A">No</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> provision was made for federal income tax, since the Company has incurred net operating losses during the three and six months ended June 30, 2023 and 2022. The Company continues to maintain a full valuation allowance against its remaining net deferred tax assets. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has a total of $<ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="Narr_qkHYOe3zfUCQ4rkhMWC3wQ">5.9</ix:nonFraction> million of gross unrecognized tax benefits, <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" scale="6" id="Narr_BjZGXD2Vn0ifEVWpd7VxpQ">none</ix:nonFraction> of which would affect the effective tax rate upon realization as it currently has a full valuation allowance against its net deferred tax assets. The reversal of related deferred tax assets will be offset by a valuation allowance, should any of these uncertain tax positions be favorably settled in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company does <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit" scale="6" id="Narr_3o1iac27a0eZQOJ4uB3P3w">no</ix:nonFraction>t expect its unrecognized tax benefits to change significantly over the next twelve months. The Company will recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. Through June 30, 2023, the Company has <ix:nonFraction unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw" contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="6" id="Narr_w3JDYVPLHk2PGbuARA6rxQ">no</ix:nonFraction>t accrued interest or penalties related to uncertain tax positions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On August 16, 2022, President Biden signed the Inflation Reduction Act of 2022 (the Inflation Act) into law. &#160;The Inflation Act contains certain tax measures, including a corporate alternative minimum tax of 15% on some large corporations and an excise tax of 1% on corporate stock buy-backs. The various provisions of the Inflation Act do not have a material impact on the Company&#8217;s financial statements.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_a4f6099c_172e_4b02_a1fb_93a60680dc14"></a><a id="ITEM2MANAGEMENTSDISCUSSIONANDANALYSISOFF"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM&#160;2.&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Forward Looking Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">This Quarterly Report on Form&#160;10-Q contains forward-looking statements within the meaning of Section&#160;27A of the Securities Act of 1933, as amended, or the Securities Act, Section&#160;21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and the Private Securities Litigation Reform Act of 1995, which are subject to the &#8220;safe harbor&#8221; created by those sections. Forward-looking statements are based on our management&#8217;s beliefs and assumptions and on information currently available to them. In some cases you can identify forward-looking statements by words such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;projects,&#8221; &#8220;predicts,&#8221; &#8220;potential,&#8221; &#8220;intend&#8221; and similar expressions intended to identify forward-looking statements. Examples of these statements include, but are not limited to, statements regarding: our future operating expenses, our future losses, the success of our strategy as a royalty aggregator, the assumptions underlying our business model; the extent to which issued and pending patents may protect the products and processes in which we have an ownership or royalty interest and prevent the use of the covered subject matter by third parties, the potential of our existing product candidates to lead to the development of commercial products, our ability to receive potential milestone or royalty payments under license and collaboration agreements and the amount and timing of receipt of those payments. These statements are based on assumptions that may not prove accurate. Actual results could differ materially from those anticipated due to certain risks inherent in the biotechnology industry and for our licensees engaged in the development of new products in a regulated market. Among other things: there can be no assurance that our revenues or expenses will meet any expectations or follow any trend(s); we may be unable to retain our key employees; litigation, arbitration or other disputes with third parties may have a material adverse effect on us; our product candidates subject to our out-license agreements are still being developed, and our licensees&#8217; may require substantial funds to continue development which may not be available; we may not be successful in entering into out-license agreements for our product candidates; if our therapeutic product candidates do not receive regulatory approval, our third-party licensees will not be able to manufacture and market them; products or technologies of other companies may render some or all of our product candidates noncompetitive or obsolete; we do not know whether there will be, or will continue to be, a viable market for the products in which we have an ownership or royalty interest; even once approved, a product may be subject to additional testing or significant marketing restrictions, its approval may be withdrawn or it may be voluntarily taken off the market; and we and our licensees are subject to various state and federal healthcare related laws and regulations that may impact the commercialization of our product candidates and could subject us to significant fines and penalties. These and other risks, including those related to current economic and financial market conditions, are contained principally in Part&#160;II, Item&#160;1A of this Quarterly Report on Form&#160;10-Q and our other filings with the SEC. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this Quarterly Report on Form&#160;10-Q. You should read this Quarterly Report on Form&#160;10-Q completely and with the understanding that our actual future results may be materially different from those we expect. Except as required by law, we assume no obligation to update these forward-looking statements, whether as a result of new information, future events or otherwise.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Forward-looking statements are inherently uncertain and you should not place undue reliance on these statements, which speak only as of the date that they were made. These cautionary statements should be considered in connection with any written or oral forward-looking statements that we may issue in the future. We do not undertake any obligation to release publicly any revisions to these forward-looking statements after completion of the filing of this Quarterly Report on Form&#160;10-Q to reflect later events or circumstances or to reflect the occurrence of unanticipated events.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based on information available to us as of the date of this Quarterly Report on Form&#160;10-Q. While we believe that information provides a reasonable basis for these statements, that information may be limited or incomplete. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely on these statements.</i></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">All references to &#8220;portfolio&#8221; in this Quarterly Report on Form&#160;10-Q are to milestone and/or royalty rights associated with a basket of drug products in development.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">We use our trademarks, trade names and services marks in this report as well as trademarks, trade names and service marks that are the property of other organizations. Solely for convenience, trademarks and trade names referred to in this report appear without the &#174; and &#8482; symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or that the applicable owner will not assert its rights, to these trademarks and trade names.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The following discussion and analysis should be read in conjunction with the unaudited financial statements and notes thereto included in Part&#160;I, Item&#160;1 of this Quarterly Report on Form&#160;10-Q and with the audited consolidated financial statements and related notes thereto included as part of our Annual Report on Form&#160;10-K for the&#160;year ended December&#160;31, 2022.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">XOMA is a biotech royalty aggregator. We have a sizable portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. Our portfolio was built through the acquisition of rights to future milestones and royalties that we have made since the royalty aggregator business model was implemented in 2017 combined with out-licensing our proprietary products and platforms from our legacy discovery and development business. Our drug royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase 1 and 2, with significant commercial sales potential that are licensed to large-cap partners. We expect that most of our future revenue will be based on payments we may receive for milestones and royalties related to these programs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The generation of future revenues related to licenses, milestones, and royalties is dependent on the achievement of milestones or product sales by our existing licensees. We generated net loss of $17.1 million and negative cash flows from operations of $12.9 million for the year ended December 31, 2022. We generated net loss of $5.4 million and $15.2 million for the three and six months ended June 30, 2023, respectively, and negative cash flows from operations of $12.1 million for the six months ended June 30, 2023, and we had an accumulated deficit of $1.2 billion as of June 30, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.6pt;text-align:justify;text-indent:-21.6pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Recent Business Developments</b></p><a id="_Hlk86853547"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Portfolio Updates &#8211; Royalty and Commercial Payment Purchase Agreements </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 2023, we entered into the LadRx AAA pursuant to the which we acquired from LadRx all of their rights, title and interest related to arimoclomol under an asset purchase agreement dated May 13, 2011, as assigned to Zevra as of June 1, 2022, between Zevra and LadRx. We also entered into the LadRx RPA, pursuant to which we acquired the right to receive all of the future royalties, regulatory and commercial milestones as well as other related payments due to LadRx from ImmunityBio related to aldoxorubicin under a license agreement dated July 27, 2017, as amended on September 27, 2018, between ImmunityBio and LadRx. The purchased rights related to arimoclomol include potential regulatory and commercial milestones of up to $52.5 million (net of certain payment obligations of up to $9.5 million based on a portion of the regulatory and commercial milestone payments) and potential royalty payments in low single-digit percentages of aggregate net sales associated with arimoclomol. The purchased payments related to aldoxorubicin include potential regulatory and commercial milestones of up to $342.7 million and royalty payments on aggregate net sales of aldoxorubicin in the low to mid-teens for sales of orphan indications and mid to high single-digit percentages on other licensed products. Upon closing of the LadRx Agreements, we paid LadRx an upfront payment of $5.0 million and may pay up to an additional $6.0 million in regulatory and commercial milestones.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 2023, Bioasis announced the suspension of all its operations and the termination of the research collaboration and license agreement between Bioasis and Chiesi. We do not expect to receive any milestone, royalty or other payments under the Biosis RPA or Second Bioasis RPA.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">In March 2023, we entered into the Aptevo CPPA, pursuant to which we acquired the full commercial payment stream and a portion of the milestone rights to IXINITY, which is marketed by Medexus for the control and prevention of bleeding episodes and postoperative management in people with Hemophilia B, from Aptevo. In the second quarter of 2023, we began receiving a mid-single digit percentage payment stream on all IXINITY sales from January 1, 2023, into the first quarter of 2035, and also will be entitled to milestone payments. Under the terms of the Aptevo CPPA, we paid Aptevo a $9.6 million upfront payment. </span>In June 2023, we received $0.6 million from Aptevo representing the first commercial payment attributable to net sales of IXINITY that occurred during the first quarter of 2023 and <span style="background:#ffffff;">paid an additional one-time payment of $50,000 to Aptevo pursuant to the Aptevo CPPA.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">In February 2023, we received $2.4 million, representing our commercial payment stream from sales of VABYSMO during the last six months of 2022 under the Affitech CPPA. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Portfolio Updates &#8211; License and Collaboration Agreements </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">In April 2023, we earned a $0.5 million milestone from Janssen, upon dosing of the first patient in a Phase 3 clinical trial evaluating one of Janssen&#8217;s biologic assets. In addition, during the second quarter of 2023, we earned a total of $0.6 million for three additional milestones pursuant to our agreement with Janssen.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In July 2023, Novartis announced that based on a benefit-risk assessment, it is discontinuing its Phase 3 investigating NIS793 in first-line metastatic pancreatic ductal adenocarcinoma. Novartis stated it will continue to investigate NIS793 in indications beyond pancreatic ductal adenocarcinoma, including its ongoing Phase 2 study in colorectal cancer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Critical Accounting Estimates </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in accordance with generally accepted accounting principles, or GAAP, requires us to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities. We evaluate our estimates on an ongoing basis. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form our basis for making judgments about the carrying values of assets and liabilities and the reported amounts of revenues and expenses that are not readily apparent from other sources. Actual results may differ from those estimates under different assumptions and conditions. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Critical accounting estimates are those estimates that involve a significant level of judgment and/or estimation uncertainty and could have or are reasonably likely to have a material impact on our financial condition or results of operations.</p><a id="_Hlk138759762"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There have been no significant changes in our critical accounting estimates during the six months ended June 30, 2023, as compared with those previously disclosed in our Annual Report on Form&#160;10-K for the&#160;year ended December&#160;31, 2022, filed with the SEC on March&#160;9, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our significant accounting policies are included in &#8220;Note 2 &#8211; Basis of Presentation and Significant Accounting Policies&#8221; in our Condensed Consolidated Financial Statements.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Revenues</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Total revenues for the three and six months ended June 30, 2023 and 2022, were as follows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:48.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:15.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:15.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:15.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:15.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr><td style="vertical-align:bottom;width:48.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Revenue from contracts with customers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,125</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 525</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 600</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,125</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,275</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2,150)</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Revenue recognized under units-of-revenue method</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 533</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 458</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 75</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 970</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 815</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 155</span></p></td></tr><tr><td style="vertical-align:bottom;width:48.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,658</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 983</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 675</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,095</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,090</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,995)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Revenue from Contracts with Customers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Revenue from contracts with customers includes upfront fees, annual license fees and milestone payments related to the out-licensing of our legacy product candidates and technologies. The increase for the three months ended June 30, 2023, as compared to the same period in 2022, was primarily due to the $1.1 million of milestones earned pursuant to the license agreement with Janssen. The decrease for the six months ended June 30, 2023, as compared to the same period in 2022, was primarily due to $2.0 million in revenue recognized in the first quarter of 2022 related to a milestone event under our Rezolute license agreement and a $0.8 million milestone earned pursuant to the Takeda Collaboration Agreement, partially offset by $1.1 million of milestones earned pursuant to the license agreement with Janssen. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Revenue Recognized under Units-of-Revenue Method</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Revenues recognized under the units-of-revenue method include the amortization of unearned revenue from the sale of royalty interests to HCRP in 2016. Revenues for the three and six months ended June 30, 2023, increased when compared with the same periods in 2022 due to an increase in sales of products underlying the agreements with HCRP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">R&amp;D Expenses </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">R&amp;D expenses were $39,000 and $0.1 million for the three and six months ended June 30, 2023, respectively, which were consistent with $40,000 and $0.1 million for the same periods in 2022. We do not expect to incur substantial R&amp;D expenses related to internally developed programs due to the focus on our royalty aggregator business model. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">G&amp;A Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">G&amp;A expenses include salaries and related personnel costs, professional fees, and facilities costs. G&amp;A expenses were $5.8 million for the three months ended June 30, 2023 compared with $5.7 million for the same period of 2022. The difference included an increase of $1.3 million in stock-based compensation expense and was offset by a decrease of $1.1 million for legal and consulting costs.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">G&amp;A expenses were $12.0 million for the six months ended June 30, 2023 and $10.8 million for the same period in 2022.</span> <span style="background:#ffffff;">The increase of $1.2 million was primarily due to a $1.9 million increase in stock-based compensation, partially offset by a $0.8 million decrease in consulting and legal expenses. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Royalty Purchase Agreement Asset Impairment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Royalty purchase agreement asset impairment of $1.6 million for the three and six months ended June 30, 2023, consisted of the impairment recorded related to our Biosasis RPAs.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Arbitration Settlement Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Arbitration settlement costs of $4.1 million for the six months ended June 30, 2023, consisted of the costs incurred related to the arbitration proceeding settlement with one of our licensees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Other Income (Expense)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Other Income (Expense), Net </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table shows the activity in other income (expense), net for the three and six months ended June 30, 2023 and 2022 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:30.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:30.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:30.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:30.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr><td style="vertical-align:bottom;width:30.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other income (expense), net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:30.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Investment income </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 472</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 83</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 389</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 853</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 98</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 755</span></p></td></tr><tr><td style="vertical-align:bottom;width:30.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Change in fair value of equity securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (25)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 35</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (14)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (251)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 237</span></p></td></tr><tr><td style="vertical-align:bottom;width:30.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Change in fair value of contingent consideration</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 75</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 75</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 75</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 75</span></p></td></tr><tr><td style="vertical-align:bottom;width:30.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 39</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (39)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 35</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (35)</span></p></td></tr><tr><td style="vertical-align:bottom;width:30.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total other income (expense), net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 557</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 97</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 460</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 914</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (118)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,032</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Investment income increased $0.4 million and $0.8 million in the three and six months ended June 30, 2023, respectively, compared with the same periods in 2022 due to higher market interest rates. The change in fair value of equity securities was due to the change in market price of equity securities we own in shares of Rezolute&#8217;s common stock. The change in fair value of contingent consideration was due to the reduction in the fair value of the $75,000 contingent consideration related to the Bioasis RPA to zero (see Note 5 of the Condensed Consolidated Financial Statements).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Provision for Income Taxes</p><a id="_Hlk108438701"></a><a id="_Hlk108438725"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We recorded no provision for federal income tax, since we incurred net operating losses during the three and six months ended June 30, 2023 and 2022. We continue to maintain a full valuation allowance against our remaining net deferred tax assets. We had a total of $5.9 million of gross unrecognized tax benefits, none of which would impact our effective tax rate to the extent that we continue to maintain a full valuation allowance against our deferred tax assets. We do not expect our unrecognized tax benefits to change significantly over the next twelve months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Liquidity and Capital Resources</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes our unrestricted cash and cash equivalents, our working capital and our cash flow activities as of and for each of the periods presented (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 31,445</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 57,826</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (26,381)</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Working capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 31,336</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 54,435</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (23,099)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six Months Ended June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (12,132)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (5,326)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (6,806)</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net cash used in investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (11,716)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (5,000)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (6,716)</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net cash used in financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2,533)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,869)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (664)</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net decrease in cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (26,381)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (12,195)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (14,186)</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Net cash used in operating activities for the six months ended June 30, 2023, was $12.1 million due to our operating expenses of $18.2 million, excluding non-cash expenses of $5.9 million including stock-based compensation of $3.7<i style="font-style:italic;"> </i>million and royalty purchase agreement asset impairment of $1.6 million. Net cash used in operating activities for the six months ended June 30, 2022, was our operating expenses of $10.9 million, excluding non-cash expenses of $2.2 million including stock-based compensation of $1.8 million, partially offset by a $2.0 million milestone payment received from Rezolute and a $0.8 million milestone payment received from Takeda.</p><a id="_Hlk100751667"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Net cash used in investing activities for the six months ended June 30, 2023, was $11.7 million due to the $9.6 million payment to Aptevo for the acquisition of payment rights pursuant to the Aptevo CPPA in March 2023, $5.0 million payment to LadRx for the acquisition of payment rights pursuant to the LadRx Agreements in June 2023, partially offset by the $2.4 million commercial payment from sales of VABYSMO and $0.6 million commercial payment from sales attributable to IXINITY. Net cash used in investing activities for the six months ended June 30, 2022, of $5.0 million was due to the $5.0 million milestone payment pursuant to the Affitech CPPA in January 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">Net cash used in financing activities for the six months ended June 30, 2023, of $2.5 million was due to the payment of dividends on our Series A and Series B Preferred Stock. Net cash used in financing activities for the six months ended June 30, 2022, of $1.9 million was primarily due to the payment of dividends on our Series A and Series B Preferred Stock of $2.7 million, partially offset by the receipt of net cash provided from the exercise of stock options after related tax payments of $0.9 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 21.3pt;"><span style="font-style:italic;font-weight:bold;">Capital Resources</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">We have incurred significant operating losses since our inception and as of June 30, 2023, we had an accumulated deficit of $1.2 billion. As of June 30, 2023, we had $31.4 million in cash and cash equivalents. Based on our current cash balance and our ability to control discretionary spending, such as royalty acquisitions, we have evaluated and concluded our financial condition is sufficient to fund our planned operations, commitments, and contractual obligations for a period of at least one year following the filing date of this report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have primarily financed our operations and acquisitions through the issuance of our common stock, Series A and Series B Preferred Stock, and amounts received as milestone payments under our license agreements. The generation of future revenues related to licenses, milestones, and royalties is dependent on the achievement of milestones or product sales by our existing licensees. Milestone payments earned in prior periods are not indicative of anticipated milestones in future periods. We may seek additional capital through the use of our 2018 Common Stock ATM Agreement or 2021 Series B Preferred Stock ATM Agreement (see Note 11 of the Condensed Consolidated Financial Statements), or through other public or private debt or equity transactions. Our ability to raise additional capital in the equity and debt markets, should we choose to do so, is dependent on a number of factors, including, but not limited to, the market demand for our common and preferred stock, which are subject to a number of development and business risks and uncertainties, our creditworthiness and the uncertainty that we would be able to raise such additional capital at a price or on terms that are favorable to us. If we are unable to raise additional funds when we need them, our business and operations may be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="font-style:italic;font-weight:bold;">Material Cash Requirements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our material cash requirements in the short and long term consist of the following expenditures:</p><a id="_Hlk138830181"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Operating expenditures:</b> Our primary uses of cash and operating expenses relate to employee and related costs, consultants to support our administrative and business development efforts, legal and accounting services, insurance, investor relations and IT services. Our planned spending includes costs to satisfy the Continuity Incentive related to the departure of Mr. Neal as CEO in December 2022, increased personnel-related costs associated with the appointment of our new Executive Chairman and Chief Investment Officer, and payments of our employee retention bonuses. In addition, in March 2023, we received an adverse decision in an arbitration proceeding in which the arbitrators ruled we were responsible for the costs incurred by the counter-party. We paid these costs of $4.1 million in April 2023.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">To support our royalty aggregator business model, we engage third parties to assist in our evaluation of potential acquisitions of milestone and royalty streams. Additional operating expenses, including consulting and legal costs, may increase in 2023 in response to an anticipated increase in the volume of acquisition targets evaluated or completed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Our headquarters lease expires in July 2023. In June 2023 we entered into an amended lease with the same counterparty for a different unit in the same building. The new lease is expected to commence in the fourth quarter of 2023 and has a term of 65 months. As of June 30, 2023, we expect to incur incremental undiscounted costs of $0.5 million associated with our current and future building lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">RPAs, AAAs, CPPAs and IP Acquisitions: </b>A significant component of our business model is to acquire rights to potential future milestone and royalty streams. We expect to continue deploying capital toward these acquisitions in the near and long term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We have potential contingent consideration of $1.0 million recorded on our consolidated balance sheets as of June 30, 2023, for milestone payments due under our agreement with LadRx. We also have up to an additional $5.0 million in milestones that may become due under the LadRx Agreements. We have evaluated and concluded our existing capital resources are adequate to meet those needs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We also have potential sales-based milestones that may become due under our agreements with Aronora, Kuros and Affitech as well as non-sales-based milestones, sales-based milestones and sales-based royalty payments that may become due under our agreement with ObsEva. All of these milestones and royalty payments represent a portion of the funds we may receive in the future pursuant to these agreements, and therefore will be fully funded by the related royalty or commercial payment receipts. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Collaborative Agreements, Royalties and Milestone Payments</b>: We have committed to make potential future milestone payments and legal fees to third parties as part of licensing and development programs. Payments under these agreements become due and payable only upon the achievement of certain developmental, regulatory and commercial milestones by our licensees. Because it is uncertain if and when these milestones will be achieved, such contingencies, aggregating up to $6.3 million (assuming one product per contract meets all milestone events) have not been recorded on our condensed consolidated balance sheet as of June 30, 2023. We are unable to determine precisely when and if our payment obligations under the agreements will become due as these obligations are based on milestone events, the achievement of which is subject to a significant number of risks and uncertainties. All payments due will be funded by a portion of the related milestone or royalty revenue we receive or will be reimbursed by our licensees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Dividends</b>: Holders of our Series A Preferred Stock are entitled to receive, when and as declared by our Board of Directors, cumulative cash dividends at the rate of 8.625% of the $25.00 liquidation preference per year (equivalent to $2.15625 per share of Series A Preferred Stock per year). Holders of Series B Depositary Shares are entitled to receive, when and as declared by our Board of Directors, cumulative cash dividends at the rate of 8.375% of the $25,000 liquidation preference per share of Series B Preferred Stock ($25.00 per depositary share) per year, which is equivalent to $2,093.75 per year per share of Series B Preferred Stock ($2.09375 per year per depositary share). Dividends on the Series A and Series B Preferred Stock are payable in arrears on or about the 15th day of January, April, July and October of each year. &#160;Since original issuance, all dividends have been paid as scheduled. We expect to continue making these dividend payments as scheduled using our existing capital resources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">*</span></span>*<span style="display:inline-block;width:31pt;"></span>*</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Changes in Commitments and Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;">Our commitments and contingencies were reported in our Annual Report on Form&#160;10-K for the&#160;year ended December&#160;31, 2022, as filed with the SEC. Except as described below, there have been no material changes from the commitment and contingencies previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2022.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">In June 2021, we initiated a binding arbitration proceeding with one of our licensees (the &#8220;Licensee&#8221;) at the American Arbitration Association/International Centre for Dispute Resolution, seeking milestone and royalty payments under our license agreement. A hearing before a panel of arbitrators was held in November 2022, and the parties submitted post-hearing briefs. On March 21, 2023, we received an adverse decision in this arbitration proceeding. The panel of arbitrators declined to award us damages and ruled that the license agreement has expired. The panel ruled that we are responsible for the Licensee&#8217;s costs as well as arbitrators&#8217; and administrative fees previously incurred by the Licensee of $4.1 million, which we paid in April 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On June 27, 2023, we executed an amended lease agreement for our corporate headquarters in Emeryville, California with the same counterparty, in a different location in the same building to replace our existing lease expiring in July 2023. The amended lease agreement has a term of 65 months and has an expected commencement date in the fourth quarter of 2023. Undiscounted future rent payments associated with the new lease through the 65-month term is expected to be $0.5 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_a58b9ef2_4120_4d02_9a0a_e3b0c15350af"></a><a id="ITEM3QUANTITATIVEANDQUALITATIVEDISCLOSUR"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM&#160;3.&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We are a smaller reporting company as defined by Rule&#160;12b-2 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and are not required to provide the information required under this item.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_955275e6_90c1_4bf1_8b17_cc092909f315"></a><a id="ITEM4CONTROLSANDPROCEDURES_732379"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM&#160;4.&#160;CONTROLS AND PROCEDURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Evaluation of Controls and Procedures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have established disclosure controls and procedures, as defined in Rule&#160;13a-15(e)&#160;and 15d-15(e)&#160;of the Exchange Act. Our Interim Chief Executive Officer (Principal Executive Officer) and our Chief Financial Officer have concluded, based on the evaluation of the effectiveness of our disclosure controls and procedures by our management, with the participation of our Interim Chief Executive Officer (Principal Executive Officer) and our Chief Financial Officer, as of the end of the period covered by this report, that our disclosure controls and procedures were effective at the reasonable assurance level.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Changes in Internal Control</p><a id="_Hlk54358175"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:2pt 0pt 2pt 0pt;">There have been no changes in our internal controls over financial reporting as defined in Rule&#160;13a-15(f)&#160;under the Exchange Act during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_5ac1b212_880d_40cc_8b67_7a6ecc3f1382"></a><a id="PARTIIOTHERINFORMATION_840286"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">PART&#160;II&#160;&#8211;&#160;OTHER INFORMATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_4b087dc0_b115_4292_863f_b7e5a1670f43"></a><a id="ITEM1LEGALPROCEEDINGS_81705"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM&#160;1.&#160;LEGAL PROCEEDINGS </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In June 2021, we initiated a binding arbitration proceeding with one of our licensees (the &#8220;Licensee&#8221;) at the American Arbitration Association/International Centre for Dispute Resolution, seeking milestone and royalty payments under our license agreement. A hearing before a panel of arbitrators was held in November 2022, and the parties submitted post-hearing briefs. On March 21, 2023, we received an adverse decision in this arbitration proceeding. The panel of arbitrators declined to award us damages and ruled that the license agreement has expired. The panel ruled that we were responsible for the Licensee&#8217;s costs as well as arbitrators&#8217; and administrative fees previously incurred by the Licensee of $4.1 million, which we paid in April 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_239bf86a_fb63_417d_b936_0c4288abe771"></a><a id="ITEM1ARISKFACTORS_925437"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ITEM&#160;1A.&#160;RISK FACTORS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;"><i style="font-style:italic;">This Quarterly Report on Form 10-Q contains forward-looking information based on our current expectations. Because our actual results may differ materially from any forward-looking statements made by or on behalf of us, this section includes a discussion of important factors that could affect our actual future results, including our revenues, </i></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">expenses, operating results, cash flows and net loss per share. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business operations. You should carefully consider these risk factors, together with all of the other information included in this Quarterly Report on Form 10-Q as well as our other publicly available filings with the U.S. Securities and Exchange Commission, or SEC.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 12pt 0pt;"><i style="font-style:italic;">We have marked with an asterisk (*) those risks described below that reflect substantive changes from, or additions to, the risks described in our Annual Report on Form 10-K for the year ended December 31, 2022.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risk Factors Summary</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Below is a summary of material factors that make an investment in our securities speculative or risky. Importantly, this summary does not address all of the risks and uncertainties that we face. Additional discussion of the risks and uncertainties summarized in this risk factor summary, as well as other risks and uncertainties that we face, can be found under &#8220;Risk Factors&#8221; below. The below summary is qualified in its entirety by that more complete discussion of such risks and uncertainties. You should consider carefully the risks and uncertainties described under &#8220;Risk Factors&#8221; below as part of your evaluation of the risks associated with an investment in our securities.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our acquisitions of potential future royalty and/or milestone payments may not produce anticipated revenues and/or may be negatively affected by a default or bankruptcy of the licensor(s) or licensee(s), and if such transactions are secured by collateral, we may be, or may become, under-secured by the collateral or such collateral may lose value and we will not be able to recuperate our capital expenditures associated with the acquisition.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Many of our potential royalty acquisitions may be associated with drug products that are in clinical development and have not yet been commercialized. To the extent that such products are not successfully developed and commercialized, our financial condition and results of operations may be negatively impacted. Acquisitions of potential royalties associated with development stage biopharmaceutical product candidates are subject to a number of uncertainties.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We depend on our licensees and royalty-agreement counterparties for the determination of royalty and milestone payments. While we typically have primary or back-up rights to audit our licensees and royalty-agreement counterparties, the independent auditors may have difficulty determining the correct royalty calculation, errors, may be undetectable and payment calculations may call for retroactive adjustments. We may have to exercise legal remedies to resolve any disputes resulting from any such audit.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The lack of liquidity of our acquisitions of future potential milestones and royalties may adversely affect our business and, if we need to sell any of our acquired assets, we may not be able to do so at a favorable price, if at all. As a result, we may suffer losses. We have sustained losses in the past, and we expect to sustain losses in the foreseeable future.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The macroeconomic conditions, such as rising inflation rates, uncertain credit and global financial markets and supply chain disruptions, and geopolitical events, have adversely impacted and could materially and adversely impact the future our licensees or royalty-agreement counterparties or their licensees, which could cause delays or elimination of our receipts of potential milestones and royalties under our licensing or royalty and milestone acquisition arrangements.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our royalty aggregator strategy may require that we register with the SEC as an &#8220;investment company&#8221; in accordance with the Investment Company Act of 1940. If we were to become an &#8220;investment company&#8221; and be subject to the restrictions of the 1940 Act, those restrictions would likely require significant changes in the way we do business and add significant administrative burdens to our operations.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our royalty aggregator strategy may require us to raise additional funds to acquire milestone and royalty interests; we cannot be certain that funds will be available or available at an acceptable cost of capital, and if </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">they are not available, we may be unsuccessful in acquiring milestone and royalty interests to sustain the business in the future.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Information available to us about the biopharmaceutical products underlying the potential royalties we buy may be limited and therefore our ability to analyze each product and its potential future cash flow may be similarly limited.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our future income is dependent upon numerous potential milestone and royalty-specific assumptions and, if these assumptions prove not to be accurate, we may not achieve our anticipated rates of returns. Reductions in potential milestone or royalty payments compared to expectations, or impairments in the value of potential milestones and royalties acquired could have a material adverse effect on our financial condition and results of operations. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A large percentage of the calculated net present value of our portfolio is represented by a limited number of products. The failure of any one of these products to move forward in clinical development or commercialization may have a material adverse effect on our financial condition and results of operation. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We rely heavily on license and collaboration relationships, and any litigation, arbitration or other disputes with our licensees, collaborators and their partners or termination or breach of any of the related agreements could reduce the financial resources available to us. In the event of any disagreement that cannot be resolved satisfactorily to us, we may end up being paid less than anticipated on such product or involved in costly and time-consuming arbitration or litigation, which could materially adversely affect our financial condition, results of operation and future prospects.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our potential milestone and royalty providers may rely on third parties to provide services in connection with their product candidate development and manufacturing programs. The inadequate performance by or loss of any of these service providers could adversely affect our potential milestone and royalty providers&#8217; product candidate development.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may not be able to successfully identify and acquire potential milestone and royalty streams on other products, product candidates, or programs, or other companies to grow and diversify our business, and, even if we are able to do so, we may not be able to successfully manage the risks associated with integrating any such products, product candidates, programs or companies into our business or we may otherwise fail to realize the anticipated benefits of these acquisitions. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our potential milestone and royalty providers face uncertain results of clinical trials of product candidates. If our potential royalty providers&#8217; therapeutic product candidates do not receive regulatory approval, our potential royalty providers will be unable to market them.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We do not know whether there will be, or will continue to be, a viable market for the product candidates in which we have an ownership, milestone or royalty interest.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If we and our potential royalty providers are unable to protect our intellectual property, in particular patent protection for principal products, product candidates and processes in which we have an ownership or royalty interest, and prevent the use of the covered subject matter by third parties, our potential royalty providers&#8217; ability to compete in the market will be harmed, and we may not realize our profit potential.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have a continuing obligation to pay quarterly dividends to holders of our Series A and Series B Preferred Stock, which will be an on-going expenditure for us and may limit our ability to borrow additional funds.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to our Royalty Aggregator Strategy</p><a id="_Hlk88064321"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our acquisitions of potential future royalty and/or milestone payments may not produce anticipated revenues and/or may be negatively affected by a default or bankruptcy of the licensor(s)&#160;or licensee(s)&#160;under the applicable license agreement(s)&#160;covering such potential royalties and/or milestones, and if such transactions are secured by collateral, we may be, or may become, under-secured by the collateral or such collateral may lose value and we will not be able to recuperate our capital expenditures associated with the acquisition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are engaged in a continual review of opportunities to acquire future royalties, milestones and other payments related to drug development and sales as part of our royalty aggregator strategy or to acquire companies that hold royalty assets. Generally, at any time, we seek to have acquisition opportunities in various stages of active review, including, for example, our engagement of consultants and advisors to analyze particular opportunities, technical, financial and other confidential information, submission of indications of interest and involvement as a bidder in competitive auctions. Many potential acquisition targets do not meet our criteria, and for those that do, we may face significant competition for these acquisitions from other royalty buyers and enterprises. Competition for future asset acquisition opportunities in our markets could increase the price we pay for such assets and could reduce the number of potential acquisition targets. The success of our acquisitions is based on our ability to make accurate assumptions regarding the valuation, probability, timing and amount of potential future royalty and milestone payments as well as the viability of the underlying technology and intellectual property. The failure of any of these acquisitions to produce anticipated revenues may materially and adversely affect our financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Some of these acquisitions may expose us to credit risk in the event of a default by or bankruptcy of the licensor(s)&#160;or licensee(s)&#160;that are parties to the applicable license agreement(s)&#160;covering the potential milestone and royalty streams being acquired. In addition, recent volatility in the capital markets may limit our licensees or royalty-agreement counterparties&#8217; ability to access additional funding. While we generally try to structure our receipt of potential milestone and royalty payments to minimize the risk associated with such a default or bankruptcy, there can be no assurance that any such default or bankruptcy will not adversely affect our ability to receive future potential royalty and/or milestone payments. To mitigate this risk, on occasion, we may obtain a security interest as collateral in such royalty, milestone and other payments. Our credit risk in respect of such counterparty may be exacerbated when the collateral held by us cannot be realized upon or is liquidated at prices not sufficient to recover the full amount we are due pursuant to the terms of the agreements covering the particular assets. This could occur in circumstances where the original collateral was not sufficient to cover a complete loss (e.g., our interests were only partially secured) or may result from the deterioration in value of the collateral, so that, in either such case, we are unable to recuperate our full capital outlay. Any such losses resulting therefrom could materially and adversely affect our financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Many of our potential royalty acquisitions may be associated with drug products that are in clinical development and have not yet been commercialized. To the extent that such products are not successfully developed and commercialized, our financial condition and results of operations may be negatively impacted. Acquisitions of potential royalties associated with development stage biopharmaceutical product candidates are subject to a number of uncertainties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As part of our royalty aggregator strategy, we may continue to purchase future potential milestone and royalty streams associated with drug products which are in clinical development and have not yet received marketing approval by any regulatory authority or been commercialized. There can be no assurance that the FDA, the EMA or other regulatory authorities will approve such products or that such products will be brought to market timely or at all, or that the market will be receptive to such products. To the extent that any such drug products are not successfully developed and subsequently commercialized, the value of our acquired potential milestone and royalty streams will be negatively affected. The ultimate success of our royalty aggregator strategy will depend on our ability to properly identify and acquire high quality products and the ability of the applicable counterparty to innovate, develop and commercialize their products, in increasingly competitive and highly regulated markets. Their inability to do so would negatively affect our ability to receive royalty and/or milestone payments. In addition, we are dependent, to a large extent, on third parties to enforce certain rights for our benefit, such as protection of a patent estate, adequate reporting and other protections, and their failure to do so would presumably negatively impact our financial condition and results of operations.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;"> </span>If the FDA, the EMA or other regulatory authority approves a development-stage product candidate that generates our royalty, the labeling, packaging, adverse event reporting, storage, advertising, promotion and recordkeeping for the product will be subject to extensive and ongoing regulatory requirements. The subsequent discovery of previously unknown problems with the product, including adverse events of unanticipated severity or frequency, may result in restrictions on the marketing of the product, and could include withdrawal of the product from the market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, the developers of these development-stage product candidates may not be able to raise additional capital to continue their discovery, development and commercialization activities, which may cause them to delay, reduce the scope of, or eliminate one or more of their clinical trials or research and development programs. If other product developers introduce and market products that are more effective, safer, less invasive or less expensive than the relevant products that generate our royalties, or if such developers introduce their products prior to the competing products underlying our royalties, such products may not achieve commercial success and thereby result in a loss for us. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Further, the developers of such products may not have sales, marketing or distribution capabilities. If no sales, marketing or distribution arrangements can be made on acceptable terms or at all, the affected product may not be able to be successfully commercialized, which will result in a loss for us. Losses from such assets could have a material adverse effect on our business, financial condition and results of operations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We intend to continue, and may increase, this strategy of acquiring development-stage product candidates. While we believe that we can readily evaluate and gain conviction about the likelihood of a development-stage product candidate&#8217;s approval and achieving significant sales, there can be no assurance that our assumptions will prove correct, that regulatory authorities will approve such development-stage product candidates, that such development-stage product candidates will be brought to market timely or at all, or that such products will achieve commercial success. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Actual or threatened epidemics, pandemics, outbreaks, or public health crises may in the future, adversely affect our and our licensees or royalty-agreement counterparties or their licensees, which could cause delays or elimination of our receipts of potential milestones and royalties under our licensing or royalty and milestone acquisition arrangements. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any actual or threatened epidemics, pandemics, outbreaks, or public health crises has adversely impacted and could materially and adversely impact in the future our licensees or royalty-agreement counterparties or their licensees, which has and could further cause delays, suspensions or cancellations of their drug development efforts including, without limitation, their clinical trials, which would correspondingly delay, suspend or negate the timing of our potential receipts of milestones and royalties under our out-licensing or royalty acquisition agreements. The disruptions to our licensees or RPA counterparties or their licensees could include, without limitation:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays or difficulties in recruiting and enrolling new patients in their clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays or difficulties in clinical site initiation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as their clinical trial sites and hospital staff supporting the conduct of their clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">interruption of key clinical trial activities, such as clinical trial site monitoring;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">limitations in employee resources that would otherwise be focused on the conduct of their clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">interruption in global shipping that may affect the transport of clinical trial supplies and materials;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential refusal by the FDA to accept data, including from clinical trials in affected geographies or failure to comply with updated FDA guidance and expectations related to the conduct of clinical trials during the COVID-19 pandemic; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in receiving approval from the FDA, the EMA and other U.S. and foreign federal, state and local regulatory authorities to initiate their planned clinical trials or to market their products.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to our Industry</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Biopharmaceutical products are subject to sales risks. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Biopharmaceutical product sales may be lower than expected due to a number of reasons, including pricing pressures, insufficient demand, product competition, failure of clinical trials, lack of market acceptance, obsolescence, loss of patent protection, government regulations or other factors, and development-stage product candidates may fail to reach the market. Unexpected side effects, safety or efficacy concerns can arise with respect to a product, leading to product recalls, withdrawals, declining sales or litigation. As a result, payments of our future potential milestones and/or royalties may be reduced or cease. In addition, these potential payments may be delayed, causing our near-term financial performance to be weaker than expected. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Biopharmaceutical products are subject to substantial competition. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The biopharmaceutical industry is a highly competitive and rapidly evolving industry. The length of any product&#8217;s commercial life cannot be predicted with certainty. There can be no assurance that one or more products on which we are entitled to a potential milestone or royalty will not be rendered obsolete or non-competitive by new products or improvements on which we are not entitled to a potential milestone or royalty, either by the current marketer of such products or by another marketer. Current marketers of products may undertake these development efforts in order to improve their products or to avoid paying our royalty. Adverse competition, obsolescence or governmental and regulatory action or healthcare policy changes could significantly affect the revenues, including royalty-related revenues, of the products which generate our potential milestones and royalties. </p><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">Competitive factors affecting the market position and success of each product include:</span>&#160;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">effectiveness; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">safety and side effect profile; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">price, including third-party insurance reimbursement policies; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">timing and introduction of the product; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">effectiveness of marketing strategy and execution; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">governmental regulation; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">availability of lower-cost generics and/or biosimilars; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">treatment innovations that eliminate or minimize the need for a product; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product liability claims.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Biopharmaceutical products that have the potential to generate future milestones and royalties for us may be rendered obsolete or non-competitive by new products, including generics and/or biosimilars, improvements on existing products or governmental or regulatory action. In addition, as biopharmaceutical companies increasingly devote significant </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">resources to innovate next-generation products and therapies using gene editing and new curative modalities, such as cell and gene therapy, products on which we have a milestone or royalty rights may become obsolete. These developments could have a material adverse effect on the sales of the biopharmaceutical products that have potential to generate our milestones and royalties, and consequently could materially adversely affect our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We depend on our licensees and royalty-agreement counterparties for the determination of royalty and milestone payments. While we typically have primary or back-up rights to audit our licensees and royalty-agreement counterparties, the independent auditors may have difficulty determining the correct royalty calculation, we may not be able to detect errors and payment calculations may call for retroactive adjustments. We may have to exercise legal remedies, if available, to resolve any disputes resulting from any such audit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The royalty, milestone and other payments we may receive are dependent on our licensees and royalty agreement counterparties and their licensees&#8217; achievement of regulatory and developmental milestones and product sales. Each licensee&#8217;s calculation of the royalty payments is subject to and dependent upon the adequacy and accuracy of its sales and accounting functions, and errors may occur from time to time in the calculations made by a licensee and/or a licensee may fail to report the achievement of royalties or milestones in whole or in part. Our license and royalty agreements typically provide us the primary or back-up right to audit the calculations and sales data for the associated royalty payments; however, such audits may occur many&#160;months following our recognition of the royalty revenue, may require us to adjust our royalty revenues in later periods and may require expense on our part. Further, our licensees and royalty-agreement counterparties may be uncooperative or have insufficient records, which may complicate and delay the audit process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Although we intend to regularly exercise our royalty audit rights as necessary and to the extent available, we rely in the first instance on our licensees and royalty-agreement counterparties to accurately report the achievement of milestones and royalty sales and calculate and pay applicable milestones and royalties and, upon exercise of such royalty and other audit rights, we rely on licensees&#8217; and royalty-agreement counterparties&#8217; cooperation in performing such audits. In the absence of such cooperation, we may be forced to incur expenses to exercise legal remedies, if available, to enforce our agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The lack of liquidity of our acquisitions of future potential milestones and royalties may adversely affect our business and, if we need to sell any of our acquired assets, we may not be able to do so at a favorable price, if at all. As a result, we may suffer losses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We generally acquire milestone and royalty rights that have limited secondary resale markets and may be subject to transfer restrictions. The illiquidity of most of our milestone and royalty receivable assets may make it difficult for us to dispose of them at a favorable price if at all and, as a result, we may suffer losses if we are required to dispose of any or all such assets in a forced liquidation or otherwise. In addition, if we liquidate all or a portion of our potential future milestone and/or purchased royalty stream interests quickly or relating to a forced liquidation, we may realize significantly less than the value at which we had previously recorded these interests.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our royalty aggregator strategy may require that we register with the SEC as an &#8220;investment company&#8221; in accordance with the Investment Company Act of 1940.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The rules&#160;and interpretations of the SEC and the courts, relating to the definition of &quot;investment company&quot; are very complex. While we currently intend to conduct our operations so that we will not be an investment company under applicable SEC interpretations, we can provide no assurance that the SEC would not take the position that the Company would be required to register under the &#8216;40 Act and comply with the &#8216;40 Act&#8217;s registration and reporting requirements, capital structure requirements, affiliate transaction restrictions, conflict of interest rules, requirements for disinterested directors, and other substantive provisions. We monitor our assets and income for compliance under the &#8216;40 Act and seek to conduct our business activities to ensure that we do not fall within its definitions of &#8220;investment company&#8221; or that we qualify under one of the exemptions or exclusions provided by the &#8216;40 Act and corresponding SEC regulations. If we were to become an &#8220;investment company&#8221; and be subject to the restrictions of the &#8216;40 Act, those restrictions likely would require significant changes in the way we do business and add significant administrative costs and burdens to our operations. To ensure we do not fall within the &#8216;40 Act, we may need to take various actions which we might otherwise not pursue. These </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">actions may include restructuring the Company and/or modifying our mixture of assets and income or a liquidation of certain of our assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our licensees or royalty-agreement counterparties or their licensees could be subject to natural disasters, public health crises, political crises and other catastrophic events that could hinder or disrupt development efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We depend on our licensees and royalty-agreement counterparties and their licensees to successfully develop and commercialize product candidates for which we may receive milestone, royalty and other payments in the future. Our licensees and royalty-agreement counterparties and their licensees operate research and development efforts in various locations in the United States and internationally. If any of their facilities is affected by natural disasters, such as earthquakes, tsunamis, power shortages or outages, floods or monsoons, public health crises, such as pandemics and epidemics, political crises, such as terrorism, war, political instability, labor disputes or strikes, other conflict, or other events outside of their control, their research and development efforts could be disrupted, which could result in the delay or discontinuation of development of one or more of the product candidates in which we have rights to future milestone and/or royalty payments which could have a material adverse effect on our business, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Because many of the companies with which we do business also are in the biotechnology sector, the volatility of that sector can affect us indirectly as well as directly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The same factors that affect us directly also can adversely affect us indirectly by affecting the ability of our partners and others with whom we do business to meet their obligations to us and reduce our ability to realize the value of the consideration provided to us by these other companies in connection with their licensing of our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to our Financial Results and Capital Requirements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We have sustained losses in the past, and we expect to sustain losses in the foreseeable future. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have incurred significant operating losses and negative cash flows from operations since our inception. We generated net losses of $5.4 million and $15.2 million for the three and six months ended June 30, 2023, negative cash flows from operations of $12.1 million for the six months ended June 30, 2023, and we had an accumulated deficit of $1.2 billion as of June 30, 2023. We do not know whether we will ever achieve sustained profitability or whether cash flow from future operations will be sufficient to meet our needs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To date, we have financed our operations primarily through the sale of equity securities and debt and royalty interests, and payments received under our collaboration and licensing arrangements. The size of our future net losses will depend, in part, on the rate of our future expenditures and our and our partners&#8217; ability to generate revenues. If our partners&#8217; product candidates are not successfully developed or commercialized, or if revenues are insufficient following regulatory approval, we will not achieve profitability and our business may fail. Our ability to achieve profitability is dependent in large part on the success of our and our partners&#8217; ability to license product candidates, and the success of our partners&#8217; development programs, both of which are uncertain. Our success is also dependent on our partners obtaining regulatory approval to market product candidates which may not materialize or prove to be successful. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Unstable market and global economic conditions, including adverse developments affecting the financial services industry, such as actual events or concerns involving liquidity, defaults or non-performance by financial institutions or transactional counterparties, may have adverse consequences on our business, financial condition and stock price.*</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">The global credit and financial markets have experienced volatility, including as a result of the COVID-19 pandemic, changes in interest rates, and economic inflation, which has included diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, high inflation, uncertainty about economic stability and changes in unemployment rates. The financial markets and the global economy may also be adversely affected by the current or anticipated impact of military conflict, acts of terrorism or other geopolitical events. Sanctions imposed by the United States and other countries in response to such conflicts, including the one in Ukraine, may also continue to adversely impact the financial markets and the global economy, and any economic countermeasures by the affected countries or others could heighten market and economic instability. There can be no assurance that further deterioration in credit and </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">financial markets and confidence in economic conditions will not occur. Our royalty aggregator strategy may be adversely affected by any such economic downturn, volatile business environment or continued unpredictable and unstable market conditions. Failure to secure any necessary financing in a timely manner could have a material adverse effect on our growth strategy, financial performance and stock price. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">In addition, actual events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems. For example, on March 10, 2023, Silicon Valley Bank was closed by the California Department of Financial Protection and Innovation, which appointed the FDIC, as receiver. Similarly, on March 12, 2023, Signature Bank and Silvergate Capital Corp. were each swept into receivership. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;">Although we assess our banking relationships as we believe necessary or appropriate, our access to funding sources in amounts adequate to finance or capitalize our current and projected future business operations could be significantly impaired by factors that affect us, the financial institutions with which we have arrangements directly, or the financial services industry or economy in general. These factors could involve financial institutions or financial services industry companies with which we have financial or business relationships, but could also include factors involving financial markets or the financial services industry generally.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our royalty aggregator strategy may require us to raise additional funds to acquire<span style="font-style:normal;font-weight:normal;"> </span>milestone and royalty interests; we cannot be certain that funds will be available or available at an acceptable cost of capital, and if they are not available, we may be unsuccessful in acquiring milestone and royalty interests to sustain the business in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may need to commit substantial funds to continue our business, and we may not be able to obtain sufficient funds on acceptable terms, if at all. If the current equity and credit markets deteriorate, it may make any additional debt or equity financing more difficult and more costly. Any additional debt financing or additional equity that we raise may contain terms that are not favorable to us and/or result in dilution to our stockholders, including pursuant to our 2018 Common Stock ATM Agreement, as amended and to our 2021 Series B Preferred Stock ATM Agreement. If we raise additional funds through licensing arrangements with third parties, we may be required to relinquish some rights to our technologies or our product candidates, grant licenses on terms that are not favorable to us or enter into a license arrangement for a product candidate at an earlier stage of development or for a lesser amount than we might otherwise choose.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If adequate funds are not available on a timely basis, we may:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reduce or eliminate royalty aggregation efforts; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">further reduce our capital or operating expenditures;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">curtail our spending on protecting our intellectual property; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">take other actions which may adversely affect our financial condition or results of operations.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Changes in the potential royalty acquisition market, including its structure and participants, or a reduction in the growth of the biopharmaceutical industry, could lead to diminished opportunities for us to acquire potential milestones and royalties, fewer potential milestones and royalties (or potential milestones or royalties of significant scale) being available, or increased competition for potential royalties. Even if we continue to acquire potential royalties and they become actual royalties, they may not generate a meaningful return for a period of several years, if at all, due to the price we pay for such royalties or other factors relating to the underlying products. As a result, we may not be able to continue to acquire potential milestones and royalties as we have in the past, or at all.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have a continuing obligation to pay quarterly dividends to holders of our Series A Preferred Stock and Series B Preferred Stock, which will be an on-going expenditure for us and may limit our ability to borrow additional funds.</span><span style="font-style:italic;font-weight:bold;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Holders of our Series A Preferred Stock are entitled to receive, when and as declared by our Board of Directors, out of funds legally available for the payment of dividends, cumulative cash dividends at the rate of 8.625% of the $25.00 liquidation preference per year (equivalent to $2.15625 per year). Dividends on the Series A Preferred Stock will accumulate and be cumulative from, and including, the date of original issue by us of the Series A Preferred Stock. Dividends will be payable in arrears on or about the 15th day of January, April, July and October. In the event of any voluntary or involuntary liquidation, dissolution or winding up of our affairs, the holders of shares of Series A Preferred Stock are entitled to be paid out of our assets legally available for distribution to our stockholders a liquidation preference of $25.00 per share, plus an amount equal to any accumulated and unpaid dividends up to the date of payment (whether or not declared), before any distribution or payment may be made to holders of shares of common stock or any other class or series of our equity stock ranking, as to liquidation rights, junior to the Series A Preferred Stock. The shares of Series A Preferred Stock are redeemable at our option, in whole or in part, at redemption prices ranging from $26.00 per share to $25.00 per share, plus any accrued and unpaid dividends, depending on the date of redemption. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Holders of depositary shares representing interests in our Series B Preferred Stock are entitled to receive, when and as declared by our Board of Directors, out of funds legally available for the payment of dividends, cumulative cash dividends at the rate of 8.375% of the $25,000 liquidation preference per share of Series B Preferred Stock ($25.00 per depositary share) per year (equivalent to $2,093.75 per year per share or $2.09375 per year per depositary share). Dividends on the Series B Preferred Stock will accumulate and be cumulative from, and including, the date of original issue by us of the Series B Preferred Stock. Dividends are payable in arrears on or about the 15th day of January, April, July and October. The shares of Series B Preferred Stock are redeemable at our option, in whole or in part, at redemption prices ranging from $26,000.00 per share ($26.00 per depositary share) to $25,000.00 per share ($25.00 per depositary share), plus any accrued and unpaid dividends, depending on the date of redemption. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The payment of cash dividends and share repurchases is subject to limitations under applicable laws and the discretion of our Board of Directors and is determined after considering current conditions, including earnings, other operating results and capital requirements. Decreases in asset values or increases in liabilities can reduce net earnings and stockholders&#8217; equity. A deficit in stockholders&#8217; equity could limit our ability to pay dividends and make share repurchases under Delaware law. On the other hand, our continued obligation to pay dividends to the holders of our Series A Preferred Stock and depositary shares representing interests in Series B Preferred Stock could restrict us from additional borrowings or make them more costly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The holders of preferred stock have rights that are senior to those of our common stockholders.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of June 30, 2023, we had issued and outstanding 984,000 shares of Series A Preferred Stock with a liquidation preference of $25.00 per share, plus an amount equal to any accumulated and unpaid dividends up to the date of payment (whether or not declared). Additionally, as of June 30, 2023, we had issued and outstanding 1,600,000 depositary shares, each representing a 1/1000th fractional interest in a share of our Series B Preferred Stock with a liquidation preference of $25,000 per share of Series B Preferred Stock ($25.00 per depositary share), plus an amount equal to any accumulated and unpaid dividends up to the date of payment (whether or not declared). Our preferred stock is senior to our shares of common stock in right of payment of dividends and other distributions. In the event of our bankruptcy, dissolution or liquidation, the holders of our preferred stock must be satisfied before any distributions can be made to our common stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Information available to us about the biopharmaceutical products underlying the potential royalties we buy may be limited and therefore our ability to analyze each product and its potential future cash flow may be similarly limited. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We may have limited information concerning the products generating the future potential milestones and royalties we are evaluating for acquisition. Often following our acquisition, the information we have regarding products underlying a potential milestone or royalty may be limited to the information that is available in the public domain. Therefore, there may be material information that relates to such products that we would like to know but do not have and may not be able to obtain. For example, we do not always know the results of studies conducted by sponsors of the products of others or </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">the nature or number of any complaints from doctors or users of such products. In addition, the market data that we obtain independently may also prove to be incomplete or incorrect. Due to these and other factors, the actual potential cash flow from a potential royalty may be significantly lower than our estimates. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our future income is dependent upon numerous potential milestone and royalty-specific assumptions and, if these assumptions prove not to be accurate, we may not achieve our expected rates of returns.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our business model is based on multiple-year internal and external forecasts regarding potential product sales and numerous product-specific assumptions in connection with each potential milestone and royalty acquisition, including where we have limited information regarding the product. There can be no assurance that the assumptions underlying our financial models, including those regarding potential product sales or competition, patent expirations or license terminations for the products underlying our portfolio, are accurate. These assumptions involve a significant element of subjective judgment and may be and in the past have been adversely affected by post-acquisition changes in market conditions and other factors affecting the underlying product. Our assumptions regarding the financial stability or operational or marketing capabilities of the partner obligated to pay us potential royalties may also prove to be incorrect. Due to these and other factors, the assets in our current portfolio or future assets may not generate our projected returns or in the time periods we expect. This could negatively impact our results of operation for a given period. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Reductions or declines in income from potential milestones and royalties, or significant reductions in potential milestone or royalty payments compared to expectations, or impairments in the value of potential milestones and royalties acquired could have a material adverse effect on our financial condition and results of operation. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The amount and duration of a royalty usually varies on a country-by-country basis and can be based on a number of factors, such as payments to third party licensors, whether the product is sold singly or in combination, patent expiration dates, regulatory exclusivity, years from first commercial sale of the applicable drug product, the entry of competing generic or biosimilar products, or other terms set out in the contracts governing the royalty. It is common for royalty durations to expire earlier or later than anticipated due to unforeseen positive or negative developments over time, including with respect to the granting of patents and patent term extensions, the invalidation of patents, claims of patent misuse, litigation between the party controlling the patents and third party challengers of the patents, the ability of third parties to design around or circumvent valid patents, the granting of regulatory exclusivity periods or extensions, timing of the arrival of generic or biosimilar competitor products, changes to legal or regulatory regimes affecting intellectual property rights or the regulation of pharmaceutical products, product life cycles, and industry consolidations. If an unexpected reduction in a royalty amount or shortening of a potential royalty term were to occur, it could result in a reduction in potential income from milestones and royalties, a significant reduction in potential milestones and royalty payments compared to expectations, or a permanent impairment of such potential milestones and royalty payments. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">A large percentage of the calculated net present value of our portfolio is represented by a limited number of products. The failure of any one of these products to move forward in clinical development or commercialization may have a material adverse effect on our financial condition and results of operation. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our asset portfolio may not be fully diversified by product, therapeutic area, geographic region or other criteria. Any significant deterioration in the amount or likelihood of receipt of potential cash flows from the top products in our asset portfolio could have a material adverse effect on our business, financial condition and results of operation. For example, in September 2021, Novartis announced its decision to discontinue its study of CFZ533 (iscalimab) in kidney transplant. In September 2022, after an interim analysis of data, Novartis also decided to discontinue its study of CFZ533 in liver transplant, and in<span style="background:#ffffff;"> July 2023, Novartis announced that it is discontinuing its Phase 3 trial investigating NIS793 in first-line metastatic pancreatic ductal adenocarcinoma. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, should the payor of any future potential milestones or royalties decline to pay such potential milestones and royalties for any reason, such failure may result in a material adverse effect on our financial condition and results of operation.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Milestone and Royalty Streams</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may not be able to successfully identify and acquire potential milestone and royalty streams on other products, product candidates, or programs, or other companies to grow and diversify our business, and, even if we are able to do so, we may not be able to successfully manage the risks associated with integrating any such products, product candidates, programs or companies into our business or we may otherwise fail to realize the anticipated benefits of these acquisitions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To grow and diversify our business, we plan to continue our business development efforts to identify and seek to acquire and/or in-license potential milestone and royalty streams or companies. Future growth through acquisition or in-licensing will depend upon the availability of suitable products, product candidates, programs or companies for acquisition or in-licensing on acceptable prices, terms and conditions. Even if appropriate opportunities are available, we may not be able to acquire rights to them on acceptable terms, or at all. The competition to acquire or in-license rights to promising products, product candidates, programs and companies is fierce, and many of our competitors are large, multinational pharmaceutical and biotechnology companies with considerably more financial, development and commercialization resources, personnel, and experience than we have. In order to compete successfully in the current business climate, we may have to pay higher prices for assets than may have been paid historically, which may make it more difficult for us to realize an adequate return on any acquisition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Even if we are able to successfully identify and acquire or in-license new products, product candidates, programs or companies, we may not be able to successfully manage the risks associated with integrating any products, product candidates, programs or companies into our business or the risks arising from anticipated and unanticipated problems in connection with an acquisition or in-licensing. Further, while we seek to mitigate risks and liabilities of potential acquisitions through, among other things, due diligence, indemnification and risk allocation, there may be risks and liabilities that such due diligence efforts fail to discover, that are not disclosed to us, or that we inadequately assess. Any failure in identifying and managing these risks and uncertainties effectively would have a material adverse effect on our business. In any event, we may not be able to realize the anticipated benefits of any acquisition or in-licensing for a variety of reasons, including the possibility that a product candidate fails to advance to clinical development, proves not to be safe or effective in clinical trials, or that a product fails to reach its forecasted commercial potential or that the integration of a product, product candidate, program or company gives rise to unforeseen difficulties and expenditures. Any failure in identifying and managing these risks and uncertainties would have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;"> If our potential royalty providers&#8217; therapeutic product candidates do not receive regulatory approval, our potential royalty providers will be unable to market them.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our potential royalty providers&#8217; product candidates cannot be manufactured and marketed in the United States or any other countries without required regulatory approvals. The U.S. government and governments of other countries extensively regulate many aspects of our partners&#8217; product candidates, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical development and testing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">labeling;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">storage;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">record keeping;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">promotion and marketing; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">importing and exporting.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the United States, the FDA regulates pharmaceutical products under the Federal Food, Drug, and Cosmetic Act and other laws, including, in the case of biologics, the Public Health Service Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Initiation of clinical trials requires approval by health authorities. Clinical trials involve the administration of the investigational new drug to healthy volunteers or to patients under the supervision of a qualified principal investigator. Clinical trials must be conducted in accordance with FDA and International Conference on Harmonization Good Clinical Practices and the European Clinical Trials Directive, as applicable, under protocols that detail the objectives of the study, the parameters to be used to monitor safety and the efficacy criteria to be evaluated. Other national, foreign and local regulations also may apply. The developer of the drug must provide information relating to the characterization and controls of the product before administration to the patients participating in the clinical trials. This requires developing approved assays of the product to test before administration to the patient and during the conduct of the trial. In addition, developers of pharmaceutical products must provide periodic data regarding clinical trials to the FDA and other health authorities, and these health authorities may issue a clinical hold upon a trial if they do not believe, or cannot confirm, that the trial can be conducted without unreasonable risk to the trial participants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The results of the preclinical studies and clinical testing, together with chemistry, manufacturing and controls information, are submitted to the FDA and other health authorities in the form of a NDA for a drug, and in the form of a BLA for a biological product, requesting approval to commence commercial sales. In responding to an NDA or BLA, the FDA or foreign health authorities may grant marketing approvals, request additional information or further research, or deny the application if they determine the application does not satisfy regulatory approval criteria. Regulatory approval of an NDA, BLA, or supplement is never guaranteed. The approval process can take several&#160;years, is extremely expensive and can vary substantially based upon the type, complexity, and novelty of the products involved, as well as the target indications. Our potential royalty providers ultimately may not be able to obtain approval in a timely fashion or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA and foreign health authorities have substantial discretion in the drug and biologics approval processes. Despite the time and expense incurred, failure can occur at any stage, and our potential development partners could encounter problems that cause abandonment of clinical trials or cause them to repeat or perform additional preclinical, clinical or manufacturing-related studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Changes in the regulatory approval policy during the development period, changes in, or the enactment of additional regulations or statutes, or changes in regulatory review for a submitted product application may cause delays in the approval or rejection of an application.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA and other regulatory agencies have substantial discretion in both the product approval process and manufacturing facility approval process, and as a result of this discretion and uncertainties about outcomes of testing, we cannot predict at what point, or whether, the FDA or other regulatory agencies will be satisfied with our licensees&#8217; submissions or whether the FDA or other regulatory agencies will raise questions that may be material and delay or preclude product approval or manufacturing facility approval. In light of this discretion and the complexities of the scientific, medical and regulatory environment, our or our potential royalty providers&#8217; interpretation or understanding of the FDA&#8217;s or other regulatory agencies&#8217; requirements, guidelines or expectations may prove incorrect, which also could delay further or increase the cost of the approval process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our potential milestone and royalty providers face uncertain results of clinical trials of product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Drug development has inherent risk, and our potential milestone and royalty providers are required to demonstrate through adequate and well-controlled clinical trials that product candidates are effective, with a favorable benefit-risk profile for use in their target profiles before they can seek regulatory approvals for commercial use. It is possible our potential royalty providers may never receive regulatory approval for any licensed product candidates. Even if a product candidate receives regulatory approval, the resulting product may not gain market acceptance among physicians, patients, healthcare payors and the medical community.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Our potential milestone and royalty providers&#8217; product candidates require significant additional research and development, extensive preclinical studies and clinical trials and regulatory approval prior to any commercial sales. This process is lengthy and expensive, often taking a number of&#160;years. As clinical results frequently are susceptible to varying </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">interpretations that may delay, limit or prevent regulatory approvals, the length of time necessary to complete clinical trials and to submit an application for marketing approval for a final decision by a regulatory authority varies significantly. As a result, it is uncertain whether:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our potential milestone and royalty providers&#8217; future filings will be delayed;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our potential milestone and royalty providers&#8217; preclinical studies will be successful;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our potential milestone and royalty providers will be successful in generating viable product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we will be successful in finding collaboration and licensing partners to advance our product candidates on our behalf;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our potential milestone and royalty providers will be able to provide necessary data;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">results of future clinical trials by our potential milestone and royalty providers will justify further development; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our potential milestone and royalty providers ultimately will achieve regulatory approval for product candidates in which we have an interest.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The timing of the commencement, continuation and completion of clinical trials by our potential milestone and royalty providers may be subject to significant delays relating to various causes, including failure to complete preclinical testing and earlier-stage clinical trials in a timely manner, inability to engage contract research organizations and other service providers, scheduling conflicts with participating clinicians and clinical institutions, changes in key personnel at clinical institutions, difficulties in identifying and enrolling patients who meet trial eligibility criteria and shortages of available drug supply. In addition, since we and our royalty agreement counterparties license our product candidates to others to fund and conduct clinical trials, we, and they, have limited control over how quickly and efficiently such licensees advance those trials. Patient enrollment is a function of many factors, including the size of the patient population, the proximity of patients to clinical sites, the concentration of patients in specialist centers, the eligibility criteria for the trial, the existence of competing clinical trials and the availability of alternative or new treatments. Regardless of the initial size or relative complexity of a clinical trial, the costs of such trial may be higher than expected due to increases in duration or size of the trial, changes in the protocol under which the trial is being conducted, additional or special requirements of one or more of the healthcare centers where the trial is being conducted, or changes in the regulatory requirements applicable to the trial or in the standards or guidelines for approval of the product candidate being tested or for other unforeseen reasons.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, our potential milestone and royalty providers may conduct clinical trials in foreign countries, which may subject them to further delays and expenses as a result of increased drug shipment costs, additional regulatory requirements and the engagement of foreign clinical research organizations, and may expose our potential milestone and royalty providers to risks associated with foreign currency transactions to make contract payments denominated in the foreign currency where the trial is being conducted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">New products and technologies of other companies may render some or all of our potential milestone and royalty providers&#8217; product candidates noncompetitive or obsolete.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">New developments by others may render our potential milestone and royalty providers&#8217; product candidates or technologies obsolete or uncompetitive. Technologies developed and utilized by the biotechnology and pharmaceutical industries are changing continuously and substantially. Competition in antibody-based technologies is intense and is expected to increase in the future as a number of established biotechnology firms and large chemical and pharmaceutical companies advance in these fields. In addition, as biopharmaceutical companies increasingly devote significant resources to innovate next-generation products and therapies using gene editing and new curative modalities, such as cell and gene therapy, products on which we have a milestone or royalty rights may become obsolete. Many of these competitors may </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">be able to develop products and processes competitive with or superior to our potential milestone and royalty providers for many reasons, including that they may have:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">significantly greater financial resources;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">larger research and development staffs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">entered into arrangements with, or acquired, biotechnology companies to enhance their capabilities; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">extensive experience in preclinical testing and human clinical trials.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">These factors may enable others to develop products and processes competitive with or superior to our own or those of our potential milestone and royalty providers. In addition, a significant amount of research in biotechnology is being carried out in universities and other non-profit research organizations. These entities are becoming increasingly interested in the commercial value of their work and may become more aggressive in seeking patent protection and licensing arrangements. Furthermore, many companies and universities tend not to announce or disclose important discoveries or development programs until their patent position is secure or, for other reasons, later. As a result, we and our potential milestone and royalty providers may not be able to track development of competitive products, particularly at the early stages.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Positive developments in connection with a potentially competing product may have an adverse impact on our future potential for receiving revenue derived from development milestones and royalties. For example, if another product is perceived to have a competitive advantage, or another product&#8217;s failure is perceived to increase the likelihood that our licensed product will fail, our potential milestone and royalty providers may halt development of product candidates in which we have an interest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our potential royalty providers may be unable to price our products effectively or obtain coverage and adequate reimbursement for sales of their products, which would prevent our potential royalty providers&#8217; products from becoming profitable and negatively affect the royalties we may receive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If our potential royalty providers succeed in bringing our product candidates to the market, they may not be considered cost effective, and reimbursement to the patient may not be available or may not be sufficient to allow our potential royalty providers to sell the products on a competitive basis. In both the United States and elsewhere, sales of medical products and treatments are dependent, in part, on the availability of coverage and adequate reimbursement from third-party payors, such as government and private insurance plans. Significant uncertainty exists as to the coverage and reimbursement status of any products for which our potential royalty providers may obtain regulatory approval. Even if coverage is available, the associated reimbursement rate may not be adequate for our potential royalty providers to cover related marketing costs. Additionally, coverage and reimbursement policies for drug products can differ significantly from payor to payor as there is no uniform policy of coverage and reimbursement for drug products among third-party payors in the United States. Therefore, the process of obtaining coverage and reimbursement is often time-consuming and costly. Thus, even if our partners&#8217; product candidates are approved by the FDA, our royalty partners may not be able to price the products effectively or obtain coverage and adequate reimbursement for their products, which could adversely affect the royalties we receive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Third-party payors are increasingly challenging the prices charged for pharmaceutical products and services. Our business is affected by the efforts of government and third-party payors to contain or reduce the cost of healthcare through various means. In the United States, there have been and will continue to be a number of federal and state proposals to implement government controls on pricing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, the emphasis on managed care in the United States has increased and will continue to increase the pressure on the pricing of pharmaceutical products. We cannot predict whether any legislative or regulatory proposals will be adopted or the effect these proposals or managed care efforts may have on our or our potential milestone and royalty providers&#8217; businesses.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We do not know whether there will be, or will continue to be, a viable market for the product candidates in which we have an ownership or royalty interest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Even if product candidates in which we have an interest receive approval in the future, they may not be accepted in the marketplace. In addition, our potential royalty providers may experience difficulties in launching new products, many of which are novel and based on technologies that are unfamiliar to the healthcare community. We have no assurance healthcare providers and patients will accept such products, if developed. Similarly, physicians may not accept a product if they believe other products to be more effective or more cost effective or are more comfortable prescribing other products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Furthermore, government agencies, as well as private organizations involved in healthcare, from time to time publish guidelines or recommendations to healthcare providers and patients. Such guidelines or recommendations can be very influential and may adversely affect product usage directly (for example, by recommending a decreased dosage of a product in conjunction with a concomitant therapy) or indirectly (for example, by recommending a competitive product over a product in which we have an ownership or royalty interest). Consequently, we do not know if physicians or patients will adopt or use products in which we have an ownership or royalty interest for their approved indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Even approved and marketed products are subject to risks relating to changes in the market for such products. Introduction or increased availability of generic or biosimilar versions of products can alter the market acceptance of branded products. In addition, unforeseen safety issues may arise at any time, regardless of the length of time a product has been on the market which may lead to litigation, increased costs and delays or removal of the product from the market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We are exposed to an increased risk of product liability claims.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The testing, marketing and sales of medical products entails an inherent risk of allegations of product liability. In the event of one or more large, unforeseen awards of damages against us, our product liability insurance may not provide adequate coverage. A significant product liability claim for which we were not adequately covered by insurance or indemnified by a third party would have to be paid from cash or other assets, which could have an adverse effect on our business, financial condition and the value of our common stock. To the extent we have sufficient insurance coverage, such a claim would presumably result in higher subsequent insurance rates. In addition, product liability claims can have various other ramifications, regardless of merit or eventual outcome, including loss of future sales opportunities, discontinuation of clinical trials, increased costs associated with replacing products, a negative impact on our goodwill and reputation, costs to defend litigation, and divert our management&#8217;s attention from our business, each of which could also adversely affect our business and operating results. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we and our potential royalty providers are unable to protect our intellectual property, in particular patent protection for principal products, product candidates and processes in which we have an ownership or royalty interest, and prevent the use of the covered subject matter by third parties, our potential royalty providers&#8217; ability to compete in the market will be harmed, and we may not realize our profit potential.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We and our potential royalty providers rely on patent protection, as well as a combination of copyright, trade secret, and trademark laws to protect our proprietary technology and prevent others from duplicating our products or product candidates. However, these means may afford only limited protection and may not:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">prevent our competitors from duplicating our products and those of our potential royalty providers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">prevent our competitors from gaining access to our proprietary information and technology and that of our potential royalty providers; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">permit us or our potential royalty providers to gain or maintain a competitive advantage.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Because of the length of time and the expense associated with bringing new products to the marketplace, we and our potential royalty providers hold and are in the process of applying for a number of patents in the United States and abroad to protect product candidates and important processes and also have obtained or have the right to obtain exclusive </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">licenses to certain patents and applications filed by others. However, the mere issuance of a patent is not conclusive as to its validity or its enforceability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The U.S. Federal Courts, the U.S. Patent&#160;&amp; Trademark Office or equivalent national courts or patent offices elsewhere may invalidate our patents or find them unenforceable. The America Invents Act introduced post-grant review procedures subjecting U.S. patents to post-grant review procedures similar to European oppositions. U.S. patents owned or licensed by us <span style="letter-spacing:-0.1pt;">or our licensees </span>may therefore be subject to post-grant review procedures, as well as other forms of review and re-examination. A decision in such proceedings adverse to our interests could result in the loss of valuable patent rights, which would have a material adverse effect on our business. In addition, the laws of foreign countries may not protect our intellectual property rights effectively or to the same extent as the laws of the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If our, and our potential royalty providers intellectual property rights are not protected adequately, our potential royalty providers may not be able to commercialize technologies or products in which we have an ownership or royalty interest, and their competitors could commercialize such technologies or products, which could result in a decrease in our potential royalty providers&#8217; sales and market share that would harm our business and operating results. Specifically, the patent position of biotechnology companies generally is highly uncertain and involves complex legal and factual questions. The legal standards governing the validity of biotechnology patents are in transition, and current defenses as to issued biotechnology patents may not be adequate or available in the future. Accordingly, there is uncertainty as to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">whether any pending or future patent applications held by us or our potential royalty providers will result in an issued patent, or whether issued patents will provide meaningful protection against competitors or competitive technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">whether competitors will be able to design around our or our potential royalty providers&#8217; patents or develop and obtain patent protection for technologies, designs or methods that are more effective than those covered by our or our potential royalty providers&#8217; patents and patent applications; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the extent to which our or our potential royalty providers&#8217; product candidates could infringe on the intellectual property rights of others, which may lead to costly litigation, result in the payment of substantial damages or royalties, reduce the royalty rate due to us, and prevent our potential royalty providers from using our technology or product candidates.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If certain patents issued to others are upheld or if certain patent applications filed by others are issued and upheld, our potential royalty providers may require licenses from others to develop and commercialize certain potential products in which we have an ownership or royalty interest. These licenses, if required, may not be available on acceptable terms, or may trigger contractual royalty offset clauses in our license agreements, or those of our royalty-agreement counterparties. We may become involved in litigation to determine the proprietary rights of others, and any such litigation will presumably be costly, time consuming, may not be adequately covered by insurance and may have other adverse effects on our business, such as inhibiting our potential royalty providers&#8217; ability to compete in the marketplace and absorbing significant management time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Due to the uncertainties regarding biotechnology patents, we also have relied and will continue to rely upon trade secrets, know-how and continuing technological advancement to develop and maintain our competitive position. Our employees and contractors are typically required to sign confidentiality agreements under which they agree not to use or disclose any of our proprietary information. Research and development contracts and relationships between us and our scientific consultants and potential licensees provide access to aspects of our know-how that are protected generally under confidentiality agreements. These confidentiality agreements may be breached or may not be enforced by a court. To the extent proprietary information is divulged to competitors or to the public generally, such disclosure may adversely affect our licensees&#8217; ability to develop or commercialize our products by giving others a competitive advantage or by undermining our patent position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In addition, periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and or applications will be due to the U.S. and various foreign patent offices at various points over the lifetime of our and our licensees&#8217; patents and/or applications. We have systems in place to remind us to pay these fees, and we rely on our </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">outside patent annuity service to pay these fees when due. Additionally, the U.S. and various foreign patent offices require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with rules applicable to the particular jurisdiction. However, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If such an event were to occur, it could have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">No assurance can be given that our, or our partners or licensees&#8217; patents will be extended upon expiration, which may have an effect on our financial condition and results of operation. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We hold and have filed applications for a number of patents in the United States and internationally to protect our products and technology and have the right to obtain licenses to, or income streams based on, certain patents and applications filed by others. However, the life of a patent, and thus the protection it affords, is limited. Significant patents in our portfolio will expire in the coming years and while various extensions may be available, on a&#160;jurisdiction-by-jurisdiction&#160;basis, continuous patent protection is not guaranteed. While we expect to seek, and expect our partners to seek, extensions of patent terms for issued patents where available and when necessary, failure to secure patent extensions may have an effect on our financial condition and results of operations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Litigation regarding intellectual property and/or the enforcement of our contractual rights against licensees and third parties can be costly and expose us to risks of counterclaims against us.*</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From time to time, we are required to engage in litigation, arbitration or other proceedings to protect our intellectual property and/or enforce our contractual rights against former or current licensees or third parties, including third-party collaborators of such licensees. The cost to us of complex proceedings of this type, even if resolved in our favor, can be substantial, and the parties opposing us in such proceedings may be able to sustain the cost of such proceedings more effectively than we can if they have substantially greater resources than we have. Any such proceedings and any negotiations leading up to them also may be time-consuming and can divert management&#8217;s attention and resources. If a proceeding of this type is resolved against us, we may lose the value associated with contract rights contained in our arrangements with licensees and third parties, the patents that are the subject of such proceeding may be declared invalid, we could be exposed to counterclaims against us, and we could be held liable for significant damages, fees and/or costs. While it is our current plan to continue to review and pursue, on a selective basis, potential material contractual breaches against licensees and third parties (including third-party collaborators of licensees) and/or infringement of our intellectual property rights or technology, there can be no assurance that any such enforcement actions will be successful, or if successful, the timing of such success or that we will have sufficient capital to prosecute any such actions to a successful conclusion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For example, in June 2021, we initiated a binding arbitration proceeding with one of our licensees (the &#8220;Licensee&#8221;) at the American Arbitration Association/International Centre for Dispute Resolution, seeking milestone and royalty payments under our license agreement. A hearing before a panel of arbitrators was held in November 2022, and the parties submitted post-hearing briefs. On March 21, 2023, we received an adverse decision in this arbitration proceeding. The panel of arbitrators declined to award us damages and ruled that the license agreement has expired. The panel ruled that we are responsible for the Licensee&#8217;s costs as well as arbitrators&#8217; and administrative fees previously incurred by the Licensee of $4.1 million, <span style="background:#ffffff;">which we paid in April 2023</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, we may be subject to claims that we, or our licensees, are infringing other parties&#8217; patents. If such claims are resolved against us, we or our licensees may be enjoined from developing, manufacturing, selling or importing products, processes or services unless we obtain a license from the other party. Such a license may not be available on reasonable terms or at all, thus preventing us, or our licensees, from using these products, processes or services and adversely affecting our potential future revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Uncertainties resulting from our participation in litigation, arbitration or other proceedings involving intellectual property and/or contractual rights could have a material adverse effect on our or our partners&#8217; ability to compete in the marketplace. There could also be public announcements of the results of hearings, motions or interim proceedings or </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">developments. If securities analysts or investors perceive these results to be negative, the perceived value of the drug product candidates as to which we hold potential milestone or royalty interests, or intellectual property or contractual rights could be diminished. Accordingly, the market price of our common stock may decline. Uncertainties resulting from the initiation and continuation of litigation, arbitration or other proceedings involving intellectual property and/or contractual rights could have a material adverse effect on our business, financial condition and results of operation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Reliance on Third Parties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We and our partners rely heavily on license and collaboration relationships, and any disputes or litigation with our partners or termination or breach of any of the related agreements could reduce the financial resources available to us, including our ability to receive milestone payments and future potential royalty and other revenues. License or collaboration agreements relating to products may, in some instances, be unilaterally terminated or disputes may arise which may affect our potential milestones, royalties and other payments.*</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">License or collaboration agreements relating to the products generating our future potential milestones and royalties and other payment rights may be terminated, which may adversely affect sales of such products and therefore the potential payments we may receive. For example, under certain license or collaboration agreements, marketers may retain the right to unilaterally terminate the agreements. When the last patent covering a product expires or is otherwise invalidated in a country, a marketer may be economically motivated to terminate the applicable license or collaboration agreement, either in whole or with respect to such country, in order to terminate its payment and other obligations. In the event of such a termination, a licensor (which may be us in the case of our out-licensed products) or collaborator may no longer receive all of the payments it expected to receive from the applicable licensee or collaborator and may also be unable to find another company to continue developing and commercializing the product on the same or similar terms as those under the license or collaboration agreement that has been terminated. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, license or collaboration agreements may fail to provide significant protection for the applicable licensor (which may be us in the case of our out-licensed products) or collaborator in case of the applicable licensee&#8217;s or collaborator&#8217;s failure to perform or in the event of disputes. License and collaboration agreements which relate to the products underlying our potential future milestones, royalties and other payment rights, are complex and certain provisions in such agreements may be susceptible to multiple interpretations. Disputes may arise regarding intellectual property, royalty terms, payment rights or other contractual terms subject to a license or collaboration agreement, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope or duration of rights granted under the license or collaboration agreement and other interpretative issues;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the amounts or timing of royalties, milestones or other payments due under the license or collaboration agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the sublicensing of patent or other rights under our license or collaboration relationships;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the diligence obligations under the license or collaboration </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">agreement and what activities satisfy such diligence obligations:</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by us or our partners; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the priority of invention of patented technology.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The resolution of any contract interpretation disagreement that may arise could narrow what the licensor (which may be us in the case of our out-licensed products) or collaborator believes to be the scope of its rights to the relevant intellectual property or technology, or decrease the licensee&#8217;s or collaborator&#8217;s financial or other obligations under the relevant agreement, any of which could in turn impact the value of our potential royalties, milestones and other payments and have a material adverse effect on our business, financial condition, results of operations and prospects. If a marketer </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">were to default on its obligations under a license or collaboration agreement, the licensor&#8217;s or collaborator&#8217;s remedy may be limited either to terminating certain licenses or collaborations related to certain countries or to generally terminate the license or collaboration agreement with respect to such country. In such cases, we may not have the right to seek to enforce the rights of the licensor or collaborator (if not us) and we may be required to rely on the resources and willingness of the licensor or collaborator (if not us) to enforce its rights against the applicable licensee or collaborator. In any of these situations, if the expected upfront, milestone, royalty or other payments under the license or collaboration agreements do not materialize, this could result in a significant loss to us and materially adversely affect our business, financial condition and results of operation. At any given time, the Company may be engaged in discussions with its licensees or collaborators regarding the interpretation of the payment and other provisions relating to products as to which we have milestones and potential royalty or other payment rights. Should any such discussions result in a disagreement regarding a particular product that cannot be resolved satisfactorily to us, we may end up being paid less than anticipated on such product should it successfully progress through clinical development and be approved for commercialization. Should our milestone and future potential royalty or other payment interests be reduced or eliminated as a result of any such disagreement, it could have an adverse effect on our business, financial condition, results of operation and prospects. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Our existing collaborations may not continue or be successful, and we may be unable to enter into future arrangements to develop and commercialize our unpartnered assets. For example, in June 2023, Bioasis announced the suspension of all its operations and the termination of the research collaboration and license agreement between Bioasis and Chiesi. As a result, we do not expect to receive any milestone, royalty or other payments under the Biosis RPA or Second Bioasis RPA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">Generally, our current collaborative partners have the right to terminate their collaborations at will or under specified circumstances. If any of our collaborative partners breach or terminate their agreements with us or otherwise fail to conduct their collaborative activities successfully (for example, by not making required payments when due, or at all or failing to engage in commercially reasonable efforts to develop products if required), our product development under these agreements will be delayed or terminated. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our potential milestone and royalty providers may rely on third parties to provide services in connection with their product candidate development and manufacturing programs. The inadequate performance by or loss of any of these service providers could affect our potential milestone and royalty providers&#8217; product candidate development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Third parties provide services in connection with preclinical and clinical development programs, including <i style="font-style:italic;">in vitro </i>and <i style="font-style:italic;">in vivo</i> studies, assay and reagent development, immunohistochemistry, toxicology, pharmacokinetics, clinical trial support, manufacturing and other outsourced activities. If these service providers do not adequately perform the services for which our potential milestone and royalty providers have contracted, or cease to continue operations, and our potential milestone and royalty partners are not able to find a replacement provider quickly or lose information or items associated with their drug product candidates, our potential milestone and royalty providers&#8217; development programs and receipt of any potential resulting income may be delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Agreements with other third parties, many of which are material to our business, expose us to numerous risks and have caused us to incur additional liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Because our licensees, suppliers and contractors are independent third parties, they may be subject to different risks than we are and have significant discretion in, and different criteria for, determining the efforts and resources they will apply related to their agreements with us. If these licensees, suppliers and contractors do not successfully perform the functions for which they are responsible, we may not have the capabilities, resources or rights to do so on our own.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We do not know whether we or our licensees will successfully develop and market any of the products that are or may become the subject of any of our licensing arrangements. In addition, third-party arrangements such as ours also increase uncertainties in the related decision-making processes and resulting progress under the arrangements, as we and our licensees may reach different conclusions, or support different paths forward, based on the same information, particularly when large amounts of technical data are involved.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, under the contracts with HCRP, the amortization for the reporting period is calculated based on the payments expected to be made by the licensees to HCRP over the term of the arrangement. Any changes to the estimated payments by the licensees to HCRP can result in a material adjustment to revenue previously reported.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Failure of our potential milestone and royalty providers&#8217; product candidates to meet current Good Manufacturing Practice standards may cause delays in regulatory approval and penalties for noncompliance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our potential milestone and royalty providers may rely on third party manufacturers and such contract manufacturers are required to produce clinical product candidates under cGMP to meet acceptable standards for use in clinical trials and for commercial sale, as applicable. If such standards change, the ability of contract manufacturers to produce our potential milestone and royalty providers&#8217; drug product candidates on the schedule required for clinical trials or to meet commercial requirements may be affected. In addition, contract manufacturers may not perform their obligations under their agreements with our potential milestone and royalty providers or may discontinue their business before the time required by us to successfully produce clinical and commercial supplies of our potential milestone and royalty providers&#8217; product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Contract manufacturers are subject to pre-approval inspections and periodic unannounced inspections by the FDA and corresponding state and foreign authorities to ensure strict compliance with cGMP and other applicable government regulations and corresponding foreign standards. We do not have control over a third-party manufacturer&#8217;s compliance with these regulations and standards. Any difficulties or delays in contractors&#8217; manufacturing and supply of our potential milestone and royalty providers&#8217; product candidates or any failure of our potential milestone and royalty providers&#8217; contractors to maintain compliance with the applicable regulations and standards could increase costs, reduce revenue, make our licensees postpone or cancel clinical trials, prevent or delay regulatory approval by the FDA and corresponding state and foreign authorities, prevent the import and/or export of our potential milestone and royalty providers&#8217; product candidates, or cause any of our potential milestone and royalty providers&#8217; products that may be approved for commercial sale to be recalled or withdrawn.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Certain of our technologies are in-licensed from third parties, so our and our licensees&#8217; use of them may be restricted and subject to additional risks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have licensed technologies from third parties. These technologies include phage display technologies licensed to us in connection with our bacterial cell expression technology licensing program and antibody products. However, our and our licensees and collaborators&#8217; use of these technologies is limited by certain contractual provisions in the licenses relating to them, and although we have obtained numerous licenses, intellectual property rights in the area of phage display are particularly complex. If we are unable to maintain our licenses, patents or other intellectual property, we could lose important protections that are material to continuing our operations and for future prospects. Our licensors also may seek to terminate our license, which could cause us and our licensees to lose the right to use the licensed intellectual property and adversely affect our and our licensees&#8217; ability to commercialize our technologies, products or services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Employees, Location, Data Integrity, and Litigation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The loss of or changes in any of our key personnel, could delay or prevent achieving our objectives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our business efforts could be adversely affected by the loss of one or more key members of our staff. We currently do not have key person insurance on any of our employees. In addition, given our minimal employee base, any pandemic outbreak in our employee population could significantly hinder our ability to meet our operating objectives. Changes in management may cause disruption in our business, strategic and employee relationships, which may delay or prevent the achievement of our business objectives. During the transition periods, there may be uncertainty among investors, employees and others concerning our future direction and performance. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Because we are a small biopharmaceutical focused company with limited resources, we may not be able to attract and retain qualified personnel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We had 11 full-time employees and one part-time employee as of August 3, 2023. We may require additional experienced executive, accounting, legal, administrative and other personnel from time to time in the future. We are highly dependent on principal members of our executive team, the loss of whose services may adversely impact the achievement of our objectives. There is intense competition for the services of these personnel, especially in California. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Moreover, we expect the high cost of living in the San Francisco Bay Area, where our headquarters is located, may impair our ability to attract and retain employees in the future. If we do not succeed in attracting new personnel and retaining and motivating existing personnel, our business may suffer, and we may be unable to implement our current initiatives or grow effectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We rely and will continue to rely on outsourcing arrangements for many of our activities, including financial reporting and accounting and human resources. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Due to our small number of employees, we rely, and expect to continue to rely, on outsourcing arrangements for a significant portion of our activities, including financial reporting and accounting and human resources, as well as for certain of our functions as a public company. We may have limited control over these third parties, and we cannot guarantee that they will perform their obligations in an effective and timely manner. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:14pt 0pt 12pt 0pt;">We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with applicable regulations, provide accurate information to regulatory authorities, comply with federal and state fraud and abuse laws and regulations, report financial information or data accurately or disclose unauthorized activities to us. In particular, the health care industry is subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our business and operations would suffer in the event of system failures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Despite the implementation of security measures, our internal computer systems and those of our current and any future licensees, suppliers, contractors and consultants are vulnerable to damage from cyberattacks, computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. We could experience failures in our information systems and computer servers, which could be the result of a cyberattacks and could result in an interruption of our normal business operations and require substantial expenditure of financial and administrative resources to remedy. System failures, accidents or security breaches can cause interruptions in our operations and can result in a material disruption of our development programs and other business operations. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">If our information technology systems or data or those of our partners or contractors are or were compromised by security incidents, our sensitive information could be exposed or stolen and we could experience adverse consequences, including regulatory investigations or actions; litigation; fines and penalties; a disruption of our business operations; reputational harm; loss of revenue or profits; and other adverse business consequences. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our business is increasingly dependent on critical, complex and interdependent information technology systems, including cloud-based systems, to support business processes as well as internal and external communications. Our computer systems, and those of our partners and contractors, are potentially vulnerable to breakdown, malicious intrusion and computer viruses that may result in the impairment of key business processes. Such disruptions and breaches of security could have a material adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the ordinary course of our business, we maintain sensitive data on our networks, including our intellectual property and proprietary or confidential business information relating to our business and that of our business partners. The secure maintenance and protection of this information is critical to our business and reputation. Threats to our systems and sensitive data can come from a variety of sources, ranging in sophistication from a person with authorized access to our network, to an individual hacker, to an organized threat actor organization, to a state-sponsored attack. Cyber threats also may be intentional or accidental. It is often difficult to anticipate or immediately detect cyber incidents and the damage caused by such incidents. Data breaches and any unauthorized access to our systems could compromise our intellectual property and expose sensitive business information. A data security breach could also lead to exposure of personal information of our employees, legacy clinical trial patients, vendors and others, which could expose us to liability under foreign, federal, or state privacy laws. Theft of proprietary information could be used to compete against us and could cause us to incur significant remediation costs, result in product development delays, disrupt key business operations and divert attention of management and key information technology resources. These incidents could also subject us to liability, expose us to significant expense and cause significant harm to our reputation and business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Authorities worldwide have been warning businesses of increased cybersecurity threats from actors seeking to exploit the COVID-19 pandemic. Moreover, failure to maintain effective internal accounting controls related to data security breaches and cybersecurity in general could impact our ability to produce timely and accurate financial statements and could subject us to regulatory scrutiny. In addition, these breaches and other inappropriate access can be difficult to detect, and any delay in identifying them may lead to increased harm of the type described above. Moreover, the prevalent use of mobile devices that access confidential information increases the risk of data security breaches, which could lead to the loss of confidential information, trade secrets or other intellectual property. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">While we have implemented security measures that are intended to protect our data security and information technology systems, such measures may not prevent all such cyber incidents. Further, we cannot be sure that our insurance coverage will be adequate or sufficient to protect us from or to mitigate liabilities arising out of our privacy and security practices, that such coverage will continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Compliance with stringent and changing obligations related to data privacy and security protection is a rigorous and time-intensive process. Our actual or perceived failure to comply with any privacy or data security obligations could lead to regulatory investigations or actions; litigation; fines and penalties; a disruption of our business operations; reputational harm; loss of revenue or profits; loss of customers or sales; and other adverse business consequences.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Many states, countries and jurisdictions strictly regulate data privacy and protection and may impose significant penalties for failure to comply with these requirements. For example, in the U.S., the CCPA became effective on January 1, 2020. The CCPA establishes a privacy framework for covered businesses, including an expansive definition of personal information and data privacy rights for California residents and the CPRA which became effective on January 1, 2023, which expands upon the CCPA. The CCPA and CPRA give California residents expanded privacy rights, including the right to request correction, access and deletion of their personal information, the right to opt out of certain personal information sharing, and the right to receive detailed information about how their information is processed. The CCPA and CPRA include a framework with potentially severe statutory damages and private rights of action and will likely impact our business activities, along with increasing our compliance costs and potential liability. If we fail to comply with </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">the CCPA and CPRA, we may face significant fines and penalties that could adversely affect our business, financial condition and results of operations. Other states are beginning to pass similar laws. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Compliance with laws and regulations concerning privacy, cybersecurity, data governance and data protection is a rigorous and time-intensive process, and we may be required to put in place additional mechanisms ensuring compliance with the laws and regulations and incur substantial expenditures. If we fail to comply with any such laws or regulations, we may face significant fines and penalties that could adversely affect our business, financial condition and results of operations. Further, data incidents experienced by us, our partners or collaborators could lead to significant fines, required corrective action, the loss of trade secrets or other intellectual property, public disclosure of sensitive clinical or commercial data, and the exposure of personally identifiable information (including sensitive personal information) of our employees, partners, and others. A data security breach or privacy violation that leads to disclosure or modification of, or prevents access to, patient information, including personally identifiable information or protected health information, could result in fines, increased costs or loss of revenue as a result of:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">harm to our reputation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fines imposed on us by regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">additional compliance obligations under federal, state or foreign laws;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">requirements for mandatory corrective action to be taken by us; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">requirements to verify the correctness of database contents and otherwise subject us to liability under laws and regulations that protect personal data.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, cyber incidents can be difficult to detect, and any delay in identifying them may lead to increased harm of the type described above. Moreover, the prevalent use of mobile devices that access confidential information increases the risk of data security breaches. While we have implemented security measures to protect our data security and information technology systems, such measures may not prevent such events. Lastly, we cannot guarantee that we are in compliance with all applicable data protection laws and regulations as they are enforced now or as they evolve. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Government Regulation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Even after FDA approval, a product may be subject to additional testing or significant marketing restrictions, its approval may be withdrawn, or it may be removed voluntarily from the market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Even if our potential royalty providers receive regulatory approval for our product candidates, they will be subject to ongoing regulatory oversight and review by the FDA and other regulatory entities. The FDA, the EMA, or another regulatory agency may impose, as a condition of the approval, ongoing requirements for post-approval studies or post-approval obligations, including additional research and development and clinical trials, and the FDA, EMA or other regulatory agency subsequently may withdraw approval based on these additional trials or obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Even for approved products, the FDA, EMA or other regulatory agency may impose significant restrictions on the indicated uses, conditions for use, labeling, advertising, promotion, marketing and production of such product. In addition, the labeling, packaging, adverse event reporting, storage, advertising, promotion and record-keeping for such products are subject to extensive regulatory requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Furthermore, marketing approval of a product may be withdrawn by the FDA, the EMA or another regulatory agency or such product may be withdrawn voluntarily by our potential royalty providers based, for example, on subsequently arising safety concerns. The FDA, EMA and other agencies also may impose various civil or criminal sanctions for failure to comply with regulatory requirements, including withdrawal of product approval.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Healthcare reform measures and other statutory or regulatory changes could adversely affect our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The United States and some foreign jurisdictions have enacted or are considering a number of legislative and regulatory proposals to change the healthcare system in ways that could affect our potential royalty providers&#8217; ability to sell products in which we have ownership or<span style="letter-spacing:-0.1pt;"> </span>and royalty interests, if approved, profitably. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively the ACA, was enacted, which, among other things, substantially changed the way healthcare is financed by both governmental and private payors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There have been judicial, Congressional and executive branch challenges to the ACA. As a result, there have been delays in the implementation of, and action taken to repeal or replace, certain aspects of the ACA. For example, on June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. In addition, there have been a number of health reform initiatives by the Biden administration that have impacted the ACA. On August 16, 2022, President Biden signed the Inflation Reduction Act of 2022, or the IRA, into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and through a newly established manufacturer discount program. It is possible that the ACA will be subject to judicial or Congressional challenges in the future. It is unclear how other such challenges, and the healthcare reform measures of the Biden administration will impact the ACA and our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Other legislative changes have also been proposed and adopted since the ACA was enacted. For example, the Budget Control Act of 2011 resulted in aggregate reductions in Medicare payments to providers of up to two percent per fiscal year, starting in 2013 and, due to subsequent legislative amendments to the statute, will remain in effect until 2032 unless additional Congressional action is taken. In addition, the American Taxpayer Relief Act of 2012, among other things, reduced Medicare payments to several types of providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. Such laws, and others that may affect our business that have been recently enacted or may in the future be enacted, may result in additional reductions in Medicare and other healthcare funding. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Also, there has been heightened governmental scrutiny recently in the U.S. over pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. For example, <span style="background:#ffffff;">in July 2021, the Biden administration released an executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to Biden&#8217;s executive order, on September 9, 2021, the Department of Health and Human Services, or HHS, released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue to advance these principles. In addition, the IRA, among other things, (i) directs the Secretary of HHS to negotiate the price of certain high-expenditure, single-source drugs and biologics covered under Medicare Part B and Medicare Part D, and subjects drug manufacturers to civil monetary penalties and a potential excise tax by offering a price that is not equal to or less than the negotiated &#8220;maximum fair price&#8221; under the law, and (ii) imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. The IRA permits HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. HHS has and will continue to issue and update guidance as these programs are implemented. These provisions will take effect progressively starting in fiscal year 2023, although the Medicare drug price negotiation program is currently subject to legal challenges. It is currently unclear how the IRA will be implemented but it is likely to have a significant impact on the pharmaceutical industry. Further, in response to the Biden administration&#8217;s October 2022 executive order, on February 14, 2023, HHS released a report outlining three new models for testing by the Center for Medicare and Medicaid Innovation which will be evaluated on their ability to lower the cost of drugs, promote accessibility, and improve quality of care. It is unclear whether the models will be utilized in any health reform measures </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">in the future. In addition, beginning in 2023, Centers for Medicare &amp; Medicaid Services, or CMS, will require manufacturers to refund CMS for certain discarded amounts of single-dose container and single-use package drugs. </span>At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, and restrictions on certain product access. In some cases, such legislation and regulations have been designed to encourage importation from other countries and bulk purchasing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">An expansion in the government&#8217;s role in the U.S. healthcare industry may cause general downward pressure on the prices of prescription drug products, lower reimbursements for providers, and reduced product utilization, any of which could adversely affect our business and results of operations. We expect that additional healthcare reform measures will be adopted in the future. We cannot know what form any such new legislation may take or the market&#8217;s perception of how such legislation would affect us. Any reduction in reimbursement from government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent our potential royalty providers from being able to generate revenue, attain profitability, develop, or commercialize our current product candidates in which we have an ownership or royalty interest. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We and our potential milestone and royalty providers are subject to various state and federal healthcare-related laws and regulations that if violated may impact the commercialization of our product candidates for which we possess milestone or royalty rights or could subject us to significant fines and penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our operations may be directly or indirectly subject to various state and federal healthcare laws, including the federal Anti-Kickback Statute, the federal False Claims Act and state and federal data privacy and security laws. These laws may impact, among other things, the commercial operations for any of our product candidates that may be approved for commercial sale.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The federal Anti-Kickback Statute prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, receiving or providing any remuneration, directly or indirectly, in cash or in kind, in exchange for or to induce either the referral of an individual for, or the furnishing or arranging for the purchase, lease, or order of a good or service for which payment may be made under a federal healthcare program, such as the Medicare and Medicaid programs. The ACA modified the federal Anti-Kickback Statute&#8217;s intent requirement so that a person or entity no longer needs to have actual knowledge of the statute or the specific intent to violate it to have committed a violation. In addition, several courts have interpreted the statute&#8217;s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal healthcare covered business, the statute has been violated. The Anti-Kickback Statute is broad and prohibits many arrangements and practices that are lawful in businesses outside of the healthcare industry. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The federal false claims laws, including the False Claims Act, and civil monetary penalties laws prohibit, among other things, persons and entities from knowingly filing, or causing to be filed, a false claim to, or the knowing use of false statements to obtain payment from the federal government. Certain suits filed under the False Claims Act, known as &#8220;qui tam&#8221; actions, can be brought by any individual on behalf of the government and such individual, commonly known as a &#8220;whistleblower&#8221;, or &#8220;relator&#8221; may share in any amounts paid by the entity to the government in fines or settlement. The filing of qui tam actions has caused a number of pharmaceutical, medical device and other healthcare companies to have to defend and/or settle a False Claims Act action. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Health Insurance Portability and Accountability Act of 1996, or HIPAA created new federal criminal statutes that prohibit, among other things, executing a scheme to defraud any healthcare benefit program, including a private payor, or falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of, or payment for, health care benefits, items or services. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">HIPAA, as amended by the Health Information Technology and Clinical Health Act, and its implementing regulations, also imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information by entities subject to the law, such as certain healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates and their subcontractors that perform certain functions or activities that involve the use or disclosure of protected health information on their behalf. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Many states also have adopted laws similar to each of the federal laws described above, some of which apply to healthcare items or services reimbursed by any source, not only federal healthcare programs, such as the Medicare and Medicaid programs. In addition, some states have laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the applicable compliance guidance promulgated by the federal government. Additionally, certain state and local laws require the registration of pharmaceutical sales representatives, restrict payments that may be made to healthcare providers and other potential referral sources, and require manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers. Further, some states have laws governing the privacy and security of health information in certain circumstances, many of which are not preempted by HIPAA and differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Because of the breadth of these laws, and the narrowness of the statutory exceptions and regulatory safe harbors available, it is possible that some of our or our potential milestone and royalty providers&#8217; business activities could be subject to challenge under one or more of such laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we or our potential milestone and royalty providers are found to be in violation of any of the laws and regulations described above or other applicable state and federal healthcare laws, we or our potential milestone and royalty providers may be subject to penalties, including significant civil, criminal, and administrative penalties, damages, fines, disgorgement, imprisonment, integrity oversight and reporting obligations, reputational harm, exclusion from government healthcare reimbursement programs and the curtailment or restructuring of our or our potential milestone and royalty providers&#8217; operations, any of which could have a material adverse effect on our business and results of operations. In addition, we and our licensees may be subject to certain analogous foreign laws and violations of such laws could result in significant penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We are subject to the U.S. Foreign Corrupt Practices Act and other anti-corruption laws, as well as export control laws, import and customs laws, trade and economic sanctions laws and other laws governing our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We are subject to the U.S. Foreign Corrupt Practices Act and other anti-corruption laws, as well as export control laws, import and customs laws, trade and economic sanctions laws and other laws governing our operations. Our operations are subject to anti-corruption laws including the FCPA, the U.S. domestic bribery statute contained in 18 U.S.C. &#167;201, the U.S. Travel Act, and other anti-corruption laws that apply in countries where we do business. The FCPA and these other laws generally prohibit us and our employees and intermediaries from authorizing, promising, offering, or providing, directly or indirectly, improper or prohibited payments, or anything else of value, to government officials or other persons to obtain or retain business or gain some other business advantage. We and the royalty agreement counterparties and licensees who generate our royalties operate in a number of jurisdictions that pose a high risk of potential FCPA violations, and we participate in collaborations and relationships with third parties whose corrupt or illegal activities could potentially subject us to liability under the FCPA or local anti-corruption laws, even if we do not explicitly authorize or have actual knowledge of such activities. In addition, we cannot predict the nature, scope or effect of future regulatory requirements to which our international operations might be subject or the manner in which existing laws might be administered or interpreted. We are also subject to other laws and regulations governing our international operations, including regulations administered by the governments of the United States and authorities in the European Union, including applicable export control regulations, economic sanctions and embargoes on certain countries and persons, anti-money laundering laws, import and customs requirements and currency exchange regulations, collectively referred to as the Trade Control laws. There is no assurance that we will be completely effective in ensuring our compliance with all applicable anti-corruption laws, including the FCPA or other legal requirements, including Trade Control laws. If we are not in compliance with the FCPA and other anticorruption laws or Trade Control laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures, and legal expenses, which could have an adverse impact on our business, financial condition, results of operations and liquidity. Likewise, any investigation of any potential violations of the FCPA, other anti-corruption laws or Trade Control laws by the United States or other authorities could also have an adverse impact on our reputation, our business, financial condition and results of operations. Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities or our business arrangements with third parties could be subject to challenge under one or more of such laws. It is possible that governmental authorities will conclude that our business practices or the </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">business practices of the royalty agreement counterparties and licensees who generate our royalties may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations or the operations of the royalty agreement counterparties and licensees who generate our royalties are found to be in violation of any of these laws or any other governmental regulations, we or the royalty agreement counterparties and licensees who generate our may be subject to significant criminal, civil and administrative sanctions, including monetary penalties, damages, fines, disgorgement, individual imprisonment and exclusion from participation in government-funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we or the royalty agreement counterparties and licensees who generate our royalties become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, reputational harm, and we or marketers of products that generate our royalties may be required to curtail or restructure operations, any of which could adversely affect our ability to operate our business and our results of operations. The risk of our being found in violation of these laws is increased by the fact that many of them have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. The shifting compliance environment and the need to build and maintain robust and expandable systems to comply with multiple jurisdictions with different compliance and/or reporting requirements increases the possibility that a healthcare company may run afoul of one or more of the requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">As we or our potential milestone and royalty providers do more business internationally, we will be subject to additional political, economic and regulatory uncertainties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We or our potential milestone and royalty providers may not be able to operate successfully in any foreign market. We believe that because the pharmaceutical industry is global in nature, international activities will be a significant part of future business activities and when and if we or our potential milestone and royalty providers are able to generate income, a substantial portion of that income will be derived from product sales and other activities outside the United States. Foreign regulatory agencies often establish standards different from those in the United States, and an inability to obtain foreign regulatory approvals on a timely basis could put us at a competitive disadvantage or make it uneconomical to proceed with a product or product candidate&#8217;s development. International sales may be limited or disrupted by many factors, including without limitation:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">imposition of government controls;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">export license requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">political or economic instability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">trade restrictions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in tariffs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on repatriating profits;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">exchange rate fluctuations; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">withholding and other taxation.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">General Risk Factors </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our share price may be volatile, and there may not be an active trading market for our common stock, Series A Preferred Stock or our Series B Preferred Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There can be no assurance that the market price of our common stock will not decline below its present market price. Additionally, there may not be an active trading market for our common stock, Series A Preferred Stock or depositary shares representing interests in our Series B Preferred Stock. The market prices of biotechnology companies have been and are likely to continue to be highly volatile. Fluctuations in our operating results and general market conditions for biotechnology stocks could have a significant impact on the volatility of our stock price or the existence of an active trading market for our common stock, Series A Preferred Stock or depositary shares representing interests in our Series B Preferred Stock. We have experienced significant volatility in the price of our common stock. From January&#160;1, 2023, through August 3, 2023, the share price of our common stock has ranged from a high of $23.51 to a low of $15.21. From January&#160;1, 2023, through August 3, 2023, the share price of our Series A Preferred Stock has ranged from a high of $25.48 to a low of $23.12. From January 1, 2023, through August 3, 2023, the share price of our Series B Preferred Stock has ranged from a high of $25.37 to a low of $22.75. Additionally, we have two significant holders of our common stock that could affect the liquidity of our stock and have a significant negative impact on our stock price if the holders were to quickly sell their ownership positions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our results of operations and liquidity needs could be materially negatively affected by market fluctuations or an economic downturn.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our results of operations could be materially negatively affected by economic conditions generally, both in the United States and elsewhere around the world. Concerns over inflation, energy costs, geopolitical issues, the availability and cost of credit, and the U.S. financial markets have in the past contributed to, and may continue in the future contribute to, increased volatility and diminished expectations for the economy and the markets. Domestic and international equity markets periodically experience heightened volatility and turmoil. These events may have an adverse effect on us. In the event of a market downturn, our results of operations could be adversely affected by those factors in many ways, including making it more difficult for us to raise funds if necessary, and our stock price may decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have issued equity securities and may issue additional equity securities from time to time, that materially and adversely affect the price of our common stock, including our Series X preferred stock, Series A Preferred Stock and depositary shares representing interests in our Series B Preferred Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We expect significant additional capital will be needed in the future to continue our planned operations. To the extent we raise additional capital by issuing equity securities, our stockholders may experience substantial dilution. We may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in such a manner as we determine from time to time, including pursuant to our 2018 Common Stock ATM Agreement, as amended, and 2021 Series B Preferred Stock ATM Agreement. If we sell common stock, convertible securities or other equity securities in more than one transaction, investors may be materially diluted by subsequent sales. These sales may also result in material dilution to our existing stockholders, and new investors could gain rights superior to our existing stockholders. If we issue additional equity securities, the price of our existing securities may be materially and adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">As of June 30, 2023, there were 5,003 shares of Series&#160;X preferred stock issued and outstanding. Each share of Series&#160;X preferred stock is convertible into 1,000 shares of registered common stock. The total number of shares of common stock issuable upon conversion of all issued Series X preferred stock would be 5,003,000 shares. Each share is convertible at the option of the holder at any time, provided that the holder will be prohibited from converting into common stock if, as a result of such conversion, the holder, together with its affiliates, would beneficially own a number of shares above a conversion blocker, which was initially set at 19.99% of our total common stock then issued and outstanding immediately following the conversion of such shares. A holder of Series X preferred shares may elect to increase or decrease the conversion blocker above or below 19.99% on 61 days&#8217; notice, provided the conversion blocker does not exceed the limits under Nasdaq Marketplace Rule 5635(b), to the extent then applicable. If holders of our Series X convertible preferred stock elect to convert their preferred shares into common stock such conversion would dilute our </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">currently outstanding common stock both in number and in earnings per share. BVF (and its affiliates), as current holders of all shares of our Series X preferred stock, would, if they converted all such shares to common stock, obtain majority voting control of the Company. As of June 30, 2023, BVF owned approximately 31.7% of our total outstanding shares of common stock, and if all of the Series X convertible preferred shares were converted, BVF would own 52.4% of our total outstanding shares of common stock. Additionally, as of June 30, 2023, we had issued and outstanding 984,000 shares of Series A Preferred Stock and 1,600,000 depositary shares, each representing a 1/1000<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup> fractional interest in a share of our Series B Preferred Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, funding from collaboration partners and others has in the past and may in the future involve issuance by us of our common stock. We cannot be certain how the purchase price of such shares, the relevant market price or premium, if any, will be determined or when such determinations will be made.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any issuance by us of equity securities, whether through an underwritten public offering, an at the market offering, a private placement, in connection with a collaboration or otherwise could result in dilution in the value of our issued and outstanding shares, and a decrease in the trading price of our securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may sell additional equity or debt securities to fund our operations, which may result in dilution to our stockholders and impose restrictions on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In order to raise additional funds to support our operations, we may sell additional equity or convertible debt securities, which would result in dilution to our stockholders and/or debt securities which may impose restrictive covenants that would adversely impact our business. The sale of additional equity or convertible debt securities could result in additional dilution or result in other rights or obligations that adversely affect our stockholders. For example, holders of shares of our Series A Preferred Stock are entitled to receive, when and as declared by our Board of Directors, out of funds legally available for the payment of dividends, cumulative cash dividends at the rate of 8.625% of the $25.00 liquidation preference per year (equivalent to $2.15625 per year). Additionally, holders of depositary shares representing interests in our Series B Preferred Stock are entitled to receive, when and as declared by our Board of Directors, out of funds legally available for the payment of dividends, cumulative cash dividends at the rate of 8.375% of the $25,000 liquidation preference per share of Series B Preferred Stock ($25.00 per depositary share) per year (equivalent to $2,093.75 per year per share or $2.09375 per year per depositary share). The incurrence of indebtedness would result in increased fixed payment obligations and could also result in certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our organizational documents contain provisions that may prevent transactions that could be beneficial to our stockholders and may insulate our management from removal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our charter and by-laws:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">require certain procedures to be followed and time periods to be met for any stockholder to propose matters to be considered at annual meetings of stockholders, including nominating directors for election at those meetings; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">authorize our Board of Directors to issue up to 1,000,000 shares of preferred stock without stockholder approval and to set the rights, preferences and other designations, including voting rights, of those shares as the Board of Directors may determine.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, we are subject to the provisions of Section&#160;203 of the Delaware General Corporation Law (the &#8220;DGCL&#8221;), that may prohibit large stockholders, in particular those owning 15% or more of our outstanding common stock, from merging or combining with us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">These provisions of our organizational documents and the DGCL, alone or in combination with each other, may discourage transactions involving actual or potential changes of control, including transactions that otherwise could involve payment of a premium over prevailing market prices to holders of common stock, could limit the ability of </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">75</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">stockholders to approve transactions that they may deem to be in their best interests, and could make it considerably more difficult for a potential acquirer to replace management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">As a public company in the United States, we are subject to the Sarbanes-Oxley Act. We have determined our disclosure controls and procedures and our internal control over financial reporting are effective. We can provide no assurance that we will, at all times, in the future be able to report that our disclosure controls and internal controls over financial reporting are effective.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Companies that file reports with the SEC, including us, are subject to the requirements of Section&#160;404 of the SOX. Section&#160;404 requires management to establish and maintain a system of internal control over financial reporting, and annual reports on Form&#160;10-K filed under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), must contain a report from management assessing the effectiveness of our internal control over financial reporting. Ensuring we have adequate internal financial and accounting controls and procedures in place to produce accurate financial statements on a timely basis is a time-consuming effort that needs to be re-evaluated frequently. Failure on our part to have effective internal financial and accounting controls would cause our financial reporting to be unreliable, could have a material adverse effect on our business, operating results, and financial condition, and could cause the trading price of our common stock to fall.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Our ability to use our NOL carry-forwards and certain other tax attributes to offset taxable income or taxes may be limited.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our net operating loss, or NOL, carryforwards could expire unused and/or be unavailable to offset future income tax liabilities. As of December 31, 2022, we had U.S. federal NOL carryforwards of $108.8 million, of which $13.6 million will begin to expire in 2036. Under the federal income tax law, federal NOLs incurred in taxable years beginning after December 31, 2017 may be carried forward indefinitely, but the deductibility of such federal NOLs is limited to 80% of current year taxable income. It is uncertain if and to what extent various states will conform to the federal tax law. In addition, Section&#160;382 of the U.S. Internal Revenue Code of 1986, as amended (or, the Code), and corresponding provisions of state law, generally limit the ability of a corporation that undergoes an &#8220;ownership change&#8221; to utilize its NOL carry-forwards and certain other tax attributes against any taxable income in taxable periods after the ownership change. An &#8220;ownership change&#8221; is generally defined as a greater than 50% change, by value, in a corporation&#8217;s equity ownership over a three-year period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Based on an analysis under Section&#160;382 of Code, we experienced an ownership change in February 2017, that significantly limits the availability of our tax attributes to offset future income. To the extent that we do not utilize our carry forwards within the applicable statutory carry-forward periods, either because of Section&#160;382 limitations or the lack of sufficient taxable income, the carry-forwards will also expire unused.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;text-align:justify;margin:6pt 0pt 0pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">Changes in tax laws or regulations</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:0.05pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">that</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:0.05pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">are applied</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:0.05pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">adversely</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:0.1pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">to us may</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:0.05pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">have a material adverse</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:0.05pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">effect</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:0.1pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">on our business,</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:0.05pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">cash flow, financial</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:0.05pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">condition,</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:0.05pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">or results</span><span style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:0.05pt;"> </span><span style="color:#231f20;font-style:italic;font-weight:bold;">of operations</span><span style="font-style:italic;font-weight:bold;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;text-align:justify;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">New tax laws, statutes, rules, regulations, or ordinances could be enacted at any time. For instance, the recently enacted Inflation Reduction Act imposes, among other rules, a 15% minimum tax on the book income of certain large corporations and a 1% excise tax on certain corporate stock repurchases. Further, existing tax laws, statutes, rules, regulations, or ordinances could be interpreted differently, changed, repealed, or modified at any time. Any such enactment, interpretation, change, repeal, or modification could adversely affect us, possibly with retroactive effect. In particular, changes in corporate tax rates, the realization of our net deferred tax assets, the taxation of foreign earnings, and the deductibility of expenses under the Tax Act, as amended by the CARES Act or any future tax reform legislation, could have a material impact on the value of our deferred tax assets, result in significant one-time charges, and increase our future tax expenses.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">76</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Stockholder and private lawsuits, and potential similar or related lawsuits, could result in substantial damages, divert management&#8217;s time and attention from our business, and have a material adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Securities-related class action and stockholder derivative litigation has often been brought against companies, including many biotechnology companies, which experience volatility in the market price of their securities. This risk is especially relevant for us because biotechnology and biopharmaceutical companies often experience significant stock price volatility in connection with their product development programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">It is possible that suits will be filed, or allegations received from stockholders, naming us and/or our officers and directors as defendants. These potential lawsuits are subject to inherent uncertainties, and the actual defense and disposition costs will depend upon many unknown factors. The outcome of these lawsuits is uncertain. We could be forced to expend significant time and resources in the defense of these suits, and we may not prevail. In addition, we may incur substantial legal fees and costs in connection with these lawsuits. Although we carry insurance to protect us from such claims, our insurance may not provide adequate coverage. It is possible that we could, in the future, incur judgments or enter into settlements of claims for monetary damages. A decision adverse to our interests on these actions could result in the payment of substantial damages, or possibly fines, and could have a material adverse effect on our cash flow, results of operations and financial position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Monitoring, initiating and defending against legal actions, including any currently pending litigation, are time-consuming for our management, are likely to be expensive and may detract from our ability to fully focus our internal resources on our business activities. The outcome of litigation is always uncertain, and in some cases could include judgments against us that require us to pay damages, enjoin us from certain activities, or otherwise affect our legal or contractual rights, which could have a significant adverse effect on our business. In addition, the inherent uncertainty of any future litigation could lead to increased volatility in our stock price and a decrease in the value of an investment in our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_037773c5_fbea_49b6_a9b2_c058b41c2cb1"></a><a id="ITEM2UNREGISTEREDSALESOFEQUITYSECURITIES"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM&#160;2.&#160;UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_9180d742_fa96_494c_929e_53c3f259e591"></a><a id="ITEM3DEFAULTSUPONSENIORSECURITIES_154961"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM&#160;3.&#160;DEFAULTS UPON SENIOR SECURITIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_16b6527b_2214_473e_80d2_eef71139ac9c"></a><a id="ITEM4MINESAFETYDISCLOSURES_257142"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM&#160;4.<b style="font-size:12pt;font-weight:bold;">&#160;</b>MINE SAFETY DISCLOSURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_45341aec_179e_4867_b5be_00b6eb8b64cd"></a><a id="ITEM5OTHERINFORMATION_588036"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM&#160;5.&#160;OTHER INFORMATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-weight:normal;">None.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">77</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_bb509845_4c74_46d1_a3de_397b77a9b636"></a><a id="ITEM6EXHIBITS_976152"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM&#160;6.&#160;EXHIBITS</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:49.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th colspan="7" style="font-weight:normal;text-align:left;vertical-align:bottom;width:38.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Incorporation By Reference</b></p></th></tr><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:49.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;Description</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.44%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.64%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.93%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SEC File No.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.64%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.12%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.64%;border-bottom:1px solid transparent;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.39%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filing Date</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.48%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;border-top:1px solid #000000;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:49.36%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;border-top:1px solid #000000;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.44%;border-top:1px solid #000000;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;border-top:1px solid #000000;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:8.93%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;border-top:1px solid #000000;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:8.12%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:9.39%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></th></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:49.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/791908/000095016212000004/ex3_1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Incorporation of XOMA Corporation</span></a></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">01/03/2012</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:49.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:7.44%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:8.93%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.2</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:49.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/791908/000095016212000069/ex3_1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment of Certificate of Incorporation of XOMA Corporation</span></a></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">05/31/2012</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:49.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:7.44%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:8.93%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.3</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/791908/000117184314002585/exh_31.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment of Amended Certificate of Incorporation of XOMA Corporation</span></a></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">05/28/2014</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.4</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/791908/000117184316012481/exh_31.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment to the Amended Certificate of Incorporation of XOMA Corporation</span></a></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10/18/2016</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:49.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:7.44%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:8.93%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.5</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/791908/000119312517046823/d317392dex31.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Designation of Preferences, Rights and Limitations of Series&#160;X Convertible Preferred Stock</span></a></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">02/16/2017</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.6</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/0000791908/000119312520316015/d39862dex31.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Designation of Preferences, Rights and Limitations of 8.625% Series A Cumulative Perpetual Preferred Stock</span></a></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12/11/2020</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.7</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/0000791908/000119312521110287/d123419dex31.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Designation of Preferences, Rights and Limitations of 8.375% Series B Cumulative Perpetual Preferred Stock</span></a></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-39801</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">04/08/2021</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.8</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000155837021010395/tmb-20210630xex3d8.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Correction of the Certificate of Designation of 8.375% Series B Cumulative Perpetual Preferred Stock dated June 9, 2021</span></a></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-39801</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.8</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">08/05/2021</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:49.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:7.44%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:8.93%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.9</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000119312521237890/d187235dex31.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment to the Certificate of Designation of 8.375% Series B Cumulative Perpetual Preferred Stock of XOMA Corporation.</span></a></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-39801</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">08/05/2021</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.10</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/791908/000095016212000004/ex3_2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">By-laws of XOMA Corporation</span></a></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.2</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">01/03/2012</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.1</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:49.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Reference is made to Exhibits 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9 and 3.10</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:49.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:7.44%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:8.93%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.2</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/791908/000095016212000004/ex4_1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Specimen of Common Stock Certificate</span></a> </p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.1</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">01/03/2012</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.3</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/0000791908/000119312521110287/d123419dex41.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Deposit Agreement, dated effective April 9, 2021, by and among XOMA Corporation, American Stock Transfer &amp; Trust Company, LLC, as depositary, and the holders of the depositary receipts issued thereunder</span></a></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-39801</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.1</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">04/08/2021</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.4</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/0000791908/000156459018019989/xoma-ex46_73.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form&#160;of Warrant (May&#160;2018 Warrant)</span></a></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.6</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">08/07/2018</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.5</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/791908/000156459019016040/xoma-ex47_58.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form&#160;of Warrant (March&#160;2019 Warrant)</span></a></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10-Q</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">000-14710</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.7</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">05/06/2019</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1*</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/791908/000119312523090874/d344283ddef14a.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">XOMA Corporation Amended and Restated 2010 Long Term Incentive and Stock Award Plan</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">DEF14A</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-39801</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Appendix A</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">04/04/2023</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.2*</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/791908/000119312523148115/d491233dex101.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Performance Stock Unit Agreement</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">001-39801</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">05/18/2023</p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.3<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+#</sup></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="xoma-20230630xex10d3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Assignment and Assumption Agreement, dated as of June 21, 2023, by and between XOMA (US) LLC and LadRx Corporation</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">78</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:49.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></th><th colspan="7" style="font-weight:normal;text-align:left;vertical-align:bottom;width:38.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Incorporation By Reference</b></p></th></tr><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:49.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;Description</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.44%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.64%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.93%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SEC File No.</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.64%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.12%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:1.64%;border-bottom:1px solid transparent;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:9.39%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filing Date</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:8.48%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;border-top:1px solid #000000;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:49.36%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;border-top:1px solid #000000;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:7.44%;border-top:1px solid #000000;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;border-top:1px solid #000000;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:8.93%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;border-top:1px solid #000000;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:8.12%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:9.39%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></th></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.4<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+#</sup></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="xoma-20230630xex10d4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Royalty Purchase Agreement, dated as of June 21, 2023, by and between XOMA (US) LLC and LadRx Corporation</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="text-decoration-line:none;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31.1<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="xoma-20230630xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Executive Chairman, as required by Rule&#160;13a-14(a) or Rule&#160;15d-14(a)</span></a></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31.2<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:49.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="xoma-20230630xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Chief Financial Officer, as required by Rule&#160;13a-14(a) or Rule&#160;15d-14(a)</span></a></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:7.44%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:8.93%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:49.36%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:7.44%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:8.93%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">32.1<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:49.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="xoma-20230630xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Executive Chairman and Chief Financial Officer, as required by Rule&#160;13a-14(b) or Rule&#160;15d-14(b) and Section&#160;1350 of Chapter&#160;63 of Title 18 of the United States Code (18 U.S.C. &#167;1350)</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></a></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:7.44%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:8.93%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.INS<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Instance Document</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.SCH<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:49.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Schema Document</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:7.44%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:8.93%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:49.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:7.44%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:8.93%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.CAL<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:49.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Calculation Linkbase Document</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:7.44%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:8.93%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:49.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:7.44%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:8.93%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.DEF<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:49.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Definition Linkbase Document</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:7.44%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:8.93%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:49.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:7.44%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:8.93%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.LAB<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:49.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Labels Linkbase Document</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:7.44%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:8.93%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:49.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:7.44%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:8.93%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.PRE<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:49.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Presentation Linkbase Document</p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:7.44%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:8.93%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">104</p></td><td style="vertical-align:top;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="background:#ffffff;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">+</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Filed herewith</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">*&#160;&#160;&#160;&#160;&#160;Indicates a management contract or compensation plan or arrangement. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">#&#160;&#160;&#160;&#160;&#160;Portions of this exhibit have been omitted as the Registrant has determined that (i) the omitted information is not material and (ii) the omitted material is of the type that the Registrant treats as private or confidential.</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(1)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">This certification accompanies the Form&#160;10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form&#160;10-Q), irrespective of any general incorporation language contained in such filing.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">79</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_66376679_15c4_4855_af75_f81c5b5ac424"></a><a id="SIGNATURES_103825"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:5.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:49.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:50.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XOMA Corporation</p></td></tr><tr><td style="vertical-align:top;width:49.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:50.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:49.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:&#160;August 8, 2023</p></td><td style="vertical-align:top;width:5.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:45.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ OWEN HUGHES</p></td></tr><tr><td style="vertical-align:top;width:49.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:5.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Owen Hughes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Executive Chairman of the Board of Directors and Interim Chief Executive Officer</p></td></tr><tr><td style="vertical-align:top;width:49.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:49.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: August 8, 2023</p></td><td style="vertical-align:top;width:5.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:45.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ THOMAS BURNS</p></td></tr><tr><td style="vertical-align:top;width:49.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:5.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:45.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Thomas Burns</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Senior Vice President, Finance and Chief Financial Officer<span style="background:#ffffff;"> (Principal Financial and Principal Accounting Officer)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">80</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>2
<FILENAME>xoma-20230630xex10d3.htm
<DESCRIPTION>EX-10.3
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 8/8/2023 02:21:35 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 10.3</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED (INDICATED BY: [***]) FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE OR CONFIDENTIAL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><font style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><font style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;text-indent:0pt;margin:12pt 0pt 0pt 0pt;"><a name="_9kP1qJ9mv455"></a><a name="_Hlk97297957"></a><a name="_Hlk138068321"></a>ASSIGNMENT AND ASSUMPTION AGREEMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">This <font style="font-variant:small-caps;">ASSIGNMENT AND ASSUMPTION AGREEMENT </font>(this &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreement</u>&#8221;)<font style="font-variant:small-caps;">,</font> dated as of June 21, 2023 (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Closing Date</u>&#8221;), is made and entered into by and between LadRx Corporation, a Delaware corporation (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assignor</u>&#8221;), on the one hand, and XOMA (US) LLC, a Delaware limited liability company (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assignee</u>&#8221;), on the other hand.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;text-indent:0pt;margin:12pt 0pt 0pt 0pt;"><b style="font-weight:bold;">RECITALS</b>:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;"><font style="font-variant:small-caps;">WHEREAS</font>, Assignor sold certain assets to Orphazyme ApS (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Orphazyme</u>&#8221;) pursuant to that certain Asset Purchase Agreement, by and between Assignor and Orphazyme, dated as of May 13, 2011, assigned by Orphazyme to Zevra Denmark A/S (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Zevra</u>&#8221;), effective as of June 1, 2022 (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Zevra Agreement</u>&#8221;). </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;"><font style="font-variant:small-caps;">WHEREAS</font>, Assignor is entitled to receive certain milestone, royalty, and other payments from Zevra pursuant to the Zevra Agreement (collectively, the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Royalty</u>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;"><font style="font-variant:small-caps;">WHEREAS</font>, Assignor desires to sell, transfer and assign to Assignee all of Assignor&#8217;s right, title, and interest in and to the Zevra Agreement, including rights to the Royalty, and Assignee desires to purchase, assume and be bound by all covenants and obligations of Assignor under the Zevra Agreement, upon and subject to the terms and conditions set forth in this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;"><font style="font-variant:small-caps;">NOW THEREFORE</font>, in consideration of the representations, warranties, covenants and agreements set forth herein and for good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, Assignor and Assignee hereby agree as follows:</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-left:0pt;margin-top:12pt;text-align:center;text-indent:0pt;text-transform:uppercase;"><font style="font-weight:normal;white-space:nowrap;">Article 1&#160;</font><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br>definitions</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:normal;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 1.1</font><a name="_Ref137644594"></a><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Definitions</u><font style="font-weight:normal;">. As used in this Agreement, the following terms shall have the following meanings:</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Acquired Patents</u>&#8221; has the meaning ascribed thereto in Article 1 of the Zevra Agreement.<font style="display:inline-block;width:0.17pt;"></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Affiliate</u>&#8221; means, with respect to any Person, any other Person that directly, or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with, such first Person.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreement</u>&#8221; is defined in the preamble.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Arimoclomol</u>&#8221; means the pharmaceutical product known as arimoclomol with the chemical structure set forth on <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule 1.1</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assignee</u>&#8221; is defined in the preamble.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assignee Fundamental Representations</u>&#8221; means the representations and warranties contained in &#8206;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section 3.2(a)</u> (Existence; Good Standing), &#8206;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section 3.2(b)</u> (Authorization), <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;&#8206;Section 3.2(c)</u> (Enforceability), <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;&#8206;Section 3.2(d)</u> (No Conflicts), and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;&#8206;Section 3.2(g)</u> (Brokers&#8217; Fees). </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assignee Indemnified Parties</u>&#8221; is defined in &#8206;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section 5.1(a)</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assignee Material Adverse Effect</u>&#8221; means any event, occurrence, fact, condition or change that, individually or in the aggregate, adversely affects in any material respect any one or more of the following: (i) the ability of Assignee to (A) consummate the transactions contemplated by this Agreement and (B) perform its obligations under this Agreement, (ii) the validity or enforceability of this Agreement against Assignee or (iii) the rights and remedies of Assignor under this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assignor</u>&#8221; is defined in the preamble.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assignor Fundamental Representations</u>&#8221; means the representations and warranties contained in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;&#8206;Section 3.1(a)</u> (Existence; Good Standing), <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;&#8206;Section 3.1(b)</u> (Authorization), <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;&#8206;Section 3.1(c)</u> (Enforceability), <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;&#8206;Section 3.1(d)</u> (No Conflicts), <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section 3.1(i)</u> (Zevra Agreement and Related Agreements), <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;&#8206;Section 3.1(j)</u> (Title to Zevra Agreement), <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section 3.1(k)</u> (Intellectual Property), and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;&#8206;Section 3.1(l)</u> (Brokers&#8217; Fees). </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assignor Indemnified Parties</u>&#8221; is defined in &#8206;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section 5.1(b)</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assignor Material Adverse Effect</u>&#8221; means any event, occurrence, fact, condition or change that, individually or in the aggregate, adversely affects in any material respect any one or more of the following: (i) the ability of Assignor to (A) consummate the transactions contemplated by this Agreement and (B) perform its obligations under this Agreement, (ii) the validity or enforceability of this Agreement against Assignor or (iii) the rights and remedies of Assignee under this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Biorex</u>&#8221; means, collectively, BIOREX Kutat&#243; &#233;s Fejleszt&#246; Rt. (&#8220;V.A.&#8221;), BRX Research and Development Company Ltd, and BRX (UK) Limited and each of their respective successors or assigns. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Biorex Agreement</u>&#8221; means that certain Asset Sale and Purchase Agreement, by and among BIOREX Kutat&#243; &#233;s Fejleszt&#246; Rt. (&#8220;V.A.&#8221;), BRX Research and Development Company Ltd, and Assignor, dated as of October 4, 2004, as assigned to BRX (UK) Limited, effective as of November 4, 2008. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Business Day</u>&#8221; means any day other than (a) a Saturday or Sunday or (b) a day on which banking institutions located in New York, USA are permitted or required by applicable law or regulation to remain closed.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">2</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Closing Date</u>&#8221; is defined in the recitals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Commercial Sale Milestone</u>&#8221; is defined in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;&#8206;Section 2.3(b)</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disclosure Schedules</u>&#8221; is defined in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;&#8206;Section 3.1</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Escrow Account</u>&#8221; means the escrow account created pursuant to the Escrow Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Escrow Agreement</u>&#8221; means an Escrow Agreement to be entered into by the Assignor, the Assignee and an escrow agent (the &#8220;Escrow Agent&#8221;), in form and content acceptable to Assignor and Assignee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Excluded Liabilities and Obligations</u>&#8221; is defined in &#8206;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;&#8206;Section 2.5</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">FDA</u>&#8221; means the U.S. Food and Drug Administration, or a successor federal agency thereto in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">First Commercial Sale</u>&#8221; means the first invoiced sale in any country in the Territory of a pharmaceutical product comprising Arimoclomol as an active pharmaceutical ingredient by Zevra or any of its Affiliates or (sub)licensees to a Third Party for end use consumption in such country following receipt of Regulatory Approval required to sell such product in such country. &#160;First Commercial Sale excludes transfers of such product to Third Parties as bona fide samples, as donations, for clinical study purposes or for any expanded access program, compassionate sales or use program (including named patient program or single patient program), indigent program, or for other charitable or promotional purposes or similar limited purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governmental Entity</u>&#8221; means any: &#160;(i) nation, principality, republic, state, commonwealth, province, territory, county, municipality, district or other jurisdiction of any nature; (ii) federal, state, local, municipal, foreign or other government; (iii) governmental or quasi-governmental authority of any nature (including any governmental division, subdivision, department, agency, bureau, branch, office, commission, council, board, instrumentality, officer, official, representative, organization, unit, body or other entity and any court, arbitrator or other tribunal); (iv) multi-national organization or body; or (v) individual, body or other entity exercising, or entitled to exercise, any executive, legislative, judicial, administrative, regulatory, police, military or taxing authority or power of any nature.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnified Party</u>&#8221;<b style="font-weight:bold;"> </b>is defined <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;&#8206;&#8206;Section 5.2</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnifying Party</u>&#8221;<b style="font-weight:bold;"> </b>is defined in &#8206;&#8206;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;&#8206;Section 5.2</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Judgment</u>&#8221; means any judgment, order, writ, injunction, citation, award or decree of any nature.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Knowledge of Assignor</u>&#8221; means the actual knowledge of the Knowledge Parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Knowledge Parties</u>&#8221;<font style="display:inline-block;width:6.37pt;"></font> means [***].</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">3</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Kriegsman Agreement</u>&#8221; means that certain Amended and Restated Employment Agreement between Assignor and Steven A. Kriegsman, dated as of March 26, 2019 as amended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Lien</u>&#8221; means any mortgage, lien, pledge, charge, adverse claim, security interest, encumbrance or restriction of any kind, including any restriction on use, transfer or exercise of any other attribute of ownership of any kind.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Loss</u>&#8221; means any and all Judgments, damages, losses, claims, costs, liabilities and expenses, including reasonable fees and out-of-pocket expenses of counsel. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">NDA</u>&#8221; means a New Drug Application as described in 21 C.F.R. &#167; 314.50 submitted to the FDA, in the United States with respect to a pharmaceutical product. The term &#8220;NDA&#8221; shall include all necessary documents, data, and other information concerning the applicable product required for Regulatory Approval of such product as a pharmaceutical product by the FDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">NDA Milestone</u>&#8221; is defined in &#8206;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;&#8206;Section 2.3(a)</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Net Sales</u>&#8221; has the meaning ascribed thereto in Article 1 of the Zevra Agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Orphazyme</u>&#8221; is defined in the recitals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Orphazyme Product</u>&#8221; has the meaning ascribed thereto in Article 1 of the Zevra Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Permitted Liens</u>&#8221; means any (i) mechanic&#8217;s, materialmen&#8217;s, and similar Liens for amounts not yet due and payable, (ii) statutory Liens for Taxes not yet due and payable or for Taxes that the taxpayer is contesting in good faith by contemporaneous proceeding and (iii) other Liens and encumbrances not incurred in connection with the borrowing of money that do not, in the aggregate, materially and adversely affect the use or value of the affected assets provided that, in each case, such Liens are automatically released upon the sale or other transfer of the affected assets (it being understood that any obligations secured by such &#8220;Permitted Liens&#8221; shall remain the obligations of Assignor).</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Person</u>&#8221; means any individual, corporation, partnership, limited liability company, trust, association, organization, or other entity or Governmental Entity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Prime Rate</u>&#8221; means the prime rate published by the Wall Street Journal, from time to time, as the prime rate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Purchase Price</u>&#8221; means the aggregate purchase price of $5,000,000, to be allocated between this Agreement and the Royalty Purchase Agreement as set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;&#8206;Section 2.2(b)</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Regulatory Approval</u>&#8221; means, with respect to a particular country or other regulatory jurisdiction, any approvals, licenses, registrations, or authorizations of any Regulatory Authority necessary for the development, manufacture or commercialization of a product for one or more indications in such country or regulatory jurisdiction, including, if applicable, necessary pricing and reimbursement approvals in such country or regulatory jurisdiction.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">4</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Regulatory Authority</u>&#8221; means any applicable Governmental Entity with jurisdiction or authority over the development, manufacture or commercialization of pharmaceutical or biologic products in a particular country or other regulatory jurisdiction, and any corresponding national or regional regulatory authorities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Royalty</u>&#8221; is defined in the recitals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Royalty Purchase Agreement</u>&#8221; means that certain Royalty Purchase Agreement by and between the Assignee and Assignor of even date hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Royalty Reduction</u>&#8221; is defined in &#8206;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section 3.1(i)(ix)</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Royalty Term</u>&#8221; has the meaning ascribed thereto in Section 2.9 of the Zevra Agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Taxes</u>&#8221; means any income, gross receipts, license, payroll, employment, excise, severance, occupation, premium, windfall profits, environmental, customs duties, capital stock, franchise, profits, withholding, social security, unemployment, disability, real property, personal property, abandoned property, value added, alternative or add-on minimum, estimated or other tax of any kind whatsoever, including any interest, penalty or addition thereto, whether disputed or not. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Territory</u>&#8221; means the United States, France, Germany, Italy, Spain, and the United Kingdom.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Third Party</u>&#8221; means any Person other than Assignor, Assignee, or their respective Affiliates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transaction Expenses</u>&#8221; is defined in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section 6.4</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Zevra</u>&#8221; is defined in the recitals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Zevra Agreement</u>&#8221; is defined in the recitals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Zevra Instruction</u>&#8221; is defined in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;&#8206;Section 4.4</u>.</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-left:0pt;margin-top:12pt;text-align:center;text-indent:0pt;text-transform:uppercase;"><font style="font-weight:normal;white-space:nowrap;">Article 2&#160;</font><font style="font-weight:normal;"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br></font><a name="_Toc163454669"></a><a name="_Toc163454736"></a><a name="_Toc163454787"></a><a name="_Toc163638383"></a><a name="_Toc163638457"></a><a name="_Toc164000385"></a><a name="_Toc164621432"></a><a name="_Toc165129415"></a><a name="_Toc165133663"></a><a name="_Toc165347284"></a><a name="_Toc165883164"></a><a name="_Toc165892799"></a><a name="_Toc172378737"></a><a name="_Toc172483462"></a><a name="_Toc172544277"></a><a name="_Toc173174527"></a><a name="_Toc173182111"></a><a name="_Toc173675435"></a><a name="_Toc173675681"></a><a name="_Toc173829977"></a><a name="_Toc174777550"></a><a name="_Toc175981455"></a><a name="_Toc175981632"></a><a name="_Toc175981745"></a><a name="_Toc176347229"></a><a name="_Toc176347285"></a><a name="_Toc176683117"></a><a name="_Toc184699277"></a><a name="_Toc185673571"></a><a name="_Toc185677447"></a><a name="_Toc185924263"></a><a name="_Toc185997216"></a><a name="_Toc189740876"></a><a name="_Toc189793218"></a><a name="_Toc189927312"></a><a name="_Toc189979055"></a><a name="_Toc189979186"></a><a name="_Toc189979194"></a><a name="_Toc191097442"></a><a name="_Toc191113758"></a><a name="_Toc191114018"></a><a name="_Toc191115665"></a><a name="_Toc191120539"></a><a name="_Toc191987153"></a><a name="_Toc192068258"></a><a name="_Toc192337926"></a><a name="_Toc277686221"></a><a name="_Ref277710162"></a><a name="_Ref277771285"></a><a name="_Toc44282624"></a><a name="_Ref96155172"></a><a name="_Toc96470021"></a><font style="font-weight:normal;">Assignment AND Assumption OF THE </font><font style="font-weight:normal;">Zevra Agreement</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:normal;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 2.1</font><a name="_Ref137460841"></a><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assignment and Assumption</u><font style="font-weight:normal;">.</font> &#160;<font style="font-weight:normal;">On the Closing Date, Assignor hereby sells, assigns, transfers, and conveys to Assignee all of Assignor&#8217;s right, title, and interest in and to the Zevra Agreement, and Assignee hereby purchases, acquires and accepts from Assignor the foregoing assignment and assumes and agrees to perform and comply with all of the covenants and obligations of Assignor under the Zevra Agreement</font><a name="_Toc163454671"></a><a name="_Toc163454738"></a><a name="_Toc163454789"></a><a name="_Toc163638385"></a><a name="_Toc163638459"></a><a name="OLE_LINK1"></a><font style="font-weight:normal;"> arising as of or after the Closing Date.</font><font style="font-weight:normal;"> </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:normal;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 2.2</font><a name="_Ref136958653"></a><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Purchase Price</u></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Purchase Price</u>. On the Closing Date, Assignee hereby agrees to deliver (or cause to be delivered) payment of the Purchase Price less the Transaction Expenses to Assignor </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">5</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:0pt;">by wire transfer of immediately available funds to one or more accounts specified by Assignor on <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit A</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref137644660"></a><a name="_Ref_ContractCompanion_9kb9Ur05D"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Allocation of Purchase Price</u>. After the Closing Date, the parties hereto shall use reasonable efforts to allocate the Purchase Price, as mutually agreed, between this Agreement and the Royalty Purchase Agreement within sixty (60) days of the Closing Date.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:normal;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 2.3</font><a name="_Ref137103152"></a><a name="_Ref_ContractCompanion_9kb9Ur07B"></a><a name="_Ref137034236"></a><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Post-Closing Payments</u><font style="font-weight:normal;">.</font><font style="font-weight:normal;"> </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref137103636"></a><a name="_Ref_ContractCompanion_9kb9Ur059"></a><a name="_Ref_ContractCompanion_9kb9Ur05B"></a>Subject to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;&#8206;Section 4.5</u> and upon Assignor&#8217;s receipt of written confirmation from Assignee of FDA acceptance for review of an Arimoclomol re-submission of an NDA filing (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">NDA Milestone</u>&#8221;), Assignee shall<b style="font-weight:bold;"> </b>make a one-time payment to Assignor of $1,000,000 by wire transfer of immediately available funds as directed by Assignor thirty (30) days after Assignee&#8217;s receipt of an invoice.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref_ContractCompanion_9kb9Ur046"></a><a name="_Ref_ContractCompanion_9kb9Ur048"></a> <a name="_Ref137103664"></a><a name="_Ref137563303"></a>Subject to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;&#8206;Section 4.6</u> and upon Assignor&#8217;s receipt of written confirmation from Assignee of the First Commercial Sale of Arimoclomol (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Commercial Sale Milestone</u>&#8221;), Assignee shall<b style="font-weight:bold;"> </b>make a one-time payment to Assignor of $1,000,000 by wire transfer of immediately available funds as directed by Assignor thirty (30) days after Assignee&#8217;s receipt of an invoice.</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:justify;text-indent:0pt;margin:12pt 0pt 0pt 0pt;"><font style="font-weight:normal;">Assignor hereby agrees and acknowledges that: (i) such payments pursuant to this &#8206;</font><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section 2.3</u><font style="font-weight:normal;"> are contingent payment obligations of Assignee and there can be no assurance regarding the occurrence of the NDA Milestone or Commercial Sale Milestone; (ii) Assignee shall have no obligation or liability with respect to such payment unless and until the NDA Milestone</font> <font style="font-weight:normal;">and/or the Commercial Sale Milestone has occurred; and (iii) Assignee shall have the right, but not the obligation, to deduct from such payments, in whole or in part, amounts owed by Assignor or claimed in good faith to be owed by Assignor to any Assignee Indemnified Party whereby Assignee simultaneous with the deduction also shall submit a notice of claim as set forth in </font><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.2</u><font style="font-weight:normal;"> if such notice of claim has not previously been submitted;[***].</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:normal;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 2.4</font><a name="_Ref137461125"></a><a name="_Ref_ContractCompanion_9kb9Ur0AE"></a><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Withholding Taxes</u><font style="font-weight:normal;">. Notwithstanding anything herein to the contrary, Assignee shall be entitled to deduct and withhold from the consideration otherwise payable pursuant to this Agreement such amounts as are required to be deducted and withheld with respect to the making of such payment under the U.S. Internal Revenue Code of 1986, as amended, or otherwise under applicable law. &#160;To the extent that amounts are so deducted and withheld, such amounts shall be (i) remitted by the deducting or withholding Person to the applicable taxing authority to the extent required by applicable law, and (ii) treated for all purposes of this Agreement as having been paid to such Person in respect of which such deduction and withholding was made.</font><font style="font-weight:normal;"> Assignee shall use commercially reasonable efforts to (a) provide Assignor with written notice prior to withholding any amounts pursuant to this </font><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;&#8206;Section 2.4</u><font style="font-weight:normal;"> and (b) cooperate with Assignor (at Assignor&#8217;s cost and expense) in mitigating any such proposed withholding whether by means of assisting in the preparation and filing of required documentation or otherwise.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:normal;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 2.5</font><a name="_Ref137563315"></a><a name="_Ref_ContractCompanion_9kb9Ur04C"></a><a name="_Ref_ContractCompanion_9kb9Ur09H"></a><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Assumed Obligations</u>. <font style="font-weight:normal;">Notwithstanding any provision in this Agreement or any other writing to the contrary, Assignee is purchasing, acquiring and accepting only Assignor&#8217;s right, title, and interest in and to the Zevra Agreement including any liability or </font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">6</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:0pt;"><font style="font-weight:normal;">obligation of Assignor under the Zevra Agreement arising as of or after the Closing Date. Except with respect to the liabilities and obligations of Assignor under the Zevra Agreement arising as of or after the Closing Date, Assignee is not assuming any liability or obligation of Assignor or any of Assignor&#8217;s Affiliates of any kind, character or description whatsoever, whether direct or indirect, known or unknown, absolute or contingent, mature or unmatured, and currently existing or hereinafter arising, including the following (collectively, the &#8220;</font><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Excluded Liabilities and Obligations</u><font style="font-weight:normal;">&#8221;):</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><font style="white-space:pre-wrap;"> </font>any liability or obligation of Assignor or any of Assignor&#8217;s Affiliates under the Zevra Agreement related to any action, event, circumstance or condition arising prior to the Closing Date; </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font>any liability arising from or related to any noncompliance with any law applicable to Assignor; and </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font><a name="_Ref137545358"></a>any liability or obligation of Assignor or any of Assignor&#8217;s Affiliates under the Biorex Agreement or the Kriegsman Agreement.</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:12pt 0pt 0pt 0pt;">All Excluded Liabilities and Obligations shall be retained by and remain liabilities and obligations of Assignor or Assignor&#8217;s Affiliates, as the case may be. </p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-left:0pt;margin-top:12pt;text-align:center;text-indent:0pt;text-transform:uppercase;"><font style="font-weight:normal;white-space:nowrap;">Article 3&#160;</font><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><a name="_Toc163454681"></a><a name="_Toc163454748"></a><a name="_Toc163454799"></a><a name="_Toc163638395"></a><a name="_Toc163638469"></a><a name="_Toc164000397"></a><a name="_Toc164621443"></a><a name="_Toc165129426"></a><a name="_Toc165133674"></a><a name="_Toc165347295"></a><a name="_Toc165883175"></a><a name="_Toc165892810"></a><a name="_Toc172378747"></a><a name="_Toc172483472"></a><a name="_Toc172544287"></a><a name="_Toc173174538"></a><a name="_Toc173182121"></a><a name="_Toc173675445"></a><a name="_Toc173675691"></a><a name="_Toc173829986"></a><a name="_Toc174777559"></a><a name="_Toc175981464"></a><a name="_Toc175981643"></a><a name="_Toc175981754"></a><a name="_Toc176347238"></a><a name="_Toc176347294"></a><a name="_Toc176683126"></a><a name="_Toc184699286"></a><a name="_Toc185673582"></a><a name="_Toc185677458"></a><a name="_Toc185924274"></a><a name="_Toc185997227"></a><a name="_Toc189740887"></a><a name="_Toc189793229"></a><a name="_Toc189927323"></a><a name="_Toc189979067"></a><a name="_Toc189979188"></a><a name="_Toc189979204"></a><a name="_Toc191097452"></a><a name="_Toc191113769"></a><a name="_Toc191114029"></a><a name="_Toc191115676"></a><a name="_Toc191120550"></a><a name="_Toc191987164"></a><a name="_Toc192068270"></a><a name="_Toc192337938"></a><a name="_Toc277686237"></a><a name="_Toc44282635"></a><a name="_Ref96155196"></a><a name="_Ref96155209"></a><a name="_Ref96468909"></a><a name="_Ref96468921"></a><a name="_Toc96470024"></a><a name="_Ref137108022"></a><font style="font-weight:normal;">REPRESENTATIONS AND WARRANTIES</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:12pt;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:normal;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 3.1</font><a name="_Toc277686238"></a><a name="_Toc44282636"></a><a name="_Toc96470025"></a><a name="_Ref137560082"></a><a name="_Ref137818449"></a><a name="_Toc163454682"></a><a name="_Toc163454749"></a><a name="_Toc163454800"></a><a name="_Toc163638396"></a><a name="_Toc163638470"></a><a name="_Toc164000398"></a><a name="_Toc164621444"></a><a name="_Toc165129427"></a><a name="_Toc165133675"></a><a name="_Toc165347296"></a><a name="_Toc165883176"></a><a name="_Toc165892811"></a><a name="_Toc172378748"></a><a name="_Toc172483473"></a><a name="_Toc172544288"></a><a name="_Toc173174539"></a><a name="_Toc173182122"></a><a name="_Toc173675446"></a><a name="_Toc173675692"></a><a name="_Toc173829987"></a><a name="_Toc174777560"></a><a name="_Toc175981465"></a><a name="_Toc175981644"></a><a name="_Toc175981755"></a><a name="_Toc176347239"></a><a name="_Toc176347295"></a><a name="_Toc176683127"></a><a name="_Toc184699287"></a><a name="_Toc185673583"></a><a name="_Toc185677459"></a><a name="_Toc185924275"></a><a name="_Toc185997228"></a><a name="_Toc189740888"></a><a name="_Toc189793230"></a><a name="_Toc189927324"></a><a name="_Toc189979068"></a><a name="_Toc189979205"></a><a name="_Toc191097453"></a><a name="_Toc191113770"></a><a name="_Toc191114030"></a><a name="_Toc191115677"></a><a name="_Toc191120551"></a><a name="_Toc191987165"></a><a name="_Toc192068271"></a><a name="_Toc192337939"></a><a name="_Ref276315247"></a><a name="_Ref276316115"></a><a name="_Ref_ContractCompanion_9kb9Ur04A"></a><a name="_Ref_ContractCompanion_9kb9Ur09F"></a><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assignor&#8217;s Representations and Warranties</u><font style="font-weight:normal;">. </font><font style="font-weight:normal;">Except as set forth in the disclosure schedules delivered by Assignor to Assignee (the &#8220;</font><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disclosure Schedules</u><font style="font-weight:normal;">&#8221;), Assignor represents and warrants to Assignee that as of the Closing Date:</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Toc175981645"></a><a name="_Toc189979069"></a><a name="_Ref137566439"></a><a name="_Ref_ContractCompanion_9kb9Ur024"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Existence; Good Standing</u>. Assignor is a corporation duly incorporated, validly existing and in good standing under the laws of Delaware. Assignor is duly licensed or qualified to do business and in corporate good standing in each jurisdiction in which the nature of the business conducted by it or the character or location of the properties and assets owned, leased or operated by it makes such licensing or qualification necessary, except where the failure to be so licensed or qualified and in corporate good standing has not and would not reasonably be expected to have, either individually or in the aggregate, an Assignor Material Adverse Effect.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref137566445"></a><a name="_Ref_ContractCompanion_9kb9Ur026"></a><a name="_Toc175981646"></a><a name="_Toc189979070"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Authorization</u>. Assignor has all requisite corporate power and authority to execute, deliver and perform its obligations under this Agreement. &#160;The execution, delivery and performance of this Agreement, and the consummation of the transactions contemplated hereby, have been duly authorized by all necessary corporate action on the part of Assignor.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font><a name="_Ref137566452"></a><a name="_Ref_ContractCompanion_9kb9Ur028"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Enforceability</u>. The Agreement has been duly executed and delivered and constitutes a valid and binding obligation of Assignor enforceable against Assignor in accordance with its terms, except as such enforceability may be limited by applicable bankruptcy, securities, insolvency, or similar laws relating to, or affecting generally the enforcement of, creditors&#8217; rights and remedies, or indemnification or by other equitable principles of general application.</div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">7</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(d)</font><a name="_Toc175981647"></a><a name="_Toc189979071"></a><a name="_Ref137566456"></a><a name="_Ref_ContractCompanion_9kb9Ur02A"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Conflicts</u>. The execution, delivery and performance by Assignor of this Agreement and the consummation of the transactions contemplated hereby do not and shall not (i) contravene or conflict with the organizational documents of Assignor, (ii) contravene or conflict with or constitute a material default under any law or Judgment binding upon or applicable to Assignor, (iii) contravene or conflict with or constitute a default under the Zevra Agreement or (iv) contravene or conflict with or constitute a material default under any other material contract or material agreement binding upon or applicable to Assignor, including but not limited to the Biorex Agreement or the Kriegsman Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(e)</font><a name="_Toc175981648"></a><a name="_Toc189979072"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Consents</u>. Except for the consent of Zevra that has been obtained on or prior to the Closing Date or filings required by the federal securities laws or stock exchange rules, no consent, approval, license, order, authorization, registration, declaration or filing with or of any Governmental Entity or other Person is required to be done or obtained by Assignor in connection with (i) the execution and delivery by Assignor of this Agreement, (ii) the performance by Assignor of its obligations under this Agreement or (iii) the consummation by Assignor of any of the transactions contemplated by this Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(f)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Litigation</u>. &#160;There is no action, suit, investigation or proceeding pending before any Governmental Entity or, to the Knowledge of Assignor, threatened to which the Assignor is a party that, individually or in the aggregate would, if determined adversely, reasonably be expected to have an Assignor Material Adverse Effect.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(g)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compliance with Laws</u>. &#160;Assignor is not in violation of, and to the Knowledge of Assignor, Assignor is not under investigation with respect to nor has the Assignor been threatened to be charged with or given notice of any violation of, any law or Judgment applicable to Assignor, which violation would reasonably be expected to have an Assignor Material Adverse Effect.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(h)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Undisclosed Events or Circumstances</u>. &#160;Except for the transactions contemplated hereby, no event or circumstance has occurred or exists with respect to Assignor, its Affiliates, or their respective businesses, properties, operations or financial condition, which, under applicable law, rule or regulation, requires public disclosure or announcement by Assignor but which has not been so publicly announced or disclosed and which, individually or in the aggregate, would constitute an Assignor Material Adverse Effect. There is no action, suit, claim, investigation or proceeding pending or, to the Knowledge of Assignor, threatened against the Assignor or any of its Affiliate which questions the validity of this Agreement or the transactions contemplated hereby or any action taken or to be taken pursuant hereto. There is no action, suit, claim, investigation or proceeding pending or, to the Knowledge of Assignor, threatened against or involving Assignor or any of its Affiliates, or any of their respective properties or assets that would be reasonably be expected to result in an Assignor Material Adverse Effect.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font><a name="_Ref137640886"></a><a name="_Ref_ContractCompanion_9kb9Ur02C"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Zevra Agreement and Related Agreements</u>. &#160;A true, correct and complete copy of the Zevra Agreement, including any amendments, modifications or side letters thereto, is attached as <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit B</u>. Assignor has delivered to Assignee true, correct and complete copies of all formal written notices provided to Assignor pursuant to Section 7.3 of the Zevra Agreement, since the date of execution of the Zevra Agreement. &#160;Assignor has delivered to Assignee true, correct and complete copies of all formal written notices provided to Assignor pursuant to Section 8.5 of </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">8</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:0pt;">the Biorex Agreement and Section 15 of the Kriegsman Agreement, each since the date of execution of the Biorex Agreement and the Kriegsman Agreement, respectively, and relating to the Zevra Agreement or to the Royalty. &#160;As of the Closing Date, there are not, and have not been, any payments made by Zevra or Orphazyme to Assignor in respect of the Royalty. &#160;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:36pt;margin-top:12pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Other Agreements</u>. &#160;Except as set forth on <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule 3.1(i)(i)</u> of the Disclosure Schedules, the Zevra Agreement is the only agreement, instrument, arrangement, waiver or understanding between Assignor (or any predecessor or Affiliate thereof), on the one hand, and Zevra (or any predecessor or Affiliate thereof), on the other hand, relating to the subject matter thereof, and there are no other agreements, instruments, arrangements, waivers or understandings between Assignor (or any predecessor or any Affiliate thereof), on the one hand, and Zevra (or any predecessor or Affiliate thereof), on the other hand, that relate to the Zevra Agreement or the Royalty. &#160;Assignor has not proposed or received any proposal, to amend or waive any provision of the Zevra Agreement, Biorex Agreement or Kriegsman Agreement in any manner that would result in a breach of this Agreement or otherwise reasonably be expected (with or without the giving of notice or the passage of time, or both) to have an Assignor Material Adverse Effect.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:36pt;margin-top:12pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(ii)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Licenses</u>. &#160;To the Knowledge of Assignor, there are no entered into by Assignor or any other Person (or any predecessor or Affiliate thereof) in respect of Assignor&#8217;s rights and obligations under the Zevra Agreement (including any Acquired Patents). </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:36pt;margin-top:12pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(iii)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Validity; Enforceability</u>. (i) the Zevra Agreement is legal, valid, binding, enforceable, and in full force and effect and will continue to be legal, valid, binding, enforceable, and in full force and effect on identical terms following the consummation of the transactions contemplated by this Agreement; (ii) Assignor is not and, to the Knowledge of Assignor, Zevra is not is in breach of or default under the Zevra Agreement, and no event has occurred that with notice or lapse of time would constitute a breach thereof or default thereunder, or permit termination, modification, or acceleration, under the Zevra Agreement; (iii) no party to the Zevra Agreement has repudiated any provision of the Zevra Agreement and Assignor has not received any notice in connection with the Zevra Agreement challenging the validity, enforceability or interpretation of any provision of such agreement, including the obligation to pay any portion of the Royalty without set-off of any kind.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:36pt;margin-top:12pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(iv)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Orphazyme Product</u>. Arimoclomol is an Orphazyme Product. &#160;Zevra and its Affiliates are required to pay milestone payments and royalties under Sections 2.6, 2.7 and 2.8 of the Zevra Agreement on the applicable milestones and on all Net Sales by or on behalf of them and any of their licensees of any Orphazyme Products on a country-by-country basis. &#160;Assignor has the right to receive the royalties on Net Sales of the Orphazyme Products for so long as Zevra, one of its Affiliates or any of its or their licensees is selling the Orphazyme Products during the Royalty Term.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:36pt;margin-top:12pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(v)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Liens or Assignments by the Assignor</u>. &#160;Assignor has not, except for Permitted Liens and as contemplated hereby, conveyed, assigned or in any other way </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">9</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:36pt;margin-top:12pt;text-align:justify;text-indent:0pt;">transferred or granted any Liens upon or security interests with respect to all or any portion of its right, title and interest in and to the Zevra Agreement or the Royalty.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:36pt;margin-top:12pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(vi)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Waivers or Releases</u>. &#160;Assignor has not granted any material waiver under the Zevra Agreement and has not released Zevra, in whole or in part, from any of its material obligations under the Zevra Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:36pt;margin-top:12pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(vii)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Breaches or Defaults; Timely Payments</u>. There is and has been no material breach or default under any provision of the Zevra Agreement, the Biorex Agreement, or the Kriegsman Agreement, either by Assignor (or any predecessor thereof) or, to the Knowledge of Assignor, by Zevra, Orphazyme, Biorex, or Steven A. Kriegsman, as applicable (or any predecessor of each), and there is no event that upon notice or the passage of time, or both, would reasonably be expected to give rise to any breach or default either by Assignor or, to the Knowledge of Assignor, by Zevra, Orphazyme, Biorex, or Steven A. Kriegsman, as applicable. All payments required to be paid by Assignor to Biorex pursuant to the Biorex Agreement and Steven A. Kriegsman pursuant to the Kriegsman Agreement with respect to the Royalty have been timely paid.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:36pt;margin-top:12pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(viii)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Assignments by Zevra</u>. &#160;Assignor has not consented to any assignment or other transfer by Zevra or any of its predecessors of any of their rights or obligations under the Zevra Agreement, and, to the Knowledge of Assignor, Zevra has not assigned or otherwise transferred or granted any Liens upon or security interest with respect to any of its rights or obligations under the Zevra Agreement to any Person.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:36pt;margin-top:12pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(ix)</font><a name="_Ref137153810"></a><a name="_Ref_ContractCompanion_9kb9Ur05F"></a><a name="_Ref_ContractCompanion_9kb9Ur068"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Royalty Reductions</u>. &#160;To the Knowledge of Assignor, the amount of the Royalty due and payable under the Zevra Agreement is not, as of the Closing Date, subject to any claim against Assignor pursuant to any right of set-off, counterclaim, credit, reduction or deduction by contract or otherwise (each, a &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Royalty Reduction</u>&#8221;). &#160;To the Knowledge of Assignor, no event or condition exists that, upon notice or passage of time or both, would reasonably be expected to permit Zevra to claim, or have the right to claim, a Royalty Reduction.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:36pt;margin-top:12pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(x)</font><a name="_Ref137641460"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Liabilities</u>. Except as disclosed in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule &#8206;3.1(i)(x)</u> of the Disclosure Schedules, Assignor has no existing liabilities or obligations under the (i) the Zevra Agreement, (ii) the Biorex Agreement, and (ii) the Kriegsman Agreement and, in each case, no event has occurred that, upon notice or the passage of time or both, would reasonably be expected to result in any liability or obligation of Assignor or Assignee under such agreement. </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:36pt;margin-top:12pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(xi)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Disputes</u>. Except as disclosed in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule 3.1(i)(xi)</u> of the Disclosure Schedules, there have been no disputes or indemnity claims related to (i) the Zevra Agreement, (ii) the Biorex Agreement, and (iii) the Kriegsman Agreement and, in each case, no event has occurred that, upon notice or the passage of time or both, would reasonably be expected to result in any dispute or indemnity claim related to or under such agreement.</div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">10</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(j)</font><a name="_Ref137640839"></a><a name="_Ref_ContractCompanion_9kb9Ur035"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Title to Zevra Agreement; Royalty</u>. Assignor has good and marketable title to the Zevra Agreement and the Royalty free and clear of all Liens (other than Permitted Liens). &#160;Upon payment of the Purchase Price by Assignee, Assignee will acquire, subject to the terms and conditions set forth in this Agreement, good and marketable title to the Zevra Agreement, including the Royalty, free and clear of all Liens (other than Liens created by Assignee, if any).</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(k)</font><a name="_Ref137640856"></a><a name="_Ref_ContractCompanion_9kb9Ur037"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Intellectual Property</u>. To the Knowledge of Assignor:</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:72pt;margin-top:12pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font><a name="_Ref137641262"></a>Zevra is the sole owner of, and has the sole interest in, all of the Acquired Patents.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:72pt;margin-top:12pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(ii)</font>There are no pending or threatened litigations, interferences, reexamination, oppositions or like procedures involving any Acquired Patents.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:72pt;margin-top:12pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(iii)</font>All of the issued Acquired Patents are in full force and effect and have not lapsed, expired or otherwise terminated, and are valid and enforceable. &#160;Neither Assignor nor Ophazyme or Zevra has received any written notice relating to the lapse, expiration or other termination of any of the Acquired Patents (excluding, with respect to patent applications during the period when such patent applications were pending, all office actions from the U.S. Patent &amp; Trademark Office and any equivalent patent office in any other jurisdiction involving such Acquired Patents during routine patent prosecution), or any written legal opinion that alleges that any of the issued Acquired Patents is invalid or unenforceable.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:72pt;margin-top:12pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(iv)</font>there is no Person who is or claims to be an inventor under any of the Acquired Patents who is not a named inventor thereof.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:72pt;margin-top:12pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(v)</font>Neither Assignor nor Ophazyme or Zevra has received any written notice of any claim by any Person challenging the inventorship or ownership of, its rights in and to, or the patentability, validity or enforceability of, any issued Acquired Patent [***], or asserting that the development, manufacture, importation, sale, offer for sale or use of any Orphazyme Product infringes any patent or other intellectual property rights of such Person.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:72pt;margin-top:12pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(vi)</font>The discovery and development of the Orphazyme Products did not and does not infringe, misappropriate or otherwise violate any patent rights or other intellectual property rights owned by any Third Party (other than Zevra). &#160;Neither Assignor nor Ophazyme or Zevra has in-licensed any patents or other intellectual property rights covering the manufacture, use, sale, offer for sale or import of the Orphazyme Products.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:72pt;margin-top:12pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(vii)</font>The manufacture, use, marketing, sale, offer for sale, importation or distribution of the Orphazyme Products has not and will not, infringe, misappropriate or otherwise violate any patent rights or other intellectual property rights owned by any other Person.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:72pt;margin-top:12pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(viii)</font>No Third Party has infringed, misappropriated or otherwise violated, or is infringing, misappropriating or otherwise violating, any of the Acquired </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">11</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:72pt;margin-top:12pt;text-align:justify;text-indent:0pt;">Patents or any other patent right claiming the composition of matter of, or the method of making or using, any Orphazyme Product.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:72pt;margin-top:12pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(ix)</font>All required maintenance fees, annuities and like payments with respect to the Acquired Patents have been paid timely.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(l)</font><a name="_Ref137566470"></a><a name="_Ref_ContractCompanion_9kb9Ur039"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Brokers&#8217; Fees</u>. Except for Roth Capital Partners, LLC, there is no investment banker, broker, finder, financial advisor or other intermediary who has been retained by or is authorized to act on behalf of Assignor who might be entitled to any fee or commission in connection with the transactions contemplated by this Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(m)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Tax Withholdings. </u>To the Knowledge of Assignor, the amount payable by <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Zevra </u>pursuant to the Zevra Agreement is not, as of the Closing Date, subject to any deduction of any withholding Taxes, value-added Taxes, or other Taxes under Section 2.17 of the Zevra Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(n)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Implied Representations and Warranties</u>. &#160;ASSIGNEE EXPRESSLY ACKNOWLEDGES AND AGREES THAT, EXCEPT AS EXPRESSLY SET FORTH IN <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;text-transform:uppercase;">Section 3.1</u>, THE ASSIGNOR MAKES NO REPRESENTATION OR WARRANTY, EXPRESSED OR IMPLIED, AT LAW OR IN EQUITY IN RESPECT OF THE ZEVRA AGREEMENT, ANY ACQUIRED PATENTS, OR THE TRANSACTIONS CONTEMPLATED HEREBY, INCLUDING WITH RESPECT TO MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, AND ANY SUCH OTHER REPRESENTATIONS OR WARRANTIES ARE HEREBY EXPRESSLY DISCLAIMED. ASSIGNEE ACKNOWLEDGES AND AGREES THAT, EXCEPT FOR FRAUD, WILLFUL MISCONDUCT, INTENTIONAL MISREPRESENTATION, INTENTIONAL BREACH, AND AS EXPRESSLY SET FORTH IN ANY REPRESENTATION OR WARRANTY IN <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;text-transform:uppercase;">Section 3.1</u>, ASSIGNEE SHALL HAVE NO CLAIM OR RIGHT REGARDING LOSSES OR DAMAGES PURSUANT TO <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;text-transform:uppercase;">Section</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> &#8206;5.1(a)</u> &#160;[***].<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> &#160;</u></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:12pt;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:27pt;"><font style="display:inline-block;font-weight:normal;min-width:81pt;text-indent:0pt;white-space:nowrap;">Section 3.2</font><a name="_Ref276323437"></a><a name="_Toc277686239"></a><a name="_Toc44282637"></a><a name="_Toc163454683"></a><a name="_Toc163454750"></a><a name="_Toc163454801"></a><a name="_Toc163638397"></a><a name="_Toc163638471"></a><a name="_Toc164000399"></a><a name="_Toc164621445"></a><a name="_Toc165129428"></a><a name="_Toc165133676"></a><a name="_Toc165347297"></a><a name="_Toc165883177"></a><a name="_Toc165892812"></a><a name="_Toc172378749"></a><a name="_Toc172483474"></a><a name="_Toc172544289"></a><a name="_Toc173174540"></a><a name="_Toc173182123"></a><a name="_Toc173675447"></a><a name="_Toc173675693"></a><a name="_Toc173829988"></a><a name="_Toc174777561"></a><a name="_Toc175981466"></a><a name="_Toc175981653"></a><a name="_Toc175981756"></a><a name="_Toc176347240"></a><a name="_Toc176347296"></a><a name="_Toc176683128"></a><a name="_Toc184699288"></a><a name="_Toc185673584"></a><a name="_Toc185677460"></a><a name="_Toc185924276"></a><a name="_Toc185997229"></a><a name="_Toc189740889"></a><a name="_Toc189793231"></a><a name="_Toc189927325"></a><a name="_Toc189979080"></a><a name="_Toc189979206"></a><a name="_Toc191097454"></a><a name="_Toc191113771"></a><a name="_Toc191114031"></a><a name="_Toc191115678"></a><a name="_Toc191120552"></a><a name="_Toc191987166"></a><a name="_Toc192068272"></a><a name="_Toc192337940"></a><a name="_Toc96470026"></a><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assignee&#8217;s Representations and Warranties</u><font style="font-weight:normal;">. Assignee represents and warrants to Assignor that as of the Closing Date:</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref137566378"></a><a name="_Ref_ContractCompanion_9kb9Ur013"></a><a name="_Toc175981654"></a><a name="_Toc189979081"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Existence; Good Standing</u>. Assignee is a limited liability company duly formed, validly existing and in good standing under the laws of Delaware. Assignee is duly licensed or qualified to do business and in good standing in each jurisdiction in which the nature of the business conducted by it or the character or location of the properties and assets owned, leased or operated by it makes such licensing or qualification necessary, except where the failure to be so licensed or qualified and in corporate good standing has not and would not reasonably be expected to have, either individually or in the aggregate, an Assignee Material Adverse Effect.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref137566384"></a><a name="_Ref_ContractCompanion_9kb9Ur015"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Authorization</u>. Assignee has all requisite organizational power and authority to execute, deliver and perform its obligations under this Agreement. &#160;The execution, delivery and performance of this Agreement, and the consummation of the transactions contemplated hereby, have been duly authorized by all necessary organizational action on the part of Assignee.</div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">12</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font><a name="_Toc175981655"></a><a name="_Toc189979082"></a><a name="_Ref137566403"></a><a name="_Ref_ContractCompanion_9kb9Ur017"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Enforceability</u>. The Agreement has been duly executed and delivered and constitutes a valid and binding obligation of Assignee enforceable against Assignee in accordance with its terms, except as such enforceability may be limited by applicable bankruptcy, securities, insolvency, or similar laws relating to, or affecting generally the enforcement of, creditors&#8217; rights and remedies, or indemnification or by other equitable principles of general application.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(d)</font><a name="_Toc175981656"></a><a name="_Toc189979083"></a><a name="_Ref137566408"></a><a name="_Ref_ContractCompanion_9kb9Ur019"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Conflicts</u>. The execution, delivery and performance by Assignee of this Agreement and the consummation of the transactions contemplated hereby do not and shall not (i) contravene or conflict with the organizational documents of Assignee, (ii) contravene or conflict with or constitute a material default under any law or Judgment binding upon or applicable to Assignee, or (iii) contravene or conflict with or constitute a material default under any other material contract or material agreement binding upon or applicable to Assignee.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(e)</font><a name="_Toc175981657"></a><a name="_Toc189979084"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Consents</u>. No consent, approval, license, order, authorization, registration, declaration or filing with or of any Governmental Entity or other Person is required to be done or obtained by Assignee in connection with (i) the execution and delivery by Assignee of this Agreement, (ii) the performance by Assignee of its obligations under this Agreement, or (iii) the consummation by Assignee of any of the transactions contemplated by this Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(f)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Financing</u>. Assignee has sufficient cash on hand to pay the entire Purchase Price. &#160;Assignee acknowledges that its obligations under this Agreement are not contingent on obtaining financing.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(g)</font><a name="_Ref137566416"></a><a name="_Ref_ContractCompanion_9kb9Ur01B"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Brokers&#8217; Fees</u>. There is no investment banker, broker, finder, financial advisor or other intermediary who has been retained by or is authorized to act on behalf of Assignee who might be entitled to any fee or commission in connection with the transactions contemplated by this Agreement. </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-left:0pt;margin-top:12pt;text-align:center;text-indent:0pt;text-transform:uppercase;"><font style="font-weight:normal;white-space:nowrap;">Article 4&#160;</font><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><a name="_Toc149736552"></a><a name="_Toc153589888"></a><a name="_Toc153591782"></a><a name="_Toc153591828"></a><a name="_Toc153685949"></a><a name="_Toc153728987"></a><a name="_Toc154399835"></a><a name="_Toc156134277"></a><a name="_Toc156382934"></a><a name="_Toc172378752"></a><a name="_Toc172483477"></a><a name="_Toc172544292"></a><a name="_Toc173174542"></a><a name="_Toc173182125"></a><a name="_Toc173675449"></a><a name="_Toc173675695"></a><a name="_Toc173829990"></a><a name="_Toc174777563"></a><a name="_Toc175981468"></a><a name="_Toc175981664"></a><a name="_Toc175981758"></a><a name="_Toc176347242"></a><a name="_Toc176347298"></a><a name="_Toc176683130"></a><a name="_Toc184699290"></a><a name="_Toc185673586"></a><a name="_Toc185677462"></a><a name="_Toc185924278"></a><a name="_Toc185997231"></a><a name="_Toc189740891"></a><a name="_Toc189793233"></a><a name="_Toc189927327"></a><a name="_Toc189979092"></a><a name="_Toc189979189"></a><a name="_Toc189979208"></a><a name="_Toc191097456"></a><a name="_Toc191113773"></a><a name="_Toc191114033"></a><a name="_Toc191115680"></a><a name="_Toc191120554"></a><a name="_Toc191987168"></a><a name="_Toc192068274"></a><a name="_Toc192337942"></a><a name="_Ref276307513"></a><a name="_Toc277686241"></a><a name="_Ref288147333"></a><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><a name="_Toc163454689"></a><a name="_Toc163454756"></a><a name="_Toc163454807"></a><a name="_Toc163638402"></a><a name="_Toc163638476"></a><a name="_Toc164000404"></a><a name="_Toc164621450"></a><a name="_Toc165129433"></a><a name="_Toc165133681"></a><a name="_Toc165347302"></a><a name="_Toc165883180"></a><a name="_Toc165892815"></a><a name="_Toc172378755"></a><a name="_Toc172483480"></a><a name="_Toc172544295"></a><a name="_Toc173174545"></a><a name="_Toc173182128"></a><a name="_Toc173675452"></a><a name="_Toc173675698"></a><a name="_Toc173829993"></a><a name="_Toc174777566"></a><a name="_Toc175981471"></a><a name="_Toc175981677"></a><a name="_Toc175981761"></a><a name="_Toc176347245"></a><a name="_Toc176347301"></a><a name="_Toc176683133"></a><a name="_Toc184699293"></a><a name="_Toc185673589"></a><a name="_Toc185677465"></a><a name="_Toc185924281"></a><a name="_Toc185997234"></a><a name="_Toc189740894"></a><a name="_Toc189793236"></a><a name="_Toc189927330"></a><a name="_Toc189979106"></a><a name="_Toc189979190"></a><a name="_Toc189979211"></a><a name="_Toc191097459"></a><a name="_Toc191113776"></a><a name="_Toc191114036"></a><a name="_Toc191115683"></a><a name="_Toc191120557"></a><a name="_Toc191987171"></a><a name="_Toc192068277"></a><a name="_Toc192337945"></a><a name="_Toc277686244"></a><a name="_Toc44282642"></a><a name="_Toc96470028"></a><font style="font-weight:normal;">COVENANTS</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:normal;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 4.1</font><a name="_Ref97551592"></a><a name="_Toc96470029"></a><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disclosures</u><font style="font-weight:normal;">. Except for a press release previously approved in form and substance by Assignor and Assignee or any other public announcement using substantially the same text as such press release, neither Assignee nor Assignor shall, and each party hereto shall cause its respective representatives, Affiliates and Affiliates&#8217; representatives not to, issue a press release or other public announcement or otherwise make any public disclosure with respect to this Agreement or the subject matter hereof without the prior written consent of the other party hereto (which consent shall not be unreasonably withheld, conditioned or delayed), except as may be required by applicable law or stock exchange rule (in which case the party hereto required to make the press release or other public announcement or disclosure shall, if not prohibited by applicable law, allow the other party hereto reasonable time to comment on such press release or other public announcement or disclosure in advance of such issuance).</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:12pt;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:normal;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 4.2</font><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Payments Received by Assignor; Interest Payments</u><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">.</u></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref137108389"></a><a name="_Ref_ContractCompanion_9kb9Ur0AG"></a><a name="_Ref97555371"></a>Commencing on the Closing Date and at all times thereafter, if any payment of any portion of the Royalty is made to Assignor, Assignor shall pay such amount to Assignee, </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">13</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:0pt;">promptly (and in any event within ten (10) Business Days) after the receipt thereof, by wire transfer of immediately available funds to an account designated in writing by Assignee. Assignor shall notify Assignee of such wire transfer and provide reasonable details regarding the Royalty payment so received by Assignor. &#160;Assignor agrees that, in the event any payment of the Royalty is paid to Assignor, Assignor shall (i) until paid to Assignee, hold such payment received in trust for the benefit of Assignee and (ii) have no right, title or interest in such payment and that it shall not pledge or otherwise grant any security interest therein. </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font>A late fee of 4% over the Prime Rate shall accrue on all unpaid amounts with respect to any sum payable under &#8206;&#8206;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section 4.2(a)</u> &#8206;beginning five (5) Business Days after receipt of such payment received in error.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:12pt;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:normal;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 4.3</font><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reports; Other Information; Notices</u><font style="font-weight:normal;">. Promptly (and in any event within five (5) Business Days) following the receipt by Assignor of any report, notice, correspondence or confidential information provided by Zevra under the Zevra Agreement or by Biorex or Steven A. Kriegsman related to the Zevra Agreement and any material report, notice or correspondence by Biorex or Steven A. Kriegsman, Assignor shall furnish a true, correct and complete copy of the same to Assignee. Promptly (and in any event within five (5) Business Days) following the receipt by Assignee of any report, notice, correspondence or confidential information related to either the NDA Milestone or Commercial Sale Milestone provided by Zevra under the Zevra Agreement, Assignee shall furnish a true, correct and complete copy of the same to Assignor.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:12pt;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:normal;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 4.4</font><a name="_Toc96470033"></a><a name="_Ref137037367"></a><a name="_Ref137563408"></a><a name="_Toc175981681"></a><a name="_Toc189979110"></a><a name="_Ref306405604"></a><a name="_Ref_ContractCompanion_9kb9Ur06E"></a><a name="_Ref_ContractCompanion_9kb9Ur06G"></a><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Instruction</u><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;white-space:pre-wrap;"> </u><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Letter</u><font style="font-weight:normal;">. </font><font style="font-weight:normal;">On the Closing Date, Assignor shall deliver to Assignee an instruction letter, in substantially the form attached hereto as </font><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit&#160;C</u><font style="font-weight:normal;"> (the &#8220;</font><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Zevra Instruction</u><font style="font-weight:normal;">&#8221;), duly executed by Assignor, instructing Zevra to pay the Royalty to the account specified by Assignee, which shall be delivered to Zevra thereafter. Promptly upon execution of the Escrow Agreement, Assignee shall deliver to Zevra an instruction letter, in substantially similar form to the Zevra Instruction, duly executed by Assignee, instructing Zevra to pay the Royalty to the Escrow Account. </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:12pt;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:normal;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 4.5</font><a name="_Ref137460513"></a><a name="_Ref_ContractCompanion_9kb9Ur079"></a><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">FDA Review</u><font style="font-weight:normal;">. Assignee shall promptly (and in any event within five (5) Business Days) notify Assignor of communication from Zevra to Assignee indicating the NDA Milestone has been achieved</font><font style="font-weight:normal;">.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:12pt;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:normal;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 4.6</font><a name="_Ref137460776"></a><a name="_Ref_ContractCompanion_9kb9Ur0AC"></a><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">First Commercial Sale</u><font style="font-weight:normal;">. Assignee shall promptly (and in any event within five (5) Business Days) notify Assignor of communication from Zevra to Assignee indicating the Commercial Sale Milestone has been achieved.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:normal;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 4.7</font><a name="_Ref137563045"></a><a name="_Ref137553306"></a><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Payments to Kriegsman; Biorex</u><font style="font-weight:normal;">.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref137564934"></a>[***]</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:normal;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 4.8</font><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Legal Opinions</u><font style="font-weight:normal;">. On the Closing Date, Haynes and Boone LLP, as counsel to the Assignor, and Richards, Layton &amp; Finger, P.A., as Delaware counsel to the Assignor, shall deliver to the Assignee duly executed legal opinions in the form previously agreed by the parties hereto, including an opinion by Richards, Layton &amp; Finger, P.A. that the authorization by the stockholders of the Assignor of the transactions contemplated hereby is not required under Section 271 of the Delaware General Corporation Law. </font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">14</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:normal;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 4.9</font><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Further Assurances</u><font style="font-weight:normal;">. After the Closing Date, Assignor and Assignee agree to execute and deliver such other documents, certificates, agreements and other writings and to take such other actions as may be reasonably necessary in order to give effect to the transactions contemplated by this Agreement.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:normal;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 4.10</font><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Escrow Agreement</u><font style="font-weight:normal;">. Assignor and Assignee agree to negotiate and enter into an Escrow Agreement within thirty (30) days of the Closing Date.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:12pt;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:normal;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 4.11</font><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Closing Certificates</u><font style="font-weight:normal;">. &#160;On the Closing Date: (i) the Assignor shall deliver to the Assignee a certificate of an authorized officer of the Assignor, dated as of the Closing Date, certifying (A) as to the incumbency of the officer of the Assignor executing this Agreement, and (B) as to the attached copies of Assignor&#8217;s certificate of incorporation, bylaws and resolutions adopted by the Assignor&#8217;s board of directors authorizing the execution and delivery by the Assignor of this Agreement and the consummation by the Assignor of the transactions contemplated hereby</font><font style="font-weight:normal;"><a name="_Toc137673344"></a><a name="_Toc137673435"></a></font><font style="font-weight:normal;">; and (ii) the Assignee shall deliver to the Assignor a certificate of an authorized officer of Assignee, dated as of the Closing Date, certifying as to the incumbency of the officer of the Assignee executing this Agreement.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-left:0pt;margin-top:12pt;text-align:center;text-indent:0pt;text-transform:uppercase;"><font style="font-weight:normal;white-space:nowrap;">Article 5&#160;</font><a name="_Toc163638414"></a><a name="_Ref_ContractCompanion_9kb9Ur07H"></a><a name="_Ref137041144"></a><a name="_Toc163454701"></a><a name="_Toc163454768"></a><a name="_Toc163454819"></a><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;text-indent:0pt;margin:12pt 0pt 0pt 0pt;">INDEMNIFICATION</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:12pt;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:normal;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 5.1</font><a name="_Ref137370952"></a><a name="_Ref_ContractCompanion_9kb9Ur08A"></a><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">General Indemnity</u><font style="font-weight:normal;">.</font><a name="_Ref131785877"></a><font style="font-weight:normal;"> </font><font style="font-weight:normal;"><a name="_Ref276335804"></a><a name="_Ref288083735"></a><a name="_Ref288084038"></a><a name="_Ref137041196"></a></font><font style="font-weight:normal;">Subject to &#8206;&#8206;</font><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section 5.3</u><font style="font-weight:normal;">, from and after the Closing Date:</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref_ContractCompanion_9kb9Ur09B"></a><a name="_Ref_ContractCompanion_9kb9Ur09D"></a><a name="_Ref137041931"></a>Assignor hereby agrees to indemnify, defend and hold harmless Assignee and its Affiliates and its and their directors, managers, trustees, officers, agents and employees (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assignee Indemnified Parties</u>&#8221;) from, against and in respect of all Losses suffered or incurred by Assignee Indemnified Parties to the extent arising out of or resulting from (i) any breach of any of the representations or warranties (in each case, when made) of Assignor in this Agreement, (ii) any breach of any of the covenants or agreements of Assignor in this Agreement, and (iii) any Excluded Liabilities and Obligations; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u>, that the foregoing shall exclude any indemnification to any Assignee Indemnified Party (i) that results from the gross negligence or willful misconduct of an Assignee Indemnified Party or (ii) that results from acts or omissions of Assignor or any of its Affiliates that are in accordance with specific written instructions from any Assignee Indemnified Party (unless Assignor is otherwise liable for such Losses pursuant to the terms of this Agreement); and</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref_ContractCompanion_9kb9Ur03B"></a><a name="_Ref_ContractCompanion_9kb9Ur03D"></a>Assignee hereby agrees to indemnify, defend and hold harmless Assignor and its Affiliates and its and their directors, officers, agents and employees (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assignor Indemnified Parties</u>&#8221;) from, against and in respect of all Losses suffered or incurred by Assignor Indemnified Parties to the extent arising out of or resulting from (i)&#160;any breach of any of the representations or warranties (in each case, when made) of Assignee in this Agreement<a name="_cp_text_1_203"></a> or (ii)&#160;any breach of any of the covenants or agreements of Assignee in this Agreement; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u>, that the foregoing shall exclude any indemnification to any Assignor Indemnified Party (i) that results from the gross negligence or willful misconduct of an Assignor Indemnified Party or (ii) that results from acts or omissions of Assignee or any of its Affiliates that are in accordance with specific written instructions from any Assignor Indemnified Party (unless Assignee is otherwise liable for such Losses pursuant to the terms of this Agreement).<a name="_Ref137101427"></a></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">15</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:normal;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 5.2</font><a name="_Ref137563337"></a><a name="_Ref_ContractCompanion_9kb9Ur04E"></a><a name="_Ref_ContractCompanion_9kb9Ur057"></a><a name="_Ref_ContractCompanion_9kb9Ur09J"></a><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notice of Claims</u><font style="font-weight:normal;">.</font> &#160;<font style="font-weight:normal;">If either an Assignee Indemnified Party, on the one hand, or an Assignor Indemnified Party, on the other hand (such Assignee Indemnified Party on the one hand and such Assignor Indemnified Party on the other hand being hereinafter referred to as an &#8220;</font><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnified Party</u><font style="font-weight:normal;">&#8221;), has suffered or incurred any Losses for which indemnification may be sought under this &#8206;&#8206;&#8206;</font><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Article 5</u><font style="font-weight:normal;">, the Indemnified Party shall so notify the other party from whom indemnification is sought under this &#8206;&#8206;&#8206;</font><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Article 5</u><font style="font-weight:normal;"> (the &#8220;</font><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnifying Party</u><font style="font-weight:normal;">&#8221;) promptly in writing describing such Loss, the amount or estimated amount thereof, if known or reasonably capable of estimation, and the method of computation of such Loss, all with reasonable particularity and containing a reference to the provisions of this Agreement in respect of which such Loss shall have occurred. &#160;If any claim, action, suit or proceeding is asserted or instituted by or against a Third Party with respect to which an Indemnified Party intends to claim any Loss under this &#8206;&#8206;</font><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;&#8206;Article 5</u><font style="font-weight:normal;">, such Indemnified Party shall promptly notify the Indemnifying Party of such claim, action, suit or proceeding and tender to the Indemnifying Party the defense of such claim, action, suit or proceeding. &#160;A failure by an Indemnified Party to give notice and to tender the defense of such claim, action, suit or proceeding in a timely manner pursuant to this &#8206;&#8206;</font><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section 5.2</u><font style="font-weight:normal;"> shall not limit the obligation of the Indemnifying Party under this &#8206;&#8206;&#8206;</font><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Article 5</u><font style="font-weight:normal;">, except to the extent such Indemnifying Party is actually prejudiced thereby.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:normal;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 5.3</font><a name="_Ref137041350"></a><a name="_Ref137554768"></a><a name="_Ref_ContractCompanion_9kb9Ur07D"></a><a name="_Ref_ContractCompanion_9kb9Ur07F"></a><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Limitations on Liability</u><font style="font-weight:normal;">.</font> &#160;<font style="font-weight:normal;">Other than with respect to Excluded Liabilities and Obligations, Losses due to any fraud, willful misconduct, intentional misrepresentation or intentional breach, no party hereto shall be liable for any consequential, punitive, indirect, special or incidental damages under this &#8206;&#8206;&#8206;</font><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Article 5</u><font style="font-weight:normal;"> (and no claim for indemnification hereunder shall be asserted) as a result of any breach or violation of any covenant or agreement of such party (including under this &#8206;</font><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Article 5</u><font style="font-weight:normal;">) in or pursuant to this Agreement, except in respect of a claim for fraud, willful misconduct, intentional misrepresentation, or to the extent a court of competent jurisdiction awards such damages to a Third Party. Notwithstanding the foregoing, the parties hereto acknowledge and agree that (x) Assignee&#8217;s Losses, if any, will typically include Losses for Royalty payments that Assignee was entitled to receive or would have received absent such breach, in each case in respect of its ownership of the Royalty, as well as expenses incurred in connection with enforcement of this Agreement, and (y) Assignee shall be entitled to make claims for all such missing, delayed or diminished Royalty payments as Losses hereunder, and such missing, delayed or diminished Royalty payments shall not be deemed consequential (including lost profits), punitive, special or incidental damages</font><font style="font-weight:normal;">. Other than with respect to Excluded Liabilities and Obligations, Losses due to any fraud, willful misconduct, intentional misrepresentation or intentional breach, in no event shall Assignor&#8217;s aggregate liability for Losses under </font><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.1(a)(i)</u><font style="font-weight:normal;"> or Assignee&#8217;s aggregate liability for Losses under </font><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.1(b)(i)</u><font style="font-weight:normal;"> exceed [***].</font><font style="font-weight:normal;"> </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:normal;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 5.4</font><a name="_Ref137041289"></a><a name="_Ref_ContractCompanion_9kb9Ur08I"></a><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Third Party Claims</u><font style="font-weight:normal;">. </font> <font style="font-weight:normal;">Upon providing notice to an Indemnifying Party by an Indemnified Party pursuant to &#8206;</font><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section 5.1(a)</u><font style="font-weight:normal;"> of the commencement of any action, suit or proceeding against such Indemnified Party by a Third Party with respect to which such Indemnified Party intends to claim any Loss under this &#8206;&#8206;</font><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;&#8206;Article 5</u><font style="font-weight:normal;">, such Indemnifying Party shall have the right to defend such claim, at such Indemnifying Party&#8217;s expense and with counsel of its choice reasonably satisfactory to the Indemnified Party. &#160;If the Indemnifying Party assumes the defense of such claim, the Indemnified Party shall, at the request of the Indemnifying Party, use commercially reasonable efforts to cooperate in such defense; provided, that the Indemnifying Party shall bear the Indemnified Party&#8217;s reasonable out-of-pocket costs and expenses incurred in connection with such cooperation. &#160;So long as the Indemnifying Party is conducting the defense of </font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">16</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:0pt;"><font style="font-weight:normal;">such claim as provided in this &#8206;&#8206;&#8206;</font><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section 5.4</u><font style="font-weight:normal;">, the Indemnified Party may retain separate co-counsel at its expense and may participate in the defense of such claim, and neither the Indemnified Party nor the Indemnifying Party shall consent to the entry of any Judgment or enter into any settlement with respect to such claim without the prior written consent of the other unless such Judgment or settlement (A) provides for the payment by the Indemnifying Party of money as sole relief (if any) for the claimant (other than customary and reasonable confidentiality obligations relating to such claim, Judgment or settlement), (B) results in the full and general release of the Indemnified Party from all liabilities arising out of, relating to or in connection with such claim and (C) does not involve a finding or admission of any violation of any law, rule, regulation or Judgment, or the rights of any Person, and has no effect on any other claims that may be made against the Indemnified Party. &#160;In the event the Indemnifying Party does not or ceases to conduct the defense of such claim as so provided, (i) the Indemnified Party may defend against, and consent to the entry of any Judgment or enter into any settlement with respect to, such claim in any manner it may reasonably deem to be appropriate, (ii) subject to the limitations set forth in </font><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;&#8206;Section 5.3</u><font style="font-weight:normal;">, the Indemnifying Party shall reimburse the Indemnified Party promptly and periodically for the reasonable out-of-pocket costs of defending against such claim, including reasonable attorneys&#8217; fees and expenses against reasonably detailed invoices, and (iii) the Indemnifying Party shall remain responsible for any Losses the Indemnified Party may suffer as a result of such claim to the full extent provided in this &#8206;&#8206;&#8206;Article 5.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:normal;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 5.5</font><a name="_Ref137564357"></a><a name="_Ref_ContractCompanion_9kb9Ur08G"></a><a name="_Ref137109982"></a><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exclusive Remedy</u>. &#160;<font style="font-weight:normal;">Except as set forth in &#8206;&#8206;</font><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;&#8206;Section 6.12</u><font style="font-weight:normal;">, from and after the Closing Date, the rights of the parties hereto pursuant to (and subject to the conditions of) this &#8206;&#8206;&#8206;Article 5 shall be the sole and exclusive remedy of the parties hereto and their respective Affiliates with respect to any claims (whether based in contract, tort or otherwise) resulting from or relating to any breach of the representations, warranties covenants and agreements made under this Agreement or any certificate, document or instrument delivered hereunder, and each party hereto hereby waives, to the fullest extent permitted under applicable law, and agrees not to assert after the Closing Date, any other claim or action in respect of any such breach. &#160;Notwithstanding the foregoing, claims for fraud shall not be waived or limited in any way by this &#8206;&#8206;&#8206;Article 5.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:normal;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 5.6</font><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Survival of Representations and Warranties.</u><font style="font-weight:normal;"> &#160;The representations and warranties contained in this Agreement shall survive the Closing Date solely for purposes of </font><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;&#8206;Section 5.1</u><font style="font-weight:normal;"> and shall terminate on the date that is eighteen (18) months after the Closing Date (other than any representation or warranty with respect to any Assignor Fundamental Representations and any Assignee Fundamental Representations, which shall survive solely for purposes of </font><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;&#8206;Section 5.1</u><font style="font-weight:normal;"> and shall terminate on the date that is five (5) years from the date the Royalty Purchase Agreement is terminated. No party hereto shall have any liability or obligation of any nature with respect to any representation or warranty after the termination thereof, unless the other party hereto shall have delivered a notice to such party, pursuant to this </font><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;&#8206;Article 5</u><font style="font-weight:normal;">, claiming such liability or obligation under &#8206;</font><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section 5.1</u><font style="font-weight:normal;"> prior to the date that is eighteen (18) months after the Closing Date (other than any liability or obligation of any nature with respect to any Assignor Fundamental Representations, any Assignee Fundamental Representations, or any Excluded Liability and Obligations, as to which such notice may be delivered at any time prior to the date that is five (5) years after the termination of the Royalty Purchase Agreement).</font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">17</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-left:0pt;margin-top:0pt;text-align:center;text-indent:0pt;text-transform:uppercase;"><font style="font-weight:normal;white-space:nowrap;">Article 6&#160;</font><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><a name="_Toc163638421"></a><a name="_Toc163638488"></a><a name="_Toc164000416"></a><a name="_Toc164621462"></a><a name="_Toc165129445"></a><a name="_Toc165133693"></a><a name="_Toc165347314"></a><a name="_Toc165883192"></a><a name="_Toc165892827"></a><a name="_Toc173174559"></a><a name="_Toc173182142"></a><a name="_Toc173675465"></a><a name="_Toc173675711"></a><a name="_Toc173830006"></a><a name="_Toc174777577"></a><a name="_Toc175981483"></a><a name="_Toc175981701"></a><a name="_Toc175981773"></a><a name="_Toc176347257"></a><a name="_Toc176347313"></a><a name="_Toc176683145"></a><a name="_Toc184699305"></a><a name="_Toc185673601"></a><a name="_Toc185677477"></a><a name="_Toc185924293"></a><a name="_Toc185997246"></a><a name="_Toc189740906"></a><a name="_Toc189793248"></a><a name="_Toc189927342"></a><a name="_Toc189979141"></a><a name="_Toc189979191"></a><a name="_Toc189979223"></a><a name="_Toc191097471"></a><a name="_Toc191113788"></a><a name="_Toc191114048"></a><a name="_Toc191115695"></a><a name="_Toc191120569"></a><a name="_Toc191987183"></a><a name="_Toc192068289"></a><a name="_Toc192337957"></a><a name="_Ref276335384"></a><a name="_Toc277686256"></a><a name="_Ref363830158"></a><a name="_Toc163638422"></a><a name="_Toc163638495"></a><a name="_Toc164000423"></a><a name="_Toc164621469"></a><a name="_Toc165129452"></a><a name="_Toc165133700"></a><a name="_Toc165347321"></a><a name="_Toc165883199"></a><a name="_Toc165892834"></a><a name="_Toc172378765"></a><a name="_Toc172483491"></a><a name="_Toc172544307"></a><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><a name="_Toc163454705"></a><a name="_Toc163454772"></a><a name="_Toc163454824"></a><a name="_Toc163638427"></a><a name="_Toc163638500"></a><a name="_Toc164000428"></a><a name="_Toc164621474"></a><a name="_Toc165129457"></a><a name="_Toc165133705"></a><a name="_Toc165347326"></a><a name="_Toc165883203"></a><a name="_Toc165892839"></a><a name="_Toc172378770"></a><a name="_Toc172483496"></a><a name="_Toc172544312"></a><a name="_Toc173174572"></a><a name="_Toc173182155"></a><a name="_Toc173675478"></a><a name="_Toc173675724"></a><a name="_Toc173830019"></a><a name="_Toc174777590"></a><a name="_Toc175981496"></a><a name="_Toc175981720"></a><a name="_Toc175981786"></a><a name="_Toc176347270"></a><a name="_Toc176347326"></a><a name="_Toc176683157"></a><a name="_Toc184699317"></a><a name="_Toc185673613"></a><a name="_Toc185677489"></a><a name="_Toc185924305"></a><a name="_Toc185997258"></a><a name="_Toc189740918"></a><a name="_Toc189793260"></a><a name="_Toc189927354"></a><a name="_Toc189979159"></a><a name="_Toc189979193"></a><a name="_Toc189979235"></a><a name="_Toc191097483"></a><a name="_Toc191113800"></a><a name="_Toc191114060"></a><a name="_Toc191115707"></a><a name="_Toc191120580"></a><a name="_Toc191987194"></a><a name="_Toc192068300"></a><a name="_Toc192337968"></a><a name="_Ref276336118"></a><a name="_Toc277686267"></a><a name="_Ref472916432"></a><a name="_Toc44282668"></a><a name="_Toc96470035"></a><font style="font-weight:normal;">MISCELLANEOUS</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:12pt;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:normal;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 6.1</font><a name="_Toc277686269"></a><a name="_Toc44282670"></a><a name="_Toc96470036"></a><a name="_Toc163454707"></a><a name="_Toc163454774"></a><a name="_Toc163454826"></a><a name="_Toc163638429"></a><a name="_Toc163638502"></a><a name="_Toc164000430"></a><a name="_Toc164621476"></a><a name="_Toc165129459"></a><a name="_Toc165133707"></a><a name="_Toc165347328"></a><a name="_Toc165883205"></a><a name="_Toc165892841"></a><a name="_Toc172378772"></a><a name="_Toc172483498"></a><a name="_Toc172544314"></a><a name="_Toc173174574"></a><a name="_Toc173182157"></a><a name="_Toc173675480"></a><a name="_Toc173675726"></a><a name="_Toc173830021"></a><a name="_Toc174777592"></a><a name="_Toc175981498"></a><a name="_Toc175981722"></a><a name="_Toc175981788"></a><a name="_Toc176347272"></a><a name="_Toc176347328"></a><a name="_Toc176683159"></a><a name="_Toc184699319"></a><a name="_Toc185673615"></a><a name="_Toc185677491"></a><a name="_Toc185924307"></a><a name="_Toc185997260"></a><a name="_Toc189740920"></a><a name="_Toc189793262"></a><a name="_Toc189927356"></a><a name="_Toc189979161"></a><a name="_Toc189979237"></a><a name="_Toc191097485"></a><a name="_Toc191113802"></a><a name="_Toc191114062"></a><a name="_Toc191115709"></a><a name="_Toc191120582"></a><a name="_Toc191987196"></a><a name="_Toc192068302"></a><a name="_Toc192337970"></a><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Certain Interpretations</u><font style="font-weight:normal;">. Except where expressly stated otherwise in this Agreement, the following rules of interpretation apply to this Agreement</font><font style="font-weight:normal;">: </font><font style="font-weight:normal;"><a name="_Toc175981729"></a><a name="_Toc189979168"></a></font><font style="font-weight:normal;">(a) &#8220;either&#8221; and &#8220;or&#8221; are not exclusive and &#8220;include,&#8221; &#8220;includes&#8221; and &#8220;including&#8221; are not limiting and shall be deemed to be followed by the words &#8220;without limitation;&#8221; (b)&#8220;extent&#8221; in the phrase &#8220;to the extent&#8221; means the degree to which a subject or other thing extends, and such phrase does not mean simply &#8220;if;&#8221; (c) &#8220;hereof,&#8221; &#8220;hereto,&#8221; &#8220;herein&#8221; and &#8220;hereunder&#8221; and words of similar import when used in this Agreement refer to this Agreement as a whole and not to any particular provision of this Agreement; (d) references to a Person are also to its permitted successors and assigns; (e) definitions are applicable to the singular as well as the plural forms of such terms; (f) unless otherwise indicated, references to an &#8220;Article&#8221;, &#8220;Section&#8221;, &#8220;Schedule&#8221; or &#8220;Exhibit&#8221; refer to an Article or Section of, or a Schedule or Exhibit to, this Agreement; (g) references to &#8220;$&#8221; or otherwise to dollar amounts refer to the lawful currency of the United States; (h) references to a contract, license, indenture, instrument or agreement mean such contract, license, indenture, instrument or agreement as from time to time amended, modified or supplemented, in each case to the extent not prohibited thereby or by this Agreement; (i) references to an agreement or other document include references to any annexes, exhibits and schedules attached thereto; and (j) references to a law include any amendment or modification to such law and any rules and regulations issued thereunder, whether such amendment or modification is made, or issuance of such rules and regulations occurs, before or after the date of this Agreement.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:12pt;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:normal;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 6.2</font><a name="_Toc277686270"></a><a name="_Toc44282671"></a><a name="_Toc96470037"></a><a name="_Toc163454708"></a><a name="_Toc163454775"></a><a name="_Toc163454827"></a><a name="_Toc163638430"></a><a name="_Toc163638503"></a><a name="_Toc164000431"></a><a name="_Toc164621477"></a><a name="_Toc165129460"></a><a name="_Toc165133708"></a><a name="_Toc165347329"></a><a name="_Toc165883206"></a><a name="_Toc165892842"></a><a name="_Toc172378773"></a><a name="_Toc172483499"></a><a name="_Toc172544315"></a><a name="_Toc173174575"></a><a name="_Toc173182158"></a><a name="_Toc173675481"></a><a name="_Toc173675727"></a><a name="_Toc173830022"></a><a name="_Toc174777593"></a><a name="_Toc175981499"></a><a name="_Toc175981730"></a><a name="_Toc175981789"></a><a name="_Toc176347273"></a><a name="_Toc176347329"></a><a name="_Toc176683160"></a><a name="_Toc184699320"></a><a name="_Toc185673616"></a><a name="_Toc185677492"></a><a name="_Toc185924308"></a><a name="_Toc185997261"></a><a name="_Toc189740921"></a><a name="_Toc189793263"></a><a name="_Toc189927357"></a><a name="_Toc189979169"></a><a name="_Toc189979238"></a><a name="_Toc191097486"></a><a name="_Toc191113803"></a><a name="_Toc191114063"></a><a name="_Toc191115710"></a><a name="_Toc191120583"></a><a name="_Toc191987197"></a><a name="_Toc192068303"></a><a name="_Toc192337971"></a><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Headings</u><font style="font-weight:normal;">. The table of contents and the descriptive headings of the several Articles and Sections of this Agreement and any Exhibits and Schedules are for convenience only, do not constitute a part of this Agreement and shall not control or affect, in any way, the meaning or interpretation of this Agreement.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:12pt;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:normal;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 6.3</font><a name="_Toc277686271"></a><a name="_Ref363830918"></a><a name="_Ref363830920"></a><a name="_Toc44282672"></a><a name="_Ref96156372"></a><a name="_Ref96156397"></a><a name="_Ref96413609"></a><a name="_Ref96468692"></a><a name="_Ref96468721"></a><a name="_Ref96468760"></a><a name="_Toc96470038"></a><a name="_Ref137564325"></a><a name="_Ref137564346"></a><a name="_Toc163454709"></a><a name="_Toc163454776"></a><a name="_Toc163454828"></a><a name="_Toc163638431"></a><a name="_Toc163638504"></a><a name="_Toc164000432"></a><a name="_Toc164621478"></a><a name="_Toc165129461"></a><a name="_Toc165133709"></a><a name="_Toc165347330"></a><a name="_Toc165883207"></a><a name="_Toc165892843"></a><a name="_Toc172378774"></a><a name="_Toc172483500"></a><a name="_Toc172544316"></a><a name="_Toc173174576"></a><a name="_Toc173182159"></a><a name="_Toc173675482"></a><a name="_Toc173675728"></a><a name="_Toc173830023"></a><a name="_Toc174777594"></a><a name="_Toc175981500"></a><a name="_Toc175981731"></a><a name="_Toc175981790"></a><a name="_Toc176347274"></a><a name="_Toc176347330"></a><a name="_Toc176683161"></a><a name="_Toc184699321"></a><a name="_Toc185673617"></a><a name="_Toc185677493"></a><a name="_Toc185924309"></a><a name="_Toc185997262"></a><a name="_Toc189740922"></a><a name="_Toc189793264"></a><a name="_Toc189927358"></a><a name="_Toc189979170"></a><a name="_Toc189979239"></a><a name="_Toc191097487"></a><a name="_Toc191113804"></a><a name="_Toc191114064"></a><a name="_Toc191115711"></a><a name="_Toc191120584"></a><a name="_Toc191987198"></a><a name="_Toc192068304"></a><a name="_Toc192337972"></a><a name="_Ref276322454"></a><a name="_Ref_ContractCompanion_9kb9Ur08C"></a><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notices</u><font style="font-weight:normal;">. All notices and other communications under this Agreement shall be in writing and shall be by email with PDF attachment, facsimile, courier service or personal delivery to the following addresses, or to such other addresses as shall be designated from time to time by a party hereto in accordance with this &#8206;&#8206;</font><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;&#8206;Section 6.3</u><font style="font-weight:normal;">:</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:12pt 0pt 0pt 0pt;">If to Assignor, to it at:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:12pt 36pt 0pt 108pt;">LadRx Corporation<br>11726 San Vicente Blvd, Suite 650<br>Los Angeles, CA 90049<br>Attention: [***]<br>Email: [***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:12pt 0pt 0pt 0pt;">With a copy to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:12pt 36pt 0pt 108pt;">Haynes and Boone, LLP<br>30 Rockefeller Plaza<br>New York, NY 10112<br><font style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">18</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 36pt 0pt 108pt;">Attention: [***]<br>Email: [***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:12pt 0pt 0pt 0pt;">If to Assignee, to it at:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:12pt 36pt 0pt 108pt;">Xoma (US) LLC<br>2200 Powell Street, Suite 310<br>Emeryville, CA 94608<br>Attention: Legal Department; [***]<br>Email: [***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:12pt 0pt 0pt 0pt;">With a copy to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:12pt 36pt 0pt 108pt;">Gibson, Dunn &amp; Crutcher LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 36pt 0pt 108pt;">555 Mission Street, 30<sup style="font-size:9pt;vertical-align:top;">th</sup> Floor</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 36pt 0pt 108pt;">San Francisco, California 94105</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 36pt 0pt 108pt;">Attention: [***]<br>E-mail: [***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:12pt 0pt 0pt 0pt;">All notices and communications under this Agreement shall be deemed to have been duly given (i)&#160;when delivered by hand, if personally delivered, (ii)&#160;when received by a recipient, if sent by email, or (iii)&#160;one (1) Business Day following sending within the United States by overnight delivery via commercial one-day overnight courier service.</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:12pt;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:normal;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 6.4</font><a name="_Toc277686272"></a><a name="_Toc44282673"></a><a name="_Toc96470039"></a><a name="_Toc163454710"></a><a name="_Toc163454777"></a><a name="_Toc163454829"></a><a name="_Toc163638432"></a><a name="_Toc163638505"></a><a name="_Toc164000433"></a><a name="_Toc164621479"></a><a name="_Toc165129462"></a><a name="_Toc165133710"></a><a name="_Toc165347331"></a><a name="_Toc165883208"></a><a name="_Toc165892844"></a><a name="_Toc172378775"></a><a name="_Toc172483501"></a><a name="_Toc172544317"></a><a name="_Toc173174577"></a><a name="_Toc173182160"></a><a name="_Toc173675483"></a><a name="_Toc173675729"></a><a name="_Toc173830024"></a><a name="_Toc174777595"></a><a name="_Toc175981501"></a><a name="_Toc175981732"></a><a name="_Toc175981791"></a><a name="_Toc176347275"></a><a name="_Toc176347331"></a><a name="_Toc176683162"></a><a name="_Toc184699322"></a><a name="_Toc185673618"></a><a name="_Toc185677494"></a><a name="_Toc185924310"></a><a name="_Toc185997263"></a><a name="_Toc189740923"></a><a name="_Toc189793265"></a><a name="_Toc189927359"></a><a name="_Toc189979171"></a><a name="_Toc189979240"></a><a name="_Toc191097488"></a><a name="_Toc191113805"></a><a name="_Toc191114065"></a><a name="_Toc191115712"></a><a name="_Toc191120585"></a><a name="_Toc191987199"></a><a name="_Toc192068305"></a><a name="_Toc192337973"></a><a name="_Ref_ContractCompanion_9kb9Ur06A"></a><a name="_Ref_ContractCompanion_9kb9Ur06C"></a><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Expenses</u><font style="font-weight:normal;">. Upon the Closing Date, Assignor shall promptly reimburse Assignee for all its reasonable and documented out-of-pocket fees, costs, and expenses (including any legal, accounting and banking fees) incurred in connection with the preparation, negotiation, execution and delivery of this Agreement and to consummate the transactions contemplated hereby</font><font style="font-weight:normal;"> [***] for this Agreement and the Royalty Purchase Agreement (&#8220;</font><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transaction Expenses</u><font style="font-weight:normal;">&#8221;).</font><font style="font-weight:normal;"> For the avoidance of doubt, Assignee shall have the right to deduct Transaction Expenses from payment of the Purchase Price. In the event the transactions contemplated hereby are not consummated, Assignor shall promptly reimburse Assignee for Transaction Expenses incurred prior to the cessation of discussions regarding the transactions contemplated hereby.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:12pt;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:normal;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 6.5</font><a name="_Toc277686273"></a><a name="_Ref472916757"></a><a name="_Toc44282674"></a><a name="_Toc96064715"></a><a name="_Toc163454711"></a><a name="_Toc163454778"></a><a name="_Toc163454830"></a><a name="_Toc163638433"></a><a name="_Toc163638506"></a><a name="_Toc164000434"></a><a name="_Toc164621480"></a><a name="_Toc165129463"></a><a name="_Toc165133711"></a><a name="_Toc165347332"></a><a name="_Toc165883209"></a><a name="_Toc165892845"></a><a name="_Toc172378776"></a><a name="_Toc172483502"></a><a name="_Toc172544318"></a><a name="_Toc173174578"></a><a name="_Toc173182161"></a><a name="_Toc173675484"></a><a name="_Toc173675730"></a><a name="_Toc173830025"></a><a name="_Toc174777596"></a><a name="_Toc175981502"></a><a name="_Toc175981733"></a><a name="_Toc175981792"></a><a name="_Toc176347276"></a><a name="_Toc176347332"></a><a name="_Toc176683163"></a><a name="_Toc184699323"></a><a name="_Toc185673619"></a><a name="_Toc185677495"></a><a name="_Toc185924311"></a><a name="_Toc185997264"></a><a name="_Toc189740924"></a><a name="_Toc189793266"></a><a name="_Toc189927360"></a><a name="_Toc189979172"></a><a name="_Toc189979241"></a><a name="_Toc191097489"></a><a name="_Toc191113806"></a><a name="_Toc191114066"></a><a name="_Toc191115713"></a><a name="_Toc191120586"></a><a name="_Toc191987200"></a><a name="_Toc192068306"></a><a name="_Toc192337974"></a><a name="_Toc96470040"></a><a name="_Ref97566421"></a><a name="_Ref137564337"></a><a name="_Ref_ContractCompanion_9kb9Ur08E"></a><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assignment</u><font style="font-weight:normal;white-space:pre-wrap;"> </font><font style="font-weight:normal;">Neither party shall sell, convey, assign, dispose, pledge, hypothecate or otherwise transfer all or any portion of its interest in this Agreement to any Third Party without the consent of the other party, which consent shall not be unreasonably withheld, conditioned or delayed. </font><font style="font-weight:normal;">Subject to the foregoing, this Agreement shall be binding upon, inure to the benefit of and be enforceable by, the parties hereto and their respective permitted successors and assigns. Assignee may assign this Agreement, provided that Assignee promptly thereafter notifies Assignor and any such assignee promptly thereafter agrees in writing to be bound by the obligations of Assignee contained in this Agreement, and in any event such assignment shall be of the Agreement in its entirety. Any purported sale, conveyance, assignment, disposition, pledge, hypothecation or transfer in violation of this </font><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;&#8206;&#8206;Section 6.5</u><font style="font-weight:normal;"> shall be null and void.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:12pt;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:normal;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 6.6</font><a name="_Toc96470041"></a><a name="_Toc163454712"></a><a name="_Toc163454779"></a><a name="_Toc163454831"></a><a name="_Toc163638434"></a><a name="_Toc163638507"></a><a name="_Toc164000435"></a><a name="_Toc164621481"></a><a name="_Toc165129464"></a><a name="_Toc165133712"></a><a name="_Toc165347333"></a><a name="_Toc165883210"></a><a name="_Toc165892846"></a><a name="_Toc172378777"></a><a name="_Toc172483503"></a><a name="_Toc172544319"></a><a name="_Toc173174579"></a><a name="_Toc173182162"></a><a name="_Toc173675485"></a><a name="_Toc173675731"></a><a name="_Toc173830026"></a><a name="_Toc174777597"></a><a name="_Toc175981503"></a><a name="_Toc175981734"></a><a name="_Toc175981793"></a><a name="_Toc176347277"></a><a name="_Toc176347333"></a><a name="_Toc176683164"></a><a name="_Toc184699324"></a><a name="_Toc185673620"></a><a name="_Toc185677496"></a><a name="_Toc185924312"></a><a name="_Toc185997265"></a><a name="_Toc189740925"></a><a name="_Toc189793267"></a><a name="_Toc189927361"></a><a name="_Toc189979173"></a><a name="_Toc189979242"></a><a name="_Toc191097490"></a><a name="_Toc191113807"></a><a name="_Toc191114067"></a><a name="_Toc191115714"></a><a name="_Toc191120587"></a><a name="_Toc191987201"></a><a name="_Toc192068307"></a><a name="_Toc192337975"></a><a name="_Toc277686274"></a><a name="_Toc44282675"></a><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendment and Waiver</u><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">.</u></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">19</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Toc175981735"></a><a name="_Toc189979174"></a>This Agreement may be amended, modified or supplemented only in a writing signed by each of the parties hereto. Any provision of this Agreement may be waived only in a writing signed by the party hereto granting such waiver.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Toc175981736"></a><a name="_Toc189979175"></a>No failure or delay on the part of any party hereto in exercising any right, power or remedy hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such right, power or remedy preclude any other or further exercise thereof or the exercise of any other right, power or remedy. No course of dealing between the parties hereto shall be effective to amend, modify, supplement or waive any provision of this Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:12pt;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:normal;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 6.7</font><a name="_Toc277686275"></a><a name="_Toc44282676"></a><a name="_Toc96470042"></a><a name="_Toc163454713"></a><a name="_Toc163454780"></a><a name="_Toc163454832"></a><a name="_Toc163638435"></a><a name="_Toc163638508"></a><a name="_Toc164000436"></a><a name="_Toc164621482"></a><a name="_Toc165129465"></a><a name="_Toc165133713"></a><a name="_Toc165347334"></a><a name="_Toc165883211"></a><a name="_Toc165892847"></a><a name="_Toc172378778"></a><a name="_Toc172483504"></a><a name="_Toc172544320"></a><a name="_Toc173174580"></a><a name="_Toc173182163"></a><a name="_Toc173675486"></a><a name="_Toc173675732"></a><a name="_Toc173830027"></a><a name="_Toc174777598"></a><a name="_Toc175981504"></a><a name="_Toc175981737"></a><a name="_Toc175981794"></a><a name="_Toc176347278"></a><a name="_Toc176347334"></a><a name="_Toc176683165"></a><a name="_Toc184699325"></a><a name="_Toc185673621"></a><a name="_Toc185677497"></a><a name="_Toc185924313"></a><a name="_Toc185997266"></a><a name="_Toc189740926"></a><a name="_Toc189793268"></a><a name="_Toc189927362"></a><a name="_Toc189979176"></a><a name="_Toc189979243"></a><a name="_Toc191097491"></a><a name="_Toc191113808"></a><a name="_Toc191114068"></a><a name="_Toc191115715"></a><a name="_Toc191120588"></a><a name="_Toc191987202"></a><a name="_Toc192068308"></a><a name="_Toc192337976"></a><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Entire Agreement</u><font style="font-weight:normal;">. </font><font style="font-weight:normal;">This Agreement and the Exhibits and Schedules annexed hereto constitute the entire understanding between the parties hereto with respect to the subject matter hereof and supersede all other understandings and negotiations with respect thereto. </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:12pt;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:normal;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 6.8</font><a name="_Toc277686276"></a><a name="_Toc44282677"></a><a name="_Toc96470043"></a><a name="_Toc163454714"></a><a name="_Toc163454781"></a><a name="_Toc163454833"></a><a name="_Toc163638436"></a><a name="_Toc163638509"></a><a name="_Toc164000437"></a><a name="_Toc164621483"></a><a name="_Toc165129466"></a><a name="_Toc165133714"></a><a name="_Toc165347335"></a><a name="_Toc165883212"></a><a name="_Toc165892848"></a><a name="_Toc172378779"></a><a name="_Toc172483505"></a><a name="_Toc172544321"></a><a name="_Toc173174581"></a><a name="_Toc173182164"></a><a name="_Toc173675487"></a><a name="_Toc173675733"></a><a name="_Toc173830028"></a><a name="_Toc174777599"></a><a name="_Toc175981505"></a><a name="_Toc175981738"></a><a name="_Toc175981795"></a><a name="_Toc176347279"></a><a name="_Toc176347335"></a><a name="_Toc176683166"></a><a name="_Toc184699326"></a><a name="_Toc185673622"></a><a name="_Toc185677498"></a><a name="_Toc185924314"></a><a name="_Toc185997267"></a><a name="_Toc189740927"></a><a name="_Toc189793269"></a><a name="_Toc189927363"></a><a name="_Toc189979177"></a><a name="_Toc189979244"></a><a name="_Toc191097492"></a><a name="_Toc191113809"></a><a name="_Toc191114069"></a><a name="_Toc191115716"></a><a name="_Toc191120589"></a><a name="_Toc191987203"></a><a name="_Toc192068309"></a><a name="_Toc192337977"></a><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Third Party Beneficiaries</u><font style="font-weight:normal;">. This Agreement is for the sole benefit of Assignor and Assignee and their permitted successors and assigns and nothing herein expressed or implied shall give or be construed to give to any Person, other than the parties hereto and such successors and assigns, any legal or equitable rights hereunder.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:12pt;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:normal;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 6.9</font><a name="_Toc277686277"></a><a name="_Toc44282678"></a><a name="_Toc96470044"></a><a name="_Toc163454715"></a><a name="_Toc163454782"></a><a name="_Toc163454834"></a><a name="_Toc163638437"></a><a name="_Toc163638510"></a><a name="_Toc164000438"></a><a name="_Toc164621484"></a><a name="_Toc165129467"></a><a name="_Toc165133715"></a><a name="_Toc165347336"></a><a name="_Toc165883213"></a><a name="_Toc165892849"></a><a name="_Toc172378780"></a><a name="_Toc172483506"></a><a name="_Toc172544322"></a><a name="_Toc173174582"></a><a name="_Toc173182165"></a><a name="_Toc173675488"></a><a name="_Toc173675734"></a><a name="_Toc173830029"></a><a name="_Toc174777600"></a><a name="_Toc175981506"></a><a name="_Toc175981739"></a><a name="_Toc175981796"></a><a name="_Toc176347280"></a><a name="_Toc176347336"></a><a name="_Toc176683167"></a><a name="_Toc184699327"></a><a name="_Toc185673623"></a><a name="_Toc185677499"></a><a name="_Toc185924315"></a><a name="_Toc185997268"></a><a name="_Toc189740928"></a><a name="_Toc189793270"></a><a name="_Toc189927364"></a><a name="_Toc189979178"></a><a name="_Toc189979245"></a><a name="_Toc191097493"></a><a name="_Toc191113810"></a><a name="_Toc191114070"></a><a name="_Toc191115717"></a><a name="_Toc191120590"></a><a name="_Toc191987204"></a><a name="_Toc192068310"></a><a name="_Toc192337978"></a><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing Law</u><font style="font-weight:normal;">. This Agreement shall be governed by, and construed in accordance with, the laws of the State of New York without giving effect to any choice or conflict of law provision or rule that would cause the application of the laws of any other jurisdiction.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:12pt;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:normal;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 6.10</font><a name="_Toc96470045"></a><a name="_Toc163454716"></a><a name="_Toc163454783"></a><a name="_Toc163454835"></a><a name="_Toc163638438"></a><a name="_Toc163638511"></a><a name="_Toc164000439"></a><a name="_Toc164621485"></a><a name="_Toc165129468"></a><a name="_Toc165133716"></a><a name="_Toc165347337"></a><a name="_Toc165883214"></a><a name="_Toc165892850"></a><a name="_Toc172378781"></a><a name="_Toc172483507"></a><a name="_Toc172544323"></a><a name="_Toc173174583"></a><a name="_Toc173182166"></a><a name="_Toc173675489"></a><a name="_Toc173675735"></a><a name="_Toc173830030"></a><a name="_Toc174777601"></a><a name="_Toc175981507"></a><a name="_Toc175981740"></a><a name="_Toc175981797"></a><a name="_Toc176347281"></a><a name="_Toc176347337"></a><a name="_Toc176683168"></a><a name="_Toc184699328"></a><a name="_Toc185673624"></a><a name="_Toc185677500"></a><a name="_Toc185924316"></a><a name="_Toc185997269"></a><a name="_Toc189740929"></a><a name="_Toc189793271"></a><a name="_Toc189927365"></a><a name="_Toc189979179"></a><a name="_Toc189979246"></a><a name="_Toc191097494"></a><a name="_Toc191113811"></a><a name="_Toc191114071"></a><a name="_Toc191115718"></a><a name="_Toc191120591"></a><a name="_Toc191987205"></a><a name="_Toc192068311"></a><a name="_Toc192337979"></a><a name="_Toc277686278"></a><a name="_Toc44282679"></a><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Jurisdiction; Venue</u><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">.</u></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Toc175981741"></a><a name="_Toc189979180"></a>EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY AND UNCONDITIONALLY SUBMITS, FOR ITSELF AND ITS RESPECTIVE PROPERTY AND ASSETS, TO THE EXCLUSIVE JURISDICTION OF ANY NEW YORK STATE COURT OR FEDERAL COURT OF THE UNITED STATES OF AMERICA SITTING IN NEW YORK COUNTY, NEW YORK, AND ANY APPELLATE COURT THEREOF, IN ANY ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT, OR FOR RECOGNITION OR ENFORCEMENT OF ANY JUDGMENT IN RESPECT THEREOF, AND ASSIGNEE AND ASSIGNOR HEREBY IRREVOCABLY AND UNCONDITIONALLY AGREE THAT ALL CLAIMS IN RESPECT OF ANY SUCH ACTION OR PROCEEDING MAY BE HEARD AND DETERMINED IN ANY SUCH NEW YORK STATE COURT OR, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, IN SUCH FEDERAL COURT. ASSIGNEE AND ASSIGNOR HEREBY AGREE THAT A FINAL JUDGMENT IN ANY SUCH ACTION OR PROCEEDING SHALL BE CONCLUSIVE AND MAY BE ENFORCED IN OTHER JURISDICTIONS BY SUIT ON THE JUDGMENT OR IN ANY OTHER MANNER PROVIDED BY APPLICABLE LAW. EACH OF ASSIGNEE AND ASSIGNOR HEREBY SUBMITS TO THE EXCLUSIVE PERSONAL JURISDICTION AND VENUE OF SUCH NEW YORK STATE AND FEDERAL COURTS. ASSIGNEE AND ASSIGNOR AGREE, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, THAT PROCESS MAY BE SERVED ON ASSIGNEE OR ASSIGNOR IN THE SAME MANNER THAT NOTICES MAY BE GIVEN PURSUANT TO <font style="text-transform:uppercase;">&#8206;&#8206;&#8206;</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;text-transform:uppercase;">&#8206;Section 6.3</u> HEREOF.</div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">20</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Toc175981742"></a><a name="_Toc189979181"></a>EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES, TO THE FULLEST EXTENT IT MAY LEGALLY AND EFFECTIVELY DO SO, ANY OBJECTION THAT IT MAY NOW OR HEREAFTER HAVE TO THE LAYING OF VENUE OF ANY ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT IN ANY NEW YORK STATE OR FEDERAL COURT. EACH OF ASSIGNEE AND ASSIGNOR HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, THE DEFENSE OF AN INCONVENIENT FORUM TO THE MAINTENANCE OF SUCH ACTION OR PROCEEDING IN ANY SUCH COURT.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:12pt;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:normal;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 6.11</font><a name="_Toc277686279"></a><a name="_Toc44282680"></a><a name="_Toc96470046"></a><a name="_Toc163454784"></a><a name="_Toc163454836"></a><a name="_Toc163638439"></a><a name="_Toc163638512"></a><a name="_Toc164000440"></a><a name="_Toc164621486"></a><a name="_Toc165129470"></a><a name="_Toc165133718"></a><a name="_Toc165347339"></a><a name="_Toc165883216"></a><a name="_Toc165892852"></a><a name="_Toc172378782"></a><a name="_Toc172483508"></a><a name="_Toc172544324"></a><a name="_Toc173174584"></a><a name="_Toc173182167"></a><a name="_Toc173675490"></a><a name="_Toc173675736"></a><a name="_Toc173830031"></a><a name="_Toc174777602"></a><a name="_Toc175981508"></a><a name="_Toc175981743"></a><a name="_Toc175981798"></a><a name="_Toc176347282"></a><a name="_Toc176347338"></a><a name="_Toc176683169"></a><a name="_Toc184699329"></a><a name="_Toc185673625"></a><a name="_Toc185677501"></a><a name="_Toc185924317"></a><a name="_Toc185997270"></a><a name="_Toc189740930"></a><a name="_Toc189793272"></a><a name="_Toc189927366"></a><a name="_Toc189979182"></a><a name="_Toc189979247"></a><a name="_Toc191097495"></a><a name="_Toc191113812"></a><a name="_Toc191114072"></a><a name="_Toc191115719"></a><a name="_Toc191120592"></a><a name="_Toc191987206"></a><a name="_Toc192068312"></a><a name="_Toc192337980"></a><a name="_Toc163454717"></a><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Severability</u><font style="font-weight:normal;">. If any term or provision of this Agreement shall for any reason be held to be invalid, illegal or unenforceable in any situation in any jurisdiction, then, to the extent that the economic and legal substance of the transactions contemplated hereby is not affected in a manner that is materially adverse to either party hereto, all other terms and provisions of this Agreement shall nevertheless remain in full force and effect and the enforceability and validity of the offending term or provision shall not be affected in any other situation or jurisdiction.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:12pt;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:normal;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 6.12</font><a name="_Ref276335952"></a><a name="_Toc277686280"></a><a name="_Toc44282681"></a><a name="_Toc96470047"></a><a name="_Toc189979183"></a><a name="_Toc189979248"></a><a name="_Toc191097496"></a><a name="_Toc191113813"></a><a name="_Toc191114073"></a><a name="_Toc191115720"></a><a name="_Toc191120593"></a><a name="_Toc191987207"></a><a name="_Toc192068313"></a><a name="_Toc192337981"></a><a name="_Toc189740932"></a><a name="_Toc189793274"></a><a name="_Toc189927368"></a><a name="_Ref_ContractCompanion_9kb9Ur0AK"></a><a name="_Toc163454785"></a><a name="_Toc163454837"></a><a name="_Toc163638440"></a><a name="_Toc163638513"></a><a name="_Toc164000441"></a><a name="_Toc164621487"></a><a name="_Toc165129471"></a><a name="_Toc165133719"></a><a name="_Toc165347340"></a><a name="_Toc165883217"></a><a name="_Toc165892853"></a><a name="_Toc172378783"></a><a name="_Toc172483509"></a><a name="_Toc172544325"></a><a name="_Toc173174585"></a><a name="_Toc173182168"></a><a name="_Toc173675491"></a><a name="_Toc173675737"></a><a name="_Toc173830032"></a><a name="_Toc174777603"></a><a name="_Toc175981509"></a><a name="_Toc175981744"></a><a name="_Toc175981799"></a><a name="_Toc176347283"></a><a name="_Toc176347339"></a><a name="_Toc176683170"></a><a name="_Toc184699330"></a><a name="_Toc185673626"></a><a name="_Toc185677502"></a><a name="_Toc185924318"></a><a name="_Toc185997271"></a><a name="_Toc189740931"></a><a name="_Toc189793273"></a><a name="_Toc189927367"></a><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Specific Performance</u><font style="font-weight:normal;">. </font><font style="font-weight:normal;">Each of the parties acknowledges and agrees that the other party would be damaged irreparably in the event any of the provisions of this Agreement are not performed in accordance with their specific terms or otherwise are breached or violated. Accordingly, notwithstanding </font><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;&#8206;&#8206;Section 5.5</u><font style="font-weight:normal;">, each of the parties agrees that, without posting bond or other undertaking, the other party shall be entitled to an injunction or injunctions to prevent breaches or violations of the provisions of this Agreement and to enforce specifically this Agreement and the terms and provisions hereof in any action, suit or other proceeding instituted in any court of the United States or any state thereof having jurisdiction over the parties and the matter in addition to any other remedy to which it may be entitled, at law or in equity. Each party further agrees that, in the event of any action for specific performance in respect of such breach or violation, it shall not assert the defense that a remedy at law will be adequate. </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:12pt;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:normal;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 6.13</font><a name="_Toc44282682"></a><a name="_Toc96470048"></a><a name="_Toc277686282"></a><a name="_Toc189979185"></a><a name="_Toc189979250"></a><a name="_Toc191097498"></a><a name="_Toc191113815"></a><a name="_Toc191114075"></a><a name="_Toc191115722"></a><a name="_Toc191120595"></a><a name="_Toc191987209"></a><a name="_Toc192068315"></a><a name="_Toc192337983"></a><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Relationship of Parties</u><font style="font-weight:normal;">.</font><font style="font-weight:normal;"> The relationship between Assignee and Assignor is solely that of purchaser and seller, and neither Assignee nor Assignor has any fiduciary or other special relationship with the other party or any of its Affiliates. This Agreement is not a partnership or similar agreement, and nothing contained herein shall be deemed to constitute Assignee and Assignor as a partnership, an association, a joint venture or any other kind of entity or legal form for any purposes, including any Tax purposes. Assignee and Assignor agree that they shall not take any inconsistent position with respect to such treatment in a filing with any Governmental Entity. If there is an inquiry by any Governmental Entity of Assignee or Assignor related to the treatment of the transactions contemplated by this Agreement for Tax purposes, the parties hereto shall cooperate with each other in responding to such inquiry in a reasonable manner.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:12pt;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-weight:normal;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 6.14</font><a name="_Toc44282683"></a><a name="_Toc96470049"></a><u style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Counterparts</u><font style="font-weight:normal;">. This Agreement may be executed in any number of counterparts and by the parties hereto in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement. Copies of executed counterparts transmitted by telecopy, or other similar means of electronic transmission, including &#8220;PDF,&#8221; shall be considered original executed counterparts, provided receipt of such counterparts is confirmed.</font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">21</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;text-indent:0pt;margin:0pt;"><a name="_Ref96468800"></a><a name="_Toc96470050"></a><a name="_Ref96155613"></a> <i style="font-style:italic;">[Signature Page Follows]</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:0pt;margin-top:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">22</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;">IN WITNESS WHEREOF, the parties hereto have caused this Assignment and Assumption Agreement to be executed and delivered by their respective representatives thereunto duly authorized as of the date first above written.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:12pt 0pt 0pt 216pt;">ASSIGNOR:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:12pt 0pt 0pt 216pt;">LADRX CORPORATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:24pt 0pt 0pt 216pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">By:</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:18.66pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">/s/ Stephen Snowdy</i><font style="text-decoration-line:none;"><br></font>Name: Dr. Stephen Snowdy<br>Title: Chief Executive Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:0pt;font-weight:bold;margin-top:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[Signature Page to Assignment and Assumption Agreement]</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:12pt 0pt 0pt 216pt;">ASSIGNEE:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:12pt 0pt 0pt 216pt;"><font style="font-variant:small-caps;">XOMA (US) LLC</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:24pt 0pt 0pt 216pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">By:</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:18.66pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">/s/ Bradley Sitko</i><br>Name: Bradley Sitko<br>Title: Chief Investment Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:0pt;margin-top:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">[Signature Page to Assignment and Assumption Agreement]</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:center;text-indent:0pt;margin:12pt 0pt 0pt 0pt;"><a name="_Toc137493058"></a><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule 1.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">[***]</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:center;margin:0pt;"><font style="font-size:0pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disclosure Schedules</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><i style="font-style:italic;">See attached.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-style:italic;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;text-indent:0pt;margin:12pt 0pt 0pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;text-indent:0pt;margin:12pt 0pt 0pt 0pt;"><a name="_Hlk137663701"></a><b style="font-weight:bold;">Account</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-style:italic;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a name="_Hlk137663715"></a><font style="font-weight:bold;text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="text-decoration-color:#000000;background:#ffffff;">[***]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">3</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit B</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;text-indent:0pt;margin:12pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Zevra Agreement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;text-indent:0pt;margin:12pt 0pt 0pt 0pt;"><i style="font-style:italic;">See attached.</i></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:justify;text-indent:0pt;margin:0pt;"><font style="font-size:0pt;margin-top:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">4</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;text-indent:0pt;margin:12pt 0pt 0pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit C</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;text-indent:0pt;margin:12pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Form of Zevra Instruction</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:12pt 0pt 0pt 0pt;"><a name="_DV_M705"></a>[***]</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>3
<FILENAME>xoma-20230630xex10d4.htm
<DESCRIPTION>EX-10.4
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 8/8/2023 02:21:35 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 10.4</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED (INDICATED BY: [***]) FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE OR CONFIDENTIAL.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><font style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><font style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:center;text-transform:uppercase;margin:0pt 0pt 24pt 0pt;"><font style="font-family:'Times New Roman Bold';font-variant:small-caps;font-weight:normal;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:center;text-transform:uppercase;margin:0pt 0pt 24pt 0pt;"><a name="OLE_LINK8"></a><a name="OLE_LINK9"></a><font style="font-variant:small-caps;font-weight:normal;text-transform:none;">Royalty Purchase Agreement</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:center;text-transform:uppercase;margin:0pt 0pt 24pt 0pt;"><font style="font-variant:small-caps;font-weight:normal;text-transform:none;">By and Between</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-variant:small-caps;font-weight:normal;">LadRx Corporation</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:center;text-transform:uppercase;margin:0pt 0pt 24pt 0pt;"><font style="font-variant:small-caps;font-weight:normal;text-transform:none;">and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:center;text-transform:uppercase;margin:0pt 0pt 24pt 0pt;"><font style="font-variant:small-caps;font-weight:normal;text-transform:none;">XOMA (US) LLC</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:center;text-transform:uppercase;margin:0pt 0pt 24pt 0pt;"><font style="font-variant:small-caps;font-weight:normal;text-transform:none;">Dated as of June 21, 2023</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;font-size:12pt;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:18pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 5.75pt 0pt 5.75pt;"><a name="zzmpTOCHeader_Primary"></a>Table of Contents</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 5.75pt 0pt 5.75pt;"><font style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 5.75pt 10pt 5.75pt;">Page</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="margin-bottom:6pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;text-transform:uppercase;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-transform:uppercase;"><a href="#_Toc138244482">Article 1 DEFINED TERMS AND RULES OF CONSTRUCTION</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-transform:uppercase;"><a href="#_Toc138244482"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-transform:uppercase;"><a href="#_Toc138244482">1</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244483">Section 1.1</a></font><font style="display:inline-block;width:2.94%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244483">Definitions</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244483"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244483">1</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244484">Section 1.2</a></font><font style="display:inline-block;width:2.94%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244484">Certain Interpretations</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244484"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244484">6</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244485">Section 1.3</a></font><font style="display:inline-block;width:2.94%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244485">Headings</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244485"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244485">6</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;text-transform:uppercase;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-transform:uppercase;"><a href="#_Toc138244486">Article 2 PURCHASE, SALE AND ASSIGNMENT OF THE PURCHASED ASSETS</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-transform:uppercase;"><a href="#_Toc138244486"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-transform:uppercase;"><a href="#_Toc138244486">7</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244487">Section 2.1</a></font><font style="display:inline-block;width:2.94%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244487">Closing</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244487"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244487">7</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244488">Section 2.2</a></font><font style="display:inline-block;width:2.94%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244488">Post-Closing Payments</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244488"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244488">7</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244489">Section 2.3</a></font><font style="display:inline-block;width:2.94%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244489">No Assumed Obligations, Etc</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244489"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244489">7</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244490">Section 2.4</a></font><font style="display:inline-block;width:2.94%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244490">True Sale</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244490"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244490">8</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244491">Section 2.5</a></font><font style="display:inline-block;width:2.94%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244491">Withholding Taxes</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244491"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244491">8</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;text-transform:uppercase;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-transform:uppercase;"><a href="#_Toc138244492">Article 3 CLOSING</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-transform:uppercase;"><a href="#_Toc138244492"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-transform:uppercase;"><a href="#_Toc138244492">9</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244493">Section 3.1</a></font><font style="display:inline-block;width:2.94%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244493">Closings; Payment of Purchase Price.</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244493"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244493">9</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244494">Section 3.2</a></font><font style="display:inline-block;width:2.94%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244494">Closing Certificates</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244494"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244494">9</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244495">Section 3.3</a></font><font style="display:inline-block;width:2.94%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244495">Bill of Sale</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244495"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244495">9</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244496">Section 3.4</a></font><font style="display:inline-block;width:2.94%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244496">Licensee Instruction</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244496"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244496">9</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244497">Section 3.5</a></font><font style="display:inline-block;width:2.94%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244497">Licensee Consent</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244497"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244497">9</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244498">Section 3.6</a></font><font style="display:inline-block;width:2.94%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244498">Legal Opinions</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244498"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244498">9</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244499">Section 3.7</a></font><font style="display:inline-block;width:2.94%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244499">Form W-9 from the Seller</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244499"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244499">10</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244500">Section 3.8</a></font><font style="display:inline-block;width:2.94%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244500">Form W-9 from the Buyer</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244500"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244500">10</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244501">Section 3.9</a></font><font style="display:inline-block;width:2.94%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244501">Power of Attorney</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244501"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244501">10</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244502">Section 3.10</a></font><font style="display:inline-block;width:1.96%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244502">Data Room</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244502"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244502">10</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244503">Section 3.11</a></font><font style="display:inline-block;width:1.96%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244503">Expenses</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244503"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244503">10</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;text-transform:uppercase;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-transform:uppercase;"><a href="#_Toc138244504">Article 4 SELLER&#8217;S REPRESENTATIONS AND WARRANTIES</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-transform:uppercase;"><a href="#_Toc138244504"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-transform:uppercase;"><a href="#_Toc138244504">10</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244505">Section 4.1</a></font><font style="display:inline-block;width:2.94%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244505">Existence; Good Standing</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244505"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244505">10</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244506">Section 4.2</a></font><font style="display:inline-block;width:2.94%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244506">Authorization</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244506"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244506">10</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244507">Section 4.3</a></font><font style="display:inline-block;width:2.94%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244507">Enforceability</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244507"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244507">11</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244508">Section 4.4</a></font><font style="display:inline-block;width:2.94%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244508">No Conflicts</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244508"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244508">11</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244509">Section 4.5</a></font><font style="display:inline-block;width:2.94%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244509">Consents</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244509"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244509">11</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244510">Section 4.6</a></font><font style="display:inline-block;width:2.94%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244510">No Litigation</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244510"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244510">11</a></font></font></p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;table-layout:auto;width:99.35%;" align="center"><tr><td style="vertical-align:top;width:44.58%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a name="zzmpTOCFooter"></a><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:10.83%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">-i-</p></td><td style="vertical-align:top;width:44.58%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:18pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 5.75pt 0pt 5.75pt;">Table of Contents</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 5.75pt 0pt 5.75pt;">(continued)</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 5.75pt 10pt 5.75pt;">Page</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244511">Section 4.7</a></font><font style="display:inline-block;width:2.94%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244511">Compliance with Laws</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244511"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244511">11</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244512">Section 4.8</a></font><font style="display:inline-block;width:2.94%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244512">No Undisclosed Events or Circumstances</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244512"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244512">11</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244513">Section 4.9</a></font><font style="display:inline-block;width:2.94%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244513">License Agreement</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244513"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244513">12</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244514">Section 4.10</a></font><font style="display:inline-block;width:1.96%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244514">Title to Purchased Assets</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244514"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244514">14</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244515">Section 4.11</a></font><font style="display:inline-block;width:1.96%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244515">Intellectual Property</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244515"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244515">14</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244516">Section 4.12</a></font><font style="display:inline-block;width:1.96%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244516">UCC Representation and Warranties</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244516"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244516">15</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244517">Section 4.13</a></font><font style="display:inline-block;width:1.96%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244517">Brokers&#8217; Fees</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244517"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244517">15</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244518">Section 4.14</a></font><font style="display:inline-block;width:1.96%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244518">No Implied Representations and Warranties</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244518"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244518">15</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;text-transform:uppercase;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-transform:uppercase;"><a href="#_Toc138244519">Article 5 BUYER&#8217;S REPRESENTATIONS AND WARRANTIES</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-transform:uppercase;"><a href="#_Toc138244519"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-transform:uppercase;"><a href="#_Toc138244519">16</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244520">Section 5.1</a></font><font style="display:inline-block;width:2.94%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244520">Existence; Good Standing</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244520"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244520">16</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244521">Section 5.2</a></font><font style="display:inline-block;width:2.94%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244521">Authorization</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244521"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244521">16</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244522">Section 5.3</a></font><font style="display:inline-block;width:2.94%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244522">Enforceability</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244522"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244522">16</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244523">Section 5.4</a></font><font style="display:inline-block;width:2.94%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244523">No Conflicts</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244523"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244523">16</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244524">Section 5.5</a></font><font style="display:inline-block;width:2.94%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244524">Consents</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244524"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244524">16</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244525">Section 5.6</a></font><font style="display:inline-block;width:2.94%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244525">No Litigation</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244525"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244525">17</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244526">Section 5.7</a></font><font style="display:inline-block;width:2.94%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244526">Financing</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244526"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244526">17</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244527">Section 5.8</a></font><font style="display:inline-block;width:2.94%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244527">Brokers&#8217; Fees</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244527"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244527">17</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;text-transform:uppercase;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-transform:uppercase;"><a href="#_Toc138244528">Article 6 COVENANTS</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-transform:uppercase;"><a href="#_Toc138244528"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-transform:uppercase;"><a href="#_Toc138244528">17</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244529">Section 6.1</a></font><font style="display:inline-block;width:2.94%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244529">Disclosures</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244529"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244529">17</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244530">Section 6.2</a></font><font style="display:inline-block;width:2.94%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244530">Payments Received In Error; Interest</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244530"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244530">17</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244531">Section 6.3</a></font><font style="display:inline-block;width:2.94%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244531">Royalty Reduction</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244531"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244531">18</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244532">Section 6.4</a></font><font style="display:inline-block;width:2.94%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244532">Seller Withholding Taxes</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244532"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244532">18</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244533">Section 6.5</a></font><font style="display:inline-block;width:2.94%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244533">Royalty Reports; Notices and Other Information from the Licensee</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244533"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244533">18</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244534">Section 6.6</a></font><font style="display:inline-block;width:2.94%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244534">Notices and Other Information to the Licensee</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244534"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244534">19</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244535">Section 6.7</a></font><font style="display:inline-block;width:2.94%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244535">Inspections and Audits of Licensee</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244535"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244535">19</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244536">Section 6.8</a></font><font style="display:inline-block;width:2.94%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244536">Amendment or Assignment of License Agreement</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244536"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244536">19</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244537">Section 6.9</a></font><font style="display:inline-block;width:2.94%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244537">Maintenance of License Agreement</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244537"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244537">19</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244538">Section 6.10</a></font><font style="display:inline-block;width:1.96%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244538">Enforcement of License Agreement</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244538"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244538">20</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244539">Section 6.11</a></font><font style="display:inline-block;width:1.96%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244539">Termination of License Agreement</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244539"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244539">20</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244540">Section 6.12</a></font><font style="display:inline-block;width:1.96%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244540">Preservation of Rights</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244540"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244540">21</a></font></font></p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;table-layout:auto;width:99.35%;" align="center"><tr><td style="vertical-align:top;width:44.58%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:10.83%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">-ii-</p></td><td style="vertical-align:top;width:44.58%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:18pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 5.75pt 0pt 5.75pt;">Table of Contents</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 5.75pt 0pt 5.75pt;">(continued)</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 5.75pt 10pt 5.75pt;">Page</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244541">Section 6.13</a></font><font style="display:inline-block;width:1.96%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244541">Enforcement; Defense; Prosecution and Maintenance</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244541"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244541">21</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244542">Section 6.14</a></font><font style="display:inline-block;width:1.96%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244542">Power of Attorney</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244542"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244542">22</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244543">Section 6.15</a></font><font style="display:inline-block;width:1.96%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244543">Efforts to Consummate Transactions</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244543"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244543">22</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244544">Section 6.16</a></font><font style="display:inline-block;width:1.96%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244544">Further Assurances</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244544"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244544">22</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;text-transform:uppercase;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-transform:uppercase;"><a href="#_Toc138244545">Article 7 CONFIDENTIALITY</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-transform:uppercase;"><a href="#_Toc138244545"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-transform:uppercase;"><a href="#_Toc138244545">22</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244546">Section 7.1</a></font><font style="display:inline-block;width:2.94%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244546">Confidentiality</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244546"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244546">22</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244547">Section 7.2</a></font><font style="display:inline-block;width:2.94%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244547">Authorized Disclosure</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244547"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244547">23</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;text-transform:uppercase;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-transform:uppercase;"><a href="#_Toc138244548">Article 8 INDEMNIFICATION</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-transform:uppercase;"><a href="#_Toc138244548"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-transform:uppercase;"><a href="#_Toc138244548">24</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244549">Section 8.1</a></font><font style="display:inline-block;width:2.94%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244549">General Indemnity</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244549"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244549">24</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244550">Section 8.2</a></font><font style="display:inline-block;width:2.94%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244550">Notice of Claims</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244550"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244550">24</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244551">Section 8.3</a></font><font style="display:inline-block;width:2.94%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244551">Limitations on Liability</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244551"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244551">25</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244552">Section 8.4</a></font><font style="display:inline-block;width:2.94%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244552">Third Party Claims</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244552"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244552">25</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244553">Section 8.5</a></font><font style="display:inline-block;width:2.94%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244553">Survival of Representations and Warranties</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244553"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244553">26</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244554">Section 8.6</a></font><font style="display:inline-block;width:2.94%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244554">Exclusive Remedy</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244554"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244554">26</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;text-transform:uppercase;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-transform:uppercase;"><a href="#_Toc138244555">Article 9 TERMINATION</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-transform:uppercase;"><a href="#_Toc138244555"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-transform:uppercase;"><a href="#_Toc138244555">26</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244556">Section 9.1</a></font><font style="display:inline-block;width:2.94%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244556">Mutual Termination</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244556"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244556">26</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244557">Section 9.2</a></font><font style="display:inline-block;width:2.94%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244557">Automatic Termination</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244557"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244557">26</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244558">Section 9.3</a></font><font style="display:inline-block;width:2.94%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244558">Survival</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244558"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244558">27</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;text-transform:uppercase;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-transform:uppercase;"><a href="#_Toc138244559">Article 10 MISCELLANEOUS</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-transform:uppercase;"><a href="#_Toc138244559"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-transform:uppercase;"><a href="#_Toc138244559">27</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244560">Section 10.1</a></font><font style="display:inline-block;width:1.96%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244560">Notices</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244560"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244560">27</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244561">Section 10.2</a></font><font style="display:inline-block;width:1.96%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244561">Expenses</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244561"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244561">28</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244562">Section 10.3</a></font><font style="display:inline-block;width:1.96%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244562">Assignment</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244562"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244562">28</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244563">Section 10.4</a></font><font style="display:inline-block;width:1.96%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244563">Amendment and Waiver</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244563"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244563">28</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244564">Section 10.5</a></font><font style="display:inline-block;width:1.96%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244564">Entire Agreement</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244564"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244564">29</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244565">Section 10.6</a></font><font style="display:inline-block;width:1.96%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244565">No Third Party Beneficiaries</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244565"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244565">29</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244566">Section 10.7</a></font><font style="display:inline-block;width:1.96%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244566">Governing Law</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244566"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244566">29</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244567">Section 10.8</a></font><font style="display:inline-block;width:1.96%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244567">JURISDICTION; VENUE</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244567"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244567">29</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244568">Section 10.9</a></font><font style="display:inline-block;width:1.96%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244568">Severability</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244568"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244568">30</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244569">Section 10.10</a></font><font style="display:inline-block;width:0.98%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244569">Specific Performance</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244569"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244569">30</a></font></font></p></div><div style="margin-bottom:6pt;margin-left:36pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:72pt;text-indent:-72pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244570">Section 10.11</a></font><font style="display:inline-block;width:0.98%;">&#9;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244570">Counterparts</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244570"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc138244570">30</a></font></font></p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;table-layout:auto;width:99.35%;" align="center"><tr><td style="vertical-align:top;width:44.58%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:10.83%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">-iii-</p></td><td style="vertical-align:top;width:44.58%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:18pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 5.75pt 0pt 5.75pt;">Table of Contents</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 5.75pt 0pt 5.75pt;">(continued)</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt 5.75pt 10pt 5.75pt;">Page</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Index of Exhibits</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:63pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">Exhibit A:</font></font>Seller&#8217;s Wire Transfer Instructions</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:63pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">Exhibit B:</font></font>Form of Bill of Sale</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:63pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">Exhibit C:</font></font>Form of Licensee Instruction Letter</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:63pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">Exhibit D:</font></font>Form of Licensee Consent</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:63pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">Exhibit E-1:</font></font>License Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">Exhibit E-2: KTB Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:63pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">Exhibit F: </font></font>Form of Power of Attorney</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-style:italic;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Index of Schedules</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:72pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">Schedule 1.1:</font></font>Aldoxorubicin Structure</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;font-size:12pt;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;table-layout:auto;width:99.35%;" align="center"><tr><td style="vertical-align:top;width:44.58%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:10.83%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">-iv-</p></td><td style="vertical-align:top;width:44.58%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="text-transform:uppercase;">ROYALTY PURCHASE AGREEMENT</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">This ROYALTY PURCHASE AGREEMENT, dated as of June 21, 2023 (this &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreement</u><font style="font-size:12pt;">&#8221;), is made and entered into by and between LadRx Corporation (formerly known as CytRx Corporation), a Delaware corporation</font> <font style="font-size:12pt;">(the &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Seller</u><font style="font-size:12pt;">&#8221;), on the one hand, and XOMA (US) LLC, a Delaware limited liability company (the &#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Buyer</u><font style="font-size:12pt;">&#8221;), on the other hand.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;text-transform:uppercase;margin:0pt 0pt 12pt 0pt;"><u style="text-decoration-line:underline;text-decoration-style:solid;">W I T N E S S E T H</u><font style="text-decoration-line:none;">:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, pursuant to the License Agreement, the Seller granted to Licensee an exclusive license with respect to the Licensed IP to (among other activities) sell the Licensed Product in the Territory, and Licensee, in partial consideration thereof, agreed to pay the Royalty and other payments to the Seller; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, the Buyer desires to purchase the Purchased Assets from the Seller, and the Seller desires to sell the Purchased Assets to the Buyer. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">NOW THEREFORE, in consideration of the representations, warranties, covenants and agreements set forth herein and for good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Seller and the Buyer hereby agree as follows:</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:center;text-indent:0pt;"><font style="color:#010000;text-transform:uppercase;white-space:nowrap;">Article 1</font> <font style="display:inline-block;width:26.68pt;"></font><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><a name="_Toc138244482"></a>DEFINED TERMS AND RULES OF CONSTRUCTION</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 1.1</font><a name="_Toc138244483"></a><a name="_Ref276305883"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Definitions</u>. &#160;As used in this Agreement, the following terms shall have the following meanings:</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Affiliate</u>&#8221; shall have the meaning ascribed thereto in Section 1 of the License Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreement</u>&#8221; is defined in the preamble.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Aldoxorubicin</u>&#8221; means the pharmaceutical product known as aldoxorubicin with the chemical structure set forth on <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule 1.1</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Applicable Patents</u>&#8221; is defined in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section 6.13(c)</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assignment Agreement</u>&#8221; means that certain assignment and assumption agreement, dated and effective as of the date hereof, by and between the Seller and the Buyer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Bankruptcy Laws</u>&#8221; means, collectively, bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, fraudulent transfer or other similar laws affecting the enforcement of creditors&#8217; rights generally.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Bill of Sale</u>&#8221; is defined in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section 3.3</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Business Day</u>&#8221; means any day other than (i)&#160;a Saturday or Sunday or (ii)&#160;a day on which banking institutions located in New York, USA are permitted or required by applicable law or regulation to remain closed.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Buyer</u>&#8221; is defined in the preamble.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Buyer Fundamental Representations</u>&#8221; means the representations and warranties contained in &#8206;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.1</u> (Existence; Good Standing), &#8206;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.2</u> (Authorization), <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section 5.3</u> (Enforceability), &#8206;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.4</u> (No Conflicts), and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section 5.8</u> (Brokers&#8217; Fees).</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Buyer Incumbency Certificate</u>&#8221; is defined in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section 3.2(b)</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Buyer Indemnified Parties</u>&#8221; is defined in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section 8.1(a)</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Buyer Transaction Expenses</u>&#8221; is defined in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section 10.2</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Closing</u>&#8221; is defined in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section 3.1</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Closing Date</u>&#8221; means the date on which the Closing occurs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Confidential Information</u>&#8221; is defined in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section 7.1</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Data Room</u>&#8221; is defined in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section 3.10</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disclosing Party</u>&#8221; is defined in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section 7.1</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disclosure Schedule</u>&#8221; means the Disclosure Schedule, dated as of the date hereof, delivered to the Buyer by the Seller concurrently with the execution of this Agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Excluded Liabilities and Obligations</u>&#8221; is defined in &#8206;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.3</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="margin-bottom:6pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">FDA</u>&#8221; means the U.S. Food and Drug Administration, or a successor federal agency thereto in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="margin-bottom:6pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 6pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">FDA Approval</u>&#8221; means payment by Licensee of the milestone payment designated as &#8220;First FDA approval of Licensed Product&#8221; as set forth in Section 3(a)(i) of the License Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governmental Entity</u>&#8221; means any: &#160;(i)&#160;nation, principality, republic, state, commonwealth, province, territory, county, municipality, district or other jurisdiction of any nature; (ii)&#160;federal, state, local, municipal, foreign or other government; (iii)&#160;governmental or quasi-governmental authority of any nature (including any governmental division, subdivision, department, agency, bureau, branch, office, commission, council, board, instrumentality, officer, official, representative, organization, unit, body or other entity and any court, arbitrator or other tribunal); (iv)&#160;multi-national organization or body; or (v)&#160;individual, body or other entity exercising, or entitled to exercise, any executive, legislative, judicial, administrative, regulatory, police, military or taxing authority or power of any nature.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnified Party</u>&#8221; is defined in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section 8.2</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnifying Party</u>&#8221; is defined in &#8206;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8.2</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Judgment</u>&#8221; means any judgment, order, writ, injunction, citation, award or decree of any nature issued by a competent Governmental Entity.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">2</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Knowledge of the Seller</u>&#8221; means the actual knowledge of the Knowledge Parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Knowledge Parties</u>&#8221; means [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">KTB</u>&#8221; means KTB Tumorforschungs GmbH (Tumor Biology Center), a privately-held corporation, and any successor thereof, as permitted pursuant to the terms of the KTB Agreement.<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> &#160;</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">KTB Agreement</u>&#8221; shall have the meaning ascribed thereto in Section 1 of the License Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">KTB Patent Rights</u>&#8221; shall have the meaning ascribed to the term Licensed Patent Rights in Section 1.7 of the KTB Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">License Agreement</u>&#8221; means that certain Exclusive License Agreement, dated and effective as of July 27, 2017, as modified by that certain Reimbursement Agreement dated and effective as of October 3, 2017, and that certain Addendum to License Agreement, dated and effective as of September 27, 2018, by and between the Seller and Licensee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Licensed Know How</u>&#8221; shall have the meaning ascribed thereto in Section 1 of the License Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Licensed IP</u>&#8221; means, collectively, the Licensed Patents and the Licensed Know How.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Licensed Patents</u>&#8221; shall have the meaning ascribed thereto in Section 1 of the License Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Licensed Product</u>&#8221; shall have the meaning ascribed thereto in Section 1 of the License Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Licensee</u>&#8221; means ImmunityBio, Inc. (formerly known as NantCell, Inc.) and any successor thereof, as permitted pursuant to the terms of this Agreement and the License Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Licensee Consent</u>&#8221; is defined in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section 3.5</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Licensee Instruction Letter</u>&#8221; is defined in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section 3.4</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Lien</u>&#8221; means any mortgage, lien, pledge, charge, adverse claim, security interest, encumbrance or restriction of any kind, including any restriction on use, transfer or exercise of any other attribute of ownership of any kind.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Loss</u>&#8221; means any and all Judgments, damages, losses, claims, costs, liabilities and expenses, including reasonable fees and out-of-pocket expenses of counsel. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Material Adverse Effect</u>&#8221; shall mean (i) a material adverse effect on: (a) the legality, validity or enforceability of any provision of this Agreement, (b) the ability of the Seller to perform any of its obligations hereunder, (c) the rights or remedies of the Buyer hereunder, (d) the rights </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">3</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">of the Seller under the License Agreement, or (e) the validity or enforceability of any of the Licensed Patents; or [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;"><font style="font-size:12pt;">&#8220;</font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Milestone Payments</u><font style="font-size:12pt;">&#8221; means (i) 100% of the regulatory milestones payable to the Seller under Section 3(a) of the License Agreement and (ii) 100% of the commercial milestones payable to Seller under Section 3(b) of the License Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Net Sales</u>&#8221; shall have the meaning ascribed thereto in Section 1 of the License Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Opinions</u>&#8221; is defined in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section 3.6</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Patent Rights</u>&#8221; shall have the meaning ascribed to the term Patents in Section 1 of the License Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Permitted Liens</u>&#8221; means any (i)&#160;mechanic&#8217;s, materialmen&#8217;s, and similar liens for amounts not yet due and payable, (ii)&#160;statutory liens for taxes not yet due and payable or for taxes that the taxpayer is contesting in good faith by contemporaneous proceedings and (iii)&#160;other liens and encumbrances not incurred in connection with the borrowing of money that do not, in the aggregate, materially and adversely affect the use or value of the affected assets provided that, in each case, such liens are automatically released upon the sale or other transfer of the affected assets (it being understood that any obligations secured by such &#8220;Permitted Liens&#8221; shall remain the obligations of the Seller).</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Permitted Reduction</u>&#8221; means a Royalty Reduction pursuant to Section 4(b) of the License Agreement (as limited by Section 4(c) of the License Agreement), excluding any such Royalty Reduction that is attributable to Seller Withholding Taxes. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Person</u>&#8221; means any corporation, limited or general partnership, limited liability company, joint venture, trust, unincorporated association, Governmental Entity, authority, bureau or agency, any other entity or body, or an individual.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Power of Attorney</u>&#8221; is defined in &#8206;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3.9</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;"> </font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Prime Rate</u>&#8221; means the prime rate published by the Wall Street Journal, from time to time, as the prime rate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Proceeds</u>&#8221; means any amounts actually recovered by the Seller as a result of any settlement or resolution of any actions, suits, proceedings, claims or disputes related to the License Agreement related to or involving the Purchased Assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Purchase Price</u>&#8221; means the aggregate purchase price of $5,000,000, to be allocated between this Agreement and the Assignment Agreement as set forth in &#8206;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.1(b)</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Purchased Assets</u>&#8221; means collectively, (i) the Purchased Receivables and (ii) the Shared Rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Purchased Receivables</u>&#8221; means (i) all Royalty payments and Milestone Payments; (ii) all payments or amounts payable to the Seller under the License Agreement in lieu of such payments </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">4</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">of the foregoing clause (i); (iii) any damages, settlements or other monetary awards recovered by Seller or any payments or amounts payable to the Seller, in each case, under Section 5(g) of the License Agreement; (iv) any payments or amounts payable to the Seller under Section 4(h) of the License Agreement; (v) any interest payments to the Seller under Section 4(e) of the License Agreement assessed on any payments described in the foregoing clauses (i), (ii), (iii) and (iv); (vi) any payments or amounts payable to the Seller under Section 9(b) of the License Agreement to the extent such payments relate to any payments described in the foregoing clauses (i), (ii), (iii), (iv), and (v); and (vii) and Proceeds payable to the Buyer in accordance with this Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Receivables</u>&#8221; means 100% of all payments due to the Seller under the License Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Receiving Party</u>&#8221; is defined in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section 7.1</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Representative</u>&#8221; means, with respect to any Person, (i)&#160;any direct or indirect stockholder, member or partner of such Person and (ii)&#160;any manager, director, officer, employee, agent, advisor or other representative (including attorneys, accountants, consultants, bankers, financial advisors and actual and potential lenders and investors) of such Person.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Royalty</u>&#8221; means all payments payable to Seller under Section 4(a) of the License Agreement with respect to Net Sales of a Licensed Product, subject to Sections 4(b) and 4(c) of the License Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Royalty Reduction</u>&#8221; is defined in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section 4.9(l)</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Royalty Reports</u>&#8221; means <a name="_Hlk17034476"></a>the quarterly reports deliverable by Licensee pursuant to Section&#160;4(e) of the License Agreement setting forth Net Sales of the Licensed Products in the Territory on a country-by-country basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Seller</u>&#8221; is defined in the preamble.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Seller Closing Certificate</u>&#8221; is defined in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section 3.2(a)</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Seller Fundamental Representations</u>&#8221; means the representations and warranties contained in &#8206;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.1</u> (Existence; Good Standing), &#8206;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.2</u> (Authorization), &#8206;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.3</u> (Enforceability), <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section 4.4</u> (No Conflicts), &#8206;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.9</u> (License Agreement), &#8206;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.10</u> (Title to Purchased Assets), <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section 4.11</u> (Intellectual Property), &#8206;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.12</u> (UCC Representations and Warranties), and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section 4.13</u>. (Brokers&#8217; Fees).</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Seller Indemnified Parties</u>&#8221; is defined in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section 8.1(b)</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Seller Withholding Taxes</u>&#8221; means any deduction of any withholding taxes, value-added taxes or other taxes, levies or charges pursuant to the License Agreement as a result of any action by the Seller after the Closing Date, such as an assignment or re-domiciliation by the Seller, or any failure on the part of the Seller to comply with applicable law (such withholding tax, &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Seller Withholding Taxes</u>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Shared Rights</u>&#8221; means, collectively, solely to the extent that the Purchased Receivables are actually due and payable, the rights of the Seller under the License Agreement to bring any </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">5</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">action, demand, proceeding or claim, whether in law or in equity, to enforce any rights to receive the Purchased Receivables.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Territory</u>&#8221; shall have the meaning ascribed thereto in Section 1 of the License Agreement and for purposes of this Agreement and the License Agreement shall include all countries of the world.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">UCC</u>&#8221; means Article&#160;9 of the New York Uniform Commercial Code, as in effect from time to time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Valid Claim</u>&#8221; shall have the meaning ascribed thereto in Section 1.20 of the KTB Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Zevra Agreement</u>&#8221; shall have the meaning ascribed thereto in the Recitals of the Assignment Agreement.</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 1.2</font><a name="_Toc138244484"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Certain Interpretations</u>. &#160;Except where expressly stated otherwise in this Agreement, the following rules of interpretation apply to this Agreement:</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font>&#8220;either&#8221; and &#8220;or&#8221; are not exclusive and &#8220;include,&#8221; &#8220;includes&#8221; and &#8220;including&#8221; are not limiting and shall be deemed to be followed by the words &#8220;without limitation;&#8221;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font>&#8220;extent&#8221; in the phrase &#8220;to the extent&#8221; means the degree to which a subject or other thing extends, and such phrase does not mean simply &#8220;if;&#8221;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font>&#8220;hereof,&#8221; &#8220;hereto,&#8221; &#8220;herein&#8221; and &#8220;hereunder&#8221; and words of similar import when used in this Agreement refer to this Agreement as a whole and not to any particular provision of this Agreement;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(d)</font>references to a Person are also to its permitted successors and assigns;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(e)</font>definitions are applicable to the singular as well as the plural forms of such terms;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(f)</font>unless otherwise indicated, references to an &#8220;Article&#8221;, &#8220;Section&#8221; or&#160;&#8220;Exhibit&#8221; refer to an Article or Section of, or an Exhibit to, this Agreement, and references to a specific &#8220;Section of the Disclosure Schedule&#8221; refers to the corresponding part of the Disclosure Schedule;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(g)</font>references to &#8220;$&#8221; or otherwise to dollar amounts refer to the lawful currency of the United States; and </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(h)</font>references to a law include any amendment or modification to such law and any rules and regulations issued thereunder, whether such amendment or modification is made, or issuance of such rules and regulations occurs, before or after the date of this Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 1.3</font><a name="_Toc138244485"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Headings</u>. &#160;The table of contents and the descriptive headings of the several Articles and Sections of this Agreement and the Exhibits and Schedules are for </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">6</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">convenience only, do not constitute a part of this Agreement and shall not control or affect, in any way, the meaning or interpretation of this Agreement.</font><font style="display:inline-block;width:29.75pt;"></font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:center;text-indent:0pt;"><font style="color:#010000;text-transform:uppercase;white-space:nowrap;">Article 2</font><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><a name="_Ref277710162"></a><a name="_Ref277771285"></a><a name="_Toc138244486"></a>PURCHASE, SALE AND ASSIGNMENT OF THE PURCHASED ASSETS</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 2.1</font><a name="_Toc16889964"></a><a name="_Toc16940115"></a><a name="_Toc16940184"></a><a name="_Toc16940375"></a><a name="_Toc16940513"></a><a name="_Toc138244487"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Closing</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">; Purchase Price</u>. &#160;<a name="_Toc16889965"></a><a name="_Toc16940116"></a><a name="_Toc16940185"></a><a name="_Toc16940376"></a><a name="_Toc16940514"></a><a name="OLE_LINK1"></a> &#160;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Purchase Price</u>. Upon the terms and subject to the conditions of this Agreement, at the Closing, the Seller shall sell, transfer, assign and convey to the Buyer, and the Buyer shall purchase, acquire and accept from the Seller all of the Seller&#8217;s right, title and interest in and to the Purchased Assets, free and clear of all Liens, and rights in and to the Shared Rights, free and clear of any and all Liens, other than the Seller&#8217;s retention of its rights, title and interest in and to the Shared Rights. &#160;The aggregate purchase price to be paid to the Seller for the sale, transfer, assignment and conveyance of the Seller&#8217;s right, title and interest in and to (i) the Purchased Assets pursuant to this Agreement and (ii) the Zevra Agreement pursuant to the Assignment Agreement, in each case to the Buyer is the Purchase Price, which, for the avoidance of doubt, shall not exceed $5,000,000. At the Closing, the Buyer shall, by wire transfer of immediately available funds, pay to the Seller &#160;cash in an amount equal to the Purchase Price to one or more accounts specified by the Seller on <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit&#160;A</u>. &#160;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Allocation of Purchase &#160;Price</u>. Following the Closing, the parties hereto shall use reasonable efforts to allocate the Purchase Price, as mutually agreed, between this Agreement and the Assignment Agreement within sixty (60) days of the Closing Date. &#160;<a name="_Ref137584599"></a></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 2.2</font><a name="_Ref137012634"></a><a name="_Toc138244488"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Post-Closing Payments</u>. &#160;Following the Closing and the Buyer&#8217;s receipt of written confirmation from the Seller of FDA Approval, the Buyer shall make a one-time payment to the Seller of $4,000,000 by wire transfer of immediately available funds as directed by the Seller thirty (30) days after the Buyer&#8217;s receipt of an invoice; provided, however, that the Buyer shall have the right, but not the obligation, to deduct from such payment, in whole or in part, amounts owed by the Seller or claimed in good faith to be owed by the Seller to any Buyer Indemnified Party whereby Buyer simultaneous with the deduction also shall submit a notice of claim as set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8.2</u> if such notice of claim has not previously been submitted; [***]. The Seller hereby agrees and acknowledges that: (i) such payment is a contingent payment obligation of Buyer and there can be no assurance regarding the occurrence of the and (ii) the Buyer shall have no obligation or liability with respect to such payment unless and until the FDA Approval has occurred.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 2.3</font><a name="_Toc16889966"></a><a name="_Toc16940117"></a><a name="_Toc16940186"></a><a name="_Toc16940377"></a><a name="_Toc16940515"></a><a name="_Ref137564343"></a><a name="_Toc138244489"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Assumed Obligations, Etc</u>. &#160;Notwithstanding any provision in this Agreement to the contrary, the Buyer is purchasing, acquiring and accepting only the Purchased Assets, and the Buyer is not assuming any liability or obligation of the Seller or any of the Seller&#8217;s Affiliates of any kind, character or description whatsoever, whether direct or indirect, known or unknown, absolute or contingent, mature or unmatured, whether currently existing or hereinafter arising, including the following (collectively, the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Excluded Liabilities and Obligations</u>&#8221;):</div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">7</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:54pt;text-indent:36pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font>any liability or obligation of the Seller or any of the Seller&#8217;s Affiliates under the License Agreement;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:54pt;text-indent:36pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font>any liability arising from or related to any noncompliance with any law applicable to the Seller; and </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:54pt;text-indent:36pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font><font style="white-space:pre-wrap;">any liability or obligation of the Seller or any of the Seller&#8217;s Affiliates, under the KTB Agreement.  </font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">All Excluded Liabilities and Obligations shall be retained by and remain liabilities and obligations of the Seller or the Seller&#8217;s Affiliates, as the case may be. Except as specifically set forth herein in respect of the Purchased Assets purchased, acquired and accepted hereunder, the Buyer does not, by such purchase, acquisition and acceptance, acquire any other contract rights of the Seller under the License Agreement or any other assets of the Seller.</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 2.4</font><a name="_Toc138244490"></a><a name="_Ref306603344"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">True Sale</u>. &#160;It is the intention of the parties hereto that the sale, transfer, assignment and conveyance contemplated by this Agreement constitute a sale of the Purchased Assets from the Seller to the Buyer and not a financing transaction, borrowing or loan. Accordingly, the Seller shall treat the sale, transfer, assignment and conveyance of the Purchased Assets as a sale of an &#8220;account&#8221; or a &#8220;payment intangible&#8221; (as appropriate) in accordance with the UCC, and the Seller hereby authorizes the Buyer to file financing statements (and continuation statements with respect to such financing statements when applicable) naming the Seller as the seller and/or debtor and the Buyer as the buyer and/or secured party in respect of the Purchased Assets. &#160;Not in derogation of the foregoing statement of the intent of the parties hereto in this regard, and for the purposes of providing additional assurance to the Buyer in the event that, despite the intent of the parties hereto, the sale, transfer, assignment and conveyance contemplated hereby is hereafter held not to be a sale, the Seller does hereby grant to the Buyer, as security for the obligations of the Seller hereunder, a first priority security interest in and to all right, title and interest of the Seller, in, to and under the Purchased Assets and any &#8220;proceeds&#8221; (as such term is defined in the UCC) thereof, and the Seller does hereby authorize the Buyer, from and after the Closing, to file such financing statements (and continuation statements with respect to such financing statements when applicable) as are necessary to perfect such security interest. </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 2.5</font><a name="_Toc138244491"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Withholding Taxes</u>. &#160;Notwithstanding anything herein to the contrary, the Buyer and any of its Affiliates shall be entitled to deduct and withhold from the consideration otherwise payable pursuant to this Agreement such amounts as are required to be deducted and withheld with respect to the making of such payment under the U.S. Internal Revenue Code of 1986, as amended, or otherwise under applicable law. &#160;To the extent that amounts are so deducted and withheld, such amounts shall be (i) remitted by the deducting or withholding person to the applicable taxing authority to the extent required by applicable law, and (ii) treated for all purposes of this Agreement as having been paid to such Person in respect of which such deduction and withholding was made.</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"> <font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">8</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:center;text-indent:0pt;"><font style="color:#010000;text-transform:uppercase;white-space:nowrap;">Article 3</font><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><a name="_Ref276307547"></a><a name="_Toc138244492"></a>CLOSING</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 3.1</font><a name="_Ref135743753"></a><a name="_Toc138244493"></a><a name="_Ref276307559"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Closings; Payment of Purchase Price</u>.<font style="margin-right:0pt;visibility:hidden;">&#8203;</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Closing</u>. &#160;The purchase and sale of the Purchased Assets shall take place on the date hereof or at such other place, time and date as the parties hereto may mutually agree (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Closing</u>&#8221;). &#160;At the Closing, the Buyer shall deliver (or cause to be delivered) payment of the Purchase Price less the Buyer Transaction Expenses to the Seller by wire transfer of immediately available funds to one or more accounts specified by the Seller on <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit A</u>.</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 3.2</font><a name="_Toc138244494"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Closing Certificates</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref276308090"></a><a name="_Ref135744106"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Seller&#8217;s Closing Certificate</u>. &#160;At the Closing, the Seller shall deliver to the Buyer a certificate of the Secretary of the Seller, dated as of the Closing Date, certifying (i)&#160;as to the incumbency of the officer of the Seller executing this Agreement, and (ii)&#160;as to the attached copies of Seller&#8217;s certificate of incorporation, bylaws and resolutions adopted by the Seller&#8217;s board of directors authorizing the execution and delivery by the Seller of this Agreement and the consummation by the Seller of the transactions contemplated hereby (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Seller Closing Certificate</u>&#8221;).</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref137022862"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Buyer&#8217;s Incumbency Certificate</u>. At the Closing, the Buyer shall deliver to the Seller a certificate of an authorized person of the Buyer certifying as to the incumbency of the officers executing this Agreement on behalf of Buyer (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Buyer Incumbency Certificate</u>&#8221;).</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 3.3</font><a name="_Ref363814207"></a><a name="_Toc138244495"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Bill of Sale</u>. &#160;<a name="OLE_LINK3"></a><a name="OLE_LINK13"></a>At the Closing, upon confirmation of the receipt of the Purchase Price, the Seller shall deliver to the Buyer a duly executed bill of sale evidencing the sale, transfer, assignment and conveyance of the Purchased Assets, substantially in the form attached hereto as <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit&#160;</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">B</u> (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Bill of Sale</u>&#8221;).</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 3.4</font><a name="_Ref135744041"></a><a name="_Toc138244496"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Licensee Instruction</u>. &#160;At the Closing, the Seller shall deliver to the Buyer an instruction letter, in substantially the form attached hereto as <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit C</u> (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Licensee Instruction Letter</u>&#8221;), duly executed by the Seller, instructing Licensee to pay the Purchased Receivables to the account specified by Buyer<a name="_Hlk137663956"></a>, which shall be delivered to the Licensee following the Closing.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 3.5</font><a name="_Ref135744034"></a><a name="_Toc138244497"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Licensee Consent</u>. &#160;At the Closing, the Seller shall deliver to the Buyer a consent letter, in substantially the form attached hereto as <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit D</u> (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Licensee Consent</u>&#8221;), duly executed by the Seller and Licensee to be acknowledged by the Buyer, pursuant to which Licensee (i) consents to the sale of the Purchased Receivables pursuant to this Agreement, (ii) consents to the assignment of rights in and to the Shared Rights pursuant to this Agreement, and (iii) agrees to pay the Purchased Receivables directly to the account specified by Buyer in accordance with the Licensee Instruction Letter to be delivered to Licensee at the Closing. </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 3.6</font><a name="_Ref135744084"></a><a name="_Toc138244498"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Legal Opinion</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">s</u>. &#160;At the Closing, Haynes and Boone LLP, as counsel to the Seller, and Richards, Layton &amp; Finger, P.A., as Delaware counsel to the Seller, shall deliver to the Buyer duly executed legal opinions in the form previously agreed by the parties hereto, </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">9</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">including an opinion by Richards, Layton &amp; Finger, P.A. that the authorization by the stockholders of the Seller of the transactions contemplated hereby is not required under Section 271 of the Delaware General Corporation Law (the &#8220;</font><u style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Opinions</u><font style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#8221;). </font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 3.7</font><a name="_cp_blt_1_39"></a><a name="_Toc138244499"></a><a name="_cp_text_1_40"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">F</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">orm W-9 from the Seller</u>. &#160;At the Closing, the Seller shall deliver to the Buyer a valid, properly executed IRS Form W-9 certifying that the Seller is exempt from U.S. federal withholding tax and &#8220;backup&#8221; withholding tax.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 3.8</font><a name="_cp_blt_1_42"></a><a name="_cp_blt_2_41"></a><a name="_Toc137155734"></a><a name="_Toc138244500"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Form W-9 from the Buyer</u>. &#160;At the Closing, the Buyer shall deliver to the Seller a valid, properly executed IRS Form W-9 certifying that the Buyer is exempt from U.S. federal withholding tax with respect to any and all payments of in respect of the Purchased Receivables.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 3.9</font><a name="_Ref138192326"></a><a name="_Toc138244501"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Power of Attorney</u>. &#160;At the Closing, the Seller shall deliver to the Buyer a duly executed power of attorney (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Power of Attorney</u>&#8221;), substantially in the form attached hereto as <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit&#160;F</u>.</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 3.10</font><a name="_Ref135743781"></a><a name="_Toc138244502"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Data Room</u>. &#160;At the Closing, the Seller shall deliver to the Buyer an electronic copy of all of the information and documents posted to the virtual data room established by the Seller as of the date hereof and made available to the Buyer (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Data Room</u>&#8221;) for archival purposes only.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 3.11</font><a name="_Toc138244503"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Expenses</u>. &#160;Subject to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section 10.2</u>, at the Closing, the Seller shall deliver payment of the Buyer Transaction Expenses to the Buyer by wire transfer of immediately available funds to one or more accounts specified by the Buyer, unless the Buyer deducts the Buyer Transaction Expenses from the Purchase Price.</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:center;text-indent:0pt;"><font style="color:#010000;text-transform:uppercase;white-space:nowrap;">Article 4</font><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><a name="_Ref136557541"></a><a name="_Toc138244504"></a>SELLER&#8217;S REPRESENTATIONS AND WARRANTIES<a name="_Ref276315247"></a><a name="_Ref276316115"></a></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 0pt 36pt;">The Seller represents and warrants to the Buyer that as of the date hereof:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 4.1</font><a name="_Ref137484494"></a><a name="_Toc138244505"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Existence; Good Standing</u>. &#160;The Seller is a corporation duly incorporated, validly existing and in good standing under the laws of Delaware. &#160;The Seller is duly licensed or qualified to do business and is in corporate good standing in each jurisdiction in which the nature of the business conducted by it or the character or location of the properties and assets owned, leased or operated by it makes such licensing or qualification necessary, except where the failure to be so licensed or qualified and in corporate good standing has not and would not reasonably be expected to have, either individually or in the aggregate, a Material Adverse Effect.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 4.2</font><a name="_Ref137484501"></a><a name="_Toc138244506"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Authorization</u>. &#160;The Seller has all requisite corporate power and authority to execute, deliver and perform its obligations under this Agreement. &#160;The execution, delivery and performance of this Agreement, and the consummation of the transactions contemplated hereby, have been duly authorized by all necessary corporate action on the part of the Seller.</div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">10</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 4.3</font><a name="_Ref137484507"></a><a name="_Toc138244507"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Enforceability</u>. &#160;The Agreement has been duly executed and delivered and constitutes a valid and binding obligation of the Seller enforceable against the Seller in accordance with its terms, except as such enforceability may be limited by applicable bankruptcy, securities, insolvency, or similar laws relating to, or affecting generally the enforcement of, creditors&#8217; rights and remedies, or indemnification or by other equitable principles of general application.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 4.4</font><a name="_Ref137484511"></a><a name="_Toc138244508"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Conflicts</u>. &#160;The execution, delivery and performance by the Seller of this Agreement and the consummation of the transactions contemplated hereby do not and shall not (i)&#160;contravene or conflict with the organizational documents of the Seller, (ii)&#160;contravene or conflict with or constitute a material default under any law or Judgment binding upon or applicable to the Seller, (iii) contravene or conflict with or constitute a default under the License Agreement or (iv)&#160;contravene or conflict with or constitute a material default under any other material contract or material agreement binding upon or applicable to the Seller.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 4.5</font><a name="_Toc138244509"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Consents</u>. &#160;Except for the Licensee Consent or filings required by the federal securities laws or stock exchange rules, no consent, approval, license, order, authorization, registration, declaration or filing with or of any Governmental Entity or other Person is required to be done or obtained by the Seller in connection with (i)&#160;the execution and delivery by the Seller of this Agreement,<a name="_cp_text_28_50"></a> (ii)&#160;the performance by the Seller of its obligations under this Agreement or (iii)&#160;the consummation by the Seller of any of the transactions contemplated by this Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 4.6</font><a name="_Toc138244510"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Litigation</u>. &#160;There is no action, suit, investigation or proceeding pending before any Governmental Entity or, to the Knowledge of the Seller, threatened to which the Seller is a party that, individually or in the aggregate would, if determined adversely, reasonably be expected to have a Material Adverse Effect.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 4.7</font><a name="_Toc138244511"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compliance with Laws</u>. &#160;The Seller is not in violation of, and to the Knowledge of the Seller, the Seller is not under investigation with respect to nor has the Seller been threatened to be charged with or given notice of any violation of, any law or Judgment applicable to the Seller, which violation would reasonably be expected to have a Material Adverse Effect.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 4.8</font><a name="_Ref138137730"></a><a name="_Toc138244512"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Undisclosed Events or Circumstances</u>. &#160;Except as set forth on <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section 4.8</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> of the Disclosure Schedule</u>, and except for the transactions contemplated hereby, no event or circumstance has occurred or exists with respect to the Seller, its Affiliates, or their respective businesses, properties, operations or financial condition, which, under applicable law, rule or regulation, requires public disclosure or announcement by the Seller but which has not been so publicly announced or disclosed and which, individually or in the aggregate, would constitute a Material Adverse Effect. There is no action, suit, claim, investigation or proceeding pending or, to the Knowledge of the Seller, threatened against the Seller or any of its Affiliate which questions the validity of this Agreement or the transactions contemplated hereby or any action taken or to be taken pursuant hereto. There is no action, suit, claim, investigation or proceeding pending or, to the Knowledge of the Seller, threatened, against or involving the Seller or any of its Affiliates, or any of their respective properties or assets that would be reasonably be expected to result in a Material Adverse Effect.</div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">11</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 4.9</font><a name="_Ref137484518"></a><a name="_Toc138244513"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">License Agreement</u>. &#160;Attached hereto as <a name="_cp_text_1_53"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibits&#160;</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">E</u><a name="_cp_text_1_55"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">-1</u> and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">E-2</u> are true, correct and complete copies of the License Agreement and the KTB Agreement, including any amendments, modifications or side letters relating to the License Agreement and the KTB Agreement. &#160;The Seller has delivered to the Buyer true, correct and complete copies of &#160;all formal written notices provided to the Seller pursuant to Section 10(m) of the License Agreement. </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref137013871"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Other Agreements</u>. &#160;The License Agreement is the only agreement, instrument, arrangement, waiver or understanding between the Seller (or any predecessor or Affiliate thereof), on the one hand, and Licensee (or any predecessor or Affiliate thereof), on the other hand, relating to the subject matter thereof, and there are no other agreements, instruments, arrangements, waivers or understandings between the Seller (or any predecessor or any Affiliate thereof), on the one hand, and Licensee (or any predecessor or Affiliate thereof), on the other hand, that relate to the License Agreement, the Licensed IP, the Licensed Products (including the development or commercialization thereof), or the Purchased Assets. &#160;The Seller has not proposed or received any proposal, to amend or waive any provision of the License Agreement in any manner that would result in a breach of this Agreement or otherwise reasonably be expected (with or without the giving of notice or the passage of time, or both) to have a Material Adverse Effect.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref137013908"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Licenses/Sublicenses</u>. &#160;To the Knowledge of the Seller, there are no licenses or sublicenses entered into by Licensee or any other Person (or any predecessor or Affiliate thereof) in respect of Licensee&#8217;s rights and obligations under the License Agreement (including any Licensed IP). &#160;The Seller has not received any request for consent from Licensee pursuant to Section 2(b) of the License Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font><a name="_Ref137013938"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Validity and Enforceability of License Agreement</u>. &#160;(i) The License Agreement is legal, valid, binding, enforceable, and in full force and effect and will continue to be legal, valid, binding, enforceable, and in full force and effect on identical terms following the consummation of the transactions contemplated by this Agreement; (ii) the Seller is not, and to the Knowledge of the Seller, Licensee is not, in breach thereof or default under the License Agreement, and to the Knowledge of the Seller, no event has occurred that with notice or lapse of time would constitute a breach thereof or default thereunder, or permit termination, modification, or acceleration, under the License Agreement; and (iii) no party to the License Agreement has repudiated any provision of the License Agreement and the Seller has not received any notice in connection with the License Agreement challenging the validity, enforceability or interpretation of any provision of such agreement, including the obligation to pay any portion of the Purchased Receivables without set-off of any kind.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(d)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Licensed Product</u>. &#160;Aldoxorubicin is a Licensed Product. Licensee and its Affiliates are required to pay royalties under Section 4(a) of the License Agreement on all Net Sales by or on behalf of them and any of their (sub)licensees of any Licensed Products in the Territory on a country-by-country basis. The Seller has the right to receive the Royalty, subject to Section 4(a) of the License Agreement, on Net Sales of the Licensed Products in the Territory for so long as Licensee, one of its Affiliates or any of its or their (sub)licensees is selling the Licensed Products.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(e)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Liens or Assignments by the Seller</u>. &#160;The Seller has not, except for Permitted Liens and as contemplated hereby, conveyed, assigned or in any other way transferred </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">12</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;">or granted any liens upon or security interests with respect to all or any portion of its right, title and interest in and to the Purchased Assets, the Licensed IP or the License Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(f)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Waivers or Releases</u>. &#160;The Seller has not granted any material waiver under the License Agreement and has not released Licensee, in whole or in part, from any of its material obligations under the License Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(g)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Termination</u>. &#160;The Seller has not (i) given Licensee any notice of termination of the License Agreement (whether in whole or in part) or any notice expressing any intention to terminate the License Agreement or (ii) received any notice of termination of the License Agreement (whether in whole or in part) or any notice expressing any intention to terminate either the License Agreement. &#160;To the Knowledge of the Seller, no event has occurred that would give rise to the expiration or termination of the License Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(h)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Breaches or Defaults</u>. &#160;There is and has been no material breach or default under any provision of the License Agreement either by the Seller (or any predecessor thereof) or, to the Knowledge of the Seller, by Licensee (or any predecessor thereof), and there is no event that upon notice or the passage of time, or both, would reasonably be expected to give rise to any breach or default either by the Seller or, to the Knowledge of the Seller, by Licensee.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Payments Made</u>. &#160;The Seller has received from Licensee the full amount of the payments due and payable under the License Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(j)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Assignments by Licensee</u>. &#160;The Seller has not consented to any assignment or other transfer by Licensee or any of its predecessors of any of their rights or obligations under the License Agreement, and, to the Knowledge of the Seller, Licensee has not assigned or otherwise transferred or granted any liens upon or security interest with respect to any of its rights or obligations under the License Agreement to any Person.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(k)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Indemnification Claims</u>. &#160;The Seller has not notified Licensee or any other Person of any claims for indemnification under the License Agreement nor has the Seller received any claims for indemnification under the License Agreement, whether pursuant to Section 9 thereof or otherwise.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(l)</font><a name="_Ref136557476"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Royalty Reductions</u>. &#160;To the Knowledge of the Seller, the amount of the Royalty due and payable under Section 4(a) of the License Agreement is not, as of the date hereof, subject to any claim against the Seller pursuant to any right of set-off, counterclaim, credit, reduction or deduction by contract or otherwise (including, for the avoidance of doubt, any deduction of any withholding taxes, value-added taxes or other taxes, levies or charges) (each, a &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Royalty Reduction</u>&#8221;), including any Permitted Reduction. &#160;To<b style="font-weight:bold;"> </b>the Knowledge of the Seller, no event or condition exists (except for the existence of Section 4(b) in the License Agreement) that, upon notice or passage of time or both, would reasonably be expected to permit Licensee to claim, or have the right to claim, a Royalty Reduction.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(m)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Notice of Infringement</u>. &#160;The Seller has not received any written notice from, or given any written notice to, Licensee pursuant to Section 5(d) of the License Agreement or otherwise.</div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">13</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(n)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Audits</u>. &#160;The Seller has not initiated, pursuant to Section&#160;4(h) of the License Agreement or otherwise, any inspection or audit of books of accounts or other records pertaining to Net Sales, the calculation of royalties or other amounts payable to the Seller under the License Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(o)</font><a name="_Ref137910872"></a><a name="_Ref137910876"></a><a name="_Ref137915779"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">In-License</u>. &#160;There are no KTB Patent Rights for which a Valid Claim remains in effect that are licensed to the Seller under the KTB Agreement. &#160;All KTB Patent Rights licensed to the Seller under the KTB Agreement are not in full force and effect and have lapsed, expired, or otherwise terminated. The KTB Agreement has expired pursuant to Section 10.1 thereof. </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 4.10</font><a name="_cp_blt_1_79"></a><a name="_cp_blt_2_78"></a><a name="_cp_blt_1_83"></a><a name="_cp_blt_2_82"></a><a name="_cp_blt_1_102"></a><a name="_cp_blt_2_101"></a><a name="_cp_blt_1_107"></a><a name="_cp_blt_2_106"></a><a name="_cp_blt_1_117"></a><a name="_cp_blt_2_116"></a><a name="_Ref137484530"></a><a name="_Toc138244514"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Title to Purchased Assets</u>. &#160;The Seller has good and marketable title to the Purchased Assets free and clear of all Liens (other than Permitted Liens). &#160;Upon payment of the Purchase Price by the Buyer, the Buyer will acquire, subject to the terms and conditions set forth in this Agreement and the License Agreement, good and marketable title to the Purchased Assets, free and clear of all Liens (other than Liens created by the Buyer).</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 4.11</font><a name="_Ref137484536"></a><a name="_Toc138244515"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Intellectual Property</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref137014006"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section 4.11(a)</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u><a name="_Ref137013992"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">of the Disclosure Schedule</u> lists all the Licensed Patents. &#160;Except for as set forth on <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.11</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;(a)</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(2) of the Disclosure Schedule</u>, the Seller is the sole owner of, and has the sole interest in, all of the Licensed Patents. &#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section 4.11(a)</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> of the Disclosure Schedule</u> specifies as to each of the Licensed Patents, as applicable, the jurisdictions by or in which each such patent has issued as a patent or such patent application has been filed, including the respective patent numbers and application numbers and issue and filing dates.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref137014020"></a>Except as set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section 4.11(b)</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> of the Disclosure Schedule</u>, there are no pending or, to the Knowledge of the Seller, threatened litigations, interferences, reexamination, oppositions or like procedures involving any Licensed Patents.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font><a name="_Ref138138027"></a>Except for as set forth on <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section 4.11(c)</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> of the Disclosure Schedule</u>, all of the issued Licensed Patents are in full force and effect and have not lapsed, expired or otherwise terminated, and, to the Knowledge of the Seller, are valid and enforceable. &#160;The Seller has not received any written notice relating to the lapse, expiration or other termination of any of the Licensed Patents (excluding, with respect to patent applications during the period when such patent applications were pending, all office actions from the U.S. Patent &amp; Trademark Office and any equivalent patent office in any other jurisdiction involving such Licensed Patents during routine patent prosecution), or any written legal opinion that alleges that any of the issued Licensed Patents is invalid or unenforceable.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(d)</font>To the Knowledge of the Seller, there is no Person who is or claims to be an inventor under any of the Licensed Patents who is not a named inventor thereof.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(e)</font>The Seller has not, and, to the Knowledge of the Seller, Licensee has not, received any written notice of any claim by any Person challenging the inventorship or ownership of, the rights of the Seller or Licensee, as applicable, in and to, or the patentability, validity or enforceability of, any Licensed Patent (excluding, with respect to patent applications during the period when such patent applications were pending, all office actions from the U.S. Patent &amp; </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">14</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;">Trademark Office and any equivalent patent office in any other jurisdiction involving such Licensed Patents during routine patent prosecution), or asserting that the development, manufacture, importation, sale, offer for sale or use of any Licensed Product infringes any patent or other intellectual property rights of such Person.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(f)</font>To the Knowledge of the Seller, the discovery and development of the Licensed Products did not and does not infringe, misappropriate or otherwise violate any patent rights or other intellectual property rights owned by any third party. &#160;Neither the Seller nor, to the Knowledge of the Seller, Licensee, has, except pursuant to the KTB Agreement (subject to &#8206;Section 4.9(o)), in-licensed any patents or other intellectual property rights covering the manufacture, use, sale, offer for sale or import of the Licensed Products.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(g)</font>To the Knowledge of the Seller, the manufacture, use, marketing, sale, offer for sale, importation or distribution of the Licensed Products has not and will not, infringe, misappropriate or otherwise violate any patent rights or other intellectual property rights owned by any other Person.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(h)</font>To the Knowledge of the Seller, no third party has infringed, misappropriated or otherwise violated, or is infringing, misappropriating or otherwise violating, any of the Licensed Patents or any other patent right claiming the composition of matter of, or the method of making or using, any Licensed Product.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font><a name="_Ref138138112"></a>Except as set forth on <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section 4.11(i)</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> of the Disclosure Schedule</u>, all required maintenance fees, annuities and like payments with respect to the Licensed Patents for which the Seller controls the prosecution and maintenance in accordance with Section 5(c) of the License Agreement, and to the Knowledge of the Seller, with respect to all other Licensed Patents, have been paid timely.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 4.12</font><a name="_Ref137568966"></a><a name="_Toc138244516"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">UCC Representation and Warranties</u>. &#160;The Seller&#8217;s exact legal name is, and as of September 26, 2022 has been, &#8220;LadRx Corporation&#8221;. &#160;From November 13, 2007 to September 26, 2022, the Seller&#8217;s exact legal name was &#8220;CytRx Corporation.&#8221; CytRx Corporation was originally incorporated under the name SynthRx, Inc. on February 28, 1985. The Seller is, and for the prior ten years has been, incorporated in Delaware.</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 4.13</font><a name="_Ref137568967"></a><a name="_Toc138244517"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Brokers&#8217; Fees</u>. &#160;Except for Roth Capital Partners, LLC, there is no investment banker, broker, finder, financial advisor or other intermediary who has been retained by or is authorized to act on behalf of the Seller who might be entitled to any fee or commission in connection with the transactions contemplated by this Agreement.</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 4.14</font><a name="_Toc138244518"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Implied Representations and Warranties</u>. &#160;BUYER EXPRESSLY ACKNOWLEDGES AND AGREES THAT, EXCEPT AS EXPRESSLY SET FORTH IN &#8206;&#8206;Article 4, THE SELLER MAKES NO REPRESENTATION OR WARRANTY, EXPRESSED OR IMPLIED, AT LAW OR IN EQUITY IN RESPECT OF THE LICENSE AGREEMENT, ANY LICENSED PATENTS, THE PURCHASED ASSETS OR THE TRANSACTIONS CONTEMPLATED HEREBY, INCLUDING WITH RESPECT TO </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">15</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-size:12pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, AND ANY SUCH OTHER REPRESENTATIONS OR WARRANTIES ARE HEREBY EXPRESSLY DISCLAIMED. </font><font style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;text-transform:uppercase;">Buyer Acknowledges and agrees that, except FOR FRAUD, WILLFUL MISCONDUCT, INTENTIONAL MISREPRESENTATION, INTENTIONAL BREACH, AND as expressly set forth in any representation or warranty in Article 4, Buyer shall have no claim or right regarding to losses or damages pursuant to SECTION 8.1(</font><font style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">a</font><font style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;text-transform:uppercase;">)[***</font><font style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">].</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"> <font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:center;text-indent:0pt;"><font style="color:#010000;text-transform:uppercase;white-space:nowrap;">Article 5</font><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><a name="_Toc138244519"></a>BUYER&#8217;S REPRESENTATIONS AND WARRANTIES</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 0pt 36pt;">The Buyer represents and warrants to the Seller that as of the date hereof:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 5.1</font><a name="_Ref137484602"></a><a name="_Toc138244520"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Existence; Good Standing</u>. &#160;The Buyer is a limited liability company duly organized, validly existing and in good standing under the laws of the State of Delaware and has all powers and authority, and all licenses, permits, franchises, authorization, consents and approvals of all Governmental Entities, required to own its property and conduct its business as now conducted.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 5.2</font><a name="_Ref137484607"></a><a name="_Toc138244521"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Authorization</u>. &#160;The Buyer has all company power and authority to execute, deliver and perform its obligations under this Agreement. &#160;The execution, delivery and performance of this Agreement, and the consummation of the transactions contemplated hereby, have been duly authorized by all necessary action on the part of the Buyer.</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 5.3</font><a name="_Ref137484612"></a><a name="_Toc138244522"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Enforceability</u>. &#160;This Agreement has been duly executed and delivered by an authorized person of the Buyer and constitutes the valid and binding obligation of the Buyer, enforceable against the Buyer in accordance with its terms, except as may be limited by applicable Bankruptcy Laws or by general principles of equity (whether considered in a proceeding in equity or at law).</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 5.4</font><a name="_Ref137484618"></a><a name="_Toc138244523"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Conflicts</u>. &#160;The execution, delivery and performance by the Buyer of this Agreement do not and shall not (i)&#160;contravene or conflict with the organizational documents of the Buyer, (ii)&#160;contravene or conflict with or constitute a default under any material provision of any law binding upon or applicable to the Buyer or (iii)&#160;contravene or conflict with or constitute a default under any material contract or other material agreement or Judgment binding upon or applicable to the Buyer.</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 5.5</font><a name="_Toc138244524"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Consents</u>. &#160;No consent, approval, license, order, authorization, registration, declaration or filing with or of any Governmental Entity or other Person is required to be done or obtained by the Buyer in connection with (i)&#160;the execution and delivery by the Buyer of this Agreement, (ii)&#160;the performance by the Buyer of its obligations under this Agreement, other </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">16</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-size:12pt;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">than the filing of financing statement(s) in accordance with </font><font style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#8206;</font><u style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><font style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">2.4</font><font style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">, or (iii)&#160;the consummation by the Buyer of any of the transactions contemplated by this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 5.6</font><a name="_Toc138244525"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Litigation</u>. &#160;There is no action, suit, investigation or proceeding pending before any Governmental Entity or, to the knowledge of the Buyer, threatened to which the Buyer is a party that, individually or in the aggregate would, if determined adversely, reasonably be expected to prevent or materially and adversely affect the ability of the Buyer to perform its obligations under this Agreement.</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 5.7</font><a name="_Toc138244526"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Financing</u>. &#160;The Buyer has sufficient cash on hand to pay the entire Purchase Price. &#160;The Buyer acknowledges that its obligations under this Agreement are not contingent on obtaining financing.</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 5.8</font><a name="_Ref137484625"></a><a name="_Toc138244527"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Brokers&#8217; Fees</u><font style="white-space:pre-wrap;">.  There is no investment banker, broker, finder, financial advisor or other intermediary who has been retained by or is authorized to act on behalf of the Buyer who might be entitled to any fee or commission in connection with the transactions contemplated by this Agreement. </font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:center;text-indent:0pt;"><font style="color:#010000;text-transform:uppercase;white-space:nowrap;">Article 6</font><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><a name="_Toc138244528"></a>COVENANTS</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 6.1</font><a name="_Toc138244529"></a><a name="_Ref306405604"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disclosures</u>. &#160;Except for a press release previously approved in form and substance by the Seller and the Buyer or any other public announcement using substantially the same text as such press release, neither the Buyer nor the Seller shall, and each party hereto shall cause its respective Representatives, Affiliates and Affiliates&#8217; Representatives not to, issue a press release or other public announcement or otherwise make any public disclosure with respect to this Agreement or the subject matter hereof without the prior written consent of the other party hereto (which consent shall not be unreasonably withheld, conditioned or delayed), except as may be required by applicable law or stock exchange rule (in which case the party hereto required to make the press release or other public announcement or disclosure shall, if not prohibited by applicable law, allow the other party hereto reasonable time to comment on such press release or other public announcement or disclosure in advance of such issuance).</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 6.2</font><a name="_Ref135729193"></a><a name="_Ref135732740"></a><a name="_Ref135732748"></a><a name="_Toc138244530"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Payments Received In Error; Interest</u>. &#160;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:76.5pt;"><font style="display:inline-block;min-width:31.5pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref135732754"></a>Commencing on the Closing Date and at all times thereafter, if any payment of any portion of the Purchased Receivables is made to the Seller, the Seller shall pay such amount to the Buyer, promptly (and in any event within ten (10) Business Days) after the receipt thereof, by wire transfer of immediately available funds to an account designated in writing by the Buyer. The Seller shall notify the Buyer of such wire transfer and provide reasonable details regarding the Purchased Receivables payment so received by the Seller. &#160;The Seller agrees that, in the event any payment of the Purchased Receivables is paid to the Seller, the Seller shall (i)&#160;until paid to the Buyer, hold such payment received in trust for the benefit of the Buyer and (ii)&#160;have no right, title </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">17</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;">or interest in such payment and that it shall not pledge or otherwise grant any security interest therein. </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:76.5pt;"><font style="display:inline-block;min-width:31.5pt;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref135729199"></a>Commencing on the Closing Date and at all times thereafter, if any payment due under the License Agreement that does not constitute the Purchased Receivables is made to the Buyer, the Buyer shall pay such amount to the Seller, promptly (and in any event within five (5) Business Days) after the receipt thereof, by wire transfer of immediately available funds to an account designated in writing by the Seller. The Buyer shall notify the Seller of such wire transfer and provide reasonable details regarding the erroneous payment so received by the Buyer. &#160;The Buyer agrees that, in the event any payment due under the License Agreement that does not constitute the Purchased Receivables is paid to the Buyer, the Buyer shall (i)&#160;until paid to the Seller, hold such payment received in trust for the benefit of the Seller and (ii)&#160;have no right, title or interest in such payment and that it shall not pledge or otherwise grant any security interest therein. &#160;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:76.5pt;"><font style="display:inline-block;min-width:31.5pt;text-indent:0pt;white-space:nowrap;">(c)</font>A late fee of 4% over the Prime Rate shall accrue on all unpaid amounts with respect to any sum payable under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section 6.2</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;(a)</u> or <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section 6.2</u><a name="_cp_text_1_151"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;(b)</u> beginning five (5) Business Days after receipt of such payment received in error.</div><div style="margin-top:12pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 6.3</font><a name="_Toc138244531"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Royalty Reduction</u>. &#160;If Licensee exercises any Royalty Reduction against any payment of the Purchased Receivables other than for a Permitted Reduction, such Royalty Reduction shall not reduce any payment of the Purchased Receivables otherwise payable to the Buyer, and if such Royalty Reduction reduces any payment of the Purchased Receivables to less than the full amount of the Purchased Receivables, then Seller shall promptly (and in any event within five (5) Business Days following the payment of the Purchased Receivables affected by such Royalty Reduction) make a true-up payment to the Buyer such that the Buyer receives the full amount of such Purchased Receivables payments that would have been payable to the Buyer had such Royalty Reduction not occurred. </div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 6.4</font><a name="_Toc138244532"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Seller Withholding Taxes</u>. &#160;If Seller Withholding Taxes reduce any payment of the Purchased Receivables to less than the full amount of the Purchased Receivables, then Seller shall promptly (and in any event within five (5) Business Days following the payment of the Purchased Receivables affected by such Seller Withholding Taxes) make a true-up payment to the Buyer such that the Buyer receives the full amount of such Purchased Receivables payments that would have been payable to the Buyer had such event triggering Seller Withholding Taxes not occurred. For the avoidance of doubt, any withholding taxes, value-added taxes or other taxes, levies or charges that exist due to Seller being a Delaware corporation complying with applicable law shall not be considered Seller Withholding Taxes. </div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 6.5</font><a name="_Ref276325095"></a><a name="_Toc138244533"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Royalty Reports; Notices and Other Information</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> from the Licensee</u>. &#160;Promptly (and in any event within five (5) Business Days) following the receipt by the Seller of any Royalty Report or other notice, correspondence or confidential information relating to the Purchased Receivables or the Licensed Product in the Territory that has been provided to the Seller under the License Agreement and that the Licensee has not provided to the Buyer directly, the Seller shall furnish a true, correct and complete copy of the same to the Buyer.</div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">18</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 6.6</font><a name="_Toc138244534"></a><a name="_Ref978290"></a><a name="_Ref978461"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notices and Other Information to the Licensee</u>. The Seller shall not send (or refrain from sending), without the prior written consent of the Buyer, any material written notice or correspondence to Licensee, except for any such material written notice or correspondence that (i) does not relate to the Purchased Receivables and (ii) would not, and does not relate to a matter that would, reasonably be expected (with or without the giving of notice or passage of time, or both) to result in a Material Adverse Effect. &#160; </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 6.7</font><a name="_Ref276325316"></a><a name="_Ref138195118"></a><a name="_Toc138244535"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Inspections and Audits of </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Licensee</u>. &#160;Pursuant to the Power of Attorney, the Buyer shall have the right to, or at the written request of the Buyer, the Seller shall, to the extent permitted under Section&#160;4(h) of the License Agreement, cause an inspection or audit by an independent public accounting firm to be made for the purpose of determining the correctness of Purchased Receivables payments made under the License Agreement. &#160;With respect to any inspection or audit (i) initiated by the Buyer pursuant to the Power of Attorney, (ii) requested by the Buyer or (iii) undertaken by the Seller on its own initiative with respect to the Purchased Receivables, the Seller shall, for purposes of Section&#160;4(h) of the License Agreement, select such independent public accounting firm as the Buyer shall recommend for such purpose (as long as such independent certified public accountant is reasonably acceptable to Licensee as required by Section&#160;4(h) of the License Agreement). &#160;The Buyer shall pay the Seller the expenses of any inspection or audit requested by the Buyer (including the fees and expenses of such independent public accounting firm designated for such purpose) that would otherwise be borne by the Seller pursuant to the License Agreement (if and as such expenses are actually incurred by the Seller).</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 6.8</font><a name="_Ref276331627"></a><a name="_Toc138244536"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendment </u><a name="_cp_text_1_160"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">or Assignment </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">of License Agreement</u>. &#160;The Seller shall not, without the prior written consent of the Buyer, <a name="_cp_text_1_162"></a>assign, amend, modify, supplement or restate (or consent to any assignment, amendment, <a name="_cp_text_1_164"></a>modification, supplement or restatement of) any provision of the License Agreement. &#160;Subject to the foregoing, promptly, and in any event within <a name="_cp_text_1_166"></a>five (<a name="_cp_text_1_168"></a>5) Business Days, following receipt by the Seller of <a name="_cp_text_1_170"></a>any final assignment, amendment, modification, supplement or restatement of the License Agreement, the Seller shall furnish a copy of <a name="_cp_text_1_172"></a>the same to the Buyer.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 6.9</font><a name="_Ref983148"></a><a name="_Ref138195238"></a><a name="_Toc138244537"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Maintenance of </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">License Agreement</u>. &#160;The Seller shall comply in all material with the Seller&#8217;s obligations under the License Agreement and shall not take any action or forego any action that would reasonably be expected to constitute a material breach thereof or default thereunder. &#160;Promptly, and in any event within <a name="_cp_text_1_174"></a>five (<a name="_cp_text_1_176"></a>5) Business Days, after receipt of any (written or oral) notice from the applicable counterparty thereto of an alleged breach or default by the Seller under the License Agreement, the Seller shall give notice thereof to the Buyer, including delivering the Buyer a copy of any such written notice. &#160;After consultation with the Buyer and as reasonably requested by the Buyer, the Seller shall use reasonable best efforts to cure any breaches or defaults by the Seller under the License Agreement and shall give written notice to the Buyer upon curing any such breach or default.<a name="_cp_text_1_177"></a> &#160;In connection with any dispute regarding an alleged breach or default by the Seller that is solely related to the Purchased Assets, involves a Licensed Patent (including patent term restoration, extension or adjustment, supplementary protection certificates and the like or any foreign equivalent), or could reasonably be expected (with or without the giving of notice or passage of time, or both) to have a Material Adverse Effect, the Seller shall employ such counsel, reasonably acceptable to the Seller, as the Buyer may select. The Seller shall not, without the prior written consent of the Buyer, (i) forgive, release or compromise any amount owed to or becoming owed to the Seller under the License Agreement in respect of </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">19</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">the Purchased Receivables or (ii) </font><font style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;"><a name="_cp_text_1_179"></a></font><font style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">waive any obligation of, or grant any consent to, the Licensee under, in respect of or related to the Purchased Assets. &#160;The Seller shall not, without the prior written consent of Buyer, exercise or enforce the Seller&#8217;s applicable rights under the License Agreement in any manner that would result in a breach of this Agreement or otherwise reasonably be expected (with or without the giving of notice or the passage of time, or both) to have a Material Adverse Effect. </font><font style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;"> The Seller shall not, without the prior written consent of the Buyer, enter into any new agreement or legally binding arrangement in respect of the Licensed Patents. </font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 6.10</font><a name="_Ref288108322"></a><a name="_Ref137145558"></a><a name="_Toc138244538"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Enforcement of </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">License Agreement</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref278968272"></a><a name="_Ref288147642"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notice of Breaches by Licensee</u>. &#160;Promptly (and in any event within five (5) Business Days) after the Seller becomes aware of, or comes to believe in good faith that there has been, a breach of the License Agreement by the applicable counterparty thereto, the Seller shall provide notice of such breach to the Buyer. &#160;In addition, the Seller shall provide to the Buyer a copy of any written notice of breach or alleged breach of the License Agreement delivered by the Seller to the applicable counterparty thereto as soon as practicable and in any event not less than <a name="_cp_text_1_183"></a>five (<a name="_cp_text_1_185"></a>5) Business Days following such delivery.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref135730845"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Enforcement of License Agreement</u>. &#160;In the case of any breach by the applicable counterparty referred to in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section 6.10(a)</u>, the Seller shall consult with the Buyer regarding the timing, manner and conduct of any enforcement of the applicable counterparty&#8217;s obligations under the License Agreement. &#160;Following such consultation, the Seller shall not, without the prior written consent of the Buyer, and if reasonably requested by the Buyer, the Seller shall exercise such rights and remedies relating to any such breach as shall be available to the Seller whether under the License Agreement or by operation of law and employ such counsel reasonably acceptable to the Seller as the Buyer shall recommend for such purpose. </div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">(c)</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Allocation of Proceeds and Costs of Enforcement</u>. &#160;Each of the Buyer and the Seller shall bear its own fees and expenses incurred in enforcing the applicable counterparty&#8217;s obligations under the License Agreement pursuant to this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section 6.10</u>, provided that the Buyer shall pay all costs and expenses pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section 6.10</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;(b)</u>. The Proceeds resulting from any enforcement of the applicable counterparty&#8217;s obligations under the License Agreement undertaken at the Buyer&#8217;s request pursuant to this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section 6.10</u> shall be applied first to reimburse the Seller and the Buyer for any expenses incurred by them in connection with such enforcement, with the remainder of the Proceeds distributed to the Buyer. &#160;The Seller hereby assigns, and, if not presently assignable, agrees to assign, to the Buyer the amount of Proceeds due to the Buyer in accordance with this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section </u>6.10. Notwithstanding anything to the contrary, nothing in this &#8206;Section 6.10 shall reduce the payments by Buyer of the payment obligations set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section 2.2</u>. </p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 6.11</font><a name="_Toc138244539"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination of License Agreement</u>. &#160;The Seller shall not, without the prior written consent of the Buyer, (i) exercise any right to terminate the License Agreement, in whole or in part, (ii) agree with Licensee to terminate the License Agreement, in whole or in part, or (iii) take, or permit any Affiliate or sublicensee to take, any action that would reasonably be expected to give Licensee the right to terminate the License Agreement, in whole or in part. &#160;</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">20</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 6.12</font><a name="_Ref276332908"></a><a name="_Toc138244540"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Preservation of Rights</u>. &#160;<a name="_Hlk17030789"></a>The Seller shall not, without the prior written consent of the Buyer, hereafter sell, transfer, hypothecate, assign or in any manner convey or mortgage, pledge or grant a security interest or other encumbrance of any kind in any the Seller&#8217;s right, title, and interest in any portion of the Licensed Patents or the License Agreement that could reasonably be expected (with or without the giving of notice or passage of time, or both) to have a Material Adverse Effect. The Seller shall not hereafter subject to a Lien (other than a Permitted Lien), sell, transfer, assign, convey title (in whole or in part), grant any right to, or otherwise dispose of any portion of the Purchased Assets.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 6.13</font><a name="_Ref135743621"></a><a name="_Toc138244541"></a><a name="_Ref277718599"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Enforcement; Defense; Prosecution and Maintenance</u>. <a name="_cp_text_1_191"></a></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_cp_blt_1_195"></a>The Seller shall promptly inform the Buyer of any suspected infringement by a third party of any of the Licensed Patents or any other patent right <a name="_cp_text_1_193"></a>claiming the composition of matter of, or the method of making or using, any Licensed Product in the Territory. &#160;The Seller shall (i) provide to the Buyer a copy of any written notice of any suspected infringement in the Territory of any of the Licensed Patents and all pleadings filed in such action and (ii) notify the Buyer of any material developments in any claim, suit or proceeding resulting from such infringement that are delivered by Licensee to the Seller under Sections 5(d) and 5(f) of the License Agreement or otherwise as soon as practicable and in any event not less than five (5) Business Days following such delivery. </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_cp_blt_1_197"></a><a name="_cp_blt_2_196"></a><a name="_Ref138195153"></a>If the Seller has the right to join an enforcement action in the Territory as set forth in Section 5(d) of the License Agreement, the Seller shall, if requested in writing by the Buyer, promptly, and in any event within five (5) Business Days after receipt of such request, exercise such right as instructed by the Buyer and the Seller shall employ such counsel reasonably acceptable to the Seller as the Buyer shall recommend for such purpose. &#160;The Seller shall not join any infringement action in the Territory under Section 5(d) of the License Agreement or initiate any infringement action in the Territory under Section 5(e) of the License Agreement without the Buyer&#8217;s prior consent, which will not be unreasonably withheld, delayed, or conditioned.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font><a name="_Ref135743625"></a><a name="_cp_blt_1_200"></a><a name="_cp_text_1_198"></a>Promptly (and in any event within five (5) Business Days) following the Seller receiving notice from the Licensee pursuant to Section 5(c) of the License Agreement of the Licensee&#8217;s intention to allow any of the Licensed Patents in the Territory to lapse or become abandoned or to not file patent applications for any of the Licensed Patents in the Territory (such Patent Rights, the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Applicable Patents</u>&#8221;), the Seller shall inform the Buyer of such notice and, as reasonably requested by the Buyer, the Seller shall exercise its rights under Section 5(c) of the License Agreement to assume the prosecution and maintenance of any such Applicable Patents. </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(d)</font><a name="_Ref135861868"></a>The Seller shall act as reasonably requested by the Buyer, and in all cases to the extent provided for in, or permitted by, the License Agreement, to (i) take any and all actions, and prepare, execute, deliver and file any and all agreements, documents and instruments, that are reasonably necessary or desirable to diligently prosecute, preserve and maintain any Licensed Patents in the Territory for which it controls the prosecution and maintenance, in accordance with Section 5(c) of the License Agreement including payment of maintenance fees or annuities on any such Licensed Patents, which, as between the parties, shall be at the sole expense of the Buyer, (ii) prosecute any corrections, substitutions, reissues, reviews and reexaminations of any Licensed Patents in the Territory, for which it controls the prosecution and maintenance, in accordance with </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">21</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;">Section 5(c) of the License Agreement, and any other forms of patent term restoration in any applicable jurisdiction in the Territory, (iii) diligently enforce and defend any Licensed Patents for which it controls the defense and enforcement in the Territory, including by bringing any legal action for infringement or defending any counterclaim of invalidity or unenforceability or action of a third party for declaratory judgment of non-infringement or non-interference), and (iv) not disclaim or abandon, or fail to take any action necessary or desirable to prevent the disclaimer or abandonment (including through lack of enforcement against third party infringers), of any Licensed Patents<a name="_cp_text_1_201"></a> in the Territory for which it controls the prosecution and maintenance, in accordance with Section 5(c) of the License Agreement. &#160;For purposes of compliance with this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section 6.13(d)</u>, the Seller shall employ such counsel reasonably acceptable to the Seller as the Buyer shall recommend for such purpose.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 6.14</font><a name="_Ref138240933"></a><a name="_Toc138244542"></a><a name="_Hlk138240573"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Power of Attorney</u>. &#160;The Buyer shall have the right to use the Power of Attorney to exercise on behalf of the Seller with respect to [***]. &#160; &#160; </div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 6.15</font><a name="_Toc138244543"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Efforts to Consummate Transactions</u>. &#160;Subject to the terms and conditions of this Agreement, each of the Seller and the Buyer shall use its commercially reasonable efforts to take, or cause to be taken, all actions and to do, or cause to be done, all things reasonably necessary under applicable law to consummate the transactions contemplated by this Agreement. &#160;Each of the Buyer and the Seller agrees to execute and deliver such other documents, certificates, agreements and other writings and to take such other actions as may be reasonably necessary in order to consummate or implement expeditiously the transactions contemplated by this Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 6.16</font><a name="_Toc138244544"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Further Assurances</u>. &#160;After the Closing, the Seller and the Buyer agree to execute and deliver such other documents, certificates, agreements and other writings and to take such other actions as may be reasonably necessary in order to give effect to the transactions contemplated by this Agreement. &#160;<a name="_Hlk137820728"></a></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:center;text-indent:0pt;"><font style="color:#010000;text-transform:uppercase;white-space:nowrap;">Article 7</font><a name="_Toc514579121"></a><a name="_Ref370725493"></a><a name="_Ref370725185"></a><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><a name="_Ref135729131"></a><a name="_Ref135730396"></a><a name="_Toc138244545"></a>CONFIDENTIALITY</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 7.1</font><a name="_Toc514579122"></a><a name="_Ref370725281"></a><a name="_Ref137023086"></a><a name="_Toc138244546"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Confidentiality</u>. &#160;Except as provided in this &#8206;Article 7 or otherwise agreed in writing by the parties, the parties hereto agree that, during the term of this Agreement and for five (5) years thereafter, each party (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Receiving Party</u>&#8221;) shall keep confidential and shall not publish or otherwise disclose and shall not use for any purpose other than as provided for in this Agreement (which includes the exercise of any rights or the performance of any obligations hereunder) any information furnished to it by or on behalf of the other party (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disclosing Party</u>&#8221;) pursuant to this Agreement (such information, &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Confidential Information</u>&#8221; of the Disclosing Party), except for that portion of such information that:</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:54pt;text-indent:0pt;white-space:nowrap;">(a)</font>was already known to the Receiving Party, other than under an obligation of confidentiality, at the time of disclosure by the Disclosing Party;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:54pt;text-indent:0pt;white-space:nowrap;">(b)</font>was generally available to the public or otherwise part of the public domain at the time of its disclosure to the Receiving Party;</div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">22</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:54pt;text-indent:0pt;white-space:nowrap;">(c)</font>became generally available to the public or otherwise part of the public domain after its disclosure and other than through any act or omission of the Receiving Party in breach of this Agreement; </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:54pt;text-indent:0pt;white-space:nowrap;">(d)</font>is independently developed by the Receiving Party or any of its Affiliates, as evidenced by written records, without the use of or reference of the Confidential Information; or</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:54pt;text-indent:0pt;white-space:nowrap;">(e)</font>is subsequently disclosed to the Receiving Party on a non-confidential basis by a third party without obligations of confidentiality with respect thereto.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:36pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 7.2</font><a name="_Toc514579123"></a><a name="_Ref135730318"></a><a name="_Toc138244547"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Authorized Disclosure</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:45pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref135730334"></a>Either party may disclose Confidential Information with the prior written consent of the Disclosing Party or to the extent such disclosure is reasonably necessary in the following situations:</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:72pt;text-align:justify;text-indent:36pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font><a name="_Ref370725148"></a>prosecuting or defending litigation;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:72pt;text-align:justify;text-indent:36pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(ii)</font><a name="_Ref370725154"></a>complying with applicable laws and regulations, including regulations promulgated by securities exchanges; </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:72pt;text-align:justify;text-indent:36pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(iii)</font><a name="_Ref370725161"></a>complying with a valid order of a court of competent jurisdiction or other Governmental Entity; </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:72pt;text-align:justify;text-indent:36pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(iv)</font><a name="_Ref370725169"></a>for regulatory, tax or customs purposes;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:72pt;text-align:justify;text-indent:36pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(v)</font>for audit purposes, provided that each recipient of Confidential Information must be bound by customary obligations of confidentiality and non-use prior to any such disclosure;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:72pt;text-align:justify;text-indent:36pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(vi)</font>disclosure to its Affiliates and Representatives on a need-to-know basis, provided that each recipient of Confidential Information must be informed of and bound by obligations of confidentiality and non-use prior to any such disclosure; or</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:72pt;text-align:justify;text-indent:36pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(vii)</font>disclosure to its actual or potential investors and co-investors, and other sources of funding, including debt financing, or potential partners, collaborators or acquirers, and their respective accountants, financial advisors and other professional representatives, provided, that such disclosure shall be made only to the extent customarily required to consummate such investment, financing transaction partnership, collaboration or acquisition and that each recipient of Confidential Information must be bound by customary obligations of confidentiality and non-use prior to any such disclosure.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:45pt;text-indent:0pt;white-space:nowrap;">(b)</font>Notwithstanding the foregoing, in the event the Receiving Party is required to make a disclosure of the Disclosing Party&#8217;s Confidential Information pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section 7.2</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;(a)(i)</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;(a)(ii)</u>, &#8206;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(a)(iii</u>) or <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;(a)(iv)</u>, it will, except where impracticable, give reasonable </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">23</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:0pt;">advance notice to the Disclosing Party of such disclosure and use reasonable efforts to secure confidential treatment of such information and to limit the required scope of such disclosure. &#160;In any event, the Buyer shall not file any patent application based upon or using the Confidential Information of Seller provided hereunder.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:center;text-indent:0pt;"><font style="color:#010000;text-transform:uppercase;white-space:nowrap;">Article 8</font><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><a name="_Ref276335384"></a><a name="_Ref363830158"></a><a name="_Toc138244548"></a>INDEMNIFICATION</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 8.1</font><a name="_Ref288083709"></a><a name="_Ref288083944"></a><a name="_Toc138244549"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">General Indemnity</u>. &#160;Subject to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section 8.3</u>, from and after the Closing:</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref276335804"></a><a name="_Ref288083735"></a><a name="_Ref288084038"></a>the Seller hereby agrees to indemnify, defend and hold harmless the Buyer and its Affiliates and its and their directors, managers, trustees, officers, agents and employees (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Buyer Indemnified Parties</u>&#8221;) from, against and in respect of all Losses suffered or incurred by the Buyer Indemnified Parties to the extent arising out of or resulting from (i)&#160;<a name="OLE_LINK2"></a><a name="OLE_LINK14"></a>any breach of any of the representations or warranties (in each case, when made) of the Seller in this Agreement<a name="_cp_text_1_202"></a>, &#160;(ii)&#160;any breach of any of the covenants or agreements of the Seller in this Agreement, and (iii) any Excluded Liabilities and Obligations; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u>, that the foregoing shall exclude any indemnification to any Buyer Indemnified Party (i) that results from the gross negligence or willful misconduct of a Buyer Indemnified Party or (ii) that results from acts or omissions of the Seller or any of its Affiliates that are in accordance with specific written instructions from any Buyer Indemnified Party (unless the Seller is otherwise liable for such Losses pursuant to the terms of this Agreement); and</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref288083812"></a><a name="_Ref288084040"></a>the Buyer hereby agrees to indemnify, defend and hold harmless the Seller and its Affiliates and its and their directors, officers, agents and employees (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Seller Indemnified Parties</u>&#8221;) from, against and in respect of all Losses suffered or incurred by the Seller Indemnified Parties to the extent arising out of or resulting from (i)&#160;any breach of any of the representations or warranties (in each case, when made) of the Buyer in this Agreement<a name="_cp_text_1_203"></a> or (ii)&#160;any breach of any of the covenants or agreements of the Buyer in this Agreement <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u>, that the foregoing shall exclude any indemnification to any Seller Indemnified Party (i) that results from the gross negligence or willful misconduct of a Seller Indemnified Party or (ii) that results from acts or omissions of the Buyer or any of its Affiliates that are in accordance with specific written instructions from any Seller Indemnified Party (unless the Buyer is otherwise liable for such Losses pursuant to the terms of this Agreement).</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 8.2</font><a name="_Ref276335428"></a><a name="_Toc138244550"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notice of Claims</u>. &#160;If either a Buyer Indemnified Party, on the one hand, or a Seller Indemnified Party, on the other hand (such Buyer Indemnified Party on the one hand and such Seller Indemnified Party on the other hand being hereinafter referred to as an&#160;&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnified Party</u>&#8221;), has suffered or incurred any Losses for which indemnification may be sought under this &#8206;Article 8, the Indemnified Party shall so notify the other party from whom indemnification is sought under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Article 8</u> (the&#160;&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnifying Party</u>&#8221;) promptly in writing describing such Loss, the amount or estimated amount thereof, if known or reasonably capable of estimation, and the method of computation of such Loss, all with reasonable particularity and containing a reference to the provisions of this Agreement in respect of which such Loss shall have occurred. &#160;If any claim, action, suit or proceeding is asserted or instituted by or against a third party </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">24</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">with respect to which an Indemnified Party intends to claim any Loss under this </font><font style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#8206;Article 8</font><font style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">, such Indemnified Party shall promptly notify the Indemnifying Party of such claim, action, suit or proceeding and tender to the Indemnifying Party the defense of such claim, action, suit or proceeding. &#160;A failure by an Indemnified Party to give notice and to tender the defense of such claim, action, suit or proceeding in a timely manner pursuant to this </font><u style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section 8.2</u><font style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;"> shall not limit the obligation of the Indemnifying Party under this </font><u style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</u><font style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Article 8</font><font style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">, except to the extent such Indemnifying Party is actually prejudiced thereby.</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 8.3</font><a name="_Ref288169455"></a><a name="_Ref288216881"></a><a name="_Ref288216956"></a><a name="_Toc138244551"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Limitations on Liability</u>. &#160;Other than with respect to Excluded Liabilities and Obligations, or any Losses due to any fraud, willful misconduct, intentional misrepresentation or intentional breach, no party hereto shall be liable for any consequential, punitive, indirect, special or incidental damages, under this &#8206;Article 8 (and no claim for indemnification hereunder shall be asserted) as a result of any breach or violation of any covenant or agreement of such party (including under this &#8206;Article 8) in or pursuant to this Agreement. Notwithstanding the foregoing, the Buyer shall be entitled to make indemnification claims, in accordance with the procedures set forth in this &#8206;Article 8, for Losses that include any portion of the Purchased Receivables that the Buyer was entitled to receive but did not receive timely or at all due to any indemnifiable events under this Agreement, and such portion of the Purchased Receivables shall not be deemed consequential, punitive, indirect, special or incidental damages for any purpose of this Agreement. Other than with respect to Excluded Liabilities and Obligations, or any Losses due to any fraud, willful misconduct, intentional misrepresentation or intentional breach, in no event shall the Seller&#8217;s aggregate liability for Losses under &#8206;Section 8.1(a)(i) or the Buyer&#8217;s aggregate liability for Losses under &#8206;Section 8.1(b)(i) exceed [***].</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 8.4</font><a name="_Ref288084112"></a><a name="_Ref363831253"></a><a name="_Toc138244552"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Third Party Claims</u>. &#160;Upon providing notice to an Indemnifying Party by an Indemnified Party pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section 8.2</u> of the commencement of any action, suit or proceeding against such Indemnified Party by a third party with respect to which such Indemnified Party intends to claim any Loss under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;</u>Article 8, such Indemnifying Party shall have the right to defend such claim, at such Indemnifying Party&#8217;s expense and with counsel of its choice reasonably satisfactory to the Indemnified Party. &#160;If the <a name="OLE_LINK26"></a><a name="OLE_LINK27"></a>Indemnifying Party assumes the defense of such claim, the Indemnified Party shall, at the request of the Indemnifying Party, use commercially reasonable efforts to cooperate in such defense; provided, that the Indemnifying Party shall bear the Indemnified Party&#8217;s reasonable out-of-pocket costs and expenses incurred in connection with such cooperation. &#160;<a name="OLE_LINK6"></a><a name="OLE_LINK7"></a>So long as the Indemnifying Party is conducting the defense of such claim as provided in this &#8206;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8.4</u>, the Indemnified Party may retain separate co-counsel at its expense and may participate in the defense of such claim, and neither the Indemnified Party nor the Indemnifying Party shall consent to the entry of any Judgment or enter into any settlement with respect to such claim without the prior written consent (which will not be unreasonably withheld, delayed, or conditioned) of the other unless such Judgment or settlement (i)&#160;provides for the payment by the Indemnifying Party of money as sole relief (if any) for the claimant (other than customary and reasonable confidentiality obligations relating to such claim, Judgment or settlement), (ii)&#160;results in the full and general release of the Indemnified Party from all liabilities arising out of, relating to or in connection with such claim and (iii)&#160;does not involve a finding or admission of any violation of any law, rule, regulation or Judgment, or the rights of any Person, and has no effect on any other claims that may be made against the Indemnified Party. &#160;In the event the Indemnifying Party does not or ceases to conduct the defense of such claim as so provided, (a)&#160;the Indemnified Party may defend against, and consent to the entry of any Judgment or enter </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">25</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">into any settlement with respect to, such claim in any manner it may reasonably deem to be appropriate, (b)&#160;subject to the limitations set forth in </font><u style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section 8.3</u><font style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">, the Indemnifying Party shall reimburse the Indemnified Party promptly and periodically for the reasonable out-of-pocket costs of defending against such claim, including reasonable attorneys&#8217; fees and expenses against reasonably detailed invoices, and (c)&#160;the Indemnifying Party shall remain responsible for any Losses the Indemnified Party may suffer as a result of such claim to the full extent provided in this </font><font style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">&#8206;Article 8</font><font style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">.</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 8.5</font><a name="_Toc138244553"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Survival of Representations and Warranties</u>. &#160;The representations and warranties contained in this Agreement shall survive Closing solely for purposes of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section 8.1</u> and shall terminate on the date that is eighteen (18) months after the Closing Date (other than any representation or warranty with respect to any Seller Fundamental Representations and any Buyer Fundamental Representations, which shall survive Closing solely for purposes of &#8206;Section 8.1 and shall terminate on the date that is five (5) years after termination of this Agreement). No Party hereto shall have any liability or obligation of any nature with respect to any representation or warranty after the termination thereof, unless the other party hereto shall have delivered a notice to such party, pursuant to this &#8206;Article 8, claiming such liability or obligation under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section 8.1</u> prior to the date that is eighteen (18) months after the Closing Date (other than any liability or obligation of any nature with respect to any Seller Fundamental Representations and any Buyer Fundamental Representations, as to which such notice may be delivered at any time prior to the date that is five (5) years after the termination of this Agreement).</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 8.6</font><a name="_Ref137013035"></a><a name="_Toc138244554"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exclusive Remedy</u>. &#160;Except as set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section 10.10</u>, from and after Closing, the rights of the parties hereto pursuant to (and subject to the conditions of) this &#8206;Article 8 shall be the sole and exclusive remedy of the parties hereto and their respective Affiliates with respect to any claims (whether based in contract, tort or otherwise) resulting from or relating to any breach of the representations, warranties covenants and agreements made under this Agreement or any certificate, document or instrument delivered hereunder, and each party hereto hereby waives, to the fullest extent permitted under applicable law, and agrees not to assert after Closing, any other claim or action in respect of any such breach. &#160;Notwithstanding the foregoing, claims for fraud shall not be waived or limited in any way by this &#8206;Article 8.</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:center;text-indent:0pt;"><font style="color:#010000;text-transform:uppercase;white-space:nowrap;">Article 9</font><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><a name="_Ref276307534"></a><a name="_Ref276323593"></a><a name="_Ref276336080"></a><a name="_Toc138244555"></a>TERMINATION</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 9.1</font><a name="_Ref136561047"></a><a name="_Toc138244556"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Mutual Termination</u>. &#160;This Agreement may be terminated at any time by mutual written agreement of the Buyer and the Seller.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 9.2</font><a name="_Toc138244557"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Automatic Termination</u>. &#160;Unless earlier terminated as provided in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section 9.1</u>, this Agreement shall continue in full force and effect until sixty (60) days after the full satisfaction of any amounts due under the License Agreement to the Seller and any payments in respect of the Purchased Receivables due under this Agreement to the Buyer, at which point this Agreement shall automatically terminate, except with respect to any rights that shall have accrued prior to such termination.</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">26</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 9.3</font><a name="_Ref135730216"></a><a name="_Toc138244558"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Survival</u>. &#160;Notwithstanding anything to the contrary in this &#8206;Article 9, the following provisions shall survive termination of this Agreement: &#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section 6.1</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u>(Disclosures), <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section 6.2</u> (Payments Received in Error; Interest), <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Article 7</u> (Confidentiality), &#8206;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article 8</u> (Indemnification), <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section 9.3</u> (Survival) and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Article 10</u> (Miscellaneous). &#160;Termination of the Agreement shall not relieve any party of liability in respect of breaches under this Agreement by any party on or prior to termination.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:2.38;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:center;text-indent:0pt;"><font style="color:#010000;text-transform:uppercase;white-space:nowrap;">Article 10</font><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><a name="_Ref276336118"></a><a name="_Toc138244559"></a>MISCELLANEOUS</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 10.1</font><a name="_Ref363830918"></a><a name="_Ref363830920"></a><a name="_Toc138244560"></a><a name="_Ref276322454"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notices</u>. &#160;All notices and other communications under this Agreement shall be in writing and shall be by email with PDF attachment, courier service or personal delivery to the following addresses, or to such other addresses as shall be designated from time to time by a party hereto in accordance with this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section 10.1</u>:</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 6pt 72pt;">If to the Seller, to it at:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 0pt 90pt;">LadRx Corporation</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 0pt 90pt;">11726 San Vicente Blvd.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 0pt 90pt;">Suite 650</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 0pt 90pt;">Los Angeles, CA 90049</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 0pt 90pt;">Attention: &#160;[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 0pt 90pt;">Email: &#160;[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 6pt 72pt;">With a copy to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 0pt 90pt;">Haynes and Boone, LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 0pt 90pt;">30 Rockefeller Plaza</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 0pt 90pt;">New York, NY 10112</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 0pt 90pt;">Attention: [***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 0pt 90pt;">Email: [***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 0pt 90pt;"><font style="margin-left:0pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 6pt 72pt;">If to the Buyer, to it at:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 36pt 0pt 90pt;">XOMA (US) LLC<font style="display:inline-block;width:1.34pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 36pt 0pt 90pt;">2200 Powell Street, Suite 310</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 36pt 0pt 90pt;">Emeryville, CA 94608</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 36pt 0pt 90pt;">Attention: Legal Department; [***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 36pt 0pt 90pt;">Email: [***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 36pt 0pt 72pt;"><font style="margin-left:0pt;margin-right:0pt;margin-top:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 36pt 0pt 72pt;">With a copy to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 36pt 0pt 90pt;">Gibson, Dunn &amp; Crutcher LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 36pt 0pt 90pt;">555 Mission Street</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 36pt 0pt 90pt;">San Francisco, CA 94105</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 36pt 0pt 90pt;">Attention: [***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 36pt 0pt 90pt;">Email: [***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">27</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">All notices and communications under this Agreement shall be deemed to have been duly given (i)&#160;when delivered by hand, if personally delivered, (ii)&#160;when received by a recipient, if sent by email, or (iii)&#160;one Business Day following sending within the United States by overnight delivery via commercial one-day overnight courier service. &#160;</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 10.2</font><a name="_Ref135914490"></a><a name="_Toc138244561"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Expenses</u>. &#160;Upon the Closing Date, the Seller shall promptly reimburse the Buyer for all its reasonable and documented out-of-pocket fees, costs, and expenses (including any legal, accounting and banking fees) incurred in connection with the preparation, negotiation, execution and delivery of this Agreement and to consummate the transactions contemplated hereby [***] for this Agreement and the Assignment and Assumption Agreement (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Buyer Transaction Expenses</u>&#8221;). &#160;For the avoidance of doubt, the Buyer shall have the right to deduct the Buyer Transaction Expenses from payment of the Purchase Price. &#160;In the event the transactions contemplated hereby are not consummated, the Seller shall promptly reimburse the Buyer for the Buyer Transaction Expenses incurred prior to the cessation of discussions regarding the transactions contemplated hereby.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 10.3</font><a name="_Ref135843762"></a><a name="_Ref135845197"></a><a name="_Toc138244562"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assignment</u>. &#160;<a name="_cp_text_1_207"></a>The Seller shall not sell, assign or otherwise transfer all or any portion of its interest in the Licensed Patents, the License Agreement, or this Agreement to any third party or to the Licensee by operation of law, merger, change of control, or otherwise<a name="_cp_text_1_210"></a>, unless in connection therewith (a) such Person acquires all of the Seller&#8217;s interest in all of the Licensed Patents, the License Agreement, and this Agreement and (b) prior to closing any such transaction, the Seller causes such Person to deliver a writing to the Buyer in which (i) if such Person is not the Licensee, such Person assumes all of the obligations of the Seller to the Buyer under this Agreement, and (ii) if such Person is the Licensee, the Licensee assumes all of the obligations of the Seller to the Buyer hereunder and agrees to pay the Purchased Receivables directly to the Buyer notwithstanding any subsequent termination of the License Agreement by the Licensee. Subject to the <a name="_cp_text_1_212"></a>first sentence<a name="_cp_text_1_213"></a> of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section 10.3</u>, this Agreement shall be binding upon, inure to the benefit of and be enforceable by, the parties hereto and their respective permitted successors and assigns.<a name="_cp_text_1_214"></a> &#160;The Buyer may assign this Agreement, provided that the Buyer promptly thereafter notifies the Seller and any such assignee promptly thereafter agrees in writing to be bound by the obligations of the Buyer contained in this Agreement, and in any event such assignment shall be of the Agreement in its entirety. &#160;Any purported assignment in violation of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section 10.3</u> shall be null and void.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 10.4</font><a name="_Toc138244563"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendment and Waiver</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font>This Agreement may be amended, modified or supplemented only in a writing signed by each of the parties hereto. &#160;Any provision of this Agreement may be waived only in a writing signed by the parties hereto granting such waiver.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font>No failure or delay on the part of any party hereto in exercising any right, power or remedy hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such right, power or remedy preclude any other or further exercise thereof or the exercise of any other right, power or remedy. &#160;No course of dealing between the parties hereto shall be effective to amend, modify, supplement or waive any provision of this Agreement.</div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">28</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 10.5</font><a name="_Toc138244564"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Entire Agreement</u>. &#160;This Agreement, the Exhibits annexed hereto, and the Disclosure Schedule constitute the entire understanding between the parties hereto with respect to the subject matter hereof and supersede all other understandings and negotiations with respect thereto. </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 10.6</font><a name="_Toc138244565"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Third Party Beneficiaries</u>. &#160;This Agreement is for the sole benefit of the Seller and the Buyer and their permitted successors and assigns and nothing herein expressed or implied shall give or be construed to give to any Person, other than the parties hereto and such successors and assigns, any legal or equitable rights hereunder.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 10.7</font><a name="_Toc138244566"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing Law</u>. &#160;This Agreement shall be governed by, and construed in accordance with, the laws of the State of New York without giving effect to any choice or conflict of law provision or rule that would cause the application of the laws of any other jurisdiction.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 10.8</font><a name="_Toc138244567"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">JURISDICTION; VENUE</u>. &#160;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font>EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY AND UNCONDITIONALLY SUBMITS, FOR ITSELF AND ITS RESPECTIVE PROPERTY AND ASSETS, TO THE EXCLUSIVE JURISDICTION OF ANY NEW YORK STATE COURT OR FEDERAL COURT OF THE UNITED STATES OF AMERICA SITTING IN NEW YORK COUNTY, NEW YORK, AND ANY APPELLATE COURT THEREOF, IN ANY ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT, OR FOR RECOGNITION OR ENFORCEMENT OF ANY JUDGMENT IN RESPECT THEREOF, AND THE BUYER AND THE SELLER HEREBY IRREVOCABLY AND UNCONDITIONALLY AGREE THAT ALL CLAIMS IN RESPECT OF ANY SUCH ACTION OR PROCEEDING MAY BE HEARD AND DETERMINED IN ANY SUCH NEW YORK STATE COURT OR, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, IN SUCH FEDERAL COURT. &#160;THE BUYER AND THE SELLER HEREBY AGREE THAT A FINAL JUDGMENT IN ANY SUCH ACTION OR PROCEEDING SHALL BE CONCLUSIVE AND MAY BE ENFORCED IN OTHER JURISDICTIONS BY SUIT ON THE JUDGMENT OR IN ANY OTHER MANNER PROVIDED BY APPLICABLE LAW. &#160;EACH OF THE BUYER AND THE SELLER HEREBY SUBMITS TO THE EXCLUSIVE PERSONAL JURISDICTION AND VENUE OF SUCH NEW YORK STATE AND FEDERAL COURTS. &#160;THE BUYER AND THE SELLER AGREE, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, THAT PROCESS MAY BE SERVED ON THE BUYER OR THE SELLER IN THE SAME MANNER THAT NOTICES MAY BE GIVEN PURSUANT TO <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;text-transform:uppercase;">&#8206;</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;text-transform:uppercase;">10.1</u> HEREOF.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font>EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES, TO THE FULLEST EXTENT IT MAY LEGALLY AND EFFECTIVELY DO SO, ANY OBJECTION THAT IT MAY NOW OR HEREAFTER HAVE TO THE LAYING OF VENUE OF ANY ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT IN ANY NEW YORK STATE OR FEDERAL COURT. &#160;EACH OF THE BUYER AND THE SELLER HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, THE DEFENSE OF AN INCONVENIENT FORUM TO THE MAINTENANCE OF SUCH ACTION OR PROCEEDING IN ANY SUCH COURT.</div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">29</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 10.9</font><a name="_Toc138244568"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Severability</u>. &#160;If any term or provision of this Agreement shall for any reason be held to be invalid, illegal or unenforceable in any situation in any jurisdiction, then, to the extent that the economic and legal substance of the transactions contemplated hereby is not affected in a manner that is materially adverse to either party hereto, all other terms and provisions of this Agreement shall nevertheless remain in full force and effect and the enforceability and validity of the offending term or provision shall not be affected in any other situation or jurisdiction. </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 10.10</font><a name="_Ref276335952"></a><a name="_Toc138244569"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Specific Performance</u>. &#160;Each of the parties acknowledges and agrees that the other parties would be damaged irreparably in the event any of the provisions of this Agreement are not performed in accordance with their specific terms or otherwise are breached or violated. &#160;Accordingly, notwithstanding <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#8206;Section 8.6</u>, each of the parties agrees that, without posting bond or other undertaking, the other parties shall be entitled to an injunction or injunctions to prevent breaches or violations of the provisions of this Agreement and to enforce specifically this Agreement and the terms and provisions hereof in any action, suit or other proceeding instituted in any court of the United States or any state thereof having jurisdiction over the parties and the matter in addition to any other remedy to which it may be entitled, at law or in equity. &#160;Each party further agrees that, in the event of any action for specific performance in respect of such breach or violation, it shall not assert that the defense that a remedy at law would be adequate.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-align:justify;text-indent:72pt;"><font style="color:#010000;display:inline-block;min-width:72pt;text-indent:0pt;white-space:nowrap;">Section 10.11</font><a name="_Toc138244570"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Counterparts</u>. &#160;This Agreement may be executed in any number of counterparts and by the parties hereto in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement. &#160;Copies of executed counterparts transmitted by telecopy or other similar means of electronic transmission, including &#8220;PDF,&#8221; shall be considered original executed counterparts, provided receipt of such counterparts is confirmed.</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><i style="font-style:italic;">[Signature Page Follows]</i></p><p style="display:none;font-size:12pt;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">30</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">IN WITNESS WHEREOF, the parties hereto have caused this Royalty Purchase Agreement to be executed and delivered by their respective representatives thereunto duly authorized as of the date first above written.</p><div align="right"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;width:47.93%;"><tr><td style="vertical-align:top;width:12.54%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:87.45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:12.54%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:87.45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:100%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:6.55pt;text-indent:-6.55pt;margin:0pt;">LADRX CORPORATION</p></td></tr><tr><td style="vertical-align:top;width:12.54%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:87.45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:12.54%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:87.45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:12.54%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:87.45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;border-bottom:1px solid #000000;margin:0pt;"><i style="font-style:italic;">/s/ Stephen Snowdy</i></p></td></tr><tr><td style="vertical-align:top;width:12.54%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:87.45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">Name: Dr. Stephen Snowdy</p></td></tr><tr><td style="vertical-align:top;width:12.54%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:87.45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">Title: Chief Executive Officer</p></td></tr><tr><td style="vertical-align:top;width:12.54%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:87.45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:12.54%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:87.45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:12.54%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:87.45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:100%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">XOMA (US) LLC</p></td></tr><tr><td style="vertical-align:top;width:12.54%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:87.45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:12.54%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:87.45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:12.54%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:87.45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:12.54%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:87.45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;border-bottom:1px solid #000000;margin:0pt;"><i style="font-style:italic;">/s/ Bradley Sitko</i></p></td></tr><tr><td style="vertical-align:top;width:12.54%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:87.45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">Name: Bradley Sitko</p></td></tr><tr><td style="vertical-align:top;width:12.54%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:87.45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">Title: Chief Investment Officer</p></td></tr><tr><td style="vertical-align:top;width:12.54%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:87.45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="display:none;font-size:12pt;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">[SIGNATURE PAGE TO THE ROYALTY PURCHASE AGREEMENT]</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;background:#ffffff;">Schedule 1.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="display:none;font-size:12pt;line-height:0pt;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;background:#ffffff;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disclosure Schedules</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><i style="font-style:italic;">See attached</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="display:none;font-size:12pt;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;background:#ffffff;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;background:#ffffff;">Exhibit A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-weight:bold;text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> Accounts</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;background:#ffffff;">[***]</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;background:#ffffff;"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br></b><font style="text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font><font style="text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;background:#ffffff;">Exhibit B</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-weight:bold;text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;background:#ffffff;">Form of Bill of Sale</b><b style="font-weight:bold;text-decoration-color:#000000;background:#ffffff;"><br></b><font style="text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;background:#ffffff;">Exhibit C</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-weight:bold;text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;background:#ffffff;">Form of Licensee Instruction Letter</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;background:#ffffff;">Exhibit D</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-weight:bold;text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;background:#ffffff;">Form of Licensee Consent</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><a name="_Hlk1046960"></a><font style="margin-top:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;background:#ffffff;">Exhibit E-1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-weight:bold;text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;background:#ffffff;">License Agreement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;background:#ffffff;">Exhibit E-2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-weight:bold;text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;background:#ffffff;">KTB Agreement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;background:#ffffff;">Exhibit F</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-weight:bold;text-decoration-color:#000000;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;background:#ffffff;">Form of Power of Attorney</b></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>xoma-20230630xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 8/8/2023 02:21:34 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Exhibit 31.1</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Certification</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">I, Owen Hughes, certify that:</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">1. I have reviewed this quarterly report on Form 10-Q of XOMA Corporation;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">2. </font><font style="font-family:'Times New Roman','Times','serif';">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">4. The registrant&#8217;s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f))) for the registrant and we have:</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:6pt 0pt 0pt 13.5pt;"><font style="font-family:'Times New Roman','Times','serif';">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:6pt 0pt 0pt 13.5pt;"><font style="font-family:'Times New Roman','Times','serif';">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:6pt 0pt 8pt 13.5pt;"><font style="font-family:'Times New Roman','Times','serif';">c) </font><font style="font-family:'Times New Roman','Times','serif';">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt 0pt 8pt 13.5pt;"><font style="font-family:'Times New Roman','Times','serif';">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">5. The registrant&#8217;s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of registrant&#8217;s board of directors (or persons performing the equivalent function):</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt 0pt 8pt 13.5pt;"><font style="font-family:'Times New Roman','Times','serif';">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt 0pt 8pt 13.5pt;"><font style="font-family:'Times New Roman','Times','serif';">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:99.89%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Date: August 8, 2023</font></p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">/s/ OWEN HUGHES</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Owen Hughes</b></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Executive Chairman of the Board of Directors and Interim Chief Executive Officer</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>xoma-20230630xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 8/8/2023 02:21:34 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Exhibit 31.2</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Certification</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">I, Thomas Burns, certify that:</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">1. I have reviewed this quarterly report on Form 10-Q of XOMA Corporation;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">2. </font><font style="font-family:'Times New Roman','Times','serif';">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:6pt 0pt 0pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">4. The registrant&#8217;s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f))) for the registrant and we have:</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:6pt 0pt 0pt 13.5pt;"><font style="font-family:'Times New Roman','Times','serif';">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:6pt 0pt 0pt 13.5pt;"><font style="font-family:'Times New Roman','Times','serif';">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:6pt 0pt 8pt 13.5pt;"><font style="font-family:'Times New Roman','Times','serif';">c) </font><font style="font-family:'Times New Roman','Times','serif';">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt 0pt 8pt 13.5pt;"><font style="font-family:'Times New Roman','Times','serif';">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">5. The registrant&#8217;s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of registrant&#8217;s board of directors (or persons performing the equivalent function):</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt 0pt 8pt 13.5pt;"><font style="font-family:'Times New Roman','Times','serif';">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;padding-left:9pt;text-align:justify;text-indent:-9pt;margin:0pt 0pt 8pt 13.5pt;"><font style="font-family:'Times New Roman','Times','serif';">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:95%;"><tr style="height:1pt;"><td style="vertical-align:top;width:42.51%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:57.48%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:42.51%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Date: August 8, 2023</font></p></td><td style="vertical-align:top;width:57.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">/s/ THOMAS BURNS</font></p></td></tr><tr><td style="vertical-align:top;width:42.51%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:57.48%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Thomas Burns</b></p></td></tr><tr><td style="vertical-align:top;width:42.51%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:57.48%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Senior Vice President, Finance and Chief Financial Officer</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>xoma-20230630xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 8/8/2023 02:21:53 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:right;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Exhibit 32.1</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">CERTIFICATION</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the &#8220;Exchange Act&#8221;) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350), Owen Hughes, Executive Chairman of the Board of Directors and Interim Chief Executive Officer of XOMA Corporation (the &#8220;Company&#8221;), and Thomas Burns, Senior Vice President, Finance and Chief Financial Officer of the Company, each hereby certifies that, to the best of his or her knowledge:</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Company&#8217;s Quarterly Report on Form 10-Q for the three and six months ended June 30, 2023, to which this Certification is attached as Exhibit 32.1, fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The information contained in Exhibit 32.1 fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.28;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">IN WITNESS WHEREOF, the undersigned have set their hands hereto as of the 8</font><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;vertical-align:top;">th</sup><font style="font-family:'Times New Roman','Times','serif';">&#160;day of August, 2023</font></p><div align="right"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;width:54.61%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">/s/ OWEN HUGHES</font></p></td></tr><tr><td style="vertical-align:bottom;width:100%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Owen Hughes</b></p></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Executive Chairman of the Board of Directors and Interim Chief Executive Officer</font></p></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">/s/ THOMAS BURNS</font></p></td></tr><tr><td style="vertical-align:bottom;width:100%;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-weight:bold;">Thomas Burns</b></p></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';">Senior Vice President, Finance and Chief Financial Officer</font></p></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of XOMA Corporation under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.</font></td></tr></table><div style="margin-top:8pt;"></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>xoma-20230630.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.3.0.9 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/8/2023 2:22:02 AM-->
<!--Modified on: 8/8/2023 2:22:02 AM-->
<xsd:schema targetNamespace="http://www.xoma.com/20230630" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:srt="http://fasb.org/srt/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:srt-roles="http://fasb.org/srt-roles/2023" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xoma="http://www.xoma.com/20230630">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets" id="StatementCondensedConsolidatedBalanceSheets">
        <link:definition>00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome" id="StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome">
        <link:definition>00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" id="StatementCondensedConsolidatedStatementsOfCashFlows">
        <link:definition>00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails" id="DisclosureCondensedConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails">
        <link:definition>40302 - Disclosure - Condensed Consolidated Financial Statements Details - Intangible assets, net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsAccruedAndOtherLiabilitiesDetails" id="DisclosureCondensedConsolidatedFinancialStatementsDetailsAccruedAndOtherLiabilitiesDetails">
        <link:definition>40303 - Disclosure - Condensed Consolidated Financial Statements Details - Accrued and Other Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsNetLossPerShareDetails" id="DisclosureCondensedConsolidatedFinancialStatementsDetailsNetLossPerShareDetails">
        <link:definition>40304 - Disclosure - Condensed Consolidated Financial Statements Details - Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails" id="DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails">
        <link:definition>40601 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Carried at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureLeaseAgreementsLeaseCostsDetails" id="DisclosureLeaseAgreementsLeaseCostsDetails">
        <link:definition>40702 - Disclosure - Lease Agreements - Lease costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" id="StatementCondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>00105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" id="StatementCondensedConsolidatedStatementsOfStockholdersEquity">
        <link:definition>00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureLeaseAgreementsTables" id="DisclosureLeaseAgreementsTables">
        <link:definition>30703 - Disclosure - Lease Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationTables" id="DisclosureStockBasedCompensationTables">
        <link:definition>31003 - Disclosure - Stock Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesCashAndCashEquivalentsDetails" id="DisclosureBasisOfPresentationAndSignificantAccountingPoliciesCashAndCashEquivalentsDetails">
        <link:definition>40201 - Disclosure - Basis of Presentation and Significant Accounting Policies - Cash and Cash Equivalents (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesIntangibleAssetsAndIncomeTaxesDetails" id="DisclosureBasisOfPresentationAndSignificantAccountingPoliciesIntangibleAssetsAndIncomeTaxesDetails">
        <link:definition>40202 - Disclosure - Basis of Presentation and Significant Accounting Policies - Intangible Assets and Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesConcentrationOfRiskDetails" id="DisclosureBasisOfPresentationAndSignificantAccountingPoliciesConcentrationOfRiskDetails">
        <link:definition>40203 - Disclosure - Basis of Presentation and Significant Accounting Policies - Concentration of Risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsEquitySecuritiesDetails" id="DisclosureCondensedConsolidatedFinancialStatementsDetailsEquitySecuritiesDetails">
        <link:definition>40301 - Disclosure - Condensed Consolidated Financial Statements Details - Equity Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsOutstandingSecuritiesConsideredAntiDilutiveDetails" id="DisclosureCondensedConsolidatedFinancialStatementsDetailsOutstandingSecuritiesConsideredAntiDilutiveDetails">
        <link:definition>40305 - Disclosure - Condensed Consolidated Financial Statements Details - Outstanding Securities Considered Anti-Dilutive (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails" id="DisclosureLicensingAndOtherArrangementsObsevaDetails">
        <link:definition>40401 - Disclosure - Licensing and Other Arrangements - ObsEva (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details" id="DisclosureLicensingAndOtherArrangementsNovartisNis793Details">
        <link:definition>40402 - Disclosure - Licensing and Other Arrangements - Novartis - NIS793 (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details" id="DisclosureLicensingAndOtherArrangementsNovartisVpm087Details">
        <link:definition>40403 - Disclosure - Licensing and Other Arrangements - Novartis - VPM087 (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails" id="DisclosureLicensingAndOtherArrangementsTakedaDetails">
        <link:definition>40404 - Disclosure - Licensing and Other Arrangements - Takeda (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails" id="DisclosureLicensingAndOtherArrangementsRezoluteDetails">
        <link:definition>40405 - Disclosure - Licensing and Other Arrangements - Rezolute (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails" id="DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails">
        <link:definition>40406 - Disclosure - Licensing and Other Arrangements - Janssen Biotech (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsAffimedDetails" id="DisclosureLicensingAndOtherArrangementsAffimedDetails">
        <link:definition>40407 - Disclosure - Licensing and Other Arrangements - Affimed (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails" id="DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails">
        <link:definition>40408 - Disclosure - Licensing and Other Arrangements - Sale of Future Revenue Streams (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryDetails" id="DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryDetails">
        <link:definition>40501 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Summary (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails" id="DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails">
        <link:definition>40502 - Disclosure - Royalty and Commercial Payment Purchase Agreements - LadRx (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails" id="DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails">
        <link:definition>40503 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Aptevo (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails" id="DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails">
        <link:definition>40504 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Agenus (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails" id="DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails">
        <link:definition>40505 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Bioasis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails" id="DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails">
        <link:definition>40506 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Aronora (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails" id="DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails">
        <link:definition>40507 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Palo (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails" id="DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails">
        <link:definition>40508 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Viracta (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails" id="DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails">
        <link:definition>40509 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Kuros (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails" id="DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails">
        <link:definition>40510 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Affitech (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails" id="DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails">
        <link:definition>40511 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Summary of Royalty Receivable Activities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureFairValueMeasurementsEquitySecuritiesDetails" id="DisclosureFairValueMeasurementsEquitySecuritiesDetails">
        <link:definition>40602 - Disclosure - Fair Value Measurements - Equity Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails" id="DisclosureFairValueMeasurementsContingentConsiderationDetails">
        <link:definition>40603 - Disclosure - Fair Value Measurements - Contingent Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureLeaseAgreementsLeasedFacilitiesDetails" id="DisclosureLeaseAgreementsLeasedFacilitiesDetails">
        <link:definition>40701 - Disclosure - Lease Agreements - Leased facilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureLeaseAgreementsAdditionalInformationDetails" id="DisclosureLeaseAgreementsAdditionalInformationDetails">
        <link:definition>40703 - Disclosure - Lease Agreements - Additional information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureCommonStockWarrantsDetails" id="DisclosureCommonStockWarrantsDetails">
        <link:definition>40801 - Disclosure - Common Stock Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesCollaborativeAgreementsRoyaltiesAndMilestonePaymentsDetails" id="DisclosureCommitmentsAndContingenciesCollaborativeAgreementsRoyaltiesAndMilestonePaymentsDetails">
        <link:definition>40901 - Disclosure - Commitments and Contingencies - Collaborative Agreements, Royalties and Milestone Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails" id="DisclosureCommitmentsAndContingenciesContingentConsiderationDetails">
        <link:definition>40902 - Disclosure - Commitments and Contingencies - Contingent Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationEsppDetails" id="DisclosureStockBasedCompensationEsppDetails">
        <link:definition>41001 - Disclosure - Stock Based Compensation - ESPP (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensation2010PlanAndInducementAwardsDetails" id="DisclosureStockBasedCompensation2010PlanAndInducementAwardsDetails">
        <link:definition>41002 - Disclosure - Stock Based Compensation - 2010 Plan and Inducement Awards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationFvAssumptionsDetails" id="DisclosureStockBasedCompensationFvAssumptionsDetails">
        <link:definition>41003 - Disclosure - Stock Based Compensation - FV Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" id="DisclosureStockBasedCompensationStockOptionActivityDetails">
        <link:definition>41004 - Disclosure - Stock Based Compensation - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsDetails" id="DisclosureStockBasedCompensationPerformanceStockUnitAwardsDetails">
        <link:definition>41005 - Disclosure - Stock Based Compensation - Performance Stock Unit Awards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsFairValueDetails" id="DisclosureStockBasedCompensationPerformanceStockUnitAwardsFairValueDetails">
        <link:definition>41006 - Disclosure - Stock Based Compensation - Performance Stock Unit Awards Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsActivityDetails" id="DisclosureStockBasedCompensationPerformanceStockUnitAwardsActivityDetails">
        <link:definition>41007 - Disclosure - Stock Based Compensation - Performance Stock Unit Awards Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" id="DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails">
        <link:definition>41008 - Disclosure - Stock Based Compensation - Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationEmployeeRetentionBonusDetails" id="DisclosureStockBasedCompensationEmployeeRetentionBonusDetails">
        <link:definition>41009 - Disclosure - Stock Based Compensation - Employee Retention Bonus (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationCeoDepartureAndContinuityIncentiveDetails" id="DisclosureStockBasedCompensationCeoDepartureAndContinuityIncentiveDetails">
        <link:definition>41010 - Disclosure - Stock Based Compensation - CEO Departure and Continuity Incentive (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails" id="DisclosureCapitalStockDividendsDetails">
        <link:definition>41101 - Disclosure - Capital Stock - Dividends (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails" id="DisclosureCapitalStockBvfOwnershipDetails">
        <link:definition>41102 - Disclosure - Capital Stock - BVF Ownership (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails" id="DisclosureCapitalStockAtmAgreementsDetails">
        <link:definition>41103 - Disclosure - Capital Stock - ATM Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureIncomeTaxesDetails" id="DisclosureIncomeTaxesDetails">
        <link:definition>41201 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureDescriptionOfBusiness" id="DisclosureDescriptionOfBusiness">
        <link:definition>10101 - Disclosure - Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies" id="DisclosureBasisOfPresentationAndSignificantAccountingPolicies">
        <link:definition>10201 - Disclosure - Basis of Presentation and Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetails" id="DisclosureCondensedConsolidatedFinancialStatementsDetails">
        <link:definition>10301 - Disclosure - Condensed Consolidated Financial Statements Details</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangements" id="DisclosureLicensingAndOtherArrangements">
        <link:definition>10401 - Disclosure - Licensing and Other Arrangements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreements" id="DisclosureRoyaltyAndCommercialPaymentPurchaseAgreements">
        <link:definition>10501 - Disclosure - Royalty and Commercial Payment Purchase Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureFairValueMeasurements" id="DisclosureFairValueMeasurements">
        <link:definition>10601 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureLeaseAgreements" id="DisclosureLeaseAgreements">
        <link:definition>10701 - Disclosure - Lease Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureCommonStockWarrants" id="DisclosureCommonStockWarrants">
        <link:definition>10801 - Disclosure - Common Stock Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>10901 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensation" id="DisclosureStockBasedCompensation">
        <link:definition>11001 - Disclosure - Stock Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureCapitalStock" id="DisclosureCapitalStock">
        <link:definition>11101 - Disclosure - Capital Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>11201 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" id="DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies">
        <link:definition>20202 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsTables" id="DisclosureCondensedConsolidatedFinancialStatementsDetailsTables">
        <link:definition>30303 - Disclosure - Condensed Consolidated Financial Statements Details (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTables" id="DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTables">
        <link:definition>30503 - Disclosure - Royalty and Commercial Payment Purchase Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureFairValueMeasurementsTables" id="DisclosureFairValueMeasurementsTables">
        <link:definition>30603 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureCommonStockWarrantsTables" id="DisclosureCommonStockWarrantsTables">
        <link:definition>30803 - Disclosure - Common Stock Warrants (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureCapitalStockTables" id="DisclosureCapitalStockTables">
        <link:definition>31103 - Disclosure - Capital Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureDescriptionOfBusinessLiquidityDetails" id="DisclosureDescriptionOfBusinessLiquidityDetails">
        <link:definition>40101 - Disclosure - Description of Business - Liquidity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsArbitrationProceedingDetails" id="DisclosureCondensedConsolidatedFinancialStatementsDetailsArbitrationProceedingDetails">
        <link:definition>40306 - Disclosure - Condensed Consolidated Financial Statements Details - Arbitration Proceeding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="xoma-20230630_pre.xml" xlink:title="Presentation Links, all" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="xoma-20230630_cal.xml" xlink:title="Calculation Links, all" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="xoma-20230630_def.xml" xlink:title="Definition Links, all" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="xoma-20230630_lab.xml" xlink:title="Label Links, all" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://www.xoma.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
  <xsd:element name="AccruedAndOtherLiabilitiesCurrent" id="xoma_AccruedAndOtherLiabilitiesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims" id="xoma_DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ConsolidatedFinancialStatementDetailAbstract" id="xoma_ConsolidatedFinancialStatementDetailAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LicensingAndOtherArrangementsTextBlock" id="xoma_LicensingAndOtherArrangementsTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LicensingAndOtherArrangementsAbstract" id="xoma_LicensingAndOtherArrangementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RoyaltyPurchaseAgreementTextBlock" id="xoma_RoyaltyPurchaseAgreementTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RevenueRecognitionDeferredRevenuePolicyTextBlock" id="xoma_RevenueRecognitionDeferredRevenuePolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EquitySecuritiesPolicy" id="xoma_EquitySecuritiesPolicy" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RezoluteIncMember" id="xoma_RezoluteIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LicenseAgreementConsiderationReceived" id="xoma_LicenseAgreementConsiderationReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ProceedsFromUpfrontPayment" id="xoma_ProceedsFromUpfrontPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="CommonStockPremium" id="xoma_CommonStockPremium" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones" id="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="NovartisPharmaAGMember" id="xoma_NovartisPharmaAGMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="XOMA052LicenseAgreementMember" id="xoma_XOMA052LicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IL1TargetLicenseAgreementMember" id="xoma_IL1TargetLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LicenseAgreementMember" id="xoma_LicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NovartisInternationalPharmaceuticalLtdMember" id="xoma_NovartisInternationalPharmaceuticalLtdMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NumberOfLicenseAgreements" id="xoma_NumberOfLicenseAgreements" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AgreementTerminationPriorWrittenNoticePeriod" id="xoma_AgreementTerminationPriorWrittenNoticePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NumberOfPerformanceObligations" id="xoma_NumberOfPerformanceObligations" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LicenseAgreementTransactionPrice" id="xoma_LicenseAgreementTransactionPrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones" id="xoma_EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="NumberOfRoyaltyInterestAcquisitionAgreements" id="xoma_NumberOfRoyaltyInterestAcquisitionAgreements" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PurchasedPercentageOfMilestones" id="xoma_PurchasedPercentageOfMilestones" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased" id="xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones" id="xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="RoyaltyPurchaseAgreementMember" id="xoma_RoyaltyPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AgenusIncMember" id="xoma_AgenusIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="SiliconValleyBankMember" id="xoma_SiliconValleyBankMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NovartisNoteMember" id="xoma_NovartisNoteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RoyaltyReceivablePercentageOnNetSales" id="xoma_RoyaltyReceivablePercentageOnNetSales" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="TwoThousandFifteenEmployeeStockPurchasePlanMember" id="xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="TwoThousandTenLongTermIncentiveAndStockAwardPlanMember" id="xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PercentageOfCompensationOfEligibleEmployeesToPurchaseSharesOfEntityCommonStockAtDiscountThroughPayrollDeductions" id="xoma_PercentageOfCompensationOfEligibleEmployeesToPurchaseSharesOfEntityCommonStockAtDiscountThroughPayrollDeductions" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge" id="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="BiotechnologyValueFundLPMember" id="xoma_BiotechnologyValueFundLPMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares" id="xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="TwoThousandEighteenAtMarketAgreementMember" id="xoma_TwoThousandEighteenAtMarketAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="TenYearWarrantsIssuedThirdRangeMember" id="xoma_TenYearWarrantsIssuedThirdRangeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ContractualObligationEstimatedMilestonePayments" id="xoma_ContractualObligationEstimatedMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="CommitmentsAndContingenciesLineItems" id="xoma_CommitmentsAndContingenciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CommitmentsAndContingenciesTable" id="xoma_CommitmentsAndContingenciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="OperatingLeasesNumberOfLeasedFacilities" id="xoma_OperatingLeasesNumberOfLeasedFacilities" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="Partner1Member" id="xoma_Partner1Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="Partner2Member" id="xoma_Partner2Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="Partner3Member" id="xoma_Partner3Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NumberOfMajorPartners" id="xoma_NumberOfMajorPartners" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="BioasisTechnologiesIncMember" id="xoma_BioasisTechnologiesIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements" id="xoma_PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="LicenseAgreementAndCommonStockPurchaseAgreementMember" id="xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="OperatingLeasePaymentsNonCash" id="xoma_OperatingLeasePaymentsNonCash" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="CommonStockWarrantDisclosureTextBlock" id="xoma_CommonStockWarrantDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PercentageOfDecreaseInFutureRoyaltyObligations" id="xoma_PercentageOfDecreaseInFutureRoyaltyObligations" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents" id="xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="PercentageOfRoyaltyOnNetSalesUponCommercialization" id="xoma_PercentageOfRoyaltyOnNetSalesUponCommercialization" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AronoraIncMember" id="xoma_AronoraIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PalobiofarmaSLMember" id="xoma_PalobiofarmaSLMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="BayerProductsMember" id="xoma_BayerProductsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NonBayerProductsMember" id="xoma_NonBayerProductsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ContingentFutureCashPayments" id="xoma_ContingentFutureCashPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="ChangesInEstimatedFairValueOfContingentConsideration" id="xoma_ChangesInEstimatedFairValueOfContingentConsideration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts" id="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="MilestonesPaymentsToAggregateAmountOfPerProduct" id="xoma_MilestonesPaymentsToAggregateAmountOfPerProduct" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="ContingentConsiderationFairValueDisclosure" id="xoma_ContingentConsiderationFairValueDisclosure" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="LicenseAgreementConsiderationReceivedDebtRepayment" id="xoma_LicenseAgreementConsiderationReceivedDebtRepayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="StockIssuedDuringPeriodValueNewIssuesCommonStock" id="xoma_StockIssuedDuringPeriodValueNewIssuesCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember" id="xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ArrangementsNumber" id="xoma_ArrangementsNumber" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RoyaltiesPeriodMinimum" id="xoma_RoyaltiesPeriodMinimum" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LicenseAgreementRz358Member" id="xoma_LicenseAgreementRz358Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RoyaltyInterestAcquisitionAgreementsMember" id="xoma_RoyaltyInterestAcquisitionAgreementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="FirstRoyaltyInterestAcquisitionAgreementMember" id="xoma_FirstRoyaltyInterestAcquisitionAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="SecondRoyaltyInterestAcquisitionAgreementMember" id="xoma_SecondRoyaltyInterestAcquisitionAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="HealthCareRoyaltyPartnersTwoLimitedPartnersMember" id="xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="MilestonePeriodsNumber" id="xoma_MilestonePeriodsNumber" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="NumberOfLicenseAgreementsFutureLicenseAgreements" id="xoma_NumberOfLicenseAgreementsFutureLicenseAgreements" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IncyteImmunoOncologyAssetsMember" id="xoma_IncyteImmunoOncologyAssetsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="MerckImmunoOncologyProductMember" id="xoma_MerckImmunoOncologyProductMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PaymentsToBeMadeUponExerciseOfOptionSecondLicenseAgreement" id="xoma_PaymentsToBeMadeUponExerciseOfOptionSecondLicenseAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="PaymentsToBeMadeUponExerciseOfOptionThirdLicenseAgreement" id="xoma_PaymentsToBeMadeUponExerciseOfOptionThirdLicenseAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="AgreementDrugCandidatesNumber" id="xoma_AgreementDrugCandidatesNumber" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount" id="xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="EmployeeMember" id="xoma_EmployeeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LeasedFacilitiesEmeryvilleCaliforniaMember" id="xoma_LeasedFacilitiesEmeryvilleCaliforniaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CommonStockWarrantExercisePrice14.71Member" id="xoma_CommonStockWarrantExercisePrice14.71Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="XomaCorporationMember" id="xoma_XomaCorporationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted" id="xoma_NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="ContractualObligationEstimatedMilestonePaymentsNumberOfProducts" id="xoma_ContractualObligationEstimatedMilestonePaymentsNumberOfProducts" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="JanssenBiotechInc.Member" id="xoma_JanssenBiotechInc.Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AgreementDrugCandidatesExclusiveLicenseOptionNumber" id="xoma_AgreementDrugCandidatesExclusiveLicenseOptionNumber" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage" id="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="ContingentFutureCashPaymentsPerProduct" id="xoma_ContingentFutureCashPaymentsPerProduct" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="AgreementPaymentPercentageFactor" id="xoma_AgreementPaymentPercentageFactor" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward" id="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LeaseDisclosureTextBlock" id="xoma_LeaseDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock" id="xoma_LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LesseeOperatingLeaseSupplementalInformationTableTextBlock" id="xoma_LesseeOperatingLeaseSupplementalInformationTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LicenseAgreementNonRz358ProductsMember" id="xoma_LicenseAgreementNonRz358ProductsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CollaborationAgreementMember" id="xoma_CollaborationAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="MezagitamabMember" id="xoma_MezagitamabMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate" id="xoma_EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="MilestoneAchieved" id="xoma_MilestoneAchieved" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="RoyaltyPurchaseAgreementTwoMember" id="xoma_RoyaltyPurchaseAgreementTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="OtherAntibodiesMember" id="xoma_OtherAntibodiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RoyaltiesPeriodMinimumScenarioOne" id="xoma_RoyaltiesPeriodMinimumScenarioOne" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ViractaTherapeuticsInc.Member" id="xoma_ViractaTherapeuticsInc.Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AccruedPreferredStockDividendCurrent" id="xoma_AccruedPreferredStockDividendCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="MilestonesReceivableExcludingConsiderationRetainedMaximum" id="xoma_MilestonesReceivableExcludingConsiderationRetainedMaximum" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="MaximumConsiderationRetained" id="xoma_MaximumConsiderationRetained" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="RegulatoryAndCommercialMilestonesReceivableMaximum" id="xoma_RegulatoryAndCommercialMilestonesReceivableMaximum" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="AffimedMember" id="xoma_AffimedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember" id="xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EligibleMilestonePaymentsReceivableUponAchievementOfPreCommercialMilestones" id="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfPreCommercialMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="LicenseAgreementInstallmentPaymentsReceived" id="xoma_LicenseAgreementInstallmentPaymentsReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="LicenseAgreementConsiderationReceivedAchievementOfFinancingActivities" id="xoma_LicenseAgreementConsiderationReceivedAchievementOfFinancingActivities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="LicenseAgreementSharesReceived" id="xoma_LicenseAgreementSharesReceived" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AtMarketIssuanceSalesAgreement2021Member" id="xoma_AtMarketIssuanceSalesAgreement2021Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="MaximumValueOfStockToBeIssued" id="xoma_MaximumValueOfStockToBeIssued" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="TakedaPharmaceuticalCompanyLimitedMember" id="xoma_TakedaPharmaceuticalCompanyLimitedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CommercialPaymentPurchaseAgreementMember" id="xoma_CommercialPaymentPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CommercialSalesReceivablePercentageOnNetSales" id="xoma_CommercialSalesReceivablePercentageOnNetSales" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AffitechResearchAsMember" id="xoma_AffitechResearchAsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="FutureMilestonesRoyaltiesPurchaseRightsAndCommercialPaymentsPolicyPolicyTextBlock" id="xoma_FutureMilestonesRoyaltiesPurchaseRightsAndCommercialPaymentsPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CommercialPaymentReceivableTerm" id="xoma_CommercialPaymentReceivableTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="MaximumPayableOnRegulatoryMilestone" id="xoma_MaximumPayableOnRegulatoryMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="MaximumPayableOnSalesMilestone" id="xoma_MaximumPayableOnSalesMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="PercentageOfGrossProceedsPaidToAgentForSaleOfShares" id="xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfShares" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AccruedSalariesAndEmployeeBenefitsCurrent" id="xoma_AccruedSalariesAndEmployeeBenefitsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="ContingentConsiderationUnderPurchaseAgreements" id="xoma_ContingentConsiderationUnderPurchaseAgreements" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="LongTermRightsReceivableNonCurrent" id="xoma_LongTermRightsReceivableNonCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="ContingentConsiderationRegulatoryMilestonesMember" id="xoma_ContingentConsiderationRegulatoryMilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" id="xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RightsReceivableCurrent" id="xoma_RightsReceivableCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="MilestonePaymentReceivedCounterparty" id="xoma_MilestonePaymentReceivedCounterparty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="MilestonePaymentReceivablePercentage" id="xoma_MilestonePaymentReceivablePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="Partner4Member" id="xoma_Partner4Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LongTermRightsReceivableReclassification" id="xoma_LongTermRightsReceivableReclassification" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="FinancialAssetsFairValueDisclosure" id="xoma_FinancialAssetsFairValueDisclosure" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="ShortTermRightsReceivableReclassification" id="xoma_ShortTermRightsReceivableReclassification" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ScheduleOfRoyaltyAndCommercialPaymentReceivablesActivityTableTextBlock" id="xoma_ScheduleOfRoyaltyAndCommercialPaymentReceivablesActivityTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" id="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="ReceiptOfRoyaltyAndCommercialPaymentReceivableCurrent" id="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="FaricimabProductMember" id="xoma_FaricimabProductMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="FaricimabSvoaVabysmoProductMember" id="xoma_FaricimabSvoaVabysmoProductMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NumberOfPeriodsCashRetentionBonus" id="xoma_NumberOfPeriodsCashRetentionBonus" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="PeriodOneRetentionBonusEligibility" id="xoma_PeriodOneRetentionBonusEligibility" type="xbrli:durationItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PeriodTwoRetentionBonusEligibility" id="xoma_PeriodTwoRetentionBonusEligibility" type="xbrli:durationItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CurrentEmployeesExcludingChiefExecutiveOfficerMember" id="xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RoyaltyAndCommercialRightsAcquiredNonCurrent" id="xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ObsevaMember" id="xoma_ObsevaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ObsevaIntellectualPropertyRightsMember" id="xoma_ObsevaIntellectualPropertyRightsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="OrganonMember" id="xoma_OrganonMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EstimatedFairValueOfContingentConsiderationUnderAssetAcquisition" id="xoma_EstimatedFairValueOfContingentConsiderationUnderAssetAcquisition" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentCommercializationAndSalesMilestones" id="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentCommercializationAndSalesMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="CompensationExpenseEmploymentAgreement" id="xoma_CompensationExpenseEmploymentAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="AccruedCompensationContinuityIncentive" id="xoma_AccruedCompensationContinuityIncentive" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="ChiefExecutiveOfficerRetiredMember" id="xoma_ChiefExecutiveOfficerRetiredMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ChiefExecutiveOfficerInterimMember" id="xoma_ChiefExecutiveOfficerInterimMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ChiefInvestmentOfficerMember" id="xoma_ChiefInvestmentOfficerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments" id="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments" id="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedPaymentArrangementNumberOfAwardsGrants" id="xoma_ShareBasedPaymentArrangementNumberOfAwardsGrants" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RetentionBonusExpenseAccrued" id="xoma_RetentionBonusExpenseAccrued" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="FiniteLivedIntangibleAssetExpectedAmortizationThroughYearFive" id="xoma_FiniteLivedIntangibleAssetExpectedAmortizationThroughYearFive" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="AronoraKurosAffitechObsevaAndMerckKgaaMember" id="xoma_AronoraKurosAffitechObsevaAndMerckKgaaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NumberOfArbitrationProceedingsInitiated" id="xoma_NumberOfArbitrationProceedingsInitiated" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="MaximumEarnOutPayments" id="xoma_MaximumEarnOutPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="MaximumEarnOutPaymentsDevelopmentAndRegulatoryMilestonePayments" id="xoma_MaximumEarnOutPaymentsDevelopmentAndRegulatoryMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="MaximumEarnOutPaymentsSalesBasedMilestonePayments" id="xoma_MaximumEarnOutPaymentsSalesBasedMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="AssetAcquisitionsPolicyPolicyTextBlock" id="xoma_AssetAcquisitionsPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AptevoMember" id="xoma_AptevoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LesseeOperatingLeaseModificationAdjustmentToRightOfUseAsset" id="xoma_LesseeOperatingLeaseModificationAdjustmentToRightOfUseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="StockOptionInducementAwardsMember" id="xoma_StockOptionInducementAwardsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CreditLossContractWithCustomerAssetPolicyTextBlock" id="xoma_CreditLossContractWithCustomerAssetPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AccruedRetentionBonus" id="xoma_AccruedRetentionBonus" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="StockOptionInducementAwardOneMember" id="xoma_StockOptionInducementAwardOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="StockOptionInducementAwardTwoMember" id="xoma_StockOptionInducementAwardTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="MaximumPaymentsBasedOnAchievementOfRegulatoryAndSalesMilestones" id="xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndSalesMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="MilestonesReceivableMaximum" id="xoma_MilestonesReceivableMaximum" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="CommercialPaymentThresholdOneTimePayment" id="xoma_CommercialPaymentThresholdOneTimePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="PaymentOfContingentConsiderationUnderPurchaseAgreements" id="xoma_PaymentOfContingentConsiderationUnderPurchaseAgreements" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="LadrxMember" id="xoma_LadrxMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ArimoclomolMember" id="xoma_ArimoclomolMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfHurdles." id="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfHurdles." type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfCalendarDays" id="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfCalendarDays" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="StockPriceHurdlesOfDollar30Member" id="xoma_StockPriceHurdlesOfDollar30Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="StockPriceHurdlesOfDollar35Member" id="xoma_StockPriceHurdlesOfDollar35Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="StockPriceHurdlesOfDollar40Member" id="xoma_StockPriceHurdlesOfDollar40Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="StockPriceHurdlesOfDollar45Member" id="xoma_StockPriceHurdlesOfDollar45Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract" id="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AssignmentAndAssumptionAgreementMember" id="xoma_AssignmentAndAssumptionAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember" id="xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="MaximumRegulatoryAndCommercialMilestones" id="xoma_MaximumRegulatoryAndCommercialMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="LongTermRightsReceivableNonCurrentIncreaseDecrease" id="xoma_LongTermRightsReceivableNonCurrentIncreaseDecrease" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="RoyaltyPurchaseAgreementAndSecondRoyaltyPurchaseAgreementMember" id="xoma_RoyaltyPurchaseAgreementAndSecondRoyaltyPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PaymentOfConsiderationUnderAgreementsInvestingActivities" id="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ReceiptsUnderAgreementsInvestingActivities" id="xoma_ReceiptsUnderAgreementsInvestingActivities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="MilestoneDosingFirstPatientInClinicalTrialMember" id="xoma_MilestoneDosingFirstPatientInClinicalTrialMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="MilestonePursuantToAgreementMember" id="xoma_MilestonePursuantToAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="MedexusMember" id="xoma_MedexusMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="MerckKgaaMember" id="xoma_MerckKgaaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="LeasedFacilitiesTwoEmeryvilleCaliforniaMember" id="xoma_LeasedFacilitiesTwoEmeryvilleCaliforniaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ImpairmentOfLongTermRightsReceivableNonCurrent" id="xoma_ImpairmentOfLongTermRightsReceivableNonCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="NumberOfMilestonesEarned" id="xoma_NumberOfMilestonesEarned" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PerformanceStockUnitsMember" id="xoma_PerformanceStockUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="MaximumPaymentsBasedOnAchievementOfRegulatoryAndCommercialMilestonesNet" id="xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndCommercialMilestonesNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="MaximumPaymentObligationsBasedOnPortionOfRegulatoryAndCommercialPayments" id="xoma_MaximumPaymentObligationsBasedOnPortionOfRegulatoryAndCommercialPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AldoxorubicinMember" id="xoma_AldoxorubicinMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>xoma-20230630_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.3.0.9 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/8/2023 2:22:02 AM-->
<!--Modified on: 8/8/2023 2:22:02 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome" roleURI="http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureCondensedConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails" roleURI="http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureCondensedConsolidatedFinancialStatementsDetailsAccruedAndOtherLiabilitiesDetails" roleURI="http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsAccruedAndOtherLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureCondensedConsolidatedFinancialStatementsDetailsNetLossPerShareDetails" roleURI="http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsNetLossPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails" roleURI="http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureLeaseAgreementsLeaseCostsDetails" roleURI="http://www.xoma.com/role/DisclosureLeaseAgreementsLeaseCostsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <calculationLink xlink:role="http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638270581177027299" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_AssetsCurrent_638270581177027299" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638270581177037498" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638270581177027299" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638270581177037498" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="us-gaap_EquitySecuritiesFvNi_638270581177037498" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638270581177027299" xlink:to="us-gaap_EquitySecuritiesFvNi_638270581177037498" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent_638270581177037498" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638270581177027299" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent_638270581177037498" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RightsReceivableCurrent" xlink:label="xoma_RightsReceivableCurrent_638270581177037498" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638270581177027299" xlink:to="xoma_RightsReceivableCurrent_638270581177037498" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638270581177037498" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638270581177027299" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638270581177037498" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638270581177037498" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638270581177037498" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638270581177037498" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638270581177037498" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LongTermRightsReceivableNonCurrent" xlink:label="xoma_LongTermRightsReceivableNonCurrent_638270581177037498" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="xoma_LongTermRightsReceivableNonCurrent_638270581177037498" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_638270581177047212" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_638270581177047212" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_638270581177047212" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_OtherAssetsNoncurrent_638270581177047212" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638270581177047212" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_638270581177047212" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638270581177047212" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638270581177047212" xlink:to="us-gaap_LiabilitiesCurrent_638270581177047212" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638270581177047212" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638270581177047212" xlink:to="us-gaap_AccountsPayableCurrent_638270581177047212" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AccruedAndOtherLiabilitiesCurrent" xlink:label="xoma_AccruedAndOtherLiabilitiesCurrent_638270581177047212" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638270581177047212" xlink:to="xoma_AccruedAndOtherLiabilitiesCurrent_638270581177047212" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ContingentConsiderationUnderPurchaseAgreements" xlink:label="xoma_ContingentConsiderationUnderPurchaseAgreements_638270581177057319" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638270581177047212" xlink:to="xoma_ContingentConsiderationUnderPurchaseAgreements_638270581177057319" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638270581177057319" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638270581177047212" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638270581177057319" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeCurrent" xlink:label="us-gaap_DeferredIncomeCurrent_638270581177057319" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638270581177047212" xlink:to="us-gaap_DeferredIncomeCurrent_638270581177057319" order="5" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AccruedPreferredStockDividendCurrent" xlink:label="xoma_AccruedPreferredStockDividendCurrent_638270581177066941" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638270581177047212" xlink:to="xoma_AccruedPreferredStockDividendCurrent_638270581177066941" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeNoncurrent" xlink:label="us-gaap_DeferredIncomeNoncurrent_638270581177066941" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638270581177047212" xlink:to="us-gaap_DeferredIncomeNoncurrent_638270581177066941" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638270581177066941" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies_638270581177066941" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638270581177066941" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_638270581177066941" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638270581177066941" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638270581177066941" xlink:to="us-gaap_PreferredStockValue_638270581177066941" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638270581177066941" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638270581177066941" xlink:to="us-gaap_CommonStockValue_638270581177066941" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638270581177077328" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638270581177066941" xlink:to="us-gaap_AdditionalPaidInCapital_638270581177077328" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638270581177077328" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638270581177066941" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638270581177077328" order="4" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome" xlink:type="extended" xlink:title="00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638270581177077328" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss_638270581177077328" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638270581177077328" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_638270581177077328" xlink:to="us-gaap_OperatingIncomeLoss_638270581177077328" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_638270581177087425" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638270581177077328" xlink:to="us-gaap_Revenues_638270581177087425" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638270581177087425" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues_638270581177087425" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638270581177087425" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="us-gaap_RevenueNotFromContractWithCustomer_638270581177087425" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues_638270581177087425" xlink:to="us-gaap_RevenueNotFromContractWithCustomer_638270581177087425" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638270581177087425" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638270581177077328" xlink:to="us-gaap_OperatingExpenses_638270581177087425" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638270581177087425" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638270581177087425" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638270581177087425" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638270581177087425" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638270581177087425" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638270581177087425" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ImpairmentOfLongTermRightsReceivableNonCurrent" xlink:label="xoma_ImpairmentOfLongTermRightsReceivableNonCurrent_638270581177087425" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638270581177087425" xlink:to="xoma_ImpairmentOfLongTermRightsReceivableNonCurrent_638270581177087425" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementExpense" xlink:label="us-gaap_LitigationSettlementExpense_638270581177097320" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638270581177087425" xlink:to="us-gaap_LitigationSettlementExpense_638270581177097320" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets_638270581177097320" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638270581177087425" xlink:to="us-gaap_AmortizationOfIntangibleAssets_638270581177097320" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_638270581177097320" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_638270581177077328" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_638270581177097320" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638270581177097320" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638270581177097320" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638270581177107325" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638270581177097320" xlink:to="us-gaap_ProfitLoss_638270581177107325" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638270581177107325" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638270581177097320" xlink:to="us-gaap_ShareBasedCompensation_638270581177107325" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ImpairmentOfLongTermRightsReceivableNonCurrent" xlink:label="xoma_ImpairmentOfLongTermRightsReceivableNonCurrent_638270581177107325" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638270581177097320" xlink:to="xoma_ImpairmentOfLongTermRightsReceivableNonCurrent_638270581177107325" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ChangesInEstimatedFairValueOfContingentConsideration" xlink:label="xoma_ChangesInEstimatedFairValueOfContingentConsideration_638270581177107325" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638270581177097320" xlink:to="xoma_ChangesInEstimatedFairValueOfContingentConsideration_638270581177107325" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims" xlink:label="xoma_DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims_638270581177107325" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638270581177097320" xlink:to="xoma_DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims_638270581177107325" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationNonproduction" xlink:label="us-gaap_DepreciationNonproduction_638270581177107325" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638270581177097320" xlink:to="us-gaap_DepreciationNonproduction_638270581177107325" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_OperatingLeasePaymentsNonCash" xlink:label="xoma_OperatingLeasePaymentsNonCash_638270581177107325" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638270581177097320" xlink:to="xoma_OperatingLeasePaymentsNonCash_638270581177107325" order="7" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedGainLoss_638270581177107325" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638270581177097320" xlink:to="us-gaap_EquitySecuritiesFvNiRealizedGainLoss_638270581177107325" order="8" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets_638270581177117305" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638270581177097320" xlink:to="us-gaap_AmortizationOfIntangibleAssets_638270581177117305" order="9" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_638270581177117305" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638270581177097320" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_638270581177117305" order="10" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638270581177117305" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638270581177097320" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638270581177117305" order="11" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638270581177117305" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638270581177097320" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638270581177117305" order="12" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_638270581177117305" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638270581177097320" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_638270581177117305" order="13" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638270581177117305" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638270581177097320" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638270581177117305" order="14" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_638270581177127289" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638270581177097320" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_638270581177127289" order="15" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638270581177127289" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638270581177127289" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" xlink:label="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities_638270581177127289" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638270581177127289" xlink:to="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities_638270581177127289" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ReceiptsUnderAgreementsInvestingActivities" xlink:label="xoma_ReceiptsUnderAgreementsInvestingActivities_638270581177127289" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638270581177127289" xlink:to="xoma_ReceiptsUnderAgreementsInvestingActivities_638270581177127289" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_638270581177127289" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638270581177127289" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets_638270581177127289" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638270581177137826" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638270581177137826" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638270581177137826" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638270581177137826" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638270581177137826" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDividends" xlink:label="us-gaap_PaymentsOfDividends_638270581177137826" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638270581177137826" xlink:to="us-gaap_PaymentsOfDividends_638270581177137826" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_638270581177137826" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638270581177137826" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_638270581177137826" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_638270581177137826" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638270581177137826" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_638270581177137826" order="4" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails" xlink:type="extended" xlink:title="40302 - Disclosure - Condensed Consolidated Financial Statements Details - Intangible assets, net (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_FiniteLivedIntangibleAssetExpectedAmortizationThroughYearFive" xlink:label="xoma_FiniteLivedIntangibleAssetExpectedAmortizationThroughYearFive" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_638270581177147303" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="xoma_FiniteLivedIntangibleAssetExpectedAmortizationThroughYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_638270581177147303" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_638270581177147303" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="xoma_FiniteLivedIntangibleAssetExpectedAmortizationThroughYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_638270581177147303" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_638270581177147303" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="xoma_FiniteLivedIntangibleAssetExpectedAmortizationThroughYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_638270581177147303" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_638270581177147303" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="xoma_FiniteLivedIntangibleAssetExpectedAmortizationThroughYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_638270581177147303" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_638270581177147303" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="xoma_FiniteLivedIntangibleAssetExpectedAmortizationThroughYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_638270581177147303" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_638270581177157317" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_638270581177157317" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_638270581177157317" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_638270581177157317" order="2" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsAccruedAndOtherLiabilitiesDetails" xlink:type="extended" xlink:title="40303 - Disclosure - Condensed Consolidated Financial Statements Details - Accrued and Other Liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AccruedAndOtherLiabilitiesCurrent" xlink:label="AccruedAndOtherLiabilitiesCurrent" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent_638270581177157317" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedAndOtherLiabilitiesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent_638270581177157317" order="1" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_638270581177157317" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedAndOtherLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_638270581177157317" order="2" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AccruedSalariesAndEmployeeBenefitsCurrent" xlink:label="xoma_AccruedSalariesAndEmployeeBenefitsCurrent_638270581177157317" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedAndOtherLiabilitiesCurrent" xlink:to="xoma_AccruedSalariesAndEmployeeBenefitsCurrent_638270581177157317" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_638270581177167235" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedAndOtherLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_638270581177167235" order="4" use="optional" weight="1" priority="3" />
  </calculationLink>
  <calculationLink xlink:role="http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsNetLossPerShareDetails" xlink:type="extended" xlink:title="40304 - Disclosure - Condensed Consolidated Financial Statements Details - Net Loss Per Share (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="NetIncomeLossAvailableToCommonStockholdersDiluted" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638270581177167235" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638270581177167235" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638270581177167235" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638270581177167235" xlink:to="us-gaap_NetIncomeLoss_638270581177167235" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact_638270581177167235" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638270581177167235" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact_638270581177167235" order="2" use="optional" weight="-1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Carried at Fair Value on Recurring Basis (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_FinancialAssetsFairValueDisclosure" xlink:label="FinancialAssetsFairValueDisclosure" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_638270581177167235" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="FinancialAssetsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_638270581177167235" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure_638270581177177349" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="FinancialAssetsFairValueDisclosure" xlink:to="us-gaap_InvestmentsFairValueDisclosure_638270581177177349" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.xoma.com/role/DisclosureLeaseAgreementsLeaseCostsDetails" xlink:type="extended" xlink:title="40702 - Disclosure - Lease Agreements - Lease costs (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="LeaseCost" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost_638270581177177349" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LeaseCost" xlink:to="us-gaap_OperatingLeaseCost_638270581177177349" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost_638270581177177349" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LeaseCost" xlink:to="us-gaap_VariableLeaseCost_638270581177177349" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>xoma-20230630_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.3.0.9 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/8/2023 2:22:02 AM-->
<!--Modified on: 8/8/2023 2:22:02 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.xoma.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#StatementCondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#StatementCondensedConsolidatedStatementsOfStockholdersEquity" roleURI="http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureStockBasedCompensationTables" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureBasisOfPresentationAndSignificantAccountingPoliciesConcentrationOfRiskDetails" roleURI="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesConcentrationOfRiskDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureCondensedConsolidatedFinancialStatementsDetailsEquitySecuritiesDetails" roleURI="http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsEquitySecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureCondensedConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails" roleURI="http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureCondensedConsolidatedFinancialStatementsDetailsNetLossPerShareDetails" roleURI="http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsNetLossPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureCondensedConsolidatedFinancialStatementsDetailsOutstandingSecuritiesConsideredAntiDilutiveDetails" roleURI="http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsOutstandingSecuritiesConsideredAntiDilutiveDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureLicensingAndOtherArrangementsObsevaDetails" roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureLicensingAndOtherArrangementsNovartisNis793Details" roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureLicensingAndOtherArrangementsNovartisVpm087Details" roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureLicensingAndOtherArrangementsTakedaDetails" roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureLicensingAndOtherArrangementsRezoluteDetails" roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails" roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureLicensingAndOtherArrangementsAffimedDetails" roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsAffimedDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails" roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryDetails" roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails" roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails" roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails" roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails" roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails" roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails" roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails" roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails" roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails" roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails" roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails" roleURI="http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureFairValueMeasurementsEquitySecuritiesDetails" roleURI="http://www.xoma.com/role/DisclosureFairValueMeasurementsEquitySecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureFairValueMeasurementsContingentConsiderationDetails" roleURI="http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureLeaseAgreementsLeasedFacilitiesDetails" roleURI="http://www.xoma.com/role/DisclosureLeaseAgreementsLeasedFacilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureCommonStockWarrantsDetails" roleURI="http://www.xoma.com/role/DisclosureCommonStockWarrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureCommitmentsAndContingenciesContingentConsiderationDetails" roleURI="http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureStockBasedCompensationEsppDetails" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationEsppDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureStockBasedCompensation2010PlanAndInducementAwardsDetails" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensation2010PlanAndInducementAwardsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureStockBasedCompensationFvAssumptionsDetails" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationFvAssumptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureStockBasedCompensationStockOptionActivityDetails" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureStockBasedCompensationPerformanceStockUnitAwardsDetails" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureStockBasedCompensationPerformanceStockUnitAwardsFairValueDetails" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsFairValueDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureStockBasedCompensationPerformanceStockUnitAwardsActivityDetails" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureStockBasedCompensationEmployeeRetentionBonusDetails" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationEmployeeRetentionBonusDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureStockBasedCompensationCeoDepartureAndContinuityIncentiveDetails" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationCeoDepartureAndContinuityIncentiveDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureCapitalStockDividendsDetails" roleURI="http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureCapitalStockBvfOwnershipDetails" roleURI="http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureCapitalStockAtmAgreementsDetails" roleURI="http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://www.xoma.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureStandardAndCustomAxisDomainDefaults" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd#eedm" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAbstract" xlink:label="LiabilitiesAbstract" xlink:title="LiabilitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="OperatingLeaseLiabilityNoncurrent" xlink:title="OperatingLeaseLiabilityNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiabilitiesAbstract" xlink:to="OperatingLeaseLiabilityNoncurrent" xlink:title="definition: LiabilitiesAbstract to OperatingLeaseLiabilityNoncurrent" use="optional" priority="0" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="OperatingLeaseLiabilityCurrent" xlink:title="OperatingLeaseLiabilityCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LiabilitiesAbstract" xlink:to="OperatingLeaseLiabilityCurrent" xlink:title="definition: LiabilitiesAbstract to OperatingLeaseLiabilityCurrent" use="optional" priority="0" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="AssetsAbstract" xlink:title="AssetsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent" xlink:label="RestrictedCashCurrent" xlink:title="RestrictedCashCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetsAbstract" xlink:to="RestrictedCashCurrent" xlink:title="definition: AssetsAbstract to RestrictedCashCurrent" use="optional" priority="0" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="RestrictedCashNoncurrent" xlink:title="RestrictedCashNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AssetsAbstract" xlink:to="RestrictedCashNoncurrent" xlink:title="definition: AssetsAbstract to RestrictedCashNoncurrent" use="optional" priority="0" order="2" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.xoma.com/role/DisclosureStandardAndCustomAxisDomainDefaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="LegalEntityAxis" xlink:title="LegalEntityAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="EntityDomain" xlink:title="EntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LegalEntityAxis" xlink:to="EntityDomain" xlink:title="definition: LegalEntityAxis to EntityDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="SubsidiarySaleOfStockAxis" xlink:title="SubsidiarySaleOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="SaleOfStockNameOfTransactionDomain" xlink:title="SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsidiarySaleOfStockAxis" xlink:to="SaleOfStockNameOfTransactionDomain" xlink:title="definition: SubsidiarySaleOfStockAxis to SaleOfStockNameOfTransactionDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain" xlink:title="definition: StatementScenarioAxis to ScenarioUnspecifiedDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="TitleOfIndividualAxis" xlink:title="TitleOfIndividualAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="definition: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsAxis" xlink:label="DividendsAxis" xlink:title="DividendsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsDomain" xlink:label="DividendsDomain" xlink:title="DividendsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DividendsAxis" xlink:to="DividendsDomain" xlink:title="definition: DividendsAxis to DividendsDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis" xlink:label="OwnershipAxis" xlink:title="OwnershipAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain" xlink:label="OwnershipDomain" xlink:title="OwnershipDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="OwnershipAxis" xlink:to="OwnershipDomain" xlink:title="definition: OwnershipAxis to OwnershipDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="CounterpartyNameAxis" xlink:title="CounterpartyNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain" xlink:title="RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CounterpartyNameAxis" xlink:to="RepurchaseAgreementCounterpartyNameDomain" xlink:title="definition: CounterpartyNameAxis to RepurchaseAgreementCounterpartyNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="DebtInstrumentRedemptionPeriodAxis" xlink:title="DebtInstrumentRedemptionPeriodAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="DebtInstrumentRedemptionPeriodDomain" xlink:title="DebtInstrumentRedemptionPeriodDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DebtInstrumentRedemptionPeriodAxis" xlink:to="DebtInstrumentRedemptionPeriodDomain" xlink:title="definition: DebtInstrumentRedemptionPeriodAxis to DebtInstrumentRedemptionPeriodDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis" xlink:label="VariableRateAxis" xlink:title="VariableRateAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="VariableRateDomain" xlink:title="VariableRateDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="VariableRateAxis" xlink:to="VariableRateDomain" xlink:title="definition: VariableRateAxis to VariableRateDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain" xlink:title="definition: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:label="EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:title="EquityMethodInvestmentNonconsolidatedInvesteeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:label="EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:title="EquityMethodInvestmentNonconsolidatedInvesteeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:to="EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:title="definition: EquityMethodInvestmentNonconsolidatedInvesteeAxis to EquityMethodInvestmentNonconsolidatedInvesteeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="ConcentrationRiskByTypeAxis" xlink:title="ConcentrationRiskByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain" xlink:title="ConcentrationRiskTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="ConcentrationRiskTypeDomain" xlink:title="definition: ConcentrationRiskByTypeAxis to ConcentrationRiskTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="ConcentrationRiskByBenchmarkAxis" xlink:title="ConcentrationRiskByBenchmarkAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain" xlink:title="ConcentrationRiskBenchmarkDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="ConcentrationRiskBenchmarkDomain" xlink:title="definition: ConcentrationRiskByBenchmarkAxis to ConcentrationRiskBenchmarkDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="MajorCustomersAxis" xlink:title="MajorCustomersAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="NameOfMajorCustomerDomain" xlink:title="NameOfMajorCustomerDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="MajorCustomersAxis" xlink:to="NameOfMajorCustomerDomain" xlink:title="definition: MajorCustomersAxis to NameOfMajorCustomerDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="AdjustmentsForNewAccountingPronouncementsAxis" xlink:title="AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="TypeOfAdoptionMember" xlink:title="TypeOfAdoptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="TypeOfAdoptionMember" xlink:title="definition: AdjustmentsForNewAccountingPronouncementsAxis to TypeOfAdoptionMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:title="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="EquityMethodInvesteeNameDomain" xlink:title="EquityMethodInvesteeNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="EquityMethodInvesteeNameDomain" xlink:title="definition: ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis to EquityMethodInvesteeNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="ProductOrServiceAxis" xlink:title="ProductOrServiceAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="ProductsAndServicesDomain" xlink:title="ProductsAndServicesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ProductOrServiceAxis" xlink:to="ProductsAndServicesDomain" xlink:title="definition: ProductOrServiceAxis to ProductsAndServicesDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="ContingentConsiderationByTypeAxis" xlink:title="ContingentConsiderationByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="ContingentConsiderationTypeDomain" xlink:title="ContingentConsiderationTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ContingentConsiderationByTypeAxis" xlink:to="ContingentConsiderationTypeDomain" xlink:title="definition: ContingentConsiderationByTypeAxis to ContingentConsiderationTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="StatementGeographicalAxis" xlink:title="StatementGeographicalAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="SegmentGeographicalDomain" xlink:title="SegmentGeographicalDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementGeographicalAxis" xlink:to="SegmentGeographicalDomain" xlink:title="definition: StatementGeographicalAxis to SegmentGeographicalDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="definition: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="MeasurementInputTypeAxis" xlink:title="MeasurementInputTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="MeasurementInputTypeDomain" xlink:title="MeasurementInputTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="MeasurementInputTypeAxis" xlink:to="MeasurementInputTypeDomain" xlink:title="definition: MeasurementInputTypeAxis to MeasurementInputTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="FinancialInstrumentAxis" xlink:title="FinancialInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FinancialInstrumentAxis" xlink:to="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="definition: FinancialInstrumentAxis to TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis_1" xlink:title="us-gaap_AssetAcquisitionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain_1" xlink:title="us-gaap_AssetAcquisitionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AssetAcquisitionAxis_1" xlink:to="us-gaap_AssetAcquisitionDomain_1" xlink:title="definition:us-gaap_AssetAcquisitionAxis_1 To us-gaap_AssetAcquisitionDomain_1" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain" xlink:title="definition: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain" xlink:title="definition: PlanNameAxis to PlanNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_1" xlink:title="us-gaap_VestingAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_1" xlink:title="us-gaap_VestingDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis_1" xlink:to="us-gaap_VestingDomain_1" xlink:title="definition:us-gaap_VestingAxis_1 To us-gaap_VestingDomain_1" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="FairValueByMeasurementBasisAxis" xlink:title="FairValueByMeasurementBasisAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="PortionAtFairValueFairValueDisclosureMember" xlink:title="PortionAtFairValueFairValueDisclosureMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByMeasurementBasisAxis" xlink:to="PortionAtFairValueFairValueDisclosureMember" xlink:title="definition: FairValueByMeasurementBasisAxis to PortionAtFairValueFairValueDisclosureMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="IncomeTaxAuthorityAxis" xlink:title="IncomeTaxAuthorityAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="IncomeTaxAuthorityDomain" xlink:title="IncomeTaxAuthorityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeTaxAuthorityAxis" xlink:to="IncomeTaxAuthorityDomain" xlink:title="definition: IncomeTaxAuthorityAxis to IncomeTaxAuthorityDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="TaxCreditCarryforwardAxis" xlink:title="TaxCreditCarryforwardAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="TaxCreditCarryforwardNameDomain" xlink:title="TaxCreditCarryforwardNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TaxCreditCarryforwardAxis" xlink:to="TaxCreditCarryforwardNameDomain" xlink:title="definition: TaxCreditCarryforwardAxis to TaxCreditCarryforwardNameDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="RestructuringCostAndReserveAxis" xlink:title="RestructuringCostAndReserveAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="TypeOfRestructuringDomain" xlink:title="TypeOfRestructuringDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RestructuringCostAndReserveAxis" xlink:to="TypeOfRestructuringDomain" xlink:title="definition: RestructuringCostAndReserveAxis to TypeOfRestructuringDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="CumulativeEffectPeriodOfAdoptionAxis" xlink:title="CumulativeEffectPeriodOfAdoptionAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="CumulativeEffectPeriodOfAdoptionDomain" xlink:title="CumulativeEffectPeriodOfAdoptionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CumulativeEffectPeriodOfAdoptionAxis" xlink:to="CumulativeEffectPeriodOfAdoptionDomain" xlink:title="definition: CumulativeEffectPeriodOfAdoptionAxis to CumulativeEffectPeriodOfAdoptionDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis" xlink:label="RestatementAxis" xlink:title="RestatementAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain" xlink:label="RestatementDomain" xlink:title="RestatementDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RestatementAxis" xlink:to="RestatementDomain" xlink:title="definition: RestatementAxis to RestatementDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" xlink:title="definition:us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1 To us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_1" xlink:title="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" xlink:label="us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain_1" xlink:title="us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_1" xlink:to="us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain_1" xlink:title="definition:us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_1 To us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain_1" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="FairValueByMeasurementFrequencyAxis" xlink:title="FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="FairValueMeasurementFrequencyDomain" xlink:title="FairValueMeasurementFrequencyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByMeasurementFrequencyAxis" xlink:to="FairValueMeasurementFrequencyDomain" xlink:title="definition: FairValueByMeasurementFrequencyAxis to FairValueMeasurementFrequencyDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="CashAndCashEquivalentsAxis" xlink:title="CashAndCashEquivalentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:title="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CashAndCashEquivalentsAxis" xlink:to="RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:title="definition: CashAndCashEquivalentsAxis to RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" xlink:title="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" xlink:title="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" xlink:title="definition:us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1 To us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_1" xlink:title="us-gaap_GranteeStatusAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_1" xlink:title="us-gaap_GranteeStatusDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_GranteeStatusAxis_1" xlink:to="us-gaap_GranteeStatusDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_GranteeStatusAxis_1 To us-gaap_GranteeStatusDomain_1" order="1" />
  </link:definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AdrMember" xlink:label="dei_AdrMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="dei_AdrMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentType" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentQuarterlyReport" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentPeriodEndDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentTransitionReport" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityFileNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityRegistrantName" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityTaxIdentificationNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityAddressAddressLine1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityAddressAddressLine2" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityAddressCityOrTown" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityAddressStateOrProvince" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityAddressPostalZipCode" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_CityAreaCode" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_LocalPhoneNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_Security12bTitle" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_TradingSymbol" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_SecurityExchangeName" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityCurrentReportingStatus" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityInteractiveDataCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityFilerCategory" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntitySmallBusiness" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityEmergingGrowthCompany" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="25" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityShellCompany" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="26" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="27" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityCentralIndexKey" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="28" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_CurrentFiscalYearEndDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="29" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentFiscalYearFocus" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="30" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="31" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_AmendmentFlag" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="us-gaap_EquitySecuritiesFvNi" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_EquitySecuritiesFvNi" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RightsReceivableCurrent" xlink:label="xoma_RightsReceivableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="xoma_RightsReceivableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LongTermRightsReceivableNonCurrent" xlink:label="xoma_LongTermRightsReceivableNonCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AssetsAbstract" xlink:to="xoma_LongTermRightsReceivableNonCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AccruedAndOtherLiabilitiesCurrent" xlink:label="xoma_AccruedAndOtherLiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="xoma_AccruedAndOtherLiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ContingentConsiderationUnderPurchaseAgreements" xlink:label="xoma_ContingentConsiderationUnderPurchaseAgreements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="xoma_ContingentConsiderationUnderPurchaseAgreements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeCurrent" xlink:label="us-gaap_DeferredIncomeCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredIncomeCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AccruedPreferredStockDividendCurrent" xlink:label="xoma_AccruedPreferredStockDividendCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="xoma_AccruedPreferredStockDividendCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeNoncurrent" xlink:label="us-gaap_DeferredIncomeNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredIncomeNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockDividendRatePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" xlink:type="extended" xlink:title="00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_SharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPreferredStockStock" xlink:label="us-gaap_DividendsPreferredStockStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_DividendsPreferredStockStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationTables" xlink:type="extended" xlink:title="31003 - Disclosure - Stock Based Compensation (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember" xlink:label="xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_StockOptionInducementAwardsMember" xlink:label="xoma_StockOptionInducementAwardsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="xoma_StockOptionInducementAwardsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_StockOptionInducementAwardOneMember" xlink:label="xoma_StockOptionInducementAwardOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="xoma_StockOptionInducementAwardsMember" xlink:to="xoma_StockOptionInducementAwardOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_StockOptionInducementAwardTwoMember" xlink:label="xoma_StockOptionInducementAwardTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="xoma_StockOptionInducementAwardsMember" xlink:to="xoma_StockOptionInducementAwardTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:label="us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" xlink:label="us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesConcentrationOfRiskDetails" xlink:type="extended" xlink:title="40203 - Disclosure - Basis of Presentation and Significant Accounting Policies - Concentration of Risk (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditConcentrationRiskMember" xlink:label="us-gaap_CreditConcentrationRiskMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CreditConcentrationRiskMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAccountsReceivableMember" xlink:label="us-gaap_TradeAccountsReceivableMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_TradeAccountsReceivableMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="srt_MajorCustomersAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_Partner1Member" xlink:label="xoma_Partner1Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="xoma_Partner1Member" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_Partner2Member" xlink:label="xoma_Partner2Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="xoma_Partner2Member" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_Partner3Member" xlink:label="xoma_Partner3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="xoma_Partner3Member" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_Partner4Member" xlink:label="xoma_Partner4Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="xoma_Partner4Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_NumberOfMajorPartners" xlink:label="xoma_NumberOfMajorPartners" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="xoma_NumberOfMajorPartners" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesLongTermContractsOrPrograms" xlink:label="us-gaap_ReceivablesLongTermContractsOrPrograms" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ReceivablesLongTermContractsOrPrograms" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsEquitySecuritiesDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Condensed Consolidated Financial Statements Details - Equity Securities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:label="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RezoluteIncMember" xlink:label="xoma_RezoluteIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="xoma_RezoluteIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:label="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFVNINoncurrent" xlink:label="us-gaap_EquitySecuritiesFVNINoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="us-gaap_EquitySecuritiesFVNINoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedGainLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiRealizedGainLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails" xlink:type="extended" xlink:title="40302 - Disclosure - Condensed Consolidated Financial Statements Details - Intangible assets, net (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntellectualPropertyMember" xlink:label="us-gaap_IntellectualPropertyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_IntellectualPropertyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_FiniteLivedIntangibleAssetExpectedAmortizationThroughYearFive" xlink:label="xoma_FiniteLivedIntangibleAssetExpectedAmortizationThroughYearFive" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="xoma_FiniteLivedIntangibleAssetExpectedAmortizationThroughYearFive" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsNetLossPerShareDetails" xlink:type="extended" xlink:title="40304 - Disclosure - Condensed Consolidated Financial Statements Details - Net Loss Per Share (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDilutedLineItems" xlink:label="us-gaap_EarningsPerShareDilutedLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_EarningsPerShareBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsOutstandingSecuritiesConsideredAntiDilutiveDetails" xlink:type="extended" xlink:title="40305 - Disclosure - Condensed Consolidated Financial Statements Details - Outstanding Securities Considered Anti-Dilutive (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Licensing and Other Arrangements - ObsEva (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTable" xlink:label="us-gaap_AssetAcquisitionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_AssetAcquisitionAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ObsevaIntellectualPropertyRightsMember" xlink:label="xoma_ObsevaIntellectualPropertyRightsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="xoma_ObsevaIntellectualPropertyRightsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LicenseAgreementMember" xlink:label="xoma_LicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_LicenseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ObsevaMember" xlink:label="xoma_ObsevaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_ObsevaMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_OrganonMember" xlink:label="xoma_OrganonMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_OrganonMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MerckKgaaMember" xlink:label="xoma_MerckKgaaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_MerckKgaaMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="us-gaap_AssetAcquisitionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentCommercializationAndSalesMilestones" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentCommercializationAndSalesMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentCommercializationAndSalesMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MaximumEarnOutPayments" xlink:label="xoma_MaximumEarnOutPayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="xoma_MaximumEarnOutPayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ChangesInEstimatedFairValueOfContingentConsideration" xlink:label="xoma_ChangesInEstimatedFairValueOfContingentConsideration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="xoma_ChangesInEstimatedFairValueOfContingentConsideration" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_CapitalizedContractCostNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MaximumEarnOutPaymentsDevelopmentAndRegulatoryMilestonePayments" xlink:label="xoma_MaximumEarnOutPaymentsDevelopmentAndRegulatoryMilestonePayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="xoma_MaximumEarnOutPaymentsDevelopmentAndRegulatoryMilestonePayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MaximumEarnOutPaymentsSalesBasedMilestonePayments" xlink:label="xoma_MaximumEarnOutPaymentsSalesBasedMilestonePayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="xoma_MaximumEarnOutPaymentsSalesBasedMilestonePayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details" xlink:type="extended" xlink:title="40402 - Disclosure - Licensing and Other Arrangements - Novartis - NIS793 (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_NovartisInternationalPharmaceuticalLtdMember" xlink:label="xoma_NovartisInternationalPharmaceuticalLtdMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_NovartisInternationalPharmaceuticalLtdMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LicenseAgreementMember" xlink:label="xoma_LicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_LicenseAgreementMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_NovartisNoteMember" xlink:label="xoma_NovartisNoteMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="xoma_NovartisNoteMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AgreementTerminationPriorWrittenNoticePeriod" xlink:label="xoma_AgreementTerminationPriorWrittenNoticePeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_AgreementTerminationPriorWrittenNoticePeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_NumberOfPerformanceObligations" xlink:label="xoma_NumberOfPerformanceObligations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_NumberOfPerformanceObligations" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ProceedsFromUpfrontPayment" xlink:label="xoma_ProceedsFromUpfrontPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ProceedsFromUpfrontPayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RoyaltiesPeriodMinimum" xlink:label="xoma_RoyaltiesPeriodMinimum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_RoyaltiesPeriodMinimum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xlink:label="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CapitalizedContractCostNet" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details" xlink:type="extended" xlink:title="40403 - Disclosure - Licensing and Other Arrangements - Novartis - VPM087 (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_NovartisPharmaAGMember" xlink:label="xoma_NovartisPharmaAGMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_NovartisPharmaAGMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember" xlink:label="xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_XOMA052LicenseAgreementMember" xlink:label="xoma_XOMA052LicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember" xlink:to="xoma_XOMA052LicenseAgreementMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_IL1TargetLicenseAgreementMember" xlink:label="xoma_IL1TargetLicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember" xlink:to="xoma_IL1TargetLicenseAgreementMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LicenseAgreementTransactionPrice" xlink:label="xoma_LicenseAgreementTransactionPrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_LicenseAgreementTransactionPrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LicenseAgreementConsiderationReceived" xlink:label="xoma_LicenseAgreementConsiderationReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_LicenseAgreementConsiderationReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ProceedsFromUpfrontPayment" xlink:label="xoma_ProceedsFromUpfrontPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ProceedsFromUpfrontPayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LicenseAgreementConsiderationReceivedDebtRepayment" xlink:label="xoma_LicenseAgreementConsiderationReceivedDebtRepayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_LicenseAgreementConsiderationReceivedDebtRepayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_StockIssuedDuringPeriodValueNewIssuesCommonStock" xlink:label="xoma_StockIssuedDuringPeriodValueNewIssuesCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_StockIssuedDuringPeriodValueNewIssuesCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_CommonStockPremium" xlink:label="xoma_CommonStockPremium" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_CommonStockPremium" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_NumberOfLicenseAgreements" xlink:label="xoma_NumberOfLicenseAgreements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_NumberOfLicenseAgreements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AgreementTerminationPriorWrittenNoticePeriod" xlink:label="xoma_AgreementTerminationPriorWrittenNoticePeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_AgreementTerminationPriorWrittenNoticePeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ArrangementsNumber" xlink:label="xoma_ArrangementsNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ArrangementsNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_NumberOfPerformanceObligations" xlink:label="xoma_NumberOfPerformanceObligations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_NumberOfPerformanceObligations" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CapitalizedContractCostNet" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails" xlink:type="extended" xlink:title="40404 - Disclosure - Licensing and Other Arrangements - Takeda (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_TakedaPharmaceuticalCompanyLimitedMember" xlink:label="xoma_TakedaPharmaceuticalCompanyLimitedMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_TakedaPharmaceuticalCompanyLimitedMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_CollaborationAgreementMember" xlink:label="xoma_CollaborationAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_CollaborationAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LicenseAgreementMember" xlink:label="xoma_LicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_LicenseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MezagitamabMember" xlink:label="xoma_MezagitamabMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="xoma_MezagitamabMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_OtherAntibodiesMember" xlink:label="xoma_OtherAntibodiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="xoma_OtherAntibodiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate" xlink:label="xoma_EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RoyaltiesPeriodMinimum" xlink:label="xoma_RoyaltiesPeriodMinimum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_RoyaltiesPeriodMinimum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RoyaltiesPeriodMinimumScenarioOne" xlink:label="xoma_RoyaltiesPeriodMinimumScenarioOne" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_RoyaltiesPeriodMinimumScenarioOne" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CapitalizedContractCostNet" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails" xlink:type="extended" xlink:title="40405 - Disclosure - Licensing and Other Arrangements - Rezolute (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RezoluteIncMember" xlink:label="xoma_RezoluteIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_RezoluteIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember" xlink:label="xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LicenseAgreementMember" xlink:label="xoma_LicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember" xlink:to="xoma_LicenseAgreementMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LicenseAgreementRz358Member" xlink:label="xoma_LicenseAgreementRz358Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="xoma_LicenseAgreementMember" xlink:to="xoma_LicenseAgreementRz358Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LicenseAgreementNonRz358ProductsMember" xlink:label="xoma_LicenseAgreementNonRz358ProductsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="xoma_LicenseAgreementMember" xlink:to="xoma_LicenseAgreementNonRz358ProductsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="xoma_RezoluteIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RoyaltiesPeriodMinimum" xlink:label="xoma_RoyaltiesPeriodMinimum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_RoyaltiesPeriodMinimum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_PercentageOfDecreaseInFutureRoyaltyObligations" xlink:label="xoma_PercentageOfDecreaseInFutureRoyaltyObligations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_PercentageOfDecreaseInFutureRoyaltyObligations" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AgreementTerminationPriorWrittenNoticePeriod" xlink:label="xoma_AgreementTerminationPriorWrittenNoticePeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_AgreementTerminationPriorWrittenNoticePeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LicenseAgreementConsiderationReceived" xlink:label="xoma_LicenseAgreementConsiderationReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_LicenseAgreementConsiderationReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LicenseAgreementConsiderationReceivedAchievementOfFinancingActivities" xlink:label="xoma_LicenseAgreementConsiderationReceivedAchievementOfFinancingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_LicenseAgreementConsiderationReceivedAchievementOfFinancingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LicenseAgreementInstallmentPaymentsReceived" xlink:label="xoma_LicenseAgreementInstallmentPaymentsReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_LicenseAgreementInstallmentPaymentsReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LicenseAgreementSharesReceived" xlink:label="xoma_LicenseAgreementSharesReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_LicenseAgreementSharesReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CapitalizedContractCostNet" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails" xlink:type="extended" xlink:title="40406 - Disclosure - Licensing and Other Arrangements - Janssen Biotech (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_JanssenBiotechInc.Member" xlink:label="xoma_JanssenBiotechInc.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_JanssenBiotechInc.Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LicenseAgreementMember" xlink:label="xoma_LicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_LicenseAgreementMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MilestoneDosingFirstPatientInClinicalTrialMember" xlink:label="xoma_MilestoneDosingFirstPatientInClinicalTrialMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="xoma_MilestoneDosingFirstPatientInClinicalTrialMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MilestonePursuantToAgreementMember" xlink:label="xoma_MilestonePursuantToAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="xoma_MilestonePursuantToAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ProceedsFromUpfrontPayment" xlink:label="xoma_ProceedsFromUpfrontPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ProceedsFromUpfrontPayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents" xlink:label="xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_PercentageOfRoyaltyOnNetSalesUponCommercialization" xlink:label="xoma_PercentageOfRoyaltyOnNetSalesUponCommercialization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_PercentageOfRoyaltyOnNetSalesUponCommercialization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_NumberOfMilestonesEarned" xlink:label="xoma_NumberOfMilestonesEarned" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_NumberOfMilestonesEarned" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CapitalizedContractCostNet" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsAffimedDetails" xlink:type="extended" xlink:title="40407 - Disclosure - Licensing and Other Arrangements - Affimed (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LicenseAgreementMember" xlink:label="xoma_LicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_LicenseAgreementMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AffimedMember" xlink:label="xoma_AffimedMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_AffimedMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CapitalizedContractCostNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails" xlink:type="extended" xlink:title="40408 - Disclosure - Licensing and Other Arrangements - Sale of Future Revenue Streams (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember" xlink:label="xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RoyaltyInterestAcquisitionAgreementsMember" xlink:label="xoma_RoyaltyInterestAcquisitionAgreementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_RoyaltyInterestAcquisitionAgreementsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_FirstRoyaltyInterestAcquisitionAgreementMember" xlink:label="xoma_FirstRoyaltyInterestAcquisitionAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="xoma_RoyaltyInterestAcquisitionAgreementsMember" xlink:to="xoma_FirstRoyaltyInterestAcquisitionAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_SecondRoyaltyInterestAcquisitionAgreementMember" xlink:label="xoma_SecondRoyaltyInterestAcquisitionAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="xoma_RoyaltyInterestAcquisitionAgreementsMember" xlink:to="xoma_SecondRoyaltyInterestAcquisitionAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_NumberOfRoyaltyInterestAcquisitionAgreements" xlink:label="xoma_NumberOfRoyaltyInterestAcquisitionAgreements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_NumberOfRoyaltyInterestAcquisitionAgreements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ProceedsFromUpfrontPayment" xlink:label="xoma_ProceedsFromUpfrontPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ProceedsFromUpfrontPayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones" xlink:label="xoma_EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MilestonePeriodsNumber" xlink:label="xoma_MilestonePeriodsNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_MilestonePeriodsNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="us-gaap_RevenueNotFromContractWithCustomer" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueNotFromContractWithCustomer" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeCurrent" xlink:label="us-gaap_DeferredIncomeCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredIncomeCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeNoncurrent" xlink:label="us-gaap_DeferredIncomeNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredIncomeNoncurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Summary (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AgenusIncMember" xlink:label="xoma_AgenusIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_AgenusIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_BioasisTechnologiesIncMember" xlink:label="xoma_BioasisTechnologiesIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_BioasisTechnologiesIncMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AronoraIncMember" xlink:label="xoma_AronoraIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_AronoraIncMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_PalobiofarmaSLMember" xlink:label="xoma_PalobiofarmaSLMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_PalobiofarmaSLMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ViractaTherapeuticsInc.Member" xlink:label="xoma_ViractaTherapeuticsInc.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_ViractaTherapeuticsInc.Member" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember" xlink:label="xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AffitechResearchAsMember" xlink:label="xoma_AffitechResearchAsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_AffitechResearchAsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RightsReceivableCurrent" xlink:label="xoma_RightsReceivableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_RightsReceivableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LongTermRightsReceivableNonCurrent" xlink:label="xoma_LongTermRightsReceivableNonCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_LongTermRightsReceivableNonCurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails" xlink:type="extended" xlink:title="40502 - Disclosure - Royalty and Commercial Payment Purchase Agreements - LadRx (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LadrxMember" xlink:label="xoma_LadrxMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_LadrxMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember" xlink:label="xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AssignmentAndAssumptionAgreementMember" xlink:label="xoma_AssignmentAndAssumptionAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember" xlink:to="xoma_AssignmentAndAssumptionAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RoyaltyPurchaseAgreementMember" xlink:label="xoma_RoyaltyPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember" xlink:to="xoma_RoyaltyPurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ArimoclomolMember" xlink:label="xoma_ArimoclomolMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="xoma_ArimoclomolMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AldoxorubicinMember" xlink:label="xoma_AldoxorubicinMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="xoma_AldoxorubicinMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ContingentConsiderationRegulatoryMilestonesMember" xlink:label="xoma_ContingentConsiderationRegulatoryMilestonesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="xoma_ContingentConsiderationRegulatoryMilestonesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndCommercialMilestonesNet" xlink:label="xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndCommercialMilestonesNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndCommercialMilestonesNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MaximumPaymentObligationsBasedOnPortionOfRegulatoryAndCommercialPayments" xlink:label="xoma_MaximumPaymentObligationsBasedOnPortionOfRegulatoryAndCommercialPayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_MaximumPaymentObligationsBasedOnPortionOfRegulatoryAndCommercialPayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MaximumRegulatoryAndCommercialMilestones" xlink:label="xoma_MaximumRegulatoryAndCommercialMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_MaximumRegulatoryAndCommercialMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" xlink:label="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndSalesMilestones" xlink:label="xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndSalesMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndSalesMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MaximumPayableOnRegulatoryMilestone" xlink:label="xoma_MaximumPayableOnRegulatoryMilestone" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_MaximumPayableOnRegulatoryMilestone" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MaximumPayableOnSalesMilestone" xlink:label="xoma_MaximumPayableOnSalesMilestone" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_MaximumPayableOnSalesMilestone" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ContingentConsiderationUnderPurchaseAgreements" xlink:label="xoma_ContingentConsiderationUnderPurchaseAgreements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ContingentConsiderationUnderPurchaseAgreements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LongTermRightsReceivableNonCurrent" xlink:label="xoma_LongTermRightsReceivableNonCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_LongTermRightsReceivableNonCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" xlink:label="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails" xlink:type="extended" xlink:title="40503 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Aptevo (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AptevoMember" xlink:label="xoma_AptevoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_AptevoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MedexusMember" xlink:label="xoma_MedexusMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_MedexusMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_CommercialPaymentPurchaseAgreementMember" xlink:label="xoma_CommercialPaymentPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_CommercialPaymentPurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ContingentConsiderationRegulatoryMilestonesMember" xlink:label="xoma_ContingentConsiderationRegulatoryMilestonesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="xoma_ContingentConsiderationRegulatoryMilestonesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MilestonesReceivableMaximum" xlink:label="xoma_MilestonesReceivableMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_MilestonesReceivableMaximum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LongTermRightsReceivableNonCurrent" xlink:label="xoma_LongTermRightsReceivableNonCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_LongTermRightsReceivableNonCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" xlink:label="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ContingentConsiderationUnderPurchaseAgreements" xlink:label="xoma_ContingentConsiderationUnderPurchaseAgreements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ContingentConsiderationUnderPurchaseAgreements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_CommercialPaymentThresholdOneTimePayment" xlink:label="xoma_CommercialPaymentThresholdOneTimePayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_CommercialPaymentThresholdOneTimePayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ReceiptsUnderAgreementsInvestingActivities" xlink:label="xoma_ReceiptsUnderAgreementsInvestingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ReceiptsUnderAgreementsInvestingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" xlink:label="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RightsReceivableCurrent" xlink:label="xoma_RightsReceivableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_RightsReceivableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" xlink:label="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails" xlink:type="extended" xlink:title="40504 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Agenus (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AgenusIncMember" xlink:label="xoma_AgenusIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_AgenusIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RoyaltyPurchaseAgreementMember" xlink:label="xoma_RoyaltyPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_RoyaltyPurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_IncyteImmunoOncologyAssetsMember" xlink:label="xoma_IncyteImmunoOncologyAssetsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="xoma_IncyteImmunoOncologyAssetsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MerckImmunoOncologyProductMember" xlink:label="xoma_MerckImmunoOncologyProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="xoma_MerckImmunoOncologyProductMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_SiliconValleyBankMember" xlink:label="xoma_SiliconValleyBankMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="xoma_SiliconValleyBankMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="xoma_AgenusIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RoyaltyReceivablePercentageOnNetSales" xlink:label="xoma_RoyaltyReceivablePercentageOnNetSales" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_RoyaltyReceivablePercentageOnNetSales" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased" xlink:label="xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_PurchasedPercentageOfMilestones" xlink:label="xoma_PurchasedPercentageOfMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_PurchasedPercentageOfMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones" xlink:label="xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" xlink:label="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LongTermRightsReceivableNonCurrent" xlink:label="xoma_LongTermRightsReceivableNonCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_LongTermRightsReceivableNonCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MilestoneAchieved" xlink:label="xoma_MilestoneAchieved" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_MilestoneAchieved" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" xlink:label="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" xlink:label="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails" xlink:type="extended" xlink:title="40505 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Bioasis (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_BioasisTechnologiesIncMember" xlink:label="xoma_BioasisTechnologiesIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_BioasisTechnologiesIncMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RoyaltyPurchaseAgreementAndSecondRoyaltyPurchaseAgreementMember" xlink:label="xoma_RoyaltyPurchaseAgreementAndSecondRoyaltyPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_RoyaltyPurchaseAgreementAndSecondRoyaltyPurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RoyaltyPurchaseAgreementMember" xlink:label="xoma_RoyaltyPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="xoma_RoyaltyPurchaseAgreementAndSecondRoyaltyPurchaseAgreementMember" xlink:to="xoma_RoyaltyPurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RoyaltyPurchaseAgreementTwoMember" xlink:label="xoma_RoyaltyPurchaseAgreementTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="xoma_RoyaltyPurchaseAgreementAndSecondRoyaltyPurchaseAgreementMember" xlink:to="xoma_RoyaltyPurchaseAgreementTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements" xlink:label="xoma_PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_NumberOfLicenseAgreementsFutureLicenseAgreements" xlink:label="xoma_NumberOfLicenseAgreementsFutureLicenseAgreements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_NumberOfLicenseAgreementsFutureLicenseAgreements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_PaymentsToBeMadeUponExerciseOfOptionSecondLicenseAgreement" xlink:label="xoma_PaymentsToBeMadeUponExerciseOfOptionSecondLicenseAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_PaymentsToBeMadeUponExerciseOfOptionSecondLicenseAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_PaymentsToBeMadeUponExerciseOfOptionThirdLicenseAgreement" xlink:label="xoma_PaymentsToBeMadeUponExerciseOfOptionThirdLicenseAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_PaymentsToBeMadeUponExerciseOfOptionThirdLicenseAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" xlink:label="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ContingentFutureCashPayments" xlink:label="xoma_ContingentFutureCashPayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ContingentFutureCashPayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ImpairmentOfLongTermRightsReceivableNonCurrent" xlink:label="xoma_ImpairmentOfLongTermRightsReceivableNonCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ImpairmentOfLongTermRightsReceivableNonCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LongTermRightsReceivableNonCurrentIncreaseDecrease" xlink:label="xoma_LongTermRightsReceivableNonCurrentIncreaseDecrease" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_LongTermRightsReceivableNonCurrentIncreaseDecrease" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ContingentConsiderationUnderPurchaseAgreements" xlink:label="xoma_ContingentConsiderationUnderPurchaseAgreements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ContingentConsiderationUnderPurchaseAgreements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ChangesInEstimatedFairValueOfContingentConsideration" xlink:label="xoma_ChangesInEstimatedFairValueOfContingentConsideration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ChangesInEstimatedFairValueOfContingentConsideration" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ReceiptsUnderAgreementsInvestingActivities" xlink:label="xoma_ReceiptsUnderAgreementsInvestingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ReceiptsUnderAgreementsInvestingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" xlink:label="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LongTermRightsReceivableNonCurrent" xlink:label="xoma_LongTermRightsReceivableNonCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_LongTermRightsReceivableNonCurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails" xlink:type="extended" xlink:title="40506 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Aronora (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AronoraIncMember" xlink:label="xoma_AronoraIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_AronoraIncMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RoyaltyPurchaseAgreementMember" xlink:label="xoma_RoyaltyPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_RoyaltyPurchaseAgreementMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_BayerProductsMember" xlink:label="xoma_BayerProductsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="xoma_BayerProductsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_NonBayerProductsMember" xlink:label="xoma_NonBayerProductsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="xoma_NonBayerProductsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_SiliconValleyBankMember" xlink:label="xoma_SiliconValleyBankMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="xoma_SiliconValleyBankMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AgreementDrugCandidatesNumber" xlink:label="xoma_AgreementDrugCandidatesNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_AgreementDrugCandidatesNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AgreementDrugCandidatesExclusiveLicenseOptionNumber" xlink:label="xoma_AgreementDrugCandidatesExclusiveLicenseOptionNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_AgreementDrugCandidatesExclusiveLicenseOptionNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RoyaltyReceivablePercentageOnNetSales" xlink:label="xoma_RoyaltyReceivablePercentageOnNetSales" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_RoyaltyReceivablePercentageOnNetSales" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts" xlink:label="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage" xlink:label="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AgreementPaymentPercentageFactor" xlink:label="xoma_AgreementPaymentPercentageFactor" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_AgreementPaymentPercentageFactor" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" xlink:label="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ContingentFutureCashPaymentsPerProduct" xlink:label="xoma_ContingentFutureCashPaymentsPerProduct" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ContingentFutureCashPaymentsPerProduct" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ContingentFutureCashPayments" xlink:label="xoma_ContingentFutureCashPayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ContingentFutureCashPayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount" xlink:label="xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MilestonesPaymentsToAggregateAmountOfPerProduct" xlink:label="xoma_MilestonesPaymentsToAggregateAmountOfPerProduct" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_MilestonesPaymentsToAggregateAmountOfPerProduct" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LongTermRightsReceivableNonCurrent" xlink:label="xoma_LongTermRightsReceivableNonCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_LongTermRightsReceivableNonCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ContingentConsiderationUnderPurchaseAgreements" xlink:label="xoma_ContingentConsiderationUnderPurchaseAgreements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ContingentConsiderationUnderPurchaseAgreements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" xlink:label="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails" xlink:type="extended" xlink:title="40507 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Palo (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_PalobiofarmaSLMember" xlink:label="xoma_PalobiofarmaSLMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_PalobiofarmaSLMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RoyaltyPurchaseAgreementMember" xlink:label="xoma_RoyaltyPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_RoyaltyPurchaseAgreementMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AgreementDrugCandidatesNumber" xlink:label="xoma_AgreementDrugCandidatesNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_AgreementDrugCandidatesNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" xlink:label="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LongTermRightsReceivableNonCurrent" xlink:label="xoma_LongTermRightsReceivableNonCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_LongTermRightsReceivableNonCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" xlink:label="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails" xlink:type="extended" xlink:title="40508 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Viracta (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ViractaTherapeuticsInc.Member" xlink:label="xoma_ViractaTherapeuticsInc.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_ViractaTherapeuticsInc.Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RoyaltyPurchaseAgreementMember" xlink:label="xoma_RoyaltyPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_RoyaltyPurchaseAgreementMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AgreementDrugCandidatesNumber" xlink:label="xoma_AgreementDrugCandidatesNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_AgreementDrugCandidatesNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" xlink:label="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MilestonesReceivableExcludingConsiderationRetainedMaximum" xlink:label="xoma_MilestonesReceivableExcludingConsiderationRetainedMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_MilestonesReceivableExcludingConsiderationRetainedMaximum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MaximumConsiderationRetained" xlink:label="xoma_MaximumConsiderationRetained" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_MaximumConsiderationRetained" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RegulatoryAndCommercialMilestonesReceivableMaximum" xlink:label="xoma_RegulatoryAndCommercialMilestonesReceivableMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_RegulatoryAndCommercialMilestonesReceivableMaximum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LongTermRightsReceivableNonCurrent" xlink:label="xoma_LongTermRightsReceivableNonCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_LongTermRightsReceivableNonCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" xlink:label="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails" xlink:type="extended" xlink:title="40509 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Kuros (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember" xlink:label="xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RoyaltyPurchaseAgreementMember" xlink:label="xoma_RoyaltyPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_RoyaltyPurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RoyaltyReceivablePercentageOnNetSales" xlink:label="xoma_RoyaltyReceivablePercentageOnNetSales" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_RoyaltyReceivablePercentageOnNetSales" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_EligibleMilestonePaymentsReceivableUponAchievementOfPreCommercialMilestones" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfPreCommercialMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfPreCommercialMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" xlink:label="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ReceiptsUnderAgreementsInvestingActivities" xlink:label="xoma_ReceiptsUnderAgreementsInvestingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ReceiptsUnderAgreementsInvestingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MaximumPayableOnSalesMilestone" xlink:label="xoma_MaximumPayableOnSalesMilestone" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_MaximumPayableOnSalesMilestone" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LongTermRightsReceivableNonCurrent" xlink:label="xoma_LongTermRightsReceivableNonCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_LongTermRightsReceivableNonCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MilestonePaymentReceivedCounterparty" xlink:label="xoma_MilestonePaymentReceivedCounterparty" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_MilestonePaymentReceivedCounterparty" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MilestonePaymentReceivablePercentage" xlink:label="xoma_MilestonePaymentReceivablePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_MilestonePaymentReceivablePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RightsReceivableCurrent" xlink:label="xoma_RightsReceivableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_RightsReceivableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" xlink:label="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" xlink:label="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails" xlink:type="extended" xlink:title="40510 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Affitech (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AffitechResearchAsMember" xlink:label="xoma_AffitechResearchAsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_AffitechResearchAsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_CommercialPaymentPurchaseAgreementMember" xlink:label="xoma_CommercialPaymentPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_CommercialPaymentPurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ContingentConsiderationRegulatoryMilestonesMember" xlink:label="xoma_ContingentConsiderationRegulatoryMilestonesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="xoma_ContingentConsiderationRegulatoryMilestonesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_FaricimabProductMember" xlink:label="xoma_FaricimabProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="xoma_FaricimabProductMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_FaricimabSvoaVabysmoProductMember" xlink:label="xoma_FaricimabSvoaVabysmoProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="xoma_FaricimabSvoaVabysmoProductMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="country_US" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EuropeMember" xlink:label="srt_EuropeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_EuropeMember" priority="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" xlink:label="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_CommercialSalesReceivablePercentageOnNetSales" xlink:label="xoma_CommercialSalesReceivablePercentageOnNetSales" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_CommercialSalesReceivablePercentageOnNetSales" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_CommercialPaymentReceivableTerm" xlink:label="xoma_CommercialPaymentReceivableTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_CommercialPaymentReceivableTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndSalesMilestones" xlink:label="xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndSalesMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndSalesMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LongTermRightsReceivableNonCurrent" xlink:label="xoma_LongTermRightsReceivableNonCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_LongTermRightsReceivableNonCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MaximumPayableOnRegulatoryMilestone" xlink:label="xoma_MaximumPayableOnRegulatoryMilestone" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_MaximumPayableOnRegulatoryMilestone" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MaximumPayableOnSalesMilestone" xlink:label="xoma_MaximumPayableOnSalesMilestone" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_MaximumPayableOnSalesMilestone" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ContingentConsiderationUnderPurchaseAgreements" xlink:label="xoma_ContingentConsiderationUnderPurchaseAgreements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ContingentConsiderationUnderPurchaseAgreements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ReceiptsUnderAgreementsInvestingActivities" xlink:label="xoma_ReceiptsUnderAgreementsInvestingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ReceiptsUnderAgreementsInvestingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" xlink:label="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" xlink:label="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RightsReceivableCurrent" xlink:label="xoma_RightsReceivableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_RightsReceivableCurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails" xlink:type="extended" xlink:title="40511 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Summary of Royalty Receivable Activities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RoyaltyPurchaseAgreementMember" xlink:label="xoma_RoyaltyPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_RoyaltyPurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AptevoMember" xlink:label="xoma_AptevoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_AptevoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ViractaTherapeuticsInc.Member" xlink:label="xoma_ViractaTherapeuticsInc.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_ViractaTherapeuticsInc.Member" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember" xlink:label="xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AffitechResearchAsMember" xlink:label="xoma_AffitechResearchAsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_AffitechResearchAsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LadrxMember" xlink:label="xoma_LadrxMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_LadrxMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_BioasisTechnologiesIncMember" xlink:label="xoma_BioasisTechnologiesIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_BioasisTechnologiesIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RightsReceivableCurrent" xlink:label="xoma_RightsReceivableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_RightsReceivableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableCurrent" xlink:label="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LongTermRightsReceivableNonCurrent" xlink:label="xoma_LongTermRightsReceivableNonCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_LongTermRightsReceivableNonCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent" xlink:label="xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" xlink:label="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ImpairmentOfLongTermRightsReceivableNonCurrent" xlink:label="xoma_ImpairmentOfLongTermRightsReceivableNonCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ImpairmentOfLongTermRightsReceivableNonCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ShortTermRightsReceivableReclassification" xlink:label="xoma_ShortTermRightsReceivableReclassification" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_ShortTermRightsReceivableReclassification" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LongTermRightsReceivableReclassification" xlink:label="xoma_LongTermRightsReceivableReclassification" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="xoma_LongTermRightsReceivableReclassification" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Carried at Fair Value on Recurring Basis (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_InvestmentsFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_FinancialAssetsFairValueDisclosure" xlink:label="xoma_FinancialAssetsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="xoma_FinancialAssetsFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ContingentConsiderationFairValueDisclosure" xlink:label="xoma_ContingentConsiderationFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="xoma_ContingentConsiderationFairValueDisclosure" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureFairValueMeasurementsEquitySecuritiesDetails" xlink:type="extended" xlink:title="40602 - Disclosure - Fair Value Measurements - Equity Securities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_MeasurementInputTypeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputSharePriceMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiMeasurementInput" xlink:label="us-gaap_EquitySecuritiesFvNiMeasurementInput" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiMeasurementInput" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails" xlink:type="extended" xlink:title="40603 - Disclosure - Fair Value Measurements - Contingent Consideration (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_BioasisTechnologiesIncMember" xlink:label="xoma_BioasisTechnologiesIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_BioasisTechnologiesIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AptevoMember" xlink:label="xoma_AptevoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_AptevoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LadrxMember" xlink:label="xoma_LadrxMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_LadrxMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RoyaltyPurchaseAgreementMember" xlink:label="xoma_RoyaltyPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_RoyaltyPurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ChangesInEstimatedFairValueOfContingentConsideration" xlink:label="xoma_ChangesInEstimatedFairValueOfContingentConsideration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="xoma_ChangesInEstimatedFairValueOfContingentConsideration" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ContingentConsiderationUnderPurchaseAgreements" xlink:label="xoma_ContingentConsiderationUnderPurchaseAgreements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="xoma_ContingentConsiderationUnderPurchaseAgreements" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureLeaseAgreementsLeasedFacilitiesDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Lease Agreements - Leased facilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LeasedFacilitiesEmeryvilleCaliforniaMember" xlink:label="xoma_LeasedFacilitiesEmeryvilleCaliforniaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="xoma_LeasedFacilitiesEmeryvilleCaliforniaMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LeasedFacilitiesTwoEmeryvilleCaliforniaMember" xlink:label="xoma_LeasedFacilitiesTwoEmeryvilleCaliforniaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="xoma_LeasedFacilitiesTwoEmeryvilleCaliforniaMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_OperatingLeasesNumberOfLeasedFacilities" xlink:label="xoma_OperatingLeasesNumberOfLeasedFacilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="xoma_OperatingLeasesNumberOfLeasedFacilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LesseeOperatingLeaseModificationAdjustmentToRightOfUseAsset" xlink:label="xoma_LesseeOperatingLeaseModificationAdjustmentToRightOfUseAsset" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="xoma_LesseeOperatingLeaseModificationAdjustmentToRightOfUseAsset" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureCommonStockWarrantsDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Common Stock Warrants (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_TenYearWarrantsIssuedThirdRangeMember" xlink:label="xoma_TenYearWarrantsIssuedThirdRangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="xoma_TenYearWarrantsIssuedThirdRangeMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_CommonStockWarrantExercisePrice14.71Member" xlink:label="xoma_CommonStockWarrantExercisePrice14.71Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="xoma_CommonStockWarrantExercisePrice14.71Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails" xlink:type="extended" xlink:title="40902 - Disclosure - Commitments and Contingencies - Contingent Consideration (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_CommitmentsAndContingenciesTable" xlink:label="xoma_CommitmentsAndContingenciesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="xoma_CommitmentsAndContingenciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RoyaltyPurchaseAgreementMember" xlink:label="xoma_RoyaltyPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_RoyaltyPurchaseAgreementMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_CommercialPaymentPurchaseAgreementMember" xlink:label="xoma_CommercialPaymentPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="xoma_CommercialPaymentPurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="xoma_CommitmentsAndContingenciesTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LadrxMember" xlink:label="xoma_LadrxMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_LadrxMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_BioasisTechnologiesIncMember" xlink:label="xoma_BioasisTechnologiesIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_BioasisTechnologiesIncMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AptevoMember" xlink:label="xoma_AptevoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_AptevoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MedexusMember" xlink:label="xoma_MedexusMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_MedexusMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AronoraKurosAffitechObsevaAndMerckKgaaMember" xlink:label="xoma_AronoraKurosAffitechObsevaAndMerckKgaaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="xoma_AronoraKurosAffitechObsevaAndMerckKgaaMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="xoma_CommitmentsAndContingenciesTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ContingentConsiderationRegulatoryMilestonesMember" xlink:label="xoma_ContingentConsiderationRegulatoryMilestonesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="xoma_ContingentConsiderationRegulatoryMilestonesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="xoma_CommitmentsAndContingenciesTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_CommitmentsAndContingenciesLineItems" xlink:label="xoma_CommitmentsAndContingenciesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="xoma_CommitmentsAndContingenciesLineItems" xlink:to="xoma_CommitmentsAndContingenciesTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ContingentConsiderationUnderPurchaseAgreements" xlink:label="xoma_ContingentConsiderationUnderPurchaseAgreements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="xoma_CommitmentsAndContingenciesLineItems" xlink:to="xoma_ContingentConsiderationUnderPurchaseAgreements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_PaymentOfContingentConsiderationUnderPurchaseAgreements" xlink:label="xoma_PaymentOfContingentConsiderationUnderPurchaseAgreements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="xoma_CommitmentsAndContingenciesLineItems" xlink:to="xoma_PaymentOfContingentConsiderationUnderPurchaseAgreements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ReceiptsUnderAgreementsInvestingActivities" xlink:label="xoma_ReceiptsUnderAgreementsInvestingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="xoma_CommitmentsAndContingenciesLineItems" xlink:to="xoma_ReceiptsUnderAgreementsInvestingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ChangesInEstimatedFairValueOfContingentConsideration" xlink:label="xoma_ChangesInEstimatedFairValueOfContingentConsideration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="xoma_CommitmentsAndContingenciesLineItems" xlink:to="xoma_ChangesInEstimatedFairValueOfContingentConsideration" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationEsppDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Stock Based Compensation - ESPP (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember" xlink:label="xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_PercentageOfCompensationOfEligibleEmployeesToPurchaseSharesOfEntityCommonStockAtDiscountThroughPayrollDeductions" xlink:label="xoma_PercentageOfCompensationOfEligibleEmployeesToPurchaseSharesOfEntityCommonStockAtDiscountThroughPayrollDeductions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="xoma_PercentageOfCompensationOfEligibleEmployeesToPurchaseSharesOfEntityCommonStockAtDiscountThroughPayrollDeductions" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensation2010PlanAndInducementAwardsDetails" xlink:type="extended" xlink:title="41002 - Disclosure - Stock Based Compensation - 2010 Plan and Inducement Awards (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_StockOptionInducementAwardsMember" xlink:label="xoma_StockOptionInducementAwardsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="xoma_StockOptionInducementAwardsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_StockOptionInducementAwardOneMember" xlink:label="xoma_StockOptionInducementAwardOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="xoma_StockOptionInducementAwardsMember" xlink:to="xoma_StockOptionInducementAwardOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_StockOptionInducementAwardTwoMember" xlink:label="xoma_StockOptionInducementAwardTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="xoma_StockOptionInducementAwardsMember" xlink:to="xoma_StockOptionInducementAwardTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember" xlink:label="xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ChiefExecutiveOfficerInterimMember" xlink:label="xoma_ChiefExecutiveOfficerInterimMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="xoma_ChiefExecutiveOfficerInterimMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ChiefInvestmentOfficerMember" xlink:label="xoma_ChiefInvestmentOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="xoma_ChiefInvestmentOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_EmployeeMember" xlink:label="xoma_EmployeeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="xoma_EmployeeMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ShareBasedPaymentArrangementNumberOfAwardsGrants" xlink:label="xoma_ShareBasedPaymentArrangementNumberOfAwardsGrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="xoma_ShareBasedPaymentArrangementNumberOfAwardsGrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationFvAssumptionsDetails" xlink:type="extended" xlink:title="41003 - Disclosure - Stock Based Compensation - FV Assumptions (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember" xlink:label="xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_StockOptionInducementAwardsMember" xlink:label="xoma_StockOptionInducementAwardsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="xoma_StockOptionInducementAwardsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_StockOptionInducementAwardOneMember" xlink:label="xoma_StockOptionInducementAwardOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="xoma_StockOptionInducementAwardsMember" xlink:to="xoma_StockOptionInducementAwardOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_StockOptionInducementAwardTwoMember" xlink:label="xoma_StockOptionInducementAwardTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="xoma_StockOptionInducementAwardsMember" xlink:to="xoma_StockOptionInducementAwardTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" xlink:type="extended" xlink:title="41004 - Disclosure - Stock Based Compensation - Stock Option Activity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsDetails" xlink:type="extended" xlink:title="41005 - Disclosure - Stock Based Compensation - Performance Stock Unit Awards (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_PerformanceStockUnitsMember" xlink:label="xoma_PerformanceStockUnitsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="xoma_PerformanceStockUnitsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember" xlink:label="xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfHurdles." xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfHurdles." />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfHurdles." priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfCalendarDays" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfCalendarDays" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfCalendarDays" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsFairValueDetails" xlink:type="extended" xlink:title="41006 - Disclosure - Stock Based Compensation - Performance Stock Unit Awards Fair Value (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_PerformanceStockUnitsMember" xlink:label="xoma_PerformanceStockUnitsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="xoma_PerformanceStockUnitsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_StockPriceHurdlesOfDollar30Member" xlink:label="xoma_StockPriceHurdlesOfDollar30Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="xoma_StockPriceHurdlesOfDollar30Member" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_StockPriceHurdlesOfDollar35Member" xlink:label="xoma_StockPriceHurdlesOfDollar35Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="xoma_StockPriceHurdlesOfDollar35Member" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_StockPriceHurdlesOfDollar40Member" xlink:label="xoma_StockPriceHurdlesOfDollar40Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="xoma_StockPriceHurdlesOfDollar40Member" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_StockPriceHurdlesOfDollar45Member" xlink:label="xoma_StockPriceHurdlesOfDollar45Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="xoma_StockPriceHurdlesOfDollar45Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsActivityDetails" xlink:type="extended" xlink:title="41007 - Disclosure - Stock Based Compensation - Performance Stock Unit Awards Activity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_PerformanceStockUnitsMember" xlink:label="xoma_PerformanceStockUnitsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="xoma_PerformanceStockUnitsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="41008 - Disclosure - Stock Based Compensation - Stock-based Compensation Expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationEmployeeRetentionBonusDetails" xlink:type="extended" xlink:title="41009 - Disclosure - Stock Based Compensation - Employee Retention Bonus (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember" xlink:label="xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_NumberOfPeriodsCashRetentionBonus" xlink:label="xoma_NumberOfPeriodsCashRetentionBonus" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="xoma_NumberOfPeriodsCashRetentionBonus" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_PeriodOneRetentionBonusEligibility" xlink:label="xoma_PeriodOneRetentionBonusEligibility" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="xoma_PeriodOneRetentionBonusEligibility" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_PeriodTwoRetentionBonusEligibility" xlink:label="xoma_PeriodTwoRetentionBonusEligibility" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="xoma_PeriodTwoRetentionBonusEligibility" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RetentionBonusExpenseAccrued" xlink:label="xoma_RetentionBonusExpenseAccrued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="xoma_RetentionBonusExpenseAccrued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AccruedRetentionBonus" xlink:label="xoma_AccruedRetentionBonus" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="xoma_AccruedRetentionBonus" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationCeoDepartureAndContinuityIncentiveDetails" xlink:type="extended" xlink:title="41010 - Disclosure - Stock Based Compensation - CEO Departure and Continuity Incentive (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ChiefExecutiveOfficerRetiredMember" xlink:label="xoma_ChiefExecutiveOfficerRetiredMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="xoma_ChiefExecutiveOfficerRetiredMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AccruedCompensationContinuityIncentive" xlink:label="xoma_AccruedCompensationContinuityIncentive" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="xoma_AccruedCompensationContinuityIncentive" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_CompensationExpenseEmploymentAgreement" xlink:label="xoma_CompensationExpenseEmploymentAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="xoma_CompensationExpenseEmploymentAgreement" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Capital Stock - Dividends (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPayableTable" xlink:label="us-gaap_DividendsPayableTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DividendsPayableTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPayableLineItems" xlink:label="us-gaap_DividendsPayableLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DividendsPayableLineItems" xlink:to="us-gaap_DividendsPayableTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendsPerShareDeclared" xlink:label="us-gaap_PreferredStockDividendsPerShareDeclared" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DividendsPayableLineItems" xlink:to="us-gaap_PreferredStockDividendsPerShareDeclared" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendsPerShareCashPaid" xlink:label="us-gaap_PreferredStockDividendsPerShareCashPaid" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DividendsPayableLineItems" xlink:to="us-gaap_PreferredStockDividendsPerShareCashPaid" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails" xlink:type="extended" xlink:title="41102 - Disclosure - Capital Stock - BVF Ownership (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_BiotechnologyValueFundLPMember" xlink:label="xoma_BiotechnologyValueFundLPMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="xoma_BiotechnologyValueFundLPMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="srt_OwnershipAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_XomaCorporationMember" xlink:label="xoma_XomaCorporationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_OwnershipDomain" xlink:to="xoma_XomaCorporationMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted" xlink:label="xoma_NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="xoma_NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails" xlink:type="extended" xlink:title="41103 - Disclosure - Capital Stock - ATM Agreements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_TwoThousandEighteenAtMarketAgreementMember" xlink:label="xoma_TwoThousandEighteenAtMarketAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="xoma_TwoThousandEighteenAtMarketAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AtMarketIssuanceSalesAgreement2021Member" xlink:label="xoma_AtMarketIssuanceSalesAgreement2021Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="xoma_AtMarketIssuanceSalesAgreement2021Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AdrMember" xlink:label="dei_AdrMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="dei_AdrMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="srt_RangeAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MaximumValueOfStockToBeIssued" xlink:label="xoma_MaximumValueOfStockToBeIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="xoma_MaximumValueOfStockToBeIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares" xlink:label="xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfShares" xlink:label="xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfShares" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>xoma-20230630_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.3.0.9 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/8/2023 2:22:02 AM-->
<!--Modified on: 8/8/2023 2:22:02 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cover [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement Class Of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">8.625% Series A Cumulative, Perpetual Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A accumulated dividends</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AdrMember" xlink:label="dei_AdrMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AdrMember" xlink:to="dei_AdrMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AdrMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B Depositary Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Quarterly Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation State Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address Address Line1</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address Address Line2</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address City Or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address State Or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security12b Title</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Small Business</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Shell Company</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONDENSED CONSOLIDATED BALANCE SHEETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">8.375% Series B Cumulative, Perpetual Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B accumulated dividends</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible preferred stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ASSETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="us-gaap_EquitySecuritiesFvNi" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNi" xlink:to="us-gaap_EquitySecuritiesFvNi_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquitySecuritiesFvNi_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Securities, FV-NI</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquitySecuritiesFvNi_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term equity securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts and Other Receivables, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade and other receivables, net</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RightsReceivableCurrent" xlink:label="xoma_RightsReceivableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_RightsReceivableCurrent" xlink:to="xoma_RightsReceivableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_RightsReceivableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty, interest and commercial payment rights receivable, due within one year or the normal operating cycle, if longer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_RightsReceivableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rights Receivable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="xoma_RightsReceivableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term royalty receivable, Balance at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="xoma_RightsReceivableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term royalty receivable, Balance at beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_RightsReceivableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term royalty and commercial payment receivables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense And Other Assets Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property Plant And Equipment Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease Right Of Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LongTermRightsReceivableNonCurrent" xlink:label="xoma_LongTermRightsReceivableNonCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LongTermRightsReceivableNonCurrent" xlink:to="xoma_LongTermRightsReceivableNonCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LongTermRightsReceivableNonCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term royalty and commercial rights receivables, non current.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LongTermRightsReceivableNonCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long Term Rights Receivable, Non-Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="xoma_LongTermRightsReceivableNonCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term royalty receivable, Balance at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="xoma_LongTermRightsReceivableNonCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term royalty receivable, Balance at beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_LongTermRightsReceivableNonCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term royalty and commercial payment receivables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible Assets, Net (Excluding Goodwill)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible assets, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Assets Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other assets - long term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities And Stockholders Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">LIABILITIES AND STOCKHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AccruedAndOtherLiabilitiesCurrent" xlink:label="xoma_AccruedAndOtherLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_AccruedAndOtherLiabilitiesCurrent" xlink:to="xoma_AccruedAndOtherLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_AccruedAndOtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of obligations incurred and payable, and liabilities classified as other, due within one year or within the normal operating cycle if longer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_AccruedAndOtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued And Other Liabilities Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_AccruedAndOtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued and other liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="xoma_AccruedAndOtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ContingentConsiderationUnderPurchaseAgreements" xlink:label="xoma_ContingentConsiderationUnderPurchaseAgreements" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ContingentConsiderationUnderPurchaseAgreements" xlink:to="xoma_ContingentConsiderationUnderPurchaseAgreements_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ContingentConsiderationUnderPurchaseAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liability recorded for contingent consideration under purchase agreements. May include royalty purchase agreements, commercial payment purchase agreements, payment interest purchase agreements and assignment and assumption agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ContingentConsiderationUnderPurchaseAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent Consideration Under Purchase Agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ContingentConsiderationUnderPurchaseAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent consideration under RPAs, AAAs and CPPAs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease Liability Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeCurrent" xlink:label="us-gaap_DeferredIncomeCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeCurrent" xlink:to="us-gaap_DeferredIncomeCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Income, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unearned revenue recognized under units-of-revenue method</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredIncomeCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unearned revenue recognized under units-of-revenue method, current</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AccruedPreferredStockDividendCurrent" xlink:label="xoma_AccruedPreferredStockDividendCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_AccruedPreferredStockDividendCurrent" xlink:to="xoma_AccruedPreferredStockDividendCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_AccruedPreferredStockDividendCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of obligations incurred through that date and payable for preferred stock dividend. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_AccruedPreferredStockDividendCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Preferred Stock Dividend, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_AccruedPreferredStockDividendCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock dividend accrual</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeNoncurrent" xlink:label="us-gaap_DeferredIncomeNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeNoncurrent" xlink:to="us-gaap_DeferredIncomeNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Income, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unearned revenue recognized under units-of-revenue method - long-term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredIncomeNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unearned revenue recognized under units-of-revenue method, noncurrent</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments And Contingencies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies (Note 9)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity, Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' equity:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, $0.0075 par value, 277,333,332 shares authorized, 11,472,808 and 11,454,025 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid In Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings Accumulated Deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities And Stockholders Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities and stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock Par Or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares authorized (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendRatePercentage" xlink:to="us-gaap_PreferredStockDividendRatePercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Dividend Rate, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, dividend rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares outstanding (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Par Or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares authorized (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares outstanding (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenues [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenues:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue From Contract With Customer Excluding Assessed Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from contracts with customers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue recognized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="us-gaap_RevenueNotFromContractWithCustomer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueNotFromContractWithCustomer" xlink:to="us-gaap_RevenueNotFromContractWithCustomer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueNotFromContractWithCustomer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Not from Contract with Customer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueNotFromContractWithCustomer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue recognized under units-of-revenue method</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total revenues</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating expenses:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research And Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General And Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ImpairmentOfLongTermRightsReceivableNonCurrent" xlink:label="xoma_ImpairmentOfLongTermRightsReceivableNonCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ImpairmentOfLongTermRightsReceivableNonCurrent" xlink:to="xoma_ImpairmentOfLongTermRightsReceivableNonCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ImpairmentOfLongTermRightsReceivableNonCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of write-down of royalty and commercial rights receivable recognized in the income statement during the period. Includes royalty purchase agreement asset impairment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ImpairmentOfLongTermRightsReceivableNonCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of Long Term Rights Receivable, Non-Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="xoma_ImpairmentOfLongTermRightsReceivableNonCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of royalty and commercial payment rights, Long-Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ImpairmentOfLongTermRightsReceivableNonCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty purchase agreement asset impairment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementExpense" xlink:label="us-gaap_LitigationSettlementExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationSettlementExpense" xlink:to="us-gaap_LitigationSettlementExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LitigationSettlementExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Litigation Settlement, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LitigationSettlementExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Arbitration settlement costs (Note 3)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LitigationSettlementExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Arbitration settlement costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of intangible assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Income Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonoperating Income Expense [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income (expense), net:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Nonoperating Income Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income (expense), net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss and comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock Dividends, Income Statement Impact</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: accumulated dividends on Series A and Series B preferred stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: accumulated dividends</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income Loss Available To Common Stockholders Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss attributable to common stockholders, basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss attributable to common stockholders, basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income Loss Available To Common Stockholders Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss attributable to common stockholders, diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss attributable to common stockholders, diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic net loss per share attributable to common stockholders (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Diluted net loss per share attributable to common stockholders (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number Of Shares Outstanding Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average shares used in computing basic net loss per share attributable to common stockholders (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number Of Diluted Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average shares used in computing diluted net loss per share attributable to common stockholders (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-In Capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase Decrease In Stockholders Equity Roll Forward</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at end of period (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at beginning of period (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period Value New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of preferred stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period Shares New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of preferred stock (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period Value Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period Shares Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares, Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of stock options (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period Value Employee Stock Purchase Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock related to ESPP</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period Shares Employee Stock Purchase Plans</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock related to ESPP (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period Value Share Based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock related to 401(k) contribution</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period Shares Share Based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock related to 401(k) contribution (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPreferredStockStock" xlink:label="us-gaap_DividendsPreferredStockStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPreferredStockStock" xlink:to="us-gaap_DividendsPreferredStockStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsPreferredStockStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividends, Preferred Stock, Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DividendsPreferredStockStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock dividends</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided By Used In Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Profit Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ChangesInEstimatedFairValueOfContingentConsideration" xlink:label="xoma_ChangesInEstimatedFairValueOfContingentConsideration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ChangesInEstimatedFairValueOfContingentConsideration" xlink:to="xoma_ChangesInEstimatedFairValueOfContingentConsideration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ChangesInEstimatedFairValueOfContingentConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in estimated fair value of contingent consideration.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ChangesInEstimatedFairValueOfContingentConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes In Estimated Fair Value Of Contingent Consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="xoma_ChangesInEstimatedFairValueOfContingentConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value of contingent consideration under RPAs, AAAs, and CPPAs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ChangesInEstimatedFairValueOfContingentConsideration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in estimated fair value of contingent consideration</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims" xlink:label="xoma_DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims" xlink:to="xoma_DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined contribution plan issuance of Common stock for services or claims.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan Issuance Of Common Stock For Services Or Claims</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock contribution to 401(k)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationNonproduction" xlink:label="us-gaap_DepreciationNonproduction" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationNonproduction" xlink:to="us-gaap_DepreciationNonproduction_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationNonproduction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_OperatingLeasePaymentsNonCash" xlink:label="xoma_OperatingLeasePaymentsNonCash" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_OperatingLeasePaymentsNonCash" xlink:to="xoma_OperatingLeasePaymentsNonCash_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_OperatingLeasePaymentsNonCash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease payments, non cash.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_OperatingLeasePaymentsNonCash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease Payments Non Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="xoma_OperatingLeasePaymentsNonCash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash lease expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:to="us-gaap_EquitySecuritiesFvNiRealizedGainLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedGainLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Securities, FV-NI, Realized Gain (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedGainLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value of equity securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedGainLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (loss) recognized due to change in fair value of investment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase Decrease In Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts and Other Receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade and other receivables, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase Decrease In Prepaid Deferred Expense And Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase Decrease In Accounts Payable And Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable and accrued liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase Decrease In Accrued Income Taxes Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income taxes payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Deferred Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unearned revenue recognized under units-of-revenue method</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided By Used In Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided By Used In Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from investing activities:</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" xlink:label="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" xlink:to="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of cash outflow for consideration under agreements, including Royalty Purchase Agreements (RPAs), Assignment and Assumption Agreements (AAAs), and Commercial payment purchase agreement. (CPPAs) classified as investing activities. Payments may include upfront payments, one-time payments, milestone payments and contingent consideration payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment of Consideration Under Agreements, Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of consideration under RPAs, AAAs and CPPAs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of consideration under RPAs, AAAs and CPPAs</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ReceiptsUnderAgreementsInvestingActivities" xlink:label="xoma_ReceiptsUnderAgreementsInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ReceiptsUnderAgreementsInvestingActivities" xlink:to="xoma_ReceiptsUnderAgreementsInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ReceiptsUnderAgreementsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of cash inflow under agreements, including Royalty Purchase Agreements (RPAs), Assignment and Assumption Agreements (AAAs), and Commercial Payment Purchase Agreements (CPPAs), classified as investing activities. Receipts may represent commercial payments attributable to net sales.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ReceiptsUnderAgreementsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receipts Under Agreements, Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ReceiptsUnderAgreementsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receipts under RPAs, AAAs and CPPAs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Productive Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment for IP acquired under the ObsEva IP Acquisition Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront cash payment to acquire assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided By Used In Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided By Used In Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from financing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDividends" xlink:label="us-gaap_PaymentsOfDividends" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDividends" xlink:to="us-gaap_PaymentsOfDividends_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDividends_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of Dividends</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfDividends_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment of preferred stock dividends</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from exercise of options and other share-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments Related To Tax Withholding For Share Based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Taxes paid related to net share settlement of equity awards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds From Issuance Of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided By Used In Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net decrease in cash, cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents and restricted cash at the end of the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents and restricted cash at the beginning of the period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental Cash Flow Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental Cash Flow Information:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes Paid Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash paid for taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-use assets obtained in exchange for operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash investing and financing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:label="us-gaap_DividendsPayableCurrentAndNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:to="us-gaap_DividendsPayableCurrentAndNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsPayableCurrentAndNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividends Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DividendsPayableCurrentAndNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock dividend accrual</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_EstimatedFairValueOfContingentConsiderationUnderAssetAcquisition" xlink:label="xoma_EstimatedFairValueOfContingentConsiderationUnderAssetAcquisition" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_EstimatedFairValueOfContingentConsiderationUnderAssetAcquisition" xlink:to="xoma_EstimatedFairValueOfContingentConsiderationUnderAssetAcquisition_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_EstimatedFairValueOfContingentConsiderationUnderAssetAcquisition_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated fair value of contingent consideration under asset acquisition agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_EstimatedFairValueOfContingentConsiderationUnderAssetAcquisition_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated Fair Value Of Contingent Consideration Under Asset Acquisition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_EstimatedFairValueOfContingentConsiderationUnderAssetAcquisition_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated fair value of contingent consideration under the LadRx Agreements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature Of Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation and Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis Of Presentation And Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation and Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ConsolidatedFinancialStatementDetailAbstract" xlink:label="xoma_ConsolidatedFinancialStatementDetailAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ConsolidatedFinancialStatementDetailAbstract" xlink:to="xoma_ConsolidatedFinancialStatementDetailAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ConsolidatedFinancialStatementDetailAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated financial statement detail.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ConsolidatedFinancialStatementDetailAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Condensed Consolidated Financial Statements Details</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:label="us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:to="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Financial Information Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Condensed Consolidated Financial Statements Details</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LicensingAndOtherArrangementsAbstract" xlink:label="xoma_LicensingAndOtherArrangementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LicensingAndOtherArrangementsAbstract" xlink:to="xoma_LicensingAndOtherArrangementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LicensingAndOtherArrangementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Licensing and other arrangements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LicensingAndOtherArrangementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Licensing and Other Arrangements</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LicensingAndOtherArrangementsTextBlock" xlink:label="xoma_LicensingAndOtherArrangementsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LicensingAndOtherArrangementsTextBlock" xlink:to="xoma_LicensingAndOtherArrangementsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LicensingAndOtherArrangementsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Licensing and other arrangements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LicensingAndOtherArrangementsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Licensing And Other Arrangements [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_LicensingAndOtherArrangementsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Licensing and Other Arrangements</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:label="xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:to="xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty and Commercial Payment Purchase Agreements</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RoyaltyPurchaseAgreementTextBlock" xlink:label="xoma_RoyaltyPurchaseAgreementTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_RoyaltyPurchaseAgreementTextBlock" xlink:to="xoma_RoyaltyPurchaseAgreementTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_RoyaltyPurchaseAgreementTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty purchase agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_RoyaltyPurchaseAgreementTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty Purchase Agreement [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="xoma_RoyaltyPurchaseAgreementTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty and Commercial Payment Purchase Agreements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease Agreements</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LeaseDisclosureTextBlock" xlink:label="xoma_LeaseDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LeaseDisclosureTextBlock" xlink:to="xoma_LeaseDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LeaseDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure of information about leases.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LeaseDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_LeaseDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease Agreements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Warrants</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_CommonStockWarrantDisclosureTextBlock" xlink:label="xoma_CommonStockWarrantDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_CommonStockWarrantDisclosureTextBlock" xlink:to="xoma_CommonStockWarrantDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_CommonStockWarrantDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock warrant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_CommonStockWarrantDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Warrant Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_CommonStockWarrantDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments And Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="us-gaap_CompensationRelatedCostsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsAbstract" xlink:to="us-gaap_CompensationRelatedCostsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Compensation Related Costs Share Based Payments [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis Of Accounting Policy Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use Of Estimates</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash And Cash Equivalents Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue From Contract With Customer Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Recognition</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RevenueRecognitionDeferredRevenuePolicyTextBlock" xlink:label="xoma_RevenueRecognitionDeferredRevenuePolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_RevenueRecognitionDeferredRevenuePolicyTextBlock" xlink:to="xoma_RevenueRecognitionDeferredRevenuePolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_RevenueRecognitionDeferredRevenuePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for sale of future revenue streams.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_RevenueRecognitionDeferredRevenuePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Recognition Deferred Revenue Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_RevenueRecognitionDeferredRevenuePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Future Revenue Streams</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation Related Costs Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_EquitySecuritiesPolicy" xlink:label="xoma_EquitySecuritiesPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_EquitySecuritiesPolicy" xlink:to="xoma_EquitySecuritiesPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_EquitySecuritiesPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for equity securities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_EquitySecuritiesPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Securities Policy</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_EquitySecuritiesPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Securities</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_FutureMilestonesRoyaltiesPurchaseRightsAndCommercialPaymentsPolicyPolicyTextBlock" xlink:label="xoma_FutureMilestonesRoyaltiesPurchaseRightsAndCommercialPaymentsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_FutureMilestonesRoyaltiesPurchaseRightsAndCommercialPaymentsPolicyPolicyTextBlock" xlink:to="xoma_FutureMilestonesRoyaltiesPurchaseRightsAndCommercialPaymentsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_FutureMilestonesRoyaltiesPurchaseRightsAndCommercialPaymentsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Policy for future milestones, royalties purchase rights and commercial payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_FutureMilestonesRoyaltiesPurchaseRightsAndCommercialPaymentsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Future Milestones, Royalties Purchase Rights And Commercial Payments Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_FutureMilestonesRoyaltiesPurchaseRightsAndCommercialPaymentsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of Rights to Future Milestones, Royalties and Commercial Payments</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_CreditLossContractWithCustomerAssetPolicyTextBlock" xlink:label="xoma_CreditLossContractWithCustomerAssetPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_CreditLossContractWithCustomerAssetPolicyTextBlock" xlink:to="xoma_CreditLossContractWithCustomerAssetPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_CreditLossContractWithCustomerAssetPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for credit loss on long-term royalty and commercial payment receivable asset.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_CreditLossContractWithCustomerAssetPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Credit Loss, Contract With Customer Asset [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_CreditLossContractWithCustomerAssetPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allowance for Current Expected Credit Losses</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AssetAcquisitionsPolicyPolicyTextBlock" xlink:label="xoma_AssetAcquisitionsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_AssetAcquisitionsPolicyPolicyTextBlock" xlink:to="xoma_AssetAcquisitionsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_AssetAcquisitionsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for asset acquisitions.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_AssetAcquisitionsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Acquisitions, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_AssetAcquisitionsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Acquisitions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee Leases Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss per Share Attributable to Common Stockholders</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Credit Risk</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration of Risk</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income Policy Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements Policy Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounting Pronouncements Recently Adopted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Finite-Lived Intangible Assets [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of cost, accumulated amortization, and net carrying value of intangible assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of projected amortization expense for next five years</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Accrued Liabilities Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of accrued and other liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of reconciliation of numerator and denominator used in calculation of basic and diluted net (loss) per share available to common stockholders</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of outstanding securities considered anti-dilutive</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ScheduleOfRoyaltyAndCommercialPaymentReceivablesActivityTableTextBlock" xlink:label="xoma_ScheduleOfRoyaltyAndCommercialPaymentReceivablesActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ScheduleOfRoyaltyAndCommercialPaymentReceivablesActivityTableTextBlock" xlink:to="xoma_ScheduleOfRoyaltyAndCommercialPaymentReceivablesActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ScheduleOfRoyaltyAndCommercialPaymentReceivablesActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of the changes in royalty and commercial payment receivables.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ScheduleOfRoyaltyAndCommercialPaymentReceivablesActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Royalty and Commercial Payment Receivables Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ScheduleOfRoyaltyAndCommercialPaymentReceivablesActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of royalty and commercial payment receivable activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Financial Assets and Liabilities Carried at Fair Value on Recurring Basis</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, Cost [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of cost components of operating leases</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock" xlink:label="xoma_LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock" xlink:to="xoma_LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The tabular disclosure of supplemental cash flows information related to leases.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Supplemental Cash Flow Information [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of supplemental cash flow information related to operating leases</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LesseeOperatingLeaseSupplementalInformationTableTextBlock" xlink:label="xoma_LesseeOperatingLeaseSupplementalInformationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LesseeOperatingLeaseSupplementalInformationTableTextBlock" xlink:to="xoma_LesseeOperatingLeaseSupplementalInformationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LesseeOperatingLeaseSupplementalInformationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The tabular disclosure of supplemental information related to operating leases. May include, but  not limited to, present value assumptions used in calculating the present value of the lease payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LesseeOperatingLeaseSupplementalInformationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Supplemental Information [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_LesseeOperatingLeaseSupplementalInformationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of present value assumptions used in calculating the present value of lease payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Stockholders Equity Note Warrants Or Rights [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Common Stock Warrants Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember" xlink:label="xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember" xlink:to="xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2010 Long Term Incentive and Share Award Plan and subsequent amendments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2010 Plan</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_StockOptionInducementAwardsMember" xlink:label="xoma_StockOptionInducementAwardsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_StockOptionInducementAwardsMember" xlink:to="xoma_StockOptionInducementAwardsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_StockOptionInducementAwardsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information pertaining to Stock Option Inducement Awards.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_StockOptionInducementAwardsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Option Inducement Awards</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_StockOptionInducementAwardOneMember" xlink:label="xoma_StockOptionInducementAwardOneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_StockOptionInducementAwardOneMember" xlink:to="xoma_StockOptionInducementAwardOneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_StockOptionInducementAwardOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information pertaining to first Stock Option Inducement Award.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_StockOptionInducementAwardOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Option Inducement Award, Exercise price of $18.66 per share</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_StockOptionInducementAwardTwoMember" xlink:label="xoma_StockOptionInducementAwardTwoMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_StockOptionInducementAwardTwoMember" xlink:to="xoma_StockOptionInducementAwardTwoMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_StockOptionInducementAwardTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information pertaining to second Stock Option Inducement Award.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_StockOptionInducementAwardTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Option Inducement Award, Exercise price of $30.00 per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Performance Stock Unit Awards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of valuation assumptions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of stock option activity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:label="us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:to="us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Performance Shares, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of grant date fair value per PSU issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" xlink:label="us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" xlink:to="us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Performance Shares, Outstanding Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of performance shares, outstanding activity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsDeclaredTableTextBlock" xlink:label="us-gaap_DividendsDeclaredTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsDeclaredTableTextBlock" xlink:to="us-gaap_DividendsDeclaredTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsDeclaredTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividends Declared [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DividendsDeclaredTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of declared and paid cash dividends</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated useful life of intangible asset</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax penalties or interest charged</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued interest or penalties related to uncertain tax positions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk By Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer Concentration Risk</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditConcentrationRiskMember" xlink:label="us-gaap_CreditConcentrationRiskMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditConcentrationRiskMember" xlink:to="us-gaap_CreditConcentrationRiskMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditConcentrationRiskMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Credit Concentration Risk</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk By Benchmark [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Benchmark</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenues.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAccountsReceivableMember" xlink:label="us-gaap_TradeAccountsReceivableMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAccountsReceivableMember" xlink:to="us-gaap_TradeAccountsReceivableMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradeAccountsReceivableMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade Receivables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MajorCustomersAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Major Customers [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_Partner1Member" xlink:label="xoma_Partner1Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_Partner1Member" xlink:to="xoma_Partner1Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_Partner1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">One partner that accounts for a concentration risk as a percentage of some financial balance or benchmark.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_Partner1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Partner 1</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_Partner2Member" xlink:label="xoma_Partner2Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_Partner2Member" xlink:to="xoma_Partner2Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_Partner2Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">A second partner that accounts for a concentration risk as a percentage of some financial balance or benchmark.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_Partner2Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Partner 2</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_Partner3Member" xlink:label="xoma_Partner3Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_Partner3Member" xlink:to="xoma_Partner3Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_Partner3Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">A third partner that accounts for a concentration risk as a percentage of some financial balance or benchmark.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_Partner3Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Partner 3</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_Partner4Member" xlink:label="xoma_Partner4Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_Partner4Member" xlink:to="xoma_Partner4Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_Partner4Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">A fourth partner that accounts for a concentration risk as a percentage of some financial balance or benchmark.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_Partner4Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Partner 4</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration of Risk</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_NumberOfMajorPartners" xlink:label="xoma_NumberOfMajorPartners" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_NumberOfMajorPartners" xlink:to="xoma_NumberOfMajorPartners_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_NumberOfMajorPartners_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of major partners.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_NumberOfMajorPartners_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Major Partners</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_NumberOfMajorPartners_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of major partners</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Percentage1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration risk (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesLongTermContractsOrPrograms" xlink:label="us-gaap_ReceivablesLongTermContractsOrPrograms" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesLongTermContractsOrPrograms" xlink:to="us-gaap_ReceivablesLongTermContractsOrPrograms_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesLongTermContractsOrPrograms_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receivables, Long-term Contracts or Programs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReceivablesLongTermContractsOrPrograms_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade receivable, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:label="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:to="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Trading, and Equity Securities, FV-NI [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment, Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="srt_EquityMethodInvesteeNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_EquityMethodInvesteeNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RezoluteIncMember" xlink:label="xoma_RezoluteIncMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_RezoluteIncMember" xlink:to="xoma_RezoluteIncMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_RezoluteIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rezolute, Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_RezoluteIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rezolute</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:label="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:to="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt and Equity Securities, FV-NI [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFVNINoncurrent" xlink:label="us-gaap_EquitySecuritiesFVNINoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFVNINoncurrent" xlink:to="us-gaap_EquitySecuritiesFVNINoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquitySecuritiesFVNINoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Securities, FV-NI, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquitySecuritiesFVNINoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term equity securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Finite-Lived Intangible Assets [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets by Major Class [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntellectualPropertyMember" xlink:label="us-gaap_IntellectualPropertyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntellectualPropertyMember" xlink:to="us-gaap_IntellectualPropertyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntellectualPropertyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ebopiprant IP</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible assets, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Net [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Accumulated Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Amortization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Carrying Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Remaining Amortization Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remaining useful life</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Projected amortization expense for the next five years</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2023 (excluding six months ended June 30, 2023)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Asset, Expected Amortization, Year One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Asset, Expected Amortization, Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2025</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Asset, Expected Amortization, Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2026</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Asset, Expected Amortization, Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2027</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_FiniteLivedIntangibleAssetExpectedAmortizationThroughYearFive" xlink:label="xoma_FiniteLivedIntangibleAssetExpectedAmortizationThroughYearFive" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_FiniteLivedIntangibleAssetExpectedAmortizationThroughYearFive" xlink:to="xoma_FiniteLivedIntangibleAssetExpectedAmortizationThroughYearFive_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_FiniteLivedIntangibleAssetExpectedAmortizationThroughYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_FiniteLivedIntangibleAssetExpectedAmortizationThroughYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Asset, Expected Amortization, Through Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="xoma_FiniteLivedIntangibleAssetExpectedAmortizationThroughYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities And Other Liabilities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued and other liabilities</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AccruedSalariesAndEmployeeBenefitsCurrent" xlink:label="xoma_AccruedSalariesAndEmployeeBenefitsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_AccruedSalariesAndEmployeeBenefitsCurrent" xlink:to="xoma_AccruedSalariesAndEmployeeBenefitsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_AccruedSalariesAndEmployeeBenefitsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Also includes carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Includes, but not limited to payroll, severance and retention costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_AccruedSalariesAndEmployeeBenefitsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Salaries and Employee Benefits, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_AccruedSalariesAndEmployeeBenefitsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued payroll, severance and retention costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedBonusesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Bonuses, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued incentive compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Professional Fees Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued legal and accounting fees</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Accrued Liabilities Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other accrued liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:to="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDilutedLineItems" xlink:label="us-gaap_EarningsPerShareDilutedLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="us-gaap_EarningsPerShareDilutedLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDilutedLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDilutedLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income Loss Available To Common Stockholders Diluted [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Numerator</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number Of Shares Outstanding [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Denominator</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities, Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants for common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded From Computation Of Earnings Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive securities excluded from computation of net loss per share (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock price (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Hurdle Price Per PSU (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_NumberOfArbitrationProceedingsInitiated" xlink:label="xoma_NumberOfArbitrationProceedingsInitiated" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_NumberOfArbitrationProceedingsInitiated" xlink:to="xoma_NumberOfArbitrationProceedingsInitiated_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_NumberOfArbitrationProceedingsInitiated_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of arbitration proceedings initiated by entity against one of its licensees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_NumberOfArbitrationProceedingsInitiated_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Arbitration Proceedings Initiated</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_NumberOfArbitrationProceedingsInitiated_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of arbitration proceedings initiated</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTable" xlink:label="us-gaap_AssetAcquisitionTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_AssetAcquisitionTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Acquisition [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Acquisition [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="us-gaap_AssetAcquisitionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Acquisition [Domain]</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ObsevaIntellectualPropertyRightsMember" xlink:label="xoma_ObsevaIntellectualPropertyRightsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ObsevaIntellectualPropertyRightsMember" xlink:to="xoma_ObsevaIntellectualPropertyRightsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ObsevaIntellectualPropertyRightsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ObsEva intellectual property rights.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ObsevaIntellectualPropertyRightsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ObsEva IP</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Type Of Arrangement [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Arrangements and Non-arrangement Transactions</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LicenseAgreementMember" xlink:label="xoma_LicenseAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LicenseAgreementMember" xlink:to="xoma_LicenseAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ObsevaMember" xlink:label="xoma_ObsevaMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ObsevaMember" xlink:to="xoma_ObsevaMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ObsevaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ObsEva.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ObsevaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ObsEva</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_OrganonMember" xlink:label="xoma_OrganonMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_OrganonMember" xlink:to="xoma_OrganonMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_OrganonMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information pertaining to Organon. The Company entered into an Acquisition Agreement with ObsEva in November 2022 pursuant to which the Company assumed ObsEva's ongoing rights and obligations under the License Agreement between Organon and ObsEva.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_OrganonMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ObsEva, Organon</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MerckKgaaMember" xlink:label="xoma_MerckKgaaMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_MerckKgaaMember" xlink:to="xoma_MerckKgaaMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_MerckKgaaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information pertaining to Merck KGaA. The Company entered into an Acquisition Agreement with ObsEva in November 2022 pursuant to which the Company assumed ObsEva's ongoing rights and obligations under the License Agreement between Merck KGaA and ObsEva.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_MerckKgaaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ObsEva, Merck KGaA</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="us-gaap_AssetAcquisitionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Acquisition [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetAcquisitionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset acquisition</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentCommercializationAndSalesMilestones" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentCommercializationAndSalesMilestones" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentCommercializationAndSalesMilestones" xlink:to="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentCommercializationAndSalesMilestones_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentCommercializationAndSalesMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum eligible milestone payments receivable upon achievement of development, commercialization and sales milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentCommercializationAndSalesMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Eligible Milestone Payments Receivable Upon Achievement Of Development, Commercialization And Sales Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentCommercializationAndSalesMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum eligible milestone payments receivable upon achievement of development, commercialization and sales-based milestones</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MaximumEarnOutPayments" xlink:label="xoma_MaximumEarnOutPayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_MaximumEarnOutPayments" xlink:to="xoma_MaximumEarnOutPayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_MaximumEarnOutPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum earn-out payments entity will be required to pay for various milestones under arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_MaximumEarnOutPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Earn-Out Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_MaximumEarnOutPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum earn-out payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Acquisition, Consideration Transferred</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost to acquire assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Acquisition, Consideration Transferred, Transaction Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transaction costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedContractCostNet" xlink:to="us-gaap_CapitalizedContractCostNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalizedContractCostNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capitalized Contract Cost Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalizedContractCostNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capitalized contract costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of Intangible Assets, Finite-Lived</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of intangible asset</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MaximumEarnOutPaymentsDevelopmentAndRegulatoryMilestonePayments" xlink:label="xoma_MaximumEarnOutPaymentsDevelopmentAndRegulatoryMilestonePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_MaximumEarnOutPaymentsDevelopmentAndRegulatoryMilestonePayments" xlink:to="xoma_MaximumEarnOutPaymentsDevelopmentAndRegulatoryMilestonePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_MaximumEarnOutPaymentsDevelopmentAndRegulatoryMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum earn-out payments entity will be required to pay for development and regulatory milestones under arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_MaximumEarnOutPaymentsDevelopmentAndRegulatoryMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Earn-Out Payments, Development And Regulatory Milestone Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_MaximumEarnOutPaymentsDevelopmentAndRegulatoryMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum earn-out payments for development and regulatory milestones</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MaximumEarnOutPaymentsSalesBasedMilestonePayments" xlink:label="xoma_MaximumEarnOutPaymentsSalesBasedMilestonePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_MaximumEarnOutPaymentsSalesBasedMilestonePayments" xlink:to="xoma_MaximumEarnOutPaymentsSalesBasedMilestonePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_MaximumEarnOutPaymentsSalesBasedMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum earn-out payments entity will be required to pay for sales-based milestones under arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_MaximumEarnOutPaymentsSalesBasedMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Earn-Out Payments, Sales-Based Milestone Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_MaximumEarnOutPaymentsSalesBasedMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum earn-out payments for sales-based milestones</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetNet" xlink:to="us-gaap_ContractWithCustomerAssetNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerAssetNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract with Customer, Asset, after Allowance for Credit Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerAssetNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract With Customer Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_NovartisInternationalPharmaceuticalLtdMember" xlink:label="xoma_NovartisInternationalPharmaceuticalLtdMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_NovartisInternationalPharmaceuticalLtdMember" xlink:to="xoma_NovartisInternationalPharmaceuticalLtdMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_NovartisInternationalPharmaceuticalLtdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Novartis International Pharmaceutical Ltd.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_NovartisInternationalPharmaceuticalLtdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Novartis International</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Name</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_NovartisNoteMember" xlink:label="xoma_NovartisNoteMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_NovartisNoteMember" xlink:to="xoma_NovartisNoteMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_NovartisNoteMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Secured note agreement and subsequent amendments with Novartis referred to as the "Note Agreement".</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_NovartisNoteMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Novartis Note</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Licensing and other arrangements</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AgreementTerminationPriorWrittenNoticePeriod" xlink:label="xoma_AgreementTerminationPriorWrittenNoticePeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_AgreementTerminationPriorWrittenNoticePeriod" xlink:to="xoma_AgreementTerminationPriorWrittenNoticePeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_AgreementTerminationPriorWrittenNoticePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Agreement termination prior written notice period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_AgreementTerminationPriorWrittenNoticePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Agreement Termination Prior Written Notice Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_AgreementTerminationPriorWrittenNoticePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Agreement termination prior written notice period</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_NumberOfPerformanceObligations" xlink:label="xoma_NumberOfPerformanceObligations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_NumberOfPerformanceObligations" xlink:to="xoma_NumberOfPerformanceObligations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_NumberOfPerformanceObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of performance obligations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_NumberOfPerformanceObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Performance Obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_NumberOfPerformanceObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of performance obligations</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ProceedsFromUpfrontPayment" xlink:label="xoma_ProceedsFromUpfrontPayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ProceedsFromUpfrontPayment" xlink:to="xoma_ProceedsFromUpfrontPayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ProceedsFromUpfrontPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash proceeds received under agreement. May include, but is not limited to, upfront payments, one-time payments and cash-portion of payments received.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ProceedsFromUpfrontPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds From Upfront Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ProceedsFromUpfrontPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash payment received</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones" xlink:to="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones. May also include potential payments for achievement of clinical milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Eligible Milestone Payments Receivable Upon Achievement Of Development Regulatory And Commercial Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RoyaltiesPeriodMinimum" xlink:label="xoma_RoyaltiesPeriodMinimum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_RoyaltiesPeriodMinimum" xlink:to="xoma_RoyaltiesPeriodMinimum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_RoyaltiesPeriodMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum period over which counterparty is obligated to pay royalties under terms of agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_RoyaltiesPeriodMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalties, Period, Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_RoyaltiesPeriodMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty payment period, minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xlink:label="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xlink:to="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Increase (Decrease), Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reduction in debt obligation</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_NovartisPharmaAGMember" xlink:label="xoma_NovartisPharmaAGMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_NovartisPharmaAGMember" xlink:to="xoma_NovartisPharmaAGMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_NovartisPharmaAGMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Novartis Pharma AG.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_NovartisPharmaAGMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Novartis Pharma AG</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember" xlink:label="xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember" xlink:to="xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">XOMA-052 license agreement and IL1 target license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gevokizumab License Agreement and IL-1 Target License Agreement</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_XOMA052LicenseAgreementMember" xlink:label="xoma_XOMA052LicenseAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_XOMA052LicenseAgreementMember" xlink:to="xoma_XOMA052LicenseAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_XOMA052LicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gevokizumab License Agreement with Novartis.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_XOMA052LicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gevokizumab License Agreement</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_IL1TargetLicenseAgreementMember" xlink:label="xoma_IL1TargetLicenseAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_IL1TargetLicenseAgreementMember" xlink:to="xoma_IL1TargetLicenseAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_IL1TargetLicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IL-1 target license agreement with Novartis.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_IL1TargetLicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IL-1 Target License Agreement</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LicenseAgreementTransactionPrice" xlink:label="xoma_LicenseAgreementTransactionPrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LicenseAgreementTransactionPrice" xlink:to="xoma_LicenseAgreementTransactionPrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LicenseAgreementTransactionPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License agreement transaction price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LicenseAgreementTransactionPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement Transaction Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_LicenseAgreementTransactionPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transaction price</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LicenseAgreementConsiderationReceived" xlink:label="xoma_LicenseAgreementConsiderationReceived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LicenseAgreementConsiderationReceived" xlink:to="xoma_LicenseAgreementConsiderationReceived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LicenseAgreementConsiderationReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License agreement consideration received.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LicenseAgreementConsiderationReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement Consideration Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_LicenseAgreementConsiderationReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License agreement consideration received</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LicenseAgreementConsiderationReceivedDebtRepayment" xlink:label="xoma_LicenseAgreementConsiderationReceivedDebtRepayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LicenseAgreementConsiderationReceivedDebtRepayment" xlink:to="xoma_LicenseAgreementConsiderationReceivedDebtRepayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LicenseAgreementConsiderationReceivedDebtRepayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of license agreement consideration received as repayment of debt.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LicenseAgreementConsiderationReceivedDebtRepayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement Consideration Received, Debt Repayment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_LicenseAgreementConsiderationReceivedDebtRepayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License agreement consideration received, repayment of debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Issued, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_StockIssuedDuringPeriodValueNewIssuesCommonStock" xlink:label="xoma_StockIssuedDuringPeriodValueNewIssuesCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_StockIssuedDuringPeriodValueNewIssuesCommonStock" xlink:to="xoma_StockIssuedDuringPeriodValueNewIssuesCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_StockIssuedDuringPeriodValueNewIssuesCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity impact of the value of new common stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering, net of issuance costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_StockIssuedDuringPeriodValueNewIssuesCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period Value New Issues, Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="xoma_StockIssuedDuringPeriodValueNewIssuesCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock, fair value</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_CommonStockPremium" xlink:label="xoma_CommonStockPremium" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_CommonStockPremium" xlink:to="xoma_CommonStockPremium_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_CommonStockPremium_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock premium received on sale of common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_CommonStockPremium_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Premium</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_CommonStockPremium_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock premium</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_NumberOfLicenseAgreements" xlink:label="xoma_NumberOfLicenseAgreements" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_NumberOfLicenseAgreements" xlink:to="xoma_NumberOfLicenseAgreements_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_NumberOfLicenseAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of license agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_NumberOfLicenseAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of License Agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_NumberOfLicenseAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of license agreements</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ArrangementsNumber" xlink:label="xoma_ArrangementsNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ArrangementsNumber" xlink:to="xoma_ArrangementsNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ArrangementsNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of arrangements the agreements are accounted for.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ArrangementsNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Arrangements, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ArrangementsNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of arrangements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligation" xlink:to="us-gaap_RevenueRemainingPerformanceObligation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Remaining Performance Obligation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remaining performance obligations</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_TakedaPharmaceuticalCompanyLimitedMember" xlink:label="xoma_TakedaPharmaceuticalCompanyLimitedMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_TakedaPharmaceuticalCompanyLimitedMember" xlink:to="xoma_TakedaPharmaceuticalCompanyLimitedMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_TakedaPharmaceuticalCompanyLimitedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Takeda Pharmaceutical Company Limited.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_TakedaPharmaceuticalCompanyLimitedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Takeda</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_CollaborationAgreementMember" xlink:label="xoma_CollaborationAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_CollaborationAgreementMember" xlink:to="xoma_CollaborationAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_CollaborationAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents about collaboration agreement member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_CollaborationAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product Or Service [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product and Service</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MezagitamabMember" xlink:label="xoma_MezagitamabMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_MezagitamabMember" xlink:to="xoma_MezagitamabMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_MezagitamabMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Mezagitamab antibody (TAK-079).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_MezagitamabMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">TAK-079</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_OtherAntibodiesMember" xlink:label="xoma_OtherAntibodiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_OtherAntibodiesMember" xlink:to="xoma_OtherAntibodiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_OtherAntibodiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other antibody technologies.  Excludes TAK-079 (mezagitamab).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_OtherAntibodiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other antibodies</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate" xlink:label="xoma_EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate" xlink:to="xoma_EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum eligible milestone payments receivable per discovery product candidate.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Eligible Milestone Payments Receivable Per Discovery Product Candidate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum eligible milestone payments receivable per discovery product candidate</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RoyaltiesPeriodMinimumScenarioOne" xlink:label="xoma_RoyaltiesPeriodMinimumScenarioOne" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_RoyaltiesPeriodMinimumScenarioOne" xlink:to="xoma_RoyaltiesPeriodMinimumScenarioOne_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_RoyaltiesPeriodMinimumScenarioOne_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum period over which counterparty is obligated to pay royalties under terms of agreement for scenario one, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_RoyaltiesPeriodMinimumScenarioOne_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalties Period, Minimum, Scenario One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_RoyaltiesPeriodMinimumScenarioOne_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty payment period from the first commercial sale of each royalty-bearing discovery product</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember" xlink:label="xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember" xlink:to="xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License agreement and common stock purchase agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement and Common Stock Purchase Agreement</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LicenseAgreementRz358Member" xlink:label="xoma_LicenseAgreementRz358Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LicenseAgreementRz358Member" xlink:to="xoma_LicenseAgreementRz358Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LicenseAgreementRz358Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License agreement related to activities associated with RZ358.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LicenseAgreementRz358Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement, RZ358</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LicenseAgreementNonRz358ProductsMember" xlink:label="xoma_LicenseAgreementNonRz358ProductsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LicenseAgreementNonRz358ProductsMember" xlink:to="xoma_LicenseAgreementNonRz358ProductsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LicenseAgreementNonRz358ProductsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License agreement related to activities associated with non-RZ358 products.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LicenseAgreementNonRz358ProductsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement, Non-RZ358 products</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Legal Entity [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_PercentageOfDecreaseInFutureRoyaltyObligations" xlink:label="xoma_PercentageOfDecreaseInFutureRoyaltyObligations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PercentageOfDecreaseInFutureRoyaltyObligations" xlink:to="xoma_PercentageOfDecreaseInFutureRoyaltyObligations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PercentageOfDecreaseInFutureRoyaltyObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of decrease in future royalty obligations upon certain conditions under the terms of the agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PercentageOfDecreaseInFutureRoyaltyObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage Of Decrease In Future Royalty Obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PercentageOfDecreaseInFutureRoyaltyObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of decrease in future royalty obligations</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LicenseAgreementConsiderationReceivedAchievementOfFinancingActivities" xlink:label="xoma_LicenseAgreementConsiderationReceivedAchievementOfFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LicenseAgreementConsiderationReceivedAchievementOfFinancingActivities" xlink:to="xoma_LicenseAgreementConsiderationReceivedAchievementOfFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LicenseAgreementConsiderationReceivedAchievementOfFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of payments received upon achievement of financing activities during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LicenseAgreementConsiderationReceivedAchievementOfFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement Consideration Received, Achievement of Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_LicenseAgreementConsiderationReceivedAchievementOfFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments received upon achievement of financing activities</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LicenseAgreementInstallmentPaymentsReceived" xlink:label="xoma_LicenseAgreementInstallmentPaymentsReceived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LicenseAgreementInstallmentPaymentsReceived" xlink:to="xoma_LicenseAgreementInstallmentPaymentsReceived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LicenseAgreementInstallmentPaymentsReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of installment payments received during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LicenseAgreementInstallmentPaymentsReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement, Installment Payments Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_LicenseAgreementInstallmentPaymentsReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Installment payments received</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LicenseAgreementSharesReceived" xlink:label="xoma_LicenseAgreementSharesReceived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LicenseAgreementSharesReceived" xlink:to="xoma_LicenseAgreementSharesReceived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LicenseAgreementSharesReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of counterparty's common stock entity received under the terms of the agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LicenseAgreementSharesReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Agreement, Shares Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_LicenseAgreementSharesReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares received</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Note, Stock Split, Conversion Ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reverse stock split</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_JanssenBiotechInc.Member" xlink:label="xoma_JanssenBiotechInc.Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_JanssenBiotechInc.Member" xlink:to="xoma_JanssenBiotechInc.Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_JanssenBiotechInc.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Janssen Biotech, Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_JanssenBiotechInc.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Janssen Biotech Inc.</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MilestoneDosingFirstPatientInClinicalTrialMember" xlink:label="xoma_MilestoneDosingFirstPatientInClinicalTrialMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_MilestoneDosingFirstPatientInClinicalTrialMember" xlink:to="xoma_MilestoneDosingFirstPatientInClinicalTrialMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_MilestoneDosingFirstPatientInClinicalTrialMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dosing of first patient in a Phase 3 clinical trial evaluating biologic assets representing milestone achieved.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_MilestoneDosingFirstPatientInClinicalTrialMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dosing of first patient in a Phase 3 clinical trial</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MilestonePursuantToAgreementMember" xlink:label="xoma_MilestonePursuantToAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_MilestonePursuantToAgreementMember" xlink:to="xoma_MilestonePursuantToAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_MilestonePursuantToAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents milestone achieved pursuant to agreement not otherwise specified.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_MilestonePursuantToAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone achieved pursuant to agreement</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents" xlink:label="xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents" xlink:to="xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum amount receivable milestone payments upon achievement of certain clinical development and regulatory approval events.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Amount Receivable Milestone Payments Upon Achievement Of Certain Clinical Development And Regulatory Approval Events</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum amount receivable milestone payments upon achievement of certain clinical development and regulatory approval events</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_PercentageOfRoyaltyOnNetSalesUponCommercialization" xlink:label="xoma_PercentageOfRoyaltyOnNetSalesUponCommercialization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PercentageOfRoyaltyOnNetSalesUponCommercialization" xlink:to="xoma_PercentageOfRoyaltyOnNetSalesUponCommercialization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PercentageOfRoyaltyOnNetSalesUponCommercialization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of royalty on net sales upon commercialization.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PercentageOfRoyaltyOnNetSalesUponCommercialization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage Of Royalty On Net Sales Upon Commercialization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PercentageOfRoyaltyOnNetSalesUponCommercialization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of royalty on worldwide net sales of each product upon commercialization</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_NumberOfMilestonesEarned" xlink:label="xoma_NumberOfMilestonesEarned" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_NumberOfMilestonesEarned" xlink:to="xoma_NumberOfMilestonesEarned_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_NumberOfMilestonesEarned_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of milestones earned during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_NumberOfMilestonesEarned_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Milestones Earned</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_NumberOfMilestonesEarned_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of milestones earned during the period</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AffimedMember" xlink:label="xoma_AffimedMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_AffimedMember" xlink:to="xoma_AffimedMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_AffimedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Affimed</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_AffimedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Affimed</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember" xlink:label="xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember" xlink:to="xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">HealthCare Royalty Partners II, L.P (HCRP).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">HealthCare Royalty Partners II, L.P</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RoyaltyInterestAcquisitionAgreementsMember" xlink:label="xoma_RoyaltyInterestAcquisitionAgreementsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_RoyaltyInterestAcquisitionAgreementsMember" xlink:to="xoma_RoyaltyInterestAcquisitionAgreementsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_RoyaltyInterestAcquisitionAgreementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty Interest Acquisition Agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_RoyaltyInterestAcquisitionAgreementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty Sale Agreements</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_FirstRoyaltyInterestAcquisitionAgreementMember" xlink:label="xoma_FirstRoyaltyInterestAcquisitionAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_FirstRoyaltyInterestAcquisitionAgreementMember" xlink:to="xoma_FirstRoyaltyInterestAcquisitionAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_FirstRoyaltyInterestAcquisitionAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">First Royalty Interest Acquisition Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_FirstRoyaltyInterestAcquisitionAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">First Royalty Sale Agreement</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_SecondRoyaltyInterestAcquisitionAgreementMember" xlink:label="xoma_SecondRoyaltyInterestAcquisitionAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_SecondRoyaltyInterestAcquisitionAgreementMember" xlink:to="xoma_SecondRoyaltyInterestAcquisitionAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_SecondRoyaltyInterestAcquisitionAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Second Royalty Interest Acquisition Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_SecondRoyaltyInterestAcquisitionAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Second Royalty Sale Agreement</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_NumberOfRoyaltyInterestAcquisitionAgreements" xlink:label="xoma_NumberOfRoyaltyInterestAcquisitionAgreements" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_NumberOfRoyaltyInterestAcquisitionAgreements" xlink:to="xoma_NumberOfRoyaltyInterestAcquisitionAgreements_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_NumberOfRoyaltyInterestAcquisitionAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of royalty interest acquisition agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_NumberOfRoyaltyInterestAcquisitionAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Royalty Interest Acquisition Agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_NumberOfRoyaltyInterestAcquisitionAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of agreements</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones" xlink:label="xoma_EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones" xlink:to="xoma_EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Eligible potential additional payments receivable upon achievement of specified future net sales milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Eligible Potential Additional Payments Receivable Upon Achievement Of Specified Future Net Sales Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Eligible potential additional payments receivable upon achievement of specified net sales milestones in future years</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MilestonePeriodsNumber" xlink:label="xoma_MilestonePeriodsNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_MilestonePeriodsNumber" xlink:to="xoma_MilestonePeriodsNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_MilestonePeriodsNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of milestone periods for which entity is eligible to receive payments upon achievement of milestone.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_MilestonePeriodsNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone Periods, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_MilestonePeriodsNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of milestone periods</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AgenusIncMember" xlink:label="xoma_AgenusIncMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_AgenusIncMember" xlink:to="xoma_AgenusIncMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_AgenusIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Agenus Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_AgenusIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Agenus</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_BioasisTechnologiesIncMember" xlink:label="xoma_BioasisTechnologiesIncMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_BioasisTechnologiesIncMember" xlink:to="xoma_BioasisTechnologiesIncMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_BioasisTechnologiesIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bioasis Technologies Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_BioasisTechnologiesIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bioasis</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_BioasisTechnologiesIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bioasis</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AronoraIncMember" xlink:label="xoma_AronoraIncMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_AronoraIncMember" xlink:to="xoma_AronoraIncMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_AronoraIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aronora, Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_AronoraIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aronora</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_AronoraIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aronora [Member]</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_PalobiofarmaSLMember" xlink:label="xoma_PalobiofarmaSLMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PalobiofarmaSLMember" xlink:to="xoma_PalobiofarmaSLMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PalobiofarmaSLMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Palobiofarma, S.L.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PalobiofarmaSLMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Palo</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PalobiofarmaSLMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Palo</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ViractaTherapeuticsInc.Member" xlink:label="xoma_ViractaTherapeuticsInc.Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ViractaTherapeuticsInc.Member" xlink:to="xoma_ViractaTherapeuticsInc.Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ViractaTherapeuticsInc.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Viracta Therapeutics, Inc. ("Viracta").</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ViractaTherapeuticsInc.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Viracta</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember" xlink:label="xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember" xlink:to="xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Kuros Biosciences AG, Kuros US LLC and Kuros Royalty Fund (US) LLC.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Kuros</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Kuros [Member]</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AffitechResearchAsMember" xlink:label="xoma_AffitechResearchAsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_AffitechResearchAsMember" xlink:to="xoma_AffitechResearchAsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_AffitechResearchAsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Affitech Research AS, a Norwegian biotech company.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_AffitechResearchAsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Affitech</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LadrxMember" xlink:label="xoma_LadrxMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LadrxMember" xlink:to="xoma_LadrxMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LadrxMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to LadRx.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LadrxMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">LadRx</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember" xlink:label="xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember" xlink:to="xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assignment and Assumption Agreement and Royalty Purchase Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assignment and Assumption Agreement and Royalty Purchase Agreement</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AssignmentAndAssumptionAgreementMember" xlink:label="xoma_AssignmentAndAssumptionAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_AssignmentAndAssumptionAgreementMember" xlink:to="xoma_AssignmentAndAssumptionAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_AssignmentAndAssumptionAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assignment and Assumption Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_AssignmentAndAssumptionAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assignment and Assumption Agreement</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RoyaltyPurchaseAgreementMember" xlink:label="xoma_RoyaltyPurchaseAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_RoyaltyPurchaseAgreementMember" xlink:to="xoma_RoyaltyPurchaseAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_RoyaltyPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty purchase agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_RoyaltyPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty Purchase Agreement</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ArimoclomolMember" xlink:label="xoma_ArimoclomolMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ArimoclomolMember" xlink:to="xoma_ArimoclomolMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ArimoclomolMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Arimoclomol.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ArimoclomolMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Arimoclomol</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AldoxorubicinMember" xlink:label="xoma_AldoxorubicinMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_AldoxorubicinMember" xlink:to="xoma_AldoxorubicinMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_AldoxorubicinMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aldoxorubicin.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_AldoxorubicinMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aldoxorubicin</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContingentConsiderationByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent Consideration by Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="us-gaap_ContingentConsiderationTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContingentConsiderationTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent Consideration Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ContingentConsiderationRegulatoryMilestonesMember" xlink:label="xoma_ContingentConsiderationRegulatoryMilestonesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ContingentConsiderationRegulatoryMilestonesMember" xlink:to="xoma_ContingentConsiderationRegulatoryMilestonesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ContingentConsiderationRegulatoryMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent consideration under purchase agreements related to regulatory milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ContingentConsiderationRegulatoryMilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Regulatory milestones</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndCommercialMilestonesNet" xlink:label="xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndCommercialMilestonesNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndCommercialMilestonesNet" xlink:to="xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndCommercialMilestonesNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndCommercialMilestonesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum payments to be made based upon achievement of commercial sales and/or regulatory milestones, net of payment obligations based on a portion of regulatory and commercial milestone payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndCommercialMilestonesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Payments Based On Achievement Of Regulatory and Commercial Milestones, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndCommercialMilestonesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum regulatory and commercial milestone payments, net</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MaximumPaymentObligationsBasedOnPortionOfRegulatoryAndCommercialPayments" xlink:label="xoma_MaximumPaymentObligationsBasedOnPortionOfRegulatoryAndCommercialPayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_MaximumPaymentObligationsBasedOnPortionOfRegulatoryAndCommercialPayments" xlink:to="xoma_MaximumPaymentObligationsBasedOnPortionOfRegulatoryAndCommercialPayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_MaximumPaymentObligationsBasedOnPortionOfRegulatoryAndCommercialPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum payment obligations based on a portion of regulatory and commercial milestone payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_MaximumPaymentObligationsBasedOnPortionOfRegulatoryAndCommercialPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Payment Obligations Based On A Portion of Regulatory and Commercial Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_MaximumPaymentObligationsBasedOnPortionOfRegulatoryAndCommercialPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum payment obligations based on a portion of regulatory and commercial milestone payments</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MaximumRegulatoryAndCommercialMilestones" xlink:label="xoma_MaximumRegulatoryAndCommercialMilestones" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_MaximumRegulatoryAndCommercialMilestones" xlink:to="xoma_MaximumRegulatoryAndCommercialMilestones_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_MaximumRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum regulatory and commercial milestones under the agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_MaximumRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Regulatory and Commercial Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_MaximumRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum regulatory and commercial milestones</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndSalesMilestones" xlink:label="xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndSalesMilestones" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndSalesMilestones" xlink:to="xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndSalesMilestones_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndSalesMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum  payments to be made based upon achievement of sales and/or regulatory milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndSalesMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Payments Based On Achievement Of Regulatory and Sales Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndSalesMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum payments based on achievement of regulatory and commercial sales milestones</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MaximumPayableOnRegulatoryMilestone" xlink:label="xoma_MaximumPayableOnRegulatoryMilestone" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_MaximumPayableOnRegulatoryMilestone" xlink:to="xoma_MaximumPayableOnRegulatoryMilestone_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_MaximumPayableOnRegulatoryMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum amount payable on regulatory milestone.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_MaximumPayableOnRegulatoryMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Payable on Regulatory Milestone</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_MaximumPayableOnRegulatoryMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum payable on regulatory milestone</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MaximumPayableOnSalesMilestone" xlink:label="xoma_MaximumPayableOnSalesMilestone" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_MaximumPayableOnSalesMilestone" xlink:to="xoma_MaximumPayableOnSalesMilestone_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_MaximumPayableOnSalesMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum amount payable on sales milestone.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_MaximumPayableOnSalesMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Payable on Sales Milestone</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_MaximumPayableOnSalesMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum payable on commercial sales milestone</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" xlink:label="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" xlink:to="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract with Customer, Asset, Allowance for Credit Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of allowance for credit losses</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AptevoMember" xlink:label="xoma_AptevoMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_AptevoMember" xlink:to="xoma_AptevoMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_AptevoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information pertaining to Aptevo.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_AptevoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aptevo</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MedexusMember" xlink:label="xoma_MedexusMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_MedexusMember" xlink:to="xoma_MedexusMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_MedexusMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information pertaining to Medexus. The Company acquired from Aptevo a portion of its milestone and commercial payment rights under a sale agreement dated February 28, 2020 between Aptevo and Medexus, related to IXINITY.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_MedexusMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Medexus</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_CommercialPaymentPurchaseAgreementMember" xlink:label="xoma_CommercialPaymentPurchaseAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_CommercialPaymentPurchaseAgreementMember" xlink:to="xoma_CommercialPaymentPurchaseAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_CommercialPaymentPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial payment purchase agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_CommercialPaymentPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial Payment Purchase Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MilestonesReceivableMaximum" xlink:label="xoma_MilestonesReceivableMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_MilestonesReceivableMaximum" xlink:to="xoma_MilestonesReceivableMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_MilestonesReceivableMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum amount of potential milestones receivable under the terms of the agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_MilestonesReceivableMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestones Receivable, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_MilestonesReceivableMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum milestone payments entitled to receive</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_CommercialPaymentThresholdOneTimePayment" xlink:label="xoma_CommercialPaymentThresholdOneTimePayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_CommercialPaymentThresholdOneTimePayment" xlink:to="xoma_CommercialPaymentThresholdOneTimePayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_CommercialPaymentThresholdOneTimePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the threshold for receipt of commercial payments attributable to net sales for which the entity will be required to make a one-time payment under agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_CommercialPaymentThresholdOneTimePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial Payment Threshold, One-Time Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_CommercialPaymentThresholdOneTimePayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial payments attributable to net sales threshold</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" xlink:label="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" xlink:to="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease in long-term rights receivable due to receipt of royalty and commercial payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receipt of Royalty and Commercial Payment Receivable Non Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receipt of royalty and commercial payments, Long-Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reduction in long-term royalty receivable balance due to receipt of payment</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_IncyteImmunoOncologyAssetsMember" xlink:label="xoma_IncyteImmunoOncologyAssetsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_IncyteImmunoOncologyAssetsMember" xlink:to="xoma_IncyteImmunoOncologyAssetsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_IncyteImmunoOncologyAssetsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Incyte immuno-oncology assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_IncyteImmunoOncologyAssetsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Incyte Immuno-Oncology Assets</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MerckImmunoOncologyProductMember" xlink:label="xoma_MerckImmunoOncologyProductMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_MerckImmunoOncologyProductMember" xlink:to="xoma_MerckImmunoOncologyProductMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_MerckImmunoOncologyProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Merck immuno-oncology product.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_MerckImmunoOncologyProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Merck Immuno-Oncology Product</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_SiliconValleyBankMember" xlink:label="xoma_SiliconValleyBankMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_SiliconValleyBankMember" xlink:to="xoma_SiliconValleyBankMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_SiliconValleyBankMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Silicon Valley Bank credit facility effective May 7, 2018 and subsequent amendments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_SiliconValleyBankMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SVB Loan</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RoyaltyReceivablePercentageOnNetSales" xlink:label="xoma_RoyaltyReceivablePercentageOnNetSales" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_RoyaltyReceivablePercentageOnNetSales" xlink:to="xoma_RoyaltyReceivablePercentageOnNetSales_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_RoyaltyReceivablePercentageOnNetSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalties entity has the right to receive as a percentage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_RoyaltyReceivablePercentageOnNetSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty Receivable Percentage On Net Sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_RoyaltyReceivablePercentageOnNetSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalties entity has right to receive (as a percent)</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased" xlink:label="xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased" xlink:to="xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of licensed products related to milestones and royalties purchased.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Licensed Products Related To Milestones And Royalties Purchased</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of licensed products related to milestone and royalties</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_PurchasedPercentageOfMilestones" xlink:label="xoma_PurchasedPercentageOfMilestones" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PurchasedPercentageOfMilestones" xlink:to="xoma_PurchasedPercentageOfMilestones_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PurchasedPercentageOfMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchased percentage of milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PurchasedPercentageOfMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchased Percentage Of Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PurchasedPercentageOfMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchased percentage of milestones</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones" xlink:label="xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones" xlink:to="xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchased eligible milestone payments receivable upon achievement of potential development, regulatory and commercial milestones. May also include clinical milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchased Eligible Milestone Payments Receivable Upon Achievement Of Potential Development Regulatory And Commercial Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchased eligible milestone payments receivable upon achievement of potential development, regulatory and commercial milestones</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MilestoneAchieved" xlink:label="xoma_MilestoneAchieved" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_MilestoneAchieved" xlink:to="xoma_MilestoneAchieved_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_MilestoneAchieved_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of milestone achieved.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_MilestoneAchieved_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone Achieved</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_MilestoneAchieved_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of milestone achieved</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RoyaltyPurchaseAgreementAndSecondRoyaltyPurchaseAgreementMember" xlink:label="xoma_RoyaltyPurchaseAgreementAndSecondRoyaltyPurchaseAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_RoyaltyPurchaseAgreementAndSecondRoyaltyPurchaseAgreementMember" xlink:to="xoma_RoyaltyPurchaseAgreementAndSecondRoyaltyPurchaseAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_RoyaltyPurchaseAgreementAndSecondRoyaltyPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty purchase agreement  and second royalty purchase agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_RoyaltyPurchaseAgreementAndSecondRoyaltyPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty Purchase Agreement and Second Royalty Purchase Agreement</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RoyaltyPurchaseAgreementTwoMember" xlink:label="xoma_RoyaltyPurchaseAgreementTwoMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_RoyaltyPurchaseAgreementTwoMember" xlink:to="xoma_RoyaltyPurchaseAgreementTwoMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_RoyaltyPurchaseAgreementTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">A second royalty purchase agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_RoyaltyPurchaseAgreementTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Second Royalty Purchase Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements" xlink:label="xoma_PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements" xlink:to="xoma_PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of royalty rights entity has option to  purchase in future license agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage Of Optional Royalty Rights Purchase On Future License Agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of option to purchase royalty right on future license agreements</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_NumberOfLicenseAgreementsFutureLicenseAgreements" xlink:label="xoma_NumberOfLicenseAgreementsFutureLicenseAgreements" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_NumberOfLicenseAgreementsFutureLicenseAgreements" xlink:to="xoma_NumberOfLicenseAgreementsFutureLicenseAgreements_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_NumberOfLicenseAgreementsFutureLicenseAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of future license agreements under optional purchase right.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_NumberOfLicenseAgreementsFutureLicenseAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of License Agreements, Future License Agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_NumberOfLicenseAgreementsFutureLicenseAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of future license agreements under optional purchase right</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_PaymentsToBeMadeUponExerciseOfOptionSecondLicenseAgreement" xlink:label="xoma_PaymentsToBeMadeUponExerciseOfOptionSecondLicenseAgreement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PaymentsToBeMadeUponExerciseOfOptionSecondLicenseAgreement" xlink:to="xoma_PaymentsToBeMadeUponExerciseOfOptionSecondLicenseAgreement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PaymentsToBeMadeUponExerciseOfOptionSecondLicenseAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum payment to be made per licensed product upon exercise of option to purchase royalty rights on second license agreement between counterparty and third-party licensees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PaymentsToBeMadeUponExerciseOfOptionSecondLicenseAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments To Be Made Upon Exercise Of Option, Second License Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PaymentsToBeMadeUponExerciseOfOptionSecondLicenseAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Obligation upon exercise of options per licensed product, second agreement</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_PaymentsToBeMadeUponExerciseOfOptionThirdLicenseAgreement" xlink:label="xoma_PaymentsToBeMadeUponExerciseOfOptionThirdLicenseAgreement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PaymentsToBeMadeUponExerciseOfOptionThirdLicenseAgreement" xlink:to="xoma_PaymentsToBeMadeUponExerciseOfOptionThirdLicenseAgreement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PaymentsToBeMadeUponExerciseOfOptionThirdLicenseAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum payment to be made per licensed product upon exercise of option to purchase royalty rights on third license agreement between counterparty and third-party licensees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PaymentsToBeMadeUponExerciseOfOptionThirdLicenseAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments To Be Made Upon Exercise Of Option, Third License Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PaymentsToBeMadeUponExerciseOfOptionThirdLicenseAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Obligation upon exercise of options per licensed product, third agreement</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ContingentFutureCashPayments" xlink:label="xoma_ContingentFutureCashPayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ContingentFutureCashPayments" xlink:to="xoma_ContingentFutureCashPayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ContingentFutureCashPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent future cash payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ContingentFutureCashPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent Future Cash Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ContingentFutureCashPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Potential future cash payments</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LongTermRightsReceivableNonCurrentIncreaseDecrease" xlink:label="xoma_LongTermRightsReceivableNonCurrentIncreaseDecrease" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LongTermRightsReceivableNonCurrentIncreaseDecrease" xlink:to="xoma_LongTermRightsReceivableNonCurrentIncreaseDecrease_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LongTermRightsReceivableNonCurrentIncreaseDecrease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) in long-term royalty and commercial rights receivables, non current during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LongTermRightsReceivableNonCurrentIncreaseDecrease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long Term Rights Receivable, Non-Current, Increase (Decrease)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_LongTermRightsReceivableNonCurrentIncreaseDecrease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reduction in long-term royalty receivables</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_BayerProductsMember" xlink:label="xoma_BayerProductsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_BayerProductsMember" xlink:to="xoma_BayerProductsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_BayerProductsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bayer products.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_BayerProductsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bayer Products</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_NonBayerProductsMember" xlink:label="xoma_NonBayerProductsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_NonBayerProductsMember" xlink:to="xoma_NonBayerProductsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_NonBayerProductsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-bayer products.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_NonBayerProductsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-Bayer Products</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AgreementDrugCandidatesNumber" xlink:label="xoma_AgreementDrugCandidatesNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_AgreementDrugCandidatesNumber" xlink:to="xoma_AgreementDrugCandidatesNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_AgreementDrugCandidatesNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of drug candidates under the terms of the agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_AgreementDrugCandidatesNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Agreement, Drug Candidates, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_AgreementDrugCandidatesNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of drug candidates</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AgreementDrugCandidatesExclusiveLicenseOptionNumber" xlink:label="xoma_AgreementDrugCandidatesExclusiveLicenseOptionNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_AgreementDrugCandidatesExclusiveLicenseOptionNumber" xlink:to="xoma_AgreementDrugCandidatesExclusiveLicenseOptionNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_AgreementDrugCandidatesExclusiveLicenseOptionNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of drug candidates subject to exclusive license option.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_AgreementDrugCandidatesExclusiveLicenseOptionNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Agreement, Drug Candidates, Exclusive License Option, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_AgreementDrugCandidatesExclusiveLicenseOptionNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of drug candidates subject to exclusive license option</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts" xlink:label="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts" xlink:to="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchased percentage of non-royalties on net sales of products.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchased Percentage Of Non Royalties On Net Sales Of Products</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-royalties to be received (as a percent)</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage" xlink:label="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage" xlink:to="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Future non-royalty payments to be received as a percent upon receipt of specified cumulative amount of consideration paid.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchased Percentage Of Non Royalties On Net Sales Of Products, Future Payment Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Future non-royalty payments to be received (as a percent)</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AgreementPaymentPercentageFactor" xlink:label="xoma_AgreementPaymentPercentageFactor" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_AgreementPaymentPercentageFactor" xlink:to="xoma_AgreementPaymentPercentageFactor_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_AgreementPaymentPercentageFactor_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Multiplier used in determining change in payment percentage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_AgreementPaymentPercentageFactor_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Agreement, Payment Percentage, Factor</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_AgreementPaymentPercentageFactor_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Multiplier for cumulative amount of consideration paid</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ContingentFutureCashPaymentsPerProduct" xlink:label="xoma_ContingentFutureCashPaymentsPerProduct" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ContingentFutureCashPaymentsPerProduct" xlink:to="xoma_ContingentFutureCashPaymentsPerProduct_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ContingentFutureCashPaymentsPerProduct_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of contingent future cash payment for each product.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ContingentFutureCashPaymentsPerProduct_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent Future Cash Payments, Per Product</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ContingentFutureCashPaymentsPerProduct_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent future cash payment for each product</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount" xlink:label="xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount" xlink:to="xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold amount of cumulative royalties on net sales per product under the terms of the agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cumulative Royalties On Net Sales Per Product, Threshold Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold amount of cumulative royalties on net sales per product</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MilestonesPaymentsToAggregateAmountOfPerProduct" xlink:label="xoma_MilestonesPaymentsToAggregateAmountOfPerProduct" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_MilestonesPaymentsToAggregateAmountOfPerProduct" xlink:to="xoma_MilestonesPaymentsToAggregateAmountOfPerProduct_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_MilestonesPaymentsToAggregateAmountOfPerProduct_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum amount of aggregate tiered milestone payments to be made under the terms of the agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_MilestonesPaymentsToAggregateAmountOfPerProduct_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestones Payments To Aggregate Amount Of Per Product</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_MilestonesPaymentsToAggregateAmountOfPerProduct_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate milestones payments per product</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MilestonesReceivableExcludingConsiderationRetainedMaximum" xlink:label="xoma_MilestonesReceivableExcludingConsiderationRetainedMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_MilestonesReceivableExcludingConsiderationRetainedMaximum" xlink:to="xoma_MilestonesReceivableExcludingConsiderationRetainedMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_MilestonesReceivableExcludingConsiderationRetainedMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum amount of potential milestones and other payments receivable, excluding consideration retained by company under the terms of the agreement.  Excludes regulatory and commercial milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_MilestonesReceivableExcludingConsiderationRetainedMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestones Receivable, Excluding Consideration Retained, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_MilestonesReceivableExcludingConsiderationRetainedMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum amount of potential milestones and other payments receivable</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MaximumConsiderationRetained" xlink:label="xoma_MaximumConsiderationRetained" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_MaximumConsiderationRetained" xlink:to="xoma_MaximumConsiderationRetained_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_MaximumConsiderationRetained_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of maximum consideration retained by Company excluded from maximum potential milestones under terms of agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_MaximumConsiderationRetained_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Consideration Retained</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_MaximumConsiderationRetained_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of maximum consideration retained</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RegulatoryAndCommercialMilestonesReceivableMaximum" xlink:label="xoma_RegulatoryAndCommercialMilestonesReceivableMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_RegulatoryAndCommercialMilestonesReceivableMaximum" xlink:to="xoma_RegulatoryAndCommercialMilestonesReceivableMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_RegulatoryAndCommercialMilestonesReceivableMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum amount of potential regulatory and commercial milestones receivable under the terms of the agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_RegulatoryAndCommercialMilestonesReceivableMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Regulatory and Commercial Milestones Receivable, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_RegulatoryAndCommercialMilestonesReceivableMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum amount of potential regulatory and commercial milestones receivable</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_EligibleMilestonePaymentsReceivableUponAchievementOfPreCommercialMilestones" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfPreCommercialMilestones" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfPreCommercialMilestones" xlink:to="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfPreCommercialMilestones_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfPreCommercialMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum eligible milestone payments receivable upon achievement of development, pre-commercial milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfPreCommercialMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Eligible Milestone Payments Receivable Upon Achievement Of Pre-Commercial Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfPreCommercialMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commercial milestone payments, maximum</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MilestonePaymentReceivedCounterparty" xlink:label="xoma_MilestonePaymentReceivedCounterparty" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_MilestonePaymentReceivedCounterparty" xlink:to="xoma_MilestonePaymentReceivedCounterparty_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_MilestonePaymentReceivedCounterparty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of milestone payment received by counterparty associated with existing license agreement related to acquired entity during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_MilestonePaymentReceivedCounterparty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone Payment Received, Counterparty</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_MilestonePaymentReceivedCounterparty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone payment received by Kuros</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MilestonePaymentReceivablePercentage" xlink:label="xoma_MilestonePaymentReceivablePercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_MilestonePaymentReceivablePercentage" xlink:to="xoma_MilestonePaymentReceivablePercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_MilestonePaymentReceivablePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of milestone payment received by counterparty entity is entitled to receive.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_MilestonePaymentReceivablePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone Payment Receivable, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_MilestonePaymentReceivablePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of milestone payment received by Kuros that company is entitled to receive</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_FaricimabProductMember" xlink:label="xoma_FaricimabProductMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_FaricimabProductMember" xlink:to="xoma_FaricimabProductMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_FaricimabProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Faricimab products.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_FaricimabProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Faricimab</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_FaricimabSvoaVabysmoProductMember" xlink:label="xoma_FaricimabSvoaVabysmoProductMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_FaricimabSvoaVabysmoProductMember" xlink:to="xoma_FaricimabSvoaVabysmoProductMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_FaricimabSvoaVabysmoProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Faricimab-svoa, (VABYSMO) products.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_FaricimabSvoaVabysmoProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">VABYSMO</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement Geographical [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Geographical</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="country_US" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">United States</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EuropeMember" xlink:label="srt_EuropeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EuropeMember" xlink:to="srt_EuropeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_EuropeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Europe</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement Scenario [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario, Unspecified</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioForecastMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forecast</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_CommercialSalesReceivablePercentageOnNetSales" xlink:label="xoma_CommercialSalesReceivablePercentageOnNetSales" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_CommercialSalesReceivablePercentageOnNetSales" xlink:to="xoma_CommercialSalesReceivablePercentageOnNetSales_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_CommercialSalesReceivablePercentageOnNetSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments entity eligible to receive as a percentage of net sales.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_CommercialSalesReceivablePercentageOnNetSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial Sales, Receivable Percentage On Net Sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_CommercialSalesReceivablePercentageOnNetSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments eligible to receive (as a percent)</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_CommercialPaymentReceivableTerm" xlink:label="xoma_CommercialPaymentReceivableTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_CommercialPaymentReceivableTerm" xlink:to="xoma_CommercialPaymentReceivableTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_CommercialPaymentReceivableTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of commercial payment receivable,  in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_CommercialPaymentReceivableTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial Payment Receivable Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_CommercialPaymentReceivableTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial payment receivable term</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableCurrent" xlink:label="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableCurrent" xlink:to="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease in short-term rights receivable due to receipt of current portion of royalty and commercial payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receipt of Royalty and Commercial Payment Receivable Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receipt of royalty and commercial payments, Short-Term</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent" xlink:label="xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent" xlink:to="xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty, interest and commercial payment rights acquired, classified as noncurrent.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty And Commercial Rights Acquired, Non-Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquisition of royalty and commercial payment rights, Long-Term</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ShortTermRightsReceivableReclassification" xlink:label="xoma_ShortTermRightsReceivableReclassification" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ShortTermRightsReceivableReclassification" xlink:to="xoma_ShortTermRightsReceivableReclassification_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ShortTermRightsReceivableReclassification_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) in short term rights receivable due to reclassification from/to long-term rights receivable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ShortTermRightsReceivableReclassification_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short Term Rights Receivable, Reclassification</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ShortTermRightsReceivableReclassification_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reclassification to short-term royalty and commercial payment receivables, Short-Term</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LongTermRightsReceivableReclassification" xlink:label="xoma_LongTermRightsReceivableReclassification" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LongTermRightsReceivableReclassification" xlink:to="xoma_LongTermRightsReceivableReclassification_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LongTermRightsReceivableReclassification_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) in long term rights receivable due to reclassification from/to short-term rights receivable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LongTermRightsReceivableReclassification_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long Term Rights Receivable, Reclassification</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_LongTermRightsReceivableReclassification_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reclassification to short-term royalty and commercial payment receivables, Long-Term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value By Measurement Frequency [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement Frequency</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Recurring</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value By Fair Value Hierarchy Level [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Quoted Prices in Active Markets for Identical Assets (Level 1)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Unobservable Inputs (Level 3)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash And Cash Equivalents [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Money market funds</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets Fair Value Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash And Cash Equivalents Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsFairValueDisclosure" xlink:to="us-gaap_InvestmentsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investments Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity securities</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_FinancialAssetsFairValueDisclosure" xlink:label="xoma_FinancialAssetsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_FinancialAssetsFairValueDisclosure" xlink:to="xoma_FinancialAssetsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_FinancialAssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of financial assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_FinancialAssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Assets, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="xoma_FinancialAssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total financial assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities Fair Value Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities:</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ContingentConsiderationFairValueDisclosure" xlink:label="xoma_ContingentConsiderationFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ContingentConsiderationFairValueDisclosure" xlink:to="xoma_ContingentConsiderationFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ContingentConsiderationFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent consideration, fair value disclosure.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ContingentConsiderationFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent Consideration Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ContingentConsiderationFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent consideration under RPAs and CPPAs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputSharePriceMember" xlink:to="us-gaap_MeasurementInputSharePriceMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Closing Common Stock Price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiMeasurementInput" xlink:label="us-gaap_EquitySecuritiesFvNiMeasurementInput" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNiMeasurementInput" xlink:to="us-gaap_EquitySecuritiesFvNiMeasurementInput_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquitySecuritiesFvNiMeasurementInput_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Securities Fv Ni Measurement Input</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquitySecuritiesFvNiMeasurementInput_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation assumptions, measurement input</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Description [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Lived Tangible Asset [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Lived Tangible Asset [Domain]</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LeasedFacilitiesEmeryvilleCaliforniaMember" xlink:label="xoma_LeasedFacilitiesEmeryvilleCaliforniaMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LeasedFacilitiesEmeryvilleCaliforniaMember" xlink:to="xoma_LeasedFacilitiesEmeryvilleCaliforniaMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LeasedFacilitiesEmeryvilleCaliforniaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leased facilities in Emeryville, California.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LeasedFacilitiesEmeryvilleCaliforniaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leased facilities, Emeryville, California, current location</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LeasedFacilitiesTwoEmeryvilleCaliforniaMember" xlink:label="xoma_LeasedFacilitiesTwoEmeryvilleCaliforniaMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LeasedFacilitiesTwoEmeryvilleCaliforniaMember" xlink:to="xoma_LeasedFacilitiesTwoEmeryvilleCaliforniaMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LeasedFacilitiesTwoEmeryvilleCaliforniaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leased facilities in Emeryville, California, in different location than previous lease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LeasedFacilitiesTwoEmeryvilleCaliforniaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leased facilities, Emeryville, California, future location</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Description [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_OperatingLeasesNumberOfLeasedFacilities" xlink:label="xoma_OperatingLeasesNumberOfLeasedFacilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_OperatingLeasesNumberOfLeasedFacilities" xlink:to="xoma_OperatingLeasesNumberOfLeasedFacilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_OperatingLeasesNumberOfLeasedFacilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating leases, number of leased facilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_OperatingLeasesNumberOfLeasedFacilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases Number Of Leased Facilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_OperatingLeasesNumberOfLeasedFacilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating leases, number of leased facilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Renewal Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period of lease extension</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LesseeOperatingLeaseModificationAdjustmentToRightOfUseAsset" xlink:label="xoma_LesseeOperatingLeaseModificationAdjustmentToRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_LesseeOperatingLeaseModificationAdjustmentToRightOfUseAsset" xlink:to="xoma_LesseeOperatingLeaseModificationAdjustmentToRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_LesseeOperatingLeaseModificationAdjustmentToRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of adjustment to right of use asset resulting from modification of operating lease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_LesseeOperatingLeaseModificationAdjustmentToRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease Modification, Adjustment to Right Of Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_LesseeOperatingLeaseModificationAdjustmentToRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustment to right of use asset for lease modification</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Term of Contract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee Operating Lease Liability Payments Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total undiscounted lease payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, Cost [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Variable Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_VariableLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Variable lease cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total lease costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash paid for amounts included in the measurement of lease liabilities, Operating cash flows under operating leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease Weighted Average Remaining Lease Term1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average remaining lease term, Operating leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease Weighted Average Discount Rate Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average discount rate, Operating leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class Of Warrant Or Right [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class Of Warrant Or Right [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_TenYearWarrantsIssuedThirdRangeMember" xlink:label="xoma_TenYearWarrantsIssuedThirdRangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_TenYearWarrantsIssuedThirdRangeMember" xlink:to="xoma_TenYearWarrantsIssuedThirdRangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_TenYearWarrantsIssuedThirdRangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock warrant with exercise price of $23.69 per share and a ten year term. Issued in May 2018.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_TenYearWarrantsIssuedThirdRangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ten Year Warrants Issued in May 2018</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_CommonStockWarrantExercisePrice14.71Member" xlink:label="xoma_CommonStockWarrantExercisePrice14.71Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_CommonStockWarrantExercisePrice14.71Member" xlink:to="xoma_CommonStockWarrantExercisePrice14.71Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_CommonStockWarrantExercisePrice14.71Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock warrant with exercise price of $14.71 per share.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_CommonStockWarrantExercisePrice14.71Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock warrant, Exercise price $14.71 per share, Issued March 2019</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class Of Warrant Or Right [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price of warrants (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class Of Warrant Or Right Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant outstanding (in shares)</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_CommitmentsAndContingenciesTable" xlink:label="xoma_CommitmentsAndContingenciesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_CommitmentsAndContingenciesTable" xlink:to="xoma_CommitmentsAndContingenciesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_CommitmentsAndContingenciesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and contingencies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_CommitmentsAndContingenciesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments And Contingencies [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_CommitmentsAndContingenciesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments And Contingencies [Table]</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_CommitmentsAndContingenciesLineItems" xlink:label="xoma_CommitmentsAndContingenciesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_CommitmentsAndContingenciesLineItems" xlink:to="xoma_CommitmentsAndContingenciesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_CommitmentsAndContingenciesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and contingencies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_CommitmentsAndContingenciesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments And Contingencies [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_CommitmentsAndContingenciesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments And Contingencies</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ContractualObligationEstimatedMilestonePayments" xlink:label="xoma_ContractualObligationEstimatedMilestonePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ContractualObligationEstimatedMilestonePayments" xlink:to="xoma_ContractualObligationEstimatedMilestonePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ContractualObligationEstimatedMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated potential obligations that come due and payable upon achievement of developmental, regulatory, or commercial milestones by company's licensees.  Represent contingent payments not recorded on balance sheet.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ContractualObligationEstimatedMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contractual Obligation Estimated Milestone Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ContractualObligationEstimatedMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimate of milestone payments</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ContractualObligationEstimatedMilestonePaymentsNumberOfProducts" xlink:label="xoma_ContractualObligationEstimatedMilestonePaymentsNumberOfProducts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ContractualObligationEstimatedMilestonePaymentsNumberOfProducts" xlink:to="xoma_ContractualObligationEstimatedMilestonePaymentsNumberOfProducts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ContractualObligationEstimatedMilestonePaymentsNumberOfProducts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assumed number of products per contract meeting milestone events used to calculate potential milestone obligations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ContractualObligationEstimatedMilestonePaymentsNumberOfProducts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contractual Obligation, Estimated Milestone Payments, Number Of Products</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ContractualObligationEstimatedMilestonePaymentsNumberOfProducts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assumed number of products per contract</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AronoraKurosAffitechObsevaAndMerckKgaaMember" xlink:label="xoma_AronoraKurosAffitechObsevaAndMerckKgaaMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_AronoraKurosAffitechObsevaAndMerckKgaaMember" xlink:to="xoma_AronoraKurosAffitechObsevaAndMerckKgaaMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_AronoraKurosAffitechObsevaAndMerckKgaaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aronora, Kuros, Affitech, ObsEva, and Merck KGaA.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_AronoraKurosAffitechObsevaAndMerckKgaaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aronora, Kuros, Affitech, ObsEva, and Merck KGaA</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_PaymentOfContingentConsiderationUnderPurchaseAgreements" xlink:label="xoma_PaymentOfContingentConsiderationUnderPurchaseAgreements" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PaymentOfContingentConsiderationUnderPurchaseAgreements" xlink:to="xoma_PaymentOfContingentConsiderationUnderPurchaseAgreements_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PaymentOfContingentConsiderationUnderPurchaseAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of cash outflow for contingent consideration liability recorded under the purchase agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PaymentOfContingentConsiderationUnderPurchaseAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment of Contingent Consideration Under Purchase Agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PaymentOfContingentConsiderationUnderPurchaseAgreements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment for contingent consideration under CPPA</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember" xlink:label="xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember" xlink:to="xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2015 Employee Stock Purchase Plan and subsequent amendments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2015 ESPP</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_PercentageOfCompensationOfEligibleEmployeesToPurchaseSharesOfEntityCommonStockAtDiscountThroughPayrollDeductions" xlink:label="xoma_PercentageOfCompensationOfEligibleEmployeesToPurchaseSharesOfEntityCommonStockAtDiscountThroughPayrollDeductions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PercentageOfCompensationOfEligibleEmployeesToPurchaseSharesOfEntityCommonStockAtDiscountThroughPayrollDeductions" xlink:to="xoma_PercentageOfCompensationOfEligibleEmployeesToPurchaseSharesOfEntityCommonStockAtDiscountThroughPayrollDeductions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PercentageOfCompensationOfEligibleEmployeesToPurchaseSharesOfEntityCommonStockAtDiscountThroughPayrollDeductions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Refers the percentage of compensation deduction in eligible employees salary to purchase entity common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PercentageOfCompensationOfEligibleEmployeesToPurchaseSharesOfEntityCommonStockAtDiscountThroughPayrollDeductions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage Of Compensation Of Eligible Employees To Purchase Shares Of Entity Common Stock At Discount Through Payroll Deductions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PercentageOfCompensationOfEligibleEmployeesToPurchaseSharesOfEntityCommonStockAtDiscountThroughPayrollDeductions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of compensation of eligible employees to purchase shares of entity common stock at discount through payroll deductions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Award</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title Of Individual [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of Individual [Domain]</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ChiefExecutiveOfficerInterimMember" xlink:label="xoma_ChiefExecutiveOfficerInterimMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ChiefExecutiveOfficerInterimMember" xlink:to="xoma_ChiefExecutiveOfficerInterimMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ChiefExecutiveOfficerInterimMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Person with designation of interim chief executive officer and Executive Chairman of the Board.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ChiefExecutiveOfficerInterimMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Executive Chairman of the Board and Interim CEO, Owen Hughes</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ChiefInvestmentOfficerMember" xlink:label="xoma_ChiefInvestmentOfficerMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ChiefInvestmentOfficerMember" xlink:to="xoma_ChiefInvestmentOfficerMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ChiefInvestmentOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Person with designation of  chief investment officer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ChiefInvestmentOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Chief Investment Officer, Bradley Sitko</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_EmployeeMember" xlink:label="xoma_EmployeeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_EmployeeMember" xlink:to="xoma_EmployeeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_EmployeeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee of entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_EmployeeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employees</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Directors</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Tranche One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Tranche Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Tranche Three</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward" xlink:to="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum age required for employees to qualify for immediate vesting of award.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Minimum Age Required For Immediate Vesting Of Award</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum age required for employees to qualify for immediate vesting of award</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge" xlink:to="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold years required for retirement age (defined as employees that are a minimum of 55 years of age and the sum of their age plus years of full-time employment with the Company).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Threshold Period For Retirement Age</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold years required for retirement age</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ShareBasedPaymentArrangementNumberOfAwardsGrants" xlink:label="xoma_ShareBasedPaymentArrangementNumberOfAwardsGrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ShareBasedPaymentArrangementNumberOfAwardsGrants" xlink:to="xoma_ShareBasedPaymentArrangementNumberOfAwardsGrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ShareBasedPaymentArrangementNumberOfAwardsGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of award grants under share-based payment arrangement with differentiated features, such as vesting and exercise price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ShareBasedPaymentArrangementNumberOfAwardsGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Number of Awards Grants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ShareBasedPaymentArrangementNumberOfAwardsGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of award grants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares, Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares, Granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price Per Share, Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting period</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments" xlink:to="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of equal quarterly installments  from grant date on which share-based compensation awards vest.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award, Vesting, Number of Equal Quarterly Installments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of equal quarterly vesting installments</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments" xlink:to="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of successive equal monthly installments  from grant date on which share-based compensation awards vest.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award, Vesting, Number of Equal Monthly Installments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of successive equal monthly vesting installments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average assumptions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividend yield</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected volatility</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average grant-date fair value (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares, Outstanding at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares, Outstanding at beginning of period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares, Forfeited, expired or cancelled</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares, Exercisable at end of period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price Per Share, Outstanding at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price Per Share, Outstanding at beginning of period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price Per Share, Exercised</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price Per Share, Forfeited, expired or cancelled</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price Per Share, Exercisable at end of period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Contractual Remaining Term, Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Contractual Remaining Term, Exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Intrinsic Value, Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Intrinsic Value, Exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options exercised, aggregate intrinsic value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized compensation expense related to stock options (in dollars)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average period over which unrecognized compensation expense is expected to be recognized</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_PerformanceStockUnitsMember" xlink:label="xoma_PerformanceStockUnitsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PerformanceStockUnitsMember" xlink:to="xoma_PerformanceStockUnitsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PerformanceStockUnitsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock units under a share-based payment arrangement awarded for meeting performance target.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PerformanceStockUnitsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Performance Stock Unit Awards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of PSUs (in shares)</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfHurdles." xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfHurdles." xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfHurdles." xlink:to="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfHurdles._lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfHurdles._lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of stock price hurdles in a share based compensation arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfHurdles._lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Number of Hurdles.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfHurdles._lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of hurdles</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfCalendarDays" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfCalendarDays" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfCalendarDays" xlink:to="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfCalendarDays_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfCalendarDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of consecutive calendar days used to calculate volume-weighted average stock price in determining if stock price hurdle has been attained in a share based compensation arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfCalendarDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Calendar Days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfCalendarDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of consecutive calendar days used to calculate volume-weighted average stock price</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_StockPriceHurdlesOfDollar30Member" xlink:label="xoma_StockPriceHurdlesOfDollar30Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_StockPriceHurdlesOfDollar30Member" xlink:to="xoma_StockPriceHurdlesOfDollar30Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_StockPriceHurdlesOfDollar30Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information pertaining to stock price hurdles of $30.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_StockPriceHurdlesOfDollar30Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Hurdle Price Per PSU - $30.00</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_StockPriceHurdlesOfDollar35Member" xlink:label="xoma_StockPriceHurdlesOfDollar35Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_StockPriceHurdlesOfDollar35Member" xlink:to="xoma_StockPriceHurdlesOfDollar35Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_StockPriceHurdlesOfDollar35Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information pertaining to stock price hurdles of $35.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_StockPriceHurdlesOfDollar35Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Hurdle Price Per PSU - $35.00</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_StockPriceHurdlesOfDollar40Member" xlink:label="xoma_StockPriceHurdlesOfDollar40Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_StockPriceHurdlesOfDollar40Member" xlink:to="xoma_StockPriceHurdlesOfDollar40Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_StockPriceHurdlesOfDollar40Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information pertaining to stock price hurdles of $40.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_StockPriceHurdlesOfDollar40Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Hurdle Price Per PSU - $40.00</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_StockPriceHurdlesOfDollar45Member" xlink:label="xoma_StockPriceHurdlesOfDollar45Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_StockPriceHurdlesOfDollar45Member" xlink:to="xoma_StockPriceHurdlesOfDollar45Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_StockPriceHurdlesOfDollar45Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information pertaining to stock price hurdles of $45.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_StockPriceHurdlesOfDollar45Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Hurdle Price Per PSU - $45.00</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Per Share (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derived Service Period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense, not yet recognized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Unvested PSUs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares, Outstanding at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares, Outstanding at beginning of period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Grant Date Fair Value Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract" xlink:to="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Exercise Price [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allocated Share Based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember" xlink:label="xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember" xlink:to="xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current employees of entity, excluding Chief Executive Officer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current employees, excluding Chief Executive Officer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Retention Bonus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Departure and Continuity Incentive</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_NumberOfPeriodsCashRetentionBonus" xlink:label="xoma_NumberOfPeriodsCashRetentionBonus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_NumberOfPeriodsCashRetentionBonus" xlink:to="xoma_NumberOfPeriodsCashRetentionBonus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_NumberOfPeriodsCashRetentionBonus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of periods in which individuals will be eligible to receive cash retention bonus under terms of amended retention plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_NumberOfPeriodsCashRetentionBonus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Periods, Cash Retention Bonus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_NumberOfPeriodsCashRetentionBonus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of periods in which employees will be eligible to receive cash retention bonus</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_PeriodOneRetentionBonusEligibility" xlink:label="xoma_PeriodOneRetentionBonusEligibility" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PeriodOneRetentionBonusEligibility" xlink:to="xoma_PeriodOneRetentionBonusEligibility_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PeriodOneRetentionBonusEligibility_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial period for which individuals will be eligible for retention bonus if employed through the period under terms of amended retention plan, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PeriodOneRetentionBonusEligibility_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period One, Retention Bonus Eligibility</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PeriodOneRetentionBonusEligibility_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial period for which employees will be eligible for retention bonus</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_PeriodTwoRetentionBonusEligibility" xlink:label="xoma_PeriodTwoRetentionBonusEligibility" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PeriodTwoRetentionBonusEligibility" xlink:to="xoma_PeriodTwoRetentionBonusEligibility_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PeriodTwoRetentionBonusEligibility_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period following initial period for which individuals will be eligible for retention bonus if employed through the period under terms of amended retention plan, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PeriodTwoRetentionBonusEligibility_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period Two, Retention Bonus Eligibility</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PeriodTwoRetentionBonusEligibility_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period following initial period for which employees will be eligible for retention bonus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Compensation Arrangement with Individual, Distribution Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of retention bonus paid</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RetentionBonusExpenseAccrued" xlink:label="xoma_RetentionBonusExpenseAccrued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_RetentionBonusExpenseAccrued" xlink:to="xoma_RetentionBonusExpenseAccrued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_RetentionBonusExpenseAccrued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount recorded as expense during the period for cash retention bonuses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_RetentionBonusExpenseAccrued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retention Bonus, Expense Accrued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_RetentionBonusExpenseAccrued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of retention bonus expense</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AccruedRetentionBonus" xlink:label="xoma_AccruedRetentionBonus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_AccruedRetentionBonus" xlink:to="xoma_AccruedRetentionBonus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_AccruedRetentionBonus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expense for cash retention bonus.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_AccruedRetentionBonus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Retention Bonus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_AccruedRetentionBonus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued retention bonus</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ChiefExecutiveOfficerRetiredMember" xlink:label="xoma_ChiefExecutiveOfficerRetiredMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_ChiefExecutiveOfficerRetiredMember" xlink:to="xoma_ChiefExecutiveOfficerRetiredMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_ChiefExecutiveOfficerRetiredMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Person with designation of chief executive officer prior to retirement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_ChiefExecutiveOfficerRetiredMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Chief Executive Officer, Retired, James R. Neal</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AccruedCompensationContinuityIncentive" xlink:label="xoma_AccruedCompensationContinuityIncentive" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_AccruedCompensationContinuityIncentive" xlink:to="xoma_AccruedCompensationContinuityIncentive_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_AccruedCompensationContinuityIncentive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expense for compensation under employment agreement related to retirement of individual.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_AccruedCompensationContinuityIncentive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Compensation, Continuity Incentive</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_AccruedCompensationContinuityIncentive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued cash payment related to Continuity Incentive under Employment Agreement</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_CompensationExpenseEmploymentAgreement" xlink:label="xoma_CompensationExpenseEmploymentAgreement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_CompensationExpenseEmploymentAgreement" xlink:to="xoma_CompensationExpenseEmploymentAgreement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_CompensationExpenseEmploymentAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of expense for compensation under employment agreement related to retirement of individual.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_CompensationExpenseEmploymentAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation Expense, Employment Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_CompensationExpenseEmploymentAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation expense related to Continuity Incentive under Employment Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPayableTable" xlink:label="us-gaap_DividendsPayableTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPayableTable" xlink:to="us-gaap_DividendsPayableTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsPayableTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividends Payable [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPayableLineItems" xlink:label="us-gaap_DividendsPayableLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPayableLineItems" xlink:to="us-gaap_DividendsPayableLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsPayableLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividends Payable [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DividendsPayableLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividends</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendsPerShareDeclared" xlink:label="us-gaap_PreferredStockDividendsPerShareDeclared" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsPerShareDeclared" xlink:to="us-gaap_PreferredStockDividendsPerShareDeclared_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendsPerShareDeclared_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Dividends Per Share, Declared</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockDividendsPerShareDeclared_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash dividend declared (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendsPerShareCashPaid" xlink:label="us-gaap_PreferredStockDividendsPerShareCashPaid" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsPerShareCashPaid" xlink:to="us-gaap_PreferredStockDividendsPerShareCashPaid_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendsPerShareCashPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Dividends, Per Share, Cash Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockDividendsPerShareCashPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash dividend paid (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_BiotechnologyValueFundLPMember" xlink:label="xoma_BiotechnologyValueFundLPMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_BiotechnologyValueFundLPMember" xlink:to="xoma_BiotechnologyValueFundLPMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_BiotechnologyValueFundLPMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Biotechnology Value Fund, L.P.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_BiotechnologyValueFundLPMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BVF</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ownership [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipDomain" xlink:to="srt_OwnershipDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ownership</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_XomaCorporationMember" xlink:label="xoma_XomaCorporationMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_XomaCorporationMember" xlink:to="xoma_XomaCorporationMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_XomaCorporationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Xoma Corporation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_XomaCorporationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Xoma Corporation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary, Sale of Stock [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary, Ownership Percentage, Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ownership interest (as a percent)</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted" xlink:label="xoma_NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted" xlink:to="xoma_NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The parent entity's interest in net assets of the subsidiary, expressed as a percentage, if shares are converted.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Noncontrolling Interest, Ownership Percentage by Parent, If Shares Converted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ownership interest, if shares are converted (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsidiary Sale Of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_TwoThousandEighteenAtMarketAgreementMember" xlink:label="xoma_TwoThousandEighteenAtMarketAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_TwoThousandEighteenAtMarketAgreementMember" xlink:to="xoma_TwoThousandEighteenAtMarketAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_TwoThousandEighteenAtMarketAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">At the Market Agreement, 2018 in which the company may sell common shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_TwoThousandEighteenAtMarketAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2018 Common Stock ATM Agreement</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AtMarketIssuanceSalesAgreement2021Member" xlink:label="xoma_AtMarketIssuanceSalesAgreement2021Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_AtMarketIssuanceSalesAgreement2021Member" xlink:to="xoma_AtMarketIssuanceSalesAgreement2021Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_AtMarketIssuanceSalesAgreement2021Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">At The Market Issuance Sales Agreement, 2021, in which the company may sell depository shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_AtMarketIssuanceSalesAgreement2021Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2021 ATM Agreement</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MaximumValueOfStockToBeIssued" xlink:label="xoma_MaximumValueOfStockToBeIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_MaximumValueOfStockToBeIssued" xlink:to="xoma_MaximumValueOfStockToBeIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_MaximumValueOfStockToBeIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum amount of stock to be issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_MaximumValueOfStockToBeIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Value Of Stock To Be Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_MaximumValueOfStockToBeIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum amount of shares to be issued</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares" xlink:label="xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares" xlink:to="xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The percentage of sales commission to gross proceeds paid to sales agents for the sale of the Company's common shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage Of Gross Proceeds Paid To Agent For Sale Of Common Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales commission paid per transaction (as a percent)</label>
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfShares" xlink:label="xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfShares" xlink:to="xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The percentage of sales commission to gross proceeds paid to sales agents for the sale of the Company's shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage Of Gross Proceeds Paid To Agent For Sale Of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales commission paid per transaction, preferred stock (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:to="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal Income Tax Expense Benefit Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal income tax provision</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized tax benefits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits That Would Impact Effective Tax Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized tax benefits that would impact effective tax rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit" xlink:label="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit" xlink:to="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized tax benefits expected to change significantly over the next twelve months</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>xoma-20230630_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.3.0.9 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/8/2023 2:22:02 AM-->
<!--Modified on: 8/8/2023 2:22:02 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.xoma.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#StatementCondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome" roleURI="http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#StatementCondensedConsolidatedStatementsOfStockholdersEquity" roleURI="http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureDescriptionOfBusiness" roleURI="http://www.xoma.com/role/DisclosureDescriptionOfBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureBasisOfPresentationAndSignificantAccountingPolicies" roleURI="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureCondensedConsolidatedFinancialStatementsDetails" roleURI="http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureLicensingAndOtherArrangements" roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureRoyaltyAndCommercialPaymentPurchaseAgreements" roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureFairValueMeasurements" roleURI="http://www.xoma.com/role/DisclosureFairValueMeasurements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureLeaseAgreements" roleURI="http://www.xoma.com/role/DisclosureLeaseAgreements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureCommonStockWarrants" roleURI="http://www.xoma.com/role/DisclosureCommonStockWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://www.xoma.com/role/DisclosureCommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureStockBasedCompensation" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureCapitalStock" roleURI="http://www.xoma.com/role/DisclosureCapitalStock" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureIncomeTaxes" roleURI="http://www.xoma.com/role/DisclosureIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" roleURI="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureCondensedConsolidatedFinancialStatementsDetailsTables" roleURI="http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTables" roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureFairValueMeasurementsTables" roleURI="http://www.xoma.com/role/DisclosureFairValueMeasurementsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureLeaseAgreementsTables" roleURI="http://www.xoma.com/role/DisclosureLeaseAgreementsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureCommonStockWarrantsTables" roleURI="http://www.xoma.com/role/DisclosureCommonStockWarrantsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureStockBasedCompensationTables" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureCapitalStockTables" roleURI="http://www.xoma.com/role/DisclosureCapitalStockTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureDescriptionOfBusinessLiquidityDetails" roleURI="http://www.xoma.com/role/DisclosureDescriptionOfBusinessLiquidityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureBasisOfPresentationAndSignificantAccountingPoliciesCashAndCashEquivalentsDetails" roleURI="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesCashAndCashEquivalentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureBasisOfPresentationAndSignificantAccountingPoliciesIntangibleAssetsAndIncomeTaxesDetails" roleURI="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesIntangibleAssetsAndIncomeTaxesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureBasisOfPresentationAndSignificantAccountingPoliciesConcentrationOfRiskDetails" roleURI="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesConcentrationOfRiskDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureCondensedConsolidatedFinancialStatementsDetailsEquitySecuritiesDetails" roleURI="http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsEquitySecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureCondensedConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails" roleURI="http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureCondensedConsolidatedFinancialStatementsDetailsAccruedAndOtherLiabilitiesDetails" roleURI="http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsAccruedAndOtherLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureCondensedConsolidatedFinancialStatementsDetailsNetLossPerShareDetails" roleURI="http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsNetLossPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureCondensedConsolidatedFinancialStatementsDetailsOutstandingSecuritiesConsideredAntiDilutiveDetails" roleURI="http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsOutstandingSecuritiesConsideredAntiDilutiveDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureCondensedConsolidatedFinancialStatementsDetailsArbitrationProceedingDetails" roleURI="http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsArbitrationProceedingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureLicensingAndOtherArrangementsObsevaDetails" roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureLicensingAndOtherArrangementsNovartisNis793Details" roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureLicensingAndOtherArrangementsNovartisVpm087Details" roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureLicensingAndOtherArrangementsTakedaDetails" roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureLicensingAndOtherArrangementsRezoluteDetails" roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails" roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureLicensingAndOtherArrangementsAffimedDetails" roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsAffimedDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails" roleURI="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryDetails" roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails" roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails" roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails" roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails" roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails" roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails" roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails" roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails" roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails" roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails" roleURI="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails" roleURI="http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureFairValueMeasurementsEquitySecuritiesDetails" roleURI="http://www.xoma.com/role/DisclosureFairValueMeasurementsEquitySecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureFairValueMeasurementsContingentConsiderationDetails" roleURI="http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureLeaseAgreementsLeasedFacilitiesDetails" roleURI="http://www.xoma.com/role/DisclosureLeaseAgreementsLeasedFacilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureLeaseAgreementsLeaseCostsDetails" roleURI="http://www.xoma.com/role/DisclosureLeaseAgreementsLeaseCostsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureLeaseAgreementsAdditionalInformationDetails" roleURI="http://www.xoma.com/role/DisclosureLeaseAgreementsAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureCommonStockWarrantsDetails" roleURI="http://www.xoma.com/role/DisclosureCommonStockWarrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureCommitmentsAndContingenciesCollaborativeAgreementsRoyaltiesAndMilestonePaymentsDetails" roleURI="http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesCollaborativeAgreementsRoyaltiesAndMilestonePaymentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureCommitmentsAndContingenciesContingentConsiderationDetails" roleURI="http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureStockBasedCompensationEsppDetails" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationEsppDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureStockBasedCompensation2010PlanAndInducementAwardsDetails" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensation2010PlanAndInducementAwardsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureStockBasedCompensationFvAssumptionsDetails" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationFvAssumptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureStockBasedCompensationStockOptionActivityDetails" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureStockBasedCompensationPerformanceStockUnitAwardsDetails" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureStockBasedCompensationPerformanceStockUnitAwardsFairValueDetails" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsFairValueDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureStockBasedCompensationPerformanceStockUnitAwardsActivityDetails" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureStockBasedCompensationEmployeeRetentionBonusDetails" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationEmployeeRetentionBonusDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureStockBasedCompensationCeoDepartureAndContinuityIncentiveDetails" roleURI="http://www.xoma.com/role/DisclosureStockBasedCompensationCeoDepartureAndContinuityIncentiveDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureCapitalStockDividendsDetails" roleURI="http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureCapitalStockBvfOwnershipDetails" roleURI="http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureCapitalStockAtmAgreementsDetails" roleURI="http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="xoma-20230630.xsd#DisclosureIncomeTaxesDetails" roleURI="http://www.xoma.com/role/DisclosureIncomeTaxesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <presentationLink xlink:role="http://www.xoma.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638270581179217034" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="us-gaap_StatementTable_638270581179217034" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638270581179217034" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638270581179217034" xlink:to="us-gaap_StatementClassOfStockAxis_638270581179217034" order="1" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638270581179227033" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638270581179217034" xlink:to="us-gaap_ClassOfStockDomain_638270581179227033" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638270581179227033" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638270581179227033" xlink:to="us-gaap_CommonStockMember_638270581179227033" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember_638270581179227033" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638270581179227033" xlink:to="us-gaap_SeriesAPreferredStockMember_638270581179227033" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AdrMember" xlink:label="dei_AdrMember_638270581179227033" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638270581179227033" xlink:to="dei_AdrMember_638270581179227033" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638270581179227033" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638270581179217034" xlink:to="us-gaap_StatementLineItems_638270581179227033" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638270581179227033" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638270581179227033" xlink:to="dei_DocumentType_638270581179227033" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport_638270581179227033" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638270581179227033" xlink:to="dei_DocumentQuarterlyReport_638270581179227033" order="2" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638270581179227033" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638270581179227033" xlink:to="dei_DocumentPeriodEndDate_638270581179227033" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_638270581179227033" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638270581179227033" xlink:to="dei_DocumentTransitionReport_638270581179227033" order="4" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638270581179227033" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638270581179227033" xlink:to="dei_EntityFileNumber_638270581179227033" order="5" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638270581179237026" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638270581179227033" xlink:to="dei_EntityRegistrantName_638270581179237026" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638270581179237026" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638270581179227033" xlink:to="dei_EntityIncorporationStateCountryCode_638270581179237026" order="7" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638270581179237026" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638270581179227033" xlink:to="dei_EntityTaxIdentificationNumber_638270581179237026" order="8" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638270581179237026" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638270581179227033" xlink:to="dei_EntityAddressAddressLine1_638270581179237026" order="9" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_638270581179237026" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638270581179227033" xlink:to="dei_EntityAddressAddressLine2_638270581179237026" order="10" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638270581179237026" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638270581179227033" xlink:to="dei_EntityAddressCityOrTown_638270581179237026" order="11" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638270581179237026" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638270581179227033" xlink:to="dei_EntityAddressStateOrProvince_638270581179237026" order="12" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638270581179237026" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638270581179227033" xlink:to="dei_EntityAddressPostalZipCode_638270581179237026" order="13" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638270581179237026" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638270581179227033" xlink:to="dei_CityAreaCode_638270581179237026" order="14" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638270581179247016" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638270581179227033" xlink:to="dei_LocalPhoneNumber_638270581179247016" order="15" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638270581179247016" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638270581179227033" xlink:to="dei_Security12bTitle_638270581179247016" order="16" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638270581179247016" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638270581179227033" xlink:to="dei_TradingSymbol_638270581179247016" order="17" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638270581179247016" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638270581179227033" xlink:to="dei_SecurityExchangeName_638270581179247016" order="18" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_638270581179247016" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638270581179227033" xlink:to="dei_EntityCurrentReportingStatus_638270581179247016" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_638270581179247016" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638270581179227033" xlink:to="dei_EntityInteractiveDataCurrent_638270581179247016" order="20" use="optional" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_638270581179257031" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638270581179227033" xlink:to="dei_EntityFilerCategory_638270581179257031" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_638270581179257031" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638270581179227033" xlink:to="dei_EntitySmallBusiness_638270581179257031" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638270581179257031" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638270581179227033" xlink:to="dei_EntityEmergingGrowthCompany_638270581179257031" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_638270581179257031" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638270581179227033" xlink:to="dei_EntityShellCompany_638270581179257031" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_638270581179257031" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638270581179227033" xlink:to="dei_EntityCommonStockSharesOutstanding_638270581179257031" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638270581179257031" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638270581179227033" xlink:to="dei_EntityCentralIndexKey_638270581179257031" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_638270581179267031" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638270581179227033" xlink:to="dei_CurrentFiscalYearEndDate_638270581179267031" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_638270581179267031" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638270581179227033" xlink:to="dei_DocumentFiscalYearFocus_638270581179267031" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_638270581179267031" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638270581179227033" xlink:to="dei_DocumentFiscalPeriodFocus_638270581179267031" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638270581179267031" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638270581179227033" xlink:to="dei_AmendmentFlag_638270581179267031" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638270581179277038" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable_638270581179277038" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638270581179277038" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638270581179277038" xlink:to="us-gaap_StatementClassOfStockAxis_638270581179277038" order="1" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638270581179277038" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638270581179277038" xlink:to="us-gaap_ClassOfStockDomain_638270581179277038" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember_638270581179277038" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638270581179277038" xlink:to="us-gaap_SeriesAPreferredStockMember_638270581179277038" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember_638270581179277038" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638270581179277038" xlink:to="us-gaap_SeriesBPreferredStockMember_638270581179277038" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember_638270581179277038" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638270581179277038" xlink:to="us-gaap_ConvertiblePreferredStockMember_638270581179277038" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638270581179277038" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638270581179277038" xlink:to="us-gaap_StatementLineItems_638270581179277038" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_638270581179277038" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638270581179277038" xlink:to="us-gaap_AssetsAbstract_638270581179277038" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_638270581179277038" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638270581179277038" xlink:to="us-gaap_AssetsCurrentAbstract_638270581179277038" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638270581179287546" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638270581179277038" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638270581179287546" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="us-gaap_EquitySecuritiesFvNi_638270581179287546" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638270581179277038" xlink:to="us-gaap_EquitySecuritiesFvNi_638270581179287546" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="us-gaap_AccountsAndOtherReceivablesNetCurrent_638270581179287546" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638270581179277038" xlink:to="us-gaap_AccountsAndOtherReceivablesNetCurrent_638270581179287546" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RightsReceivableCurrent" xlink:label="xoma_RightsReceivableCurrent_638270581179287546" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638270581179277038" xlink:to="xoma_RightsReceivableCurrent_638270581179287546" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638270581179287546" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638270581179277038" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638270581179287546" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638270581179287546" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638270581179277038" xlink:to="us-gaap_AssetsCurrent_638270581179287546" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638270581179287546" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638270581179277038" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638270581179287546" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638270581179287546" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638270581179277038" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638270581179287546" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LongTermRightsReceivableNonCurrent" xlink:label="xoma_LongTermRightsReceivableNonCurrent_638270581179287546" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638270581179277038" xlink:to="xoma_LongTermRightsReceivableNonCurrent_638270581179287546" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_638270581179297034" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638270581179277038" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_638270581179297034" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_638270581179297034" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638270581179277038" xlink:to="us-gaap_OtherAssetsNoncurrent_638270581179297034" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_638270581179297034" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638270581179277038" xlink:to="us-gaap_Assets_638270581179297034" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638270581179297034" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638270581179277038" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638270581179297034" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_638270581179297034" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638270581179297034" xlink:to="us-gaap_LiabilitiesCurrentAbstract_638270581179297034" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638270581179297034" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638270581179297034" xlink:to="us-gaap_AccountsPayableCurrent_638270581179297034" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AccruedAndOtherLiabilitiesCurrent" xlink:label="xoma_AccruedAndOtherLiabilitiesCurrent_638270581179307032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638270581179297034" xlink:to="xoma_AccruedAndOtherLiabilitiesCurrent_638270581179307032" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ContingentConsiderationUnderPurchaseAgreements" xlink:label="xoma_ContingentConsiderationUnderPurchaseAgreements_638270581179307032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638270581179297034" xlink:to="xoma_ContingentConsiderationUnderPurchaseAgreements_638270581179307032" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638270581179307032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638270581179297034" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638270581179307032" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeCurrent" xlink:label="us-gaap_DeferredIncomeCurrent_638270581179307032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638270581179297034" xlink:to="us-gaap_DeferredIncomeCurrent_638270581179307032" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AccruedPreferredStockDividendCurrent" xlink:label="xoma_AccruedPreferredStockDividendCurrent_638270581179307032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638270581179297034" xlink:to="xoma_AccruedPreferredStockDividendCurrent_638270581179307032" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638270581179307032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638270581179297034" xlink:to="us-gaap_LiabilitiesCurrent_638270581179307032" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeNoncurrent" xlink:label="us-gaap_DeferredIncomeNoncurrent_638270581179307032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638270581179297034" xlink:to="us-gaap_DeferredIncomeNoncurrent_638270581179307032" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638270581179317035" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638270581179297034" xlink:to="us-gaap_Liabilities_638270581179317035" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638270581179317035" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638270581179297034" xlink:to="us-gaap_CommitmentsAndContingencies_638270581179317035" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_638270581179317035" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638270581179297034" xlink:to="us-gaap_StockholdersEquityAbstract_638270581179317035" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638270581179317035" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638270581179317035" xlink:to="us-gaap_PreferredStockValue_638270581179317035" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638270581179317035" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638270581179317035" xlink:to="us-gaap_CommonStockValue_638270581179317035" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638270581179317035" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638270581179317035" xlink:to="us-gaap_AdditionalPaidInCapital_638270581179317035" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638270581179317035" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638270581179317035" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638270581179317035" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638270581179327025" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638270581179317035" xlink:to="us-gaap_StockholdersEquity_638270581179327025" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_638270581179327025" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638270581179277038" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_638270581179327025" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638270581179327025" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable_638270581179327025" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638270581179327025" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638270581179327025" xlink:to="us-gaap_StatementClassOfStockAxis_638270581179327025" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638270581179327025" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638270581179327025" xlink:to="us-gaap_ClassOfStockDomain_638270581179327025" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember_638270581179327025" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638270581179327025" xlink:to="us-gaap_SeriesAPreferredStockMember_638270581179327025" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember_638270581179327025" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638270581179327025" xlink:to="us-gaap_SeriesBPreferredStockMember_638270581179327025" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember_638270581179337035" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638270581179327025" xlink:to="us-gaap_ConvertiblePreferredStockMember_638270581179337035" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638270581179337035" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638270581179327025" xlink:to="us-gaap_StatementLineItems_638270581179337035" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_638270581179337035" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638270581179337035" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_638270581179337035" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_638270581179337035" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638270581179337035" xlink:to="us-gaap_PreferredStockSharesAuthorized_638270581179337035" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage_638270581179337035" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638270581179337035" xlink:to="us-gaap_PreferredStockDividendRatePercentage_638270581179337035" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_638270581179337035" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638270581179337035" xlink:to="us-gaap_PreferredStockSharesIssued_638270581179337035" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_638270581179337035" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638270581179337035" xlink:to="us-gaap_PreferredStockSharesOutstanding_638270581179337035" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638270581179337035" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638270581179337035" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638270581179337035" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638270581179337035" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638270581179337035" xlink:to="us-gaap_CommonStockSharesAuthorized_638270581179337035" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638270581179337035" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638270581179337035" xlink:to="us-gaap_CommonStockSharesIssued_638270581179337035" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638270581179347025" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638270581179337035" xlink:to="us-gaap_CommonStockSharesOutstanding_638270581179347025" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome" xlink:type="extended" xlink:title="00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract_638270581179347025" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_RevenuesAbstract_638270581179347025" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638270581179347025" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_638270581179347025" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638270581179347025" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="us-gaap_RevenueNotFromContractWithCustomer_638270581179347025" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_638270581179347025" xlink:to="us-gaap_RevenueNotFromContractWithCustomer_638270581179347025" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_638270581179347025" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_638270581179347025" xlink:to="us-gaap_Revenues_638270581179347025" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_638270581179347025" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_638270581179347025" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638270581179347025" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638270581179347025" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638270581179347025" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638270581179347025" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638270581179347025" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638270581179347025" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ImpairmentOfLongTermRightsReceivableNonCurrent" xlink:label="xoma_ImpairmentOfLongTermRightsReceivableNonCurrent_638270581179347025" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638270581179347025" xlink:to="xoma_ImpairmentOfLongTermRightsReceivableNonCurrent_638270581179347025" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementExpense" xlink:label="us-gaap_LitigationSettlementExpense_638270581179357035" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638270581179347025" xlink:to="us-gaap_LitigationSettlementExpense_638270581179357035" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets_638270581179357035" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638270581179347025" xlink:to="us-gaap_AmortizationOfIntangibleAssets_638270581179357035" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638270581179357035" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638270581179347025" xlink:to="us-gaap_OperatingExpenses_638270581179357035" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638270581179357035" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OperatingIncomeLoss_638270581179357035" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_638270581179357035" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_638270581179357035" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_638270581179357035" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638270581179357035" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_638270581179357035" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638270581179357035" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss_638270581179357035" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_638270581179357035" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_638270581179357035" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact_638270581179357035" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact_638270581179357035" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638270581179367559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638270581179367559" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_638270581179367559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_638270581179367559" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638270581179367559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_EarningsPerShareBasic_638270581179367559" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638270581179367559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_EarningsPerShareDiluted_638270581179367559" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638270581179367559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638270581179367559" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638270581179367559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638270581179367559" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" xlink:type="extended" xlink:title="00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638270581179377043" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_638270581179377043" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638270581179377043" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638270581179377043" xlink:to="us-gaap_StatementEquityComponentsAxis_638270581179377043" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember_638270581179377043" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638270581179377043" xlink:to="us-gaap_PreferredStockMember_638270581179377043" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638270581179377043" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638270581179377043" xlink:to="us-gaap_CommonStockMember_638270581179377043" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_638270581179377043" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638270581179377043" xlink:to="us-gaap_AdditionalPaidInCapitalMember_638270581179377043" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_638270581179377043" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638270581179377043" xlink:to="us-gaap_RetainedEarningsMember_638270581179377043" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638270581179377043" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638270581179377043" xlink:to="us-gaap_EquityComponentDomain_638270581179377043" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638270581179377043" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638270581179377043" xlink:to="us-gaap_StatementClassOfStockAxis_638270581179377043" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember_638270581179377043" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638270581179377043" xlink:to="us-gaap_SeriesAPreferredStockMember_638270581179377043" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember_638270581179377043" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638270581179377043" xlink:to="us-gaap_SeriesBPreferredStockMember_638270581179377043" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember_638270581179377043" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638270581179377043" xlink:to="us-gaap_ConvertiblePreferredStockMember_638270581179377043" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638270581179387038" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638270581179377043" xlink:to="us-gaap_ClassOfStockDomain_638270581179387038" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638270581179387038" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638270581179377043" xlink:to="us-gaap_StatementLineItems_638270581179387038" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638270581179387038" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638270581179387038" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638270581179387038" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638270581179387038" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638270581179387038" xlink:to="us-gaap_StockholdersEquity_638270581179387038" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638270581179387038" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638270581179387038" xlink:to="us-gaap_SharesOutstanding_638270581179387038" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_638270581179387038" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638270581179387038" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_638270581179387038" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638270581179387038" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues_638270581179387038" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638270581179387038" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638270581179387038" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638270581179387038" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638270581179387038" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638270581179387038" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638270581179387038" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638270581179387038" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_638270581179397029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638270581179387038" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_638270581179397029" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_638270581179397029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_638270581179397029" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_638270581179397029" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_638270581179397029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638270581179387038" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_638270581179397029" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_638270581179397029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_638270581179397029" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_638270581179397029" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638270581179397029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638270581179387038" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638270581179397029" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPreferredStockStock" xlink:label="us-gaap_DividendsPreferredStockStock_638270581179397029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638270581179387038" xlink:to="us-gaap_DividendsPreferredStockStock_638270581179397029" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638270581179397029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638270581179387038" xlink:to="us-gaap_NetIncomeLoss_638270581179397029" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638270581179397029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638270581179387038" xlink:to="us-gaap_StockholdersEquity_638270581179397029" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638270581179397029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638270581179387038" xlink:to="us-gaap_SharesOutstanding_638270581179397029" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638270581179407031" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638270581179407031" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638270581179407031" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638270581179407031" xlink:to="us-gaap_ProfitLoss_638270581179407031" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638270581179407031" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638270581179407031" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638270581179407031" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638270581179407031" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638270581179407031" xlink:to="us-gaap_ShareBasedCompensation_638270581179407031" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ImpairmentOfLongTermRightsReceivableNonCurrent" xlink:label="xoma_ImpairmentOfLongTermRightsReceivableNonCurrent_638270581179407031" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638270581179407031" xlink:to="xoma_ImpairmentOfLongTermRightsReceivableNonCurrent_638270581179407031" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ChangesInEstimatedFairValueOfContingentConsideration" xlink:label="xoma_ChangesInEstimatedFairValueOfContingentConsideration_638270581179407031" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638270581179407031" xlink:to="xoma_ChangesInEstimatedFairValueOfContingentConsideration_638270581179407031" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims" xlink:label="xoma_DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims_638270581179407031" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638270581179407031" xlink:to="xoma_DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims_638270581179407031" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets_638270581179407031" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638270581179407031" xlink:to="us-gaap_AmortizationOfIntangibleAssets_638270581179407031" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationNonproduction" xlink:label="us-gaap_DepreciationNonproduction_638270581179417041" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638270581179407031" xlink:to="us-gaap_DepreciationNonproduction_638270581179417041" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_OperatingLeasePaymentsNonCash" xlink:label="xoma_OperatingLeasePaymentsNonCash_638270581179417041" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638270581179407031" xlink:to="xoma_OperatingLeasePaymentsNonCash_638270581179417041" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedGainLoss_638270581179417041" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638270581179407031" xlink:to="us-gaap_EquitySecuritiesFvNiRealizedGainLoss_638270581179417041" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638270581179417041" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638270581179407031" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638270581179417041" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_638270581179417041" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638270581179417041" xlink:to="us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_638270581179417041" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638270581179417041" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638270581179417041" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638270581179417041" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638270581179417041" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638270581179417041" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638270581179417041" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_638270581179417041" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638270581179417041" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_638270581179417041" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638270581179417041" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638270581179417041" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638270581179417041" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_638270581179417041" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638270581179417041" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_638270581179417041" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638270581179417041" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638270581179407031" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638270581179417041" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638270581179427032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638270581179427032" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" xlink:label="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities_638270581179427032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638270581179427032" xlink:to="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities_638270581179427032" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ReceiptsUnderAgreementsInvestingActivities" xlink:label="xoma_ReceiptsUnderAgreementsInvestingActivities_638270581179427032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638270581179427032" xlink:to="xoma_ReceiptsUnderAgreementsInvestingActivities_638270581179427032" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_638270581179427032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638270581179427032" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets_638270581179427032" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638270581179427032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638270581179427032" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638270581179427032" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638270581179427032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638270581179427032" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDividends" xlink:label="us-gaap_PaymentsOfDividends_638270581179427032" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638270581179427032" xlink:to="us-gaap_PaymentsOfDividends_638270581179427032" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_638270581179437039" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638270581179427032" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_638270581179437039" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_638270581179437039" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638270581179427032" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_638270581179437039" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638270581179437039" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638270581179427032" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638270581179437039" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638270581179437039" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638270581179427032" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638270581179437039" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638270581179437039" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638270581179437039" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638270581179447046" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638270581179447046" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6382705811794470461" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6382705811794470461" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_638270581179447046" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_638270581179447046" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet_638270581179447046" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638270581179447046" xlink:to="us-gaap_IncomeTaxesPaidNet_638270581179447046" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_638270581179447046" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638270581179447046" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_638270581179447046" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638270581179457039" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638270581179457039" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:label="us-gaap_DividendsPayableCurrentAndNoncurrent_638270581179457039" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638270581179457039" xlink:to="us-gaap_DividendsPayableCurrentAndNoncurrent_638270581179457039" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_EstimatedFairValueOfContingentConsiderationUnderAssetAcquisition" xlink:label="xoma_EstimatedFairValueOfContingentConsiderationUnderAssetAcquisition_638270581179457039" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638270581179457039" xlink:to="xoma_EstimatedFairValueOfContingentConsiderationUnderAssetAcquisition_638270581179457039" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureDescriptionOfBusiness" xlink:type="extended" xlink:title="10101 - Disclosure - Description of Business" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations_638270581179467052" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations_638270581179467052" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies" xlink:type="extended" xlink:title="10201 - Disclosure - Basis of Presentation and Significant Accounting Policies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_638270581179467052" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_638270581179467052" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetails" xlink:type="extended" xlink:title="10301 - Disclosure - Condensed Consolidated Financial Statements Details" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ConsolidatedFinancialStatementDetailAbstract" xlink:label="ConsolidatedFinancialStatementDetailAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:label="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_638270581179467052" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedFinancialStatementDetailAbstract" xlink:to="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_638270581179467052" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangements" xlink:type="extended" xlink:title="10401 - Disclosure - Licensing and Other Arrangements" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LicensingAndOtherArrangementsAbstract" xlink:label="LicensingAndOtherArrangementsAbstract" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LicensingAndOtherArrangementsTextBlock" xlink:label="xoma_LicensingAndOtherArrangementsTextBlock_638270581179477049" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicensingAndOtherArrangementsAbstract" xlink:to="xoma_LicensingAndOtherArrangementsTextBlock_638270581179477049" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreements" xlink:type="extended" xlink:title="10501 - Disclosure - Royalty and Commercial Payment Purchase Agreements" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:label="RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RoyaltyPurchaseAgreementTextBlock" xlink:label="xoma_RoyaltyPurchaseAgreementTextBlock_638270581179477049" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:to="xoma_RoyaltyPurchaseAgreementTextBlock_638270581179477049" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureFairValueMeasurements" xlink:type="extended" xlink:title="10601 - Disclosure - Fair Value Measurements" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_638270581179477049" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock_638270581179477049" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureLeaseAgreements" xlink:type="extended" xlink:title="10701 - Disclosure - Lease Agreements" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LeaseDisclosureTextBlock" xlink:label="xoma_LeaseDisclosureTextBlock_638270581179477049" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="xoma_LeaseDisclosureTextBlock_638270581179477049" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureCommonStockWarrants" xlink:type="extended" xlink:title="10801 - Disclosure - Common Stock Warrants" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="WarrantsAndRightsNoteDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_CommonStockWarrantDisclosureTextBlock" xlink:label="xoma_CommonStockWarrantDisclosureTextBlock_638270581179487050" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsAndRightsNoteDisclosureAbstract" xlink:to="xoma_CommonStockWarrantDisclosureTextBlock_638270581179487050" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="10901 - Disclosure - Commitments and Contingencies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638270581179487050" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638270581179487050" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensation" xlink:type="extended" xlink:title="11001 - Disclosure - Stock Based Compensation" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="CompensationRelatedCostsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638270581179497083" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CompensationRelatedCostsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638270581179497083" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureCapitalStock" xlink:type="extended" xlink:title="11101 - Disclosure - Capital Stock" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638270581179497083" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638270581179497083" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="11201 - Disclosure - Income Taxes" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_638270581179497083" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_638270581179497083" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20202 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638270581179507048" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638270581179507048" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_638270581179507048" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_638270581179507048" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638270581179507048" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638270581179507048" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_638270581179507048" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_638270581179507048" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RevenueRecognitionDeferredRevenuePolicyTextBlock" xlink:label="xoma_RevenueRecognitionDeferredRevenuePolicyTextBlock_638270581179507048" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="xoma_RevenueRecognitionDeferredRevenuePolicyTextBlock_638270581179507048" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_638270581179507048" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_638270581179507048" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_EquitySecuritiesPolicy" xlink:label="xoma_EquitySecuritiesPolicy_638270581179507048" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="xoma_EquitySecuritiesPolicy_638270581179507048" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_FutureMilestonesRoyaltiesPurchaseRightsAndCommercialPaymentsPolicyPolicyTextBlock" xlink:label="xoma_FutureMilestonesRoyaltiesPurchaseRightsAndCommercialPaymentsPolicyPolicyTextBlock_638270581179507048" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="xoma_FutureMilestonesRoyaltiesPurchaseRightsAndCommercialPaymentsPolicyPolicyTextBlock_638270581179507048" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_CreditLossContractWithCustomerAssetPolicyTextBlock" xlink:label="xoma_CreditLossContractWithCustomerAssetPolicyTextBlock_638270581179507048" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="xoma_CreditLossContractWithCustomerAssetPolicyTextBlock_638270581179507048" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AssetAcquisitionsPolicyPolicyTextBlock" xlink:label="xoma_AssetAcquisitionsPolicyPolicyTextBlock_638270581179507048" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="xoma_AssetAcquisitionsPolicyPolicyTextBlock_638270581179507048" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_638270581179517044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_638270581179517044" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_638270581179517044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_638270581179517044" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_638270581179517044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_638270581179517044" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_638270581179517044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_638270581179517044" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk_638270581179517044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk_638270581179517044" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_638270581179517044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_638270581179517044" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638270581179517044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638270581179517044" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsTables" xlink:type="extended" xlink:title="30303 - Disclosure - Condensed Consolidated Financial Statements Details (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ConsolidatedFinancialStatementDetailAbstract" xlink:label="xoma_ConsolidatedFinancialStatementDetailAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_638270581179527169" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_ConsolidatedFinancialStatementDetailAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_638270581179527169" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_638270581179527169" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_ConsolidatedFinancialStatementDetailAbstract" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_638270581179527169" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_638270581179527169" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_ConsolidatedFinancialStatementDetailAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_638270581179527169" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_638270581179527169" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_ConsolidatedFinancialStatementDetailAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_638270581179527169" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638270581179527169" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_ConsolidatedFinancialStatementDetailAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638270581179527169" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTables" xlink:type="extended" xlink:title="30503 - Disclosure - Royalty and Commercial Payment Purchase Agreements (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:label="RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ScheduleOfRoyaltyAndCommercialPaymentReceivablesActivityTableTextBlock" xlink:label="xoma_ScheduleOfRoyaltyAndCommercialPaymentReceivablesActivityTableTextBlock_638270581179527169" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:to="xoma_ScheduleOfRoyaltyAndCommercialPaymentReceivablesActivityTableTextBlock_638270581179527169" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureFairValueMeasurementsTables" xlink:type="extended" xlink:title="30603 - Disclosure - Fair Value Measurements (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_638270581179537048" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_1" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_638270581179537048" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureLeaseAgreementsTables" xlink:type="extended" xlink:title="30703 - Disclosure - Lease Agreements (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock_638270581179537048" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock_638270581179537048" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock" xlink:label="xoma_LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock_638270581179537048" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="xoma_LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock_638270581179537048" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LesseeOperatingLeaseSupplementalInformationTableTextBlock" xlink:label="xoma_LesseeOperatingLeaseSupplementalInformationTableTextBlock_638270581179537048" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="xoma_LesseeOperatingLeaseSupplementalInformationTableTextBlock_638270581179537048" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureCommonStockWarrantsTables" xlink:type="extended" xlink:title="30803 - Disclosure - Common Stock Warrants (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="WarrantsAndRightsNoteDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_638270581179547060" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_638270581179547060" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationTables" xlink:type="extended" xlink:title="31003 - Disclosure - Stock Based Compensation (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="us-gaap_CompensationRelatedCostsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638270581179547060" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationRelatedCostsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638270581179547060" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638270581179547060" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638270581179547060" xlink:to="us-gaap_PlanNameAxis_638270581179547060" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638270581179547060" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638270581179547060" xlink:to="us-gaap_PlanNameDomain_638270581179547060" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember" xlink:label="xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_638270581179547060" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638270581179547060" xlink:to="xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_638270581179547060" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_StockOptionInducementAwardsMember" xlink:label="xoma_StockOptionInducementAwardsMember_638270581179547060" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638270581179547060" xlink:to="xoma_StockOptionInducementAwardsMember_638270581179547060" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_StockOptionInducementAwardOneMember" xlink:label="xoma_StockOptionInducementAwardOneMember_638270581179547060" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_StockOptionInducementAwardsMember_638270581179547060" xlink:to="xoma_StockOptionInducementAwardOneMember_638270581179547060" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_StockOptionInducementAwardTwoMember" xlink:label="xoma_StockOptionInducementAwardTwoMember_638270581179547060" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_StockOptionInducementAwardsMember_638270581179547060" xlink:to="xoma_StockOptionInducementAwardTwoMember_638270581179547060" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638270581179547060" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638270581179547060" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638270581179547060" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638270581179557221" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638270581179547060" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638270581179557221" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638270581179557221" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638270581179547060" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638270581179557221" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638270581179557221" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638270581179547060" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638270581179557221" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:label="us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_638270581179557221" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638270581179547060" xlink:to="us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_638270581179557221" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock" xlink:label="us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_638270581179577036" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638270581179547060" xlink:to="us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock_638270581179577036" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureCapitalStockTables" xlink:type="extended" xlink:title="31103 - Disclosure - Capital Stock (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsDeclaredTableTextBlock" xlink:label="us-gaap_DividendsDeclaredTableTextBlock_638270581179577036" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_DividendsDeclaredTableTextBlock_638270581179577036" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureDescriptionOfBusinessLiquidityDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Description of Business - Liquidity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638270581179587083" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638270581179587083" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesCashAndCashEquivalentsDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Basis of Presentation and Significant Accounting Policies - Cash and Cash Equivalents (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash_638270581179587083" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_Cash_638270581179587083" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_638270581179587083" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_638270581179587083" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesIntangibleAssetsAndIncomeTaxesDetails" xlink:type="extended" xlink:title="40202 - Disclosure - Basis of Presentation and Significant Accounting Policies - Intangible Assets and Income Taxes (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_638270581179587083" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_638270581179587083" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_638270581179587083" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_638270581179587083" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesConcentrationOfRiskDetails" xlink:type="extended" xlink:title="40203 - Disclosure - Basis of Presentation and Significant Accounting Policies - Concentration of Risk (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable_638270581179597075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskTable_638270581179597075" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_638270581179597075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_638270581179597075" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_638270581179597075" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_638270581179597075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis_638270581179597075" xlink:to="us-gaap_ConcentrationRiskTypeDomain_638270581179597075" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember_638270581179597075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain_638270581179597075" xlink:to="us-gaap_CustomerConcentrationRiskMember_638270581179597075" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditConcentrationRiskMember" xlink:label="us-gaap_CreditConcentrationRiskMember_638270581179597075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain_638270581179597075" xlink:to="us-gaap_CreditConcentrationRiskMember_638270581179597075" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_638270581179597075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_638270581179597075" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_638270581179597075" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_638270581179597075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis_638270581179597075" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_638270581179597075" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember_638270581179607100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain_638270581179597075" xlink:to="us-gaap_SalesRevenueNetMember_638270581179607100" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAccountsReceivableMember" xlink:label="us-gaap_TradeAccountsReceivableMember_638270581179607100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain_638270581179597075" xlink:to="us-gaap_TradeAccountsReceivableMember_638270581179607100" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis_638270581179607100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_638270581179597075" xlink:to="srt_MajorCustomersAxis_638270581179607100" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_638270581179607100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis_638270581179607100" xlink:to="srt_NameOfMajorCustomerDomain_638270581179607100" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_Partner1Member" xlink:label="xoma_Partner1Member_638270581179607100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_638270581179607100" xlink:to="xoma_Partner1Member_638270581179607100" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_Partner2Member" xlink:label="xoma_Partner2Member_638270581179607100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_638270581179607100" xlink:to="xoma_Partner2Member_638270581179607100" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_Partner3Member" xlink:label="xoma_Partner3Member_638270581179607100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_638270581179607100" xlink:to="xoma_Partner3Member_638270581179607100" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_Partner4Member" xlink:label="xoma_Partner4Member_638270581179607100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_638270581179607100" xlink:to="xoma_Partner4Member_638270581179607100" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems_638270581179607100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_638270581179597075" xlink:to="us-gaap_ConcentrationRiskLineItems_638270581179607100" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_NumberOfMajorPartners" xlink:label="xoma_NumberOfMajorPartners_638270581179607100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems_638270581179607100" xlink:to="xoma_NumberOfMajorPartners_638270581179607100" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1_638270581179617045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems_638270581179607100" xlink:to="us-gaap_ConcentrationRiskPercentage1_638270581179617045" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesLongTermContractsOrPrograms" xlink:label="us-gaap_ReceivablesLongTermContractsOrPrograms_638270581179617045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems_638270581179607100" xlink:to="us-gaap_ReceivablesLongTermContractsOrPrograms_638270581179617045" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsEquitySecuritiesDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Condensed Consolidated Financial Statements Details - Equity Securities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ConsolidatedFinancialStatementDetailAbstract" xlink:label="ConsolidatedFinancialStatementDetailAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:label="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_638270581179617045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedFinancialStatementDetailAbstract" xlink:to="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_638270581179617045" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_638270581179617045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_638270581179617045" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_638270581179617045" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain_638270581179617045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_638270581179617045" xlink:to="srt_EquityMethodInvesteeNameDomain_638270581179617045" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RezoluteIncMember" xlink:label="xoma_RezoluteIncMember_638270581179617045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain_638270581179617045" xlink:to="xoma_RezoluteIncMember_638270581179617045" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems" xlink:label="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_638270581179617045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_638270581179617045" xlink:to="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_638270581179617045" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFVNINoncurrent" xlink:label="us-gaap_EquitySecuritiesFVNINoncurrent_638270581179617045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_638270581179617045" xlink:to="us-gaap_EquitySecuritiesFVNINoncurrent_638270581179617045" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedGainLoss_638270581179617045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems_638270581179617045" xlink:to="us-gaap_EquitySecuritiesFvNiRealizedGainLoss_638270581179617045" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails" xlink:type="extended" xlink:title="40302 - Disclosure - Condensed Consolidated Financial Statements Details - Intangible assets, net (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ConsolidatedFinancialStatementDetailAbstract" xlink:label="ConsolidatedFinancialStatementDetailAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638270581179627041" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedFinancialStatementDetailAbstract_1" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638270581179627041" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638270581179627041" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638270581179627041" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638270581179627041" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638270581179627041" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638270581179627041" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638270581179627041" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntellectualPropertyMember" xlink:label="us-gaap_IntellectualPropertyMember_638270581179627041" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638270581179627041" xlink:to="us-gaap_IntellectualPropertyMember_638270581179627041" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_638270581179627041" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638270581179627041" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_638270581179627041" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_638270581179627041" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_638270581179627041" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_638270581179627041" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_638270581179627041" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_638270581179627041" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_638270581179627041" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_638270581179627041" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_638270581179627041" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_638270581179627041" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_638270581179627041" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_638270581179627041" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_638270581179627041" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_638270581179627041" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_638270581179627041" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_638270581179627041" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_638270581179637056" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_638270581179627041" xlink:to="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_638270581179637056" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_638270581179637056" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_638270581179637056" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_638270581179637056" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_638270581179637056" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_638270581179637056" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_638270581179637056" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_638270581179637056" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_638270581179637056" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_638270581179637056" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_638270581179637056" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_638270581179637056" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_638270581179637056" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_638270581179637056" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_638270581179637056" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_638270581179637056" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_FiniteLivedIntangibleAssetExpectedAmortizationThroughYearFive" xlink:label="xoma_FiniteLivedIntangibleAssetExpectedAmortizationThroughYearFive_638270581179637056" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_638270581179637056" xlink:to="xoma_FiniteLivedIntangibleAssetExpectedAmortizationThroughYearFive_638270581179637056" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsAccruedAndOtherLiabilitiesDetails" xlink:type="extended" xlink:title="40303 - Disclosure - Condensed Consolidated Financial Statements Details - Accrued and Other Liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ConsolidatedFinancialStatementDetailAbstract" xlink:label="ConsolidatedFinancialStatementDetailAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_638270581179637056" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedFinancialStatementDetailAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_638270581179637056" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AccruedSalariesAndEmployeeBenefitsCurrent" xlink:label="xoma_AccruedSalariesAndEmployeeBenefitsCurrent_638270581179647044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_638270581179637056" xlink:to="xoma_AccruedSalariesAndEmployeeBenefitsCurrent_638270581179647044" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent_638270581179647044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_638270581179637056" xlink:to="us-gaap_AccruedBonusesCurrent_638270581179647044" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_638270581179647044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_638270581179637056" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_638270581179647044" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_638270581179647044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_638270581179637056" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_638270581179647044" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AccruedAndOtherLiabilitiesCurrent" xlink:label="xoma_AccruedAndOtherLiabilitiesCurrent_638270581179647044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_638270581179637056" xlink:to="xoma_AccruedAndOtherLiabilitiesCurrent_638270581179647044" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsNetLossPerShareDetails" xlink:type="extended" xlink:title="40304 - Disclosure - Condensed Consolidated Financial Statements Details - Net Loss Per Share (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ConsolidatedFinancialStatementDetailAbstract" xlink:label="xoma_ConsolidatedFinancialStatementDetailAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_638270581179647044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_ConsolidatedFinancialStatementDetailAbstract_1" xlink:to="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_638270581179647044" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638270581179647044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_638270581179647044" xlink:to="us-gaap_StatementClassOfStockAxis_638270581179647044" order="1" use="optional" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638270581179647044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638270581179647044" xlink:to="us-gaap_ClassOfStockDomain_638270581179647044" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember_638270581179647044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638270581179647044" xlink:to="us-gaap_SeriesAPreferredStockMember_638270581179647044" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember_638270581179647044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638270581179647044" xlink:to="us-gaap_SeriesBPreferredStockMember_638270581179647044" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDilutedLineItems" xlink:label="us-gaap_EarningsPerShareDilutedLineItems_638270581179647044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_638270581179647044" xlink:to="us-gaap_EarningsPerShareDilutedLineItems_638270581179647044" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_638270581179657049" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedLineItems_638270581179647044" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_638270581179657049" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638270581179657049" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_638270581179657049" xlink:to="us-gaap_NetIncomeLoss_638270581179657049" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact_638270581179657049" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_638270581179657049" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact_638270581179657049" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638270581179657049" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_638270581179657049" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638270581179657049" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_638270581179657049" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_638270581179657049" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_638270581179657049" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638270581179657049" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedLineItems_638270581179647044" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638270581179657049" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638270581179657049" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638270581179657049" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638270581179657049" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638270581179657049" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638270581179657049" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638270581179657049" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638270581179657049" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638270581179657049" xlink:to="us-gaap_EarningsPerShareBasic_638270581179657049" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638270581179667083" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638270581179657049" xlink:to="us-gaap_EarningsPerShareDiluted_638270581179667083" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsOutstandingSecuritiesConsideredAntiDilutiveDetails" xlink:type="extended" xlink:title="40305 - Disclosure - Condensed Consolidated Financial Statements Details - Outstanding Securities Considered Anti-Dilutive (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ConsolidatedFinancialStatementDetailAbstract" xlink:label="xoma_ConsolidatedFinancialStatementDetailAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638270581179727058" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_ConsolidatedFinancialStatementDetailAbstract_2" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638270581179727058" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638270581179727058" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638270581179727058" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638270581179727058" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_638270581179727058" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638270581179727058" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_638270581179727058" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember_638270581179727058" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638270581179727058" xlink:to="us-gaap_ConvertiblePreferredStockMember_638270581179727058" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638270581179727058" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638270581179727058" xlink:to="us-gaap_EmployeeStockOptionMember_638270581179727058" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_638270581179727058" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638270581179727058" xlink:to="us-gaap_WarrantMember_638270581179727058" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638270581179737063" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638270581179727058" xlink:to="us-gaap_StatementEquityComponentsAxis_638270581179737063" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638270581179737063" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638270581179737063" xlink:to="us-gaap_EquityComponentDomain_638270581179737063" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638270581179737063" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_638270581179737063" xlink:to="us-gaap_CommonStockMember_638270581179737063" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638270581179737063" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638270581179727058" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638270581179737063" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638270581179737063" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638270581179737063" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638270581179737063" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_638270581179737063" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638270581179737063" xlink:to="us-gaap_SharePrice_638270581179737063" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsArbitrationProceedingDetails" xlink:type="extended" xlink:title="40306 - Disclosure - Condensed Consolidated Financial Statements Details - Arbitration Proceeding (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ConsolidatedFinancialStatementDetailAbstract" xlink:label="ConsolidatedFinancialStatementDetailAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_638270581179737063" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedFinancialStatementDetailAbstract_2" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_638270581179737063" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_NumberOfArbitrationProceedingsInitiated" xlink:label="xoma_NumberOfArbitrationProceedingsInitiated_638270581179737063" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_638270581179737063" xlink:to="xoma_NumberOfArbitrationProceedingsInitiated_638270581179737063" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementExpense" xlink:label="us-gaap_LitigationSettlementExpense_638270581179747061" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_638270581179737063" xlink:to="us-gaap_LitigationSettlementExpense_638270581179747061" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Licensing and Other Arrangements - ObsEva (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LicensingAndOtherArrangementsAbstract" xlink:label="LicensingAndOtherArrangementsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTable" xlink:label="us-gaap_AssetAcquisitionTable_638270581179747061" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicensingAndOtherArrangementsAbstract_1" xlink:to="us-gaap_AssetAcquisitionTable_638270581179747061" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis_638270581179747061" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable_638270581179747061" xlink:to="us-gaap_AssetAcquisitionAxis_638270581179747061" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain_638270581179747061" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAxis_638270581179747061" xlink:to="us-gaap_AssetAcquisitionDomain_638270581179747061" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ObsevaIntellectualPropertyRightsMember" xlink:label="xoma_ObsevaIntellectualPropertyRightsMember_638270581179747061" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionDomain_638270581179747061" xlink:to="xoma_ObsevaIntellectualPropertyRightsMember_638270581179747061" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638270581179747061" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable_638270581179747061" xlink:to="us-gaap_TypeOfArrangementAxis_638270581179747061" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638270581179747061" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638270581179747061" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638270581179747061" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LicenseAgreementMember" xlink:label="xoma_LicenseAgreementMember_638270581179747061" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638270581179747061" xlink:to="xoma_LicenseAgreementMember_638270581179747061" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638270581179747061" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable_638270581179747061" xlink:to="srt_CounterpartyNameAxis_638270581179747061" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638270581179747061" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638270581179747061" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638270581179747061" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ObsevaMember" xlink:label="xoma_ObsevaMember_638270581179747061" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638270581179747061" xlink:to="xoma_ObsevaMember_638270581179747061" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_OrganonMember" xlink:label="xoma_OrganonMember_638270581179757569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638270581179747061" xlink:to="xoma_OrganonMember_638270581179757569" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MerckKgaaMember" xlink:label="xoma_MerckKgaaMember_638270581179757569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638270581179747061" xlink:to="xoma_MerckKgaaMember_638270581179757569" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="us-gaap_AssetAcquisitionLineItems_638270581179757569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable_638270581179747061" xlink:to="us-gaap_AssetAcquisitionLineItems_638270581179757569" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentCommercializationAndSalesMilestones" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentCommercializationAndSalesMilestones_638270581179757569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638270581179757569" xlink:to="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentCommercializationAndSalesMilestones_638270581179757569" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_638270581179757569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638270581179757569" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets_638270581179757569" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MaximumEarnOutPayments" xlink:label="xoma_MaximumEarnOutPayments_638270581179757569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638270581179757569" xlink:to="xoma_MaximumEarnOutPayments_638270581179757569" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred_638270581179757569" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638270581179757569" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred_638270581179757569" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_638270581179767109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638270581179757569" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_638270581179767109" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ChangesInEstimatedFairValueOfContingentConsideration" xlink:label="xoma_ChangesInEstimatedFairValueOfContingentConsideration_638270581179767109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638270581179757569" xlink:to="xoma_ChangesInEstimatedFairValueOfContingentConsideration_638270581179767109" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet_638270581179767109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638270581179757569" xlink:to="us-gaap_CapitalizedContractCostNet_638270581179767109" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_638270581179767109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638270581179757569" xlink:to="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_638270581179767109" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_638270581179767109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638270581179757569" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_638270581179767109" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets_638270581179767109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638270581179757569" xlink:to="us-gaap_AmortizationOfIntangibleAssets_638270581179767109" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MaximumEarnOutPaymentsDevelopmentAndRegulatoryMilestonePayments" xlink:label="xoma_MaximumEarnOutPaymentsDevelopmentAndRegulatoryMilestonePayments_638270581179767109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638270581179757569" xlink:to="xoma_MaximumEarnOutPaymentsDevelopmentAndRegulatoryMilestonePayments_638270581179767109" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MaximumEarnOutPaymentsSalesBasedMilestonePayments" xlink:label="xoma_MaximumEarnOutPaymentsSalesBasedMilestonePayments_638270581179767109" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638270581179757569" xlink:to="xoma_MaximumEarnOutPaymentsSalesBasedMilestonePayments_638270581179767109" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet_638270581179777071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638270581179757569" xlink:to="us-gaap_ContractWithCustomerAssetNet_638270581179777071" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability_638270581179777071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638270581179757569" xlink:to="us-gaap_ContractWithCustomerLiability_638270581179777071" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638270581179777071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems_638270581179757569" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638270581179777071" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details" xlink:type="extended" xlink:title="40402 - Disclosure - Licensing and Other Arrangements - Novartis - NIS793 (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LicensingAndOtherArrangementsAbstract" xlink:label="LicensingAndOtherArrangementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581179777071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicensingAndOtherArrangementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581179777071" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638270581179777071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581179777071" xlink:to="srt_CounterpartyNameAxis_638270581179777071" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638270581179777071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638270581179777071" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638270581179777071" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_NovartisInternationalPharmaceuticalLtdMember" xlink:label="xoma_NovartisInternationalPharmaceuticalLtdMember_638270581179777071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638270581179777071" xlink:to="xoma_NovartisInternationalPharmaceuticalLtdMember_638270581179777071" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638270581179777071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581179777071" xlink:to="us-gaap_TypeOfArrangementAxis_638270581179777071" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638270581179787059" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638270581179777071" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638270581179787059" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LicenseAgreementMember" xlink:label="xoma_LicenseAgreementMember_638270581179787059" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638270581179787059" xlink:to="xoma_LicenseAgreementMember_638270581179787059" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638270581179787059" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581179777071" xlink:to="us-gaap_DebtInstrumentAxis_638270581179787059" order="3" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638270581179787059" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638270581179787059" xlink:to="us-gaap_DebtInstrumentNameDomain_638270581179787059" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_NovartisNoteMember" xlink:label="xoma_NovartisNoteMember_638270581179787059" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638270581179787059" xlink:to="xoma_NovartisNoteMember_638270581179787059" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179787059" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581179777071" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179787059" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AgreementTerminationPriorWrittenNoticePeriod" xlink:label="xoma_AgreementTerminationPriorWrittenNoticePeriod_638270581179787059" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179787059" xlink:to="xoma_AgreementTerminationPriorWrittenNoticePeriod_638270581179787059" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_NumberOfPerformanceObligations" xlink:label="xoma_NumberOfPerformanceObligations_638270581179787059" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179787059" xlink:to="xoma_NumberOfPerformanceObligations_638270581179787059" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ProceedsFromUpfrontPayment" xlink:label="xoma_ProceedsFromUpfrontPayment_638270581179787059" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179787059" xlink:to="xoma_ProceedsFromUpfrontPayment_638270581179787059" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638270581179787059" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179787059" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638270581179787059" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones_638270581179787059" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179787059" xlink:to="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones_638270581179787059" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RoyaltiesPeriodMinimum" xlink:label="xoma_RoyaltiesPeriodMinimum_638270581179787059" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179787059" xlink:to="xoma_RoyaltiesPeriodMinimum_638270581179787059" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xlink:label="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_638270581179797074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179787059" xlink:to="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_638270581179797074" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet_638270581179797074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179787059" xlink:to="us-gaap_ContractWithCustomerAssetNet_638270581179797074" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability_638270581179797074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179787059" xlink:to="us-gaap_ContractWithCustomerLiability_638270581179797074" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet_638270581179797074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179787059" xlink:to="us-gaap_CapitalizedContractCostNet_638270581179797074" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details" xlink:type="extended" xlink:title="40403 - Disclosure - Licensing and Other Arrangements - Novartis - VPM087 (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LicensingAndOtherArrangementsAbstract" xlink:label="LicensingAndOtherArrangementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581179797074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicensingAndOtherArrangementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581179797074" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638270581179797074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581179797074" xlink:to="srt_CounterpartyNameAxis_638270581179797074" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638270581179797074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638270581179797074" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638270581179797074" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_NovartisPharmaAGMember" xlink:label="xoma_NovartisPharmaAGMember_638270581179797074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638270581179797074" xlink:to="xoma_NovartisPharmaAGMember_638270581179797074" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638270581179807218" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581179797074" xlink:to="us-gaap_TypeOfArrangementAxis_638270581179807218" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638270581179807218" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638270581179807218" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638270581179807218" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember" xlink:label="xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_638270581179807218" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638270581179807218" xlink:to="xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_638270581179807218" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_XOMA052LicenseAgreementMember" xlink:label="xoma_XOMA052LicenseAgreementMember_638270581179807218" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_638270581179807218" xlink:to="xoma_XOMA052LicenseAgreementMember_638270581179807218" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_IL1TargetLicenseAgreementMember" xlink:label="xoma_IL1TargetLicenseAgreementMember_638270581179807218" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_638270581179807218" xlink:to="xoma_IL1TargetLicenseAgreementMember_638270581179807218" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638270581179807218" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581179797074" xlink:to="us-gaap_StatementEquityComponentsAxis_638270581179807218" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638270581179807218" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638270581179807218" xlink:to="us-gaap_EquityComponentDomain_638270581179807218" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638270581179807218" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_638270581179807218" xlink:to="us-gaap_CommonStockMember_638270581179807218" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179807218" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581179797074" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179807218" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LicenseAgreementTransactionPrice" xlink:label="xoma_LicenseAgreementTransactionPrice_638270581179807218" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179807218" xlink:to="xoma_LicenseAgreementTransactionPrice_638270581179807218" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LicenseAgreementConsiderationReceived" xlink:label="xoma_LicenseAgreementConsiderationReceived_638270581179817099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179807218" xlink:to="xoma_LicenseAgreementConsiderationReceived_638270581179817099" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ProceedsFromUpfrontPayment" xlink:label="xoma_ProceedsFromUpfrontPayment_638270581179817099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179807218" xlink:to="xoma_ProceedsFromUpfrontPayment_638270581179817099" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LicenseAgreementConsiderationReceivedDebtRepayment" xlink:label="xoma_LicenseAgreementConsiderationReceivedDebtRepayment_638270581179817099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179807218" xlink:to="xoma_LicenseAgreementConsiderationReceivedDebtRepayment_638270581179817099" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638270581179817099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179807218" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638270581179817099" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638270581179817099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179807218" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638270581179817099" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_638270581179817099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179807218" xlink:to="us-gaap_SharesIssuedPricePerShare_638270581179817099" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_StockIssuedDuringPeriodValueNewIssuesCommonStock" xlink:label="xoma_StockIssuedDuringPeriodValueNewIssuesCommonStock_638270581179817099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179807218" xlink:to="xoma_StockIssuedDuringPeriodValueNewIssuesCommonStock_638270581179817099" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_638270581179817099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179807218" xlink:to="us-gaap_SharePrice_638270581179817099" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_CommonStockPremium" xlink:label="xoma_CommonStockPremium_638270581179817099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179807218" xlink:to="xoma_CommonStockPremium_638270581179817099" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones_638270581179827061" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179807218" xlink:to="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones_638270581179827061" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_NumberOfLicenseAgreements" xlink:label="xoma_NumberOfLicenseAgreements_638270581179827061" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179807218" xlink:to="xoma_NumberOfLicenseAgreements_638270581179827061" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AgreementTerminationPriorWrittenNoticePeriod" xlink:label="xoma_AgreementTerminationPriorWrittenNoticePeriod_638270581179827061" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179807218" xlink:to="xoma_AgreementTerminationPriorWrittenNoticePeriod_638270581179827061" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ArrangementsNumber" xlink:label="xoma_ArrangementsNumber_638270581179827061" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179807218" xlink:to="xoma_ArrangementsNumber_638270581179827061" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_NumberOfPerformanceObligations" xlink:label="xoma_NumberOfPerformanceObligations_638270581179827061" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179807218" xlink:to="xoma_NumberOfPerformanceObligations_638270581179827061" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_638270581179827061" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179807218" xlink:to="us-gaap_RevenueRemainingPerformanceObligation_638270581179827061" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638270581179827061" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179807218" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638270581179827061" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet_638270581179827061" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179807218" xlink:to="us-gaap_ContractWithCustomerAssetNet_638270581179827061" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability_638270581179837059" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179807218" xlink:to="us-gaap_ContractWithCustomerLiability_638270581179837059" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet_638270581179837059" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179807218" xlink:to="us-gaap_CapitalizedContractCostNet_638270581179837059" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails" xlink:type="extended" xlink:title="40404 - Disclosure - Licensing and Other Arrangements - Takeda (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LicensingAndOtherArrangementsAbstract" xlink:label="LicensingAndOtherArrangementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581179837059" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicensingAndOtherArrangementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581179837059" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638270581179837059" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581179837059" xlink:to="srt_CounterpartyNameAxis_638270581179837059" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638270581179837059" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638270581179837059" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638270581179837059" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_TakedaPharmaceuticalCompanyLimitedMember" xlink:label="xoma_TakedaPharmaceuticalCompanyLimitedMember_638270581179837059" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638270581179837059" xlink:to="xoma_TakedaPharmaceuticalCompanyLimitedMember_638270581179837059" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638270581179837059" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581179837059" xlink:to="us-gaap_TypeOfArrangementAxis_638270581179837059" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638270581179847077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638270581179837059" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638270581179847077" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_CollaborationAgreementMember" xlink:label="xoma_CollaborationAgreementMember_638270581179847077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638270581179847077" xlink:to="xoma_CollaborationAgreementMember_638270581179847077" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LicenseAgreementMember" xlink:label="xoma_LicenseAgreementMember_638270581179847077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638270581179847077" xlink:to="xoma_LicenseAgreementMember_638270581179847077" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638270581179847077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581179837059" xlink:to="srt_ProductOrServiceAxis_638270581179847077" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638270581179847077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638270581179847077" xlink:to="srt_ProductsAndServicesDomain_638270581179847077" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MezagitamabMember" xlink:label="xoma_MezagitamabMember_638270581179847077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638270581179847077" xlink:to="xoma_MezagitamabMember_638270581179847077" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_OtherAntibodiesMember" xlink:label="xoma_OtherAntibodiesMember_638270581179847077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638270581179847077" xlink:to="xoma_OtherAntibodiesMember_638270581179847077" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179847077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581179837059" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179847077" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones_638270581179847077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179847077" xlink:to="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones_638270581179847077" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate" xlink:label="xoma_EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate_638270581179847077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179847077" xlink:to="xoma_EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate_638270581179847077" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RoyaltiesPeriodMinimum" xlink:label="xoma_RoyaltiesPeriodMinimum_638270581179847077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179847077" xlink:to="xoma_RoyaltiesPeriodMinimum_638270581179847077" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RoyaltiesPeriodMinimumScenarioOne" xlink:label="xoma_RoyaltiesPeriodMinimumScenarioOne_638270581179847077" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179847077" xlink:to="xoma_RoyaltiesPeriodMinimumScenarioOne_638270581179847077" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638270581179857099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179847077" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638270581179857099" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet_638270581179857099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179847077" xlink:to="us-gaap_ContractWithCustomerAssetNet_638270581179857099" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability_638270581179857099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179847077" xlink:to="us-gaap_ContractWithCustomerLiability_638270581179857099" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet_638270581179857099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179847077" xlink:to="us-gaap_CapitalizedContractCostNet_638270581179857099" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails" xlink:type="extended" xlink:title="40405 - Disclosure - Licensing and Other Arrangements - Rezolute (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LicensingAndOtherArrangementsAbstract" xlink:label="LicensingAndOtherArrangementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581179867102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicensingAndOtherArrangementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581179867102" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638270581179867102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581179867102" xlink:to="srt_CounterpartyNameAxis_638270581179867102" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638270581179867102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638270581179867102" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638270581179867102" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RezoluteIncMember" xlink:label="xoma_RezoluteIncMember_638270581179867102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638270581179867102" xlink:to="xoma_RezoluteIncMember_638270581179867102" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638270581179867102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581179867102" xlink:to="us-gaap_TypeOfArrangementAxis_638270581179867102" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638270581179867102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638270581179867102" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638270581179867102" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember" xlink:label="xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_638270581179867102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638270581179867102" xlink:to="xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_638270581179867102" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LicenseAgreementMember" xlink:label="xoma_LicenseAgreementMember_638270581179867102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_638270581179867102" xlink:to="xoma_LicenseAgreementMember_638270581179867102" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LicenseAgreementRz358Member" xlink:label="xoma_LicenseAgreementRz358Member_638270581179867102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_LicenseAgreementMember_638270581179867102" xlink:to="xoma_LicenseAgreementRz358Member_638270581179867102" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LicenseAgreementNonRz358ProductsMember" xlink:label="xoma_LicenseAgreementNonRz358ProductsMember_638270581179867102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_LicenseAgreementMember_638270581179867102" xlink:to="xoma_LicenseAgreementNonRz358ProductsMember_638270581179867102" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638270581179867102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581179867102" xlink:to="dei_LegalEntityAxis_638270581179867102" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638270581179867102" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638270581179867102" xlink:to="dei_EntityDomain_638270581179867102" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RezoluteIncMember" xlink:label="xoma_RezoluteIncMember_6382705811798671021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638270581179867102" xlink:to="xoma_RezoluteIncMember_6382705811798671021" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179877064" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581179867102" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179877064" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones_638270581179877064" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179877064" xlink:to="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones_638270581179877064" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RoyaltiesPeriodMinimum" xlink:label="xoma_RoyaltiesPeriodMinimum_638270581179877064" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179877064" xlink:to="xoma_RoyaltiesPeriodMinimum_638270581179877064" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_PercentageOfDecreaseInFutureRoyaltyObligations" xlink:label="xoma_PercentageOfDecreaseInFutureRoyaltyObligations_638270581179877064" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179877064" xlink:to="xoma_PercentageOfDecreaseInFutureRoyaltyObligations_638270581179877064" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AgreementTerminationPriorWrittenNoticePeriod" xlink:label="xoma_AgreementTerminationPriorWrittenNoticePeriod_638270581179877064" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179877064" xlink:to="xoma_AgreementTerminationPriorWrittenNoticePeriod_638270581179877064" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LicenseAgreementConsiderationReceived" xlink:label="xoma_LicenseAgreementConsiderationReceived_638270581179877064" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179877064" xlink:to="xoma_LicenseAgreementConsiderationReceived_638270581179877064" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638270581179877064" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179877064" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638270581179877064" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LicenseAgreementConsiderationReceivedAchievementOfFinancingActivities" xlink:label="xoma_LicenseAgreementConsiderationReceivedAchievementOfFinancingActivities_638270581179877064" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179877064" xlink:to="xoma_LicenseAgreementConsiderationReceivedAchievementOfFinancingActivities_638270581179877064" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LicenseAgreementInstallmentPaymentsReceived" xlink:label="xoma_LicenseAgreementInstallmentPaymentsReceived_638270581179877064" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179877064" xlink:to="xoma_LicenseAgreementInstallmentPaymentsReceived_638270581179877064" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LicenseAgreementSharesReceived" xlink:label="xoma_LicenseAgreementSharesReceived_638270581179877064" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179877064" xlink:to="xoma_LicenseAgreementSharesReceived_638270581179877064" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_638270581179887064" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179877064" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_638270581179887064" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet_638270581179887064" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179877064" xlink:to="us-gaap_ContractWithCustomerAssetNet_638270581179887064" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability_638270581179887064" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179877064" xlink:to="us-gaap_ContractWithCustomerLiability_638270581179887064" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet_638270581179887064" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179877064" xlink:to="us-gaap_CapitalizedContractCostNet_638270581179887064" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails" xlink:type="extended" xlink:title="40406 - Disclosure - Licensing and Other Arrangements - Janssen Biotech (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LicensingAndOtherArrangementsAbstract" xlink:label="LicensingAndOtherArrangementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581179887064" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicensingAndOtherArrangementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581179887064" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638270581179887064" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581179887064" xlink:to="srt_CounterpartyNameAxis_638270581179887064" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638270581179887064" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638270581179887064" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638270581179887064" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_JanssenBiotechInc.Member" xlink:label="xoma_JanssenBiotechInc.Member_638270581179897117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638270581179887064" xlink:to="xoma_JanssenBiotechInc.Member_638270581179897117" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638270581179897117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581179887064" xlink:to="us-gaap_TypeOfArrangementAxis_638270581179897117" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638270581179897117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638270581179897117" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638270581179897117" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LicenseAgreementMember" xlink:label="xoma_LicenseAgreementMember_638270581179897117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638270581179897117" xlink:to="xoma_LicenseAgreementMember_638270581179897117" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638270581179897117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581179887064" xlink:to="srt_ProductOrServiceAxis_638270581179897117" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638270581179897117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638270581179897117" xlink:to="srt_ProductsAndServicesDomain_638270581179897117" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MilestoneDosingFirstPatientInClinicalTrialMember" xlink:label="xoma_MilestoneDosingFirstPatientInClinicalTrialMember_638270581179897117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638270581179897117" xlink:to="xoma_MilestoneDosingFirstPatientInClinicalTrialMember_638270581179897117" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MilestonePursuantToAgreementMember" xlink:label="xoma_MilestonePursuantToAgreementMember_638270581179897117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638270581179897117" xlink:to="xoma_MilestonePursuantToAgreementMember_638270581179897117" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179897117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581179887064" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179897117" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ProceedsFromUpfrontPayment" xlink:label="xoma_ProceedsFromUpfrontPayment_638270581179897117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179897117" xlink:to="xoma_ProceedsFromUpfrontPayment_638270581179897117" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents" xlink:label="xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents_638270581179907071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179897117" xlink:to="xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents_638270581179907071" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_PercentageOfRoyaltyOnNetSalesUponCommercialization" xlink:label="xoma_PercentageOfRoyaltyOnNetSalesUponCommercialization_638270581179907071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179897117" xlink:to="xoma_PercentageOfRoyaltyOnNetSalesUponCommercialization_638270581179907071" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_NumberOfMilestonesEarned" xlink:label="xoma_NumberOfMilestonesEarned_638270581179907071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179897117" xlink:to="xoma_NumberOfMilestonesEarned_638270581179907071" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638270581179907071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179897117" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638270581179907071" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet_638270581179907071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179897117" xlink:to="us-gaap_ContractWithCustomerAssetNet_638270581179907071" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability_638270581179907071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179897117" xlink:to="us-gaap_ContractWithCustomerLiability_638270581179907071" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet_638270581179907071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179897117" xlink:to="us-gaap_CapitalizedContractCostNet_638270581179907071" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsAffimedDetails" xlink:type="extended" xlink:title="40407 - Disclosure - Licensing and Other Arrangements - Affimed (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LicensingAndOtherArrangementsAbstract" xlink:label="LicensingAndOtherArrangementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581179917067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicensingAndOtherArrangementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581179917067" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638270581179917067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581179917067" xlink:to="us-gaap_TypeOfArrangementAxis_638270581179917067" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638270581179917067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638270581179917067" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638270581179917067" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LicenseAgreementMember" xlink:label="xoma_LicenseAgreementMember_638270581179917067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638270581179917067" xlink:to="xoma_LicenseAgreementMember_638270581179917067" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638270581179917067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581179917067" xlink:to="srt_CounterpartyNameAxis_638270581179917067" order="2" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638270581179917067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638270581179917067" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638270581179917067" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AffimedMember" xlink:label="xoma_AffimedMember_638270581179917067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638270581179917067" xlink:to="xoma_AffimedMember_638270581179917067" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179917067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581179917067" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179917067" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="us-gaap_ContractWithCustomerAssetNet_638270581179927443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179917067" xlink:to="us-gaap_ContractWithCustomerAssetNet_638270581179927443" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability_638270581179927443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179917067" xlink:to="us-gaap_ContractWithCustomerLiability_638270581179927443" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet_638270581179927443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179917067" xlink:to="us-gaap_CapitalizedContractCostNet_638270581179927443" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638270581179927443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179917067" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638270581179927443" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails" xlink:type="extended" xlink:title="40408 - Disclosure - Licensing and Other Arrangements - Sale of Future Revenue Streams (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LicensingAndOtherArrangementsAbstract" xlink:label="LicensingAndOtherArrangementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581179927443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicensingAndOtherArrangementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581179927443" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638270581179927443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581179927443" xlink:to="srt_CounterpartyNameAxis_638270581179927443" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638270581179927443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638270581179927443" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638270581179927443" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember" xlink:label="xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_638270581179927443" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638270581179927443" xlink:to="xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_638270581179927443" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638270581179937091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581179927443" xlink:to="us-gaap_TypeOfArrangementAxis_638270581179937091" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638270581179937091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638270581179937091" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638270581179937091" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RoyaltyInterestAcquisitionAgreementsMember" xlink:label="xoma_RoyaltyInterestAcquisitionAgreementsMember_638270581179937091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638270581179937091" xlink:to="xoma_RoyaltyInterestAcquisitionAgreementsMember_638270581179937091" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_FirstRoyaltyInterestAcquisitionAgreementMember" xlink:label="xoma_FirstRoyaltyInterestAcquisitionAgreementMember_638270581179937091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_RoyaltyInterestAcquisitionAgreementsMember_638270581179937091" xlink:to="xoma_FirstRoyaltyInterestAcquisitionAgreementMember_638270581179937091" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_SecondRoyaltyInterestAcquisitionAgreementMember" xlink:label="xoma_SecondRoyaltyInterestAcquisitionAgreementMember_638270581179937091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_RoyaltyInterestAcquisitionAgreementsMember_638270581179937091" xlink:to="xoma_SecondRoyaltyInterestAcquisitionAgreementMember_638270581179937091" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179937091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581179927443" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179937091" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_NumberOfRoyaltyInterestAcquisitionAgreements" xlink:label="xoma_NumberOfRoyaltyInterestAcquisitionAgreements_638270581179937091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179937091" xlink:to="xoma_NumberOfRoyaltyInterestAcquisitionAgreements_638270581179937091" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ProceedsFromUpfrontPayment" xlink:label="xoma_ProceedsFromUpfrontPayment_638270581179937091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179937091" xlink:to="xoma_ProceedsFromUpfrontPayment_638270581179937091" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones" xlink:label="xoma_EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones_638270581179937091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179937091" xlink:to="xoma_EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones_638270581179937091" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MilestonePeriodsNumber" xlink:label="xoma_MilestonePeriodsNumber_638270581179937091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179937091" xlink:to="xoma_MilestonePeriodsNumber_638270581179937091" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_638270581179937091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179937091" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_638270581179937091" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="us-gaap_RevenueNotFromContractWithCustomer_638270581179937091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179937091" xlink:to="us-gaap_RevenueNotFromContractWithCustomer_638270581179937091" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeCurrent" xlink:label="us-gaap_DeferredIncomeCurrent_638270581179947071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179937091" xlink:to="us-gaap_DeferredIncomeCurrent_638270581179947071" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeNoncurrent" xlink:label="us-gaap_DeferredIncomeNoncurrent_638270581179947071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179937091" xlink:to="us-gaap_DeferredIncomeNoncurrent_638270581179947071" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Summary (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:label="RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581179947071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581179947071" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638270581179947071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581179947071" xlink:to="srt_CounterpartyNameAxis_638270581179947071" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638270581179947071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638270581179947071" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638270581179947071" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AgenusIncMember" xlink:label="xoma_AgenusIncMember_638270581179947071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638270581179947071" xlink:to="xoma_AgenusIncMember_638270581179947071" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_BioasisTechnologiesIncMember" xlink:label="xoma_BioasisTechnologiesIncMember_638270581179947071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638270581179947071" xlink:to="xoma_BioasisTechnologiesIncMember_638270581179947071" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AronoraIncMember" xlink:label="xoma_AronoraIncMember_638270581179947071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638270581179947071" xlink:to="xoma_AronoraIncMember_638270581179947071" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_PalobiofarmaSLMember" xlink:label="xoma_PalobiofarmaSLMember_638270581179947071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638270581179947071" xlink:to="xoma_PalobiofarmaSLMember_638270581179947071" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ViractaTherapeuticsInc.Member" xlink:label="xoma_ViractaTherapeuticsInc.Member_638270581179957070" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638270581179947071" xlink:to="xoma_ViractaTherapeuticsInc.Member_638270581179957070" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember" xlink:label="xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_638270581179957070" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638270581179947071" xlink:to="xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_638270581179957070" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AffitechResearchAsMember" xlink:label="xoma_AffitechResearchAsMember_638270581179957070" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638270581179947071" xlink:to="xoma_AffitechResearchAsMember_638270581179957070" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179957070" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581179947071" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179957070" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RightsReceivableCurrent" xlink:label="xoma_RightsReceivableCurrent_638270581179957070" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179957070" xlink:to="xoma_RightsReceivableCurrent_638270581179957070" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LongTermRightsReceivableNonCurrent" xlink:label="xoma_LongTermRightsReceivableNonCurrent_638270581179957070" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179957070" xlink:to="xoma_LongTermRightsReceivableNonCurrent_638270581179957070" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails" xlink:type="extended" xlink:title="40502 - Disclosure - Royalty and Commercial Payment Purchase Agreements - LadRx (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:label="xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581179957070" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract_1" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581179957070" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638270581179957070" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581179957070" xlink:to="srt_CounterpartyNameAxis_638270581179957070" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638270581179957070" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638270581179957070" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638270581179957070" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LadrxMember" xlink:label="xoma_LadrxMember_638270581179957070" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638270581179957070" xlink:to="xoma_LadrxMember_638270581179957070" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638270581179967184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581179957070" xlink:to="us-gaap_TypeOfArrangementAxis_638270581179967184" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638270581179967184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638270581179967184" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638270581179967184" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember" xlink:label="xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_638270581179967184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638270581179967184" xlink:to="xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_638270581179967184" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AssignmentAndAssumptionAgreementMember" xlink:label="xoma_AssignmentAndAssumptionAgreementMember_638270581179967184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_638270581179967184" xlink:to="xoma_AssignmentAndAssumptionAgreementMember_638270581179967184" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RoyaltyPurchaseAgreementMember" xlink:label="xoma_RoyaltyPurchaseAgreementMember_638270581179967184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_638270581179967184" xlink:to="xoma_RoyaltyPurchaseAgreementMember_638270581179967184" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638270581179967184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581179957070" xlink:to="srt_ProductOrServiceAxis_638270581179967184" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638270581179967184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638270581179967184" xlink:to="srt_ProductsAndServicesDomain_638270581179967184" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ArimoclomolMember" xlink:label="xoma_ArimoclomolMember_638270581179967184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638270581179967184" xlink:to="xoma_ArimoclomolMember_638270581179967184" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AldoxorubicinMember" xlink:label="xoma_AldoxorubicinMember_638270581179967184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638270581179967184" xlink:to="xoma_AldoxorubicinMember_638270581179967184" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis_638270581179977097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581179957070" xlink:to="us-gaap_ContingentConsiderationByTypeAxis_638270581179977097" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain_638270581179977097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationByTypeAxis_638270581179977097" xlink:to="us-gaap_ContingentConsiderationTypeDomain_638270581179977097" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ContingentConsiderationRegulatoryMilestonesMember" xlink:label="xoma_ContingentConsiderationRegulatoryMilestonesMember_638270581179977097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain_638270581179977097" xlink:to="xoma_ContingentConsiderationRegulatoryMilestonesMember_638270581179977097" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179977097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581179957070" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179977097" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndCommercialMilestonesNet" xlink:label="xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndCommercialMilestonesNet_638270581179977097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179977097" xlink:to="xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndCommercialMilestonesNet_638270581179977097" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MaximumPaymentObligationsBasedOnPortionOfRegulatoryAndCommercialPayments" xlink:label="xoma_MaximumPaymentObligationsBasedOnPortionOfRegulatoryAndCommercialPayments_638270581179977097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179977097" xlink:to="xoma_MaximumPaymentObligationsBasedOnPortionOfRegulatoryAndCommercialPayments_638270581179977097" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MaximumRegulatoryAndCommercialMilestones" xlink:label="xoma_MaximumRegulatoryAndCommercialMilestones_638270581179977097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179977097" xlink:to="xoma_MaximumRegulatoryAndCommercialMilestones_638270581179977097" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" xlink:label="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities_638270581179977097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179977097" xlink:to="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities_638270581179977097" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndSalesMilestones" xlink:label="xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndSalesMilestones_638270581179977097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179977097" xlink:to="xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndSalesMilestones_638270581179977097" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MaximumPayableOnRegulatoryMilestone" xlink:label="xoma_MaximumPayableOnRegulatoryMilestone_638270581179977097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179977097" xlink:to="xoma_MaximumPayableOnRegulatoryMilestone_638270581179977097" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MaximumPayableOnSalesMilestone" xlink:label="xoma_MaximumPayableOnSalesMilestone_638270581179987075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179977097" xlink:to="xoma_MaximumPayableOnSalesMilestone_638270581179987075" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ContingentConsiderationUnderPurchaseAgreements" xlink:label="xoma_ContingentConsiderationUnderPurchaseAgreements_638270581179987075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179977097" xlink:to="xoma_ContingentConsiderationUnderPurchaseAgreements_638270581179987075" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LongTermRightsReceivableNonCurrent" xlink:label="xoma_LongTermRightsReceivableNonCurrent_638270581179987075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179977097" xlink:to="xoma_LongTermRightsReceivableNonCurrent_638270581179987075" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" xlink:label="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss_638270581179987075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581179977097" xlink:to="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss_638270581179987075" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails" xlink:type="extended" xlink:title="40503 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Aptevo (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:label="xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581179987075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581179987075" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638270581179987075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581179987075" xlink:to="srt_CounterpartyNameAxis_638270581179987075" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638270581179997114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638270581179987075" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638270581179997114" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AptevoMember" xlink:label="xoma_AptevoMember_638270581179997114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638270581179997114" xlink:to="xoma_AptevoMember_638270581179997114" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MedexusMember" xlink:label="xoma_MedexusMember_638270581179997114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638270581179997114" xlink:to="xoma_MedexusMember_638270581179997114" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638270581179997114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581179987075" xlink:to="us-gaap_TypeOfArrangementAxis_638270581179997114" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638270581179997114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638270581179997114" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638270581179997114" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_CommercialPaymentPurchaseAgreementMember" xlink:label="xoma_CommercialPaymentPurchaseAgreementMember_638270581179997114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638270581179997114" xlink:to="xoma_CommercialPaymentPurchaseAgreementMember_638270581179997114" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis_638270581179997114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581179987075" xlink:to="us-gaap_ContingentConsiderationByTypeAxis_638270581179997114" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain_638270581179997114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationByTypeAxis_638270581179997114" xlink:to="us-gaap_ContingentConsiderationTypeDomain_638270581179997114" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ContingentConsiderationRegulatoryMilestonesMember" xlink:label="xoma_ContingentConsiderationRegulatoryMilestonesMember_638270581179997114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain_638270581179997114" xlink:to="xoma_ContingentConsiderationRegulatoryMilestonesMember_638270581179997114" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638270581179997114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581179987075" xlink:to="srt_RangeAxis_638270581179997114" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638270581179997114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638270581179997114" xlink:to="srt_RangeMember_638270581179997114" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638270581179997114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638270581179997114" xlink:to="srt_MinimumMember_638270581179997114" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180007165" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581179987075" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180007165" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MilestonesReceivableMaximum" xlink:label="xoma_MilestonesReceivableMaximum_638270581180007165" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180007165" xlink:to="xoma_MilestonesReceivableMaximum_638270581180007165" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LongTermRightsReceivableNonCurrent" xlink:label="xoma_LongTermRightsReceivableNonCurrent_638270581180007165" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180007165" xlink:to="xoma_LongTermRightsReceivableNonCurrent_638270581180007165" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" xlink:label="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities_638270581180007165" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180007165" xlink:to="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities_638270581180007165" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ContingentConsiderationUnderPurchaseAgreements" xlink:label="xoma_ContingentConsiderationUnderPurchaseAgreements_638270581180007165" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180007165" xlink:to="xoma_ContingentConsiderationUnderPurchaseAgreements_638270581180007165" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_CommercialPaymentThresholdOneTimePayment" xlink:label="xoma_CommercialPaymentThresholdOneTimePayment_638270581180007165" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180007165" xlink:to="xoma_CommercialPaymentThresholdOneTimePayment_638270581180007165" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ReceiptsUnderAgreementsInvestingActivities" xlink:label="xoma_ReceiptsUnderAgreementsInvestingActivities_638270581180007165" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180007165" xlink:to="xoma_ReceiptsUnderAgreementsInvestingActivities_638270581180007165" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" xlink:label="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent_638270581180007165" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180007165" xlink:to="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent_638270581180007165" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RightsReceivableCurrent" xlink:label="xoma_RightsReceivableCurrent_638270581180007165" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180007165" xlink:to="xoma_RightsReceivableCurrent_638270581180007165" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" xlink:label="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss_638270581180007165" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180007165" xlink:to="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss_638270581180007165" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails" xlink:type="extended" xlink:title="40504 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Agenus (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:label="RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581180017074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581180017074" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638270581180017074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581180017074" xlink:to="srt_CounterpartyNameAxis_638270581180017074" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638270581180017074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638270581180017074" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638270581180017074" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AgenusIncMember" xlink:label="xoma_AgenusIncMember_638270581180017074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638270581180017074" xlink:to="xoma_AgenusIncMember_638270581180017074" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638270581180017074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581180017074" xlink:to="us-gaap_TypeOfArrangementAxis_638270581180017074" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638270581180017074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638270581180017074" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638270581180017074" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RoyaltyPurchaseAgreementMember" xlink:label="xoma_RoyaltyPurchaseAgreementMember_638270581180017074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638270581180017074" xlink:to="xoma_RoyaltyPurchaseAgreementMember_638270581180017074" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638270581180017074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581180017074" xlink:to="srt_ProductOrServiceAxis_638270581180017074" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638270581180017074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638270581180017074" xlink:to="srt_ProductsAndServicesDomain_638270581180017074" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_IncyteImmunoOncologyAssetsMember" xlink:label="xoma_IncyteImmunoOncologyAssetsMember_638270581180027115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638270581180017074" xlink:to="xoma_IncyteImmunoOncologyAssetsMember_638270581180027115" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MerckImmunoOncologyProductMember" xlink:label="xoma_MerckImmunoOncologyProductMember_638270581180027115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638270581180017074" xlink:to="xoma_MerckImmunoOncologyProductMember_638270581180027115" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638270581180027115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581180017074" xlink:to="us-gaap_DebtInstrumentAxis_638270581180027115" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638270581180027115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638270581180027115" xlink:to="us-gaap_DebtInstrumentNameDomain_638270581180027115" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_SiliconValleyBankMember" xlink:label="xoma_SiliconValleyBankMember_638270581180027115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638270581180027115" xlink:to="xoma_SiliconValleyBankMember_638270581180027115" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638270581180027115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581180017074" xlink:to="dei_LegalEntityAxis_638270581180027115" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638270581180027115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638270581180027115" xlink:to="dei_EntityDomain_638270581180027115" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AgenusIncMember" xlink:label="xoma_AgenusIncMember_638270581180027115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638270581180027115" xlink:to="xoma_AgenusIncMember_638270581180027115" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180027115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581180017074" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180027115" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RoyaltyReceivablePercentageOnNetSales" xlink:label="xoma_RoyaltyReceivablePercentageOnNetSales_638270581180037232" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180027115" xlink:to="xoma_RoyaltyReceivablePercentageOnNetSales_638270581180037232" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased" xlink:label="xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased_638270581180037232" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180027115" xlink:to="xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased_638270581180037232" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_PurchasedPercentageOfMilestones" xlink:label="xoma_PurchasedPercentageOfMilestones_638270581180037232" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180027115" xlink:to="xoma_PurchasedPercentageOfMilestones_638270581180037232" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones" xlink:label="xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones_638270581180037232" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180027115" xlink:to="xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones_638270581180037232" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" xlink:label="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities_638270581180037232" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180027115" xlink:to="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities_638270581180037232" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LongTermRightsReceivableNonCurrent" xlink:label="xoma_LongTermRightsReceivableNonCurrent_638270581180037232" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180027115" xlink:to="xoma_LongTermRightsReceivableNonCurrent_638270581180037232" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MilestoneAchieved" xlink:label="xoma_MilestoneAchieved_638270581180037232" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180027115" xlink:to="xoma_MilestoneAchieved_638270581180037232" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" xlink:label="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss_638270581180037232" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180027115" xlink:to="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss_638270581180037232" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" xlink:label="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent_638270581180047084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180027115" xlink:to="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent_638270581180047084" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails" xlink:type="extended" xlink:title="40505 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Bioasis (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:label="RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581180047084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581180047084" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638270581180047084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581180047084" xlink:to="srt_CounterpartyNameAxis_638270581180047084" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638270581180047084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638270581180047084" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638270581180047084" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_BioasisTechnologiesIncMember" xlink:label="xoma_BioasisTechnologiesIncMember_638270581180047084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638270581180047084" xlink:to="xoma_BioasisTechnologiesIncMember_638270581180047084" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638270581180047084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581180047084" xlink:to="us-gaap_TypeOfArrangementAxis_638270581180047084" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638270581180047084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638270581180047084" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638270581180047084" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RoyaltyPurchaseAgreementAndSecondRoyaltyPurchaseAgreementMember" xlink:label="xoma_RoyaltyPurchaseAgreementAndSecondRoyaltyPurchaseAgreementMember_638270581180047084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638270581180047084" xlink:to="xoma_RoyaltyPurchaseAgreementAndSecondRoyaltyPurchaseAgreementMember_638270581180047084" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RoyaltyPurchaseAgreementMember" xlink:label="xoma_RoyaltyPurchaseAgreementMember_638270581180047084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_RoyaltyPurchaseAgreementAndSecondRoyaltyPurchaseAgreementMember_638270581180047084" xlink:to="xoma_RoyaltyPurchaseAgreementMember_638270581180047084" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RoyaltyPurchaseAgreementTwoMember" xlink:label="xoma_RoyaltyPurchaseAgreementTwoMember_638270581180047084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_RoyaltyPurchaseAgreementAndSecondRoyaltyPurchaseAgreementMember_638270581180047084" xlink:to="xoma_RoyaltyPurchaseAgreementTwoMember_638270581180047084" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638270581180057080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581180047084" xlink:to="srt_RangeAxis_638270581180057080" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638270581180057080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638270581180057080" xlink:to="srt_RangeMember_638270581180057080" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638270581180057080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638270581180057080" xlink:to="srt_MaximumMember_638270581180057080" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180057080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581180047084" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180057080" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements" xlink:label="xoma_PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements_638270581180057080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180057080" xlink:to="xoma_PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements_638270581180057080" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_NumberOfLicenseAgreementsFutureLicenseAgreements" xlink:label="xoma_NumberOfLicenseAgreementsFutureLicenseAgreements_638270581180057080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180057080" xlink:to="xoma_NumberOfLicenseAgreementsFutureLicenseAgreements_638270581180057080" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_PaymentsToBeMadeUponExerciseOfOptionSecondLicenseAgreement" xlink:label="xoma_PaymentsToBeMadeUponExerciseOfOptionSecondLicenseAgreement_638270581180057080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180057080" xlink:to="xoma_PaymentsToBeMadeUponExerciseOfOptionSecondLicenseAgreement_638270581180057080" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_PaymentsToBeMadeUponExerciseOfOptionThirdLicenseAgreement" xlink:label="xoma_PaymentsToBeMadeUponExerciseOfOptionThirdLicenseAgreement_638270581180057080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180057080" xlink:to="xoma_PaymentsToBeMadeUponExerciseOfOptionThirdLicenseAgreement_638270581180057080" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" xlink:label="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities_638270581180057080" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180057080" xlink:to="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities_638270581180057080" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ContingentFutureCashPayments" xlink:label="xoma_ContingentFutureCashPayments_638270581180067091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180057080" xlink:to="xoma_ContingentFutureCashPayments_638270581180067091" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ImpairmentOfLongTermRightsReceivableNonCurrent" xlink:label="xoma_ImpairmentOfLongTermRightsReceivableNonCurrent_638270581180067091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180057080" xlink:to="xoma_ImpairmentOfLongTermRightsReceivableNonCurrent_638270581180067091" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LongTermRightsReceivableNonCurrentIncreaseDecrease" xlink:label="xoma_LongTermRightsReceivableNonCurrentIncreaseDecrease_638270581180067091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180057080" xlink:to="xoma_LongTermRightsReceivableNonCurrentIncreaseDecrease_638270581180067091" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ContingentConsiderationUnderPurchaseAgreements" xlink:label="xoma_ContingentConsiderationUnderPurchaseAgreements_638270581180067091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180057080" xlink:to="xoma_ContingentConsiderationUnderPurchaseAgreements_638270581180067091" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ChangesInEstimatedFairValueOfContingentConsideration" xlink:label="xoma_ChangesInEstimatedFairValueOfContingentConsideration_638270581180067091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180057080" xlink:to="xoma_ChangesInEstimatedFairValueOfContingentConsideration_638270581180067091" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ReceiptsUnderAgreementsInvestingActivities" xlink:label="xoma_ReceiptsUnderAgreementsInvestingActivities_638270581180067091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180057080" xlink:to="xoma_ReceiptsUnderAgreementsInvestingActivities_638270581180067091" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" xlink:label="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss_638270581180077123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180057080" xlink:to="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss_638270581180077123" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LongTermRightsReceivableNonCurrent" xlink:label="xoma_LongTermRightsReceivableNonCurrent_638270581180077123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180057080" xlink:to="xoma_LongTermRightsReceivableNonCurrent_638270581180077123" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails" xlink:type="extended" xlink:title="40506 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Aronora (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:label="RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581180077123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581180077123" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638270581180077123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581180077123" xlink:to="srt_CounterpartyNameAxis_638270581180077123" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638270581180077123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638270581180077123" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638270581180077123" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AronoraIncMember" xlink:label="xoma_AronoraIncMember_638270581180077123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638270581180077123" xlink:to="xoma_AronoraIncMember_638270581180077123" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638270581180087216" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581180077123" xlink:to="us-gaap_TypeOfArrangementAxis_638270581180087216" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638270581180087216" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638270581180087216" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638270581180087216" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RoyaltyPurchaseAgreementMember" xlink:label="xoma_RoyaltyPurchaseAgreementMember_638270581180087216" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638270581180087216" xlink:to="xoma_RoyaltyPurchaseAgreementMember_638270581180087216" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638270581180087216" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581180077123" xlink:to="srt_ProductOrServiceAxis_638270581180087216" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638270581180087216" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638270581180087216" xlink:to="srt_ProductsAndServicesDomain_638270581180087216" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_BayerProductsMember" xlink:label="xoma_BayerProductsMember_638270581180087216" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638270581180087216" xlink:to="xoma_BayerProductsMember_638270581180087216" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_NonBayerProductsMember" xlink:label="xoma_NonBayerProductsMember_638270581180087216" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638270581180087216" xlink:to="xoma_NonBayerProductsMember_638270581180087216" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638270581180087216" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581180077123" xlink:to="us-gaap_DebtInstrumentAxis_638270581180087216" order="4" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638270581180087216" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638270581180087216" xlink:to="us-gaap_DebtInstrumentNameDomain_638270581180087216" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_SiliconValleyBankMember" xlink:label="xoma_SiliconValleyBankMember_638270581180087216" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638270581180087216" xlink:to="xoma_SiliconValleyBankMember_638270581180087216" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638270581180087216" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581180077123" xlink:to="srt_RangeAxis_638270581180087216" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638270581180097139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638270581180087216" xlink:to="srt_RangeMember_638270581180097139" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638270581180097139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638270581180097139" xlink:to="srt_MaximumMember_638270581180097139" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180097139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581180077123" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180097139" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AgreementDrugCandidatesNumber" xlink:label="xoma_AgreementDrugCandidatesNumber_638270581180097139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180097139" xlink:to="xoma_AgreementDrugCandidatesNumber_638270581180097139" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AgreementDrugCandidatesExclusiveLicenseOptionNumber" xlink:label="xoma_AgreementDrugCandidatesExclusiveLicenseOptionNumber_638270581180097139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180097139" xlink:to="xoma_AgreementDrugCandidatesExclusiveLicenseOptionNumber_638270581180097139" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RoyaltyReceivablePercentageOnNetSales" xlink:label="xoma_RoyaltyReceivablePercentageOnNetSales_638270581180097139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180097139" xlink:to="xoma_RoyaltyReceivablePercentageOnNetSales_638270581180097139" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts" xlink:label="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts_638270581180097139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180097139" xlink:to="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts_638270581180097139" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage" xlink:label="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage_638270581180097139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180097139" xlink:to="xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage_638270581180097139" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AgreementPaymentPercentageFactor" xlink:label="xoma_AgreementPaymentPercentageFactor_638270581180097139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180097139" xlink:to="xoma_AgreementPaymentPercentageFactor_638270581180097139" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" xlink:label="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities_638270581180107113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180097139" xlink:to="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities_638270581180107113" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ContingentFutureCashPaymentsPerProduct" xlink:label="xoma_ContingentFutureCashPaymentsPerProduct_638270581180107113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180097139" xlink:to="xoma_ContingentFutureCashPaymentsPerProduct_638270581180107113" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ContingentFutureCashPayments" xlink:label="xoma_ContingentFutureCashPayments_638270581180107113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180097139" xlink:to="xoma_ContingentFutureCashPayments_638270581180107113" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount" xlink:label="xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount_638270581180107113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180097139" xlink:to="xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount_638270581180107113" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MilestonesPaymentsToAggregateAmountOfPerProduct" xlink:label="xoma_MilestonesPaymentsToAggregateAmountOfPerProduct_638270581180107113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180097139" xlink:to="xoma_MilestonesPaymentsToAggregateAmountOfPerProduct_638270581180107113" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LongTermRightsReceivableNonCurrent" xlink:label="xoma_LongTermRightsReceivableNonCurrent_638270581180107113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180097139" xlink:to="xoma_LongTermRightsReceivableNonCurrent_638270581180107113" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ContingentConsiderationUnderPurchaseAgreements" xlink:label="xoma_ContingentConsiderationUnderPurchaseAgreements_638270581180107113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180097139" xlink:to="xoma_ContingentConsiderationUnderPurchaseAgreements_638270581180107113" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" xlink:label="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss_638270581180107113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180097139" xlink:to="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss_638270581180107113" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails" xlink:type="extended" xlink:title="40507 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Palo (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:label="RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581180117087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581180117087" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638270581180117087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581180117087" xlink:to="srt_CounterpartyNameAxis_638270581180117087" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638270581180117087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638270581180117087" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638270581180117087" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_PalobiofarmaSLMember" xlink:label="xoma_PalobiofarmaSLMember_638270581180117087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638270581180117087" xlink:to="xoma_PalobiofarmaSLMember_638270581180117087" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638270581180117087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581180117087" xlink:to="us-gaap_TypeOfArrangementAxis_638270581180117087" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638270581180117087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638270581180117087" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638270581180117087" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RoyaltyPurchaseAgreementMember" xlink:label="xoma_RoyaltyPurchaseAgreementMember_638270581180127089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638270581180117087" xlink:to="xoma_RoyaltyPurchaseAgreementMember_638270581180127089" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180127089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581180117087" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180127089" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AgreementDrugCandidatesNumber" xlink:label="xoma_AgreementDrugCandidatesNumber_638270581180127089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180127089" xlink:to="xoma_AgreementDrugCandidatesNumber_638270581180127089" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" xlink:label="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities_638270581180127089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180127089" xlink:to="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities_638270581180127089" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LongTermRightsReceivableNonCurrent" xlink:label="xoma_LongTermRightsReceivableNonCurrent_638270581180127089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180127089" xlink:to="xoma_LongTermRightsReceivableNonCurrent_638270581180127089" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" xlink:label="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss_638270581180127089" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180127089" xlink:to="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss_638270581180127089" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails" xlink:type="extended" xlink:title="40508 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Viracta (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:label="RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581180137150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581180137150" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638270581180137150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581180137150" xlink:to="srt_CounterpartyNameAxis_638270581180137150" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638270581180137150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638270581180137150" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638270581180137150" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ViractaTherapeuticsInc.Member" xlink:label="xoma_ViractaTherapeuticsInc.Member_638270581180137150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638270581180137150" xlink:to="xoma_ViractaTherapeuticsInc.Member_638270581180137150" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638270581180137150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581180137150" xlink:to="us-gaap_TypeOfArrangementAxis_638270581180137150" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638270581180137150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638270581180137150" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638270581180137150" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RoyaltyPurchaseAgreementMember" xlink:label="xoma_RoyaltyPurchaseAgreementMember_638270581180137150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638270581180137150" xlink:to="xoma_RoyaltyPurchaseAgreementMember_638270581180137150" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180137150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581180137150" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180137150" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AgreementDrugCandidatesNumber" xlink:label="xoma_AgreementDrugCandidatesNumber_638270581180137150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180137150" xlink:to="xoma_AgreementDrugCandidatesNumber_638270581180137150" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" xlink:label="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities_638270581180137150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180137150" xlink:to="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities_638270581180137150" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MilestonesReceivableExcludingConsiderationRetainedMaximum" xlink:label="xoma_MilestonesReceivableExcludingConsiderationRetainedMaximum_638270581180137150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180137150" xlink:to="xoma_MilestonesReceivableExcludingConsiderationRetainedMaximum_638270581180137150" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MaximumConsiderationRetained" xlink:label="xoma_MaximumConsiderationRetained_638270581180137150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180137150" xlink:to="xoma_MaximumConsiderationRetained_638270581180137150" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RegulatoryAndCommercialMilestonesReceivableMaximum" xlink:label="xoma_RegulatoryAndCommercialMilestonesReceivableMaximum_638270581180147788" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180137150" xlink:to="xoma_RegulatoryAndCommercialMilestonesReceivableMaximum_638270581180147788" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LongTermRightsReceivableNonCurrent" xlink:label="xoma_LongTermRightsReceivableNonCurrent_638270581180147788" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180137150" xlink:to="xoma_LongTermRightsReceivableNonCurrent_638270581180147788" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" xlink:label="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss_638270581180147788" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180137150" xlink:to="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss_638270581180147788" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails" xlink:type="extended" xlink:title="40509 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Kuros (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:label="RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581180147788" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581180147788" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638270581180147788" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581180147788" xlink:to="srt_CounterpartyNameAxis_638270581180147788" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638270581180157160" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638270581180147788" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638270581180157160" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember" xlink:label="xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_638270581180157160" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638270581180157160" xlink:to="xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_638270581180157160" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638270581180157160" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581180147788" xlink:to="us-gaap_TypeOfArrangementAxis_638270581180157160" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638270581180157160" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638270581180157160" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638270581180157160" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RoyaltyPurchaseAgreementMember" xlink:label="xoma_RoyaltyPurchaseAgreementMember_638270581180157160" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638270581180157160" xlink:to="xoma_RoyaltyPurchaseAgreementMember_638270581180157160" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180157160" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581180147788" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180157160" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RoyaltyReceivablePercentageOnNetSales" xlink:label="xoma_RoyaltyReceivablePercentageOnNetSales_638270581180157160" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180157160" xlink:to="xoma_RoyaltyReceivablePercentageOnNetSales_638270581180157160" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_EligibleMilestonePaymentsReceivableUponAchievementOfPreCommercialMilestones" xlink:label="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfPreCommercialMilestones_638270581180157160" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180157160" xlink:to="xoma_EligibleMilestonePaymentsReceivableUponAchievementOfPreCommercialMilestones_638270581180157160" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" xlink:label="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities_638270581180157160" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180157160" xlink:to="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities_638270581180157160" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ReceiptsUnderAgreementsInvestingActivities" xlink:label="xoma_ReceiptsUnderAgreementsInvestingActivities_638270581180157160" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180157160" xlink:to="xoma_ReceiptsUnderAgreementsInvestingActivities_638270581180157160" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MaximumPayableOnSalesMilestone" xlink:label="xoma_MaximumPayableOnSalesMilestone_638270581180157160" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180157160" xlink:to="xoma_MaximumPayableOnSalesMilestone_638270581180157160" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LongTermRightsReceivableNonCurrent" xlink:label="xoma_LongTermRightsReceivableNonCurrent_638270581180157160" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180157160" xlink:to="xoma_LongTermRightsReceivableNonCurrent_638270581180157160" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MilestonePaymentReceivedCounterparty" xlink:label="xoma_MilestonePaymentReceivedCounterparty_638270581180167485" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180157160" xlink:to="xoma_MilestonePaymentReceivedCounterparty_638270581180167485" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MilestonePaymentReceivablePercentage" xlink:label="xoma_MilestonePaymentReceivablePercentage_638270581180167485" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180157160" xlink:to="xoma_MilestonePaymentReceivablePercentage_638270581180167485" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RightsReceivableCurrent" xlink:label="xoma_RightsReceivableCurrent_638270581180167485" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180157160" xlink:to="xoma_RightsReceivableCurrent_638270581180167485" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" xlink:label="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent_638270581180167485" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180157160" xlink:to="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent_638270581180167485" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" xlink:label="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss_638270581180167485" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180157160" xlink:to="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss_638270581180167485" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails" xlink:type="extended" xlink:title="40510 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Affitech (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:label="RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581180177521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581180177521" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638270581180177521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581180177521" xlink:to="srt_CounterpartyNameAxis_638270581180177521" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638270581180177521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638270581180177521" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638270581180177521" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AffitechResearchAsMember" xlink:label="xoma_AffitechResearchAsMember_638270581180177521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638270581180177521" xlink:to="xoma_AffitechResearchAsMember_638270581180177521" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638270581180177521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581180177521" xlink:to="us-gaap_TypeOfArrangementAxis_638270581180177521" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638270581180177521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638270581180177521" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638270581180177521" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_CommercialPaymentPurchaseAgreementMember" xlink:label="xoma_CommercialPaymentPurchaseAgreementMember_638270581180177521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638270581180177521" xlink:to="xoma_CommercialPaymentPurchaseAgreementMember_638270581180177521" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis_638270581180177521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581180177521" xlink:to="us-gaap_ContingentConsiderationByTypeAxis_638270581180177521" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain_638270581180177521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationByTypeAxis_638270581180177521" xlink:to="us-gaap_ContingentConsiderationTypeDomain_638270581180177521" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ContingentConsiderationRegulatoryMilestonesMember" xlink:label="xoma_ContingentConsiderationRegulatoryMilestonesMember_638270581180177521" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain_638270581180177521" xlink:to="xoma_ContingentConsiderationRegulatoryMilestonesMember_638270581180177521" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638270581180187527" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581180177521" xlink:to="srt_ProductOrServiceAxis_638270581180187527" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638270581180187527" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638270581180187527" xlink:to="srt_ProductsAndServicesDomain_638270581180187527" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_FaricimabProductMember" xlink:label="xoma_FaricimabProductMember_638270581180187527" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638270581180187527" xlink:to="xoma_FaricimabProductMember_638270581180187527" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_FaricimabSvoaVabysmoProductMember" xlink:label="xoma_FaricimabSvoaVabysmoProductMember_638270581180187527" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638270581180187527" xlink:to="xoma_FaricimabSvoaVabysmoProductMember_638270581180187527" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_638270581180187527" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581180177521" xlink:to="srt_StatementGeographicalAxis_638270581180187527" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_638270581180187527" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_638270581180187527" xlink:to="srt_SegmentGeographicalDomain_638270581180187527" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US" xlink:label="country_US_638270581180187527" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638270581180187527" xlink:to="country_US_638270581180187527" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EuropeMember" xlink:label="srt_EuropeMember_638270581180187527" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638270581180187527" xlink:to="srt_EuropeMember_638270581180187527" order="2" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638270581180187527" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581180177521" xlink:to="srt_StatementScenarioAxis_638270581180187527" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638270581180197519" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638270581180187527" xlink:to="srt_ScenarioUnspecifiedDomain_638270581180197519" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember_638270581180197519" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638270581180197519" xlink:to="srt_ScenarioForecastMember_638270581180197519" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180197519" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581180177521" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180197519" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities" xlink:label="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities_638270581180197519" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180197519" xlink:to="xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities_638270581180197519" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_CommercialSalesReceivablePercentageOnNetSales" xlink:label="xoma_CommercialSalesReceivablePercentageOnNetSales_638270581180197519" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180197519" xlink:to="xoma_CommercialSalesReceivablePercentageOnNetSales_638270581180197519" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_CommercialPaymentReceivableTerm" xlink:label="xoma_CommercialPaymentReceivableTerm_638270581180197519" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180197519" xlink:to="xoma_CommercialPaymentReceivableTerm_638270581180197519" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndSalesMilestones" xlink:label="xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndSalesMilestones_638270581180197519" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180197519" xlink:to="xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndSalesMilestones_638270581180197519" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LongTermRightsReceivableNonCurrent" xlink:label="xoma_LongTermRightsReceivableNonCurrent_638270581180207360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180197519" xlink:to="xoma_LongTermRightsReceivableNonCurrent_638270581180207360" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MaximumPayableOnRegulatoryMilestone" xlink:label="xoma_MaximumPayableOnRegulatoryMilestone_638270581180207360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180197519" xlink:to="xoma_MaximumPayableOnRegulatoryMilestone_638270581180207360" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MaximumPayableOnSalesMilestone" xlink:label="xoma_MaximumPayableOnSalesMilestone_638270581180207360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180197519" xlink:to="xoma_MaximumPayableOnSalesMilestone_638270581180207360" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ContingentConsiderationUnderPurchaseAgreements" xlink:label="xoma_ContingentConsiderationUnderPurchaseAgreements_638270581180207360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180197519" xlink:to="xoma_ContingentConsiderationUnderPurchaseAgreements_638270581180207360" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ReceiptsUnderAgreementsInvestingActivities" xlink:label="xoma_ReceiptsUnderAgreementsInvestingActivities_638270581180207360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180197519" xlink:to="xoma_ReceiptsUnderAgreementsInvestingActivities_638270581180207360" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" xlink:label="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent_638270581180207360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180197519" xlink:to="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent_638270581180207360" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss" xlink:label="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss_638270581180217401" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180197519" xlink:to="us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss_638270581180217401" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RightsReceivableCurrent" xlink:label="xoma_RightsReceivableCurrent_638270581180217401" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180197519" xlink:to="xoma_RightsReceivableCurrent_638270581180217401" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails" xlink:type="extended" xlink:title="40511 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Summary of Royalty Receivable Activities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:label="RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581180217401" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581180217401" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638270581180217401" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581180217401" xlink:to="us-gaap_TypeOfArrangementAxis_638270581180217401" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638270581180227464" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638270581180217401" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638270581180227464" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RoyaltyPurchaseAgreementMember" xlink:label="xoma_RoyaltyPurchaseAgreementMember_638270581180227464" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638270581180227464" xlink:to="xoma_RoyaltyPurchaseAgreementMember_638270581180227464" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638270581180227464" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581180217401" xlink:to="srt_CounterpartyNameAxis_638270581180227464" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638270581180227464" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638270581180227464" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638270581180227464" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AffitechResearchAsMember" xlink:label="xoma_AffitechResearchAsMember_638270581180227464" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638270581180227464" xlink:to="xoma_AffitechResearchAsMember_638270581180227464" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AptevoMember" xlink:label="xoma_AptevoMember_638270581180227464" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638270581180227464" xlink:to="xoma_AptevoMember_638270581180227464" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LadrxMember" xlink:label="xoma_LadrxMember_638270581180287547" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638270581180227464" xlink:to="xoma_LadrxMember_638270581180287547" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_BioasisTechnologiesIncMember" xlink:label="xoma_BioasisTechnologiesIncMember_638270581180287547" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638270581180227464" xlink:to="xoma_BioasisTechnologiesIncMember_638270581180287547" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ViractaTherapeuticsInc.Member" xlink:label="xoma_ViractaTherapeuticsInc.Member_638270581180287547" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638270581180227464" xlink:to="xoma_ViractaTherapeuticsInc.Member_638270581180287547" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember" xlink:label="xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_638270581180287547" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638270581180227464" xlink:to="xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_638270581180287547" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180287547" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638270581180217401" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180287547" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RightsReceivableCurrent" xlink:label="xoma_RightsReceivableCurrent_638270581180287547" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180287547" xlink:to="xoma_RightsReceivableCurrent_638270581180287547" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableCurrent" xlink:label="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableCurrent_638270581180287547" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180287547" xlink:to="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableCurrent_638270581180287547" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RightsReceivableCurrent" xlink:label="xoma_RightsReceivableCurrent_638270581180297179" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180287547" xlink:to="xoma_RightsReceivableCurrent_638270581180297179" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LongTermRightsReceivableNonCurrent" xlink:label="xoma_LongTermRightsReceivableNonCurrent_638270581180297179" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180287547" xlink:to="xoma_LongTermRightsReceivableNonCurrent_638270581180297179" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent" xlink:label="xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent_638270581180297179" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180287547" xlink:to="xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent_638270581180297179" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent" xlink:label="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent_638270581180297179" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180287547" xlink:to="xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent_638270581180297179" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ImpairmentOfLongTermRightsReceivableNonCurrent" xlink:label="xoma_ImpairmentOfLongTermRightsReceivableNonCurrent_638270581180297179" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180287547" xlink:to="xoma_ImpairmentOfLongTermRightsReceivableNonCurrent_638270581180297179" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LongTermRightsReceivableNonCurrent" xlink:label="xoma_LongTermRightsReceivableNonCurrent_6382705811802971791" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180287547" xlink:to="xoma_LongTermRightsReceivableNonCurrent_6382705811802971791" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ShortTermRightsReceivableReclassification" xlink:label="xoma_ShortTermRightsReceivableReclassification_638270581180297179" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180287547" xlink:to="xoma_ShortTermRightsReceivableReclassification_638270581180297179" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LongTermRightsReceivableReclassification" xlink:label="xoma_LongTermRightsReceivableReclassification_638270581180297179" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638270581180287547" xlink:to="xoma_LongTermRightsReceivableReclassification_638270581180297179" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Carried at Fair Value on Recurring Basis (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638270581180307522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_2" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638270581180307522" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_638270581180307522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638270581180307522" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_638270581180307522" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_638270581180307522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_638270581180307522" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_638270581180307522" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_638270581180307522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain_638270581180307522" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_638270581180307522" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_638270581180307522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638270581180307522" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_638270581180307522" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638270581180307522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_638270581180307522" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638270581180307522" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member_638270581180307522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638270581180307522" xlink:to="us-gaap_FairValueInputsLevel1Member_638270581180307522" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_638270581180307522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638270581180307522" xlink:to="us-gaap_FairValueInputsLevel3Member_638270581180307522" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis_638270581180307522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638270581180307522" xlink:to="us-gaap_CashAndCashEquivalentsAxis_638270581180307522" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638270581180317496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis_638270581180307522" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638270581180317496" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember_638270581180317496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638270581180317496" xlink:to="us-gaap_MoneyMarketFundsMember_638270581180317496" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638270581180317496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638270581180307522" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638270581180317496" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_638270581180317496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638270581180317496" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_638270581180317496" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_638270581180317496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract_638270581180317496" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_638270581180317496" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure_638270581180317496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract_638270581180317496" xlink:to="us-gaap_InvestmentsFairValueDisclosure_638270581180317496" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_FinancialAssetsFairValueDisclosure" xlink:label="xoma_FinancialAssetsFairValueDisclosure_638270581180317496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract_638270581180317496" xlink:to="xoma_FinancialAssetsFairValueDisclosure_638270581180317496" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_638270581180317496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638270581180317496" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract_638270581180317496" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ContingentConsiderationFairValueDisclosure" xlink:label="xoma_ContingentConsiderationFairValueDisclosure_638270581180317496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract_638270581180317496" xlink:to="xoma_ContingentConsiderationFairValueDisclosure_638270581180317496" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureFairValueMeasurementsEquitySecuritiesDetails" xlink:type="extended" xlink:title="40602 - Disclosure - Fair Value Measurements - Equity Securities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638270581180327182" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_4" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638270581180327182" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_638270581180327182" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638270581180327182" xlink:to="us-gaap_MeasurementInputTypeAxis_638270581180327182" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_638270581180327182" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis_638270581180327182" xlink:to="us-gaap_MeasurementInputTypeDomain_638270581180327182" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember_638270581180327182" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638270581180327182" xlink:to="us-gaap_MeasurementInputSharePriceMember_638270581180327182" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638270581180327182" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638270581180327182" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638270581180327182" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiMeasurementInput" xlink:label="us-gaap_EquitySecuritiesFvNiMeasurementInput_638270581180327182" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638270581180327182" xlink:to="us-gaap_EquitySecuritiesFvNiMeasurementInput_638270581180327182" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails" xlink:type="extended" xlink:title="40603 - Disclosure - Fair Value Measurements - Contingent Consideration (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638270581180327182" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_6" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638270581180327182" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638270581180327182" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638270581180327182" xlink:to="srt_CounterpartyNameAxis_638270581180327182" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638270581180327182" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638270581180327182" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638270581180327182" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_BioasisTechnologiesIncMember" xlink:label="xoma_BioasisTechnologiesIncMember_638270581180327182" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638270581180327182" xlink:to="xoma_BioasisTechnologiesIncMember_638270581180327182" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AptevoMember" xlink:label="xoma_AptevoMember_638270581180337467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638270581180327182" xlink:to="xoma_AptevoMember_638270581180337467" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LadrxMember" xlink:label="xoma_LadrxMember_638270581180337467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638270581180327182" xlink:to="xoma_LadrxMember_638270581180337467" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638270581180337467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638270581180327182" xlink:to="us-gaap_TypeOfArrangementAxis_638270581180337467" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638270581180337467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638270581180337467" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638270581180337467" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RoyaltyPurchaseAgreementMember" xlink:label="xoma_RoyaltyPurchaseAgreementMember_638270581180337467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638270581180337467" xlink:to="xoma_RoyaltyPurchaseAgreementMember_638270581180337467" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638270581180337467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638270581180327182" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638270581180337467" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ChangesInEstimatedFairValueOfContingentConsideration" xlink:label="xoma_ChangesInEstimatedFairValueOfContingentConsideration_638270581180337467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638270581180337467" xlink:to="xoma_ChangesInEstimatedFairValueOfContingentConsideration_638270581180337467" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ContingentConsiderationUnderPurchaseAgreements" xlink:label="xoma_ContingentConsiderationUnderPurchaseAgreements_638270581180337467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638270581180337467" xlink:to="xoma_ContingentConsiderationUnderPurchaseAgreements_638270581180337467" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureLeaseAgreementsLeasedFacilitiesDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Lease Agreements - Leased facilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable_638270581180337467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable_638270581180337467" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638270581180337467" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638270581180337467" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638270581180337467" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638270581180347555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638270581180337467" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638270581180347555" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LeasedFacilitiesEmeryvilleCaliforniaMember" xlink:label="xoma_LeasedFacilitiesEmeryvilleCaliforniaMember_638270581180347555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638270581180347555" xlink:to="xoma_LeasedFacilitiesEmeryvilleCaliforniaMember_638270581180347555" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LeasedFacilitiesTwoEmeryvilleCaliforniaMember" xlink:label="xoma_LeasedFacilitiesTwoEmeryvilleCaliforniaMember_638270581180347555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638270581180347555" xlink:to="xoma_LeasedFacilitiesTwoEmeryvilleCaliforniaMember_638270581180347555" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638270581180347555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638270581180337467" xlink:to="srt_StatementScenarioAxis_638270581180347555" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638270581180347555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638270581180347555" xlink:to="srt_ScenarioUnspecifiedDomain_638270581180347555" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember_638270581180347555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638270581180347555" xlink:to="srt_ScenarioForecastMember_638270581180347555" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_638270581180347555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638270581180337467" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_638270581180347555" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_OperatingLeasesNumberOfLeasedFacilities" xlink:label="xoma_OperatingLeasesNumberOfLeasedFacilities_638270581180347555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638270581180347555" xlink:to="xoma_OperatingLeasesNumberOfLeasedFacilities_638270581180347555" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_638270581180347555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638270581180347555" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_638270581180347555" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LesseeOperatingLeaseModificationAdjustmentToRightOfUseAsset" xlink:label="xoma_LesseeOperatingLeaseModificationAdjustmentToRightOfUseAsset_638270581180347555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638270581180347555" xlink:to="xoma_LesseeOperatingLeaseModificationAdjustmentToRightOfUseAsset_638270581180347555" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_638270581180347555" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638270581180347555" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_638270581180347555" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638270581180357384" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638270581180347555" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638270581180357384" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638270581180357384" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638270581180347555" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638270581180357384" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureLeaseAgreementsLeaseCostsDetails" xlink:type="extended" xlink:title="40702 - Disclosure - Lease Agreements - Lease costs (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract_638270581180357384" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="us-gaap_LeaseCostAbstract_638270581180357384" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost_638270581180357384" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract_638270581180357384" xlink:to="us-gaap_OperatingLeaseCost_638270581180357384" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost_638270581180357384" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract_638270581180357384" xlink:to="us-gaap_VariableLeaseCost_638270581180357384" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost_638270581180357384" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract_638270581180357384" xlink:to="us-gaap_LeaseCost_638270581180357384" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="9" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureLeaseAgreementsAdditionalInformationDetails" xlink:type="extended" xlink:title="40703 - Disclosure - Lease Agreements - Additional information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments_638270581180367477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="us-gaap_OperatingLeasePayments_638270581180367477" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_638270581180367477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_638270581180367477" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_638270581180367477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_638270581180367477" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureCommonStockWarrantsDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Common Stock Warrants (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="WarrantsAndRightsNoteDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable_638270581180367477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable_638270581180367477" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638270581180367477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_638270581180367477" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638270581180367477" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638270581180367477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638270581180367477" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638270581180367477" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_TenYearWarrantsIssuedThirdRangeMember" xlink:label="xoma_TenYearWarrantsIssuedThirdRangeMember_638270581180367477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638270581180367477" xlink:to="xoma_TenYearWarrantsIssuedThirdRangeMember_638270581180367477" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_CommonStockWarrantExercisePrice14.71Member" xlink:label="xoma_CommonStockWarrantExercisePrice14.71Member_638270581180367477" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638270581180367477" xlink:to="xoma_CommonStockWarrantExercisePrice14.71Member_638270581180367477" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_638270581180377615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_638270581180367477" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_638270581180377615" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638270581180377615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638270581180377615" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638270581180377615" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_638270581180377615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638270581180377615" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_638270581180377615" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesCollaborativeAgreementsRoyaltiesAndMilestonePaymentsDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Commitments and Contingencies - Collaborative Agreements, Royalties and Milestone Payments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ContractualObligationEstimatedMilestonePayments" xlink:label="xoma_ContractualObligationEstimatedMilestonePayments_638270581180377615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="xoma_ContractualObligationEstimatedMilestonePayments_638270581180377615" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ContractualObligationEstimatedMilestonePaymentsNumberOfProducts" xlink:label="xoma_ContractualObligationEstimatedMilestonePaymentsNumberOfProducts_638270581180377615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="xoma_ContractualObligationEstimatedMilestonePaymentsNumberOfProducts_638270581180377615" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails" xlink:type="extended" xlink:title="40902 - Disclosure - Commitments and Contingencies - Contingent Consideration (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_CommitmentsAndContingenciesTable" xlink:label="xoma_CommitmentsAndContingenciesTable_638270581180377615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="xoma_CommitmentsAndContingenciesTable_638270581180377615" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638270581180377615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_CommitmentsAndContingenciesTable_638270581180377615" xlink:to="us-gaap_TypeOfArrangementAxis_638270581180377615" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638270581180377615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638270581180377615" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638270581180377615" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RoyaltyPurchaseAgreementMember" xlink:label="xoma_RoyaltyPurchaseAgreementMember_638270581180377615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638270581180377615" xlink:to="xoma_RoyaltyPurchaseAgreementMember_638270581180377615" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_CommercialPaymentPurchaseAgreementMember" xlink:label="xoma_CommercialPaymentPurchaseAgreementMember_638270581180377615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638270581180377615" xlink:to="xoma_CommercialPaymentPurchaseAgreementMember_638270581180377615" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638270581180377615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_CommitmentsAndContingenciesTable_638270581180377615" xlink:to="srt_CounterpartyNameAxis_638270581180377615" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638270581180377615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638270581180377615" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638270581180377615" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_LadrxMember" xlink:label="xoma_LadrxMember_638270581180377615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638270581180377615" xlink:to="xoma_LadrxMember_638270581180377615" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_BioasisTechnologiesIncMember" xlink:label="xoma_BioasisTechnologiesIncMember_638270581180377615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638270581180377615" xlink:to="xoma_BioasisTechnologiesIncMember_638270581180377615" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AptevoMember" xlink:label="xoma_AptevoMember_638270581180377615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638270581180377615" xlink:to="xoma_AptevoMember_638270581180377615" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MedexusMember" xlink:label="xoma_MedexusMember_638270581180377615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638270581180377615" xlink:to="xoma_MedexusMember_638270581180377615" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AronoraKurosAffitechObsevaAndMerckKgaaMember" xlink:label="xoma_AronoraKurosAffitechObsevaAndMerckKgaaMember_638270581180377615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638270581180377615" xlink:to="xoma_AronoraKurosAffitechObsevaAndMerckKgaaMember_638270581180377615" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis_638270581180377615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_CommitmentsAndContingenciesTable_638270581180377615" xlink:to="us-gaap_ContingentConsiderationByTypeAxis_638270581180377615" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain_638270581180377615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationByTypeAxis_638270581180377615" xlink:to="us-gaap_ContingentConsiderationTypeDomain_638270581180377615" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ContingentConsiderationRegulatoryMilestonesMember" xlink:label="xoma_ContingentConsiderationRegulatoryMilestonesMember_638270581180377615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain_638270581180377615" xlink:to="xoma_ContingentConsiderationRegulatoryMilestonesMember_638270581180377615" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638270581180377615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_CommitmentsAndContingenciesTable_638270581180377615" xlink:to="srt_RangeAxis_638270581180377615" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638270581180377615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638270581180377615" xlink:to="srt_RangeMember_638270581180377615" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638270581180377615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638270581180377615" xlink:to="srt_MinimumMember_638270581180377615" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_CommitmentsAndContingenciesLineItems" xlink:label="xoma_CommitmentsAndContingenciesLineItems_638270581180377615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_CommitmentsAndContingenciesTable_638270581180377615" xlink:to="xoma_CommitmentsAndContingenciesLineItems_638270581180377615" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ContingentConsiderationUnderPurchaseAgreements" xlink:label="xoma_ContingentConsiderationUnderPurchaseAgreements_638270581180377615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_CommitmentsAndContingenciesLineItems_638270581180377615" xlink:to="xoma_ContingentConsiderationUnderPurchaseAgreements_638270581180377615" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_PaymentOfContingentConsiderationUnderPurchaseAgreements" xlink:label="xoma_PaymentOfContingentConsiderationUnderPurchaseAgreements_638270581180377615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_CommitmentsAndContingenciesLineItems_638270581180377615" xlink:to="xoma_PaymentOfContingentConsiderationUnderPurchaseAgreements_638270581180377615" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ReceiptsUnderAgreementsInvestingActivities" xlink:label="xoma_ReceiptsUnderAgreementsInvestingActivities_638270581180377615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_CommitmentsAndContingenciesLineItems_638270581180377615" xlink:to="xoma_ReceiptsUnderAgreementsInvestingActivities_638270581180377615" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ChangesInEstimatedFairValueOfContingentConsideration" xlink:label="xoma_ChangesInEstimatedFairValueOfContingentConsideration_638270581180377615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_CommitmentsAndContingenciesLineItems_638270581180377615" xlink:to="xoma_ChangesInEstimatedFairValueOfContingentConsideration_638270581180377615" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationEsppDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Stock Based Compensation - ESPP (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="CompensationRelatedCostsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638270581180377615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CompensationRelatedCostsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638270581180377615" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638270581180377615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638270581180377615" xlink:to="us-gaap_PlanNameAxis_638270581180377615" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638270581180377615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638270581180377615" xlink:to="us-gaap_PlanNameDomain_638270581180377615" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember" xlink:label="xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_638270581180377615" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638270581180377615" xlink:to="xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_638270581180377615" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638270581180415144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638270581180377615" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638270581180415144" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_PercentageOfCompensationOfEligibleEmployeesToPurchaseSharesOfEntityCommonStockAtDiscountThroughPayrollDeductions" xlink:label="xoma_PercentageOfCompensationOfEligibleEmployeesToPurchaseSharesOfEntityCommonStockAtDiscountThroughPayrollDeductions_638270581180415144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638270581180415144" xlink:to="xoma_PercentageOfCompensationOfEligibleEmployeesToPurchaseSharesOfEntityCommonStockAtDiscountThroughPayrollDeductions_638270581180415144" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensation2010PlanAndInducementAwardsDetails" xlink:type="extended" xlink:title="41002 - Disclosure - Stock Based Compensation - 2010 Plan and Inducement Awards (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="CompensationRelatedCostsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638270581180417134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CompensationRelatedCostsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638270581180417134" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638270581180417134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638270581180417134" xlink:to="us-gaap_PlanNameAxis_638270581180417134" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638270581180417134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638270581180417134" xlink:to="us-gaap_PlanNameDomain_638270581180417134" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember" xlink:label="xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_638270581180417134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638270581180417134" xlink:to="xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_638270581180417134" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_StockOptionInducementAwardsMember" xlink:label="xoma_StockOptionInducementAwardsMember_638270581180417134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638270581180417134" xlink:to="xoma_StockOptionInducementAwardsMember_638270581180417134" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_StockOptionInducementAwardOneMember" xlink:label="xoma_StockOptionInducementAwardOneMember_638270581180417134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_StockOptionInducementAwardsMember_638270581180417134" xlink:to="xoma_StockOptionInducementAwardOneMember_638270581180417134" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_StockOptionInducementAwardTwoMember" xlink:label="xoma_StockOptionInducementAwardTwoMember_638270581180417134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_StockOptionInducementAwardsMember_638270581180417134" xlink:to="xoma_StockOptionInducementAwardTwoMember_638270581180417134" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638270581180417134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638270581180417134" xlink:to="us-gaap_AwardTypeAxis_638270581180417134" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638270581180427482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638270581180417134" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638270581180427482" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638270581180427482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638270581180427482" xlink:to="us-gaap_EmployeeStockOptionMember_638270581180427482" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_638270581180427482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638270581180417134" xlink:to="srt_TitleOfIndividualAxis_638270581180427482" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638270581180427482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_638270581180427482" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638270581180427482" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ChiefExecutiveOfficerInterimMember" xlink:label="xoma_ChiefExecutiveOfficerInterimMember_638270581180427482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638270581180427482" xlink:to="xoma_ChiefExecutiveOfficerInterimMember_638270581180427482" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ChiefInvestmentOfficerMember" xlink:label="xoma_ChiefInvestmentOfficerMember_638270581180427482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638270581180427482" xlink:to="xoma_ChiefInvestmentOfficerMember_638270581180427482" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_EmployeeMember" xlink:label="xoma_EmployeeMember_638270581180427482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638270581180427482" xlink:to="xoma_EmployeeMember_638270581180427482" order="3" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember_638270581180427482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638270581180427482" xlink:to="srt_DirectorMember_638270581180427482" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_638270581180437524" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638270581180417134" xlink:to="us-gaap_VestingAxis_638270581180437524" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_638270581180437524" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis_638270581180437524" xlink:to="us-gaap_VestingDomain_638270581180437524" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_638270581180437524" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638270581180437524" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_638270581180437524" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_638270581180437524" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638270581180437524" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_638270581180437524" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_638270581180437524" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638270581180437524" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_638270581180437524" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638270581180437524" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638270581180417134" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638270581180437524" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward_638270581180437524" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638270581180437524" xlink:to="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward_638270581180437524" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge_638270581180437524" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638270581180437524" xlink:to="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge_638270581180437524" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ShareBasedPaymentArrangementNumberOfAwardsGrants" xlink:label="xoma_ShareBasedPaymentArrangementNumberOfAwardsGrants_638270581180447188" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638270581180437524" xlink:to="xoma_ShareBasedPaymentArrangementNumberOfAwardsGrants_638270581180447188" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_638270581180447188" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638270581180437524" xlink:to="us-gaap_SharePrice_638270581180447188" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638270581180447188" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638270581180437524" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638270581180447188" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638270581180447188" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638270581180437524" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638270581180447188" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_638270581180447188" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638270581180437524" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_638270581180447188" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638270581180457570" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638270581180437524" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638270581180457570" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments_638270581180457570" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638270581180437524" xlink:to="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments_638270581180457570" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments_638270581180457570" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638270581180437524" xlink:to="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments_638270581180457570" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationFvAssumptionsDetails" xlink:type="extended" xlink:title="41003 - Disclosure - Stock Based Compensation - FV Assumptions (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="CompensationRelatedCostsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638270581180457570" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CompensationRelatedCostsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638270581180457570" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638270581180467510" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638270581180457570" xlink:to="us-gaap_AwardTypeAxis_638270581180467510" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638270581180467510" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638270581180467510" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638270581180467510" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638270581180467510" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638270581180467510" xlink:to="us-gaap_EmployeeStockOptionMember_638270581180467510" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638270581180467510" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638270581180457570" xlink:to="us-gaap_PlanNameAxis_638270581180467510" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638270581180467510" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638270581180467510" xlink:to="us-gaap_PlanNameDomain_638270581180467510" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember" xlink:label="xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_638270581180467510" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638270581180467510" xlink:to="xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_638270581180467510" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_StockOptionInducementAwardsMember" xlink:label="xoma_StockOptionInducementAwardsMember_638270581180467510" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638270581180467510" xlink:to="xoma_StockOptionInducementAwardsMember_638270581180467510" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_StockOptionInducementAwardOneMember" xlink:label="xoma_StockOptionInducementAwardOneMember_638270581180467510" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_StockOptionInducementAwardsMember_638270581180467510" xlink:to="xoma_StockOptionInducementAwardOneMember_638270581180467510" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_StockOptionInducementAwardTwoMember" xlink:label="xoma_StockOptionInducementAwardTwoMember_638270581180467510" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_StockOptionInducementAwardsMember_638270581180467510" xlink:to="xoma_StockOptionInducementAwardTwoMember_638270581180467510" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638270581180477536" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638270581180457570" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638270581180477536" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638270581180477536" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638270581180477536" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638270581180477536" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638270581180477536" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638270581180477536" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638270581180477536" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638270581180477536" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638270581180477536" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638270581180477536" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638270581180477536" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638270581180477536" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638270581180477536" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638270581180477536" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638270581180477536" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638270581180477536" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638270581180477536" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638270581180477536" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638270581180477536" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638270581180477536" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638270581180477536" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638270581180477536" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638270581180487507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638270581180477536" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638270581180487507" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" xlink:type="extended" xlink:title="41004 - Disclosure - Stock Based Compensation - Stock Option Activity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="CompensationRelatedCostsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638270581180487507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CompensationRelatedCostsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638270581180487507" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638270581180487507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638270581180487507" xlink:to="us-gaap_AwardTypeAxis_638270581180487507" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638270581180487507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638270581180487507" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638270581180487507" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638270581180487507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638270581180487507" xlink:to="us-gaap_EmployeeStockOptionMember_638270581180487507" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638270581180487507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638270581180487507" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638270581180487507" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638270581180487507" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638270581180487507" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638270581180487507" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638270581180497504" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638270581180487507" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638270581180497504" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638270581180497504" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638270581180487507" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638270581180497504" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_638270581180497504" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638270581180487507" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_638270581180497504" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638270581180497504" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638270581180487507" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638270581180497504" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638270581180497504" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638270581180487507" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638270581180497504" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638270581180497504" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638270581180487507" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638270581180497504" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638270581180497504" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638270581180487507" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638270581180497504" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638270581180497504" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638270581180487507" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638270581180497504" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_638270581180497504" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638270581180487507" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_638270581180497504" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6382705811804975041" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638270581180487507" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6382705811804975041" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638270581180507784" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638270581180487507" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638270581180507784" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638270581180507784" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638270581180487507" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638270581180507784" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_638270581180507784" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638270581180487507" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_638270581180507784" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638270581180507784" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638270581180487507" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638270581180507784" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_638270581180507784" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638270581180487507" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_638270581180507784" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_638270581180507784" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638270581180487507" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_638270581180507784" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638270581180507784" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638270581180487507" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638270581180507784" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_638270581180517580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638270581180487507" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_638270581180517580" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638270581180517580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638270581180487507" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638270581180517580" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsDetails" xlink:type="extended" xlink:title="41005 - Disclosure - Stock Based Compensation - Performance Stock Unit Awards (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="us-gaap_CompensationRelatedCostsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638270581180517580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationRelatedCostsAbstract_1" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638270581180517580" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638270581180517580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638270581180517580" xlink:to="us-gaap_AwardTypeAxis_638270581180517580" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638270581180517580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638270581180517580" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638270581180517580" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_PerformanceStockUnitsMember" xlink:label="xoma_PerformanceStockUnitsMember_638270581180527519" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638270581180517580" xlink:to="xoma_PerformanceStockUnitsMember_638270581180527519" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638270581180527519" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638270581180517580" xlink:to="us-gaap_PlanNameAxis_638270581180527519" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638270581180527519" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638270581180527519" xlink:to="us-gaap_PlanNameDomain_638270581180527519" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember" xlink:label="xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_638270581180527519" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638270581180527519" xlink:to="xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_638270581180527519" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_638270581180527519" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638270581180517580" xlink:to="us-gaap_VestingAxis_638270581180527519" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_638270581180527519" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis_638270581180527519" xlink:to="us-gaap_VestingDomain_638270581180527519" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_638270581180527519" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638270581180527519" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_638270581180527519" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_638270581180527519" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638270581180527519" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_638270581180527519" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_638270581180527519" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638270581180527519" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_638270581180527519" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638270581180537508" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638270581180517580" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638270581180537508" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638270581180537508" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638270581180537508" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638270581180537508" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfHurdles." xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfHurdles._638270581180537508" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638270581180537508" xlink:to="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfHurdles._638270581180537508" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638270581180537508" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638270581180537508" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638270581180537508" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_638270581180537508" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638270581180537508" xlink:to="us-gaap_SharePrice_638270581180537508" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfCalendarDays" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfCalendarDays_638270581180537508" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638270581180537508" xlink:to="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfCalendarDays_638270581180537508" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_638270581180537508" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638270581180537508" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_638270581180537508" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsFairValueDetails" xlink:type="extended" xlink:title="41006 - Disclosure - Stock Based Compensation - Performance Stock Unit Awards Fair Value (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="us-gaap_CompensationRelatedCostsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638270581180547698" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationRelatedCostsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638270581180547698" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638270581180547698" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638270581180547698" xlink:to="us-gaap_AwardTypeAxis_638270581180547698" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638270581180547698" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638270581180547698" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638270581180547698" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_PerformanceStockUnitsMember" xlink:label="xoma_PerformanceStockUnitsMember_638270581180547698" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638270581180547698" xlink:to="xoma_PerformanceStockUnitsMember_638270581180547698" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638270581180547698" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638270581180547698" xlink:to="srt_StatementScenarioAxis_638270581180547698" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638270581180547698" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638270581180547698" xlink:to="srt_ScenarioUnspecifiedDomain_638270581180547698" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_StockPriceHurdlesOfDollar30Member" xlink:label="xoma_StockPriceHurdlesOfDollar30Member_638270581180547698" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638270581180547698" xlink:to="xoma_StockPriceHurdlesOfDollar30Member_638270581180547698" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_StockPriceHurdlesOfDollar35Member" xlink:label="xoma_StockPriceHurdlesOfDollar35Member_638270581180547698" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638270581180547698" xlink:to="xoma_StockPriceHurdlesOfDollar35Member_638270581180547698" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_StockPriceHurdlesOfDollar40Member" xlink:label="xoma_StockPriceHurdlesOfDollar40Member_638270581180547698" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638270581180547698" xlink:to="xoma_StockPriceHurdlesOfDollar40Member_638270581180547698" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_StockPriceHurdlesOfDollar45Member" xlink:label="xoma_StockPriceHurdlesOfDollar45Member_638270581180557585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638270581180547698" xlink:to="xoma_StockPriceHurdlesOfDollar45Member_638270581180557585" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638270581180557585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638270581180547698" xlink:to="srt_RangeAxis_638270581180557585" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638270581180597578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638270581180557585" xlink:to="srt_RangeMember_638270581180597578" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638270581180597578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638270581180597578" xlink:to="srt_MinimumMember_638270581180597578" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638270581180597578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638270581180597578" xlink:to="srt_MaximumMember_638270581180597578" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638270581180597578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638270581180547698" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638270581180597578" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_638270581180597578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638270581180597578" xlink:to="us-gaap_SharePrice_638270581180597578" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638270581180607514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638270581180597578" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638270581180607514" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638270581180607514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638270581180597578" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638270581180607514" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_638270581180607514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638270581180597578" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_638270581180607514" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_638270581180607514" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638270581180597578" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_638270581180607514" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsActivityDetails" xlink:type="extended" xlink:title="41007 - Disclosure - Stock Based Compensation - Performance Stock Unit Awards Activity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="us-gaap_CompensationRelatedCostsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638270581180617958" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationRelatedCostsAbstract_1" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638270581180617958" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638270581180617958" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638270581180617958" xlink:to="us-gaap_AwardTypeAxis_638270581180617958" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638270581180617958" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638270581180617958" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638270581180617958" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_PerformanceStockUnitsMember" xlink:label="xoma_PerformanceStockUnitsMember_638270581180617958" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638270581180617958" xlink:to="xoma_PerformanceStockUnitsMember_638270581180617958" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638270581180617958" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638270581180617958" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638270581180617958" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638270581180617958" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638270581180617958" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638270581180617958" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638270581180617958" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638270581180617958" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638270581180617958" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638270581180617958" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638270581180617958" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638270581180617958" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6382705811806179581" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638270581180617958" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6382705811806179581" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_638270581180627529" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638270581180617958" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_638270581180627529" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638270581180627529" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_638270581180627529" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638270581180627529" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_638270581180627529" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_638270581180627529" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_638270581180627529" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract" xlink:label="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract_638270581180627529" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638270581180617958" xlink:to="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract_638270581180627529" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638270581180627529" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract_638270581180627529" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638270581180627529" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_638270581180627529" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract_638270581180627529" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_638270581180627529" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638270581180627529" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract_638270581180627529" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638270581180627529" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="41008 - Disclosure - Stock Based Compensation - Stock-based Compensation Expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="CompensationRelatedCostsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638270581180637559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CompensationRelatedCostsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638270581180637559" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638270581180637559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638270581180637559" xlink:to="us-gaap_IncomeStatementLocationAxis_638270581180637559" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638270581180637559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638270581180637559" xlink:to="us-gaap_IncomeStatementLocationDomain_638270581180637559" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_638270581180637559" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638270581180637559" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_638270581180637559" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638270581180647510" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638270581180637559" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638270581180647510" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638270581180647510" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638270581180647510" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638270581180647510" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationEmployeeRetentionBonusDetails" xlink:type="extended" xlink:title="41009 - Disclosure - Stock Based Compensation - Employee Retention Bonus (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="CompensationRelatedCostsAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_638270581180647510" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CompensationRelatedCostsAbstract_2" xlink:to="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_638270581180647510" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_638270581180647510" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_638270581180647510" xlink:to="srt_TitleOfIndividualAxis_638270581180647510" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638270581180647510" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_638270581180647510" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638270581180647510" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember" xlink:label="xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_638270581180647510" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638270581180647510" xlink:to="xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_638270581180647510" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638270581180647510" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_638270581180647510" xlink:to="srt_StatementScenarioAxis_638270581180647510" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638270581180647510" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638270581180647510" xlink:to="srt_ScenarioUnspecifiedDomain_638270581180647510" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember_638270581180657522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638270581180647510" xlink:to="srt_ScenarioForecastMember_638270581180657522" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_638270581180657522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_638270581180647510" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_638270581180657522" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_NumberOfPeriodsCashRetentionBonus" xlink:label="xoma_NumberOfPeriodsCashRetentionBonus_638270581180657522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_638270581180657522" xlink:to="xoma_NumberOfPeriodsCashRetentionBonus_638270581180657522" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_PeriodOneRetentionBonusEligibility" xlink:label="xoma_PeriodOneRetentionBonusEligibility_638270581180657522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_638270581180657522" xlink:to="xoma_PeriodOneRetentionBonusEligibility_638270581180657522" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_PeriodTwoRetentionBonusEligibility" xlink:label="xoma_PeriodTwoRetentionBonusEligibility_638270581180657522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_638270581180657522" xlink:to="xoma_PeriodTwoRetentionBonusEligibility_638270581180657522" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid_638270581180657522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_638270581180657522" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid_638270581180657522" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_RetentionBonusExpenseAccrued" xlink:label="xoma_RetentionBonusExpenseAccrued_638270581180657522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_638270581180657522" xlink:to="xoma_RetentionBonusExpenseAccrued_638270581180657522" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AccruedRetentionBonus" xlink:label="xoma_AccruedRetentionBonus_638270581180657522" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_638270581180657522" xlink:to="xoma_AccruedRetentionBonus_638270581180657522" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureStockBasedCompensationCeoDepartureAndContinuityIncentiveDetails" xlink:type="extended" xlink:title="41010 - Disclosure - Stock Based Compensation - CEO Departure and Continuity Incentive (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="CompensationRelatedCostsAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_638270581180667578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CompensationRelatedCostsAbstract_4" xlink:to="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_638270581180667578" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_638270581180667578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_638270581180667578" xlink:to="srt_TitleOfIndividualAxis_638270581180667578" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638270581180667578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_638270581180667578" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638270581180667578" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_ChiefExecutiveOfficerRetiredMember" xlink:label="xoma_ChiefExecutiveOfficerRetiredMember_638270581180667578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638270581180667578" xlink:to="xoma_ChiefExecutiveOfficerRetiredMember_638270581180667578" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_638270581180667578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_638270581180667578" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_638270581180667578" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AccruedCompensationContinuityIncentive" xlink:label="xoma_AccruedCompensationContinuityIncentive_638270581180667578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_638270581180667578" xlink:to="xoma_AccruedCompensationContinuityIncentive_638270581180667578" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_CompensationExpenseEmploymentAgreement" xlink:label="xoma_CompensationExpenseEmploymentAgreement_638270581180667578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems_638270581180667578" xlink:to="xoma_CompensationExpenseEmploymentAgreement_638270581180667578" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Capital Stock - Dividends (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPayableTable" xlink:label="us-gaap_DividendsPayableTable_638270581180687753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_DividendsPayableTable_638270581180687753" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638270581180687753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DividendsPayableTable_638270581180687753" xlink:to="us-gaap_StatementClassOfStockAxis_638270581180687753" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638270581180687753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638270581180687753" xlink:to="us-gaap_ClassOfStockDomain_638270581180687753" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember_638270581180687753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638270581180687753" xlink:to="us-gaap_SeriesAPreferredStockMember_638270581180687753" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember_638270581180687753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638270581180687753" xlink:to="us-gaap_SeriesBPreferredStockMember_638270581180687753" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPayableLineItems" xlink:label="us-gaap_DividendsPayableLineItems_638270581180687753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DividendsPayableTable_638270581180687753" xlink:to="us-gaap_DividendsPayableLineItems_638270581180687753" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendsPerShareDeclared" xlink:label="us-gaap_PreferredStockDividendsPerShareDeclared_638270581180697554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DividendsPayableLineItems_638270581180687753" xlink:to="us-gaap_PreferredStockDividendsPerShareDeclared_638270581180697554" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendsPerShareCashPaid" xlink:label="us-gaap_PreferredStockDividendsPerShareCashPaid_638270581180697554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DividendsPayableLineItems_638270581180687753" xlink:to="us-gaap_PreferredStockDividendsPerShareCashPaid_638270581180697554" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails" xlink:type="extended" xlink:title="41102 - Disclosure - Capital Stock - BVF Ownership (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638270581180697554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638270581180697554" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638270581180697554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638270581180697554" xlink:to="dei_LegalEntityAxis_638270581180697554" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638270581180697554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638270581180697554" xlink:to="dei_EntityDomain_638270581180697554" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_BiotechnologyValueFundLPMember" xlink:label="xoma_BiotechnologyValueFundLPMember_638270581180697554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638270581180697554" xlink:to="xoma_BiotechnologyValueFundLPMember_638270581180697554" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis_638270581180697554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638270581180697554" xlink:to="srt_OwnershipAxis_638270581180697554" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain_638270581180697554" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis_638270581180697554" xlink:to="srt_OwnershipDomain_638270581180697554" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_XomaCorporationMember" xlink:label="xoma_XomaCorporationMember_638270581180707584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipDomain_638270581180697554" xlink:to="xoma_XomaCorporationMember_638270581180707584" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638270581180707584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638270581180697554" xlink:to="us-gaap_StatementEquityComponentsAxis_638270581180707584" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638270581180707584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638270581180707584" xlink:to="us-gaap_EquityComponentDomain_638270581180707584" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638270581180707584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_638270581180707584" xlink:to="us-gaap_CommonStockMember_638270581180707584" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_638270581180707584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638270581180697554" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_638270581180707584" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_638270581180707584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638270581180707584" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_638270581180707584" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted" xlink:label="xoma_NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted_638270581180707584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638270581180707584" xlink:to="xoma_NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted_638270581180707584" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails" xlink:type="extended" xlink:title="41103 - Disclosure - Capital Stock - ATM Agreements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638270581180717224" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638270581180717224" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638270581180717224" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638270581180717224" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638270581180717224" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638270581180717224" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638270581180717224" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638270581180717224" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_TwoThousandEighteenAtMarketAgreementMember" xlink:label="xoma_TwoThousandEighteenAtMarketAgreementMember_638270581180717224" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638270581180717224" xlink:to="xoma_TwoThousandEighteenAtMarketAgreementMember_638270581180717224" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_AtMarketIssuanceSalesAgreement2021Member" xlink:label="xoma_AtMarketIssuanceSalesAgreement2021Member_638270581180717224" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638270581180717224" xlink:to="xoma_AtMarketIssuanceSalesAgreement2021Member_638270581180717224" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638270581180717224" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638270581180717224" xlink:to="us-gaap_StatementEquityComponentsAxis_638270581180717224" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638270581180717224" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638270581180717224" xlink:to="us-gaap_EquityComponentDomain_638270581180717224" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638270581180717224" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_638270581180717224" xlink:to="us-gaap_CommonStockMember_638270581180717224" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638270581180717224" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638270581180717224" xlink:to="us-gaap_StatementClassOfStockAxis_638270581180717224" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638270581180717224" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638270581180717224" xlink:to="us-gaap_ClassOfStockDomain_638270581180717224" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AdrMember" xlink:label="dei_AdrMember_638270581180717224" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638270581180717224" xlink:to="dei_AdrMember_638270581180717224" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638270581180727602" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638270581180717224" xlink:to="srt_RangeAxis_638270581180727602" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638270581180727602" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638270581180727602" xlink:to="srt_RangeMember_638270581180727602" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638270581180727602" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638270581180727602" xlink:to="srt_MaximumMember_638270581180727602" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_638270581180727602" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_638270581180717224" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_638270581180727602" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638270581180727602" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638270581180727602" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638270581180727602" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_MaximumValueOfStockToBeIssued" xlink:label="xoma_MaximumValueOfStockToBeIssued_638270581180727602" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638270581180727602" xlink:to="xoma_MaximumValueOfStockToBeIssued_638270581180727602" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares" xlink:label="xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares_638270581180727602" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638270581180727602" xlink:to="xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares_638270581180727602" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="xoma-20230630.xsd#xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfShares" xlink:label="xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfShares_638270581180727602" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems_638270581180727602" xlink:to="xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfShares_638270581180727602" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.xoma.com/role/DisclosureIncomeTaxesDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Income Taxes (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_638270581180737547" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_638270581180737547" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_638270581180737547" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits_638270581180737547" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_638270581180737547" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_638270581180737547" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit" xlink:label="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit_638270581180737547" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit_638270581180737547" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_638270581180737547" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_638270581180737547" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140070011351680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Aug. 03, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">XOMA Corporation<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">52-2154066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address Address Line1</a></td>
<td class="text">2200 Powell Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address Address Line2</a></td>
<td class="text">Suite&#160;310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address City Or Town</a></td>
<td class="text">Emeryville<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address State Or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address Postal Zip Code</a></td>
<td class="text">94608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">204-7200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,472,808<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000791908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security12b Title</a></td>
<td class="text">Common Stock, $0.0075 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">XOMA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">8.625% Series A Cumulative, Perpetual Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security12b Title</a></td>
<td class="text">8.625% Series A Cumulative Perpetual Preferred Stock, par value $0.05 <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">XOMAP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=dei_AdrMember', window );">Series B Depositary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security12b Title</a></td>
<td class="text">Depositary Shares (each representing 1/1000th interest in a share of 8.375% Series B Cumulative Perpetual Preferred Stock, par value $0.05)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">XOMAO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=dei_AdrMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=dei_AdrMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140070009834256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 31,445<span></span>
</td>
<td class="nump">$ 57,826<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Short-term equity securities</a></td>
<td class="nump">320<span></span>
</td>
<td class="nump">335<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsAndOtherReceivablesNetCurrent', window );">Trade and other receivables, net</a></td>
<td class="nump">901<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RightsReceivableCurrent', window );">Short-term royalty and commercial payment receivables</a></td>
<td class="nump">4,958<span></span>
</td>
<td class="nump">2,366<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">799<span></span>
</td>
<td class="nump">725<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">38,423<span></span>
</td>
<td class="nump">61,253<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LongTermRightsReceivableNonCurrent', window );">Long-term royalty and commercial payment receivables</a></td>
<td class="nump">72,232<span></span>
</td>
<td class="nump">63,683<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">14,701<span></span>
</td>
<td class="nump">15,150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets - long term</a></td>
<td class="nump">283<span></span>
</td>
<td class="nump">260<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">125,661<span></span>
</td>
<td class="nump">140,382<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">740<span></span>
</td>
<td class="nump">524<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_AccruedAndOtherLiabilitiesCurrent', window );">Accrued and other liabilities</a></td>
<td class="nump">1,933<span></span>
</td>
<td class="nump">2,918<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContingentConsiderationUnderPurchaseAgreements', window );">Contingent consideration under RPAs, AAAs and CPPAs</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeCurrent', window );">Unearned revenue recognized under units-of-revenue method</a></td>
<td class="nump">2,029<span></span>
</td>
<td class="nump">1,899<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_AccruedPreferredStockDividendCurrent', window );">Preferred stock dividend accrual</a></td>
<td class="nump">1,368<span></span>
</td>
<td class="nump">1,368<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">7,087<span></span>
</td>
<td class="nump">6,818<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeNoncurrent', window );">Unearned revenue recognized under units-of-revenue method - long-term</a></td>
<td class="nump">8,450<span></span>
</td>
<td class="nump">9,550<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">15,537<span></span>
</td>
<td class="nump">16,368<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Note 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0075 par value, 277,333,332 shares authorized, 11,472,808 and 11,454,025 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively</a></td>
<td class="nump">86<span></span>
</td>
<td class="nump">86<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">1,307,594<span></span>
</td>
<td class="nump">1,306,271<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,197,605)<span></span>
</td>
<td class="num">(1,182,392)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">110,124<span></span>
</td>
<td class="nump">124,014<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">125,661<span></span>
</td>
<td class="nump">140,382<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">8.625% Series A Cumulative, Perpetual Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock</a></td>
<td class="nump">49<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">8.375% Series B Cumulative, Perpetual Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsAndOtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsAndOtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481174/470-10-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481174/470-10-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482736/825-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_AccruedAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, and liabilities classified as other, due within one year or within the normal operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_AccruedAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_AccruedPreferredStockDividendCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for preferred stock dividend. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_AccruedPreferredStockDividendCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ContingentConsiderationUnderPurchaseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability recorded for contingent consideration under purchase agreements. May include royalty purchase agreements, commercial payment purchase agreements, payment interest purchase agreements and assignment and assumption agreements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ContingentConsiderationUnderPurchaseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LongTermRightsReceivableNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term royalty and commercial rights receivables, non current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LongTermRightsReceivableNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RightsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty, interest and commercial payment rights receivable, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RightsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140070009535264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0075<span></span>
</td>
<td class="nump">$ 0.0075<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">277,333,332<span></span>
</td>
<td class="nump">277,333,332<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">11,472,808<span></span>
</td>
<td class="nump">11,454,025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">11,472,808<span></span>
</td>
<td class="nump">11,454,025<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">8.625% Series A Cumulative, Perpetual Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Preferred stock, dividend rate (as a percent)</a></td>
<td class="nump">8.625%<span></span>
</td>
<td class="nump">8.625%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">984,000<span></span>
</td>
<td class="nump">984,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">984,000<span></span>
</td>
<td class="nump">984,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">8.375% Series B Cumulative, Perpetual Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Preferred stock, dividend rate (as a percent)</a></td>
<td class="nump">8.375%<span></span>
</td>
<td class="nump">8.375%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">5,003<span></span>
</td>
<td class="nump">5,003<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">5,003<span></span>
</td>
<td class="nump">5,003<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140070012250000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="nump">$ 1,125<span></span>
</td>
<td class="nump">$ 525<span></span>
</td>
<td class="nump">$ 1,125<span></span>
</td>
<td class="nump">$ 3,275<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Revenue recognized under units-of-revenue method</a></td>
<td class="nump">533<span></span>
</td>
<td class="nump">458<span></span>
</td>
<td class="nump">970<span></span>
</td>
<td class="nump">815<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">1,658<span></span>
</td>
<td class="nump">983<span></span>
</td>
<td class="nump">2,095<span></span>
</td>
<td class="nump">4,090<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="nump">93<span></span>
</td>
<td class="nump">96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">5,777<span></span>
</td>
<td class="nump">5,710<span></span>
</td>
<td class="nump">11,973<span></span>
</td>
<td class="nump">10,826<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ImpairmentOfLongTermRightsReceivableNonCurrent', window );">Royalty purchase agreement asset impairment</a></td>
<td class="nump">1,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Arbitration settlement costs (Note 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">7,615<span></span>
</td>
<td class="nump">5,750<span></span>
</td>
<td class="nump">18,222<span></span>
</td>
<td class="nump">10,922<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(5,957)<span></span>
</td>
<td class="num">(4,767)<span></span>
</td>
<td class="num">(16,127)<span></span>
</td>
<td class="num">(6,832)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense), net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">557<span></span>
</td>
<td class="nump">97<span></span>
</td>
<td class="nump">914<span></span>
</td>
<td class="num">(118)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(5,400)<span></span>
</td>
<td class="num">(4,670)<span></span>
</td>
<td class="num">(15,213)<span></span>
</td>
<td class="num">(6,950)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">(5,400)<span></span>
</td>
<td class="num">(4,670)<span></span>
</td>
<td class="num">(15,213)<span></span>
</td>
<td class="num">(6,950)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">Less: accumulated dividends on Series A and Series B preferred stock</a></td>
<td class="num">(1,368)<span></span>
</td>
<td class="num">(1,368)<span></span>
</td>
<td class="num">(2,736)<span></span>
</td>
<td class="num">(2,736)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders, basic</a></td>
<td class="num">(6,768)<span></span>
</td>
<td class="num">(6,038)<span></span>
</td>
<td class="num">(17,949)<span></span>
</td>
<td class="num">(9,686)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss attributable to common stockholders, diluted</a></td>
<td class="num">$ (6,768)<span></span>
</td>
<td class="num">$ (6,038)<span></span>
</td>
<td class="num">$ (17,949)<span></span>
</td>
<td class="num">$ (9,686)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per share attributable to common stockholders (in dollars per share)</a></td>
<td class="num">$ (0.59)<span></span>
</td>
<td class="num">$ (0.53)<span></span>
</td>
<td class="num">$ (1.57)<span></span>
</td>
<td class="num">$ (0.85)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per share attributable to common stockholders (in dollars per share)</a></td>
<td class="num">$ (0.59)<span></span>
</td>
<td class="num">$ (0.53)<span></span>
</td>
<td class="num">$ (1.57)<span></span>
</td>
<td class="num">$ (0.85)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares used in computing basic net loss per share attributable to common stockholders (in shares)</a></td>
<td class="nump">11,466<span></span>
</td>
<td class="nump">11,421<span></span>
</td>
<td class="nump">11,463<span></span>
</td>
<td class="nump">11,376<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares used in computing diluted net loss per share attributable to common stockholders (in shares)</a></td>
<td class="nump">11,466<span></span>
</td>
<td class="nump">11,421<span></span>
</td>
<td class="nump">11,463<span></span>
</td>
<td class="nump">11,376<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsIncomeStatementImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsIncomeStatementImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueNotFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue that is not accounted for under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueNotFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ImpairmentOfLongTermRightsReceivableNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of royalty and commercial rights receivable recognized in the income statement during the period. Includes royalty purchase agreement asset impairment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ImpairmentOfLongTermRightsReceivableNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140070007431632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Preferred Stock </div>
<div>8.625% Series A Cumulative, Perpetual Preferred Stock</div>
</th>
<th class="th">
<div>Preferred Stock </div>
<div>8.375% Series B Cumulative, Perpetual Preferred Stock</div>
</th>
<th class="th">
<div>Preferred Stock </div>
<div>Convertible preferred stock</div>
</th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period at Dec. 31, 2021</a></td>
<td class="nump">$ 49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85<span></span>
</td>
<td class="nump">$ 1,307,030<span></span>
</td>
<td class="num">$ (1,165,288)<span></span>
</td>
<td class="nump">$ 141,876<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at beginning of period (in shares) at Dec. 31, 2021</a></td>
<td class="nump">984,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">11,315,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">633<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock related to 401(k) contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock related to 401(k) contribution (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">978<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPreferredStockStock', window );">Preferred stock dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,368)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,368)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,280)<span></span>
</td>
<td class="num">(2,280)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Mar. 31, 2022</a></td>
<td class="nump">$ 49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 86<span></span>
</td>
<td class="nump">1,307,357<span></span>
</td>
<td class="num">(1,167,568)<span></span>
</td>
<td class="nump">139,924<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end of period (in shares) at Mar. 31, 2022</a></td>
<td class="nump">984,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">11,410,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period at Dec. 31, 2021</a></td>
<td class="nump">$ 49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85<span></span>
</td>
<td class="nump">1,307,030<span></span>
</td>
<td class="num">(1,165,288)<span></span>
</td>
<td class="nump">141,876<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at beginning of period (in shares) at Dec. 31, 2021</a></td>
<td class="nump">984,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">11,315,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,950)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Jun. 30, 2022</a></td>
<td class="nump">$ 49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 86<span></span>
</td>
<td class="nump">1,307,059<span></span>
</td>
<td class="num">(1,172,238)<span></span>
</td>
<td class="nump">134,956<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end of period (in shares) at Jun. 30, 2022</a></td>
<td class="nump">984,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">11,424,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period at Mar. 31, 2022</a></td>
<td class="nump">$ 49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 86<span></span>
</td>
<td class="nump">1,307,357<span></span>
</td>
<td class="num">(1,167,568)<span></span>
</td>
<td class="nump">139,924<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at beginning of period (in shares) at Mar. 31, 2022</a></td>
<td class="nump">984,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">11,410,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">189<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock related to ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock related to ESPP (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">836<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPreferredStockStock', window );">Preferred stock dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,368)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,368)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,670)<span></span>
</td>
<td class="num">(4,670)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Jun. 30, 2022</a></td>
<td class="nump">$ 49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 86<span></span>
</td>
<td class="nump">1,307,059<span></span>
</td>
<td class="num">(1,172,238)<span></span>
</td>
<td class="nump">134,956<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end of period (in shares) at Jun. 30, 2022</a></td>
<td class="nump">984,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">11,424,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period at Dec. 31, 2022</a></td>
<td class="nump">$ 49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 86<span></span>
</td>
<td class="nump">1,306,271<span></span>
</td>
<td class="num">(1,182,392)<span></span>
</td>
<td class="nump">124,014<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at beginning of period (in shares) at Dec. 31, 2022</a></td>
<td class="nump">984,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">11,454,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock related to 401(k) contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock related to 401(k) contribution (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,570<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPreferredStockStock', window );">Preferred stock dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,368)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,368)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,813)<span></span>
</td>
<td class="num">(9,813)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Mar. 31, 2023</a></td>
<td class="nump">$ 49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 86<span></span>
</td>
<td class="nump">1,306,596<span></span>
</td>
<td class="num">(1,192,205)<span></span>
</td>
<td class="nump">114,526<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end of period (in shares) at Mar. 31, 2023</a></td>
<td class="nump">984,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">11,461,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period at Dec. 31, 2022</a></td>
<td class="nump">$ 49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 86<span></span>
</td>
<td class="nump">1,306,271<span></span>
</td>
<td class="num">(1,182,392)<span></span>
</td>
<td class="nump">$ 124,014<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at beginning of period (in shares) at Dec. 31, 2022</a></td>
<td class="nump">984,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">11,454,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,473<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (15,213)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Jun. 30, 2023</a></td>
<td class="nump">$ 49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 86<span></span>
</td>
<td class="nump">1,307,594<span></span>
</td>
<td class="num">(1,197,605)<span></span>
</td>
<td class="nump">110,124<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end of period (in shares) at Jun. 30, 2023</a></td>
<td class="nump">984,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">11,472,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period at Mar. 31, 2023</a></td>
<td class="nump">$ 49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 86<span></span>
</td>
<td class="nump">1,306,596<span></span>
</td>
<td class="num">(1,192,205)<span></span>
</td>
<td class="nump">114,526<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at beginning of period (in shares) at Mar. 31, 2023</a></td>
<td class="nump">984,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">11,461,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">153<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock related to ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock related to ESPP (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,163<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPreferredStockStock', window );">Preferred stock dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,368)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,368)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,400)<span></span>
</td>
<td class="num">(5,400)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Jun. 30, 2023</a></td>
<td class="nump">$ 49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 86<span></span>
</td>
<td class="nump">$ 1,307,594<span></span>
</td>
<td class="num">$ (1,197,605)<span></span>
</td>
<td class="nump">$ 110,124<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end of period (in shares) at Jun. 30, 2023</a></td>
<td class="nump">984,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">11,472,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStockStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -SubTopic 405<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481071/942-405-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStockStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140070011442000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (15,213)<span></span>
</td>
<td class="num">$ (6,950)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,733<span></span>
</td>
<td class="nump">1,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ImpairmentOfLongTermRightsReceivableNonCurrent', window );">Royalty purchase agreement asset impairment</a></td>
<td class="nump">$ 1,575<span></span>
</td>
<td class="nump">1,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ChangesInEstimatedFairValueOfContingentConsideration', window );">Change in fair value of contingent consideration under RPAs, AAAs, and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(75)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims', window );">Common stock contribution to 401(k)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123<span></span>
</td>
<td class="nump">85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">224<span></span>
</td>
<td class="nump">449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationNonproduction', window );">Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_OperatingLeasePaymentsNonCash', window );">Non-cash lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97<span></span>
</td>
<td class="nump">84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss', window );">Change in fair value of equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables', window );">Trade and other receivables, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(900)<span></span>
</td>
<td class="nump">204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(97)<span></span>
</td>
<td class="num">(398)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(769)<span></span>
</td>
<td class="nump">582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income taxes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(91)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(102)<span></span>
</td>
<td class="num">(96)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Unearned revenue recognized under units-of-revenue method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(970)<span></span>
</td>
<td class="num">(815)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,132)<span></span>
</td>
<td class="num">(5,326)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities', window );">Payments of consideration under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,650)<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ReceiptsUnderAgreementsInvestingActivities', window );">Receipts under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,716)<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDividends', window );">Payment of preferred stock dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,736)<span></span>
</td>
<td class="num">(2,736)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from exercise of options and other share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">208<span></span>
</td>
<td class="nump">1,905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of equity awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="num">(1,038)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,533)<span></span>
</td>
<td class="num">(1,869)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash, cash equivalents and restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26,381)<span></span>
</td>
<td class="num">(12,195)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at the beginning of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,826<span></span>
</td>
<td class="nump">95,377<span></span>
</td>
<td class="nump">$ 95,377<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at the end of the period</a></td>
<td class="nump">31,445<span></span>
</td>
<td class="nump">31,445<span></span>
</td>
<td class="nump">83,182<span></span>
</td>
<td class="nump">$ 57,826<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Cash Flow Information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrentAndNoncurrent', window );">Preferred stock dividend accrual</a></td>
<td class="nump">$ 1,368<span></span>
</td>
<td class="nump">1,368<span></span>
</td>
<td class="nump">$ 1,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_EstimatedFairValueOfContingentConsiderationUnderAssetAcquisition', window );">Estimated fair value of contingent consideration under the LadRx Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationNonproduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expense recognized in the current period that allocates the cost of nonproduction tangible assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationNonproduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 405<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480191/946-405-45-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ChangesInEstimatedFairValueOfContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Changes in estimated fair value of contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ChangesInEstimatedFairValueOfContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined contribution plan issuance of Common stock for services or claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_EstimatedFairValueOfContingentConsiderationUnderAssetAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated fair value of contingent consideration under asset acquisition agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_EstimatedFairValueOfContingentConsiderationUnderAssetAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ImpairmentOfLongTermRightsReceivableNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of royalty and commercial rights receivable recognized in the income statement during the period. Includes royalty purchase agreement asset impairment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ImpairmentOfLongTermRightsReceivableNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_OperatingLeasePaymentsNonCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease payments, non cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_OperatingLeasePaymentsNonCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for consideration under agreements, including Royalty Purchase Agreements (RPAs), Assignment and Assumption Agreements (AAAs), and Commercial payment purchase agreement. (CPPAs) classified as investing activities. Payments may include upfront payments, one-time payments, milestone payments and contingent consideration payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ReceiptsUnderAgreementsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow under agreements, including Royalty Purchase Agreements (RPAs), Assignment and Assumption Agreements (AAAs), and Commercial Payment Purchase Agreements (CPPAs), classified as investing activities. Receipts may represent commercial payments attributable to net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ReceiptsUnderAgreementsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140070012233184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Description of Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Description of Business</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1. Description of Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">XOMA, a Delaware corporation, is a biotech royalty aggregator with a sizable portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company&#8217;s portfolio was built through the acquisition of rights to future milestones and royalties that the Company has made since the royalty aggregator business model was implemented in 2017 combined with out-licensing its proprietary products and platforms from its legacy discovery and development business. The Company&#8217;s drug royalty aggregator business is primarily focused on early to mid-stage clinical assets in Phase 1 and 2 with significant commercial sales potential that are licensed to large-cap partners. The Company expects that most of its future revenue will be based on payments the Company may receive for milestones and royalties related to these programs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Liquidity and Financial Condition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has incurred significant operating losses and negative cash flows from operations since its inception. As of June 30, 2023, the Company had cash and cash equivalents of $31.4 million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Based on the Company&#8217;s current cash balance and its ability to control discretionary spending, such as milestone and royalty acquisitions, the Company has evaluated and concluded its financial condition is sufficient to fund its planned operations and commitments and contractual obligations for a period of at least one year following the date that these condensed consolidated financial statements are issued.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140070014373696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Basis of Presentation and Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Significant Accounting Policies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2. Basis of Presentation and Significant Accounting Policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions among consolidated entities were eliminated upon consolidation. The unaudited condensed consolidated financial statements were prepared in accordance with GAAP in the United States for interim financial information and with the instructions to Form&#160;10-Q and Article&#160;10 of Regulation S-X. As permitted under those rules&#160;certain footnotes or other financial information can be condensed or omitted. These condensed consolidated financial statements and related disclosures have been prepared with the assumption that users of the interim financial information have read or have access to the audited consolidated financial statements for the preceding fiscal&#160;year. Accordingly, these statements should be read in conjunction with the audited consolidated financial statements and related notes included in the Company&#8217;s Annual Report on Form&#160;10-K for the&#160;year ended December&#160;31, 2022, filed with the SEC on March&#160;9, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">These condensed consolidated financial statements have been prepared on the same basis as the Company&#8217;s annual consolidated financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal and recurring adjustments that are necessary for a fair statement of the Company&#8217;s consolidated financial information. The interim results of operations are not necessarily indicative of the results that may be expected for the full&#160;year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The preparation of financial statements in conformity with GAAP in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates including, but not limited to, those related to revenue recognition, revenue recognized under the units-of-revenue method, royalty and commercial payment receivables, </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">intangible assets, legal contingencies, contingent consideration and stock-based compensation. The Company bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Actual results may differ significantly from these estimates, such as the Company&#8217;s amortization of the payments received from HCRP. Under the contracts with HCRP, the amortization for the reporting period is calculated based on the payments expected to be made by the licensees to HCRP over the term of the arrangement. Any changes to the estimated payments by the licensees to HCRP can result in a material adjustment to revenue previously reported.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash and Cash Equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash consists of bank deposits held in business checking and interest-bearing deposit accounts. As of June 30, 2023, the Company had a cash balance of $1.3 million and cash equivalent balances of $30.1 million, defined as highly liquid financial instruments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. As of December 31, 2022, the Company had a cash balance of $27.5 million and cash equivalent balances of $30.3 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Revenue Recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes revenue from all contracts with customers according to ASC 606, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i)&#160;identify the contract(s)&#160;with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation based on relative fair values, when (or as) the performance obligation is satisfied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes revenue from its license and collaboration arrangements and royalties. The terms of the arrangements generally include payment to the Company of one or more of the following: non-refundable, upfront license fees, development, regulatory and commercial milestone payments, and royalties on net sales of licensed products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 18pt;">License of intellectual property</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, such as transfer of related materials, process and know-how, the Company utilizes judgement to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. Under the Company&#8217;s license agreements, the nature of the combined performance obligation is the granting of licenses to the customers as the other promises are not separately identifiable in the context of the arrangement. Since the Company grants the license to a customer as it exists at the point of transfer and is not involved in any future development or commercialization of the products related to the license, the nature of the license is a right to use the Company&#8217;s intellectual property as transferred. As such, the Company recognizes revenue related to the combined performance obligation upon completion of the delivery of the related materials, process and know-how (i.e., at a point in time).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 18pt;">Milestone payments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of each arrangement that includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price. ASC 606 suggests two alternatives to use when estimating the amount of variable consideration: the expected value method and the most likely amount method. Under the expected value method, an entity considers the sum of probability-weighted amounts in a range of possible consideration amounts. Under the most likely amount method, an entity considers the single most likely amount in a range of possible consideration amounts. The Company uses the most likely amount method for development and regulatory milestone payments. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If it is probable that a significant cumulative revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis. The Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability or achievement of each such milestone and any related constraint, and if necessary, adjusts its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and earnings in the period of adjustment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 18pt;">Royalties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upfront payments and fees are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts payable to the Company are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one&#160;year or less.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Sale of Future Revenue Streams</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has sold its rights to receive certain milestones and royalties on product sales. In the circumstance where the Company has sold its rights to future milestones and royalties under a license agreement and also maintains limited continuing involvement in the arrangement (but not significant continuing involvement in the generation of the cash flows that are due to the purchaser), the Company defers recognition of the proceeds it receives for the sale of milestone or royalty streams and recognizes such unearned revenue as revenue under the units-of-revenue method over the life of the underlying license agreement. Under the units-of-revenue method, amortization for a reporting period is calculated by computing a ratio of the proceeds received from the purchaser to the total payments expected to be made to the purchaser over the term of the agreement, and then applying that ratio to the period&#8217;s cash payment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Estimating the total payments expected to be received by the purchaser over the term of such arrangements requires management to use subjective estimates and assumptions. Changes to the Company&#8217;s estimate of the payments expected to be made to the purchaser over the term of such arrangements could have a material effect on the amount of revenues recognized in any particular period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company recognizes compensation expense for all stock-based payment awards made to the Company&#8217;s employees, consultants and directors that are expected to vest based on estimated fair values. The valuation of stock option awards is determined at the date of grant using the Black-Scholes Model. The Black-Scholes Model requires inputs such </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">as the expected term of the option, expected volatility and risk-free interest rate. To establish an estimate of expected term, the Company considers the vesting period and contractual period of the award and its historical experience of stock option exercises, post-vesting cancellations and volatility. The estimate of expected volatility is based on the Company&#8217;s historical volatility. The risk-free rate is based on the yield available on United States Treasury zero-coupon issues corresponding to the expected term of the award. The Company records forfeitures when they occur. The Company records compensation expense for service-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the award, or to the date on which retirement eligibility is achieved, if shorter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The grant date fair value of PSUs with market conditions are determined using the Monte Carlo valuation model. The Company records compensation expenses for PSUs based on graded expense attribution over the requisite service periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Equity Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company entered into a license agreement with Rezolute in December 2017, in which it received shares of common stock from Rezolute (Note 4). Equity investments in Rezolute are classified in the condensed consolidated balance sheets as equity securities. The equity securities are measured at fair value, with changes in fair value recorded in the other income (expense), net line item of the condensed consolidated statement of operations and comprehensive loss at each reporting period. The Company remeasures its equity investments at each reporting period until such time that the investment is sold or disposed of. If the Company sells an investment, any realized gains and losses on the sale of the securities will be recognized in the condensed consolidated statement of operations and comprehensive loss in the period of sale.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Purchase of Rights to Future Milestones, Royalties and Commercial Payments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has purchased rights to receive a portion of certain future developmental, regulatory and commercial sales milestones, royalties and option fees on sales of products currently in clinical development or recently commercialized. The Company acquired such rights from various entities and recorded the amount paid for these rights as long-term royalty receivables (Note 5). In addition, the Company may be obligated to make contingent payments related to certain product development milestones, fees upon exercise of options related to future license products and sales-based milestones. The contingent payments are evaluated to determine if they are freestanding instruments or embedded derivatives. If the contingent payments fall within the scope of ASC 815, the contingent payments are measured at fair value at the inception of the arrangement, and subject to remeasurement to fair value each reporting period. Any changes in the estimated fair value are recorded in the condensed consolidated statement of operations and comprehensive loss. Contingent consideration payments that do not fall within the scope of ASC 815 are recognized when the amount is probable and estimable according to ASC 450.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for milestone and royalty rights related to developmental pipeline or recently commercialized products on a non-accrual basis using the cost recovery method. These developmental pipeline products are non-commercialized, non-approved products that require FDA or other regulatory approval, and thus have uncertain cash flows. The recently commercialized products do not have an established reliable sales pattern, and thus have uncertain cash flows. The Company is not yet able to reliably forecast future cash flows given their stages of development and commercialization. The related receivable balance is classified as noncurrent or current based on whether payments are probable and reasonably estimable to be received in the near term. Under the cost recovery method, any milestone or royalty payment received is recorded as a direct reduction of the recorded receivable balance. When the recorded receivable balance has been fully collected, any additional amounts collected are recognized as revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Allowance for Current Expected Credit Losses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company evaluates the long-term royalty and commercial payment receivables on a collective, i.e., pool, basis if they share similar risk characteristics. The Company would evaluate a royalty and commercial payment receivable individually if its risk characteristics are not similar to other royalty and commercial payment receivables. The Company reviews public information on clinical trials, press releases and updates from its partners regularly to identify any impairment indicators or changes in expected recoverability of the long-term royalty and commercial payment receivable </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">asset. At each reporting date, if the Company determines expected future cash flows discounted to the current period are less than the carrying value of the asset, the Company will record impairment. The impairment will be recognized as an allowance expense that increases the long-term royalty and commercial payment receivable asset&#8217;s cumulative allowance, which reduces the net carrying value of the long-term royalty and commercial payment receivable asset. In a subsequent period, if there is an increase in expected future cash flows, or if the actual cash flows are greater than previously expected, the Company will reduce the previously established cumulative allowance. Amounts not expected to be collected are written off against the allowance at the time that such a determination is made. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Asset Acquisitions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As a first step, for each acquisition, the Company determines if it is an acquisition of a business or an asset acquisition under ASC 805. Acquisitions of assets or a group of assets that do not meet the definition of a business are accounted for as asset acquisitions under ASC 805-50, using the cost accumulation method, whereby the cost of the acquisition, including certain transaction costs, is allocated to the assets acquired on the basis of relative fair values (Note 4). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Contingent payments are evaluated whether they are freestanding instruments or embedded derivatives. If the contingent payments fall within the scope of ASC 815, the contingent payments are measured at fair value at the acquisition date, and subject to remeasurement to fair value each reporting period. The estimated fair value at the acquisition date is included in the cost of the acquired assets. Any subsequent changes in the estimated fair value are recorded in the condensed consolidated statement of operations and comprehensive loss. Contingent consideration payments that do not fall within the scope of ASC 815 are recognized when the amount is probable and estimable according to ASC 450. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash payments related to acquired assets are reflected as an investing cash flow in the Company&#8217;s condensed consolidated statement of cash flows. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Intangible Assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The identifiable intangible asset consists of IP acquired in the ObsEva IP Acquisition Agreement in 2022. This intangible asset is amortized on a straight-line basis over its estimated useful life of 17 years. The straight-line method of amortization represents the Company&#8217;s best estimate of the distribution of the economic value of the identifiable intangible asset. The intangible asset is carried at cost less accumulated amortization. Amortization will be included in amortization of intangible assets in the condensed consolidated statement of operations and comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amount of an asset group to the future net undiscounted cash flows that the assets are expected to generate. If the carrying amount of an asset group exceeds its estimated future cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset group exceeds the fair value of the asset group. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company leases its headquarters office space in Emeryville, California.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company determines the initial classification and measurement of its right-of-use assets and lease liabilities at the lease commencement date and thereafter if modified. The lease term includes any renewal options and termination options that the Company is reasonably certain to exercise. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its incremental borrowing rate. The incremental borrowing rate is determined by using the rate of interest that the Company would pay to borrow on a collateralized basis an amount equal to the lease payments for a similar term and in a similar economic environment. The Company built its incremental borrowing rate starting with the interest rate on its fully collateralized debt and then adjusted it for lease term length.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Rent expense for the operating lease is recognized on a straight-line basis, over the reasonably assured lease term based on the total lease payments and is included in operating expenses in the condensed consolidated statements of operations and comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has elected the practical expedient to not separate lease and non-lease components. The Company&#8217;s non-lease components are primarily related to property maintenance, which varies based on future outcomes, and thus is recognized in rent expense when incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for income taxes using the liability method under which deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount which is more likely than not to be realizable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The recognition, derecognition and measurement of a tax position is based on management&#8217;s best judgment given the facts, circumstances and information available at each reporting date. The Company&#8217;s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Net Loss per Share Attributable to Common Stockholders</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company calculates basic and diluted loss per share attributable to common stockholders using the two-class method. The Company&#8217;s convertible Series X preferred stocks participate in any dividends declared by the Company on its common stock and are therefore considered to be participating securities. The Company&#8217;s Series A and Series B Preferred Stock do not participate in any dividends or distribution by the Company on its common stock and are therefore not considered to be participating securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the two-class method, net income, as adjusted for any accumulated dividends on Series A and Series B Preferred Stock for the period, is allocated to each class of common stock and participating security as if all of the net income for the period had been distributed. Undistributed earnings allocated to participating securities are subtracted from net income in determining net income attributable to common stockholders. During periods of loss, the Company allocates no loss to participating securities because they have no contractual obligation to share in the losses of the Company. Basic net loss per share attributable to common stockholders is then calculated by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. All participating securities are excluded from the basic weighted average common shares outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Diluted net loss per share attributable to common stockholders is based on the weighted average number of shares outstanding during the period, adjusted to include the assumed exercise of certain stock options and warrants for common stock using the treasury method, if dilutive. The calculation assumes that any proceeds that could be obtained upon exercise of options and warrants would be used to purchase common stock at the average market price during the period. Adjustments to the denominator are required to reflect the related dilutive shares. The Company&#8217;s Series A and Series B Preferred Stock become convertible upon the occurrence of specific events other than a change in the Company&#8217;s share price and, therefore, are not included in the diluted shares until the contingency is resolved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Concentration of Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash, cash equivalents and receivables are financial instruments which potentially subject the Company to concentrations of credit risk, as well as liquidity risk. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company maintains cash balances at commercial banks. Balances commonly exceed the amount insured by the FDIC. The Company has not experienced any losses in such accounts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company monitors the creditworthiness of its customers to which it grants credit terms in the normal course of business but does not generally require collateral on receivables. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the three months ended June 30, 2023, two partners represented 66% and 32% of total revenues. For the six months ended June 30, 2023, two partners represented 53% and 46% of total revenues. For the three months ended June 30, 2022, two partners represented 51% and 47% of total revenues. For the six months ended June 30, 2022, four partners represented 49%, 20%, 18% and 12% of total revenues. One partner represented 100% of the trade receivables, net balance as of June 30, 2023. There were no trade receivables, net balance as of December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Comprehensive Loss</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Comprehensive loss is comprised of two components: net loss and other comprehensive loss. Other comprehensive loss refers to gains and losses that under U.S. GAAP are recorded as an element of stockholders&#8217; equity but are excluded from net loss. The Company did not record any transactions within other comprehensive loss in the periods presented and, therefore, the net loss and comprehensive loss were the same for all periods presented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Accounting Pronouncements Recently Adopted</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (ASC 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 replaced the incurred loss impairment methodology under current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. ASU 2016-13 requires use of a forward-looking expected credit loss model for accounts receivables, loans, and other financial instruments. Adoption of the standard requires using a modified retrospective approach through a cumulative-effect adjustment to retained earnings as of the effective date to align existing credit loss methodology with the new standard. The Company adopted ASU 2016-13 and related updates on January 1, 2023. The adoption of ASU 2016-13 had no impact on the condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In October 2021, the FASB issued ASU 2021-08, Business Combinations &#8211; Accounting for Contract Assets and Contact Liabilities from Contracts with Customers. The guidance is intended to improve the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice. The guidance requires an acquirer to recognize and measure contract assets and liabilities acquired in a business combination in accordance with ASC 606 as if they had originated the contracts, as opposed to at fair value on the acquisition date. The Company adopted ASU 2021-08 and related updates on January 1, 2023. The adoption of ASU 2021-08 had no impact on the condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140070016145152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Financial Statements Details<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ConsolidatedFinancialStatementDetailAbstract', window );"><strong>Condensed Consolidated Financial Statements Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock', window );">Condensed Consolidated Financial Statements Details</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">3.&#160;Condensed Consolidated Financial Statements Details</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Equity Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Equity securities consisted of an investment in Rezolute&#8217;s common stock of $0.3 million for both June 30, 2023 and December 31, 2022 (Note 4). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the three and six months ended June 30, 2023, the Company recognized a gain of $10,000 and a loss of $15,000, respectively, due to the change in fair value of its investment in Rezolute&#8217;s common stock in the other income (expense), net line item of the condensed consolidated statements of operations and comprehensive loss. For the three and six months ended June 30, 2022, the Company recognized a loss of $25,000 and $0.3 million, respectively, due to the change in fair value of its investment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Intangible assets, net</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes cost, accumulated amortization, and net carrying value of the intangible assets as of June 30, 2023 (in thousands): </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net Carrying</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortization</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As of June 30, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Ebopiprant IP (Note 4) </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,247</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 546</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,701</p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total intangible assets </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,247</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 546</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,701</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table summarizes cost, accumulated amortization, and net carrying value of the intangible assets as of December 31, 2022 (in thousands): </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net Carrying</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortization</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As of December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Ebopiprant IP (Note 4) </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,247</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 97</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,150</p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total intangible assets </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,247</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 97</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,150</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The remaining life of the intangible assets is 16.4 years. The following table presents the projected amortization expense for the next five years (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;"> </span><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intangible Asset</b></p></td></tr><tr><td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortization</b></p></td></tr><tr><td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:83.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2023 (excluding six months ended June 30, 2023)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 448</p></td></tr><tr><td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 897</p></td></tr><tr><td style="vertical-align:bottom;width:83.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 897</p></td></tr><tr><td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 897</p></td></tr><tr><td style="vertical-align:bottom;width:83.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 897</p></td></tr><tr><td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,036</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Accrued and Other Liabilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Accrued and other liabilities consisted of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued payroll, severance and retention costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 978</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,449</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued incentive compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 604</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 562</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued legal and accounting fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 331</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 867</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,933</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,918</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Net Loss Per Share Attributable to Common Stockholders </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following is a reconciliation of the numerator (net loss) and the denominator (number of shares) used in the calculation of basic and diluted net loss per share attributable to common stockholders (in thousands, except per share amounts):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six Months Ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Numerator</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:55.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,400)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,670)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (15,213)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,950)</p></td></tr><tr><td style="vertical-align:bottom;width:55.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: Series A accumulated dividends </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (530)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (530)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,061)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,061)</p></td></tr><tr><td style="vertical-align:bottom;width:55.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: Series B accumulated dividends </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (838)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (838)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,675)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,675)</p></td></tr><tr><td style="vertical-align:bottom;width:55.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss attributable to common stockholders, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,768)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,038)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (17,949)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,686)</p></td></tr><tr><td style="vertical-align:bottom;width:55.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Denominator</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average shares used in computing basic and diluted net loss per share attributable to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,466</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,421</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,463</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,376</p></td></tr><tr><td style="vertical-align:bottom;width:55.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Basic and diluted net loss per share attributable to common stockholders </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.59)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.53)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.57)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.85)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Potentially dilutive securities are excluded from the calculation of diluted net loss per share attributable to common stockholders if their inclusion is anti-dilutive. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table shows the weighted-average shares from outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net loss per share attributable to common stockholders (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six Months Ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Convertible preferred stock </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,003</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,003</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,003</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,003</p></td></tr><tr><td style="vertical-align:bottom;width:55.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Common stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,719</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 889</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,634</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 813</p></td></tr><tr><td style="vertical-align:bottom;width:55.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants for common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6</p></td></tr><tr><td style="vertical-align:bottom;width:55.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,728</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,898</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,643</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,822</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;background:#00ff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">For PSUs with market conditions, if the market conditions have not been satisfied by the end of the reporting period, the number of shares that would be issuable based on the market price at the end of the reporting period, as if the end of the reporting period were the end of the contingency period, will be included in the calculation of diluted earnings per share if the effect is dilutive. No shares would be issuable based on the market price of $18.89 per share as of June 30, 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Arbitration Proceeding </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In June 2021, the Company initiated a binding arbitration proceeding with one of its licensees (the &#8220;Licensee&#8221;) at the American Arbitration Association/International Centre for Dispute Resolution, seeking milestone and royalty payments under its license agreement. A hearing before a panel of arbitrators was held in November 2022, and the parties submitted post-hearing briefs. On March 21, 2023, the Company received an adverse decision in this arbitration proceeding. The panel of arbitrators declined to award the Company damages and ruled that the license agreement has expired. The panel ruled that the Company is responsible for the Licensee&#8217;s costs as well as arbitrators&#8217; and administrative fees previously incurred by the Licensee of $4.1 million, which the Company paid in April 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalFinancialInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ConsolidatedFinancialStatementDetailAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Consolidated financial statement detail.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ConsolidatedFinancialStatementDetailAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140070010693520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Licensing and Other Arrangements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LicensingAndOtherArrangementsAbstract', window );"><strong>Licensing and Other Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LicensingAndOtherArrangementsTextBlock', window );">Licensing and Other Arrangements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">4. Licensing and Other Arrangements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">ObsEva </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On November 21, 2022, the Company entered into the ObsEva IP Acquisition Agreement pursuant to which the Company acquired all of ObsEva&#8217;s intellectual property (patents and know-how) and license agreement rights related to ebopiprant, an investigational compound previously licensed by ObsEva from Merck KGaA. The Company also assumed ObsEva&#8217;s ongoing rights and obligations under the Organon License Agreement and the Merck KGaA License Agreement. Pursuant to the Organon License Agreement, XOMA is eligible to receive up to $475.0 million in payments for ebopiprant development, commercialization and sales-based milestones. If ebopiprant is successfully commercialized, the Company will be entitled to receive royalties on net sales that range from low to mid-teens from Organon and will be required to make mid-single-digit royalty payments on net sales to Merck KGaA. The Company paid ObsEva a $15.0 million upfront payment at closing and will pay potential earn-out payments of up to $97.5 million for development, regulatory and sales-based milestones, representing a portion of what the Company would receive pursuant to the Organon License Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The transaction was treated as an acquisition of a finite-lived intangible asset (Note 2). As such, the Company&#8217;s cost to acquire said intangible asset of $15.2 million, consisting of $15.0 million cash paid upon closing of the ObsEva IP Acquisition Agreement and direct incremental transaction costs of $0.2 million, was recognized as a long-term asset in the consolidated balance sheet for the year ended December 31, 2022. The estimated useful life of the intangible asset at acquisition represented 17 years. No impairment indicators were identified, and no impairment was recorded as of June 30, 2023 and December 31, 2022. The Company recognized $0.2 million and $0.4 million of amortization expense in the condensed consolidated statement of operations and comprehensive loss for the three and six months ended June 30, 2023, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company concluded that the development and regulatory milestone payments of $46.5 million, sales-based milestones payments of $51.0 million and royalty payments to Merck KGaA do not meet the definition of a derivative under ASC 815 and a liability will be recognized at the time that the underlying revenue is recognized under the Organon License Agreement for the corresponding development and regulatory milestone payments, sales-based milestone payments, and royalty payments. ASC 450 may require recognition of the contingent consideration if it is probable that a liability has been incurred and the amount of that liability can be reasonably estimated. Due to the nature of the non-sales and sales-based milestones the Company expects the contingent payments to be probable of payment at the same time that revenue from the Organon License Agreement would be recorded.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of June 30, 2023 and December 31, 2022, there were no contract assets or contract liabilities related to this arrangement. The Company did not recognize any revenue related to this arrangement during the three and six months ended June 30, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Novartis&#160;&#8211; Anti-TGF&#946; Antibody (NIS793)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On September&#160;30, 2015, the Company and Novartis entered into the Anti-TGF&#946; Antibody License Agreement under which the Company granted Novartis an exclusive, world-wide, royalty-bearing license to the Company&#8217;s anti-transforming growth factor beta (&#8220;TGF&#946;&#8221;) antibody program (now &#8220;NIS793&#8221;). Under the terms of the Anti-TGF&#946; Antibody License Agreement, Novartis has worldwide rights to NIS793 and is responsible for the development and commercialization of antibodies and products containing antibodies arising from NIS793. Unless terminated earlier, the Anti-TGF&#946; Antibody License Agreement will remain in effect, on a country-by-country and product-by-product basis, until Novartis&#8217; royalty obligations end. The Anti-TGF&#946; Antibody License Agreement contains customary termination rights relating to material breach by either party. Novartis also has a unilateral right to terminate the Anti-TGF&#946; Antibody License Agreement on an antibody-by-antibody and country-by-country basis or in its entirety on one hundred eighty days&#8217; notice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company concluded that there were multiple promised goods and services under the Anti-TGF&#946; Antibody License Agreement, including the transfer of license, regulatory services and transfer of materials, process and know-how, which were determined to represent one combined performance obligation. The Company recognized the entire upfront </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">payment of $37.0 million as revenue in the consolidated statement of comprehensive loss in 2015 as it had completed its performance obligations as of December&#160;31, 2015.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company was eligible to receive up to a total of $480.0 million in development, regulatory and commercial milestones under the Anti-TGF&#946; Antibody License Agreement. During the year ended December 31, 2017, Novartis achieved a clinical development milestone pursuant to the Anti-TGF&#946; Antibody License Agreement, and as a result, the Company earned a $10.0 million milestone payment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company concluded that the development and regulatory milestone payments are solely dependent on Novartis&#8217; performance and achievement of the specified events. The Company determined that it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the remaining development and regulatory milestones are fully constrained and excluded from the transaction price. Any consideration related to commercial milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the licenses granted to Novartis and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is also eligible to receive royalties on sales of licensed products, which are tiered based on sales levels and range from a mid-single-digit percentage rate to up to a low double-digit percentage rate. Novartis&#8217; obligation to pay royalties with respect to a particular product and country will continue for the longer of the date of expiration of the last valid patent claim covering the product in that country, or ten years from the date of the first commercial sale of the product in that country.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In October 2020, the Company earned a $25.0 million milestone upon the dosing of the first patient in Novartis&#8217; first NIS793 Phase 2 clinical trial. As specified under the terms of the Anti-TGF&#946; Antibody License Agreement, the Company received $17.7 million in cash, and the remaining balance of $7.3 million was recognized as a reduction to the Company's debt obligation to Novartis. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In October 2021, the Company earned a $35.0 million milestone payment upon dosing of the first patient in Novartis&#8217; first NIS793 Phase 3 clinical trial. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is eligible to receive remaining milestones up to a total of $410.0 million under the Anti-TGF&#946; Antibody License Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of June 30, 2023 and December 31, 2022, there were no contract assets or contract liabilities related to this arrangement. None of the costs to obtain or fulfill the contract were capitalized. The Company did not recognize any revenue related to this arrangement during the three and six months ended June 30, 2023 and 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Novartis&#160;&#8211; Anti-IL-1&#946; Antibody (VPM087) </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On August&#160;24, 2017, the Company and Novartis entered into the Gevokizumab License Agreement under which the Company granted to Novartis an exclusive, worldwide, royalty-bearing license to gevokizumab (&#8220;VPM087&#8221;), a novel anti-Interleukin-1 (&#8220;IL-1&#8221;) beta allosteric monoclonal antibody and related know-how and patents. Under the terms of the Gevokizumab License Agreement, Novartis is solely responsible for the development and commercialization of VPM087 and products containing VPM087. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On August&#160;24, 2017, pursuant to a separate agreement (the &#8220;IL-1 Target License Agreement&#8221;), the Company granted to Novartis non-exclusive licenses to its intellectual property covering the use of IL-1 beta targeting antibodies in the treatment and prevention of cardiovascular disease and other diseases and conditions, and an option to obtain an exclusive license (the &#8220;Exclusivity Option&#8221;) to such intellectual property for the treatment and prevention of cardiovascular disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Under the Gevokizumab License Agreement, the Company received total consideration of $30.0 million for the license and rights granted to Novartis. Of the total consideration, $15.7 million was paid in cash and $14.3 million (equal </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">to &#8364;12.0 million) was paid by Novartis, on behalf of the Company, to settle the Company&#8217;s outstanding debt with Les Laboratories Servier (&#8220;Servier&#8221;) (the &#8220;Servier Loan&#8221;). In addition, Novartis extended the maturity date on the Company&#8217;s debt to Novartis. The Company also received $5.0 million cash related to the sale of 539,131 shares of the Company&#8217;s common stock, at a purchase price of $9.2742 per share. The fair market value of the common stock issued to Novartis was $4.8 million, based on the closing stock price of $8.93 per share on August&#160;24, 2017, resulting in a $0.2 million premium paid to the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Based on the achievement of pre-specified criteria, the Company is eligible to receive up to $438.0 million in development, regulatory and commercial milestones under the Gevokizumab License Agreement. The Company is also eligible to receive royalties on sales of licensed products, which are tiered based on sales levels and range from the high single-digits to mid teens. Under the IL-1 Target License Agreement, the Company received an upfront cash payment of $10.0 million and is eligible to receive low single-digit royalties on canakinumab sales in cardiovascular indications covered by the Company&#8217;s patents. Should Novartis exercise the Exclusivity Option, the royalties on canakinumab sales will increase to the mid single-digits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Unless terminated earlier, the Gevokizumab License Agreement and IL-1 Target License Agreement will remain in effect, on a country-by-country and product-by-product basis, until Novartis&#8217; royalty obligations end. The two agreements contain customary termination rights relating to material breach by either party. Novartis also has a unilateral right to terminate the Gevokizumab License Agreement on a product-by-product and country-by-country basis or in its entirety on six months&#8217; prior written notice to the Company. Under the IL-1 Target License Agreement, Novartis has a unilateral right to terminate the agreement on a product-by-product and country-by-country basis or in its entirety upon a prior written notice. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Gevokizumab License Agreement and IL-1 Target License Agreement were accounted for as one arrangement because they were entered into at the same time in contemplation of each other. The Company concluded that there are multiple promised goods and services under the combined arrangement, including the transfer of license to IL-1 beta targeting antibodies, and the transfer of license, know-how, process, materials and inventory related to the VPM087 antibody, which were determined to represent two distinct performance obligations. The Company determined that the Exclusivity Option is not an option with material right because the upfront payments to the Company were not negotiated to provide an incremental discount for the future additional royalties upon exercise of the Exclusivity Option. Therefore, the Company concluded that the Exclusivity Option is not a performance obligation. The additional royalties will be recognized as revenue when, and if, Novartis exercises its option because the Company has no further performance obligations at that point.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of the arrangement, the Company determined that the transaction price under the arrangement was $40.2 million, which consisted of the $25.7 million upfront cash payments, the $14.3 million Servier Loan payoff and the $0.2 million premium on the sale of the common stock. The transaction price was allocated to the two performance obligations based on their standalone selling prices. The Company determined that the nature of the two performance obligations is the right to use the licenses as they exist at the point of transfer, which occurred when the transfer of materials, process and know-how, and filings to regulatory authority were completed. During the&#160;year ended December&#160;31, 2017, the Company recognized the entire transaction price of $40.2 million as revenue upon completion of the delivery of the licenses and related materials, process and know-how, and filings to regulatory authority.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company concluded that the development and regulatory milestone payments are solely dependent on Novartis&#8217; performance and achievement of specified events. The Company determined that it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the development and regulatory milestones are fully constrained and excluded from the transaction price until the respective milestone is achieved. Any consideration related to commercial milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the licenses granted to Novartis and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of June 30, 2023 and December 31, 2022, there were no contract assets or contract liabilities related to this arrangement, and none of the costs to obtain or fulfill the contract were capitalized. The Company did not recognize any revenue related to this arrangement during the three and six months ended June 30, 2023 and 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Takeda</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On November 1,&#160;2006, the Company entered into the Takeda Collaboration Agreement with Takeda under which the Company agreed to discover and optimize therapeutic antibodies against multiple targets selected by Takeda.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Takeda Collaboration Agreement, the Company may receive additional milestone payments aggregating up to $19.0 million relating to TAK-079 (mezagitamab) and TAK-169 (MT-0169), and low single-digit royalties on future sales of all products subject to this license. The Company&#8217;s right to milestone payments expires on the later of the receipt of payment from Takeda of the last amount to be paid under the agreement or the cessation by Takeda of all research and development activities with respect to all program antibodies, collaboration targets or collaboration products. The Company&#8217;s right to royalties expires on the later of 13.5&#160;years from the first commercial sale of each royalty-bearing discovery product or the expiration of the last-to-expire licensed patent (or 12 years from first commercial sale if there is significant generic competition post patent-expiration).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In February&#160;2009, the Company expanded the existing collaboration to provide Takeda with access to multiple antibody technologies, including a suite of research and development technologies and integrated information and data management systems. The Company may receive milestones of up to $3.3 million per discovery product candidate and low single-digit royalties on future sales of all antibody products subject to this license. The Company&#8217;s right to milestone payments expires on the later of the receipt of payment from Takeda of the last amount to be paid under the agreement or the cessation by Takeda of all research and development activities with respect to all program antibodies, collaboration targets or collaboration products. The Company&#8217;s right to royalties expires on the later of 10 years from the first commercial sale of such royalty-bearing discovery product or the expiration of the last-to-expire licensed patent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2020, the first patient was dosed in Takeda&#8217;s Phase 2 study of mezagitamab and the Company earned a $2.0 million milestone payment from Takeda. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In August 2021, Molecular Templates, Inc., assumed full rights to TAK-169 from Takeda, including full control of TAK-169 clinical development, per the terms of its terminated collaboration agreement with Takeda.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In January 2022, the Company earned a development milestone pursuant to the Takeda Collaboration and recognized $0.8 million as revenue from contracts with customers in the condensed consolidated statement of operations and comprehensive loss for the six months ended June 30, 2022. No revenue was recognized for the three and six months ended June 30, 2023, or for the three months ended June 30, 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of June 30, 2023 and December 31, 2022 there were no contract assets or contract liabilities related to this arrangement and none of the costs to obtain or fulfill the contract were capitalized. The Company is eligible to receive remaining milestones up to a total of $16.0 million under the Takeda Collaboration Agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Rezolute</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December&#160;6, 2017, the Company entered into a license agreement with Rezolute pursuant to which the Company granted an exclusive global license to Rezolute to develop and commercialize X358 (now &#8220;RZ358&#8221;) products for all indications. The Company and Rezolute also entered into a common stock purchase agreement pursuant to which Rezolute agreed to issue to the Company, as consideration for receiving the license for RZ358, a certain number of its common stock related to its future financing activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Under the terms of the license agreement, Rezolute is responsible for all development, regulatory, manufacturing and commercialization activities associated with RZ358 and is required to make certain development, regulatory and commercial milestone payments to the Company of up to $232.0 million in the aggregate based on the achievement of </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">pre-specified criteria. Under the license agreement, the Company is also eligible to receive royalties ranging from the high single-digits to the mid-teens based upon annual net sales of any commercial product incorporating RZ358. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company concluded that the development and regulatory milestone payments are solely dependent on Rezolute&#8217;s performance and achievement of the specified events. The Company determined that it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the remaining development and regulatory milestones are fully constrained and excluded from the transaction price until the respective milestone is achieved. Any consideration related to commercial milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the licenses granted to Rezolute and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Rezolute&#8217;s obligation to pay royalties with respect to a particular RZ358 product and country will continue for the longer of the date of expiration of the last valid patent claim covering the product in that country, or twelve years from the date of the first commercial sale of the product in that country. Rezolute&#8217;s future royalty obligations in the United States will be reduced by 20% if the manufacture, use or sale of a licensed product is not covered by a valid XOMA patent claim, until such a claim is issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the license agreement, XOMA is eligible to receive a low single-digit royalty on sales of Rezolute&#8217;s other non-RZ358 products from its current programs, including RZ402 which is in Phase 2 clinical testing. Rezolute&#8217;s obligation to pay royalties with respect to a particular Rezolute product and country will continue for the longer of twelve years from the date of the first commercial sale of the product in that country or for so long as Rezolute or its licensee is selling such product in such country, provided that any such licensee royalty will terminate upon the termination of the licensee&#8217;s obligation to make payments to Rezolute based on sales of such product in such country</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The license agreement contains customary termination rights relating to material breach by either party. Rezolute also has a unilateral right to terminate the license agreement in its entirety on ninety days&#8217; notice at any time. To the extent permitted by applicable laws, the Company has the right to terminate the license agreement if Rezolute challenges the licensed patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">No consideration was exchanged upon execution of the arrangement. In consideration for receiving the license for RZ358, Rezolute agreed to issue shares of its common stock and pay cash to the Company upon the occurrence of Rezolute&#8217;s financing activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The license agreement was subsequently amended in 2018, 2019 and 2020. Pursuant to the terms of the license agreement as amended, the Company received a total of $6.0 million upon Rezolute&#8217;s financing and $8.5 million in installment payments through October 2020. The Company also received 161,861 shares of Rezolute&#8217;s common stock (as adjusted for the <span style="-sec-ix-hidden:Hidden_U1OJbQlzmUOeCcJTMgU3Qw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1</span></span>:50 reverse stock split in October 2020). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In January 2022, Rezolute dosed the last patient in its Phase 2b clinical trial for RZ358, which triggered a $2.0 million milestone payment due to the Company pursuant to the Rezolute License Agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">No revenue was recognized for the three and six months ended June 30, 2023. The Company recognized no revenue and $2.0 million as revenue from contracts with customers in the condensed consolidated statement of operations and comprehensive loss for the three and six months ended June 30, 2022, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of June 30, 2023 and December 31, 2022 there were no contract assets or contract liabilities related to this arrangement. None of the costs to obtain or fulfill the contract were capitalized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Janssen Biotech</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">The Company and Janssen were parties to a license agreement which was terminated in 2017.</span> In August 2019, the Company and Janssen entered into a new agreement pursuant to which the Company granted a non-exclusive license </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">to Janssen to develop and commercialize certain drug candidates under the XOMA patents and know-how. Under the new agreement, Janssen made a one-time payment of $2.5 million to XOMA. Additionally, for each drug candidate, the Company is entitled to receive milestone payments of up to $3.0 million upon Janssen&#8217;s achievement of certain clinical development and regulatory approval events. Additional milestones may be due for drug candidates which are the subject of multiple clinical trials. Upon commercialization, the Company is eligible to receive 0.75% royalty on net sales of each product. Janssen&#8217;s obligation to pay royalties with respect to a particular product and country will continue until the eighth-year-and-sixth-month anniversary of the first commercial sale of the product in such country. The new agreement will remain in effect unless terminated by mutual written agreement of the parties. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company concluded that the new agreement should be accounted for separately from any prior arrangements with Janssen and that the license grant is the only performance obligation under the new agreement. The Company recognized the entire one-time payment of $2.5 million as revenue for the year ended December 31, 2019 as it had completed its performance obligation. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company concluded that the development and regulatory milestone payments are solely dependent on Janssen&#8217;s performance and achievement of specified events and thus it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the development and regulatory milestones are fully constrained and excluded from the transaction price until the respective milestone is achieved. Any consideration related to royalties will be recognized when the related sales occur as they were determined to relate predominantly to the license granted to Janssen and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of June 30, 2023 and December 31, 2022, there were no contract assets or contract liabilities related to this arrangement. None of the costs to obtain or fulfill the contract were capitalized. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In April 2023, the Company earned a $0.5 million milestone from Janssen, upon dosing of the first patient in a Phase 3 clinical trial evaluating one of Janssen&#8217;s biologic assets. In addition, during the second quarter of 2023, the Company also earned $0.6 million total for three additional milestones pursuant to its agreement with Janssen. The Company recognized milestone revenue of $1.1 million for the three and six months ended June 30, 2023. The Company did not recognize any revenue related to this arrangement during the three and six months ended June 30, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Affimed</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In April 2021, the Company and Affimed entered into a contractual agreement, under which the Company is eligible to receive payments from Affimed on potential future commercial sales related to three ICE<span style="font-size:12pt;"> </span>molecules and preloaded natural killer cells containing the ICE molecules. Additionally, the Company is eligible to receive a milestone upon the first product candidate in each program achieving marketing approval. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company concluded that the commercial milestone payments are solely dependent on Affimed&#8217;s performance and achievement of specified events. The Company determined that it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the commercial milestones are fully constrained and excluded from the transaction price until the respective milestone is achieved. Any consideration related to commercial milestones (including royalties) will be recognized when the related approvals occur and therefore have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of June 30, 2023 and December 31, 2022, there were no contract assets or contract liabilities related to this arrangement. None of the costs to obtain or fulfill the contract were capitalized. The Company did not recognize any revenue related to this arrangement during the three and six months ended June 30, 2023 and 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Sale of Future Revenue Streams</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December&#160;21, 2016, the Company entered into two royalty interest sale agreements (together, the &#8220;Royalty Sale Agreements&#8221;) with HCRP. Under the first Royalty Sale Agreement, the Company sold its right to receive milestone payments and royalties on future sales of products subject to a License Agreement, dated August&#160;18, 2005, between XOMA and Wyeth Pharmaceuticals (subsequently acquired by Pfizer) for an upfront cash payment of $6.5 million, plus potential additional payments totaling $4.0 million in the event three specified net sales milestones were met in 2017, 2018 and 2019. Based on actual sales, 2017, 2018, and 2019 sales milestones were not achieved. Under the second Royalty Sale Agreement entered into in December&#160;2016, the Company sold its right to receive certain royalties under an Amended and Restated License Agreement dated October&#160;27, 2006 between XOMA and Dyax Corp. for a cash payment of $11.5 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company classified the proceeds received from HCRP as unearned revenue, to be recognized as revenue under the units-of-revenue method over the life of the license agreements because of the Company&#8217;s limited continuing involvement in the Acquisition Agreements. Such limited continuing involvement is related to the Company&#8217;s undertaking to cooperate with HCRP in the event of litigation or a dispute related to the license agreements. Because the transaction was structured as a non-cancellable sale, the Company does not have significant continuing involvement in the generation of the cash flows due to HCRP and there are no guaranteed rates of return to HCRP, the Company recorded the total proceeds of $18.0 million as unearned revenue recognized under the units-of-revenue method. The Company allocated the total proceeds between the two Royalty Sale Agreements based on the relative fair value of expected payments to be made to HCRP under the license agreements. The unearned revenue is being recognized as revenue over the life of the underlying license agreements under the "units-of-revenue" method. Under this method, amortization for a reporting period is calculated by computing a ratio of the allocated proceeds received from HCRP to the payments expected to be made by the licensees to HCRP over the term of the Acquisition Agreements and then applying that ratio to the period&#8217;s cash payment. During the third quarter of 2018, the Shire product underlying the Dyax Corp. license agreement was approved, and the Company began recognizing revenue under the units-of-revenue method due to sales of the approved product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognized $0.5 million and $1.0 million as revenue under the units-of-revenue method under these arrangements during the three and six months ended June 30, 2023, respectively. The Company recognized $0.5 million and $0.8 million as revenue under the units-of-revenue method under these arrangements during the three and six months ended June 30, 2022, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2022, the current and non-current portion of the remaining unearned revenue recognized under the units-of-revenue method was $1.9 million and $9.6 million, respectively. As of June 30, 2023, the Company classified $2.0 million and $8.5 million as current and non-current unearned revenue recognized under the units-of-revenue method, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LicensingAndOtherArrangementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Licensing and other arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LicensingAndOtherArrangementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LicensingAndOtherArrangementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Licensing and other arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LicensingAndOtherArrangementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140070012747792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Royalty and Commercial Payment Purchase Agreements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract', window );"><strong>Royalty and Commercial Payment Purchase Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RoyaltyPurchaseAgreementTextBlock', window );">Royalty and Commercial Payment Purchase Agreements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">5. Royalty and Commercial Payment Purchase Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Short-term royalty and commercial payment receivables were $5.0 million and $2.4 million as of June 30, 2023 and December 31, 2022, respectively. Long-term royalty and commercial payment receivables were $72.2 million and $63.7 million as of June 30, 2023 and December 31, 2022, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">LadRx Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On June 21, 2023, the Company entered into the LadRx AAA pursuant to which the Company acquired from LadRx all of its rights, title and interest related to arimoclomol under an asset purchase agreement dated May 13, 2011 between Zevra and LadRx. The Company also entered into the LadRx RPA, pursuant to which the Company acquired the right to receive all of the future royalties, regulatory and commercial milestones as well as other related payments due to LadRx from ImmunityBio related to aldoxorubicin under a license agreement dated July 27, 2017, as amended on September 27, 2018, between ImmunityBio and LadRx. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The purchased rights related to arimoclomol include potential regulatory and commercial milestones of up to $52.5 million (net of certain payment obligations of up to $9.5 million based on a portion of the regulatory and commercial milestone payments) and potential royalty payments in low single-digit percentages of aggregate net sales associated with arimoclomol. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The purchased payments related to aldoxorubicin include potential regulatory and commercial milestones of up to $342.7 million and royalty payments on aggregate net sales of aldoxorubicin in the low to mid-teens for sales of orphan indications and mid to high single-digit percentages on other licensed products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upon closing of the LadRx Agreements, the Company paid LadRx an upfront payment of $5.0 million and may pay up to an additional $6.0 million in regulatory and commercial sales milestones which included $5.0 million related to regulatory milestones and $1.0 million related to commercial sales milestones. The Company concluded that the regulatory milestone payments of $5.0 million met the definition of a derivative under ASC 815 and should be accounted for at fair value and recorded as a current liability at the inception of the transaction. The fair value of the regulatory milestone payments was estimated to be $1.0 million. The Company concluded the commercial milestone payment of $1.0 million did not meet the definition of a derivative under ASC 815 and a liability will be recognized when probable and estimable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of the LadRx Agreements, the Company recorded $6.0 million as long-term royalty receivables related to the aggregate of the arimoclomol and aldoxorubicin<i style="font-style:italic;"> </i>payment rights acquired, which included the $5.0 million upfront payment and $1.0 million for the estimated fair value of the regulatory milestone payments.<span style="display:inline-block;width:33.22pt;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the cost recovery method, the Company does not expect to recognize any income related to royalties, milestones and other payments until the purchase price has been fully collected. The Company performed its impairment assessment and no allowance for credit losses was recorded as of June 30, 2023. <span style="display:inline-block;width:0.76pt;"></span> <span style="display:inline-block;width:33.5pt;"></span><span style="display:inline-block;width:36pt;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Aptevo Commercial Payment Purchase Agreement </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On March 29, 2023, the Company entered into the Aptevo CPPA, pursuant to which the Company acquired from Aptevo a portion of its milestone and commercial payment rights under a sale agreement dated February 28, 2020 between Aptevo and Medexus, related to IXINITY, which is marketed by Medexus for the control and prevention of bleeding episodes and postoperative management in people with Hemophilia B. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is entitled to receive a mid-single digit percentage of all IXINITY quarterly net sales from January 1, 2023 into the first quarter of 2035, and will be entitled to milestone payments of up to $5.3 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of the Aptevo CPPA, the Company recorded $9.7 million as long-term royalty receivables which included a $9.6 million upfront payment and a $50,000 one-time payment in its condensed consolidated balance sheet, which would be due if XOMA received more than $0.5 million in receipts for first quarter 2023 sales of IXINITY. At inception of the agreement, the Company concluded the one-time payment of $50,000 was probable and reasonably estimable. Therefore, the payment was recorded as contingent liabilities under ASC 450 in its condensed consolidated balance sheet (the &#8220;Aptevo Contingent Consideration&#8221;) at inception and was paid in June 2023 when related receipts exceeded $0.5 million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 2023, the Company received $0.6 million from Medexus representing the first commercial payment attributable to net sales of IXINITY that occurred during the first quarter of 2023. In accordance with the cost recovery method, the $0.6 million received was recorded as a direct reduction of the long-term royalty receivable balance. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Based upon limited available information, the Company is unable to reasonably estimate its commercial payment stream from sales of future net sales and the commercial payments to be received during the twelve-month period following the balance sheet date of June 30, 2023 and, as such, no amounts are reflected as short-term royalty and commercial payment receivables.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the cost recovery method, the Company does not expect to recognize any income related to milestones and commercial payment received until the purchase price has been fully collected.&#160;The Company performed its impairment assessment and no allowance for credit losses was recorded as of June 30, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Agenus Royalty Purchase Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On September 20, 2018, the Company entered into the Agenus RPA, pursuant to which the Company acquired the right to receive 33% of the future royalties on six Incyte Europe S.a.r.l. (&#8220;Incyte&#8221;) immuno-oncology assets, currently in development, due to Agenus from Incyte (net of certain royalties payable by Agenus to a third party) and 10% of all future developmental, regulatory and commercial milestones related to these assets. However, the Company did not have a right to the expected near-term milestone associated with the entry of INCAGN2390 (anti-TIM-3) into its Phase 1 clinical trial. The future royalties due to Agenus from Incyte are based on low single to mid teen-digit percentage of applicable net sales. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, the Company acquired the right to receive 33% of the future royalties on MK-4830, an immuno-oncology product currently in clinical development, due to Agenus from Merck and 10% of all future developmental, regulatory and commercial milestones related to this asset. The future royalties due to Agenus from Merck are based on low single-digit percentage of applicable net sales. Pursuant to the Agenus RPA, the Company&#8217;s share in future potential development, regulatory and commercial milestones is up to $59.5 million. There is no limit on the amount of future royalties on sales that the Company may receive under the agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Agenus RPA, the Company paid Agenus $15.0 million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of the agreement, the Company recorded $15.0 million as long-term royalty receivables in the consolidated balance sheets. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2020, MK-4830 advanced into Phase 2 development, and Agenus earned a $10.0 million clinical development milestone under its license agreement with Merck, of which the Company earned $1.0 million. In accordance with the cost recovery method, the $1.0 million milestone received was recorded as a direct reduction of the recorded long-term royalty receivable balance. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company continues to assess that no further payments are probable to be received under this agreement in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to milestones and royalties received until the purchase price has been fully collected.&#160;The Company performed its impairment assessment and no allowance for credit losses was recorded as of June 30, 2023 or December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Bioasis Royalty Purchase Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On February 25, 2019, the Company entered into the Bioasis RPA, pursuant to which the Company acquired potential future milestone and royalty rights from Bioasis for product candidates that are being developed pursuant to a license agreement between Bioasis and Prothena Biosciences Limited. In addition, the Company was granted options to purchase a 1% royalty right on the next two license agreements entered into between Bioasis and third-party licensees subject to certain payments and conditions as well as a right of first negotiation on the purchase of royalty rights on subsequent Bioasis license agreements with third parties. Upon exercise of the option related to the second license agreement executed by Bioasis, the Company would have been obligated to pay up to $0.3 million per licensed product. Upon exercise of the option related to the third license agreement executed by Bioasis, the Company may be obligated to pay up to $0.4 million per licensed product. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Bioasis RPA, the Company paid $0.3 million and would have made contingent future cash payments of up to $0.2 million to Bioasis as the licensed product candidates reach certain development milestones (the &#8220;Bioasis Contingent Consideration&#8221;). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of the agreement, the Company recorded $0.4 million as long-term royalty receivables in its consolidated balance sheet, including the estimated fair value of the Bioasis Contingent Consideration of $75,000. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On November 2, 2020, the Company entered into the Second Bioasis RPA, pursuant to which the Company acquired potential future milestone and other payments, and royalty rights from Bioasis for product candidates that were being developed pursuant to a research collaboration and license agreement between Bioasis and Chiesi. The Company paid Bioasis $1.2 million upon closing of the Second Bioasis RPA for the purchased rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of the Second Bioasis RPA, the Company recorded $1.2 million as long-term royalty receivables in its consolidated balance sheet. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On June 20, 2023, Bioasis announced the suspension of all its operations and the termination of the research collaboration and license agreement between Bioasis and Chiesi. As a result, the Company recorded an impairment of $1.6 million under royalty purchase agreement asset impairment in its condensed consolidated statement of operations and a reduction of $1.6 million under long-term royalty receivables related to the Bioasis RPA and Second Bioasis RPA. As the impaired amount was not expected to be collected, no allowance for credit losses was recorded as of June 30, 2023. There was no allowance for credit losses recorded as of December 31, 2022. The fair value of the Bioasis Contingent Consideration was reduced to $0 with the change in the estimated fair value recognized in other income (expense), net in the condensed consolidated statement of operations and comprehensive loss. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Aronora<span style="font-style:normal;font-weight:normal;"> </span>Royalty Purchase Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On April 7, 2019, the Company entered into the Aronora RPA which closed on June 26, 2019. Under the Aronora RPA, the Company acquired the right to receive future royalties and a portion of upfront, milestone, and option payments (the &#8220;Non-Royalties&#8221;) related to five anti-thrombotic hematology drug candidates. Three candidates were subject to Aronora&#8217;s collaboration with Bayer (the &#8220;Bayer Products&#8221;), including one which was subject to an exclusive license option by Bayer. The Company will receive 100% of future royalties and 10% of future Non-Royalties economics from these Bayer Products. The other two candidates are unpartnered (the &#8220;non-Bayer Products&#8221;) for which the Company will receive low single-digit percentage of net sales and 10% of Non-Royalties. The future payment percentage for Non-Royalties will be reduced from 10% to 5% upon the Company&#8217;s receipt of two times the total cumulative amount of consideration paid by the Company to Aronora. In July 2020, Bayer elected to not exercise its option on the third Bayer Product and that product is now subject to the same economics as the non-Bayer Products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Aronora RPA, the Company paid Aronora a $6.0 million upfront payment at the close of the transaction. The Company financed $3.0 million of the upfront payment with a term loan under its Loan and Security Agreement with SVB. The Company was required to make a contingent future cash payment of $1.0 million for each of the three Bayer Products that were active on September 1, 2019 (up to a total of $3.0 million, the &#8220;Aronora Contingent Consideration&#8221;). Pursuant to the Aronora RPA, if the Company receives $250.0 million in cumulative royalties on net sales per product, the Company will be required to pay associated tiered milestone payments to Aronora in an aggregate amount of up to $85.0 million per product (the &#8220;Royalty Milestones&#8221;).&#160;The Royalty Milestones are paid based upon various royalty tiers prior to reaching $250.0 million in cumulative royalties on net sales per product.&#160;Royalties per product in excess of $250.0 million are retained by the Company. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of the agreement, the Company recorded $9.0 million as long-term royalty receivables in its consolidated balance sheet, including the estimated fair value of the Aronora Contingent Consideration of $3.0 million. In September 2019, the Company paid the $3.0 million contingent consideration to Aronora. As the Company receives royalties from Aronora for a product, the Company will recognize the liability for future Royalty Milestones for such product when probable and estimable. The Company continues to assess that no payments are probable to be received under this agreement in the near term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the cost recovery method, the Company does not expect to recognize any income related to milestones and royalties received until the purchase price has been fully collected. The Company performed its impairment assessment and no allowance for credit losses was recorded as of June 30, 2023 or December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Palobiofarma Royalty Purchase Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On September 26, 2019, the Company entered into the Palo RPA, pursuant to which the Company acquired the rights to potential royalty payments in low single-digit percentages of aggregate net sales associated with six drug candidates in various clinical development stages, targeting the adenosine pathway with potential applications in solid tumors, non-Hodgkin&#8217;s lymphoma, asthma/chronic obstructive pulmonary disease, ulcerative colitis, idiopathic pulmonary fibrosis, lung cancer, psoriasis and nonalcoholic steatohepatitis and other indications (the &#8220;Palo Licensed Products&#8221;) that are being developed by Palo. Novartis is a development partner on NIR178, one of the Palo Licensed Products, and NIR178 is being developed pursuant to a license agreement between Palo and Novartis. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Palo RPA, the Company paid Palo a $10.0 million payment at the close of the transaction, which occurred simultaneously upon parties&#8217; entry into the Palo RPA on September 26, 2019. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of the agreement, the Company recorded $10.0 million as long-term royalty receivables in its consolidated balance sheet. The Company continues to assess that no payments are probable to be received under this agreement in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to royalties received until the purchase price has been fully collected. The Company performed its impairment assessment and no allowance for credit losses was recorded as of June 30, 2023 or December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Viracta Royalty Purchase Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On March 22, 2021, the Company entered into the Viracta RPA, pursuant to which the Company acquired the right to receive future royalties, milestones, and other payments related to two clinical-stage drug candidates for $13.5 million. The first candidate, DAY101 (pan-RAF kinase inhibitor), is being developed by Day One Biopharmaceuticals, and the second candidate, vosaroxin (topoisomerase II inhibitor), is being developed by Denovo Biopharma. The Company acquired the right to receive (i) up to $54.0 million in potential milestones, potential royalties on sales, if approved, and other payments related to DAY101, excluding up to $20.0 million consideration retained by Viracta, and (ii) up to $57.0 million in potential regulatory and commercial milestones and high single-digit royalties on sales related to vosaroxin, if approved. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of the Viracta RPA, the Company recorded $13.5 million as long-term royalty receivables in its consolidated balance sheet. No payments are probable to be received under the Viracta RPA in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to royalties, milestones and other payments until the purchase price has been fully collected. The Company performed its impairment assessment and no allowance for credit losses was recorded as of June 30, 2023 or December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Kuros Royalty Purchase Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On July 14, 2021, the Company entered into the Kuros RPA, pursuant to which the Company acquired the rights to 100% of the potential future royalties from commercial sales, which are tiered from high single-digit to low double-digits, and up to $25.5 million in pre-commercial milestone payments associated with an existing license agreement related to Checkmate Pharmaceuticals&#8217; vidutolimod (CMP-001), a Toll-like receptor 9 agonist, packaged in a virus-like particle, for an upfront payment of $7.0 million. The Company may pay up to an additional $142.5 million to Kuros in sales-based milestones. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of the Kuros RPA, the Company recorded $7.0 million as long-term royalty receivables in its consolidated balance sheet. Under the cost recovery method, the Company does not expect to recognize any income related to royalties, milestones and other payments until the purchase price has been fully collected. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In May 2022, Regeneron completed its acquisition of Checkmate Pharmaceuticals resulting in a $5.0 million milestone payment to Kuros. Pursuant to the Kuros RPA, the Company is entitled to 50% of the milestone payment, which was received by XOMA in July 2022. In accordance with the cost recovery method, the $2.5 million milestone received was recorded as a direct reduction of the recorded long-term royalty receivable balance.<b style="font-weight:bold;"> </b>As of June 30, 2023, no payments are probable to be received under the Kuros RPA in the near term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company performed its impairment assessment and no allowance for credit losses was recorded as of June 30, 2023 or December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Commercial Payment Purchase Agreement with Affitech </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On October 6, 2021, the Company entered into the Affitech CPPA, pursuant to which, the Company purchased a future stream of commercial payment rights to Roche&#8217;s faricimab from Affitech for an upfront payment of $6.0 million. The Company is eligible to receive 0.5% of future net sales of faricimab for a ten-year period following the first commercial sales in each applicable jurisdiction. Under the terms of the Affitech CPPA, the Company may pay up to an additional $20.0 million based on the achievement of certain regulatory and sales milestones. At the inception of the Affitech CPPA, the Company recorded $14.0 million as long-term royalty receivables which included the $6.0 million upfront payment and $8.0 million in regulatory milestones in its consolidated balance sheet. The Company concluded the regulatory milestone payments of $8.0 million met the definition of a derivative under ASC 815 and should be accounted at fair value and recorded as a current liability at the inception of the transaction. Therefore, the regulatory milestone payments were recorded as contingent liabilities in its consolidated balance sheet. The Company concluded the sales-based milestone payments of $12.0 million do not meet the definition of a derivative under ASC 815 and a liability will be recognized when probable and estimable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In January 2022, Roche received approval from the FDA to commercialize VABYSMO (faricimab-svoa) for the treatment of wet, or neovascular, age-related macular degeneration and diabetic macular edema. In September 2022, Roche received approval from the European Commission to commercialize VABYSMO for the treatment of wet, or neovascular, age-related macular degeneration and visual impairment due to diabetic macular edema. Pursuant to the Affitech CPPA, the Company paid Affitech a $5.0 million milestone tied to the U.S. marketing approvals and a $3.0 million milestone tied to the EC approvals. The Company may pay an additional $12.0 million based on the achievement of certain sales milestones.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In August 2022, the Company received $0.5 million from Roche representing the first commercial payment for sales of VABYSMO during the first six months of 2022. In accordance with the cost recovery method, the $0.5 million received was recorded as a direct reduction of the long-term royalty receivable balance. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In February 2023, the Company received $2.4 million, representing its commercial payment stream from sales of VABYSMO during the last six months of 2022. The payment amount was classified as a short-term royalty and commercial payment receivable as of December 31, 2022. In accordance with the cost recovery method, the $2.4 million received in February 2023 was recorded as a direct reduction of the short-term royalty receivable balance as of June 30, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company estimated $5.0 million of commercial payments from sales of VABYSMO during the first six months of 2023 would be received in August 2023, within &#160;twelve-months of the balance sheet date of June 30, 2023 and, as such, reclassified this amount as short-term royalty and commercial payment receivable as of June 30, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the cost recovery method, the Company does not expect to recognize any income related to future commercial payment receipts until the purchase price has been fully collected. The Company performed its impairment assessment and no allowance for credit losses was recorded as of June 30, 2023 or December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the royalty and commercial payment receivable activities during the six months ended June 30, 2023 (in thousands): </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Short-Term</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Long-Term</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at January 1, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,366</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 63,683</p></td></tr><tr><td style="vertical-align:bottom;width:75.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Acquisition of royalty and commercial payment receivables:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Aptevo</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,650</p></td></tr><tr><td style="vertical-align:bottom;width:75.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">LadRx</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,000</p></td></tr><tr><td style="vertical-align:bottom;width:75.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Receipt of royalty and commercial payments:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Affitech</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,366)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Aptevo</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (568)</p></td></tr><tr><td style="vertical-align:bottom;width:75.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Impairment of royalty and commercial payment receivables:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Bioasis</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,575)</p></td></tr><tr><td style="vertical-align:bottom;width:75.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Reclassification to short-term royalty and commercial payment receivables:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Affitech</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,958</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,958)</p></td></tr><tr><td style="vertical-align:bottom;width:75.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at June&#160;30,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,958</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 72,232</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RoyaltyPurchaseAgreementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RoyaltyPurchaseAgreementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140070014217808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">6. Fair Value Measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company records its financial assets and liabilities at fair value. The carrying amounts of certain of the Company&#8217;s financial instruments, including cash, trade receivables, net and accounts payable, approximate their fair value due to their short maturities. Fair value is defined as the exchange price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The accounting guidance for fair value establishes a framework for measuring fair value and a fair value hierarchy that prioritizes the inputs used in valuation techniques. The accounting standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">Level 1&#160;&#8211; Observable inputs, such as unadjusted quoted prices in active markets for identical assets or liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">Level 2&#160;&#8211; Observable inputs, either directly or indirectly, other than quoted prices in active markets for identical assets or liabilities, such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">Level 3&#160;&#8211; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities; therefore, requiring an entity to develop its own valuation techniques and assumptions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following tables set forth the Company&#8217;s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as follows (in thousands): </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements&#160;at&#160;June&#160;30,&#160;2023 Using: </b></p></td></tr><tr><td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Quoted&#160;Prices&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Active&#160;Markets&#160;for</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Identical&#160;Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30,102</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30,102</p></td></tr><tr><td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total cash equivalents </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30,102</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30,102</p></td></tr><tr><td style="vertical-align:bottom;width:50.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Equity securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 320</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 320</p></td></tr><tr><td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total financial assets </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30,422</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30,422</p></td></tr><tr><td style="vertical-align:bottom;width:50.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Contingent consideration under RPAs, AAAs and CPPAs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,000</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements&#160;at&#160;December&#160;31,&#160;2022 Using:</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Quoted&#160;Prices&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Active&#160;Markets&#160;for</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Identical&#160;Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30,334</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30,334</p></td></tr><tr><td style="vertical-align:bottom;width:49.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total cash equivalents </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30,334</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30,334</p></td></tr><tr><td style="vertical-align:bottom;width:49.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Equity securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 335</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 335</p></td></tr><tr><td style="vertical-align:bottom;width:49.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total financial assets </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30,669</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30,669</p></td></tr><tr><td style="vertical-align:bottom;width:49.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Contingent consideration under RPAs, AAAs and CPPAs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 75</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:12pt 0pt 12pt 0pt;">Equity Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The equity securities consisted of an investment in Rezolute&#8217;s common stock and are classified on the condensed consolidated balance sheets as current assets as of June 30, 2023 and December&#160;31, 2022. The equity securities are revalued each reporting period with changes in fair value recorded in the other income (expense), net line item of the condensed consolidated statements of operations and comprehensive loss. As of June 30, 2023 and December&#160;31, 2022, the Company valued the equity securities using the closing price for Rezolute&#8217;s common stock traded on the Nasdaq Stock Market of $1.98 and $2.07, respectively. The inputs that were used to calculate the fair value of the equity securities were observable prices in active markets and therefore were classified as a Level 1 fair value measurement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Contingent Consideration</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The estimated fair value of the Bioasis Contingent Consideration liability at the inception of the Bioasis RPA represents the future consideration that is contingent upon the achievement of specified development milestones for a product candidate. The fair value measurement is based on significant Level 3 inputs such as anticipated timelines and probability of achieving development milestones of each licensed product candidate. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The estimated fair value of the LadRx contingent consideration liability at the inception of the LadRx Agreements represents the future consideration that is contingent upon the achievement of specified regulatory milestones for the product candidates related to arimoclomol and aldoxorubicin. The fair value measurement is based on significant Level 3 inputs such as anticipated timelines and probability of achieving development milestones of each product candidate. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Changes in the fair value of the liability for contingent consideration will be recorded in the other income (expense), net line item of the condensed consolidated statements of operations and comprehensive loss until settlement. During the six months ended June 30, 2023, the estimated fair value of the contingent consideration recorded pursuant to the Bioasis RPA was reduced to $0 from the initial value of $0.1 million. There were no changes in the estimated fair value of the contingent consideration recorded pursuant to the LadRx Agreements from the initial value of $1.0 million.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140070014212208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Agreements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Lease Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LeaseDisclosureTextBlock', window );">Lease Agreements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">7. Lease Agreements </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">The Company leases one facility in Emeryville, California under an operating lease. In January 2023, the Company amended the original lease to extend the lease term five months from its original expiration of February 28, 2023 to July 31, 2023. The Company retains no option to further extend, renew or terminate the lease under the amended terms and all other material terms and conditions, including the monthly base rent, will remain consistent with the original lease. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">In accordance with ASC 842, the Company accounted for the amendment to extend the lease term as a modification of the original lease and, as such, remeasured the lease liability and recognized a corresponding adjustment to the&#160;right-of-use asset of $0.1 million to reflect the changes in the lease payments due to the extended lease term. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">On June 27, 2023, the Company executed an amended lease agreement for its corporate headquarters lease in Emeryville, California with the same counterparty, in a different location in the same building to replace its existing lease expiring in July 2023. The amended lease agreement has a term of 65 months and has an expected commencement date in the fourth quarter of 2023. Undiscounted future rent payments associated with the new lease through the 65-month term is expected to be $0.5 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;">As of June 30, 2023 and December 31, 2022 the total net lease liability was $17,000 and $34,000, respectively. &#160; </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table summarizes the cost components of the Company&#8217;s operating lease for the three and six months ended June 30, 2023 and 2022 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:54.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six Months Ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:10.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease costs:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 51</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 44</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 99</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 88</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Variable lease cost <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total lease costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 58</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 46</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 111</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 93</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;padding-left:18pt;text-align:justify;text-indent:-18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">(1)</span>Under the terms of the lease agreement, the Company is also responsible for certain variable lease payments that are not included in the measurement of the lease liability. Variable lease payments include non-lease components such as common area maintenance fees.</div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following information represents supplemental disclosure for the statement of cash flows related to operating leases (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:12pt;"> </span><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> &#160;&#160;&#160;&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six Months Ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash paid for amounts included in the measurement of lease liabilities</p></td><td style="vertical-align:bottom;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating cash flows under operating leases</p></td><td style="vertical-align:bottom;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 104</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 101</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The present value assumptions used in calculating the present value of the lease payments for the Company&#8217;s operating lease as of June 30, 2023 and December 31, 2022 were as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;"> </span><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> &#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average remaining lease term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.08 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.17 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average discount rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.51</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.51</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><span style="display:inline-block;min-width:18pt;white-space:nowrap;">(1)</span>Prior to the extension of the end of the lease term from February 28, 2023 to July 31, 2023 &#160;</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LeaseDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of information about leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LeaseDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140070014163312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Warrants<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Common Stock Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_CommonStockWarrantDisclosureTextBlock', window );">Common Stock Warrants</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">8. Common Stock Warrants</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of June 30, 2023 and December&#160;31, 2022, the following common stock warrants were outstanding:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:18.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:18.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:18.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issuance Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Expiration&#160;Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance&#160;Sheet&#160;Classification</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">per&#160;Share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:18.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">May&#160;2018</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">May&#160;2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23.69</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,332</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,332</p></td></tr><tr><td style="vertical-align:bottom;width:18.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">March&#160;2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">March&#160;2029</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14.71</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,845</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,845</p></td></tr><tr><td style="vertical-align:bottom;width:18.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,177</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,177</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:3pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_CommonStockWarrantDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock warrant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_CommonStockWarrantDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140070014152720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">9. Commitments and Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Collaborative Agreements, Royalties and Milestone Payments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has committed to make potential future milestone payments and legal fees to third parties as part of licensing and development programs. Payments under these agreements become due and payable only upon the achievement of certain developmental, regulatory and commercial milestones by the Company&#8217;s licensees. Because it is uncertain if and when these milestones will be achieved, such contingencies, aggregating up to $6.3 million (assuming one product per contract meets all milestone events) have not been recorded on the accompanying condensed consolidated balance sheets. The Company is unable to determine precisely when and if payment obligations under the agreements will become due as these obligations are based on milestone events, the achievement of which is subject to a significant number of risks and uncertainties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Contingent Consideration</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Company&#8217;s agreements with Bioasis, Aronora, Kuros, Affitech, ObsEva and Aptevo the Company has committed to pay the Bioasis Contingent Consideration, the Aronora Royalty Milestones, the Kuros Sales Milestones, the Affitech Sales Milestones, the ObsEva Sales Milestones, the ObsEva Non-Sales Milestones, the Merck KGaA royalties and the Aptevo Contingent Consideration.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recorded $75,000 for the Bioasis Contingent Consideration that represented the estimated fair value of the potential future payments at the inception of the Bioasis RPA. The Bioasis Contingent Consideration is remeasured at fair value at each reporting period, with changes in fair value recorded in other income (expense), net. As of June 30, 2023, the estimated fair value of the Bioasis Contingent Consideration was reduced to $0.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recorded $1.0 million for the LadRx contingent consideration that represents the estimated fair value of the potential future payments upon the achievement of regulatory milestones related to arimoclomol and aldoxorubicin<i style="font-style:italic;"> </i>at the inception of the LadRx Agreements. Such contingent consideration related to regulatory milestones is remeasured at fair value at each reporting period, with changes in fair value recorded in other income (expense), net. As of June 30, 2023, there has been no change in the estimated fair value from the initial value. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In the first quarter of 2023, the Company recorded a contingent liability of $50,000 under ASC 450 for the Aptevo Contingent Consideration at the inception of the Aptevo CPPA. During the six months ended June 30, 2023, the contingent </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">liability recorded pursuant to the Aptevo CPPA decreased to zero after the Company paid Aptevo $50,000 upon achievement of the related commercial sales milestone.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The liability for future Aronora Royalty Milestones, Kuros Sales Milestones, Affitech Sales Milestones and LadRx sales milestones will be recorded when the amounts, by product, are estimable and probable. The liability for future ObsEva Non-Sales Milestones, ObsEva Sales Milestones and Merck KGaA royalties will be recorded at the time that the corresponding underlying revenue under the Organon License Agreement is estimatable and probable. As of June 30, 2023, none of these Aronora Royalty Milestones, Kuros Sales Milestones, Affitech Sales Milestones, ObsEva Non-Sales Milestones, ObsEva Sales Milestones, or Merck KGaA royalties were assessed to be probable and as such, no liability was recorded on the condensed consolidated balance sheet. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140070014128496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsAbstract', window );"><strong>Stock Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock Based Compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">10. Stock Based Compensation </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company may grant qualified and non-qualified stock options, common stock, PSUs and other stock-based awards under various plans to directors, officers, employees and other individuals. Stock options are granted at exercise prices of not less than the fair market value of the Company&#8217;s common stock on the date of grant. Additionally, the Company has an ESPP that allows employees to purchase Company shares at a purchase price equal to 85% of the lower of the fair market value of the Company&#8217;s common stock on the first trading day of the offering period or on the last day of the offering period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock Options and Other Benefit Plans</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">2010 Plan Stock Options </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Stock options issued under the 2010 Plan generally vest monthly over three years for employees and one year for directors. Stock options held by employees who qualify for retirement age (defined as employees that are a minimum of 55 years of age and the sum of their age plus years of full-time employment with the Company exceeds 70 years) vest on the earlier of scheduled vest date or the date of retirement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Stock Option Inducement Awards </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December&#160;30, 2022, the Board appointed Owen Hughes as Executive Chairman of the Board and Interim CEO (principal executive officer) and Bradley Sitko as the Company&#8217;s Chief Investment Officer, effective as of January&#160;1, 2023. Pursuant to the terms of their respective employment agreements, Mr. Hughes and Mr. Sitko were each granted two separate awards of non-qualified stock options on January 3, 2023 (collectively, the &#8220;Stock Option Inducement Awards&#8221;) when the Company&#8217;s stock price was $18.66 per share. The Stock Option Inducement Awards were granted to Mr. Hughes and Mr. Sitko outside the 2010 Plan as an inducement material to entering into their respective employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) but are subject to the terms and conditions of the 2010 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On January 3, 2023, the Company granted Mr. Hughes two separate non-qualified stock options to purchase: (i) 100,000 shares of the Company&#8217;s common stock at a fair market value exercise price of $18.66 per share that will vest in a series of four equal installments on March 31, 2023, June 30, 2023, September 30, 2023 and December 31, 2023 and (ii) 75,000 shares of the Company&#8217;s common stock at an above fair market value exercise price of $30.00 per share that will vest in a series of 36 successive equal monthly installments measured from January 1, 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On January 3, 2023, the Company granted Mr. Sitko two separate non-qualified stock options to purchase: (i) 300,000 shares of the Company&#8217;s common stock at a fair market value exercise price of $18.66 per share and (ii) 250,000 shares of the Company&#8217;s common stock at an above fair market value exercise price of $30.00 per share. Twenty-five percent of the shares subject to Mr. Sitko&#8217;s option grants will vest and become exercisable on January 3, 2024, and the balance of the shares will vest and become exercisable in a series of 36 successive equal monthly installments thereafter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Fair Value Assumptions</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The fair value of the stock options granted under the 2010 Plan during the three and six months ended June 30, 2023 and 2022, was estimated based on the following weighted average assumptions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six Months Ended June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:50.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 69</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:50.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.60</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.90</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.60</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:50.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5.79 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5.61 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5.79 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5.65 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The weighted-average grant-date fair value per share of the options granted under the 2010 Plan during the six months ended June 30, 2023 and 2022 was $13.46 and $12.21, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The fair value of the stock options granted to Mr. Hughes and Mr. Sitko at an exercise price of $18.66 per share during the six months ended June 30, 2023, was estimated based on the following weighted average assumptions: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six Months Ended June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023 </b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022 </b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 69</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.92</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">5.79 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:22.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">No</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Stock Option Inducement Awards were granted during the three months ended June 30, 2023 or the three and six months ended June 30, 2022. </span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The weighted-average grant-date fair value per share of options granted to Mr. Hughes and Mr. Sitko at an exercise price of $18.66 per share during the first quarter of 2023 was $11.91.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The fair value of the stock options granted to Mr. Hughes and Mr. Sitko at an exercise price of $30.00 per share during the first quarter of 2023 was estimated based on the following weighted average assumptions: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six Months Ended June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023 </b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022 </b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 91</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.86</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">8.01 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:40.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">No</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Stock Option Inducement Awards were granted during the three months ended June 30, 2023 or the three and six months ended June 30, 2022.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The weighted-average grant-date fair value per share of options granted to Mr. Hughes and Mr. Sitko at an exercise price of $30.00 per share during the first quarter of 2023 was $14.68.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The activity for all stock options for the six months ended June 30, 2023, was as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.51%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual&#160;</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining Term</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">shares</b></p></td><td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Per&#160;Share</b></p></td><td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;years)</b></p></td><td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:15.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="vertical-align:middle;width:38.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at January 1, 2023</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,025,542</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20.24</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,804</p></td></tr><tr><td style="vertical-align:middle;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 796,802</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23.50</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:middle;width:38.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8,473)</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18.29</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:middle;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited, expired or cancelled</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (71,123)</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36.36</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:middle;width:38.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at June 30, 2023</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,742,748</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20.78</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.76</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,430</p></td></tr><tr><td style="vertical-align:middle;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable at June 30, 2023</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,815,920</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19.30</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.44</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,296</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The aggregate intrinsic value of stock options exercised during the six months ended June 30, 2023 and 2022 was $18,000 and $2.1 million, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of June 30, 2023, $11.0 million of total unrecognized compensation expense related to stock options is expected to be recognized over a weighted average period of 2.72 years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Performance Stock Unit Awards</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In May 2023, the Company granted employees 430,400 PSUs in the aggregate under the 2010 Plan. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The PSUs are subject to market-based vesting conditions and the number of PSUs vested will be based on the stock price of the Company&#8217;s common stock as compared to four stock price hurdles over a three-year period from the May 2023 grant date (the &#8220;performance period&#8221;). A stock price hurdle is considered attained when, at any time during the performance period, the Company&#8217;s volume-weighted average stock price equals or exceeds the hurdle stock price value for 30 consecutive calendar days. Upon attainment of a stock price hurdle, <span style="-sec-ix-hidden:Hidden_pz-y6RJKqkG2-1h8_aEPqw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1/3</span></span> of the earned PSUs will vest immediately upon achievement, <span style="-sec-ix-hidden:Hidden_mBhYOSdezkKayi1Fqww_nQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1/3</span></span> will vest upon the two-year anniversary of the grant date and <span style="-sec-ix-hidden:Hidden_npSSwNAmG0yLnAtmVxINPw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1/3</span></span> will vest on the three-year anniversary of the grant date. If no stock price hurdle is attained during the performance period, then no PSUs will vest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The fair value of the PSUs granted was estimated based on Monte Carlo valuation model which incorporates into the valuation the possibility that the stock price hurdles may not be satisfied. </p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The range of grant date fair values of the PSUs issued in May 2023 were estimated as follows:<div style="display:inline-block;height:24pt;width:24pt;"><div style="height:24pt;left:0pt;padding-bottom:0pt;position:relative;width:24pt;"></div></div><div style="display:inline-block;height:24pt;width:24pt;"><div style="height:24pt;left:0pt;padding-bottom:0pt;position:relative;width:24pt;"></div></div></div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.8%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.8%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.8%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:25.89%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Derived</b></p></td></tr><tr><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Hurdle Price</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:25.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Service Period</b></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:21.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Per Share</b></p></td><td style="vertical-align:top;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:21.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">PSUs</b></p></td><td style="vertical-align:top;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:21.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Per&#160;Share</b></p></td><td style="vertical-align:top;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:25.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;years)</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 232,956</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">16.36-17.45</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">0.69-0.76</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:18.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 35.00</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 87,708</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:18.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">15.03-16.07</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">0.93-0.99</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:18.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 40.00</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 57,851</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:18.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">13.82-14.84</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">1.12-1.18</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:18.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 45.00</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 51,885</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:18.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">12.75-13.72</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">1.27-1.33</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 430,400</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company estimates that it will recognize total stock-based compensation expense of approximately $6.7 million in aggregate using the graded expense attribution method over the requisite service period of each tranche. If the stock price hurdles are met sooner than the requisite service period, the stock-based compensation expense for the respective stock price hurdle will be accelerated. Stock-based compensation expense will be recognized over the requisite service period if the grantees continue to provide service to the Company, regardless of whether the PSU stock price hurdles are achieved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The activity for all PSUs for the six months ended June 30, 2023, was as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:56.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.24%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.56%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.22%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Grant Date</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:19.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unvested PSUs</b></p></td><td style="vertical-align:top;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:19.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Per&#160;Share</b></p></td></tr><tr><td style="vertical-align:middle;width:56.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested balance at January 1, 2023</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:56.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 430,400</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15.61</p></td></tr><tr><td style="vertical-align:middle;width:56.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:16.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:56.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:56.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested balance at June 30, 2023</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 430,400</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:16.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15.61</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recorded $0.5 million of stock-based compensation expense related to the PSUs during the three and six months ended June 30, 2023. As of June 30, 2023, there was $6.2 million unrecognized stock-based compensation expense related to outstanding PSUs granted to employees, with a weighted-average remaining recognition period of 1.85 years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Stock-based Compensation Expense</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">All stock-based compensation expense is recorded in G&amp;A expense. The following table shows total stock-based compensation expense for stock options and PSUs issued under the 2010 Plan, the Stock Option Inducement Awards and ESPP in the condensed consolidated statements of operations and comprehensive loss (in thousands): </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six Months Ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total stock-based compensation expense included in G&amp;A </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,163</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 837</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,733</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,815</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:6pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Employee Retention Bonus </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In October 2022, the Company approved the Amended Retention Plan which provides that each of its then current employees, excluding the CEO, will be eligible to receive a cash retention bonus if employed through each of two periods: (1) the three-month anniversary of November 1, 2022 (the &#8220;Initial Period&#8221;) and (2) the nine-month period immediately following the Initial Period. All other terms of the Amended Retention Plan remain consistent with the Retention Plan. The Company is accruing and recognizing the cost of the cash retention bonus as expense on a straight-line basis from November 1, 2022 through October 31, 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company paid $0.2 million of cash retention bonuses accrued over the Initial Period in January 2023. Pursuant to the Amended Retention Plan, as of June 30, 2023, the Company expects to pay an additional $0.5 million in cash in 2023 related to the cash retention bonuses. The Company recognized $0.2 million and $0.4 million for cash retention bonuses in operating expenses in the condensed consolidated statement of operations and comprehensive loss during the three and six months ended June 30, 2023, respectively, and will recognize the remaining amount of $0.2 million for cash retention bonuses in operating expenses through October 31, 2023. The Company accrued cash retention bonuses in accrued and other liabilities in the condensed consolidated balance sheets of $0.3 million as of June 30, 2023 and $0.1 million as of December 31, 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">James R. Neal Departure and Continuity Incentive</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:6pt 0pt 0pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">James R. Neal retired as the Company&#8217;s CEO effective as of December 31, 2022 (the &#8220;Departure Date&#8221;) and resigned as a member of the Board and Chairman of the Board, effective as of January 1, 2023. Pursuant to Mr. Neal&#8217;s Amended and Restated Employment Agreement, dated December 15, 2021, by and between the Company and Mr. Neal, following the Departure Date, Mr. Neal is entitled to a cash payment of </span><span style="font-weight:normal;">$1.2</span><span style="font-weight:normal;"> million (the &#8220;Continuity Incentive&#8221;) which will be made in equal monthly installments starting in January 2023 through December 2023, less deductions and withholdings. The Company accrued the full </span><span style="font-weight:normal;">$1.2</span><span style="font-weight:normal;"> million Continuity Incentive in operating expenses in the consolidated statement of operations and comprehensive loss during the year ended December 31, 2022. The unpaid accrued Continuity Incentive</span><span style="font-weight:normal;"> recorded in accrued and other liabilities in the condensed consolidated balance sheets as of June 30, 2023 and December 31, 2022 was </span><span style="font-weight:normal;">$0.6</span><span style="font-weight:normal;"> million and </span><span style="font-weight:normal;">$1.2</span><span style="font-weight:normal;"> million, respectively</span>.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140070014227568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Stock<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Capital Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Capital Stock</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">11. Capital Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Dividends</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the six months ended June 30, 2023, the Company&#8217;s Board of Directors declared and paid cash dividends on the Company&#8217;s Series A Preferred Stock and Series B Depositary shares as follows: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:42.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:16.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:42.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:17.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Series A&#160;Preferred Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:18.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Series B&#160;Depositary Share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:42.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:17.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cash Dividend Declared</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:18.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cash Dividend Declared</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:42.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dividend Declaration Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">($ per share)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">($ per share)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dividend Payment Date</b></p></td></tr><tr><td style="vertical-align:top;width:42.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">October 26, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_6FlVNMctY0q9dw8fCOKxTg;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.53906</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_9royLRcMl0Knqef269WU1Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.52344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">January 17, 2023</p></td></tr><tr><td style="vertical-align:top;width:42.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">February 22, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_qWHrIk0HxkKu1Feelg1QWg;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.53906</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_zyL_9MT4C06Qx4obkYEVKw;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.52344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">April 17, 2023</p></td></tr><tr><td style="vertical-align:top;width:42.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">May 17, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_hWIxlEMoI06Nfvonzanuzg;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.53906</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_Q-ZWoTYYE0qrtlCrmMWbHw;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.52344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">July 17, 2023</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">BVF Ownership</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of June 30, 2023, BVF owned approximately 31.7% of the Company&#8217;s total outstanding shares of common stock, and if all the Series X convertible preferred shares were converted, BVF would own 52.4% of the Company&#8217;s total outstanding shares of common stock. The Company&#8217;s Series A Preferred Stock becomes convertible upon the occurrence of specific events and as of June 30, 2023, the contingency was not met, therefore the Series A Preferred Stock owned by BVF is not included in the as-converted ownership calculation. Due to its significant equity ownership, BVF is considered a related party of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2018 Common Stock ATM Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December 18, 2018, the Company entered into the 2018 Common Stock ATM Agreement with HCW, under which the Company may offer and sell from time to time at its sole discretion shares of its common stock through HCW as its sales agent, in an aggregate amount not to exceed $30.0 million. HCW may sell the shares by any method permitted by law deemed to be an &#8220;at the market&#8221; offering as defined in Rule 415 of the Securities Act and will use its commercially reasonable efforts consistent with its normal trading and sales practices to sell the shares up to the amount specified. The Company will pay HCW a commission of up to 3% of the gross proceeds of any shares of common stock sold under the 2018 Common Stock ATM Agreement. On March 10, 2021, the Company amended the 2018 Common Stock ATM Agreement with HCW to increase the aggregate amount of shares of its common stock that it could sell through HCW as its sales agent to $50.0 million. No shares have been sold under the 2018 Common Stock ATM Agreement since the agreement was executed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2021 Series B Preferred Stock ATM Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On August 5, 2021, the Company entered into the 2021 Series B Preferred Stock ATM Agreement with B. Riley, under which the Company may offer and sell from time to time, at its sole discretion, through or to B. Riley, as agent or principal an aggregate amount not to exceed $50.0 million of its Series B Depositary Shares. B. Riley may sell the shares by any method permitted by law deemed to be an &#8220;at the market&#8221; offering as defined in Rule 415 of the Securities Act and </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">will use its commercially reasonable efforts consistent with its normal trading and sales practices to sell the shares up to the amount specified. The Company will pay B. Riley a commission of up to 3% of the gross proceeds of any Series B Depositary Shares sold under the 2021 Series B Preferred Stock ATM Agreement. No shares have been sold under the 2021 Series B Preferred Stock ATM Agreement since the agreement was executed. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140070014128496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">12. Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">No provision was made for federal income tax, since the Company has incurred net operating losses during the three and six months ended June 30, 2023 and 2022. The Company continues to maintain a full valuation allowance against its remaining net deferred tax assets. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has a total of $5.9 million of gross unrecognized tax benefits, none of which would affect the effective tax rate upon realization as it currently has a full valuation allowance against its net deferred tax assets. The reversal of related deferred tax assets will be offset by a valuation allowance, should any of these uncertain tax positions be favorably settled in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company does not expect its unrecognized tax benefits to change significantly over the next twelve months. The Company will recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. Through June 30, 2023, the Company has not accrued interest or penalties related to uncertain tax positions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On August 16, 2022, President Biden signed the Inflation Reduction Act of 2022 (the Inflation Act) into law. &#160;The Inflation Act contains certain tax measures, including a corporate alternative minimum tax of 15% on some large corporations and an excise tax of 1% on corporate stock buy-backs. The various provisions of the Inflation Act do not have a material impact on the Company&#8217;s financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140070011544592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Basis of Presentation and Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions among consolidated entities were eliminated upon consolidation. The unaudited condensed consolidated financial statements were prepared in accordance with GAAP in the United States for interim financial information and with the instructions to Form&#160;10-Q and Article&#160;10 of Regulation S-X. As permitted under those rules&#160;certain footnotes or other financial information can be condensed or omitted. These condensed consolidated financial statements and related disclosures have been prepared with the assumption that users of the interim financial information have read or have access to the audited consolidated financial statements for the preceding fiscal&#160;year. Accordingly, these statements should be read in conjunction with the audited consolidated financial statements and related notes included in the Company&#8217;s Annual Report on Form&#160;10-K for the&#160;year ended December&#160;31, 2022, filed with the SEC on March&#160;9, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">These condensed consolidated financial statements have been prepared on the same basis as the Company&#8217;s annual consolidated financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal and recurring adjustments that are necessary for a fair statement of the Company&#8217;s consolidated financial information. The interim results of operations are not necessarily indicative of the results that may be expected for the full&#160;year.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The preparation of financial statements in conformity with GAAP in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates including, but not limited to, those related to revenue recognition, revenue recognized under the units-of-revenue method, royalty and commercial payment receivables, </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">intangible assets, legal contingencies, contingent consideration and stock-based compensation. The Company bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Actual results may differ significantly from these estimates, such as the Company&#8217;s amortization of the payments received from HCRP. Under the contracts with HCRP, the amortization for the reporting period is calculated based on the payments expected to be made by the licensees to HCRP over the term of the arrangement. Any changes to the estimated payments by the licensees to HCRP can result in a material adjustment to revenue previously reported.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash and Cash Equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash consists of bank deposits held in business checking and interest-bearing deposit accounts. As of June 30, 2023, the Company had a cash balance of $1.3 million and cash equivalent balances of $30.1 million, defined as highly liquid financial instruments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. As of December 31, 2022, the Company had a cash balance of $27.5 million and cash equivalent balances of $30.3 million.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Revenue Recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes revenue from all contracts with customers according to ASC 606, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i)&#160;identify the contract(s)&#160;with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation based on relative fair values, when (or as) the performance obligation is satisfied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company recognizes revenue from its license and collaboration arrangements and royalties. The terms of the arrangements generally include payment to the Company of one or more of the following: non-refundable, upfront license fees, development, regulatory and commercial milestone payments, and royalties on net sales of licensed products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 18pt;">License of intellectual property</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, such as transfer of related materials, process and know-how, the Company utilizes judgement to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. Under the Company&#8217;s license agreements, the nature of the combined performance obligation is the granting of licenses to the customers as the other promises are not separately identifiable in the context of the arrangement. Since the Company grants the license to a customer as it exists at the point of transfer and is not involved in any future development or commercialization of the products related to the license, the nature of the license is a right to use the Company&#8217;s intellectual property as transferred. As such, the Company recognizes revenue related to the combined performance obligation upon completion of the delivery of the related materials, process and know-how (i.e., at a point in time).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 18pt;">Milestone payments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the inception of each arrangement that includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price. ASC 606 suggests two alternatives to use when estimating the amount of variable consideration: the expected value method and the most likely amount method. Under the expected value method, an entity considers the sum of probability-weighted amounts in a range of possible consideration amounts. Under the most likely amount method, an entity considers the single most likely amount in a range of possible consideration amounts. The Company uses the most likely amount method for development and regulatory milestone payments. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If it is probable that a significant cumulative revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis. The Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability or achievement of each such milestone and any related constraint, and if necessary, adjusts its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and earnings in the period of adjustment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 18pt;">Royalties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upfront payments and fees are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts payable to the Company are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one&#160;year or less.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RevenueRecognitionDeferredRevenuePolicyTextBlock', window );">Sale of Future Revenue Streams</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Sale of Future Revenue Streams</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has sold its rights to receive certain milestones and royalties on product sales. In the circumstance where the Company has sold its rights to future milestones and royalties under a license agreement and also maintains limited continuing involvement in the arrangement (but not significant continuing involvement in the generation of the cash flows that are due to the purchaser), the Company defers recognition of the proceeds it receives for the sale of milestone or royalty streams and recognizes such unearned revenue as revenue under the units-of-revenue method over the life of the underlying license agreement. Under the units-of-revenue method, amortization for a reporting period is calculated by computing a ratio of the proceeds received from the purchaser to the total payments expected to be made to the purchaser over the term of the agreement, and then applying that ratio to the period&#8217;s cash payment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Estimating the total payments expected to be received by the purchaser over the term of such arrangements requires management to use subjective estimates and assumptions. Changes to the Company&#8217;s estimate of the payments expected to be made to the purchaser over the term of such arrangements could have a material effect on the amount of revenues recognized in any particular period.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company recognizes compensation expense for all stock-based payment awards made to the Company&#8217;s employees, consultants and directors that are expected to vest based on estimated fair values. The valuation of stock option awards is determined at the date of grant using the Black-Scholes Model. The Black-Scholes Model requires inputs such </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">as the expected term of the option, expected volatility and risk-free interest rate. To establish an estimate of expected term, the Company considers the vesting period and contractual period of the award and its historical experience of stock option exercises, post-vesting cancellations and volatility. The estimate of expected volatility is based on the Company&#8217;s historical volatility. The risk-free rate is based on the yield available on United States Treasury zero-coupon issues corresponding to the expected term of the award. The Company records forfeitures when they occur. The Company records compensation expense for service-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the award, or to the date on which retirement eligibility is achieved, if shorter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The grant date fair value of PSUs with market conditions are determined using the Monte Carlo valuation model. The Company records compensation expenses for PSUs based on graded expense attribution over the requisite service periods.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_EquitySecuritiesPolicy', window );">Equity Securities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Equity Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company entered into a license agreement with Rezolute in December 2017, in which it received shares of common stock from Rezolute (Note 4). Equity investments in Rezolute are classified in the condensed consolidated balance sheets as equity securities. The equity securities are measured at fair value, with changes in fair value recorded in the other income (expense), net line item of the condensed consolidated statement of operations and comprehensive loss at each reporting period. The Company remeasures its equity investments at each reporting period until such time that the investment is sold or disposed of. If the Company sells an investment, any realized gains and losses on the sale of the securities will be recognized in the condensed consolidated statement of operations and comprehensive loss in the period of sale.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_FutureMilestonesRoyaltiesPurchaseRightsAndCommercialPaymentsPolicyPolicyTextBlock', window );">Purchase of Rights to Future Milestones, Royalties and Commercial Payments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Purchase of Rights to Future Milestones, Royalties and Commercial Payments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has purchased rights to receive a portion of certain future developmental, regulatory and commercial sales milestones, royalties and option fees on sales of products currently in clinical development or recently commercialized. The Company acquired such rights from various entities and recorded the amount paid for these rights as long-term royalty receivables (Note 5). In addition, the Company may be obligated to make contingent payments related to certain product development milestones, fees upon exercise of options related to future license products and sales-based milestones. The contingent payments are evaluated to determine if they are freestanding instruments or embedded derivatives. If the contingent payments fall within the scope of ASC 815, the contingent payments are measured at fair value at the inception of the arrangement, and subject to remeasurement to fair value each reporting period. Any changes in the estimated fair value are recorded in the condensed consolidated statement of operations and comprehensive loss. Contingent consideration payments that do not fall within the scope of ASC 815 are recognized when the amount is probable and estimable according to ASC 450.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for milestone and royalty rights related to developmental pipeline or recently commercialized products on a non-accrual basis using the cost recovery method. These developmental pipeline products are non-commercialized, non-approved products that require FDA or other regulatory approval, and thus have uncertain cash flows. The recently commercialized products do not have an established reliable sales pattern, and thus have uncertain cash flows. The Company is not yet able to reliably forecast future cash flows given their stages of development and commercialization. The related receivable balance is classified as noncurrent or current based on whether payments are probable and reasonably estimable to be received in the near term. Under the cost recovery method, any milestone or royalty payment received is recorded as a direct reduction of the recorded receivable balance. When the recorded receivable balance has been fully collected, any additional amounts collected are recognized as revenue.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_CreditLossContractWithCustomerAssetPolicyTextBlock', window );">Allowance for Current Expected Credit Losses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Allowance for Current Expected Credit Losses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company evaluates the long-term royalty and commercial payment receivables on a collective, i.e., pool, basis if they share similar risk characteristics. The Company would evaluate a royalty and commercial payment receivable individually if its risk characteristics are not similar to other royalty and commercial payment receivables. The Company reviews public information on clinical trials, press releases and updates from its partners regularly to identify any impairment indicators or changes in expected recoverability of the long-term royalty and commercial payment receivable </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">asset. At each reporting date, if the Company determines expected future cash flows discounted to the current period are less than the carrying value of the asset, the Company will record impairment. The impairment will be recognized as an allowance expense that increases the long-term royalty and commercial payment receivable asset&#8217;s cumulative allowance, which reduces the net carrying value of the long-term royalty and commercial payment receivable asset. In a subsequent period, if there is an increase in expected future cash flows, or if the actual cash flows are greater than previously expected, the Company will reduce the previously established cumulative allowance. Amounts not expected to be collected are written off against the allowance at the time that such a determination is made. &#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_AssetAcquisitionsPolicyPolicyTextBlock', window );">Asset Acquisitions</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Asset Acquisitions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As a first step, for each acquisition, the Company determines if it is an acquisition of a business or an asset acquisition under ASC 805. Acquisitions of assets or a group of assets that do not meet the definition of a business are accounted for as asset acquisitions under ASC 805-50, using the cost accumulation method, whereby the cost of the acquisition, including certain transaction costs, is allocated to the assets acquired on the basis of relative fair values (Note 4). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Contingent payments are evaluated whether they are freestanding instruments or embedded derivatives. If the contingent payments fall within the scope of ASC 815, the contingent payments are measured at fair value at the acquisition date, and subject to remeasurement to fair value each reporting period. The estimated fair value at the acquisition date is included in the cost of the acquired assets. Any subsequent changes in the estimated fair value are recorded in the condensed consolidated statement of operations and comprehensive loss. Contingent consideration payments that do not fall within the scope of ASC 815 are recognized when the amount is probable and estimable according to ASC 450. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash payments related to acquired assets are reflected as an investing cash flow in the Company&#8217;s condensed consolidated statement of cash flows. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">Intangible Assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:6pt 0pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The identifiable intangible asset consists of IP acquired in the ObsEva IP Acquisition Agreement in 2022. This intangible asset is amortized on a straight-line basis over its estimated useful life of 17 years. The straight-line method of amortization represents the Company&#8217;s best estimate of the distribution of the economic value of the identifiable intangible asset. The intangible asset is carried at cost less accumulated amortization. Amortization will be included in amortization of intangible assets in the condensed consolidated statement of operations and comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amount of an asset group to the future net undiscounted cash flows that the assets are expected to generate. If the carrying amount of an asset group exceeds its estimated future cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset group exceeds the fair value of the asset group. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company leases its headquarters office space in Emeryville, California.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company determines the initial classification and measurement of its right-of-use assets and lease liabilities at the lease commencement date and thereafter if modified. The lease term includes any renewal options and termination options that the Company is reasonably certain to exercise. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its incremental borrowing rate. The incremental borrowing rate is determined by using the rate of interest that the Company would pay to borrow on a collateralized basis an amount equal to the lease payments for a similar term and in a similar economic environment. The Company built its incremental borrowing rate starting with the interest rate on its fully collateralized debt and then adjusted it for lease term length.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Rent expense for the operating lease is recognized on a straight-line basis, over the reasonably assured lease term based on the total lease payments and is included in operating expenses in the condensed consolidated statements of operations and comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has elected the practical expedient to not separate lease and non-lease components. The Company&#8217;s non-lease components are primarily related to property maintenance, which varies based on future outcomes, and thus is recognized in rent expense when incurred.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for income taxes using the liability method under which deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount which is more likely than not to be realizable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The recognition, derecognition and measurement of a tax position is based on management&#8217;s best judgment given the facts, circumstances and information available at each reporting date. The Company&#8217;s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share Attributable to Common Stockholders</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Net Loss per Share Attributable to Common Stockholders</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company calculates basic and diluted loss per share attributable to common stockholders using the two-class method. The Company&#8217;s convertible Series X preferred stocks participate in any dividends declared by the Company on its common stock and are therefore considered to be participating securities. The Company&#8217;s Series A and Series B Preferred Stock do not participate in any dividends or distribution by the Company on its common stock and are therefore not considered to be participating securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the two-class method, net income, as adjusted for any accumulated dividends on Series A and Series B Preferred Stock for the period, is allocated to each class of common stock and participating security as if all of the net income for the period had been distributed. Undistributed earnings allocated to participating securities are subtracted from net income in determining net income attributable to common stockholders. During periods of loss, the Company allocates no loss to participating securities because they have no contractual obligation to share in the losses of the Company. Basic net loss per share attributable to common stockholders is then calculated by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. All participating securities are excluded from the basic weighted average common shares outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Diluted net loss per share attributable to common stockholders is based on the weighted average number of shares outstanding during the period, adjusted to include the assumed exercise of certain stock options and warrants for common stock using the treasury method, if dilutive. The calculation assumes that any proceeds that could be obtained upon exercise of options and warrants would be used to purchase common stock at the average market price during the period. Adjustments to the denominator are required to reflect the related dilutive shares. The Company&#8217;s Series A and Series B Preferred Stock become convertible upon the occurrence of specific events other than a change in the Company&#8217;s share price and, therefore, are not included in the diluted shares until the contingency is resolved.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Risk</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Concentration of Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash, cash equivalents and receivables are financial instruments which potentially subject the Company to concentrations of credit risk, as well as liquidity risk. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company maintains cash balances at commercial banks. Balances commonly exceed the amount insured by the FDIC. The Company has not experienced any losses in such accounts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company monitors the creditworthiness of its customers to which it grants credit terms in the normal course of business but does not generally require collateral on receivables. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the three months ended June 30, 2023, two partners represented 66% and 32% of total revenues. For the six months ended June 30, 2023, two partners represented 53% and 46% of total revenues. For the three months ended June 30, 2022, two partners represented 51% and 47% of total revenues. For the six months ended June 30, 2022, four partners represented 49%, 20%, 18% and 12% of total revenues. One partner represented 100% of the trade receivables, net balance as of June 30, 2023. There were no trade receivables, net balance as of December 31, 2022.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Comprehensive Loss</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Comprehensive loss is comprised of two components: net loss and other comprehensive loss. Other comprehensive loss refers to gains and losses that under U.S. GAAP are recorded as an element of stockholders&#8217; equity but are excluded from net loss. The Company did not record any transactions within other comprehensive loss in the periods presented and, therefore, the net loss and comprehensive loss were the same for all periods presented.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Accounting Pronouncements Recently Adopted</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Accounting Pronouncements Recently Adopted</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (ASC 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 replaced the incurred loss impairment methodology under current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. ASU 2016-13 requires use of a forward-looking expected credit loss model for accounts receivables, loans, and other financial instruments. Adoption of the standard requires using a modified retrospective approach through a cumulative-effect adjustment to retained earnings as of the effective date to align existing credit loss methodology with the new standard. The Company adopted ASU 2016-13 and related updates on January 1, 2023. The adoption of ASU 2016-13 had no impact on the condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In October 2021, the FASB issued ASU 2021-08, Business Combinations &#8211; Accounting for Contract Assets and Contact Liabilities from Contracts with Customers. The guidance is intended to improve the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice. The guidance requires an acquirer to recognize and measure contract assets and liabilities acquired in a business combination in accordance with ASC 606 as if they had originated the contracts, as opposed to at fair value on the acquisition date. The Company adopted ASU 2021-08 and related updates on January 1, 2023. The adoption of ASU 2021-08 had no impact on the condensed consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_AssetAcquisitionsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for asset acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_AssetAcquisitionsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_CreditLossContractWithCustomerAssetPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit loss on long-term royalty and commercial payment receivable asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_CreditLossContractWithCustomerAssetPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_EquitySecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_EquitySecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_FutureMilestonesRoyaltiesPurchaseRightsAndCommercialPaymentsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Policy for future milestones, royalties purchase rights and commercial payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_FutureMilestonesRoyaltiesPurchaseRightsAndCommercialPaymentsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RevenueRecognitionDeferredRevenuePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for sale of future revenue streams.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RevenueRecognitionDeferredRevenuePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140070014758784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Financial Statements Details (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ConsolidatedFinancialStatementDetailAbstract', window );"><strong>Condensed Consolidated Financial Statements Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of cost, accumulated amortization, and net carrying value of intangible assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes cost, accumulated amortization, and net carrying value of the intangible assets as of June 30, 2023 (in thousands): </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net Carrying</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortization</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As of June 30, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Ebopiprant IP (Note 4) </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,247</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 546</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,701</p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total intangible assets </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,247</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 546</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14,701</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table summarizes cost, accumulated amortization, and net carrying value of the intangible assets as of December 31, 2022 (in thousands): </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net Carrying</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortization</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As of December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Ebopiprant IP (Note 4) </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,247</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 97</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,150</p></td></tr><tr><td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total intangible assets </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,247</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 97</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,150</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of projected amortization expense for next five years</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The remaining life of the intangible assets is 16.4 years. The following table presents the projected amortization expense for the next five years (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;"> </span><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intangible Asset</b></p></td></tr><tr><td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortization</b></p></td></tr><tr><td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:83.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2023 (excluding six months ended June 30, 2023)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 448</p></td></tr><tr><td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 897</p></td></tr><tr><td style="vertical-align:bottom;width:83.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 897</p></td></tr><tr><td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 897</p></td></tr><tr><td style="vertical-align:bottom;width:83.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 897</p></td></tr><tr><td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,036</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued and other liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Accrued and other liabilities consisted of the following (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued payroll, severance and retention costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 978</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,449</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued incentive compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 604</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 562</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accrued legal and accounting fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 331</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 867</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,933</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,918</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of reconciliation of numerator and denominator used in calculation of basic and diluted net (loss) per share available to common stockholders</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following is a reconciliation of the numerator (net loss) and the denominator (number of shares) used in the calculation of basic and diluted net loss per share attributable to common stockholders (in thousands, except per share amounts):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six Months Ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Numerator</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:55.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,400)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,670)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (15,213)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,950)</p></td></tr><tr><td style="vertical-align:bottom;width:55.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: Series A accumulated dividends </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (530)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (530)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,061)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,061)</p></td></tr><tr><td style="vertical-align:bottom;width:55.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less: Series B accumulated dividends </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (838)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (838)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,675)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,675)</p></td></tr><tr><td style="vertical-align:bottom;width:55.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss attributable to common stockholders, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,768)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,038)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (17,949)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,686)</p></td></tr><tr><td style="vertical-align:bottom;width:55.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Denominator</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average shares used in computing basic and diluted net loss per share attributable to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,466</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,421</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,463</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,376</p></td></tr><tr><td style="vertical-align:bottom;width:55.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Basic and diluted net loss per share attributable to common stockholders </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.59)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.53)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.57)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.85)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of outstanding securities considered anti-dilutive</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table shows the weighted-average shares from outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net loss per share attributable to common stockholders (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six Months Ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Convertible preferred stock </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,003</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,003</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,003</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,003</p></td></tr><tr><td style="vertical-align:bottom;width:55.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Common stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,719</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 889</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,634</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 813</p></td></tr><tr><td style="vertical-align:bottom;width:55.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants for common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6</p></td></tr><tr><td style="vertical-align:bottom;width:55.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,728</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,898</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,643</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,822</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ConsolidatedFinancialStatementDetailAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Consolidated financial statement detail.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ConsolidatedFinancialStatementDetailAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140070014282944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Royalty and Commercial Payment Purchase Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract', window );"><strong>Royalty and Commercial Payment Purchase Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ScheduleOfRoyaltyAndCommercialPaymentReceivablesActivityTableTextBlock', window );">Summary of royalty and commercial payment receivable activities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the royalty and commercial payment receivable activities during the six months ended June 30, 2023 (in thousands): </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Short-Term</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Long-Term</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at January 1, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,366</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 63,683</p></td></tr><tr><td style="vertical-align:bottom;width:75.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Acquisition of royalty and commercial payment receivables:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Aptevo</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,650</p></td></tr><tr><td style="vertical-align:bottom;width:75.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">LadRx</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,000</p></td></tr><tr><td style="vertical-align:bottom;width:75.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Receipt of royalty and commercial payments:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Affitech</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,366)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Aptevo</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (568)</p></td></tr><tr><td style="vertical-align:bottom;width:75.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Impairment of royalty and commercial payment receivables:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Bioasis</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,575)</p></td></tr><tr><td style="vertical-align:bottom;width:75.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Reclassification to short-term royalty and commercial payment receivables:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Affitech</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,958</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,958)</p></td></tr><tr><td style="vertical-align:bottom;width:75.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at June&#160;30,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,958</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 72,232</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ScheduleOfRoyaltyAndCommercialPaymentReceivablesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in royalty and commercial payment receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ScheduleOfRoyaltyAndCommercialPaymentReceivablesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140070014255024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Financial Assets and Liabilities Carried at Fair Value on Recurring Basis</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following tables set forth the Company&#8217;s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as follows (in thousands): </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements&#160;at&#160;June&#160;30,&#160;2023 Using: </b></p></td></tr><tr><td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Quoted&#160;Prices&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Active&#160;Markets&#160;for</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Identical&#160;Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30,102</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30,102</p></td></tr><tr><td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total cash equivalents </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30,102</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30,102</p></td></tr><tr><td style="vertical-align:bottom;width:50.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Equity securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 320</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 320</p></td></tr><tr><td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total financial assets </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30,422</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30,422</p></td></tr><tr><td style="vertical-align:bottom;width:50.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Contingent consideration under RPAs, AAAs and CPPAs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,000</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;Value&#160;Measurements&#160;at&#160;December&#160;31,&#160;2022 Using:</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Quoted&#160;Prices&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant&#160;Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Active&#160;Markets&#160;for</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Identical&#160;Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30,334</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30,334</p></td></tr><tr><td style="vertical-align:bottom;width:49.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total cash equivalents </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30,334</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30,334</p></td></tr><tr><td style="vertical-align:bottom;width:49.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Equity securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 335</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 335</p></td></tr><tr><td style="vertical-align:bottom;width:49.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total financial assets </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30,669</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30,669</p></td></tr><tr><td style="vertical-align:bottom;width:49.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Contingent consideration under RPAs, AAAs and CPPAs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 75</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140070009543200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Lease Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of cost components of operating leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table summarizes the cost components of the Company&#8217;s operating lease for the three and six months ended June 30, 2023 and 2022 (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:54.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six Months Ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:10.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease costs:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 51</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 44</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 99</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 88</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Variable lease cost <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total lease costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 58</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 46</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 111</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 93</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;padding-left:18pt;text-align:justify;text-indent:-18pt;"><span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;">(1)</span>Under the terms of the lease agreement, the Company is also responsible for certain variable lease payments that are not included in the measurement of the lease liability. Variable lease payments include non-lease components such as common area maintenance fees.</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock', window );">Summary of supplemental cash flow information related to operating leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following information represents supplemental disclosure for the statement of cash flows related to operating leases (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:12pt;"> </span><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> &#160;&#160;&#160;&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six Months Ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash paid for amounts included in the measurement of lease liabilities</p></td><td style="vertical-align:bottom;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating cash flows under operating leases</p></td><td style="vertical-align:bottom;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 104</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 101</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LesseeOperatingLeaseSupplementalInformationTableTextBlock', window );">Schedule of present value assumptions used in calculating the present value of lease payments</a></td>
<td class="text"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;"> </span><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> &#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average remaining lease term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.08 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.17 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td></tr><tr><td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average discount rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.51</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.51</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><span style="display:inline-block;min-width:18pt;white-space:nowrap;">(1)</span>Prior to the extension of the end of the lease term from February 28, 2023 to July 31, 2023 &#160;</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of supplemental cash flows information related to leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LesseeOperatingLeaseSupplementalInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of supplemental information related to operating leases. May include, but  not limited to, present value assumptions used in calculating the present value of the lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LesseeOperatingLeaseSupplementalInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140070014220272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Warrants (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Common Stock Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Summary of Common Stock Warrants Outstanding</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:18.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:18.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:18.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issuance Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Expiration&#160;Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance&#160;Sheet&#160;Classification</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">per&#160;Share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:18.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">May&#160;2018</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">May&#160;2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23.69</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,332</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,332</p></td></tr><tr><td style="vertical-align:bottom;width:18.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">March&#160;2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">March&#160;2029</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14.71</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,845</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,845</p></td></tr><tr><td style="vertical-align:bottom;width:18.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,177</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,177</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140070007297808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of stock option activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.51%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual&#160;</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining Term</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">shares</b></p></td><td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Per&#160;Share</b></p></td><td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;years)</b></p></td><td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:15.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="vertical-align:middle;width:38.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at January 1, 2023</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,025,542</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20.24</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,804</p></td></tr><tr><td style="vertical-align:middle;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 796,802</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23.50</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:middle;width:38.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8,473)</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18.29</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:middle;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited, expired or cancelled</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (71,123)</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 36.36</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:middle;width:38.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at June 30, 2023</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,742,748</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20.78</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.76</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,430</p></td></tr><tr><td style="vertical-align:middle;width:38.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable at June 30, 2023</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,815,920</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19.30</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.44</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,296</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of stock-based compensation expense</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">All stock-based compensation expense is recorded in G&amp;A expense. The following table shows total stock-based compensation expense for stock options and PSUs issued under the 2010 Plan, the Stock Option Inducement Awards and ESPP in the condensed consolidated statements of operations and comprehensive loss (in thousands): </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six Months Ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total stock-based compensation expense included in G&amp;A </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,163</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 837</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,733</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,815</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock', window );">Schedule of grant date fair value per PSU issued</a></td>
<td class="text"><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The range of grant date fair values of the PSUs issued in May 2023 were estimated as follows:<div style="display:inline-block;height:24pt;width:24pt;"><div style="height:24pt;left:0pt;padding-bottom:0pt;position:relative;width:24pt;"></div></div><div style="display:inline-block;height:24pt;width:24pt;"><div style="height:24pt;left:0pt;padding-bottom:0pt;position:relative;width:24pt;"></div></div></div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.8%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.8%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.8%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:25.89%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Derived</b></p></td></tr><tr><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Hurdle Price</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:25.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Service Period</b></p></td></tr><tr><td colspan="2" style="vertical-align:top;white-space:nowrap;width:21.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Per Share</b></p></td><td style="vertical-align:top;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:21.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">PSUs</b></p></td><td style="vertical-align:top;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:21.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Per&#160;Share</b></p></td><td style="vertical-align:top;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:25.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;years)</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 232,956</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">16.36-17.45</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">0.69-0.76</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:18.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 35.00</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 87,708</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:18.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">15.03-16.07</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">0.93-0.99</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:18.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 40.00</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 57,851</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:18.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">13.82-14.84</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">1.12-1.18</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:18.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 45.00</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 51,885</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:18.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">12.75-13.72</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">1.27-1.33</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 430,400</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock', window );">Schedule of performance shares, outstanding activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:56.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.24%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.56%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.22%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Grant Date</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:19.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unvested PSUs</b></p></td><td style="vertical-align:top;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;white-space:nowrap;width:19.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Per&#160;Share</b></p></td></tr><tr><td style="vertical-align:middle;width:56.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested balance at January 1, 2023</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:56.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 430,400</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15.61</p></td></tr><tr><td style="vertical-align:middle;width:56.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:16.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:56.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:56.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested balance at June 30, 2023</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 430,400</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:16.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15.61</p></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember', window );">2010 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of valuation assumptions</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six Months Ended June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:50.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 69</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:50.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.60</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.90</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.60</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:50.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5.79 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5.61 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5.79 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5.65 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=xoma_StockOptionInducementAwardOneMember', window );">Stock Option Inducement Award, Exercise price of $18.66 per share</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of valuation assumptions</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six Months Ended June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023 </b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022 </b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 69</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.92</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">5.79 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:22.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">No</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Stock Option Inducement Awards were granted during the three months ended June 30, 2023 or the three and six months ended June 30, 2022. </span></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=xoma_StockOptionInducementAwardTwoMember', window );">Stock Option Inducement Award, Exercise price of $30.00 per share</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of valuation assumptions</a></td>
<td class="text"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six Months Ended June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023 </b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022 </b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 91</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.86</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">8.01 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:40.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">No</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Stock Option Inducement Awards were granted during the three months ended June 30, 2023 or the three and six months ended June 30, 2022.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for outstanding performance shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Subparagraph (c)<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of number and weighted-average grant date fair value for nonvested performance shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Subparagraph (c)<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=xoma_StockOptionInducementAwardOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=xoma_StockOptionInducementAwardOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=xoma_StockOptionInducementAwardTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=xoma_StockOptionInducementAwardTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140070014285808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Capital Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsDeclaredTableTextBlock', window );">Schedule of declared and paid cash dividends</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:42.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:16.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:42.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:17.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Series A&#160;Preferred Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:18.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Series B&#160;Depositary Share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:42.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:17.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cash Dividend Declared</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:18.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cash Dividend Declared</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:42.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dividend Declaration Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">($ per share)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">($ per share)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Dividend Payment Date</b></p></td></tr><tr><td style="vertical-align:top;width:42.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">October 26, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_6FlVNMctY0q9dw8fCOKxTg;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.53906</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_9royLRcMl0Knqef269WU1Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.52344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">January 17, 2023</p></td></tr><tr><td style="vertical-align:top;width:42.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">February 22, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_qWHrIk0HxkKu1Feelg1QWg;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.53906</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_zyL_9MT4C06Qx4obkYEVKw;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.52344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">April 17, 2023</p></td></tr><tr><td style="vertical-align:top;width:42.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">May 17, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_hWIxlEMoI06Nfvonzanuzg;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.53906</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_Q-ZWoTYYE0qrtlCrmMWbHw;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.52344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">July 17, 2023</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsDeclaredTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to dividends declared, including paid and unpaid dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsDeclaredTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140070014248304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Description of Business - Liquidity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Description of Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 31,445<span></span>
</td>
<td class="nump">$ 57,826<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140070005916032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies - Cash and Cash Equivalents (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Basis of Presentation and Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="nump">$ 27.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 30.1<span></span>
</td>
<td class="nump">$ 30.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140070012567216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies - Intangible Assets and Income Taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Nov. 21, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Basis of Presentation and Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Estimated useful life of intangible asset</a></td>
<td class="text">17 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Income tax penalties or interest charged</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140070003558704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies - Concentration of Risk (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>customer</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>customer</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>customer</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>customer</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration of Risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesLongTermContractsOrPrograms', window );">Trade receivable, net | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Revenues.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration of Risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_NumberOfMajorPartners', window );">Number of major partners</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Revenues. | Partner 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration of Risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (as a percent)</a></td>
<td class="nump">66.00%<span></span>
</td>
<td class="nump">51.00%<span></span>
</td>
<td class="nump">53.00%<span></span>
</td>
<td class="nump">49.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Revenues. | Partner 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration of Risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (as a percent)</a></td>
<td class="nump">32.00%<span></span>
</td>
<td class="nump">47.00%<span></span>
</td>
<td class="nump">46.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Revenues. | Partner 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration of Risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Revenues. | Partner 4</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration of Risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember', window );">Credit Concentration Risk | Trade Receivables | Partner 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration of Risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_NumberOfMajorPartners', window );">Number of major partners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481027/954-310-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesLongTermContractsOrPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount to be collected within one year of the balance sheet date (or one operating cycle, if longer) from customers in accordance with the contractual provisions of long-term contracts or programs including amounts billed and unbilled as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesLongTermContractsOrPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_NumberOfMajorPartners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of major partners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_NumberOfMajorPartners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=xoma_Partner1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=xoma_Partner1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=xoma_Partner2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=xoma_Partner2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=xoma_Partner3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=xoma_Partner3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=xoma_Partner4Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=xoma_Partner4Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_TradeAccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_TradeAccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140070011411360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Financial Statements Details - Equity Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems', window );"><strong>Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss', window );">Gain (loss) recognized due to change in fair value of investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (15)<span></span>
</td>
<td class="num">$ (251)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=xoma_RezoluteIncMember', window );">Rezolute</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems', window );"><strong>Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFVNINoncurrent', window );">Long-term equity securities</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss', window );">Gain (loss) recognized due to change in fair value of investment</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="num">$ (25)<span></span>
</td>
<td class="num">$ (15)<span></span>
</td>
<td class="num">$ (300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFVNINoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482736/825-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFVNINoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=xoma_RezoluteIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=xoma_RezoluteIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140070009395248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Financial Statements Details - Intangible assets, net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">$ 15,247<span></span>
</td>
<td class="nump">$ 15,247<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">546<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Value</a></td>
<td class="nump">$ 14,701<span></span>
</td>
<td class="nump">15,150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Remaining useful life</a></td>
<td class="text">16 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract', window );"><strong>Projected amortization expense for the next five years</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">2023 (excluding six months ended June 30, 2023)</a></td>
<td class="nump">$ 448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2024</a></td>
<td class="nump">897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2025</a></td>
<td class="nump">897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2026</a></td>
<td class="nump">897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2027</a></td>
<td class="nump">897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_FiniteLivedIntangibleAssetExpectedAmortizationThroughYearFive', window );">Total</a></td>
<td class="nump">4,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember', window );">Ebopiprant IP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">15,247<span></span>
</td>
<td class="nump">15,247<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">546<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Value</a></td>
<td class="nump">$ 14,701<span></span>
</td>
<td class="nump">$ 15,150<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483147/928-340-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_FiniteLivedIntangibleAssetExpectedAmortizationThroughYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_FiniteLivedIntangibleAssetExpectedAmortizationThroughYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140070012260720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Financial Statements Details - Accrued and Other Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued and other liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_AccruedSalariesAndEmployeeBenefitsCurrent', window );">Accrued payroll, severance and retention costs</a></td>
<td class="nump">$ 978<span></span>
</td>
<td class="nump">$ 1,449<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Accrued incentive compensation</a></td>
<td class="nump">604<span></span>
</td>
<td class="nump">562<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued legal and accounting fees</a></td>
<td class="nump">331<span></span>
</td>
<td class="nump">867<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_AccruedAndOtherLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 1,933<span></span>
</td>
<td class="nump">$ 2,918<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_AccruedAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, and liabilities classified as other, due within one year or within the normal operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_AccruedAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_AccruedSalariesAndEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Also includes carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Includes, but not limited to payroll, severance and retention costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_AccruedSalariesAndEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140070009421056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Financial Statements Details - Net Loss Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract', window );"><strong>Numerator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (5,400)<span></span>
</td>
<td class="num">$ (9,813)<span></span>
</td>
<td class="num">$ (4,670)<span></span>
</td>
<td class="num">$ (2,280)<span></span>
</td>
<td class="num">$ (15,213)<span></span>
</td>
<td class="num">$ (6,950)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">Less: accumulated dividends</a></td>
<td class="num">(1,368)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,368)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,736)<span></span>
</td>
<td class="num">(2,736)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders, basic</a></td>
<td class="num">(6,768)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,038)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,949)<span></span>
</td>
<td class="num">(9,686)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss attributable to common stockholders, diluted</a></td>
<td class="num">$ (6,768)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (6,038)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (17,949)<span></span>
</td>
<td class="num">$ (9,686)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares used in computing basic net loss per share attributable to common stockholders (in shares)</a></td>
<td class="nump">11,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,463<span></span>
</td>
<td class="nump">11,376<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares used in computing diluted net loss per share attributable to common stockholders (in shares)</a></td>
<td class="nump">11,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,463<span></span>
</td>
<td class="nump">11,376<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per share attributable to common stockholders (in dollars per share)</a></td>
<td class="num">$ (0.59)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.53)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1.57)<span></span>
</td>
<td class="num">$ (0.85)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per share attributable to common stockholders (in dollars per share)</a></td>
<td class="num">$ (0.59)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.53)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1.57)<span></span>
</td>
<td class="num">$ (0.85)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A accumulated dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract', window );"><strong>Numerator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">Less: accumulated dividends</a></td>
<td class="num">$ (530)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (530)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,061)<span></span>
</td>
<td class="num">$ (1,061)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B accumulated dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract', window );"><strong>Numerator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">Less: accumulated dividends</a></td>
<td class="num">$ (838)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (838)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,675)<span></span>
</td>
<td class="num">$ (1,675)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsIncomeStatementImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsIncomeStatementImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140070003574896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Financial Statements Details - Outstanding Securities Considered Anti-Dilutive (Details) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of net loss per share (in shares)</a></td>
<td class="nump">6,728<span></span>
</td>
<td class="nump">5,898<span></span>
</td>
<td class="nump">6,643<span></span>
</td>
<td class="nump">5,822<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price (in dollars per share)</a></td>
<td class="nump">$ 18.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of net loss per share (in shares)</a></td>
<td class="nump">5,003<span></span>
</td>
<td class="nump">5,003<span></span>
</td>
<td class="nump">5,003<span></span>
</td>
<td class="nump">5,003<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Common stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of net loss per share (in shares)</a></td>
<td class="nump">1,719<span></span>
</td>
<td class="nump">889<span></span>
</td>
<td class="nump">1,634<span></span>
</td>
<td class="nump">813<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants for common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of net loss per share (in shares)</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140070011425760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Financial Statements Details - Arbitration Proceeding (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>item</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_NumberOfArbitrationProceedingsInitiated', window );">Number of arbitration proceedings initiated | item</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Arbitration settlement costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,132<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_NumberOfArbitrationProceedingsInitiated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of arbitration proceedings initiated by entity against one of its licensees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_NumberOfArbitrationProceedingsInitiated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140070007470048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Licensing and Other Arrangements - ObsEva (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 21, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset acquisition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ChangesInEstimatedFairValueOfContingentConsideration', window );">Changes in estimated fair value of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Estimated useful life of intangible asset</a></td>
<td class="text">17 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,125<span></span>
</td>
<td class="nump">$ 525<span></span>
</td>
<td class="nump">1,125<span></span>
</td>
<td class="nump">$ 3,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementMember', window );">License Agreement | ObsEva</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset acquisition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementMember', window );">License Agreement | ObsEva, Organon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset acquisition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentCommercializationAndSalesMilestones', window );">Maximum eligible milestone payments receivable upon achievement of development, commercialization and sales-based milestones</a></td>
<td class="nump">$ 475,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementMember', window );">License Agreement | ObsEva, Merck KGaA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset acquisition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_MaximumEarnOutPaymentsDevelopmentAndRegulatoryMilestonePayments', window );">Maximum earn-out payments for development and regulatory milestones</a></td>
<td class="nump">46,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_MaximumEarnOutPaymentsSalesBasedMilestonePayments', window );">Maximum earn-out payments for sales-based milestones</a></td>
<td class="nump">51,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=xoma_ObsevaIntellectualPropertyRightsMember', window );">ObsEva IP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset acquisition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Upfront cash payment to acquire assets</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Cost to acquire assets</a></td>
<td class="nump">15,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost', window );">Transaction costs</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Estimated useful life of intangible asset</a></td>
<td class="text">17 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=xoma_ObsevaIntellectualPropertyRightsMember', window );">ObsEva IP | License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset acquisition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_MaximumEarnOutPayments', window );">Maximum earn-out payments</a></td>
<td class="nump">$ 97,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479908/805-50-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction cost incurred as part of consideration transferred in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479908/805-50-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ChangesInEstimatedFairValueOfContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Changes in estimated fair value of contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ChangesInEstimatedFairValueOfContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentCommercializationAndSalesMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum eligible milestone payments receivable upon achievement of development, commercialization and sales milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentCommercializationAndSalesMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_MaximumEarnOutPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum earn-out payments entity will be required to pay for various milestones under arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_MaximumEarnOutPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_MaximumEarnOutPaymentsDevelopmentAndRegulatoryMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum earn-out payments entity will be required to pay for development and regulatory milestones under arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_MaximumEarnOutPaymentsDevelopmentAndRegulatoryMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_MaximumEarnOutPaymentsSalesBasedMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum earn-out payments entity will be required to pay for sales-based milestones under arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_MaximumEarnOutPaymentsSalesBasedMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_ObsevaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_ObsevaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_OrganonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_OrganonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_MerckKgaaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_MerckKgaaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=xoma_ObsevaIntellectualPropertyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=xoma_ObsevaIntellectualPropertyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140070009872848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Licensing and Other Arrangements - Novartis - NIS793 (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Oct. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,125<span></span>
</td>
<td class="nump">$ 525<span></span>
</td>
<td class="nump">$ 1,125<span></span>
</td>
<td class="nump">$ 3,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=xoma_NovartisNoteMember', window );">Novartis Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet', window );">Reduction in debt obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_NovartisInternationalPharmaceuticalLtdMember', window );">Novartis International | License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_AgreementTerminationPriorWrittenNoticePeriod', window );">Agreement termination prior written notice period</a></td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_NumberOfPerformanceObligations', window );">Number of performance obligations | item</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ProceedsFromUpfrontPayment', window );">Cash payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">$ 37,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones', window );">Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones</a></td>
<td class="nump">$ 480,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">410,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">410,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RoyaltiesPeriodMinimum', window );">Royalty payment period, minimum</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNet', window );">Capitalized contract costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479483/340-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net increase or decrease in the carrying amount of the debt instrument for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_AgreementTerminationPriorWrittenNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreement termination prior written notice period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_AgreementTerminationPriorWrittenNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones. May also include potential payments for achievement of clinical milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_NumberOfPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of performance obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_NumberOfPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ProceedsFromUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash proceeds received under agreement. May include, but is not limited to, upfront payments, one-time payments and cash-portion of payments received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ProceedsFromUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RoyaltiesPeriodMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum period over which counterparty is obligated to pay royalties under terms of agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RoyaltiesPeriodMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=xoma_NovartisNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=xoma_NovartisNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_NovartisInternationalPharmaceuticalLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_NovartisInternationalPharmaceuticalLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140070008947952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Licensing and Other Arrangements - Novartis - VPM087 (Details)<br> $ / shares in Units, $ in Thousands, &#8364; in Millions</strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 24, 2017 </div>
<div>USD ($) </div>
<div>agreement </div>
<div>item </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 24, 2017 </div>
<div>EUR (&#8364;) </div>
<div>agreement </div>
<div>item </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,125<span></span>
</td>
<td class="nump">$ 525<span></span>
</td>
<td class="nump">$ 1,125<span></span>
</td>
<td class="nump">$ 3,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_NovartisPharmaAGMember', window );">Novartis Pharma AG | Gevokizumab License Agreement and IL-1 Target License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LicenseAgreementTransactionPrice', window );">Transaction price</a></td>
<td class="nump">$ 40,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ProceedsFromUpfrontPayment', window );">Cash payment received</a></td>
<td class="nump">25,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LicenseAgreementConsiderationReceivedDebtRepayment', window );">License agreement consideration received, repayment of debt</a></td>
<td class="nump">14,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_CommonStockPremium', window );">Common stock premium</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_NumberOfLicenseAgreements', window );">Number of license agreements | agreement</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ArrangementsNumber', window );">Number of arrangements | item</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_NumberOfPerformanceObligations', window );">Number of performance obligations | item</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="nump">$ 40,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNet', window );">Capitalized contract costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_NovartisPharmaAGMember', window );">Novartis Pharma AG | Gevokizumab License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LicenseAgreementConsiderationReceived', window );">License agreement consideration received</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ProceedsFromUpfrontPayment', window );">Cash payment received</a></td>
<td class="nump">15,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LicenseAgreementConsiderationReceivedDebtRepayment', window );">License agreement consideration received, repayment of debt</a></td>
<td class="nump">14,300<span></span>
</td>
<td class="nump">&#8364; 12.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_CommonStockPremium', window );">Common stock premium</a></td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones', window );">Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones</a></td>
<td class="nump">$ 438,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_AgreementTerminationPriorWrittenNoticePeriod', window );">Agreement termination prior written notice period</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_NovartisPharmaAGMember', window );">Novartis Pharma AG | Gevokizumab License Agreement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares) | shares</a></td>
<td class="nump">539,131<span></span>
</td>
<td class="nump">539,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Purchase price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 9.2742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_StockIssuedDuringPeriodValueNewIssuesCommonStock', window );">Issuance of common stock, fair value</a></td>
<td class="nump">$ 4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 8.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_NovartisPharmaAGMember', window );">Novartis Pharma AG | IL-1 Target License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ProceedsFromUpfrontPayment', window );">Cash payment received</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479483/340-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_AgreementTerminationPriorWrittenNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreement termination prior written notice period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_AgreementTerminationPriorWrittenNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ArrangementsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of arrangements the agreements are accounted for.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ArrangementsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_CommonStockPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock premium received on sale of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_CommonStockPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones. May also include potential payments for achievement of clinical milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LicenseAgreementConsiderationReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License agreement consideration received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LicenseAgreementConsiderationReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LicenseAgreementConsiderationReceivedDebtRepayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of license agreement consideration received as repayment of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LicenseAgreementConsiderationReceivedDebtRepayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LicenseAgreementTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License agreement transaction price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LicenseAgreementTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_NumberOfLicenseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of license agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_NumberOfLicenseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_NumberOfPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of performance obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_NumberOfPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ProceedsFromUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash proceeds received under agreement. May include, but is not limited to, upfront payments, one-time payments and cash-portion of payments received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ProceedsFromUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_StockIssuedDuringPeriodValueNewIssuesCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new common stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering, net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_StockIssuedDuringPeriodValueNewIssuesCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_NovartisPharmaAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_NovartisPharmaAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_XOMA052LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_XOMA052LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_IL1TargetLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_IL1TargetLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140070003026736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Licensing and Other Arrangements - Takeda (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 01, 2006</div></th>
<th class="th"><div>Nov. 30, 2020</div></th>
<th class="th"><div>Feb. 28, 2009</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,125<span></span>
</td>
<td class="nump">$ 525<span></span>
</td>
<td class="nump">$ 1,125<span></span>
</td>
<td class="nump">$ 3,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_TakedaPharmaceuticalCompanyLimitedMember', window );">Takeda | Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones', window );">Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNet', window );">Capitalized contract costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_TakedaPharmaceuticalCompanyLimitedMember', window );">Takeda | Collaboration Agreement | TAK-079</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones', window );">Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones</a></td>
<td class="nump">$ 19,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RoyaltiesPeriodMinimum', window );">Royalty payment period, minimum</a></td>
<td class="text">13 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RoyaltiesPeriodMinimumScenarioOne', window );">Royalty payment period from the first commercial sale of each royalty-bearing discovery product</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_TakedaPharmaceuticalCompanyLimitedMember', window );">Takeda | Collaboration Agreement | Other antibodies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate', window );">Maximum eligible milestone payments receivable per discovery product candidate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RoyaltiesPeriodMinimum', window );">Royalty payment period, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479483/340-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum eligible milestone payments receivable per discovery product candidate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones. May also include potential payments for achievement of clinical milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RoyaltiesPeriodMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum period over which counterparty is obligated to pay royalties under terms of agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RoyaltiesPeriodMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RoyaltiesPeriodMinimumScenarioOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum period over which counterparty is obligated to pay royalties under terms of agreement for scenario one, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RoyaltiesPeriodMinimumScenarioOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_TakedaPharmaceuticalCompanyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_TakedaPharmaceuticalCompanyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_CollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_CollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=xoma_MezagitamabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=xoma_MezagitamabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=xoma_OtherAntibodiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=xoma_OtherAntibodiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140070009116864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Licensing and Other Arrangements - Rezolute (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">37 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 06, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,125<span></span>
</td>
<td class="nump">$ 525<span></span>
</td>
<td class="nump">$ 1,125<span></span>
</td>
<td class="nump">$ 3,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=xoma_RezoluteIncMember', window );">Rezolute</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_RezoluteIncMember', window );">Rezolute | License Agreement and Common Stock Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LicenseAgreementConsiderationReceivedAchievementOfFinancingActivities', window );">Payments received upon achievement of financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LicenseAgreementInstallmentPaymentsReceived', window );">Installment payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LicenseAgreementSharesReceived', window );">Number of shares received | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">161,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_RezoluteIncMember', window );">Rezolute | License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PercentageOfDecreaseInFutureRoyaltyObligations', window );">Percentage of decrease in future royalty obligations</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_AgreementTerminationPriorWrittenNoticePeriod', window );">Agreement termination prior written notice period</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LicenseAgreementConsiderationReceived', window );">License agreement consideration received</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNet', window );">Capitalized contract costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_RezoluteIncMember', window );">Rezolute | License Agreement, RZ358</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones', window );">Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones</a></td>
<td class="nump">$ 232,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RoyaltiesPeriodMinimum', window );">Royalty payment period, minimum</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_RezoluteIncMember', window );">Rezolute | License Agreement, Non-RZ358 products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RoyaltiesPeriodMinimum', window );">Royalty payment period, minimum</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479483/340-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_AgreementTerminationPriorWrittenNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreement termination prior written notice period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_AgreementTerminationPriorWrittenNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones. May also include potential payments for achievement of clinical milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LicenseAgreementConsiderationReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License agreement consideration received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LicenseAgreementConsiderationReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LicenseAgreementConsiderationReceivedAchievementOfFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payments received upon achievement of financing activities during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LicenseAgreementConsiderationReceivedAchievementOfFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LicenseAgreementInstallmentPaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of installment payments received during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LicenseAgreementInstallmentPaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LicenseAgreementSharesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of counterparty's common stock entity received under the terms of the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LicenseAgreementSharesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PercentageOfDecreaseInFutureRoyaltyObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of decrease in future royalty obligations upon certain conditions under the terms of the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PercentageOfDecreaseInFutureRoyaltyObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RoyaltiesPeriodMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum period over which counterparty is obligated to pay royalties under terms of agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RoyaltiesPeriodMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=xoma_RezoluteIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=xoma_RezoluteIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_RezoluteIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_RezoluteIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementRz358Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementRz358Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementNonRz358ProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementNonRz358ProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140070007685056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Licensing and Other Arrangements - Janssen Biotech (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,125<span></span>
</td>
<td class="nump">$ 525<span></span>
</td>
<td class="nump">$ 1,125<span></span>
</td>
<td class="nump">$ 3,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_JanssenBiotechInc.Member', window );">Janssen Biotech Inc. | License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ProceedsFromUpfrontPayment', window );">Cash payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents', window );">Maximum amount receivable milestone payments upon achievement of certain clinical development and regulatory approval events</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PercentageOfRoyaltyOnNetSalesUponCommercialization', window );">Percentage of royalty on worldwide net sales of each product upon commercialization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_NumberOfMilestonesEarned', window );">Number of milestones earned during the period | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNet', window );">Capitalized contract costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_JanssenBiotechInc.Member', window );">Janssen Biotech Inc. | License Agreement | Dosing of first patient in a Phase 3 clinical trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_JanssenBiotechInc.Member', window );">Janssen Biotech Inc. | License Agreement | Milestone achieved pursuant to agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479483/340-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount receivable milestone payments upon achievement of certain clinical development and regulatory approval events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_NumberOfMilestonesEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of milestones earned during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_NumberOfMilestonesEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PercentageOfRoyaltyOnNetSalesUponCommercialization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalty on net sales upon commercialization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PercentageOfRoyaltyOnNetSalesUponCommercialization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ProceedsFromUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash proceeds received under agreement. May include, but is not limited to, upfront payments, one-time payments and cash-portion of payments received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ProceedsFromUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_JanssenBiotechInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_JanssenBiotechInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=xoma_MilestoneDosingFirstPatientInClinicalTrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=xoma_MilestoneDosingFirstPatientInClinicalTrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=xoma_MilestonePursuantToAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=xoma_MilestonePursuantToAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140070011360288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Licensing and Other Arrangements - Affimed (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="nump">$ 1,125<span></span>
</td>
<td class="nump">$ 525<span></span>
</td>
<td class="nump">$ 1,125<span></span>
</td>
<td class="nump">$ 3,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementMember', window );">License Agreement | Affimed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNet', window );">Capitalized contract costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contracts with customers</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479483/340-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_AffimedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_AffimedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140070009800000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Licensing and Other Arrangements - Sale of Future Revenue Streams (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 21, 2016 </div>
<div>USD ($) </div>
<div>agreement </div>
<div>period</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Unearned revenue recognized under units-of-revenue method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (970)<span></span>
</td>
<td class="num">$ (815)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Revenue recognized under units-of-revenue method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 533<span></span>
</td>
<td class="nump">$ 458<span></span>
</td>
<td class="nump">970<span></span>
</td>
<td class="nump">815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeCurrent', window );">Unearned revenue recognized under units-of-revenue method, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,899<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeNoncurrent', window );">Unearned revenue recognized under units-of-revenue method, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,550<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember', window );">HealthCare Royalty Partners II, L.P | Royalty Sale Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_NumberOfRoyaltyInterestAcquisitionAgreements', window );">Number of agreements | agreement</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Unearned revenue recognized under units-of-revenue method</a></td>
<td class="nump">$ 18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Revenue recognized under units-of-revenue method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeCurrent', window );">Unearned revenue recognized under units-of-revenue method, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeNoncurrent', window );">Unearned revenue recognized under units-of-revenue method, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember', window );">HealthCare Royalty Partners II, L.P | First Royalty Sale Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ProceedsFromUpfrontPayment', window );">Cash payment received</a></td>
<td class="nump">6,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones', window );">Eligible potential additional payments receivable upon achievement of specified net sales milestones in future years</a></td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_MilestonePeriodsNumber', window );">Number of milestone periods | period</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember', window );">HealthCare Royalty Partners II, L.P | Second Royalty Sale Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Licensing and other arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ProceedsFromUpfrontPayment', window );">Cash payment received</a></td>
<td class="nump">$ 11,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481174/470-10-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481174/470-10-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueNotFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue that is not accounted for under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueNotFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Eligible potential additional payments receivable upon achievement of specified future net sales milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_MilestonePeriodsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of milestone periods for which entity is eligible to receive payments upon achievement of milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_MilestonePeriodsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_NumberOfRoyaltyInterestAcquisitionAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of royalty interest acquisition agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_NumberOfRoyaltyInterestAcquisitionAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ProceedsFromUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash proceeds received under agreement. May include, but is not limited to, upfront payments, one-time payments and cash-portion of payments received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ProceedsFromUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_RoyaltyInterestAcquisitionAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_RoyaltyInterestAcquisitionAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_FirstRoyaltyInterestAcquisitionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_FirstRoyaltyInterestAcquisitionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_SecondRoyaltyInterestAcquisitionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_SecondRoyaltyInterestAcquisitionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140070005913504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Royalty and Commercial Payment Purchase Agreements - Summary (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RightsReceivableCurrent', window );">Short-term royalty and commercial payment receivables</a></td>
<td class="nump">$ 4,958<span></span>
</td>
<td class="nump">$ 2,366<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LongTermRightsReceivableNonCurrent', window );">Long-term royalty and commercial payment receivables</a></td>
<td class="nump">$ 72,232<span></span>
</td>
<td class="nump">$ 63,683<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LongTermRightsReceivableNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term royalty and commercial rights receivables, non current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LongTermRightsReceivableNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RightsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty, interest and commercial payment rights receivable, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RightsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140070007205408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Royalty and Commercial Payment Purchase Agreements - LadRx (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 21, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities', window );">Payments of consideration under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,650<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContingentConsiderationUnderPurchaseAgreements', window );">Contingent consideration under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LongTermRightsReceivableNonCurrent', window );">Long-term royalty and commercial payment receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63,683<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember', window );">Assignment and Assumption Agreement and Royalty Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LongTermRightsReceivableNonCurrent', window );">Long-term royalty and commercial payment receivables</a></td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_LadrxMember', window );">LadRx</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContingentConsiderationUnderPurchaseAgreements', window );">Contingent consideration under RPAs, AAAs and CPPAs</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_LadrxMember', window );">LadRx | Assignment and Assumption Agreement and Royalty Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities', window );">Payments of consideration under RPAs, AAAs and CPPAs</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndSalesMilestones', window );">Maximum payments based on achievement of regulatory and commercial sales milestones</a></td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_MaximumPayableOnRegulatoryMilestone', window );">Maximum payable on regulatory milestone</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_MaximumPayableOnSalesMilestone', window );">Maximum payable on commercial sales milestone</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss', window );">Amount of allowance for credit losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_LadrxMember', window );">LadRx | Assignment and Assumption Agreement and Royalty Purchase Agreement | Regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContingentConsiderationUnderPurchaseAgreements', window );">Contingent consideration under RPAs, AAAs and CPPAs</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_LadrxMember', window );">LadRx | Assignment and Assumption Agreement | Arimoclomol</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndCommercialMilestonesNet', window );">Maximum regulatory and commercial milestone payments, net</a></td>
<td class="nump">52,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_MaximumPaymentObligationsBasedOnPortionOfRegulatoryAndCommercialPayments', window );">Maximum payment obligations based on a portion of regulatory and commercial milestone payments</a></td>
<td class="nump">9,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_LadrxMember', window );">LadRx | Royalty Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContingentConsiderationUnderPurchaseAgreements', window );">Contingent consideration under RPAs, AAAs and CPPAs</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_LadrxMember', window );">LadRx | Royalty Purchase Agreement | Aldoxorubicin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_MaximumRegulatoryAndCommercialMilestones', window );">Maximum regulatory and commercial milestones</a></td>
<td class="nump">$ 342,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss for right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ContingentConsiderationUnderPurchaseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability recorded for contingent consideration under purchase agreements. May include royalty purchase agreements, commercial payment purchase agreements, payment interest purchase agreements and assignment and assumption agreements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ContingentConsiderationUnderPurchaseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LongTermRightsReceivableNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term royalty and commercial rights receivables, non current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LongTermRightsReceivableNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_MaximumPayableOnRegulatoryMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount payable on regulatory milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_MaximumPayableOnRegulatoryMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_MaximumPayableOnSalesMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount payable on sales milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_MaximumPayableOnSalesMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_MaximumPaymentObligationsBasedOnPortionOfRegulatoryAndCommercialPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum payment obligations based on a portion of regulatory and commercial milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_MaximumPaymentObligationsBasedOnPortionOfRegulatoryAndCommercialPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndCommercialMilestonesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum payments to be made based upon achievement of commercial sales and/or regulatory milestones, net of payment obligations based on a portion of regulatory and commercial milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndCommercialMilestonesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndSalesMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum  payments to be made based upon achievement of sales and/or regulatory milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndSalesMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_MaximumRegulatoryAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum regulatory and commercial milestones under the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_MaximumRegulatoryAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for consideration under agreements, including Royalty Purchase Agreements (RPAs), Assignment and Assumption Agreements (AAAs), and Commercial payment purchase agreement. (CPPAs) classified as investing activities. Payments may include upfront payments, one-time payments, milestone payments and contingent consideration payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_LadrxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_LadrxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=xoma_ContingentConsiderationRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=xoma_ContingentConsiderationRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_AssignmentAndAssumptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_AssignmentAndAssumptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=xoma_ArimoclomolMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=xoma_ArimoclomolMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=xoma_AldoxorubicinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=xoma_AldoxorubicinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140070007676432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Royalty and Commercial Payment Purchase Agreements - Aptevo (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 29, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LongTermRightsReceivableNonCurrent', window );">Long-term royalty and commercial payment receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 72,232<span></span>
</td>
<td class="nump">$ 72,232<span></span>
</td>
<td class="nump">$ 72,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63,683<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities', window );">Payments of consideration under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,650<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContingentConsiderationUnderPurchaseAgreements', window );">Contingent consideration under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ReceiptsUnderAgreementsInvestingActivities', window );">Receipts under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RightsReceivableCurrent', window );">Short-term royalty and commercial payment receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,958<span></span>
</td>
<td class="nump">4,958<span></span>
</td>
<td class="nump">4,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,366<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_AptevoMember', window );">Aptevo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent', window );">Reduction in long-term royalty receivable balance due to receipt of payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_AptevoMember', window );">Aptevo | Commercial Payment Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_MilestonesReceivableMaximum', window );">Maximum milestone payments entitled to receive</a></td>
<td class="nump">$ 5,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LongTermRightsReceivableNonCurrent', window );">Long-term royalty and commercial payment receivables</a></td>
<td class="nump">9,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities', window );">Payments of consideration under RPAs, AAAs and CPPAs</a></td>
<td class="nump">9,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContingentConsiderationUnderPurchaseAgreements', window );">Contingent consideration under RPAs, AAAs and CPPAs</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_CommercialPaymentThresholdOneTimePayment', window );">Commercial payments attributable to net sales threshold</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent', window );">Reduction in long-term royalty receivable balance due to receipt of payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RightsReceivableCurrent', window );">Short-term royalty and commercial payment receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss', window );">Amount of allowance for credit losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_AptevoMember', window );">Aptevo | Commercial Payment Purchase Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ReceiptsUnderAgreementsInvestingActivities', window );">Receipts under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_MedexusMember', window );">Medexus | Commercial Payment Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ReceiptsUnderAgreementsInvestingActivities', window );">Receipts under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss for right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_CommercialPaymentThresholdOneTimePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the threshold for receipt of commercial payments attributable to net sales for which the entity will be required to make a one-time payment under agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_CommercialPaymentThresholdOneTimePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ContingentConsiderationUnderPurchaseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability recorded for contingent consideration under purchase agreements. May include royalty purchase agreements, commercial payment purchase agreements, payment interest purchase agreements and assignment and assumption agreements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ContingentConsiderationUnderPurchaseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LongTermRightsReceivableNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term royalty and commercial rights receivables, non current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LongTermRightsReceivableNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_MilestonesReceivableMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of potential milestones receivable under the terms of the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_MilestonesReceivableMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for consideration under agreements, including Royalty Purchase Agreements (RPAs), Assignment and Assumption Agreements (AAAs), and Commercial payment purchase agreement. (CPPAs) classified as investing activities. Payments may include upfront payments, one-time payments, milestone payments and contingent consideration payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in long-term rights receivable due to receipt of royalty and commercial payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ReceiptsUnderAgreementsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow under agreements, including Royalty Purchase Agreements (RPAs), Assignment and Assumption Agreements (AAAs), and Commercial Payment Purchase Agreements (CPPAs), classified as investing activities. Receipts may represent commercial payments attributable to net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ReceiptsUnderAgreementsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RightsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty, interest and commercial payment rights receivable, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RightsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_AptevoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_AptevoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_CommercialPaymentPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_CommercialPaymentPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_MedexusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_MedexusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140070011497200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Royalty and Commercial Payment Purchase Agreements - Agenus (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 20, 2018 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities', window );">Payments of consideration under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,650<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LongTermRightsReceivableNonCurrent', window );">Long-term royalty and commercial payment receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63,683<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember', window );">Royalty Purchase Agreement | Merck Immuno-Oncology Product | Agenus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_MilestoneAchieved', window );">Amount of milestone achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_AgenusIncMember', window );">Agenus | Royalty Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities', window );">Payments of consideration under RPAs, AAAs and CPPAs</a></td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LongTermRightsReceivableNonCurrent', window );">Long-term royalty and commercial payment receivables</a></td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss', window );">Amount of allowance for credit losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_AgenusIncMember', window );">Agenus | Royalty Purchase Agreement | Incyte Immuno-Oncology Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RoyaltyReceivablePercentageOnNetSales', window );">Royalties entity has right to receive (as a percent)</a></td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased', window );">Number of licensed products related to milestone and royalties | item</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PurchasedPercentageOfMilestones', window );">Purchased percentage of milestones</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_AgenusIncMember', window );">Agenus | Royalty Purchase Agreement | Merck Immuno-Oncology Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RoyaltyReceivablePercentageOnNetSales', window );">Royalties entity has right to receive (as a percent)</a></td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PurchasedPercentageOfMilestones', window );">Purchased percentage of milestones</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones', window );">Purchased eligible milestone payments receivable upon achievement of potential development, regulatory and commercial milestones</a></td>
<td class="nump">$ 59,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_MilestoneAchieved', window );">Amount of milestone achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent', window );">Reduction in long-term royalty receivable balance due to receipt of payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss for right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LongTermRightsReceivableNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term royalty and commercial rights receivables, non current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LongTermRightsReceivableNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_MilestoneAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of milestone achieved.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_MilestoneAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of licensed products related to milestones and royalties purchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for consideration under agreements, including Royalty Purchase Agreements (RPAs), Assignment and Assumption Agreements (AAAs), and Commercial payment purchase agreement. (CPPAs) classified as investing activities. Payments may include upfront payments, one-time payments, milestone payments and contingent consideration payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchased eligible milestone payments receivable upon achievement of potential development, regulatory and commercial milestones. May also include clinical milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PurchasedPercentageOfMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchased percentage of milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PurchasedPercentageOfMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in long-term rights receivable due to receipt of royalty and commercial payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RoyaltyReceivablePercentageOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalties entity has the right to receive as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RoyaltyReceivablePercentageOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=xoma_MerckImmunoOncologyProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=xoma_MerckImmunoOncologyProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=xoma_AgenusIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=xoma_AgenusIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_AgenusIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_AgenusIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=xoma_IncyteImmunoOncologyAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=xoma_IncyteImmunoOncologyAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140070008667168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Royalty and Commercial Payment Purchase Agreements - Bioasis (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 20, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 02, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 25, 2019 </div>
<div>USD ($) </div>
<div>agreement</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities', window );">Payments of consideration under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,650<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ImpairmentOfLongTermRightsReceivableNonCurrent', window );">Royalty purchase agreement asset impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,575<span></span>
</td>
<td class="nump">1,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContingentConsiderationUnderPurchaseAgreements', window );">Contingent consideration under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ChangesInEstimatedFairValueOfContingentConsideration', window );">Changes in estimated fair value of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ReceiptsUnderAgreementsInvestingActivities', window );">Receipts under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LongTermRightsReceivableNonCurrent', window );">Long-term royalty and commercial payment receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,232<span></span>
</td>
<td class="nump">72,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,683<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_BioasisTechnologiesIncMember', window );">Bioasis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ImpairmentOfLongTermRightsReceivableNonCurrent', window );">Royalty purchase agreement asset impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_BioasisTechnologiesIncMember', window );">Bioasis | Royalty Purchase Agreement and Second Royalty Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ImpairmentOfLongTermRightsReceivableNonCurrent', window );">Royalty purchase agreement asset impairment</a></td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LongTermRightsReceivableNonCurrentIncreaseDecrease', window );">Reduction in long-term royalty receivables</a></td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss', window );">Amount of allowance for credit losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LongTermRightsReceivableNonCurrent', window );">Long-term royalty and commercial payment receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_BioasisTechnologiesIncMember', window );">Bioasis | Royalty Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements', window );">Percentage of option to purchase royalty right on future license agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_NumberOfLicenseAgreementsFutureLicenseAgreements', window );">Number of future license agreements under optional purchase right | agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PaymentsToBeMadeUponExerciseOfOptionSecondLicenseAgreement', window );">Obligation upon exercise of options per licensed product, second agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PaymentsToBeMadeUponExerciseOfOptionThirdLicenseAgreement', window );">Obligation upon exercise of options per licensed product, third agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities', window );">Payments of consideration under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContingentConsiderationUnderPurchaseAgreements', window );">Contingent consideration under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LongTermRightsReceivableNonCurrent', window );">Long-term royalty and commercial payment receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_BioasisTechnologiesIncMember', window );">Bioasis | Royalty Purchase Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContingentFutureCashPayments', window );">Potential future cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_BioasisTechnologiesIncMember', window );">Bioasis | Second Royalty Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities', window );">Payments of consideration under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LongTermRightsReceivableNonCurrent', window );">Long-term royalty and commercial payment receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss for right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ChangesInEstimatedFairValueOfContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Changes in estimated fair value of contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ChangesInEstimatedFairValueOfContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ContingentConsiderationUnderPurchaseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability recorded for contingent consideration under purchase agreements. May include royalty purchase agreements, commercial payment purchase agreements, payment interest purchase agreements and assignment and assumption agreements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ContingentConsiderationUnderPurchaseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ContingentFutureCashPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent future cash payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ContingentFutureCashPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ImpairmentOfLongTermRightsReceivableNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of royalty and commercial rights receivable recognized in the income statement during the period. Includes royalty purchase agreement asset impairment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ImpairmentOfLongTermRightsReceivableNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LongTermRightsReceivableNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term royalty and commercial rights receivables, non current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LongTermRightsReceivableNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LongTermRightsReceivableNonCurrentIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in long-term royalty and commercial rights receivables, non current during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LongTermRightsReceivableNonCurrentIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_NumberOfLicenseAgreementsFutureLicenseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of future license agreements under optional purchase right.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_NumberOfLicenseAgreementsFutureLicenseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for consideration under agreements, including Royalty Purchase Agreements (RPAs), Assignment and Assumption Agreements (AAAs), and Commercial payment purchase agreement. (CPPAs) classified as investing activities. Payments may include upfront payments, one-time payments, milestone payments and contingent consideration payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PaymentsToBeMadeUponExerciseOfOptionSecondLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum payment to be made per licensed product upon exercise of option to purchase royalty rights on second license agreement between counterparty and third-party licensees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PaymentsToBeMadeUponExerciseOfOptionSecondLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PaymentsToBeMadeUponExerciseOfOptionThirdLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum payment to be made per licensed product upon exercise of option to purchase royalty rights on third license agreement between counterparty and third-party licensees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PaymentsToBeMadeUponExerciseOfOptionThirdLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalty rights entity has option to  purchase in future license agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ReceiptsUnderAgreementsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow under agreements, including Royalty Purchase Agreements (RPAs), Assignment and Assumption Agreements (AAAs), and Commercial Payment Purchase Agreements (CPPAs), classified as investing activities. Receipts may represent commercial payments attributable to net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ReceiptsUnderAgreementsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_BioasisTechnologiesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_BioasisTechnologiesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementAndSecondRoyaltyPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementAndSecondRoyaltyPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140070009179776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Royalty and Commercial Payment Purchase Agreements - Aronora (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 07, 2019 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities', window );">Payments of consideration under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,650<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LongTermRightsReceivableNonCurrent', window );">Long-term royalty and commercial payment receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63,683<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContingentConsiderationUnderPurchaseAgreements', window );">Contingent consideration under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_AronoraIncMember', window );">Aronora | Royalty Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_AgreementDrugCandidatesNumber', window );">Number of drug candidates | item</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts', window );">Non-royalties to be received (as a percent)</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage', window );">Future non-royalty payments to be received (as a percent)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_AgreementPaymentPercentageFactor', window );">Multiplier for cumulative amount of consideration paid | item</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities', window );">Payments of consideration under RPAs, AAAs and CPPAs</a></td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount', window );">Threshold amount of cumulative royalties on net sales per product</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_MilestonesPaymentsToAggregateAmountOfPerProduct', window );">Aggregate milestones payments per product</a></td>
<td class="nump">85,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LongTermRightsReceivableNonCurrent', window );">Long-term royalty and commercial payment receivables</a></td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContingentConsiderationUnderPurchaseAgreements', window );">Contingent consideration under RPAs, AAAs and CPPAs</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss', window );">Amount of allowance for credit losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_AronoraIncMember', window );">Aronora | Royalty Purchase Agreement | SVB Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities', window );">Payments of consideration under RPAs, AAAs and CPPAs</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_AronoraIncMember', window );">Aronora | Royalty Purchase Agreement | Bayer Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_AgreementDrugCandidatesNumber', window );">Number of drug candidates | item</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_AgreementDrugCandidatesExclusiveLicenseOptionNumber', window );">Number of drug candidates subject to exclusive license option | item</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RoyaltyReceivablePercentageOnNetSales', window );">Royalties entity has right to receive (as a percent)</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts', window );">Non-royalties to be received (as a percent)</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContingentFutureCashPaymentsPerProduct', window );">Contingent future cash payment for each product</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_AronoraIncMember', window );">Aronora | Royalty Purchase Agreement | Bayer Products | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContingentFutureCashPayments', window );">Potential future cash payments</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_AronoraIncMember', window );">Aronora | Royalty Purchase Agreement | Non-Bayer Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_AgreementDrugCandidatesNumber', window );">Number of drug candidates | item</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts', window );">Non-royalties to be received (as a percent)</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss for right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_AgreementDrugCandidatesExclusiveLicenseOptionNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of drug candidates subject to exclusive license option.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_AgreementDrugCandidatesExclusiveLicenseOptionNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_AgreementDrugCandidatesNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of drug candidates under the terms of the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_AgreementDrugCandidatesNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_AgreementPaymentPercentageFactor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Multiplier used in determining change in payment percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_AgreementPaymentPercentageFactor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ContingentConsiderationUnderPurchaseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability recorded for contingent consideration under purchase agreements. May include royalty purchase agreements, commercial payment purchase agreements, payment interest purchase agreements and assignment and assumption agreements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ContingentConsiderationUnderPurchaseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ContingentFutureCashPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent future cash payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ContingentFutureCashPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ContingentFutureCashPaymentsPerProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contingent future cash payment for each product.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ContingentFutureCashPaymentsPerProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold amount of cumulative royalties on net sales per product under the terms of the agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LongTermRightsReceivableNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term royalty and commercial rights receivables, non current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LongTermRightsReceivableNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_MilestonesPaymentsToAggregateAmountOfPerProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of aggregate tiered milestone payments to be made under the terms of the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_MilestonesPaymentsToAggregateAmountOfPerProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for consideration under agreements, including Royalty Purchase Agreements (RPAs), Assignment and Assumption Agreements (AAAs), and Commercial payment purchase agreement. (CPPAs) classified as investing activities. Payments may include upfront payments, one-time payments, milestone payments and contingent consideration payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchased percentage of non-royalties on net sales of products.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future non-royalty payments to be received as a percent upon receipt of specified cumulative amount of consideration paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RoyaltyReceivablePercentageOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalties entity has the right to receive as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RoyaltyReceivablePercentageOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_AronoraIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_AronoraIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=xoma_SiliconValleyBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=xoma_SiliconValleyBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=xoma_BayerProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=xoma_BayerProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=xoma_NonBayerProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=xoma_NonBayerProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140070007283696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Royalty and Commercial Payment Purchase Agreements - Palo (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 26, 2019 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities', window );">Payments of consideration under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,650<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LongTermRightsReceivableNonCurrent', window );">Long-term royalty and commercial payment receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63,683<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_PalobiofarmaSLMember', window );">Palo | Royalty Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_AgreementDrugCandidatesNumber', window );">Number of drug candidates | item</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities', window );">Payments of consideration under RPAs, AAAs and CPPAs</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LongTermRightsReceivableNonCurrent', window );">Long-term royalty and commercial payment receivables</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss', window );">Amount of allowance for credit losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss for right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_AgreementDrugCandidatesNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of drug candidates under the terms of the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_AgreementDrugCandidatesNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LongTermRightsReceivableNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term royalty and commercial rights receivables, non current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LongTermRightsReceivableNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for consideration under agreements, including Royalty Purchase Agreements (RPAs), Assignment and Assumption Agreements (AAAs), and Commercial payment purchase agreement. (CPPAs) classified as investing activities. Payments may include upfront payments, one-time payments, milestone payments and contingent consideration payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_PalobiofarmaSLMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_PalobiofarmaSLMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140070009879136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Royalty and Commercial Payment Purchase Agreements - Viracta (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 22, 2021 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities', window );">Payments of consideration under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,650<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LongTermRightsReceivableNonCurrent', window );">Long-term royalty and commercial payment receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63,683<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_ViractaTherapeuticsInc.Member', window );">Viracta | Royalty Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_AgreementDrugCandidatesNumber', window );">Number of drug candidates | item</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities', window );">Payments of consideration under RPAs, AAAs and CPPAs</a></td>
<td class="nump">$ 13,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_MilestonesReceivableExcludingConsiderationRetainedMaximum', window );">Maximum amount of potential milestones and other payments receivable</a></td>
<td class="nump">54,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_MaximumConsiderationRetained', window );">Amount of maximum consideration retained</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RegulatoryAndCommercialMilestonesReceivableMaximum', window );">Maximum amount of potential regulatory and commercial milestones receivable</a></td>
<td class="nump">57,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LongTermRightsReceivableNonCurrent', window );">Long-term royalty and commercial payment receivables</a></td>
<td class="nump">$ 13,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss', window );">Amount of allowance for credit losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss for right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_AgreementDrugCandidatesNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of drug candidates under the terms of the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_AgreementDrugCandidatesNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LongTermRightsReceivableNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term royalty and commercial rights receivables, non current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LongTermRightsReceivableNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_MaximumConsiderationRetained">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of maximum consideration retained by Company excluded from maximum potential milestones under terms of agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_MaximumConsiderationRetained</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_MilestonesReceivableExcludingConsiderationRetainedMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of potential milestones and other payments receivable, excluding consideration retained by company under the terms of the agreement.  Excludes regulatory and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_MilestonesReceivableExcludingConsiderationRetainedMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for consideration under agreements, including Royalty Purchase Agreements (RPAs), Assignment and Assumption Agreements (AAAs), and Commercial payment purchase agreement. (CPPAs) classified as investing activities. Payments may include upfront payments, one-time payments, milestone payments and contingent consideration payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RegulatoryAndCommercialMilestonesReceivableMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of potential regulatory and commercial milestones receivable under the terms of the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RegulatoryAndCommercialMilestonesReceivableMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_ViractaTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_ViractaTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140070009731792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Royalty and Commercial Payment Purchase Agreements - Kuros (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 14, 2021</div></th>
<th class="th"><div>Jul. 31, 2022</div></th>
<th class="th"><div>May 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities', window );">Payments of consideration under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,650<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ReceiptsUnderAgreementsInvestingActivities', window );">Receipts under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LongTermRightsReceivableNonCurrent', window );">Long-term royalty and commercial payment receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63,683<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RightsReceivableCurrent', window );">Short-term royalty and commercial payment receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,366<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember', window );">Kuros | Royalty Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RoyaltyReceivablePercentageOnNetSales', window );">Royalties entity has right to receive (as a percent)</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_EligibleMilestonePaymentsReceivableUponAchievementOfPreCommercialMilestones', window );">Pre-commercial milestone payments, maximum</a></td>
<td class="nump">$ 25,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities', window );">Payments of consideration under RPAs, AAAs and CPPAs</a></td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_MaximumPayableOnSalesMilestone', window );">Maximum payable on commercial sales milestone</a></td>
<td class="nump">142,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LongTermRightsReceivableNonCurrent', window );">Long-term royalty and commercial payment receivables</a></td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_MilestonePaymentReceivedCounterparty', window );">Milestone payment received by Kuros</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_MilestonePaymentReceivablePercentage', window );">Percentage of milestone payment received by Kuros that company is entitled to receive</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent', window );">Reduction in long-term royalty receivable balance due to receipt of payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss', window );">Amount of allowance for credit losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss for right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_EligibleMilestonePaymentsReceivableUponAchievementOfPreCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum eligible milestone payments receivable upon achievement of development, pre-commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_EligibleMilestonePaymentsReceivableUponAchievementOfPreCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LongTermRightsReceivableNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term royalty and commercial rights receivables, non current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LongTermRightsReceivableNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_MaximumPayableOnSalesMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount payable on sales milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_MaximumPayableOnSalesMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_MilestonePaymentReceivablePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of milestone payment received by counterparty entity is entitled to receive.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_MilestonePaymentReceivablePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_MilestonePaymentReceivedCounterparty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of milestone payment received by counterparty associated with existing license agreement related to acquired entity during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_MilestonePaymentReceivedCounterparty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for consideration under agreements, including Royalty Purchase Agreements (RPAs), Assignment and Assumption Agreements (AAAs), and Commercial payment purchase agreement. (CPPAs) classified as investing activities. Payments may include upfront payments, one-time payments, milestone payments and contingent consideration payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in long-term rights receivable due to receipt of royalty and commercial payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ReceiptsUnderAgreementsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow under agreements, including Royalty Purchase Agreements (RPAs), Assignment and Assumption Agreements (AAAs), and Commercial Payment Purchase Agreements (CPPAs), classified as investing activities. Receipts may represent commercial payments attributable to net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ReceiptsUnderAgreementsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RightsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty, interest and commercial payment rights receivable, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RightsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RoyaltyReceivablePercentageOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalties entity has the right to receive as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RoyaltyReceivablePercentageOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140070008834624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Royalty and Commercial Payment Purchase Agreements - Affitech (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 06, 2021</div></th>
<th class="th"><div>Aug. 31, 2023</div></th>
<th class="th"><div>Feb. 28, 2023</div></th>
<th class="th"><div>Aug. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jan. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities', window );">Payments of consideration under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,650<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LongTermRightsReceivableNonCurrent', window );">Long-term royalty and commercial payment receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63,683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContingentConsiderationUnderPurchaseAgreements', window );">Contingent consideration under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ReceiptsUnderAgreementsInvestingActivities', window );">Receipts under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RightsReceivableCurrent', window );">Short-term royalty and commercial payment receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_AffitechResearchAsMember', window );">Affitech | Commercial Payment Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities', window );">Payments of consideration under RPAs, AAAs and CPPAs</a></td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndSalesMilestones', window );">Maximum payments based on achievement of regulatory and commercial sales milestones</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LongTermRightsReceivableNonCurrent', window );">Long-term royalty and commercial payment receivables</a></td>
<td class="nump">14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_MaximumPayableOnRegulatoryMilestone', window );">Maximum payable on regulatory milestone</a></td>
<td class="nump">8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_MaximumPayableOnSalesMilestone', window );">Maximum payable on commercial sales milestone</a></td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ReceiptsUnderAgreementsInvestingActivities', window );">Receipts under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent', window );">Reduction in long-term royalty receivable balance due to receipt of payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss', window );">Amount of allowance for credit losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_AffitechResearchAsMember', window );">Affitech | Commercial Payment Purchase Agreement | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities', window );">Payments of consideration under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_AffitechResearchAsMember', window );">Affitech | Commercial Payment Purchase Agreement | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities', window );">Payments of consideration under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_AffitechResearchAsMember', window );">Affitech | Commercial Payment Purchase Agreement | Faricimab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_CommercialSalesReceivablePercentageOnNetSales', window );">Payments eligible to receive (as a percent)</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_CommercialPaymentReceivableTerm', window );">Commercial payment receivable term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_AffitechResearchAsMember', window );">Affitech | Commercial Payment Purchase Agreement | VABYSMO | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ReceiptsUnderAgreementsInvestingActivities', window );">Receipts under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_AffitechResearchAsMember', window );">Affitech | Commercial Payment Purchase Agreement | Regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContingentConsiderationUnderPurchaseAgreements', window );">Contingent consideration under RPAs, AAAs and CPPAs</a></td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss for right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_CommercialPaymentReceivableTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of commercial payment receivable,  in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_CommercialPaymentReceivableTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_CommercialSalesReceivablePercentageOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments entity eligible to receive as a percentage of net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_CommercialSalesReceivablePercentageOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ContingentConsiderationUnderPurchaseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability recorded for contingent consideration under purchase agreements. May include royalty purchase agreements, commercial payment purchase agreements, payment interest purchase agreements and assignment and assumption agreements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ContingentConsiderationUnderPurchaseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LongTermRightsReceivableNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term royalty and commercial rights receivables, non current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LongTermRightsReceivableNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_MaximumPayableOnRegulatoryMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount payable on regulatory milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_MaximumPayableOnRegulatoryMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_MaximumPayableOnSalesMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount payable on sales milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_MaximumPayableOnSalesMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndSalesMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum  payments to be made based upon achievement of sales and/or regulatory milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndSalesMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for consideration under agreements, including Royalty Purchase Agreements (RPAs), Assignment and Assumption Agreements (AAAs), and Commercial payment purchase agreement. (CPPAs) classified as investing activities. Payments may include upfront payments, one-time payments, milestone payments and contingent consideration payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in long-term rights receivable due to receipt of royalty and commercial payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ReceiptsUnderAgreementsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow under agreements, including Royalty Purchase Agreements (RPAs), Assignment and Assumption Agreements (AAAs), and Commercial Payment Purchase Agreements (CPPAs), classified as investing activities. Receipts may represent commercial payments attributable to net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ReceiptsUnderAgreementsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RightsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty, interest and commercial payment rights receivable, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RightsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_AffitechResearchAsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_AffitechResearchAsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_CommercialPaymentPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_CommercialPaymentPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=xoma_FaricimabProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=xoma_FaricimabProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=xoma_FaricimabSvoaVabysmoProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=xoma_FaricimabSvoaVabysmoProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=xoma_ContingentConsiderationRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=xoma_ContingentConsiderationRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140070009744704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Royalty and Commercial Payment Purchase Agreements - Summary of Royalty Receivable Activities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RightsReceivableCurrent', window );">Short-term royalty receivable, Balance at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,366<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RightsReceivableCurrent', window );">Short-term royalty receivable, Balance at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,958<span></span>
</td>
<td class="nump">4,958<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LongTermRightsReceivableNonCurrent', window );">Long-term royalty receivable, Balance at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,683<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ImpairmentOfLongTermRightsReceivableNonCurrent', window );">Impairment of royalty and commercial payment rights, Long-Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,575)<span></span>
</td>
<td class="num">(1,575)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LongTermRightsReceivableNonCurrent', window );">Long-term royalty receivable, Balance at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 72,232<span></span>
</td>
<td class="nump">72,232<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_AffitechResearchAsMember', window );">Affitech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableCurrent', window );">Receipt of royalty and commercial payments, Short-Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,366)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ShortTermRightsReceivableReclassification', window );">Reclassification to short-term royalty and commercial payment receivables, Short-Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,958<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LongTermRightsReceivableReclassification', window );">Reclassification to short-term royalty and commercial payment receivables, Long-Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,958)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_AptevoMember', window );">Aptevo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent', window );">Acquisition of royalty and commercial payment rights, Long-Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent', window );">Receipt of royalty and commercial payments, Long-Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(568)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_LadrxMember', window );">LadRx</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent', window );">Acquisition of royalty and commercial payment rights, Long-Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_BioasisTechnologiesIncMember', window );">Bioasis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ImpairmentOfLongTermRightsReceivableNonCurrent', window );">Impairment of royalty and commercial payment rights, Long-Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,575)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember', window );">Royalty Purchase Agreement | Kuros</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent', window );">Receipt of royalty and commercial payments, Long-Term</a></td>
<td class="num">$ (2,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ImpairmentOfLongTermRightsReceivableNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of royalty and commercial rights receivable recognized in the income statement during the period. Includes royalty purchase agreement asset impairment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ImpairmentOfLongTermRightsReceivableNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LongTermRightsReceivableNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term royalty and commercial rights receivables, non current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LongTermRightsReceivableNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LongTermRightsReceivableReclassification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in long term rights receivable due to reclassification from/to short-term rights receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LongTermRightsReceivableReclassification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in short-term rights receivable due to receipt of current portion of royalty and commercial payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in long-term rights receivable due to receipt of royalty and commercial payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RightsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty, interest and commercial payment rights receivable, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RightsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty, interest and commercial payment rights acquired, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ShortTermRightsReceivableReclassification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in short term rights receivable due to reclassification from/to long-term rights receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ShortTermRightsReceivableReclassification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_AffitechResearchAsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_AffitechResearchAsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_AptevoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_AptevoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_LadrxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_LadrxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_BioasisTechnologiesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_BioasisTechnologiesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140070105610016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Financial Assets and Liabilities Carried at Fair Value on Recurring Basis (Details) - Fair Value, Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 30,102<span></span>
</td>
<td class="nump">$ 30,334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Equity securities</a></td>
<td class="nump">320<span></span>
</td>
<td class="nump">335<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_FinancialAssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">30,422<span></span>
</td>
<td class="nump">30,669<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContingentConsiderationFairValueDisclosure', window );">Contingent consideration under RPAs and CPPAs</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">30,102<span></span>
</td>
<td class="nump">30,334<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">30,102<span></span>
</td>
<td class="nump">30,334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Equity securities</a></td>
<td class="nump">320<span></span>
</td>
<td class="nump">335<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_FinancialAssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">30,422<span></span>
</td>
<td class="nump">30,669<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Quoted Prices in Active Markets for Identical Assets (Level 1) | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">30,102<span></span>
</td>
<td class="nump">30,334<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContingentConsiderationFairValueDisclosure', window );">Contingent consideration under RPAs and CPPAs</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ContingentConsiderationFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent consideration, fair value disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ContingentConsiderationFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_FinancialAssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_FinancialAssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140070015866496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Equity Securities (Details)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Closing Common Stock Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiMeasurementInput', window );">Valuation assumptions, measurement input</a></td>
<td class="nump">1.98<span></span>
</td>
<td class="nump">2.07<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140070009152208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Contingent Consideration (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 21, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Feb. 25, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ChangesInEstimatedFairValueOfContingentConsideration', window );">Changes in estimated fair value of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContingentConsiderationUnderPurchaseAgreements', window );">Contingent consideration under RPAs, AAAs and CPPAs</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_BioasisTechnologiesIncMember', window );">Bioasis | Royalty Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContingentConsiderationUnderPurchaseAgreements', window );">Contingent consideration under RPAs, AAAs and CPPAs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_LadrxMember', window );">LadRx</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ChangesInEstimatedFairValueOfContingentConsideration', window );">Changes in estimated fair value of contingent consideration</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContingentConsiderationUnderPurchaseAgreements', window );">Contingent consideration under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_LadrxMember', window );">LadRx | Royalty Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ChangesInEstimatedFairValueOfContingentConsideration', window );">Changes in estimated fair value of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContingentConsiderationUnderPurchaseAgreements', window );">Contingent consideration under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ChangesInEstimatedFairValueOfContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Changes in estimated fair value of contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ChangesInEstimatedFairValueOfContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ContingentConsiderationUnderPurchaseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability recorded for contingent consideration under purchase agreements. May include royalty purchase agreements, commercial payment purchase agreements, payment interest purchase agreements and assignment and assumption agreements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ContingentConsiderationUnderPurchaseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_BioasisTechnologiesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_BioasisTechnologiesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_LadrxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_LadrxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140070007214352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Agreements - Leased facilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>facility</div>
</th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=xoma_LeasedFacilitiesEmeryvilleCaliforniaMember', window );">Leased facilities, Emeryville, California, current location</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_OperatingLeasesNumberOfLeasedFacilities', window );">Operating leases, number of leased facilities | facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Period of lease extension</a></td>
<td class="text">5 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_LesseeOperatingLeaseModificationAdjustmentToRightOfUseAsset', window );">Adjustment to right of use asset for lease modification</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=xoma_LeasedFacilitiesTwoEmeryvilleCaliforniaMember', window );">Leased facilities, Emeryville, California, future location | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">65 months<span></span>
</td>
<td class="text">65 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_LesseeOperatingLeaseModificationAdjustmentToRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of adjustment to right of use asset resulting from modification of operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_LesseeOperatingLeaseModificationAdjustmentToRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_OperatingLeasesNumberOfLeasedFacilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating leases, number of leased facilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_OperatingLeasesNumberOfLeasedFacilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=xoma_LeasedFacilitiesEmeryvilleCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=xoma_LeasedFacilitiesEmeryvilleCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=xoma_LeasedFacilitiesTwoEmeryvilleCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=xoma_LeasedFacilitiesTwoEmeryvilleCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140070003130640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Agreements - Lease costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease costs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 51<span></span>
</td>
<td class="nump">$ 44<span></span>
</td>
<td class="nump">$ 99<span></span>
</td>
<td class="nump">$ 88<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease costs</a></td>
<td class="nump">$ 58<span></span>
</td>
<td class="nump">$ 46<span></span>
</td>
<td class="nump">$ 111<span></span>
</td>
<td class="nump">$ 93<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140070011401904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Agreements - Additional information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Lease Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of lease liabilities, Operating cash flows under operating leases</a></td>
<td class="nump">$ 104<span></span>
</td>
<td class="nump">$ 101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term, Operating leases</a></td>
<td class="text">29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 months 1 day<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate, Operating leases</a></td>
<td class="nump">5.51%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.51%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140070012772288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Common Stock Warrants (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrant outstanding (in shares)</a></td>
<td class="nump">11,177<span></span>
</td>
<td class="nump">11,177<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xoma_TenYearWarrantsIssuedThirdRangeMember', window );">Ten Year Warrants Issued in May 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="nump">$ 23.69<span></span>
</td>
<td class="nump">$ 23.69<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrant outstanding (in shares)</a></td>
<td class="nump">6,332<span></span>
</td>
<td class="nump">6,332<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=xoma_CommonStockWarrantExercisePrice14.71Member', window );">Common stock warrant, Exercise price $14.71 per share, Issued March 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="nump">$ 14.71<span></span>
</td>
<td class="nump">$ 14.71<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrant outstanding (in shares)</a></td>
<td class="nump">4,845<span></span>
</td>
<td class="nump">4,845<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=xoma_TenYearWarrantsIssuedThirdRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=xoma_TenYearWarrantsIssuedThirdRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=xoma_CommonStockWarrantExercisePrice14.71Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=xoma_CommonStockWarrantExercisePrice14.71Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140070014280608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Collaborative Agreements, Royalties and Milestone Payments (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>product</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContractualObligationEstimatedMilestonePayments', window );">Estimate of milestone payments | $</a></td>
<td class="nump">$ 6.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContractualObligationEstimatedMilestonePaymentsNumberOfProducts', window );">Assumed number of products per contract | product</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ContractualObligationEstimatedMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated potential obligations that come due and payable upon achievement of developmental, regulatory, or commercial milestones by company's licensees.  Represent contingent payments not recorded on balance sheet.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ContractualObligationEstimatedMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ContractualObligationEstimatedMilestonePaymentsNumberOfProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assumed number of products per contract meeting milestone events used to calculate potential milestone obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ContractualObligationEstimatedMilestonePaymentsNumberOfProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140070003537648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Contingent Consideration (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 21, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 29, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Feb. 25, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContingentConsiderationUnderPurchaseAgreements', window );">Contingent consideration under RPAs, AAAs and CPPAs</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ReceiptsUnderAgreementsInvestingActivities', window );">Receipts under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ChangesInEstimatedFairValueOfContingentConsideration', window );">Changes in estimated fair value of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_LadrxMember', window );">LadRx</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContingentConsiderationUnderPurchaseAgreements', window );">Contingent consideration under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ChangesInEstimatedFairValueOfContingentConsideration', window );">Changes in estimated fair value of contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=xoma_AronoraKurosAffitechObsevaAndMerckKgaaMember', window );">Aronora, Kuros, Affitech, ObsEva, and Merck KGaA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContingentConsiderationUnderPurchaseAgreements', window );">Contingent consideration under RPAs, AAAs and CPPAs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember', window );">Royalty Purchase Agreement | LadRx</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContingentConsiderationUnderPurchaseAgreements', window );">Contingent consideration under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ChangesInEstimatedFairValueOfContingentConsideration', window );">Changes in estimated fair value of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember', window );">Royalty Purchase Agreement | Bioasis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContingentConsiderationUnderPurchaseAgreements', window );">Contingent consideration under RPAs, AAAs and CPPAs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=xoma_CommercialPaymentPurchaseAgreementMember', window );">Commercial Payment Purchase Agreement | Aptevo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ContingentConsiderationUnderPurchaseAgreements', window );">Contingent consideration under RPAs, AAAs and CPPAs</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PaymentOfContingentConsiderationUnderPurchaseAgreements', window );">Payment for contingent consideration under CPPA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=xoma_CommercialPaymentPurchaseAgreementMember', window );">Commercial Payment Purchase Agreement | Aptevo | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ReceiptsUnderAgreementsInvestingActivities', window );">Receipts under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=xoma_CommercialPaymentPurchaseAgreementMember', window );">Commercial Payment Purchase Agreement | Medexus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ReceiptsUnderAgreementsInvestingActivities', window );">Receipts under RPAs, AAAs and CPPAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ChangesInEstimatedFairValueOfContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Changes in estimated fair value of contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ChangesInEstimatedFairValueOfContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ContingentConsiderationUnderPurchaseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability recorded for contingent consideration under purchase agreements. May include royalty purchase agreements, commercial payment purchase agreements, payment interest purchase agreements and assignment and assumption agreements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ContingentConsiderationUnderPurchaseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PaymentOfContingentConsiderationUnderPurchaseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash outflow for contingent consideration liability recorded under the purchase agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PaymentOfContingentConsiderationUnderPurchaseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ReceiptsUnderAgreementsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow under agreements, including Royalty Purchase Agreements (RPAs), Assignment and Assumption Agreements (AAAs), and Commercial Payment Purchase Agreements (CPPAs), classified as investing activities. Receipts may represent commercial payments attributable to net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ReceiptsUnderAgreementsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_LadrxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_LadrxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_AronoraKurosAffitechObsevaAndMerckKgaaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_AronoraKurosAffitechObsevaAndMerckKgaaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_RoyaltyPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_BioasisTechnologiesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_BioasisTechnologiesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=xoma_CommercialPaymentPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=xoma_CommercialPaymentPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_AptevoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_AptevoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=xoma_MedexusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=xoma_MedexusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140070014163312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation - ESPP (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember', window );">2015 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PercentageOfCompensationOfEligibleEmployeesToPurchaseSharesOfEntityCommonStockAtDiscountThroughPayrollDeductions', window );">Percentage of compensation of eligible employees to purchase shares of entity common stock at discount through payroll deductions</a></td>
<td class="nump">85.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PercentageOfCompensationOfEligibleEmployeesToPurchaseSharesOfEntityCommonStockAtDiscountThroughPayrollDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Refers the percentage of compensation deduction in eligible employees salary to purchase entity common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PercentageOfCompensationOfEligibleEmployeesToPurchaseSharesOfEntityCommonStockAtDiscountThroughPayrollDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140070008254960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation - 2010 Plan and Inducement Awards (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jan. 03, 2023 </div>
<div>installment </div>
<div>item </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares, Granted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">796,802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember', window );">2010 Plan | Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward', window );">Minimum age required for employees to qualify for immediate vesting of award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">55 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge', window );">Threshold years required for retirement age</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">70 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember', window );">2010 Plan | Stock Options | Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember', window );">2010 Plan | Stock Options | Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=xoma_StockOptionInducementAwardsMember', window );">Stock Option Inducement Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price (in dollars per share)</a></td>
<td class="nump">$ 18.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=xoma_StockOptionInducementAwardsMember', window );">Stock Option Inducement Awards | Executive Chairman of the Board and Interim CEO, Owen Hughes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ShareBasedPaymentArrangementNumberOfAwardsGrants', window );">Number of award grants | item</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=xoma_StockOptionInducementAwardsMember', window );">Stock Option Inducement Awards | Chief Investment Officer, Bradley Sitko</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ShareBasedPaymentArrangementNumberOfAwardsGrants', window );">Number of award grants | item</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=xoma_StockOptionInducementAwardsMember', window );">Stock Option Inducement Awards | Chief Investment Officer, Bradley Sitko | Share-Based Payment Arrangement, Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting (as a percent)</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=xoma_StockOptionInducementAwardsMember', window );">Stock Option Inducement Awards | Chief Investment Officer, Bradley Sitko | Share-Based Payment Arrangement, Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments', window );">Number of successive equal monthly vesting installments | installment</a></td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=xoma_StockOptionInducementAwardOneMember', window );">Stock Option Inducement Award, Exercise price of $18.66 per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares, Granted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=xoma_StockOptionInducementAwardOneMember', window );">Stock Option Inducement Award, Exercise price of $18.66 per share | Executive Chairman of the Board and Interim CEO, Owen Hughes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares, Granted | shares</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 18.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments', window );">Number of equal quarterly vesting installments | installment</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=xoma_StockOptionInducementAwardOneMember', window );">Stock Option Inducement Award, Exercise price of $18.66 per share | Chief Investment Officer, Bradley Sitko</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares, Granted | shares</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 18.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=xoma_StockOptionInducementAwardTwoMember', window );">Stock Option Inducement Award, Exercise price of $30.00 per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares, Granted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=xoma_StockOptionInducementAwardTwoMember', window );">Stock Option Inducement Award, Exercise price of $30.00 per share | Executive Chairman of the Board and Interim CEO, Owen Hughes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares, Granted | shares</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 30.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments', window );">Number of successive equal monthly vesting installments | installment</a></td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=xoma_StockOptionInducementAwardTwoMember', window );">Stock Option Inducement Award, Exercise price of $30.00 per share | Chief Investment Officer, Bradley Sitko</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares, Granted | shares</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 30.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum age required for employees to qualify for immediate vesting of award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold years required for retirement age (defined as employees that are a minimum of 55 years of age and the sum of their age plus years of full-time employment with the Company).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of successive equal monthly installments  from grant date on which share-based compensation awards vest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of equal quarterly installments  from grant date on which share-based compensation awards vest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ShareBasedPaymentArrangementNumberOfAwardsGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of award grants under share-based payment arrangement with differentiated features, such as vesting and exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ShareBasedPaymentArrangementNumberOfAwardsGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=xoma_EmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=xoma_EmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=xoma_StockOptionInducementAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=xoma_StockOptionInducementAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=xoma_ChiefExecutiveOfficerInterimMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=xoma_ChiefExecutiveOfficerInterimMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=xoma_ChiefInvestmentOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=xoma_ChiefInvestmentOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=xoma_StockOptionInducementAwardOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=xoma_StockOptionInducementAwardOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=xoma_StockOptionInducementAwardTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=xoma_StockOptionInducementAwardTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140070011576752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation - FV Assumptions (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted average assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">796,802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember', window );">2010 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted average assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.46<span></span>
</td>
<td class="nump">$ 12.21<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=xoma_StockOptionInducementAwardOneMember', window );">Stock Option Inducement Award, Exercise price of $18.66 per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted average assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares, Granted</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=xoma_StockOptionInducementAwardTwoMember', window );">Stock Option Inducement Award, Exercise price of $30.00 per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted average assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares, Granted</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | 2010 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted average assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69.00%<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="nump">3.60%<span></span>
</td>
<td class="nump">2.17%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years 9 months 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 7 months 9 days<span></span>
</td>
<td class="text">5 years 9 months 14 days<span></span>
</td>
<td class="text">5 years 7 months 24 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | Stock Option Inducement Award, Exercise price of $18.66 per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted average assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.92%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 9 months 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options | Stock Option Inducement Award, Exercise price of $30.00 per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted average assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.86%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=xoma_StockOptionInducementAwardOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=xoma_StockOptionInducementAwardOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=xoma_StockOptionInducementAwardTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=xoma_StockOptionInducementAwardTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140070013481184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation - Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, Outstanding at beginning of period</a></td>
<td class="nump">2,025,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares, Granted</a></td>
<td class="nump">796,802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of shares, Exercised</a></td>
<td class="num">(8,473)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Number of shares, Forfeited, expired or cancelled</a></td>
<td class="num">(71,123)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, Outstanding at end of period</a></td>
<td class="nump">2,742,748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,025,542<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of shares, Exercisable at end of period</a></td>
<td class="nump">1,815,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Outstanding at beginning of period</a></td>
<td class="nump">$ 20.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Granted</a></td>
<td class="nump">23.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Exercised</a></td>
<td class="nump">18.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Forfeited, expired or cancelled</a></td>
<td class="nump">36.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Outstanding at end of period</a></td>
<td class="nump">20.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Exercisable at end of period</a></td>
<td class="nump">$ 19.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Contractual Remaining Term, Outstanding</a></td>
<td class="text">6 years 9 months 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Contractual Remaining Term, Exercisable</a></td>
<td class="text">5 years 5 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding</a></td>
<td class="nump">$ 11,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,804<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="nump">11,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Options exercised, aggregate intrinsic value</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense related to stock options (in dollars)</a></td>
<td class="nump">$ 11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period over which unrecognized compensation expense is expected to be recognized</a></td>
<td class="text">2 years 8 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140070007285328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation - Performance Stock Unit Awards (Details) - Performance Stock Unit Awards<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>May 31, 2023 </div>
<div>D </div>
<div>item </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Performance Stock Unit Awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">430,400<span></span>
</td>
<td class="nump">430,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfHurdles.', window );">Number of hurdles | item</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfCalendarDays', window );">Number of consecutive calendar days used to calculate volume-weighted average stock price | D</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=xoma_PerformanceStockUnitsMember', window );">Share-Based Payment Arrangement, Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Performance Stock Unit Awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting (as a percent)</a></td>
<td class="nump">33.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=xoma_PerformanceStockUnitsMember', window );">Share-Based Payment Arrangement, Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Performance Stock Unit Awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting (as a percent)</a></td>
<td class="nump">33.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=xoma_PerformanceStockUnitsMember', window );">Share-Based Payment Arrangement, Tranche Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Performance Stock Unit Awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting (as a percent)</a></td>
<td class="nump">33.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=xoma_PerformanceStockUnitsMember', window );">2010 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Performance Stock Unit Awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">430,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfCalendarDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of consecutive calendar days used to calculate volume-weighted average stock price in determining if stock price hurdle has been attained in a share based compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfCalendarDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfHurdles.">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of stock price hurdles in a share based compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfHurdles.</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=xoma_PerformanceStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=xoma_PerformanceStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140070008456496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation - Performance Stock Unit Awards Fair Value (Details) - Performance Stock Unit Awards - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of PSUs (in shares)</a></td>
<td class="nump">430,400<span></span>
</td>
<td class="nump">430,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Stock-based compensation expense, not yet recognized</a></td>
<td class="nump">$ 6.7<span></span>
</td>
<td class="nump">$ 6.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=xoma_PerformanceStockUnitsMember', window );">Hurdle Price Per PSU - $30.00</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Hurdle Price Per PSU (in dollars per share)</a></td>
<td class="nump">$ 30.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of PSUs (in shares)</a></td>
<td class="nump">232,956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=xoma_PerformanceStockUnitsMember', window );">Hurdle Price Per PSU - $30.00 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair Value Per Share (in dollars per share)</a></td>
<td class="nump">$ 16.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Derived Service Period</a></td>
<td class="text">8 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=xoma_PerformanceStockUnitsMember', window );">Hurdle Price Per PSU - $30.00 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair Value Per Share (in dollars per share)</a></td>
<td class="nump">$ 17.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Derived Service Period</a></td>
<td class="text">9 months 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=xoma_PerformanceStockUnitsMember', window );">Hurdle Price Per PSU - $35.00</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Hurdle Price Per PSU (in dollars per share)</a></td>
<td class="nump">$ 35.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of PSUs (in shares)</a></td>
<td class="nump">87,708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=xoma_PerformanceStockUnitsMember', window );">Hurdle Price Per PSU - $35.00 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair Value Per Share (in dollars per share)</a></td>
<td class="nump">$ 15.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Derived Service Period</a></td>
<td class="text">11 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=xoma_PerformanceStockUnitsMember', window );">Hurdle Price Per PSU - $35.00 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair Value Per Share (in dollars per share)</a></td>
<td class="nump">$ 16.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Derived Service Period</a></td>
<td class="text">11 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=xoma_PerformanceStockUnitsMember', window );">Hurdle Price Per PSU - $40.00</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Hurdle Price Per PSU (in dollars per share)</a></td>
<td class="nump">$ 40.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of PSUs (in shares)</a></td>
<td class="nump">57,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=xoma_PerformanceStockUnitsMember', window );">Hurdle Price Per PSU - $40.00 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair Value Per Share (in dollars per share)</a></td>
<td class="nump">$ 13.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Derived Service Period</a></td>
<td class="text">1 year 1 month 13 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=xoma_PerformanceStockUnitsMember', window );">Hurdle Price Per PSU - $40.00 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair Value Per Share (in dollars per share)</a></td>
<td class="nump">$ 14.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Derived Service Period</a></td>
<td class="text">1 year 2 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=xoma_PerformanceStockUnitsMember', window );">Hurdle Price Per PSU - $45.00</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Hurdle Price Per PSU (in dollars per share)</a></td>
<td class="nump">$ 45.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of PSUs (in shares)</a></td>
<td class="nump">51,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=xoma_PerformanceStockUnitsMember', window );">Hurdle Price Per PSU - $45.00 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair Value Per Share (in dollars per share)</a></td>
<td class="nump">$ 12.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Derived Service Period</a></td>
<td class="text">1 year 3 months 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=xoma_PerformanceStockUnitsMember', window );">Hurdle Price Per PSU - $45.00 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair Value Per Share (in dollars per share)</a></td>
<td class="nump">$ 13.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Derived Service Period</a></td>
<td class="text">1 year 3 months 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=xoma_PerformanceStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=xoma_PerformanceStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=xoma_StockPriceHurdlesOfDollar30Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=xoma_StockPriceHurdlesOfDollar30Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=xoma_StockPriceHurdlesOfDollar35Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=xoma_StockPriceHurdlesOfDollar35Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=xoma_StockPriceHurdlesOfDollar40Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=xoma_StockPriceHurdlesOfDollar40Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=xoma_StockPriceHurdlesOfDollar45Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=xoma_StockPriceHurdlesOfDollar45Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140070012768064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation - Performance Stock Unit Awards Activity (Details) - Performance Stock Unit Awards - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Unvested PSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">430,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">430,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares, Outstanding at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">430,400<span></span>
</td>
<td class="nump">430,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract', window );"><strong>Weighted Average Grant Date Fair Value Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.61<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Balance (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.61<span></span>
</td>
<td class="nump">$ 15.61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract', window );"><strong>Weighted Average Exercise Price Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Stock-based compensation expense, not yet recognized</a></td>
<td class="nump">$ 6.7<span></span>
</td>
<td class="nump">$ 6.2<span></span>
</td>
<td class="nump">$ 6.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period over which unrecognized compensation expense is expected to be recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 10 months 6 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=xoma_PerformanceStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=xoma_PerformanceStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140070007174336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation - Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 2,163<span></span>
</td>
<td class="nump">$ 837<span></span>
</td>
<td class="nump">$ 3,733<span></span>
</td>
<td class="nump">$ 1,815<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140070009345168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation - Employee Retention Bonus (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 01, 2022 </div>
<div>period</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems', window );"><strong>Employee Retention Bonus</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_AccruedRetentionBonus', window );">Accrued retention bonus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember', window );">Current employees, excluding Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems', window );"><strong>Employee Retention Bonus</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_NumberOfPeriodsCashRetentionBonus', window );">Number of periods in which employees will be eligible to receive cash retention bonus | period</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PeriodOneRetentionBonusEligibility', window );">Initial period for which employees will be eligible for retention bonus</a></td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PeriodTwoRetentionBonusEligibility', window );">Period following initial period for which employees will be eligible for retention bonus</a></td>
<td class="text">9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid', window );">Amount of retention bonus paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RetentionBonusExpenseAccrued', window );">Amount of retention bonus expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember', window );">Current employees, excluding Chief Executive Officer | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems', window );"><strong>Employee Retention Bonus</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid', window );">Amount of retention bonus paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_RetentionBonusExpenseAccrued', window );">Amount of retention bonus expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of distribution made to individual in accordance with deferred compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_AccruedRetentionBonus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued expense for cash retention bonus.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_AccruedRetentionBonus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_NumberOfPeriodsCashRetentionBonus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of periods in which individuals will be eligible to receive cash retention bonus under terms of amended retention plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_NumberOfPeriodsCashRetentionBonus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PeriodOneRetentionBonusEligibility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial period for which individuals will be eligible for retention bonus if employed through the period under terms of amended retention plan, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PeriodOneRetentionBonusEligibility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PeriodTwoRetentionBonusEligibility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period following initial period for which individuals will be eligible for retention bonus if employed through the period under terms of amended retention plan, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PeriodTwoRetentionBonusEligibility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_RetentionBonusExpenseAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recorded as expense during the period for cash retention bonuses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_RetentionBonusExpenseAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140070015861792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation - CEO Departure and Continuity Incentive (Details) - Chief Executive Officer, Retired, James R. Neal - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems', window );"><strong>Departure and Continuity Incentive</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_AccruedCompensationContinuityIncentive', window );">Accrued cash payment related to Continuity Incentive under Employment Agreement</a></td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_CompensationExpenseEmploymentAgreement', window );">Compensation expense related to Continuity Incentive under Employment Agreement</a></td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_AccruedCompensationContinuityIncentive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued expense for compensation under employment agreement related to retirement of individual.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_AccruedCompensationContinuityIncentive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_CompensationExpenseEmploymentAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for compensation under employment agreement related to retirement of individual.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_CompensationExpenseEmploymentAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=xoma_ChiefExecutiveOfficerRetiredMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=xoma_ChiefExecutiveOfficerRetiredMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140070009433456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Capital Stock - Dividends (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Jul. 17, 2023</div></th>
<th class="th"><div>May 17, 2023</div></th>
<th class="th"><div>Apr. 17, 2023</div></th>
<th class="th"><div>Feb. 22, 2023</div></th>
<th class="th"><div>Jan. 17, 2023</div></th>
<th class="th"><div>Oct. 26, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">8.625% Series A Cumulative, Perpetual Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableLineItems', window );"><strong>Dividends</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsPerShareDeclared', window );">Cash dividend declared (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.53906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.53906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.53906<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsPerShareCashPaid', window );">Cash dividend paid (in dollars per share)</a></td>
<td class="nump">$ 0.53906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.53906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.53906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">8.375% Series B Cumulative, Perpetual Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableLineItems', window );"><strong>Dividends</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsPerShareDeclared', window );">Cash dividend declared (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.52344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.52344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.52344<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsPerShareCashPaid', window );">Cash dividend paid (in dollars per share)</a></td>
<td class="nump">$ 0.52344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.52344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.52344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsPerShareCashPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends paid during the period for each share of preferred stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsPerShareCashPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of preferred stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140070011604608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Capital Stock - BVF Ownership (Details) - BVF - Xoma Corporation - Common Stock<br></strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership interest (as a percent)</a></td>
<td class="nump">31.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted', window );">Ownership interest, if shares are converted (as a percent)</a></td>
<td class="nump">52.40%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage, if shares are converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=xoma_BiotechnologyValueFundLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=xoma_BiotechnologyValueFundLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=xoma_XomaCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=xoma_XomaCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140070003406896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Stock - ATM Agreements (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">20 Months Ended</th>
<th class="th" colspan="1">51 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 05, 2021</div></th>
<th class="th"><div>Mar. 10, 2021</div></th>
<th class="th"><div>Dec. 18, 2018</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=xoma_TwoThousandEighteenAtMarketAgreementMember', window );">2018 Common Stock ATM Agreement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_MaximumValueOfStockToBeIssued', window );">Maximum amount of shares to be issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="nump">$ 30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=xoma_TwoThousandEighteenAtMarketAgreementMember', window );">2018 Common Stock ATM Agreement | Common Stock | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares', window );">Sales commission paid per transaction (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=xoma_AtMarketIssuanceSalesAgreement2021Member', window );">2021 ATM Agreement | Series B Depositary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_MaximumValueOfStockToBeIssued', window );">Maximum amount of shares to be issued</a></td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=xoma_AtMarketIssuanceSalesAgreement2021Member', window );">2021 ATM Agreement | Series B Depositary Shares | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Sale of stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfShares', window );">Sales commission paid per transaction, preferred stock (as a percent)</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_MaximumValueOfStockToBeIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of stock to be issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_MaximumValueOfStockToBeIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of sales commission to gross proceeds paid to sales agents for the sale of the Company's common shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of sales commission to gross proceeds paid to sales agents for the sale of the Company's shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>xoma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=xoma_TwoThousandEighteenAtMarketAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=xoma_TwoThousandEighteenAtMarketAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=xoma_AtMarketIssuanceSalesAgreement2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=xoma_AtMarketIssuanceSalesAgreement2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=dei_AdrMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=dei_AdrMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140070013261968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations', window );">Federal income tax provision</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">5.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would impact effective tax rate</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit', window );">Unrecognized tax benefits expected to change significantly over the next twelve months</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrued interest or penalties related to uncertain tax positions</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current and deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current and deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the unrecognized tax benefit of a position taken for which it is reasonably possible that the total amount thereof will significantly increase or decrease within twelve months of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>xoma-20230630x10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2023"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xoma="http://www.xoma.com/20230630"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="xoma-20230630.xsd" xlink:type="simple"/>
    <context id="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardsMember_TzcgwgvPHk2deHWsM1h3OA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:ChiefInvestmentOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:StockOptionInducementAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-03</startDate>
            <endDate>2023-01-03</endDate>
        </period>
    </context>
    <context id="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerInterimMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardsMember_whB55KBpZUikUKiuuCNJVw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:ChiefExecutiveOfficerInterimMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:StockOptionInducementAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-03</startDate>
            <endDate>2023-01-03</endDate>
        </period>
    </context>
    <context id="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardsMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_oW0kv2blbEWaKJNbPntI9A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:ChiefInvestmentOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:StockOptionInducementAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-03</startDate>
            <endDate>2023-01-03</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_B01Z3JtpTkOkqmAnGrSDdg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:LadrxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_12_6_2017_To_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementRz358Member_qYjemo3WTUmBR58bLQH00g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementRz358Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-06</startDate>
            <endDate>2017-12-06</endDate>
        </period>
    </context>
    <context id="Duration_12_6_2017_To_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementNonRz358ProductsMember_X1c9jKDf5EOZolxEicyXRw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementNonRz358ProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-06</startDate>
            <endDate>2017-12-06</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2006_To_11_1_2006_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_srt_ProductOrServiceAxis_xoma_MezagitamabMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_nbtuFUC-fkqYmHeLy348AA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:MezagitamabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2006-11-01</startDate>
            <endDate>2006-11-01</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_10_31_2023_srt_StatementScenarioAxis_srt_ScenarioForecastMember_srt_TitleOfIndividualAxis_xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_VlkReAnbnkaiZ8DMeCw8ZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:CurrentEmployeesExcludingChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_srt_TitleOfIndividualAxis_xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_tUWKdWxSsEqTeepdcpaR-g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:CurrentEmployeesExcludingChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_8_1_2023_To_8_31_2023_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_srt_ProductOrServiceAxis_xoma_FaricimabSvoaVabysmoProductMember_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_REdIh2M4tEqC4XSc5ixlSg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffitechResearchAsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:FaricimabSvoaVabysmoProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-31</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_MedexusMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_uvMhw-Lcqk-4prmxG0MKyQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:MedexusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_3_29_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_wWf39cBN3Ey7XT6o94A4AQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AptevoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-29</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember__RhK022Z4kyD4eKqg0JNCA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AptevoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_2_1_2023_To_2_28_2023_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_3qo6LMNvTEKUouebN2XnWA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffitechResearchAsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2023-02-28</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_euIclIwai0uxoAqBVaGjlw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AptevoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_8_1_2022_To_8_31_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_OH8fvv_h9keoJxZOMgPK5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffitechResearchAsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="As_Of_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_MerckImmunoOncologyProductMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_NG5TrsNyD0Oet2286g9H0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AgenusIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:MerckImmunoOncologyProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-20</instant>
        </period>
    </context>
    <context id="As_Of_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_IncyteImmunoOncologyAssetsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember__94jAcnsd02lqy6kaK-0kQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AgenusIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:IncyteImmunoOncologyAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-20</instant>
        </period>
    </context>
    <context id="Duration_9_20_2018_To_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_MerckImmunoOncologyProductMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_rdQZOj-p50uveOBE4byiYQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AgenusIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:MerckImmunoOncologyProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-20</startDate>
            <endDate>2018-09-20</endDate>
        </period>
    </context>
    <context id="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_IL1TargetLicenseAgreementMember_1_yPty6sVUuiOqjDzbtIAg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:IL1TargetLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-24</startDate>
            <endDate>2017-08-24</endDate>
        </period>
    </context>
    <context id="Duration_12_21_2016_To_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_SecondRoyaltyInterestAcquisitionAgreementMember_Ue-jD_6tzkiEEl7k3z6Zvg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:SecondRoyaltyInterestAcquisitionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-21</startDate>
            <endDate>2016-12-21</endDate>
        </period>
    </context>
    <context id="Duration_12_21_2016_To_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_FirstRoyaltyInterestAcquisitionAgreementMember_1g3j3qkUPUilXtpAyP_pQg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:FirstRoyaltyInterestAcquisitionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-21</startDate>
            <endDate>2016-12-21</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2022_To_11_1_2022_srt_TitleOfIndividualAxis_xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_r2cXPnKQNkCZpd4DuftB1Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:CurrentEmployeesExcludingChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-01</endDate>
        </period>
    </context>
    <context id="Duration_8_5_2021_To_8_5_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_AtMarketIssuanceSalesAgreement2021Member_aVcwCvFvaEm9M_QNOIF3YA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xoma:AtMarketIssuanceSalesAgreement2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-05</startDate>
            <endDate>2021-08-05</endDate>
        </period>
    </context>
    <context id="Duration_12_18_2018_To_12_18_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_TwoThousandEighteenAtMarketAgreementMember_6lxjXvcF7UG8eC23SZUejg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xoma:TwoThousandEighteenAtMarketAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-18</startDate>
            <endDate>2018-12-18</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_VZ3-yhq8FE25TUInBBrGZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandFifteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_qKDIT7AlPEumlQb_qY84ng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AptevoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_6_21_2023_To_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_e8EdDKpfoE63WcXU__Eu4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:LadrxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-21</startDate>
            <endDate>2023-06-21</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_srt_StatementGeographicalAxis_srt_EuropeMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_91bx_J3VVUaNfNyS-gIThg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffitechResearchAsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_p8h6imE-V0uwNs1HrXGY2A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffitechResearchAsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_10_6_2021_To_10_6_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_7mFvjte_dEevmb4jPsGqCg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffitechResearchAsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-06</startDate>
            <endDate>2021-10-06</endDate>
        </period>
    </context>
    <context id="Duration_3_22_2021_To_3_22_2021_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_Yzb76SH-JEWCZntLrcxS8w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:ViractaTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-22</startDate>
            <endDate>2021-03-22</endDate>
        </period>
    </context>
    <context id="Duration_11_2_2020_To_11_2_2020_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementTwoMember_lIg02dx4pU2AOp3fc9Nh0Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:BioasisTechnologiesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-02</startDate>
            <endDate>2020-11-02</endDate>
        </period>
    </context>
    <context id="Duration_9_26_2019_To_9_26_2019_srt_CounterpartyNameAxis_xoma_PalobiofarmaSLMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_aaICGPfxhkOTZpQUaO0Yqw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:PalobiofarmaSLMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-26</startDate>
            <endDate>2019-09-26</endDate>
        </period>
    </context>
    <context id="Duration_9_1_2019_To_9_30_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_gG7wFWBERkClqJ60IJyBXw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_o9TK8egh80G0mWjo56c-jg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:SiliconValleyBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-07</startDate>
            <endDate>2019-04-07</endDate>
        </period>
    </context>
    <context id="Duration_9_20_2018_To_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_CDSnZwcrZEu2Ca2UBiaJ0g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AgenusIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-20</startDate>
            <endDate>2018-09-20</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesEmeryvilleCaliforniaMember_j4Za8qhjGEunE9GIsiSNhg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xoma:LeasedFacilitiesEmeryvilleCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_11_1_2022_srt_TitleOfIndividualAxis_xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_rYMNfnEL9EOqQXV7Em0Nyg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:CurrentEmployeesExcludingChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-01</instant>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_v_4086cVDUmoGR5d7CgO0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_e0nlQVVkQEC_RcJPbx3_LQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_qONAes1cy0G9lDzJGggO0Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_heK3HldCNE-r5gSRWagnnQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_9_20_2018_To_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_IncyteImmunoOncologyAssetsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_XSaCTgtO1EiCFqoqTgeZVw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AgenusIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:IncyteImmunoOncologyAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-20</startDate>
            <endDate>2018-09-20</endDate>
        </period>
    </context>
    <context id="Duration_2_25_2019_To_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_YrCq7J8e4kyLGJ4RpNNinw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:BioasisTechnologiesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-25</startDate>
            <endDate>2019-02-25</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2021_To_6_30_2021_xtjjCBFLBUi_Ojs50RRq5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_5_1_2022_To_5_31_2022_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_ksZbC81p30-S2MPeTooszw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_7_31_2022_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_XIw7qGqY0EK6f05CwdTGoA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2020_To_11_30_2020_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_MerckImmunoOncologyProductMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_yWJTxLzPL0y7_WmwB5wNNw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AgenusIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:MerckImmunoOncologyProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2020_To_11_30_2020_dei_LegalEntityAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_MerckImmunoOncologyProductMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_gu6YuHtIt0y_GOYnfbfPoA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:MerckImmunoOncologyProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">xoma:AgenusIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="Duration_8_5_2021_To_8_5_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_AtMarketIssuanceSalesAgreement2021Member_cuvo8QXwwkSA9m8xw1ZRjg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xoma:AtMarketIssuanceSalesAgreement2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-05</startDate>
            <endDate>2021-08-05</endDate>
        </period>
    </context>
    <context id="Duration_3_10_2021_To_3_10_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_TwoThousandEighteenAtMarketAgreementMember_lPXdwcXrLkWjZpFxVg8zQg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xoma:TwoThousandEighteenAtMarketAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-10</startDate>
            <endDate>2021-03-10</endDate>
        </period>
    </context>
    <context id="Duration_12_18_2018_To_12_18_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_TwoThousandEighteenAtMarketAgreementMember_w7kNNs1WoE-BxhkhRzlqSg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xoma:TwoThousandEighteenAtMarketAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-18</startDate>
            <endDate>2018-12-18</endDate>
        </period>
    </context>
    <context id="As_Of_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_srt_ProductOrServiceAxis_xoma_AldoxorubicinMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_pNlSw8P-5EajUFyzP-8uPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:LadrxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:AldoxorubicinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-21</instant>
        </period>
    </context>
    <context id="As_Of_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_srt_ProductOrServiceAxis_xoma_ArimoclomolMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementMember_K3A3TuR8B0uQ0wOH9CRISw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:LadrxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:ArimoclomolMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:AssignmentAndAssumptionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-21</instant>
        </period>
    </context>
    <context id="As_Of_1_31_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_P2FOnn42CUiAAEHfWUjQNw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffitechResearchAsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="As_Of_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_NqbS9eqGFkerYvUUwG7Maw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:LadrxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-21</instant>
        </period>
    </context>
    <context id="As_Of_11_21_2022_srt_CounterpartyNameAxis_xoma_MerckKgaaMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_9bKtdq3Xq022OPaePZccLw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:MerckKgaaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-21</instant>
        </period>
    </context>
    <context id="As_Of_11_21_2022_us-gaap_AssetAcquisitionAxis_xoma_ObsevaIntellectualPropertyRightsMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_eP4cyYTR-k2h0sxHIlensA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">xoma:ObsevaIntellectualPropertyRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-21</instant>
        </period>
    </context>
    <context id="Duration_8_1_2019_To_8_31_2019_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_7abmyDQDN0asJM3WaMklhA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:JanssenBiotechInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_WO4UYUGV_02Sv2V6Sl4utw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffitechResearchAsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_21_2023_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_1-O-Wc5qm0GpfWvtLfA5QQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-21</instant>
        </period>
    </context>
    <context id="As_Of_10_6_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_utnG5LOjWkaEzqc0Xpgs4A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffitechResearchAsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-06</instant>
        </period>
    </context>
    <context id="As_Of_7_14_2021_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_Xh1jjLmK9029VV5PJj8xKg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-14</instant>
        </period>
    </context>
    <context id="As_Of_11_2_2020_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementTwoMember_EKVUME649EuA-3BW_SUmRA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:BioasisTechnologiesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-02</instant>
        </period>
    </context>
    <context id="As_Of_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_W3hVIOjItkyJRWGnXKpi0w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AgenusIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-20</instant>
        </period>
    </context>
    <context id="Duration_12_6_2017_To_12_31_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_mT3lLicYEUilKoGSWcL_yw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementAndCommonStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-06</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_1_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesEmeryvilleCaliforniaMember_jFg3GanTsESUiaQdv4hx4g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xoma:LeasedFacilitiesEmeryvilleCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="Duration_6_20_2023_To_6_20_2023_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementAndSecondRoyaltyPurchaseAgreementMember_Eqxr4CXcuE-FFTbVv-ujhg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:BioasisTechnologiesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementAndSecondRoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-20</startDate>
            <endDate>2023-06-20</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_ka9FAFONVkeMeIE9zPwx5Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:BioasisTechnologiesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_FirstRoyaltyInterestAcquisitionAgreementMember_gLlWNbiZNUK_fa6Qh_xfcA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:FirstRoyaltyInterestAcquisitionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-21</instant>
        </period>
    </context>
    <context id="Duration_7_14_2021_To_7_14_2021_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_s0z0PXoS5k-BNomvO5_j6g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-14</startDate>
            <endDate>2021-07-14</endDate>
        </period>
    </context>
    <context id="As_Of_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementRz358Member_k_y6teG2YUSWNLFytU9KEg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementRz358Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-06</instant>
        </period>
    </context>
    <context id="As_Of_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_LoKvCYQB9EOeQYU95Ohdpw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:XOMA052LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-24</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2015_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_AFuvSscA3kS3Ogj-V-41CQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-09-30</instant>
        </period>
    </context>
    <context id="As_Of_11_1_2006_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_srt_ProductOrServiceAxis_xoma_MezagitamabMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_eN1YCwnkIUCnKDhhfVJ8PA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:MezagitamabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2006-11-01</instant>
        </period>
    </context>
    <context id="As_Of_11_21_2022_srt_CounterpartyNameAxis_xoma_OrganonMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_VI6RYGqQZkeAVJnnIv4sTQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:OrganonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-21</instant>
        </period>
    </context>
    <context id="Duration_2_1_2009_To_2_28_2009_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_srt_ProductOrServiceAxis_xoma_OtherAntibodiesMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_nb8ggrHRR0i-B34ppjt3fQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:OtherAntibodiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-02-01</startDate>
            <endDate>2009-02-28</endDate>
        </period>
    </context>
    <context id="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_pn2tVWcS10-XUKZrEdxpPg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-07</startDate>
            <endDate>2019-04-07</endDate>
        </period>
    </context>
    <context id="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_BayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_HRYppcTJikmUXTKgI4BWvQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:BayerProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-07</startDate>
            <endDate>2019-04-07</endDate>
        </period>
    </context>
    <context id="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_BayerProductsMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_abyt3ov_LEidqaXYxUPESw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:BayerProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-07</instant>
        </period>
    </context>
    <context id="As_Of_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_QHXUcnameU2HPDbtouGcNQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:BioasisTechnologiesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-25</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_2Aj5seKcO0-XhIAauxBBGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:BioasisTechnologiesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_AronoraKurosAffitechObsevaAndMerckKgaaMember_Jg_8omFpTEO2btPaF3ItlQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraKurosAffitechObsevaAndMerckKgaaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_ContingentConsiderationByTypeAxis_xoma_ContingentConsiderationRegulatoryMilestonesMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_CJwILMODfU2DPiygsj2I2Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:LadrxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">xoma:ContingentConsiderationRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-21</instant>
        </period>
    </context>
    <context id="As_Of_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_dUxKhnDLWESjshb_a_VOiQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:LadrxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-21</instant>
        </period>
    </context>
    <context id="As_Of_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_m3fGmRg0ukuCv0wBM5jhzQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:LadrxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-21</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_ILbmTBFAdkeabm8OMvrxMg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AptevoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_29_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_BVEo8QgBSkmfz1ozUkIwXw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AptevoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-29</instant>
        </period>
    </context>
    <context id="As_Of_10_6_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_ContingentConsiderationByTypeAxis_xoma_ContingentConsiderationRegulatoryMilestonesMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_vyMgtLcJvEi0juGqwh3ASQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffitechResearchAsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">xoma:ContingentConsiderationRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-06</instant>
        </period>
    </context>
    <context id="As_Of_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_mAQNTbueYkGTdJGdXydMXQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:BioasisTechnologiesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-25</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_s8DXfaV1hU-kNpb0otcEew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_9t8qE3DtCUGDnjtaLsnr7g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerRetiredMember_-DtLW9eN0kelXo4Sr64YSg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:ChiefExecutiveOfficerRetiredMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_3_29_2023_To_3_29_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_7trh9U9BgEOiGwvVb10qXg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AptevoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-29</startDate>
            <endDate>2023-03-29</endDate>
        </period>
    </context>
    <context id="Duration_10_6_2021_To_10_6_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_srt_ProductOrServiceAxis_xoma_FaricimabProductMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_wnbrqh2QZE2B_rph576ABA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffitechResearchAsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:FaricimabProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-06</startDate>
            <endDate>2021-10-06</endDate>
        </period>
    </context>
    <context id="Duration_6_21_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_o0jHZU6txku5HZbpgBRroQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:LadrxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-21</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_A0raaKROwE6F7PlIHJx7HA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:LadrxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_12_6_2017_To_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_YD6dXAdo7E2njL-IcLEMGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-06</startDate>
            <endDate>2017-12-06</endDate>
        </period>
    </context>
    <context id="Duration_9_30_2015_To_9_30_2015_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_27gU5riISEy0SIhW5x2uJg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-09-30</startDate>
            <endDate>2015-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_3_22_2021_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_46O6ygYv-kiSXEivuByfuw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:ViractaTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-22</instant>
        </period>
    </context>
    <context id="As_Of_9_26_2019_srt_CounterpartyNameAxis_xoma_PalobiofarmaSLMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_zT4QsAb7u0eLPQ9twhpAFA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:PalobiofarmaSLMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-26</instant>
        </period>
    </context>
    <context id="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_NonBayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_3_W-6bd8Rk-v259MRO0Muw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:NonBayerProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-07</instant>
        </period>
    </context>
    <context id="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_HVql9Pa7t0Olldm6QQhOFg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-07</instant>
        </period>
    </context>
    <context id="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_BayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_Pw_lMHeh_0G7t1NpeC5DRQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:BayerProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-07</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerRetiredMember_AOpX5sV2ukSJWYQ3A3lEaQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:ChiefExecutiveOfficerRetiredMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerRetiredMember_YyRGgFdv-E6X0DuiU_Edmg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:ChiefExecutiveOfficerRetiredMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_JyWKfa6Y2kCEdbWR9Enhww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Y8pSKqQVN0qvZ3Xp6DQmKg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_8_5_2021_To_3_31_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_AtMarketIssuanceSalesAgreement2021Member_LyhgNqHmQEOuPgMQ7sVrxA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xoma:AtMarketIssuanceSalesAgreement2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-05</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_12_18_2018_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_TwoThousandEighteenAtMarketAgreementMember_7W6KMaqUekmIWDswlSxORw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">xoma:TwoThousandEighteenAtMarketAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-18</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_t9TRI6XjwEKzRs1Mh2hslQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:XOMA052LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-24</startDate>
            <endDate>2017-08-24</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_q7cIlXaQfEaTUzSmFF8pow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_nZVAZEbax02Nn2_S_0USBA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2020_To_10_31_2020_dei_LegalEntityAxis_xoma_RezoluteIncMember_ajuHCP8Cvkqkr0Grn5eRPw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__SjruGbNMke6VHotvJqC3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_edqle5HbXEm7yuZsNCNZ5Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_6kc5MkORGEWUHpL16Dho2Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_x45gr-vUZEyje19LB7OGtA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_X5C7oga02EiygboostYHVw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ULAJkPFmo0GKfvexehN6Xw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_gXsLP4N9SkWM0pvx20VSug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_nRVamYzhRUqPa-9YjzTLLA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_YqOEWTXU0Ua6QvAhBoXz7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_YzMe_e-yGUGbNiPtf12IwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sHK3ZNTAH0aMwFqH9faHRw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2022_wXICAr6QekumvGjfUaFcqw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_oECYzd9liEiyvMRgwShVYg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_S54NSxp5yk2I3fcHshTcMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_mN21iu-7y0Ob71zpxfq1UQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_3elDeOQbAkSzA4XPNTMvKw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_czcB2xp3ZkO5ufWJGf_Lgg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_tKe_WjiZ-0ecu0LnoPu_Vw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_gUvLnlJ3mkOEbSXAHiiecQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_NVGVumu2RU2aSm58xyzVnQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__q8-WGlpF0afujkbjDrhAQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_PeotIRnSfEqGsKf-u1aQaA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_F7GJ2ijBaESNLxxCWOPV9Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_mjGDeVHtJEy-hmsEfPC5Jw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vprHlJrRr0yw8rVJERIeVg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_63gYMzNqtUeLw4EgBOljpw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_nAb-HKUTNkWZ5BAQ0-qIHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_vUW8gOL5lUS22XQyQHoMYg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_54FxiDHYMUSAo0wczwNo8w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_eGV1-nMv9EyGZf3q_EpMbw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_jps57Fyqu0WWl7CaOtheOg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_q6JWreHPR0i_czphX2lVDQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zdAm_dbVtUOANrU35KRi-w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_2zCuoTh9XU-z3zmcVTU37A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_6rQbM7sQNky8O85-NJM6Kw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_uuOaeeICIE63neZVbvxrYw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xTypNCJw2kecFDKsOR8hwA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vo9zKMnZO0aHN96tsj24CA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_5_31_2023_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar45Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_G0SYyex3eUy7MyZY9jFEqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">xoma:StockPriceHurdlesOfDollar45Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="As_Of_5_31_2023_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar40Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_M7IRrCKea0iCZRqtsZ7RWg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">xoma:StockPriceHurdlesOfDollar40Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="As_Of_5_31_2023_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar35Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_6tvbW7uZUEOHE7gMti2gpA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">xoma:StockPriceHurdlesOfDollar35Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="As_Of_5_31_2023_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar30Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_k94cSi-Zwk2VBrdcAKVvmA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">xoma:StockPriceHurdlesOfDollar30Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="As_Of_1_3_2023_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardsMember_O8EOxHD7p0K-aApJeodsyg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:StockOptionInducementAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-03</instant>
        </period>
    </context>
    <context id="As_Of_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_8Kg_25tsBUmCq2SIaH9sdg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:XOMA052LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-24</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_qMnU5lLEOEWtPeR71nBTRQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_-JwjlMwfKEGUbHpTjDxUDQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:StockOptionInducementAwardTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_jSfoRez_iE22iNJRZuTv-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:StockOptionInducementAwardOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_QvduteacZ0y6e-l0bH1cfQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandTenLongTermIncentiveAndStockAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_fvpJiV95o0G_Lx6Po8Z0Qg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:StockOptionInducementAwardTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_UkUp6s2yF0molMuQVionzw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:StockOptionInducementAwardOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_2sdFXHfUykChvD4tIF6z0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:ChiefInvestmentOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:StockOptionInducementAwardTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-03</startDate>
            <endDate>2023-01-03</endDate>
        </period>
    </context>
    <context id="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_-tCFSx98TEGfywwRhcC7ZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:ChiefInvestmentOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:StockOptionInducementAwardOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-03</startDate>
            <endDate>2023-01-03</endDate>
        </period>
    </context>
    <context id="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerInterimMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_ifxCZ1Dza0CPpbZTGry9HQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:ChiefExecutiveOfficerInterimMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:StockOptionInducementAwardTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-03</startDate>
            <endDate>2023-01-03</endDate>
        </period>
    </context>
    <context id="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerInterimMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_iFhJ1Ec6iUaNhMqAZWDmbg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:ChiefExecutiveOfficerInterimMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:StockOptionInducementAwardOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-03</startDate>
            <endDate>2023-01-03</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_HFe1p--7QUyXIpXph3Ep4A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:StockOptionInducementAwardTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_UCA8w-FN5E6MpfSkha4Snw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:StockOptionInducementAwardOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_nc6cD9y6eky4_H4Gmdgf2Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:StockOptionInducementAwardTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_OxGaeDYzykWU3vEhrxw_Mw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:StockOptionInducementAwardOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_xL-t6UGWVk6DJsv8uctHqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandTenLongTermIncentiveAndStockAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_-fCNRL3sJk2hkKbH29QN5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandTenLongTermIncentiveAndStockAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_kkqRS-Yr_kK7p5s-7yOqJg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:StockOptionInducementAwardTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_8s2qytOsIE6JM7loesF-Zg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:StockOptionInducementAwardOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_6P9--i9dukq4YkLcJp4PvQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandTenLongTermIncentiveAndStockAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_hI8wxtoK_020YtrtWXgEww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandTenLongTermIncentiveAndStockAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_5_1_2023_To_5_31_2023_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar45Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_sJUAR2OjXECHMqedJgu-yQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">xoma:StockPriceHurdlesOfDollar45Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="Duration_5_1_2023_To_5_31_2023_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar40Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_6r4sVlcI50y97OHzEy_aBg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">xoma:StockPriceHurdlesOfDollar40Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="Duration_5_1_2023_To_5_31_2023_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar35Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_YZ1bWx-iUUeKV_tBnvEWAw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">xoma:StockPriceHurdlesOfDollar35Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="Duration_5_1_2023_To_5_31_2023_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar30Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_nNrXvBglBEuLwgpeNxml8A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">xoma:StockPriceHurdlesOfDollar30Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="Duration_5_1_2023_To_5_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_XYLfgmBs1kapqrjpQTeEpQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandTenLongTermIncentiveAndStockAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="Duration_5_1_2023_To_5_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_gHPGrk0L1EOQ1hUygp_Gpw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardsMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_sfgRwFcTcUelc4rTBp-b3Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:ChiefInvestmentOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:StockOptionInducementAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-03</startDate>
            <endDate>2023-01-03</endDate>
        </period>
    </context>
    <context id="Duration_5_1_2023_To_5_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_jGf-N4U7oEWRkZ347gsAlA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="Duration_5_1_2023_To_5_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_aWe1HEcOJkO4GJNqP9UK8w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="Duration_5_1_2023_To_5_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_Cf49xhpajkCvIANGtFeezA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_srt_TitleOfIndividualAxis_xoma_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_zTu1OSjDqkSzjQ_HoRydQw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandTenLongTermIncentiveAndStockAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_-kWVMpk2b0K-si5i-kPxAg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandTenLongTermIncentiveAndStockAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_5_1_2023_To_5_31_2023_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar45Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_0Czk0OqbEkepDfJ3xsELBw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">xoma:StockPriceHurdlesOfDollar45Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="Duration_5_1_2023_To_5_31_2023_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar40Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_QN3fukmQcEymV8gdhnI3ow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">xoma:StockPriceHurdlesOfDollar40Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="Duration_5_1_2023_To_5_31_2023_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar35Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_lT2QTmiVC0-u-Gq59mHj8A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">xoma:StockPriceHurdlesOfDollar35Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="Duration_5_1_2023_To_5_31_2023_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar30Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_eRdy_9rQG0eihqb4EruBVA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">xoma:StockPriceHurdlesOfDollar30Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="Duration_5_1_2023_To_5_31_2023_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar45Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_132lsM87s0-SgeiFzFNGPw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">xoma:StockPriceHurdlesOfDollar45Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="Duration_5_1_2023_To_5_31_2023_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar40Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_yYP93SxHqUaWiML_VD6qSQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">xoma:StockPriceHurdlesOfDollar40Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="Duration_5_1_2023_To_5_31_2023_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar35Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_EP_RDzS2Y0G8ZWnpyMII1w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">xoma:StockPriceHurdlesOfDollar35Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="Duration_5_1_2023_To_5_31_2023_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar30Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_NtPgJkGsykWMLfBzzhabEg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">xoma:StockPriceHurdlesOfDollar30Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_bltKeBtI3UmSSHjoiD4k4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:TwoThousandTenLongTermIncentiveAndStockAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_-e_kcpPy9Uijv53NXnwNjA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:StockOptionInducementAwardTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_YDoryzJQpUuWG8MDo2Kh5Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">xoma:StockOptionInducementAwardOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_m5ftMp6cYUSGHtQQJFDZ4g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyInterestAcquisitionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_a3PpicXMp0e6hJa2jrYpvg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyInterestAcquisitionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_n_zJPqyMuUyhRwCGh98ETg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyInterestAcquisitionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_ydN4fj43pUqEu9cZio79ng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyInterestAcquisitionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_srt_ProductOrServiceAxis_xoma_MilestonePursuantToAgreementMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_A9EfiA2PT0GB4VJ2dpb9fQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:JanssenBiotechInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:MilestonePursuantToAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_Ri7Rd8o8XUKc4YOMeBumXQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_V9oe_Umn1kmDzVa04Ga_yw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_ObsevaMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_K7Mk8P8VwES9_5DBUAZzMw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:ObsevaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_fDllYLxwC021lmWGRzTQow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_1mMiwj9oK0ik7StNSZF-NA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_JvsZS46lPEq8PkHBxYXxJw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:JanssenBiotechInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_AffimedMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_EbE0yio0rEiufpaULNthlw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffimedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_4_30_2023_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_srt_ProductOrServiceAxis_xoma_MilestoneDosingFirstPatientInClinicalTrialMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_d9RUr6mklkyYekHk6uD6mg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:JanssenBiotechInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">xoma:MilestoneDosingFirstPatientInClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-04-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_VOxATG70-EaP_DZtrrA64w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_X4k_iI4JX0qMI82W0g9pVg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_ObsevaMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_XJPmp5bo-kmu5UyKiVXplA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:ObsevaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_m4wda9YuHE2PtS0eldU6mg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_mc8GGMwdb0i-WiWEDrANiQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_FSjLU5cFwkCknzTRDnkzlA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:JanssenBiotechInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_AffimedMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_79M6vRT4qEukxFoiKPpVGg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffimedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_QDr-ldinb0Wu3jl9Rx21UA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_vwInn_PHZEilesm4Dyrjqw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_jFCmb1gQLUCZ9hjyvX5kmw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_RLV8-2lAs0iAHxQrgpOq0w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_y5qiBk4TN0G3EitwLEYTCQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:JanssenBiotechInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_srt_CounterpartyNameAxis_xoma_AffimedMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_oY96KBMfAEOyCowvi6apdg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffimedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_vXBkO4OEpkinf_t3RM0D2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_vmQFJdPsf0mcV98nQ1FxGg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_rGGwTzCaJEKNgoHyMNh1gw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_9uhBqAbJnkGLmYVcrsplwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_jHYkB6cDy0SVSmvTMeT8oQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:JanssenBiotechInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_srt_CounterpartyNameAxis_xoma_AffimedMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_uepwPESgtkiCvIXYBSvbng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffimedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_84g9TjGclUmNwYUUvpo37g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2021_To_10_31_2021_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_xqc5RHdAf0e8Ok9zCOunNA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2020_To_11_30_2020_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_adu7bNhKOUupBKfuF3sIbA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2020_To_10_31_2020_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_HhVju1hJBE6OfB_ni4aRJg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_V2ptKzpjEUCLS85R4yB7vA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:JanssenBiotechInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_niKO_iOCski7xDCZeqBm0g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-24</startDate>
            <endDate>2017-08-24</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2017_To_12_31_2017_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_Zf-09DuHLUy9gAfOBsfCZw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2015_To_12_31_2015_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_UKHVP4QfBUyD1MV8rF2yOQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_M2UiaYqolEG6eD-krPLPrQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:XOMA052LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-24</startDate>
            <endDate>2017-08-24</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_B7d29QvlcEe4N-_OPoM0aw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_HnMB9b7CRUKpmLvME2vUuQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_6973Ln0mrUSWVWSvhpZzAw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_GAngHNpHWkmY3_zgBQQUhg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_ORljYJEjFUKKL0etVMNkrA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_brrjfnRro02jXTsYqcCsLA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_5_17_2023_To_5_17_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_IblNCk2dpE-dmOagVLa7JA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-17</startDate>
            <endDate>2023-05-17</endDate>
        </period>
    </context>
    <context id="Duration_5_17_2023_To_5_17_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_zIuocAB-x0yti_KN6IbA-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-17</startDate>
            <endDate>2023-05-17</endDate>
        </period>
    </context>
    <context id="Duration_2_22_2023_To_2_22_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_-2EK4u-0ckW1nFdNOq609w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-22</startDate>
            <endDate>2023-02-22</endDate>
        </period>
    </context>
    <context id="Duration_2_22_2023_To_2_22_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_sYdPxIxRXkGzRg8T4Svv8w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-22</startDate>
            <endDate>2023-02-22</endDate>
        </period>
    </context>
    <context id="Duration_10_26_2022_To_10_26_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_xycxsSZ67ECdvujJaYBpbg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-26</startDate>
            <endDate>2022-10-26</endDate>
        </period>
    </context>
    <context id="Duration_10_26_2022_To_10_26_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_f-NSs0JDB0Om2BdwXRGLGw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-26</startDate>
            <endDate>2022-10-26</endDate>
        </period>
    </context>
    <context id="Duration_7_17_2023_To_7_17_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_D4y9SqGnwUyCojdGJ8gVXQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-17</startDate>
            <endDate>2023-07-17</endDate>
        </period>
    </context>
    <context id="Duration_7_17_2023_To_7_17_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_tFHfgUHPO0eyTGuDDDFz_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-17</startDate>
            <endDate>2023-07-17</endDate>
        </period>
    </context>
    <context id="Duration_4_17_2023_To_4_17_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_Z6poHWjacUe3yoIoMnG5Gw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-17</startDate>
            <endDate>2023-04-17</endDate>
        </period>
    </context>
    <context id="Duration_4_17_2023_To_4_17_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_DiAyNLOtMkyP4bogjr0ljA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-17</startDate>
            <endDate>2023-04-17</endDate>
        </period>
    </context>
    <context id="Duration_1_17_2023_To_1_17_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_I1U0dl2b_U6ewgR9AxdDcA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-17</startDate>
            <endDate>2023-01-17</endDate>
        </period>
    </context>
    <context id="Duration_1_17_2023_To_1_17_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_lz1JUm8bHUSBbGCkkt6ACA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-17</startDate>
            <endDate>2023-01-17</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_-1YcQgV4D0GXoCudlGfzsQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_709bNt4Pc0ah6gEtj2ui5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_q_kRVdOaKUGqFvcO4YBRYg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_d2IDvzwTtEeRbBTwLkWiZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_WOYOn9euaESUo_Fdt2xQDQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_gy4yRQy_g0efVGsZ9JvfSg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_mZzBVYXOQEiwSAFnA-OODw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_vzagK5EjmEqHa32z1YO0qQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_xCuxHxFsWUK7HkZ9m3D7Zg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_A3D1KiJFt0CNaMkMfhVNww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_fyrP0G4Pj0-aaN04bSkICQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_7O1rzT-yJUuZnLhCfrcYOg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_KGG7iA9QeU-x58nvnAGyAA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2023_dei_LegalEntityAxis_xoma_BiotechnologyValueFundLPMember_srt_OwnershipAxis_xoma_XomaCorporationMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_OPWHgi5OoUOvpKGH_7ayMg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">xoma:XomaCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">xoma:BiotechnologyValueFundLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesTwoEmeryvilleCaliforniaMember_TMMvkmy6s0ygPCJWud7LzQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xoma:LeasedFacilitiesTwoEmeryvilleCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_1_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesEmeryvilleCaliforniaMember_qE4Q6lsyXk-n_6Q8orOVvg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xoma:LeasedFacilitiesEmeryvilleCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesTwoEmeryvilleCaliforniaMember_x-BSsUsmOEefcCTi34VfUw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">xoma:LeasedFacilitiesTwoEmeryvilleCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="Duration_12_21_2016_To_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_u-wkh1XOjEKGxjaNdt0ZHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyInterestAcquisitionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-21</startDate>
            <endDate>2016-12-21</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AssetAcquisitionAxis_xoma_ObsevaIntellectualPropertyRightsMember_aKWzGNtzM0-dDhbT2Gyirg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">xoma:ObsevaIntellectualPropertyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_Gfw9LK-Od0iMS_KhAfKpsg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_ruM398xI60a2mOzUa9tLiw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_PwcTNnqVHEurE6RMUONPsw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_EPzxT9qkbUedyZWvfkZUhA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_NuaPtHy1BU6__HgLOoJDdw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_Abl8Ryg010astqw5xtuhDg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2023_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_LzgovgUcyUqFQMy5t8ndVg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_OFKp4An1GUS4-brDAQB8ew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_BSWfJSEpmEGBgXlGS4MC4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_79gnR1guSka7Q_vWe08uww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Nn8D-tR9RUaR3oXEwhegJw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_fUdJCDTZZkCC-dGe4IpNTw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_5_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_DFqUQBhRC0ifvbBc0bGVmg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_3UfIUbfYm0S1MerajhgXqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_rWEkuydSCkGeJt7pRAiu2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyInterestAcquisitionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_AXaUv2IOz0qjMzgGNRTTfQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:HealthCareRoyaltyPartnersTwoLimitedPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyInterestAcquisitionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_12_31_2023_srt_StatementScenarioAxis_srt_ScenarioForecastMember_srt_TitleOfIndividualAxis_xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_MqTx9tpzQE-VCd4MN0ETHw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:CurrentEmployeesExcludingChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_srt_TitleOfIndividualAxis_xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_oCigQGadskqvS1qhL-UxEw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">xoma:CurrentEmployeesExcludingChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2020_To_10_31_2020_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_pUHf37jdqkO7GsZ6tJj4dA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">xoma:NovartisNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_ObsevaMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_zyUxaH6CvkmKfmQE_-3YjQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:ObsevaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_ObsevaMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_YH_2bboTUkyRnEvX6o0V4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:ObsevaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_t0Nk1HTAG0K7OHjnARYZew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:ViractaTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_PalobiofarmaSLMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_ipZkO7zZN06t3XJUxHlDgQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:PalobiofarmaSLMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_UCOXnlEMH0KhLJITjc3RcQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:LadrxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_l6eBrvgOik6JwWWl-dCq7g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementAndSecondRoyaltyPurchaseAgreementMember_FU0POSqmREazZyKHBvapXA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:BioasisTechnologiesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementAndSecondRoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_m716wsI3XE6pmBu2Tce2QA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_Ag4rXqT5_U2u9t7EHdT2Vw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AptevoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_AgenusIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_sSr_eim9wkmE2gHiwusgvQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AgenusIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_tbP6vsd5eUOJL3GPMRb5Sw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffitechResearchAsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_6tHZOwbzlkiu2oefkSmJmg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:ViractaTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_PalobiofarmaSLMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_YM8JsAYwe02uTcAIJfsjVw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:PalobiofarmaSLMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_1wOk0To-60ebzBx-MLxW0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementAndSecondRoyaltyPurchaseAgreementMember_p9m5gzIpdUSkItjQbZWuTA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:BioasisTechnologiesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementAndSecondRoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_o6zurAuWbE6ntKuKdPP1yg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AronoraIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_AgenusIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_bp0e2gt5REKDawtfAHfiFA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AgenusIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:RoyaltyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_t4tt47wP20iV85oZnDl0kQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffitechResearchAsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CommercialPaymentPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_srt_MajorCustomersAxis_xoma_Partner2Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_sqEiwRkHBkmAPGUe0Ez5pg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">xoma:Partner2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_srt_MajorCustomersAxis_xoma_Partner1Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_UPb9E7A4oUG9Ls-shtbyPg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">xoma:Partner1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_srt_MajorCustomersAxis_xoma_Partner2Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_R1d0cYWaYUKU7Z4Y59JDYQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">xoma:Partner2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_srt_MajorCustomersAxis_xoma_Partner1Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_TradeAccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_-LRlYQJJLk-TqPh3pxJ8_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">xoma:Partner1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_srt_MajorCustomersAxis_xoma_Partner1Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_3vOSN9-0P0-FLZiHWIajhw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">xoma:Partner1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_srt_MajorCustomersAxis_xoma_Partner2Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_uLAkeS_2ikqgahYM_BFpvQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">xoma:Partner2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_srt_MajorCustomersAxis_xoma_Partner1Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_3OysOB_GGkiYd3yyjB2f9A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">xoma:Partner1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_srt_MajorCustomersAxis_xoma_Partner4Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_SHilGTcI4ECxZyoz6P8uNQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">xoma:Partner4Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_srt_MajorCustomersAxis_xoma_Partner3Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_eW6Ihd4mvke6ewsUy3Hagg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">xoma:Partner3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_srt_MajorCustomersAxis_xoma_Partner2Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_VFb8t0MUH0G_Z4BDZPkyFw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">xoma:Partner2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_srt_MajorCustomersAxis_xoma_Partner1Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_OklwX0sEhUKh7TG7yMRNEw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">xoma:Partner1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_R8Pr3r4-T0atb20N_SOFQg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:TenYearWarrantsIssuedThirdRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_xvSWiZXzv0KYrc1BLRxaDA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:CommonStockWarrantExercisePrice14.71Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_TPmH3rSX0kqVVDT3mwjQVA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:TenYearWarrantsIssuedThirdRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_IW4xedCf1EONa-iq8razoA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">xoma:CommonStockWarrantExercisePrice14.71Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_lyjBTUwVbUyOd4KtP5Gu-g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021__kfZV7JTZUaYuVCcUwl-Cg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_9fLx36Xpp0Oo2wwcPihyCQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_8L7cEkq67EeCxAnI09lGvA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_0k9Iaqnwd06OsUIk7HwMEw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_wkmIyE0jUkOmFM4P8qQX2A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_7KGCjOdAWkKDUJtQiWx04A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_YKgnRcgp30yLgGtobgVXyQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_p69-pIRmOU6cPwJMvLqNSA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_m8qyydbCFEaJdTCv-WBD4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_akCqUsNekUK0f0Q6DuRi7A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_82zqclNhY0GJGFKyo32O1Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_-LsGHkQ-r0C10A2ulFZGhA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_Gr7k7W5HhEC0zf3RWdymsw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_LbLsp9ZkfkCPh5v5V7bOsw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:JanssenBiotechInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_AffimedMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_mOwWuP4wskCXg5lMAASlgQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffimedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_0J69dylAF0i8-z1WvitMYQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:TakedaPharmaceuticalCompanyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_f8hS_ZhC6kyh-a2nsLAegA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:RezoluteIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_GIL1i6m_ikWj4R2Nl1_z1Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisPharmaAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_jNqsIu1EwE6fPsDB8xZzrg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:NovartisInternationalPharmaceuticalLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember__kbO___xJkGjYQIiIFsysw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:JanssenBiotechInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_AffimedMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_U6vKLThuqke8EfnRv8dUJQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">xoma:AffimedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">xoma:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_2Ja-erVJsE2TwmalqlMXlA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_Ly-nCcCNVEyOwbUV0qBVsg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember_5ZLg9x5yckWz22fWebcY8g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_V2QHn9TZ1U2Os4nccw_I7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_lxT004blek2W7cHNT8xELA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember_4EdMPylUGUe0Dt4op523HQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_89XiQrxi6U-bxg6UnFGjBA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_s4acrI5TS06hk24i6x3lNw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember_oMboSz0lqEOTYykVt-gofg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_q9rTRUIKZEeJEnJsjreVeA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_NYjwGA24DUagvxCWxn84Ow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember_q5E1VWyBm0qYx76IUNrtVg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_us-gaap_AssetAcquisitionAxis_xoma_ObsevaIntellectualPropertyRightsMember_ZsDO0IohTEmlxBFNZXxV-w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">xoma:ObsevaIntellectualPropertyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_us-gaap_AssetAcquisitionAxis_xoma_ObsevaIntellectualPropertyRightsMember_sYlzh40hyE6ZDGRh_bcjVw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">xoma:ObsevaIntellectualPropertyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_aLWj_8kVOUatUIpAaoSESA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember__apnO9afP0Citfd-cUI30g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_pg3TjcmZJki500S9VQ6N9A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">xoma:PerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_SYto29SUgUamWkI0SK6jEA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_z5dcpbt0dECbfqWaQSAHWA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_ulujEwUlBE-e-GfNhQVDxA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_VNTGe6PXiUSOTsNqLTklWQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_c02-OgQ2jEOGpEYnSgm2XA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_jn81l2KzzkioG_n6D7Y7SA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_rx0lmQ0x-ka_ICeF8O4eFw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_MkbIQ9bQc0eX6Gc5LtLGHQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_C-Lb32e_Qk26nc_aMAPFCA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_FsR-R6AfnkSXmuWs510eUg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_11_21_2022_To_11_21_2022_us-gaap_AssetAcquisitionAxis_xoma_ObsevaIntellectualPropertyRightsMember_lo8MSWY_Dk2sar0rv1imYg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">xoma:ObsevaIntellectualPropertyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-21</startDate>
            <endDate>2022-11-21</endDate>
        </period>
    </context>
    <context id="Duration_11_21_2022_To_11_21_2022_dk2CWh67HkeKPZD69Opgyw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
        </entity>
        <period>
            <startDate>2022-11-21</startDate>
            <endDate>2022-11-21</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_5kIt1X7W_UGV93RZQkNN3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_CDvlhsZi9Uuy4KUBUsPHcA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_mma7TpqpuUuqcv9mj7e4bw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_8_3_2023_r6fXR4PsX0-CCWc7zpOJBg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
        </entity>
        <period>
            <instant>2023-08-03</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000791908</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_customer_DppB2cRPP0aciLos32fCZw">
        <measure>xoma:customer</measure>
    </unit>
    <unit id="Unit_Standard_facility_xUSd_1xCIUaR1gnI0x8O9w">
        <measure>xoma:facility</measure>
    </unit>
    <unit id="Unit_Standard_D_PCYEJUif70CZJGJolwi3Yw">
        <measure>xoma:D</measure>
    </unit>
    <unit id="Unit_Standard_installment_8yYMWsdF_EOJHx1V1lAgKg">
        <measure>xoma:installment</measure>
    </unit>
    <unit id="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_item_ZJDcTjbqbUC2tIGJY9M-pg">
        <measure>xoma:item</measure>
    </unit>
    <unit id="Unit_Standard_product_mDp-u_9SnEGI1mu01OYOVA">
        <measure>xoma:product</measure>
    </unit>
    <unit id="Unit_Standard_EUR_cFLXt4pWsUCag8uS-iVkYw">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="Unit_Standard_period_Oxx3Sge1w0O2HvNr__SG-A">
        <measure>xoma:period</measure>
    </unit>
    <unit id="Unit_Standard_agreement_8WD-ZASWEUe8fofDOT9VGw">
        <measure>xoma:agreement</measure>
    </unit>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ"
      id="Hidden_NPWKx_bg_0qAoDF6yFNvtg"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg"
      id="Hidden_NMX77_cSTku-OJ-pXw1IbA"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_B7d29QvlcEe4N-_OPoM0aw"
      id="Hidden_rG8qdelPsE2MZDrhfrBOUw"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_GAngHNpHWkmY3_zgBQQUhg"
      id="Hidden_hwGUEJwvdUSJVpS6POw7GQ"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_6973Ln0mrUSWVWSvhpZzAw"
      id="Hidden_IsaLZDRs0E2--Y-WLDu3kw"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_brrjfnRro02jXTsYqcCsLA"
      id="Hidden_yk9AWBRJokWIwrr3poqSwA"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw"
      xsi:nil="true"/>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      id="Tc_0AW44bk-k0SF_-_g-ZyaIg_2_1">0000791908</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      id="Tc_SyvKAqS-I0ebvuIxboXhDg_3_1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      id="Tc_MI2QgBkQmk2Lc2tUtsQD9Q_4_1">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      id="Tc_nRomgyjoo06EUZeazLH85w_5_1">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      id="Tc_yTyHC_A3vkShen9-18t6Gw_6_1">false</dei:AmendmentFlag>
    <us-gaap:PreferredStockDividendsPerShareCashPaid
      contextRef="Duration_1_17_2023_To_1_17_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_lz1JUm8bHUSBbGCkkt6ACA"
      decimals="5"
      id="Hidden_6FlVNMctY0q9dw8fCOKxTg"
      unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg">0.53906</us-gaap:PreferredStockDividendsPerShareCashPaid>
    <us-gaap:PreferredStockDividendsPerShareCashPaid
      contextRef="Duration_1_17_2023_To_1_17_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_I1U0dl2b_U6ewgR9AxdDcA"
      decimals="5"
      id="Hidden_9royLRcMl0Knqef269WU1Q"
      unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg">0.52344</us-gaap:PreferredStockDividendsPerShareCashPaid>
    <us-gaap:PreferredStockDividendsPerShareCashPaid
      contextRef="Duration_4_17_2023_To_4_17_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_DiAyNLOtMkyP4bogjr0ljA"
      decimals="5"
      id="Hidden_qWHrIk0HxkKu1Feelg1QWg"
      unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg">0.53906</us-gaap:PreferredStockDividendsPerShareCashPaid>
    <us-gaap:PreferredStockDividendsPerShareCashPaid
      contextRef="Duration_4_17_2023_To_4_17_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_Z6poHWjacUe3yoIoMnG5Gw"
      decimals="5"
      id="Hidden_zyL_9MT4C06Qx4obkYEVKw"
      unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg">0.52344</us-gaap:PreferredStockDividendsPerShareCashPaid>
    <us-gaap:PreferredStockDividendsPerShareCashPaid
      contextRef="Duration_7_17_2023_To_7_17_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_tFHfgUHPO0eyTGuDDDFz_A"
      decimals="5"
      id="Hidden_hWIxlEMoI06Nfvonzanuzg"
      unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg">0.53906</us-gaap:PreferredStockDividendsPerShareCashPaid>
    <us-gaap:PreferredStockDividendsPerShareCashPaid
      contextRef="Duration_7_17_2023_To_7_17_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_D4y9SqGnwUyCojdGJ8gVXQ"
      decimals="5"
      id="Hidden_Q-ZWoTYYE0qrtlCrmMWbHw"
      unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg">0.52344</us-gaap:PreferredStockDividendsPerShareCashPaid>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="Duration_10_1_2020_To_10_31_2020_dei_LegalEntityAxis_xoma_RezoluteIncMember_ajuHCP8Cvkqkr0Grn5eRPw"
      decimals="2"
      id="Hidden_U1OJbQlzmUOeCcJTMgU3Qw"
      unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ">0.02</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_5_1_2023_To_5_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_gHPGrk0L1EOQ1hUygp_Gpw"
      decimals="3"
      id="Hidden_pz-y6RJKqkG2-1h8_aEPqw"
      unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ">0.333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_5_1_2023_To_5_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_jGf-N4U7oEWRkZ347gsAlA"
      decimals="3"
      id="Hidden_mBhYOSdezkKayi1Fqww_nQ"
      unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ">0.333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_5_1_2023_To_5_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_aWe1HEcOJkO4GJNqP9UK8w"
      decimals="3"
      id="Hidden_npSSwNAmG0yLnAtmVxINPw"
      unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ">0.333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <dei:DocumentType
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      id="Narr_Kc5wecrTWkyuEh5louYcIA">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      id="Tc_FOyOapdRsUWdtbtVhk1LsA_1_0">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      id="Narr_Uz-8Qil1n0CP9dzozX_HKg">2023-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      id="Tc_V9mb4Bv7k0KkITRo40qNZg_1_0">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      id="Narr_q6_xZRid50OQOn5HCtKM7g">001-39801</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      id="Narr_c_1KadjLv0uo04-DjCw5PA">XOMA Corporation</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      id="Tc_eOMVIEvTIEabk_0Jr1NOhQ_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      id="Tc_mnbhobmSbUuiqlqK3viJnQ_1_2">52-2154066</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      id="Narr_IqhBfKiw1Ei5nLcApWnNvQ">2200 Powell Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      id="Narr_M2f-8DpRBU2B-QMx7B2NXA">Suite&#160;310</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      id="Narr_9AO7inETmUK0mlIwjO5-FQ">Emeryville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      id="Narr_344_jadOP0Ot2gocHbvMfQ">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      id="Tc_rdBzJX5Xa0elx-8_rZEBrA_6_2">94608</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      id="Narr_lA4YAdsaZUKiaigVcrsMhw">510</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      id="Narr_bGkQ3JSyfEK0AGUU5DkSWw">204-7200</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_CDvlhsZi9Uuy4KUBUsPHcA"
      id="Tc_7IZ-DSWeUUyeOGYIKzOB8w_2_0">Common Stock, $0.0075 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_CDvlhsZi9Uuy4KUBUsPHcA"
      id="Tc_PJAmnnlZ3EeDUk9X2UXUYA_2_1">XOMA</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_CDvlhsZi9Uuy4KUBUsPHcA"
      id="Tc_wTOsb6wqeUGaoq9fX41Gsg_2_2">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_5kIt1X7W_UGV93RZQkNN3A"
      id="Tc_oVvxkeqLzkK5hqYjnXgXvw_3_0">8.625% Series A Cumulative Perpetual Preferred Stock, par value $0.05 </dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_5kIt1X7W_UGV93RZQkNN3A"
      id="Tc_olpGeYeqP0yvcDwiUwkR7g_3_1">XOMAP</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_5kIt1X7W_UGV93RZQkNN3A"
      id="Tc_GVFnMUfgwUmGHWbayR2hMQ_3_2">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_mma7TpqpuUuqcv9mj7e4bw"
      id="Tc_gSCMX6NmeUKa4XOB-XzXoQ_4_0">Depositary Shares (each representing 1/1000th interest in a share of 8.375% Series B Cumulative Perpetual Preferred Stock, par value $0.05)</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_mma7TpqpuUuqcv9mj7e4bw"
      id="Tc_LPsUpwK7UkK1jZ-aasb34Q_4_1">XOMAO</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_mma7TpqpuUuqcv9mj7e4bw"
      id="Tc_hqYKlUlmXk2UxEaAqOCqgA_4_2">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      id="Narr_7p0kLGQDNEiAZiQ_E2-09A">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      id="Narr_ejKl7Q2wIEi79yv1PKM-4g">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      id="Tc_onaFXdfvLUq9loO7m474IQ_2_0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      id="Tc_zw6amU5UFEGqcyNEZGjHSQ_2_4">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      id="Tc_ln2jLcZE40GYBD9uJTIZlg_3_4">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      id="Narr_1j_Rmwc3eUOncJ2G9dJimA">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_8_3_2023_r6fXR4PsX0-CCWc7zpOJBg"
      decimals="INF"
      id="Narr_fibhZ2HWbk2Yw02UmupPnw"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">11472808</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ"
      decimals="-3"
      id="Tc_mnBMrhlOH0CxBSRn0Q0lsw_6_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">31445000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg"
      decimals="-3"
      id="Tc_7bisubx6-EKEF45xSo-ggA_6_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">57826000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ"
      decimals="-3"
      id="Tc_wrMFB36xlUicnW_latYCaQ_7_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">320000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg"
      decimals="-3"
      id="Tc_BBl1Fkqh9UK3ClWOGAOgOg_7_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">335000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent
      contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ"
      decimals="-3"
      id="Tc_YhClj17fDk2d2jlH3OI5aQ_8_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">901000</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent
      contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg"
      decimals="-3"
      id="Tc_tPAnJc0xQka95V09NA4u-A_8_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">1000</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <xoma:RightsReceivableCurrent
      contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ"
      decimals="-3"
      id="Tc_6UvBAC3Cl0Sl2hqm_5UVlA_9_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">4958000</xoma:RightsReceivableCurrent>
    <xoma:RightsReceivableCurrent
      contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg"
      decimals="-3"
      id="Tc_amoMYgtYbkiIRk21mIDGNg_9_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">2366000</xoma:RightsReceivableCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ"
      decimals="-3"
      id="Tc_QH8YaiPbwE6Hg1oSyAas8A_10_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">799000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg"
      decimals="-3"
      id="Tc_k6w1iyE7wE6QLC4MMwpNJQ_10_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">725000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ"
      decimals="-3"
      id="Tc_qEE_a4lEUUShgnIfr4oVgw_11_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">38423000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg"
      decimals="-3"
      id="Tc_p7-mZTCYrEWSPxv-GK4XnA_11_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">61253000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ"
      decimals="-3"
      id="Tc_99KZ4LWb50-6joCVyWHknA_12_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">5000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg"
      decimals="-3"
      id="Tc_G5AKC6vlSk6IYEcen--e7Q_12_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">7000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ"
      decimals="-3"
      id="Tc_xVFmYnmDW0Sb75gAkXRQ_w_13_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">17000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg"
      decimals="-3"
      id="Tc_zbOfDpifSkiQ2iYn9VMNgQ_13_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">29000</us-gaap:OperatingLeaseRightOfUseAsset>
    <xoma:LongTermRightsReceivableNonCurrent
      contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ"
      decimals="-3"
      id="Tc_hn3LeFMK80a_9Wk5bKCtiA_14_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">72232000</xoma:LongTermRightsReceivableNonCurrent>
    <xoma:LongTermRightsReceivableNonCurrent
      contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg"
      decimals="-3"
      id="Tc_ccietED86E-c_APFZxNKLw_14_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">63683000</xoma:LongTermRightsReceivableNonCurrent>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ"
      decimals="-3"
      id="Tc_H14ohIkH-kiMw5UgmeTlEw_15_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">14701000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg"
      decimals="-3"
      id="Tc_Xx3kPRQ3-Eyym4Xez6Wt-A_15_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">15150000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ"
      decimals="-3"
      id="Tc_J_1s3xvCQ0Ka_7fGqi7Yww_16_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">283000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg"
      decimals="-3"
      id="Tc_0OF1W-R4j0u3IoSmnszoBQ_16_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">260000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ"
      decimals="-3"
      id="Tc_KHTpH93TZ0eYrsAbzz2zqQ_17_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">125661000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg"
      decimals="-3"
      id="Tc_TnuZeym5Dk-H0FqLbupvcQ_17_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">140382000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ"
      decimals="-3"
      id="Tc_fBySUXT1lkq6uKYNGY_xNg_21_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">740000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg"
      decimals="-3"
      id="Tc_e79ff7E1cEa7lKb384oHfA_21_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">524000</us-gaap:AccountsPayableCurrent>
    <xoma:AccruedAndOtherLiabilitiesCurrent
      contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ"
      decimals="-3"
      id="Tc_RKrp0pcFSkuZpziI63yY0Q_22_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">1933000</xoma:AccruedAndOtherLiabilitiesCurrent>
    <xoma:AccruedAndOtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg"
      decimals="-3"
      id="Tc__NbyUrSX0E6ccRp8ECqJLw_22_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">2918000</xoma:AccruedAndOtherLiabilitiesCurrent>
    <xoma:ContingentConsiderationUnderPurchaseAgreements
      contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ"
      decimals="-3"
      id="Tc_0KikkdIKOUSOCFOPHbXZdw_23_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">1000000</xoma:ContingentConsiderationUnderPurchaseAgreements>
    <xoma:ContingentConsiderationUnderPurchaseAgreements
      contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg"
      decimals="-3"
      id="Tc_FzVmzvXwhku5MZSVJNxE5Q_23_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">75000</xoma:ContingentConsiderationUnderPurchaseAgreements>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ"
      decimals="-3"
      id="Tc__a29X3I0lUaZqBqJACrclQ_24_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">17000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg"
      decimals="-3"
      id="Tc_9ut3iumdlE2my3W8uk1Byw_24_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">34000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:DeferredIncomeCurrent
      contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ"
      decimals="-3"
      id="Tc_cxAgVluMpUiDDLp5bJZ0Uw_25_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">2029000</us-gaap:DeferredIncomeCurrent>
    <us-gaap:DeferredIncomeCurrent
      contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg"
      decimals="-3"
      id="Tc_Rahx76xc2EmUU-uA0NPb-g_25_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">1899000</us-gaap:DeferredIncomeCurrent>
    <xoma:AccruedPreferredStockDividendCurrent
      contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ"
      decimals="-3"
      id="Tc_EZCcAmv380ujzqitvLlosQ_26_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">1368000</xoma:AccruedPreferredStockDividendCurrent>
    <xoma:AccruedPreferredStockDividendCurrent
      contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg"
      decimals="-3"
      id="Tc_MICFAAf1n0e52qWInxfeVQ_26_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">1368000</xoma:AccruedPreferredStockDividendCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ"
      decimals="-3"
      id="Tc_oV4gp5YauUGZzV8dFyhapw_27_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">7087000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg"
      decimals="-3"
      id="Tc_dutY5mp_bE-05iLXKgjI-A_27_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">6818000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredIncomeNoncurrent
      contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ"
      decimals="-3"
      id="Tc_Zj9mL5rWUUyZclGWwewfvA_28_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">8450000</us-gaap:DeferredIncomeNoncurrent>
    <us-gaap:DeferredIncomeNoncurrent
      contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg"
      decimals="-3"
      id="Tc_1Vke-2w2akuuxEna425xkA_28_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">9550000</us-gaap:DeferredIncomeNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ"
      decimals="-3"
      id="Tc_fy66ePV-W0aztdngv2ZnwA_29_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">15537000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg"
      decimals="-3"
      id="Tc_EyL5dcYx-0-svkx32KgD0g_29_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">16368000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ"
      decimals="INF"
      id="Narr_BtWhmKAXyECzt6havANjaA"
      unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg">0.05</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg"
      decimals="INF"
      id="Narr_vlm8cwM6FUmWGJtNHCufXg"
      unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg">0.05</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ"
      decimals="INF"
      id="Narr_IOayXYMqZEqEXOXashOQLQ"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg"
      decimals="INF"
      id="Narr_G-Y6L21A2E-gaSWXPsBBMg"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_5kIt1X7W_UGV93RZQkNN3A"
      decimals="INF"
      id="Narr_k31wrLmgGkuiHRQToQ7wfQ"
      unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ">0.08625</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_xCuxHxFsWUK7HkZ9m3D7Zg"
      decimals="INF"
      id="Narr_j1QXeZ27Bki1E1X3h3ax0g"
      unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ">0.08625</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_HnMB9b7CRUKpmLvME2vUuQ"
      decimals="0"
      id="Narr_cbOJ1ZtZAkS0dSBMISdTZA"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">984000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_ORljYJEjFUKKL0etVMNkrA"
      decimals="0"
      id="Narr_B6MQVLttZ0uopFYadd3l7Q"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">984000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_HnMB9b7CRUKpmLvME2vUuQ"
      decimals="0"
      id="Narr_VE-44KbL1EWB4mSn9ARY_Q"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">984000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_ORljYJEjFUKKL0etVMNkrA"
      decimals="0"
      id="Narr_PqWkPw7k7ke7e1cGphnK0g"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">984000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_HnMB9b7CRUKpmLvME2vUuQ"
      decimals="-3"
      id="Tc_FK8HfYnYrku8JQbt13UwKQ_35_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">49000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_ORljYJEjFUKKL0etVMNkrA"
      decimals="-3"
      id="Tc_4YSYYYZk80aXLbJ9w20l3w_35_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">49000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_mZzBVYXOQEiwSAFnA-OODw"
      decimals="INF"
      id="Narr_pDPq4QE3y0eZ81WUQOnjwg"
      unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ">0.08375</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_vzagK5EjmEqHa32z1YO0qQ"
      decimals="INF"
      id="Narr_juyuxGEQ_k-Ia3ZEjgUUng"
      unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ">0.08375</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_B7d29QvlcEe4N-_OPoM0aw"
      decimals="0"
      id="Narr_BGJwp-lyGUSrbokhHzJ0HA"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">1600</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_GAngHNpHWkmY3_zgBQQUhg"
      decimals="0"
      id="Narr_uEbvI7H1806S0PDvLKPxvQ"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">1600</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_B7d29QvlcEe4N-_OPoM0aw"
      decimals="0"
      id="Narr_4X0tbkbsDUONUBGPPNHAGA"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">1600</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_GAngHNpHWkmY3_zgBQQUhg"
      decimals="0"
      id="Narr_dvPT1vjIdkCnS6zrdXd_sw"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">1600</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_6973Ln0mrUSWVWSvhpZzAw"
      decimals="0"
      id="Narr_woxZfLpr2kqrJoQHtHK7yQ"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">5003</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_brrjfnRro02jXTsYqcCsLA"
      decimals="0"
      id="Narr_QmROh7mnJUedeyseEj0wjg"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">5003</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_6973Ln0mrUSWVWSvhpZzAw"
      decimals="0"
      id="Narr_2gjH48B6iUq451f24MXHUw"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">5003</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_brrjfnRro02jXTsYqcCsLA"
      decimals="0"
      id="Narr_NTk0SkEcwk6XDI5eAz0fIQ"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">5003</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ"
      decimals="INF"
      id="Narr_3PVWXd1C4UGyzAy-6dB61A"
      unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg">0.0075</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg"
      decimals="INF"
      id="Narr_bCafT5MtyEi9lSV1HK97vA"
      unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg">0.0075</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ"
      decimals="INF"
      id="Narr_HIgzcMH3Mkal3ueGN8htQQ"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">277333332</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg"
      decimals="INF"
      id="Narr_37l-LAElp0O6JxFfMWpIpA"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">277333332</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ"
      decimals="INF"
      id="Narr_SBlSaaI1tEu8bxT6fctDvA"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">11472808</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ"
      decimals="INF"
      id="Narr_rOKbC7NkcEOG4Y0dWp-j4w"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">11472808</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg"
      decimals="INF"
      id="Narr_pQRohTiIjUuc6EWpCnRlxg"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">11454025</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg"
      decimals="INF"
      id="Narr_KqapPWwJzEGk-M1zYZVB2A"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">11454025</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ"
      decimals="-3"
      id="Tc_HXrpsloYTkqPgfj-KKKWoQ_38_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">86000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg"
      decimals="-3"
      id="Tc_98E4XZ9DAEi7b7JG_vm0pg_38_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">86000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ"
      decimals="-3"
      id="Tc_GWc_9_2OEU2vu8fxKdx5bA_39_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">1307594000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg"
      decimals="-3"
      id="Tc_I395dD7isUaL9fOEEQlvmw_39_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">1306271000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ"
      decimals="-3"
      id="Tc_8JbMg0JBO0OmSiwZP2j_Mw_40_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">-1197605000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg"
      decimals="-3"
      id="Tc_JrEy0dGCvUaNUlSRaetCmA_40_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">-1182392000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ"
      decimals="-3"
      id="Tc_f0EfPPjgDEWVUxes6lTrfA_41_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">110124000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg"
      decimals="-3"
      id="Tc_dm90CQ3U30iT-OIsRUpymw_41_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">124014000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ"
      decimals="-3"
      id="Tc_v5s9VNgOoEOZHdfXY6kcnA_42_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">125661000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg"
      decimals="-3"
      id="Tc_Qhekhl8UZEG2sf4x3U-NaA_42_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">140382000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg"
      decimals="-3"
      id="Tc_KYwslB6Rz0CPxYO1raADgQ_5_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">1125000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_4_1_2022_To_6_30_2022_MkbIQ9bQc0eX6Gc5LtLGHQ"
      decimals="-3"
      id="Tc_WViOMeN6ukyHVntbDbzluQ_5_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">525000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      decimals="-3"
      id="Tc_gNUaOnrYNkaSOXMgiZENrw_5_9"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">1125000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw"
      decimals="-3"
      id="Tc_Ent9xjGwvEKxbyHX1_LT8Q_5_12"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">3275000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg"
      decimals="-3"
      id="Tc_AOGinyvjEkeS63-SCzb_9w_6_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">533000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="Duration_4_1_2022_To_6_30_2022_MkbIQ9bQc0eX6Gc5LtLGHQ"
      decimals="-3"
      id="Tc_WLfV2-vOUk-Z8ayrJHO2Vw_6_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">458000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      decimals="-3"
      id="Tc_pqkkutIFP0WpXmXx8KpKlQ_6_9"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">970000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw"
      decimals="-3"
      id="Tc_plVt_4shmkqhd0cHtBm9tQ_6_12"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">815000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:Revenues
      contextRef="Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg"
      decimals="-3"
      id="Tc_q6UhMiTKPU2OPahOvACDNg_7_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">1658000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_4_1_2022_To_6_30_2022_MkbIQ9bQc0eX6Gc5LtLGHQ"
      decimals="-3"
      id="Tc_otJ1AirNOEivJKxTm-8P7A_7_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">983000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      decimals="-3"
      id="Tc_jFRVr32d50a5d2o9z9sUbQ_7_9"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">2095000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw"
      decimals="-3"
      id="Tc_i5p0sYZrcUWsCIEugwrAxw_7_12"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">4090000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg"
      decimals="-3"
      id="Tc_2b1yCf2RekCsMeLYk4JgEw_10_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">39000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_4_1_2022_To_6_30_2022_MkbIQ9bQc0eX6Gc5LtLGHQ"
      decimals="-3"
      id="Tc_-BPXF-VM50iE2Q8FWmF11w_10_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">40000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      decimals="-3"
      id="Tc_0JBOOCL0nUWp9-wC1yGDsQ_10_9"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">93000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw"
      decimals="-3"
      id="Tc_eV6qnpiEnkiHubyKEysMCw_10_12"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">96000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg"
      decimals="-3"
      id="Tc_5Wnk5c-ukUuA2lyxs0k0Gg_11_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">5777000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_4_1_2022_To_6_30_2022_MkbIQ9bQc0eX6Gc5LtLGHQ"
      decimals="-3"
      id="Tc_2VExbtoBHkeDAOc-FGlDpA_11_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">5710000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      decimals="-3"
      id="Tc_bCjiUXVxw0CoOx7HrPoeNQ_11_9"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">11973000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw"
      decimals="-3"
      id="Tc_Cw7oh8EEKEKRd41V8zQAnA_11_12"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">10826000</us-gaap:GeneralAndAdministrativeExpense>
    <xoma:ImpairmentOfLongTermRightsReceivableNonCurrent
      contextRef="Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg"
      decimals="-3"
      id="Tc_sXCv4DS9ZEuZNW2GbC227w_12_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">1575000</xoma:ImpairmentOfLongTermRightsReceivableNonCurrent>
    <xoma:ImpairmentOfLongTermRightsReceivableNonCurrent
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      decimals="-3"
      id="Tc_HFL7-YNSH0ON8Rb2pvyzgw_12_9"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">1575000</xoma:ImpairmentOfLongTermRightsReceivableNonCurrent>
    <us-gaap:LitigationSettlementExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      decimals="-3"
      id="Tc_7qpLO1eFS0akOpG6oicWbw_13_9"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">4132000</us-gaap:LitigationSettlementExpense>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg"
      decimals="-3"
      id="Tc_sRP3kM3rZUaUp8YW_LQazw_14_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">224000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      decimals="-3"
      id="Tc_DDco_JnhCEaf9Z-dHTX8SA_14_9"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">449000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:OperatingExpenses
      contextRef="Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg"
      decimals="-3"
      id="Tc_uU2ntOUt8EiSziZxBqxe7w_15_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">7615000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_4_1_2022_To_6_30_2022_MkbIQ9bQc0eX6Gc5LtLGHQ"
      decimals="-3"
      id="Tc_7EBD3cN3bk2DLSX_n09x8g_15_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">5750000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      decimals="-3"
      id="Tc_28QJw4UffE-PTrPk4st7qA_15_9"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">18222000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw"
      decimals="-3"
      id="Tc_yDJmzwpf_E2_OamJrpBHbg_15_12"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">10922000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg"
      decimals="-3"
      id="Tc_J6aNDZnpi0K-xqKqGZEq4Q_17_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">-5957000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_4_1_2022_To_6_30_2022_MkbIQ9bQc0eX6Gc5LtLGHQ"
      decimals="-3"
      id="Tc_l1Rz2lRoGkChaMqfrKU8GQ_17_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">-4767000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      decimals="-3"
      id="Tc_GcqcgNtAoEulHPyW6BdhEA_17_9"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">-16127000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw"
      decimals="-3"
      id="Tc_hCQnslicx0K-cNxMdwXhcQ_17_12"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">-6832000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg"
      decimals="-3"
      id="Tc_7h3Rf6DhF0-fW2Es2gA4Ew_18_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">557000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_4_1_2022_To_6_30_2022_MkbIQ9bQc0eX6Gc5LtLGHQ"
      decimals="-3"
      id="Tc_6DCbLMZTREuc5kkeHPBQMQ_18_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">97000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      decimals="-3"
      id="Tc_JzHNhY8HkkyuA9ugaj8Y1g_18_9"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">914000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw"
      decimals="-3"
      id="Tc_8gSOx1aXY0uxyPQwhVtf3Q_18_12"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">-118000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg"
      decimals="-3"
      id="Tc_qA_eJWfGs0eodEnej0JWrw_19_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">-5400000</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg"
      decimals="-3"
      id="Tc_qA_eJWfGs0eodEnej0JWrw_19_3_2"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">-5400000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2022_To_6_30_2022_MkbIQ9bQc0eX6Gc5LtLGHQ"
      decimals="-3"
      id="Tc_L5sHkm8e3EOmSIHK7A_7sQ_19_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">-4670000</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_4_1_2022_To_6_30_2022_MkbIQ9bQc0eX6Gc5LtLGHQ"
      decimals="-3"
      id="Tc_L5sHkm8e3EOmSIHK7A_7sQ_19_6_2"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">-4670000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      decimals="-3"
      id="Tc_RNHJpBL-KkSi4NhyPGiVZA_19_9"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">-15213000</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      decimals="-3"
      id="Tc_RNHJpBL-KkSi4NhyPGiVZA_19_9_2"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">-15213000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw"
      decimals="-3"
      id="Tc_7CBde6iyKkK_f8J58nUJCA_19_12"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">-6950000</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw"
      decimals="-3"
      id="Tc_7CBde6iyKkK_f8J58nUJCA_19_12_2"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">-6950000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg"
      decimals="-3"
      id="Tc_pb_U-xxAk0-Ze_jPfje92w_20_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">1368000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="Duration_4_1_2022_To_6_30_2022_MkbIQ9bQc0eX6Gc5LtLGHQ"
      decimals="-3"
      id="Tc_sye2smMFckGXO9Q4_OFV3Q_20_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">1368000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      decimals="-3"
      id="Tc_F0FQEtHXK0mWwGqOdD7Peg_20_9"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">2736000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw"
      decimals="-3"
      id="Tc_cjHu1cnPpUaa2Lvs0wpfvw_20_12"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">2736000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg"
      decimals="-3"
      id="Tc_EtadPIiCMkaG5XVDghriHg_21_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">-6768000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg"
      decimals="-3"
      id="Tc_EtadPIiCMkaG5XVDghriHg_21_3_2"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">-6768000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_4_1_2022_To_6_30_2022_MkbIQ9bQc0eX6Gc5LtLGHQ"
      decimals="-3"
      id="Tc__g-RY8KLYEifyP2GwjfmeA_21_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">-6038000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="Duration_4_1_2022_To_6_30_2022_MkbIQ9bQc0eX6Gc5LtLGHQ"
      decimals="-3"
      id="Tc__g-RY8KLYEifyP2GwjfmeA_21_6_2"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">-6038000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      decimals="-3"
      id="Tc_NHqf0rRbZUWFvVqrTdcGiA_21_9"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">-17949000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      decimals="-3"
      id="Tc_NHqf0rRbZUWFvVqrTdcGiA_21_9_2"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">-17949000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw"
      decimals="-3"
      id="Tc_L5-ZkzkFyEKHEPxnz9g3cA_21_12"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">-9686000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw"
      decimals="-3"
      id="Tc_L5-ZkzkFyEKHEPxnz9g3cA_21_12_2"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">-9686000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg"
      decimals="2"
      id="Tc__r4QnhvHJU-MZZsx5Uwu2A_22_3"
      unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg">-0.59</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg"
      decimals="2"
      id="Tc__r4QnhvHJU-MZZsx5Uwu2A_22_3_2"
      unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg">-0.59</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_4_1_2022_To_6_30_2022_MkbIQ9bQc0eX6Gc5LtLGHQ"
      decimals="2"
      id="Tc_mUSmPJ84z0-AqDe3bsTwgQ_22_6"
      unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg">-0.53</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_4_1_2022_To_6_30_2022_MkbIQ9bQc0eX6Gc5LtLGHQ"
      decimals="2"
      id="Tc_mUSmPJ84z0-AqDe3bsTwgQ_22_6_2"
      unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg">-0.53</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      decimals="2"
      id="Tc_ER53x1tEQ06YE0aO-qyX2Q_22_9"
      unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg">-1.57</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      decimals="2"
      id="Tc_ER53x1tEQ06YE0aO-qyX2Q_22_9_2"
      unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg">-1.57</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw"
      decimals="2"
      id="Tc_q4ATuF7RSEGtl9hZQK7yhg_22_12"
      unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg">-0.85</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw"
      decimals="2"
      id="Tc_q4ATuF7RSEGtl9hZQK7yhg_22_12_2"
      unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg">-0.85</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg"
      decimals="0"
      id="Tc_3KpI8E4mTEuHRUVHMidqWg_23_3"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">11466</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg"
      decimals="0"
      id="Tc_3KpI8E4mTEuHRUVHMidqWg_23_3_2"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">11466</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_4_1_2022_To_6_30_2022_MkbIQ9bQc0eX6Gc5LtLGHQ"
      decimals="0"
      id="Tc_l99oJ_fWl0Kxq6EeWOQsLg_23_6"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">11421</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_4_1_2022_To_6_30_2022_MkbIQ9bQc0eX6Gc5LtLGHQ"
      decimals="0"
      id="Tc_l99oJ_fWl0Kxq6EeWOQsLg_23_6_2"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">11421</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      decimals="0"
      id="Tc_kzQNd2w640q0wyr4NL2-Ww_23_9"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">11463</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      decimals="0"
      id="Tc_kzQNd2w640q0wyr4NL2-Ww_23_9_2"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">11463</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw"
      decimals="0"
      id="Tc_MyaFDnapwEG2SzS41fVLZw_23_12"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">11376</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw"
      decimals="0"
      id="Tc_MyaFDnapwEG2SzS41fVLZw_23_12_2"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">11376</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_F7GJ2ijBaESNLxxCWOPV9Q"
      decimals="-3"
      id="Tc_2Fpl34MVQEq8nvwvE1V4Zw_4_1"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">984000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_F7GJ2ijBaESNLxxCWOPV9Q"
      decimals="-3"
      id="Tc_1LwoGBpkhkCXXarf4sKYCQ_4_4"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">49000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_PeotIRnSfEqGsKf-u1aQaA"
      decimals="-3"
      id="Tc_mJ9ru5yRDk6bVh_lKuC0gg_4_6"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">2000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_mjGDeVHtJEy-hmsEfPC5Jw"
      decimals="-3"
      id="Tc_iFMkhEB-2kmDkD6hC4sVMA_4_11"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">5000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vprHlJrRr0yw8rVJERIeVg"
      decimals="-3"
      id="Tc_f10v1UPuykaB85QQgkKNew_4_16"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">11454000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vprHlJrRr0yw8rVJERIeVg"
      decimals="-3"
      id="Tc_BqGRGfaqA0KAQW33nRiDdA_4_19"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">86000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_gXsLP4N9SkWM0pvx20VSug"
      decimals="-3"
      id="Tc_z6EqXBCjh02Oy-j9-pRVHA_4_22"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">1306271000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ULAJkPFmo0GKfvexehN6Xw"
      decimals="-3"
      id="Tc_BME_NV1qWkKqceDA8l8MQQ_4_25"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">-1182392000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg"
      decimals="-3"
      id="Tc_6L2pXaDWS0mLHygCNpdcbA_4_28"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">124014000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_JyWKfa6Y2kCEdbWR9Enhww"
      decimals="-3"
      id="Tc_2BSDnpnKeUGmDeegUSPDpw_5_16"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">7000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_c02-OgQ2jEOGpEYnSgm2XA"
      decimals="-3"
      id="Tc_vNruytLBv0qDvNxq4hJEPg_5_22"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">123000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2023_To_3_31_2023_jn81l2KzzkioG_n6D7Y7SA"
      decimals="-3"
      id="Tc_A9GPlyx2Skm_PLn87hqlKw_5_28"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">123000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_c02-OgQ2jEOGpEYnSgm2XA"
      decimals="-3"
      id="Tc_UroshkgjaU6d9NvLAR1BWg_6_22"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">1570000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2023_To_3_31_2023_jn81l2KzzkioG_n6D7Y7SA"
      decimals="-3"
      id="Tc_mRDJTayyY06quX7SzAcryQ_6_28"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">1570000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:DividendsPreferredStockStock
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_c02-OgQ2jEOGpEYnSgm2XA"
      decimals="-3"
      id="Tc_Ax-XVhfIrk2XlyHRBopXQg_7_22"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">1368000</us-gaap:DividendsPreferredStockStock>
    <us-gaap:DividendsPreferredStockStock
      contextRef="Duration_1_1_2023_To_3_31_2023_jn81l2KzzkioG_n6D7Y7SA"
      decimals="-3"
      id="Tc_Q3UaekEgwkG5YhpIcoyp5w_7_28"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">1368000</us-gaap:DividendsPreferredStockStock>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_fyrP0G4Pj0-aaN04bSkICQ"
      decimals="-3"
      id="Tc_rEGImT3yp0KxutSDTcG2tQ_8_25"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">-9813000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_3_31_2023_jn81l2KzzkioG_n6D7Y7SA"
      decimals="-3"
      id="Tc_zEncx1zLDEymZJHzH8pgGg_8_28"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">-9813000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_gUvLnlJ3mkOEbSXAHiiecQ"
      decimals="-3"
      id="Tc_nH_n9uz4WUSgAa7XCVTscg_9_1"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">984000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_gUvLnlJ3mkOEbSXAHiiecQ"
      decimals="-3"
      id="Tc_jsmJvMUNU0SOjb1-IyJZ2w_9_4"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">49000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_tKe_WjiZ-0ecu0LnoPu_Vw"
      decimals="-3"
      id="Tc_MSjoan6JiU6jxOY6USUnnw_9_6"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">2000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_3_31_2023_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_NVGVumu2RU2aSm58xyzVnQ"
      decimals="-3"
      id="Tc_e0_WAJLK2kiRKHeIbh95Pw_9_11"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">5000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__q8-WGlpF0afujkbjDrhAQ"
      decimals="-3"
      id="Tc_QA9VRdqvk06juL8hWUognw_9_16"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">11461000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__q8-WGlpF0afujkbjDrhAQ"
      decimals="-3"
      id="Tc_Jm_wMjvUOU2HrSd4q6LyDA_9_19"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">86000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_x45gr-vUZEyje19LB7OGtA"
      decimals="-3"
      id="Tc_ruNsLux_wky_Htwd6bgIaQ_9_22"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">1306596000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_6kc5MkORGEWUHpL16Dho2Q"
      decimals="-3"
      id="Tc_mWEMxJgfQUaCMAqNR7yNzg_9_25"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">-1192205000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2023_X5C7oga02EiygboostYHVw"
      decimals="-3"
      id="Tc_eZIecwjOS0yMdSwz_53Gow_9_28"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">114526000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_q7cIlXaQfEaTUzSmFF8pow"
      decimals="-3"
      id="Tc_4b1_TVYAvka0UyQ5PLHLqg_10_16"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">8000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_VNTGe6PXiUSOTsNqLTklWQ"
      decimals="-3"
      id="Tc_P6piJuK_lkCL8BVMUZVbbA_10_22"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">153000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg"
      decimals="-3"
      id="Tc_XtNYBKoglE2k1uyXKIHUhQ_10_28"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">153000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_q7cIlXaQfEaTUzSmFF8pow"
      decimals="-3"
      id="Tc_ohe7QCCm8U20bgvYcTFuOA_11_16"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">3000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_VNTGe6PXiUSOTsNqLTklWQ"
      decimals="-3"
      id="Tc_hJRooew0SE2DLOD1GrVVLA_11_22"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">50000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg"
      decimals="-3"
      id="Tc_DaipW3h29UCWcQxDo9z4gw_11_28"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">50000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_VNTGe6PXiUSOTsNqLTklWQ"
      decimals="-3"
      id="Tc_3SPe1PVTu0-KQrB47-mPpg_12_22"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">2163000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg"
      decimals="-3"
      id="Tc_CoDjaKAbqEaVOCr0q60WBw_12_28"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">2163000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:DividendsPreferredStockStock
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_VNTGe6PXiUSOTsNqLTklWQ"
      decimals="-3"
      id="Tc_HchDjdYtGEaHPnDwCWmhxA_13_22"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">1368000</us-gaap:DividendsPreferredStockStock>
    <us-gaap:DividendsPreferredStockStock
      contextRef="Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg"
      decimals="-3"
      id="Tc_v08ImJc3b0e2AIM3pdj-PQ_13_28"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">1368000</us-gaap:DividendsPreferredStockStock>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_A3D1KiJFt0CNaMkMfhVNww"
      decimals="-3"
      id="Tc_MSNowiaRjEyTSQFJNXObog_14_25"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">-5400000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg"
      decimals="-3"
      id="Tc_mFAVq4PG50Onrq9HqVgeRw_14_28"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">-5400000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_3elDeOQbAkSzA4XPNTMvKw"
      decimals="-3"
      id="Tc_ppLKPK-n0kyTHGJvJrjWjw_15_1"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">984000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_3elDeOQbAkSzA4XPNTMvKw"
      decimals="-3"
      id="Tc_0BPYG__Vik6FDtbKEtS6Cg_15_4"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">49000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_mN21iu-7y0Ob71zpxfq1UQ"
      decimals="-3"
      id="Tc_jmER6xUpOU2RPwUm1broVw_15_6"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">2000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_6_30_2023_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_czcB2xp3ZkO5ufWJGf_Lgg"
      decimals="-3"
      id="Tc_Pl8NUHi8uUmBH7ZoYYM8rQ_15_11"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">5000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vo9zKMnZO0aHN96tsj24CA"
      decimals="-3"
      id="Tc_p0IgP_fBuE2W6Pnnl_jt0A_15_16"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">11472000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vo9zKMnZO0aHN96tsj24CA"
      decimals="-3"
      id="Tc_KJrDjyxDgUq8DbgZwiB0DQ_15_19"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">86000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_edqle5HbXEm7yuZsNCNZ5Q"
      decimals="-3"
      id="Tc_uulqSvNU-U6k_DSCUQaLLQ_15_22"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">1307594000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember__SjruGbNMke6VHotvJqC3A"
      decimals="-3"
      id="Tc_Ioaowpj840mijIXc66Ffmw_15_25"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">-1197605000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ"
      decimals="-3"
      id="Tc_pMCFgKtYOE6nVnB9MDgoNw_15_28"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">110124000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_6rQbM7sQNky8O85-NJM6Kw"
      decimals="-3"
      id="Tc_mlsLCXNwHUmcs-Rs1h1CuQ_4_1"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">984000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_6rQbM7sQNky8O85-NJM6Kw"
      decimals="-3"
      id="Tc_8A-yi7Om_UOP0jF4flp3eQ_4_4"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">49000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_2zCuoTh9XU-z3zmcVTU37A"
      decimals="-3"
      id="Tc_M7vFosx7OUmPlPp74emiew_4_6"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">2000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_uuOaeeICIE63neZVbvxrYw"
      decimals="-3"
      id="Tc_vsrBKXIQv06WOiEQWFuAqw_4_11"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">5000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xTypNCJw2kecFDKsOR8hwA"
      decimals="-3"
      id="Tc_Ig5s-6V_c0OrSza3vmQ2Kg_4_16"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">11315000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xTypNCJw2kecFDKsOR8hwA"
      decimals="-3"
      id="Tc_TvuqeA1DpkidDQQ4kVDHPA_4_19"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">85000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_S54NSxp5yk2I3fcHshTcMA"
      decimals="-3"
      id="Tc_MUNz_BK5eUyHHVXvw9z3AQ_4_22"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">1307030000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_oECYzd9liEiyvMRgwShVYg"
      decimals="-3"
      id="Tc_xXDEa-eTA0G1i06f7PxuZQ_4_25"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">-1165288000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021__kfZV7JTZUaYuVCcUwl-Cg"
      decimals="-3"
      id="Tc_x1ORCdXf3EG6ZgMqNoJpPw_4_28"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">141876000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Y8pSKqQVN0qvZ3Xp6DQmKg"
      decimals="-3"
      id="Tc_lBv9xDd9TECLmNVDzHI7Ng_5_16"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">91000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Y8pSKqQVN0qvZ3Xp6DQmKg"
      decimals="-3"
      id="Tc_lMIWccllOEO-PMlc3KwzXA_5_19"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_C-Lb32e_Qk26nc_aMAPFCA"
      decimals="-3"
      id="Tc_qyzAamIac0OlLHHnukGaLA_5_22"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">632000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2022_To_3_31_2022_FsR-R6AfnkSXmuWs510eUg"
      decimals="-3"
      id="Tc_sPMCeEOnM0CwP40IIvwrtw_5_28"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">633000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Y8pSKqQVN0qvZ3Xp6DQmKg"
      decimals="-3"
      id="Tc_-16ItjWPQk-PCN1j8yVrtg_6_16"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">4000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_C-Lb32e_Qk26nc_aMAPFCA"
      decimals="-3"
      id="Tc__rfUGAHKgECKPxZ3PrGy9A_6_22"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">85000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2022_To_3_31_2022_FsR-R6AfnkSXmuWs510eUg"
      decimals="-3"
      id="Tc_RWnxy95MZkm8Vxum1E3atA_6_28"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">85000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_C-Lb32e_Qk26nc_aMAPFCA"
      decimals="-3"
      id="Tc_La_4MFX5YU21--WRgB3zSw_7_22"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">978000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2022_To_3_31_2022_FsR-R6AfnkSXmuWs510eUg"
      decimals="-3"
      id="Tc_Li7ulYn3ZkW_39VwZOjYeg_7_28"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">978000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:DividendsPreferredStockStock
      contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_C-Lb32e_Qk26nc_aMAPFCA"
      decimals="-3"
      id="Tc_YJQmhSo5LE21Ykan7Dkqng_8_22"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">1368000</us-gaap:DividendsPreferredStockStock>
    <us-gaap:DividendsPreferredStockStock
      contextRef="Duration_1_1_2022_To_3_31_2022_FsR-R6AfnkSXmuWs510eUg"
      decimals="-3"
      id="Tc_N218XHbT_0Kb8EtgDg6rYg_8_28"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">1368000</us-gaap:DividendsPreferredStockStock>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_KGG7iA9QeU-x58nvnAGyAA"
      decimals="-3"
      id="Tc_ooWAvVSgfE61bEeIJg8yAw_9_25"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">-2280000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_3_31_2022_FsR-R6AfnkSXmuWs510eUg"
      decimals="-3"
      id="Tc_BLTh-SJBkE-BkwJbwbE_zw_9_28"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">-2280000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_3_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_jps57Fyqu0WWl7CaOtheOg"
      decimals="-3"
      id="Tc_3DKB05-YBkGSHefDaEJ-QA_10_1"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">984000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_jps57Fyqu0WWl7CaOtheOg"
      decimals="-3"
      id="Tc_eLwiW4AvWEiukcd-kKeLrA_10_4"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">49000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_3_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_eGV1-nMv9EyGZf3q_EpMbw"
      decimals="-3"
      id="Tc_3oY_ojRcuUi1bEs5FXss4g_10_6"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">2000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_3_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_q6JWreHPR0i_czphX2lVDQ"
      decimals="-3"
      id="Tc_IKfmHK-_jkKtGs5FPdKCOw_10_11"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">5000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zdAm_dbVtUOANrU35KRi-w"
      decimals="-3"
      id="Tc_fry31WtadkKMvL6A7F0faQ_10_16"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">11410000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_zdAm_dbVtUOANrU35KRi-w"
      decimals="-3"
      id="Tc_pviTtbP-2UG13QNwotDptw_10_19"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">86000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sHK3ZNTAH0aMwFqH9faHRw"
      decimals="-3"
      id="Tc_AfFQR3GquUKsa5075Yb9uw_10_22"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">1307357000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_YzMe_e-yGUGbNiPtf12IwQ"
      decimals="-3"
      id="Tc_mS1smY2URUGYVL088dRLuA_10_25"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">-1167568000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2022_wXICAr6QekumvGjfUaFcqw"
      decimals="-3"
      id="Tc_7eOahH-e1Emxg3DFOAgmgg_10_28"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">139924000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_nZVAZEbax02Nn2_S_0USBA"
      decimals="-3"
      id="Tc_AoapxW74bEuNasjH8IzFKg_11_16"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">11000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_rx0lmQ0x-ka_ICeF8O4eFw"
      decimals="-3"
      id="Tc_vvt9xfsru06spCGUJYZQbQ_11_22"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">189000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_4_1_2022_To_6_30_2022_MkbIQ9bQc0eX6Gc5LtLGHQ"
      decimals="-3"
      id="Tc_Sl0PCDMrd0ypimojZO1-Hw_11_28"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">189000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_nZVAZEbax02Nn2_S_0USBA"
      decimals="-3"
      id="Tc_D-9-crNysU-iRzvcc2Jhbg_12_16"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">3000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_rx0lmQ0x-ka_ICeF8O4eFw"
      decimals="-3"
      id="Tc_4Szj5lKUHE6ZIaOFRRkoiQ_12_22"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">45000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_4_1_2022_To_6_30_2022_MkbIQ9bQc0eX6Gc5LtLGHQ"
      decimals="-3"
      id="Tc_B_OUTnuDN0edk1TPizK7gw_12_28"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">45000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_rx0lmQ0x-ka_ICeF8O4eFw"
      decimals="-3"
      id="Tc_rPywTddWBkWOhOf3E_7OPw_13_22"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">836000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_4_1_2022_To_6_30_2022_MkbIQ9bQc0eX6Gc5LtLGHQ"
      decimals="-3"
      id="Tc_vJfH12Yoz0KKWoOeTgzJqw_13_28"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">836000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:DividendsPreferredStockStock
      contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_rx0lmQ0x-ka_ICeF8O4eFw"
      decimals="-3"
      id="Tc_kIHm_4yRikSVWOjN_dRLXA_14_22"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">1368000</us-gaap:DividendsPreferredStockStock>
    <us-gaap:DividendsPreferredStockStock
      contextRef="Duration_4_1_2022_To_6_30_2022_MkbIQ9bQc0eX6Gc5LtLGHQ"
      decimals="-3"
      id="Tc_vAa1l6skF0eOGm0SLXRRBg_14_28"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">1368000</us-gaap:DividendsPreferredStockStock>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_7O1rzT-yJUuZnLhCfrcYOg"
      decimals="-3"
      id="Tc_f_vGeZEj8k-0WUFo74YXhQ_15_25"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">-4670000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2022_To_6_30_2022_MkbIQ9bQc0eX6Gc5LtLGHQ"
      decimals="-3"
      id="Tc_voj8Ni7cf0WlrSSQChG6Bg_15_28"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">-4670000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_6_30_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_nAb-HKUTNkWZ5BAQ0-qIHA"
      decimals="-3"
      id="Tc_pFd0TerwGk2av9sp8Xi4Ig_16_1"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">984000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_nAb-HKUTNkWZ5BAQ0-qIHA"
      decimals="-3"
      id="Tc_6QdERVv4906hkddIY91V4g_16_4"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">49000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_6_30_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_63gYMzNqtUeLw4EgBOljpw"
      decimals="-3"
      id="Tc_Ic2DRbm_E0SGa3j0btCa8A_16_6"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">2000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_6_30_2022_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_vUW8gOL5lUS22XQyQHoMYg"
      decimals="-3"
      id="Tc_WK-QP3quJEOuDuahf_vrjw_16_11"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">5000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_54FxiDHYMUSAo0wczwNo8w"
      decimals="-3"
      id="Tc_1aBz_-z3Wkm74AefweJznA_16_16"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">11424000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_54FxiDHYMUSAo0wczwNo8w"
      decimals="-3"
      id="Tc_XgKr2RQHtESI2zIQwHeQ6w_16_19"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">86000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_YqOEWTXU0Ua6QvAhBoXz7Q"
      decimals="-3"
      id="Tc_9LqSB5tov0O07MeeniFCWg_16_22"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">1307059000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_nRVamYzhRUqPa-9YjzTLLA"
      decimals="-3"
      id="Tc_RLptXSHZh026MwQL3Rl7cQ_16_25"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">-1172238000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2022_lyjBTUwVbUyOd4KtP5Gu-g"
      decimals="-3"
      id="Tc_eeF21vbgYUqD2rvUMg68Lw_16_28"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">134956000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      decimals="-3"
      id="Tc_tBRcfxJMrUuXdOv_eNB_HQ_4_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">-15213000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw"
      decimals="-3"
      id="Tc_vaglJGBRI0OR6Y8ktxVruw_4_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">-6950000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      decimals="-3"
      id="Tc_bWPxS25PS0GJvSoMoxu7Mg_6_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">3733000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw"
      decimals="-3"
      id="Tc_aCSmmeK9nUuaarE2GcbczA_6_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">1815000</us-gaap:ShareBasedCompensation>
    <xoma:ImpairmentOfLongTermRightsReceivableNonCurrent
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      decimals="-3"
      id="Tc_5DxC-6VLCEqQnfcQ_Xjbew_7_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">1575000</xoma:ImpairmentOfLongTermRightsReceivableNonCurrent>
    <xoma:ChangesInEstimatedFairValueOfContingentConsideration
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      decimals="-3"
      id="Tc_e9lw8g7MTEqqr-yRjXawbQ_8_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">75000</xoma:ChangesInEstimatedFairValueOfContingentConsideration>
    <xoma:DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      decimals="-3"
      id="Tc_98O3wJqWY0qqUV4QVhRFxw_9_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">123000</xoma:DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims>
    <xoma:DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims
      contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw"
      decimals="-3"
      id="Tc_Fqnoaq5cfUWAi7NuEe2pNQ_9_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">85000</xoma:DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      decimals="-3"
      id="Tc_xnQlRfcUvUevkipDPpcMBA_10_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">449000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:DepreciationNonproduction
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      decimals="-3"
      id="Tc_FXsUK8XEaE295kfxuCfakw_11_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">2000</us-gaap:DepreciationNonproduction>
    <us-gaap:DepreciationNonproduction
      contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw"
      decimals="-3"
      id="Tc_8C7F1PswJk-zHK5Sh-djYw_11_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">3000</us-gaap:DepreciationNonproduction>
    <xoma:OperatingLeasePaymentsNonCash
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      decimals="-3"
      id="Tc_XIZCfcbWyEKlGRQDXa2iew_12_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">-97000</xoma:OperatingLeasePaymentsNonCash>
    <xoma:OperatingLeasePaymentsNonCash
      contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw"
      decimals="-3"
      id="Tc_mlMFHc-r3EqtSMaYZ0wMfQ_12_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">-84000</xoma:OperatingLeasePaymentsNonCash>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      decimals="-3"
      id="Tc_6tRmxyvfkU2nkW3PX7JiEw_13_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">-15000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw"
      decimals="-3"
      id="Tc_BvPQTVk54EOywKt4Adpgsg_13_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">-251000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      decimals="-3"
      id="Tc_x31zilHb4EW02Kl4KhZQIA_15_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">900000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables
      contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw"
      decimals="-3"
      id="Tc_rg29uwwzFEqrF1_DFKvNtQ_15_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">-204000</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      decimals="-3"
      id="Tc_z9oyFdpICEuXwue9xEHbmA_16_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">97000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw"
      decimals="-3"
      id="Tc_cHibKVJ6tUqI7KNRlqXAvw_16_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">398000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      decimals="-3"
      id="Tc_cJRXqWnbxU25YdtztYeMbw_17_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">-769000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw"
      decimals="-3"
      id="Tc_m-aRFhJu60eofp384Ndzig_17_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">582000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw"
      decimals="-3"
      id="Tc_JF9GKTQ8O0SkmsOsn5TgeA_18_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">-91000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      decimals="-3"
      id="Tc_RvGeofFMm0Kk2C2QAenzbA_19_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">-102000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw"
      decimals="-3"
      id="Tc_BI50nIfRAkmQ3emoaiG6Ig_19_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">-96000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      decimals="-3"
      id="Tc_wTrYwyzxKUGz_ia70_xoxw_20_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">-970000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw"
      decimals="-3"
      id="Tc_-9fsj8GPe02d7BcTUz-Uxw_20_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">-815000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      decimals="-3"
      id="Tc_CVGUwkEtkEqoqZS6wmC9FQ_21_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">-12132000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw"
      decimals="-3"
      id="Tc_4E28U2Mly02v28rhSnOQMA_21_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">-5326000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      decimals="-3"
      id="Tc_7lJ8-AG0006QGx3yrv63gg_24_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">14650000</xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities>
    <xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities
      contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw"
      decimals="-3"
      id="Tc_NxTsAVq__kWeNdVEeRWrVg_24_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">5000000</xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities>
    <xoma:ReceiptsUnderAgreementsInvestingActivities
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      decimals="-3"
      id="Tc_RfoCZC_r1UOAW-VQOyo3eQ_25_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">2934000</xoma:ReceiptsUnderAgreementsInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      decimals="-3"
      id="Tc_7ciEq_846EiavLKVke3bpQ_26_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">-11716000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw"
      decimals="-3"
      id="Tc_8Xt3Otlw0kScUb7Aijnf0g_26_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">-5000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsOfDividends
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      decimals="-3"
      id="Tc_YmCQH82BYkOBrCXDP1hphQ_29_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">2736000</us-gaap:PaymentsOfDividends>
    <us-gaap:PaymentsOfDividends
      contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw"
      decimals="-3"
      id="Tc_wHKmQVMAP0mBjJRmEpNmyw_29_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">2736000</us-gaap:PaymentsOfDividends>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      decimals="-3"
      id="Tc_eCnrxxRLPUaLMsg4wZY46Q_30_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">208000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw"
      decimals="-3"
      id="Tc_3EKXefh2hkG23f5vDp_hsQ_30_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">1905000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      decimals="-3"
      id="Tc_NIVcuu4rsEGmgvIegmSWLg_31_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">5000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw"
      decimals="-3"
      id="Tc_bdY3h9wLHk25hRdXbLKqwQ_31_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">1038000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      decimals="-3"
      id="Tc_OmboFEiBXkan6OVmAm__Ig_32_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">-2533000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw"
      decimals="-3"
      id="Tc_dWpH5eOGwE-Su0_qKMw-hg_32_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">-1869000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      decimals="-3"
      id="Tc_5Scs57uWsEq-55XEHHAg6w_34_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">-26381000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw"
      decimals="-3"
      id="Tc_7uXoDkLr1EeiHeCxSshqnw_34_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">-12195000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg"
      decimals="-3"
      id="Tc_48rxOQMGPUyoD2UtnHP7LA_35_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">57826000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021__kfZV7JTZUaYuVCcUwl-Cg"
      decimals="-3"
      id="Tc_HplmKhZ9RkWCIReWB8hevg_35_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">95377000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ"
      decimals="-3"
      id="Tc_Wg5HPjf2EU2yKrPA3p8Fjw_36_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">31445000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_6_30_2022_lyjBTUwVbUyOd4KtP5Gu-g"
      decimals="-3"
      id="Tc_NfERUeMGZUywne2kATQdiQ_36_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">83182000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw"
      decimals="-3"
      id="Tc_7_t5Ka0WZ0Kg7h5BsIwJ7g_39_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">95000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      decimals="-3"
      id="Tc_5NIblfaBEEuTxTzYioHLyw_40_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">85000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:DividendsPayableCurrentAndNoncurrent
      contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ"
      decimals="-3"
      id="Tc_EXpNIWrK3Em5QPm0CYhxuw_42_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">1368000</us-gaap:DividendsPayableCurrentAndNoncurrent>
    <us-gaap:DividendsPayableCurrentAndNoncurrent
      contextRef="As_Of_6_30_2022_lyjBTUwVbUyOd4KtP5Gu-g"
      decimals="-3"
      id="Tc_-yJ13vhftEydVpGPlCPAiw_42_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">1368000</us-gaap:DividendsPayableCurrentAndNoncurrent>
    <xoma:EstimatedFairValueOfContingentConsiderationUnderAssetAcquisition
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      decimals="-3"
      id="Tc_RAqJPQKs40uSXycOimegJQ_43_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">1000000</xoma:EstimatedFairValueOfContingentConsiderationUnderAssetAcquisition>
    <us-gaap:NatureOfOperations
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      id="Tb_aOpjyGPa6UOmkUumc2Crxw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;1. Description of Business&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;XOMA, a Delaware corporation, is a biotech royalty aggregator with a sizable portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company&#x2019;s portfolio was built through the acquisition of rights to future milestones and royalties that the Company has made since the royalty aggregator business model was implemented in 2017 combined with out-licensing its proprietary products and platforms from its legacy discovery and development business. The Company&#x2019;s drug royalty aggregator business is primarily focused on early to mid-stage clinical assets in Phase 1 and 2 with significant commercial sales potential that are licensed to large-cap partners. The Company expects that most of its future revenue will be based on payments the Company may receive for milestones and royalties related to these programs. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Liquidity and Financial Condition&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has incurred significant operating losses and negative cash flows from operations since its inception. As of June 30, 2023, the Company had cash and cash equivalents of $31.4 million. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Based on the Company&#x2019;s current cash balance and its ability to control discretionary spending, such as milestone and royalty acquisitions, the Company has evaluated and concluded its financial condition is sufficient to fund its planned operations and commitments and contractual obligations for a period of at least one year following the date that these condensed consolidated financial statements are issued.&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ"
      decimals="-5"
      id="Narr_kJ2ReBWpXkmQOjL_jPHSQg"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">31400000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      id="Tb_WNFn53gzeUOY2PA0RZN8AA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;2. Basis of Presentation and Significant Accounting Policies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Basis of Presentation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions among consolidated entities were eliminated upon consolidation. The unaudited condensed consolidated financial statements were prepared in accordance with GAAP in the United States for interim financial information and with the instructions to Form&#160;10-Q and Article&#160;10 of Regulation S-X. As permitted under those rules&#160;certain footnotes or other financial information can be condensed or omitted. These condensed consolidated financial statements and related disclosures have been prepared with the assumption that users of the interim financial information have read or have access to the audited consolidated financial statements for the preceding fiscal&#160;year. Accordingly, these statements should be read in conjunction with the audited consolidated financial statements and related notes included in the Company&#x2019;s Annual Report on Form&#160;10-K for the&#160;year ended December&#160;31, 2022, filed with the SEC on March&#160;9, 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;These condensed consolidated financial statements have been prepared on the same basis as the Company&#x2019;s annual consolidated financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal and recurring adjustments that are necessary for a fair statement of the Company&#x2019;s consolidated financial information. The interim results of operations are not necessarily indicative of the results that may be expected for the full&#160;year.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Use of Estimates&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The preparation of financial statements in conformity with GAAP in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates including, but not limited to, those related to revenue recognition, revenue recognized under the units-of-revenue method, royalty and commercial payment receivables, &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;intangible assets, legal contingencies, contingent consideration and stock-based compensation. The Company bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Actual results may differ significantly from these estimates, such as the Company&#x2019;s amortization of the payments received from HCRP. Under the contracts with HCRP, the amortization for the reporting period is calculated based on the payments expected to be made by the licensees to HCRP over the term of the arrangement. Any changes to the estimated payments by the licensees to HCRP can result in a material adjustment to revenue previously reported.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Cash and Cash Equivalents&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Cash consists of bank deposits held in business checking and interest-bearing deposit accounts. As of June 30, 2023, the Company had a cash balance of $1.3 million and cash equivalent balances of $30.1 million, defined as highly liquid financial instruments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. As of December 31, 2022, the Company had a cash balance of $27.5 million and cash equivalent balances of $30.3 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Revenue Recognition&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes revenue from all contracts with customers according to ASC 606, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i)&#160;identify the contract(s)&#160;with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation based on relative fair values, when (or as) the performance obligation is satisfied.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes revenue from its license and collaboration arrangements and royalties. The terms of the arrangements generally include payment to the Company of one or more of the following: non-refundable, upfront license fees, development, regulatory and commercial milestone payments, and royalties on net sales of licensed products.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;License of intellectual property&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, such as transfer of related materials, process and know-how, the Company utilizes judgement to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. Under the Company&#x2019;s license agreements, the nature of the combined performance obligation is the granting of licenses to the customers as the other promises are not separately identifiable in the context of the arrangement. Since the Company grants the license to a customer as it exists at the point of transfer and is not involved in any future development or commercialization of the products related to the license, the nature of the license is a right to use the Company&#x2019;s intellectual property as transferred. As such, the Company recognizes revenue related to the combined performance obligation upon completion of the delivery of the related materials, process and know-how (i.e., at a point in time).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Milestone payments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;At the inception of each arrangement that includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price. ASC 606 suggests two alternatives to use when estimating the amount of variable consideration: the expected value method and the most likely amount method. Under the expected value method, an entity considers the sum of probability-weighted amounts in a range of possible consideration amounts. Under the most likely amount method, an entity considers the single most likely amount in a range of possible consideration amounts. The Company uses the most likely amount method for development and regulatory milestone payments. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;If it is probable that a significant cumulative revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis. The Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability or achievement of each such milestone and any related constraint, and if necessary, adjusts its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and earnings in the period of adjustment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Royalties&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Upfront payments and fees are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts payable to the Company are recorded as accounts receivable when the Company&#x2019;s right to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one&#160;year or less.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;"&gt;Sale of Future Revenue Streams&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has sold its rights to receive certain milestones and royalties on product sales. In the circumstance where the Company has sold its rights to future milestones and royalties under a license agreement and also maintains limited continuing involvement in the arrangement (but not significant continuing involvement in the generation of the cash flows that are due to the purchaser), the Company defers recognition of the proceeds it receives for the sale of milestone or royalty streams and recognizes such unearned revenue as revenue under the units-of-revenue method over the life of the underlying license agreement. Under the units-of-revenue method, amortization for a reporting period is calculated by computing a ratio of the proceeds received from the purchaser to the total payments expected to be made to the purchaser over the term of the agreement, and then applying that ratio to the period&#x2019;s cash payment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Estimating the total payments expected to be received by the purchaser over the term of such arrangements requires management to use subjective estimates and assumptions. Changes to the Company&#x2019;s estimate of the payments expected to be made to the purchaser over the term of such arrangements could have a material effect on the amount of revenues recognized in any particular period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;"&gt;Stock-Based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company recognizes compensation expense for all stock-based payment awards made to the Company&#x2019;s employees, consultants and directors that are expected to vest based on estimated fair values. The valuation of stock option awards is determined at the date of grant using the Black-Scholes Model. The Black-Scholes Model requires inputs such &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;as the expected term of the option, expected volatility and risk-free interest rate. To establish an estimate of expected term, the Company considers the vesting period and contractual period of the award and its historical experience of stock option exercises, post-vesting cancellations and volatility. The estimate of expected volatility is based on the Company&#x2019;s historical volatility. The risk-free rate is based on the yield available on United States Treasury zero-coupon issues corresponding to the expected term of the award. The Company records forfeitures when they occur. The Company records compensation expense for service-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the award, or to the date on which retirement eligibility is achieved, if shorter.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The grant date fair value of PSUs with market conditions are determined using the Monte Carlo valuation model. The Company records compensation expenses for PSUs based on graded expense attribution over the requisite service periods.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;"&gt;Equity Securities&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company entered into a license agreement with Rezolute in December 2017, in which it received shares of common stock from Rezolute (Note 4). Equity investments in Rezolute are classified in the condensed consolidated balance sheets as equity securities. The equity securities are measured at fair value, with changes in fair value recorded in the other income (expense), net line item of the condensed consolidated statement of operations and comprehensive loss at each reporting period. The Company remeasures its equity investments at each reporting period until such time that the investment is sold or disposed of. If the Company sells an investment, any realized gains and losses on the sale of the securities will be recognized in the condensed consolidated statement of operations and comprehensive loss in the period of sale.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;"&gt;Purchase of Rights to Future Milestones, Royalties and Commercial Payments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has purchased rights to receive a portion of certain future developmental, regulatory and commercial sales milestones, royalties and option fees on sales of products currently in clinical development or recently commercialized. The Company acquired such rights from various entities and recorded the amount paid for these rights as long-term royalty receivables (Note 5). In addition, the Company may be obligated to make contingent payments related to certain product development milestones, fees upon exercise of options related to future license products and sales-based milestones. The contingent payments are evaluated to determine if they are freestanding instruments or embedded derivatives. If the contingent payments fall within the scope of ASC 815, the contingent payments are measured at fair value at the inception of the arrangement, and subject to remeasurement to fair value each reporting period. Any changes in the estimated fair value are recorded in the condensed consolidated statement of operations and comprehensive loss. Contingent consideration payments that do not fall within the scope of ASC 815 are recognized when the amount is probable and estimable according to ASC 450.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for milestone and royalty rights related to developmental pipeline or recently commercialized products on a non-accrual basis using the cost recovery method. These developmental pipeline products are non-commercialized, non-approved products that require FDA or other regulatory approval, and thus have uncertain cash flows. The recently commercialized products do not have an established reliable sales pattern, and thus have uncertain cash flows. The Company is not yet able to reliably forecast future cash flows given their stages of development and commercialization. The related receivable balance is classified as noncurrent or current based on whether payments are probable and reasonably estimable to be received in the near term. Under the cost recovery method, any milestone or royalty payment received is recorded as a direct reduction of the recorded receivable balance. When the recorded receivable balance has been fully collected, any additional amounts collected are recognized as revenue.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;"&gt;Allowance for Current Expected Credit Losses&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company evaluates the long-term royalty and commercial payment receivables on a collective, i.e., pool, basis if they share similar risk characteristics. The Company would evaluate a royalty and commercial payment receivable individually if its risk characteristics are not similar to other royalty and commercial payment receivables. The Company reviews public information on clinical trials, press releases and updates from its partners regularly to identify any impairment indicators or changes in expected recoverability of the long-term royalty and commercial payment receivable &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;asset. At each reporting date, if the Company determines expected future cash flows discounted to the current period are less than the carrying value of the asset, the Company will record impairment. The impairment will be recognized as an allowance expense that increases the long-term royalty and commercial payment receivable asset&#x2019;s cumulative allowance, which reduces the net carrying value of the long-term royalty and commercial payment receivable asset. In a subsequent period, if there is an increase in expected future cash flows, or if the actual cash flows are greater than previously expected, the Company will reduce the previously established cumulative allowance. Amounts not expected to be collected are written off against the allowance at the time that such a determination is made. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;"&gt;Asset Acquisitions&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As a first step, for each acquisition, the Company determines if it is an acquisition of a business or an asset acquisition under ASC 805. Acquisitions of assets or a group of assets that do not meet the definition of a business are accounted for as asset acquisitions under ASC 805-50, using the cost accumulation method, whereby the cost of the acquisition, including certain transaction costs, is allocated to the assets acquired on the basis of relative fair values (Note 4). &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Contingent payments are evaluated whether they are freestanding instruments or embedded derivatives. If the contingent payments fall within the scope of ASC 815, the contingent payments are measured at fair value at the acquisition date, and subject to remeasurement to fair value each reporting period. The estimated fair value at the acquisition date is included in the cost of the acquired assets. Any subsequent changes in the estimated fair value are recorded in the condensed consolidated statement of operations and comprehensive loss. Contingent consideration payments that do not fall within the scope of ASC 815 are recognized when the amount is probable and estimable according to ASC 450. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Cash payments related to acquired assets are reflected as an investing cash flow in the Company&#x2019;s condensed consolidated statement of cash flows. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:6pt 0pt 0pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Intangible Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:6pt 0pt 0pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The identifiable intangible asset consists of IP acquired in the ObsEva IP Acquisition Agreement in 2022. This intangible asset is amortized on a straight-line basis over its estimated useful life of 17 years. The straight-line method of amortization represents the Company&#x2019;s best estimate of the distribution of the economic value of the identifiable intangible asset. The intangible asset is carried at cost less accumulated amortization. Amortization will be included in amortization of intangible assets in the condensed consolidated statement of operations and comprehensive loss.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amount of an asset group to the future net undiscounted cash flows that the assets are expected to generate. If the carrying amount of an asset group exceeds its estimated future cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset group exceeds the fair value of the asset group. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company leases its headquarters office space in Emeryville, California.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company determines the initial classification and measurement of its right-of-use assets and lease liabilities at the lease commencement date and thereafter if modified. The lease term includes any renewal options and termination options that the Company is reasonably certain to exercise. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its incremental borrowing rate. The incremental borrowing rate is determined by using the rate of interest that the Company would pay to borrow on a collateralized basis an amount equal to the lease payments for a similar term and in a similar economic environment. The Company built its incremental borrowing rate starting with the interest rate on its fully collateralized debt and then adjusted it for lease term length.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Rent expense for the operating lease is recognized on a straight-line basis, over the reasonably assured lease term based on the total lease payments and is included in operating expenses in the condensed consolidated statements of operations and comprehensive loss.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has elected the practical expedient to not separate lease and non-lease components. The Company&#x2019;s non-lease components are primarily related to property maintenance, which varies based on future outcomes, and thus is recognized in rent expense when incurred.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;"&gt;Income Taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for income taxes using the liability method under which deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount which is more likely than not to be realizable.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The recognition, derecognition and measurement of a tax position is based on management&#x2019;s best judgment given the facts, circumstances and information available at each reporting date. The Company&#x2019;s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;"&gt;Net Loss per Share Attributable to Common Stockholders&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company calculates basic and diluted loss per share attributable to common stockholders using the two-class method. The Company&#x2019;s convertible Series X preferred stocks participate in any dividends declared by the Company on its common stock and are therefore considered to be participating securities. The Company&#x2019;s Series A and Series B Preferred Stock do not participate in any dividends or distribution by the Company on its common stock and are therefore not considered to be participating securities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the two-class method, net income, as adjusted for any accumulated dividends on Series A and Series B Preferred Stock for the period, is allocated to each class of common stock and participating security as if all of the net income for the period had been distributed. Undistributed earnings allocated to participating securities are subtracted from net income in determining net income attributable to common stockholders. During periods of loss, the Company allocates no loss to participating securities because they have no contractual obligation to share in the losses of the Company. Basic net loss per share attributable to common stockholders is then calculated by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. All participating securities are excluded from the basic weighted average common shares outstanding.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Diluted net loss per share attributable to common stockholders is based on the weighted average number of shares outstanding during the period, adjusted to include the assumed exercise of certain stock options and warrants for common stock using the treasury method, if dilutive. The calculation assumes that any proceeds that could be obtained upon exercise of options and warrants would be used to purchase common stock at the average market price during the period. Adjustments to the denominator are required to reflect the related dilutive shares. The Company&#x2019;s Series A and Series B Preferred Stock become convertible upon the occurrence of specific events other than a change in the Company&#x2019;s share price and, therefore, are not included in the diluted shares until the contingency is resolved.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;"&gt;Concentration of Risk&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Cash, cash equivalents and receivables are financial instruments which potentially subject the Company to concentrations of credit risk, as well as liquidity risk. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company maintains cash balances at commercial banks. Balances commonly exceed the amount insured by the FDIC. The Company has not experienced any losses in such accounts.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company monitors the creditworthiness of its customers to which it grants credit terms in the normal course of business but does not generally require collateral on receivables. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;For the three months ended June 30, 2023, two partners represented 66% and 32% of total revenues. For the six months ended June 30, 2023, two partners represented 53% and 46% of total revenues. For the three months ended June 30, 2022, two partners represented 51% and 47% of total revenues. For the six months ended June 30, 2022, four partners represented 49%, 20%, 18% and 12% of total revenues. One partner represented 100% of the trade receivables, net balance as of June 30, 2023. There were no trade receivables, net balance as of December 31, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;"&gt;Comprehensive Loss&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Comprehensive loss is comprised of two components: net loss and other comprehensive loss. Other comprehensive loss refers to gains and losses that under U.S. GAAP are recorded as an element of stockholders&#x2019; equity but are excluded from net loss. The Company did not record any transactions within other comprehensive loss in the periods presented and, therefore, the net loss and comprehensive loss were the same for all periods presented.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;"&gt;Accounting Pronouncements Recently Adopted&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (ASC 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 replaced the incurred loss impairment methodology under current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. ASU 2016-13 requires use of a forward-looking expected credit loss model for accounts receivables, loans, and other financial instruments. Adoption of the standard requires using a modified retrospective approach through a cumulative-effect adjustment to retained earnings as of the effective date to align existing credit loss methodology with the new standard. The Company adopted ASU 2016-13 and related updates on January 1, 2023. The adoption of ASU 2016-13 had no impact on the condensed consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;In October 2021, the FASB issued ASU 2021-08, Business Combinations &#x2013; Accounting for Contract Assets and Contact Liabilities from Contracts with Customers. The guidance is intended to improve the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice. The guidance requires an acquirer to recognize and measure contract assets and liabilities acquired in a business combination in accordance with ASC 606 as if they had originated the contracts, as opposed to at fair value on the acquisition date. The Company adopted ASU 2021-08 and related updates on January 1, 2023. The adoption of ASU 2021-08 had no impact on the condensed consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      id="Tb_clHDyGq0n0aPaXNHJj74qg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Basis of Presentation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions among consolidated entities were eliminated upon consolidation. The unaudited condensed consolidated financial statements were prepared in accordance with GAAP in the United States for interim financial information and with the instructions to Form&#160;10-Q and Article&#160;10 of Regulation S-X. As permitted under those rules&#160;certain footnotes or other financial information can be condensed or omitted. These condensed consolidated financial statements and related disclosures have been prepared with the assumption that users of the interim financial information have read or have access to the audited consolidated financial statements for the preceding fiscal&#160;year. Accordingly, these statements should be read in conjunction with the audited consolidated financial statements and related notes included in the Company&#x2019;s Annual Report on Form&#160;10-K for the&#160;year ended December&#160;31, 2022, filed with the SEC on March&#160;9, 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;These condensed consolidated financial statements have been prepared on the same basis as the Company&#x2019;s annual consolidated financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal and recurring adjustments that are necessary for a fair statement of the Company&#x2019;s consolidated financial information. The interim results of operations are not necessarily indicative of the results that may be expected for the full&#160;year.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      id="Tb_VW3ZNDVNT026Ij1KHUOOaQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Use of Estimates&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The preparation of financial statements in conformity with GAAP in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates including, but not limited to, those related to revenue recognition, revenue recognized under the units-of-revenue method, royalty and commercial payment receivables, &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;intangible assets, legal contingencies, contingent consideration and stock-based compensation. The Company bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Actual results may differ significantly from these estimates, such as the Company&#x2019;s amortization of the payments received from HCRP. Under the contracts with HCRP, the amortization for the reporting period is calculated based on the payments expected to be made by the licensees to HCRP over the term of the arrangement. Any changes to the estimated payments by the licensees to HCRP can result in a material adjustment to revenue previously reported.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      id="Tb_RPTILXPi90mCmWjXS_n4xw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Cash and Cash Equivalents&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Cash consists of bank deposits held in business checking and interest-bearing deposit accounts. As of June 30, 2023, the Company had a cash balance of $1.3 million and cash equivalent balances of $30.1 million, defined as highly liquid financial instruments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. As of December 31, 2022, the Company had a cash balance of $27.5 million and cash equivalent balances of $30.3 million.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:Cash
      contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ"
      decimals="-5"
      id="Narr_Xb9J82FfXE6CsNW-y_3Cpw"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">1300000</us-gaap:Cash>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ"
      decimals="-5"
      id="Narr_PP5aeO_ciEuO7yaA_Tmxtg"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">30100000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:Cash
      contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg"
      decimals="-5"
      id="Narr_fHsCdSHrdU-oT1NGjYZqLQ"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">27500000</us-gaap:Cash>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg"
      decimals="-5"
      id="Narr_C54cLEmIm0CnxExTb-IURQ"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">30300000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      id="Tb_-ZSovfvV8kqzRqktKc_v0w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Revenue Recognition&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes revenue from all contracts with customers according to ASC 606, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i)&#160;identify the contract(s)&#160;with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation based on relative fair values, when (or as) the performance obligation is satisfied.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes revenue from its license and collaboration arrangements and royalties. The terms of the arrangements generally include payment to the Company of one or more of the following: non-refundable, upfront license fees, development, regulatory and commercial milestone payments, and royalties on net sales of licensed products.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;License of intellectual property&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, upfront fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, such as transfer of related materials, process and know-how, the Company utilizes judgement to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. Under the Company&#x2019;s license agreements, the nature of the combined performance obligation is the granting of licenses to the customers as the other promises are not separately identifiable in the context of the arrangement. Since the Company grants the license to a customer as it exists at the point of transfer and is not involved in any future development or commercialization of the products related to the license, the nature of the license is a right to use the Company&#x2019;s intellectual property as transferred. As such, the Company recognizes revenue related to the combined performance obligation upon completion of the delivery of the related materials, process and know-how (i.e., at a point in time).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Milestone payments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;At the inception of each arrangement that includes development and regulatory milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price. ASC 606 suggests two alternatives to use when estimating the amount of variable consideration: the expected value method and the most likely amount method. Under the expected value method, an entity considers the sum of probability-weighted amounts in a range of possible consideration amounts. Under the most likely amount method, an entity considers the single most likely amount in a range of possible consideration amounts. The Company uses the most likely amount method for development and regulatory milestone payments. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;If it is probable that a significant cumulative revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis. The Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability or achievement of each such milestone and any related constraint, and if necessary, adjusts its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and earnings in the period of adjustment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 18pt;"&gt;Royalties&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Upfront payments and fees are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts payable to the Company are recorded as accounts receivable when the Company&#x2019;s right to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one&#160;year or less.&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <xoma:RevenueRecognitionDeferredRevenuePolicyTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      id="Tb_Eyglr_xazU643xHbj17Yfw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;"&gt;Sale of Future Revenue Streams&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has sold its rights to receive certain milestones and royalties on product sales. In the circumstance where the Company has sold its rights to future milestones and royalties under a license agreement and also maintains limited continuing involvement in the arrangement (but not significant continuing involvement in the generation of the cash flows that are due to the purchaser), the Company defers recognition of the proceeds it receives for the sale of milestone or royalty streams and recognizes such unearned revenue as revenue under the units-of-revenue method over the life of the underlying license agreement. Under the units-of-revenue method, amortization for a reporting period is calculated by computing a ratio of the proceeds received from the purchaser to the total payments expected to be made to the purchaser over the term of the agreement, and then applying that ratio to the period&#x2019;s cash payment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Estimating the total payments expected to be received by the purchaser over the term of such arrangements requires management to use subjective estimates and assumptions. Changes to the Company&#x2019;s estimate of the payments expected to be made to the purchaser over the term of such arrangements could have a material effect on the amount of revenues recognized in any particular period.&lt;/p&gt;</xoma:RevenueRecognitionDeferredRevenuePolicyTextBlock>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      id="Tb_nAR2T42qQUGZLf7frb5BJg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;"&gt;Stock-Based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company recognizes compensation expense for all stock-based payment awards made to the Company&#x2019;s employees, consultants and directors that are expected to vest based on estimated fair values. The valuation of stock option awards is determined at the date of grant using the Black-Scholes Model. The Black-Scholes Model requires inputs such &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;as the expected term of the option, expected volatility and risk-free interest rate. To establish an estimate of expected term, the Company considers the vesting period and contractual period of the award and its historical experience of stock option exercises, post-vesting cancellations and volatility. The estimate of expected volatility is based on the Company&#x2019;s historical volatility. The risk-free rate is based on the yield available on United States Treasury zero-coupon issues corresponding to the expected term of the award. The Company records forfeitures when they occur. The Company records compensation expense for service-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the award, or to the date on which retirement eligibility is achieved, if shorter.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The grant date fair value of PSUs with market conditions are determined using the Monte Carlo valuation model. The Company records compensation expenses for PSUs based on graded expense attribution over the requisite service periods.&lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <xoma:EquitySecuritiesPolicy
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      id="Tb_efvJ4gkSaEKIYJY-28c8_w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;"&gt;Equity Securities&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company entered into a license agreement with Rezolute in December 2017, in which it received shares of common stock from Rezolute (Note 4). Equity investments in Rezolute are classified in the condensed consolidated balance sheets as equity securities. The equity securities are measured at fair value, with changes in fair value recorded in the other income (expense), net line item of the condensed consolidated statement of operations and comprehensive loss at each reporting period. The Company remeasures its equity investments at each reporting period until such time that the investment is sold or disposed of. If the Company sells an investment, any realized gains and losses on the sale of the securities will be recognized in the condensed consolidated statement of operations and comprehensive loss in the period of sale.&lt;/p&gt;</xoma:EquitySecuritiesPolicy>
    <xoma:FutureMilestonesRoyaltiesPurchaseRightsAndCommercialPaymentsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      id="Tb_Bwjfd7tTokKoj0UyO-6oaw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;"&gt;Purchase of Rights to Future Milestones, Royalties and Commercial Payments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has purchased rights to receive a portion of certain future developmental, regulatory and commercial sales milestones, royalties and option fees on sales of products currently in clinical development or recently commercialized. The Company acquired such rights from various entities and recorded the amount paid for these rights as long-term royalty receivables (Note 5). In addition, the Company may be obligated to make contingent payments related to certain product development milestones, fees upon exercise of options related to future license products and sales-based milestones. The contingent payments are evaluated to determine if they are freestanding instruments or embedded derivatives. If the contingent payments fall within the scope of ASC 815, the contingent payments are measured at fair value at the inception of the arrangement, and subject to remeasurement to fair value each reporting period. Any changes in the estimated fair value are recorded in the condensed consolidated statement of operations and comprehensive loss. Contingent consideration payments that do not fall within the scope of ASC 815 are recognized when the amount is probable and estimable according to ASC 450.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for milestone and royalty rights related to developmental pipeline or recently commercialized products on a non-accrual basis using the cost recovery method. These developmental pipeline products are non-commercialized, non-approved products that require FDA or other regulatory approval, and thus have uncertain cash flows. The recently commercialized products do not have an established reliable sales pattern, and thus have uncertain cash flows. The Company is not yet able to reliably forecast future cash flows given their stages of development and commercialization. The related receivable balance is classified as noncurrent or current based on whether payments are probable and reasonably estimable to be received in the near term. Under the cost recovery method, any milestone or royalty payment received is recorded as a direct reduction of the recorded receivable balance. When the recorded receivable balance has been fully collected, any additional amounts collected are recognized as revenue.&lt;/p&gt;</xoma:FutureMilestonesRoyaltiesPurchaseRightsAndCommercialPaymentsPolicyPolicyTextBlock>
    <xoma:CreditLossContractWithCustomerAssetPolicyTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      id="Tb_uW46dy75FUOFLbZ_pfNWbw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;"&gt;Allowance for Current Expected Credit Losses&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company evaluates the long-term royalty and commercial payment receivables on a collective, i.e., pool, basis if they share similar risk characteristics. The Company would evaluate a royalty and commercial payment receivable individually if its risk characteristics are not similar to other royalty and commercial payment receivables. The Company reviews public information on clinical trials, press releases and updates from its partners regularly to identify any impairment indicators or changes in expected recoverability of the long-term royalty and commercial payment receivable &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;asset. At each reporting date, if the Company determines expected future cash flows discounted to the current period are less than the carrying value of the asset, the Company will record impairment. The impairment will be recognized as an allowance expense that increases the long-term royalty and commercial payment receivable asset&#x2019;s cumulative allowance, which reduces the net carrying value of the long-term royalty and commercial payment receivable asset. In a subsequent period, if there is an increase in expected future cash flows, or if the actual cash flows are greater than previously expected, the Company will reduce the previously established cumulative allowance. Amounts not expected to be collected are written off against the allowance at the time that such a determination is made. &#160;&lt;/p&gt;</xoma:CreditLossContractWithCustomerAssetPolicyTextBlock>
    <xoma:AssetAcquisitionsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      id="Tb_31L6rpdGjkKE5c3rb1LACA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;"&gt;Asset Acquisitions&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As a first step, for each acquisition, the Company determines if it is an acquisition of a business or an asset acquisition under ASC 805. Acquisitions of assets or a group of assets that do not meet the definition of a business are accounted for as asset acquisitions under ASC 805-50, using the cost accumulation method, whereby the cost of the acquisition, including certain transaction costs, is allocated to the assets acquired on the basis of relative fair values (Note 4). &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Contingent payments are evaluated whether they are freestanding instruments or embedded derivatives. If the contingent payments fall within the scope of ASC 815, the contingent payments are measured at fair value at the acquisition date, and subject to remeasurement to fair value each reporting period. The estimated fair value at the acquisition date is included in the cost of the acquired assets. Any subsequent changes in the estimated fair value are recorded in the condensed consolidated statement of operations and comprehensive loss. Contingent consideration payments that do not fall within the scope of ASC 815 are recognized when the amount is probable and estimable according to ASC 450. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Cash payments related to acquired assets are reflected as an investing cash flow in the Company&#x2019;s condensed consolidated statement of cash flows. &lt;/p&gt;</xoma:AssetAcquisitionsPolicyPolicyTextBlock>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      id="Tb_jkXjKzk1mEC5p2nVXiNl0w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:6pt 0pt 0pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Intangible Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:6pt 0pt 0pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The identifiable intangible asset consists of IP acquired in the ObsEva IP Acquisition Agreement in 2022. This intangible asset is amortized on a straight-line basis over its estimated useful life of 17 years. The straight-line method of amortization represents the Company&#x2019;s best estimate of the distribution of the economic value of the identifiable intangible asset. The intangible asset is carried at cost less accumulated amortization. Amortization will be included in amortization of intangible assets in the condensed consolidated statement of operations and comprehensive loss.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amount of an asset group to the future net undiscounted cash flows that the assets are expected to generate. If the carrying amount of an asset group exceeds its estimated future cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset group exceeds the fair value of the asset group. &lt;/p&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="Duration_11_21_2022_To_11_21_2022_dk2CWh67HkeKPZD69Opgyw"
      id="Narr_5fY3Qs1Ky0WIL_gumb8IiA">P17Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      id="Tb_WY44v84YiUeJhRpQzID0jQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company leases its headquarters office space in Emeryville, California.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company determines the initial classification and measurement of its right-of-use assets and lease liabilities at the lease commencement date and thereafter if modified. The lease term includes any renewal options and termination options that the Company is reasonably certain to exercise. The present value of lease payments is determined by using the interest rate implicit in the lease, if that rate is readily determinable; otherwise, the Company uses its incremental borrowing rate. The incremental borrowing rate is determined by using the rate of interest that the Company would pay to borrow on a collateralized basis an amount equal to the lease payments for a similar term and in a similar economic environment. The Company built its incremental borrowing rate starting with the interest rate on its fully collateralized debt and then adjusted it for lease term length.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Rent expense for the operating lease is recognized on a straight-line basis, over the reasonably assured lease term based on the total lease payments and is included in operating expenses in the condensed consolidated statements of operations and comprehensive loss.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has elected the practical expedient to not separate lease and non-lease components. The Company&#x2019;s non-lease components are primarily related to property maintenance, which varies based on future outcomes, and thus is recognized in rent expense when incurred.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      id="Tb_Tbq6k5CSZEuT00RZDM-oRg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;"&gt;Income Taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for income taxes using the liability method under which deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount which is more likely than not to be realizable.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The recognition, derecognition and measurement of a tax position is based on management&#x2019;s best judgment given the facts, circumstances and information available at each reporting date. The Company&#x2019;s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ"
      decimals="-5"
      id="Narr_qwJC_Ly8o0G7a83M0GKEuQ"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      id="Tb_B60HWjHbTkKxxMBdVBXv8w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;"&gt;Net Loss per Share Attributable to Common Stockholders&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company calculates basic and diluted loss per share attributable to common stockholders using the two-class method. The Company&#x2019;s convertible Series X preferred stocks participate in any dividends declared by the Company on its common stock and are therefore considered to be participating securities. The Company&#x2019;s Series A and Series B Preferred Stock do not participate in any dividends or distribution by the Company on its common stock and are therefore not considered to be participating securities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the two-class method, net income, as adjusted for any accumulated dividends on Series A and Series B Preferred Stock for the period, is allocated to each class of common stock and participating security as if all of the net income for the period had been distributed. Undistributed earnings allocated to participating securities are subtracted from net income in determining net income attributable to common stockholders. During periods of loss, the Company allocates no loss to participating securities because they have no contractual obligation to share in the losses of the Company. Basic net loss per share attributable to common stockholders is then calculated by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period. All participating securities are excluded from the basic weighted average common shares outstanding.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Diluted net loss per share attributable to common stockholders is based on the weighted average number of shares outstanding during the period, adjusted to include the assumed exercise of certain stock options and warrants for common stock using the treasury method, if dilutive. The calculation assumes that any proceeds that could be obtained upon exercise of options and warrants would be used to purchase common stock at the average market price during the period. Adjustments to the denominator are required to reflect the related dilutive shares. The Company&#x2019;s Series A and Series B Preferred Stock become convertible upon the occurrence of specific events other than a change in the Company&#x2019;s share price and, therefore, are not included in the diluted shares until the contingency is resolved.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      id="Tb_LqVgkf9dZUGZA7aZ9GsbUw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;"&gt;Concentration of Risk&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Cash, cash equivalents and receivables are financial instruments which potentially subject the Company to concentrations of credit risk, as well as liquidity risk. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company maintains cash balances at commercial banks. Balances commonly exceed the amount insured by the FDIC. The Company has not experienced any losses in such accounts.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company monitors the creditworthiness of its customers to which it grants credit terms in the normal course of business but does not generally require collateral on receivables. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;For the three months ended June 30, 2023, two partners represented 66% and 32% of total revenues. For the six months ended June 30, 2023, two partners represented 53% and 46% of total revenues. For the three months ended June 30, 2022, two partners represented 51% and 47% of total revenues. For the six months ended June 30, 2022, four partners represented 49%, 20%, 18% and 12% of total revenues. One partner represented 100% of the trade receivables, net balance as of June 30, 2023. There were no trade receivables, net balance as of December 31, 2022.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <xoma:NumberOfMajorPartners
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_v_4086cVDUmoGR5d7CgO0A"
      decimals="INF"
      id="Narr_iQxDvbz2DUy8ZKeb77WHIw"
      unitRef="Unit_Standard_customer_DppB2cRPP0aciLos32fCZw">2</xoma:NumberOfMajorPartners>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_4_1_2023_To_6_30_2023_srt_MajorCustomersAxis_xoma_Partner1Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_UPb9E7A4oUG9Ls-shtbyPg"
      decimals="2"
      id="Narr_2INIojdWxkeumIHwLgnawQ"
      unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ">0.66</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_4_1_2023_To_6_30_2023_srt_MajorCustomersAxis_xoma_Partner2Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_sqEiwRkHBkmAPGUe0Ez5pg"
      decimals="2"
      id="Narr_3w5u4Ym3RUauYIpNE_gZCA"
      unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ">0.32</us-gaap:ConcentrationRiskPercentage1>
    <xoma:NumberOfMajorPartners
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_e0nlQVVkQEC_RcJPbx3_LQ"
      decimals="INF"
      id="Narr_D5pWRXD4OE-yiAYTncXuig"
      unitRef="Unit_Standard_customer_DppB2cRPP0aciLos32fCZw">2</xoma:NumberOfMajorPartners>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2023_To_6_30_2023_srt_MajorCustomersAxis_xoma_Partner1Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_3vOSN9-0P0-FLZiHWIajhw"
      decimals="2"
      id="Narr_dO1tfYcx5kSRuPqjFtA6DA"
      unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ">0.53</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2023_To_6_30_2023_srt_MajorCustomersAxis_xoma_Partner2Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_R1d0cYWaYUKU7Z4Y59JDYQ"
      decimals="2"
      id="Narr_PbCbpUEEfEqL9XXON_pf_A"
      unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ">0.46</us-gaap:ConcentrationRiskPercentage1>
    <xoma:NumberOfMajorPartners
      contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_qONAes1cy0G9lDzJGggO0Q"
      decimals="INF"
      id="Narr_zBXG57hUXkGVi5KBrlOxSA"
      unitRef="Unit_Standard_customer_DppB2cRPP0aciLos32fCZw">2</xoma:NumberOfMajorPartners>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_4_1_2022_To_6_30_2022_srt_MajorCustomersAxis_xoma_Partner1Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_3OysOB_GGkiYd3yyjB2f9A"
      decimals="2"
      id="Narr_zZAyhjpH1EqJsKCGLn2qKA"
      unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ">0.51</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_4_1_2022_To_6_30_2022_srt_MajorCustomersAxis_xoma_Partner2Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_uLAkeS_2ikqgahYM_BFpvQ"
      decimals="2"
      id="Narr_xpNVZRUe7ES6z2lnTPCRqA"
      unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ">0.47</us-gaap:ConcentrationRiskPercentage1>
    <xoma:NumberOfMajorPartners
      contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_heK3HldCNE-r5gSRWagnnQ"
      decimals="INF"
      id="Narr_7WsgZsPEQEOvBqzFkkrzuw"
      unitRef="Unit_Standard_customer_DppB2cRPP0aciLos32fCZw">4</xoma:NumberOfMajorPartners>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_MajorCustomersAxis_xoma_Partner1Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_OklwX0sEhUKh7TG7yMRNEw"
      decimals="2"
      id="Narr_n6S6yZ27lk6P9k8YDSiaGg"
      unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ">0.49</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_MajorCustomersAxis_xoma_Partner2Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_VFb8t0MUH0G_Z4BDZPkyFw"
      decimals="2"
      id="Narr_aWGY4bdwN0OiLgo_7tsaow"
      unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ">0.20</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_MajorCustomersAxis_xoma_Partner3Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_eW6Ihd4mvke6ewsUy3Hagg"
      decimals="2"
      id="Narr_2EnX5d5vqE-1sLm_2fTWtw"
      unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_MajorCustomersAxis_xoma_Partner4Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_SHilGTcI4ECxZyoz6P8uNQ"
      decimals="2"
      id="Narr_164wSxfCJUi_BjFTXIDpsA"
      unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ">0.12</us-gaap:ConcentrationRiskPercentage1>
    <xoma:NumberOfMajorPartners
      contextRef="Duration_1_1_2023_To_6_30_2023_srt_MajorCustomersAxis_xoma_Partner1Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_TradeAccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_-LRlYQJJLk-TqPh3pxJ8_A"
      decimals="INF"
      id="Narr_yztWsDQ1x0CJIvQYgdkjHA"
      unitRef="Unit_Standard_customer_DppB2cRPP0aciLos32fCZw">1</xoma:NumberOfMajorPartners>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2023_To_6_30_2023_srt_MajorCustomersAxis_xoma_Partner1Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_TradeAccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_-LRlYQJJLk-TqPh3pxJ8_A"
      decimals="2"
      id="Narr_mOMIoAwUcUSlDqOMKqG9ng"
      unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ReceivablesLongTermContractsOrPrograms
      contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg"
      decimals="-5"
      id="Narr_0DPdYAu5hk6XaKvqKiKhdA"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:ReceivablesLongTermContractsOrPrograms>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      id="Tb_Ilxq1TW2wkKQ6AWTHys1_w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;"&gt;Comprehensive Loss&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Comprehensive loss is comprised of two components: net loss and other comprehensive loss. Other comprehensive loss refers to gains and losses that under U.S. GAAP are recorded as an element of stockholders&#x2019; equity but are excluded from net loss. The Company did not record any transactions within other comprehensive loss in the periods presented and, therefore, the net loss and comprehensive loss were the same for all periods presented.&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      id="Tb_kGEkR1Ya-0mslUOmjoukYw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;"&gt;Accounting Pronouncements Recently Adopted&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (ASC 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 replaced the incurred loss impairment methodology under current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. ASU 2016-13 requires use of a forward-looking expected credit loss model for accounts receivables, loans, and other financial instruments. Adoption of the standard requires using a modified retrospective approach through a cumulative-effect adjustment to retained earnings as of the effective date to align existing credit loss methodology with the new standard. The Company adopted ASU 2016-13 and related updates on January 1, 2023. The adoption of ASU 2016-13 had no impact on the condensed consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;In October 2021, the FASB issued ASU 2021-08, Business Combinations &#x2013; Accounting for Contract Assets and Contact Liabilities from Contracts with Customers. The guidance is intended to improve the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice. The guidance requires an acquirer to recognize and measure contract assets and liabilities acquired in a business combination in accordance with ASC 606 as if they had originated the contracts, as opposed to at fair value on the acquisition date. The Company adopted ASU 2021-08 and related updates on January 1, 2023. The adoption of ASU 2021-08 had no impact on the condensed consolidated financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:AdditionalFinancialInformationDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      id="Tb_Ol4NC3iHKUS9oWZCarVwpw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;3.&#160;Condensed Consolidated Financial Statements Details&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Equity Securities&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Equity securities consisted of an investment in Rezolute&#x2019;s common stock of $0.3 million for both June 30, 2023 and December 31, 2022 (Note 4). &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;For the three and six months ended June 30, 2023, the Company recognized a gain of $10,000 and a loss of $15,000, respectively, due to the change in fair value of its investment in Rezolute&#x2019;s common stock in the other income (expense), net line item of the condensed consolidated statements of operations and comprehensive loss. For the three and six months ended June 30, 2022, the Company recognized a loss of $25,000 and $0.3 million, respectively, due to the change in fair value of its investment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;"&gt;Intangible assets, net&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes cost, accumulated amortization, and net carrying value of the intangible assets as of June 30, 2023 (in thousands): &lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Accumulated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net Carrying&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortization&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;As of June 30, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Ebopiprant IP (Note 4) &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,247&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 546&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,701&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total intangible assets &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,247&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 546&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,701&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The following table summarizes cost, accumulated amortization, and net carrying value of the intangible assets as of December 31, 2022 (in thousands): &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Accumulated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net Carrying&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortization&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;As of December 31, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Ebopiprant IP (Note 4) &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,247&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 97&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,150&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total intangible assets &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,247&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 97&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,150&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The remaining life of the intangible assets is 16.4 years. The following table presents the projected amortization expense for the next five years (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:12pt;"&gt; &lt;/span&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intangible Asset&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortization&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2023 (excluding six months ended June 30, 2023)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 448&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 897&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 897&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 897&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 897&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,036&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Accrued and Other Liabilities&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Accrued and other liabilities consisted of the following (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued payroll, severance and retention costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 978&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,449&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued incentive compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 604&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 562&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued legal and accounting fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 331&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 867&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other accrued liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 40&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,933&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,918&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Net Loss Per Share Attributable to Common Stockholders &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The following is a reconciliation of the numerator (net loss) and the denominator (number of shares) used in the calculation of basic and diluted net loss per share attributable to common stockholders (in thousands, except per share amounts):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:55.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six Months Ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Numerator&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net loss &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,400)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4,670)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (15,213)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6,950)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Less: Series A accumulated dividends &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (530)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (530)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,061)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,061)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Less: Series B accumulated dividends &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (838)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (838)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,675)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,675)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net loss attributable to common stockholders, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6,768)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6,038)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (17,949)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9,686)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Denominator&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average shares used in computing basic and diluted net loss per share attributable to common stockholders&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,466&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,421&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,463&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,376&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Basic and diluted net loss per share attributable to common stockholders &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.59)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.53)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1.57)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.85)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Potentially dilutive securities are excluded from the calculation of diluted net loss per share attributable to common stockholders if their inclusion is anti-dilutive. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The following table shows the weighted-average shares from outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net loss per share attributable to common stockholders (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:55.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six Months Ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Convertible preferred stock &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,003&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,003&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,003&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,003&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Common stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,719&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 889&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,634&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 813&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Warrants for common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,728&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,898&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,643&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,822&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;background:#00ff00;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;For PSUs with market conditions, if the market conditions have not been satisfied by the end of the reporting period, the number of shares that would be issuable based on the market price at the end of the reporting period, as if the end of the reporting period were the end of the contingency period, will be included in the calculation of diluted earnings per share if the effect is dilutive. No shares would be issuable based on the market price of $18.89 per share as of June 30, 2023. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Arbitration Proceeding &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;In June 2021, the Company initiated a binding arbitration proceeding with one of its licensees (the &#x201c;Licensee&#x201d;) at the American Arbitration Association/International Centre for Dispute Resolution, seeking milestone and royalty payments under its license agreement. A hearing before a panel of arbitrators was held in November 2022, and the parties submitted post-hearing briefs. On March 21, 2023, the Company received an adverse decision in this arbitration proceeding. The panel of arbitrators declined to award the Company damages and ruled that the license agreement has expired. The panel ruled that the Company is responsible for the Licensee&#x2019;s costs as well as arbitrators&#x2019; and administrative fees previously incurred by the Licensee of $4.1 million, which the Company paid in April 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:AdditionalFinancialInformationDisclosureTextBlock>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="As_Of_6_30_2023_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_LzgovgUcyUqFQMy5t8ndVg"
      decimals="-5"
      id="Narr_48MZe2-lVUmJGDPIKfNE7A"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">300000</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:EquitySecuritiesFVNINoncurrent
      contextRef="As_Of_12_31_2022_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_OFKp4An1GUS4-brDAQB8ew"
      decimals="-5"
      id="Narr_HE2iAdTfck-Sokyb3ePnSg"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">300000</us-gaap:EquitySecuritiesFVNINoncurrent>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="Duration_4_1_2023_To_6_30_2023_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_PwcTNnqVHEurE6RMUONPsw"
      decimals="-3"
      id="Narr_tFx6rZbtyEuWNuX6WntqVA"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">10000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="Duration_1_1_2023_To_6_30_2023_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_EPzxT9qkbUedyZWvfkZUhA"
      decimals="-3"
      id="Narr_GiS66EJ1o0ynwkXZ_9Ayvg"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">-15000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="Duration_4_1_2022_To_6_30_2022_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_NuaPtHy1BU6__HgLOoJDdw"
      decimals="-3"
      id="Narr_7Jniw-K550q1w48xLyAzpw"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">-25000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_Abl8Ryg010astqw5xtuhDg"
      decimals="-5"
      id="Narr_pFB9b71otkO6jZOmp2tMWg"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">-300000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      id="Tb_U5QvpoG60U-qdRuHO5Tjnw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes cost, accumulated amortization, and net carrying value of the intangible assets as of June 30, 2023 (in thousands): &lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Accumulated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net Carrying&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortization&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;As of June 30, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Ebopiprant IP (Note 4) &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,247&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 546&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,701&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total intangible assets &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,247&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 546&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14,701&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The following table summarizes cost, accumulated amortization, and net carrying value of the intangible assets as of December 31, 2022 (in thousands): &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Accumulated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net Carrying&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortization&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;As of December 31, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Ebopiprant IP (Note 4) &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,247&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 97&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,150&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total intangible assets &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,247&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 97&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,150&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_6_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_Gfw9LK-Od0iMS_KhAfKpsg"
      decimals="-3"
      id="Tc_8InTHeBuAU66vydABDpnDw_4_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">15247000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="As_Of_6_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_Gfw9LK-Od0iMS_KhAfKpsg"
      decimals="-3"
      id="Tc_UeFrxKIKDECS5hKD4lvJ2A_4_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">546000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="As_Of_6_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_Gfw9LK-Od0iMS_KhAfKpsg"
      decimals="-3"
      id="Tc_Hd82jmIpL0qSbwbAwi3yHg_4_9"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">14701000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ"
      decimals="-3"
      id="Tc_31xHGqxA00CYrlt8bGtOxg_5_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">15247000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ"
      decimals="-3"
      id="Tc_7dng_N4fFU2Vy87ymgK7Qg_5_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">546000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ"
      decimals="-3"
      id="Tc__fW-QMH4vUS4Vd0ekkMZxA_5_9"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">14701000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_ruM398xI60a2mOzUa9tLiw"
      decimals="-3"
      id="Tc_sWQ88ybKkE2SCBBogkzO6w_4_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">15247000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_ruM398xI60a2mOzUa9tLiw"
      decimals="-3"
      id="Tc__pviEn79mUSMg_dJkdE8aA_4_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">97000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_ruM398xI60a2mOzUa9tLiw"
      decimals="-3"
      id="Tc_PWEK9bkv-k2ALBKqC2wIcw_4_9"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">15150000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg"
      decimals="-3"
      id="Tc_of_qWHAWCkmS_M-GxZRfng_5_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">15247000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg"
      decimals="-3"
      id="Tc_ncJX3HtUxk2mbY2QPamYmA_5_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">97000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg"
      decimals="-3"
      id="Tc_ln7b-n-reka6JJVIMvuciA_5_9"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">15150000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      id="Tb_ToyRHX3lA0ap040XPAJsJA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The remaining life of the intangible assets is 16.4 years. The following table presents the projected amortization expense for the next five years (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:12pt;"&gt; &lt;/span&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intangible Asset&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortization&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2023 (excluding six months ended June 30, 2023)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 448&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 897&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 897&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 897&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 897&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,036&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ"
      id="Narr_gtpIQfYVrkG5TvjAB8Nocg">P16Y4M24D</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ"
      decimals="-3"
      id="Tc_53zABuA2ekq0cjjnIAgmhA_4_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">448000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ"
      decimals="-3"
      id="Tc_xzphs7sMO0GcahPo3-9dKw_5_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">897000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ"
      decimals="-3"
      id="Tc_Xvj2v0fackGSjtnKw6MOlQ_6_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">897000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ"
      decimals="-3"
      id="Tc_AO7VXa2yBEW7tP2CUlWNBg_7_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">897000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ"
      decimals="-3"
      id="Tc_EWAITbryMUOZt_0YIQIaIw_8_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">897000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <xoma:FiniteLivedIntangibleAssetExpectedAmortizationThroughYearFive
      contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ"
      decimals="-3"
      id="Tc_2q9y7P1NU0OpkypkY7Hmsw_9_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">4036000</xoma:FiniteLivedIntangibleAssetExpectedAmortizationThroughYearFive>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      id="Tb_krzR2S5j90yZnItSF81MMA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Accrued and other liabilities consisted of the following (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued payroll, severance and retention costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 978&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,449&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued incentive compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 604&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 562&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accrued legal and accounting fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 331&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 867&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other accrued liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 40&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,933&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,918&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <xoma:AccruedSalariesAndEmployeeBenefitsCurrent
      contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ"
      decimals="-3"
      id="Tc_-QSiiTg_hECwKVgSXpGqCg_3_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">978000</xoma:AccruedSalariesAndEmployeeBenefitsCurrent>
    <xoma:AccruedSalariesAndEmployeeBenefitsCurrent
      contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg"
      decimals="-3"
      id="Tc_NJAx2MZrcEikCW7hHIHHzg_3_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">1449000</xoma:AccruedSalariesAndEmployeeBenefitsCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ"
      decimals="-3"
      id="Tc_m_6pbYKYDUSSnBPlniUnEA_4_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">604000</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg"
      decimals="-3"
      id="Tc_3t-aABtqNkOUCjl6prkEeQ_4_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">562000</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ"
      decimals="-3"
      id="Tc_7B8YpVORm02U5F2iF9yf9A_5_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">331000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg"
      decimals="-3"
      id="Tc_Gz6A8jw0RE-K50EFkEUwcA_5_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">867000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ"
      decimals="-3"
      id="Tc_yhzqZ9HkpEOKE841TdhHaw_6_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">20000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg"
      decimals="-3"
      id="Tc_Y6xkk0PjIkOhVHG_CCJ_LQ_6_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">40000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <xoma:AccruedAndOtherLiabilitiesCurrent
      contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ"
      decimals="-3"
      id="Tc_g5O81YcVBEihbmoGR2-BBQ_7_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">1933000</xoma:AccruedAndOtherLiabilitiesCurrent>
    <xoma:AccruedAndOtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg"
      decimals="-3"
      id="Tc_riTwS2f62kCDe1qPnjn5SQ_7_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">2918000</xoma:AccruedAndOtherLiabilitiesCurrent>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      id="Tb_A7wNBwO2vE6I2yjS8quQRw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The following is a reconciliation of the numerator (net loss) and the denominator (number of shares) used in the calculation of basic and diluted net loss per share attributable to common stockholders (in thousands, except per share amounts):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:55.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six Months Ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Numerator&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net loss &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,400)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4,670)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (15,213)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6,950)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Less: Series A accumulated dividends &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (530)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (530)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,061)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,061)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Less: Series B accumulated dividends &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (838)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (838)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,675)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,675)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net loss attributable to common stockholders, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6,768)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6,038)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (17,949)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9,686)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Denominator&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average shares used in computing basic and diluted net loss per share attributable to common stockholders&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,466&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,421&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,463&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,376&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Basic and diluted net loss per share attributable to common stockholders &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.59)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.53)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1.57)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.85)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg"
      decimals="-3"
      id="Tc_jtUGeNFJfUOGv7SI-OJ9Jg_4_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">-5400000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2022_To_6_30_2022_MkbIQ9bQc0eX6Gc5LtLGHQ"
      decimals="-3"
      id="Tc_fMiCQBZ_tESdilML6kCvHQ_4_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">-4670000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      decimals="-3"
      id="Tc_5aXXg5Y_FkWMcyvtLYrtNA_4_9"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">-15213000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw"
      decimals="-3"
      id="Tc_vsOYh6FPgUGYGRBODV1Ldw_4_12"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">-6950000</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_709bNt4Pc0ah6gEtj2ui5A"
      decimals="-3"
      id="Tc_05X3Xj7r4UmJQBiZG14F0A_5_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">530000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_d2IDvzwTtEeRbBTwLkWiZA"
      decimals="-3"
      id="Tc_YpjQkHNFYkWcAHdprSUNjg_5_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">530000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_5kIt1X7W_UGV93RZQkNN3A"
      decimals="-3"
      id="Tc_M2Lpf2KV806Flc63A_t2WA_5_9"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">1061000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_gy4yRQy_g0efVGsZ9JvfSg"
      decimals="-3"
      id="Tc_6ih8LX22S0SELzj8ux7cOw_5_12"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">1061000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_-1YcQgV4D0GXoCudlGfzsQ"
      decimals="-3"
      id="Tc_5LQimo34KkiPbjygQV-fDQ_6_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">838000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_q_kRVdOaKUGqFvcO4YBRYg"
      decimals="-3"
      id="Tc_dv9-BoOIkEeoe0WYTLhzDQ_6_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">838000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_mZzBVYXOQEiwSAFnA-OODw"
      decimals="-3"
      id="Tc_QINOd5fm4U2PcNi7S2dACw_6_9"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">1675000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_WOYOn9euaESUo_Fdt2xQDQ"
      decimals="-3"
      id="Tc_pmDah6DBKkqSkE137dr7wQ_6_12"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">1675000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg"
      decimals="-3"
      id="Tc_ZCzEuDg56E2NgVqb6ztjGw_7_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">-6768000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg"
      decimals="-3"
      id="Tc_ZCzEuDg56E2NgVqb6ztjGw_7_3_2"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">-6768000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_4_1_2022_To_6_30_2022_MkbIQ9bQc0eX6Gc5LtLGHQ"
      decimals="-3"
      id="Tc_sf1z9LdISUCYDFQL2VLywg_7_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">-6038000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="Duration_4_1_2022_To_6_30_2022_MkbIQ9bQc0eX6Gc5LtLGHQ"
      decimals="-3"
      id="Tc_sf1z9LdISUCYDFQL2VLywg_7_6_2"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">-6038000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      decimals="-3"
      id="Tc_k8bf7dpgs0KDmSVJfYuiGQ_7_9"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">-17949000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      decimals="-3"
      id="Tc_k8bf7dpgs0KDmSVJfYuiGQ_7_9_2"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">-17949000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw"
      decimals="-3"
      id="Tc_bxiFoyh950O4bsxlPseiXg_7_12"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">-9686000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw"
      decimals="-3"
      id="Tc_bxiFoyh950O4bsxlPseiXg_7_12_2"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">-9686000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg"
      decimals="0"
      id="Tc_R-63WqtCcEuldX2oNjJpOw_10_3"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">11466</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg"
      decimals="0"
      id="Tc_R-63WqtCcEuldX2oNjJpOw_10_3_2"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">11466</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_4_1_2022_To_6_30_2022_MkbIQ9bQc0eX6Gc5LtLGHQ"
      decimals="0"
      id="Tc_Z5MQAuG7pU60Xlt2N_4MPA_10_6"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">11421</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_4_1_2022_To_6_30_2022_MkbIQ9bQc0eX6Gc5LtLGHQ"
      decimals="0"
      id="Tc_Z5MQAuG7pU60Xlt2N_4MPA_10_6_2"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">11421</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      decimals="0"
      id="Tc_g2M52UF9TkisAZx6a52d1Q_10_9"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">11463</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      decimals="0"
      id="Tc_g2M52UF9TkisAZx6a52d1Q_10_9_2"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">11463</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw"
      decimals="0"
      id="Tc_4B_uW7B47k-7ZuPRRKwcaA_10_12"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">11376</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw"
      decimals="0"
      id="Tc_4B_uW7B47k-7ZuPRRKwcaA_10_12_2"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">11376</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg"
      decimals="2"
      id="Tc_WZYCsQ7jekSnRJTe9nJj-A_11_3"
      unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg">-0.59</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg"
      decimals="2"
      id="Tc_WZYCsQ7jekSnRJTe9nJj-A_11_3_2"
      unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg">-0.59</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_4_1_2022_To_6_30_2022_MkbIQ9bQc0eX6Gc5LtLGHQ"
      decimals="2"
      id="Tc_WkeKTNVc5UaznFlr8iDovg_11_6"
      unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg">-0.53</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_4_1_2022_To_6_30_2022_MkbIQ9bQc0eX6Gc5LtLGHQ"
      decimals="2"
      id="Tc_WkeKTNVc5UaznFlr8iDovg_11_6_2"
      unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg">-0.53</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      decimals="2"
      id="Tc_xlrPlxAmgUmko1T2XGq98w_11_9"
      unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg">-1.57</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      decimals="2"
      id="Tc_xlrPlxAmgUmko1T2XGq98w_11_9_2"
      unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg">-1.57</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw"
      decimals="2"
      id="Tc_niX5K8YRp06qiqwr9aKcmw_11_12"
      unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg">-0.85</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw"
      decimals="2"
      id="Tc_niX5K8YRp06qiqwr9aKcmw_11_12_2"
      unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg">-0.85</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      id="Tb_bK69XbZe9U2WaRqQJ7c13A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The following table shows the weighted-average shares from outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net loss per share attributable to common stockholders (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:55.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six Months Ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Convertible preferred stock &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,003&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,003&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,003&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,003&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Common stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,719&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 889&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,634&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 813&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Warrants for common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,728&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,898&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,643&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,822&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember_5ZLg9x5yckWz22fWebcY8g"
      decimals="-3"
      id="Tc_Q_TJlI5DSU-MHpCVlXR8oQ_3_2"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">5003000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember_oMboSz0lqEOTYykVt-gofg"
      decimals="-3"
      id="Tc_qju7z5rJQUuCi9elCZAtWQ_3_4"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">5003000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember_4EdMPylUGUe0Dt4op523HQ"
      decimals="-3"
      id="Tc_IkP3EsyHoEu7-TOKBto67g_3_6"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">5003000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember_q5E1VWyBm0qYx76IUNrtVg"
      decimals="-3"
      id="Tc_5Aahoe9F_UqlolcchEMypQ_3_8"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">5003000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_Ly-nCcCNVEyOwbUV0qBVsg"
      decimals="-3"
      id="Tc_58unOf4hrki0A2-03Ye32w_4_2"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">1719000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_s4acrI5TS06hk24i6x3lNw"
      decimals="-3"
      id="Tc_jLiY5y3Kb06oIgSRwiZ3zA_4_4"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">889000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_lxT004blek2W7cHNT8xELA"
      decimals="-3"
      id="Tc_TVz6Y03ZRUaydWmPaIvBWw_4_6"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">1634000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_NYjwGA24DUagvxCWxn84Ow"
      decimals="-3"
      id="Tc_oL4OZySjNEqA6QpSazwvqA_4_8"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">813000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_2Ja-erVJsE2TwmalqlMXlA"
      decimals="-3"
      id="Tc_ukLDH-0XeE26j86Mo9tfUA_5_2"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">6000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_89XiQrxi6U-bxg6UnFGjBA"
      decimals="-3"
      id="Tc_EALJbi6Uh0-85lX3RzhdLg_5_4"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">6000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_V2QHn9TZ1U2Os4nccw_I7w"
      decimals="-3"
      id="Tc_Z8VN6apZoU2I64Out4zAWA_5_6"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">6000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_q9rTRUIKZEeJEnJsjreVeA"
      decimals="-3"
      id="Tc_9QCcxcT9T0qqxY55HZ40Cw_5_8"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">6000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg"
      decimals="-3"
      id="Tc_1lTrp2yQIUqD2SQekSVx2g_6_2"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">6728000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_4_1_2022_To_6_30_2022_MkbIQ9bQc0eX6Gc5LtLGHQ"
      decimals="-3"
      id="Tc_jdrReyVDv0a3n2WOatC9Hg_6_4"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">5898000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      decimals="-3"
      id="Tc_SsSRkYzZykWV5N963BIlzA_6_6"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">6643000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw"
      decimals="-3"
      id="Tc_JfsbN7gBVkijqFbMdWACVg_6_8"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">5822000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SharePrice
      contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vo9zKMnZO0aHN96tsj24CA"
      decimals="2"
      id="Narr_GKVNEPoD9k-PJD2Sdfun7A"
      unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg">18.89</us-gaap:SharePrice>
    <xoma:NumberOfArbitrationProceedingsInitiated
      contextRef="Duration_6_1_2021_To_6_30_2021_xtjjCBFLBUi_Ojs50RRq5w"
      decimals="INF"
      id="Narr_6gA5ZE0xeUy8_UnqffYE1w"
      unitRef="Unit_Standard_item_ZJDcTjbqbUC2tIGJY9M-pg">1</xoma:NumberOfArbitrationProceedingsInitiated>
    <us-gaap:LitigationSettlementExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      decimals="-5"
      id="Narr_BmcVSN9_vE-QGTGIUK9Ejw"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">4100000</us-gaap:LitigationSettlementExpense>
    <xoma:LicensingAndOtherArrangementsTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      id="Tb_rU4qsB3c40mxkEtUpzEhxQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;4. Licensing and Other Arrangements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;"&gt;ObsEva &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On November 21, 2022, the Company entered into the ObsEva IP Acquisition Agreement pursuant to which the Company acquired all of ObsEva&#x2019;s intellectual property (patents and know-how) and license agreement rights related to ebopiprant, an investigational compound previously licensed by ObsEva from Merck KGaA. The Company also assumed ObsEva&#x2019;s ongoing rights and obligations under the Organon License Agreement and the Merck KGaA License Agreement. Pursuant to the Organon License Agreement, XOMA is eligible to receive up to $475.0 million in payments for ebopiprant development, commercialization and sales-based milestones. If ebopiprant is successfully commercialized, the Company will be entitled to receive royalties on net sales that range from low to mid-teens from Organon and will be required to make mid-single-digit royalty payments on net sales to Merck KGaA. The Company paid ObsEva a $15.0 million upfront payment at closing and will pay potential earn-out payments of up to $97.5 million for development, regulatory and sales-based milestones, representing a portion of what the Company would receive pursuant to the Organon License Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The transaction was treated as an acquisition of a finite-lived intangible asset (Note 2). As such, the Company&#x2019;s cost to acquire said intangible asset of $15.2 million, consisting of $15.0 million cash paid upon closing of the ObsEva IP Acquisition Agreement and direct incremental transaction costs of $0.2 million, was recognized as a long-term asset in the consolidated balance sheet for the year ended December 31, 2022. The estimated useful life of the intangible asset at acquisition represented 17 years. No impairment indicators were identified, and no impairment was recorded as of June 30, 2023 and December 31, 2022. The Company recognized $0.2 million and $0.4 million of amortization expense in the condensed consolidated statement of operations and comprehensive loss for the three and six months ended June 30, 2023, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company concluded that the development and regulatory milestone payments of $46.5 million, sales-based milestones payments of $51.0 million and royalty payments to Merck KGaA do not meet the definition of a derivative under ASC 815 and a liability will be recognized at the time that the underlying revenue is recognized under the Organon License Agreement for the corresponding development and regulatory milestone payments, sales-based milestone payments, and royalty payments. ASC 450 may require recognition of the contingent consideration if it is probable that a liability has been incurred and the amount of that liability can be reasonably estimated. Due to the nature of the non-sales and sales-based milestones the Company expects the contingent payments to be probable of payment at the same time that revenue from the Organon License Agreement would be recorded.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of June 30, 2023 and December 31, 2022, there were no contract assets or contract liabilities related to this arrangement. The Company did not recognize any revenue related to this arrangement during the three and six months ended June 30, 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;"&gt;Novartis&#160;&#x2013; Anti-TGF&#x3b2; Antibody (NIS793)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On September&#160;30, 2015, the Company and Novartis entered into the Anti-TGF&#x3b2; Antibody License Agreement under which the Company granted Novartis an exclusive, world-wide, royalty-bearing license to the Company&#x2019;s anti-transforming growth factor beta (&#x201c;TGF&#x3b2;&#x201d;) antibody program (now &#x201c;NIS793&#x201d;). Under the terms of the Anti-TGF&#x3b2; Antibody License Agreement, Novartis has worldwide rights to NIS793 and is responsible for the development and commercialization of antibodies and products containing antibodies arising from NIS793. Unless terminated earlier, the Anti-TGF&#x3b2; Antibody License Agreement will remain in effect, on a country-by-country and product-by-product basis, until Novartis&#x2019; royalty obligations end. The Anti-TGF&#x3b2; Antibody License Agreement contains customary termination rights relating to material breach by either party. Novartis also has a unilateral right to terminate the Anti-TGF&#x3b2; Antibody License Agreement on an antibody-by-antibody and country-by-country basis or in its entirety on one hundred eighty days&#x2019; notice.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company concluded that there were multiple promised goods and services under the Anti-TGF&#x3b2; Antibody License Agreement, including the transfer of license, regulatory services and transfer of materials, process and know-how, which were determined to represent one combined performance obligation. The Company recognized the entire upfront &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;payment of $37.0 million as revenue in the consolidated statement of comprehensive loss in 2015 as it had completed its performance obligations as of December&#160;31, 2015.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company was eligible to receive up to a total of $480.0 million in development, regulatory and commercial milestones under the Anti-TGF&#x3b2; Antibody License Agreement. During the year ended December 31, 2017, Novartis achieved a clinical development milestone pursuant to the Anti-TGF&#x3b2; Antibody License Agreement, and as a result, the Company earned a $10.0 million milestone payment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company concluded that the development and regulatory milestone payments are solely dependent on Novartis&#x2019; performance and achievement of the specified events. The Company determined that it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the remaining development and regulatory milestones are fully constrained and excluded from the transaction price. Any consideration related to commercial milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the licenses granted to Novartis and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is also eligible to receive royalties on sales of licensed products, which are tiered based on sales levels and range from a mid-single-digit percentage rate to up to a low double-digit percentage rate. Novartis&#x2019; obligation to pay royalties with respect to a particular product and country will continue for the longer of the date of expiration of the last valid patent claim covering the product in that country, or ten years from the date of the first commercial sale of the product in that country.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In October 2020, the Company earned a $25.0 million milestone upon the dosing of the first patient in Novartis&#x2019; first NIS793 Phase 2 clinical trial. As specified under the terms of the Anti-TGF&#x3b2; Antibody License Agreement, the Company received $17.7 million in cash, and the remaining balance of $7.3 million was recognized as a reduction to the Company's debt obligation to Novartis. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In October 2021, the Company earned a $35.0 million milestone payment upon dosing of the first patient in Novartis&#x2019; first NIS793 Phase 3 clinical trial. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is eligible to receive remaining milestones up to a total of $410.0 million under the Anti-TGF&#x3b2; Antibody License Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of June 30, 2023 and December 31, 2022, there were no contract assets or contract liabilities related to this arrangement. None of the costs to obtain or fulfill the contract were capitalized. The Company did not recognize any revenue related to this arrangement during the three and six months ended June 30, 2023 and 2022. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;"&gt;Novartis&#160;&#x2013; Anti-IL-1&#x3b2; Antibody (VPM087) &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On August&#160;24, 2017, the Company and Novartis entered into the Gevokizumab License Agreement under which the Company granted to Novartis an exclusive, worldwide, royalty-bearing license to gevokizumab (&#x201c;VPM087&#x201d;), a novel anti-Interleukin-1 (&#x201c;IL-1&#x201d;) beta allosteric monoclonal antibody and related know-how and patents. Under the terms of the Gevokizumab License Agreement, Novartis is solely responsible for the development and commercialization of VPM087 and products containing VPM087. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On August&#160;24, 2017, pursuant to a separate agreement (the &#x201c;IL-1 Target License Agreement&#x201d;), the Company granted to Novartis non-exclusive licenses to its intellectual property covering the use of IL-1 beta targeting antibodies in the treatment and prevention of cardiovascular disease and other diseases and conditions, and an option to obtain an exclusive license (the &#x201c;Exclusivity Option&#x201d;) to such intellectual property for the treatment and prevention of cardiovascular disease.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Under the Gevokizumab License Agreement, the Company received total consideration of $30.0 million for the license and rights granted to Novartis. Of the total consideration, $15.7 million was paid in cash and $14.3 million (equal &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;to &#x20ac;12.0 million) was paid by Novartis, on behalf of the Company, to settle the Company&#x2019;s outstanding debt with Les Laboratories Servier (&#x201c;Servier&#x201d;) (the &#x201c;Servier Loan&#x201d;). In addition, Novartis extended the maturity date on the Company&#x2019;s debt to Novartis. The Company also received $5.0 million cash related to the sale of 539,131 shares of the Company&#x2019;s common stock, at a purchase price of $9.2742 per share. The fair market value of the common stock issued to Novartis was $4.8 million, based on the closing stock price of $8.93 per share on August&#160;24, 2017, resulting in a $0.2 million premium paid to the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Based on the achievement of pre-specified criteria, the Company is eligible to receive up to $438.0 million in development, regulatory and commercial milestones under the Gevokizumab License Agreement. The Company is also eligible to receive royalties on sales of licensed products, which are tiered based on sales levels and range from the high single-digits to mid teens. Under the IL-1 Target License Agreement, the Company received an upfront cash payment of $10.0 million and is eligible to receive low single-digit royalties on canakinumab sales in cardiovascular indications covered by the Company&#x2019;s patents. Should Novartis exercise the Exclusivity Option, the royalties on canakinumab sales will increase to the mid single-digits.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Unless terminated earlier, the Gevokizumab License Agreement and IL-1 Target License Agreement will remain in effect, on a country-by-country and product-by-product basis, until Novartis&#x2019; royalty obligations end. The two agreements contain customary termination rights relating to material breach by either party. Novartis also has a unilateral right to terminate the Gevokizumab License Agreement on a product-by-product and country-by-country basis or in its entirety on six months&#x2019; prior written notice to the Company. Under the IL-1 Target License Agreement, Novartis has a unilateral right to terminate the agreement on a product-by-product and country-by-country basis or in its entirety upon a prior written notice. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Gevokizumab License Agreement and IL-1 Target License Agreement were accounted for as one arrangement because they were entered into at the same time in contemplation of each other. The Company concluded that there are multiple promised goods and services under the combined arrangement, including the transfer of license to IL-1 beta targeting antibodies, and the transfer of license, know-how, process, materials and inventory related to the VPM087 antibody, which were determined to represent two distinct performance obligations. The Company determined that the Exclusivity Option is not an option with material right because the upfront payments to the Company were not negotiated to provide an incremental discount for the future additional royalties upon exercise of the Exclusivity Option. Therefore, the Company concluded that the Exclusivity Option is not a performance obligation. The additional royalties will be recognized as revenue when, and if, Novartis exercises its option because the Company has no further performance obligations at that point.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;At the inception of the arrangement, the Company determined that the transaction price under the arrangement was $40.2 million, which consisted of the $25.7 million upfront cash payments, the $14.3 million Servier Loan payoff and the $0.2 million premium on the sale of the common stock. The transaction price was allocated to the two performance obligations based on their standalone selling prices. The Company determined that the nature of the two performance obligations is the right to use the licenses as they exist at the point of transfer, which occurred when the transfer of materials, process and know-how, and filings to regulatory authority were completed. During the&#160;year ended December&#160;31, 2017, the Company recognized the entire transaction price of $40.2 million as revenue upon completion of the delivery of the licenses and related materials, process and know-how, and filings to regulatory authority.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company concluded that the development and regulatory milestone payments are solely dependent on Novartis&#x2019; performance and achievement of specified events. The Company determined that it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the development and regulatory milestones are fully constrained and excluded from the transaction price until the respective milestone is achieved. Any consideration related to commercial milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the licenses granted to Novartis and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of June 30, 2023 and December 31, 2022, there were no contract assets or contract liabilities related to this arrangement, and none of the costs to obtain or fulfill the contract were capitalized. The Company did not recognize any revenue related to this arrangement during the three and six months ended June 30, 2023 and 2022. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;"&gt;Takeda&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On November 1,&#160;2006, the Company entered into the Takeda Collaboration Agreement with Takeda under which the Company agreed to discover and optimize therapeutic antibodies against multiple targets selected by Takeda.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the terms of the Takeda Collaboration Agreement, the Company may receive additional milestone payments aggregating up to $19.0 million relating to TAK-079 (mezagitamab) and TAK-169 (MT-0169), and low single-digit royalties on future sales of all products subject to this license. The Company&#x2019;s right to milestone payments expires on the later of the receipt of payment from Takeda of the last amount to be paid under the agreement or the cessation by Takeda of all research and development activities with respect to all program antibodies, collaboration targets or collaboration products. The Company&#x2019;s right to royalties expires on the later of 13.5&#160;years from the first commercial sale of each royalty-bearing discovery product or the expiration of the last-to-expire licensed patent (or 12 years from first commercial sale if there is significant generic competition post patent-expiration).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In February&#160;2009, the Company expanded the existing collaboration to provide Takeda with access to multiple antibody technologies, including a suite of research and development technologies and integrated information and data management systems. The Company may receive milestones of up to $3.3 million per discovery product candidate and low single-digit royalties on future sales of all antibody products subject to this license. The Company&#x2019;s right to milestone payments expires on the later of the receipt of payment from Takeda of the last amount to be paid under the agreement or the cessation by Takeda of all research and development activities with respect to all program antibodies, collaboration targets or collaboration products. The Company&#x2019;s right to royalties expires on the later of 10 years from the first commercial sale of such royalty-bearing discovery product or the expiration of the last-to-expire licensed patent.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In November 2020, the first patient was dosed in Takeda&#x2019;s Phase 2 study of mezagitamab and the Company earned a $2.0 million milestone payment from Takeda. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In August 2021, Molecular Templates, Inc., assumed full rights to TAK-169 from Takeda, including full control of TAK-169 clinical development, per the terms of its terminated collaboration agreement with Takeda.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In January 2022, the Company earned a development milestone pursuant to the Takeda Collaboration and recognized $0.8 million as revenue from contracts with customers in the condensed consolidated statement of operations and comprehensive loss for the six months ended June 30, 2022. No revenue was recognized for the three and six months ended June 30, 2023, or for the three months ended June 30, 2022. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of June 30, 2023 and December 31, 2022 there were no contract assets or contract liabilities related to this arrangement and none of the costs to obtain or fulfill the contract were capitalized. The Company is eligible to receive remaining milestones up to a total of $16.0 million under the Takeda Collaboration Agreement. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;"&gt;Rezolute&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On December&#160;6, 2017, the Company entered into a license agreement with Rezolute pursuant to which the Company granted an exclusive global license to Rezolute to develop and commercialize X358 (now &#x201c;RZ358&#x201d;) products for all indications. The Company and Rezolute also entered into a common stock purchase agreement pursuant to which Rezolute agreed to issue to the Company, as consideration for receiving the license for RZ358, a certain number of its common stock related to its future financing activities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Under the terms of the license agreement, Rezolute is responsible for all development, regulatory, manufacturing and commercialization activities associated with RZ358 and is required to make certain development, regulatory and commercial milestone payments to the Company of up to $232.0 million in the aggregate based on the achievement of &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;pre-specified criteria. Under the license agreement, the Company is also eligible to receive royalties ranging from the high single-digits to the mid-teens based upon annual net sales of any commercial product incorporating RZ358. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company concluded that the development and regulatory milestone payments are solely dependent on Rezolute&#x2019;s performance and achievement of the specified events. The Company determined that it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the remaining development and regulatory milestones are fully constrained and excluded from the transaction price until the respective milestone is achieved. Any consideration related to commercial milestones (including royalties) will be recognized when the related sales occur as they were determined to relate predominantly to the licenses granted to Rezolute and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Rezolute&#x2019;s obligation to pay royalties with respect to a particular RZ358 product and country will continue for the longer of the date of expiration of the last valid patent claim covering the product in that country, or twelve years from the date of the first commercial sale of the product in that country. Rezolute&#x2019;s future royalty obligations in the United States will be reduced by 20% if the manufacture, use or sale of a licensed product is not covered by a valid XOMA patent claim, until such a claim is issued.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Pursuant to the license agreement, XOMA is eligible to receive a low single-digit royalty on sales of Rezolute&#x2019;s other non-RZ358 products from its current programs, including RZ402 which is in Phase 2 clinical testing. Rezolute&#x2019;s obligation to pay royalties with respect to a particular Rezolute product and country will continue for the longer of twelve years from the date of the first commercial sale of the product in that country or for so long as Rezolute or its licensee is selling such product in such country, provided that any such licensee royalty will terminate upon the termination of the licensee&#x2019;s obligation to make payments to Rezolute based on sales of such product in such country&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The license agreement contains customary termination rights relating to material breach by either party. Rezolute also has a unilateral right to terminate the license agreement in its entirety on ninety days&#x2019; notice at any time. To the extent permitted by applicable laws, the Company has the right to terminate the license agreement if Rezolute challenges the licensed patents.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;No consideration was exchanged upon execution of the arrangement. In consideration for receiving the license for RZ358, Rezolute agreed to issue shares of its common stock and pay cash to the Company upon the occurrence of Rezolute&#x2019;s financing activities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The license agreement was subsequently amended in 2018, 2019 and 2020. Pursuant to the terms of the license agreement as amended, the Company received a total of $6.0 million upon Rezolute&#x2019;s financing and $8.5 million in installment payments through October 2020. The Company also received 161,861 shares of Rezolute&#x2019;s common stock (as adjusted for the &lt;span style="-sec-ix-hidden:Hidden_U1OJbQlzmUOeCcJTMgU3Qw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;1&lt;/span&gt;&lt;/span&gt;:50 reverse stock split in October 2020). &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In January 2022, Rezolute dosed the last patient in its Phase 2b clinical trial for RZ358, which triggered a $2.0 million milestone payment due to the Company pursuant to the Rezolute License Agreement. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;No revenue was recognized for the three and six months ended June 30, 2023. The Company recognized no revenue and $2.0 million as revenue from contracts with customers in the condensed consolidated statement of operations and comprehensive loss for the three and six months ended June 30, 2022, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of June 30, 2023 and December 31, 2022 there were no contract assets or contract liabilities related to this arrangement. None of the costs to obtain or fulfill the contract were capitalized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;"&gt;Janssen Biotech&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="background:#ffffff;"&gt;The Company and Janssen were parties to a license agreement which was terminated in 2017.&lt;/span&gt; In August 2019, the Company and Janssen entered into a new agreement pursuant to which the Company granted a non-exclusive license &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;to Janssen to develop and commercialize certain drug candidates under the XOMA patents and know-how. Under the new agreement, Janssen made a one-time payment of $2.5 million to XOMA. Additionally, for each drug candidate, the Company is entitled to receive milestone payments of up to $3.0 million upon Janssen&#x2019;s achievement of certain clinical development and regulatory approval events. Additional milestones may be due for drug candidates which are the subject of multiple clinical trials. Upon commercialization, the Company is eligible to receive 0.75% royalty on net sales of each product. Janssen&#x2019;s obligation to pay royalties with respect to a particular product and country will continue until the eighth-year-and-sixth-month anniversary of the first commercial sale of the product in such country. The new agreement will remain in effect unless terminated by mutual written agreement of the parties. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company concluded that the new agreement should be accounted for separately from any prior arrangements with Janssen and that the license grant is the only performance obligation under the new agreement. The Company recognized the entire one-time payment of $2.5 million as revenue for the year ended December 31, 2019 as it had completed its performance obligation. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company concluded that the development and regulatory milestone payments are solely dependent on Janssen&#x2019;s performance and achievement of specified events and thus it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the development and regulatory milestones are fully constrained and excluded from the transaction price until the respective milestone is achieved. Any consideration related to royalties will be recognized when the related sales occur as they were determined to relate predominantly to the license granted to Janssen and therefore, have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of June 30, 2023 and December 31, 2022, there were no contract assets or contract liabilities related to this arrangement. None of the costs to obtain or fulfill the contract were capitalized. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In April 2023, the Company earned a $0.5 million milestone from Janssen, upon dosing of the first patient in a Phase 3 clinical trial evaluating one of Janssen&#x2019;s biologic assets. In addition, during the second quarter of 2023, the Company also earned $0.6 million total for three additional milestones pursuant to its agreement with Janssen. The Company recognized milestone revenue of $1.1 million for the three and six months ended June 30, 2023. The Company did not recognize any revenue related to this arrangement during the three and six months ended June 30, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;"&gt;Affimed&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In April 2021, the Company and Affimed entered into a contractual agreement, under which the Company is eligible to receive payments from Affimed on potential future commercial sales related to three ICE&lt;span style="font-size:12pt;"&gt; &lt;/span&gt;molecules and preloaded natural killer cells containing the ICE molecules. Additionally, the Company is eligible to receive a milestone upon the first product candidate in each program achieving marketing approval. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company concluded that the commercial milestone payments are solely dependent on Affimed&#x2019;s performance and achievement of specified events. The Company determined that it is not probable that a significant cumulative revenue reversal will not occur in future periods for these future payments. Therefore, the commercial milestones are fully constrained and excluded from the transaction price until the respective milestone is achieved. Any consideration related to commercial milestones (including royalties) will be recognized when the related approvals occur and therefore have also been excluded from the transaction price. At the end of each reporting period, the Company will update its assessment of whether an estimate of variable consideration is constrained and update the estimated transaction price accordingly.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of June 30, 2023 and December 31, 2022, there were no contract assets or contract liabilities related to this arrangement. None of the costs to obtain or fulfill the contract were capitalized. The Company did not recognize any revenue related to this arrangement during the three and six months ended June 30, 2023 and 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;"&gt;Sale of Future Revenue Streams&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On December&#160;21, 2016, the Company entered into two royalty interest sale agreements (together, the &#x201c;Royalty Sale Agreements&#x201d;) with HCRP. Under the first Royalty Sale Agreement, the Company sold its right to receive milestone payments and royalties on future sales of products subject to a License Agreement, dated August&#160;18, 2005, between XOMA and Wyeth Pharmaceuticals (subsequently acquired by Pfizer) for an upfront cash payment of $6.5 million, plus potential additional payments totaling $4.0 million in the event three specified net sales milestones were met in 2017, 2018 and 2019. Based on actual sales, 2017, 2018, and 2019 sales milestones were not achieved. Under the second Royalty Sale Agreement entered into in December&#160;2016, the Company sold its right to receive certain royalties under an Amended and Restated License Agreement dated October&#160;27, 2006 between XOMA and Dyax Corp. for a cash payment of $11.5 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company classified the proceeds received from HCRP as unearned revenue, to be recognized as revenue under the units-of-revenue method over the life of the license agreements because of the Company&#x2019;s limited continuing involvement in the Acquisition Agreements. Such limited continuing involvement is related to the Company&#x2019;s undertaking to cooperate with HCRP in the event of litigation or a dispute related to the license agreements. Because the transaction was structured as a non-cancellable sale, the Company does not have significant continuing involvement in the generation of the cash flows due to HCRP and there are no guaranteed rates of return to HCRP, the Company recorded the total proceeds of $18.0 million as unearned revenue recognized under the units-of-revenue method. The Company allocated the total proceeds between the two Royalty Sale Agreements based on the relative fair value of expected payments to be made to HCRP under the license agreements. The unearned revenue is being recognized as revenue over the life of the underlying license agreements under the "units-of-revenue" method. Under this method, amortization for a reporting period is calculated by computing a ratio of the allocated proceeds received from HCRP to the payments expected to be made by the licensees to HCRP over the term of the Acquisition Agreements and then applying that ratio to the period&#x2019;s cash payment. During the third quarter of 2018, the Shire product underlying the Dyax Corp. license agreement was approved, and the Company began recognizing revenue under the units-of-revenue method due to sales of the approved product.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognized $0.5 million and $1.0 million as revenue under the units-of-revenue method under these arrangements during the three and six months ended June 30, 2023, respectively. The Company recognized $0.5 million and $0.8 million as revenue under the units-of-revenue method under these arrangements during the three and six months ended June 30, 2022, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December&#160;31, 2022, the current and non-current portion of the remaining unearned revenue recognized under the units-of-revenue method was $1.9 million and $9.6 million, respectively. As of June 30, 2023, the Company classified $2.0 million and $8.5 million as current and non-current unearned revenue recognized under the units-of-revenue method, respectively.&lt;/p&gt;</xoma:LicensingAndOtherArrangementsTextBlock>
    <xoma:EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentCommercializationAndSalesMilestones
      contextRef="As_Of_11_21_2022_srt_CounterpartyNameAxis_xoma_OrganonMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_VI6RYGqQZkeAVJnnIv4sTQ"
      decimals="-5"
      id="Narr_pSx_uLvC4E6q1-aIQoLdtA"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">475000000.0</xoma:EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentCommercializationAndSalesMilestones>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="Duration_11_21_2022_To_11_21_2022_us-gaap_AssetAcquisitionAxis_xoma_ObsevaIntellectualPropertyRightsMember_lo8MSWY_Dk2sar0rv1imYg"
      decimals="-5"
      id="Narr_oxW3YS_xP0maziaJwBqNnQ"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">15000000.0</us-gaap:PaymentsToAcquireProductiveAssets>
    <xoma:MaximumEarnOutPayments
      contextRef="As_Of_11_21_2022_us-gaap_AssetAcquisitionAxis_xoma_ObsevaIntellectualPropertyRightsMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_eP4cyYTR-k2h0sxHIlensA"
      decimals="-5"
      id="Narr_o3FQrmp64EKYLmEyDJPPDg"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">97500000</xoma:MaximumEarnOutPayments>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="Duration_11_21_2022_To_11_21_2022_us-gaap_AssetAcquisitionAxis_xoma_ObsevaIntellectualPropertyRightsMember_lo8MSWY_Dk2sar0rv1imYg"
      decimals="-5"
      id="Narr_DL0K8u5nD0GeqFqtB972zA"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">15200000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="Duration_11_21_2022_To_11_21_2022_us-gaap_AssetAcquisitionAxis_xoma_ObsevaIntellectualPropertyRightsMember_lo8MSWY_Dk2sar0rv1imYg"
      decimals="-5"
      id="Narr_G09_VXLldEG0exllFzVW5g"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">15000000.0</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost
      contextRef="Duration_11_21_2022_To_11_21_2022_us-gaap_AssetAcquisitionAxis_xoma_ObsevaIntellectualPropertyRightsMember_lo8MSWY_Dk2sar0rv1imYg"
      decimals="-5"
      id="Narr_fZQFi_6LOkKV5BjIUrYaaA"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">200000</us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="Duration_11_21_2022_To_11_21_2022_us-gaap_AssetAcquisitionAxis_xoma_ObsevaIntellectualPropertyRightsMember_lo8MSWY_Dk2sar0rv1imYg"
      id="Narr_3RviYvaVgU-g_tcKTjBMow">P17Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AssetAcquisitionAxis_xoma_ObsevaIntellectualPropertyRightsMember_sYlzh40hyE6ZDGRh_bcjVw"
      decimals="-6"
      id="Narr_28LMoJ6RDkiJrhOmPDCJZg"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AssetAcquisitionAxis_xoma_ObsevaIntellectualPropertyRightsMember_aKWzGNtzM0-dDhbT2Gyirg"
      decimals="-6"
      id="Narr__F-nqJrMlEifyZ1zSOSbZA"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_AssetAcquisitionAxis_xoma_ObsevaIntellectualPropertyRightsMember_ZsDO0IohTEmlxBFNZXxV-w"
      decimals="-5"
      id="Narr__5kv_aNe_k6vXnISbhjwIA"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">200000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AssetAcquisitionAxis_xoma_ObsevaIntellectualPropertyRightsMember_sYlzh40hyE6ZDGRh_bcjVw"
      decimals="-5"
      id="Narr_AqvvT4CV9Uq7orXTs8GzQw"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">400000</us-gaap:AmortizationOfIntangibleAssets>
    <xoma:MaximumEarnOutPaymentsDevelopmentAndRegulatoryMilestonePayments
      contextRef="As_Of_11_21_2022_srt_CounterpartyNameAxis_xoma_MerckKgaaMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_9bKtdq3Xq022OPaePZccLw"
      decimals="-5"
      id="Narr_2caj2OhmYU2RmaoxmprgpA"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">46500000</xoma:MaximumEarnOutPaymentsDevelopmentAndRegulatoryMilestonePayments>
    <xoma:MaximumEarnOutPaymentsSalesBasedMilestonePayments
      contextRef="As_Of_11_21_2022_srt_CounterpartyNameAxis_xoma_MerckKgaaMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_9bKtdq3Xq022OPaePZccLw"
      decimals="-5"
      id="Narr_SYJ7wYL76k-dcVxtkuK_SA"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">51000000.0</xoma:MaximumEarnOutPaymentsSalesBasedMilestonePayments>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_ObsevaMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_zyUxaH6CvkmKfmQE_-3YjQ"
      decimals="-5"
      id="Narr_oiwBPlLwhUGFkUAh6adr-g"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_ObsevaMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_YH_2bboTUkyRnEvX6o0V4w"
      decimals="-5"
      id="Narr_VLhOefcFR0-z5Zxz8bO6dw"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_ObsevaMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_zyUxaH6CvkmKfmQE_-3YjQ"
      decimals="-5"
      id="Narr_ziN4E2A7y0q883838_JKoQ"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_ObsevaMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_YH_2bboTUkyRnEvX6o0V4w"
      decimals="-5"
      id="Narr_QkY8MFtoCkGXE80bGCUBLA"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_4_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_ObsevaMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_K7Mk8P8VwES9_5DBUAZzMw"
      decimals="-5"
      id="Narr_qRoKeGO-L0uG5ZD0onCyYA"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_ObsevaMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_XJPmp5bo-kmu5UyKiVXplA"
      decimals="-5"
      id="Narr_gNJOP1s3yESxAC93ezkHaw"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <xoma:AgreementTerminationPriorWrittenNoticePeriod
      contextRef="Duration_9_30_2015_To_9_30_2015_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_27gU5riISEy0SIhW5x2uJg"
      id="Narr_7KbCso8g6Ea-IWs-pzkPEA">P180D</xoma:AgreementTerminationPriorWrittenNoticePeriod>
    <xoma:NumberOfPerformanceObligations
      contextRef="Duration_9_30_2015_To_9_30_2015_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_27gU5riISEy0SIhW5x2uJg"
      decimals="INF"
      id="Narr_lPGXHLm7qUqfb2elgdrRcw"
      unitRef="Unit_Standard_item_ZJDcTjbqbUC2tIGJY9M-pg">1</xoma:NumberOfPerformanceObligations>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2015_To_12_31_2015_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_UKHVP4QfBUyD1MV8rF2yOQ"
      decimals="-5"
      id="Narr_klqmJ9DEiE26qElTePF_yg"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">37000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <xoma:ProceedsFromUpfrontPayment
      contextRef="Duration_1_1_2015_To_12_31_2015_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_UKHVP4QfBUyD1MV8rF2yOQ"
      decimals="-5"
      id="Narr_xmQDA0f7wUueFlkJGok87Q"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">37000000.0</xoma:ProceedsFromUpfrontPayment>
    <xoma:EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones
      contextRef="As_Of_9_30_2015_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_AFuvSscA3kS3Ogj-V-41CQ"
      decimals="-5"
      id="Narr_6bNz3tIymk6JKe6k3X92OQ"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">480000000.0</xoma:EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2017_To_12_31_2017_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_Zf-09DuHLUy9gAfOBsfCZw"
      decimals="-5"
      id="Narr_-MSdDBENnUOTvfg8elYv7w"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">10000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <xoma:RoyaltiesPeriodMinimum
      contextRef="Duration_9_30_2015_To_9_30_2015_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_27gU5riISEy0SIhW5x2uJg"
      id="Narr_AZ8TD9Fk7kCOqYsUqE-_6w">P10Y</xoma:RoyaltiesPeriodMinimum>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_10_1_2020_To_10_31_2020_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_HhVju1hJBE6OfB_ni4aRJg"
      decimals="-5"
      id="Narr_RkDy6sOrZ06m7k-54YJuFQ"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">25000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <xoma:ProceedsFromUpfrontPayment
      contextRef="Duration_10_1_2020_To_10_31_2020_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_HhVju1hJBE6OfB_ni4aRJg"
      decimals="-5"
      id="Narr_rFOshff3REqF5fQ0JgbAhA"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">17700000</xoma:ProceedsFromUpfrontPayment>
    <us-gaap:DebtInstrumentIncreaseDecreaseForPeriodNet
      contextRef="Duration_10_1_2020_To_10_31_2020_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_pUHf37jdqkO7GsZ6tJj4dA"
      decimals="-5"
      id="Narr_3zm0Ef2hQ06vtzpziTUFyw"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">-7300000</us-gaap:DebtInstrumentIncreaseDecreaseForPeriodNet>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_10_1_2021_To_10_31_2021_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_xqc5RHdAf0e8Ok9zCOunNA"
      decimals="-5"
      id="Narr_DJQVJ6rQlk20vwKaDP6sOA"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">35000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <xoma:EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones
      contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_Gr7k7W5HhEC0zf3RWdymsw"
      decimals="-5"
      id="Narr_LMZaoi0x3UOQ7iiYLlFCYQ"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">410000000.0</xoma:EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_Gr7k7W5HhEC0zf3RWdymsw"
      decimals="-6"
      id="Narr_0i61JTNs-ku5GSbmqhOCWQ"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_jNqsIu1EwE6fPsDB8xZzrg"
      decimals="-6"
      id="Narr_Bt2ZK49geESc1H2UekibUg"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_Gr7k7W5HhEC0zf3RWdymsw"
      decimals="-6"
      id="Narr_wFKF9bBWeUyvAnldQ9u25g"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_jNqsIu1EwE6fPsDB8xZzrg"
      decimals="-6"
      id="Narr_OZ-BtTiS5E-xx2_Q8MkwCw"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:CapitalizedContractCostNet
      contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_Gr7k7W5HhEC0zf3RWdymsw"
      decimals="-6"
      id="Narr_W0NxlJ1NJkG-UVAprIP8cA"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:CapitalizedContractCostNet>
    <us-gaap:CapitalizedContractCostNet
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_jNqsIu1EwE6fPsDB8xZzrg"
      decimals="-6"
      id="Narr_s9p3Y141U0ut6qp6SNIpww"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:CapitalizedContractCostNet>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_9uhBqAbJnkGLmYVcrsplwQ"
      decimals="-6"
      id="Narr_PFXSNhDpGEy0iKNovN3QKw"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_4_1_2022_To_6_30_2022_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_RLV8-2lAs0iAHxQrgpOq0w"
      decimals="-6"
      id="Narr_J6HDCXIozUuHUNO3-3rYTA"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_mc8GGMwdb0i-WiWEDrANiQ"
      decimals="-6"
      id="Narr_LPbZMqRTukecpb3xXDETSQ"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_4_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_NovartisInternationalPharmaceuticalLtdMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_1mMiwj9oK0ik7StNSZF-NA"
      decimals="-6"
      id="Narr_RFQJZKiUP0Wx2EpFOnP52g"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <xoma:LicenseAgreementConsiderationReceived
      contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_M2UiaYqolEG6eD-krPLPrQ"
      decimals="-5"
      id="Narr_gTrP7b8-E0msepzZABe1og"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">30000000.0</xoma:LicenseAgreementConsiderationReceived>
    <xoma:ProceedsFromUpfrontPayment
      contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_M2UiaYqolEG6eD-krPLPrQ"
      decimals="-5"
      id="Narr_jJRj_GVMB0CHfJNnq73T7g"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">15700000</xoma:ProceedsFromUpfrontPayment>
    <xoma:LicenseAgreementConsiderationReceivedDebtRepayment
      contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_M2UiaYqolEG6eD-krPLPrQ"
      decimals="-5"
      id="Narr_I7m1yGMSkU6y1-5bAYZ7Zg"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">14300000</xoma:LicenseAgreementConsiderationReceivedDebtRepayment>
    <xoma:LicenseAgreementConsiderationReceivedDebtRepayment
      contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_M2UiaYqolEG6eD-krPLPrQ"
      decimals="-5"
      id="Narr_Itw1MdDM0UicdRAOF6JbjA"
      unitRef="Unit_Standard_EUR_cFLXt4pWsUCag8uS-iVkYw">12000000.0</xoma:LicenseAgreementConsiderationReceivedDebtRepayment>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_M2UiaYqolEG6eD-krPLPrQ"
      decimals="-5"
      id="Narr_rsXm2Mdee0CTKkh3mWvboA"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">5000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_t9TRI6XjwEKzRs1Mh2hslQ"
      decimals="INF"
      id="Narr_f9xaPHpgAUuHkNeNmbxChQ"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">539131</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_8Kg_25tsBUmCq2SIaH9sdg"
      decimals="5"
      id="Narr_fM2Uavj9UUWc9XTJFk7n5Q"
      unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg">9.2742</us-gaap:SharesIssuedPricePerShare>
    <xoma:StockIssuedDuringPeriodValueNewIssuesCommonStock
      contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_t9TRI6XjwEKzRs1Mh2hslQ"
      decimals="-5"
      id="Narr_-oJkXRBEmEWZUD66_pOSqQ"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">4800000</xoma:StockIssuedDuringPeriodValueNewIssuesCommonStock>
    <us-gaap:SharePrice
      contextRef="As_Of_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_8Kg_25tsBUmCq2SIaH9sdg"
      decimals="2"
      id="Narr_VOv6lxm470qAsElJXjSeCg"
      unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg">8.93</us-gaap:SharePrice>
    <xoma:CommonStockPremium
      contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_M2UiaYqolEG6eD-krPLPrQ"
      decimals="-5"
      id="Narr_HWWjzHbtRUqxykiSSbLaJg"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">200000</xoma:CommonStockPremium>
    <xoma:EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones
      contextRef="As_Of_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_LoKvCYQB9EOeQYU95Ohdpw"
      decimals="-5"
      id="Narr_mZGsIFA2xEiLReSqazKi_A"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">438000000.0</xoma:EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones>
    <xoma:ProceedsFromUpfrontPayment
      contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_IL1TargetLicenseAgreementMember_1_yPty6sVUuiOqjDzbtIAg"
      decimals="-5"
      id="Narr_JqcSwQbUt0uiUK7zrht8uQ"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">10000000.0</xoma:ProceedsFromUpfrontPayment>
    <xoma:NumberOfLicenseAgreements
      contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_niKO_iOCski7xDCZeqBm0g"
      decimals="INF"
      id="Narr_5DnV0I2p2UyY3a6hpSAohQ"
      unitRef="Unit_Standard_agreement_8WD-ZASWEUe8fofDOT9VGw">2</xoma:NumberOfLicenseAgreements>
    <xoma:AgreementTerminationPriorWrittenNoticePeriod
      contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_XOMA052LicenseAgreementMember_M2UiaYqolEG6eD-krPLPrQ"
      id="Narr_JPzEhj2Op0mMm3PKDXBr1A">P6M</xoma:AgreementTerminationPriorWrittenNoticePeriod>
    <xoma:ArrangementsNumber
      contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_niKO_iOCski7xDCZeqBm0g"
      decimals="INF"
      id="Narr_E-ium1JIiE6BtaCRYwtufA"
      unitRef="Unit_Standard_item_ZJDcTjbqbUC2tIGJY9M-pg">1</xoma:ArrangementsNumber>
    <xoma:NumberOfPerformanceObligations
      contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_niKO_iOCski7xDCZeqBm0g"
      decimals="INF"
      id="Narr_RYhRvtGXeUW6t_vmP4CCYw"
      unitRef="Unit_Standard_item_ZJDcTjbqbUC2tIGJY9M-pg">2</xoma:NumberOfPerformanceObligations>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_-LsGHkQ-r0C10A2ulFZGhA"
      decimals="-5"
      id="Narr_fVKgQEucPEeP0tG4np281A"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:RevenueRemainingPerformanceObligation>
    <xoma:LicenseAgreementTransactionPrice
      contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_niKO_iOCski7xDCZeqBm0g"
      decimals="-5"
      id="Narr_HQVAJuSqFkqH1VbiNoADsw"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">40200000</xoma:LicenseAgreementTransactionPrice>
    <xoma:ProceedsFromUpfrontPayment
      contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_niKO_iOCski7xDCZeqBm0g"
      decimals="-5"
      id="Narr_wl692D4dQEyny5vDjcaOgQ"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">25700000</xoma:ProceedsFromUpfrontPayment>
    <xoma:LicenseAgreementConsiderationReceivedDebtRepayment
      contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_niKO_iOCski7xDCZeqBm0g"
      decimals="-5"
      id="Narr_iybQSzIFV0OQDJfFl9Mu2g"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">14300000</xoma:LicenseAgreementConsiderationReceivedDebtRepayment>
    <xoma:CommonStockPremium
      contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_niKO_iOCski7xDCZeqBm0g"
      decimals="-5"
      id="Narr_IenB3DPLPkOzPR0EifkJ4Q"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">200000</xoma:CommonStockPremium>
    <xoma:NumberOfPerformanceObligations
      contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_niKO_iOCski7xDCZeqBm0g"
      decimals="INF"
      id="Narr_07tbyFioK0WZZevndjm1Aw"
      unitRef="Unit_Standard_item_ZJDcTjbqbUC2tIGJY9M-pg">2</xoma:NumberOfPerformanceObligations>
    <xoma:NumberOfPerformanceObligations
      contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_niKO_iOCski7xDCZeqBm0g"
      decimals="INF"
      id="Narr_SM0hI-fjyUS8i1H1QXIhkQ"
      unitRef="Unit_Standard_item_ZJDcTjbqbUC2tIGJY9M-pg">2</xoma:NumberOfPerformanceObligations>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_niKO_iOCski7xDCZeqBm0g"
      decimals="-5"
      id="Narr_3BQdoqa3U0CwPVwRqXQpuQ"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">40200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_-LsGHkQ-r0C10A2ulFZGhA"
      decimals="-5"
      id="Narr_66MILv0U2UexMuzaa5Gp0w"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_GIL1i6m_ikWj4R2Nl1_z1Q"
      decimals="-5"
      id="Narr_5HTjJw_JJEq898nbntwhtQ"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_-LsGHkQ-r0C10A2ulFZGhA"
      decimals="-5"
      id="Narr_OL9AWqgQgE-JkuAWvDGkcw"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_GIL1i6m_ikWj4R2Nl1_z1Q"
      decimals="-5"
      id="Narr_dcGdeM-pMU-LADvnEgMq3w"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:CapitalizedContractCostNet
      contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_-LsGHkQ-r0C10A2ulFZGhA"
      decimals="-5"
      id="Narr_QuBApTvTn0y4LXUb6EsP3w"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:CapitalizedContractCostNet>
    <us-gaap:CapitalizedContractCostNet
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_GIL1i6m_ikWj4R2Nl1_z1Q"
      decimals="-5"
      id="Narr_dxNs_rUM2kqbC79xt1PZfg"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:CapitalizedContractCostNet>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_rGGwTzCaJEKNgoHyMNh1gw"
      decimals="-6"
      id="Narr_bH3IieF8jUq9bZtJroDQ7w"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_4_1_2022_To_6_30_2022_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_jFCmb1gQLUCZ9hjyvX5kmw"
      decimals="-6"
      id="Narr_PAJhuEGNBEWRX2KVYAgoVQ"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_m4wda9YuHE2PtS0eldU6mg"
      decimals="-6"
      id="Narr_TJpVu6xYUky7ANLBVn6Npw"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_4_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_fDllYLxwC021lmWGRzTQow"
      decimals="-6"
      id="Narr_-LFcQzlef0e4noY-Tv4zBA"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <xoma:EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones
      contextRef="As_Of_11_1_2006_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_srt_ProductOrServiceAxis_xoma_MezagitamabMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_eN1YCwnkIUCnKDhhfVJ8PA"
      decimals="-5"
      id="Narr_zbLfHFr8Q0SOweCERE24NQ"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">19000000.0</xoma:EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones>
    <xoma:RoyaltiesPeriodMinimum
      contextRef="Duration_11_1_2006_To_11_1_2006_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_srt_ProductOrServiceAxis_xoma_MezagitamabMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_nbtuFUC-fkqYmHeLy348AA"
      id="Narr_dDAorQXae0GLbBCVh96oLw">P13Y6M</xoma:RoyaltiesPeriodMinimum>
    <xoma:RoyaltiesPeriodMinimumScenarioOne
      contextRef="Duration_11_1_2006_To_11_1_2006_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_srt_ProductOrServiceAxis_xoma_MezagitamabMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_nbtuFUC-fkqYmHeLy348AA"
      id="Narr_iBOzlH4ZpEGQXa8w9HK5wA">P12Y</xoma:RoyaltiesPeriodMinimumScenarioOne>
    <xoma:EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate
      contextRef="Duration_2_1_2009_To_2_28_2009_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_srt_ProductOrServiceAxis_xoma_OtherAntibodiesMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_nb8ggrHRR0i-B34ppjt3fQ"
      decimals="-5"
      id="Narr_m84CTE0NyESjUs9jlW5hsg"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">3300000</xoma:EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate>
    <xoma:RoyaltiesPeriodMinimum
      contextRef="Duration_2_1_2009_To_2_28_2009_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_srt_ProductOrServiceAxis_xoma_OtherAntibodiesMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_nb8ggrHRR0i-B34ppjt3fQ"
      id="Narr_pRxWFvXQ4EKrVoJeZohAHw">P10Y</xoma:RoyaltiesPeriodMinimum>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_11_1_2020_To_11_30_2020_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_adu7bNhKOUupBKfuF3sIbA"
      decimals="-5"
      id="Narr_tKuCE5YkcE2q1re7HR6iVA"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">2000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_vXBkO4OEpkinf_t3RM0D2g"
      decimals="-5"
      id="Narr_4QpmVco2F0qKg25fiGfBCg"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_4_1_2022_To_6_30_2022_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_QDr-ldinb0Wu3jl9Rx21UA"
      decimals="-5"
      id="Narr_IAXpak9Qw0Wayy8qFunKAA"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_VOxATG70-EaP_DZtrrA64w"
      decimals="-5"
      id="Narr_YfO0nGVX2U6A8kRHGXlDhA"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_4_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_Ri7Rd8o8XUKc4YOMeBumXQ"
      decimals="-5"
      id="Narr_DW5_FnhjWU-JOrKBev86dw"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_akCqUsNekUK0f0Q6DuRi7A"
      decimals="-6"
      id="Narr_MSHQfYerCUihVEeazUHssw"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_0J69dylAF0i8-z1WvitMYQ"
      decimals="-6"
      id="Narr_zlCQ2UoeBkWcdSkY_INNQw"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_akCqUsNekUK0f0Q6DuRi7A"
      decimals="-6"
      id="Narr_wjIq-u26_EWkomOHaPrV6Q"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_0J69dylAF0i8-z1WvitMYQ"
      decimals="-6"
      id="Narr_p30vxrsZbkGTWdk4HQ1AbA"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:CapitalizedContractCostNet
      contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_akCqUsNekUK0f0Q6DuRi7A"
      decimals="-6"
      id="Narr_Dr4WmgcVPkac6fU4jXHrCQ"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:CapitalizedContractCostNet>
    <us-gaap:CapitalizedContractCostNet
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_0J69dylAF0i8-z1WvitMYQ"
      decimals="-6"
      id="Narr_RT_DY3HXEEGQCsjtn-plVA"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:CapitalizedContractCostNet>
    <xoma:EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones
      contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_akCqUsNekUK0f0Q6DuRi7A"
      decimals="-5"
      id="Narr_cLjGzC48M0qzwvGkhe0d0Q"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">16000000.0</xoma:EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones>
    <xoma:EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones
      contextRef="As_Of_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementRz358Member_k_y6teG2YUSWNLFytU9KEg"
      decimals="-5"
      id="Narr_jfFhSfD9IUG1d9Vjk6CNHA"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">232000000.0</xoma:EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones>
    <xoma:RoyaltiesPeriodMinimum
      contextRef="Duration_12_6_2017_To_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementRz358Member_qYjemo3WTUmBR58bLQH00g"
      id="Narr_xAy9SCiukEm-9g-3anvd_g">P12Y</xoma:RoyaltiesPeriodMinimum>
    <xoma:PercentageOfDecreaseInFutureRoyaltyObligations
      contextRef="Duration_12_6_2017_To_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_YD6dXAdo7E2njL-IcLEMGA"
      decimals="2"
      id="Narr_CDk1haDlXk-bdJnWPK0ozg"
      unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ">0.20</xoma:PercentageOfDecreaseInFutureRoyaltyObligations>
    <xoma:RoyaltiesPeriodMinimum
      contextRef="Duration_12_6_2017_To_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementNonRz358ProductsMember_X1c9jKDf5EOZolxEicyXRw"
      id="Narr_seFaZleZ3Eittiv0VL8FUQ">P12Y</xoma:RoyaltiesPeriodMinimum>
    <xoma:AgreementTerminationPriorWrittenNoticePeriod
      contextRef="Duration_12_6_2017_To_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_YD6dXAdo7E2njL-IcLEMGA"
      id="Narr_Gvwh6orZEEm4Rp9l-LrGvQ">P90D</xoma:AgreementTerminationPriorWrittenNoticePeriod>
    <xoma:LicenseAgreementConsiderationReceived
      contextRef="Duration_12_6_2017_To_12_6_2017_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_YD6dXAdo7E2njL-IcLEMGA"
      decimals="-5"
      id="Narr_y7q48-v26UGtK9LFMDmveQ"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</xoma:LicenseAgreementConsiderationReceived>
    <xoma:LicenseAgreementConsiderationReceivedAchievementOfFinancingActivities
      contextRef="Duration_12_6_2017_To_12_31_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_mT3lLicYEUilKoGSWcL_yw"
      decimals="-5"
      id="Narr_NaJqJOYDKkW1IklPwp0WWQ"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">6000000.0</xoma:LicenseAgreementConsiderationReceivedAchievementOfFinancingActivities>
    <xoma:LicenseAgreementInstallmentPaymentsReceived
      contextRef="Duration_12_6_2017_To_12_31_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_mT3lLicYEUilKoGSWcL_yw"
      decimals="-5"
      id="Narr_bSlthcwP30amTNVFjAY6Xg"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">8500000</xoma:LicenseAgreementInstallmentPaymentsReceived>
    <xoma:LicenseAgreementSharesReceived
      contextRef="Duration_12_6_2017_To_12_31_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_mT3lLicYEUilKoGSWcL_yw"
      decimals="INF"
      id="Narr_cKa9JnpK30iCN0_sApLCKg"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">161861</xoma:LicenseAgreementSharesReceived>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_1_31_2022_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_84g9TjGclUmNwYUUvpo37g"
      decimals="-5"
      id="Narr_vrtQE9SWc06PXUOM_g5P3g"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">2000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_X4k_iI4JX0qMI82W0g9pVg"
      decimals="-5"
      id="Narr_VZtCscNdnkCW7suXyEvnRw"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_4_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_V9oe_Umn1kmDzVa04Ga_yw"
      decimals="-5"
      id="Narr_tWC0eghNwUOHIa4jbJSChg"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_4_1_2022_To_6_30_2022_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_vwInn_PHZEilesm4Dyrjqw"
      decimals="-6"
      id="Narr_LrR4cCe4OkW_vWM-yXmzng"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_vmQFJdPsf0mcV98nQ1FxGg"
      decimals="-5"
      id="Narr_t9pkduow2U2eDVEuTHNzjw"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">2000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_82zqclNhY0GJGFKyo32O1Q"
      decimals="-5"
      id="Narr_9pUaxtJX4U2HJtQPfMWKtA"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_f8hS_ZhC6kyh-a2nsLAegA"
      decimals="-5"
      id="Narr_T1sTAU3DxE-hvPkpRRVptQ"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_82zqclNhY0GJGFKyo32O1Q"
      decimals="-5"
      id="Narr_GT-MxAfkeEuGgc_fcuhupQ"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_f8hS_ZhC6kyh-a2nsLAegA"
      decimals="-5"
      id="Narr_HJE8GBLEhkebIhwkaW7-5w"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:CapitalizedContractCostNet
      contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_82zqclNhY0GJGFKyo32O1Q"
      decimals="-5"
      id="Narr_IKnDyu1TSUSS3qvwcuXtzA"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:CapitalizedContractCostNet>
    <us-gaap:CapitalizedContractCostNet
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_f8hS_ZhC6kyh-a2nsLAegA"
      decimals="-5"
      id="Narr_Qjf1fuZ3I0SeH8tsZvoEJg"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:CapitalizedContractCostNet>
    <xoma:ProceedsFromUpfrontPayment
      contextRef="Duration_8_1_2019_To_8_31_2019_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_7abmyDQDN0asJM3WaMklhA"
      decimals="-5"
      id="Narr_CRKfbqAC9UiwjZ633o3UaA"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">2500000</xoma:ProceedsFromUpfrontPayment>
    <xoma:MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents
      contextRef="Duration_8_1_2019_To_8_31_2019_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_7abmyDQDN0asJM3WaMklhA"
      decimals="-5"
      id="Narr_jsfbIMJC-UmbSvwnSoKbaA"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">3000000.0</xoma:MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents>
    <xoma:PercentageOfRoyaltyOnNetSalesUponCommercialization
      contextRef="Duration_8_1_2019_To_8_31_2019_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_7abmyDQDN0asJM3WaMklhA"
      decimals="4"
      id="Narr_HAL2pqODpku-jL3d6ZuY4A"
      unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ">0.0075</xoma:PercentageOfRoyaltyOnNetSalesUponCommercialization>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2019_To_12_31_2019_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_V2ptKzpjEUCLS85R4yB7vA"
      decimals="-5"
      id="Narr_M97M57_7UkSofeJS9SIZdA"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">2500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_LbLsp9ZkfkCPh5v5V7bOsw"
      decimals="-5"
      id="Narr_mSYUxHYDh0aJ5zkXoRqw9A"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember__kbO___xJkGjYQIiIFsysw"
      decimals="-5"
      id="Narr_Xdtb-xy5-0y-kDDHy4Odkw"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_LbLsp9ZkfkCPh5v5V7bOsw"
      decimals="-5"
      id="Narr_VB0pcaq5hkuNpXXk_QqXwg"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember__kbO___xJkGjYQIiIFsysw"
      decimals="-5"
      id="Narr_qz4Ra9Qwa0mFBewU3GE7WA"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:CapitalizedContractCostNet
      contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_LbLsp9ZkfkCPh5v5V7bOsw"
      decimals="-5"
      id="Narr_D8V6s_EtsUyBhZ84fLVz-Q"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:CapitalizedContractCostNet>
    <us-gaap:CapitalizedContractCostNet
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember__kbO___xJkGjYQIiIFsysw"
      decimals="-5"
      id="Narr_PuSO72AGX0qGiaBa8T_VWw"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:CapitalizedContractCostNet>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_4_1_2023_To_4_30_2023_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_srt_ProductOrServiceAxis_xoma_MilestoneDosingFirstPatientInClinicalTrialMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_d9RUr6mklkyYekHk6uD6mg"
      decimals="-5"
      id="Narr_zsxZgnRKoUyka7ZJIJhf7w"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_4_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_srt_ProductOrServiceAxis_xoma_MilestonePursuantToAgreementMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_A9EfiA2PT0GB4VJ2dpb9fQ"
      decimals="-5"
      id="Narr_Fg_KIa8630mztEJz8WhccQ"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <xoma:NumberOfMilestonesEarned
      contextRef="Duration_4_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_JvsZS46lPEq8PkHBxYXxJw"
      decimals="INF"
      id="Narr_20XkmIVpZ0mSi0ic6Jzj8w"
      unitRef="Unit_Standard_item_ZJDcTjbqbUC2tIGJY9M-pg">3</xoma:NumberOfMilestonesEarned>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_FSjLU5cFwkCknzTRDnkzlA"
      decimals="-5"
      id="Narr_IWN1FlWwnUajLawRqtDhvA"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">1100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_4_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_JvsZS46lPEq8PkHBxYXxJw"
      decimals="-5"
      id="Narr_5xbyDdrxV0aQoRVpfCT8kQ"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">1100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_4_1_2022_To_6_30_2022_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_y5qiBk4TN0G3EitwLEYTCQ"
      decimals="-6"
      id="Narr_4cQP9SlY7UyqptIbfZurcQ"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_jHYkB6cDy0SVSmvTMeT8oQ"
      decimals="-6"
      id="Narr_pirkSKcAqUCskjuT2jZkTQ"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_AffimedMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_mOwWuP4wskCXg5lMAASlgQ"
      decimals="-5"
      id="Narr_CJEXW7pA7U2eQYQTJ7Ukpw"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_AffimedMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_U6vKLThuqke8EfnRv8dUJQ"
      decimals="-5"
      id="Narr_UOox7Rpv_kWinOHyNVunkg"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_AffimedMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_mOwWuP4wskCXg5lMAASlgQ"
      decimals="-5"
      id="Narr_p238B6QOqki7iWm9wBY4mQ"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_AffimedMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_U6vKLThuqke8EfnRv8dUJQ"
      decimals="-5"
      id="Narr_IbApm97Qcke8rYaLZALyTw"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:CapitalizedContractCostNet
      contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_AffimedMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_mOwWuP4wskCXg5lMAASlgQ"
      decimals="-6"
      id="Narr_RKjMblnyp0u8nFWgmqtd1w"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:CapitalizedContractCostNet>
    <us-gaap:CapitalizedContractCostNet
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_AffimedMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_U6vKLThuqke8EfnRv8dUJQ"
      decimals="-6"
      id="Narr_rVDD0u0ZXE-lX46sw88yqw"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:CapitalizedContractCostNet>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_CounterpartyNameAxis_xoma_AffimedMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_uepwPESgtkiCvIXYBSvbng"
      decimals="-5"
      id="Narr__nrDWvB7R0a3qyfvCtNXBA"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_4_1_2022_To_6_30_2022_srt_CounterpartyNameAxis_xoma_AffimedMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_oY96KBMfAEOyCowvi6apdg"
      decimals="-5"
      id="Narr_kZKqxu0u406HcyxQ1vRKXQ"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_AffimedMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_79M6vRT4qEukxFoiKPpVGg"
      decimals="-5"
      id="Narr_5dRfBmuQT0Sz0SUz-ibK4A"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_4_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_AffimedMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_EbE0yio0rEiufpaULNthlw"
      decimals="-5"
      id="Narr_as7bwwaGtUm_-5GMcThtAg"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <xoma:NumberOfRoyaltyInterestAcquisitionAgreements
      contextRef="Duration_12_21_2016_To_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_u-wkh1XOjEKGxjaNdt0ZHA"
      decimals="INF"
      id="Narr_O5wAVY6mBEaoOpY0D7TSzA"
      unitRef="Unit_Standard_agreement_8WD-ZASWEUe8fofDOT9VGw">2</xoma:NumberOfRoyaltyInterestAcquisitionAgreements>
    <xoma:ProceedsFromUpfrontPayment
      contextRef="Duration_12_21_2016_To_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_FirstRoyaltyInterestAcquisitionAgreementMember_1g3j3qkUPUilXtpAyP_pQg"
      decimals="-5"
      id="Narr_nL6vd_HvH0GADkGq-_1dgQ"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">6500000</xoma:ProceedsFromUpfrontPayment>
    <xoma:EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones
      contextRef="As_Of_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_FirstRoyaltyInterestAcquisitionAgreementMember_gLlWNbiZNUK_fa6Qh_xfcA"
      decimals="-5"
      id="Narr_whjAFu03jUKkgSdj5OQcaA"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">4000000.0</xoma:EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones>
    <xoma:MilestonePeriodsNumber
      contextRef="As_Of_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_FirstRoyaltyInterestAcquisitionAgreementMember_gLlWNbiZNUK_fa6Qh_xfcA"
      decimals="INF"
      id="Narr_Wo6jpf5JVU-w-BdXDctpnA"
      unitRef="Unit_Standard_period_Oxx3Sge1w0O2HvNr__SG-A">3</xoma:MilestonePeriodsNumber>
    <xoma:ProceedsFromUpfrontPayment
      contextRef="Duration_12_21_2016_To_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_SecondRoyaltyInterestAcquisitionAgreementMember_Ue-jD_6tzkiEEl7k3z6Zvg"
      decimals="-5"
      id="Narr_bSjigKbdX0yh3TKw_g6hbg"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">11500000</xoma:ProceedsFromUpfrontPayment>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="Duration_12_21_2016_To_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_u-wkh1XOjEKGxjaNdt0ZHA"
      decimals="-5"
      id="Narr_8-KCLDDIxEiz4aflRJyHHQ"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">18000000.0</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <xoma:NumberOfRoyaltyInterestAcquisitionAgreements
      contextRef="Duration_12_21_2016_To_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_u-wkh1XOjEKGxjaNdt0ZHA"
      decimals="INF"
      id="Narr_4Ygpxs5DfkWbkStehHL5AA"
      unitRef="Unit_Standard_agreement_8WD-ZASWEUe8fofDOT9VGw">2</xoma:NumberOfRoyaltyInterestAcquisitionAgreements>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="Duration_4_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_m5ftMp6cYUSGHtQQJFDZ4g"
      decimals="-5"
      id="Narr_KfHsyMnYI0yNcr864N4arA"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">500000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="Duration_1_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_a3PpicXMp0e6hJa2jrYpvg"
      decimals="-5"
      id="Narr_kgoldRybHk2oi6YmuA7eHQ"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">1000000.0</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="Duration_4_1_2022_To_6_30_2022_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_n_zJPqyMuUyhRwCGh98ETg"
      decimals="-5"
      id="Narr_x4YdGj8-2kyeEnLuFAqY6g"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">500000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_ydN4fj43pUqEu9cZio79ng"
      decimals="-5"
      id="Narr_JgvQi-DB4UGskjLUG2L_5Q"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">800000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:DeferredIncomeCurrent
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_AXaUv2IOz0qjMzgGNRTTfQ"
      decimals="-5"
      id="Narr_N3XnK1CpJ0mgOsR_c_9ysw"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">1900000</us-gaap:DeferredIncomeCurrent>
    <us-gaap:DeferredIncomeNoncurrent
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_AXaUv2IOz0qjMzgGNRTTfQ"
      decimals="-5"
      id="Narr_GdeqEri7pEKiiIvLYq-Iiw"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">9600000</us-gaap:DeferredIncomeNoncurrent>
    <us-gaap:DeferredIncomeCurrent
      contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_rWEkuydSCkGeJt7pRAiu2g"
      decimals="-5"
      id="Narr_nUMFsloJSkmTBZtRjqYfog"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">2000000.0</us-gaap:DeferredIncomeCurrent>
    <us-gaap:DeferredIncomeNoncurrent
      contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_rWEkuydSCkGeJt7pRAiu2g"
      decimals="-5"
      id="Narr_XVReJ6_Gwkm8rNi7B7PbPg"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">8500000</us-gaap:DeferredIncomeNoncurrent>
    <xoma:RoyaltyPurchaseAgreementTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      id="Tb_kLeOsNdGHU--0YTLdm9I3w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;5. Royalty and Commercial Payment Purchase Agreements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Short-term royalty and commercial payment receivables were $5.0 million and $2.4 million as of June 30, 2023 and December 31, 2022, respectively. Long-term royalty and commercial payment receivables were $72.2 million and $63.7 million as of June 30, 2023 and December 31, 2022, respectively. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;"&gt;LadRx Agreements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On June 21, 2023, the Company entered into the LadRx AAA pursuant to which the Company acquired from LadRx all of its rights, title and interest related to arimoclomol under an asset purchase agreement dated May 13, 2011 between Zevra and LadRx. The Company also entered into the LadRx RPA, pursuant to which the Company acquired the right to receive all of the future royalties, regulatory and commercial milestones as well as other related payments due to LadRx from ImmunityBio related to aldoxorubicin under a license agreement dated July 27, 2017, as amended on September 27, 2018, between ImmunityBio and LadRx. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The purchased rights related to arimoclomol include potential regulatory and commercial milestones of up to $52.5 million (net of certain payment obligations of up to $9.5 million based on a portion of the regulatory and commercial milestone payments) and potential royalty payments in low single-digit percentages of aggregate net sales associated with arimoclomol. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The purchased payments related to aldoxorubicin include potential regulatory and commercial milestones of up to $342.7 million and royalty payments on aggregate net sales of aldoxorubicin in the low to mid-teens for sales of orphan indications and mid to high single-digit percentages on other licensed products.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Upon closing of the LadRx Agreements, the Company paid LadRx an upfront payment of $5.0 million and may pay up to an additional $6.0 million in regulatory and commercial sales milestones which included $5.0 million related to regulatory milestones and $1.0 million related to commercial sales milestones. The Company concluded that the regulatory milestone payments of $5.0 million met the definition of a derivative under ASC 815 and should be accounted for at fair value and recorded as a current liability at the inception of the transaction. The fair value of the regulatory milestone payments was estimated to be $1.0 million. The Company concluded the commercial milestone payment of $1.0 million did not meet the definition of a derivative under ASC 815 and a liability will be recognized when probable and estimable.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;At the inception of the LadRx Agreements, the Company recorded $6.0 million as long-term royalty receivables related to the aggregate of the arimoclomol and aldoxorubicin&lt;i style="font-style:italic;"&gt; &lt;/i&gt;payment rights acquired, which included the $5.0 million upfront payment and $1.0 million for the estimated fair value of the regulatory milestone payments.&lt;span style="display:inline-block;width:33.22pt;"&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the cost recovery method, the Company does not expect to recognize any income related to royalties, milestones and other payments until the purchase price has been fully collected. The Company performed its impairment assessment and no allowance for credit losses was recorded as of June 30, 2023. &lt;span style="display:inline-block;width:0.76pt;"&gt;&lt;/span&gt; &lt;span style="display:inline-block;width:33.5pt;"&gt;&lt;/span&gt;&lt;span style="display:inline-block;width:36pt;"&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;"&gt;Aptevo Commercial Payment Purchase Agreement &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On March 29, 2023, the Company entered into the Aptevo CPPA, pursuant to which the Company acquired from Aptevo a portion of its milestone and commercial payment rights under a sale agreement dated February 28, 2020 between Aptevo and Medexus, related to IXINITY, which is marketed by Medexus for the control and prevention of bleeding episodes and postoperative management in people with Hemophilia B. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is entitled to receive a mid-single digit percentage of all IXINITY quarterly net sales from January 1, 2023 into the first quarter of 2035, and will be entitled to milestone payments of up to $5.3 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;At the inception of the Aptevo CPPA, the Company recorded $9.7 million as long-term royalty receivables which included a $9.6 million upfront payment and a $50,000 one-time payment in its condensed consolidated balance sheet, which would be due if XOMA received more than $0.5 million in receipts for first quarter 2023 sales of IXINITY. At inception of the agreement, the Company concluded the one-time payment of $50,000 was probable and reasonably estimable. Therefore, the payment was recorded as contingent liabilities under ASC 450 in its condensed consolidated balance sheet (the &#x201c;Aptevo Contingent Consideration&#x201d;) at inception and was paid in June 2023 when related receipts exceeded $0.5 million. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In June 2023, the Company received $0.6 million from Medexus representing the first commercial payment attributable to net sales of IXINITY that occurred during the first quarter of 2023. In accordance with the cost recovery method, the $0.6 million received was recorded as a direct reduction of the long-term royalty receivable balance. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Based upon limited available information, the Company is unable to reasonably estimate its commercial payment stream from sales of future net sales and the commercial payments to be received during the twelve-month period following the balance sheet date of June 30, 2023 and, as such, no amounts are reflected as short-term royalty and commercial payment receivables.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the cost recovery method, the Company does not expect to recognize any income related to milestones and commercial payment received until the purchase price has been fully collected.&#160;The Company performed its impairment assessment and no allowance for credit losses was recorded as of June 30, 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;"&gt;Agenus Royalty Purchase Agreement&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On September 20, 2018, the Company entered into the Agenus RPA, pursuant to which the Company acquired the right to receive 33% of the future royalties on six Incyte Europe S.a.r.l. (&#x201c;Incyte&#x201d;) immuno-oncology assets, currently in development, due to Agenus from Incyte (net of certain royalties payable by Agenus to a third party) and 10% of all future developmental, regulatory and commercial milestones related to these assets. However, the Company did not have a right to the expected near-term milestone associated with the entry of INCAGN2390 (anti-TIM-3) into its Phase 1 clinical trial. The future royalties due to Agenus from Incyte are based on low single to mid teen-digit percentage of applicable net sales. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In addition, the Company acquired the right to receive 33% of the future royalties on MK-4830, an immuno-oncology product currently in clinical development, due to Agenus from Merck and 10% of all future developmental, regulatory and commercial milestones related to this asset. The future royalties due to Agenus from Merck are based on low single-digit percentage of applicable net sales. Pursuant to the Agenus RPA, the Company&#x2019;s share in future potential development, regulatory and commercial milestones is up to $59.5 million. There is no limit on the amount of future royalties on sales that the Company may receive under the agreements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the terms of the Agenus RPA, the Company paid Agenus $15.0 million. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;At the inception of the agreement, the Company recorded $15.0 million as long-term royalty receivables in the consolidated balance sheets. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In November 2020, MK-4830 advanced into Phase 2 development, and Agenus earned a $10.0 million clinical development milestone under its license agreement with Merck, of which the Company earned $1.0 million. In accordance with the cost recovery method, the $1.0 million milestone received was recorded as a direct reduction of the recorded long-term royalty receivable balance. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company continues to assess that no further payments are probable to be received under this agreement in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to milestones and royalties received until the purchase price has been fully collected.&#160;The Company performed its impairment assessment and no allowance for credit losses was recorded as of June 30, 2023 or December 31, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;"&gt;Bioasis Royalty Purchase Agreement&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On February 25, 2019, the Company entered into the Bioasis RPA, pursuant to which the Company acquired potential future milestone and royalty rights from Bioasis for product candidates that are being developed pursuant to a license agreement between Bioasis and Prothena Biosciences Limited. In addition, the Company was granted options to purchase a 1% royalty right on the next two license agreements entered into between Bioasis and third-party licensees subject to certain payments and conditions as well as a right of first negotiation on the purchase of royalty rights on subsequent Bioasis license agreements with third parties. Upon exercise of the option related to the second license agreement executed by Bioasis, the Company would have been obligated to pay up to $0.3 million per licensed product. Upon exercise of the option related to the third license agreement executed by Bioasis, the Company may be obligated to pay up to $0.4 million per licensed product. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the terms of the Bioasis RPA, the Company paid $0.3 million and would have made contingent future cash payments of up to $0.2 million to Bioasis as the licensed product candidates reach certain development milestones (the &#x201c;Bioasis Contingent Consideration&#x201d;). &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;At the inception of the agreement, the Company recorded $0.4 million as long-term royalty receivables in its consolidated balance sheet, including the estimated fair value of the Bioasis Contingent Consideration of $75,000. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On November 2, 2020, the Company entered into the Second Bioasis RPA, pursuant to which the Company acquired potential future milestone and other payments, and royalty rights from Bioasis for product candidates that were being developed pursuant to a research collaboration and license agreement between Bioasis and Chiesi. The Company paid Bioasis $1.2 million upon closing of the Second Bioasis RPA for the purchased rights.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;At the inception of the Second Bioasis RPA, the Company recorded $1.2 million as long-term royalty receivables in its consolidated balance sheet. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On June 20, 2023, Bioasis announced the suspension of all its operations and the termination of the research collaboration and license agreement between Bioasis and Chiesi. As a result, the Company recorded an impairment of $1.6 million under royalty purchase agreement asset impairment in its condensed consolidated statement of operations and a reduction of $1.6 million under long-term royalty receivables related to the Bioasis RPA and Second Bioasis RPA. As the impaired amount was not expected to be collected, no allowance for credit losses was recorded as of June 30, 2023. There was no allowance for credit losses recorded as of December 31, 2022. The fair value of the Bioasis Contingent Consideration was reduced to $0 with the change in the estimated fair value recognized in other income (expense), net in the condensed consolidated statement of operations and comprehensive loss. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;"&gt;Aronora&lt;span style="font-style:normal;font-weight:normal;"&gt; &lt;/span&gt;Royalty Purchase Agreement&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On April 7, 2019, the Company entered into the Aronora RPA which closed on June 26, 2019. Under the Aronora RPA, the Company acquired the right to receive future royalties and a portion of upfront, milestone, and option payments (the &#x201c;Non-Royalties&#x201d;) related to five anti-thrombotic hematology drug candidates. Three candidates were subject to Aronora&#x2019;s collaboration with Bayer (the &#x201c;Bayer Products&#x201d;), including one which was subject to an exclusive license option by Bayer. The Company will receive 100% of future royalties and 10% of future Non-Royalties economics from these Bayer Products. The other two candidates are unpartnered (the &#x201c;non-Bayer Products&#x201d;) for which the Company will receive low single-digit percentage of net sales and 10% of Non-Royalties. The future payment percentage for Non-Royalties will be reduced from 10% to 5% upon the Company&#x2019;s receipt of two times the total cumulative amount of consideration paid by the Company to Aronora. In July 2020, Bayer elected to not exercise its option on the third Bayer Product and that product is now subject to the same economics as the non-Bayer Products.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the terms of the Aronora RPA, the Company paid Aronora a $6.0 million upfront payment at the close of the transaction. The Company financed $3.0 million of the upfront payment with a term loan under its Loan and Security Agreement with SVB. The Company was required to make a contingent future cash payment of $1.0 million for each of the three Bayer Products that were active on September 1, 2019 (up to a total of $3.0 million, the &#x201c;Aronora Contingent Consideration&#x201d;). Pursuant to the Aronora RPA, if the Company receives $250.0 million in cumulative royalties on net sales per product, the Company will be required to pay associated tiered milestone payments to Aronora in an aggregate amount of up to $85.0 million per product (the &#x201c;Royalty Milestones&#x201d;).&#160;The Royalty Milestones are paid based upon various royalty tiers prior to reaching $250.0 million in cumulative royalties on net sales per product.&#160;Royalties per product in excess of $250.0 million are retained by the Company. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;At the inception of the agreement, the Company recorded $9.0 million as long-term royalty receivables in its consolidated balance sheet, including the estimated fair value of the Aronora Contingent Consideration of $3.0 million. In September 2019, the Company paid the $3.0 million contingent consideration to Aronora. As the Company receives royalties from Aronora for a product, the Company will recognize the liability for future Royalty Milestones for such product when probable and estimable. The Company continues to assess that no payments are probable to be received under this agreement in the near term.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the cost recovery method, the Company does not expect to recognize any income related to milestones and royalties received until the purchase price has been fully collected. The Company performed its impairment assessment and no allowance for credit losses was recorded as of June 30, 2023 or December 31, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;"&gt;Palobiofarma Royalty Purchase Agreement&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On September 26, 2019, the Company entered into the Palo RPA, pursuant to which the Company acquired the rights to potential royalty payments in low single-digit percentages of aggregate net sales associated with six drug candidates in various clinical development stages, targeting the adenosine pathway with potential applications in solid tumors, non-Hodgkin&#x2019;s lymphoma, asthma/chronic obstructive pulmonary disease, ulcerative colitis, idiopathic pulmonary fibrosis, lung cancer, psoriasis and nonalcoholic steatohepatitis and other indications (the &#x201c;Palo Licensed Products&#x201d;) that are being developed by Palo. Novartis is a development partner on NIR178, one of the Palo Licensed Products, and NIR178 is being developed pursuant to a license agreement between Palo and Novartis. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the terms of the Palo RPA, the Company paid Palo a $10.0 million payment at the close of the transaction, which occurred simultaneously upon parties&#x2019; entry into the Palo RPA on September 26, 2019. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;At the inception of the agreement, the Company recorded $10.0 million as long-term royalty receivables in its consolidated balance sheet. The Company continues to assess that no payments are probable to be received under this agreement in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to royalties received until the purchase price has been fully collected. The Company performed its impairment assessment and no allowance for credit losses was recorded as of June 30, 2023 or December 31, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;"&gt;Viracta Royalty Purchase Agreement&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On March 22, 2021, the Company entered into the Viracta RPA, pursuant to which the Company acquired the right to receive future royalties, milestones, and other payments related to two clinical-stage drug candidates for $13.5 million. The first candidate, DAY101 (pan-RAF kinase inhibitor), is being developed by Day One Biopharmaceuticals, and the second candidate, vosaroxin (topoisomerase II inhibitor), is being developed by Denovo Biopharma. The Company acquired the right to receive (i) up to $54.0 million in potential milestones, potential royalties on sales, if approved, and other payments related to DAY101, excluding up to $20.0 million consideration retained by Viracta, and (ii) up to $57.0 million in potential regulatory and commercial milestones and high single-digit royalties on sales related to vosaroxin, if approved. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;At the inception of the Viracta RPA, the Company recorded $13.5 million as long-term royalty receivables in its consolidated balance sheet. No payments are probable to be received under the Viracta RPA in the near term. Under the cost recovery method, the Company does not expect to recognize any income related to royalties, milestones and other payments until the purchase price has been fully collected. The Company performed its impairment assessment and no allowance for credit losses was recorded as of June 30, 2023 or December 31, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;"&gt;Kuros Royalty Purchase Agreement&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On July 14, 2021, the Company entered into the Kuros RPA, pursuant to which the Company acquired the rights to 100% of the potential future royalties from commercial sales, which are tiered from high single-digit to low double-digits, and up to $25.5 million in pre-commercial milestone payments associated with an existing license agreement related to Checkmate Pharmaceuticals&#x2019; vidutolimod (CMP-001), a Toll-like receptor 9 agonist, packaged in a virus-like particle, for an upfront payment of $7.0 million. The Company may pay up to an additional $142.5 million to Kuros in sales-based milestones. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;At the inception of the Kuros RPA, the Company recorded $7.0 million as long-term royalty receivables in its consolidated balance sheet. Under the cost recovery method, the Company does not expect to recognize any income related to royalties, milestones and other payments until the purchase price has been fully collected. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In May 2022, Regeneron completed its acquisition of Checkmate Pharmaceuticals resulting in a $5.0 million milestone payment to Kuros. Pursuant to the Kuros RPA, the Company is entitled to 50% of the milestone payment, which was received by XOMA in July 2022. In accordance with the cost recovery method, the $2.5 million milestone received was recorded as a direct reduction of the recorded long-term royalty receivable balance.&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;As of June 30, 2023, no payments are probable to be received under the Kuros RPA in the near term.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company performed its impairment assessment and no allowance for credit losses was recorded as of June 30, 2023 or December 31, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;"&gt;Commercial Payment Purchase Agreement with Affitech &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On October 6, 2021, the Company entered into the Affitech CPPA, pursuant to which, the Company purchased a future stream of commercial payment rights to Roche&#x2019;s faricimab from Affitech for an upfront payment of $6.0 million. The Company is eligible to receive 0.5% of future net sales of faricimab for a ten-year period following the first commercial sales in each applicable jurisdiction. Under the terms of the Affitech CPPA, the Company may pay up to an additional $20.0 million based on the achievement of certain regulatory and sales milestones. At the inception of the Affitech CPPA, the Company recorded $14.0 million as long-term royalty receivables which included the $6.0 million upfront payment and $8.0 million in regulatory milestones in its consolidated balance sheet. The Company concluded the regulatory milestone payments of $8.0 million met the definition of a derivative under ASC 815 and should be accounted at fair value and recorded as a current liability at the inception of the transaction. Therefore, the regulatory milestone payments were recorded as contingent liabilities in its consolidated balance sheet. The Company concluded the sales-based milestone payments of $12.0 million do not meet the definition of a derivative under ASC 815 and a liability will be recognized when probable and estimable.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In January 2022, Roche received approval from the FDA to commercialize VABYSMO (faricimab-svoa) for the treatment of wet, or neovascular, age-related macular degeneration and diabetic macular edema. In September 2022, Roche received approval from the European Commission to commercialize VABYSMO for the treatment of wet, or neovascular, age-related macular degeneration and visual impairment due to diabetic macular edema. Pursuant to the Affitech CPPA, the Company paid Affitech a $5.0 million milestone tied to the U.S. marketing approvals and a $3.0 million milestone tied to the EC approvals. The Company may pay an additional $12.0 million based on the achievement of certain sales milestones.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In August 2022, the Company received $0.5 million from Roche representing the first commercial payment for sales of VABYSMO during the first six months of 2022. In accordance with the cost recovery method, the $0.5 million received was recorded as a direct reduction of the long-term royalty receivable balance. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In February 2023, the Company received $2.4 million, representing its commercial payment stream from sales of VABYSMO during the last six months of 2022. The payment amount was classified as a short-term royalty and commercial payment receivable as of December 31, 2022. In accordance with the cost recovery method, the $2.4 million received in February 2023 was recorded as a direct reduction of the short-term royalty receivable balance as of June 30, 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company estimated $5.0 million of commercial payments from sales of VABYSMO during the first six months of 2023 would be received in August 2023, within &#160;twelve-months of the balance sheet date of June 30, 2023 and, as such, reclassified this amount as short-term royalty and commercial payment receivable as of June 30, 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the cost recovery method, the Company does not expect to recognize any income related to future commercial payment receipts until the purchase price has been fully collected. The Company performed its impairment assessment and no allowance for credit losses was recorded as of June 30, 2023 or December 31, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes the royalty and commercial payment receivable activities during the six months ended June 30, 2023 (in thousands): &lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Short-Term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Long-Term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at January 1, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,366&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 63,683&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Acquisition of royalty and commercial payment receivables:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Aptevo&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,650&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;LadRx&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Receipt of royalty and commercial payments:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Affitech&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,366)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Aptevo&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (568)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Impairment of royalty and commercial payment receivables:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Bioasis&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,575)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Reclassification to short-term royalty and commercial payment receivables:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Affitech&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,958&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4,958)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at June&#160;30,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,958&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 72,232&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</xoma:RoyaltyPurchaseAgreementTextBlock>
    <xoma:RightsReceivableCurrent
      contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ"
      decimals="-5"
      id="Narr_Ed8Sey4_SEKutrECkjCKfQ"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">5000000.0</xoma:RightsReceivableCurrent>
    <xoma:RightsReceivableCurrent
      contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg"
      decimals="-5"
      id="Narr_r78ATcCb5UGbR--arWAyhA"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">2400000</xoma:RightsReceivableCurrent>
    <xoma:LongTermRightsReceivableNonCurrent
      contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ"
      decimals="-5"
      id="Narr_qv6JxqvHrUijsw0tE4B7DQ"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">72200000</xoma:LongTermRightsReceivableNonCurrent>
    <xoma:LongTermRightsReceivableNonCurrent
      contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg"
      decimals="-5"
      id="Narr_wM9Vn4mTsUGoM8-Z4pZWGg"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">63700000</xoma:LongTermRightsReceivableNonCurrent>
    <xoma:MaximumPaymentsBasedOnAchievementOfRegulatoryAndCommercialMilestonesNet
      contextRef="As_Of_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_srt_ProductOrServiceAxis_xoma_ArimoclomolMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementMember_K3A3TuR8B0uQ0wOH9CRISw"
      decimals="-5"
      id="Narr_4kO4Lwpg5EyQyDltmpLa2A"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">52500000</xoma:MaximumPaymentsBasedOnAchievementOfRegulatoryAndCommercialMilestonesNet>
    <xoma:MaximumPaymentObligationsBasedOnPortionOfRegulatoryAndCommercialPayments
      contextRef="As_Of_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_srt_ProductOrServiceAxis_xoma_ArimoclomolMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementMember_K3A3TuR8B0uQ0wOH9CRISw"
      decimals="-5"
      id="Narr_YsTEqkm15E-WtjVfd_UG5w"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">9500000</xoma:MaximumPaymentObligationsBasedOnPortionOfRegulatoryAndCommercialPayments>
    <xoma:MaximumRegulatoryAndCommercialMilestones
      contextRef="As_Of_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_srt_ProductOrServiceAxis_xoma_AldoxorubicinMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_pNlSw8P-5EajUFyzP-8uPA"
      decimals="-5"
      id="Narr_u1siqNUObUKMRq0LnvfV1Q"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">342700000</xoma:MaximumRegulatoryAndCommercialMilestones>
    <xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities
      contextRef="Duration_6_21_2023_To_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_e8EdDKpfoE63WcXU__Eu4Q"
      decimals="-5"
      id="Narr_bCDwTG95yUOjOmPYNyn1CQ"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">5000000.0</xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities>
    <xoma:MaximumPaymentsBasedOnAchievementOfRegulatoryAndSalesMilestones
      contextRef="As_Of_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_NqbS9eqGFkerYvUUwG7Maw"
      decimals="-5"
      id="Narr_9CJFIhVelEGi0AqBaxTPyw"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">6000000.0</xoma:MaximumPaymentsBasedOnAchievementOfRegulatoryAndSalesMilestones>
    <xoma:MaximumPayableOnRegulatoryMilestone
      contextRef="As_Of_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_NqbS9eqGFkerYvUUwG7Maw"
      decimals="-5"
      id="Narr_LoiMIb4DV0-EJZ67iB0I6w"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">5000000.0</xoma:MaximumPayableOnRegulatoryMilestone>
    <xoma:MaximumPayableOnSalesMilestone
      contextRef="As_Of_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_NqbS9eqGFkerYvUUwG7Maw"
      decimals="-5"
      id="Narr_0W6pxh8970CQfJEBbn7hXA"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">1000000.0</xoma:MaximumPayableOnSalesMilestone>
    <xoma:MaximumPayableOnRegulatoryMilestone
      contextRef="As_Of_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_NqbS9eqGFkerYvUUwG7Maw"
      decimals="-5"
      id="Narr_ZTF80S5R1EKF6AXGHHhBpg"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">5000000.0</xoma:MaximumPayableOnRegulatoryMilestone>
    <xoma:ContingentConsiderationUnderPurchaseAgreements
      contextRef="As_Of_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_ContingentConsiderationByTypeAxis_xoma_ContingentConsiderationRegulatoryMilestonesMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_CJwILMODfU2DPiygsj2I2Q"
      decimals="-5"
      id="Narr_I_HK9XzKrE-iSMbQPQqmhg"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">1000000.0</xoma:ContingentConsiderationUnderPurchaseAgreements>
    <xoma:MaximumPayableOnSalesMilestone
      contextRef="As_Of_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_NqbS9eqGFkerYvUUwG7Maw"
      decimals="-5"
      id="Narr_xeA4edmxj0aQgmI7IFdgbA"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">1000000.0</xoma:MaximumPayableOnSalesMilestone>
    <xoma:LongTermRightsReceivableNonCurrent
      contextRef="As_Of_6_21_2023_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_1-O-Wc5qm0GpfWvtLfA5QQ"
      decimals="-5"
      id="Narr_TW20mND00U69yMuCE4NTPg"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">6000000.0</xoma:LongTermRightsReceivableNonCurrent>
    <xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities
      contextRef="Duration_6_21_2023_To_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_e8EdDKpfoE63WcXU__Eu4Q"
      decimals="-5"
      id="Narr_VDMUjJ85YEe5y3AW3gqcoA"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">5000000.0</xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities>
    <xoma:MaximumPayableOnSalesMilestone
      contextRef="As_Of_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_NqbS9eqGFkerYvUUwG7Maw"
      decimals="-5"
      id="Narr_MVxgqXl3zEG75bWsvl-xNA"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">1000000.0</xoma:MaximumPayableOnSalesMilestone>
    <us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
      contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_UCOXnlEMH0KhLJITjc3RcQ"
      decimals="-5"
      id="Narr_FAA0OVJ5rUydFKa09P78Dw"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss>
    <xoma:MilestonesReceivableMaximum
      contextRef="As_Of_3_29_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_BVEo8QgBSkmfz1ozUkIwXw"
      decimals="-5"
      id="Narr_Wp2dyBaa90K1D498kxtptA"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">5300000</xoma:MilestonesReceivableMaximum>
    <xoma:LongTermRightsReceivableNonCurrent
      contextRef="As_Of_3_29_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_BVEo8QgBSkmfz1ozUkIwXw"
      decimals="-5"
      id="Narr_FZd5t8Bn0E-yzAKv7G4yew"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">9700000</xoma:LongTermRightsReceivableNonCurrent>
    <xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities
      contextRef="Duration_3_29_2023_To_3_29_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_7trh9U9BgEOiGwvVb10qXg"
      decimals="-5"
      id="Narr_7mWPfTE8MEGzAIMWt_ORLA"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">9600000</xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities>
    <xoma:ContingentConsiderationUnderPurchaseAgreements
      contextRef="As_Of_3_29_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_BVEo8QgBSkmfz1ozUkIwXw"
      decimals="-3"
      id="Narr_iq899mQxi0WCAhEA9NhVpg"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">50000</xoma:ContingentConsiderationUnderPurchaseAgreements>
    <xoma:CommercialPaymentThresholdOneTimePayment
      contextRef="Duration_3_29_2023_To_3_29_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_7trh9U9BgEOiGwvVb10qXg"
      decimals="-5"
      id="Narr_K1oPM-JS-k63lhltOM3r6g"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">500000</xoma:CommercialPaymentThresholdOneTimePayment>
    <xoma:ContingentConsiderationUnderPurchaseAgreements
      contextRef="As_Of_3_29_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_BVEo8QgBSkmfz1ozUkIwXw"
      decimals="-3"
      id="Narr_m-7Gu2L2zk-Na7-zqxLyLA"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">50000</xoma:ContingentConsiderationUnderPurchaseAgreements>
    <xoma:ReceiptsUnderAgreementsInvestingActivities
      contextRef="Duration_3_29_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_wWf39cBN3Ey7XT6o94A4AQ"
      decimals="-5"
      id="Narr_o9M5m4rrnESd6ch1ZHaICg"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">500000</xoma:ReceiptsUnderAgreementsInvestingActivities>
    <xoma:ReceiptsUnderAgreementsInvestingActivities
      contextRef="Duration_6_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_MedexusMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_uvMhw-Lcqk-4prmxG0MKyQ"
      decimals="-5"
      id="Narr_Z0-uEDHabkq83PFApKFbog"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">600000</xoma:ReceiptsUnderAgreementsInvestingActivities>
    <xoma:ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent
      contextRef="Duration_6_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember__RhK022Z4kyD4eKqg0JNCA"
      decimals="-5"
      id="Narr_Ctn-QPnBLEaoo1dS_W6IWg"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">600000</xoma:ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent>
    <xoma:RightsReceivableCurrent
      contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_Ag4rXqT5_U2u9t7EHdT2Vw"
      decimals="-5"
      id="Narr_-KYIT1dAM0ea3eXkb493eg"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</xoma:RightsReceivableCurrent>
    <us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
      contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_Ag4rXqT5_U2u9t7EHdT2Vw"
      decimals="-5"
      id="Narr_cnptVPDlA0q_AILxiUZBvg"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss>
    <xoma:RoyaltyReceivablePercentageOnNetSales
      contextRef="Duration_9_20_2018_To_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_IncyteImmunoOncologyAssetsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_XSaCTgtO1EiCFqoqTgeZVw"
      decimals="2"
      id="Narr_Fmx0r_BF9Ea0WWuOzmY_cA"
      unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ">0.33</xoma:RoyaltyReceivablePercentageOnNetSales>
    <xoma:NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased
      contextRef="Duration_9_20_2018_To_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_IncyteImmunoOncologyAssetsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_XSaCTgtO1EiCFqoqTgeZVw"
      decimals="INF"
      id="Narr_OHG4cWiaP0C4NqoCHyy2JQ"
      unitRef="Unit_Standard_item_ZJDcTjbqbUC2tIGJY9M-pg">6</xoma:NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased>
    <xoma:PurchasedPercentageOfMilestones
      contextRef="As_Of_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_IncyteImmunoOncologyAssetsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember__94jAcnsd02lqy6kaK-0kQ"
      decimals="2"
      id="Narr_Aa4FbSsSNE2Jz9D97PYxvg"
      unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ">0.10</xoma:PurchasedPercentageOfMilestones>
    <xoma:RoyaltyReceivablePercentageOnNetSales
      contextRef="Duration_9_20_2018_To_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_MerckImmunoOncologyProductMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_rdQZOj-p50uveOBE4byiYQ"
      decimals="2"
      id="Narr_zqgTGdanjUuHmFet80P_IQ"
      unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ">0.33</xoma:RoyaltyReceivablePercentageOnNetSales>
    <xoma:PurchasedPercentageOfMilestones
      contextRef="As_Of_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_MerckImmunoOncologyProductMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_NG5TrsNyD0Oet2286g9H0A"
      decimals="2"
      id="Narr_eV8YTw-ml02yXPaJw-NE7g"
      unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ">0.10</xoma:PurchasedPercentageOfMilestones>
    <xoma:PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones
      contextRef="Duration_9_20_2018_To_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_MerckImmunoOncologyProductMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_rdQZOj-p50uveOBE4byiYQ"
      decimals="-5"
      id="Narr_pATui3KYKUOPy9JF0tbKJA"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">59500000</xoma:PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones>
    <xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities
      contextRef="Duration_9_20_2018_To_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_CDSnZwcrZEu2Ca2UBiaJ0g"
      decimals="-5"
      id="Narr_t3hTNqPiQEiOEPrr4Js5cQ"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">15000000.0</xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities>
    <xoma:LongTermRightsReceivableNonCurrent
      contextRef="As_Of_9_20_2018_srt_CounterpartyNameAxis_xoma_AgenusIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_W3hVIOjItkyJRWGnXKpi0w"
      decimals="-5"
      id="Narr_MTXjR70HwEaTHIEuhu4TXw"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">15000000.0</xoma:LongTermRightsReceivableNonCurrent>
    <xoma:MilestoneAchieved
      contextRef="Duration_11_1_2020_To_11_30_2020_dei_LegalEntityAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_MerckImmunoOncologyProductMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_gu6YuHtIt0y_GOYnfbfPoA"
      decimals="-5"
      id="Narr_JzZ4RiylIU2nve32eP7EnA"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">10000000.0</xoma:MilestoneAchieved>
    <xoma:MilestoneAchieved
      contextRef="Duration_11_1_2020_To_11_30_2020_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_MerckImmunoOncologyProductMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_yWJTxLzPL0y7_WmwB5wNNw"
      decimals="-5"
      id="Narr_a_rC6Trf4UexdVVKT4rPrA"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">1000000.0</xoma:MilestoneAchieved>
    <xoma:ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent
      contextRef="Duration_11_1_2020_To_11_30_2020_srt_CounterpartyNameAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_MerckImmunoOncologyProductMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_yWJTxLzPL0y7_WmwB5wNNw"
      decimals="-5"
      id="Narr_XRUKdffw3EqKWkUG5Uawjg"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">1000000.0</xoma:ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent>
    <us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
      contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_AgenusIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_sSr_eim9wkmE2gHiwusgvQ"
      decimals="-5"
      id="Narr_uWxXKmGA8kCPwiCCrVDBUA"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss>
    <us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_AgenusIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_bp0e2gt5REKDawtfAHfiFA"
      decimals="-5"
      id="Narr_vrpsoVByjkudrIN5AqVsBw"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss>
    <xoma:PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements
      contextRef="As_Of_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_mAQNTbueYkGTdJGdXydMXQ"
      decimals="2"
      id="Narr_l7dXxC4wUUK-F1RD5QDfqw"
      unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ">0.01</xoma:PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements>
    <xoma:NumberOfLicenseAgreementsFutureLicenseAgreements
      contextRef="Duration_2_25_2019_To_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_YrCq7J8e4kyLGJ4RpNNinw"
      decimals="INF"
      id="Narr_xe1c7bjBC0iYagUFKCmXVQ"
      unitRef="Unit_Standard_agreement_8WD-ZASWEUe8fofDOT9VGw">2</xoma:NumberOfLicenseAgreementsFutureLicenseAgreements>
    <xoma:PaymentsToBeMadeUponExerciseOfOptionSecondLicenseAgreement
      contextRef="As_Of_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_mAQNTbueYkGTdJGdXydMXQ"
      decimals="-5"
      id="Narr_P9OULkGJwEGwNAUmieFRFw"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">300000</xoma:PaymentsToBeMadeUponExerciseOfOptionSecondLicenseAgreement>
    <xoma:PaymentsToBeMadeUponExerciseOfOptionThirdLicenseAgreement
      contextRef="Duration_2_25_2019_To_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_YrCq7J8e4kyLGJ4RpNNinw"
      decimals="-5"
      id="Narr_6Atnx-M1GkWad_p_0Cj5IA"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">400000</xoma:PaymentsToBeMadeUponExerciseOfOptionThirdLicenseAgreement>
    <xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities
      contextRef="Duration_2_25_2019_To_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_YrCq7J8e4kyLGJ4RpNNinw"
      decimals="-5"
      id="Narr_ciTZEX7gNUyy6x65ZCq90Q"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">300000</xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities>
    <xoma:ContingentFutureCashPayments
      contextRef="As_Of_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_QHXUcnameU2HPDbtouGcNQ"
      decimals="-5"
      id="Narr_VErzBZ2uKE6xasqGgvKQPA"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">200000</xoma:ContingentFutureCashPayments>
    <xoma:LongTermRightsReceivableNonCurrent
      contextRef="As_Of_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_mAQNTbueYkGTdJGdXydMXQ"
      decimals="-5"
      id="Narr__Nt6wNOfY0O5DyoJFi2dqw"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">400000</xoma:LongTermRightsReceivableNonCurrent>
    <xoma:ContingentConsiderationUnderPurchaseAgreements
      contextRef="As_Of_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_mAQNTbueYkGTdJGdXydMXQ"
      decimals="-3"
      id="Narr_AYKX9IAqy0iHn9Zg74aRNQ"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">75000</xoma:ContingentConsiderationUnderPurchaseAgreements>
    <xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities
      contextRef="Duration_11_2_2020_To_11_2_2020_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementTwoMember_lIg02dx4pU2AOp3fc9Nh0Q"
      decimals="-5"
      id="Narr_dFJVluVYUk6iKX1BqzlMRA"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">1200000</xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities>
    <xoma:LongTermRightsReceivableNonCurrent
      contextRef="As_Of_11_2_2020_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementTwoMember_EKVUME649EuA-3BW_SUmRA"
      decimals="-5"
      id="Narr_RM82M5xYqki9Fwn-zSE7Bw"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">1200000</xoma:LongTermRightsReceivableNonCurrent>
    <xoma:ImpairmentOfLongTermRightsReceivableNonCurrent
      contextRef="Duration_6_20_2023_To_6_20_2023_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementAndSecondRoyaltyPurchaseAgreementMember_Eqxr4CXcuE-FFTbVv-ujhg"
      decimals="-5"
      id="Narr_CCOoUTyXDk64UF6HZ4WntA"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">1600000</xoma:ImpairmentOfLongTermRightsReceivableNonCurrent>
    <xoma:LongTermRightsReceivableNonCurrentIncreaseDecrease
      contextRef="Duration_6_20_2023_To_6_20_2023_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementAndSecondRoyaltyPurchaseAgreementMember_Eqxr4CXcuE-FFTbVv-ujhg"
      decimals="-5"
      id="Narr_Gvoz3gCgrUaoeWTss5sq4w"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">1600000</xoma:LongTermRightsReceivableNonCurrentIncreaseDecrease>
    <us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
      contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementAndSecondRoyaltyPurchaseAgreementMember_FU0POSqmREazZyKHBvapXA"
      decimals="-5"
      id="Narr_VTDHDAsR70ei7-AhSRAXdA"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss>
    <us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementAndSecondRoyaltyPurchaseAgreementMember_p9m5gzIpdUSkItjQbZWuTA"
      decimals="-5"
      id="Narr_u696YGKo10ye6XsQn6L8RA"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss>
    <xoma:LongTermRightsReceivableNonCurrent
      contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementAndSecondRoyaltyPurchaseAgreementMember_FU0POSqmREazZyKHBvapXA"
      decimals="-5"
      id="Narr_i5Ph2EbUF0yInlxnVL32fQ"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</xoma:LongTermRightsReceivableNonCurrent>
    <xoma:AgreementDrugCandidatesNumber
      contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_HVql9Pa7t0Olldm6QQhOFg"
      decimals="INF"
      id="Narr_7gLWqCNOqE-eoS-k8HeTSA"
      unitRef="Unit_Standard_item_ZJDcTjbqbUC2tIGJY9M-pg">5</xoma:AgreementDrugCandidatesNumber>
    <xoma:AgreementDrugCandidatesNumber
      contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_BayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_Pw_lMHeh_0G7t1NpeC5DRQ"
      decimals="INF"
      id="Narr_8gjHnVICiEm9WVuFr1ZKiw"
      unitRef="Unit_Standard_item_ZJDcTjbqbUC2tIGJY9M-pg">3</xoma:AgreementDrugCandidatesNumber>
    <xoma:AgreementDrugCandidatesExclusiveLicenseOptionNumber
      contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_BayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_Pw_lMHeh_0G7t1NpeC5DRQ"
      decimals="INF"
      id="Narr_UUKQPeLp_0ydVdPFEHyFxQ"
      unitRef="Unit_Standard_item_ZJDcTjbqbUC2tIGJY9M-pg">1</xoma:AgreementDrugCandidatesExclusiveLicenseOptionNumber>
    <xoma:RoyaltyReceivablePercentageOnNetSales
      contextRef="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_BayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_HRYppcTJikmUXTKgI4BWvQ"
      decimals="2"
      id="Narr_kwWIhIe8REypic1P4ETGRw"
      unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ">1</xoma:RoyaltyReceivablePercentageOnNetSales>
    <xoma:PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts
      contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_BayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_Pw_lMHeh_0G7t1NpeC5DRQ"
      decimals="2"
      id="Narr_tzNOMBXjjUmqVJgTOweuIg"
      unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ">0.10</xoma:PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts>
    <xoma:AgreementDrugCandidatesNumber
      contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_NonBayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_3_W-6bd8Rk-v259MRO0Muw"
      decimals="INF"
      id="Narr_ftOCCgojdEq4yuacPUqAbw"
      unitRef="Unit_Standard_item_ZJDcTjbqbUC2tIGJY9M-pg">2</xoma:AgreementDrugCandidatesNumber>
    <xoma:PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts
      contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_NonBayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_3_W-6bd8Rk-v259MRO0Muw"
      decimals="2"
      id="Narr_HQBdBwwh1EqrbHRf9HXizQ"
      unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ">0.10</xoma:PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts>
    <xoma:PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts
      contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_HVql9Pa7t0Olldm6QQhOFg"
      decimals="2"
      id="Narr_rV7l2xw5C0u-6otJUS8m9w"
      unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ">0.10</xoma:PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts>
    <xoma:PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage
      contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_HVql9Pa7t0Olldm6QQhOFg"
      decimals="2"
      id="Narr_BZnvNrDhz0iyjBEcTXJ6-Q"
      unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ">0.05</xoma:PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage>
    <xoma:AgreementPaymentPercentageFactor
      contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_HVql9Pa7t0Olldm6QQhOFg"
      decimals="INF"
      id="Narr_4tBOSZNyAEiTsAqIuqbUvQ"
      unitRef="Unit_Standard_item_ZJDcTjbqbUC2tIGJY9M-pg">2</xoma:AgreementPaymentPercentageFactor>
    <xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities
      contextRef="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_pn2tVWcS10-XUKZrEdxpPg"
      decimals="-5"
      id="Narr_ozekyPLjy0uEjRm4YyFI0A"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">6000000.0</xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities>
    <xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities
      contextRef="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_DebtInstrumentAxis_xoma_SiliconValleyBankMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_o9TK8egh80G0mWjo56c-jg"
      decimals="-5"
      id="Narr_apgDSmp4GE2oeNAR7nSqnw"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">3000000.0</xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities>
    <xoma:ContingentFutureCashPaymentsPerProduct
      contextRef="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_BayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_HRYppcTJikmUXTKgI4BWvQ"
      decimals="-5"
      id="Narr_WVHiMVNENUqyoCCxTf86hw"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">1000000.0</xoma:ContingentFutureCashPaymentsPerProduct>
    <xoma:AgreementDrugCandidatesNumber
      contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_BayerProductsMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_Pw_lMHeh_0G7t1NpeC5DRQ"
      decimals="INF"
      id="Narr_p0nWwmMduUimiBXR8JsMBA"
      unitRef="Unit_Standard_item_ZJDcTjbqbUC2tIGJY9M-pg">3</xoma:AgreementDrugCandidatesNumber>
    <xoma:ContingentFutureCashPayments
      contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_srt_ProductOrServiceAxis_xoma_BayerProductsMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_abyt3ov_LEidqaXYxUPESw"
      decimals="-5"
      id="Narr_fMpyN3NNJEOklX6gnzToPQ"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">3000000.0</xoma:ContingentFutureCashPayments>
    <xoma:CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount
      contextRef="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_pn2tVWcS10-XUKZrEdxpPg"
      decimals="-5"
      id="Narr_r3BeHA6W1U6X4zYH4CY3og"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">250000000.0</xoma:CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount>
    <xoma:MilestonesPaymentsToAggregateAmountOfPerProduct
      contextRef="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_pn2tVWcS10-XUKZrEdxpPg"
      decimals="-5"
      id="Narr_gBDIEtNFZUCl4ULfb6Km7A"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">85000000.0</xoma:MilestonesPaymentsToAggregateAmountOfPerProduct>
    <xoma:CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount
      contextRef="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_pn2tVWcS10-XUKZrEdxpPg"
      decimals="-5"
      id="Narr_5HyGTzmoF0aS7FuP04RYMg"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">250000000.0</xoma:CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount>
    <xoma:CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount
      contextRef="Duration_4_7_2019_To_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_pn2tVWcS10-XUKZrEdxpPg"
      decimals="-5"
      id="Narr_4MWJQ1O-EkKb2VIHm0C8SQ"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">250000000.0</xoma:CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount>
    <xoma:LongTermRightsReceivableNonCurrent
      contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_HVql9Pa7t0Olldm6QQhOFg"
      decimals="-5"
      id="Narr_0NsquHiMdE6pKihozYvqxw"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">9000000.0</xoma:LongTermRightsReceivableNonCurrent>
    <xoma:ContingentConsiderationUnderPurchaseAgreements
      contextRef="As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_HVql9Pa7t0Olldm6QQhOFg"
      decimals="-5"
      id="Narr_ulahkp1mikWWrT0vQ12gIg"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">3000000.0</xoma:ContingentConsiderationUnderPurchaseAgreements>
    <xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities
      contextRef="Duration_9_1_2019_To_9_30_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_gG7wFWBERkClqJ60IJyBXw"
      decimals="-5"
      id="Narr_UH_aSouApkuUyeuCSWqNtg"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">3000000.0</xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities>
    <us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
      contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_m716wsI3XE6pmBu2Tce2QA"
      decimals="-5"
      id="Narr_8Th73X_1kUSkYdgM6jrCmg"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss>
    <us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_o6zurAuWbE6ntKuKdPP1yg"
      decimals="-5"
      id="Narr_1Lxy2b-XoEqzj43_rNtgbw"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss>
    <xoma:AgreementDrugCandidatesNumber
      contextRef="As_Of_9_26_2019_srt_CounterpartyNameAxis_xoma_PalobiofarmaSLMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_zT4QsAb7u0eLPQ9twhpAFA"
      decimals="INF"
      id="Narr_Pxq3lUdcnkGqrLt-F7A_jQ"
      unitRef="Unit_Standard_item_ZJDcTjbqbUC2tIGJY9M-pg">6</xoma:AgreementDrugCandidatesNumber>
    <xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities
      contextRef="Duration_9_26_2019_To_9_26_2019_srt_CounterpartyNameAxis_xoma_PalobiofarmaSLMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_aaICGPfxhkOTZpQUaO0Yqw"
      decimals="-5"
      id="Narr_3hoQYUwZyEyBUc3uw7bSpw"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">10000000.0</xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities>
    <xoma:LongTermRightsReceivableNonCurrent
      contextRef="As_Of_9_26_2019_srt_CounterpartyNameAxis_xoma_PalobiofarmaSLMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_zT4QsAb7u0eLPQ9twhpAFA"
      decimals="-5"
      id="Narr_saezXYJO3kSMR7f_Jzi43A"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">10000000.0</xoma:LongTermRightsReceivableNonCurrent>
    <us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
      contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_PalobiofarmaSLMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_ipZkO7zZN06t3XJUxHlDgQ"
      decimals="-5"
      id="Narr__VCKG8ROwkGJpbXhxK-o5Q"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss>
    <us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_PalobiofarmaSLMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_YM8JsAYwe02uTcAIJfsjVw"
      decimals="-5"
      id="Narr_DZ7MLyBtb0u8bocCxz2oLg"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss>
    <xoma:AgreementDrugCandidatesNumber
      contextRef="As_Of_3_22_2021_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_46O6ygYv-kiSXEivuByfuw"
      decimals="INF"
      id="Narr_9sO_q1OUZkSD7B9pQ51PuA"
      unitRef="Unit_Standard_item_ZJDcTjbqbUC2tIGJY9M-pg">2</xoma:AgreementDrugCandidatesNumber>
    <xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities
      contextRef="Duration_3_22_2021_To_3_22_2021_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_Yzb76SH-JEWCZntLrcxS8w"
      decimals="-5"
      id="Narr_RaMo6KhtMEiBGj8jJIbC-w"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">13500000</xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities>
    <xoma:MilestonesReceivableExcludingConsiderationRetainedMaximum
      contextRef="As_Of_3_22_2021_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_46O6ygYv-kiSXEivuByfuw"
      decimals="-5"
      id="Narr_ykOAeJ_ls0-fF2xWQrj9Xw"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">54000000.0</xoma:MilestonesReceivableExcludingConsiderationRetainedMaximum>
    <xoma:MaximumConsiderationRetained
      contextRef="As_Of_3_22_2021_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_46O6ygYv-kiSXEivuByfuw"
      decimals="-5"
      id="Narr_eD7xyEo2akiz-O0t0x1Zsg"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">20000000.0</xoma:MaximumConsiderationRetained>
    <xoma:RegulatoryAndCommercialMilestonesReceivableMaximum
      contextRef="As_Of_3_22_2021_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_46O6ygYv-kiSXEivuByfuw"
      decimals="-5"
      id="Narr_r9LWkBzCDEybhZGarrGPmw"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">57000000.0</xoma:RegulatoryAndCommercialMilestonesReceivableMaximum>
    <xoma:LongTermRightsReceivableNonCurrent
      contextRef="As_Of_3_22_2021_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_46O6ygYv-kiSXEivuByfuw"
      decimals="-5"
      id="Narr_cS6SB7t4OEOQkX3HTXJD3Q"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">13500000</xoma:LongTermRightsReceivableNonCurrent>
    <us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
      contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_t0Nk1HTAG0K7OHjnARYZew"
      decimals="-5"
      id="Narr_JtEAzCAw90uZAns0QT9DlA"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss>
    <us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_6tHZOwbzlkiu2oefkSmJmg"
      decimals="-5"
      id="Narr_hYlESv86jkKfzWU701Ffaw"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss>
    <xoma:RoyaltyReceivablePercentageOnNetSales
      contextRef="Duration_7_14_2021_To_7_14_2021_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_s0z0PXoS5k-BNomvO5_j6g"
      decimals="INF"
      id="Narr_PkZrRBscrEGzUIOOYNEpbw"
      unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ">1</xoma:RoyaltyReceivablePercentageOnNetSales>
    <xoma:EligibleMilestonePaymentsReceivableUponAchievementOfPreCommercialMilestones
      contextRef="Duration_7_14_2021_To_7_14_2021_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_s0z0PXoS5k-BNomvO5_j6g"
      decimals="-5"
      id="Narr_0Tqttc8oq06AD533soT8BQ"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">25500000</xoma:EligibleMilestonePaymentsReceivableUponAchievementOfPreCommercialMilestones>
    <xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities
      contextRef="Duration_7_14_2021_To_7_14_2021_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_s0z0PXoS5k-BNomvO5_j6g"
      decimals="-5"
      id="Narr_fqSaY005eUyo732I31T-LQ"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">7000000.0</xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities>
    <xoma:MaximumPayableOnSalesMilestone
      contextRef="As_Of_7_14_2021_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_Xh1jjLmK9029VV5PJj8xKg"
      decimals="-5"
      id="Narr_dRj2R6hZqkGyK5KLUiDd6g"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">142500000</xoma:MaximumPayableOnSalesMilestone>
    <xoma:LongTermRightsReceivableNonCurrent
      contextRef="As_Of_7_14_2021_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_Xh1jjLmK9029VV5PJj8xKg"
      decimals="-5"
      id="Narr_p1WEOVMsuUSVxY568rxMTQ"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">7000000.0</xoma:LongTermRightsReceivableNonCurrent>
    <xoma:MilestonePaymentReceivedCounterparty
      contextRef="Duration_5_1_2022_To_5_31_2022_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_ksZbC81p30-S2MPeTooszw"
      decimals="-5"
      id="Narr_WfXkSPvTfECn5Wjc4S3RaQ"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">5000000.0</xoma:MilestonePaymentReceivedCounterparty>
    <xoma:MilestonePaymentReceivablePercentage
      contextRef="Duration_7_1_2022_To_7_31_2022_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_XIw7qGqY0EK6f05CwdTGoA"
      decimals="2"
      id="Narr__eeAg0iL10KTzKi1DntV-g"
      unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ">0.50</xoma:MilestonePaymentReceivablePercentage>
    <xoma:ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent
      contextRef="Duration_7_1_2022_To_7_31_2022_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_XIw7qGqY0EK6f05CwdTGoA"
      decimals="-5"
      id="Narr_MJdwyTAN9k6BsRNeSu3Q7w"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">2500000</xoma:ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent>
    <us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
      contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_l6eBrvgOik6JwWWl-dCq7g"
      decimals="-5"
      id="Narr_wSzc399dW0C1gUSCMRGxAA"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss>
    <us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_1wOk0To-60ebzBx-MLxW0A"
      decimals="-5"
      id="Narr_d7EFOrErsUWfnMVKp_1whg"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss>
    <xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities
      contextRef="Duration_10_6_2021_To_10_6_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_7mFvjte_dEevmb4jPsGqCg"
      decimals="-5"
      id="Narr_maSAWSbAD0GvwRDdeJXi6Q"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">6000000.0</xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities>
    <xoma:CommercialSalesReceivablePercentageOnNetSales
      contextRef="Duration_10_6_2021_To_10_6_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_srt_ProductOrServiceAxis_xoma_FaricimabProductMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_wnbrqh2QZE2B_rph576ABA"
      decimals="4"
      id="Narr_MTZsJxh2AEmfByemOxZ8UA"
      unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ">0.005</xoma:CommercialSalesReceivablePercentageOnNetSales>
    <xoma:CommercialPaymentReceivableTerm
      contextRef="Duration_10_6_2021_To_10_6_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_srt_ProductOrServiceAxis_xoma_FaricimabProductMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_wnbrqh2QZE2B_rph576ABA"
      id="Narr_Xu6fy-a7ckiPY3reUR5bqA">P10Y</xoma:CommercialPaymentReceivableTerm>
    <xoma:MaximumPaymentsBasedOnAchievementOfRegulatoryAndSalesMilestones
      contextRef="As_Of_10_6_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_utnG5LOjWkaEzqc0Xpgs4A"
      decimals="-5"
      id="Narr_Seh5sZ-13EyMDKS8JtQ8VA"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">20000000.0</xoma:MaximumPaymentsBasedOnAchievementOfRegulatoryAndSalesMilestones>
    <xoma:LongTermRightsReceivableNonCurrent
      contextRef="As_Of_10_6_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_utnG5LOjWkaEzqc0Xpgs4A"
      decimals="-5"
      id="Narr_RlmQgqZDNU6Tqan5CkDqVw"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">14000000.0</xoma:LongTermRightsReceivableNonCurrent>
    <xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities
      contextRef="Duration_10_6_2021_To_10_6_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_7mFvjte_dEevmb4jPsGqCg"
      decimals="-5"
      id="Narr_bleVLtOPw0WFjPwOCsZyxg"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">6000000.0</xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities>
    <xoma:MaximumPayableOnRegulatoryMilestone
      contextRef="As_Of_10_6_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_utnG5LOjWkaEzqc0Xpgs4A"
      decimals="-5"
      id="Narr_ysG7oOKAzUi_BGYEMzf8dg"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">8000000.0</xoma:MaximumPayableOnRegulatoryMilestone>
    <xoma:ContingentConsiderationUnderPurchaseAgreements
      contextRef="As_Of_10_6_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_ContingentConsiderationByTypeAxis_xoma_ContingentConsiderationRegulatoryMilestonesMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_vyMgtLcJvEi0juGqwh3ASQ"
      decimals="-5"
      id="Narr_fHzZ3tWhL0O8g9WdLrTi7w"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">8000000.0</xoma:ContingentConsiderationUnderPurchaseAgreements>
    <xoma:MaximumPayableOnSalesMilestone
      contextRef="As_Of_10_6_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_utnG5LOjWkaEzqc0Xpgs4A"
      decimals="-5"
      id="Narr_-wtiTpsovU-ug964YLNdgg"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">12000000.0</xoma:MaximumPayableOnSalesMilestone>
    <xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_p8h6imE-V0uwNs1HrXGY2A"
      decimals="-5"
      id="Narr_itLrxG9c90-dasQFfiO4Eg"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">5000000.0</xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities>
    <xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_srt_StatementGeographicalAxis_srt_EuropeMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_91bx_J3VVUaNfNyS-gIThg"
      decimals="-5"
      id="Narr_EbMXcIK8TEy4-Mcnerer-Q"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">3000000.0</xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities>
    <xoma:MaximumPayableOnSalesMilestone
      contextRef="As_Of_1_31_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_P2FOnn42CUiAAEHfWUjQNw"
      decimals="-5"
      id="Narr_gti87HHGxE2JNT8obmFneA"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">12000000.0</xoma:MaximumPayableOnSalesMilestone>
    <xoma:ReceiptsUnderAgreementsInvestingActivities
      contextRef="Duration_8_1_2022_To_8_31_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_OH8fvv_h9keoJxZOMgPK5A"
      decimals="-5"
      id="Narr_LVSwTIAUEEOgOQibJEwpaw"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">500000</xoma:ReceiptsUnderAgreementsInvestingActivities>
    <xoma:ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent
      contextRef="Duration_8_1_2022_To_8_31_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_OH8fvv_h9keoJxZOMgPK5A"
      decimals="-5"
      id="Narr_8E3nH8HrQEuIDjtLsC1Lwg"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">500000</xoma:ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent>
    <xoma:ReceiptsUnderAgreementsInvestingActivities
      contextRef="Duration_2_1_2023_To_2_28_2023_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_3qo6LMNvTEKUouebN2XnWA"
      decimals="-5"
      id="Narr_LodfAq6FzE2CpTVe5SZ2kw"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">2400000</xoma:ReceiptsUnderAgreementsInvestingActivities>
    <xoma:ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent
      contextRef="Duration_2_1_2023_To_2_28_2023_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_3qo6LMNvTEKUouebN2XnWA"
      decimals="-5"
      id="Narr_dSj_UkQpeEm8sbMJVbOMSQ"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">2400000</xoma:ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent>
    <xoma:ReceiptsUnderAgreementsInvestingActivities
      contextRef="Duration_8_1_2023_To_8_31_2023_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_srt_ProductOrServiceAxis_xoma_FaricimabSvoaVabysmoProductMember_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_REdIh2M4tEqC4XSc5ixlSg"
      decimals="-5"
      id="Narr_Lptux4XmgkGSJWVBo0XFJw"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">5000000.0</xoma:ReceiptsUnderAgreementsInvestingActivities>
    <us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
      contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_tbP6vsd5eUOJL3GPMRb5Sw"
      decimals="-5"
      id="Narr_joxr9MTeHEas9Gpy1AvKYQ"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss>
    <us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
      contextRef="As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_t4tt47wP20iV85oZnDl0kQ"
      decimals="-5"
      id="Narr_mYo6sCIAeUG3313jJQTpcw"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss>
    <xoma:ScheduleOfRoyaltyAndCommercialPaymentReceivablesActivityTableTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      id="Tb_8BNmxGrUok22vVjK3UgVog">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes the royalty and commercial payment receivable activities during the six months ended June 30, 2023 (in thousands): &lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Short-Term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Long-Term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at January 1, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,366&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 63,683&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Acquisition of royalty and commercial payment receivables:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Aptevo&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,650&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;LadRx&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Receipt of royalty and commercial payments:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Affitech&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,366)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Aptevo&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (568)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Impairment of royalty and commercial payment receivables:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Bioasis&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,575)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Reclassification to short-term royalty and commercial payment receivables:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Affitech&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,958&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4,958)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at June&#160;30,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,958&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 72,232&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</xoma:ScheduleOfRoyaltyAndCommercialPaymentReceivablesActivityTableTextBlock>
    <xoma:RightsReceivableCurrent
      contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg"
      decimals="-3"
      id="Tc_WD5uktLIj0qIlEzN1THHhQ_2_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">2366000</xoma:RightsReceivableCurrent>
    <xoma:LongTermRightsReceivableNonCurrent
      contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg"
      decimals="-3"
      id="Tc_lH3L1L-QOkCfj8pUi7Y13Q_2_5"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">63683000</xoma:LongTermRightsReceivableNonCurrent>
    <xoma:RoyaltyAndCommercialRightsAcquiredNonCurrent
      contextRef="Duration_1_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_euIclIwai0uxoAqBVaGjlw"
      decimals="-3"
      id="Tc_Wiv3oy-qOEutZ87lDwBmzw_4_5"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">9650000</xoma:RoyaltyAndCommercialRightsAcquiredNonCurrent>
    <xoma:RoyaltyAndCommercialRightsAcquiredNonCurrent
      contextRef="Duration_1_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_B01Z3JtpTkOkqmAnGrSDdg"
      decimals="-3"
      id="Tc_djnSNhjjMESSQGGdhs9P5Q_5_5"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">6000000</xoma:RoyaltyAndCommercialRightsAcquiredNonCurrent>
    <xoma:ReceiptOfRoyaltyAndCommercialPaymentReceivableCurrent
      contextRef="Duration_1_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_WO4UYUGV_02Sv2V6Sl4utw"
      decimals="-3"
      id="Tc_3hoxFQqWFki8O1BRey32Wg_7_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">2366000</xoma:ReceiptOfRoyaltyAndCommercialPaymentReceivableCurrent>
    <xoma:ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent
      contextRef="Duration_1_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_euIclIwai0uxoAqBVaGjlw"
      decimals="-3"
      id="Tc_fOGDhEni0USGZKw1PGYt-A_8_5"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">568000</xoma:ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent>
    <xoma:ImpairmentOfLongTermRightsReceivableNonCurrent
      contextRef="Duration_1_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_ka9FAFONVkeMeIE9zPwx5Q"
      decimals="-3"
      id="Tc_bVN0yasKsUGkQP4w1ctwiA_10_5"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">1575000</xoma:ImpairmentOfLongTermRightsReceivableNonCurrent>
    <xoma:ShortTermRightsReceivableReclassification
      contextRef="Duration_1_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_WO4UYUGV_02Sv2V6Sl4utw"
      decimals="-3"
      id="Tc_NB3v8sMc6kWTdJenpy706Q_12_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">4958000</xoma:ShortTermRightsReceivableReclassification>
    <xoma:LongTermRightsReceivableReclassification
      contextRef="Duration_1_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_WO4UYUGV_02Sv2V6Sl4utw"
      decimals="-3"
      id="Tc_hRcEgH5hx0SFj0z2nP_L1g_12_5"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">-4958000</xoma:LongTermRightsReceivableReclassification>
    <xoma:RightsReceivableCurrent
      contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ"
      decimals="-3"
      id="Tc_YQSDJw0O_U2E1GxIRI-OmQ_13_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">4958000</xoma:RightsReceivableCurrent>
    <xoma:LongTermRightsReceivableNonCurrent
      contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ"
      decimals="-3"
      id="Tc_Dac8x5nycUWc9Z0oTy9yVA_13_5"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">72232000</xoma:LongTermRightsReceivableNonCurrent>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      id="Tb_Q84-uX5X0EK8CHj7JgLnXQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;6. Fair Value Measurements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company records its financial assets and liabilities at fair value. The carrying amounts of certain of the Company&#x2019;s financial instruments, including cash, trade receivables, net and accounts payable, approximate their fair value due to their short maturities. Fair value is defined as the exchange price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The accounting guidance for fair value establishes a framework for measuring fair value and a fair value hierarchy that prioritizes the inputs used in valuation techniques. The accounting standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"&gt;Level 1&#160;&#x2013; Observable inputs, such as unadjusted quoted prices in active markets for identical assets or liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"&gt;Level 2&#160;&#x2013; Observable inputs, either directly or indirectly, other than quoted prices in active markets for identical assets or liabilities, such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"&gt;Level 3&#160;&#x2013; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities; therefore, requiring an entity to develop its own valuation techniques and assumptions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The following tables set forth the Company&#x2019;s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as follows (in thousands): &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&#160;Measurements&#160;at&#160;June&#160;30,&#160;2023 Using: &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted&#160;Prices&#160;in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&#160;Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Active&#160;Markets&#160;for&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Observable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Identical&#160;Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash equivalents:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30,102&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30,102&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total cash equivalents &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30,102&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30,102&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Equity securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 320&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 320&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total financial assets &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30,422&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30,422&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Contingent consideration under RPAs, AAAs and CPPAs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:49.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&#160;Measurements&#160;at&#160;December&#160;31,&#160;2022 Using:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted&#160;Prices&#160;in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&#160;Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Active&#160;Markets&#160;for&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Observable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Identical&#160;Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash equivalents:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30,334&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30,334&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total cash equivalents &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30,334&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30,334&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Equity securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 335&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 335&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total financial assets &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30,669&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30,669&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Contingent consideration under RPAs, AAAs and CPPAs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 75&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 75&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:12pt 0pt 12pt 0pt;"&gt;Equity Securities&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The equity securities consisted of an investment in Rezolute&#x2019;s common stock and are classified on the condensed consolidated balance sheets as current assets as of June 30, 2023 and December&#160;31, 2022. The equity securities are revalued each reporting period with changes in fair value recorded in the other income (expense), net line item of the condensed consolidated statements of operations and comprehensive loss. As of June 30, 2023 and December&#160;31, 2022, the Company valued the equity securities using the closing price for Rezolute&#x2019;s common stock traded on the Nasdaq Stock Market of $1.98 and $2.07, respectively. The inputs that were used to calculate the fair value of the equity securities were observable prices in active markets and therefore were classified as a Level 1 fair value measurement. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Contingent Consideration&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The estimated fair value of the Bioasis Contingent Consideration liability at the inception of the Bioasis RPA represents the future consideration that is contingent upon the achievement of specified development milestones for a product candidate. The fair value measurement is based on significant Level 3 inputs such as anticipated timelines and probability of achieving development milestones of each licensed product candidate. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The estimated fair value of the LadRx contingent consideration liability at the inception of the LadRx Agreements represents the future consideration that is contingent upon the achievement of specified regulatory milestones for the product candidates related to arimoclomol and aldoxorubicin. The fair value measurement is based on significant Level 3 inputs such as anticipated timelines and probability of achieving development milestones of each product candidate. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Changes in the fair value of the liability for contingent consideration will be recorded in the other income (expense), net line item of the condensed consolidated statements of operations and comprehensive loss until settlement. During the six months ended June 30, 2023, the estimated fair value of the contingent consideration recorded pursuant to the Bioasis RPA was reduced to $0 from the initial value of $0.1 million. There were no changes in the estimated fair value of the contingent consideration recorded pursuant to the LadRx Agreements from the initial value of $1.0 million.&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      id="Tb_gLExRHFIb0GPC_vStQwDxQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The following tables set forth the Company&#x2019;s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as follows (in thousands): &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&#160;Measurements&#160;at&#160;June&#160;30,&#160;2023 Using: &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted&#160;Prices&#160;in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&#160;Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Active&#160;Markets&#160;for&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Observable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Identical&#160;Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash equivalents:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30,102&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30,102&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total cash equivalents &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30,102&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30,102&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Equity securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 320&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 320&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total financial assets &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30,422&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30,422&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Contingent consideration under RPAs, AAAs and CPPAs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:49.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:48.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&#160;Measurements&#160;at&#160;December&#160;31,&#160;2022 Using:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted&#160;Prices&#160;in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&#160;Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Active&#160;Markets&#160;for&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Observable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Identical&#160;Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash equivalents:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30,334&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30,334&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total cash equivalents &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30,334&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30,334&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Equity securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 335&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 335&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total financial assets &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30,669&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30,669&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:49.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Contingent consideration under RPAs, AAAs and CPPAs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 75&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 75&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_6_30_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_9fLx36Xpp0Oo2wwcPihyCQ"
      decimals="-3"
      id="Tc_orTeOSg0NE-GFP2oHBjy3g_8_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">30102000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_6_30_2023_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_8L7cEkq67EeCxAnI09lGvA"
      decimals="-3"
      id="Tc_lyENrkBg1EuxPibZS9G4Nw_8_12"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">30102000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_6_30_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_0k9Iaqnwd06OsUIk7HwMEw"
      decimals="-3"
      id="Tc_dFb7dFodAUewi_Jk7UvZfQ_9_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">30102000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_6_30_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_wkmIyE0jUkOmFM4P8qQX2A"
      decimals="-3"
      id="Tc_2bCZifxzBkmQCb6eMhujbQ_9_12"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">30102000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_6_30_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_0k9Iaqnwd06OsUIk7HwMEw"
      decimals="-3"
      id="Tc_nvavo_FwNECcySBpfM4p-Q_10_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">320000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_6_30_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_wkmIyE0jUkOmFM4P8qQX2A"
      decimals="-3"
      id="Tc_zBQsMuwjakuE0dSV09hKNg_10_12"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">320000</us-gaap:InvestmentsFairValueDisclosure>
    <xoma:FinancialAssetsFairValueDisclosure
      contextRef="As_Of_6_30_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_0k9Iaqnwd06OsUIk7HwMEw"
      decimals="-3"
      id="Tc_AFlVwYhn90aOtCF1EYPFXg_11_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">30422000</xoma:FinancialAssetsFairValueDisclosure>
    <xoma:FinancialAssetsFairValueDisclosure
      contextRef="As_Of_6_30_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_wkmIyE0jUkOmFM4P8qQX2A"
      decimals="-3"
      id="Tc_Je9mp2EmaE-PcP-itbMnqg_11_12"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">30422000</xoma:FinancialAssetsFairValueDisclosure>
    <xoma:ContingentConsiderationFairValueDisclosure
      contextRef="As_Of_6_30_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_s8DXfaV1hU-kNpb0otcEew"
      decimals="-3"
      id="Tc_e8xkc7-hdUCJlYL5agD-ig_13_9"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">1000000</xoma:ContingentConsiderationFairValueDisclosure>
    <xoma:ContingentConsiderationFairValueDisclosure
      contextRef="As_Of_6_30_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_wkmIyE0jUkOmFM4P8qQX2A"
      decimals="-3"
      id="Tc__VeAL9jlx0CJmP8NVVhVmw_13_12"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">1000000</xoma:ContingentConsiderationFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_7KGCjOdAWkKDUJtQiWx04A"
      decimals="-3"
      id="Tc_DqmXDDqMPkS0wQHSjSzXPg_8_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">30334000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_YKgnRcgp30yLgGtobgVXyQ"
      decimals="-3"
      id="Tc_TP0s5X0fkkSVGabIwbHlMg_8_12"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">30334000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_p69-pIRmOU6cPwJMvLqNSA"
      decimals="-3"
      id="Tc_KO7ck2eHJE2hRXNpt9Pbqw_9_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">30334000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_m8qyydbCFEaJdTCv-WBD4Q"
      decimals="-3"
      id="Tc_znOMbpim-0SBKT08_7OC8A_9_12"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">30334000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_p69-pIRmOU6cPwJMvLqNSA"
      decimals="-3"
      id="Tc_NYAufeGLL0uqUvQ0Gy2C6g_10_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">335000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_m8qyydbCFEaJdTCv-WBD4Q"
      decimals="-3"
      id="Tc_FvSb2srt40mdEyinPCvz9A_10_12"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">335000</us-gaap:InvestmentsFairValueDisclosure>
    <xoma:FinancialAssetsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_p69-pIRmOU6cPwJMvLqNSA"
      decimals="-3"
      id="Tc_nv3zEPIvAUmxK8Vz9xUJfg_11_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">30669000</xoma:FinancialAssetsFairValueDisclosure>
    <xoma:FinancialAssetsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_m8qyydbCFEaJdTCv-WBD4Q"
      decimals="-3"
      id="Tc_zhkFsuXka02OmbIjiTFQ8w_11_12"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">30669000</xoma:FinancialAssetsFairValueDisclosure>
    <xoma:ContingentConsiderationFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_9t8qE3DtCUGDnjtaLsnr7g"
      decimals="-3"
      id="Tc_kzziWCecbUWJH3ljZGY8BQ_13_9"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">75000</xoma:ContingentConsiderationFairValueDisclosure>
    <xoma:ContingentConsiderationFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_m8qyydbCFEaJdTCv-WBD4Q"
      decimals="-3"
      id="Tc_A7SU8D-nEka3kkzkyRA_Ww_13_12"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">75000</xoma:ContingentConsiderationFairValueDisclosure>
    <us-gaap:EquitySecuritiesFvNiMeasurementInput
      contextRef="As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_BSWfJSEpmEGBgXlGS4MC4w"
      decimals="2"
      id="Narr_fnmYrsypGU6fNErtDOXH9A"
      unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ">1.98</us-gaap:EquitySecuritiesFvNiMeasurementInput>
    <us-gaap:EquitySecuritiesFvNiMeasurementInput
      contextRef="As_Of_12_31_2022_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_79gnR1guSka7Q_vWe08uww"
      decimals="2"
      id="Narr_WgGYHxme6UyFAJTIIyIA2w"
      unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ">2.07</us-gaap:EquitySecuritiesFvNiMeasurementInput>
    <xoma:ContingentConsiderationUnderPurchaseAgreements
      contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_2Aj5seKcO0-XhIAauxBBGA"
      decimals="-5"
      id="Narr_gpNP4LvyFUO0npMRX-YTIg"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</xoma:ContingentConsiderationUnderPurchaseAgreements>
    <xoma:ContingentConsiderationUnderPurchaseAgreements
      contextRef="As_Of_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_mAQNTbueYkGTdJGdXydMXQ"
      decimals="-5"
      id="Narr_d9Bg8eOmYUqwd4esnK3dXw"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">100000</xoma:ContingentConsiderationUnderPurchaseAgreements>
    <xoma:ChangesInEstimatedFairValueOfContingentConsideration
      contextRef="Duration_6_21_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_o0jHZU6txku5HZbpgBRroQ"
      decimals="-5"
      id="Narr_6SoLZ-O6Kku4gJrLDyZ8Dg"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</xoma:ChangesInEstimatedFairValueOfContingentConsideration>
    <xoma:ContingentConsiderationUnderPurchaseAgreements
      contextRef="As_Of_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_m3fGmRg0ukuCv0wBM5jhzQ"
      decimals="-5"
      id="Narr_T6QHmZvxW0GViazDtPXr-w"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">1000000.0</xoma:ContingentConsiderationUnderPurchaseAgreements>
    <xoma:LeaseDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      id="Tb_ToHcy5IeCUK8hkQaetgmtg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;7. Lease Agreements &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;The Company leases one facility in Emeryville, California under an operating lease. In January 2023, the Company amended the original lease to extend the lease term five months from its original expiration of February 28, 2023 to July 31, 2023. The Company retains no option to further extend, renew or terminate the lease under the amended terms and all other material terms and conditions, including the monthly base rent, will remain consistent with the original lease. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;In accordance with ASC 842, the Company accounted for the amendment to extend the lease term as a modification of the original lease and, as such, remeasured the lease liability and recognized a corresponding adjustment to the&#160;right-of-use asset of $0.1 million to reflect the changes in the lease payments due to the extended lease term. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;On June 27, 2023, the Company executed an amended lease agreement for its corporate headquarters lease in Emeryville, California with the same counterparty, in a different location in the same building to replace its existing lease expiring in July 2023. The amended lease agreement has a term of 65 months and has an expected commencement date in the fourth quarter of 2023. Undiscounted future rent payments associated with the new lease through the 65-month term is expected to be $0.5 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:12pt 0pt 12pt 0pt;"&gt;As of June 30, 2023 and December 31, 2022 the total net lease liability was $17,000 and $34,000, respectively. &#160; &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The following table summarizes the cost components of the Company&#x2019;s operating lease for the three and six months ended June 30, 2023 and 2022 (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:54.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:54.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six Months Ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:54.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:10.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:54.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Lease costs:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:54.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Operating lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 51&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 44&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 99&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 88&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:54.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Variable lease cost &lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:54.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total lease costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 58&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 46&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 111&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 93&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;padding-left:18pt;text-align:justify;text-indent:-18pt;"&gt;&lt;span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;"&gt;(1)&lt;/span&gt;Under the terms of the lease agreement, the Company is also responsible for certain variable lease payments that are not included in the measurement of the lease liability. Variable lease payments include non-lease components such as common area maintenance fees.&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The following information represents supplemental disclosure for the statement of cash flows related to operating leases (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:12pt;"&gt; &lt;/span&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt; &#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six Months Ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Operating cash flows under operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 104&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 101&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The present value assumptions used in calculating the present value of the lease payments for the Company&#x2019;s operating lease as of June 30, 2023 and December 31, 2022 were as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:12pt;"&gt; &lt;/span&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt; &#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted-average remaining lease term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.08 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.17 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted-average discount rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.51&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.51&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-top:0pt;text-align:justify;text-indent:0pt;"&gt;&lt;span style="display:inline-block;min-width:18pt;white-space:nowrap;"&gt;(1)&lt;/span&gt;Prior to the extension of the end of the lease term from February 28, 2023 to July 31, 2023 &#160;&lt;/div&gt;</xoma:LeaseDisclosureTextBlock>
    <xoma:OperatingLeasesNumberOfLeasedFacilities
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesEmeryvilleCaliforniaMember_j4Za8qhjGEunE9GIsiSNhg"
      decimals="INF"
      id="Narr_qlvgig6-uUyVC1Te6coKfQ"
      unitRef="Unit_Standard_facility_xUSd_1xCIUaR1gnI0x8O9w">1</xoma:OperatingLeasesNumberOfLeasedFacilities>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="As_Of_1_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesEmeryvilleCaliforniaMember_qE4Q6lsyXk-n_6Q8orOVvg"
      id="Narr_qgxd5RP7MECEV9xg4u1KSA">P5M</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <xoma:LesseeOperatingLeaseModificationAdjustmentToRightOfUseAsset
      contextRef="Duration_1_1_2023_To_1_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesEmeryvilleCaliforniaMember_jFg3GanTsESUiaQdv4hx4g"
      decimals="-5"
      id="Narr_uLnYCeteskGPWCi9tw_23g"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">100000</xoma:LesseeOperatingLeaseModificationAdjustmentToRightOfUseAsset>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="As_Of_12_31_2023_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesTwoEmeryvilleCaliforniaMember_TMMvkmy6s0ygPCJWud7LzQ"
      id="Narr_3V5K0dJiskKXiiwpUOFe_Q">P65M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="As_Of_9_30_2023_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesTwoEmeryvilleCaliforniaMember_x-BSsUsmOEefcCTi34VfUw"
      id="Narr_VRCLDOHaZkmRQ0UDqmzMdQ">P65M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="As_Of_9_30_2023_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesTwoEmeryvilleCaliforniaMember_x-BSsUsmOEefcCTi34VfUw"
      decimals="-5"
      id="Narr_VoJoW9Bp8UOGdu04MKM9lw"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">500000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ"
      decimals="-3"
      id="Narr_hges0AYUV0CchpQHWWwxiw"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">17000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg"
      decimals="-3"
      id="Narr_BwNAlIOTkEGPpOBiKjgbFQ"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">34000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      id="Tb_y0XAZ-vfF0qPKS8pMGzU_A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The following table summarizes the cost components of the Company&#x2019;s operating lease for the three and six months ended June 30, 2023 and 2022 (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:54.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:54.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six Months Ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:54.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:10.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:54.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Lease costs:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:54.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Operating lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 51&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 44&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 99&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 88&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:54.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Variable lease cost &lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:54.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total lease costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 58&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 46&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 111&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 93&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;padding-left:18pt;text-align:justify;text-indent:-18pt;"&gt;&lt;span style="display:inline-block;min-width:18pt;text-indent:0pt;white-space:nowrap;"&gt;(1)&lt;/span&gt;Under the terms of the lease agreement, the Company is also responsible for certain variable lease payments that are not included in the measurement of the lease liability. Variable lease payments include non-lease components such as common area maintenance fees.&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg"
      decimals="-3"
      id="Tc_QRV4sYLUkE2evGZTwRhI6w_4_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">51000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_4_1_2022_To_6_30_2022_MkbIQ9bQc0eX6Gc5LtLGHQ"
      decimals="-3"
      id="Tc_0KYbUtjRTUKLFYQDOoVRrg_4_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">44000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      decimals="-3"
      id="Tc_SmoyZBB_M02GzLTX0DzGuQ_4_9"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">99000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw"
      decimals="-3"
      id="Tc_wXkAUuHCoUy0BvdWU1ip-Q_4_12"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">88000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg"
      decimals="-3"
      id="Tc_5-yZeg9JSkCt83tajN9GuA_5_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">7000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="Duration_4_1_2022_To_6_30_2022_MkbIQ9bQc0eX6Gc5LtLGHQ"
      decimals="-3"
      id="Tc_BV4l9kVBHU6ZWh1atf1mLg_5_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">2000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      decimals="-3"
      id="Tc_j6VtmMkxFk2VAGsl30sCrQ_5_9"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">12000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw"
      decimals="-3"
      id="Tc_UQkZaKi2rU2BiABMdVn9-g_5_12"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">5000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg"
      decimals="-3"
      id="Tc_iTWP4_2zs0mQSXOUHOS3Ew_6_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">58000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="Duration_4_1_2022_To_6_30_2022_MkbIQ9bQc0eX6Gc5LtLGHQ"
      decimals="-3"
      id="Tc_tvBz2KrgTE-Eo7-i61mMXQ_6_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">46000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      decimals="-3"
      id="Tc_d_d8k7nxAECW3JwuzrYyeg_6_9"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">111000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw"
      decimals="-3"
      id="Tc_mM0Ot7bgqEet1JzI5KzNxw_6_12"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">93000</us-gaap:LeaseCost>
    <xoma:LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      id="Tb_G0sLITfT6U2Ig3KqmVANVg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The following information represents supplemental disclosure for the statement of cash flows related to operating leases (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:12pt;"&gt; &lt;/span&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt; &#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six Months Ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Operating cash flows under operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 104&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 101&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</xoma:LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      decimals="-3"
      id="Tc_5LSeLaEccUytGJJ72sycsw_4_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">104000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw"
      decimals="-3"
      id="Tc_OcqRCZbgvU-dXeX2sOzGeg_4_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">101000</us-gaap:OperatingLeasePayments>
    <xoma:LesseeOperatingLeaseSupplementalInformationTableTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      id="Tb_kjNufZyMx06iy7sE59CB7w">&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:12pt;"&gt; &lt;/span&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt; &#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted-average remaining lease term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.08 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.17 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted-average discount rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.51&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.51&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-top:0pt;text-align:justify;text-indent:0pt;"&gt;&lt;span style="display:inline-block;min-width:18pt;white-space:nowrap;"&gt;(1)&lt;/span&gt;Prior to the extension of the end of the lease term from February 28, 2023 to July 31, 2023 &#160;&lt;/div&gt;</xoma:LesseeOperatingLeaseSupplementalInformationTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ"
      id="Narr_J3T4nT5xZE2m903ewPI6Pg">P0Y29D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg"
      id="Narr_Ls9T--8MpkOtGxnCSeFzWw">P0Y2M1D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ"
      decimals="4"
      id="Tc_9S0_QOwDpEqfNDkUS3GB0w_4_2"
      unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ">0.0551</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg"
      decimals="4"
      id="Tc_HSefDbfmykOIWSL0fbo6PA_4_5"
      unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ">0.0551</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <xoma:CommonStockWarrantDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      id="Tb_jf3S5B2nH0GMpcMEVxTnZA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;8. Common Stock Warrants&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of June 30, 2023 and December&#160;31, 2022, the following common stock warrants were outstanding:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:18.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:18.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&#160;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:18.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Issuance Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Expiration&#160;Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance&#160;Sheet&#160;Classification&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;per&#160;Share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:18.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;May&#160;2018&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;May&#160;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stockholders&#x2019; equity&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 23.69&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,332&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,332&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:18.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;March&#160;2019&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;March&#160;2029&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stockholders&#x2019; equity&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14.71&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,845&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,845&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:18.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,177&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,177&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:3pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</xoma:CommonStockWarrantDisclosureTextBlock>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      id="Tb_QvfGS95J1E28RhJIkUzt8Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:18.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:18.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&#160;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:18.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Issuance Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Expiration&#160;Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance&#160;Sheet&#160;Classification&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;per&#160;Share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:18.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;May&#160;2018&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;May&#160;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stockholders&#x2019; equity&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 23.69&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,332&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,332&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:18.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;March&#160;2019&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;March&#160;2029&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stockholders&#x2019; equity&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14.71&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,845&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,845&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:18.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,177&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,177&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_6_30_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_R8Pr3r4-T0atb20N_SOFQg"
      decimals="INF"
      id="Tc_ttqqiCPnIUaiathpVQLcZQ_3_7"
      unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg">23.69</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_TPmH3rSX0kqVVDT3mwjQVA"
      decimals="INF"
      id="Tc_ttqqiCPnIUaiathpVQLcZQ_3_7_2"
      unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg">23.69</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_6_30_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_R8Pr3r4-T0atb20N_SOFQg"
      decimals="INF"
      id="Tc_BIvj1Ap1H0uu5Bs-PdyBXA_3_9"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">6332</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_xoma_TenYearWarrantsIssuedThirdRangeMember_TPmH3rSX0kqVVDT3mwjQVA"
      decimals="INF"
      id="Tc_x-9Bl160PkCmtTZhKxirDA_3_11"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">6332</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_6_30_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_xvSWiZXzv0KYrc1BLRxaDA"
      decimals="INF"
      id="Tc_xWoElPG_5k-ne0BkeUm8WQ_4_7"
      unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg">14.71</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_IW4xedCf1EONa-iq8razoA"
      decimals="INF"
      id="Tc_xWoElPG_5k-ne0BkeUm8WQ_4_7_2"
      unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg">14.71</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_6_30_2023_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_xvSWiZXzv0KYrc1BLRxaDA"
      decimals="INF"
      id="Tc_6H5a8lAoZUSZrdzm4wK3Ew_4_9"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">4845</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_ClassOfWarrantOrRightAxis_xoma_CommonStockWarrantExercisePrice14.71Member_IW4xedCf1EONa-iq8razoA"
      decimals="INF"
      id="Tc_eHNOxETwi0CjFUlOLCp5ow_4_11"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">4845</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ"
      decimals="INF"
      id="Tc_cnm_yWb1XUeICDLR-kI4CA_5_9"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">11177</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg"
      decimals="INF"
      id="Tc_WCcNqFVfcEOY0Coc1OBNig_5_11"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">11177</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      id="Tb_fJfW970qt0a8aScYovWQwg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;9. Commitments and Contingencies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Collaborative Agreements, Royalties and Milestone Payments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has committed to make potential future milestone payments and legal fees to third parties as part of licensing and development programs. Payments under these agreements become due and payable only upon the achievement of certain developmental, regulatory and commercial milestones by the Company&#x2019;s licensees. Because it is uncertain if and when these milestones will be achieved, such contingencies, aggregating up to $6.3 million (assuming one product per contract meets all milestone events) have not been recorded on the accompanying condensed consolidated balance sheets. The Company is unable to determine precisely when and if payment obligations under the agreements will become due as these obligations are based on milestone events, the achievement of which is subject to a significant number of risks and uncertainties.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Contingent Consideration&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Pursuant to the Company&#x2019;s agreements with Bioasis, Aronora, Kuros, Affitech, ObsEva and Aptevo the Company has committed to pay the Bioasis Contingent Consideration, the Aronora Royalty Milestones, the Kuros Sales Milestones, the Affitech Sales Milestones, the ObsEva Sales Milestones, the ObsEva Non-Sales Milestones, the Merck KGaA royalties and the Aptevo Contingent Consideration.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recorded $75,000 for the Bioasis Contingent Consideration that represented the estimated fair value of the potential future payments at the inception of the Bioasis RPA. The Bioasis Contingent Consideration is remeasured at fair value at each reporting period, with changes in fair value recorded in other income (expense), net. As of June 30, 2023, the estimated fair value of the Bioasis Contingent Consideration was reduced to $0.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recorded $1.0 million for the LadRx contingent consideration that represents the estimated fair value of the potential future payments upon the achievement of regulatory milestones related to arimoclomol and aldoxorubicin&lt;i style="font-style:italic;"&gt; &lt;/i&gt;at the inception of the LadRx Agreements. Such contingent consideration related to regulatory milestones is remeasured at fair value at each reporting period, with changes in fair value recorded in other income (expense), net. As of June 30, 2023, there has been no change in the estimated fair value from the initial value. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;In the first quarter of 2023, the Company recorded a contingent liability of $50,000 under ASC 450 for the Aptevo Contingent Consideration at the inception of the Aptevo CPPA. During the six months ended June 30, 2023, the contingent &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;liability recorded pursuant to the Aptevo CPPA decreased to zero after the Company paid Aptevo $50,000 upon achievement of the related commercial sales milestone.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The liability for future Aronora Royalty Milestones, Kuros Sales Milestones, Affitech Sales Milestones and LadRx sales milestones will be recorded when the amounts, by product, are estimable and probable. The liability for future ObsEva Non-Sales Milestones, ObsEva Sales Milestones and Merck KGaA royalties will be recorded at the time that the corresponding underlying revenue under the Organon License Agreement is estimatable and probable. As of June 30, 2023, none of these Aronora Royalty Milestones, Kuros Sales Milestones, Affitech Sales Milestones, ObsEva Non-Sales Milestones, ObsEva Sales Milestones, or Merck KGaA royalties were assessed to be probable and as such, no liability was recorded on the condensed consolidated balance sheet. &lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <xoma:ContractualObligationEstimatedMilestonePayments
      contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ"
      decimals="-5"
      id="Narr_NCD_S3C0EEGGV1FLkx_p2Q"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">6300000</xoma:ContractualObligationEstimatedMilestonePayments>
    <xoma:ContractualObligationEstimatedMilestonePaymentsNumberOfProducts
      contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ"
      decimals="INF"
      id="Narr_31Jb9FYz9E-Aa8-IqUR3eA"
      unitRef="Unit_Standard_product_mDp-u_9SnEGI1mu01OYOVA">1</xoma:ContractualObligationEstimatedMilestonePaymentsNumberOfProducts>
    <xoma:ContingentConsiderationUnderPurchaseAgreements
      contextRef="As_Of_2_25_2019_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_mAQNTbueYkGTdJGdXydMXQ"
      decimals="-3"
      id="Narr_vN4S-EKHFkmj1-YCBhkaCQ"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">75000</xoma:ContingentConsiderationUnderPurchaseAgreements>
    <xoma:ContingentConsiderationUnderPurchaseAgreements
      contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_2Aj5seKcO0-XhIAauxBBGA"
      decimals="-5"
      id="Narr_wRf0StZVEUOLApD6fz3Z4g"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</xoma:ContingentConsiderationUnderPurchaseAgreements>
    <xoma:ContingentConsiderationUnderPurchaseAgreements
      contextRef="As_Of_6_21_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_dUxKhnDLWESjshb_a_VOiQ"
      decimals="-5"
      id="Narr_f6Oj_kHzlEKXw-ZmovJv-A"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">1000000.0</xoma:ContingentConsiderationUnderPurchaseAgreements>
    <xoma:ChangesInEstimatedFairValueOfContingentConsideration
      contextRef="Duration_1_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_LadrxMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_A0raaKROwE6F7PlIHJx7HA"
      decimals="-5"
      id="Narr_UiaVC9lnYkaFBXWJe_5iGw"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</xoma:ChangesInEstimatedFairValueOfContingentConsideration>
    <xoma:ContingentConsiderationUnderPurchaseAgreements
      contextRef="As_Of_3_31_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_ILbmTBFAdkeabm8OMvrxMg"
      decimals="-3"
      id="Narr_BXunQKKXCk6eruDXYVPXSw"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">50000</xoma:ContingentConsiderationUnderPurchaseAgreements>
    <xoma:ContingentConsiderationUnderPurchaseAgreements
      contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_Ag4rXqT5_U2u9t7EHdT2Vw"
      decimals="-3"
      id="Narr_8JjlxPo1DUWCLVeAvEQHkA"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</xoma:ContingentConsiderationUnderPurchaseAgreements>
    <xoma:PaymentOfContingentConsiderationUnderPurchaseAgreements
      contextRef="Duration_1_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_qKDIT7AlPEumlQb_qY84ng"
      decimals="-3"
      id="Narr_91yPVW5eEkSpm3ErhQY7kA"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">50000</xoma:PaymentOfContingentConsiderationUnderPurchaseAgreements>
    <xoma:ContingentConsiderationUnderPurchaseAgreements
      contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_xoma_AronoraKurosAffitechObsevaAndMerckKgaaMember_Jg_8omFpTEO2btPaF3ItlQ"
      decimals="-5"
      id="Narr_6noyMDDwnEGoI_Pi-kFXBw"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</xoma:ContingentConsiderationUnderPurchaseAgreements>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      id="Tb_ogFd1K6J9UW-1_F2CkoMFw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;10. Stock Based Compensation &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company may grant qualified and non-qualified stock options, common stock, PSUs and other stock-based awards under various plans to directors, officers, employees and other individuals. Stock options are granted at exercise prices of not less than the fair market value of the Company&#x2019;s common stock on the date of grant. Additionally, the Company has an ESPP that allows employees to purchase Company shares at a purchase price equal to 85% of the lower of the fair market value of the Company&#x2019;s common stock on the first trading day of the offering period or on the last day of the offering period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Stock Options and Other Benefit Plans&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;2010 Plan Stock Options &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Stock options issued under the 2010 Plan generally vest monthly over three years for employees and one year for directors. Stock options held by employees who qualify for retirement age (defined as employees that are a minimum of 55 years of age and the sum of their age plus years of full-time employment with the Company exceeds 70 years) vest on the earlier of scheduled vest date or the date of retirement. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Stock Option Inducement Awards &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On December&#160;30, 2022, the Board appointed Owen Hughes as Executive Chairman of the Board and Interim CEO (principal executive officer) and Bradley Sitko as the Company&#x2019;s Chief Investment Officer, effective as of January&#160;1, 2023. Pursuant to the terms of their respective employment agreements, Mr. Hughes and Mr. Sitko were each granted two separate awards of non-qualified stock options on January 3, 2023 (collectively, the &#x201c;Stock Option Inducement Awards&#x201d;) when the Company&#x2019;s stock price was $18.66 per share. The Stock Option Inducement Awards were granted to Mr. Hughes and Mr. Sitko outside the 2010 Plan as an inducement material to entering into their respective employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) but are subject to the terms and conditions of the 2010 Plan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On January 3, 2023, the Company granted Mr. Hughes two separate non-qualified stock options to purchase: (i) 100,000 shares of the Company&#x2019;s common stock at a fair market value exercise price of $18.66 per share that will vest in a series of four equal installments on March 31, 2023, June 30, 2023, September 30, 2023 and December 31, 2023 and (ii) 75,000 shares of the Company&#x2019;s common stock at an above fair market value exercise price of $30.00 per share that will vest in a series of 36 successive equal monthly installments measured from January 1, 2023. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On January 3, 2023, the Company granted Mr. Sitko two separate non-qualified stock options to purchase: (i) 300,000 shares of the Company&#x2019;s common stock at a fair market value exercise price of $18.66 per share and (ii) 250,000 shares of the Company&#x2019;s common stock at an above fair market value exercise price of $30.00 per share. Twenty-five percent of the shares subject to Mr. Sitko&#x2019;s option grants will vest and become exercisable on January 3, 2024, and the balance of the shares will vest and become exercisable in a series of 36 successive equal monthly installments thereafter.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Fair Value Assumptions&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The fair value of the stock options granted under the 2010 Plan during the three and six months ended June 30, 2023 and 2022, was estimated based on the following weighted average assumptions:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:50.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six Months Ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 70&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 69&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 70&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 70&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.60&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.90&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.60&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.17&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5.79 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5.61 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5.79 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5.65 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The weighted-average grant-date fair value per share of the options granted under the 2010 Plan during the six months ended June 30, 2023 and 2022 was $13.46 and $12.21, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The fair value of the stock options granted to Mr. Hughes and Mr. Sitko at an exercise price of $18.66 per share during the six months ended June 30, 2023, was estimated based on the following weighted average assumptions: &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six Months Ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023 &lt;/b&gt;&lt;sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022 &lt;/b&gt;&lt;sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 69&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.92&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;5.79 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:22.5pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;No&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; Stock Option Inducement Awards were granted during the three months ended June 30, 2023 or the three and six months ended June 30, 2022. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The weighted-average grant-date fair value per share of options granted to Mr. Hughes and Mr. Sitko at an exercise price of $18.66 per share during the first quarter of 2023 was $11.91.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The fair value of the stock options granted to Mr. Hughes and Mr. Sitko at an exercise price of $30.00 per share during the first quarter of 2023 was estimated based on the following weighted average assumptions: &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six Months Ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023 &lt;/b&gt;&lt;sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022 &lt;/b&gt;&lt;sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 91&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.86&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;8.01 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:40.5pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;No&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; Stock Option Inducement Awards were granted during the three months ended June 30, 2023 or the three and six months ended June 30, 2022.&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 0pt 54pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The weighted-average grant-date fair value per share of options granted to Mr. Hughes and Mr. Sitko at an exercise price of $30.00 per share during the first quarter of 2023 was $14.68.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The activity for all stock options for the six months ended June 30, 2023, was as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:38.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.51%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining Term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Per&#160;Share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in&#160;years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;white-space:nowrap;width:15.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:38.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at January 1, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,025,542&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20.24&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.10&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,804&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:38.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 796,802&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:38.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (8,473)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18.29&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:38.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Forfeited, expired or cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (71,123)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 36.36&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:38.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at June 30, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,742,748&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20.78&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.76&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,430&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:38.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercisable at June 30, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,815,920&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19.30&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.44&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,296&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The aggregate intrinsic value of stock options exercised during the six months ended June 30, 2023 and 2022 was $18,000 and $2.1 million, respectively. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of June 30, 2023, $11.0 million of total unrecognized compensation expense related to stock options is expected to be recognized over a weighted average period of 2.72 years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Performance Stock Unit Awards&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In May 2023, the Company granted employees 430,400 PSUs in the aggregate under the 2010 Plan. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The PSUs are subject to market-based vesting conditions and the number of PSUs vested will be based on the stock price of the Company&#x2019;s common stock as compared to four stock price hurdles over a three-year period from the May 2023 grant date (the &#x201c;performance period&#x201d;). A stock price hurdle is considered attained when, at any time during the performance period, the Company&#x2019;s volume-weighted average stock price equals or exceeds the hurdle stock price value for 30 consecutive calendar days. Upon attainment of a stock price hurdle, &lt;span style="-sec-ix-hidden:Hidden_pz-y6RJKqkG2-1h8_aEPqw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;1/3&lt;/span&gt;&lt;/span&gt; of the earned PSUs will vest immediately upon achievement, &lt;span style="-sec-ix-hidden:Hidden_mBhYOSdezkKayi1Fqww_nQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;1/3&lt;/span&gt;&lt;/span&gt; will vest upon the two-year anniversary of the grant date and &lt;span style="-sec-ix-hidden:Hidden_npSSwNAmG0yLnAtmVxINPw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;1/3&lt;/span&gt;&lt;/span&gt; will vest on the three-year anniversary of the grant date. If no stock price hurdle is attained during the performance period, then no PSUs will vest.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The fair value of the PSUs granted was estimated based on Monte Carlo valuation model which incorporates into the valuation the possibility that the stock price hurdles may not be satisfied. &lt;/p&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The range of grant date fair values of the PSUs issued in May 2023 were estimated as follows:&lt;div style="display:inline-block;height:24pt;width:24pt;"&gt;&lt;div style="height:24pt;left:0pt;padding-bottom:0pt;position:relative;width:24pt;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:inline-block;height:24pt;width:24pt;"&gt;&lt;div style="height:24pt;left:0pt;padding-bottom:0pt;position:relative;width:24pt;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.8%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.8%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.8%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:25.89%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Derived&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Hurdle Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:25.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Service Period&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="vertical-align:top;white-space:nowrap;width:21.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Per Share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;white-space:nowrap;width:21.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;PSUs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;white-space:nowrap;width:21.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Per&#160;Share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;white-space:nowrap;width:25.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in&#160;years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 232,956&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;16.36-17.45&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;0.69-0.76&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 35.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 87,708&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;15.03-16.07&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;0.93-0.99&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 40.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 57,851&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;13.82-14.84&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;1.12-1.18&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 45.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 51,885&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;12.75-13.72&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;1.27-1.33&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 430,400&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;background:#ffff00;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company estimates that it will recognize total stock-based compensation expense of approximately $6.7 million in aggregate using the graded expense attribution method over the requisite service period of each tranche. If the stock price hurdles are met sooner than the requisite service period, the stock-based compensation expense for the respective stock price hurdle will be accelerated. Stock-based compensation expense will be recognized over the requisite service period if the grantees continue to provide service to the Company, regardless of whether the PSU stock price hurdles are achieved.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The activity for all PSUs for the six months ended June 30, 2023, was as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:56.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.24%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.56%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.22%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Grant Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;white-space:nowrap;width:19.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unvested PSUs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;white-space:nowrap;width:19.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Per&#160;Share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:56.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested balance at January 1, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:56.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 430,400&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15.61&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:56.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:56.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:56.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested balance at June 30, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 430,400&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15.61&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company recorded $0.5 million of stock-based compensation expense related to the PSUs during the three and six months ended June 30, 2023. As of June 30, 2023, there was $6.2 million unrecognized stock-based compensation expense related to outstanding PSUs granted to employees, with a weighted-average remaining recognition period of 1.85 years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Stock-based Compensation Expense&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;All stock-based compensation expense is recorded in G&amp;amp;A expense. The following table shows total stock-based compensation expense for stock options and PSUs issued under the 2010 Plan, the Stock Option Inducement Awards and ESPP in the condensed consolidated statements of operations and comprehensive loss (in thousands): &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:55.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six Months Ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total stock-based compensation expense included in G&amp;amp;A &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,163&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 837&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,733&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,815&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:6pt 0pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Employee Retention Bonus &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:6pt 0pt 0pt 0pt;"&gt;&lt;span style="visibility:hidden;background:#ffff00;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;In October 2022, the Company approved the Amended Retention Plan which provides that each of its then current employees, excluding the CEO, will be eligible to receive a cash retention bonus if employed through each of two periods: (1) the three-month anniversary of November 1, 2022 (the &#x201c;Initial Period&#x201d;) and (2) the nine-month period immediately following the Initial Period. All other terms of the Amended Retention Plan remain consistent with the Retention Plan. The Company is accruing and recognizing the cost of the cash retention bonus as expense on a straight-line basis from November 1, 2022 through October 31, 2023. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company paid $0.2 million of cash retention bonuses accrued over the Initial Period in January 2023. Pursuant to the Amended Retention Plan, as of June 30, 2023, the Company expects to pay an additional $0.5 million in cash in 2023 related to the cash retention bonuses. The Company recognized $0.2 million and $0.4 million for cash retention bonuses in operating expenses in the condensed consolidated statement of operations and comprehensive loss during the three and six months ended June 30, 2023, respectively, and will recognize the remaining amount of $0.2 million for cash retention bonuses in operating expenses through October 31, 2023. The Company accrued cash retention bonuses in accrued and other liabilities in the condensed consolidated balance sheets of $0.3 million as of June 30, 2023 and $0.1 million as of December 31, 2022. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;James R. Neal Departure and Continuity Incentive&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:6pt 0pt 0pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:normal;"&gt;James R. Neal retired as the Company&#x2019;s CEO effective as of December 31, 2022 (the &#x201c;Departure Date&#x201d;) and resigned as a member of the Board and Chairman of the Board, effective as of January 1, 2023. Pursuant to Mr. Neal&#x2019;s Amended and Restated Employment Agreement, dated December 15, 2021, by and between the Company and Mr. Neal, following the Departure Date, Mr. Neal is entitled to a cash payment of &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;$1.2&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; million (the &#x201c;Continuity Incentive&#x201d;) which will be made in equal monthly installments starting in January 2023 through December 2023, less deductions and withholdings. The Company accrued the full &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;$1.2&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; million Continuity Incentive in operating expenses in the consolidated statement of operations and comprehensive loss during the year ended December 31, 2022. The unpaid accrued Continuity Incentive&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; recorded in accrued and other liabilities in the condensed consolidated balance sheets as of June 30, 2023 and December 31, 2022 was &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;$0.6&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; million and &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;$1.2&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; million, respectively&lt;/span&gt;.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <xoma:PercentageOfCompensationOfEligibleEmployeesToPurchaseSharesOfEntityCommonStockAtDiscountThroughPayrollDeductions
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_VZ3-yhq8FE25TUInBBrGZQ"
      decimals="INF"
      id="Narr_owhlnngVSkqq0T6r7vSfdQ"
      unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ">0.85</xoma:PercentageOfCompensationOfEligibleEmployeesToPurchaseSharesOfEntityCommonStockAtDiscountThroughPayrollDeductions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2023_To_6_30_2023_srt_TitleOfIndividualAxis_xoma_EmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_zTu1OSjDqkSzjQ_HoRydQw"
      id="Narr_EuYsuL38t06_XO4fR2Hogw">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2023_To_6_30_2023_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_-kWVMpk2b0K-si5i-kPxAg"
      id="Narr_CL3KzxcGS0-MGIbSU03GVA">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_-fCNRL3sJk2hkKbH29QN5A"
      id="Narr_mHM6GL1fEUW6UrlmJe74sw">P55Y</xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward>
    <xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_-fCNRL3sJk2hkKbH29QN5A"
      id="Narr_pGVyApSOxUuJqqIKcqQmjg">P70Y</xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge>
    <xoma:ShareBasedPaymentArrangementNumberOfAwardsGrants
      contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardsMember_TzcgwgvPHk2deHWsM1h3OA"
      decimals="INF"
      id="Narr__ahtGh-5WUayOrxQSkI4EA"
      unitRef="Unit_Standard_item_ZJDcTjbqbUC2tIGJY9M-pg">2</xoma:ShareBasedPaymentArrangementNumberOfAwardsGrants>
    <us-gaap:SharePrice
      contextRef="As_Of_1_3_2023_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardsMember_O8EOxHD7p0K-aApJeodsyg"
      decimals="2"
      id="Narr_ywai6pZOyUG4yZNEdVUh-Q"
      unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg">18.66</us-gaap:SharePrice>
    <xoma:ShareBasedPaymentArrangementNumberOfAwardsGrants
      contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerInterimMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardsMember_whB55KBpZUikUKiuuCNJVw"
      decimals="INF"
      id="Narr_86jJpQAMoESj5ujXK8LzXQ"
      unitRef="Unit_Standard_item_ZJDcTjbqbUC2tIGJY9M-pg">2</xoma:ShareBasedPaymentArrangementNumberOfAwardsGrants>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerInterimMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_iFhJ1Ec6iUaNhMqAZWDmbg"
      decimals="INF"
      id="Narr_vDRWiSlNlUWfdIjZl34yfQ"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerInterimMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_iFhJ1Ec6iUaNhMqAZWDmbg"
      decimals="2"
      id="Narr_KlWdUwwIDkis_aFnt28FpA"
      unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg">18.66</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments
      contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerInterimMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_iFhJ1Ec6iUaNhMqAZWDmbg"
      decimals="INF"
      id="Narr_EmmuhTnzP06EMFnOZtLuGQ"
      unitRef="Unit_Standard_installment_8yYMWsdF_EOJHx1V1lAgKg">4</xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerInterimMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_ifxCZ1Dza0CPpbZTGry9HQ"
      decimals="INF"
      id="Narr_4jECiuzJO0Gwo2etWgm4dA"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">75000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerInterimMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_ifxCZ1Dza0CPpbZTGry9HQ"
      decimals="2"
      id="Narr_uzvJxaom9Uu6G_qtBtLhoA"
      unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg">30.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments
      contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerInterimMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_ifxCZ1Dza0CPpbZTGry9HQ"
      decimals="INF"
      id="Narr_2pVTvVkKi06F6NQtcE2uOQ"
      unitRef="Unit_Standard_installment_8yYMWsdF_EOJHx1V1lAgKg">36</xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments>
    <xoma:ShareBasedPaymentArrangementNumberOfAwardsGrants
      contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardsMember_TzcgwgvPHk2deHWsM1h3OA"
      decimals="INF"
      id="Narr_FyWGAldPGE-z_6IZPeEFag"
      unitRef="Unit_Standard_item_ZJDcTjbqbUC2tIGJY9M-pg">2</xoma:ShareBasedPaymentArrangementNumberOfAwardsGrants>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_-tCFSx98TEGfywwRhcC7ZA"
      decimals="INF"
      id="Narr_DqKSiIQTFEOPgcPKns4V9g"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_-tCFSx98TEGfywwRhcC7ZA"
      decimals="2"
      id="Narr_PZlB_2hwc0WEYWhAe8kImw"
      unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg">18.66</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_2sdFXHfUykChvD4tIF6z0A"
      decimals="INF"
      id="Narr_qgd_anUshUuGPYF0I1Gy6w"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_2sdFXHfUykChvD4tIF6z0A"
      decimals="2"
      id="Narr_FF5kiWYOdEiEHfRfs_NhqA"
      unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg">30.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardsMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_sfgRwFcTcUelc4rTBp-b3Q"
      decimals="2"
      id="Narr_iG_MN9SpqUS3cn1lmZmnJw"
      unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments
      contextRef="Duration_1_3_2023_To_1_3_2023_srt_TitleOfIndividualAxis_xoma_ChiefInvestmentOfficerMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardsMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_oW0kv2blbEWaKJNbPntI9A"
      decimals="INF"
      id="Narr_ztuPrrVVYE2K1FvDDjCayA"
      unitRef="Unit_Standard_installment_8yYMWsdF_EOJHx1V1lAgKg">36</xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_bltKeBtI3UmSSHjoiD4k4Q"
      id="Tb_c3BeKRIX7Ue68R7vT3OMrA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:50.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six Months Ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 70&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 69&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 70&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 70&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.60&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.90&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.60&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.17&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5.79 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5.61 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5.79 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5.65 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_xL-t6UGWVk6DJsv8uctHqg"
      decimals="2"
      id="Tc_MFZRoU0eRUC9fiKzV_Dr0w_3_2"
      unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_6P9--i9dukq4YkLcJp4PvQ"
      decimals="2"
      id="Tc_P0PSc0l3d0anvd9ZNDCANQ_3_4"
      unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_-fCNRL3sJk2hkKbH29QN5A"
      decimals="2"
      id="Tc_Y4IqXdGjikaYSVKgKZlPUQ_3_7"
      unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_hI8wxtoK_020YtrtWXgEww"
      decimals="2"
      id="Tc_EE3lf9gbjU-cwwWluu1Kyg_3_9"
      unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_xL-t6UGWVk6DJsv8uctHqg"
      decimals="2"
      id="Tc_nu_WP9ycek6ifMefmvRB5g_4_2"
      unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ">0.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_6P9--i9dukq4YkLcJp4PvQ"
      decimals="2"
      id="Tc_ADw_hySzPEOIHhCIJq39Pg_4_4"
      unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ">0.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_-fCNRL3sJk2hkKbH29QN5A"
      decimals="2"
      id="Tc_Qzm9UKxpcku9_jCuqFTSQQ_4_7"
      unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ">0.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_hI8wxtoK_020YtrtWXgEww"
      decimals="2"
      id="Tc_3cJbGnWFSE2NGY2m8Mi6Tw_4_9"
      unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ">0.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_xL-t6UGWVk6DJsv8uctHqg"
      decimals="4"
      id="Tc_GUHuMK8RwEqSexh4Sq4zog_5_2"
      unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ">0.0360</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_6P9--i9dukq4YkLcJp4PvQ"
      decimals="4"
      id="Tc_Idkk6TM0p0aXxQ5akeqDUQ_5_4"
      unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ">0.0290</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_-fCNRL3sJk2hkKbH29QN5A"
      decimals="4"
      id="Tc_rRrVD7hW50GW4IrZksBBdw_5_7"
      unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ">0.0360</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_hI8wxtoK_020YtrtWXgEww"
      decimals="4"
      id="Tc_gZOnzDfpJEysJY3R7v1_Vw_5_9"
      unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ">0.0217</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_xL-t6UGWVk6DJsv8uctHqg"
      id="Narr_DkPMvwNB0kOHDaoZkqSz1Q">P5Y9M14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_6P9--i9dukq4YkLcJp4PvQ"
      id="Narr_hh3VsK4FiEO5TylSKkbzXg">P5Y7M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_-fCNRL3sJk2hkKbH29QN5A"
      id="Narr_pMu8deuOJ0CjYSiDCDJ-Ig">P5Y9M14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_hI8wxtoK_020YtrtWXgEww"
      id="Narr_6Y0_GH_Yb02291_C84bc_Q">P5Y7M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_bltKeBtI3UmSSHjoiD4k4Q"
      decimals="2"
      id="Narr_oifoPefHH0euAMl4hm2VQw"
      unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg">13.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_QvduteacZ0y6e-l0bH1cfQ"
      decimals="2"
      id="Narr_gG1PTjCbQkGF4OpH8czTKQ"
      unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg">12.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_YDoryzJQpUuWG8MDo2Kh5Q"
      decimals="2"
      id="Narr_O1K6Mq7ft0Ct5QGDyK7fcQ"
      unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg">18.66</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_YDoryzJQpUuWG8MDo2Kh5Q"
      id="Tb_0MxrhftarEOWB44Fy2P39g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six Months Ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023 &lt;/b&gt;&lt;sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022 &lt;/b&gt;&lt;sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 69&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.92&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;5.79 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:22.5pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;No&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; Stock Option Inducement Awards were granted during the three months ended June 30, 2023 or the three and six months ended June 30, 2022. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_8s2qytOsIE6JM7loesF-Zg"
      decimals="2"
      id="Tc_JhX_z-qQHUWQgZpCc2H9WQ_3_7"
      unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_8s2qytOsIE6JM7loesF-Zg"
      decimals="2"
      id="Tc_5L-0ZMOJmEuJY9OGZOjBmg_4_7"
      unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ">0.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_8s2qytOsIE6JM7loesF-Zg"
      decimals="4"
      id="Tc_6Hy7d8sH0k6tsvcHVMBHig_5_7"
      unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ">0.0392</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_8s2qytOsIE6JM7loesF-Zg"
      id="Narr_MZceAQPqXEOxpB68KfsG0w">P5Y9M14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_OxGaeDYzykWU3vEhrxw_Mw"
      decimals="INF"
      id="Narr_PkZLYw5-a0endN0Yrjtk6w"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_UCA8w-FN5E6MpfSkha4Snw"
      decimals="INF"
      id="Narr_3RJvCxtNLECpAX1nYUH8oA"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_UkUp6s2yF0molMuQVionzw"
      decimals="INF"
      id="Narr_fVS8-zRYXUmyYHqSUP39Xw"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_jSfoRez_iE22iNJRZuTv-A"
      decimals="2"
      id="Narr_Iapt7aTBLEyeHgFwFD1IEQ"
      unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg">18.66</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardOneMember_jSfoRez_iE22iNJRZuTv-A"
      decimals="2"
      id="Narr_HX7Bs8NrKUitn3l9X2gkbw"
      unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg">11.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_-JwjlMwfKEGUbHpTjDxUDQ"
      decimals="2"
      id="Narr_wqKfaS3Lv0StAsmw61YREA"
      unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg">30.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_-e_kcpPy9Uijv53NXnwNjA"
      id="Tb_C6gCNVtgJEibS1UBtokjTw">&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six Months Ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023 &lt;/b&gt;&lt;sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022 &lt;/b&gt;&lt;sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 91&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.86&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:7.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;8.01 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:7.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:40.5pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;No&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; Stock Option Inducement Awards were granted during the three months ended June 30, 2023 or the three and six months ended June 30, 2022.&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_kkqRS-Yr_kK7p5s-7yOqJg"
      decimals="2"
      id="Tc_wRJ5BH_zgkKCEst3qa9v4A_3_7"
      unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_kkqRS-Yr_kK7p5s-7yOqJg"
      decimals="2"
      id="Tc_PSD6hMC3xk2aoS0RnsvThQ_4_7"
      unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ">0.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_kkqRS-Yr_kK7p5s-7yOqJg"
      decimals="4"
      id="Tc_0GIVLUsBGkK5rOV4MKpSQA_5_7"
      unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ">0.0386</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_kkqRS-Yr_kK7p5s-7yOqJg"
      id="Narr_BZA1pr66f02VMWsZiHMc8g">P8Y3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_nc6cD9y6eky4_H4Gmdgf2Q"
      decimals="INF"
      id="Narr_2uOTIUQJEk-Lgg4T6wLGqg"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_HFe1p--7QUyXIpXph3Ep4A"
      decimals="INF"
      id="Narr_rjOnoRNnNU-oPXfltthcrw"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_fvpJiV95o0G_Lx6Po8Z0Qg"
      decimals="INF"
      id="Narr_PGxOQNZobUmBeKiHeyiLkA"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_-JwjlMwfKEGUbHpTjDxUDQ"
      decimals="2"
      id="Narr_zIzTartVM0OAoKmulVYArQ"
      unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg">30.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_PlanNameAxis_xoma_StockOptionInducementAwardTwoMember_-JwjlMwfKEGUbHpTjDxUDQ"
      decimals="2"
      id="Narr_o0tXaQPS3ku_v38oegRjuQ"
      unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg">14.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      id="Tb_9C3aa6GeQ0awHwiTCFtZ6g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:38.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.51%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:13.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining Term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:38.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Per&#160;Share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in&#160;years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;white-space:nowrap;width:15.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:38.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at January 1, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,025,542&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20.24&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.10&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,804&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:38.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 796,802&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:38.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (8,473)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18.29&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:38.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Forfeited, expired or cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (71,123)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 36.36&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:38.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding at June 30, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,742,748&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20.78&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.76&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,430&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:38.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercisable at June 30, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,815,920&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19.30&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.44&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,296&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg"
      decimals="INF"
      id="Tc_jxgto--yX0Gl9paiYCUd6A_6_3"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">2025542</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg"
      decimals="2"
      id="Tc_G5YDqk-XFke9cehH2RNQNw_6_6"
      unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg">20.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2022_To_12_31_2022_qMnU5lLEOEWtPeR71nBTRQ"
      id="Tc_l926NtawVUSKghou9NyrSA_6_9">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg"
      decimals="-3"
      id="Tc_gEIBzgTYMEOXKbs0w6XkMw_6_12"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">10804000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      decimals="INF"
      id="Tc_EwY7BG9ZlEOqQ1SLSKecxA_7_3"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">796802</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      decimals="2"
      id="Tc_XIM6rb1RY0qP5vXUcKBYUw_7_6"
      unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg">23.50</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      decimals="INF"
      id="Tc_Vh_mXuRjEESFqOoPFmorKA_8_3"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">8473</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      decimals="2"
      id="Tc__yQO5S3Qv0-zHyi8s97o_A_8_6"
      unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg">18.29</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      decimals="INF"
      id="Tc_-SFgLj2uHUe5QA-4o6RzcA_9_3"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">71123</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      decimals="2"
      id="Tc_0vlfVIhaKkuCSWO787WMKA_9_6"
      unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg">36.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ"
      decimals="INF"
      id="Tc_ga8K_TwD0Umg8xmoNyzrlw_10_3"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">2742748</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ"
      decimals="2"
      id="Tc_-TYEaY1IzkuUeFK9jb0O3Q_10_6"
      unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg">20.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      id="Tc_C3T3Bbh7EEyc_ndmcGu7Vw_10_9">P6Y9M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ"
      decimals="-3"
      id="Tc_AlIzosbJH0CPBfDeKIhLVw_10_12"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">11430000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ"
      decimals="INF"
      id="Tc_ufDqbZk1v0aMUggBaXKGOA_11_3"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">1815920</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ"
      decimals="2"
      id="Tc_l4szYi6cUUS9nTZnIubR2A_11_6"
      unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg">19.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      id="Tc_m_ZCDcekq0eMk1639yHNZQ_11_9">P5Y5M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ"
      decimals="-3"
      id="Tc_9QxyCxLsBUWUztpNG0eleA_11_12"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">11296000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      decimals="-3"
      id="Narr_79NV5jiYpEGsc6ndVUfyUg"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">18000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw"
      decimals="-5"
      id="Narr_29NHgfHRSUWvMtxlrCm0HQ"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">2100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="As_Of_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_Nn8D-tR9RUaR3oXEwhegJw"
      decimals="-5"
      id="Narr_iW1c7IE2pES-IJAXlZSBmQ"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">11000000.0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_3UfIUbfYm0S1MerajhgXqg"
      id="Narr_uuZlGHRnBka2K_g6YcaqVw">P2Y8M19D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_5_1_2023_To_5_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_XYLfgmBs1kapqrjpQTeEpQ"
      decimals="INF"
      id="Narr_HNT7spNArUus9pY5bzme5w"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">430400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfHurdles.
      contextRef="As_Of_5_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_DFqUQBhRC0ifvbBc0bGVmg"
      decimals="INF"
      id="Narr_vGibJBIKMU2xqv97ze9ZxA"
      unitRef="Unit_Standard_item_ZJDcTjbqbUC2tIGJY9M-pg">4</xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfHurdles.>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_5_1_2023_To_5_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_Cf49xhpajkCvIANGtFeezA"
      id="Narr_frIE3rq9UEae0WovI42liw">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfCalendarDays
      contextRef="As_Of_5_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_DFqUQBhRC0ifvbBc0bGVmg"
      decimals="INF"
      id="Narr_uWp87CbDyEqr_Iw83W9phg"
      unitRef="Unit_Standard_D_PCYEJUif70CZJGJolwi3Yw">30</xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfCalendarDays>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_5_1_2023_To_5_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_jGf-N4U7oEWRkZ347gsAlA"
      id="Narr_OaV_R4FXd0OwlmYMMGAx8A">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_5_1_2023_To_5_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_aWe1HEcOJkO4GJNqP9UK8w"
      id="Narr_UbwY9gV1G0uXsK-GPRsSpw">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      id="Tb_BXxY40GS4EuBEo26CItDNg">&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The range of grant date fair values of the PSUs issued in May 2023 were estimated as follows:&lt;div style="display:inline-block;height:24pt;width:24pt;"&gt;&lt;div style="height:24pt;left:0pt;padding-bottom:0pt;position:relative;width:24pt;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:inline-block;height:24pt;width:24pt;"&gt;&lt;div style="height:24pt;left:0pt;padding-bottom:0pt;position:relative;width:24pt;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.8%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.8%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.8%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:25.89%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Derived&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Hurdle Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:21.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:25.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Service Period&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="vertical-align:top;white-space:nowrap;width:21.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Per Share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;white-space:nowrap;width:21.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;PSUs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;white-space:nowrap;width:21.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Per&#160;Share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;white-space:nowrap;width:25.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in&#160;years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 232,956&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;16.36-17.45&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;0.69-0.76&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 35.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 87,708&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;15.03-16.07&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;0.93-0.99&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 40.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 57,851&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;13.82-14.84&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;1.12-1.18&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 45.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 51,885&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;12.75-13.72&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;1.27-1.33&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 430,400&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock>
    <us-gaap:SharePrice
      contextRef="As_Of_5_31_2023_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar30Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_k94cSi-Zwk2VBrdcAKVvmA"
      decimals="2"
      id="Tc_dt9xeSzbS0iZAsfYWODb8g_4_1"
      unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg">30.00</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_5_1_2023_To_5_31_2023_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar30Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_nNrXvBglBEuLwgpeNxml8A"
      decimals="INF"
      id="Tc_zWcHrhlptUGijdevUnIpFA_4_4"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">232956</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_5_1_2023_To_5_31_2023_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar30Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_eRdy_9rQG0eihqb4EruBVA"
      decimals="2"
      id="Narr_XZE7h3WbJEiGnD_LZvCnaA"
      unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg">16.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_5_1_2023_To_5_31_2023_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar30Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_NtPgJkGsykWMLfBzzhabEg"
      decimals="2"
      id="Narr_gxazmwtPW0y2s3y405HEZA"
      unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg">17.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="Duration_5_1_2023_To_5_31_2023_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar30Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_eRdy_9rQG0eihqb4EruBVA"
      id="Narr_je7_AI3dREqQnrFlTL8knA">P0Y8M8D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="Duration_5_1_2023_To_5_31_2023_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar30Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_NtPgJkGsykWMLfBzzhabEg"
      id="Narr_0yCrRXl9Xk-GEGsygiN5lA">P0Y9M3D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:SharePrice
      contextRef="As_Of_5_31_2023_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar35Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_6tvbW7uZUEOHE7gMti2gpA"
      decimals="2"
      id="Tc_Mh-aagbSnkiLwUZpkwAHNQ_5_1"
      unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg">35.00</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_5_1_2023_To_5_31_2023_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar35Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_YZ1bWx-iUUeKV_tBnvEWAw"
      decimals="INF"
      id="Tc_kpIBTXNyjk6R71hSFAzQZg_5_4"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">87708</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_5_1_2023_To_5_31_2023_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar35Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_lT2QTmiVC0-u-Gq59mHj8A"
      decimals="2"
      id="Narr_EDPfGcG8t0ud3TC69_6cqA"
      unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg">15.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_5_1_2023_To_5_31_2023_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar35Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_EP_RDzS2Y0G8ZWnpyMII1w"
      decimals="2"
      id="Narr_UYDIbI6ZtUGuZCQkFJuKNQ"
      unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg">16.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="Duration_5_1_2023_To_5_31_2023_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar35Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_lT2QTmiVC0-u-Gq59mHj8A"
      id="Narr_EVVO7o4VVkiEW5z5EUjSCA">P0Y11M4D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="Duration_5_1_2023_To_5_31_2023_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar35Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_EP_RDzS2Y0G8ZWnpyMII1w"
      id="Narr_aG21w7c8dECOIxEl7_OIsQ">P0Y11M26D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:SharePrice
      contextRef="As_Of_5_31_2023_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar40Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_M7IRrCKea0iCZRqtsZ7RWg"
      decimals="2"
      id="Tc_C8LiGFT34ka0SbMpcueCDQ_6_1"
      unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg">40.00</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_5_1_2023_To_5_31_2023_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar40Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_6r4sVlcI50y97OHzEy_aBg"
      decimals="INF"
      id="Tc_X483B_dyl0-FoTMt3dVK1Q_6_4"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">57851</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_5_1_2023_To_5_31_2023_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar40Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_QN3fukmQcEymV8gdhnI3ow"
      decimals="2"
      id="Narr_WSFFGUO6GkeZO9jTptPg0w"
      unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg">13.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_5_1_2023_To_5_31_2023_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar40Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_yYP93SxHqUaWiML_VD6qSQ"
      decimals="2"
      id="Narr_JmOvyOGP_0WKmVyNRv7FLA"
      unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg">14.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="Duration_5_1_2023_To_5_31_2023_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar40Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_QN3fukmQcEymV8gdhnI3ow"
      id="Narr_63AP3VEJ70yK5_6q09UQ8Q">P1Y1M13D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="Duration_5_1_2023_To_5_31_2023_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar40Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_yYP93SxHqUaWiML_VD6qSQ"
      id="Narr_4_xZ-aksSkSmzwAK_fSwIg">P1Y2M4D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:SharePrice
      contextRef="As_Of_5_31_2023_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar45Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_G0SYyex3eUy7MyZY9jFEqg"
      decimals="2"
      id="Tc_SaFcbEupcEucWCTFAelCMA_7_1"
      unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg">45.00</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_5_1_2023_To_5_31_2023_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar45Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_sJUAR2OjXECHMqedJgu-yQ"
      decimals="INF"
      id="Tc_I5n0i-FaSEyl2664EM1gwg_7_4"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">51885</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_5_1_2023_To_5_31_2023_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar45Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_0Czk0OqbEkepDfJ3xsELBw"
      decimals="2"
      id="Narr_YSe73GHO4UuvQvXlPRkjVw"
      unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg">12.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_5_1_2023_To_5_31_2023_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar45Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_132lsM87s0-SgeiFzFNGPw"
      decimals="2"
      id="Narr_jgRIOeLzu0uj2V_gjRojYQ"
      unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg">13.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="Duration_5_1_2023_To_5_31_2023_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar45Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_0Czk0OqbEkepDfJ3xsELBw"
      id="Narr_QC4-7FTeR0yEyNAX6oSQCg">P1Y3M7D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="Duration_5_1_2023_To_5_31_2023_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar45Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_132lsM87s0-SgeiFzFNGPw"
      id="Narr_Xl-UeI-r0US1sIW_WjGLkQ">P1Y3M29D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_5_1_2023_To_5_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_Cf49xhpajkCvIANGtFeezA"
      decimals="INF"
      id="Tc_YuxUHdYVlUG9K7eemAF6bw_8_4"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">430400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="As_Of_5_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_DFqUQBhRC0ifvbBc0bGVmg"
      decimals="-5"
      id="Narr_yMBu_VrhLku1sdI5yw3qvg"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">6700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      id="Tb_VWs96NrSWkSCcjaWg-6sNA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:56.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.24%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.56%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.22%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Grant Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:19.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;white-space:nowrap;width:19.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unvested PSUs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;white-space:nowrap;width:19.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Per&#160;Share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:56.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested balance at January 1, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:56.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 430,400&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15.61&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:56.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:56.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:56.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested balance at June 30, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 430,400&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15.61&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_pg3TjcmZJki500S9VQ6N9A"
      decimals="INF"
      id="Tc_bH0hn_zNTUW2r9PWAc6quQ_7_3"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">430400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_pg3TjcmZJki500S9VQ6N9A"
      decimals="2"
      id="Tc_zN_kAUpUJUSLG4DMyTERnA_7_6"
      unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg">15.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_6_30_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_fUdJCDTZZkCC-dGe4IpNTw"
      decimals="INF"
      id="Tc_nZnnPiX6sEqZJgUxb_Pi9w_10_3"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">430400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_6_30_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_fUdJCDTZZkCC-dGe4IpNTw"
      decimals="2"
      id="Tc_oLgmv0TWIEGZ6jyn5NRWxQ_10_6"
      unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg">15.61</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_pg3TjcmZJki500S9VQ6N9A"
      decimals="-5"
      id="Narr_8VsO8zjv7kaJhGZYVotOgQ"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_aLWj_8kVOUatUIpAaoSESA"
      decimals="-5"
      id="Narr_q8RGTThxJ0eJl_O2VuysUw"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="As_Of_6_30_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_fUdJCDTZZkCC-dGe4IpNTw"
      decimals="-5"
      id="Narr_h3y3gpzB2UmHFbGAeRmL3g"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">6200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_pg3TjcmZJki500S9VQ6N9A"
      id="Narr_Ouca1nzxvEG8ace3GdfT2A">P1Y10M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      id="Tb_jF9_KFQQBECZDWjQyZ5hyA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;All stock-based compensation expense is recorded in G&amp;amp;A expense. The following table shows total stock-based compensation expense for stock options and PSUs issued under the 2010 Plan, the Stock Option Inducement Awards and ESPP in the condensed consolidated statements of operations and comprehensive loss (in thousands): &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:55.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six Months Ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total stock-based compensation expense included in G&amp;amp;A &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,163&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 837&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,733&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,815&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember__apnO9afP0Citfd-cUI30g"
      decimals="-3"
      id="Tc_lvXVqiAwfEOcPZelg5Z7bw_3_3"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">2163000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_4_1_2022_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_z5dcpbt0dECbfqWaQSAHWA"
      decimals="-3"
      id="Tc_1QaoJpRhFUWJc-3LoUAs0A_3_6"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">837000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_SYto29SUgUamWkI0SK6jEA"
      decimals="-3"
      id="Tc__O0S5MoV8kuuNwDIuSyfNQ_3_9"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">3733000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_6_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_ulujEwUlBE-e-GfNhQVDxA"
      decimals="-3"
      id="Tc_fQ-hF3nYbUyJlvuwCQLcRw_3_12"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">1815000</us-gaap:AllocatedShareBasedCompensationExpense>
    <xoma:NumberOfPeriodsCashRetentionBonus
      contextRef="As_Of_11_1_2022_srt_TitleOfIndividualAxis_xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_rYMNfnEL9EOqQXV7Em0Nyg"
      decimals="INF"
      id="Narr_Rko2rIAGSkejFPg1f-UNXg"
      unitRef="Unit_Standard_period_Oxx3Sge1w0O2HvNr__SG-A">2</xoma:NumberOfPeriodsCashRetentionBonus>
    <xoma:PeriodOneRetentionBonusEligibility
      contextRef="Duration_11_1_2022_To_11_1_2022_srt_TitleOfIndividualAxis_xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_r2cXPnKQNkCZpd4DuftB1Q"
      id="Narr_Qja5dkFsp0uh1yDy-y9Qfw">P3M</xoma:PeriodOneRetentionBonusEligibility>
    <xoma:PeriodTwoRetentionBonusEligibility
      contextRef="Duration_11_1_2022_To_11_1_2022_srt_TitleOfIndividualAxis_xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_r2cXPnKQNkCZpd4DuftB1Q"
      id="Narr_BP7NgCqc3E-T9MOZvr_1lw">P9M</xoma:PeriodTwoRetentionBonusEligibility>
    <us-gaap:DeferredCompensationArrangementWithIndividualDistributionPaid
      contextRef="Duration_1_1_2023_To_6_30_2023_srt_TitleOfIndividualAxis_xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_oCigQGadskqvS1qhL-UxEw"
      decimals="-5"
      id="Narr_EM2DBvdCTUiO2YbT9tjrUw"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">200000</us-gaap:DeferredCompensationArrangementWithIndividualDistributionPaid>
    <us-gaap:DeferredCompensationArrangementWithIndividualDistributionPaid
      contextRef="Duration_7_1_2023_To_12_31_2023_srt_StatementScenarioAxis_srt_ScenarioForecastMember_srt_TitleOfIndividualAxis_xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_MqTx9tpzQE-VCd4MN0ETHw"
      decimals="-5"
      id="Narr_8hpVP9z0HUyhdyCBBmsb5w"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">500000</us-gaap:DeferredCompensationArrangementWithIndividualDistributionPaid>
    <xoma:RetentionBonusExpenseAccrued
      contextRef="Duration_4_1_2023_To_6_30_2023_srt_TitleOfIndividualAxis_xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_tUWKdWxSsEqTeepdcpaR-g"
      decimals="-5"
      id="Narr_8_OQebAp6UaKRgjxxD-3-w"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">200000</xoma:RetentionBonusExpenseAccrued>
    <xoma:RetentionBonusExpenseAccrued
      contextRef="Duration_1_1_2023_To_6_30_2023_srt_TitleOfIndividualAxis_xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_oCigQGadskqvS1qhL-UxEw"
      decimals="-5"
      id="Narr_E_pqm8-rXUiZ4CvDxlw5xw"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">400000</xoma:RetentionBonusExpenseAccrued>
    <xoma:RetentionBonusExpenseAccrued
      contextRef="Duration_7_1_2023_To_10_31_2023_srt_StatementScenarioAxis_srt_ScenarioForecastMember_srt_TitleOfIndividualAxis_xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember_VlkReAnbnkaiZ8DMeCw8ZA"
      decimals="-5"
      id="Narr__paNA88TGEe6Y6-W-XX7mg"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">200000</xoma:RetentionBonusExpenseAccrued>
    <xoma:AccruedRetentionBonus
      contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ"
      decimals="-5"
      id="Narr_A2AMsN018k-xpd8PoFExYg"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">300000</xoma:AccruedRetentionBonus>
    <xoma:AccruedRetentionBonus
      contextRef="As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg"
      decimals="-5"
      id="Narr_DlOXRIFkZUmNlWlEo-7-1Q"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">100000</xoma:AccruedRetentionBonus>
    <xoma:AccruedCompensationContinuityIncentive
      contextRef="As_Of_12_31_2022_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerRetiredMember_YyRGgFdv-E6X0DuiU_Edmg"
      decimals="-5"
      id="Narr_6d-K1tEaKkaPvnfTrrL9RQ"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">1200000</xoma:AccruedCompensationContinuityIncentive>
    <xoma:CompensationExpenseEmploymentAgreement
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerRetiredMember_-DtLW9eN0kelXo4Sr64YSg"
      decimals="-5"
      id="Narr_ydjr204XGUCx8QOO5pJ2jA"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">1200000</xoma:CompensationExpenseEmploymentAgreement>
    <xoma:AccruedCompensationContinuityIncentive
      contextRef="As_Of_6_30_2023_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerRetiredMember_AOpX5sV2ukSJWYQ3A3lEaQ"
      decimals="-5"
      id="Narr_9OggBNpqJ0CVz3vToeciNg"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">600000</xoma:AccruedCompensationContinuityIncentive>
    <xoma:CompensationExpenseEmploymentAgreement
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerRetiredMember_-DtLW9eN0kelXo4Sr64YSg"
      decimals="-5"
      id="Narr_CMPT0RGCpUaZo9Du_PTqpw"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">1200000</xoma:CompensationExpenseEmploymentAgreement>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      id="Tb_pDD_YB06eEqHBqw3eCoeuA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;11. Capital Stock&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Dividends&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;During the six months ended June 30, 2023, the Company&#x2019;s Board of Directors declared and paid cash dividends on the Company&#x2019;s Series A Preferred Stock and Series B Depositary shares as follows: &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:42.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:16.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:42.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:17.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Series A&#160;Preferred Stock&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:18.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Series B&#160;Depositary Share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:42.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:17.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cash Dividend Declared&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:18.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cash Dividend Declared&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:42.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Dividend Declaration Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;($ per share)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;($ per share)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Dividend Payment Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:42.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;October 26, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_6FlVNMctY0q9dw8fCOKxTg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.53906&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_9royLRcMl0Knqef269WU1Q;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.52344&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:16.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;January 17, 2023&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:42.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;February 22, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_qWHrIk0HxkKu1Feelg1QWg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.53906&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_zyL_9MT4C06Qx4obkYEVKw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.52344&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:16.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;April 17, 2023&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:42.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;May 17, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_hWIxlEMoI06Nfvonzanuzg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.53906&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_Q-ZWoTYYE0qrtlCrmMWbHw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.52344&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:16.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;July 17, 2023&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;BVF Ownership&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of June 30, 2023, BVF owned approximately 31.7% of the Company&#x2019;s total outstanding shares of common stock, and if all the Series X convertible preferred shares were converted, BVF would own 52.4% of the Company&#x2019;s total outstanding shares of common stock. The Company&#x2019;s Series A Preferred Stock becomes convertible upon the occurrence of specific events and as of June 30, 2023, the contingency was not met, therefore the Series A Preferred Stock owned by BVF is not included in the as-converted ownership calculation. Due to its significant equity ownership, BVF is considered a related party of the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;2018 Common Stock ATM Agreement&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On December 18, 2018, the Company entered into the 2018 Common Stock ATM Agreement with HCW, under which the Company may offer and sell from time to time at its sole discretion shares of its common stock through HCW as its sales agent, in an aggregate amount not to exceed $30.0 million. HCW may sell the shares by any method permitted by law deemed to be an &#x201c;at the market&#x201d; offering as defined in Rule 415 of the Securities Act and will use its commercially reasonable efforts consistent with its normal trading and sales practices to sell the shares up to the amount specified. The Company will pay HCW a commission of up to 3% of the gross proceeds of any shares of common stock sold under the 2018 Common Stock ATM Agreement. On March 10, 2021, the Company amended the 2018 Common Stock ATM Agreement with HCW to increase the aggregate amount of shares of its common stock that it could sell through HCW as its sales agent to $50.0 million. No shares have been sold under the 2018 Common Stock ATM Agreement since the agreement was executed.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;2021 Series B Preferred Stock ATM Agreement&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;On August 5, 2021, the Company entered into the 2021 Series B Preferred Stock ATM Agreement with B. Riley, under which the Company may offer and sell from time to time, at its sole discretion, through or to B. Riley, as agent or principal an aggregate amount not to exceed $50.0 million of its Series B Depositary Shares. B. Riley may sell the shares by any method permitted by law deemed to be an &#x201c;at the market&#x201d; offering as defined in Rule 415 of the Securities Act and &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;will use its commercially reasonable efforts consistent with its normal trading and sales practices to sell the shares up to the amount specified. The Company will pay B. Riley a commission of up to 3% of the gross proceeds of any Series B Depositary Shares sold under the 2021 Series B Preferred Stock ATM Agreement. No shares have been sold under the 2021 Series B Preferred Stock ATM Agreement since the agreement was executed. &lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:DividendsDeclaredTableTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      id="Tb_RQxQd35ZKEO0YTSA0UMrmA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:42.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:16.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:42.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:17.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Series A&#160;Preferred Stock&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:18.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Series B&#160;Depositary Share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:42.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:17.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cash Dividend Declared&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;white-space:nowrap;width:18.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cash Dividend Declared&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:42.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Dividend Declaration Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;($ per share)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;($ per share)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Dividend Payment Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:42.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;October 26, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_6FlVNMctY0q9dw8fCOKxTg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.53906&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_9royLRcMl0Knqef269WU1Q;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.52344&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:16.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;January 17, 2023&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:42.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;February 22, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_qWHrIk0HxkKu1Feelg1QWg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.53906&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_zyL_9MT4C06Qx4obkYEVKw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.52344&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:16.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;April 17, 2023&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:42.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;May 17, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_hWIxlEMoI06Nfvonzanuzg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.53906&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_Q-ZWoTYYE0qrtlCrmMWbHw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.52344&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:16.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;July 17, 2023&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DividendsDeclaredTableTextBlock>
    <us-gaap:PreferredStockDividendsPerShareDeclared
      contextRef="Duration_10_26_2022_To_10_26_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_f-NSs0JDB0Om2BdwXRGLGw"
      decimals="5"
      id="Tc_E7M9LkUpsEioxIHcP48MtA_4_3"
      unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg">0.53906</us-gaap:PreferredStockDividendsPerShareDeclared>
    <us-gaap:PreferredStockDividendsPerShareDeclared
      contextRef="Duration_10_26_2022_To_10_26_2022_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_xycxsSZ67ECdvujJaYBpbg"
      decimals="5"
      id="Tc_v6m6IeuQIEmW1hwIbpkOMQ_4_6"
      unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg">0.52344</us-gaap:PreferredStockDividendsPerShareDeclared>
    <us-gaap:PreferredStockDividendsPerShareDeclared
      contextRef="Duration_2_22_2023_To_2_22_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_sYdPxIxRXkGzRg8T4Svv8w"
      decimals="5"
      id="Tc_m2OzFqLxSEGuDz296XwaGg_5_3"
      unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg">0.53906</us-gaap:PreferredStockDividendsPerShareDeclared>
    <us-gaap:PreferredStockDividendsPerShareDeclared
      contextRef="Duration_2_22_2023_To_2_22_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_-2EK4u-0ckW1nFdNOq609w"
      decimals="5"
      id="Tc_TIEkHh8w1k27wSCpiytYTQ_5_6"
      unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg">0.52344</us-gaap:PreferredStockDividendsPerShareDeclared>
    <us-gaap:PreferredStockDividendsPerShareDeclared
      contextRef="Duration_5_17_2023_To_5_17_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_zIuocAB-x0yti_KN6IbA-Q"
      decimals="5"
      id="Tc_vK6Pjh_yKkCwjftolUB6sw_6_3"
      unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg">0.53906</us-gaap:PreferredStockDividendsPerShareDeclared>
    <us-gaap:PreferredStockDividendsPerShareDeclared
      contextRef="Duration_5_17_2023_To_5_17_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_IblNCk2dpE-dmOagVLa7JA"
      decimals="5"
      id="Tc_LkGNc7orYUCehaBO8AT-eA_6_6"
      unitRef="Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg">0.52344</us-gaap:PreferredStockDividendsPerShareDeclared>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="As_Of_6_30_2023_dei_LegalEntityAxis_xoma_BiotechnologyValueFundLPMember_srt_OwnershipAxis_xoma_XomaCorporationMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_OPWHgi5OoUOvpKGH_7ayMg"
      decimals="3"
      id="Narr_ZVqltUTqGk-OBMDaT8lUFQ"
      unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ">0.317</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <xoma:NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted
      contextRef="As_Of_6_30_2023_dei_LegalEntityAxis_xoma_BiotechnologyValueFundLPMember_srt_OwnershipAxis_xoma_XomaCorporationMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_OPWHgi5OoUOvpKGH_7ayMg"
      decimals="3"
      id="Narr_0FvbmJ4uikq42EUIdORH6Q"
      unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ">0.524</xoma:NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted>
    <xoma:MaximumValueOfStockToBeIssued
      contextRef="Duration_12_18_2018_To_12_18_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_TwoThousandEighteenAtMarketAgreementMember_w7kNNs1WoE-BxhkhRzlqSg"
      decimals="-5"
      id="Narr_Rdf3SaYnDkWuNBC3di0ejw"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">30000000.0</xoma:MaximumValueOfStockToBeIssued>
    <xoma:PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares
      contextRef="Duration_12_18_2018_To_12_18_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_TwoThousandEighteenAtMarketAgreementMember_6lxjXvcF7UG8eC23SZUejg"
      decimals="2"
      id="Narr_zcuDyPTLNUKxpYxcd1GD5g"
      unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ">0.03</xoma:PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares>
    <xoma:MaximumValueOfStockToBeIssued
      contextRef="Duration_3_10_2021_To_3_10_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_TwoThousandEighteenAtMarketAgreementMember_lPXdwcXrLkWjZpFxVg8zQg"
      decimals="-5"
      id="Narr_hKBa7k0-0kChx0z-3ULyOg"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">50000000.0</xoma:MaximumValueOfStockToBeIssued>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_12_18_2018_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_TwoThousandEighteenAtMarketAgreementMember_7W6KMaqUekmIWDswlSxORw"
      decimals="INF"
      id="Narr_zTYvAFh5qEmyHFG0axLPKg"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <xoma:MaximumValueOfStockToBeIssued
      contextRef="Duration_8_5_2021_To_8_5_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_AtMarketIssuanceSalesAgreement2021Member_cuvo8QXwwkSA9m8xw1ZRjg"
      decimals="-5"
      id="Narr_Ky2cWYV8GUisY9nIG8loXw"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">50000000.0</xoma:MaximumValueOfStockToBeIssued>
    <xoma:PercentageOfGrossProceedsPaidToAgentForSaleOfShares
      contextRef="Duration_8_5_2021_To_8_5_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_AtMarketIssuanceSalesAgreement2021Member_aVcwCvFvaEm9M_QNOIF3YA"
      decimals="2"
      id="Narr_8sAb_jRI_E6NvYNYuQUi-w"
      unitRef="Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ">0.03</xoma:PercentageOfGrossProceedsPaidToAgentForSaleOfShares>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_8_5_2021_To_3_31_2023_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_AtMarketIssuanceSalesAgreement2021Member_LyhgNqHmQEOuPgMQ7sVrxA"
      decimals="INF"
      id="Narr_G1iAtbxG30We-vNj0V0GBQ"
      unitRef="Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      id="Tb_xMX_1-joikuYRxLXIJBacQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;12. Income Taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;No provision was made for federal income tax, since the Company has incurred net operating losses during the three and six months ended June 30, 2023 and 2022. The Company continues to maintain a full valuation allowance against its remaining net deferred tax assets. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has a total of $5.9 million of gross unrecognized tax benefits, none of which would affect the effective tax rate upon realization as it currently has a full valuation allowance against its net deferred tax assets. The reversal of related deferred tax assets will be offset by a valuation allowance, should any of these uncertain tax positions be favorably settled in the future.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company does not expect its unrecognized tax benefits to change significantly over the next twelve months. The Company will recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. Through June 30, 2023, the Company has not accrued interest or penalties related to uncertain tax positions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;On August 16, 2022, President Biden signed the Inflation Reduction Act of 2022 (the Inflation Act) into law. &#160;The Inflation Act contains certain tax measures, including a corporate alternative minimum tax of 15% on some large corporations and an excise tax of 1% on corporate stock buy-backs. The various provisions of the Inflation Act do not have a material impact on the Company&#x2019;s financial statements.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="Duration_1_1_2022_To_6_30_2022_9HNTEH7zM0-bV1QPz3Cfmw"
      decimals="-5"
      id="Narr_ktn47z1WrEGxx_hrOZqNRw"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="Duration_4_1_2022_To_6_30_2022_MkbIQ9bQc0eX6Gc5LtLGHQ"
      decimals="-5"
      id="Narr_QlTp-kN6702qbiotpUxmsw"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw"
      decimals="-5"
      id="Narr_uIpTM_-OoE2Spu-eyqGJQw"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg"
      decimals="-5"
      id="Narr_CcZvvEzTskyMy2-2DTnt_A"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ"
      decimals="-5"
      id="Narr_qkHYOe3zfUCQ4rkhMWC3wQ"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">5900000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ"
      decimals="-5"
      id="Narr_BjZGXD2Vn0ifEVWpd7VxpQ"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit
      contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ"
      decimals="-5"
      id="Narr_3o1iac27a0eZQOJ4uB3P3w"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ"
      decimals="-5"
      id="Narr_w3JDYVPLHk2PGbuARA6rxQ"
      unitRef="Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>91
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MORD O97:RUHQD.3A9%-O%#< G/+J+J_M$S/T\V0P(-8::P.W/(-;'LY'-3(
M+J SP-QJK V\\@Q>>3@1?4,*P(60%- &7'D&KCR<AO:=<4JN^$:DH6)RMY_T
M6%V^$27MK;?!7)YA+@]'IGKCO.*UV^M:(S]QYJ^)Y'F1DWR=SNVY,%E2:Q+J
MI2V>*C@@K-AC0L22C$Z],Y,7ILWRPL_6&FX#_OH&_OHX_%7GA0H!G1?NK#LJ
MV@"]O@&]?CW0J\X+%4+E>0$/_%:'O:/-4GJA*M]#EA)?OW,N]DT=KA[VJ4WR
MW5D]<WNQR>TCT^M<*8GX$D*=TS-X]LABWUAQHL0FWWKU()02<7ZXYBS@4M\
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M    >&PO=V]R:W-H965T<R]S:&5E=#,N>&ULK5AKDZ(X%/TK*?91,U6]\E+
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MOZ&?D8[X3O;RD2XD#X6F^\<Q9_F8U@MC.N@+E6 <+>, @AK_>;._:34 Z#(
M112LYRC,K$;$/]*XAVSC#EF&9=<1:G9?@"_=S<S=:J!C%Y-B9WCV"W@KN92!
M,0B0G'__Z0XEF*$]#E- [TB, AJ&F'&4 ,OGX'W='.1#N-D0*IGW$Z-G#$;Z
M_E17BU&%?;]@W^_&/E\G"*=B1QGY3SY0*O+>6NHY?O^$E6EDUQG[=KN*@$$A
M8- H8$ZC2.XP;XA]CN]5PVJXY]%O-:O0=PKZ3@?ZG8/O7 35<EU;7=89_6LL
M*PK<0H';70'A/&UG[UXN";/O6I[AG9&O-1ST#>N%Z'L%=Z\[=WE^<H'C@,3;
M-@'>M0)J#1L$# L!PT8!7L^Q!K^@-3 BF4_1/(W2$*O#]@ZM@"4@4ARB,LG7
M2FF=DL9A5'ERSQ/LPUB3]0<'M@=M\NM/IF/\7K<!WPBL$A'3* ])H]N6%I ]
M"2 .$,-";@Q8)IC:$GQY2-;.ZA%_6$UUS['ZPY/K;(8[.E6UG10 YJNVZ^OR
M[0A^N@R'7O]RJVZWJ]*W2OK6J^AW2+GC".T:6NVJ&LKCWFP^[[V>[98I-WM]
MRC6/TS7G;H56C4I91I@=ZXC.2=>OS1_[XAR^PK"JH:PDS.92XHW)-;C<XYW+
M9=EB5:5>5A%F<QEQB\2ZK!#J^+=85?F7-8395D3$>V""/(: DJJ66JZ-:)U3
MYT9H5>UE#6(V%R%O7':7I<7 ,.SS:6NQJE(OJP^SN?RXQ;(;7L6_Q2KGKY^\
M6D? MMD7!XY\FL8B?\LN>HNO&M/L75XOS?-/(E\PVY*8HQ VTM7HN3)O6?Z5
M(6\(FF0OZH]4R-?^['8'. "F#.3S#:7BN:$&*+[U3/X'4$L#!!0    ( "T]
M"%>!_/APM08  !$@   8    >&PO=V]R:W-H965T<R]S:&5E=#0N>&ULO5IK
M;]LV%/TKA%<,*=#$(O6RLL1 $JEKAKP0I]UGQ:)MH9+HD933]M>/>L2RR6O5
M68U]B2WYW$N>PTOR4,K9"^-?Q8)2B;[E62'.!PLIEZ?#H9@N:!Z+$[:DA?IE
MQG@>2W7)YT.QY#1.ZJ \&Q++\H9YG!:#\5E][X&/SU@IL[2@#QR),L]C_OV2
M9NSE?( 'KS<>T_E"5C>&X[-E/*<3*C\O'[BZ&JZS)&E."Y&R G$Z.Q]<X-.(
MN%5 C?B2TA>Q\1U55)X9^UI=7"?G ZOJ$<WH5%8I8O6QHE<TRZI,JA__M$D'
MZS:KP,WOK]D_UN05F>=8T"N6_9TF<G$^& U00F=QF<E']O*)MH3J#DY9)NJ_
MZ*7%6@,T+85D>1NL>I"G1?,9?VN%V A0>>  T@80/<#9$6"W ?:^+3AM@+-O
M"VX;4%,?-MQKX<)8QN,SSEX0K] J6_6E5K^.5GJE154H$\G5KZF*D^.K^[LP
MNIM$(5+?)O<WU^'%D[J8/*F/V^CN:8+N/Z+[A^CQXNE: =#%786\?7B,/JFP
MZR\1.KJYGTS>H^L[=3M"Q^CS)$1'[]ZC=R@MT-."E2(N$G$VE*JW59O#:=NS
MRZ9G9$?/;'3+"KD0*"H2F@#Q87^\UQ,_5"JMI2*O4EV2WH1_E<4)LJT/B%C$
M!OISM7\X@>C\6NO1?VY]2PQ[73=VG<_=D>^1KFA14G$*#6P3:L.AU=)W*I;Q
ME)X/U-HF*%_1P?CWW[!G_0&I>LADX2&310=*MJ6_L];?Z<O^JC^:<9:CJ2IT
MKI9<H18/N6B7#<K!2=>D]>JTU2ZR&F-,W+/A:E-S$^3JF'"?1)$)LHG?@;:H
MNVOJ[E[4.9VR>9'^H DJU13GZF\JQ3&;'?,6D5.Y8-#2<=FTX&P2M&U-!!/C
MN"--!!,3^):F@8D9X1T2>&L)O%X)GIB,,]32!(?9,QK%GM[[*Q,4C#050A-#
MK$ ?9A/D6($%<_37'/W>%>9^27DLTV*.Z#=EB\2.M<8_Y%ISR&3A(9-%!TJV
M-1*C]4B,?C+A!(WY=('41JY,V$JYRZ7RBA(:CI%1"7:@59T)<;0I$YJ00*O+
M"(!X<,$%:YI!+\T_::$J+JM9QHGR6JF0506N*$0T,%<0W_<UJA (ZV1-$,:!
MK_,%4-:([*",K<[^6?UCR[['F?R.EJ4:8&6X43SGE%:CBV(AU$$ES9=QRG<-
M=YM]JUNNKV\G_7UXZ[S:J\WH4&UNZ[IAJW&OKA?\.:VK1QV&E(PR:S2=,J%V
MZ:,[)BFRWX.*]N9]ZX)VT&QAFVUKZF*;Z,H?J,UMY4FG/.E7/F=<IC\:Z=E,
MG4)D7,S3YXPV%0T?18BYS1%'+^/>AM\LIMFDXP2ZE@=J<EO+SN3C7@_;^@QF
M[,2@A+;!Q_>PL128*#5W]2410.$1(4:E 3 KV(!MT^Z\->XWUS=,B,99M]19
M 5-VC/:/W<#5=P$(YOB>KY,&8-C#Q-=9 SAO9.]BW=EJ[/8;+KE0)CHMINKL
M@([:H7[_ 154@LX+]]KT-Z]4A\P6'C1;=*ALVP/3F7W<[_9[!@8<%].-NV9-
M M[?*$@ @QV]&DW0,<:C'<78F7_<ZVC'=\IZ9&H:@@1]8-HYEJ53!&".IQ_/
M0@B&78)U P;AO,#=<<K!G;G&_>[ZBN6J:A;5L]<5W<W9]+L@9P &<09@(&<
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ML.8/>9&N=H7+&JR2]?/_\??=@3@H,&XKP'8%6-\"SJZ TRC@NBT%W%T!MU'
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M;/>8]6IZ26-[0>$N5(U#U4)&K'-U_.9I"LIL.U+*IJF)+=,36Z-E:WHM8[=
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M=,=QF?+S@9"M49B#I+GSI_K.Z)4[A^ ;+<6&@[A,26KQ7[K]QV_YQVY_B!P
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MDTKZ.BMQF1Q3TKTJ/*]HD5>TV!=:-T*M9$1NR=B4=%71)?Z:,":SOU[22&6
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M_<TU0T\%@]#U<WYZ]B7UC,@^]M';^HWI.'. 27L@E!69D$88Z^$_'?SWZ:-
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M^%DII U94OST]?=O+H_C7JT0\V$8/L4OYAUUF&J]X9K3C%P'08*30SF\WCV
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M$H=4,I:@0J.FQ$]WCL].)E/025F&]$WSJ!1;YAVP%1Y.04E>@O(O>6) Y@:
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MP.ZG^5 7);V@>5'4=;&A/]<2%%V%#\#ORP+\>_T!%[!O['[\/U!+ P04
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MP"9R8.PPM@%F=XM?FI"AG<,D%!_*S,P0O%&N$Y_QR*.QRVX\AZ49C<ZGO<Y
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MU-7PXL =$88 *?O<J'70+)'BUE0":YJI/'7N6;MKDVOH0.NG9#K!"$1AXB_
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ML\C0V8V,5]Q50Q8,3 ;+C*;H:8G8X/!.^QP>*FP*$<(=9].X=32<^6NAP2%
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M8DDD[_T>\HZG"V,_N!S B_M"E^ZLEWM?'0\&+LVAD*YO*BAQ9&9L(3V^VOG
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MV8AKY&'D@^0RTL!4O&^8Q>8L#\CA\,!7T4C,^C8]A&=8%P25R,OGFW>+32#
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MA"9G7"EF@BIT!F$EX.X6,Z-S22;=$''.5)U3$$E1\!60J9&0<3]$O4.5%=1
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MQ4UD%U0:]#:C\B!S>WMD$+BG;V823ML)F39?)Q-Y@E+9T'!R!?A<,?W6*W\
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MUCOLK1]<JT7N^<%P>EK)!=V0_[VZLK@;MBB9*JATRI3"TORL-SM\?7[$X\.
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M H=0!I83Q);F$H@.++I!;7WPV("399:\Z9[3?<5.\*(O2O(#,7/,&GT M7U
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MB<] &[_+XXTW5?@63HS'EW6XS$E"!3P [^<&7MS<\ 3MCR/3?P!02P,$%
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M(AL GCAO1#C4RND*+2R.<$MJXS$JDRE)!>11"M>Q@D=_& )J/!!E+5;8U_Z
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M4T'Z19-Q- T;Z>[JH)=XM#5IN^6S=8GW$\\!D4\!^RA ,]]CQV-9N<;"=[:
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MGUY<K)Y_W6:7==W#&._MP35=!K,J4_VGWQKN!(0)!_D.-KE? U,\69$&OEC
M.JKX4*Z_O\)1?C1-OLN^8C7].0PQ<?".=]":O47[#&K*M)-[,KRG>Y%KH81Q
MA[)&J@/_[$T-. 4?62 >05R1&5!%IO@WV&EZ=4&CERV9!%>C_MH Q8&_*CF$
MO&\:_#)ZB=D4]I+5%KD-P!$1V60;4S9A80--Z?<ULZ&(L5F/*>^#  %D(9$
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M0 E\S6&>8]D.;D/TR@3DX$I4?>V:AOMV2-$69VQFOC^U@4;LB-_(N.<$1;V
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M!\Q&_\02%MO@ _ ]_JRH_H$3^-^B?O7?4$L#!!0    ( "T]"%=%F+='3@8
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MQ"1/8LI&C,0$Z8.]RKHTJ*:X5\[A@+<Y0B:8*6[*EZ =7EWA]"<JT.;X;XA
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MM.EFSBS,[P.D!9CY7 C=.7:!_H>4_ %02P,$%     @ +3T(5Q+:"2'U!@
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M/C"<-\_-#SWHKU$L6W>-K;*NUQT&FN/;]6[,0+?"C77@B<<D 7H:(H^SA $
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M"..@[PO.U<$P#3_.]_0W4$L#!!0    ( "T]"%=C!8FL>P(  ) &   9
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M]?7KK,?#\ @2A+M]\$XL_;;P_(IO^@3?60GUU4=-X?=3F)X[5WN:P-+"IJI
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M)@6ED,V;/[9YZ '"-T< 40N(?@-$T1% W )B9[11YFQ=<^3)5*L=TS::V.S
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M@?I,P 8!0/U9*,V#TGPH+4#1J@(H_5GZ/TY\/,"VS7RTA[:6"]1?A=)\*"U
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M?7/]L:%^7WUI^V_.WGUS=[81>+M97A![^('8 VM"OGQRR;N?WQ.^3$7QS9%
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M@!0:D%6T=@GICS_6EJ]MMGSWG1X&_#D( QFT)U+-F*X]#Z6Y%<W4\]" _NF
M%!J0&0/J/5][L_8I;W8=2!X&?XO%_C*M-K+V7[X9UKG_H3YN13,-Z=" _NF
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MU',?47[D5>XHOBJ^ )IQI7A:;"XIB:G(+]#GYYRKEYT\0/VIW?0?4$L#!!0
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MU6*>L( Y*_XBF<RGUK6%,EC@=2'OV?8C- L::KZ4%:+Z1=LZ=J2"T[60K&S
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MAY]A"\=VZ. "![H( $HC4#13GG81 %_S6!Z#/I<'I06@- )%,V5H5P*P?24
M:K)\>]%D&?3I/"B-0-',GWNV2P/^94L#5LN_3"+^S$7^&(=QUOO#4%"K#TH+
M0&D$BF;*U5I]_QJK[X-:?5!: $HC4#13AM;J^W:K/V"6W"\4[BQ ^F,\ZQ0N
M>S<&2P#J\J%HE03.R0L*.H?;\LT0J3.:9ZKZ+7^SMWG[9%F^<_%J_\J["ZIW
M2%I,]4K+%RJVL9XW)VRCD>['F;[)1/662+6A^+Y\#>*1*\73\N..43T<%0?H
M[S><J^-&T4#SKL[B/U!+ P04    "  M/0A7K]RY"M0&   U00  &0   'AL
M+W=O<FMS:&5E=',O<VAE970T-RYX;6RUG&MOHT84AO_*R%U56VDW-F"PDR:6
M''-KU4A6TFT_$WMBHP7&A7$N4G]\ATO &#R!^MTOL<%SGADXK^?@=R#7+RS^
MGFPIY>0U#*+D9K#E?'<U'":K+0V]Y(+M:"0^>6)QZ'&Q&6^&R2ZFWCH+"H.A
M.AH9P]#SH\'L.MNWC&?7;,\#/Z++F"3[,/3BMUL:L)>;@3)XWW'O;[8\W3&<
M7>^\#7V@_-MN&8NM84E9^R&-$I]%)*9/-X.Y<N6JDS0@:_&73U^2@_<D/91'
MQKZG&[^M;P:C=$0TH"N>(CSQ\DP7- A2DAC'/P5T4/:9!AZ^?Z?;V<&+@WGT
M$KI@P=_^FF]O!M,!6=,G;Q_P>_;BTN* ])2W8D&2_24O1=O1@*SV"6=A$2Q&
M$/I1_NJ]%B?B($ 9GPA0BP#U.$ _$: 5 5K7@'$1,.X:H!<!>M=C,(H HVO
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M!N+S)\;X^T;:0?F?$F;_ 5!+ P04    "  M/0A7R^1_P$X&  !.,   &0
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MC/I,9!? ^0V'\;_<R0JH_H5@\1]02P,$%     @ +3T(5\E),VX?"   KU,
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MMKM#;I_D<EWN-?@@\UPFY<.5X'K*+!KHOR^DOG"IGA0=[/?HG/P'4$L#!!0
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M+SXEY0KB\76:%J]WR@;-U>[G_P-02P,$%     @ +3T(5X3W1; -!0  F2(
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M/,OVCX_O_SG$+S/59M:<J:4$P!UH +R/"+ 9-:D 7,H W)4.P/L) :M9HQ+
MI13 K0WXR"V/_D7[]:KV* [>'_^'J,"EJL##=]>!5D%R,,^.T.H\2Q6"VV7(
M7G7@?+\Z8#-KK@.E<L"M37ORR%:<+2$W0>(]<3$WDT#F$45W?).4F1K8FU.G
MZJ(KM/IG:2DO?.\H4>^WJI.#/T\[0JN3+86*WRY4CA;V.7[UR]2B["U6;Z2]
M6SFJ,>=D4#A7C"L4T24X>6=#6#"9'3UE%UILTM.;N=!:Q.EP30F$;0S@^5)
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M.7C9WLN)9+GI7RLF53<TPT3=B(!K@'J_9DSN)SI ?<<*?P-02P,$%     @
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MU\!U@'J_8$QN%WJ"JR?VZ ]02P,$%     @ +3T(5_D[-U93 @  # 4  !D
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M@X]TK*;MO=9PN@[W?:4==4\8;NFY0N,=:'VMM3L:OH7Z![#X U!+ P04
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M<VAE971S+W-H965T-C8N>&ULO9UK;]LX%H;_"N$9##I )M;53C))@,8B.;-
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M,J'W9^1^+5+RQ^II<<"V@YJ[4%H I5$HC4%I'$73R]N4Z>M8L*'+@?J\4%H
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MYDV9+>N5F1^SLLR2^N5"A#.15S^0W\^SK'Q]4P78+E!^^S]02P,$%     @
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M_B:K'1H5O'D29N7_9%MM:_7(?)WE250%JQ%$0;S[*[Y5A3@(H*,C ;0*H(T
M>W@DP*D"G&:&8P'#*F!X[I!&5<#HW "W"BC%'.R*55;:$[F87:7)EJ3%UHI6
MO"CE*J-5@8.XF%F?\U2]&ZBX?/8Y3^9/Y%9IXY.[)%(3-A.EY!>$?R$WF9IQ
MJV(Y(V\]F8L@S-ZIM]Z0 <F6(I79U2!7HRA8@WF5\7:7D1[)Z)"/29PO,\)B
M7_HM\<P<[QKB!VKO]R6@+R6XI4;@[^NX3QSK/:$6=5K&<V<._RA2%6X?#??.
MST[;JO%]@^?_.;M62V<_G9R2-SK"^UH>R6HNB8U,U9F)B'H&M4V5'<UIIQ5G
MU<ML)>;RNJ=.FYE,-[(W^_DGV[5^:=,)"?.0,(:$<1!,TW>XUW=HHL_^6$</
M,B7)HCK\WY-?4Q'GK<?QK1'555PDS$/"V XV+&'%A7PS&T_=B:4.I\VA;*"<
MFFRCO6PCHVSLFTSG02;)*@WFDKP-8N(G82C2C*R4G*66[]HD-&*[2HB$>4@8
MV\'&!Q)2IS]J" C*J GH[@5TC0)2R[;(?2CB-I&,H5U%0L(\)(PA81P$T\0<
M[\4<0R^28Z2^2)B'A#$DC(-@FKZ3O;X3X\'ZHN_%B[Z/Q37RPA>Y) L1I&0C
MPG67L[ Q7=<)@(1Y2!C;P6SGX#1L._VAVS@/3UZ=K&W:I_9^*TVSZ5ZSJ5&S
MW7W0G^5!2#[$_GHNU?US3FZV(O7?D\8%5/4_;^Q)WW5KX=IT,Z;LJAL2YB%A
M# GC()@V"6RKOANVH*?F"@>2&$KSH#0&I7$439?YP/2P<;<Q%>NPP;?T4]*=
M.5UGX4XF9-"$W)A0+S&M2TQ_S"V'F=OYD**OKQ;%B5NOIP=-RLY+RE%)=85J
MJ\8V.@7X-L6<K[-R3DL[8/>G=E,ZJ%,#I7$435>X-FMLLUO3O:EQK+YEF9L:
M<\[.*D-]'2B-06D<1=/G0NT V2-L9P.U?J T#TIC4!I'T729:Y_(-AM%W3H;
M]W1G _6#3B=DT(3<F% O<>W>V$;SX#LZ&ZB14]$.=\VQFM=&J$$#I7$435>Q
M]FCL_]FD,>?KK&Z+RS'LNY.FP% #!DKC*)HN<&WHV.<[.AGYAQ@M=#.KLWA0
MKP9*8U :1]'T#^YKNX9B[1H*M6N@- ]*8U :1]%TF6N[AIKM&B_8!+Z,??(<
MR+"UDZD MFUH9<Q).LMU.B,[8QMNWD8O6&V^T%/FRTK.B^-BDX0B#\(@?VZM
M&FW)W1\WZX;T1KSVG.YDJOUK%O*<@?)36^G%K'T2:O9)/@79T\4BE9($JI%6
MNYB35'4)K06M/ NMW^Q;CMLL*?11E2-9Z:LJGC<Z?HQG'RME;4A0LR&QGY>J
MCE%K <WQ(_(LBTYL2J+=,V#VD/CBN>U<?V=&=:[Q>0,;OPQL>FQ<#+>+O.N@
M:!M*E[+V$ZCYD9)F>_5#/D SCZ'S]1IJ0D!I#$KC*)H^-VH3@KK8M@SZ! N4
MYD%I#$KC*)HN<VV$4+,1<D9;!G4\H#0/2F,5S=SJ_0C'@]:.!S4['N<VA5 ?
M TKSH#16T3JUHAPU!%W$VM6@9E>C2S,*]32@- ]*8Q7M56,[;3Z#BTJK/QM?
MVQ6.\3[Y=/MKCN_\/#S4GX#2V(E*=>F"40/31:W-"<=L3GQ_(WS&AZ[F,72>
M&% G!$IC4!I'T?2Y4?LP#H4VP@[TV1<HS8/2&)3&431=YH,O/9D=HM.-L!G0
M65BH?02EL8IF;(11&76Y:A?*.=.%,C?"9DIGS:!V%)3&*EJC$6X^:<512779
M:L?),3M.'5I?,ZFS=%#?"$IC%>U5ZSMIFKJHM+IXM27DF)]+.=WZ0CT@*,V#
MTMB)2DVJUM<YWO!";9_!P9?'(YD^EE_SS\@\6<=YD>1@[?ZG!&[*+] WUM_:
MEY[=LI[9EWSW0P$U?O>[!1]%^ABHICF4"Y7*ZH_5'$UW/P6P6\B35?G5]8<D
MSY.H?+F4PI=IL8%Z?Y$D^<M"D6#_@PRS?P%02P,$%     @ +3T(5^B--B>K
M!0  "R   !D   !X;"]W;W)K<VAE971S+W-H965T-C@N>&ULM9EK;]LV%(;_
M"N$50PNDEDCYFB4&8KO;.J!KT#3M9UJB;:(2Z9%TG.S7CY1DW2PS4<8"@:/;
M><_10XH\A[PZ</%#;@E1X#&)F;SN;97:77J>#+<DP;+/=X3I.VLN$JSTJ=AX
M<B<(CE*C)/:0[X^\!%/6FUVEUV[%[(KO54P9N15 [I,$BZ<YB?GAN@=[QPM?
MZ&:KS 5O=K7#&W)'U/WN5N@SKU"):$*8I)P!0=;7O1MXN40#8Y ^\8V2@ZP<
M _,J*\Y_F)./T77/-Q&1F(3*2&#][X$L2!P;)1W'/[EHK_!I#*O'1_7?TY?7
M+[/"DBQX_)U&:GO=F_1 1-9X'ZLO_/ GR5]H:/1"'LOT%QSR9_T>"/=2\20W
MUA$DE&7_\6,.HF* AF<,4&Z &@9P<,8@R V"IH?@C,$@-TA1>]FKI!R66.'9
ME> '(,S36LT<I#!3:_WZE)EVOU-"WZ7:3LWN% ]_@+DF%X$%3W1WDCAMD/<@
MN_5YEY[>F/:AZ@F\71*%:2S?Z2?N[Y;@[9MWX WP@-QB022@#-PSJN2%OJB/
MOV[Y7F(6R2M/Z6B-3R_,(YMGD:$SD8W )\[45H(/+")1B_W2;@^11<#3F I6
MZ,AJCJR*?^U9'P3^!4 ^"EH"6KS<'+6]C]U\24)M#MO,:V\3%"T?I'K#<RUO
M&NS]*FWYL-+R;2V5*07M2F9HNI0[')+KGAY[)!$/I#?[]1<X\G]KH^12;.E(
MK$9P4! <V-1G?^^3%1& K_/.?P$^[Y54NKM3M@%8@1794,;,B7YF1P3E;?UX
MGGD9I%[,./TPTTT\' YT*S]4P5FCZ0K.D5@-W+  -^P([@^!F6K]RN?#$SKC
MZ6CB-^%8/7:%XTBL!F=4P!EUA//AD8B0RG8\HQ,\[R>#<="@8W79E8XCL1J=
M<4%GW)&.GO[7A.K.<P'(XXX*/9QQ 4+,0IU,M#,;GS(;0XB:T*R1=(7F2*P&
M;5) F_R_@8JPR#Y$34Z'J/% _TT:R*QQ=$76XK0Q+M9H3 L:T]=]8'@5DQ?1
MF)X$!B=P.$5^@X8UCJXT'(G5D$&_3!-]*[3O:0*MOZV;!R)T05 ,2N!6T%#_
M:J)I1O':23#W/ZZU=A\-&DCM879EZDJM#K62>T-74"T39.X$!E5T07_8)&>-
MI3,Y1VIU<J@DAUR1L\Z>N9L:.SCIHVD3GC6<SO <J=7AE8D_M&;%7>"]8G+-
MG=>0!J-^,&HB=5H'N%*K(RTK 6@O!5X_/#X[V>2>ZY^WWQ\WIUY[A)UY#IX9
MCNN@RLP?VE/_[A_NBV?EW',U9#CM-Y,Z>WR=,?V,2@&6I0*TUPHG-!><*8%#
MM<<Q^$+,NI_I9E^)2&H=KQ6?W=4(/!$L))B")%M5"4"$G]K6=19VI<Z(7Q87
MS.("HY:PZG3+4@/::XU.="N]M96NW=4P?XOAD>[D/%VG98DKM3KBLC"!]LKD
M9K,19(,5 1\U6LHD#<$W'._)\]TU$QY5OW8X")HIN-U_9UHM3OV)?VY4+"L2
M:"])+!B>ZU<MM0A$TY/)UFDIXDJMO@I;UB+(7HMD2])29R1Y9G<!< &0%@ ?
M#, V9KE\O7YK ,N?J;8T@GZC=RWM@;X61%D_('O]4%VA;UUAM]MW7;AUJK9T
MI59G5U80"#E;_D8NL_^%4[6E*[4ZQK*60/9:XIX)$O(-H_\V.)IZ01\3($B,
MS22J.)!I?^7YY_N6,A#Q.-;SWKM6ZD'+".\WO\&%/<#..']&'8'*.@*]L([
M><J1I;N ZU-PV-)P"_;/$J<R/0QSZBO3!D>+5M#VF%">FTR.N0F<GDU.[%*=
M&\/I)H57V25-B-BDN\U2(]PSE6T"%E>+'>V;=!^W<7T.+Q?9OG0IDVV3?\)B
MHR<?$).UEM1%FAY]1+;SG)THODOW8E=<*9ZDAUN"(R+, _K^FG-U/#$.BOW_
MV7]02P,$%     @ +3T(5T$#*J8=!   N14  !D   !X;"]W;W)K<VAE971S
M+W-H965T-CDN>&ULM5AM;Z,X$/XK%B>=NM*V8,A+VTN0FO1>I=Y%V]V]SRY,
M BK8.=N$C;0__FQ#(>D2-XGHE\0&S^-YQA[[828EX\\B 9#H6YY1,742*=>W
MKBNB!'(BKM@:J'JS9#PG4G7YRA5K#B0V1GGF^IXW<G.24B><F&<+'DY8(;.4
MPH(C4>0YX=L99*R<.MAY>? I7252/W##R9JLX!'DE_6"JY[;H,1I#E2DC"(.
MRZESAV_GOC$P([ZF4(J=-M)4GAA[UIT_XZGC:8\@@TAJ"*+^-C"'+--(RH__
M:E"GF5,;[K9?T'\SY!69)R)@SK)_TU@F4^?:03$L29')3ZS\ VI"0XT7L4R8
M7U368ST'1860+*^-E0=Y2JM_\JT.Q(Z!/SY@X-<&_FL#?, @J T"0[3RS-"Z
M)Y*$$\Y*Q/5HA:8;)C;&6K%)J5[&1\G5VU39R?!1LN@9S50@8C1GN=H=@ICX
M7J(%<+--: 2H&O:%IA+=E83' EW<@R1I)CZ\-7+B2N6GGLV-:I]FE4_^ 9\P
M>F!4)@+]2F.(.^SG=ON1Q=Y5\6F"Y+\$:>9; 1_(%@7X(_(]/T#W*)60(Y$0
M#EWDYG:LOPIZA0*O!NM"V7,Q:-8Q,+## [ G+T$%%W3#Z</C5JQ)!%-'G0X"
M^ :<\.>?\,C[I8MR3V![S <-\X$-/?R=$RK5[KU(:1W.#UU\*Y"! =%GVR8<
M!-[ \R;N9I?)F\/V?!PV/@ZM/OY=Y$_ $5NBI.!Q!@)]-[NHR]'ACQZ\\M$Z
MUYG1'C5,1E8F7T'(E*[0&GC*NG)S9K</T!8([\P;J^&9M,8-K?&1"Q0Q*B J
M].6"(I(!C0E',=D*5.@S4C+]-"HR(@%M6%;D<%F:NT*])!O@ZNY#PB3@FJ<J
M&;^C^ZXHC7]8Y>#U5K1Z?&8\KIMX7%OC\:@3Z;*Z%A9DJ^YM=99PE6DKT.V/
MZ+-J*TF!_J'01<^*?NKITA/87B!NFD#<]'NNWO3)O">P/>;8:Z6!=U2N7Q"!
MB,[X2"U]Y^%: ^'=_>Q=!4'P:DO;)SR7T([6P?WLZL\EZZ1IA3]U<?M"VP^&
MWP;#[W=GUWA]L>\);9]]*Y>P59,<<8^] > ?OLCLEN=2:_40M@NB$])V<&3:
M6B<\EU KGK!=/1V?M@F'SNO(/L')6_<]!!AN%1@>]9RX/2FKFOU[Z#3<"C5L
M5VI')*X=P*) [9;G4FLU%[:+KA,2]_K(Q'T/Z81;[82M B7T/>RA149H)X=>
ME5)?:/OU@58J^5Z_.>GWI(3JDL-[Z"J_U56^75<=^0E>H[SY#6Z?[50V[DYQ
M+ >^,C5#H;[S"BJK.EGSM*E+WIEJG-L.KXJ:#X2O4BI0!DMEZEV-U7;@59VP
MZDBV-J6V)R8ERTTS 1(#UP/4^R5C\J6C)VBJM>'_4$L#!!0    ( "T]"%>O
MPI]KF 8  $$T   9    >&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;+6;:V^C
M.!2&_XK%CE8STDP VR1D-HW4RXYF5^JJFJJSG]W@-JB LX8T[6I__)I+,! P
MA9HO+1#\XM><@Y^<X-6!\:=X2VD"7L(@BL^,;9+LOIIFO-G2D,0SMJ.1^.2!
M\9 D8I<_FO&.4^)EC<+ A)8U-T/B1\9ZE1V[X>L5VR>!']$;#N)]&!+^>D$#
M=C@S;.-XX(?_N$W2 ^9ZM2./])8F=[L;+O;,4L7S0QK%/HL IP]GQKG]]=)!
M:8/LC)\^/<25;9!:N6?L*=WYPSLSK+1'-*";))4@XM\SO:1!D"J)?OQ3B!KE
M-=.&U>VC^K?,O#!S3V)ZR8*_?2_9GAFN 3SZ0/9!\H,=OM/"D)/J;5@09W_!
MH3C7,L!F'R<L+!J+'H1^E/\G+\5 5!I W-$ %@U@HX&X<'L#5#3(1L[,>Y;9
MNB()6:\X.P">GBW4THUL;++6PHT?I;?Q-N'B4U^T2]:W"=L\@0LQ$!ZX9*&(
MCIADX_L%W%">A4FTH2 _[2[R$W!^(-R+P3?B<_"3!'L*/E[1A/A!_*FWT1=P
M=WL%/G[X!#X $\1;PFD,_"@[)_XL#HKM:S\(1 ?BE9D(?VDOS4WAY2+W CN\
MV.":1<DV!K]''O5:VE^JV\\5[4TQKN7@PN/@7D"EX#5Y!<C^#* %45MWU*W_
MW$<S@*RVYK7>H/)6HTS/Z;K5Z7!_N<]N]:9RJ]L&.E="[4KIH^5KO",;>F:(
M9T=,^3,UUK_^8L^MW]IL:A*KF<:E::Q27_^U#^\I!^P!W-S>Q>"C"+ \[#ZU
MV<ZU<*:5/@"?UQA9V+)6YG/54.]IM:XZ95<=95>S=&FY/X"^I-OT,XA8 E[%
MHYW3#7N,_'];@_PBOXIM5;HWGRT:%EI/@NT&YJ6!N=+ ]SWW @INN"^27SP(
MTB$7*?\!6;-T;$Y[JI0;&F6:Q&K.%Z7SA;;46N@TK4FL9MHM3;O#;W>:8!X+
M L)CL!/'LF1KS;5<?%X)0-3,,^7U1[I;ENZ6&A\<RY,G D1PZ<P;AI27'&G(
MMN14;XW/3_"?F'DC/]R'K1.O4GEHU.I2JX]#!7EL;=E:2.DRKDFM;AQ*XU 9
M !5F2V]_-@X#,K907U2BW)[/4#/(U9T8:U)2CJWDB?45Y>*+@0=NA7(1Z#YK
MG2A[A%P0YCCH H^\MO'HI5IAK%7)-K8:;GH3FKQT)K12>7!<:U*KCX,$)]O1
ME]!*"!ML7)-:W;@$+EM-7.]-Z/EI0B]FV&DF]!1H94NVLI44,R2AU4++8T*C
M[H2> JAL253V"*1*$]KI(&BUWN!HG@*X;$E<]E)?&FM"J<+X%& &)9C!$6#V
M]C0NU&LHW<QA=0_&.I3(!95D,Y"F"[$J3KN+A>4V/4U!4U#2%%33E#)9U3BM
M5AX:O;K4ZN,@@0OJJRM!K84E76IUXQ*_H!J_WCG[%NJUV5>$#FI&^11L!25;
M0755ZNVS;X^0;1^G7]PY_:HEQGJ5. 5'%K"<7IY6*P\.["F("TKB@OK*65!K
M/4N76MVXY"^HYJ_W9K3;]@79:M9>U9T8:U)B%E17M@9DM%I(9C2<=Z?T%&B%
M)%JA<34OW%635NL-_NEC"NQ"$KN0ODH7TEKITJ56-R[9#(U@L[<G<J%>)6K<
M+$ZK>S#68>7'/'5U:AA1%V)5HG86KF,W/4T!5$@"%1I7S\+]!6JU\N#HG8*Y
MD&0NI*^>A;36LW2IU8U+ $.3UK-02ST+S5S8C/(IZ I)ND*ZZED]0C9XI82#
M8A8&=G=92RTTUK'$*C2NK(7[Z]1JY<'A/05Y(4E>2%^!"VDM<.E2J[^#(2D,
MJRGLG7E=J-?R&L]<W'PM8PK8PA*VL+K&]?:\[A$J\AKV?U]6"XUU+"D+CZN
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M S<CE#F3D7TV%Y,1WZJ4,IP+D-LL(^(PPY3OQX[OO#SX3M>),@_<R6A#UKA
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M5%I8T]Q!ZVWH:'&/L'RVY7"P>^C^I!S@M=A+A$Y%&)D7*\+M>FL\&B<?U6>
M2@N[>] _CC22SW:DO7VD/?3W:)VXAEQGMK%4G3HP>KQ8!Y@T'Y46H-)"5%J$
M16OK:K_OZN)MO+JH.Z^H-!^5%J#20E1:A$5K"V:__^J^LP%[>0:"NA&+2O-1
M:8';N8,Z:*\D(:K/"(O6EL-^>]<U[^_^7 :"NIN+2O-KFCF?"5!]AJBT"(M6
M*<(^^',[!;$JSRU(DA1AK_Z9;4J;LQ'WY8F H_+ O0NK$PY[3'7@XB$6*YI)
MPF"ID<[5M>Z J,XP5#>*;\J_T.=<*9Z6EVN(%R"*"OKYDG/U=E,X:$Z23/X#
M4$L#!!0    ( "T]"%=+)]1QMP(  "X'   9    >&PO=V]R:W-H965T<R]S
M:&5E=#<T+GAM;*U5:V_:,!3]*U=9-;521QX\-G40B=>T5NI:@;I]=I,;8M6Q
M,]L!^N]G.R&#"=@F]0OQXY[C<^XUU\.-D"\J1]2P+1A7(R_7NKSQ?97D6!#5
M$25RLY,)61!MIG+EJU(B21VH8'X4! ._()1[\="M/<IX*"K-*,='":HJ"B)?
M)\C$9N2%WFYA05>YM@M^/"S)"I>HG\I':69^RY+2 KFB@H/$;.2-PYMIW\:[
M@.\4-VIO#-;)LQ O=G*;CKS "D*&B;8,Q'S6.$7&+)&1\;/A]-HC+7!_O&/_
MXKP;+\]$X52P'S35^<C[Y$&*&:F87HC-5VS\.(&)8,K]PJ:)#3Q(*J5%T8"-
M@H+R^DNV31[V .'@!"!J -&?@-X)0+<!=)W16IFS-2.:Q$,I-B!MM&&S Y<;
MAS9N*+=57&II=JG!Z7BI1?("$Y.(%*:B,)=#$9??#S"=/\ ,2R)U)1$(MP%<
M4UY1_0JW/$%N*P"7,]2$,G5E(3G%#.9;3"JW]Y!E-$%Y#0O45&)Z#7>D0 6+
M#GQ#P@SB:3F#RXLKN #*X9XR9LY60U\;:U:@GS0V)K6-Z(2-,()[(RY7,.<I
MIH<$OLE)FYAHEYA)=)9QADD'NN$U1$$4'1$T/0^_J[B!!P[>/2.GV]:IZ_CZ
M)^7\K1#'DE9S=H]SV@9QHTJ2X,@S'4"A7*,7OW\7#H+/QPR_$=F!_5YKOW>.
M/1XGB:S,%4V(RJ$DKZ:/:--$&-%F48OC-[,R5T'"O"B9J 'CE42THV.YJ@6$
M@5-@F]\Z#CNF\NO]'!P)"CJ#-NC 6[_UUC_K[>!OAUL[QC?VUO\7;V=5_F]]
M_;V65*!<N4ZM(!$5UW5W:E?;QV#L>J#_.[Q^2>Z)7%&N@&%FH$'GHQ$JZ^Y<
M3[0H78-[%MJT2S?,S8.&T@:8_4P(O9O8 ]HG,OX%4$L#!!0    ( "T]"%<@
MGWC'90,  !P5   9    >&PO=V]R:W-H965T<R]S:&5E=#<U+GAM;+58_X^:
M,!S]5QKV)5MR$P5!O:G)G0+;DLO,7;;]7.&C-E<H:ZO>_ONUP#&]*,.E^T5I
MZ7NOY3T^)1WO&7\4&P")GE*:B8FUD3*_MFT1;R#%HL-RR-2=%>,IEJK)U[;(
M.>"D *74=KI=WTXQR:SIN.A;\.F8;24E&2PX$MLTQ?S7+5"VGU@]Z[GCGJPW
M4G?8TW&.U_  \EN^X*IEURP)22$3A&6(PVIBW?2NHY$>7PSX3F O#JZ17LF2
ML4?=^)Q,K*Z>$%"(I6; ZF\',Z!4$ZEI_*PXK5I2 P^OG]G#8NUJ+4LL8,;H
M#Y+(S<0:6BB!%=Y2><_VGZ!:CZ?Y8D9%\8OVY5BO;Z%X*R1+*[":04JR\A\_
M5<_A - [!W J@/,2X)X!N!7 ;:O0KP#]M@"O GAM 7X%\-L"!A5@4)A5/MW"
MFCF6>#KF;(^X'JW8]$7A;X%6CI!,)_%!<G67*)R<SG!.)*;H0;+X$7U <[(C
M"62)0._F(#&AXKWJ?8UL)#:8@QC;4JEJK!U7"K>E@G-&X<N6=E!O<(6<KN.>
M@,^:X7?X5Q-ZWHR^R7FC>- ,#V'908YS%A[^9>DX:U2/FN%?8ZG4_0+N',-M
M97/MM5-[[11\[AF^8<=WO#?H 3@!@6[0;)MN*=:EX HM@.<@MRH)"U4+@'-(
MRDR<,KQ11M?.:Y'C&":6*HX"^ ZLZ=M7/;_[\93])LGF)LD"DV2A2;+($-E1
MBMPZ16[![IU)45TA3B7#-9D,DV1SDV2!2;+0)%EDB.PH&?TZ&?W&^C+#8H.2
M*A[J>R"F6)>1=R1#":.J(5 .O-Q(WI]*3R/]I>DIR7I^P:8_R';3;L=S1UU_
M;.\.DV%2-6BK&II4C5JH'CGJU8YZ%SB:8W*)FU[+1S%KG,.E[WE;U<"D:MA6
M-3*D>N2F7[OI_V7_=P=_]O_;?]__&V4N?4]-DLU-D@4FR4*39)$ALJ,4#>H4
M#?Y]_Q^83(9)LKE)LL D66B2+#)$=I2,89V,X?_=_QOI+TW/\&1)=MQ^_\7^
M;U(U:*L:FE2-6J@>.3JJ'1W]O_U_U/)1S!KG<.E[WE8U,*D:ME6-#*F6;MH'
MYS[ZW/ .\S7)!**P4O3=SD#5<%Z>Q94-R?+B*&C)I&1I<;D!G #7 ]3]%6/R
MN:%/E^H#T>EO4$L#!!0    ( "T]"%>[I:(3+@(  -@$   9    >&PO=V]R
M:W-H965T<R]S:&5E=#<V+GAM;)64;V_3,!#&O\HI2&B36).FW89&&HEVF@ )
M,:UB\-9+KXTU_PGVM1G?GK.3A8+:"=XD=[:?)[]S?"Y:ZQY]C4CPI)7QLZ0F
M:J[2U%<U:N%'MD'#,VOKM"!.W2;UC4.QBB*MTCS++E(MI$G*(H[=NK*P6U+2
MX*T#O]5:N)]S5+:=)>/D>>!.;FH* VE9-&*#2Z2OS:WC+!U<5E*C\=(:<+B>
M)>_'5_-I6!\7W$ML_5X,H9(':Q]#\G$U2[( A HK"@Z"7SM<H%+!B#%^])[)
M\,D@W(^?W6]B[5S+@_"XL.J;7%$]2]XFL,*UV"JZL^T'[.LY#WZ553X^H>W7
M9@E46T]6]V(FT-)T;_'4[\.>8#P](LA[01ZYNP]%RFM!HBR<;<&%U>P6@EAJ
M5#.<-.&G+,GQK&0=E0O12!(*EF2K1SB#^?T-?&D-.E_+!DZND814_K2?.8/O
M5@M86-=8)^*VGG&F-0?1H4B)H8)U6O4 \PX@/P+P:6M&,,G>0)[EDS_E*=<R
M%)0/!>71[_R(WU(H!+L&?PRGDT\.RT,/7/E&5#A+^)![=#M,RM>OQA?9NQ?@
M)@/<Y"7W\O?.2D/(_@0GPH. !EV%ADX/ 7>6X3RP9VBR79F-)N/+(MT=0)D.
M*-/_1'D#DK>M%AP#/Z"R9H>.</4/C--#C.?Y]"_&=.^@AI[_+-Q&&@\*UZS+
M1I?\5UW71UU"MHEG]\$2=T(,:[YZT(4%/+^VEIZ3T [#95;^ E!+ P04
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M)6UH][4_8<^*#IP/\N3J<C:_7,YGPG];7IV?S:;7_N!X>CZ]/)D+ AD"R'!
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M]_M/CI^?]>"Z\26?S7]ZOOX-4$L! A0#%     @ +3T(5P=!36*!    L0
M !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M"  M/0A70M1$3.\    K @  $0              @ &O    9&]C4')O<',O
M8V]R92YX;6Q02P$"% ,4    "  M/0A7F5R<(Q &  "<)P  $P
M    @ '- 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( "T]"%>V
M5=?#NP8  ,DG   8              " @0X(  !X;"]W;W)K<VAE971S+W-H
M965T,2YX;6Q02P$"% ,4    "  M/0A75=$6>C '   G(@  &
M    @('_#@  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @
M+3T(5POI?Q$1!   ]Q$  !@              ("!918  'AL+W=O<FMS:&5E
M=',O<VAE970S+GAM;%!+ 0(4 Q0    ( "T]"%>!_/APM08  !$@   8
M          " @:P:  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4
M    "  M/0A7:WM6WX,,  ".A0  &               @(&7(0  >&PO=V]R
M:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ +3T(5U&J.=<!"0  ;CD
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M965T,3 N>&UL4$L! A0#%     @ +3T(5XSW4&IJ%@  H5X  !D
M     ("!*(0  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "T]"%>;D!#EU@\  .,[   9              "
M@>NR  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ +3T(
M5W^)'>[D!0  ,!(  !D              ("!^,(  'AL+W=O<FMS:&5E=',O
M<VAE970Q-RYX;6Q02P$"% ,4    "  M/0A7:)QC:&$$   6"@  &0
M        @($3R0  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0
M   ( "T]"%=NTM"#VR(  )=Z   9              " @:O-  !X;"]W;W)K
M<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ +3T(5T68MT=.!@  O1@
M !D              ("!O?   'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q0
M2P$"% ,4    "  M/0A7_$,I2"$#  #0"   &0              @(%"]P
M>&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( "T]"%>$XPD.
MT@,  #$0   9              " @9KZ  !X;"]W;W)K<VAE971S+W-H965T
M,C(N>&UL4$L! A0#%     @ +3T(5U7:1>7$ P  J L  !D
M ("!H_X  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    "  M
M/0A7 +5@ *4"  "<!@  &0              @(&> @$ >&PO=V]R:W-H965T
M<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( "T]"%<2V@DA]08  #0?   9
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M970R.2YX;6Q02P$"% ,4    "  M/0A7$.:UZB$%  !_*P  &0
M    @($5%P$ >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    (
M "T]"%=]V;T79@,  - /   9              " @6T< 0!X;"]W;W)K<VAE
M971S+W-H965T,S$N>&UL4$L! A0#%     @ +3T(5WDNL3/H P  LQ   !D
M             ("!"B ! 'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"
M% ,4    "  M/0A7:ZOFCM4"  #@!P  &0              @($I) $ >&PO
M=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( "T]"%>63B7)=04
M  PD   9              " @34G 0!X;"]W;W)K<VAE971S+W-H965T,S0N
M>&UL4$L! A0#%     @ +3T(5U:^][-J!   CQH  !D              ("!
MX2P! 'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    "  M/0A7
MJ0Y2'J0"   >!P  &0              @(&",0$ >&PO=V]R:W-H965T<R]S
M:&5E=#,V+GAM;%!+ 0(4 Q0    ( "T]"%?O^6:,( <   A    9
M      " @5TT 0!X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%
M  @ +3T(5_?\ 6*P!@  4SL  !D              ("!M#L! 'AL+W=O<FMS
M:&5E=',O<VAE970S."YX;6Q02P$"% ,4    "  M/0A7'+Y8-88)  !*7@
M&0              @(&;0@$ >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+
M 0(4 Q0    ( "T]"%=,JXF$4P8  '8W   9              " @5A, 0!X
M;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ +3T(5W7T\C$:
M"   OU4  !D              ("!XE(! 'AL+W=O<FMS:&5E=',O<VAE970T
M,2YX;6Q02P$"% ,4    "  M/0A7T+;B<(\&  #%-P  &0
M@($S6P$ >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( "T]
M"%>UB:3ID0,    2   9              " @?EA 0!X;"]W;W)K<VAE971S
M+W-H965T-#,N>&UL4$L! A0#%     @ +3T(5S6.#B@;!@  VB\  !D
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M=#0X+GAM;%!+ 0(4 Q0    ( "T]"%?)23-N'P@  *]3   9
M  " @9^" 0!X;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @
M+3T(5XCLY0U_!P  Y4$  !D              ("!]8H! 'AL+W=O<FMS:&5E
M=',O<VAE970U,"YX;6Q02P$"% ,4    "  M/0A7*ZF+Q=(#  !"$@  &0
M            @(&KD@$ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4
M Q0    ( "T]"%=O^,],9 0   $7   9              " @;26 0!X;"]W
M;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @ +3T(5^,#[3*I!0
MQ2<  !D              ("!3YL! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX
M;6Q02P$"% ,4    "  M/0A7.>F'LVP(  #Y7@  &0              @($O
MH0$ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( "T]"%>$
M]T6P#04  )DB   9              " @=*I 0!X;"]W;W)K<VAE971S+W-H
M965T-34N>&UL4$L! A0#%     @ +3T(5_*J/%DG!   #!0  !D
M     ("!%J\! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "T]"%>?==XI! ,  &()   9              "
M@<G! 0!X;"]W;W)K<VAE971S+W-H965T-C$N>&UL4$L! A0#%     @ +3T(
M5W H30K] @  O0L  !D              ("!!,4! 'AL+W=O<FMS:&5E=',O
M<VAE970V,BYX;6Q02P$"% ,4    "  M/0A7^3LW5E,"   ,!0  &0
M        @($XR $ >&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0
M   ( "T]"%<:7R!3;0<  &%;   9              " @<+* 0!X;"]W;W)K
M<VAE971S+W-H965T-C0N>&UL4$L! A0#%     @ +3T(5ZF0T?)G @  G04
M !D              ("!9M(! 'AL+W=O<FMS:&5E=',O<VAE970V-2YX;6Q0
M2P$"% ,4    "  M/0A7:^R/Z4,*  "L?   &0              @($$U0$
M>&PO=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+ 0(4 Q0    ( "T]"%?"J$'P
M]08  )Q!   9              " @7[? 0!X;"]W;W)K<VAE971S+W-H965T
M-C<N>&UL4$L! A0#%     @ +3T(5^B--B>K!0  "R   !D
M ("!JN8! 'AL+W=O<FMS:&5E=',O<VAE970V."YX;6Q02P$"% ,4    "  M
M/0A700,JIAT$  "Y%0  &0              @(&,[ $ >&PO=V]R:W-H965T
M<R]S:&5E=#8Y+GAM;%!+ 0(4 Q0    ( "T]"%>OPI]KF 8  $$T   9
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M970W-"YX;6Q02P$"% ,4    "  M/0A7()]XQV4#   <%0  &0
M    @(&L!@( >&PO=V]R:W-H965T<R]S:&5E=#<U+GAM;%!+ 0(4 Q0    (
M "T]"%>[I:(3+@(  -@$   9              " @4@* @!X;"]W;W)K<VAE
M971S+W-H965T-S8N>&UL4$L! A0#%     @ +3T(5Z#3<F)B!   2A\  !D
M             ("!K0P" 'AL+W=O<FMS:&5E=',O<VAE970W-RYX;6Q02P$"
M% ,4    "  M/0A7I"SCG5$#   8#0  &0              @(%&$0( >&PO
M=V]R:W-H965T<R]S:&5E=#<X+GAM;%!+ 0(4 Q0    ( "T]"%<)51+C> ,
M +47   -              "  <X4 @!X;"]S='EL97,N>&UL4$L! A0#%
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K @!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !6 %8 D1<  ,XC @    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>392</ContextCount>
  <ElementCount>354</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>117</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>13</UnitCount>
  <MyReports>
    <Report instance="xoma-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="xoma-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="xoma-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="xoma-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="xoma-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="xoma-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="xoma-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>10101 - Disclosure - Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureDescriptionOfBusiness</Role>
      <ShortName>Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="xoma-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10201 - Disclosure - Basis of Presentation and Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="xoma-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10301 - Disclosure - Condensed Consolidated Financial Statements Details</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetails</Role>
      <ShortName>Condensed Consolidated Financial Statements Details</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="xoma-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10401 - Disclosure - Licensing and Other Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureLicensingAndOtherArrangements</Role>
      <ShortName>Licensing and Other Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="xoma-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10501 - Disclosure - Royalty and Commercial Payment Purchase Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreements</Role>
      <ShortName>Royalty and Commercial Payment Purchase Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="xoma-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10601 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="xoma-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10701 - Disclosure - Lease Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureLeaseAgreements</Role>
      <ShortName>Lease Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="xoma-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10801 - Disclosure - Common Stock Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureCommonStockWarrants</Role>
      <ShortName>Common Stock Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="xoma-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10901 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="xoma-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>11001 - Disclosure - Stock Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureStockBasedCompensation</Role>
      <ShortName>Stock Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="xoma-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>11101 - Disclosure - Capital Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureCapitalStock</Role>
      <ShortName>Capital Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="xoma-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>11201 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="xoma-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>20202 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="xoma-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>30303 - Disclosure - Condensed Consolidated Financial Statements Details (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsTables</Role>
      <ShortName>Condensed Consolidated Financial Statements Details (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetails</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="xoma-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>30503 - Disclosure - Royalty and Commercial Payment Purchase Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTables</Role>
      <ShortName>Royalty and Commercial Payment Purchase Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreements</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="xoma-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>30603 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureFairValueMeasurements</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="xoma-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>30703 - Disclosure - Lease Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureLeaseAgreementsTables</Role>
      <ShortName>Lease Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureLeaseAgreements</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="xoma-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>30803 - Disclosure - Common Stock Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureCommonStockWarrantsTables</Role>
      <ShortName>Common Stock Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureCommonStockWarrants</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="xoma-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>31003 - Disclosure - Stock Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureStockBasedCompensation</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="xoma-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>31103 - Disclosure - Capital Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureCapitalStockTables</Role>
      <ShortName>Capital Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureCapitalStock</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="xoma-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>40101 - Disclosure - Description of Business - Liquidity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureDescriptionOfBusinessLiquidityDetails</Role>
      <ShortName>Description of Business - Liquidity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="xoma-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>40201 - Disclosure - Basis of Presentation and Significant Accounting Policies - Cash and Cash Equivalents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesCashAndCashEquivalentsDetails</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies - Cash and Cash Equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="xoma-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>40202 - Disclosure - Basis of Presentation and Significant Accounting Policies - Intangible Assets and Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesIntangibleAssetsAndIncomeTaxesDetails</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies - Intangible Assets and Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="xoma-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>40203 - Disclosure - Basis of Presentation and Significant Accounting Policies - Concentration of Risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesConcentrationOfRiskDetails</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies - Concentration of Risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="xoma-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>40301 - Disclosure - Condensed Consolidated Financial Statements Details - Equity Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsEquitySecuritiesDetails</Role>
      <ShortName>Condensed Consolidated Financial Statements Details - Equity Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="xoma-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>40302 - Disclosure - Condensed Consolidated Financial Statements Details - Intangible assets, net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails</Role>
      <ShortName>Condensed Consolidated Financial Statements Details - Intangible assets, net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="xoma-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>40303 - Disclosure - Condensed Consolidated Financial Statements Details - Accrued and Other Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsAccruedAndOtherLiabilitiesDetails</Role>
      <ShortName>Condensed Consolidated Financial Statements Details - Accrued and Other Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="xoma-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>40304 - Disclosure - Condensed Consolidated Financial Statements Details - Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsNetLossPerShareDetails</Role>
      <ShortName>Condensed Consolidated Financial Statements Details - Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="xoma-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>40305 - Disclosure - Condensed Consolidated Financial Statements Details - Outstanding Securities Considered Anti-Dilutive (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsOutstandingSecuritiesConsideredAntiDilutiveDetails</Role>
      <ShortName>Condensed Consolidated Financial Statements Details - Outstanding Securities Considered Anti-Dilutive (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="xoma-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>40306 - Disclosure - Condensed Consolidated Financial Statements Details - Arbitration Proceeding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsArbitrationProceedingDetails</Role>
      <ShortName>Condensed Consolidated Financial Statements Details - Arbitration Proceeding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="xoma-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>40401 - Disclosure - Licensing and Other Arrangements - ObsEva (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails</Role>
      <ShortName>Licensing and Other Arrangements - ObsEva (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="xoma-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>40402 - Disclosure - Licensing and Other Arrangements - Novartis - NIS793 (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details</Role>
      <ShortName>Licensing and Other Arrangements - Novartis - NIS793 (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="xoma-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>40403 - Disclosure - Licensing and Other Arrangements - Novartis - VPM087 (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details</Role>
      <ShortName>Licensing and Other Arrangements - Novartis - VPM087 (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="xoma-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>40404 - Disclosure - Licensing and Other Arrangements - Takeda (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails</Role>
      <ShortName>Licensing and Other Arrangements - Takeda (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="xoma-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>40405 - Disclosure - Licensing and Other Arrangements - Rezolute (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails</Role>
      <ShortName>Licensing and Other Arrangements - Rezolute (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="xoma-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>40406 - Disclosure - Licensing and Other Arrangements - Janssen Biotech (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails</Role>
      <ShortName>Licensing and Other Arrangements - Janssen Biotech (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="xoma-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>40407 - Disclosure - Licensing and Other Arrangements - Affimed (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsAffimedDetails</Role>
      <ShortName>Licensing and Other Arrangements - Affimed (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="xoma-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>40408 - Disclosure - Licensing and Other Arrangements - Sale of Future Revenue Streams (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails</Role>
      <ShortName>Licensing and Other Arrangements - Sale of Future Revenue Streams (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="xoma-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>40501 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Summary (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryDetails</Role>
      <ShortName>Royalty and Commercial Payment Purchase Agreements - Summary (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="xoma-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>40502 - Disclosure - Royalty and Commercial Payment Purchase Agreements - LadRx (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails</Role>
      <ShortName>Royalty and Commercial Payment Purchase Agreements - LadRx (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="xoma-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>40503 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Aptevo (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails</Role>
      <ShortName>Royalty and Commercial Payment Purchase Agreements - Aptevo (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="xoma-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>40504 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Agenus (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails</Role>
      <ShortName>Royalty and Commercial Payment Purchase Agreements - Agenus (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="xoma-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>40505 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Bioasis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails</Role>
      <ShortName>Royalty and Commercial Payment Purchase Agreements - Bioasis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="xoma-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>40506 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Aronora (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails</Role>
      <ShortName>Royalty and Commercial Payment Purchase Agreements - Aronora (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="xoma-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>40507 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Palo (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails</Role>
      <ShortName>Royalty and Commercial Payment Purchase Agreements - Palo (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="xoma-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>40508 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Viracta (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails</Role>
      <ShortName>Royalty and Commercial Payment Purchase Agreements - Viracta (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="xoma-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>40509 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Kuros (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails</Role>
      <ShortName>Royalty and Commercial Payment Purchase Agreements - Kuros (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="xoma-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>40510 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Affitech (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails</Role>
      <ShortName>Royalty and Commercial Payment Purchase Agreements - Affitech (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="xoma-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>40511 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Summary of Royalty Receivable Activities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails</Role>
      <ShortName>Royalty and Commercial Payment Purchase Agreements - Summary of Royalty Receivable Activities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="xoma-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>40601 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Carried at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Financial Assets and Liabilities Carried at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="xoma-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>40602 - Disclosure - Fair Value Measurements - Equity Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureFairValueMeasurementsEquitySecuritiesDetails</Role>
      <ShortName>Fair Value Measurements - Equity Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="xoma-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>40603 - Disclosure - Fair Value Measurements - Contingent Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails</Role>
      <ShortName>Fair Value Measurements - Contingent Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="xoma-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>40701 - Disclosure - Lease Agreements - Leased facilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureLeaseAgreementsLeasedFacilitiesDetails</Role>
      <ShortName>Lease Agreements - Leased facilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="xoma-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>40702 - Disclosure - Lease Agreements - Lease costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureLeaseAgreementsLeaseCostsDetails</Role>
      <ShortName>Lease Agreements - Lease costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="xoma-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>40703 - Disclosure - Lease Agreements - Additional information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureLeaseAgreementsAdditionalInformationDetails</Role>
      <ShortName>Lease Agreements - Additional information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="xoma-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>40801 - Disclosure - Common Stock Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureCommonStockWarrantsDetails</Role>
      <ShortName>Common Stock Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureCommonStockWarrantsTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="xoma-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>40901 - Disclosure - Commitments and Contingencies - Collaborative Agreements, Royalties and Milestone Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesCollaborativeAgreementsRoyaltiesAndMilestonePaymentsDetails</Role>
      <ShortName>Commitments and Contingencies - Collaborative Agreements, Royalties and Milestone Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="xoma-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>40902 - Disclosure - Commitments and Contingencies - Contingent Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails</Role>
      <ShortName>Commitments and Contingencies - Contingent Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="xoma-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>41001 - Disclosure - Stock Based Compensation - ESPP (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureStockBasedCompensationEsppDetails</Role>
      <ShortName>Stock Based Compensation - ESPP (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="xoma-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>41002 - Disclosure - Stock Based Compensation - 2010 Plan and Inducement Awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureStockBasedCompensation2010PlanAndInducementAwardsDetails</Role>
      <ShortName>Stock Based Compensation - 2010 Plan and Inducement Awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="xoma-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>41003 - Disclosure - Stock Based Compensation - FV Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureStockBasedCompensationFvAssumptionsDetails</Role>
      <ShortName>Stock Based Compensation - FV Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="xoma-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>41004 - Disclosure - Stock Based Compensation - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails</Role>
      <ShortName>Stock Based Compensation - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="xoma-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>41005 - Disclosure - Stock Based Compensation - Performance Stock Unit Awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsDetails</Role>
      <ShortName>Stock Based Compensation - Performance Stock Unit Awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="xoma-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>41006 - Disclosure - Stock Based Compensation - Performance Stock Unit Awards Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsFairValueDetails</Role>
      <ShortName>Stock Based Compensation - Performance Stock Unit Awards Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="xoma-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>41007 - Disclosure - Stock Based Compensation - Performance Stock Unit Awards Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsActivityDetails</Role>
      <ShortName>Stock Based Compensation - Performance Stock Unit Awards Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="xoma-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>41008 - Disclosure - Stock Based Compensation - Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock Based Compensation - Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="xoma-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>41009 - Disclosure - Stock Based Compensation - Employee Retention Bonus (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureStockBasedCompensationEmployeeRetentionBonusDetails</Role>
      <ShortName>Stock Based Compensation - Employee Retention Bonus (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="xoma-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>41010 - Disclosure - Stock Based Compensation - CEO Departure and Continuity Incentive (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureStockBasedCompensationCeoDepartureAndContinuityIncentiveDetails</Role>
      <ShortName>Stock Based Compensation - CEO Departure and Continuity Incentive (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="xoma-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>41101 - Disclosure - Capital Stock - Dividends (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails</Role>
      <ShortName>Capital Stock - Dividends (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="xoma-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>41102 - Disclosure - Capital Stock - BVF Ownership (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails</Role>
      <ShortName>Capital Stock - BVF Ownership (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="xoma-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>41103 - Disclosure - Capital Stock - ATM Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails</Role>
      <ShortName>Capital Stock - ATM Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="xoma-20230630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>41201 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.xoma.com/role/DisclosureIncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.xoma.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>78</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 10 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:PreferredStockDividendsPerShareCashPaid, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage, us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 -  xoma-20230630x10q.htm 9</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Not-Referenced] WARN: 2 fact(s) appearing in ix:hidden were not referenced by any -sec-ix-hidden style property: us-gaap:CommitmentsAndContingencies -  xoma-20230630x10q.htm 9</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="xoma-20230630x10q.htm">xoma-20230630x10q.htm</File>
    <File>xoma-20230630.xsd</File>
    <File>xoma-20230630_cal.xml</File>
    <File>xoma-20230630_def.xml</File>
    <File>xoma-20230630_lab.xml</File>
    <File>xoma-20230630_pre.xml</File>
    <File>xoma-20230630xex10d3.htm</File>
    <File>xoma-20230630xex10d4.htm</File>
    <File>xoma-20230630xex31d1.htm</File>
    <File>xoma-20230630xex31d2.htm</File>
    <File>xoma-20230630xex32d1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="737">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="36">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>97
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "xoma-20230630x10q.htm": {
   "axisCustom": 0,
   "axisStandard": 31,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 737,
    "http://xbrl.sec.gov/dei/2023": 36
   },
   "contextCount": 392,
   "dts": {
    "calculationLink": {
     "local": [
      "xoma-20230630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "xoma-20230630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "xoma-20230630x10q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "xoma-20230630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "xoma-20230630_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "xoma-20230630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    }
   },
   "elementCount": 609,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2023": 16,
    "http://xbrl.sec.gov/dei/2023": 5,
    "total": 21
   },
   "keyCustom": 122,
   "keyStandard": 232,
   "memberCustom": 81,
   "memberStandard": 30,
   "nsprefix": "xoma",
   "nsuri": "http://www.xoma.com/20230630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.xoma.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "xoma:LicensingAndOtherArrangementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10401 - Disclosure - Licensing and Other Arrangements",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangements",
     "shortName": "Licensing and Other Arrangements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "xoma:LicensingAndOtherArrangementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "xoma:RoyaltyPurchaseAgreementTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10501 - Disclosure - Royalty and Commercial Payment Purchase Agreements",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreements",
     "shortName": "Royalty and Commercial Payment Purchase Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "xoma:RoyaltyPurchaseAgreementTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10601 - Disclosure - Fair Value Measurements",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.xoma.com/role/DisclosureFairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "xoma:LeaseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10701 - Disclosure - Lease Agreements",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.xoma.com/role/DisclosureLeaseAgreements",
     "shortName": "Lease Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "xoma:LeaseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "xoma:CommonStockWarrantDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10801 - Disclosure - Common Stock Warrants",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.xoma.com/role/DisclosureCommonStockWarrants",
     "shortName": "Common Stock Warrants",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "xoma:CommonStockWarrantDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10901 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.xoma.com/role/DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11001 - Disclosure - Stock Based Compensation",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.xoma.com/role/DisclosureStockBasedCompensation",
     "shortName": "Stock Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11101 - Disclosure - Capital Stock",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.xoma.com/role/DisclosureCapitalStock",
     "shortName": "Capital Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11201 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.xoma.com/role/DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "20202 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "19",
     "role": "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies",
     "shortName": "Basis of Presentation and Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:EquitySecuritiesFvNi",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30303 - Disclosure - Condensed Consolidated Financial Statements Details (Tables)",
     "menuCat": "Tables",
     "order": "20",
     "role": "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsTables",
     "shortName": "Condensed Consolidated Financial Statements Details (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "xoma:ScheduleOfRoyaltyAndCommercialPaymentReceivablesActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30503 - Disclosure - Royalty and Commercial Payment Purchase Agreements (Tables)",
     "menuCat": "Tables",
     "order": "21",
     "role": "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTables",
     "shortName": "Royalty and Commercial Payment Purchase Agreements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "xoma:ScheduleOfRoyaltyAndCommercialPaymentReceivablesActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30603 - Disclosure - Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://www.xoma.com/role/DisclosureFairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "xoma:LeaseDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30703 - Disclosure - Lease Agreements (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://www.xoma.com/role/DisclosureLeaseAgreementsTables",
     "shortName": "Lease Agreements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "xoma:LeaseDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "xoma:CommonStockWarrantDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30803 - Disclosure - Common Stock Warrants (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://www.xoma.com/role/DisclosureCommonStockWarrantsTables",
     "shortName": "Common Stock Warrants (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "xoma:CommonStockWarrantDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31003 - Disclosure - Stock Based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://www.xoma.com/role/DisclosureStockBasedCompensationTables",
     "shortName": "Stock Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DividendsDeclaredTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31103 - Disclosure - Capital Stock (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.xoma.com/role/DisclosureCapitalStockTables",
     "shortName": "Capital Stock (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DividendsDeclaredTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40101 - Disclosure - Description of Business - Liquidity (Details)",
     "menuCat": "Details",
     "order": "27",
     "role": "http://www.xoma.com/role/DisclosureDescriptionOfBusinessLiquidityDetails",
     "shortName": "Description of Business - Liquidity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40201 - Disclosure - Basis of Presentation and Significant Accounting Policies - Cash and Cash Equivalents (Details)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesCashAndCashEquivalentsDetails",
     "shortName": "Basis of Presentation and Significant Accounting Policies - Cash and Cash Equivalents (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IntangibleAssetsFiniteLivedPolicy",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_11_21_2022_To_11_21_2022_dk2CWh67HkeKPZD69Opgyw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40202 - Disclosure - Basis of Presentation and Significant Accounting Policies - Intangible Assets and Income Taxes (Details)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesIntangibleAssetsAndIncomeTaxesDetails",
     "shortName": "Basis of Presentation and Significant Accounting Policies - Intangible Assets and Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ReceivablesLongTermContractsOrPrograms",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40203 - Disclosure - Basis of Presentation and Significant Accounting Policies - Concentration of Risk (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesConcentrationOfRiskDetails",
     "shortName": "Basis of Presentation and Significant Accounting Policies - Concentration of Risk (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ReceivablesLongTermContractsOrPrograms",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EquitySecuritiesFvNiRealizedGainLoss",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40301 - Disclosure - Condensed Consolidated Financial Statements Details - Equity Securities (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsEquitySecuritiesDetails",
     "shortName": "Condensed Consolidated Financial Statements Details - Equity Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EquitySecuritiesFVNINoncurrent",
       "p",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "As_Of_12_31_2022_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_xoma_RezoluteIncMember_OFKp4An1GUS4-brDAQB8ew",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:EquitySecuritiesFVNINoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40302 - Disclosure - Condensed Consolidated Financial Statements Details - Intangible assets, net (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails",
     "shortName": "Condensed Consolidated Financial Statements Details - Intangible assets, net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "xoma:AccruedSalariesAndEmployeeBenefitsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40303 - Disclosure - Condensed Consolidated Financial Statements Details - Accrued and Other Liabilities (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsAccruedAndOtherLiabilitiesDetails",
     "shortName": "Condensed Consolidated Financial Statements Details - Accrued and Other Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "xoma:AccruedSalariesAndEmployeeBenefitsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40304 - Disclosure - Condensed Consolidated Financial Statements Details - Net Loss Per Share (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsNetLossPerShareDetails",
     "shortName": "Condensed Consolidated Financial Statements Details - Net Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_4_1_2023_To_6_30_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_709bNt4Pc0ah6gEtj2ui5A",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:PreferredStockDividendsIncomeStatementImpact",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40305 - Disclosure - Condensed Consolidated Financial Statements Details - Outstanding Securities Considered Anti-Dilutive (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsOutstandingSecuritiesConsideredAntiDilutiveDetails",
     "shortName": "Condensed Consolidated Financial Statements Details - Outstanding Securities Considered Anti-Dilutive (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_6_1_2021_To_6_30_2021_xtjjCBFLBUi_Ojs50RRq5w",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "xoma:NumberOfArbitrationProceedingsInitiated",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_item_ZJDcTjbqbUC2tIGJY9M-pg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40306 - Disclosure - Condensed Consolidated Financial Statements Details - Arbitration Proceeding (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsArbitrationProceedingDetails",
     "shortName": "Condensed Consolidated Financial Statements Details - Arbitration Proceeding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_6_1_2021_To_6_30_2021_xtjjCBFLBUi_Ojs50RRq5w",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "xoma:NumberOfArbitrationProceedingsInitiated",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_item_ZJDcTjbqbUC2tIGJY9M-pg",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "xoma:ChangesInEstimatedFairValueOfContingentConsideration",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40401 - Disclosure - Licensing and Other Arrangements - ObsEva (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails",
     "shortName": "Licensing and Other Arrangements - ObsEva (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ContractWithCustomerAssetNet",
       "us-gaap:ContractWithCustomerLiability",
       "us-gaap:ContractWithCustomerLiability",
       "p",
       "xoma:LicensingAndOtherArrangementsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_ObsevaMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_YH_2bboTUkyRnEvX6o0V4w",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:ContractWithCustomerAssetNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40402 - Disclosure - Licensing and Other Arrangements - Novartis - NIS793 (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details",
     "shortName": "Licensing and Other Arrangements - Novartis - NIS793 (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_10_1_2020_To_10_31_2020_us-gaap_DebtInstrumentAxis_xoma_NovartisNoteMember_pUHf37jdqkO7GsZ6tJj4dA",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:DebtInstrumentIncreaseDecreaseForPeriodNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40403 - Disclosure - Licensing and Other Arrangements - Novartis - VPM087 (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details",
     "shortName": "Licensing and Other Arrangements - Novartis - VPM087 (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_8_24_2017_To_8_24_2017_srt_CounterpartyNameAxis_xoma_NovartisPharmaAGMember_us-gaap_TypeOfArrangementAxis_xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember_niKO_iOCski7xDCZeqBm0g",
      "decimals": "-5",
      "lang": null,
      "name": "xoma:LicenseAgreementTransactionPrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40404 - Disclosure - Licensing and Other Arrangements - Takeda (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails",
     "shortName": "Licensing and Other Arrangements - Takeda (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_11_1_2020_To_11_30_2020_srt_CounterpartyNameAxis_xoma_TakedaPharmaceuticalCompanyLimitedMember_us-gaap_TypeOfArrangementAxis_xoma_CollaborationAgreementMember_adu7bNhKOUupBKfuF3sIbA",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40405 - Disclosure - Licensing and Other Arrangements - Rezolute (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails",
     "shortName": "Licensing and Other Arrangements - Rezolute (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_12_6_2017_To_12_31_2020_srt_CounterpartyNameAxis_xoma_RezoluteIncMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember_mT3lLicYEUilKoGSWcL_yw",
      "decimals": "-5",
      "lang": null,
      "name": "xoma:LicenseAgreementConsiderationReceivedAchievementOfFinancingActivities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40406 - Disclosure - Licensing and Other Arrangements - Janssen Biotech (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails",
     "shortName": "Licensing and Other Arrangements - Janssen Biotech (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_8_1_2019_To_8_31_2019_srt_CounterpartyNameAxis_xoma_JanssenBiotechInc.Member_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_7abmyDQDN0asJM3WaMklhA",
      "decimals": "-5",
      "lang": null,
      "name": "xoma:ProceedsFromUpfrontPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40407 - Disclosure - Licensing and Other Arrangements - Affimed (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsAffimedDetails",
     "shortName": "Licensing and Other Arrangements - Affimed (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ContractWithCustomerAssetNet",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "As_Of_12_31_2022_srt_CounterpartyNameAxis_xoma_AffimedMember_us-gaap_TypeOfArrangementAxis_xoma_LicenseAgreementMember_U6vKLThuqke8EfnRv8dUJQ",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:ContractWithCustomerAssetNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncreaseDecreaseInDeferredRevenue",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40408 - Disclosure - Licensing and Other Arrangements - Sale of Future Revenue Streams (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails",
     "shortName": "Licensing and Other Arrangements - Sale of Future Revenue Streams (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_12_21_2016_To_12_21_2016_srt_CounterpartyNameAxis_xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyInterestAcquisitionAgreementsMember_u-wkh1XOjEKGxjaNdt0ZHA",
      "decimals": "INF",
      "lang": null,
      "name": "xoma:NumberOfRoyaltyInterestAcquisitionAgreements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_agreement_8WD-ZASWEUe8fofDOT9VGw",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "xoma:RightsReceivableCurrent",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40501 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Summary (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryDetails",
     "shortName": "Royalty and Commercial Payment Purchase Agreements - Summary (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40502 - Disclosure - Royalty and Commercial Payment Purchase Agreements - LadRx (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails",
     "shortName": "Royalty and Commercial Payment Purchase Agreements - LadRx (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "As_Of_6_21_2023_us-gaap_TypeOfArrangementAxis_xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember_1-O-Wc5qm0GpfWvtLfA5QQ",
      "decimals": "-5",
      "lang": null,
      "name": "xoma:LongTermRightsReceivableNonCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "xoma:LongTermRightsReceivableNonCurrent",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40503 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Aptevo (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails",
     "shortName": "Royalty and Commercial Payment Purchase Agreements - Aptevo (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "As_Of_3_29_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_BVEo8QgBSkmfz1ozUkIwXw",
      "decimals": "-5",
      "lang": null,
      "name": "xoma:MilestonesReceivableMaximum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40504 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Agenus (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails",
     "shortName": "Royalty and Commercial Payment Purchase Agreements - Agenus (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_11_1_2020_To_11_30_2020_dei_LegalEntityAxis_xoma_AgenusIncMember_srt_ProductOrServiceAxis_xoma_MerckImmunoOncologyProductMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_gu6YuHtIt0y_GOYnfbfPoA",
      "decimals": "-5",
      "lang": null,
      "name": "xoma:MilestoneAchieved",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40505 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Bioasis (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails",
     "shortName": "Royalty and Commercial Payment Purchase Agreements - Bioasis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_6_20_2023_To_6_20_2023_srt_CounterpartyNameAxis_xoma_BioasisTechnologiesIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementAndSecondRoyaltyPurchaseAgreementMember_Eqxr4CXcuE-FFTbVv-ujhg",
      "decimals": "-5",
      "lang": null,
      "name": "xoma:ImpairmentOfLongTermRightsReceivableNonCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_6rQbM7sQNky8O85-NJM6Kw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_1_1_2022_To_3_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Y8pSKqQVN0qvZ3Xp6DQmKg",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40506 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Aronora (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails",
     "shortName": "Royalty and Commercial Payment Purchase Agreements - Aronora (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "As_Of_4_7_2019_srt_CounterpartyNameAxis_xoma_AronoraIncMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_HVql9Pa7t0Olldm6QQhOFg",
      "decimals": "INF",
      "lang": null,
      "name": "xoma:AgreementDrugCandidatesNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_item_ZJDcTjbqbUC2tIGJY9M-pg",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40507 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Palo (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails",
     "shortName": "Royalty and Commercial Payment Purchase Agreements - Palo (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "As_Of_9_26_2019_srt_CounterpartyNameAxis_xoma_PalobiofarmaSLMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_zT4QsAb7u0eLPQ9twhpAFA",
      "decimals": "INF",
      "lang": null,
      "name": "xoma:AgreementDrugCandidatesNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_item_ZJDcTjbqbUC2tIGJY9M-pg",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40508 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Viracta (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails",
     "shortName": "Royalty and Commercial Payment Purchase Agreements - Viracta (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "As_Of_3_22_2021_srt_CounterpartyNameAxis_xoma_ViractaTherapeuticsInc.Member_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_46O6ygYv-kiSXEivuByfuw",
      "decimals": "INF",
      "lang": null,
      "name": "xoma:AgreementDrugCandidatesNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_item_ZJDcTjbqbUC2tIGJY9M-pg",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40509 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Kuros (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails",
     "shortName": "Royalty and Commercial Payment Purchase Agreements - Kuros (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_7_14_2021_To_7_14_2021_srt_CounterpartyNameAxis_xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember_us-gaap_TypeOfArrangementAxis_xoma_RoyaltyPurchaseAgreementMember_s0z0PXoS5k-BNomvO5_j6g",
      "decimals": "INF",
      "lang": null,
      "name": "xoma:RoyaltyReceivablePercentageOnNetSales",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40510 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Affitech (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
     "shortName": "Royalty and Commercial Payment Purchase Agreements - Affitech (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_10_6_2021_To_10_6_2021_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_7mFvjte_dEevmb4jPsGqCg",
      "decimals": "-5",
      "lang": null,
      "name": "xoma:PaymentOfConsiderationUnderAgreementsInvestingActivities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "xoma:RightsReceivableCurrent",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40511 - Disclosure - Royalty and Commercial Payment Purchase Agreements - Summary of Royalty Receivable Activities (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails",
     "shortName": "Royalty and Commercial Payment Purchase Agreements - Summary of Royalty Receivable Activities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "xoma:ScheduleOfRoyaltyAndCommercialPaymentReceivablesActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_AffitechResearchAsMember_WO4UYUGV_02Sv2V6Sl4utw",
      "decimals": "-3",
      "lang": null,
      "name": "xoma:ReceiptOfRoyaltyAndCommercialPaymentReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "As_Of_6_30_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_wkmIyE0jUkOmFM4P8qQX2A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40601 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Carried at Fair Value on Recurring Basis (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails",
     "shortName": "Fair Value Measurements - Financial Assets and Liabilities Carried at Fair Value on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "As_Of_6_30_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_wkmIyE0jUkOmFM4P8qQX2A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_BSWfJSEpmEGBgXlGS4MC4w",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:EquitySecuritiesFvNiMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40602 - Disclosure - Fair Value Measurements - Equity Securities (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.xoma.com/role/DisclosureFairValueMeasurementsEquitySecuritiesDetails",
     "shortName": "Fair Value Measurements - Equity Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "As_Of_6_30_2023_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_BSWfJSEpmEGBgXlGS4MC4w",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:EquitySecuritiesFvNiMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "xoma:ChangesInEstimatedFairValueOfContingentConsideration",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40603 - Disclosure - Fair Value Measurements - Contingent Consideration (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails",
     "shortName": "Fair Value Measurements - Contingent Consideration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseLiabilityCurrent",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40701 - Disclosure - Lease Agreements - Leased facilities (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.xoma.com/role/DisclosureLeaseAgreementsLeasedFacilitiesDetails",
     "shortName": "Lease Agreements - Leased facilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "xoma:LeaseDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_xoma_LeasedFacilitiesEmeryvilleCaliforniaMember_j4Za8qhjGEunE9GIsiSNhg",
      "decimals": "INF",
      "lang": null,
      "name": "xoma:OperatingLeasesNumberOfLeasedFacilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_facility_xUSd_1xCIUaR1gnI0x8O9w",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "xoma:LeaseDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40702 - Disclosure - Lease Agreements - Lease costs (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.xoma.com/role/DisclosureLeaseAgreementsLeaseCostsDetails",
     "shortName": "Lease Agreements - Lease costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "xoma:LeaseDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "xoma:LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock",
       "xoma:LeaseDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40703 - Disclosure - Lease Agreements - Additional information (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://www.xoma.com/role/DisclosureLeaseAgreementsAdditionalInformationDetails",
     "shortName": "Lease Agreements - Additional information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "xoma:LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock",
       "xoma:LeaseDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "xoma:CommonStockWarrantDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40801 - Disclosure - Common Stock Warrants (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://www.xoma.com/role/DisclosureCommonStockWarrantsDetails",
     "shortName": "Common Stock Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "xoma:CommonStockWarrantDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "xoma:ContractualObligationEstimatedMilestonePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40901 - Disclosure - Commitments and Contingencies - Collaborative Agreements, Royalties and Milestone Payments (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesCollaborativeAgreementsRoyaltiesAndMilestonePaymentsDetails",
     "shortName": "Commitments and Contingencies - Collaborative Agreements, Royalties and Milestone Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "xoma:ContractualObligationEstimatedMilestonePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "xoma:ContingentConsiderationUnderPurchaseAgreements",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40902 - Disclosure - Commitments and Contingencies - Contingent Consideration (Details)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails",
     "shortName": "Commitments and Contingencies - Contingent Consideration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_srt_CounterpartyNameAxis_xoma_AptevoMember_us-gaap_TypeOfArrangementAxis_xoma_CommercialPaymentPurchaseAgreementMember_qKDIT7AlPEumlQb_qY84ng",
      "decimals": "-3",
      "lang": null,
      "name": "xoma:PaymentOfContingentConsiderationUnderPurchaseAgreements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_VZ3-yhq8FE25TUInBBrGZQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "xoma:PercentageOfCompensationOfEligibleEmployeesToPurchaseSharesOfEntityCommonStockAtDiscountThroughPayrollDeductions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41001 - Disclosure - Stock Based Compensation - ESPP (Details)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://www.xoma.com/role/DisclosureStockBasedCompensationEsppDetails",
     "shortName": "Stock Based Compensation - ESPP (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_us-gaap_PlanNameAxis_xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember_VZ3-yhq8FE25TUInBBrGZQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "xoma:PercentageOfCompensationOfEligibleEmployeesToPurchaseSharesOfEntityCommonStockAtDiscountThroughPayrollDeductions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41002 - Disclosure - Stock Based Compensation - 2010 Plan and Inducement Awards (Details)",
     "menuCat": "Details",
     "order": "66",
     "role": "http://www.xoma.com/role/DisclosureStockBasedCompensation2010PlanAndInducementAwardsDetails",
     "shortName": "Stock Based Compensation - 2010 Plan and Inducement Awards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_-fCNRL3sJk2hkKbH29QN5A",
      "decimals": null,
      "lang": "en-US",
      "name": "xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41003 - Disclosure - Stock Based Compensation - FV Assumptions (Details)",
     "menuCat": "Details",
     "order": "67",
     "role": "http://www.xoma.com/role/DisclosureStockBasedCompensationFvAssumptionsDetails",
     "shortName": "Stock Based Compensation - FV Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_us-gaap_PlanNameAxis_xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember_bltKeBtI3UmSSHjoiD4k4Q",
      "decimals": "2",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41004 - Disclosure - Stock Based Compensation - Stock Option Activity (Details)",
     "menuCat": "Details",
     "order": "68",
     "role": "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails",
     "shortName": "Stock Based Compensation - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_5_1_2023_To_5_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_Cf49xhpajkCvIANGtFeezA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41005 - Disclosure - Stock Based Compensation - Performance Stock Unit Awards (Details)",
     "menuCat": "Details",
     "order": "69",
     "role": "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsDetails",
     "shortName": "Stock Based Compensation - Performance Stock Unit Awards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "As_Of_5_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_DFqUQBhRC0ifvbBc0bGVmg",
      "decimals": "INF",
      "lang": null,
      "name": "xoma:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfHurdles.",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_item_ZJDcTjbqbUC2tIGJY9M-pg",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10101 - Disclosure - Description of Business",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://www.xoma.com/role/DisclosureDescriptionOfBusiness",
     "shortName": "Description of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_5_1_2023_To_5_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_Cf49xhpajkCvIANGtFeezA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41006 - Disclosure - Stock Based Compensation - Performance Stock Unit Awards Fair Value (Details)",
     "menuCat": "Details",
     "order": "70",
     "role": "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsFairValueDetails",
     "shortName": "Stock Based Compensation - Performance Stock Unit Awards Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "As_Of_5_31_2023_srt_StatementScenarioAxis_xoma_StockPriceHurdlesOfDollar30Member_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_k94cSi-Zwk2VBrdcAKVvmA",
      "decimals": "2",
      "lang": null,
      "name": "us-gaap:SharePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_5_1_2023_To_5_31_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_Cf49xhpajkCvIANGtFeezA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41007 - Disclosure - Stock Based Compensation - Performance Stock Unit Awards Activity (Details)",
     "menuCat": "Details",
     "order": "71",
     "role": "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsActivityDetails",
     "shortName": "Stock Based Compensation - Performance Stock Unit Awards Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_us-gaap_AwardTypeAxis_xoma_PerformanceStockUnitsMember_pg3TjcmZJki500S9VQ6N9A",
      "decimals": "2",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_4_1_2023_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember__apnO9afP0Citfd-cUI30g",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41008 - Disclosure - Stock Based Compensation - Stock-based Compensation Expense (Details)",
     "menuCat": "Details",
     "order": "72",
     "role": "http://www.xoma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails",
     "shortName": "Stock Based Compensation - Stock-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_4_1_2023_To_6_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember__apnO9afP0Citfd-cUI30g",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "As_Of_6_30_2023_GAgzVWCAbUaTsZC_Mtl8lQ",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "xoma:AccruedRetentionBonus",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41009 - Disclosure - Stock Based Compensation - Employee Retention Bonus (Details)",
     "menuCat": "Details",
     "order": "73",
     "role": "http://www.xoma.com/role/DisclosureStockBasedCompensationEmployeeRetentionBonusDetails",
     "shortName": "Stock Based Compensation - Employee Retention Bonus (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "As_Of_12_31_2022_bVJzn-iVa06haEKGyyfGQg",
      "decimals": "-5",
      "lang": null,
      "name": "xoma:AccruedRetentionBonus",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "As_Of_12_31_2022_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerRetiredMember_YyRGgFdv-E6X0DuiU_Edmg",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "xoma:AccruedCompensationContinuityIncentive",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41010 - Disclosure - Stock Based Compensation - CEO Departure and Continuity Incentive (Details)",
     "menuCat": "Details",
     "order": "74",
     "role": "http://www.xoma.com/role/DisclosureStockBasedCompensationCeoDepartureAndContinuityIncentiveDetails",
     "shortName": "Stock Based Compensation - CEO Departure and Continuity Incentive (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "As_Of_12_31_2022_srt_TitleOfIndividualAxis_xoma_ChiefExecutiveOfficerRetiredMember_YyRGgFdv-E6X0DuiU_Edmg",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "xoma:AccruedCompensationContinuityIncentive",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DividendsDeclaredTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_5_17_2023_To_5_17_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_zIuocAB-x0yti_KN6IbA-Q",
      "decimals": "5",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockDividendsPerShareDeclared",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41101 - Disclosure - Capital Stock - Dividends (Details)",
     "menuCat": "Details",
     "order": "75",
     "role": "http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails",
     "shortName": "Capital Stock - Dividends (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DividendsDeclaredTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_5_17_2023_To_5_17_2023_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_zIuocAB-x0yti_KN6IbA-Q",
      "decimals": "5",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockDividendsPerShareDeclared",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_VMV8sH0P_0GYxIwovkmcsg",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "As_Of_6_30_2023_dei_LegalEntityAxis_xoma_BiotechnologyValueFundLPMember_srt_OwnershipAxis_xoma_XomaCorporationMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_OPWHgi5OoUOvpKGH_7ayMg",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:MinorityInterestOwnershipPercentageByParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41102 - Disclosure - Capital Stock - BVF Ownership (Details)",
     "menuCat": "Details",
     "order": "76",
     "role": "http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails",
     "shortName": "Capital Stock - BVF Ownership (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "As_Of_6_30_2023_dei_LegalEntityAxis_xoma_BiotechnologyValueFundLPMember_srt_OwnershipAxis_xoma_XomaCorporationMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_OPWHgi5OoUOvpKGH_7ayMg",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:MinorityInterestOwnershipPercentageByParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_vv5L0a-ZWE-oRPt6EzdAwQ",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_12_18_2018_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_TwoThousandEighteenAtMarketAgreementMember_7W6KMaqUekmIWDswlSxORw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41103 - Disclosure - Capital Stock - ATM Agreements (Details)",
     "menuCat": "Details",
     "order": "77",
     "role": "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails",
     "shortName": "Capital Stock - ATM Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_12_18_2018_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_xoma_TwoThousandEighteenAtMarketAgreementMember_7W6KMaqUekmIWDswlSxORw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_FLWQNVjt00OuAD6YKin68Q",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations",
       "us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations",
       "us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41201 - Disclosure - Income Taxes (Details)",
     "menuCat": "Details",
     "order": "78",
     "role": "http://www.xoma.com/role/DisclosureIncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations",
       "us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations",
       "us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_4_1_2023_To_6_30_2023_miTKj9Kn7Ea1zxmzpLJjsg",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_n432h8N1M0GLClB4xDwFQw",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10201 - Disclosure - Basis of Presentation and Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies",
     "shortName": "Basis of Presentation and Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10301 - Disclosure - Condensed Consolidated Financial Statements Details",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetails",
     "shortName": "Condensed Consolidated Financial Statements Details",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "xoma-20230630x10q.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_Ln5KcK3OgkmELTW_OpDZiw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 117,
   "tag": {
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AdrMember": {
     "auth_ref": [
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "American Depositary Receipt (or American Depositary Share, ADS).",
        "label": "Series B Depositary Shares"
       }
      }
     },
     "localname": "AdrMember",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails",
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line1"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address Address Line2"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock Shares Outstanding",
        "verboseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r143",
      "r144",
      "r228",
      "r244",
      "r391",
      "r552",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsAffimedDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r626",
      "r691"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Directors"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensation2010PlanAndInducementAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [
      "r194",
      "r195",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsEquitySecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [
      "r695",
      "r696",
      "r697",
      "r698"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r193",
      "r568",
      "r638",
      "r688",
      "r689"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Major Customers [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesConcentrationOfRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r212",
      "r213",
      "r214",
      "r215",
      "r279",
      "r396",
      "r426",
      "r458",
      "r459",
      "r513",
      "r516",
      "r520",
      "r521",
      "r523",
      "r544",
      "r545",
      "r559",
      "r565",
      "r572",
      "r580",
      "r636",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r212",
      "r213",
      "r214",
      "r215",
      "r279",
      "r396",
      "r426",
      "r458",
      "r459",
      "r513",
      "r516",
      "r520",
      "r521",
      "r523",
      "r544",
      "r545",
      "r559",
      "r565",
      "r572",
      "r580",
      "r636",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r193",
      "r568",
      "r638",
      "r688",
      "r689"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesConcentrationOfRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r190",
      "r400",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r548",
      "r566",
      "r579",
      "r607",
      "r632",
      "r633",
      "r638",
      "r688"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Or Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r190",
      "r400",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r548",
      "r566",
      "r579",
      "r607",
      "r632",
      "r633",
      "r638",
      "r688"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r212",
      "r213",
      "r214",
      "r215",
      "r272",
      "r279",
      "r308",
      "r309",
      "r310",
      "r395",
      "r396",
      "r426",
      "r458",
      "r459",
      "r513",
      "r516",
      "r520",
      "r521",
      "r523",
      "r544",
      "r545",
      "r559",
      "r565",
      "r572",
      "r580",
      "r583",
      "r630",
      "r636",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails",
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r212",
      "r213",
      "r214",
      "r215",
      "r272",
      "r279",
      "r308",
      "r309",
      "r310",
      "r395",
      "r396",
      "r426",
      "r458",
      "r459",
      "r513",
      "r516",
      "r520",
      "r521",
      "r523",
      "r544",
      "r545",
      "r559",
      "r565",
      "r572",
      "r580",
      "r583",
      "r630",
      "r636",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails",
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r143",
      "r144",
      "r228",
      "r244",
      "r391",
      "r553",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsAffimedDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r280",
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementsLeasedFacilitiesDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationEmployeeRetentionBonusDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r159",
      "r280",
      "r601",
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario, Unspecified"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementsLeasedFacilitiesDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationEmployeeRetentionBonusDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r194",
      "r195",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsEquitySecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r191",
      "r192",
      "r455",
      "r456",
      "r457",
      "r515",
      "r518",
      "r522",
      "r525",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r549",
      "r567",
      "r583",
      "r638",
      "r688"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r191",
      "r192",
      "r455",
      "r456",
      "r457",
      "r515",
      "r518",
      "r522",
      "r525",
      "r532",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r549",
      "r567",
      "r583",
      "r638",
      "r688"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r159",
      "r280",
      "r601",
      "r602",
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementsLeasedFacilitiesDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationEmployeeRetentionBonusDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r626",
      "r676"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title Of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensation2010PlanAndInducementAwardsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationCeoDepartureAndContinuityIncentiveDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationEmployeeRetentionBonusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensation2010PlanAndInducementAwardsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationCeoDepartureAndContinuityIncentiveDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationEmployeeRetentionBonusDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation and Significant Accounting Policies"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsAndOtherReceivablesNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.",
        "label": "Accounts and Other Receivables, Net, Current",
        "terseLabel": "Trade and other receivables, net"
       }
      }
     },
     "localname": "AccountsAndOtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r15",
      "r578"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedBonusesCurrent": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsAccruedAndOtherLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "xoma_AccruedAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Bonuses, Current",
        "terseLabel": "Accrued incentive compensation"
       }
      }
     },
     "localname": "AccruedBonusesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsAccruedAndOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities And Other Liabilities [Abstract]",
        "terseLabel": "Accrued and other liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsAccruedAndOtherLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsAccruedAndOtherLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "xoma_AccruedAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees Current",
        "terseLabel": "Accrued legal and accounting fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsAccruedAndOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Estimated useful life of intangible asset"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesIntangibleAssetsAndIncomeTaxesDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.",
        "label": "Additional Financial Information Disclosure [Text Block]",
        "terseLabel": "Condensed Consolidated Financial Statements Details"
       }
      }
     },
     "localname": "AdditionalFinancialInformationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetails"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r66",
      "r578",
      "r692"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid In Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r317",
      "r318",
      "r319",
      "r442",
      "r620",
      "r621",
      "r622",
      "r671",
      "r693"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r54",
      "r55",
      "r283"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r312",
      "r320"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share Based Compensation Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsActivityDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r4",
      "r41",
      "r45"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of intangible assets",
        "verboseLabel": "Amortization expense"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails",
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount",
        "terseLabel": "Antidilutive securities excluded from computation of net loss per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsOutstandingSecuritiesConsideredAntiDilutiveDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsOutstandingSecuritiesConsideredAntiDilutiveDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsOutstandingSecuritiesConsideredAntiDilutiveDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsOutstandingSecuritiesConsideredAntiDilutiveDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements and Non-arrangement Transactions"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsAffimedDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionAxis": {
     "auth_ref": [
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by asset acquisition.",
        "label": "Asset Acquisition [Axis]"
       }
      }
     },
     "localname": "AssetAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionConsiderationTransferred": {
     "auth_ref": [
      "r574",
      "r668",
      "r669",
      "r670"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.",
        "label": "Asset Acquisition, Consideration Transferred",
        "terseLabel": "Cost to acquire assets"
       }
      }
     },
     "localname": "AssetAcquisitionConsiderationTransferred",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost": {
     "auth_ref": [
      "r574",
      "r668",
      "r669",
      "r670"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction cost incurred as part of consideration transferred in asset acquisition.",
        "label": "Asset Acquisition, Consideration Transferred, Transaction Cost",
        "terseLabel": "Transaction costs"
       }
      }
     },
     "localname": "AssetAcquisitionConsiderationTransferredTransactionCost",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetAcquisitionDomain": {
     "auth_ref": [
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition.",
        "label": "Asset Acquisition [Domain]"
       }
      }
     },
     "localname": "AssetAcquisitionDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionLineItems": {
     "auth_ref": [
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Asset Acquisition [Line Items]",
        "terseLabel": "Asset acquisition"
       }
      }
     },
     "localname": "AssetAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionTable": {
     "auth_ref": [
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset acquisition.",
        "label": "Asset Acquisition [Table]"
       }
      }
     },
     "localname": "AssetAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r92",
      "r117",
      "r140",
      "r179",
      "r184",
      "r188",
      "r197",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r344",
      "r348",
      "r369",
      "r407",
      "r481",
      "r578",
      "r592",
      "r634",
      "r635",
      "r677"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r112",
      "r122",
      "r140",
      "r197",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r344",
      "r348",
      "r369",
      "r578",
      "r634",
      "r635",
      "r677"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensation2010PlanAndInducementAwardsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationFvAssumptionsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsActivityDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsFairValueDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis Of Accounting Policy Policy [Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis Of Presentation And Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of Presentation and Significant Accounting Policies"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalizedContractCostNet": {
     "auth_ref": [
      "r203"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.",
        "label": "Capitalized Contract Cost Net",
        "terseLabel": "Capitalized contract costs"
       }
      }
     },
     "localname": "CapitalizedContractCostNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsAffimedDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r99",
      "r409",
      "r453",
      "r476",
      "r578",
      "r592",
      "r609"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesCashAndCashEquivalentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r24",
      "r114",
      "r550"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureDescriptionOfBusinessLiquidityDetails",
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash And Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "xoma_FinancialAssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash And Cash Equivalents Fair Value Disclosure",
        "verboseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash And Cash Equivalents Policy [Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r24",
      "r75",
      "r138"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at the end of the period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at the beginning of the period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r0",
      "r75"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r609",
      "r687"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesCashAndCashEquivalentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]",
        "terseLabel": "Non-cash investing and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r109",
      "r119",
      "r120",
      "r121",
      "r140",
      "r163",
      "r164",
      "r171",
      "r173",
      "r177",
      "r178",
      "r197",
      "r216",
      "r218",
      "r219",
      "r220",
      "r223",
      "r224",
      "r242",
      "r243",
      "r246",
      "r249",
      "r255",
      "r369",
      "r435",
      "r436",
      "r437",
      "r438",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r454",
      "r468",
      "r490",
      "r508",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r600",
      "r617",
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails",
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsNetLossPerShareDetails",
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation",
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class Of Warrant Or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommonStockWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommonStockWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1",
        "terseLabel": "Exercise price of warrants (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommonStockWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class Of Warrant Or Right [Line Items]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommonStockWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class Of Warrant Or Right Outstanding",
        "terseLabel": "Warrant outstanding (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommonStockWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class Of Warrant Or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommonStockWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Agreements",
        "verboseLabel": "Licensing and other arrangements"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsAffimedDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r20",
      "r58",
      "r408",
      "r467"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments And Contingencies.",
        "terseLabel": "Commitments and Contingencies (Note 9)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsArbitrationProceedingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r84",
      "r210",
      "r211",
      "r534",
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments And Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r581",
      "r582",
      "r583",
      "r585",
      "r586",
      "r587",
      "r588",
      "r620",
      "r621",
      "r671",
      "r690",
      "r693"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails",
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsOutstandingSecuritiesConsideredAntiDilutiveDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details",
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation",
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock Par Or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r65",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock Shares Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r6",
      "r65",
      "r468",
      "r487",
      "r693",
      "r694"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock Shares Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r65",
      "r411",
      "r578"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock Value",
        "terseLabel": "Common stock, $0.0075 par value, 277,333,332 shares authorized, 11,472,808 and 11,454,025 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationRelatedCostsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Based Compensation"
       }
      }
     },
     "localname": "CompensationRelatedCostsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Compensation Related Costs Policy [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r22",
      "r124",
      "r126",
      "r132",
      "r403",
      "r417"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income Policy Policy [Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r33",
      "r35",
      "r56",
      "r57",
      "r193",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesConcentrationOfRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r33",
      "r35",
      "r56",
      "r57",
      "r193",
      "r432",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk By Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesConcentrationOfRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r33",
      "r35",
      "r56",
      "r57",
      "r193",
      "r533",
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk By Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesConcentrationOfRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r59",
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk Credit Risk",
        "terseLabel": "Concentration of Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration of Risk"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesConcentrationOfRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r33",
      "r35",
      "r56",
      "r57",
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk Percentage1",
        "terseLabel": "Concentration risk (as a percent)"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesConcentrationOfRiskDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r32",
      "r33",
      "r35",
      "r36",
      "r56",
      "r91",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesConcentrationOfRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r33",
      "r35",
      "r56",
      "r57",
      "r193",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesConcentrationOfRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of contingent consideration.",
        "label": "Contingent Consideration by Type [Axis]"
       }
      }
     },
     "localname": "ContingentConsiderationByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of contingent payment arrangement.",
        "label": "Contingent Consideration Type [Domain]"
       }
      }
     },
     "localname": "ContingentConsiderationTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss": {
     "auth_ref": [
      "r200",
      "r201",
      "r202",
      "r260"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss for right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract with Customer, Asset, Allowance for Credit Loss",
        "terseLabel": "Amount of allowance for credit losses"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "auth_ref": [
      "r258",
      "r260",
      "r271"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss",
        "terseLabel": "Contract assets"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsAffimedDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r258",
      "r259",
      "r271"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract With Customer Liability",
        "terseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsAffimedDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [
      "r242",
      "r243",
      "r246",
      "r585",
      "r586",
      "r587",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible preferred stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsOutstandingSecuritiesConsideredAntiDilutiveDetails",
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CreditConcentrationRiskMember": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that a specified receivable or amount at risk from a counterparty under a contractual arrangement is to a specified benchmark, such as total receivables, net revenues, pretax results. Risk is the materially adverse effects of loss attributable to (a) the failure to collect a significant receivable from a major customer or group of homogeneous accounts, or (b) a failure by a counterparty to perform under terms of a contractual arrangement.",
        "label": "Credit Concentration Risk"
       }
      }
     },
     "localname": "CreditConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesConcentrationOfRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r34",
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesConcentrationOfRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r13",
      "r61",
      "r62",
      "r93",
      "r95",
      "r145",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r376",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet": {
     "auth_ref": [
      "r618"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net increase or decrease in the carrying amount of the debt instrument for the period.",
        "label": "Debt Instrument, Increase (Decrease), Net",
        "negatedLabel": "Reduction in debt obligation"
       }
      }
     },
     "localname": "DebtInstrumentIncreaseDecreaseForPeriodNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r19",
      "r145",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r376",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualDistributionPaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of distribution made to individual in accordance with deferred compensation arrangement.",
        "label": "Deferred Compensation Arrangement with Individual, Distribution Paid",
        "terseLabel": "Amount of retention bonus paid"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualDistributionPaid",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationEmployeeRetentionBonusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]",
        "terseLabel": "Employee Retention Bonus",
        "verboseLabel": "Departure and Continuity Incentive"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationCeoDepartureAndContinuityIncentiveDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationEmployeeRetentionBonusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeCurrent": {
     "auth_ref": [
      "r603"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Deferred Income, Current",
        "terseLabel": "Unearned revenue recognized under units-of-revenue method",
        "verboseLabel": "Unearned revenue recognized under units-of-revenue method, current"
       }
      }
     },
     "localname": "DeferredIncomeCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails",
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeNoncurrent": {
     "auth_ref": [
      "r603"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Deferred Income, Noncurrent",
        "terseLabel": "Unearned revenue recognized under units-of-revenue method - long-term",
        "verboseLabel": "Unearned revenue recognized under units-of-revenue method, noncurrent"
       }
      }
     },
     "localname": "DeferredIncomeNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails",
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationNonproduction": {
     "auth_ref": [
      "r4",
      "r46"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The expense recognized in the current period that allocates the cost of nonproduction tangible assets over their useful lives.",
        "label": "Depreciation"
       }
      }
     },
     "localname": "DepreciationNonproduction",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r281",
      "r285",
      "r313",
      "r314",
      "r316",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Disclosure Of Compensation Related Costs Share Based Payments [Text Block]",
        "verboseLabel": "Stock Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DividendsDeclaredTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information related to dividends declared, including paid and unpaid dividends.",
        "label": "Dividends Declared [Table Text Block]",
        "terseLabel": "Schedule of declared and paid cash dividends"
       }
      }
     },
     "localname": "DividendsDeclaredTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DividendsPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r62",
      "r63",
      "r94",
      "r589",
      "r686"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.",
        "label": "Dividends Payable",
        "terseLabel": "Preferred stock dividend accrual"
       }
      }
     },
     "localname": "DividendsPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsPayableLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Dividends Payable [Line Items]",
        "terseLabel": "Dividends"
       }
      }
     },
     "localname": "DividendsPayableLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsPayableTable": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table that contains information regarding dividends that have been declared but not paid as of the financial reporting date. This information may contain the amount, amount per share, declared date, and date to be paid.",
        "label": "Dividends Payable [Table]"
       }
      }
     },
     "localname": "DividendsPayableTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsPreferredStockStock": {
     "auth_ref": [
      "r2",
      "r86"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in stock.",
        "label": "Dividends, Preferred Stock, Stock",
        "negatedLabel": "Preferred stock dividends"
       }
      }
     },
     "localname": "DividendsPreferredStockStock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r133",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r160",
      "r163",
      "r171",
      "r172",
      "r173",
      "r175",
      "r358",
      "r359",
      "r404",
      "r418",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share Basic",
        "verboseLabel": "Basic net loss per share attributable to common stockholders (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsNetLossPerShareDetails",
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r133",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r163",
      "r171",
      "r172",
      "r173",
      "r175",
      "r358",
      "r359",
      "r404",
      "r418",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share Diluted",
        "verboseLabel": "Diluted net loss per share attributable to common stockholders (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsNetLossPerShareDetails",
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDilutedLineItems": {
     "auth_ref": [
      "r163",
      "r164",
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareDilutedLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r29",
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share Policy [Text Block]",
        "verboseLabel": "Net Loss per Share Attributable to Common Stockholders"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1",
        "terseLabel": "Weighted average period over which unrecognized compensation expense is expected to be recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsActivityDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r666"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Stock-based compensation expense, not yet recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsActivityDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r666"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options",
        "terseLabel": "Unrecognized compensation expense related to stock options (in dollars)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Stock Options",
        "verboseLabel": "Common stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsOutstandingSecuritiesConsideredAntiDilutiveDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensation2010PlanAndInducementAwardsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationFvAssumptionsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r6",
      "r110",
      "r128",
      "r129",
      "r130",
      "r146",
      "r147",
      "r148",
      "r150",
      "r156",
      "r158",
      "r176",
      "r198",
      "r199",
      "r257",
      "r317",
      "r318",
      "r319",
      "r336",
      "r337",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r357",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r390",
      "r427",
      "r428",
      "r429",
      "r442",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails",
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsOutstandingSecuritiesConsideredAntiDilutiveDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details",
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesFVNINoncurrent": {
     "auth_ref": [
      "r368"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as noncurrent.",
        "label": "Equity Securities, FV-NI, Noncurrent",
        "terseLabel": "Long-term equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFVNINoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsEquitySecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r118",
      "r368",
      "r551"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.",
        "label": "Equity Securities, FV-NI",
        "terseLabel": "Short-term equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiMeasurementInput": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities Fv Ni Measurement Input",
        "terseLabel": "Valuation assumptions, measurement input"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsEquitySecuritiesDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": {
     "auth_ref": [
      "r419",
      "r627"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Realized Gain (Loss)",
        "negatedLabel": "Change in fair value of equity securities",
        "terseLabel": "Gain (loss) recognized due to change in fair value of investment"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsEquitySecuritiesDetails",
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [
      "r361",
      "r362",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r361",
      "r362",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsEquitySecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsEquitySecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r233",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r362",
      "r392",
      "r393",
      "r394",
      "r561",
      "r562",
      "r569",
      "r570",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value By Fair Value Hierarchy Level [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r361",
      "r362",
      "r364",
      "r365",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Fair Value By Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r233",
      "r273",
      "r278",
      "r362",
      "r392",
      "r569",
      "r570",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Quoted Prices in Active Markets for Identical Assets (Level 1)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r233",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r362",
      "r394",
      "r561",
      "r562",
      "r569",
      "r570",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Significant Unobservable Inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Fair Value, Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r233",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r392",
      "r393",
      "r394",
      "r561",
      "r562",
      "r569",
      "r570",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r360",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations": {
     "auth_ref": [
      "r141",
      "r326"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current and deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current and deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Federal Income Tax Expense Benefit Continuing Operations",
        "verboseLabel": "Federal income tax provision"
       }
      }
     },
     "localname": "FederalIncomeTaxExpenseBenefitContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r115",
      "r206"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "terseLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails": {
       "order": 2.0,
       "parentTag": "xoma_FiniteLivedIntangibleAssetExpectedAmortizationThroughYearFive",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails": {
       "order": 1.0,
       "parentTag": "xoma_FiniteLivedIntangibleAssetExpectedAmortizationThroughYearFive",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "terseLabel": "2023 (excluding six months ended June 30, 2023)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails": {
       "order": 5.0,
       "parentTag": "xoma_FiniteLivedIntangibleAssetExpectedAmortizationThroughYearFive",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails": {
       "order": 4.0,
       "parentTag": "xoma_FiniteLivedIntangibleAssetExpectedAmortizationThroughYearFive",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails": {
       "order": 3.0,
       "parentTag": "xoma_FiniteLivedIntangibleAssetExpectedAmortizationThroughYearFive",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r204",
      "r205",
      "r206",
      "r207",
      "r401",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Projected amortization expense for the next five years"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r81",
      "r402"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Cost"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r42",
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r81",
      "r401"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Net Carrying Value"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net [Abstract]",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Assets, Remaining Amortization Period",
        "terseLabel": "Remaining useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r73",
      "r492"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General And Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "auth_ref": [
      "r616",
      "r629"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.",
        "label": "Impairment of Intangible Assets, Finite-Lived",
        "terseLabel": "Impairment of intangible asset"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r208",
      "r209",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r209",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r142",
      "r322",
      "r327",
      "r331",
      "r334",
      "r338",
      "r339",
      "r340",
      "r341",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r127",
      "r324",
      "r325",
      "r331",
      "r332",
      "r333",
      "r335",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax Policy [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r26"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid Net",
        "terseLabel": "Cash paid for taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables": {
     "auth_ref": [
      "r3"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.",
        "label": "Increase (Decrease) in Accounts and Other Receivables",
        "negatedLabel": "Trade and other receivables, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsAndOtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r3"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase Decrease In Accounts Payable And Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "auth_ref": [
      "r3"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.",
        "label": "Increase Decrease In Accrued Income Taxes Payable",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "auth_ref": [
      "r546"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Deferred Revenue",
        "terseLabel": "Unearned revenue recognized under units-of-revenue method"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails",
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Operating Capital [Abstract]",
        "terseLabel": "Changes in assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r606",
      "r615"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r3"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase Decrease In Stockholders Equity Roll Forward",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "auth_ref": [
      "r44",
      "r397",
      "r398",
      "r399",
      "r401",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "terseLabel": "Intangible Assets"
       }
      }
     },
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r40",
      "r43"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntellectualPropertyMember": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible asset arising from original creative thought. Include, but is not limited to, trademarks, patents, and copyrights.",
        "label": "Ebopiprant IP"
       }
      }
     },
     "localname": "IntellectualPropertyMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r361"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "xoma_FinancialAssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments Fair Value Disclosure",
        "terseLabel": "Equity securities"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r382",
      "r577"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureLeaseAgreementsLeaseCostsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease costs"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementsLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]",
        "terseLabel": "Lease costs"
       }
      }
     },
     "localname": "LeaseCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementsLeaseCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r675"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of cost components of operating leases"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Agreements"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementsLeasedFacilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementsLeasedFacilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee Leases Policy [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r389"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee Operating Lease Liability Payments Due",
        "terseLabel": "Total undiscounted lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementsLeasedFacilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Period of lease extension"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementsLeasedFacilitiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementsLeasedFacilitiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r16",
      "r140",
      "r197",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r345",
      "r348",
      "r349",
      "r369",
      "r466",
      "r557",
      "r592",
      "r634",
      "r677",
      "r678"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r70",
      "r96",
      "r413",
      "r578",
      "r619",
      "r628",
      "r673"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities And Stockholders Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities And Stockholders Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r18",
      "r113",
      "r140",
      "r197",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r345",
      "r348",
      "r349",
      "r369",
      "r578",
      "r634",
      "r677",
      "r678"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationSettlementExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.",
        "label": "Litigation Settlement, Expense",
        "terseLabel": "Arbitration settlement costs (Note 3)",
        "verboseLabel": "Arbitration settlement costs"
       }
      }
     },
     "localname": "LitigationSettlementExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsArbitrationProceedingDetails",
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "auth_ref": [
      "r672"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using share price of saleable stock.",
        "label": "Closing Common Stock Price"
       }
      }
     },
     "localname": "MeasurementInputSharePriceMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsEquitySecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsEquitySecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsEquitySecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.",
        "label": "Subsidiary, Ownership Percentage, Parent",
        "terseLabel": "Ownership interest (as a percent)"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r639"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r100",
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature Of Operations",
        "terseLabel": "Description of Business"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureDescriptionOfBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r137"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided By Used In Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r137"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided By Used In Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r75",
      "r76",
      "r77"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided By Used In Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r71",
      "r77",
      "r97",
      "r111",
      "r123",
      "r125",
      "r130",
      "r140",
      "r149",
      "r151",
      "r152",
      "r153",
      "r154",
      "r157",
      "r158",
      "r169",
      "r179",
      "r183",
      "r187",
      "r189",
      "r197",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r359",
      "r369",
      "r416",
      "r489",
      "r506",
      "r507",
      "r558",
      "r590",
      "r634"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsNetLossPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      },
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income Loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss and comprehensive loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsNetLossPerShareDetails",
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome",
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r134",
      "r151",
      "r152",
      "r153",
      "r154",
      "r160",
      "r161",
      "r170",
      "r173",
      "r179",
      "r183",
      "r187",
      "r189",
      "r558"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsNetLossPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income Loss Available To Common Stockholders Basic",
        "totalLabel": "Net loss attributable to common stockholders, basic",
        "verboseLabel": "Net loss attributable to common stockholders, basic"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsNetLossPerShareDetails",
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r134",
      "r162",
      "r165",
      "r166",
      "r167",
      "r168",
      "r170",
      "r173"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsNetLossPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income Loss Available To Common Stockholders Diluted",
        "totalLabel": "Net loss attributable to common stockholders, diluted",
        "verboseLabel": "Net loss attributable to common stockholders, diluted"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsNetLossPerShareDetails",
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income Loss Available To Common Stockholders Diluted [Abstract]",
        "terseLabel": "Numerator"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements Policy Policy [Text Block]",
        "terseLabel": "Accounting Pronouncements Recently Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income Expense [Abstract]",
        "verboseLabel": "Other income (expense), net:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r179",
      "r183",
      "r187",
      "r189",
      "r558"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income Loss",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r383",
      "r577"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureLeaseAgreementsLeaseCostsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementsLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r378"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease Liability Current",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementsLeasedFacilitiesDetails",
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r379",
      "r385"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease Payments",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities, Operating cash flows under operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r377"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease Right Of Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r388",
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease Weighted Average Discount Rate Percent",
        "terseLabel": "Weighted-average discount rate, Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r387",
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease Weighted Average Remaining Lease Term1",
        "terseLabel": "Weighted-average remaining lease term, Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of Business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsAccruedAndOtherLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "xoma_AccruedAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities Current",
        "terseLabel": "Other accrued liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsAccruedAndOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r116"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets Noncurrent",
        "terseLabel": "Other assets - long term"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income Expense",
        "verboseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDividends": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.",
        "label": "Payments of Dividends",
        "negatedLabel": "Payment of preferred stock dividends"
       }
      }
     },
     "localname": "PaymentsOfDividends",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r135"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payments Related To Tax Withholding For Share Based Compensation",
        "negatedLabel": "Taxes paid related to net share settlement of equity awards"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "auth_ref": [
      "r98",
      "r668",
      "r669",
      "r670"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Payments to Acquire Productive Assets",
        "negatedLabel": "Payment for IP acquired under the ObsEva IP Acquisition Agreement",
        "terseLabel": "Upfront cash payment to acquire assets"
       }
      }
     },
     "localname": "PaymentsToAcquireProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails",
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensation2010PlanAndInducementAwardsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationEsppDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationFvAssumptionsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensation2010PlanAndInducementAwardsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationEsppDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationFvAssumptionsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockDividendRatePercentage": {
     "auth_ref": [
      "r243",
      "r514",
      "r517",
      "r519",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage rate used to calculate dividend payments on preferred stock.",
        "label": "Preferred Stock, Dividend Rate, Percentage",
        "terseLabel": "Preferred stock, dividend rate (as a percent)"
       }
      }
     },
     "localname": "PreferredStockDividendRatePercentage",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_PreferredStockDividendsIncomeStatementImpact": {
     "auth_ref": [],
     "calculation": {
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsNetLossPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.",
        "label": "Preferred Stock Dividends, Income Statement Impact",
        "negatedLabel": "Less: accumulated dividends on Series A and Series B preferred stock",
        "negatedTerseLabel": "Less: accumulated dividends"
       }
      }
     },
     "localname": "PreferredStockDividendsIncomeStatementImpact",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsNetLossPerShareDetails",
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockDividendsPerShareCashPaid": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends paid during the period for each share of preferred stock outstanding.",
        "label": "Preferred Stock, Dividends, Per Share, Cash Paid",
        "terseLabel": "Cash dividend paid (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockDividendsPerShareCashPaid",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockDividendsPerShareDeclared": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of preferred stock outstanding.",
        "label": "Preferred Stock, Dividends Per Share, Declared",
        "terseLabel": "Cash dividend declared (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [
      "r581",
      "r582",
      "r585",
      "r586",
      "r587",
      "r588",
      "r690",
      "r693"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r64",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock Par Or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r64",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r64",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r64",
      "r468",
      "r487",
      "r693",
      "r694"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r64",
      "r410",
      "r578"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock Value",
        "terseLabel": "Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r613"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense And Other Assets Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r1"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds From Issuance Of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details",
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r1",
      "r10"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised",
        "terseLabel": "Proceeds from exercise of options and other share-based compensation"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r111",
      "r123",
      "r125",
      "r136",
      "r140",
      "r149",
      "r157",
      "r158",
      "r179",
      "r183",
      "r187",
      "r189",
      "r197",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r343",
      "r346",
      "r347",
      "r359",
      "r369",
      "r405",
      "r415",
      "r441",
      "r489",
      "r506",
      "r507",
      "r558",
      "r575",
      "r576",
      "r591",
      "r614",
      "r634"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Profit Loss",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementsLeasedFacilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r5",
      "r406",
      "r414",
      "r578"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementsLeasedFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReceivablesLongTermContractsOrPrograms": {
     "auth_ref": [
      "r612"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount to be collected within one year of the balance sheet date (or one operating cycle, if longer) from customers in accordance with the contractual provisions of long-term contracts or programs including amounts billed and unbilled as of the balance sheet date.",
        "label": "Receivables, Long-term Contracts or Programs",
        "terseLabel": "Trade receivable, net"
       }
      }
     },
     "localname": "ReceivablesLongTermContractsOrPrograms",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesConcentrationOfRiskDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r60",
      "r321",
      "r685"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research And Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r67",
      "r86",
      "r412",
      "r430",
      "r431",
      "r439",
      "r469",
      "r578"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated undistributed earnings (deficit).",
        "label": "Retained Earnings Accumulated Deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r110",
      "r146",
      "r147",
      "r148",
      "r150",
      "r156",
      "r158",
      "r198",
      "r199",
      "r317",
      "r318",
      "r319",
      "r336",
      "r337",
      "r350",
      "r352",
      "r353",
      "r355",
      "r357",
      "r427",
      "r429",
      "r442",
      "r693"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated undistributed earnings (deficit).",
        "label": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r180",
      "r181",
      "r182",
      "r185",
      "r186",
      "r190",
      "r191",
      "r193",
      "r269",
      "r270",
      "r400"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue From Contract With Customer Excluding Assessed Tax",
        "terseLabel": "Revenue from contracts with customers",
        "verboseLabel": "Revenue recognized"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsAffimedDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails",
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r108",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue From Contract With Customer Policy [Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueNotFromContractWithCustomer": {
     "auth_ref": [
      "r608"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue that is not accounted for under Topic 606.",
        "label": "Revenue Not from Contract with Customer",
        "terseLabel": "Revenue recognized under units-of-revenue method"
       }
      }
     },
     "localname": "RevenueNotFromContractWithCustomer",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails",
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r106"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue Remaining Performance Obligation",
        "terseLabel": "Remaining performance obligations"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r131",
      "r140",
      "r180",
      "r181",
      "r182",
      "r185",
      "r186",
      "r190",
      "r191",
      "r193",
      "r197",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r369",
      "r405",
      "r634"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "totalLabel": "Total revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r386",
      "r577"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r193",
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenues."
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesConcentrationOfRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule Of Accrued Liabilities Table [Text Block]",
        "terseLabel": "Schedule of accrued and other liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsOutstandingSecuritiesConsideredAntiDilutiveDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]",
        "terseLabel": "Schedule of outstanding securities considered anti-dilutive"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]",
        "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsAffimedDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable": {
     "auth_ref": [
      "r47",
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule, table or text reflecting arrangements that are not equity-based payments, or pension and other postretirement benefits, with individual employees. The arrangements (for example, profit sharing, deferred bonuses or certain split-dollar life insurance arrangements) are generally based on employment contracts between the entity and one or more selected officers or key employees, and which contain a promise by the employer to pay certain amounts at designated future dates, sometimes including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period and the carrying amount as of the balance sheet date of the related liability.",
        "label": "Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]"
       }
      }
     },
     "localname": "ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationCeoDepartureAndContinuityIncentiveDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationEmployeeRetentionBonusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]",
        "terseLabel": "Schedule of reconciliation of numerator and denominator used in calculation of basic and diluted net (loss) per share available to common stockholders"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable": {
     "auth_ref": [
      "r28",
      "r31",
      "r163",
      "r164",
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Complete disclosure pertaining to an entity's diluted earnings per share.",
        "label": "Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareDilutedByCommonClassTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]",
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]",
        "terseLabel": "Summary of stock-based compensation expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r361",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block]",
        "terseLabel": "Schedule of Financial Assets and Liabilities Carried at Fair Value on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r42",
      "r44",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r42",
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of cost, accumulated amortization, and net carrying value of intangible assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r282",
      "r284",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensation2010PlanAndInducementAwardsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationEsppDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationFvAssumptionsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsActivityDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsFairValueDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r8",
      "r9",
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of stock option activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]",
        "terseLabel": "Schedule of valuation assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule Of Stockholders Equity Note Warrants Or Rights [Text Block]",
        "terseLabel": "Summary of Common Stock Warrants Outstanding"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommonStockWarrantsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt and Equity Securities, FV-NI [Line Items]",
        "terseLabel": "Equity Securities"
       }
      }
     },
     "localname": "ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsEquitySecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security with change in fair value recognized in net income (FV-NI).",
        "label": "Debt Securities, Trading, and Equity Securities, FV-NI [Table]"
       }
      }
     },
     "localname": "ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsEquitySecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of projected amortization expense for next five years"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [
      "r610",
      "r611",
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A preferred stock.",
        "label": "8.625% Series A Cumulative, Perpetual Preferred Stock",
        "terseLabel": "Series A accumulated dividends"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails",
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsNetLossPerShareDetails",
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation",
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "auth_ref": [
      "r610",
      "r611",
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B preferred stock.",
        "label": "8.375% Series B Cumulative, Perpetual Preferred Stock",
        "terseLabel": "Series B accumulated dividends"
       }
      }
     },
     "localname": "SeriesBPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails",
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsNetLossPerShareDetails",
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r3"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share Based Compensation",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "auth_ref": [
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period",
        "terseLabel": "Derived Service Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsFairValueDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensation2010PlanAndInducementAwardsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)",
        "verboseLabel": "Number of PSUs (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsActivityDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsFairValueDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Fair Value Per Share (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsFairValueDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r297",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Number of shares, Outstanding at end of period",
        "periodStartLabel": "Number of shares, Outstanding at beginning of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of Unvested PSUs"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology [Abstract]",
        "terseLabel": "Weighted average assumptions"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationFvAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationFvAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationFvAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationFvAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [
      "r282",
      "r284",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "terseLabel": "Share-based compensation",
        "verboseLabel": "Performance Stock Unit Awards"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensation2010PlanAndInducementAwardsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationEsppDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationFvAssumptionsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsActivityDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsFairValueDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number",
        "periodEndLabel": "Number of shares, Exercisable at end of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price Per Share, Exercisable at end of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r304"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value",
        "terseLabel": "Options exercised, aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r646"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period",
        "negatedLabel": "Number of shares, Forfeited, expired or cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r646"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price Per Share, Forfeited, expired or cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross",
        "terseLabel": "Number of shares, Granted",
        "verboseLabel": "Number of shares, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensation2010PlanAndInducementAwardsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationFvAssumptionsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant-date fair value (in dollars per share)",
        "verboseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationFvAssumptionsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsActivityDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r49"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r289",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number",
        "periodEndLabel": "Number of shares, Outstanding at end of period",
        "periodStartLabel": "Number of shares, Outstanding at beginning of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r289",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price Per Share, Outstanding at end of period",
        "periodStartLabel": "Weighted Average Exercise Price Per Share, Outstanding at beginning of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Equity Award"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensation2010PlanAndInducementAwardsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationFvAssumptionsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsActivityDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsFairValueDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price Per Share, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price Per Share, Granted",
        "verboseLabel": "Exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensation2010PlanAndInducementAwardsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationFvAssumptionsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche One"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensation2010PlanAndInducementAwardsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche Three"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheThreeMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensation2010PlanAndInducementAwardsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche Two"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensation2010PlanAndInducementAwardsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for outstanding performance shares.",
        "label": "Share-Based Payment Arrangement, Performance Shares, Outstanding Activity [Table Text Block]",
        "terseLabel": "Schedule of performance shares, outstanding activity"
       }
      }
     },
     "localname": "ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of number and weighted-average grant date fair value for nonvested performance shares.",
        "label": "Share-Based Payment Arrangement, Performance Shares, Activity [Table Text Block]",
        "terseLabel": "Schedule of grant date fair value per PSU issued"
       }
      }
     },
     "localname": "ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Stock price (in dollars per share)",
        "verboseLabel": "Hurdle Price Per PSU (in dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsOutstandingSecuritiesConsideredAntiDilutiveDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details",
      "http://www.xoma.com/role/DisclosureStockBasedCompensation2010PlanAndInducementAwardsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsFairValueDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vesting (as a percent)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensation2010PlanAndInducementAwardsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1",
        "terseLabel": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationFvAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r49"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1",
        "terseLabel": "Weighted Average Contractual Remaining Term, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of non-vested options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price",
        "terseLabel": "Balance (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Average Grant Date Fair Value Per Share"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2",
        "terseLabel": "Weighted Average Contractual Remaining Term, Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Purchase price (in dollars per share)"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares Outstanding",
        "periodEndLabel": "Balance at end of period (in shares)",
        "periodStartLabel": "Balance at beginning of period (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit": {
     "auth_ref": [
      "r90"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the unrecognized tax benefit of a position taken for which it is reasonably possible that the total amount thereof will significantly increase or decrease within twelve months of the balance sheet date.",
        "label": "Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit",
        "terseLabel": "Unrecognized tax benefits expected to change significantly over the next twelve months"
       }
      }
     },
     "localname": "SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r109",
      "r119",
      "r120",
      "r121",
      "r140",
      "r163",
      "r164",
      "r171",
      "r173",
      "r177",
      "r178",
      "r197",
      "r216",
      "r218",
      "r219",
      "r220",
      "r223",
      "r224",
      "r242",
      "r243",
      "r246",
      "r249",
      "r255",
      "r369",
      "r435",
      "r436",
      "r437",
      "r438",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r454",
      "r468",
      "r490",
      "r508",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r600",
      "r617",
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Statement Class Of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockDividendsDetails",
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsNetLossPerShareDetails",
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation",
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r6",
      "r21",
      "r110",
      "r128",
      "r129",
      "r130",
      "r146",
      "r147",
      "r148",
      "r150",
      "r156",
      "r158",
      "r176",
      "r198",
      "r199",
      "r257",
      "r317",
      "r318",
      "r319",
      "r336",
      "r337",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r357",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r390",
      "r427",
      "r428",
      "r429",
      "r442",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Statement Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails",
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsOutstandingSecuritiesConsideredAntiDilutiveDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details",
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [
      "r146",
      "r147",
      "r148",
      "r176",
      "r400",
      "r433",
      "r454",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r468",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r477",
      "r478",
      "r479",
      "r480",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r488",
      "r491",
      "r492",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r508",
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation",
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED BALANCE SHEETS"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r146",
      "r147",
      "r148",
      "r176",
      "r400",
      "r433",
      "r454",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r468",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r477",
      "r478",
      "r479",
      "r480",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r488",
      "r491",
      "r492",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r508",
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DocumentDocumentAndEntityInformation",
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r6",
      "r64",
      "r65",
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period Shares Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock related to ESPP (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r6",
      "r64",
      "r65",
      "r86",
      "r435",
      "r508",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period Shares New Issues",
        "terseLabel": "Issuance of preferred stock (in shares)",
        "verboseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details",
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r6",
      "r64",
      "r65",
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Stock Issued During Period Shares Share Based Compensation",
        "verboseLabel": "Issuance of common stock related to 401(k) contribution (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r6",
      "r64",
      "r65",
      "r86",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Stock Issued During Period Shares Stock Options Exercised",
        "negatedLabel": "Number of shares, Exercised",
        "terseLabel": "Exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails",
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r6",
      "r64",
      "r65",
      "r86"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period Value Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock related to ESPP"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r6",
      "r64",
      "r65",
      "r86",
      "r442",
      "r508",
      "r527",
      "r591"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period Value New Issues",
        "verboseLabel": "Issuance of preferred stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r52",
      "r64",
      "r65",
      "r86"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Stock Issued During Period Value Share Based Compensation",
        "verboseLabel": "Issuance of common stock related to 401(k) contribution"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r6",
      "r21",
      "r86"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period Value Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r65",
      "r68",
      "r69",
      "r79",
      "r470",
      "r487",
      "r509",
      "r510",
      "r578",
      "r592",
      "r619",
      "r628",
      "r673",
      "r693"
     ],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.",
        "label": "Equity, Attributable to Parent",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Stock"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r85",
      "r139",
      "r241",
      "r243",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r257",
      "r356",
      "r511",
      "r512",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for equity.",
        "label": "Stockholders Equity Note Disclosure [Text Block]",
        "terseLabel": "Capital Stock"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Reverse stock split"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Subsidiary Sale Of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Sale of stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails",
      "http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental Cash Flow Information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TradeAccountsReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due from customers or clients for goods or services that have been delivered or sold in the normal course of business.",
        "label": "Trade Receivables"
       }
      }
     },
     "localname": "TradeAccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesConcentrationOfRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Type Of Arrangement [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsAffimedDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r323",
      "r329"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "verboseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r328"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued",
        "terseLabel": "Income tax penalties or interest charged",
        "verboseLabel": "Accrued interest or penalties related to uncertain tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesIntangibleAssetsAndIncomeTaxesDetails",
      "http://www.xoma.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r330"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits That Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized tax benefits that would impact effective tax rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r37",
      "r38",
      "r39",
      "r101",
      "r102",
      "r104",
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use Of Estimates",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r384",
      "r577"
     ],
     "calculation": {
      "http://www.xoma.com/role/DisclosureLeaseAgreementsLeaseCostsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementsLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensation2010PlanAndInducementAwardsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensation2010PlanAndInducementAwardsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [
      "r581",
      "r582",
      "r585",
      "r586",
      "r587",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrants for common stock"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsOutstandingSecuritiesConsideredAntiDilutiveDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsNoteDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Warrants"
       }
      }
     },
     "localname": "WarrantsAndRightsNoteDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r162",
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number Of Diluted Shares Outstanding",
        "verboseLabel": "Weighted average shares used in computing diluted net loss per share attributable to common stockholders (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsNetLossPerShareDetails",
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number Of Shares Outstanding [Abstract]",
        "terseLabel": "Denominator"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r160",
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number Of Shares Outstanding Basic",
        "verboseLabel": "Weighted average shares used in computing basic net loss per share attributable to common stockholders (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsNetLossPerShareDetails",
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "sharesItemType"
    },
    "xoma_AccruedAndOtherLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsAccruedAndOtherLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, and liabilities classified as other, due within one year or within the normal operating cycle if longer.",
        "label": "Accrued And Other Liabilities Current",
        "terseLabel": "Accrued and other liabilities",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AccruedAndOtherLiabilitiesCurrent",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsAccruedAndOtherLiabilitiesDetails",
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_AccruedCompensationContinuityIncentive": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued expense for compensation under employment agreement related to retirement of individual.",
        "label": "Accrued Compensation, Continuity Incentive",
        "terseLabel": "Accrued cash payment related to Continuity Incentive under Employment Agreement"
       }
      }
     },
     "localname": "AccruedCompensationContinuityIncentive",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationCeoDepartureAndContinuityIncentiveDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_AccruedPreferredStockDividendCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for preferred stock dividend. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Preferred Stock Dividend, Current",
        "terseLabel": "Preferred stock dividend accrual"
       }
      }
     },
     "localname": "AccruedPreferredStockDividendCurrent",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_AccruedRetentionBonus": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued expense for cash retention bonus.",
        "label": "Accrued Retention Bonus",
        "terseLabel": "Accrued retention bonus"
       }
      }
     },
     "localname": "AccruedRetentionBonus",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationEmployeeRetentionBonusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_AccruedSalariesAndEmployeeBenefitsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsAccruedAndOtherLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "xoma_AccruedAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Also includes carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Includes, but not limited to payroll, severance and retention costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Salaries and Employee Benefits, Current",
        "terseLabel": "Accrued payroll, severance and retention costs"
       }
      }
     },
     "localname": "AccruedSalariesAndEmployeeBenefitsCurrent",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsAccruedAndOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_AffimedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affimed",
        "label": "Affimed"
       }
      }
     },
     "localname": "AffimedMember",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsAffimedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_AffitechResearchAsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affitech Research AS, a Norwegian biotech company.",
        "label": "Affitech"
       }
      }
     },
     "localname": "AffitechResearchAsMember",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_AgenusIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agenus Inc.",
        "label": "Agenus"
       }
      }
     },
     "localname": "AgenusIncMember",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_AgreementDrugCandidatesExclusiveLicenseOptionNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of drug candidates subject to exclusive license option.",
        "label": "Agreement, Drug Candidates, Exclusive License Option, Number",
        "terseLabel": "Number of drug candidates subject to exclusive license option"
       }
      }
     },
     "localname": "AgreementDrugCandidatesExclusiveLicenseOptionNumber",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "xoma_AgreementDrugCandidatesNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of drug candidates under the terms of the agreement.",
        "label": "Agreement, Drug Candidates, Number",
        "terseLabel": "Number of drug candidates"
       }
      }
     },
     "localname": "AgreementDrugCandidatesNumber",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "xoma_AgreementPaymentPercentageFactor": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Multiplier used in determining change in payment percentage.",
        "label": "Agreement, Payment Percentage, Factor",
        "terseLabel": "Multiplier for cumulative amount of consideration paid"
       }
      }
     },
     "localname": "AgreementPaymentPercentageFactor",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "xoma_AgreementTerminationPriorWrittenNoticePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement termination prior written notice period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days",
        "label": "Agreement Termination Prior Written Notice Period",
        "terseLabel": "Agreement termination prior written notice period"
       }
      }
     },
     "localname": "AgreementTerminationPriorWrittenNoticePeriod",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "xoma_AldoxorubicinMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aldoxorubicin.",
        "label": "Aldoxorubicin"
       }
      }
     },
     "localname": "AldoxorubicinMember",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_AptevoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to Aptevo.",
        "label": "Aptevo"
       }
      }
     },
     "localname": "AptevoMember",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_ArimoclomolMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arimoclomol.",
        "label": "Arimoclomol"
       }
      }
     },
     "localname": "ArimoclomolMember",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_AronoraIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aronora, Inc.",
        "label": "Aronora",
        "terseLabel": "Aronora [Member]"
       }
      }
     },
     "localname": "AronoraIncMember",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_AronoraKurosAffitechObsevaAndMerckKgaaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aronora, Kuros, Affitech, ObsEva, and Merck KGaA.",
        "label": "Aronora, Kuros, Affitech, ObsEva, and Merck KGaA"
       }
      }
     },
     "localname": "AronoraKurosAffitechObsevaAndMerckKgaaMember",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_ArrangementsNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of arrangements the agreements are accounted for.",
        "label": "Arrangements, Number",
        "terseLabel": "Number of arrangements"
       }
      }
     },
     "localname": "ArrangementsNumber",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details"
     ],
     "xbrltype": "integerItemType"
    },
    "xoma_AssetAcquisitionsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for asset acquisitions.",
        "label": "Asset Acquisitions, Policy [Policy Text Block]",
        "terseLabel": "Asset Acquisitions"
       }
      }
     },
     "localname": "AssetAcquisitionsPolicyPolicyTextBlock",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "xoma_AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assignment and Assumption Agreement and Royalty Purchase Agreement.",
        "label": "Assignment and Assumption Agreement and Royalty Purchase Agreement"
       }
      }
     },
     "localname": "AssignmentAndAssumptionAgreementAndRoyaltyPurchaseAgreementMember",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_AssignmentAndAssumptionAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assignment and Assumption Agreement.",
        "label": "Assignment and Assumption Agreement"
       }
      }
     },
     "localname": "AssignmentAndAssumptionAgreementMember",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_AtMarketIssuanceSalesAgreement2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At The Market Issuance Sales Agreement, 2021, in which the company may sell depository shares.",
        "label": "2021 ATM Agreement"
       }
      }
     },
     "localname": "AtMarketIssuanceSalesAgreement2021Member",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_BayerProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bayer products.",
        "label": "Bayer Products"
       }
      }
     },
     "localname": "BayerProductsMember",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_BioasisTechnologiesIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bioasis Technologies Inc.",
        "label": "Bioasis",
        "terseLabel": "Bioasis"
       }
      }
     },
     "localname": "BioasisTechnologiesIncMember",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_BiotechnologyValueFundLPMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Biotechnology Value Fund, L.P.",
        "label": "BVF"
       }
      }
     },
     "localname": "BiotechnologyValueFundLPMember",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_ChangesInEstimatedFairValueOfContingentConsideration": {
     "auth_ref": [],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Changes in estimated fair value of contingent consideration.",
        "label": "Changes In Estimated Fair Value Of Contingent Consideration",
        "negatedLabel": "Change in fair value of contingent consideration under RPAs, AAAs, and CPPAs",
        "terseLabel": "Changes in estimated fair value of contingent consideration"
       }
      }
     },
     "localname": "ChangesInEstimatedFairValueOfContingentConsideration",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails",
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_ChiefExecutiveOfficerInterimMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Person with designation of interim chief executive officer and Executive Chairman of the Board.",
        "label": "Executive Chairman of the Board and Interim CEO, Owen Hughes"
       }
      }
     },
     "localname": "ChiefExecutiveOfficerInterimMember",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensation2010PlanAndInducementAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_ChiefExecutiveOfficerRetiredMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Person with designation of chief executive officer prior to retirement.",
        "label": "Chief Executive Officer, Retired, James R. Neal"
       }
      }
     },
     "localname": "ChiefExecutiveOfficerRetiredMember",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationCeoDepartureAndContinuityIncentiveDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_ChiefInvestmentOfficerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Person with designation of  chief investment officer.",
        "label": "Chief Investment Officer, Bradley Sitko"
       }
      }
     },
     "localname": "ChiefInvestmentOfficerMember",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensation2010PlanAndInducementAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_CollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents about collaboration agreement member.",
        "label": "Collaboration Agreement"
       }
      }
     },
     "localname": "CollaborationAgreementMember",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_CommercialPaymentPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial payment purchase agreement.",
        "label": "Commercial Payment Purchase Agreement"
       }
      }
     },
     "localname": "CommercialPaymentPurchaseAgreementMember",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_CommercialPaymentReceivableTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of commercial payment receivable,  in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Commercial Payment Receivable Term",
        "terseLabel": "Commercial payment receivable term"
       }
      }
     },
     "localname": "CommercialPaymentReceivableTerm",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "xoma_CommercialPaymentThresholdOneTimePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the threshold for receipt of commercial payments attributable to net sales for which the entity will be required to make a one-time payment under agreement.",
        "label": "Commercial Payment Threshold, One-Time Payment",
        "terseLabel": "Commercial payments attributable to net sales threshold"
       }
      }
     },
     "localname": "CommercialPaymentThresholdOneTimePayment",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_CommercialSalesReceivablePercentageOnNetSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments entity eligible to receive as a percentage of net sales.",
        "label": "Commercial Sales, Receivable Percentage On Net Sales",
        "terseLabel": "Payments eligible to receive (as a percent)"
       }
      }
     },
     "localname": "CommercialSalesReceivablePercentageOnNetSales",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "xoma_CommitmentsAndContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies.",
        "label": "Commitments And Contingencies [Line Items]",
        "terseLabel": "Commitments And Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesLineItems",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "xoma_CommitmentsAndContingenciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies.",
        "label": "Commitments And Contingencies [Table]",
        "terseLabel": "Commitments And Contingencies [Table]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesTable",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "xoma_CommonStockPremium": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock premium received on sale of common stock.",
        "label": "Common Stock Premium",
        "terseLabel": "Common stock premium"
       }
      }
     },
     "localname": "CommonStockPremium",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_CommonStockWarrantDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock warrant.",
        "label": "Common Stock Warrant Disclosure [Text Block]",
        "terseLabel": "Common Stock Warrants"
       }
      }
     },
     "localname": "CommonStockWarrantDisclosureTextBlock",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommonStockWarrants"
     ],
     "xbrltype": "textBlockItemType"
    },
    "xoma_CommonStockWarrantExercisePrice14.71Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock warrant with exercise price of $14.71 per share.",
        "label": "Common stock warrant, Exercise price $14.71 per share, Issued March 2019"
       }
      }
     },
     "localname": "CommonStockWarrantExercisePrice14.71Member",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommonStockWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_CompensationExpenseEmploymentAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for compensation under employment agreement related to retirement of individual.",
        "label": "Compensation Expense, Employment Agreement",
        "terseLabel": "Compensation expense related to Continuity Incentive under Employment Agreement"
       }
      }
     },
     "localname": "CompensationExpenseEmploymentAgreement",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationCeoDepartureAndContinuityIncentiveDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_ConsolidatedFinancialStatementDetailAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consolidated financial statement detail.",
        "label": "Condensed Consolidated Financial Statements Details"
       }
      }
     },
     "localname": "ConsolidatedFinancialStatementDetailAbstract",
     "nsuri": "http://www.xoma.com/20230630",
     "xbrltype": "stringItemType"
    },
    "xoma_ContingentConsiderationFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent consideration, fair value disclosure.",
        "label": "Contingent Consideration Fair Value Disclosure",
        "terseLabel": "Contingent consideration under RPAs and CPPAs"
       }
      }
     },
     "localname": "ContingentConsiderationFairValueDisclosure",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_ContingentConsiderationRegulatoryMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent consideration under purchase agreements related to regulatory milestones.",
        "label": "Regulatory milestones"
       }
      }
     },
     "localname": "ContingentConsiderationRegulatoryMilestonesMember",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_ContingentConsiderationUnderPurchaseAgreements": {
     "auth_ref": [],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability recorded for contingent consideration under purchase agreements. May include royalty purchase agreements, commercial payment purchase agreements, payment interest purchase agreements and assignment and assumption agreements",
        "label": "Contingent Consideration Under Purchase Agreements",
        "terseLabel": "Contingent consideration under RPAs, AAAs and CPPAs"
       }
      }
     },
     "localname": "ContingentConsiderationUnderPurchaseAgreements",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails",
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_ContingentFutureCashPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent future cash payments.",
        "label": "Contingent Future Cash Payments",
        "terseLabel": "Potential future cash payments"
       }
      }
     },
     "localname": "ContingentFutureCashPayments",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_ContingentFutureCashPaymentsPerProduct": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contingent future cash payment for each product.",
        "label": "Contingent Future Cash Payments, Per Product",
        "terseLabel": "Contingent future cash payment for each product"
       }
      }
     },
     "localname": "ContingentFutureCashPaymentsPerProduct",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_ContractualObligationEstimatedMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated potential obligations that come due and payable upon achievement of developmental, regulatory, or commercial milestones by company's licensees.  Represent contingent payments not recorded on balance sheet.",
        "label": "Contractual Obligation Estimated Milestone Payments",
        "terseLabel": "Estimate of milestone payments"
       }
      }
     },
     "localname": "ContractualObligationEstimatedMilestonePayments",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesCollaborativeAgreementsRoyaltiesAndMilestonePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_ContractualObligationEstimatedMilestonePaymentsNumberOfProducts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assumed number of products per contract meeting milestone events used to calculate potential milestone obligations.",
        "label": "Contractual Obligation, Estimated Milestone Payments, Number Of Products",
        "terseLabel": "Assumed number of products per contract"
       }
      }
     },
     "localname": "ContractualObligationEstimatedMilestonePaymentsNumberOfProducts",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesCollaborativeAgreementsRoyaltiesAndMilestonePaymentsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "xoma_CreditLossContractWithCustomerAssetPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit loss on long-term royalty and commercial payment receivable asset.",
        "label": "Credit Loss, Contract With Customer Asset [Policy Text Block]",
        "terseLabel": "Allowance for Current Expected Credit Losses"
       }
      }
     },
     "localname": "CreditLossContractWithCustomerAssetPolicyTextBlock",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "xoma_CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold amount of cumulative royalties on net sales per product under the terms of the agreement",
        "label": "Cumulative Royalties On Net Sales Per Product, Threshold Amount",
        "terseLabel": "Threshold amount of cumulative royalties on net sales per product"
       }
      }
     },
     "localname": "CumulativeRoyaltiesOnNetSalesPerProductThresholdAmount",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_CurrentEmployeesExcludingChiefExecutiveOfficerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current employees of entity, excluding Chief Executive Officer.",
        "label": "Current employees, excluding Chief Executive Officer"
       }
      }
     },
     "localname": "CurrentEmployeesExcludingChiefExecutiveOfficerMember",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationEmployeeRetentionBonusDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims": {
     "auth_ref": [],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined contribution plan issuance of Common stock for services or claims.",
        "label": "Defined Contribution Plan Issuance Of Common Stock For Services Or Claims",
        "terseLabel": "Common stock contribution to 401(k)"
       }
      }
     },
     "localname": "DefinedContributionPlanIssuanceOfCommonStockForServicesOrClaims",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum eligible milestone payments receivable per discovery product candidate.",
        "label": "Eligible Milestone Payments Receivable Per Discovery Product Candidate",
        "terseLabel": "Maximum eligible milestone payments receivable per discovery product candidate"
       }
      }
     },
     "localname": "EligibleMilestonePaymentsReceivablePerDiscoveryProductCandidate",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentCommercializationAndSalesMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum eligible milestone payments receivable upon achievement of development, commercialization and sales milestones.",
        "label": "Eligible Milestone Payments Receivable Upon Achievement Of Development, Commercialization And Sales Milestones",
        "terseLabel": "Maximum eligible milestone payments receivable upon achievement of development, commercialization and sales-based milestones"
       }
      }
     },
     "localname": "EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentCommercializationAndSalesMilestones",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones. May also include potential payments for achievement of clinical milestones.",
        "label": "Eligible Milestone Payments Receivable Upon Achievement Of Development Regulatory And Commercial Milestones",
        "terseLabel": "Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones"
       }
      }
     },
     "localname": "EligibleMilestonePaymentsReceivableUponAchievementOfDevelopmentRegulatoryAndCommercialMilestones",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_EligibleMilestonePaymentsReceivableUponAchievementOfPreCommercialMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum eligible milestone payments receivable upon achievement of development, pre-commercial milestones.",
        "label": "Eligible Milestone Payments Receivable Upon Achievement Of Pre-Commercial Milestones",
        "terseLabel": "Pre-commercial milestone payments, maximum"
       }
      }
     },
     "localname": "EligibleMilestonePaymentsReceivableUponAchievementOfPreCommercialMilestones",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eligible potential additional payments receivable upon achievement of specified future net sales milestones.",
        "label": "Eligible Potential Additional Payments Receivable Upon Achievement Of Specified Future Net Sales Milestones",
        "terseLabel": "Eligible potential additional payments receivable upon achievement of specified net sales milestones in future years"
       }
      }
     },
     "localname": "EligiblePotentialAdditionalPaymentsReceivableUponAchievementOfSpecifiedFutureNetSalesMilestones",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_EmployeeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee of entity.",
        "label": "Employees"
       }
      }
     },
     "localname": "EmployeeMember",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensation2010PlanAndInducementAwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_EquitySecuritiesPolicy": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for equity securities.",
        "label": "Equity Securities Policy",
        "terseLabel": "Equity Securities"
       }
      }
     },
     "localname": "EquitySecuritiesPolicy",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "xoma_EstimatedFairValueOfContingentConsiderationUnderAssetAcquisition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated fair value of contingent consideration under asset acquisition agreements.",
        "label": "Estimated Fair Value Of Contingent Consideration Under Asset Acquisition",
        "terseLabel": "Estimated fair value of contingent consideration under the LadRx Agreements"
       }
      }
     },
     "localname": "EstimatedFairValueOfContingentConsiderationUnderAssetAcquisition",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_FaricimabProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Faricimab products.",
        "label": "Faricimab"
       }
      }
     },
     "localname": "FaricimabProductMember",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_FaricimabSvoaVabysmoProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Faricimab-svoa, (VABYSMO) products.",
        "label": "VABYSMO"
       }
      }
     },
     "localname": "FaricimabSvoaVabysmoProductMember",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_FinancialAssetsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial assets.",
        "label": "Financial Assets, Fair Value Disclosure",
        "totalLabel": "Total financial assets"
       }
      }
     },
     "localname": "FinancialAssetsFairValueDisclosure",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsFinancialAssetsAndLiabilitiesCarriedAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_FiniteLivedIntangibleAssetExpectedAmortizationThroughYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Through Year Five",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetExpectedAmortizationThroughYearFive",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_FirstRoyaltyInterestAcquisitionAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First Royalty Interest Acquisition Agreement.",
        "label": "First Royalty Sale Agreement"
       }
      }
     },
     "localname": "FirstRoyaltyInterestAcquisitionAgreementMember",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_FutureMilestonesRoyaltiesPurchaseRightsAndCommercialPaymentsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Policy for future milestones, royalties purchase rights and commercial payments.",
        "label": "Future Milestones, Royalties Purchase Rights And Commercial Payments Policy [Policy Text Block]",
        "terseLabel": "Purchase of Rights to Future Milestones, Royalties and Commercial Payments"
       }
      }
     },
     "localname": "FutureMilestonesRoyaltiesPurchaseRightsAndCommercialPaymentsPolicyPolicyTextBlock",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "xoma_HealthCareRoyaltyPartnersTwoLimitedPartnersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HealthCare Royalty Partners II, L.P (HCRP).",
        "label": "HealthCare Royalty Partners II, L.P"
       }
      }
     },
     "localname": "HealthCareRoyaltyPartnersTwoLimitedPartnersMember",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_IL1TargetLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "IL-1 target license agreement with Novartis.",
        "label": "IL-1 Target License Agreement"
       }
      }
     },
     "localname": "IL1TargetLicenseAgreementMember",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_ImpairmentOfLongTermRightsReceivableNonCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of royalty and commercial rights receivable recognized in the income statement during the period. Includes royalty purchase agreement asset impairment.",
        "label": "Impairment of Long Term Rights Receivable, Non-Current",
        "negatedLabel": "Impairment of royalty and commercial payment rights, Long-Term",
        "terseLabel": "Royalty purchase agreement asset impairment"
       }
      }
     },
     "localname": "ImpairmentOfLongTermRightsReceivableNonCurrent",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails",
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_IncyteImmunoOncologyAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incyte immuno-oncology assets.",
        "label": "Incyte Immuno-Oncology Assets"
       }
      }
     },
     "localname": "IncyteImmunoOncologyAssetsMember",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_JanssenBiotechInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Janssen Biotech, Inc.",
        "label": "Janssen Biotech Inc."
       }
      }
     },
     "localname": "JanssenBiotechInc.Member",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Kuros Biosciences AG, Kuros US LLC and Kuros Royalty Fund (US) LLC.",
        "label": "Kuros",
        "terseLabel": "Kuros [Member]"
       }
      }
     },
     "localname": "KurosBiosciencesAgKurosUsLlcAndKurosRoyaltyFundUsLlcMember",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_LadrxMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to LadRx.",
        "label": "LadRx"
       }
      }
     },
     "localname": "LadrxMember",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_LeaseDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of information about leases.",
        "label": "Lease Disclosure [Text Block]",
        "terseLabel": "Lease Agreements"
       }
      }
     },
     "localname": "LeaseDisclosureTextBlock",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "xoma_LeasedFacilitiesEmeryvilleCaliforniaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leased facilities in Emeryville, California.",
        "label": "Leased facilities, Emeryville, California, current location"
       }
      }
     },
     "localname": "LeasedFacilitiesEmeryvilleCaliforniaMember",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementsLeasedFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_LeasedFacilitiesTwoEmeryvilleCaliforniaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leased facilities in Emeryville, California, in different location than previous lease.",
        "label": "Leased facilities, Emeryville, California, future location"
       }
      }
     },
     "localname": "LeasedFacilitiesTwoEmeryvilleCaliforniaMember",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementsLeasedFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_LesseeOperatingLeaseModificationAdjustmentToRightOfUseAsset": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of adjustment to right of use asset resulting from modification of operating lease.",
        "label": "Lessee, Operating Lease Modification, Adjustment to Right Of Use Asset",
        "terseLabel": "Adjustment to right of use asset for lease modification"
       }
      }
     },
     "localname": "LesseeOperatingLeaseModificationAdjustmentToRightOfUseAsset",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementsLeasedFacilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure of supplemental cash flows information related to leases.",
        "label": "Lessee, Operating Lease, Supplemental Cash Flow Information [Table Text Block]",
        "terseLabel": "Summary of supplemental cash flow information related to operating leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseSupplementalCashFlowInformationTableTextBlock",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "xoma_LesseeOperatingLeaseSupplementalInformationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure of supplemental information related to operating leases. May include, but  not limited to, present value assumptions used in calculating the present value of the lease payments.",
        "label": "Lessee, Operating Lease, Supplemental Information [Table Text Block]",
        "terseLabel": "Schedule of present value assumptions used in calculating the present value of lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseSupplementalInformationTableTextBlock",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "xoma_LicenseAgreementAndCommonStockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement and common stock purchase agreement.",
        "label": "License Agreement and Common Stock Purchase Agreement"
       }
      }
     },
     "localname": "LicenseAgreementAndCommonStockPurchaseAgreementMember",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_LicenseAgreementConsiderationReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement consideration received.",
        "label": "License Agreement Consideration Received",
        "terseLabel": "License agreement consideration received"
       }
      }
     },
     "localname": "LicenseAgreementConsiderationReceived",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_LicenseAgreementConsiderationReceivedAchievementOfFinancingActivities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payments received upon achievement of financing activities during the period.",
        "label": "License Agreement Consideration Received, Achievement of Financing Activities",
        "terseLabel": "Payments received upon achievement of financing activities"
       }
      }
     },
     "localname": "LicenseAgreementConsiderationReceivedAchievementOfFinancingActivities",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_LicenseAgreementConsiderationReceivedDebtRepayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of license agreement consideration received as repayment of debt.",
        "label": "License Agreement Consideration Received, Debt Repayment",
        "terseLabel": "License agreement consideration received, repayment of debt"
       }
      }
     },
     "localname": "LicenseAgreementConsiderationReceivedDebtRepayment",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_LicenseAgreementInstallmentPaymentsReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of installment payments received during the period.",
        "label": "License Agreement, Installment Payments Received",
        "terseLabel": "Installment payments received"
       }
      }
     },
     "localname": "LicenseAgreementInstallmentPaymentsReceived",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_LicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement.",
        "label": "License Agreement"
       }
      }
     },
     "localname": "LicenseAgreementMember",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsAffimedDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_LicenseAgreementNonRz358ProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement related to activities associated with non-RZ358 products.",
        "label": "License Agreement, Non-RZ358 products"
       }
      }
     },
     "localname": "LicenseAgreementNonRz358ProductsMember",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_LicenseAgreementRz358Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement related to activities associated with RZ358.",
        "label": "License Agreement, RZ358"
       }
      }
     },
     "localname": "LicenseAgreementRz358Member",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_LicenseAgreementSharesReceived": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of counterparty's common stock entity received under the terms of the agreement.",
        "label": "License Agreement, Shares Received",
        "terseLabel": "Number of shares received"
       }
      }
     },
     "localname": "LicenseAgreementSharesReceived",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "xoma_LicenseAgreementTransactionPrice": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement transaction price.",
        "label": "License Agreement Transaction Price",
        "terseLabel": "Transaction price"
       }
      }
     },
     "localname": "LicenseAgreementTransactionPrice",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_LicensingAndOtherArrangementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Licensing and other arrangements.",
        "label": "Licensing and Other Arrangements"
       }
      }
     },
     "localname": "LicensingAndOtherArrangementsAbstract",
     "nsuri": "http://www.xoma.com/20230630",
     "xbrltype": "stringItemType"
    },
    "xoma_LicensingAndOtherArrangementsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Licensing and other arrangements.",
        "label": "Licensing And Other Arrangements [Text Block]",
        "terseLabel": "Licensing and Other Arrangements"
       }
      }
     },
     "localname": "LicensingAndOtherArrangementsTextBlock",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "xoma_LongTermRightsReceivableNonCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term royalty and commercial rights receivables, non current.",
        "label": "Long Term Rights Receivable, Non-Current",
        "periodEndLabel": "Long-term royalty receivable, Balance at end of period",
        "periodStartLabel": "Long-term royalty receivable, Balance at beginning of period",
        "terseLabel": "Long-term royalty and commercial payment receivables"
       }
      }
     },
     "localname": "LongTermRightsReceivableNonCurrent",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails",
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_LongTermRightsReceivableNonCurrentIncreaseDecrease": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in long-term royalty and commercial rights receivables, non current during the period.",
        "label": "Long Term Rights Receivable, Non-Current, Increase (Decrease)",
        "terseLabel": "Reduction in long-term royalty receivables"
       }
      }
     },
     "localname": "LongTermRightsReceivableNonCurrentIncreaseDecrease",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_LongTermRightsReceivableReclassification": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in long term rights receivable due to reclassification from/to short-term rights receivable.",
        "label": "Long Term Rights Receivable, Reclassification",
        "terseLabel": "Reclassification to short-term royalty and commercial payment receivables, Long-Term"
       }
      }
     },
     "localname": "LongTermRightsReceivableReclassification",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount receivable milestone payments upon achievement of certain clinical development and regulatory approval events.",
        "label": "Maximum Amount Receivable Milestone Payments Upon Achievement Of Certain Clinical Development And Regulatory Approval Events",
        "terseLabel": "Maximum amount receivable milestone payments upon achievement of certain clinical development and regulatory approval events"
       }
      }
     },
     "localname": "MaximumAmountReceivableMilestonePaymentsUponAchievementOfCertainClinicalDevelopmentAndRegulatoryApprovalEvents",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_MaximumConsiderationRetained": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of maximum consideration retained by Company excluded from maximum potential milestones under terms of agreement.",
        "label": "Maximum Consideration Retained",
        "terseLabel": "Amount of maximum consideration retained"
       }
      }
     },
     "localname": "MaximumConsiderationRetained",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_MaximumEarnOutPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum earn-out payments entity will be required to pay for various milestones under arrangement.",
        "label": "Maximum Earn-Out Payments",
        "terseLabel": "Maximum earn-out payments"
       }
      }
     },
     "localname": "MaximumEarnOutPayments",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_MaximumEarnOutPaymentsDevelopmentAndRegulatoryMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum earn-out payments entity will be required to pay for development and regulatory milestones under arrangement.",
        "label": "Maximum Earn-Out Payments, Development And Regulatory Milestone Payments",
        "terseLabel": "Maximum earn-out payments for development and regulatory milestones"
       }
      }
     },
     "localname": "MaximumEarnOutPaymentsDevelopmentAndRegulatoryMilestonePayments",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_MaximumEarnOutPaymentsSalesBasedMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum earn-out payments entity will be required to pay for sales-based milestones under arrangement.",
        "label": "Maximum Earn-Out Payments, Sales-Based Milestone Payments",
        "terseLabel": "Maximum earn-out payments for sales-based milestones"
       }
      }
     },
     "localname": "MaximumEarnOutPaymentsSalesBasedMilestonePayments",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_MaximumPayableOnRegulatoryMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount payable on regulatory milestone.",
        "label": "Maximum Payable on Regulatory Milestone",
        "terseLabel": "Maximum payable on regulatory milestone"
       }
      }
     },
     "localname": "MaximumPayableOnRegulatoryMilestone",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_MaximumPayableOnSalesMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount payable on sales milestone.",
        "label": "Maximum Payable on Sales Milestone",
        "terseLabel": "Maximum payable on commercial sales milestone"
       }
      }
     },
     "localname": "MaximumPayableOnSalesMilestone",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_MaximumPaymentObligationsBasedOnPortionOfRegulatoryAndCommercialPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum payment obligations based on a portion of regulatory and commercial milestone payments.",
        "label": "Maximum Payment Obligations Based On A Portion of Regulatory and Commercial Payments",
        "terseLabel": "Maximum payment obligations based on a portion of regulatory and commercial milestone payments"
       }
      }
     },
     "localname": "MaximumPaymentObligationsBasedOnPortionOfRegulatoryAndCommercialPayments",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndCommercialMilestonesNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum payments to be made based upon achievement of commercial sales and/or regulatory milestones, net of payment obligations based on a portion of regulatory and commercial milestone payments.",
        "label": "Maximum Payments Based On Achievement Of Regulatory and Commercial Milestones, Net",
        "terseLabel": "Maximum regulatory and commercial milestone payments, net"
       }
      }
     },
     "localname": "MaximumPaymentsBasedOnAchievementOfRegulatoryAndCommercialMilestonesNet",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_MaximumPaymentsBasedOnAchievementOfRegulatoryAndSalesMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum  payments to be made based upon achievement of sales and/or regulatory milestones.",
        "label": "Maximum Payments Based On Achievement Of Regulatory and Sales Milestones",
        "terseLabel": "Maximum payments based on achievement of regulatory and commercial sales milestones"
       }
      }
     },
     "localname": "MaximumPaymentsBasedOnAchievementOfRegulatoryAndSalesMilestones",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_MaximumRegulatoryAndCommercialMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum regulatory and commercial milestones under the agreement.",
        "label": "Maximum Regulatory and Commercial Milestones",
        "terseLabel": "Maximum regulatory and commercial milestones"
       }
      }
     },
     "localname": "MaximumRegulatoryAndCommercialMilestones",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_MaximumValueOfStockToBeIssued": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount of stock to be issued.",
        "label": "Maximum Value Of Stock To Be Issued",
        "terseLabel": "Maximum amount of shares to be issued"
       }
      }
     },
     "localname": "MaximumValueOfStockToBeIssued",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_MedexusMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to Medexus. The Company acquired from Aptevo a portion of its milestone and commercial payment rights under a sale agreement dated February 28, 2020 between Aptevo and Medexus, related to IXINITY.",
        "label": "Medexus"
       }
      }
     },
     "localname": "MedexusMember",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_MerckImmunoOncologyProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Merck immuno-oncology product.",
        "label": "Merck Immuno-Oncology Product"
       }
      }
     },
     "localname": "MerckImmunoOncologyProductMember",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_MerckKgaaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to Merck KGaA. The Company entered into an Acquisition Agreement with ObsEva in November 2022 pursuant to which the Company assumed ObsEva's ongoing rights and obligations under the License Agreement between Merck KGaA and ObsEva.",
        "label": "ObsEva, Merck KGaA"
       }
      }
     },
     "localname": "MerckKgaaMember",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_MezagitamabMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mezagitamab antibody (TAK-079).",
        "label": "TAK-079"
       }
      }
     },
     "localname": "MezagitamabMember",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_MilestoneAchieved": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of milestone achieved.",
        "label": "Milestone Achieved",
        "terseLabel": "Amount of milestone achieved"
       }
      }
     },
     "localname": "MilestoneAchieved",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_MilestoneDosingFirstPatientInClinicalTrialMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dosing of first patient in a Phase 3 clinical trial evaluating biologic assets representing milestone achieved.",
        "label": "Dosing of first patient in a Phase 3 clinical trial"
       }
      }
     },
     "localname": "MilestoneDosingFirstPatientInClinicalTrialMember",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_MilestonePaymentReceivablePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of milestone payment received by counterparty entity is entitled to receive.",
        "label": "Milestone Payment Receivable, Percentage",
        "terseLabel": "Percentage of milestone payment received by Kuros that company is entitled to receive"
       }
      }
     },
     "localname": "MilestonePaymentReceivablePercentage",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "xoma_MilestonePaymentReceivedCounterparty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of milestone payment received by counterparty associated with existing license agreement related to acquired entity during the period.",
        "label": "Milestone Payment Received, Counterparty",
        "terseLabel": "Milestone payment received by Kuros"
       }
      }
     },
     "localname": "MilestonePaymentReceivedCounterparty",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_MilestonePeriodsNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of milestone periods for which entity is eligible to receive payments upon achievement of milestone.",
        "label": "Milestone Periods, Number",
        "terseLabel": "Number of milestone periods"
       }
      }
     },
     "localname": "MilestonePeriodsNumber",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "xoma_MilestonePursuantToAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents milestone achieved pursuant to agreement not otherwise specified.",
        "label": "Milestone achieved pursuant to agreement"
       }
      }
     },
     "localname": "MilestonePursuantToAgreementMember",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_MilestonesPaymentsToAggregateAmountOfPerProduct": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount of aggregate tiered milestone payments to be made under the terms of the agreement.",
        "label": "Milestones Payments To Aggregate Amount Of Per Product",
        "terseLabel": "Aggregate milestones payments per product"
       }
      }
     },
     "localname": "MilestonesPaymentsToAggregateAmountOfPerProduct",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_MilestonesReceivableExcludingConsiderationRetainedMaximum": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount of potential milestones and other payments receivable, excluding consideration retained by company under the terms of the agreement.  Excludes regulatory and commercial milestones.",
        "label": "Milestones Receivable, Excluding Consideration Retained, Maximum",
        "terseLabel": "Maximum amount of potential milestones and other payments receivable"
       }
      }
     },
     "localname": "MilestonesReceivableExcludingConsiderationRetainedMaximum",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_MilestonesReceivableMaximum": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount of potential milestones receivable under the terms of the agreement.",
        "label": "Milestones Receivable, Maximum",
        "terseLabel": "Maximum milestone payments entitled to receive"
       }
      }
     },
     "localname": "MilestonesReceivableMaximum",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_NonBayerProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-bayer products.",
        "label": "Non-Bayer Products"
       }
      }
     },
     "localname": "NonBayerProductsMember",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage, if shares are converted.",
        "label": "Noncontrolling Interest, Ownership Percentage by Parent, If Shares Converted",
        "terseLabel": "Ownership interest, if shares are converted (as a percent)"
       }
      }
     },
     "localname": "NoncontrollingInterestOwnershipPercentageByParentIfSharesConverted",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "xoma_NovartisInternationalPharmaceuticalLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Novartis International Pharmaceutical Ltd.",
        "label": "Novartis International"
       }
      }
     },
     "localname": "NovartisInternationalPharmaceuticalLtdMember",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_NovartisNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Secured note agreement and subsequent amendments with Novartis referred to as the \"Note Agreement\".",
        "label": "Novartis Note"
       }
      }
     },
     "localname": "NovartisNoteMember",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_NovartisPharmaAGMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Novartis Pharma AG.",
        "label": "Novartis Pharma AG"
       }
      }
     },
     "localname": "NovartisPharmaAGMember",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_NumberOfArbitrationProceedingsInitiated": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of arbitration proceedings initiated by entity against one of its licensees.",
        "label": "Number of Arbitration Proceedings Initiated",
        "terseLabel": "Number of arbitration proceedings initiated"
       }
      }
     },
     "localname": "NumberOfArbitrationProceedingsInitiated",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsArbitrationProceedingDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "xoma_NumberOfLicenseAgreements": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of license agreements.",
        "label": "Number Of License Agreements",
        "terseLabel": "Number of license agreements"
       }
      }
     },
     "localname": "NumberOfLicenseAgreements",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details"
     ],
     "xbrltype": "integerItemType"
    },
    "xoma_NumberOfLicenseAgreementsFutureLicenseAgreements": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of future license agreements under optional purchase right.",
        "label": "Number Of License Agreements, Future License Agreements",
        "terseLabel": "Number of future license agreements under optional purchase right"
       }
      }
     },
     "localname": "NumberOfLicenseAgreementsFutureLicenseAgreements",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "xoma_NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of licensed products related to milestones and royalties purchased.",
        "label": "Number Of Licensed Products Related To Milestones And Royalties Purchased",
        "terseLabel": "Number of licensed products related to milestone and royalties"
       }
      }
     },
     "localname": "NumberOfLicensedProductsRelatedToMilestonesAndRoyaltiesPurchased",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "xoma_NumberOfMajorPartners": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of major partners.",
        "label": "Number Of Major Partners",
        "terseLabel": "Number of major partners"
       }
      }
     },
     "localname": "NumberOfMajorPartners",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesConcentrationOfRiskDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "xoma_NumberOfMilestonesEarned": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of milestones earned during the period.",
        "label": "Number Of Milestones Earned",
        "terseLabel": "Number of milestones earned during the period"
       }
      }
     },
     "localname": "NumberOfMilestonesEarned",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "xoma_NumberOfPerformanceObligations": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of performance obligations.",
        "label": "Number Of Performance Obligations",
        "terseLabel": "Number of performance obligations"
       }
      }
     },
     "localname": "NumberOfPerformanceObligations",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details"
     ],
     "xbrltype": "integerItemType"
    },
    "xoma_NumberOfPeriodsCashRetentionBonus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of periods in which individuals will be eligible to receive cash retention bonus under terms of amended retention plan.",
        "label": "Number of Periods, Cash Retention Bonus",
        "terseLabel": "Number of periods in which employees will be eligible to receive cash retention bonus"
       }
      }
     },
     "localname": "NumberOfPeriodsCashRetentionBonus",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationEmployeeRetentionBonusDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "xoma_NumberOfRoyaltyInterestAcquisitionAgreements": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of royalty interest acquisition agreements.",
        "label": "Number Of Royalty Interest Acquisition Agreements",
        "terseLabel": "Number of agreements"
       }
      }
     },
     "localname": "NumberOfRoyaltyInterestAcquisitionAgreements",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "xoma_ObsevaIntellectualPropertyRightsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ObsEva intellectual property rights.",
        "label": "ObsEva IP"
       }
      }
     },
     "localname": "ObsevaIntellectualPropertyRightsMember",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_ObsevaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ObsEva.",
        "label": "ObsEva"
       }
      }
     },
     "localname": "ObsevaMember",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_OperatingLeasePaymentsNonCash": {
     "auth_ref": [],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease payments, non cash.",
        "label": "Operating Lease Payments Non Cash",
        "negatedLabel": "Non-cash lease expense"
       }
      }
     },
     "localname": "OperatingLeasePaymentsNonCash",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_OperatingLeasesNumberOfLeasedFacilities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating leases, number of leased facilities.",
        "label": "Operating Leases Number Of Leased Facilities",
        "terseLabel": "Operating leases, number of leased facilities"
       }
      }
     },
     "localname": "OperatingLeasesNumberOfLeasedFacilities",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLeaseAgreementsLeasedFacilitiesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "xoma_OrganonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to Organon. The Company entered into an Acquisition Agreement with ObsEva in November 2022 pursuant to which the Company assumed ObsEva's ongoing rights and obligations under the License Agreement between Organon and ObsEva.",
        "label": "ObsEva, Organon"
       }
      }
     },
     "localname": "OrganonMember",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsObsevaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_OtherAntibodiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other antibody technologies.  Excludes TAK-079 (mezagitamab).",
        "label": "Other antibodies"
       }
      }
     },
     "localname": "OtherAntibodiesMember",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_PalobiofarmaSLMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Palobiofarma, S.L.",
        "label": "Palo",
        "terseLabel": "Palo"
       }
      }
     },
     "localname": "PalobiofarmaSLMember",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_Partner1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One partner that accounts for a concentration risk as a percentage of some financial balance or benchmark.",
        "label": "Partner 1"
       }
      }
     },
     "localname": "Partner1Member",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesConcentrationOfRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_Partner2Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A second partner that accounts for a concentration risk as a percentage of some financial balance or benchmark.",
        "label": "Partner 2"
       }
      }
     },
     "localname": "Partner2Member",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesConcentrationOfRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_Partner3Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A third partner that accounts for a concentration risk as a percentage of some financial balance or benchmark.",
        "label": "Partner 3"
       }
      }
     },
     "localname": "Partner3Member",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesConcentrationOfRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_Partner4Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A fourth partner that accounts for a concentration risk as a percentage of some financial balance or benchmark.",
        "label": "Partner 4"
       }
      }
     },
     "localname": "Partner4Member",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesConcentrationOfRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_PaymentOfConsiderationUnderAgreementsInvestingActivities": {
     "auth_ref": [],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for consideration under agreements, including Royalty Purchase Agreements (RPAs), Assignment and Assumption Agreements (AAAs), and Commercial payment purchase agreement. (CPPAs) classified as investing activities. Payments may include upfront payments, one-time payments, milestone payments and contingent consideration payments.",
        "label": "Payment of Consideration Under Agreements, Investing Activities",
        "negatedLabel": "Payments of consideration under RPAs, AAAs and CPPAs",
        "terseLabel": "Payments of consideration under RPAs, AAAs and CPPAs"
       }
      }
     },
     "localname": "PaymentOfConsiderationUnderAgreementsInvestingActivities",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails",
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_PaymentOfContingentConsiderationUnderPurchaseAgreements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash outflow for contingent consideration liability recorded under the purchase agreements.",
        "label": "Payment of Contingent Consideration Under Purchase Agreements",
        "terseLabel": "Payment for contingent consideration under CPPA"
       }
      }
     },
     "localname": "PaymentOfContingentConsiderationUnderPurchaseAgreements",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_PaymentsToBeMadeUponExerciseOfOptionSecondLicenseAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum payment to be made per licensed product upon exercise of option to purchase royalty rights on second license agreement between counterparty and third-party licensees.",
        "label": "Payments To Be Made Upon Exercise Of Option, Second License Agreement",
        "terseLabel": "Obligation upon exercise of options per licensed product, second agreement"
       }
      }
     },
     "localname": "PaymentsToBeMadeUponExerciseOfOptionSecondLicenseAgreement",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_PaymentsToBeMadeUponExerciseOfOptionThirdLicenseAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum payment to be made per licensed product upon exercise of option to purchase royalty rights on third license agreement between counterparty and third-party licensees.",
        "label": "Payments To Be Made Upon Exercise Of Option, Third License Agreement",
        "terseLabel": "Obligation upon exercise of options per licensed product, third agreement"
       }
      }
     },
     "localname": "PaymentsToBeMadeUponExerciseOfOptionThirdLicenseAgreement",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_PercentageOfCompensationOfEligibleEmployeesToPurchaseSharesOfEntityCommonStockAtDiscountThroughPayrollDeductions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Refers the percentage of compensation deduction in eligible employees salary to purchase entity common stock.",
        "label": "Percentage Of Compensation Of Eligible Employees To Purchase Shares Of Entity Common Stock At Discount Through Payroll Deductions",
        "terseLabel": "Percentage of compensation of eligible employees to purchase shares of entity common stock at discount through payroll deductions"
       }
      }
     },
     "localname": "PercentageOfCompensationOfEligibleEmployeesToPurchaseSharesOfEntityCommonStockAtDiscountThroughPayrollDeductions",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationEsppDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "xoma_PercentageOfDecreaseInFutureRoyaltyObligations": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of decrease in future royalty obligations upon certain conditions under the terms of the agreement.",
        "label": "Percentage Of Decrease In Future Royalty Obligations",
        "terseLabel": "Percentage of decrease in future royalty obligations"
       }
      }
     },
     "localname": "PercentageOfDecreaseInFutureRoyaltyObligations",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of sales commission to gross proceeds paid to sales agents for the sale of the Company's common shares.",
        "label": "Percentage Of Gross Proceeds Paid To Agent For Sale Of Common Shares",
        "terseLabel": "Sales commission paid per transaction (as a percent)"
       }
      }
     },
     "localname": "PercentageOfGrossProceedsPaidToAgentForSaleOfCommonShares",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "xoma_PercentageOfGrossProceedsPaidToAgentForSaleOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of sales commission to gross proceeds paid to sales agents for the sale of the Company's shares.",
        "label": "Percentage Of Gross Proceeds Paid To Agent For Sale Of Shares",
        "terseLabel": "Sales commission paid per transaction, preferred stock (as a percent)"
       }
      }
     },
     "localname": "PercentageOfGrossProceedsPaidToAgentForSaleOfShares",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "xoma_PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of royalty rights entity has option to  purchase in future license agreements.",
        "label": "Percentage Of Optional Royalty Rights Purchase On Future License Agreements",
        "terseLabel": "Percentage of option to purchase royalty right on future license agreements"
       }
      }
     },
     "localname": "PercentageOfOptionalRoyaltyRightsPurchaseOnFutureLicenseAgreements",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "xoma_PercentageOfRoyaltyOnNetSalesUponCommercialization": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of royalty on net sales upon commercialization.",
        "label": "Percentage Of Royalty On Net Sales Upon Commercialization",
        "terseLabel": "Percentage of royalty on worldwide net sales of each product upon commercialization"
       }
      }
     },
     "localname": "PercentageOfRoyaltyOnNetSalesUponCommercialization",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "xoma_PerformanceStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock units under a share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Stock Unit Awards"
       }
      }
     },
     "localname": "PerformanceStockUnitsMember",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsActivityDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_PeriodOneRetentionBonusEligibility": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial period for which individuals will be eligible for retention bonus if employed through the period under terms of amended retention plan, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Period One, Retention Bonus Eligibility",
        "terseLabel": "Initial period for which employees will be eligible for retention bonus"
       }
      }
     },
     "localname": "PeriodOneRetentionBonusEligibility",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationEmployeeRetentionBonusDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "xoma_PeriodTwoRetentionBonusEligibility": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period following initial period for which individuals will be eligible for retention bonus if employed through the period under terms of amended retention plan, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Period Two, Retention Bonus Eligibility",
        "terseLabel": "Period following initial period for which employees will be eligible for retention bonus"
       }
      }
     },
     "localname": "PeriodTwoRetentionBonusEligibility",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationEmployeeRetentionBonusDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "xoma_ProceedsFromUpfrontPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash proceeds received under agreement. May include, but is not limited to, upfront payments, one-time payments and cash-portion of payments received.",
        "label": "Proceeds From Upfront Payment",
        "terseLabel": "Cash payment received"
       }
      }
     },
     "localname": "ProceedsFromUpfrontPayment",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsJanssenBiotechDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased eligible milestone payments receivable upon achievement of potential development, regulatory and commercial milestones. May also include clinical milestones.",
        "label": "Purchased Eligible Milestone Payments Receivable Upon Achievement Of Potential Development Regulatory And Commercial Milestones",
        "terseLabel": "Purchased eligible milestone payments receivable upon achievement of potential development, regulatory and commercial milestones"
       }
      }
     },
     "localname": "PurchasedEligibleMilestonePaymentsReceivableUponAchievementOfPotentialDevelopmentRegulatoryAndCommercialMilestones",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_PurchasedPercentageOfMilestones": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased percentage of milestones.",
        "label": "Purchased Percentage Of Milestones",
        "terseLabel": "Purchased percentage of milestones"
       }
      }
     },
     "localname": "PurchasedPercentageOfMilestones",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased percentage of non-royalties on net sales of products.",
        "label": "Purchased Percentage Of Non Royalties On Net Sales Of Products",
        "terseLabel": "Non-royalties to be received (as a percent)"
       }
      }
     },
     "localname": "PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProducts",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "xoma_PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future non-royalty payments to be received as a percent upon receipt of specified cumulative amount of consideration paid.",
        "label": "Purchased Percentage Of Non Royalties On Net Sales Of Products, Future Payment Percentage",
        "terseLabel": "Future non-royalty payments to be received (as a percent)"
       }
      }
     },
     "localname": "PurchasedPercentageOfNonRoyaltiesOnNetSalesOfProductsFuturePaymentPercentage",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in short-term rights receivable due to receipt of current portion of royalty and commercial payments.",
        "label": "Receipt of Royalty and Commercial Payment Receivable Current",
        "negatedLabel": "Receipt of royalty and commercial payments, Short-Term"
       }
      }
     },
     "localname": "ReceiptOfRoyaltyAndCommercialPaymentReceivableCurrent",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in long-term rights receivable due to receipt of royalty and commercial payments.",
        "label": "Receipt of Royalty and Commercial Payment Receivable Non Current",
        "negatedLabel": "Receipt of royalty and commercial payments, Long-Term",
        "terseLabel": "Reduction in long-term royalty receivable balance due to receipt of payment"
       }
      }
     },
     "localname": "ReceiptOfRoyaltyAndCommercialPaymentReceivableNonCurrent",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_ReceiptsUnderAgreementsInvestingActivities": {
     "auth_ref": [],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow under agreements, including Royalty Purchase Agreements (RPAs), Assignment and Assumption Agreements (AAAs), and Commercial Payment Purchase Agreements (CPPAs), classified as investing activities. Receipts may represent commercial payments attributable to net sales.",
        "label": "Receipts Under Agreements, Investing Activities",
        "terseLabel": "Receipts under RPAs, AAAs and CPPAs"
       }
      }
     },
     "localname": "ReceiptsUnderAgreementsInvestingActivities",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails",
      "http://www.xoma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_RegulatoryAndCommercialMilestonesReceivableMaximum": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount of potential regulatory and commercial milestones receivable under the terms of the agreement.",
        "label": "Regulatory and Commercial Milestones Receivable, Maximum",
        "terseLabel": "Maximum amount of potential regulatory and commercial milestones receivable"
       }
      }
     },
     "localname": "RegulatoryAndCommercialMilestonesReceivableMaximum",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_RetentionBonusExpenseAccrued": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recorded as expense during the period for cash retention bonuses.",
        "label": "Retention Bonus, Expense Accrued",
        "terseLabel": "Amount of retention bonus expense"
       }
      }
     },
     "localname": "RetentionBonusExpenseAccrued",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationEmployeeRetentionBonusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_RevenueRecognitionDeferredRevenuePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for sale of future revenue streams.",
        "label": "Revenue Recognition Deferred Revenue Policy [Text Block]",
        "terseLabel": "Sale of Future Revenue Streams"
       }
      }
     },
     "localname": "RevenueRecognitionDeferredRevenuePolicyTextBlock",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "xoma_RezoluteIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rezolute, Inc.",
        "label": "Rezolute"
       }
      }
     },
     "localname": "RezoluteIncMember",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCondensedConsolidatedFinancialStatementsDetailsEquitySecuritiesDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_RightsReceivableCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty, interest and commercial payment rights receivable, due within one year or the normal operating cycle, if longer.",
        "label": "Rights Receivable, Current",
        "periodEndLabel": "Short-term royalty receivable, Balance at end of period",
        "periodStartLabel": "Short-term royalty receivable, Balance at beginning of period",
        "terseLabel": "Short-term royalty and commercial payment receivables"
       }
      }
     },
     "localname": "RightsReceivableCurrent",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAffitechDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAptevoDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails",
      "http://www.xoma.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_RoyaltiesPeriodMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum period over which counterparty is obligated to pay royalties under terms of agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days",
        "label": "Royalties, Period, Minimum",
        "terseLabel": "Royalty payment period, minimum"
       }
      }
     },
     "localname": "RoyaltiesPeriodMinimum",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisNis793Details",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsRezoluteDetails",
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "xoma_RoyaltiesPeriodMinimumScenarioOne": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum period over which counterparty is obligated to pay royalties under terms of agreement for scenario one, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days",
        "label": "Royalties Period, Minimum, Scenario One",
        "terseLabel": "Royalty payment period from the first commercial sale of each royalty-bearing discovery product"
       }
      }
     },
     "localname": "RoyaltiesPeriodMinimumScenarioOne",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "xoma_RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Royalty and Commercial Payment Purchase Agreements"
       }
      }
     },
     "localname": "RoyaltyAndCommercialPaymentPurchaseAgreementsAbstract",
     "nsuri": "http://www.xoma.com/20230630",
     "xbrltype": "stringItemType"
    },
    "xoma_RoyaltyAndCommercialRightsAcquiredNonCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty, interest and commercial payment rights acquired, classified as noncurrent.",
        "label": "Royalty And Commercial Rights Acquired, Non-Current",
        "terseLabel": "Acquisition of royalty and commercial payment rights, Long-Term"
       }
      }
     },
     "localname": "RoyaltyAndCommercialRightsAcquiredNonCurrent",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_RoyaltyInterestAcquisitionAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Interest Acquisition Agreements.",
        "label": "Royalty Sale Agreements"
       }
      }
     },
     "localname": "RoyaltyInterestAcquisitionAgreementsMember",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_RoyaltyPurchaseAgreementAndSecondRoyaltyPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty purchase agreement  and second royalty purchase agreement.",
        "label": "Royalty Purchase Agreement and Second Royalty Purchase Agreement"
       }
      }
     },
     "localname": "RoyaltyPurchaseAgreementAndSecondRoyaltyPurchaseAgreementMember",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_RoyaltyPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty purchase agreement.",
        "label": "Royalty Purchase Agreement"
       }
      }
     },
     "localname": "RoyaltyPurchaseAgreementMember",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommitmentsAndContingenciesContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureFairValueMeasurementsContingentConsiderationDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsLadrxDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsPaloDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_RoyaltyPurchaseAgreementTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty purchase agreement.",
        "label": "Royalty Purchase Agreement [Text Block]",
        "verboseLabel": "Royalty and Commercial Payment Purchase Agreements"
       }
      }
     },
     "localname": "RoyaltyPurchaseAgreementTextBlock",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "xoma_RoyaltyPurchaseAgreementTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A second royalty purchase agreement.",
        "label": "Second Royalty Purchase Agreement"
       }
      }
     },
     "localname": "RoyaltyPurchaseAgreementTwoMember",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsBioasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_RoyaltyReceivablePercentageOnNetSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalties entity has the right to receive as a percentage.",
        "label": "Royalty Receivable Percentage On Net Sales",
        "terseLabel": "Royalties entity has right to receive (as a percent)"
       }
      }
     },
     "localname": "RoyaltyReceivablePercentageOnNetSales",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsKurosDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "xoma_ScheduleOfRoyaltyAndCommercialPaymentReceivablesActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in royalty and commercial payment receivables.",
        "label": "Schedule of Royalty and Commercial Payment Receivables Activity [Table Text Block]",
        "terseLabel": "Summary of royalty and commercial payment receivable activities"
       }
      }
     },
     "localname": "ScheduleOfRoyaltyAndCommercialPaymentReceivablesActivityTableTextBlock",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "xoma_SecondRoyaltyInterestAcquisitionAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second Royalty Interest Acquisition Agreement.",
        "label": "Second Royalty Sale Agreement"
       }
      }
     },
     "localname": "SecondRoyaltyInterestAcquisitionAgreementMember",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsSaleOfFutureRevenueStreamsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price Per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageExercisePriceAbstract",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum age required for employees to qualify for immediate vesting of award.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Minimum Age Required For Immediate Vesting Of Award",
        "terseLabel": "Minimum age required for employees to qualify for immediate vesting of award"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMinimumAgeRequiredForImmediateVestingOfAward",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensation2010PlanAndInducementAwardsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfCalendarDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of consecutive calendar days used to calculate volume-weighted average stock price in determining if stock price hurdle has been attained in a share based compensation arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Calendar Days",
        "terseLabel": "Number of consecutive calendar days used to calculate volume-weighted average stock price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfCalendarDays",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfHurdles.": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of stock price hurdles in a share based compensation arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number of Hurdles.",
        "terseLabel": "Number of hurdles"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfHurdles.",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold years required for retirement age (defined as employees that are a minimum of 55 years of age and the sum of their age plus years of full-time employment with the Company).",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Threshold Period For Retirement Age",
        "terseLabel": "Threshold years required for retirement age"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdPeriodForRetirementAge",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensation2010PlanAndInducementAwardsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of successive equal monthly installments  from grant date on which share-based compensation awards vest.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Vesting, Number of Equal Monthly Installments",
        "terseLabel": "Number of successive equal monthly vesting installments"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualMonthlyInstallments",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensation2010PlanAndInducementAwardsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "xoma_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of equal quarterly installments  from grant date on which share-based compensation awards vest.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Vesting, Number of Equal Quarterly Installments",
        "terseLabel": "Number of equal quarterly vesting installments"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingNumberOfEqualQuarterlyInstallments",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensation2010PlanAndInducementAwardsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "xoma_ShareBasedPaymentArrangementNumberOfAwardsGrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of award grants under share-based payment arrangement with differentiated features, such as vesting and exercise price.",
        "label": "Share-Based Payment Arrangement, Number of Awards Grants",
        "terseLabel": "Number of award grants"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementNumberOfAwardsGrants",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensation2010PlanAndInducementAwardsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "xoma_ShortTermRightsReceivableReclassification": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in short term rights receivable due to reclassification from/to long-term rights receivable.",
        "label": "Short Term Rights Receivable, Reclassification",
        "terseLabel": "Reclassification to short-term royalty and commercial payment receivables, Short-Term"
       }
      }
     },
     "localname": "ShortTermRightsReceivableReclassification",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_SiliconValleyBankMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Silicon Valley Bank credit facility effective May 7, 2018 and subsequent amendments.",
        "label": "SVB Loan"
       }
      }
     },
     "localname": "SiliconValleyBankMember",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAgenusDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsAronoraDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_StockIssuedDuringPeriodValueNewIssuesCommonStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new common stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering, net of issuance costs.",
        "label": "Stock Issued During Period Value New Issues, Common Stock",
        "verboseLabel": "Issuance of common stock, fair value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssuesCommonStock",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "xoma_StockOptionInducementAwardOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to first Stock Option Inducement Award.",
        "label": "Stock Option Inducement Award, Exercise price of $18.66 per share"
       }
      }
     },
     "localname": "StockOptionInducementAwardOneMember",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensation2010PlanAndInducementAwardsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationFvAssumptionsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_StockOptionInducementAwardTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to second Stock Option Inducement Award.",
        "label": "Stock Option Inducement Award, Exercise price of $30.00 per share"
       }
      }
     },
     "localname": "StockOptionInducementAwardTwoMember",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensation2010PlanAndInducementAwardsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationFvAssumptionsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_StockOptionInducementAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to Stock Option Inducement Awards.",
        "label": "Stock Option Inducement Awards"
       }
      }
     },
     "localname": "StockOptionInducementAwardsMember",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensation2010PlanAndInducementAwardsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationFvAssumptionsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_StockPriceHurdlesOfDollar30Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to stock price hurdles of $30.",
        "label": "Hurdle Price Per PSU - $30.00"
       }
      }
     },
     "localname": "StockPriceHurdlesOfDollar30Member",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_StockPriceHurdlesOfDollar35Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to stock price hurdles of $35.",
        "label": "Hurdle Price Per PSU - $35.00"
       }
      }
     },
     "localname": "StockPriceHurdlesOfDollar35Member",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_StockPriceHurdlesOfDollar40Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to stock price hurdles of $40.",
        "label": "Hurdle Price Per PSU - $40.00"
       }
      }
     },
     "localname": "StockPriceHurdlesOfDollar40Member",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_StockPriceHurdlesOfDollar45Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to stock price hurdles of $45.",
        "label": "Hurdle Price Per PSU - $45.00"
       }
      }
     },
     "localname": "StockPriceHurdlesOfDollar45Member",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_TakedaPharmaceuticalCompanyLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Takeda Pharmaceutical Company Limited.",
        "label": "Takeda"
       }
      }
     },
     "localname": "TakedaPharmaceuticalCompanyLimitedMember",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsTakedaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_TenYearWarrantsIssuedThirdRangeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock warrant with exercise price of $23.69 per share and a ten year term. Issued in May 2018.",
        "label": "Ten Year Warrants Issued in May 2018"
       }
      }
     },
     "localname": "TenYearWarrantsIssuedThirdRangeMember",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCommonStockWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_TwoThousandEighteenAtMarketAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At the Market Agreement, 2018 in which the company may sell common shares.",
        "label": "2018 Common Stock ATM Agreement"
       }
      }
     },
     "localname": "TwoThousandEighteenAtMarketAgreementMember",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockAtmAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_TwoThousandFifteenEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2015 Employee Stock Purchase Plan and subsequent amendments.",
        "label": "2015 ESPP"
       }
      }
     },
     "localname": "TwoThousandFifteenEmployeeStockPurchasePlanMember",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensationEsppDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_TwoThousandTenLongTermIncentiveAndStockAwardPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2010 Long Term Incentive and Share Award Plan and subsequent amendments.",
        "label": "2010 Plan"
       }
      }
     },
     "localname": "TwoThousandTenLongTermIncentiveAndStockAwardPlanMember",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureStockBasedCompensation2010PlanAndInducementAwardsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationFvAssumptionsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationPerformanceStockUnitAwardsDetails",
      "http://www.xoma.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_ViractaTherapeuticsInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Viracta Therapeutics, Inc. (\"Viracta\").",
        "label": "Viracta"
       }
      }
     },
     "localname": "ViractaTherapeuticsInc.Member",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsSummaryOfRoyaltyReceivableActivitiesDetails",
      "http://www.xoma.com/role/DisclosureRoyaltyAndCommercialPaymentPurchaseAgreementsViractaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_XOMA052LicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gevokizumab License Agreement with Novartis.",
        "label": "Gevokizumab License Agreement"
       }
      }
     },
     "localname": "XOMA052LicenseAgreementMember",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "XOMA-052 license agreement and IL1 target license agreement.",
        "label": "Gevokizumab License Agreement and IL-1 Target License Agreement"
       }
      }
     },
     "localname": "Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureLicensingAndOtherArrangementsNovartisVpm087Details"
     ],
     "xbrltype": "domainItemType"
    },
    "xoma_XomaCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Xoma Corporation.",
        "label": "Xoma Corporation"
       }
      }
     },
     "localname": "XomaCorporationMember",
     "nsuri": "http://www.xoma.com/20230630",
     "presentation": [
      "http://www.xoma.com/role/DisclosureCapitalStockBvfOwnershipDetails"
     ],
     "xbrltype": "domainItemType"
    }
   },
   "unitCount": 13
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org//275/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org//606/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r109": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "44",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-44",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.B)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147481071/942-405-45-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "https://asc.fasb.org//1943274/2147479483/340-40-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org//718/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-16",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org//740/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "808",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(iii)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(iv)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(i)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-21",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(b)",
   "Topic": "920",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(d)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "27",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(b)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(e)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(f)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(g)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(h)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-21",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(b)(2)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(a)(2)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(e)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(f)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(14))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(15))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(17))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "https://asc.fasb.org//1943274/2147483070/710-10-25-11",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(19))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(8))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-05(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-05(4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(b)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "220",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(9))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(b)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479908/805-50-55-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(b)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(a)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480191/946-405-45-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r593": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r594": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r595": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r596": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d-3",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r597": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r598": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r599": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481174/470-10-25-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org//450/tableOfContent",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147480123/805-50-15-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147480060/805-50-25-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(18))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org//235/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org//440/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org//505/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "https://asc.fasb.org//1943274/2147483043/710-10-30-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>98
<FILENAME>0001558370-23-013756-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-23-013756-xbrl.zip
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MPOZ^A;#CAJRXI5[F;64^F,^)AYTVPMZJ6B'E'UI(.6ZAEVY;Z4Z0B\?SZS
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M0A:+5Q3&"'MQU137Y7H^?O(QXTNB\\]6@5<(3?6Z;PGM\LNUE2+M!5=3<(/
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MS4+Q<GH4,W=+T"S.33@,&0.X:/D0Z\^_:\!&"[0@B'STJ ]&.7NY 2M>3);
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MA=A)I<DXQ84\F=-.)'&NZH9&" SLBZR9E;WU/)XG"V8B83ZEB7PG2P3&)H
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MPM+7'4T_'@LFN+W$'OKI?P%02P,$%     @ +3T(5RP;YTLT#@  P+H  !4
M  !X;VUA+3(P,C,P-C,P7V-A;"YX;6SM75MSXC@6?M^J_0]>]F6F:@FW=$A2
MG9DBA'2GB@0*Z)G9IRFW+8)JC,5*)I?Y]7LD;+#!LF5SL2!=M;,=;.GX?.<[
MEHZ/;I]_?9LZQ@NB#!/WIE0[JY8,Y%K$QN[S36G.RB:S,"[]^LL___'Y7^7R
M'[>#KF$3:SY%KF=8%)D>LHU7[$V,$9G-3-=X1)1BQS%N*;:?D6'4JF>-L^K9
ME5$N^S)N309UB&L(8?6SVO).VY='W&OCLG)9J5?K#:-^7:]?5^M&ZW%9[A'4
M&^.T@@YV_[KF__<='F@ 3)==OS%\4YIXWNRZ4GE]?3U[;9P1^@SUJ[7*'X_=
MH35!4[.,7>:9KH5*!I2_9N)BEUBF)VP4JO[VG3J!@$9E^2QI"?ZK'!0K\TOE
M6KW<J)V],;ODJ\AO*SPD*,[OXH3R(2R+\AOR?1O4KJZN*N)N":QG&)\I<=
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M9(\LQ%SW)J:_F<X</2*3_Q:*+G5?O!C <8C>M@E1#Q#O+:OVW &RYG#5?8:
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M3HA))6BZ-ZLMV\8+E?HFAB"@;<ZP9\H&\R2EH\B;S4:]Z DNN4G-@E#W)G?
M9_F[R.Z8U(7.GR^_F4\Y$\B&J ];6!;OIE<\(<9S@LV9B_A<65M!L;=E%3F6
M.X9XDJZ\J*NNO!B.X)_'SM-H:/3NC5Z_,VB-'J" T7KB)1_[@\Y7J/;P6\?X
MJ=L;#G\V'I[@<J>DZQJ-B-W\SR7D]<8C\TW>^<EK'+@Q@ <O-.",2_2-E-'O
M%5<@(/QBIZ/1<,;_,BN:2E9,2?TH2^<@(3%\?.P-T MRY])D0W ["N>R>5[_
M5#!/JC:/ZSX3,.E+T3W YTD1:EK>[]B;M.?, ^!T.:>+SQR"_]GRUCV')/V(
M3Z1/RO;6F/5UC"?BR= E^T%"Q5.A/2M$E8_?HOI7?QU#:N\:E-./P_QMMAJX
M5/;*1;RD#(&-^ K/._!)AXAE"SX,Z?N94$=C6A/)B7M'L\+4L!'^@EQ [P"&
MECW%+F8>M\4+2F8XI=;I<)P'Z.X;8<F(^L-T9F+*G:XWSK?F(YN$XZ=U5Z U
MG/O4Q1Y^%O8:(L]S4'HSG5 C"OH*NK7JD3&=%Z2&:X%:4T(]_+< T1NO+XN1
M#1PD5CH=?G/@U'5]$+0Y)!IA)K^_R97THSA7:BH[1O7NMYBA@?"^?RKY__-\
M^?]V:_C5N._V?M=W#R9NB;5M8R"F]BBVP&3^MC+1"Z&2?40QX9.H*)_->H<6
M_\+O13ZD\V9-H"E  S!;9SQ&EFSH[=!*''X4@NO<IX1/(K1OW[\Q/O5LV=RV
M+ AGDU:*J0O0K\4IQL'6AD2VL9Z&'XP 98R]A&&258$(I%H5(!7]O; E'9O\
MIH#5D#^QG:78\IJ/[D%/)6PFF]H76_@#\)H!^,?XW#\MFG=EC=WG 63KW$1?
MPQ[<#O/P5&Q=N]Q/=2Q9S!7G 7GDG+H?[,PFJ;F#[/E[B3OP>5*N^,2 V.7[
MG#^';RWTP-B<[^S*U5Y.E;PG=(CH"[80Z]&V8^)I[#K(+46>NI/LPSP:)B+N
MT(PB"PO;0MLWH\2>6PD!@K3\"?M#/NPJ*[1VTC9$EWGVS7>1=^ =&:"/>_,3
M*YPPCSG!^T0V=1JEC=NQ=8!,!_^-["\F=A,^UU2JGK 3;&T&WQTN=7*'?8\8
MP'^-ZLFY0 X#^.1?:=2#;R:L$K;WE;A")AD?P#.VMT>0"*KJU$QLPO*WG V6
M*,=N/:OL,RK"/J3SY#9,X$7R?*(67K2V_Q.?/+/8UR!]7[I\PCZD%^4V3.!%
M.LT2C87'P2S&>T?F&PJ 9O&<> D?U5TR6"/P$9UF.&UBDNQHI.PADOH?TC^R
MV"+P#IUF26TB"OI7?RZ]LE>LU8M:H-ZL7Q:]1=0!O$'%!H$7Z)2_E)CFP7U!
M;)OI#C$"]/,+;:<[J%KO8$.I?IY/#.^L[7ZXVO4PW6FVDJ6?_VS)WEIF=:=V
M29U(L;.A-?$E/_-8/F=0KWWJ]&]I"0U7L@6# R/2LJ#=I*COC_B\)"=64^N=
ML"ML9X/4Z14%I#LDIO$/P<T?8<0(B-JDT;RL7_R(,+:SGH8+=P"*A9#-^$+?
MV.D$\GF6R?7T<Y\MR8MI5G+90,-9F4'[V!L'N[VF]2:ADA^!:$74.BZACG=2
M,<-T$1U!$PC8>%?HVO$33_E4([9L*85G]P2TA$G8^WOF1_"W@]M/QY[)?^D&
M2&S.-B(C\XUO0<$W?0-(?)I;ELGD><5]!'?;I6DR3$/=Y0JX.\PLA[ Y1;%+
MX'SCF,YJ+=P=WPC083$'O?EW2A$Z)2ODSJN-:MTH&ZOG\R5R@0I&6 =CJ<1J
M/1TS_(=!K94FABE4^8_A(L_XR2_Q<VE/*^DDJ0C0%GRP"XV,O68C/F3,(^SP
ME)71A)+Y\^2_R*3W4"4N.[&EP ,W/W)M65A-?_A\@*8FYBUS;WP/GF Z7&])
M2[0#R=$W[[S9J#8*:I1VYRKA%FE?)M(P]LX&]0F:H=$K<E[0(W&]B2P VT[H
M#^_*;!T-$X;94')[C5[)3OS)E_7#C52-HF'TG0,</%DVS)U3V@\/4C>+AEO'
M9(=W3^:[B9H"83\\2-DJ&JX'2T 'GVG9'454T@?#%RI?&)-6+4HA/UJM67!:
M0HTL1>>58SRR$'YUND#X?<S1QL4+.G$WR((Z0_)=B\23_*#;K/FGQF[R3[Y"
MANG:AE#)".E46!HJZVG)"N4/?SPWU^B6N."8*>>LQY;5YR57)F/M0&Y%3-D.
MP2I@96-P0"89(\:$;O=(D5))I=/@-@NX;$=D[?C\UZ'IF'1Q'%]G.G/(.T*W
MR$5C["D<OIY>^4C9W %(#5,8B_5L&ZN24L[C3JP4A7[1K#>*6IN1ZVW- 2[;
MN5<-K2(LB#?YPOD^6HQ?9@VKSG<35H$6!E?# #T,H<C^8ZG='A_5>@%E^6*M
M$0E-;O(/7[O#SMQ;V<]_G7+4+_* K$0-;TV&+4ESD5&*/NU';H*E1V[E1*_[
MP:?;':16*,>[I"F%_*.D-OZ@>_]\Q&5;SC?JD^[?FT7$1W&,K6VBE,G9\V&;
MJXY_N1W?(S+Y;]&_+_M\/T_E1N(IDT($;;>\U4Y^[H#O[4.Q^\PMF3'#<U&M
MK8<B7+(A1!MAM?B=932R4$VD<\*)'%\[P_3"4HAK+%4TA(Y%3CP*VW9IQ)4!
MUEY&E0J'/BY[L1IA;0U".I3,]?5I5-1IBYRJO150#0<#%JN4IMGH3JX4A=YL
M-LZ+6J&5C^,<Z(HY1F&EE-B&8+5N4/QL$^9E;+F;FW-#A2AC)7IYR>+BC^#3
M<&F+-5\.72_JD#^9:O*"^KQ:&[K'GN"7K+CN ?=O)L4\PDSC::/<D="DIG>V
M!'AB=/NYLC"?WQ+\\G]02P,$%     @ +3T(5YC.>D,S70  $6@' !4   !X
M;VUA+3(P,C,P-C,P7V1E9BYX;6SM?5ESXSBVYON-F/^@R?LP=R(F,YU+=2W1
M=2?DK=JW;<O75F9USTL%34(2NRA"Q45IU:\?@(O$!0#!%8<T(BHJ;1/+V; =
M?.?@K__W9>O,]LCS;>S^_.;#N[,W,^2:V++=]<]OPF#U]H<W__<__\>__?5_
MOGW[C_/'VYF%S7"+W&!F>L@(D#7[9@>;V1+O=H8[NT.>9SO.[-RSK36:S3Z<
MO?OT[NS=C[.W;_\S:N+<\$D5[,ZBMCZ^^Y!^N$A:P^Y/LQ_>__#^X]G'3[./
M/WW\^-/9Q]G\+BUV1PA;V17E'-O]_2?ZOV?2VXSPY_H_O?CVSV\V0;#[Z?W[
M;]^^O?OVZ1WVUJ3ZV8?W_[B[?3(W:&N\M5T_,%P3O9F1\C_YT1]OL6D$D7 R
MU5^>/2=MX-/[8U_<$O2WMVFQM_1/;S]\?/OIP[L7WWJ3D$@_2W22%J=?;4'Y
M#"_'\E9PK) M_-W[^..Q:(F41%P??OSQQ_?1US?_^6^SV5\][*!'M)I%?_HI
M..S0SV]\>[MS:*_1WS8>6OW\Y@43X5)5G?WETQGE^=\O$S-*_YV[UI4;V,'A
MQEUA;QM)_,V,MO_E\2;/)6GKG8FW[^G']W+M1&Q)R?9]2[Z> F+&E) +[%K(
M)=9.?O"Q8UO4O,\-AZKD:8-0X,NP5ZLYD%P^&!XIMT&!;1I.QRP7VH;"__&K
MOU@]!=C\?8,=B\RP5W^$Q##;RZ"J_>'D<&G[IH/]T$,1'='L?H&W.T)R-/*6
MQK.#I Q=MB45O!%B;"+J!P_Y1.@1.62:>;+7+EF+3(-,.J:)0S+KN.L'HB/3
M1CY1ETG*>E'AQ>K1]G^_1(%A.S6%T7'7*J3'-.%KVR7#V#:<DRTG1,9&_(3,
MT+,#PDXCL775YPCD=4/,PEW;9'3,?9_,B?<H&$)DHFY'(#5"[BWV_0?D/6W(
M(C*$Q'A=CD!:BS"@>TEZ)C@-$EK5)LL.LN9D_KFTG3"P]X-(L@DY*J1\:Y.)
MV"=4DBE[0;8IWMSSR*!)ENYG'^V-1N*JTRXXON_QWO "V[^W_>]__-0]_YSV
MP<KAZVY[]L/W_<FAT#XX.2R-WY'5PS@HM N.[T?T)R9S5+,)LU[+X'C_+\,E
MFP;WW,8!,C?=2X#3/C@YS%<K>XNL[@50;!@<YT^&@Q:KZS @!1_1'KDA.?=Y
MR-@VV^^W[4N%?![QP7"" Z&8G'.WR*-;G0?C0$E^"#US0[J;KSV4\!!NMX9W
M:"2<5AV!E\RM87DO_<LEWPUXJ<QW =KC_L52Z >^7-9D^#>;8]KT UXN9*FD
MGJ;^!5/L"+QDYAYVL==L@]JJ(_"2>3"< 6:87"_@9?+5]@PS&,!:BAV!E\S?
M0P\/,+_DNP$O%;I1;WP&:M<3>-DD6]'%*JGUB$QD[^D]T-P,['WSVX'^J% A
MTVO#]KX:3HCND$%_CZ@^.D]C[SQA]=8VGFTG=I4:GF<C:QX<JR[<1^I(]<@)
MZKSQ/J!70L!(MI/[J7HM@^'] D<WC?&]=.1MCRX9NQ-!50=*_!@H?Q"DOUK7
MAIG8<#-_A62;:NZ&MEOL1K?POQK4C1(TO8/EMZ.*+SN(UT(Z\R>6EER9=V;7
M+;J!@]NX\G>[1MQ+- >'RX]G'\X>'(,B*FY<*S2CP3C_9GA6,XMOW@L<F5SO
MR4(=;G?TYRZEP&X7#M_17Q<1><F^KIFSM7[K<&3P@+P(,TGQ=;3 %]?N?CA(
M=#(&B1RW+X.(IMS;&&34PT"JT1D<"7$6Q1?Z8Y?V(]</'+E<D4;P 9'6 [(D
MDC^<XZ;.^48=P)'$!<*7:&=X](KRN&L,(Q0[Q7(VQ56U[DS)/MW8V0%%?1':
M+\F0MI#;< $2MZ2:M_/]:O'-19Z_L9OMM2L;4\WA/-B>SKBM662W5I?'B(V4
MT7ICR7 MLM#0$1/Z =[.7VS_DA2VR0%N981.%('1:F:0Z$""B97A/T?\A_[;
MM6'L8D80LK;OKUX""I-X=M"5&VZ3X^>M[<N03EOWT[BA4A^4I_>(D$C_0COT
M(S8C%FG7.<H-STR)3WXL*@'Y1 DH]/"._A/U^1[Y:/4^*?_^&ST]OW4-S\/?
MD"='?=$^',\[MD<[?)O\0BC_\,/;#Q_>?HS"L_Z]V)<T)\>>;#=X;]G;8V^&
MXS0C.1.K18/(OHOHBUIK3Q3YF1H'=M]:L;EU2"*C[4X)CD9)/_0F37= ;M32
MVRW:/C>U6#:M^7;;$[HA-'EF^(S>'L70(;G,UC-$$P.QR:8^FIC<WW/](CI]
M6<A*>Z;4MISV:+]ISPXV<]TY-/ 3>XVG0?J7TRR8_.&WS/7'_-D/Z"UNVH-C
M/"/GYS>"$H$=4):9)=X/S\MB%PG374<.[)2JPSUVZ1T.6:<+G$F73_B4*)_C
M^F0[<R_//['MM.W$S!L.V)6'MV(5X?I\GNC^:<9H>A;@F423H4^:PI&3B49#
M[CP;>Z3(SV_.WLRP1]:PG]]\@&0F%W5LY**.@5R,T3K8'#8WC8L:=O%1B5TD
M5\+L69#],9%*\:,"XA\1Z=PV W*V-OP-VY:%91)6.&746"Y'Z%B.E:RMYENB
M9LII >RLE:>7NZ95%6.J6?T*)JMIJ36K2MDU5ZET-OKK>\:.L/U.L>TI7\%$
M23W<2](!I:8X3[*^I=-D_IN"012%NI8\D-GHC//#J4P"PHK(/M'N6O3Z]-[8
MHLO<.2\10)]=)'+LIXL^!S[O+)\,?J;-X$%DF9LWLG30::.?_@M3CM)5Y1(]
M!S<NF1SC;#7E\<POD B054 Y(]S1656,R12,42+0!)9F+&ONY0:IS?,;@F2W
MIXPTCN&G>6<8YEM9+IU2^>44<)<E@FG&_ ()/ZP"ZDRW6@M8@J>L[7);I";,
M:@FD\<806[JV8#="Z D,6%2V:,3LL@HX+1#"M&5AF80S3AD %BU4"Y;CCFG8
MK(:I<7,:[,N^?62^6^/]>PO9L<+)#R<]DU]^NT5KP[F*DMPQ[)?S-?4<%[_V
M3FW<&=L0&9]2^\M]4F=V/&EB(?4YIUV^A<BB<C5[GRA]+\A,'>2WDX+(+[\]
MTKTUPY!*?T\]&:>_#TGA7<Z)D:4Q_R5+Y5WV3DR)_92%B$549PWG6#7RIV2K
M@%I:PV??MFS#.\1I%KC[PJIRZ9+*+Z>"NQ,-=&.^6"W)2=0WS BVSW1&2%=(
M^96HH'#5K=0:;L!S;OGE]1"Y R1:5CU]'O</3R9R#<_&HCTEJTQQ+YDO,Q07
M2:=?7'^'S"C%,MN^J\JEW/#+ =A#,M6 Y;EC[A^SC4;&RV],M<TN*1N+U8UK
M451D:#@,FQ662>3 *:.*BU_M8/.(G,AG2(&02RS8?#:LS>.\JK8ZJQ<K$K>5
M1'8L,+NB8Z%V%Y"V.$?H,,M;R_J6^C3SWU12SG;-LK\6J5=OP6PAXRH.<J[7
M;!.1U[58%9+%12.#WF]XP2&SY?'/#]DOK#-;[8K'ZVGYBHH%PK1E?@$&@^HM
MNH&>L 23N>.C=!?Q?7VY:=6[E&-  \/0F=]24%C^V]#4,NV3\[5(L7K+9 L6
M5W&0M;Q<$Q% K5A5M65=T)3YR*,Q4 =ZL&08F*A(>N7#+#*43PSMBJEJBO1P
M)LJ:]8[SIW0]=<8K5!INSGS6NEE]Q#.H=-N0MAKYV^='9*$X1O\!D:.K58E/
M$%5@7NVS*X!C7 ++(*XBQ;SZ$5-#FR7,@Y0 ^/@'5F=E/ 2O$TACZ*OAV30A
MV"/90C%&#.]S(J'R9\4L,&V?7X#!AGJ[YLH<2["2M=EB0]1"60U LL<$CI%D
M75IXC_9ZPX*:59;+8UM8Y:!P)P+MB$J*.%1OQ=4*PG6XS&UC>$UG\#SL)B%9
M.@5\+E89?"C+D2TJD[ISV654Q,1DL_B[UCUVC=-?LN=XYGUXP]HI7+QN;85.
M;:%2<5M)Y)S:K*[H**G=!:21$Z.:[E"PP=:-NT=^E+*.!FIDGF"*/R#6IJ9Q
M_1S K%9]Z%(2@.T:M=!$4NK7K.:&@;N05G;DUB;E!/>K20*DD9U[_Y&^_GA^
MX(0.290\NKH$)2'P2*EA[P&K2_)XS)94Z=.J5A*NPV?>F<5M/-H'BAH%;O/G
MR#4W6\-C@=%DB_.MOU <!,LI27+C@%.<RW*Q.*@1P=8>:UB(V:X8&[ENF .D
MU+SJJXX[XU_8BT-9D<=",/ +)#)A%1B(^!CTER. :=R5Y1)6!.74F;-  5B>
MM:SEEENDMBIH"=)4/K?^%<9[+O\:>_?H6^:%:_I"3NB:R9&+$0O=I&YZ^*U7
M5YVSPXH5Q3S_BXKD71V%(@ICD1OI#$OQFHLUKM-/A%ECMJ]Z/G\R-\@**9B.
M?5 I_Q4ASA5W%TT=X;YMFAI(=#PB),_MK,+<(WJ^L$+(<Q<Z9A[,!>+(P:-;
M$, ^CN<[!K5TD=G$2AX>/SWC<O5B.J&%K&NB$!I%& ;1;I$(Q/!<,OL<7X0_
M/[ ;8"UT_?>4+HM]]@1&1]QI0+:X4%HPIH(A; ;7EEANB>Z/PLA?7TF9ZL6=
M;$2LT P6WA/R]K;)6K1%11*1LHL,RP*]$$FZ9X//*\OEF6&54S>4A$K \LQE
MC9_5)K5:05N0UC[.VT8BW[-<^9-#JJH\'*Y%WFBY\F*NP7BF)56(ZW->\,2)
M.TI<<54=J)[>CZ&"OR"\]HS=QC:9H7>5Y8HAH^5R0W&$UL7^V6&C5>52COCE
M (2-<M6!Y3EDAHX6&X["1_D-0IKWCR\3G1^./_[-)H//,S>'6[1'+ .O5RF1
MG&PEE4+(O7Q:(I(Y-!K5+8I$KJZZ(513X;B=6+)C3*YG.N!J]@AI$&8HOG')
M 8FSYZHJEE[X<(L!88TYCJH+"MA3/T(J=8-KL)B[#.(T3$U>U" D^SX^(BW,
MG%E1*ITS>:54W.A0D."*WM&EASNR@UVL&"3Z5#4^^Q,[O4$/3:<W2)TVK7!1
MJK 7W*L4<XL4FY+H%JI3"B -ZBAI^-S\([3]6./E$2TJ^MN'@D"K"@-@D3E2
MQ86EV3P55S>B)/6%:S.=&2SB/F9+/*MN&](P>/#P#GG!@2:M#L@@IQ=>.SIH
MN:ZS&C5.3M3J&I!XY^[R:M2HXAW&OJ^.,G$3_@L^YJK.$I=S=2>@QE"2\)TU
M6!B?4LO(?5)(-MO214GTX3PEP)0OKB _9Y.9!B+C YR\_RORJ8]9L%/)E."N
MW(4RZO@0;D=R9:IX@;3Y8*L RW+&V&KD6LSN,$HM03+6&]?$6W3T,=_23MC;
M;(F2B7"$)>'PR#1LJ;)B/M5/MS*JPO5XS4[&@N;IW%S1+"3KIWEET1\A19CM
MDYT+ZZ9-7"J3DYA9"@9?[!NWJG)\WM1;>95:L#Q_Q5S#C&:CVS9^<Y"L.G.;
MD?'=GAN^S4()2I8NWZ^Q2ZO8(6,O,KG@2-SQA].;;4PD?(.:Z=ZZ3DT05VI"
MY>(VLN#<I+$ZC/;N=3J"-*[BA6UIO,S#8!.]1\C=)O$*Y78.Y4(@F!+LB_C%
MN(RI7R<J-(*EF2OO@8J-GK8_K,8@V3*A[\)#EAU<&)YW6&$O>AZ/D1>EJEQZ
MW<,O!X4[KA-%LK2(4QANEFIEX;K<YG*<\)J/KJ"JFH5D_='#LZ$9A!XYF%]@
MG_HOR=^0MV>^<2-7^I@#LZ*TLJ# '&7LD5!5+A<>R"RG,EVRG)JP/)_Y5,G"
MYD_!@,QF5:-*+\)M2!/I[]'5:H7,(,Z3>(I<9(&O:U1)D<A258"PS,9>UZHD
MR;;ZL5%+E[BA&')H;(D.(T"V9$>JQP\=U(E#B[-",+YF5H3<U^%I9MHZ]WN9
M;O46S!,QKN:C.(MGFDE?H2]4A[178;]V'?W53XX8?R+KBTM(C-[ 6L1Y<!V#
M9O&_>D&>:?OHP;--Q'O#K\>>N%="/?4U+OV4^1!>MO704Q_Z$?6E_N*O7R/'
MPVJ+<0W9"W_9Z\R>^((TY5ZB%?*\/(.9/)[T6:K3(U5QY#'9ZI\$\V <XB0A
MKO5 #@H>"NS$#XI<HK' CY$TBQ6S(_X$K9PN[G0!@C*%EG*.W3 BWL.$6LH7
MA0*<!'!BGD8@>H89\-D1K@']=5BIVWZZ5+\B@+#=\OHQH*89RP@ H607G7Z%
M 6GM85^@77O1O;/)NG&J44-XB5NH 21"\DB5=%PDIX8@&K)4 ]J%+5N9G !(
M,?_5E[6YSG@QCZ5.((VA"\/?D$F"_D-1R7O#0>Q4@-4%4P^?H*"J^PO;#)#%
M)HS]5R8$HHNFLC<?C9M2Z!RMM@+<J:!RCE)NYZEOJGFGD,;D->48W=I[FA<]
M(.NU_>R@*/B&; 7B?*/T/1'!Z:=&"]R];,TV8,GI1!_W*KMA*TWDQ6M'_8:^
MF:'@[J3'V$_7HBF[\VU "Z1A_PM]&PA%:.!0-+A+Y;@FR2RIFC/A8&24E..N
MS:#*#PF1>'%E[P6#ZFK4\D<+@]SLF."063#TO[XO2.N6_!I]R/\IH2;'S+=O
MW]Z]D(;?F7C[/N+B$IMA?$44_TLCWJ+'Z&_<%?:VT8GR34X9Z"5 KH6L KMG
M9V<_GLW>SM*&LC\:KC6+6YWEF]TZKI\G+I7VQ[.S3Q&CS^38_28UDV%N/M)K
MLR5]YXYW:5$H]%X-B<EC99%'6G0%QB^?$M[MDK8A-3TS?$9OC\,D:\C,&PRF
MV'-7#WPN"D-Y6&UDR1'.F*R"_<@_,SDE_4@*GV=063VPV%"K +S=8C>BAWD8
M%)3K2?R15-YNDT[$LN>;3T[H9=IWGAT!<7]^\U&Q IZ01W/-/GB)/[):%<(:
M0RKE8QNE"+GH3",^,M^M\?Z]A>Q8&>2'DP[(+[_-+8\I[<*W(>7ZJ8E<"_2J
MM>ECI)_MHAOR8^7BFBG8CZ0-QY&>R$M4,U?29*TM[H0) 5;PDXG)=O0EN'*B
MHC^_\>.LC*?O#O:1]?.;P M;[8"J[3O=2=);#X:)YS\#F#W$6BB3?)K)R\>2
M(>3ZWZ'A!<AS#H]HA[U (.)220!SBKRT2]2K%GR,"[URK4O"@D#LA7)#"OUS
M6Z$7:%<M\BBI6"2S2F,O%QU2\-^UGEM*Y*N2?7SXO[8==!]RMBGE(D/*^B]-
M95TF6ZV,']':]@/J2*+.4ZZ<B\6&E/7W[61=)%VMO&E8I$<&5XP6I"Q<T(>U
MO,,%MOCBKZ@UI#9^:*>-"D[4*F=IO-Q8A =[9<?).BIF'V[Y(17R8SN%<'E0
MJXJY97G(]Y-_* \?N&I@EAW447/63@=,!J#)_V,-^7\<6/Z-#K<5#("0_P7Y
M<>$M\;>BBUA8<E#9-S[2<LD'(?F(_H7WX.&][9K\I9E7?% =-#[HBGD H0B*
MFS6<_V?OA#LD=N%!E=#XX"OB0)4*Z'B<>\C@"#W_>5 Q-S[FYFE6)5B:!\YY
MV&"7?[0M%QE4P(W/MF6Z50DY>;'P\.'C\Y+"#1A"+A<95,B-#[5ENE4)>>D9
M4;##8?N,'8:$"]\'%6_C4VJ!:-4&?/5B;FA0!\<YPRXVJ*0;'S_9M*O=<ER$
MGD=HCMV?U PB:!5WT\$K/NB-4LNS)X\'U6ZR -&P)7N/+HW 2(@4^,?8Q0=5
M1,M#*(\']3YX[X)PL,;>0>B&SY0:5.PMSY\%TM5*^VEK.,YYZ!.2??ZT4R@U
MJ+1;GC0+I*N5]M46>6LRY?WBX6_!AL9$&B[?QCFE!Y5^RR,FAP7%-K]!CE,E
M_'RA067>^+S)HESQ]N:$"8P352S"P \,E^YX^9L<8:5!5='RUE7,B6+5(!JG
M[=RX%GKY.^(/A%*Y0170\BJV1+PR[U:\N;JV?=-P_HD,CX^HX1<=5/*-#[1\
M^E4#:TXD79._L+8[W)*#BK[Q"9=+/@S)QS@K.=GGR@X*X6M\O!4PH$K^<T*/
M%='D&*P%M_!]4#DW/KT6B*Z4[5_?=Q2*=HI!P61!<:-,7*Z/'=LB?[?.#<=P
M342V7R@XT2R.2/MP1B/2CNV2GR\6]Y=7]T]7E_2GI\7MS>5\27XYG]_.[R^N
M9D]_N[I:/KW1@6DZ,$T'ING M-<<%]4J6&V8N*CF&CFOK1%.#0"Q)G4TPN%"
M<?"FNT=>0/,_U-!*92T <2FR@9T5G.@HN%<1!=?XC75__NQ'.0$YFBD6 C!G
MR>FG2'@_Q[SF<D]<,5+B+Y4%L):SK:>L@1+M<!3!23,6O]9CN^LHOQ]O"9&K
M"T91''/+K25R+,'1'Z4R."30$;)!N=[?VQQUL8L"F,RDM</F (XRYJ9)8W=H
M(MI%L$'>(S(1L2&R-OKW*&!C-FK6!; KDU:7)$N=Z8]ZPR*EG/WETUFD&/J7
MWQ[M]2;P3YVS]2 N"B!>N%+L8@[@C!*R2=\9MG7U0C,NH]0X<NQQQHA430 1
MQM(C1(HA.)J3T9%";7!NP^7G*ZAR?_#PCIQP#_2QC"C!'%D'=W3W3Z91[E 1
M50&SZ(L'AX@%.-I9$"H-BA2]18:/H@EXL?KBQ\DX.>JIJ -FE1?IIX*'OI?U
M6^RNE\C;%E>\>^P*5GB96F 6>^XJ+\,%G %2S$]+QN_Q98A?,+:^V4XQ7*)>
M53!+OFBXR+$"1VN9K0@Q*U.XZ'/*@EG\A=,8FW8XBHAI$VZW0.0?D?6&09+M
MK6T\VT[D3" [C.C68(,=PJ4?^QHJ7)/RU0&LZ'(^8WF60&I1SJ4LJ@# 75G7
M*CGZ ^QV3EU##\:![Y*I*@Q+4S4<8D5&^MXJDWZ]$%FI?Z%,-&NG+%$)P#%2
M3@&R#/6M"/KX&-GNQ1 ]W[90G/8I>A3S(?3,#3E(S=<>BJ;IXI+?J 4 ZTX-
M%=7E#LZ$EC\,IRP?Q!-;524 !]%Z$UP50W#TE3[\1].O;2O6'TY9 *?.>MKA
M\#'0ZI/'YES2YQB1:U4O0!7U )PQZZ]!%3S!&2:56P5100!GTGH#I-<M0<=3
M5J5/AE\<UK:M]@F'SQ@<767XJQXPT'9I;<Z<D)1 PUOM('UN^+BW-/E*$=:
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M.+XP2T44NIS:B;/$":AS;N6]!+^\NHN&*AY$IUQ58>:<H7#EV%'VI3O;07Z
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M"N$VW,.MO;4#9/%#>>3KCC8669Y%'9"L Y*[5*D.2.XE(+F72_:C'1)I54=
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MI81$+%9&]+&M>CE-B !2';8_K'_O2/CY(6,=UQ[Z(T2N>1"@I*1J@L%,=6X
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MV:!SL;_!CO6 "(F4AT<4$&ZB FMF+M[^^@*PO$$RL4IY#6=5*5DGHM,G(&/
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M?U9B[9]Z$?MG)=;^N8FU?U9B[9_[$7LGUMYH57VDFP+.EB?S;=I R *S:I3
M' .EK^JW+R6+R4E0F2'?$7%LPRU7BH7OBG<F#(VG8BP0.KP@C1>Q(//?%>\U
M1(+,$PK;<:1Q8QHW-NEK[^&Q5S"3EVI,WPB!6"/&](W&:@=/#=4]?1HDUK^,
M)S PHO\](B(:WP[2?#!]@AFY?4T;]]:]O. 87W_9L(XMQ96* Y9CH KIF1R.
M#X!,QX"\FIN!O2<TU@5>?=\9\"JE0,.N-.RJ3U^XAEUIV)6&76G8U9A@5]HY
MKIWC()WCO;@QCKOP1^PXU]BCE0;W5[&)F+:3?T!!PCG\#\!Y/T^NU^]_#*MS
M+[/&P)8^H>?<]6W9<!/T"$P<^,U:DZC)HFPKKTWFSW[T1)S(U@<F9-IWQ ,+
M$YA--Y$IC#OA,=S\BK8I2F83_;K0P I0/HW#V;3 ,/B!A XV@XO\-E#TT#AG
MEP*+M,EA?&")%\YT/G>B=K.WY5G97+W0'WE3L6QEA?L&6'IG7$!*BA".Q6A,
MCA),SL=QV35D5,_XAXI^VY#I\GBU@P+\XXCLOR:K6UUHVP\UH&W1I[?/Y4])
MWV,"M4F93[*A(#\M5D4#H:;CRP'<.NUKV%GWQB5FB8[Y1VX3$@70-V$-@$"X
M'@PA.TT)Q7&:4SXJ7ETY9 J!;Q5U8"#8) Q80ETI3W 4]@MRR7KIS%UK;FV)
M?.E"21_12J9BX8L@DG4!>*BES#*K/TG6X.BQF^FG"M;6>2_*,&X]R8L->.MT
M;1#9W B0<)-S;G'N" 8PL,[\5(,=.5*A/")RD*!_.,=N6/LM]A]KG#72'F?'
M+F=1GV,Z8URB%?(\[MGY5SO8W+B6O;>MT'"N7DPGM&QW73I0^Q2I38S*0X'M
MQ:=NLLJM; JW75+I+E:G9DA9\E?"'KM[N0,+7,+[3V93)HR=ZHI3#N )!ZXV
M3U.C0**#IS,JT4$E](B<B')_8^^6^(K,2,&!FTRT=@OJ<W0)S9ZKH2J^>KAQ
MO@B),;E!NC[X1X.]V-AH=?6"S)!N^!>K%5F]/7Z$3[-V%"<!:VB:QTO;9DSK
M#,NM,RR/90[6J9L[GE=5IFYN)?EK["'3\ -N5C]>P3%D<!;1K]0=U/L\4>4I
M&I( 94ZDX:7,]B_!714&]T]Q=GOI$V.Q:\6_,/Q-W@?!VMI)5 +@:%)CA+("
MZALX&G>]< LNI2O'7MO/MD-Z9FE6IA: ,!&%JI61T#"Z77[##70KK@4 2JM<
MMV()P0%LU1+4);VILY]#6NC!L'DAEBW;!)"\3NW6HZ7\^IXX"G8=WX/,39-L
M)XH6(5$>0)8WA9.%6#9]:S+IJ'JOQBD(X-U3A;KC" 7.?> %PI=H9W@!*4'X
MNR#G MN-$9_T*59[7Q>'^.&LQMW@Q=5B=NQ^9KBT0$K [$B!OBG4-X7ZIE#?
M%.J;PM=Z4\BZTWJ,;-(2W M*U!K[+: $B^,Y.FHON/:"3]P+GIP'\I%+I2VW
MX'A56?-U^\-EI=3WJ9F! HVA&E%<W=I#*#&T\JHE6?-U.\=EI:3BH'UA[.S
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M.)#_XQ,ZU L:3RBG1[-V"O,+R_KN;_WB^ %=RQXCH617WM'MDY/XKD*"_:'
M=JV&4E'N,;M!P'6PIHR,M$]%)4KT&"&QNEW1:)&AM;\'G$DT?&/5B#M=H09>
MCG&%GJ:22]\-Y2(D \S;7OA!EBJK\)K ^58\;D,R9CXW!_(M>-TF*[/YW1PQ
M<,\[IGCT/8PWG6Q&];Z0I#.+![YT8MI@/2F:,[1%M:JQL#UI*X>BMY0.A.L1
MV\DU5=P":M5&9+IX4L-RIV&20:'WB]Q&RUXA.M8*J,M(4SCM,9)Z]++LMR7>
M40Q=C@V/M?Q(K'C"Z,3 CL=B-(>S?%O^&=,7D]A;$V$ZS_@VVS_A>+,]*0_?
MMC[WA0';[HTD(GJ#7@#@^@@S-DP-JL"&<G2(XT.;K:1Y@M70P))<G%PN>6.%
M+.%E .BU?L92MIZ&!A<6>S,H9)I[6=V6*_VA+-(3=4E%PQ>I0"S.&W4R,H$_
M*M;^>9JZF'NDZ673Z9.\X6$2C(XQXEG-Y3\S/SWJ]XEIG0O; _62@*(GC'HB
M7&_3CWSC=!Z=_B\/CYOSO_YE<W-Q>?_P/;K\CR_7CW^S:@Q<"#05*0K)/Y/U
M5U^5KMPU9R'*W\:Q5.EE$Q:@[*UDFRIYE8C#P:,*/OH[Q=!\)#3/$5:=U8MH
M[_C-(F%=8V%K;RN'M<,KV4"XVMI.KO'!54,W[>=5?L8TBE,(03$4MD:V\:?.
MA^3CX.IC*[4CY3=:*=7C>3Y]J>P$=X[O78?GSL%/G:!5+;OFP-9/+8YK=7K:
M)L#56#VRC2NWE- 1!7]V':(<@9V*ZBE9'K!7W .TJJ]R,&R];>>Q7CQ=-A*N
MIG;0:ZRB0M+O!=[ZKF]EO;\.W1@3@BXP_^]U>+K7O(^"X"J*7YU8=;W:'PIL
M;3:4BJCF/4' U7]31HPKP.;X4($073=RS?(XF2)%.58K#UBM2>9-@?$'>M(I
M(OT^%XZ5PQG-&Y+EW8%HW7(LZ!YC_-/X>:XA>#GQR[#UM=/XS'URR$27WA8@
M''KTO2<GI.5J8$1V'U(G3JTQ_(2?_9#&/5ILSW0(3/S==9)DV+M@I>;O&%D_
M.4&&;_$K^T9]&*PW%[@_ZB.!^N&PQD3 ?JL7^>:'Q?0U)T>#.![$$2&&"1%4
M_&M;%1KFD0,%P]P M?S6!YHVS9Y[/T.[/YV\2,-7R$##\ALS%V?Z*OHGL/T\
MQ)G6^#OW'#/)H<7VIXYZS/W?Z,K ?W&?:P/@J(=]MSFPFIZ77VF3E$29"6\"
M9Y%.L5LRNI&1%,CB7*4&*Y-%3'Q CA>5B"%YT G%4T"BSI2[T.A@K?YNJ^\<
MP9&T UJD)]&0C7:H]6WX$AU>I@O!YO F^M5U+(@H3P.F[H1A6<%TJ5.*0.E3
M(<=IE_M#$!TQ7V;N\A9N=T0"!DM5&ZQ%>ED]">G&;$I B_.UFNQ,%KL5J'.W
M6R!'%#LD;S.QG,0=L?A, ,687^*G$;I\N+L#Y'.X_U6*Q.BLK!7:(OV.KI2T
M0SPUJ,7Y'FV&I@OVVMP/P".X"66EZX$@1T!%'0OLT2QG'":RQMB# "W2!VG(
M1ONP2@IE<9Y'AY?ICJN*TB_D>Q$SK./N*46DXVM^\^[]FU]^(%^'_!'EJ8#L
M!S]C^)L.2(MT.#K2T3_3^C9<CA8S$YYJ+<+I3"HD0Z]C.^!9>_^5)2E]7I@\
M1HJ'#4QB3TV)W>-_9G[BI_@!QR^^B[F,[[$;/8<,"O/QBE]H!K2P?=M<<J\_
MMYD6)URO.1OGYH]^2@)IE=+&&R!4O0%"%9DU3XM*0E%.:>&B!5IYB&BGRS?T
M7X"M&6=<L*XH6(O-L\L*_O4WDNQ_%'+NF +;*>KP*SJTMO%PG9$6U>9U]<I&
M'HTWL"OI4]BY;AHG9?JND>5EM1&%4/KDW$EV5T'TFNC7NI%-@6VT.OPJ*MN<
MC(=KM%I43UK'YGS]\!=T=;/Y^<%2P7_*]UT<4=/R/AV_D(7R.BR[?:_=E!A=
MZN,N73<"!-L"S&73J/G?$PI<:QG RY#"[10G*I"B3T=$T=+@N42,*LP3=]G6
M:2$ZMXR8?+;4=2&JP:AJ5^R4R*QTWR9"V/II2]_>V@#8WN"4EWIMEN);N-8K
MH=$\,J.@[/7I'9$516?;^4_IZ-8W=/T U[IC/$;CK,\3H8)MLU/*5WD"-Q(>
MN'YD4FY'.FDKR4+-MD&T6="2X@GPTDXC%)?2+@O:DD_IWRX5=5'_%DQ<TN\*
M=J&WK/H7J4N[*YWH.G3&R\[NA*X)KWS'/0W_&NT=9F'O?O?Q';,R^LD_SG>$
M0IQ<AY=)ZN_I,>*5X\?L3'^S/8]"Z@:(^R!_)<1IQ3(#' ('IFT.E@PU6V,@
M=BW:B]R,+ABC_M+#M\X<*5V=<($6;0E>],+2KMBM?X&:_EGA?CN%8Y#Y/?O2
M(:%1B191O'E2VF:+*M2HAGOF^PC;,J(*I*<V* O)G^C^;IVLT'I-_Y?V'3^_
M(Q_,NM38%IF1T8VW0-$"AR%=7JND'9H37>3[4.[+9I1749S?4B>;^#QP_'WS
M0&LDD("7K9'D5:Y@ ^$!7\S&XL[XOICCK^>D'0@P5CJB2&@[%Q/:ME&,DIP.
M1/YV&27SKG)0Q"82P)YUH#(/<+.M-1NFU1Z+U)P$;6+$*9G?D]L674V7:FI7
M9DA:R;7!AQB[/C/4VR@\Q)&7N2V[_;;Q,+VS-J>U%!O58+C;_FZ2S:V^@CQ>
M@%&>O]W0LJAWSI$=EQ'*Z6&=S(*[)L!4/WU>RZ6_=33PA5V/=E--K Z@ U95
M]Y##7Z&0.%)ZF#KO>CP7MPP\*N C@H =TMO81$[+,H%SQL[$^>]K,0F5%V5^
MP&X6LX/XJY=;_QX[@?\K]O[L^&'+K;WF5)C^RH3_T[9 [?/@+J*]J!_8-*C"
MLD)7/YW=7J]0@0I17.@-Q39NP3[]S-59)*$Z',)<0DF)W<HEPRPBX+\TO1/\
M@=T3/H=, ;R,=[=4",@/7S"_8(31@:)<%?(W#1W9%KT P/:3_671WG)"-1NN
MSS3@8=1&$U685#P6LIR2,*- A*-B)TDPB0WI87G@.T]^8"]_X%0 :]>-,MH:
M,O0VZ0[']]C%_@OMX:L*HOK"6)J7T)!(NZ-H ; D7Z'#QLC=5PJ4S%884B1@
MM11OS2N9Q]CQ,.,_8OS'%>P534R"X37N8GQP?.\B?^9TR7>#A3S6S.%IBU,3
MV-+\2!\9M3L4'4A+\BR]^!DU(LDQHP(URG&C=>EP.'HPOF86615BR4]U$L'_
M.#)Q6(Y5[IPC=8A$".23.",BK<*JWDZ\ ]C2O$X?&>F%,6V0EN1U>O$SJM<I
MPYH<-?,V.7(D8 >R)YI%4*5,#KE,J,MQ<ID$2IG8\SR4,)ZY_NA\Q85P^@A5
M"6&!/J9=&IV.13Y]8=ZD@XFQ70BSC/Q!"$-8N!,X;F,ZB5"F4\;T0<JT[=-5
M=N=6^,=C_^.GD_E+\PD=DM \6JU/7I(_Z&)AY).2Y@UTB1"(,YA*',T\ W"1
M0K%1N\<O.%26F].9MS0/H."\W?(;DY9D\2K21[;T\J@BQP/$P,?F_DN(G9AF
ML,8<H'CERA\>9*&?)F?1]JP8L<?I+FHV:0%6?$8ASUX 8#N"_K(P*S(#US48
M\#!;49E)O$64.D&;MYA9()U/M0&YB&N6'C)"?:IV0(MT&1JRT7 =+5 6YT)T
M>)G$E92( =63L""C9GTJOQ3+L#H0BL3[/&>7O5^L7@Y^H='/^CG&K-Q?(N&W
M(;"AL& ZCU$D5&;RFP("GN0_F"WCX_P]/<UG#V"IS4192LV&/<V3/2)V2F)6
MQ*C<(/.H4=U'1R=(CU5?HHIF](:^._YA1:]G_>>0?L9N#,@_LSUK5E@;3)\G
M_Y"_3X[V>]K>T F*1PGH4, OR7B+WK!WS#_0QX,$P]8G?M!)I ;_MDKWWSO'
MG'R,L@/14PJ\?/D0A?@L]??B8XB]'Q!XY(OR,T:C\LEU,6K>QQ/6M"A'S%]X
MBG)@N(5?>"5=H6R\NK MJR1_=-[R3M_F,_TEBV? 2LXRP@YI8K9V]YH->+7N
M+X5R?=:?"GQ%-F!DI#78#]D2;'/!+?RY%#Y?<%=:*VXA1;;BQO35:\(7R^;:
M3JPYY0^X65)!7LPM<<BR.^\:.N/O7@K'PBJIM0C8D,6H7G[P:5"Q&CU&:_>?
MF1_CN_P1^ MN39;5F0=S >C->:TH<=<DN"<Y^J0/CFR(<\MQH J)W?S5V;AG
M.\OK.[)(,#3%'5&ZPVCSE%R^./1+1D/BUQ<K.V6?)Y?+EWS[R9;^8J-+-"07
MD,4\7OUSN\$'?^"]87]9F)UXP_6/!CS,=L(-Z;)L*H'4+LMDP38@%W'EAT[H
MCG!9U@YHD2Y#0S8:KJ,%RN)<B XOD[B2$C'\R[(I9=2\+-N68K'=S"4/OC;;
MLNE;1YA6'PG;/[1P)]M2"</@6G@;L6,<")=0+6^3)N"/LG> U'Z0N" 78R^Y
M(EI;U73DK:_9@= U^2!D.Z'0DU>/I^4@D^OBU)(5@MRP(\B6[DR3X@3N$>:0
M>*.'U'0( 7NI6=@V?]/+J5LAL1,\IV[%_YOW4R@\QSJ.:<T2^C<].2XN"3A!
MZ/(K/6DGXVWUS5J K'G@@W-)47E''(/PH#H1).^JNW7,&AG=XX N68_1H_/U
M9S_=[:* RHA6V^W3<&8 .. >=:"<9(%87UB _>!0C@:'=#EFVB*+X$8"<E[E
M>HX&.?VCO]GE]9@_H/3I*PLNL>*"E$DHP6D:X"**S$O].:].#"ER%*J!]UHK
MZO. ^QM=SKNC,&$28 ^B3?K@%9JB4-;$!Q3:3,(\3V(6PD%7J'T/^^!W\#D7
M>*/O+PNS UZX;L" A]D.="'=#4TED-K=D.SXUH:+H *@_T]K_KXX 0^<DC3V
M71*_T"_(AJ_^@3#R#L=^Y)V^7LTW@9=?>1G?>Q(+76ZW6'FO-#L1L%V5G=]$
M='?S4@#795J2PZ [(O8_ AFH(I!_1\MC-3\3QW.ZD:Q03G%H5=".*/&(4V_%
MA2_L!Z++@%>(T^>=.U9\8<#"+T"/L^+J%W)/6U[ 7QNF^,&^;<\]NB/^1OWJ
M*&YR=>+W5B=.T6EWE%,XO -S29=AZPD7!.GI^"SDI"QE%-/3^2W[D_,WG>0>
M4B=.OR79/>%G/PSIFMLFP5F6@X?L<.#GETY &;D*HM?K<!O%>W9^VI$[IC\;
MMHOO*071F6M.A>NV^S)@:B8B'NYV*28DH+*=  9'$K8:7515*'V/A+4*.4D'
MPC9P-6^-6FN-47#-MH76@35#BT*IOH=N3YHGS&.)$S!WSA]Y$*;H,QA6%]6&
MD=W[S[MTL_V2\$<LFZ?4H9U\K\-B8WH5Q?TJI Z#"-ML1Y"6:-\#P,%U!&,P
M9?QTE.*F]06_)/DK.E3@IR<AY8D2-3E8Y5=!2"U+BD=F*!+$AD6Q1;"JMQ9Q
MT2TQ7O)G]>0F]"17+!=^X@91DL6X8R,Q EC8GFPLN37/D8; A.O31N-L4+3
MHO*<!/'Q&]G82]^O5'38WLE8EU_9^EAX+D?$!N9]2_F&(*^W?Y[%,=F/$?E0
MD?%_*&2K.16V.^K#O^AR=.;!=2N]J#=5_1*)U5X3L[!ZIW@TPYO2.,%XQ:$N
MB0_9T^S+*\>/?Z*-@UEYK+P"G*10%HVJA%H&#2F-!1.FD8\JL;*\U%" P(M.
MC<:>J3&5!#2Z8RL+'>95JMBNRQ'*=E1UJ^8MWP1(@I0"Q$C@Z:JE!*4E$ID$
M!4+FK_8$2'2]E(_>7=TXWOU7H8*6C7!N$S\[H?\K(XU**PI\CY_9A]X=+WS&
M_KG9YN&O$SR03SC!'5O3L6##7"LFD: 8,8X"&&Y(.2Y[QC$G3MS8YX\.B=5^
MRA(_Q(F=NB1.2C:2FVU^>*9^<"P="-M(U+S5TLI/1L%5WQ9:C;?^#"1==RN@
M=NIYC,\;(#O+FX&2Q?F.^!RWN\Y/ZP38=M?-JVA_ZM%P[5"#9E.=_>0D/JO@
M(2Y'[#3NP7\._:WO.O0A>TD *BBPH=6,V,U6))4^3J\(/174(_Z:?@K43QL'
M@H1M&6/(2[2=(?#@6M<H7 VSOTW#_M;=]H?^3HE C H[UP@ Y#:/WU*<.E8!
M/?9.P_<+G#I^H%AU3>;#=#7&DBA/#OM,!GY*:,2*\26D@*RX.G,"E!3HD,?P
MS7O*-[<$/!SR&A2"+$J\J-I+(X[:3BSN>>P8S@E*RH1DSNIZM2M4,8$#TVD,
MEDPMH.\+!&XD8LZ*<8>+$J-@-F+2M9BU8#O@F%\\\W@817QQX[L$-\_+V-!*
M5T(Y,=5VOM=$F,ZA/^]E**$U"W@,T8\'4\4NL0AUU!P!T;Q1@PV>&1ZQ0M]<
MEJM:YOO-7*KM2I?R'M.6;+WCK4L+,M\IF%Y+[==>@&+OIY_2B^6]S @[50.R
MO-)>T7ZLNM=OBT=, 0'V<8-D4_7D,X$"W ,.X\D\HQAY>.N'>8[3"XG$:5[C
MS!WJK+!>M!S4[Q0XNHLXX:XUQM&9!-_TNWENFKEZQC),6H/^H3HLZ2-MPX)G
MX/34+"</7UYP_!2U-96<C?E)7=7@\]HRR[(Z4>K*GNB8 M.;]>%7/'!M&P_W
M;%6+:E/%%C**/V.'P@:EO5TW"UUSEJ>_K3<&K1.6I<'C^69!A07X]@_]9^/:
MMN&R9^1="\W)(-BF*>=)M,7Z"+C&IZ#3^!0'3[4E8Y"[+Y6[QL+4*RT.JQ-E
MQ4#@VZU.LHV[5;#"?"EM7NQ5U[K1%OG"A:_S%&4IKR8Q]S'R5'QS8X-PDST'
MGW8W3S^S:X@TH345:2&3Y#9*\6D) 867U9\-TS\92D%<$#6GPETI^S)@GIM1
MM1E!!=(QLSO+=B$Y<,U%57<B3 WNS[N0R*DQ"_C:VX^'@:K+RR*\<CQSYVG.
MR&?-1.&LP_9D8*<V%R'$3_G=$[VARI]NN[T*<?6$ =/'#9)(K<16'P!P5VPS
M-H881(XMOP@0\($UC*XCU-Y O@'3:#UD[0=AX<8Q[G)16,>Z:1T@UDX @H'B
M-LI&HGGCT?,HZ2P8HC$-O&O0XKOA#%KG@#9_/<J-R[VSP+"SE>Y,=0\+NV7M
M,J6,5YUTBZZ[74OC<*BP#6(DJ=4+*0X""=><QF+,O/QBN8#R3K4E!67+:T9#
MK<-UV17;8H8.% %"<E>,%MKCFX0JEZRW-CUJ[&I*TS4)MK/1X[G6@J9U!EQ7
MH4FW>0WG@Y^R%WR6.C7+^=/?<?:9OT2=UMQG:D]>FJ9/L8D2,2&."E%<H#:6
M\XG#N@\H.]EHG\"VSX!MYQK<2OLM+>DL58=H4W45.S !T=:N1:ICRN+TM74I
M:AN_*(T=S\-6*@MJB9F)9ZM5\AK5MX[\?S7KX75/AFVZ_60@J7'7,1.N.?>D
M?W#=NF:)M6/Q'^M&/JLD&I7H;-C]EP1OMD6I=E5=Y9-!L.U8SI-HK_41<.U2
M0:>IUM&6>L3Z2H!6+&P"GB(U3[-UL*/7F?4NX'IKI^Y<V";72P+-AG.=$^$:
M:#_RS8\<DAV_V*=_"(C +)LSRL&1R,%*VUW\@L,,7Q$[H&D%=+/^LY_NSK,D
M)9%\K&?]O8' =@-F,JGUT^T% :YC,.3#^)$\1X<H/E0@1!0C*E""\1661'./
MW>@YE'5C&E++A ,78%_D_>OR;]K=@"D,F%Y@D$2JPB<] 0!_'&#,S@C9"B0N
M=JJ=]H';/^T G9!EDWZ[S5ACE3@WD22-L;.?^07?[ *2. 14H$3%E[:=I1W1
M/.1Z<<7UHA#& ]<+2 F3FILK[=DP/:JA%'2R*$%Y49-DRM$W%^J\+MO.8&Y1
ML*OMLU'RM53-=]D5_0-VLYAU[.8<R'R@<B1,B]7@KFI_*QT&/)[I('K*J 7S
MW).DQ#US,]II.,\S:BJXN;NQT#)V)@;'<R,\3OGL!YCL'4.<\%IQE/2\*AQ_
M3"XKKIGH7'!.A@2P\YI,IJ7?&QT#<)<Y';^F)GE7.=5\"[@OJ5NAN*"O*JT9
M,PK9V:M;U6 \Y$3.ZX?AB3/?+GT69%@2516HY&3E#_2:=2RK(#/_K]6-)SP1
MEU(DT4$NR#1"K8*7%PP=L]H'V8C[Z4V4)+)S3-9076-Y,8(">/TPETI5%*0W
M". KP "&I@RH7486(L,21#:]010^GQ''L,]7@*/"WZ,8N]A_H;72D4-IG[D,
MR?S"Y"@1Q;E27:\PQ##<MP4)K8,@>G6(9V"*=9[%,564RZ\'[+)SE$J 8\;_
MC)6U2S88"3L>U0_JM6<"]K3]N"^]J]XTX!ZU)Q-3>E'F LEW%2WS^L.91,']
MFXAG!2IFM28&.Z\J4D*^3U9@1D]R1;N8X!O_!7O2H]0^\V!ZO-Z<UQ]9=$R"
M>_VA3[KYTX," X]AB%US)&<,"Q@KMR@1.Z6]"6K,2TCKW7:VSX!MUAK<UBN
M*X?#-64=HLW+^%+8B ,'<V$Y+<>.V5YBO">->F;9,ARV37;Q*7W&N!AK[*1X
MA.>+4.QP!E[MF.*E$X=D.Y;<X9@5L-&SR.Y9L U3DVO1/CNFP#537<*-;Z=S
M^(@@R LXS62U&H6;IF;^%O,S.70HF5^G:>P_92D[W4TC))8BSNMKV,D#)%9!
MSS)9[I.?_,)/%.E?"MFUSX!MX!K<UG/\E,/A&K8.T>:Y? )L1$$6)]#T;TNY
M>W.QRVY(3[B<+5LWQCO::_H%\]B@3QV!'M.AVV\_.303=G7F0K;LGAP,2=DM
M$:$\%@564,"2,.BJ;L,#W.)7H79"'(7D3Q=K)]P-  /;(YC*1?0,?6' ]1#&
MG)@'NJ^UHB,UE-!<QNS244OF'M/ (CBBM1<=4NQ9J7GI[K"7!7BS%4[ZFY<
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M'JUNE!YKWU_]='9[/?J[VXZD%Z$ /:/H,TYWD7?-:BK3K=WIIQC3= M%-M9
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M++=<Q8E>L=Q@]FP@805*OJ/45>5)OK,3S(PHHI)9"M/.H>W@7=Y-1\F2D5'
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M/TT)=I4?^JY0#GI^MSPIB\=R^U'<,.RE?%K(S+L.W1@34B\P_^]5%',)J-_
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M+,5)=#,P0NFP4RNF+R$87I:/65[LA%&*(OJR_]6G0>D!N_[6MV;ST\GFLZ9
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M<;L.W6.*K_?[+(PVH4L[@Q]9'DW+-;O&',"+E2['Y:+4-0'XXJ--OOF5/46
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MCU&;+G)RGD\UB[UV&O.Y("MTO=GRVDOU!SHG[.7M4&5",04$V&\.DHWP;M
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M--GL;Z$F9K<HIKGQ1.9Y)QW4Q#(-+2<PU[OQ;R:B*?TKIT44,61AC3C52>\
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M:Z #OTZD!:GB!T3*GO@*26"$R;;$(7P8'OI4VSL=[E18@[2D3']&Y@?J53Q
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M>" R32_"(Y&[?,)DF#82M+76"W0@4:J[>]O%W;1M.#L!WJ+0L!U!%(0KUX'
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M(#/R[="NJ3]9[^P 7L5V\Q6%;4#&>FT'4,/-QH^0E>W:/MK&F^VTIC>.MW<
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M!-]];NN8"V2B+.WRE,OD$K NL\AG(75BW-%,_H"(JS4%8IO5KRM*'US31T:
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M:/<Q'3PLA7U.2B:M=AB#/W.)3$*,,L+?B((=B17>KD)U0.ELFA]P-C=;U5I
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MDVJT^HZT;?7\-VC(AZ-^RYM"F(+X4^_^C/!4X\9;;SPW[OWH$S]F&2BL:Y\
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M1\8Z$#W-NZQQFD?>/O(6H^3]H_0#1ND7' _YCH=\NOLNL(=\;<SF.Y6A"<
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M[E<4QC<T,#9UV07SL)Q.3TY/M&I-.>7E&[\U0%(:P2A).U\CTC7/%X\VMBE
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M_D?:O]Y'KA7_GGZZ6[\V2"PWHZNP%I,,";@N0I]?D#Z1:!M-Q-&1= 2B12\
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M*#17H3*WE>>XE5D,QZ#*4J 9K\%<T0VH'@#@.HKC^6WU4O XG#8>3H%0*.F
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MWC5*3"[;E&86Z)4&:IK;D9O%4L><^>(7WPN")]\S$2(!Z+;UZLV6^(_WGI^
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M&;NT\4,"WBD!UYX%N1D:[5:*;6YA5Z[[9#[?JM>-76]4?U#KK1KK=@/U<_Q
M7Q8SRU8K:9;AT1OUYG7$5TG99FBT";Q7I"QLWM2 $M"HS31B+&"2EQUY%;?J
MHCY/,R-C.IFVXV=XPEY,)_1\R-8WEZVS?=7NW3=-\!9FOC-<+E66*.CYU1(;
M=^-7%?KH;G8N(+]?=[-4N)GU>1/@[D/\>I=I[:&X%(9V0QW,QE9YU9?RZ_BU
M5WUT&+L.\.$)\U<"_G#H+=OYQ0_RRYS::CG8P*20XDI6Y>Y:F\?OL.\'Y*]:
M=/GZIGI/]:D?:3!UV?4G--%<F;8W"0ADG(#_X]Z^U=+89;Z-9"@PX\K^NHWD
MO7;LO/VOZ#?UAKM_AOS?Q<,_J-,]Z47UV9.K;B %MJ*;@F;JIG:]#+S5)FQ[
MIWJ*2/6\;KZ(>AUTR50*9+?*)BVU]"6R<,J$VTK"=>Q+AD1@<3JVLXV7&<-(
MXR2G$ 15F0ZX62=YN=0?T\/F:#\%BATL#]Q#3W]).\S6?,(6X)PNJ] >+3AN
M2>>:(&D(_9GM,&^H0[$M7-]2HIL4;3T@V_60;9P_8ZPPJ;OB/#6<!P]EV@"V
MQX+02!H.3\AQ6RR>)^3-U"&&W09@.\ALZA,/S\#9(X:9.' !PF-R- T*KA=8
MA.T6SFX8];[#;K^"/=A."_ZHUT547$:=5:6J!:-B%Z+M,'&.4%M(7$>I!RPO
MI-'R!_U>MB? OUG'60-&P!.CJ)BAF_2^MG&O0#(')KI?ZI1:*'!JS=0 -%5-
MCATDWU"'K]$EZ0 \K=>\\G3WIZ&W:([[OL,"7@M\!DR:&W%TGT=Q=H'WLZR6
M]MRDF>!W!RN?3?K?;X?^<TSQ)9$"AC#(0,C,=92VIH.%VY@2F4YL-R0]O/AX
M=?/U7(/.-)C90 74>BZ@0TMRTDDS:#\R$W+2H/>SJ,SQ6/H:5-ZW-EC&9K.&
M7B^@>*'?S[1KL_RJ'KL5RD=M\'M0C.80+!V9;HU--UZJWN>:5#9=H#P"214'
M/,OIW:0IUOCM\KI)-]X#/)XTV/TL'N_7E&Z0DOM59E9U5;_6'=#&L&XI:.*B
MAN_9E.X9;Z=;7B/(E&#XQKW$<D<GL[RE$+MP;6J>"]\%P=.0/K!>!^4VKR%3
M[Z6TX,H1Q2E:W:39@=#@_:0A\P6]OC9Y<A6E;Y9;R84E0]<=(X'>ZN"A36YE
MMZA\XSZ*92E% Z/G4"RG@(ZX2,NK=.R\SA_01Q&+%DG9)^.\/QCQJC3=K3S'
M@%,L#%[SK70/-5_9:7(H>!12+O<F_07BS>+7U#-Q?N65Y+^E(&2OZY)Q.O1.
MZ>J+<J""0IDH,ZV^"INP2A76[>4J$[N<Y"U FMRT=> J;O+66/8-SE=@(" R
M"6RXDY5@C %M)XC-&HJNN%#<?7.]6BPKMN-N[Q<NE-K0.5I,/=VKU] &K8DR
M;G%U?@JR'9E?386D1=?O)N1M5>/[6'"C>"@;^HN1KAP_)S8W'1 2D.5TT#7:
M'IIL1D6*+5-?,!E^EDV:B7]D.4_W(!WF.=_8@W0X- *]OLT'?$$&H+M.9?([
M)X#WLRZD\1''#EJ-LN]RA3J5-!C?.<X_H.>-%.Y)+/_9A&>>Q]/7H*UE+H(O
M%:<MA^=D$?3UD!LR30+-X*\4Z#3,^H(<=8H%BH&=$5?(,+)H)2VY=)XXMT7>
M1;+>#'MH'L$C6_S9G0.6N1)[&R?'V'@)0'NBM; Y/1-H#5?\=*T84?86K",0
M*95-,=(,Z2-IC$Q:$/0>6B6]?NP F9GC(\ B6)8,0ROTK="J!U0H@F/RAAM;
M@>%O X*=B_A&LY0UD!07Z&#RGI(130,3\\EK?E&*V\)&Y-)0JQQIU$NR/.W7
M\HG;+7DM=3^.XS<[IYSPY=8%*J]S]#9R@V:C.N[DG1L>&%L"AOF.W<&OZ.Q^
M-=L=T?/.6(5$OV88U47:Z25-9Q\1X_LHY1M4E>-/:GG7'3C_].%+=#3CRM F
M@HE/3%&![RKMNZ"GC4E>DNQ*MXLJ2#&5MJR9FYHF#;]WU]-G>?,]=/5A4@+=
M-"J^*MG\-!2/H$O$3<Y$_40;" -W^P.!Q5!DR-7'-B6NK';2DA0_Y0#?^YTT
M&@58+]N#(O"AO?TYNN,9*MV190F]FJ+JW+!7EZKIXF"1-'L0';S?T/MG>/ 0
MI8A$Z<FA_SK9":_HAB3?# L_-<%*T3T],MD"$]]-F0N^02GB' Q'*ZY-):YK
M2C)E*WS6GKF__PT_'G'WNTCM04;J1! _&UE'<A;*[66L4QER@A&\$8=7VJ6)
M:WJTT$J:_;I-M=//E('#@U4^W_PE@E*GSV,<)V89!]8%)@A!Y"H!O%6Q2"<M
MMQJ_BKZ;IJ).:J^^"HE;:[TIGMAM>GQJ+D$8XFG3EYK$YTV];/4H!I^X;5!.
M55TM:;KS/3-."J\_WG**#.ZF!")@N,%?3D#VI_#TM+;]E6%=*'D:<$W;;RH:
M=%S3>$_>\?,[U<G:LMIH,J4IAY?:BB\Y,[R*)PV0D?:T>I.?^^S@.QEZ6Y7[
M0S;JWZ@YW!M2(G*KNFR4&@.*G3GRA =\GU%^M)3$T_K?%V=Z:DKK70GU5(]<
MH,MB,S.3U]\1);'B5&J_W^P-/\URX<*\7B5<W:ZCVICHO6*9$%4()GJ>:2X"
M B9NN>* .K=>5;MKBXY4>)I =,U*4SQ>N"OZBGW*S'>D(JOJTS5FKCFUNAPF
M+N/YH]"'%R*KQ8FJ;=$]@YBKH;[PFY+;$&H+2D%G'CU?RBF"39I]O5U?I(0&
M+M^K95-,SC/7B4ZK-_'@2*5[8HT6A[[8'"9-5'Y6_O)VF?0=G,I L?M \V#1
MW_]9"1@7JB&_ 1=0V^#KQ?"J87FNLQF0.D'HP2V;$#B>O2%3V89S#QJ"?_Y^
M!R.=+A0\VP[4T6[Y*E\:3D$?DSE$;5D3U'0%"L;.G=EAZ#J*/A]\=(&DGP?T
M%;PX\R87F)&,W.V^G0Z>** 7W/R<2I5<DJ-+QLP%#<>P<[&+&A] _P30\>,^
M.U'TD3HX./X ]Z&KT5/<\-RSJB$J"T7T@';@8,L*G%*K8,ZNL@C&3!4!VEWH
M*O:^+AHIN8U! ;90%6I#,\W:V?0H?L?,A?["V7GN7,DW)WJK\JVG,U"N/4T]
MZO9+STF(S0&>=\Y(Y%Q;+G"%HD0Q"KU<]"<8.A_&$DL_-B-QVM[D,"?Q1GN3
MPZ%1M+G99S!"E?;9=,;EDL0RL .ZZ6#R[E/*K\;^TIC8<QGOC"F\R-N6G,EE
MB6+2ZD:B3U&\48=XGC'?7.Q.$@^7NT\<#8VFS=K[VTL=KG69Z*PRYK+N2O4R
ME?'$DHI=VTQ:@N%&:UUGFHA];?.H3S41BW;EG$!M .I=9DEER[FV5JW45KE*
MTA3B-UPYOWN#LU=[XWY=8YSME:-25AP2HIFC<&/60*I"@VHFKM;SSCUQ;@O0
M=S2W/1T: 4"?6Y@$ (U9/Q,\)W$96ZFRE(^R57F06>%>+6FQUD_J9W($ZY..
M)I=@?3+TLWN^4CR.7Q-I]14;""[HR= &UH87SOO.;'O#/4AGF:POC1:(JK!#
M2EEX17_JQ2[=_P9^+Q+INS@,Q^>#I! \RO,8LM<LF;:!9DX4<QKJ!;81&037
MO73'(28Y#X6-=J?@+F6+*"?-_)^CS?=#7KA$6D#PR!;K;[/SM64:M]DXGN('
M2'8BYKLJLL SA6:709N)4Y9?MKGU/!N^IU!$N0OU?GT_*OVY5FB#G(LRFB;J
MV4Y'9LI)<V:_:]^/^ 'N'KT[VDM>:U:@S*-TSL5:%B0SI6[2TI[)["_P4\3A
M.$_[N65]@K&&&:>/>RI;&XPZ*2*E42"6<(W/LOZ75"I]GK4COTM+97&!4-DA
M6O(4CJ=$/9;&,I:LO5EMSK8&X_0,+-8%[D85A4<_N7[8.L\T@H_.4>78P?EA
M6S;7_$%]"K(C7"4I<3+H%BA#7L;.Y]_IYHNS?*[)>C'-F*QLI&YR*AI^B C\
MTX@8Y2VV/N_T6^A\,4X-K6RIH\?OO-W8(N)=A5I1(R+/9_;%+A=T!*D!QV&F
M&W)LT"!"A2=$^\2-9;V)HX@*L'T6A!KV>?R3P^PV@:U"M^HX'C $& YR]BY1
M^!K;^S5\66K-*WJ'8KRVU.SDG+Z]BET&[ 6B3JGT^]^ 3'_V9/J\I_DJ?7=^
M])4$OF$)"9I'T,R=M!O.8_FG<W0CM7A7HKNW-'NRZ3G $"E%DET(C1T_7A0D
M#K+U)IAS4-6K@Y*SU-@5T_TY-C0RO%]/\INMF.5#MPW+WP?QS^>H!("/Z%"5
MSTK)AP]E<0N];C4[G"VI^KKK8$T9EYW$=2*ZU:$L]Y/!6!P'<U)[<70@S.7:
MBZ.AD?3X/5? ]EGAF>>$JC8$G2D%>MR:U<OEO&7^'(,005"5OENY6/H@J-HA
MXO-!E3'N$V-J E8HWC)PGN51CHU?W79L$8%?CP@\^@)"] D2Z'8+06K[*0R:
M&E "&K69QJ7B03#S*F0[3R[4N6JCM&UD8+<=.X40AC<G$WIW]=]G.8UN2M&O
MXO1F:!0.V&O[F:\3]BYT@6) D0*VH1C2;BV(9V>V1T]:315F^Q737=3F9"KI
M$G]^KLG(CG^4OX0H*MN20:"(58,$EN(";<MF*,XUF*E,AI2>\[VQTR);X_B=
M>OU.-E^<<C*X_=%\P2O2G%6%3%-ENC0UX"I6 \N69#-^;2QC+LW1]L7Z&'\O
M2_,JG9%L9,&-*7\&L4*CF&-H-^E*^T[2?!MN#S-DSI0 BE.*+TU,TW%'E?[-
M/:F[3OY, XI/Z3*N0=34=EDW4;H^7< 5E%O9^'5TB[,NBVQQ]Y,,OJS,I*'3
M:*=;!58=-%%KL<+1/NLE?2'O'LHL8G9_-*OPBC@;W3[01VNYR\W; "F,9NM>
MHY%TF_7%XGR30"-::1[-&6K0&W(H![*=!2$7S>$ZEW0/]#[2?)- (R)I'JV;
MD(>(3W/TI*6TW2F&5Y=)9_-72_,M7,]HI=FIU%/C5H^HH*"Y+,\KA2FH)'[)
M^$[2?!MN+X=5DK"S':AZ^H*>33E0%N8Q"S0BGOS>#\6BT64F18[68D%3@EAM
MT>Q*2U;NCY+N@'ZI+L-N%&B\E\&7E1F;2;?8E97Q5;R:F@H51^X)S:1[H/=0
M9A&S^T+&^T4%X'Y$\ SH%-LVG$+;AN+9RJFK,'/V%GH+QQ0/R?DH,\EA:VLU
MG6-<_-V;EZ6 ^R&OT^O+RD3>]?!89>D_CE#B5@A-0:T$F<Z$4-DUD1ZV6[WF
MHAY_S^PMA)ZEUP.A-T$H:1H+:+O*1(.W0JFP%HKXRDJ-52;C30<U>LHWI/B[
M5J^C] V:/9#ZF16Q>UE[MP[YP4P9(R@4/+1AF&V/O_UBS</:QWX5+S;67N(6
M#4.KI725H2;LD*@H"A22[X_^)&M_;X1^@;5O]>F^IWMXE\,!JV?R*W_=-Y*,
MTI]I[>-0__*R-)F?YY$!K5EE%$R]F3J9E6R9B#^X[EB:?)]2CWLY<6UHNM6N
MP4ZI.>W4IXB'@0Z(?W;OX<1]?;'*O;RX<HZNX<JL""BVU5BMR '3[A?BK\(>
M7ER,(/H%;IP^HTNP7W%KE(_(ND--VV2FEN1P^ >Z<7$I_7OIQRTLNZ+5[*Z-
M^LN\W:]1W2KLQS\E& \_[NM*_.[EQF53TJBY;LU=#C:6:4HJ,MK,2K+R^7%N
MW%<5*=[+BS.("5*I<[V6.AAGBD0'1>;5^!WE\?#B8HS0+W#B%MP@+S&-C,:Q
M.#[L^)V*V4Q 4=/#B8M?P?=+'RZ3+J^44F74Y%C"1)?">MDR\_$WTG'QX;ZJ
ML/M>/ARD^QAB-!<%RJ?'T]2<IZSF)/[P>/AP7UZ:?B\?;F8YF5S9GWOH8*#E
M2,"X,F22;!U_G@]W;X1^@0\WS]8&-JRTNZC""VM+'N):OY3D?/'/].'BL,WG
MI0^W%@F=%R=]EV.(ELVE,O6N@L3?2,?&A_NJ'2WW<N+P->F9/;DPY)!U:JT+
M_1Z7RB4_S?%CG+@OW)-S+R\N:W<FS9S3::E^GLEGD%:MF7W4P#\@^AZ(?H$;
MYWD,@+!*5JELRH#C_F2QLD=)AND/=./BLL/QI1^WZOE6BZPM<14*Y5+=8;IY
M>1E_.QT//^[K=C*^=Y7<+*SK36/,H*#2*F1=9X:GR0=7[[)C);.O80U;G._G
MR@K0 ,&=GANJ;F;6MA4!5CQ;U&"@/4NFI@$[G3FQ)L02V&+8X_KYXC:TIZ:M
M;PY0"._#&<K^P#8:94<^7*4@Y^>:_GA4F)6I>>S256&3\K/4V79G?9,\GS<<
M1W3=G0G[.F%OA[],A%HE ORAG\-?,U?MVF0= E0AQ]VYZXQSW<$WPA_ZP-]-
M\9?ZI/[+NHO)(.>-.8JI4#FIZ2JX9,7.&GX8?ZF'_KLQ_CZI_]1"6F 59+Q4
M\7[1%@6BWE_HWPA_#_UW,5CC4\=.?5L#QO'I-IN),5;8B*5JB)ZP8<&&&#L(
M,7F*655*.0NM(X"P:M 4'3]V)G0?61_,\! ]EZ9X.V9B")J*BIE)/Z\H7Y=X
M/.,Z14XGYSA;!96"(\8.1X_SB@YF^V7G%1T<QGQR!%%TY[IN#IPYV XP;QI<
M1FM0##5PV[";PXQB[_8G@5]!#.?#IUT>I82B.__TE1-QWV-,>DMSJP:0VG*F
M-9?3.D5SDXK5FY567'Q+ ]YE3O:3C%(TG+B=AAL!&A@#[LJ9V*G9A6M>H7!<
M:=6Z8Z^W0&+GGWX(#?M)?FLTO'*,UTLT')P]V8-&PS2D'K3U:N!;&^')X83Q
MM!:R(5UX]18@G87HN1 (8]3/0D1#)Q5,F"9)77QLWC?#S/M.3[[-T6^O' ;X
M,7LR75@UI5_(F"C--U;9MID?HYW8N97QM2=W/P@P C0\VQ-.Y:RL@_ME5#>U
MIM?I!X/7L5VQCI\]N1\:]KF*T$O?_1U&NCW%#<\R#JBA+!31 ]HS(DA9@<$/
M"^BXX8R9Z32(5$X/6?^86L$=L3RL3#E?)>5%*>U6R]DU&CO')(Q6S])GBZ9+
M!/I\Z!@_97:8;WD#OH=#OPM\G_4@XI)E=E7(]RAZZB^775D@<^,'?&.N?1,(
M7VH%!2]T9+?,J8:9,T6/1 <KTQ4YQDIK@))M:S+NT;9?J,3.][\*Q!?)]-#$
MWQ3*S_I8*<LUC!*R"@=:<G-.C <E?1*[*"5Q4/[F6OGR4>D?4ZJ5,L0L!,EU
M.']8M8:6G**L=.P\@Y@JMKL>DQX=&@[B99+(+Y%R*T-EF]:456609HU'O)P
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M7@NE4Y3B+AO4J$<F+8_V([(0B4-K5%D(<U3(UHO-*4$Q/FDN%TH66.(C"_'
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MIVJ#V)8779SQ,V(N3OE[^K+GD:(KO?JL4#=R%,#6*WUM-6JSVV]72!3A#IW
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M+#>7?.*98->5D\\/2LB88 <4!_-3<UIB>H4^_8JFW%]U^<E_*ZL_@028GBU
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M2T=QAA 67,N\)K(WF9M__T%QY&^:C+.IS2"V\.WSP[AYZN9:^\GGJP1U0Z7
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MAPD9ZG4R^;.&?$EZ_?Y)YK.CV(8M'7(Y0GD_B8B B#^5E?R6F_<JQ=U+:J.
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M*Y-? 7+,X22]:[&;]Y6>8QF>"WXCX_U^@'V^HGYM#5G]/)BKD6\Z9U@ )Q'
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MRC>U""<]PV=F,M'+</X94)6!_>I;MJDK*$O \<8H6(*V'M3E5M&DY#6Z#,I
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M0-ONI*IN(G7OPJ9[U,5ANE8B3;5D8=RHE^ZS\ZR7B,.F>]0E1L^D6['328T
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M!F/#3\*&5_>!,39\9YCB8]C0*??;=&PFMD:H9M[2OBV(=!MA W?U#QM/8FS
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MZ:$C.D:\&!$!L )@!?1KN$;_X#MA)=H9:.1U:II3GPB4B,M";82)&:P0 %8
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MD;RFVC)1'MLPU$<7_B0E)UL5TY$%4LV:*"'J2BJJ'E1'U3;M32,QF[.P_<5
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M?U"F9&RSS\9M//UQ!;5^9X7(9Y&B?DME*E<@P)<0R0 R $ ,@!@08 !B0 8
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M2WR/AML:H69'1BDP2X>6#<$RV]9)7Z(Y'R$&-72@?]1%]ZF[ @&^B! ND $
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MU]19'^BK+CJMT04BD+>H1*VIJ3E+U^&: +:8R.]SD>1#/5?8=-2IV!F/%A.
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M_6^'!Z2LD99?UO5H <AED-OWC/E&Q3P@2<:]9;[9'$Q:N?I&!4<P&7,.F F
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M!J--3$%629L!0#,3L;S5UGC$MSIC%%QXH,@"INNP]<"MJM.7%*\_AAU=MK8
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M&^V.F5@F)C^D/A&'W)VM+[@N.GM;D(UHT$8@SO*C#Y\]Z@; [AT#M3ZQ5ZT
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MVA;FFS>!".,O^]D.^ONQ_R\$'>-OW[TB)Y Q10X.X<S+_)2%(V[">JT0GPC
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M\Y==7N=OX?72STDLTNMW]71K<NP$Q)CM; A+%U'/,/UOO[C%?-KPL6:7[$4
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MG:"%W?D/!Q%D543AJK\HZ?U]AQ/],;/%<3<GHS?P%+[>?:?]K=<ZF*/A"5N
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M%FF-,*6Y5:<O=*M^Z:X@UZ%2X\U7<.QKV,I@AZP9* 9$WS0/S6,TF$[=*4K
M1+UT!7O8G;66R! 6NW&$/?^02C(ZB]'I;H-%!'RYK--L+#R" (6A$3=V53C'
M&4\YI9/;/_U3Z'_7R' TC R'D>%/*X.-ORL G#C_CA=%YI4"P% 3P&5)1U:F
MA&LL9+^#U-,=R9V0<J+6XNFWENKM"D!EK1W,12X#T@U#H/:HKRVX8S"CS?D]
M']BC2M0W#TNEPV!<%AO@>!6P9U=P=  [\&07ONB$O_\IH\5[]4RS=$J;G#?>
M.;%%J+/2-R''>_#9_W@/Q&WDK2JS Z0$F#KI$Z$Z9_9)GA-HXA@I10,:>_>
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MI['XN)I@Y4WW>2I/ 9<;=N#*DUM*F:8IK#I2MK 9YE4]STE*<H%6OC)=Z>5
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M5VH@O/>OX?M7W/.C$QFR@3+^:6&$6Q]PN:S^=Y_!A^CD&T>G0RF(GUP,0'>
M:P$$R]3L#T@M /[DD^L%4J^E\84YN9]6+Q +DZ-O 1#1^W@X_.\6 )&YY^(A
M(&X $"%KNA% A*SI1@ 13F'\6$"\TR7WJM9ZTV-3+L.$OU8!RH>,CDF]2(-7
M+Y9 ><PD"23&WMG9(),0%RZ#"S>-"O9<'8H.T4!T>#L3/'</G\07_WP<Z??@
ME.D3XG@)]N=KS"87XHE?N, ,N6>_"I.\:33XZEC _:OR0LH(KYWI8;O0U\)!
MUQ3ECC$ W+6@B@![U76 O,(H3B9JAFE\&,Y?^]C7" ''KS-ZZ3(9O\3S%2;\
M?E"HEY)A3U $708&KTJ%U5K1#@!D@0JFLFGD+%V'I!@0UHUT>K+<GXWGA=RN
M]C#KC=:E36XVCJ&P;B;U4D%32,0_GHAO;BK6%^WS^*^IN%GE]USC21<+\C(W
M3,W+E7+Y&5%Q\M<_T;MX//-QZ6+7\$W9>H:L(E4+]=<3M15*H*.-&FY?E[X=
M_O/-#_E:4.U[L*"+I:]22LMJJF6 %QC.:IQ<3QYKC_E!KZ=FVXHJ#]0"K8-.
MLO'+J0W?''U_"HU>UK-]$S1ZN7;0;R72&#P_GS4WS65KD%LHR;6^+( .F865
M2'(?KA-<6[6UU00%S 0%>R $483;,5'6WA2 T /QU8V7:^D3/]#*N;2*T=:U
M*3 ,N%]!*8*7V%@JFWY</[2Z*Y8;)(J<7,P<_G_VWK0W=6Q;%_Y^I?L?4.UW
M'U5)(<<8,*;J54D&3-^#Z;X@8QLP;G%#]^OOG-,-I@DA"01G+<X^6I4$8WO.
MT<[1/&.:IAQTA'@\]@Q1/*7\&<L(JY-RO9@7=@1%+M98FXY6DAB=EVAFS;G3
M:DCBA@UOCXA@. T>K.>@'#5Z/ ]&UVJFW[N?UW5&GKV[]_%,D)">]D*]K;*V
M\]URE"Y*.MVHT&0BUN7G17;MP*/@ET;L/&7]*>O/T<0/]4\^+.Q#8B-)6'-1
MDAKS7K$PSF;+XRK$0@+^2>*&\X/#$$SQ!P@3^FW;]9_'JG#-S+MY4_^;\9*'
M+_71JNRNM1^4RB.%=I4FFR4;9&S(]3*T.)\H6J&-1S.9EH.N%'M)Q^//D,I3
M]F\917GX4A\M^_<M&?F0\!MB=]W!IP0N97-";-E4%VJR X4?N#'X2SKV+H:U
MA^,1%ND\@A.!O[MP%*S[^J@/*]!>QLD":T!NGGL !1YGPM>X1W_9F\7">"+@
M;#F;$$L>]Y#]W_]ST!SGRQ?$:-",OSTA"BS+;<K#D3S-A*C3>\=.P9/_9N4U
MNS4]9S/]ZD/P_.W+(=R'2 Q[C2?_&PG\#/?C9#,A_D-@RP[P'=RO'4(\>']\
MIP?0I8REZ7_CL5>$? %^=1>6B+VFDG>BU9$73/B$^?_9R-R ,OV?;B-[M@T$
M_@R8$8BN?- UY/X).-((:$.;1K(:0LPP?4YF@YV#;_'JX4Z?VT 6B?F8(PA^
MBF.)\03CR7%B@G/C"<D)8RS)3Z=QDHREIY,_G*>ZWYA,A72:$";C*3LEQHFX
M@(W3$X(?)_ 8SG*I*3GE8@?? *IDV;$VNXI:[DC+76+,C4?;F$U0$)'F^,J9
M.C8;JRRQ9K8&J2X)9B'QM1:XDCR^LKL9=!:M$IUB[$2RM$OILI12UF/\])[9
MF%VI902ARF1[LT*1R/2E>G$&KDP>7XG'JP.LJ)$9FHU':Z7*L"4:&@6N/'EZ
MI9:GF%JGFI;$'3=OLQ8YU&UX9>QD\=UJ"QLOEF1/8JEU16C-+5Q>PI([[.3*
M;MO>97.](I,5^[MZ<AL7!R9,PY]<N0$;9.SP9I[9JCR=B1I2$Z_.P)4GBT^)
MV0JG5U<BO<2(CCAJU(8DOP97GBP^EK<WA=Z G$@%LMK3N'ESUS/@TT\6GRW2
MN#@:M!3,7F9R3'$A]:<M^/33Q9>D>:Y6G$LCJ4\4!]/!NM>HEF"L_F1)@F)O
M6(-L-*1.OUP8$52WI)?AJ?GD2KO>-A)$E"<8<:[G4EL+)[ =-$PG5S**M.,2
M:Z(O+1>[S*X7E;!JC )7GBRIW*F1&9F)DUA%7A.FQA,)''!H^O2>8Y$H]$6Z
MG\0Z>#^6;E1)JZ7-QC'L]-+.=C9<;;,Y@Q&WT?G.7#"IO+4&NW1Z:9&1QM%%
M0\@S2YQ: %.<)AJ=&;STA*(&,R^2B3S?P[)MIE])J^-*76C!2T]6-4E+[+2F
MS1B&[55'RV))&Y4WZ*Y'E!KCJ52:(&))H =2<: '>'8\$0BP?%; \3A)\&F!
M.V&M@1KO=7EA"*2Z/.D5"W5+7;7.2G6[0(VR--7 EO0,JQ6+&;M>!!L!78DC
MUIIU1^*XO(I*8F='I:=&:]8PSTKU8M#G<ATZ:6-"<K:F!\4.7^"A5">.KVSM
MVE6-+$^+=".=XX89T5 372BK)T\O;CM:CVH,^S2QG;-166QFT]19^2]U5A*0
MK;1"BS$^B?69B3$0U^>$FAYF^P6%F<TP<:#;JQ&A56/CV3FA9HR-W>BE69'I
MCQ9R5,IUTC(@[!E921<R^72MBFTQ@:4V1%[@HH4\%9"5(]?&0^5JR(EZ-BX6
M*TPGK?5'6=;HK?4U0MN"^_O&MRYB=)WSH[X=(:TN6)&J9IJ1IF!$.G/6$"*4
M91GBQ'8 JRP-V%%% 4OJ6!HGS<'=!,.,?"]V&LT:<"BY"=X1O6*&-44.>.0Y
M$:(5\&\ J5&I=3VS;N KFBCAVT6'7-JM]CHLT&B'\]!%,\)&# 'L(0?<<8>'
M7% T%>XO:VE&Y$\5$$L&Q/H+%5[!#\'-->"SN1_;L#\8?L^$NP0NLTU4T8TN
M!9J1LV7_UA.XA^@^O+.+$>_N$1W<!-TAPAZQ N>P@AEDA0.HMI>(L.$$P%V!
M>RBP/.P)XA9N$+=D\A5_CK@^:C=_U*SQ)V15. @1NXC9_"3$-Q&"?$T^)2(,
MA(B]DD\0MW 0(O8TUF$@1/H5BST)$0)"/+VFT!#BZ36%@A"I5^()]!D&0@"O
MZ:F:PD&(IVH*!2%2K^13-=V0$!^L?GTWUO<+0M^^YQ_^4+C3Y&?Q_?#8#\?W
M0V,M(\ZX[PBM\@(?N1]8[I-[CO8C_9IZ;)?45]FG(VX^R#RA4[(GV*&1A\S-
MNZ]@A!8@-?W#]><-47+?"PO_NDP0P]"1XF>S ?Y3C&1HV8!\)4^FA_XT+KBA
M,OA-N2#]BOULG^C+D-FNS_/P!J1+BZQ[Y50WU7J/7O+-$&>=&-FCE_/]CJQ3
M8Q N=)HC]74S3^W1U+TELX9!W3P MP!FG7]]9GUJUE^ 69T\Y*_/K.2367\%
M9B5_#K.&+B)Y2L&ZUU/P$^(+86# ]W+4(84E>*]$]SN$)/+GC7$%_"ZFQ-DN
M)D7L5A;IBIJBV=ANH^ST:GEA?AXL"8A*2>4T18#M6']$3+!*<(<SZ (+BRD(
M]7QYRC0*JU2G%&V4T^69@PN??$E@ISA)?_V$(&](I.^[->1M0$$N5Z'^$M*'
M!Z4/']>D2:F5GK0X3!@0!2Y9M:J%XN=Q":^6OFE-S+8RH[%%=WA1KE4)*;LJ
MNH#OB1<B=2_I>]J^L$K?>X66/UOZ/M;!>V_I2[*#P2PY'.>E?HW;KJSJT+#J
M<"9*&H*ZO."Q4URM&QF_I_B%5OPN%Q/^$N)W9/S2Q7J7+J9V-2PZZ<5:S5T\
M.U6^0?Q69F,X)_+-&5,8%MJ91JX7JR)(E!C^Q[_$2SIYT?K]P&S2$4AG53#-
MOR,= 0Z/BU 0:]Q68$^] +OH5R(03/Z&1]W?+_P2CK#3S:)H(4TJ??=!V54S
M\+Z6H BJE959TVQ,$:((M1'-_15(LJBF(4P%PQ!X=$4-C;T?I[#TI&XEFAS&
MSHD9;2UP6TQ2G]9YA\_(>=+KZ$'_34L*H.HYB#\L.8@/%BDCP2CE5D8<%6*)
M/.8.3$G&[WD$?[1T/.I4_NAUWW"H:RBS=]]]@+^-5N#Q4FZU6W<M6FA/,MUU
M5>J+HX=IA:&^:$G%>GXH]3FJR.M&AZDO9LY\E?MIA:>O\ MHA9"F2;\[L' ;
MK9"42E9LD.J/F4(O'6^/6E*]'G^85JCA57V*5WHD1N1ECHA38POO0U\!!BU>
M,.)TO-KM8A:/EH^G7O@U,]+?'?&XC5Z8;1/;=FL[GF'"M%<P1^GR:MKY?,KN
MBWJ!$.=D=8#C':Q#5W<+TMZDN,8:Z 4837E7,80]^W\I=)*Y=^CD]]!QO_?T
M)C>Z$M[I33\@U)(YJR:CL2'7FO42.:PPT+(V+Q>F._/SN=4OJLEDM24J6CQ1
MD<3F9+&=M7K1::[E3( CXZ>S%)[5#A^+J_S>6L2-QOS>6N2+SM9Y+;(<2^T>
MWV K3&&97W&-Q##3'C[,V>)7Z6A&:Y0D6M $K#_L5N>[G#M:[GY:Y.F+_!Y:
MQ(W>_*9:Y#:AG/-:1!GM,KWAH-&BQ76'RJM4M-'(?3[5_44MTBK5&WQRJB08
MO,G5Q50'YZDLG$:+0CE$*ODL/WGJD:]'>WYO/7(7;Z3?&#;4M&"S=(?1QGG>
MPC>MW,/.-+J28^=$+E.1EAV)CL53O)%:0V_$"?V\HTA^8"%-L!?DBJD2+Z?S
M*9ZILMN'Q!\^-#(<(:00;DRXPDKW;'6A5JPHHPD^FC-I*#AH"$WZN521.,KN
M:#LW2Q(T7I_UEA-B9RT*:V?.[F^R1^X4I,_MTA@5;J:(<R-)GR5,]R]A>KBB
M"4?X+80;$ZZ0W#W;G;ZF@<UI;)>N\J4.DQWF\JTJWJMNUS-GV/%OLD=7:."W
M=\G1P-B9$.2S7.SW\X%OUY 6QJ6&*T!YSR:VK^E4B9Q,4[P^,[%*3NGTRM.A
M+1;@G-[T_71JR/;H"IWZ]BY!G1I+O:03Z6]S:Y]*-52:)AQQW!!N3+ABN_=L
M9/R:"IYLQ+RVG:>36",Q,3=RTQ3$ 7388OC==7!8-ND*'7QAFZ 23K\0)/$A
M'1SVLL9_WL$7C2!<T:#".;GHUT!F#X.:?4#+^HV;0Q^K[A]!L=^FL.X77V08
M0(=^P8$782#M ]3JHTJV?C_^_6U*B7ZF6Q *.)M/D^QG5J9<=.AS@JHIHOK+
MC0P(4;3H9TIJ2-%='N73/YJN(4KJ_TQ^#BLNR:.<_$<3]JF@?TU(C4<Y_8^F
MZY.??U$HB&\^+7PK\?KH+"#P$1:\&3L3(N:<-<#M;!/\351A[;IN6^ =3@O6
M(ZI7\*X+AO.]:TK?GT&J7_^0__#8?R2^!^A (GQ=0M-A_G&^VF_5>PL+PQHV
ME2.&%5$ER-:-JZ6Q#Z0T/2FE'"&MV[#EIS'MH-=MV)8)%P#VU\OZ.EE,S,]B
MMJ-$O+^TLAQMR_P U^J+LMY8CV/8!\K(?]C>N+G=DRWZV.Z@0IO82X*X(LG[
MS!X]LT?AR1Y]OP;\<+7R=VK 4;+6HNQ"2F<(;"!;>'V<J#4I*./7EW'_L+WY
M@ :\L#N>!L1/P;KNHP&?KEVH7;N'IQ6_4;%]MF3X.Q7;#*\E<2:?[DJB28TV
M!)O$^5@+BN[UM=0_;&\^H-@N[([OVIV.5+F3:_=4;.%6; ].3'^_8OMP'>YW
M*K9$9FSW4YE$2HJF1G:SW:ZL.1;Y)!^H4/YAF_,!S79I>US5%D]]Z-3Z,VL;
M,C<*2S['VOST/,3MYKR&+P7Q3MN*@\^#^C%<C=>K]4BSB#7'6&&X*:VUE:1P
M,,9VTS =_@&-1[.&"G;-; H&4F]O-*CL%5Q_-,R:K=1"D#IJN]P5TFIY$04*
M+O9^S/(';L>;K2A7;0A4^-AK\ONZ 9_U,+_1NL-:./,M2O'#D;O[*D5)J'3K
M/2[)L#LU+QNDF--6,Z@#W@UC_L#MN$8IOKTAKE*\XGC_Q)UX^GZA+:>ZLYK[
M;!SOKFIN(QM->4,I,T:1M%@7'Q26:7(-I?K=H.8/W(XKU-R%#4&'_==DZHD$
M\51S/[G*[EO4W(>#>G=5<ZHX2%;(85O'B*6X7!MIML(I2*K?#W'^P/VX0L]=
MVA''GR-/D8/?A5OX7Q3X"X\F<EZW;BO@_MP=Q&MAFY8XW3I_$E7P(M;?<>+@
MU5&B(8;[V8:F9H&K1%:6MTX@55P)$5/@;$.TX$0K&$45-IQL\P(?F1J:$K'F
M0@20CX-#KB![:M.O1F#%*;RI:$1$%3S(A#<5P9/!:T6]5WIUPK0'&W@+0W[(
MN!UN+O"V+#2F%'BX]^R.OQNTNQ%YL ]95""+GMF8'G-\%[Q61@9+=!E\,IY4
MB/1@,A+2#-YGV\M6.<7%X.1& 8B"#E[!,FSA'AKW"I8 7- %-)UJLJRM8<6O
M0RQSKJU-1.VUF[2('M4*(W;0]MF*(-\ VIA 3QFPPCA(2!2Q!S<U!*!.SK+6
M?E]OP%I_BBJXJV:;X+'F7W\C)GK0'A]H#.<3'PD?R..UZ"DN<9S;N*A+'" =
MJYO"W]X/P9>%+S)W.C\5=A-%0J-Z[Q:5A:GU-VM;FO<'9**=O[C>@'--P#UP
MKX%_<9TD#/LO7*%E>"_F/C#FK/SZQ-+%3"POKL[<7P/WG +.]7;-^ST*?9^_
M)X; 2M$UV*=_=,T4(5O];0A0=:V$HWNZQ$ /]BYE)Z8&&?!HH?>9*?B*)7V]
M?(JTXWSO>D;Y7[ T_]^[UF8]Z?(8NJ1?$_B3+N&C"_YZL03X298'J3'L-99Z
M$B:$A'G:EU#2!=B7IS\60KK@K]C%;J$G71Y#%_(U]I27^]'E$W6*WU#8^XE-
M(#^P"3^JJ>:>.\!I,OPCPNC]I-J,O:8>.H.0/ P;<8)J"<;E[;L$X-6=&X(0
MJ8$/YF:$5F$4K6RK@E,8'\=>O KY&V)[/5G)W8WTK\5*'7'S049Z*N/021#Y
MS@8X9#S]]R:5@C 2]>O( \P9W4AQOA,,^LE4=P,JOQ39\9]B+Q\K[8\=YAQF
M:;]\-/_)9'>.M[\4V?%;.#4/+0X[77-64]%+PS2Q[DWS=K+BOTBO6_A\.]?_
M"55MG=-6'-RE[T?#\@;8?[&<)K,]?P-J(YK^,P)\?SC$OB; )MMQ<E2=I3?)
M+2?U=S@^[0L3;DA^?H[Q%Y=$*8!/K#.#AUKC;EDN)7,=)EHKZMF>/&B36LMI
M]4J^8-BYMH;;.*E/F3[KW3Z%^JA8-$Q"K=4F6F>'R4NZT1UNI9X5G6G3\ GU
M<F&G=DFCW&+LK)@6Y.R(LOI0J!-W%.JGI7[[[/(;"_7Y MDP"76"YFO-K<P4
M& '+60E-3^+Q+\R[OI=0EZ1FG#:W18VV4]%NHY*Q-"(U T)-W-528X_NP0Z?
M4+LGTZ=0A]A2+Y-TK-??9A1L.=RDB!)3-ZQ>^"QUDF+GFI#.CYFEK,D<-Z=K
M6QU::O)]H?YY.9%LH&0^HNEP/3\1I_NM,-C-3O:_C1YY_#&>5G19VPH"TAT-
MQ)*N!JENHVJ6R]9[]+:QGC ];)GIF2'4(*0-+D_,#4G$*#R*Q8="'%^#G87]
MNB^IV#FPEM!GF;Y/X-ZMTOTU)>Z!EOMMB3,3+&>4DMT.1LPE/"$2F[A<__R
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M:@4X8R8P:..J8-\"U(^W5^)PQ?9F3'0VMKA*=Y&I:6L@\RE$%/.XQ@F5A(C
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M/;VF.5D>5C?K+(;'9*5?:.^Z+2T$\A6MYKG63A:FF)!0M6&TNTKL,N<K-9^
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M$V(/^+.7IF6<VHF@W@\1T%+)@SB&_!U[B=0T67#0$;L.A XT R65>WV!A1E
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M)'RK(_[>.N-#]5F/YC-UO"LWE]N:S6SG[76V,$^3=/?;^6R3&/*%!1G%I:U
MJU4[3RV'Q"P$.N-'T7++UQ/312*N,TO:3G,C44NE+]9)WH66Y=FJ)49SF013
M,*5%E2G@U7$2P9&0X=,9(9]C>ABA/NB4BG V.%^[8+PH@N/^CESS?<#%@5F'
MV_*E4S-R1.^6JKNN9/S1\D4-6&:%EQH[;+FH[6:%>KO;_0+^CQ<B*:G@M"1D
M'?*=%:EZ?*!68EF]C"FSAMD><^,T!(0#9CC]O>KQ2; ]P>J:REV@68$7EK0A
MIG2Z(HJE576XC)9$0+/T!52F8P?F3._D8=0S$)R_#ZE_BKML]&G)WO*=K%00
MRE9*;U.BC7_>]%TOFBI3RYNR5NY(2C<SLMJ+Y7"JS=X;\7TWT7S2ZWW)'/3:
M0ID8%]:20AIU,95)-2=-0#+RG1$);QG<+]G5<_[':=WSK<MAC^=3K@"=G$[!
MO^<B#_P3< $,>&'Q?_RR5AU6S<)-'!=E*4V2\7@L&?O#J7?=?Q!+8#$RGDXF
MW$^<_:S;P%L4N8\<SZMJLL)5XHV9I-#5;G_<T',CH#^#\6*/=6V#@V"*/I-U
MP2,RLL9)?WA%LU)5:)AUOE!DHE%LV*WR2KH47Y^.V3M_'2JNC?T1$0 SZ>#A
MEF$+MRVU?:^PUB%9\M4/6D,>W$\KBKBYZ(BW%8$09V@\VLX<.*91%),U JL(
MH$%X!0V&7Y_DEGO<6U<6J-FNU\]2$X;MFJ/LN&;)I/QQ/\%A2DC)0(G5)>-!
M\V1'V";&';IB6P:=E1;9"O!/ *$?8CP"?MVD5]ZI4;''8L2<I2N%[79:^&S%
MX4=VQ$B15)?+3I),8=*.1EFC3VWG:'Q-XJ)NOA9BXM"_JFKJ[-?G2+C*+ECD
M,1V F;Q$BN6**&^6JZ+!B MSC5ET(I/* >9,X:_X+\2=G]R==2W=4Q-*UV0*
M6HV,CA+ZJ%\ 3@01?TW=@5-#@SQ69?GV)HSFI:$Z^^HT<9S@=0=+_^ '[CHH
MZIT!UWX%.TI..M]B91F2T:\,-,&SX&Q21$J_D2!0I,,:HJ)QLJ9H\KY0$,$B
MP*<[%IL]*@VLL=M(+([J(6-^(<)(6!DL>@QZD^-2!HCE?'ZA[2;U<NU*4=3H
MN.+173-J8W#:"_S:QY>#$9J'"C2(/@55)[@+E $$A^1MD)_E=3.2SANC_2[]
M/_;>K$E1;5T4?;\1]S\8M<\^,5=$FHM&46OM71&HV/>*W8N!@(H@*(V(O_Z,
M0:.HI-F4IF0F#W-6JH-FC*_O5RO(.ZRLH)R<I\0I.T4UI@(K>)/K@J:D.R=9
M,20KYB17P@13&%!U<S0!17;YM>Z0'G9(/O5.V_]TWYD?=/2C8OOU*A/QJ#(Q
MJDR\;67B=>/I':86=L^)YN_,.?#X,^>R^I?8NM.]CO<5O;R)*=YM7+6G4&+H
M6]Q!@+.INS<UV">/>WZ[8XC48,JH_9W,@0_&:AV4L%W%2;QG=-)9Q&@C9K.4
MR77*W??WB?:/M/9*7NR2@^9IK8MO/K7,'8WI8ZW+2SU?$F(S43/7\R1EM:V\
MI*_6-08#1DKRZI#-?V"QA&\@]2%]_S H,T*'3T*'YO'(7<1H.4&S%Y'"PZ-
M?!AI/6HCKM D%1_HR_X,@*68M%W]5]#AD&;(7$;L7F4<!YWI7T[_V2/3<>W8
M@TX%$$U2S!@<1B+Q<4Z8"SI,:'/G8-L8Q\S!P<]A)OJQG <HIPIX)&1T=GJZ
MC]6%K$OLD4$?]ORBIOACF+1_U^_VWU_X4]T[K!M2UTRWXDF*6=(%:]^*IXW6
M!ZL477I\E04'TIN!:L*F03>G=+7>V2 U>3OKH^U??_ $=M7X/M1)^^@#?A^
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MK,Z UXMAF3>EL'J[;+TCM].9D>M<>))X /G.44*\E ;O:(9>PN5IJVPWV[+
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M.X 28*\\_=0G:L@>.5TH+CKOZAD7E*C9,TD=.CY0H-O@P%<-)U_DB)TU_C_
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M<8C'@,6V%>M*+MLYSL.,=M<\@(_RO5'07#ZO(XQW?_A\H#F!UY89^*7&"CS
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MAZDK1'6AURDA6URFEY7R-!>'MA3^?%D'?$RPL&OR[6&L![ ^Q?+D"$70V#^
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MEP@L(00+^IR*^%@8 ?.*(RZ"RZ/@<KW]7@27!\$%>4Y%!!-&P$2,+*1PN=Z
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MW8HG:*M 5GKELE4F,?/7'^P925T<\A-@ =J:!Q^ 76(Y3$:P+16 ^8P>,WG
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MX+;7$=M+%9\8=3"/>NOD:9&4MOT!14X8KF>-*;9NJQGUX^W/GT$XY9=Q7W2
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M%>%^6_6G_M)!BW++.YL;G,TO&S<<VX+&%[01;EDWOC.LNOQ,F#JJT!0]2,\
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ME.#[^[ZY90*?'Y#(U,LF0SI4O:R<"3-:P"%YRI0U38D#E(74_"3WDTL-/>+
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MB&VOQF+X@1XSW)FJZU*_JRR7:"]EIE==<0JD;^;\LNR_=H0&",$/IWZ:'/T
MK6URGBTWY3:[+P..$LRG9 0T=8*OJ!SXQO,K[U1WY+-U<\?6@/>;'N_G!%T
ME@T"B>BF!;X?U=>7DE,XBJ'>CI'C8QTJ\#!H@F-9*GN]\PZL_Z=C $L/F'A
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M5]"1$G!+_(M4]%K@'>_"&34#_@/8[K[DT_\B8/,R#!O*&D+13>0?X$/JO+P
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M_;+N.PY%T[">N:"5[PSDKMI0F8$X+<_'*I'8B%!0H\]4CP0YB+=$H;T\Q7D
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M&C,C)!S@Y ?![WV#[_0H'Y]=>*?=]W;=1H[:C!P7$NRJ1"YU@9@^M?7U6PK
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M+K,,S0GHP%B5$[@*W+Z_]LP4A!A4QV<Z.C""1-/0/";8:15?D2!3*#3^@7^
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M)=V\GU^>)YVD E6,)=/_$GR?$1XKP!Q*TZ@/9%Q#1S72M7_QU]SOJ';UOC2
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M/93A9/=$F)Y;>+J;[@AL#UP .\!ZN8\[9=T#HZ27R,8UO6Y<<!9TQ<WY+3#
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M+\BFC]%A-]ES7!P1Q;V(B^*/7K6B.GD%3',&.;2CN'QX%!<>Q7WP*"[XRJ!
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ME( );ZS*+U<0S9<!:AK,;$OU'QF[_HY/6&-E3Q>X$8]\O22^I;Q07!=,@3.
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M]15UX6UH7AAM029254<CPW,IX_- _:*$YC@O]I#@*PZ<5*$:07/EQ;4QQMM
MBRX3"&Q? (*7!HIB:CX%MV7A+O&N SU9P',KMP@A]:Q<I+*4.1KI@%^NR_5L
M'K]D=! %C./-9EO"TV:\,"/1QDGX$1UB>A>)Z(8,UI*J UQB\[72\VD%YU^Y
M03*?D_AF]/OJ'3)#@GAK.O\=!.HNZCT#/[/-)6 -CC)CQ_W@B1 Z@HP9M.:>
M>K<4\68ULE!!EO$J("ZVY-ZL#=;A%BBBD>0[W5J7>*#2\P[PSF@Z.>4H=L:#
MUP3@%XP#*O01OE=^KT.CMV1-X;10N(FXMP0L?AUEB(G:\^O&*[>Y'QVEY\L&
M]A6O8YD].".]9\EB1_S0%(Q5>M63QU;Y&1V.-[^WZ\^C4+R:R;R)&6]_:KM5
MZ%ATP1N4G9(RD<ARJ;PML'I>'G'2/%WZ./+OZJ-]%5-8*97@TDR:Y>3>8W=O
M$1G\"L32#5!_UK#!\UW<_."YWE_()8^X(11ZV\.K#$BO^].,:2^M&!"#ZY_#
M'[0HSYP"CC3IO60$ /$!?AE,7AAG':[6HF5^3,WNY4D*GGQ+HY$TOX+"H&'!
M<F7$Q-)]5PRL\=NNO@LK<Y@SP,QOM2P3W/R:4H#.GSU)XN.N^9983MWB-GD.
M^-C0>.+)/$E P_,ZQ("+6S<;DK_-RL+Q"+GMQAPQI8IF;.!%1--':W@C<D!8
M'L/+E:5H^H G53P@L]QPCQKG$<#8TBEB/)G+IO/93.(KCQ'?%IPF\17+UQ=O
MU[&Z&U1N4N/^51SZ[:.WCJ M=DW4)%[^&+U(CCGV("VTF2O.6';,]C/ (GC9
MA2@+E^EP4!I&88_FMW_0_<F.QL[B;5&_F@(G0E:)>]U@GN3'$X^O#1O-"]>[
M.*(B$HCUACEO\_"SK^RE7^7?\/%]><N(DZ*!"T<D%?TY?R<>D]27RZT=6.@X
M'H:.P]#Q7D/'[[#5:W,E-"_;OFVWX?60QFN+8Z928*1I@[KGG@7WWJPMKQ!\
MA%TKE2R>UFT)?]$#7]:JU/K[%]TQBV:Z8H/R>)0>_HTL\LO]X-\@+IYS&!*;
MS(ATD:?]N5.,H5>%IFVZL_+1XHR!;,6K]@A6$BIU#DHF?_DHJ5PLD?N7OU0D
MG\\M&^EC#]_XF'&*26MN^4CW[^C$E$:_F 3$TE-O2AZN#.C$[J,2EH1P;+)C
MB;,^H$<?'&U<>M:G.?[S;UO9 .Q]U291&$!&Z87@<K<9RZ1"1 0"$6*(B" @
M(AW+)4-$!  1()K2(2("@0@QY(@@( )$4R)$1  0$5I-@4%$:#4% A'I6#8;
M(B( B A%4V 0$5I-@4!$:#4%!!&A: H,(D+1% A$A*(I((@(15-@$!&*ID @
M(A-+AXC8(B+^;9MX:KJU$]*OVW7N';O>J1#^VBVO)"&\$P:RH>&7__V1_O%1
M>*1CR=W2 .[SQ<0E/LEK]4X:-*OABF4SE&@V@U?FY#O1PD=1G_@HZC-O&(8[
MSEG;.7-\!Z((AH!X]8AT[P*BKDY#\;!]\9"-I3/?5CR$EM*!D7\P!&'.37+V
M>KF/I@)-'A?<].D "TI, N57"<0(^Q"*RM"2"@7(EUI2H0 )/*V$ME9H:WTO
M6RNWLN/7^)RQ]NI_5YA]*ZHS>] R$2_4;$\([M[3#BH5'+9FQ-M4AZ(*@TP%
MB8.F@B*]<A[202@-MJD30BHX6"H(=<)V/*,#IH)U.N%C'I&_*ITL$]+M?JV3
MQ*_!L[H^M-RIA$U\:!D2V;%@O<2TMD;L^][M@DOX14Z@&(!]_]S"3MCUUCWL
MQ,>HM*B OX9"<J$\R@)Z_1O!%EUT*S]^"_%(/)'>JI>?WC^"]T+8^R&'71!V
MXCL0=GK+9!T N17*Z\]>K#M\LLZ(8DC6H;3^;M)Z^V9(2-@A80> L).11#8D
M[)"PERZ$!(NP-R7FOQ*1>%K\^Q"/O]W(CDEDHZ?#,PJOTXS= ZVHT8VZ/8>'
MQ.X;RB%$- /"F*F]!B]7@> &:K<5X]GSWK;M%R>3VP[W?'\2#P 9[(S$]WL>
MO0L23Z5S!Y2W%! 2#YH4_WH@\!#1]^*%[3L?WYP*0FE_8!2>SVX](AJ2>$CB
M02+Q7#R4X@=/XE\/!!YJ^EZ\$$^O\L)A)ALMMK@(@\/;/Z5>)/TDD+YB.-CI
M8R\"8*=I1WO?ZM8/!#-;]N+#O*1 T<O7G1CN?:O;=GARVXW@ACHC4-3R=:E/
M>]_JMG.CPI/V4&.$&F.5,1(1,1^R1L@:(6NLGA4":X09M2%K;"&!:^];W4:&
M5SR2SZ=?R/#Z-VV3&AB*W57;7)] $=VFM/'<:.5^8''Q?F!QX7Y@$'KH;G2;
MT>U';@G."![4;:%+B!41)-;0'0""+<3IE[2I+FR$P*LZ$4;2C/8.%VCM::((
MMD%[]!J.'66O86]RHTM[D6ND)\DS860:BB/;@@Q#T7;D;%";R'W=T(R>2JR8
MT.C3+NDFD7#BA<Z_FW:MYTNQI"&L$T!KT';KO"$P/#@R58";BIWL 4#\Z9_Q
M6!SWIV&[=5BWMU684#)U&';DF):#S=?Y&RYTI!XL#H'!@'LNZ99%=+83A2SM
MY/7.Q9_<Q\]$3/3V (^:JWF/M/\Q+$<U+5MX<B33)B9N%T?UXU+RX1I'L7G&
M)**S1IYI#?$U$$!\2L)/,9;SUN$;9ST<&]* *!)PE*9)($99P_N".V0$2 U$
MM*3!-HUNUR*VT)GM %O[EBJUY=S4IIN;ZCYQ-<]-#9" L5:S:A'<+V36N@*'
M/B,-#<#L,T,X(!$X@>'.],LNQ@*L'[QIS"3-GL$H0+: < NQ>U:LW3#&B&=B
M0NVC7<,CGMA1A$F?Z',^I(2RQ(F6RXHN[TGZ7&S!3[ABVNZ="SV+P4:;H5BD
MFW?ID,MDW$4L,!WA_Y\T'/US+)2F(V0::YO<\4FJXRLC[LIHA_>?R7P$C"R*
M91 ^<]'P?B( LAH1&;LI:#,0LWU5[K,Y0(=:JF5[DN-G2GQ]SG74$A-:H!0,
M03=LN@69RB<@'!"KEM.Q;)!8(.N$E6WZ1#,E?IT*1 6(73-&*.Y,HV=*0\NO
MTKH&*'H!>0M&=UE'Z@'A]20;%MEQ0$D3RP)X*$3;L0A\!_6=TLT7/.H+#/$M
M&*I^)Z!+_^=;NH<W5]Z!/ !5S2T>%YE '):AZT0#X@)A%D$L=@$A0$5  ZXI
MI@A=24:+&%^G#\:$E7D8&Z1]>G=3VVE)SL$8V==(V346N'VC=KLPLRX3=Z?*
M@B2$AT%5)_U&":AI>1#M4#F+4\/ZF0;@>Z$[1O-FKNVEN1W%!EQD-C0O-?H:
M\JBCV2AC&:"V[S)\.04QS,;]IMUFQB233'%Q#4VL,2E=4 EO+W'!1&<(27A3
MK#5,)7PF[Z,"GZ)\@1S6VWU+MJ5'%JKNQSUNG!&%"T44;KMW'M^C8;DXOG%,
MN8\[\ Q>H6#A9LO E*J)7P2&>-TUC]PU^^Q^NF;56S,GB\PG%+&K;ZG$P5=]
MHZ/):2I$\:M%5')'JF%)\)90NRE8,5\3(5]7)%D#*Q,#/7V^52]H@[O<15ND
M%\LK)5+SF"6'<2JQW/KH?_]GH:>3QY!1&7QF\Y<;7_)MB_>22M!04X]$6<LH
MJ0LS_Y*TB32SW.)3^9B7(_;+"U$E*=I%+.8L^#XC/%: .92F41_(>&0KJI&N
M_8N_YGYGL@97_,LW6E=QS-C&Z%<"R C)$O[D&TO%8]GTCG"U1/V9N>26!"#=
M[G]__%^C4EP2Y#Y)H!OF4-(6) '_"N0F1M"0FC%XA):_)Y.DWQO0ZB*DUP$P
M '*M8'94F_OP=6+;&I,/1=3&@1%D_D5:\T52DX%*KM0Z<_Z]\HH-1VU[<U%4
M4?_/MP8P^V1"D$O\RZ'F&,9-W"@:BV 0*S!N8@4V8@IE'?0V$?[BYOK?^XJD
MK%]-!*:S]^>_<G.I:VB:,:&^/Q4"5M^86(P.T-=4:4Q#,.@.5+X#XNU AQV\
M5X'21VB XB\:\S,<"[ZQ_OZU15!\.HK/@<%5&SM"D3$..++(+_>#?U8$+M<"
M*!!E)D@7]8[OB(4KG57%;IONK+[&BS\VS2%.BF]<?0T;.WY1A\U$+!</$1$
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M:U2*:_/-\3/PFCF4M(5T>_[5C]\-6EO$Z&+G;2P28GF4*_DO+;U$JXN07@?
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MCNV8*'3'1'>(-9>;ACL X-Z;A],!(TI<+"!.(4BT5#GHW!CKJS"<JR_F+PM
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MVCFB/]RKM 6JD?(X8Q9V<F6OMBJ8(]F$<>#56,E#DQ.[32P+W,X^Y?W0ASV
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M)K@Z_"L6',8<78Y<)WZ;A2_^42\>&E%PDJ2!MA)QX =5@Z.R%YNB0B$?P)4
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M0 4BGB@^3P*U7Z LA^\@<=8T5S<.3.11#*=1Y">AVBM4Y(UNF#H'7ACDACW
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MF0QE8C;P5B[#X$!NY)CK#K9*+KFGA,Z B)4@;G:/T@[;4;K!NHN\O=:7[B=
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M?+C?&),+]$Y$)3@@$Z8J@PD-,PLB=D/\PG%DE%QOVM225C,G;T=X$"'W,5#
M!3AJ$X@ P$8"-9#L R.$,+\LSL\L?J%8&*T$GR0.X.*$ SCA #X=M@!M$A!
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MM.EZX2T%?S<F[V(>2/9C]X:9XMRSI<HJQ 4^GOC4XX313+X"N%$DZ..C=^%
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MNUGYR="'W,NMUME'PT\?6+P4GOP .FD](4*F#6JQ0MJMR6-GD0HF*=9/ADG
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M^QV'9F!'9'P)0V!8'0L$"J-,=<_5O;=7XBN.*?O'>\VR'G<,^W[AQP$,&%#
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M/"7!JP9#>CQV$3'1?')Q,>$$XAERC#TE5XDWG?X-]?+%Y+*[HGM.'LFD#1A
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M%K+@UD@A"G1!3OLS'_+H@X2K^B<ZHOQTXIDB%P_T)88QIJ4"[D]EOR5+)K;
MSL;/[1=%_R;)'G7S,VFL"7\&@EM:^,*B7"-A3(<%3U*R>=&MC.Z6(H3ZKF8V
M]#5COWO:^RKS:0*LDC8D=22A_><4''+BG4XSM]/PRAIT)*;>F7J4$6H9#;RZ
MT'G96*6$ 1+#Y]=YTE%R9<'!^?%^]V\_;/*(8A&=*(89HNS#S!":]L^U%BD5
MWQ8UENA&V8JJV-S6S;O!=,3=."_O.XD>C:Y5/%?N5'@P8-T/"R$=?7UDXBDD
M*'C%^B!%A?A?UV$#K% I*].[<CN;GM_1&T<]QW=APNTVY-1=L-';-;C;W(RL
M28J;G+<"98>0P^;LN1:WVGK-'!T6#NF7% DD6;M^L&6+T!<##8'XA$QY.>^@
ME&?ON'(D?ZB;J[S"]S=XB@E.LOU:W5J,9D+B[@SMZ378MQ 1G4^><WBDWW:H
MPFF:=H2U$1.8+RV;59,?6$6XORS):.=DU#R%-:4D]S0YA6@LFM.0TE(_7\D7
MIIJ]"9\[%UA=./L6)H_$J_WWJ-#'8-CO$'#EB(AO?DRJSR>7(A']<,9-*R>'
M:RY)QW6(1.3=]S.A/0B8U,)GVSYE"X]Z%Q>$#/'<8G^!(:51<,)S$:(8;5U2
M,']F:5UI)$=:ET[V#=^8LVHX?0N<SAWQ4O1W.DU_VS3WF%US 7< GP9:#9_3
M0@1<VG6U$<(LQAA!E7259&8>4AO2"WSI\!3<GK!1@>:'<I@U_@A_?8<Q=Z5
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M9+%$149&O.J6 PFQ=ON(R!PAO*&FR1<K@=IUT5CI9!'TK^?F =I9RR3/^M9
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M6&M:HQFCXJ+:>H(7M5>+;;UK#M67=@LVP7GB\D"7\M&>9!)$._BFG("'S0#
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MZETTW6Y_$V#DYZ 'I;B]U@V23 :G' R\"4O)'24\S:Z$;@@Q$JF 4C H,I"
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M6!EVP#M%K>KWJ\A)0E4W<%=$RX)IW$; JCZ%('AD#YPZRM%YX4>H:EOZE$7
M#E&-$8%5UC*Z4% MB0'P[>"$K6-J;(HOMP(;U;6A?JM2'#D\(L^-M$%F*B82
MJ>I&+DT>88@!&P:#^%F*-H/?7T;3B1(IRZR@L!"VU%"?Q\9&<JWETNDA1&H0
M5]"Y9"I&:"?R4'#!^/<()3/U&^II?\F5N'@JV,4R!Q7*SFG6;NP_MP:G"*A(
MM2\69+#0@:1=A1GQNNC^JG""N5^(G:?G.DA:P0P5^92KI^M3&ZB)./<71BV'
M9=_0^A6^L*_')=]4A5-CTIR-.JL<W7VKL_0^@B>%'?J8*4Q=#]2/..$F/#HZ
MH/COVX_'QP&XKD#/@YFL1-T4'9%R-&P!:\XOAT P>%B,+R%3E%:8&TD[6<"4
ME+<PE[15C.G:N#A4.*]4A-^BXBIJQZQ(CO%DS^VV4).(>IC/HB\*'ZG?@1J!
M_06NOC$&]9<HE3C.)=;D:\5 1>=IRNG7.FD]%E/H-W*C.=Z4TH#QVEVJ>9Y8
MN,R-ZQC8-(EK$B5A31+Y6ZO:_[.I]D>N3U42RQ_55P$H1NV8L J,2=%A6IX*
M^2I?HU/5:S>58I\7\5LZ/ 28T0)YR&RL&M57YLZK4N1A/W9UT5@&FXY-*^"H
MP_L.N%0N-'XP9+^R0\W6.N#NE[.XS):E=F\4?X.((S/)& ]:463C1%=?T ?E
M^.R&AG0>18ZN+C6^R5*5"#*_O&JHCI@,X18E+N MF)=8&]>Q"9J (=T^[:TD
M53X,?23.1^*:%HG[!CUM=3P@#4HF(WO&$6,K%S($69#"=.* 6/Q,B9NF11$=
M[>4'1A5*JK#,E?+M95S<L8*IE.34PEPAA)RKC?+BVZQRUV"%P?(BX/QQ3JCC
M5+BP%$!SH%^I5<.JQ!!MZZIJ\1N;?09R<L14>RL71%*A>&A*'\2_0!+%<GH1
M+<SE6F=8'.N8"#AKE&(WGKQI-E:[J"9+GID+D]M8 <C4U .R38#= L,$7XD2
MF&)^5F*UY9E#_XHK!6Z.-<$_*TB@W$.Z42+YGU>&<#'YI=)(DNFDU9#,F_"N
MGW"N/*2RX/#FES<%E%*D13WNUV.V4GWJ18CV01FXM6Y24R/D\C#IG1HG^7@Y
M@THX7("9$SZ#X3 -DIC-61((A2/;2 )N/C(\Z>PNB'G9\9%C5:KJ40)/(UL&
MW!ZFMP;X08!%  5Q'"U*I-M<Q]@<_^HK+O1B;067JM3&)O_.Y-)CNF&4YQ#W
M*0K7.X8T--<<O7.B']A +9J 2R@?85M%U8NIQ:ED;N6.4HC@P%:<.G<-VZ@"
MX)I.%Z:=H@4W3?$<>1 X>H()VXJ)!-WSC=DM8ES_UG5!\9\ NF*?39):K-K9
M)# 9E_71J]*U94*9ENJ]0Y#E>X9>9;#2KBW;=+7/*;K"6MJ4YDI-*Y402<OU
M0[BO2DO1=$ML?I'EY'.DNN>DR%+^ET0X%Z2/2DQ-3#GC\AQ5VD*!K2Z'7.B<
M"\M/XX2%[2"V23KE4RA5(G2DH5SSG"Z3)>AW]N7\F;-CPDFU&0C?U@1Z74J"
M@RRN3)!6RA,T[A1U6Z]K:>5Z9A?@/;!Y9?$16JX+YPA7.-EKFTL]<A>W]4%K
M-P2M$UC>\(Q/LAQ;LW[4#G$5?>2C";[V,7U(4?*U;#,8R/_SA4Y]8E<S)@61
M1QF;DRD?-#4G0 \QEETD8XL71Z\^O;ITIV=.^':CC<MV>5V#4IB\--&Z<9<C
M"R<?CZVJ\UA>Q=!@&^J81N!R4]$=E<J'*4'A$#]]T@[^\D-X</BRV[$KUS_G
M4F%,C6]J]1IR/ <M(/3]J30TY+\ #1%GI@B6Z)U4VQN"*O8B41[7]$9[3E6[
M9*<I!1<L0N='Z(^<Z[B'ZGNMZ<*8.<R$@^T@\)J8[XP:=O#'<20BUA";^?EN
MT)&+9!\:8&-C<>MVR+"IIF*B(_S/81L30<'+ /]FNA3FP04:,HBK\'M&.T/M
MSD)>?IC,I6X7=35$%P"6*7MQB6%)J%C@13-:^NK2RC_"[@3X?20!G--/$[?6
MW^67(7\:!"HCK.+1;*KFZL)]-HI=]\(ANA!JB(XBH]JR6"#4E-)IYI,$\OIX
M+G+T!7'^PIF'W9M2N40%.CJ]V=:2_JJC1 T^*(^T3F<(YITDT<8ZG^LYIAY,
M;TSS>GC*RO@TF?)ZJ-5;E3/TI-T#"\X8G@NDQG)_,"[.=_=$%;>NX#*#N1(6
M4$W>\U2!&SL]!U&1=7'K;+\T):-*]1E,J+J"LE[4MQ10P^AREML1<1+37+@]
MP4'\S<DO0U=77:X:M TE'<I:>S#L/#"'4AM!5>(>JZN"RIL\78(JB%+XM-MT
MQD+1I<O#\=S77!!X;\Q&\HK+A),\[&;QLJ9HD2!"D!CRCE!:U0;47E'.[M,O
M<BIAU5DKS@@=(AMR2I!/@;U-G_&R.[%N1E3DQ$V3PL=40$W1#ZL<5#2AI0Q
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M6CH]S!6)&S6;,::,2B_G9/VIB5R#NC8E"(;7%5U^JL&+"LBI#*/5+6)::--
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MT._C;L \OX^[ >6^&;SM+Z+15/SR<YQ\_?.#;9N+;8\6ZH7U$^7VG\F_JW!
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M3)S%OP+][ J^#3>:/PS-/GTZ90_&G;=40U.*-VG:AMXL5@]M5WKM[87[W+W
M$;33(2"/ZMYPGPS;FR7VS7X%-.7Z4^9OR-""Y6I!OMK)7<'(1;1G[^V^MPH2
M-/YZ(8S5='$HMT;>,K87RJ!NX&3,:%2)%^2H+<\D_ZTKX*R@P^OAPTO0DW0E
MKAL<4!*@Y2"P.UB>IT?DB7$N.P'1L4;?5T!\4J[=V$9 ?.(1/DL!L?%,!<2&
M2T!\&O&^ 9R'AU.$4^"5N B8I>A?'WN@EO'^+N,=(X0@@QOI(3[A4GZ6H9T
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MM">T4S0/6B]:OST*4V22",]18)D*0\33&I1>[BZ-TFD2WWK#Z138KE6.#[R
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M:O1W/KN%USQH]%RYA5_2H8X>^U"?8)62 /-VKX#/HA&1"0WRXE\ISV"&-Y:
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M,%5OJBXW.2Z4)][?D2$JQ+/.<GR_&E3VE^1'^Q<-< \0G2;=<4^WW%.:*[#
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MAP/ 0< /ZU@$^.$ DR#PPP7@0.#'P-6&P _K6@OPHT(;L)\E:FNX@"8$"G&
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MZSXP]^L[WD/N-[#.G;A?RS$6XG[6.'KB?MV&=1^$^W5M7!/.Y@!H4\MV-]M
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M !@4V^T1J2*V._)7D-CN$,U)['-E:$*QO2(3BCW;D(CMCKP7)+8[H,<DMCM
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M=#;064$;!R9TKI<*$H9V%EB#*$IF@%'G8\^]9O--RQK&DP9 ZTJ/]0/0@P9
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M.-HF>AZL%7JV,>_&G0C1ICZ Q0Q]<=_@9EVIL'ZXV6YPL\'-*N+H9-SA=YX
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M(JP[-[ZQ3NV[1H%56T*LGS#6;A18#716$4?'A,ZURD.#0SL+K"\^='[B!1$
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MHR5L-Y!J$]S6)%SH5AM;*Y%,K[&U-K;6VMI:C<-"ZA P.\IU@/P.\$ZH]0*
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M[_6ZO44:J(,5'F)G 7(U"6+9>5H=IV4-XXEYE)T%,=)I)+-?Y KG%GW54F4
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M=)"0U$ZQ)Q'I.O/9;A8114F 9H9'?UJS&$O%O'J9=\.!:>C4^^1M4Z17X=:
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MJ%35*AT#E8^&MM88F102X" F&(@>)/ B82ZE0U"-Q<R!X^L1!J3BF"C6G]+
MF=UK6;Z1LH:_Y0>9!#9D$&.?$4J2+?-, /(#DK*U;&)C6B4J?IUFN38#F6[1
MBVHP16T1YJ^FQM(_U>F3>X-X(,RF)Y-@YR96GQUETY')5C&SO\G\)/RDDT;^
M%P/V,YR8G F5:4=FII UDO'=((F-F%V5CE":%]1II/)?&/.VP?*:>C U.HZQ
M^*XA:E'%68&"F:Z@PFD\' '[3SB;)2X VJ*0]0% ZR#FB8EAK^)+P-2"4!DF
M'A7%E1(D8J=VUM'=-6T4-)L\YL<LAS'IDJ) TL01PYZX 8@M^BQ ?RD90W!7
M-8MZG@27=,7JJW">2X:Y2.V/Z20J+IU;Y4%%;2$=XH6F* PC=H7GWFZ_<] ^
M*-27DO>ZG7ZO4)S)N+? XZ"[2E_9"Y73XU(E'#WQK6$8!N&1=2++-YA'0.W/
M]+WMW2*-/)1VIDTO+9=XIJK,#*WKKCRECVE_DIU >@4>PX;#/S]P%BG'XAS)
MM*,CCB@GXQ,!!F>9TG6JV,\R-'VJTBI0O'"(#I1$>68[N7*-K<(Q1P(^[759
M)]UT0F@A5,WF,:#RAO1MINR(I/M"G$:5&J#_1GMG$]Z07L ?[/MHTZ(1<%I9
M[-4\5@F"6PAZ=ZA,8"966EEG) O%I#F[M5V/,&X*M!NQ_*(*7,(Q$,&*JX00
M> "1=M%0G&=R3>B#!L@CJUNG46<[0DXTZ&/B"!-J'93(O,B,MJJ<=[5649 F
M[LWP.26)SC.1:5)-R9.<6_V%R\TY:1Y8;FT[AZETO<P[<LFQVKM*G\L?UN/
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M1D'X.&>?9XZ@6@:VEE0[E *8T3Y"91'!4G![!BV&'M:2DE>:5Z-01^A'.H3
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M<H[DL^Z^N.-@1:R[L5)IU :Z86))"2/3H9GE$&]NM@I+J\0JN7J<D7>CA&V
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MX!V6*=JW8S+P*&NLG^"F2O_*'=XPO , !D883AK<'GB]!+Q FA?QM-9/[!T
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M9XQ?X=Z%/B7] *HB7 SF611B&W"BPFC*?RTE'B6N6*H6V;F*-'V4@8MZ4$;
M8P=U'HEL1\\Y 0_,0.U1HY%56*=8%: (S31<, \?P-5&JB?KH3E4;0NDA_,*
M'0_W=@_V;;"T^+=&_:B@ V:_3%C:1!WH6MI.ZLEC[J=W*NSEV$/,37R:T71)
M6PDQ5B83V0&IH5O[6/9/E742\([[!@"G!2Z4S/R5Z29@C+AT P"VY&@PL<GF
MYR=@$8$"Q<3B*FB!%)[(#01RQ1D/;CSB 0OF44B^D)J0=6WJVY+"F_$%3,.
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MHRD4:11X2R6OR@P]W@S]NLVY"\5)>L#D_#8(1TOQ/[?SZ>3W_P=02P,$%
M  @ +CT(5[Y4I^!G"   ^R@  !@   !X;VUA+3(P,C,P-C,P>&5X,S%D,2YH
M=&WM6FUOVS@2_BN\+'IM ,NRXZ1-[#1 FF0W!;;-7B_%WGVD)-KB11*U)&7'
M]^OO&5*R%<?=YL7I->@6:&Q3P^&\/'QF*.GP;T%P5J2\B$7"SB\__,H2%5>Y
M*"R+M> 6HS-I4W:IRI(7[(/06F89>Z=E,A&,'73[N]U>]^!U$!P=0M5)/4<5
M0[8?[H<[O9T!Z^T,=_K#P2X[_L!>?;X\V7;"IQ<GE__^[<PO^MOG=[^^/V%;
M01C^/C@)P]/+4W\!VOOL4O/"2"M5P;,P//NXQ;92:\MA&,YFL^YLT%5Z$EY^
M"E.;9[MAII01W<0F6T>'-(*_@B='A[FPG,4IUT;8MUN?+W\.]B%AI<W$T6'8
M?'K92"7SH\-$3IFQ\TR\W<JYGL@BL*H<#GJE'6%FB,LK,M?!3"8V'?9[O1>C
MDB>)+"9!)L9VV.]WW[Q>CFDY29>#RCLWU"+C5DX%:6_IC3/!]3!2-AVM+K%N
M9MG,&ZO"!F.>RVP^?'G",QEI^;+S\EQD4V%ES/'=(+"!$5J.7XZ<N)'_%= -
M#S-9B" 5WM#NSO[(BFL;0,L$R]'HR,=D"&%&__?])YD0K37A4N;"L(]BQCZI
MG!=8WHV0&2T+9G[)2&4)5)U=IS*2E@WZW?YA&"'JY3?Q,,8.$/J;N'@BM)5C
M6$N9_)8^_J<R6'C^)TZ2LH?YN77TOL,N9J)@Y]4D%:;#8N?FG-F4V^%A2.J>
MT-/^P<W]=P")-:Z[(5DDR/8P()DZ%J_K6/0V$XM^E[UG*9\*IL54BAD8TJ;2
ML#\JK@&S;([Q4FD+WF0_*YVS?B_X!U-C]J^+#\?L1&E<=/ 8_6"!V^FRQN/'
MJ'G'C2M*+)^SJT+-,H'JU?$YJ".?*"@I%,H>='-9,%[,655870FLBJ+F:B)2
MPEF.7UKRC(UYC"'-5 Z&LLK+W1(H1"R,X7I.(CF_$EBWI=-@+($Q6#*C'- :
M)!!+C4(,,91F TL2H=DLE7'*3$5_EO-G0HM:"3F02X."01GTI5L+4XK8&4AZ
M2YBF$K@YQ;2$1?-V&'XT? VZ[(O8$&PL"T2?$KF,=@? @#@NZ]9U68RQ;=T6
MQ?<XJQ+H1$9;H>T #9*V>HF$$)8(8VBE%F"I\V16E@8>$U?D.R1191  0A32
MZ)8SSIZ8FY2-,S4S#7RTF$ACT3A9QFG0VPTK.RT4F,:86];^:$#8[;++&U'[
M^T_[._TW(U.GNJY>M*G4&,5::!_X]XQKX5*'5,@H$Q1B)H"7*),F)7D2R\$H
MQ"KT.Y$FSI2I,(^X1JO,JRJU0A..8<->(66)  9\7LZNT;86Z+>/L8T_51DD
M^@,>]/=>B6TWM;^7M'Y):ET*#QU2SVBKMQ#E,TRFW'F=\?;VMO-L%5I8;B9<
M:7M6-;T_Z.X]'C1\FYT*@[41/D?*7T]MA^I%S"MS]RE$W)% GNJ5?"E0E88"
M;..I-(X<("4*IX<ZK"6MM*G)'Q.0^+H6+#/9J6F++DI0#&PQ*I.).\V9*C(R
MD5Q+<D#ZBN7(LB!-E:$JXO:)<27'40D.83 (QRHWJ42C(^,JX\2 <,L9L:Q&
MF.%K6[LDXULD2! DA?DB>5:DM!F(1:L0N_/FOH6TN]/"G0$'D$YE0CCB!H=S
MHC]N@$'J60A<7"=-H@$]R2.923NG$K5N68*]PX1+MT?L#=%6S^-8]KIVJ*S0
M(!N$DDIJ'"N=. -<]S,1!2IE!M3ABB@)SB2"SLXC"["7)9BN^URPM;\Q;,7;
M&VFNSZ8\JQQ/4/+$>(PF1DX1=K.F&5F4U3OPGO^YOC]Q<,1$<);Q75"D*OME
M"^["S'PA+:C%&W^]7691TSRZ'29\).B<1LJ?'%$XSC\&4;V-(RH!6_E WTX8
MG:?J]L)=68N*>W 4%3D5QY6FM+0JRAJMN3(6XW1/![I,#$7UR=NK2;E9U$LB
M"@<@D3@&=0[4[#;'">U*9/5!;D6^\VB?GAUH-M!W[SVX[W:W4Y(&;9WE5B1F
M:&=\N2MI3]^C?MYJDA:V<31*5M6FD(P;@,H\E]8*00NMF18I%$2ZEDC8YA2\
M L1 ,88H#)_4JC5 %G]4$J8[T%9%3 YL/WV3_=UQ"IKL8QR3J1=Q=TFAB8XL
ML11(6%TE%LWN3/ KHGW?"SCB=UV,NTO3')GO!8.Z+_6GO#4\P!-,-&)! U^$
M3-W[8 IRCQ:EXVN/0>$Q58[P(2'.F9HOU]Y<>'84L;$N^!CE8ZRQSSK(B'#<
M@)RZ^UUU\CN>S&4Q5?"9&+W@D_JVG:[I1.1EIN8"5V>I\A3";T +4-A(?=IT
M.]E?EZ2GH.058%"S[Y$[3&6"5$,[1:,WN'$8HZ=5#AQOMP@Q]%S-G09J$R+@
M7>@@5EG&2R.&S9?V:NAO1[5S])2+ HS4C?S3KH.#[O[!"_+,ZD9I$PGOL4V:
M\2F5#-3X&JU6E;62O=Z+5L@:B+OP[75WZR"Z;RL/X%HK4;[I/EL3C>9W,-.\
M'$:@B*M@!F^_^E!O<9U'.&A75HSHV2+9U7J^MYFG>;>Q@Z-(*Q#K\.)GWAT
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M78FC7>#;.SY&*H9\JF12X_7-Z^[NFP5A^K&>>V7/O]?G7A0\^A]02P,$%
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MKGVP!+%'B=+RN<<@\9@JA_L0$&=,S9<K;RX\.XI86Q5\A/0QTCAG+41$.&Y
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MZQ0^E5\^*+[-,/P#4$L! A0#%     @ +3T(5YS5)BN&'P  S' ! !$
M         ( !     'AO;6$M,C R,S V,S N>'-D4$L! A0#%     @ +3T(
M5RP;YTLT#@  P+H  !4              ( !M1\  'AO;6$M,C R,S V,S!?
M8V%L+GAM;%!+ 0(4 Q0    ( "T]"%>8SGI#,UT  !%H!P 5
M  "  1PN  !X;VUA+3(P,C,P-C,P7V1E9BYX;6Q02P$"% ,4    "  M/0A7
M)DAZ%,Z@  "-^PD %0              @ &"BP  >&]M82TR,#(S,#8S,%]L
M86(N>&UL4$L! A0#%     @ +3T(5X$]?4\+>   3^L) !4
M ( !@RP! 'AO;6$M,C R,S V,S!?<')E+GAM;%!+ 0(4 Q0    ( "T]"%=>
MHVT;BGX# %U^)0 5              "  <&D 0!X;VUA+3(P,C,P-C,P>#$P
M<2YH=&U02P$"% ,4    "  N/0A7SJ$X&KEU  #B'0, &
M@ %^(P4 >&]M82TR,#(S,#8S,'AE>#$P9#,N:'1M4$L! A0#%     @ +CT(
M5PC"AZR9E0  I@(& !@              ( !;9D% 'AO;6$M,C R,S V,S!X
M97@Q,&0T+FAT;5!+ 0(4 Q0    ( "X]"%>^5*?@9P@  /LH   8
M      "  3PO!@!X;VUA+3(P,C,P-C,P>&5X,S%D,2YH=&U02P$"% ,4
M"  N/0A7V($ 9FH(  #]*   &               @ '9-P8 >&]M82TR,#(S
M,#8S,'AE>#,Q9#(N:'1M4$L! A0#%     @ +CT(5[F3&6H\!P  H"$  !@
M             ( !>4 & 'AO;6$M,C R,S V,S!X97@S,F0Q+FAT;5!+!08
1    "P + .P"  #K1P8    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
